<SEC-DOCUMENT>0000200406-22-000022.txt : 20220217
<SEC-HEADER>0000200406-22-000022.hdr.sgml : 20220217
<ACCEPTANCE-DATETIME>20220217160650
ACCESSION NUMBER:		0000200406-22-000022
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		133
CONFORMED PERIOD OF REPORT:	20220102
FILED AS OF DATE:		20220217
DATE AS OF CHANGE:		20220217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0102

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		22648093

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>jnj-20220102.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:2ac3ec12-1a04-4290-8adc-1ec251a989dd,g:c9588643-da6b-4c23-b331-47586e9dc1a5,d:01be8f8f216a4c39adb513a606bfe937--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:jnj="http://www.jnj.com/20220102" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>jnj-20220102</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN180L2ZyYWc6YWFmNWJjYjVlM2EwNDY5ODkxNTliNTk5NzRmOWYwZGEvdGFibGU6ZTg4OTBhNWJhZjc3NDQyOGI2Mzg3ZDFmOWFjNmUwMjMvdGFibGVyYW5nZTplODg5MGE1YmFmNzc0NDI4YjYzODdkMWY5YWM2ZTAyM18yLTEtMS0xLTI5NzI2_7ce5f9cd-4e40-4c94-a616-e68ee571d44a">0000200406</ix:nonNumeric><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN180L2ZyYWc6YWFmNWJjYjVlM2EwNDY5ODkxNTliNTk5NzRmOWYwZGEvdGFibGU6ZTg4OTBhNWJhZjc3NDQyOGI2Mzg3ZDFmOWFjNmUwMjMvdGFibGVyYW5nZTplODg5MGE1YmFmNzc0NDI4YjYzODdkMWY5YWM2ZTAyM18zLTEtMS0xLTI5NzI2_f5ccba38-3823-4b92-89f7-af9b27f505bc">2021</ix:nonNumeric><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN180L2ZyYWc6YWFmNWJjYjVlM2EwNDY5ODkxNTliNTk5NzRmOWYwZGEvdGFibGU6ZTg4OTBhNWJhZjc3NDQyOGI2Mzg3ZDFmOWFjNmUwMjMvdGFibGVyYW5nZTplODg5MGE1YmFmNzc0NDI4YjYzODdkMWY5YWM2ZTAyM180LTEtMS0xLTI5NzI2_f69fbbc2-2786-417b-9dfc-f6719b860cfd">FY</ix:nonNumeric><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN180L2ZyYWc6YWFmNWJjYjVlM2EwNDY5ODkxNTliNTk5NzRmOWYwZGEvdGFibGU6ZTg4OTBhNWJhZjc3NDQyOGI2Mzg3ZDFmOWFjNmUwMjMvdGFibGVyYW5nZTplODg5MGE1YmFmNzc0NDI4YjYzODdkMWY5YWM2ZTAyM181LTEtMS0xLTI5NzI2_34bb7b98-5f39-47ae-81cc-ea4842d35e66">false</ix:nonNumeric><ix:nonNumeric contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTI0_2cce01d2-b420-436a-93e5-bea5f12e0c78">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTI0_dee6b310-adcd-43bf-a063-cd1559b71416">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODU5_5e9c1949-8e21-4631-bf9f-ba8181485230">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTM2_2dbaf7d6-873f-4b21-881f-1b610527d361">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODgz_5fa03461-5e24-4b61-b8c9-f2468f3220fb">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODgz_8dab58da-7c04-4417-a1bc-72271f9a3a36">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="jnj-20220102.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i358cc237f97d4810a1abd5b9de60ad85_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idab25bcb2e7e45a48ac378b27f9146f5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i392be2e4ae3149e8afab760b8a03cf5a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72f05d226e504140b886d1d1d2e1240e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4245bb20b07345a4913a280495de0ce9_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic57d5f238fed45668d8b43777b0d8cec_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i90afe5d53fd9474bad9a6c64ad556568_I20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2291de62b68a41a0b629948bd1c56c1c_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2087646dc6744a28755f382fc0a83c8_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37828c53082f418d82b181eca97c9828_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8503a818334a40a588f1d51c6b02cbdd_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9eaed1449a745b293b614e71ca57f4e_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ad9ecbc1c9a4fc99c00bdc33b0042a9_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7363031583c4556a56c66f8230d2edb_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i506f1bb3ec9a4c2fa89004c3dc9d077b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f88c24f46d04306b18b2052c29a8b77_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70ed7bf48d664a018365719e86ad0f9b_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c3c777d14a94558a9524c8d48022809_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00d93b4bd07f45c5b3b285162b1f7ac1_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32714d4caccf4a978d06df9c559c7342_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dbfa2026c924048a41d1a2e7ab20fe2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if090847b243c45b38f83514b26483411_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa5fa270dceb439ab74cfc1fa351ade8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5986c2c6f01d4f0ba394a6d7cad02794_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2264aac360274fdbb45a327357031ad9_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice303ba3fb57401c902937dcecc85b8a_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice5631336113469c8d53050918b83329_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a3fc6829cad467cbb53b7a1fe81a50a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide5f195a7f1f400580767c19f5aada99_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91696814d2cc4ce18c1ad6fe530463f4_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i456831c91d5b4616a6190fa546fd617b_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i857ac21d217c4940938fa16c01722dcd_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i864da61d817849afadab2a86db4b41cb_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32f1b367b80b48e593609d66c7aa128c_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>jnj:Employee</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>jnj:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i43031434703546208388df65cfb38be8_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i014ba6f3e80849a28122f5bc50cd0d40_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id99da0671adc429480c2f2f9dfd88fcc_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i698e54dd726c4d32801340b6a2864ac6_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia09026d98ab54d0ab3a6818b803f2d60_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bd54d7094d64fd0b19d0a1281d9b700_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0ad24090c2d488cb2a8dadbaca511fa_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28f696c1c6874735a62135bedd0cf600_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19a5a3c7ee35405ba80137bf84570da6_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib90b59b163b542a1adf97f356be068eb_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i460777456be14637947184c662627b8b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9624c6a1bedd497c80dbb2352574e47f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i093d06247d2c44aa8f18996fcd289352_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2ccb55418494f0c9e1a4c75f0b03e66_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if755ebb14d5b4945b2b45f2055df1f4d_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2214ef047a294d0ca9d41d06ad0fb607_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13202586bd644a6e92b8bfdf9c3a4ede_D20170102-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-02</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90352e12079c4d1fb386797dfa54f1b7_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe0d9084821448c9b54197410a611a82_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied5749f9adf2410da151a894ff6b6ef6_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i252e4b54420c4dde85f5fd67aa0422b4_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i452410a40d07461f83a08316f634a401_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70e8bf5abffa4483b11b26ea2161affe_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if52d136488484e92a32ea314340d972c_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fb97dbd3891498f92976302fc99a0ec_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id14a4eca31dd4e00a85267ec8f40ec78_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf6e725073c14b38991908baa96e1d7d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">jnj:OtherSovereignSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7ea071f45f34fd7ba90322c1178679b_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica9cfb292ef54c7a93d6ee930b4c18b6_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22c801516ef3458cb70b9d6768e94cc8_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71f498cef62e47498c8115a8257a7f5c_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d7e47ac51a74794aa5dd2b7dddcbc9a_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dda7dc33acb494ab90787cb95a42bd6_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ec8bdf1492e47008be52fa4584b89b6_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f3e3e39127c4af6809fdfd339d25195_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d963d3b70ad451fab86f669cf84769c_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ee19fc5a38645fd8e5d2c3bde0c13ae_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2732aa7ddf3c4fc584a545a80ed55496_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">jnj:OtherSovereignSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b07805351ce42b98b594c790d5114ee_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c6300a66b9a4b979eb41526a4c94fb3_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a7352ca619841d79bdbb2c6ab3f2250_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib364b47fe9454f339d85cae2d78e751e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0f4b2d54b954ffba9bb73844eeb14ce_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88b324b449f448d9b34e40182d15e032_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f40ebb739fb428985cccbc8ef38df17_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia56c56468be347ee80d5f33b118fa31d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ed4936b7ad042b8b7e83fda8d3b4873_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1204533ce0a4d7aaffb4e685bdbfa57_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ae060052d4740af8581a0a0eb3df2c9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48cb4cc5378a4a059f9b5fdc68b7045f_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc2ea168b3aa471788ebf1eb8f662c13_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i663b04fe910b4db3913be35f413b1086_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee8c7d3f6c6c4979b1116a020a60940f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic27bd4dd176844408f1e04f435bb2a53_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07a8e81747cd49fdb8dd11022b941933_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabc2d103024d42f6b18c1c1e3fead71d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c822c4eb5ed4bbcb5d13167c9341beb_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7efc7098a12d46b8a4268c1f5f6471f0_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b8d65d037cb434ebb1aab6adcf3472e_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7e98efb6dee498ba2fde96801469678_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if43f753e349c40788db498a0b8a5fe34_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9f7770a07704889bef20acb8a0c5220_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86ddb5ada6e24683aa7c697889661250_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87ca486a39254f2e9a23c4f2f015bf3a_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bd00e52fe1e423e8c220d276d67dac9_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1198f98bdb8f4597b4a10112426c5f06_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98801c17d85a449bba4c52f12426dc9a_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i795ce14783b64a95bab66ad564c35fe9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44e7c974360849d3ba8c0295bf5a75f9_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i003dc23bbef8425a95b799e88c2ea3cc_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i481d55d4f8994158a9674ef0152c9f10_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide40f8c8eeea4d2e8f7770aabdc662ff_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife54767ac5ea4ca28081964675153a39_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd2d53c5c93540bc8d713ea6f655ed74_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84703fb2bb5c49cabc6f3a6a621d65b8_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i808995d91a27460c9150c476dd1da392_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0192bf715a243bf91d01442328393a5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id60bdb5b63a8467fa3b6eeb112fbe483_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b7e0a2b5849409ca6652a1b1d9009f8_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c3d3ec9cd0343bea423885018d25702_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c38412ef9e6497482c4931bff7adc40_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19a92a1966c547b5b282d744cb467936_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6100225b54fc4ad197e03ca829ba928d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib720add8d11a4684b8b6655ee5659b4c_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i106b831f4ff540dab0212fc0f723cb2f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52a259e92c5049eda0dbf8c42cea6804_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id786d862a5f04ff48bcbb29805518774_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i985b96ccd9484a66b346bc504f80d0a1_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dbc1cc0cc71418babaecbd428b53b3b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ec2a313be1445888459a2cb95ec031b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d672893c8cc417db3f3cd8f14697306_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dd978faac464658a1798c339c543b0a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if14f023407364aa181f33d20d53b160b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3c166abab67452688a30d1ef04d16f1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5665ea9b95743bf9c890aefaf80d04a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b31f531f8d1475f88bdb4724aace2fd_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92c7f67b422f4287a1a96e34cff07706_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0446032e1785439f985c59f1a7df1bcc_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63c2845f743f49b9b13f7ad7d5f81f15_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia828ba075e524e7090012a4cdc4a5662_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05d7cbac295a4d9d8247f5d8e6c2cdaa_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78f4b6c63cab436a8845f1c2ac4c66f9_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i848c6b8efe174f4e9f95b5f1dd159ef4_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07bde8491d87476ca7b9ebedfa820539_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i634edb5f28be4c3db07ca7a3116c19fb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0123bf3fb024b76ae1885d1761a5b82_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfd790bc28d74dff8d098e4985e0db53_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ae16c703b374886a06975f54aceaedc_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d4ccba4445542b791db72cb4a2b0c5e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eb2552df8fe44b0a4e1444a56e55504_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i032a01d82e6b46aca1a6b8385c458f94_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9affd553b7d74c819ed99f3018b801a6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief391a34b2eb4d2d8fe2aaaff100ce78_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if28f0b8b33504b4f9f89e9d449f06cb6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa5a045453b74d8195dd434da3e842f7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if076b21d69e44a83b09033d94b086ac3_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52546e6d078c45f7ac9bd5ced9ab7cf3_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92e2a8e7af49412bbc0f28e465623b6f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i174a527600c44ee8992a7b48db2a0f80_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie117c70d8dab414e86a30cd9df792971_D20211004-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2a9a8b7f5c64483bd4a1030ddd50c04_D20200928-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-28</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd102efd0d744d738ffe8f80c0ea4d4f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8082b83eab643a19df9232e909a1570_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i223217fcf82c4c9fbd27757bd7ab98f3_D20211004-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf5fca83f72e4903ab75e0c5be5d0b90_D20200928-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-28</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaba88d1e19f44fdeb865036ee60e1e26_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i039392ea3c3b403db051bc1af156bce0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ded06cef625444b86727e06867cbda7_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0a4bb0a45cf4321a078221f082dc745_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bb81f8d839b475bac63d7d23d05d99b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id87a7804b1f44de484b175a96356f43f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bbf538e3b42487aabaada415c912f2b_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaec68da81f3f4ed78748a512faa1b83a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e2c57afbb094c14a7064ef903706da7_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i904861e4f8ed471381dbacfc8e3ab52e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c8d98bc79544f2796d5f14b04f588e5_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc765a63065f4fc7a9606b02f261afad_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i071cfab120ae4af6b209509a7218091d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4babc1d42ff4632a1e3e6b5c723c86f_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b06190f006c4dce9af3c9f28a239d36_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcee04e7edb6498692d55fa0db8bfab5_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b3713ead11f41faa96420921c930eba_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieab28e9d35ce41f88040fcdf057e21e4_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6fce32d455546de8f77cd04c86b5dd7_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i769b6005fa4c4532801176ab7112c4aa_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ed3758031c041a586a6a2d9b7ea4c75_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac6290a59e7c45c899a410f1f0e2c835_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e2707e7b5d243d78d1b3c5313fcea06_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7b9bae4686a473695740b6d4c2202f6_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81f3450daac144e3af1b7a08f181808b_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5254374306bb4a078614cffdec9aabe0_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i093bf273c79847d989c1c903a61b7968_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia24860d7401b457eba3d9b0be9935de4_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d16f4e3e01647648ac49ed4c2dda9b8_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3965bff979ef4a58b0bbda03ce593630_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb6f78322e8048bd9abad306b8359695_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if923e101b65a4eb9b85820250bc20ec0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id163764cde774d6e9f3063f4dd81d013_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5edd790b7e564a90a840e7e6dc7e272b_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a7fe279402746beaab8e640a5291e42_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1abb55e4e6ba4d30a5bddbb2e70b1191_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a0bea261b2440189c3155cacb540621_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.65Notesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i904410fb32534db6ae296a0c7b27b0ca_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.65Notesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69182c330b4b414e89f02252079a1706_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="if497493118ae4cde8380f3ccac17ff11_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i550e73b82fa342f982d286fe29ff7070_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.25Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90668084b50c4dd2ba37011a73641c3e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.25Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i813c37b3fb784cd4be0ce6ef143587ab_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d636f7f126a4235961db45e96929aee_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c3b7af038464a8783ea5368d254f51b_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6319e5cd14e849fb9bc1d26f55976e25_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46c00efd504548b0a772f17dfaaf31a4_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaad724dc80d4d528b251ff223f924c3_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie52eb5fe20d44487a51c329a11aaefdb_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35d501ad10624baf887280017b6b88cf_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic325e42974444401b43cd0f7a06ca840_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i23ebbe6c25ea4f94a4f7a79af3ae380c_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id03e49fef75f4ad086ee0152d3b7896f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7856d21e578e46b9b1070fee609a0e37_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice544b21d87b4663b518b0e214c4294b_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A055NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib04d55053c914695966b620bbf97d8eb_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A055NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff56df08a53e4e72b5ba1d8f127ae174_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i739863a8ea5642299f1ea5847ac97114_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1a46192ec1b4ed09aaafc90b80400a3_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1831bd89995549639d1c19d6d216a958_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i972bf884bfea41ffb590c5a7eac07cd4_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i205cddf8beb44dffb12b506c83e24428_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fa3f9944b0c403d9f46170a329df816_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c5bee0e48bf4e4099a183bdeee52392_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cf895e15ef54040bfac0247f96946b9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37d3ee2aa4344396b0069afab5218f8a_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bbfeb41492140249fab5192b682546a_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i658f3103f74c4c7fbb7b36c491a45202_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57a48838d3bc409fbed2cc1936c123cd_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A130NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0408738fa2104741b459f57515ad3ab1_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A130NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17953ea1893e452cb3c1c9dd6916994c_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c0880f1340c45b89ff33b5be547b0ce_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2976154beffb47c4be5a474bc8db9894_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5d27e50b0964bbcb629a108b11c7420_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae7e9316990b44f98989c64c67ff0c10_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2685a9e688f94a75a231df74311feb24_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie17e8d053df0468983d5b9c5221888e5_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if74440cec8d14911a94f8cbf380782ef_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0adb5ffb62d14519a2797379c107d86e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47b9c1e7af3946a08254176836ec29a7_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ed9c4f37ce1466fa53ccf042656f5d6_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia83c020a1a4849fb88e0231815c8866d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0118c5eed732427f9cf06f31486fc01c_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife7c692d97564c858b7b4ed1c803b286_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic38bc0786162462d9877b064a6a205e6_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i726718a28d4d4e549a41a17182d08fe6_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53a8fedc553f4f0f9de5d0a709173803_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62b1dedd1b83419bb98c00b29d60b882_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bd1c41b5d0d42c69a6f96b89a46e668_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5eb48543498494ca45ded9c606d3d15_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib69f13bfa815433e85d3e00eef71fedf_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8d56c9e88f342bea407c38d6cd7e55f_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfa4a27c5acc457f8dfe7f024890432d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if36ddad29b164d53899d8ee23f080abd_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11c0c665fc394565a535f0b2c5c1317b_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54250135a56c4cd5be1d66d5f63431cf_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50afe1be5edb4180890a7b5b27e4d27a_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3faf3f90111144d7a940a9a2c71d768d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e28fa051d454297b4accf2668e5f29a_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbd71c42f6294b2fbf205f288d70c25a_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i168b47008a8445648dc5777fadae1587_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7aefbac28e2470ea9d6063671ef8da1_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03664ec5ebbe4d8da845ff31701a77f2_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd4a9a1de87b4f128a0bb747c7a11f74_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aa10255024e47998e73466dc7e568bc_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec495cbb0c2c4cedbd4600d7d89a94d8_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied2f6ed477eb4ce6ad7d7bfaa6f716d3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64bd5e8b71f34e13ac4ffb87991525cb_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie196b853653742808afbef735bb258c5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:context id="i8cd6b32233734c51bca233601a3752ae_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf0d50ada4f346ffb63114cb3d32ba28_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f79758b58cf409fb7e5e1f32144e7f6_D20211004-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b0c1ad768954c3cb5d973a4cb0b4f0d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i161f67e1e8fc4b20952f5d16b610a1cc_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:RisperdalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aa69bd5ba1f43b3b6d5887ae14e8e86_D20211004-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b5fd248c6fa4b22b336af4f57cb8a47_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if70cf172b8f449b8bb218775e0fcb014_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i063d308c5d8f4797bb4e17583565d9b7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OpiodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4882989be8b64ae0bf4ca80baf92c148_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OpiodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f6076db24f64e8b8d695cf2700ed061_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9954ad68ee94f408f19784fd44dc96b_D20191001-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a80321fb97a41e480b2b933fde2af82_D20191201-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb7ecccc89964876b8660c4b222156cc_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6a7535dcc684ff5971979c84c966ae9_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i152260c6c54041ec8a625469070aec87_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if217fbfb3878426eba07b1762dc50833_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb9083ce9021495581a16b2fab55b31b_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20e1360ceda342bdac619fa006a12c36_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08e791c0544949eea59d9bb4511c337e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00ddcc25df744b98bd6075a18db56c7a_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cf76105357f41648e3142ea1703f16a_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58b503af83254025807546f7f976450b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a1c5e25bdb6461788f20271b3996e97_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58f88b3066f8425fb8a00e6f0f402f0c_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:QualifiedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e8d176ee39d4902bc1ae66d486ece07_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:QualifiedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia15acadd24374bdd89b9144660681aac_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:NonQualifiedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70e0e58ded464efe87df57667936575e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:NonQualifiedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib54b3dfabff34851a1673d1bd91d3667_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:FundedPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie541284941f54eb39c0cdd62a5aff1ac_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:FundedPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1605c791bdd4560a2228fadfa81e2c5_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:UnfundedPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7fcbc33c13a41e8885b35d3df83c640_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:UnfundedPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52c49a8c4db34117958d49e77780d7e7_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b45609e47e840bd9bc2b4829a2dfa26_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5c7a5058f0d4ea482b056a1543610b3_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie47761f8002e45c199053ae0a267c678_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaafdd23d13d0493891e7d7ac9afa2c86_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c80cbf0e584468d8ffebcfcd75988d6_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fe30c736fe24e1ca4d36fc6c3007110_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4dd9dc19e6149b88426c05b99e85df6_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id064b00e4ce442d3ab5bb43fe94a8111_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c1a29cf707e4f78a4258d452faef951_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6980acd8ab1348a7a9d21340b15bbad1_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i547106227f34401da5bb7b68702b3644_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f22835beae34a80914d14a3e622b9b6_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc5fd4a09af04cc889161a3e85ab6ebb_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedb15225c1b941948e9771dbfe0bec89_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93af333b5f5246b98690e521de9166f3_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3af6ce2fee94f8b8ad34e9cbe4c2959_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id97dc2bfbc6b4c75a3fda94dda89b30d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6398c3336be94b3782104a66be75812c_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fa9057e6eac45ea8abc150ad50bb903_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bae6b71cd68453fb9432e997b2ec281_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99cb936201fa4622b0837f8dfecd6b89_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic774cb65db23481fa83313228c547f8e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc8a4ada79bb4caea9c29a70213afbb9_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f76e7653f5d4d2aa16e4e2b1264054d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibee6b63499d74ba8843e5919b699a3d5_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2811f795aee94f61a4b7ca5101e1bb88_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb935c546f034a40abf2db76a024a9ce_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d95f694324341bc841a0a7101ef54b5_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie917ced662c542a288e1c9403b69f779_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5498d11f3d2542428717838316f8244c_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b5e7375ea064e46babac18112aa607e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7140a79533384965ad078f1d35179c5d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b431efe4f564593ae595088e0d47426_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7c92fe0ae4748908db33019e0c4de42_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5a1066842f549089f6164c20f388be6_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i783e5becfec34efabd5b62b1ed29b447_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64a34f28344246b3b17696830a6b62bb_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica3bf1a545d84c639cb2f963349213d2_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc20ad9303354673b2fc373f330c597f_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d0542bd36b04ade9a1445e4d2bd9293_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dab0c78d2044636b1b0795ffb41ceba_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05353447c3f44422a85c9a643c4158e7_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9481f72b68741a38d64130564e80f8b_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9ef3d78b9964c72bc181499fe2a8a48_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8663f2154b743c0a9082ef7ef48c04c_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib44c796f51604beeb234f0a74a350c2f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic90e615b8bd94bd0bd916ce166a2e1a5_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia206a3f6344d4adb8fd0339224dd9315_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice03248f0c7342dd9422615211a7ce92_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic68aa1aedc3b40c5b7b80e1388117a04_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f74ff9d83eb4bff80eca87771ac8af3_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic288cd72530f4cd2842d023a50460e18_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia30f04104b444cd3b652b8554c878f2c_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic047ffb5ebe44765a2e2ca57b1137125_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52201b2d7c81445d9be675a280747548_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65a16fd18d26435eb42b51c0b3b1b851_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20eeda577995420193ec4dd9d63bba01_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65cf763a87bd4988a9339426e416baea_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i011f2815be9247198ea2477163de1299_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia84d82cf676c42178e9d4fe5cfa9c970_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7161773f423d4d04b3b04039512ea242_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8c97df697f946a4a28e06f21b923b40_D20220104-20220104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-04</xbrli:startDate><xbrli:endDate>2022-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7122062f1c554f58bcf1918e884a09af_I20181217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">jnj:December172018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia54143af8e294de8a878b870cb6ea183_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4f8e689cd0845169580efef9b726eb8_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfa5021c9521460ea844d42abe8a5aeb_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i484c2311f67440a3876482adeb22ccb3_I20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b3e5218e47b4138b803ab86e37ed163_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dadf43537624342b93174d221447d45_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d10b1357d4345dabd40e640f459d595_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb2239aebff9499e9a34c274aaeb6c7f_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09358b98b87140529a0feb97fb9db596_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51768edbfc634fdda12f4209d23a3fe8_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40dc9b8885b14646ad4ca14020da2020_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia91a8b98474c492b93ac66dd2c441f86_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i491bbfb299144dc0a55fa842720b7ce9_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb17cd90126f48b89e2321d3bacf6a95_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c595eaa21f3452191aa3045d9aaf15e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d84caefa07e483fb905ffb4ad67b125_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i803bbc6136dd4d39b64cf980705d6a38_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc1c4f9ce70e4d3ebe6058b0e4183d02_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21cfba8b0adc47c8a606f3009b7f1da4_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b43e493bfda4958aafcf54a1f7de911_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf4efa66d2f54bfe8f36fb497d4ba3c0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9de3dfaa4b2047e3b29dfc3f5c5f3140_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fddeabd9fa049fe9b79fddca48ac307_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bb21536fb564a0d91048d2a7f920ea4_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2e15d2205eb426fb0faa00095711ac7_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5aa9d5da1c0d4119a4ea3ab746d49fa9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id50338dbd5c54672ae5cc0b8d7addd69_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief6a4d3a16fb4a8695e2f75ad4fe9856_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="stockbasedcompensationplans"><xbrli:measure>jnj:StockBasedCompensationPlans</xbrli:measure></xbrli:unit><xbrli:context id="ibac73284db3c4555ab751fa7712d96fa_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">jnj:A2012LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i878c87afdf46469b95b60a72ffa60b1f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67642e6fd25c46c7b9f6124eab76fddc_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife1e770bea9143ada35c3572dfd2a7ec_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd89ef5ec708419d83c0f50bd2e3f33a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd5b16b5eb54677834e76fbba9c913b_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idec9b1a5f62642c0b966a067f115c2f0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie82cdef29cc04363906a567a9d6829fd_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8082802da5c34e03b65215fbc1747020_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53a0b42ef8b740cb82bebc7e9ad442e7_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42e155106ee54d669ceeb882529be05f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id67bcb0b84aa42ffbafbcc561a13093e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic399470ff9944abebce0ebbbfc9f95be_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i239ccf8862324768acca0b6dd0899121_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2ff139955b84bebb659527301f2d7f3_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6608a73388e94a39a929181aeaf3e2ea_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7982e382a8c642f3ab7e8d233cd63f23_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cf80e986c6a49168d7e1239ef86064b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8597ec09b7848ea847316c99dd326ef_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7038702487ec4c45a376b222a0a20d05_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31cd18cf81d841f5a062c0c4dff7e8d9_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i164575311ea140df89ecfa92b9b8b764_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia84f3c7aa69a4e3ca4e10cee006b35d6_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a880d0282e64618a404c4e5c8cda751_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa26f4b3444e4c15a4078dc66b339b0d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7364abb0a14f4216bcad7a962281ebf6_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ed28ab7d2664b82bbdff0bc1302e139_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7b0fdaa9d9e46c9afcb09b831c329a4_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i192bc4de755f43dea6fc766f7aea65d0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffb82aff41a04d54b8471dfaef55cbfb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9131515b36de452dba77389706d7cf68_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcd0fc1997c54c228fd7a7bd70bf4aac_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icebbd7181a854a83b106002262a3f05a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d99e38809f24798a6aa6262467560c6_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c63ea6850a74252ba3d49fa9fe7b74a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ba444b93d124ce393b5b3f193a70f2f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94f3652f4af1446da52491a28d5ec451_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d10f0f5f973460c82f6e46d69e2962a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief6f2ac5fd8f4812a89cc848a4c1df06_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32966c9a84284da0b58c8d0ae0faa3c8_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3128d308ffe4613906d97816a65e9bd_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a561bfd58ec4ccabd2025a6e7cf9bd5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i400f84b397df414cbbedb7f3a7926c43_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3d80b5dc4e343d19875dae1cb177ef0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ac3647e660b4922bcde7ec55782e160_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fdb4bd463a34c9fa3b35815b52e6ef3_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadd4ee8352f9426fae8e6bdc7fe52372_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1577281a68942e6b6973a3973d33136_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8cfdad6d51e400e8669811b1b2b4267_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35d06bb332e74e4982e637a9ca92913d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dc75eb155004e52844ffebf7174bbd0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i375d3135400b433096c8e5dab3fa38a1_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6952a648640445fbdd6cdd36431a750_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07542366df9243c6abac2d16b1dfb58b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i064e7c0f8fa548429b040cde3913d49f_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77b6cd743a414007b81cd6a3d310ef78_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2fafb4659f34a019ee6e466fc04640f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdbca246df0847e9a8c4c4c568f2f273_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i022c563362694b598da5b24ae2277042_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9241b397d581403bba8152c090405eca_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6771db02e5f8466e9669560f1ce16529_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84e86bd12edd4e36b8b1f925a62c221d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f3c558885324ba1953b737d2adc0dd0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2db5485b4bd4b42a522def325281378_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f56f359990241d3a0b4c60663ba73e8_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i050c5285c0d645479744c7f00e88de1a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cb9f8fb040f4aa586cf78caa70caec0_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23807e0c5b084f52943e64733569f8b6_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eefeafc846f4408a7e000284e1799b2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dbbbd6fc37c4d11acae7021cffb7cfd_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad865eab405c42688b73a15ad42a8b8d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifef895456d614fdabb4ee70a7406be36_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieda9b733b51a4ce4b729836ac29a9802_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6576ad6b7f6341ec9b085c6461df5f80_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65ba73df1e8b4801b72d2316d8a633c3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i615e942c7fdf4b2f990bb45b5b38934e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4735078cb2534ea1aac702a26e874601_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08b088a9453b40469d5f8fbb460e6662_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffdc846cb23b49548ae67d105477e7ca_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75581ba7e91e4e2680d33c3738c407a9_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id405ef4ec29047a392666ca100c5896f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44c0cd51f839449b841b58440ac22a33_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cd93ab841884a5493587a7b877c5d6b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9be280a895e24bc2b461be2b202dc790_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a50b9c81baf410eace82766e4ac78e0_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ea74d1c2c27413fad7f2b508f4aa451_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5d8bff62eea4ed39c39a6731f599a92_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4495a7b68b684dcc8ad8b2dd0d0cb678_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib63ccacb9faa4b73878a9057b0fd6b30_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00834d1d0411420090b5c1edf63e1dfa_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6071637def043888bf3deb3a4c15799_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22f5ca4ce57845c5b53fc4f1d13397db_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icba87799cace4d7ea02ee1f5e0a4d031_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5c52e9cc9c14137918169f0b8a1bdb5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedf0e8d371a6458193259414109945a4_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23071b0ab3d54897a0d5dd7749feafe6_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i931a1c9f97ec484da90098853ca3c244_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9c2e9c0297b447e93e02db4e79afb3c_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07618356beec49e9917628c554e15b4b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6280e9e226a04001a209231428e7818e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaf44ff1272d49ce93687c31a2fcd512_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00f4796c099b4277b9207e1042e91c37_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ab4cfd32f2b4e75a6eb344b3faa7585_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i128aea28460a455aaf7714a32b5ec211_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied68b4d63a6e47f99762e52306477051_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78385204266240099fc582cb7e7fbd51_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iced1449a3371463397b9b7085addc2d0_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i650a133233af49bfaee6ed4af066a9d6_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3e283c3e9214f85ae2918d74ac3d82d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94ce48e00f8545ec8e7a84f01797b22c_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d4bf4b9e3694ef285c9c31b956b677e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd06b502c49a4f488fc11fb2c3838ef3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i233cf7fe392245428889ea57e0fc2d22_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4c61950fc8949c5b32766ec79d02eaf_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebf3d76775d644ba97bdf492a1dd1267_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05a8ae6b440b4b81b32f6a052e5a8558_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i875c8735b8514e90bad447aeb6eadbc2_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f3798ee8de34093a99e42ecc9db1ecd_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a3f22a534874f458fb9c7bdc05cb65c_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i387f05cfe3524712bad1d9f54eb5cccd_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia62cfbf9f33d4aa284727311f21d634e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15b688eb12f54afc92d5afd59ea3c706_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ff56877211249dd8ac926ef0d64f13b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i522f8a96ab7444c9b0a072059a13e972_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27123f6e396341619661b5c3adc7e7d7_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7809d87d5c845608f30c8285db41530_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f1a5560e5b14f0893f3ee125948348a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcd59309ca0944688a41953f08782f58_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25b9271bf3d148c1862fbcdce1ca1e53_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc8570ebb01c438ea0f57235642eacc7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e5920e5bf6749e2a8feab5aaad9c855_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia490b063eb8a46d3bdd2ff016e7d7783_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4565c280598049f3aa2278617178658f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8317c263da5445e96ef10c57d87335e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08a754bdc99b4589aafca7079db10c80_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82dfe65f5fd84478bfecb83176d8cf1a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61a8303dc0bc4b82b4eb802262faa800_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5106140dfc9c442095b0f77e74bd6ab5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92703c0c3b7349978b612c21f233b393_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i590ff19ce91142bcb3863bd2c6e2f069_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9f224616f5a463b8f804675e284a7d3_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife046f7abde54338b2b69413c736da26_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83e3aa3c5f51435b93d1dbe65ac91d90_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5465f74052f34acfb49d0e1a25300dc8_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie74fbb87373b4b59ab055d2fff965e07_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3530f8c2ec644b0780f82d2251ffd602_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf363f3dae664585a3f17f32b6970829_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40eda5c751a24278a262d5a7707bbf96_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69b0b0d154c1422f9d32b3d2082d49eb_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2db3c45977049f1acbf33a46b8f1197_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b2cef1544584a32a4606c9be98a902b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib308904527464b1f9f083c28369a2106_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id02c8176e6b54fbd95f6a63b9d32b50f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee1ededb6af34beeb2892f0c47c60708_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c7e3cb454244e8fbcbbac2736af573a_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ddc954bdfca40e5b84a70e77aa5b0ff_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5d8535a6c304a3ca7e7a68a08f5c836_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib18a2c82e5bd42faa30e52df5f67d0f1_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1bea3a5e88f4153ac03408e384f810b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fa30ec743194334be89aabe3830b90b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08d85765adf1424dbaac0219f0177c84_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cb2fe12284743f396b4f94eba5b3803_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idff0f007396e4810b440aabe3054aef9_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i789f89f97ffa47c7b42b23eb088f0422_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id21042f6fd3244f6887b53a8d4813430_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf047bcbe355467c8f65460dba57e264_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8bc791af8b648d782365c72c1a39a7c_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4861e2b2aeb543fbb746c4b4f1195f46_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b56e952fcde4c7e91401eb5a85ca321_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1625d21dd2242ec893225588e77f1b9_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i805f444f9b4f4b78a5e115f7da23f40b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67a0e2e227a4493a886e7e12cc63281f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb4f242ab4b94ba3bb07fea9dbb6f194_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d93d7178a424340b255ab8cc1671993_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50a2f88597bb4e56babe220ec155c933_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icba7b86a3b9b4ffc8203367aff4b1f12_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00ca4566672f4e21b57db409f2ca399b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72fd0da598264bf58922963c2e268f9f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68dfc09b6cc74b269337c9823085c75d_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0dbfabf4ce84c5dadfb5096deb252aa_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71a5ddf6505c49959a39142a4734937d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7eef150a18e4e7c9fb366789c95e51b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i844da3be083d4b0991bcf4a93b302f05_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93f0f46a5f794204849d8974443208af_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c3bc420ba184db5b0c0a09e582ba601_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90a6c337bc74400ead0814dfe3ded9ac_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d256c783ba14651b3deabb6dbca6ac3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23065d742db5456abc56ab20b4266dea_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if55330cd78f747a88fbccd460f0ec00f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d1488ec3e3c4b168ab09734e1cb2ef9_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1b7f8f06d9d4045bbceff6b94ee3210_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb742dc6f1a14657ade44dbb3734869a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7b5d7e03ed1438bb2eb5544aa5e51a0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3ecc659932b4e20a391e656b1cf4600_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e82f975ef30440e880e83c96d9d5a6d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7172a6f847d4499da4684dd32ff6587d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id47c5bf1c0fe4beb961f5f32232ec895_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8d54437eaba48faad57862e220ec9ba_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic172a5b3e234408b904ca83aea199d14_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i716ef7913074441580f76f25ff473db3_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i045f6bb81e3d4317b32f42c7864f0ce5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeea74059fd94beeac322670b9baabca_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f7304198142471ca4e3ba8d2b8b2dbb_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62a4d2b818ce406f90793b13460001fb_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f347c3391bc41aa85bcd9845a2709af_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec40c04f9d454e2f8463d169e94a0db7_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib20ac18affec473182fcb58284b62b0e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9073991f08b1465283d39628e414f9d0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icffef1f5716b4b64b0f0bdfba755b0e7_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e1c17df3e194f1e91c5e45244f1f77c_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eaeef50117a46faa8df83f358a7edea_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70636291997f49208bb484bc59053d07_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd513a7d62984d5f9d3b9a8b8e403e60_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia04a63eca2254a59a36cde0f40f8f746_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf8ef533f70c490d94f9db77743e9b87_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cc68bd95fc3478a9e77570132e953cf_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2255cd9d9c44cf8a9e8c1c315f656b6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01e4b54306a4415da8f707b8ded967a0_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i814ea4ac6baf497f8b3622d1588dd4fe_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib635c2bb6a9c4682b88d93ff9e2e12c6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i370e769b4db246bf866de99ce8aec22c_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dc879599c5a46cdbbdff6a01666beef_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d5dec1e00694287b6044e170dc592de_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8d79f0300124a3fb9fc87ac1735b564_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic94160fb0a474a0687f27b40423f5cb5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4222851f7d5c417c83afe973ae5d0159_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8de04364812e434785d220fe797cd119_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c934290591045e6af2df7d8b360299f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dc793642dc34fb8bc13264db3c2b910_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08089cf711014f1e98f6d9a9cdf4e5a6_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib48aeb94da2f440daa0044b9d1b46d05_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dabbfb12da541ddb881aa0135400f3b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabe57c96bf62464fa90fd751cdaa6812_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if16b1050a2ea4ac38b8dbfa679f48f95_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56944bb518044ff2b8fd31922efe406c_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2d0a9ad27884389aa902fa95d666252_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5923e8e2b04e40f0b40227e5c5493fbc_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e85127952964447a44873c81135f105_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0167f5d01f2e48d5bf9bf67a240ff929_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8677e4e7312c443d8f02f7836a90e787_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12482888cede42db9e124e85eb782d12_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic22cf04ce4d04163abd28d1680da2cc6_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia95a87c453d545bd97f71c7a6e370768_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf575c6968d644f098e6c4cd687f9282_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4feb8a8b5d184238a0d534cd46a60f1b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b56ab9b20b540b0827829a4d1b8215c_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf7815787e2f468c9ad07ae016d7952f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f9d60e84a26463286cb9128b46e9bf0_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e6ad08ba3564fa58b0dd76578714f7c_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb9d9b491866496f84b91c1509866032_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30dae1e51bed48feafdb469324840549_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08ea090a5dab4707b69bb4be8924ab82_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40e6f8b6cb1d43a5be16680ce48b6661_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ecec90ffdef42469fcadfbe71238277_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3085b2c60dfb4078a65276bee9eeeb4f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f25409391b04e50bb4df4caaef16032_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0083624867b449aeaf811f3a98d73be4_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84eb225252644245a3b20653e29a4713_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i855fb40e563f4b2f99bad8082fb5326e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2f5f8e7f36e4be19b1b70e62c43a23a_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fb5c6e054854c3fb2c00e7bcc0e2daa_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i416100c083414a9baae7c6d73ede58a3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f73cee4bf7345c49d627dffc1663c72_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26ad055634a14d8ab152b50284444586_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaf78fa003384e408fb12bf4bd5f741e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bc205f26e72447cb7d40dbcea60293e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69934e81fab444219448ad5bb5307afa_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife0fe4d393c848648fc39692c666de5d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b8d232b64864d51b020808f0bad00c3_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib916361cb7fa43a59ebd580516312c23_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7977fec0d5a6435aa250b1252dbcb344_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i508045fb141245bebe09d1c312027357_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2492cd00dc6a41f19230bb05436b06c3_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb3e5d251b9a41f0974af3234b4d0c1e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d5d82a3078b4b23af81af36ccc607cc_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c61c8c074234f0789152b71643a576c_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64bb03a2c1e24381b5b0b4ede7a5b34b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ba710a9effd497494383ecca075e6ba_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacd5e055a14f4fb6a23943dca90aaf64_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id445257ea7744bfd9a8983407adc2143_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia936a49b95f0497a8473b15cdbbce2ae_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec35270655784d61a34b51b61a34c955_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97e5cdc0c9e3484eb182d85a7402eb77_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bd1c0392a134aa99e761b2f95847293_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9318604febe14a94af81eecc0a785bb1_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if25ceca79c15413b8f30df32f846e465_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9ac0f5fe82940299f1a331d5d44bd02_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4829eb8419034125807a23e98d8ee355_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43084feb39e24663ad525e292889d8d8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09244b74cab94aa2a7ad31bd955792cc_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b994b9bb38d4894bcf7722b7dd244de_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07925528b3644a4e9e4ed3e3b71c3c9d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5efd22e32d44db38c958a3060f57dba_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87d7442d0ab6421c845a0cfc7bee4bef_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie18c8a66affb47e294a84056ff86c0fb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i271b0b2860ef4bc48fe0bb5645096466_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16bab441088648eeac5e89da18478b3d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i281b34eb0d124b8090359d19f5649c26_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21c2f4162852419f9469e508c07e9f59_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bdc57ec26d64526a8a02e0b5eefbdce_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75393431ba4b43ec999c0c626b97a85a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24ed0f45654143e7bd119e8dba14a248_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00781dd599394b27a4548a96fdf47dcd_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5285c14317334dcdb114e8f542b05e55_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0142ba4580f9403e859c146d50423865_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c0c0ffc4f67453684f177809b84b6d1_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i603a5b11ffb34e64b886e811464da6d1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33e35fd935b449cd87da860775063b45_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icff8555c708a43078ad2afecb67d66e6_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i766c492cc7c9493e81c043bab5ce0792_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63014d356cf948fb90cbd74710d1a00f_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c41d11433d64accb3db5ddb31b09a77_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d1ffed8e4c846e99dc9439de4ed307b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7944381e57ad429a8fcb8c4561513ca1_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44edb1d49d2f465e924c4e1e880b74a1_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57c87e25c87c4e1a9a1aaed707a48369_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b3120cc75a64c70b1146e4c34e24ae6_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3dd0bb1f6a24599b7fae40ad2e6e3a1_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5969e842241246218b535a59d92380f8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4064a0928a04ccbbdd9885f05ec28ca_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd90a7b4fb61410a89aeeeaaa41f4305_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ff91543c3e8429f958c8e05d94d0522_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93d13747093f4c91ad73a481a62db2a5_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic61250cfcef0490b8e1042b72907be02_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if19796a0c1cd4f1b8e7233548fdde432_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice1a20fa60764b468728eb227dfcf93f_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaab1d242f57c4857bc07508d3fef7f57_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i675381e27e8e4f8c92cf3dee1a9f85e1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c624bba8b9c43b0aff6e81143910b91_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4abe8cd280bc4dc38415f6a54595a59e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c16bc456bd940bb901d164807f45809_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5243c3d264ac40d09b1366108f2813a5_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i297695ea47c64a8ab41165f4e8cd24ca_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09d261dd66bc4a6fa3474295db120684_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6585c5f17b5243029be20ef4718f4ea1_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84ccf738ed9a45f9bbe93e37729899b0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i211d1d903be349e7b8c4d90c4d8e7ea8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic41939995d744557b2fadc86190eb309_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59cfc473af604a8da15221699e4b413a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67b7e2f978c5475796d2aeac43f69af0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i258c4fd8ba0447d5964abdb213044818_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e04698c0f76437fa764204c1042ea2a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15858ed4ab2a40ba98560ad9c345f601_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8d2d7a4b4074a02adf791b11dbeea4b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cb15999bd6c4c56a5291296be65bdc9_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic841ebde283e4fe69105c52901291b20_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ed18e2587674e6bb9e55bb50d6174e6_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ebc2042874040a2b7bab4e67bea27e1_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1242f0ab963e4cdebfae1b38000d1c0e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88046ddeac01478aae7aa3b6fd4cd0f2_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6fd4aec56fe4857881bc9ca6e2ebc28_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f3a036d977f4825a3d6b45499f1bf73_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i545bab733e4f449cafdf90c3798807d7_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a2648c41e074ca5a9b6e8509a34ba69_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida37c995a07f44bdb1293caa0b49b88f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i830c2e05cc524c80a9769de9a4ecc07f_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65a015a3eee243aaba77cfdb4761746f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib761e394f720484e86bb1215c1c4a5d7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i128f3aaa257a46b78b36a2dfb202715e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i876ae032ad75425dbf80231e9170bcbc_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7ab917ab8b04eda955e8203c8814bad_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4de6312edbab4fc1b98af49b4891a217_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ad086a689a4494b8f7603e98b20bf80_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf56df821a7c433d8bce9033b393786f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia277734b806943c9a73e6ecb6dbe0eef_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1daa11474a049bdaebda77832fe66e0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e24ec61f60841539515b9dad3105f4d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2b6cac63b0c4cb4af1c8513a38855bd_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9df7f3da552d44fe9c15d7efd001a255_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e6d423063d240c680e574f22c368d85_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39fe54bd882c4e64976ec42f3c86ea0d_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67be3029faf745a8adc9589c55128db4_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9efd22575fd4bcfbf17627fcfa7cbd2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i443b2dc23fbc4bb9b95e55dbe54d0032_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65dfeabf7bf04ff3b9e4a50912b6534e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if74ce695258e4192a81f8bd943d68de8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaed80240aaab4a27988be21654755b5a_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2cf37c66bfb4ef5bce478f5333fb5df_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60ed8921747044c5a0cacb0bdbb61ee5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14e5877a920f4ed5b8884f48704c60dd_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d312ed9a008438aafe8e2616054ee50_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8a398a171a24a8498a76f0430bf01d8_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice5069a97d424275971a265d90db25f2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6664751dc074f608b93f8348f757b2b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47511162d73d4b6d9f5256e85c7e0459_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i643aacdc85d74fc88245ec3722a90e65_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0d5c2adced94c5db905a0ccc543024b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i636b39044d77475baa810025fccb74fc_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i106843425fe24320805510bfc4532f23_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib806ab041535413685cecd33d2128890_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64dc60886f8947f0b033db2e2d716436_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie402bd95c7f249bcb616b6d175dbf07b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fa0825611594020b2fe056c0e4efae8_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f0fac6b04c84b689a79771f385713c2_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i816f338852d14f0fb2d6dfbdc728effd_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib46440e9fa084f209298e0c8b233ad13_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51e39d41add6463b9092b617f971b75f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice66c64ac61048f19a21734cafb5097d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib72662fc19e040589f8f2ec556ad1d4c_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75c9d64349fb47d0be110ff26bce965f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d4d5a35e0264fa3a59ab55f6e08dc1b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8dfb56f1cc3472b91d0ad823df8d237_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id20b1d22e77a4da4a5261a8d5004c3d7_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a6ff7e9dc76409ab4354387f1f95d6e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf0f0d1cba3e4983876bb49c63f4d22f_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1865f77461f6431495acc8c63093e96f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie347616036fd4a74b6a373520ba980d7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b643a5b78824e2497a25c62b3737d1e_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7196fd596c74749bad40acfaea1b70a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64ccbb362945429fac924633eba5f320_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12ce06e19cb740a191f99093f0e41f93_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0420b48e154a40cd94667e4f7c079b72_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id844326b0acb41a7b4c00cb04e75dcc9_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic34d26533be64f5db220b79da72535d4_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e00c0c4a5a54349a215833e43d01f5c_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eac76a3b41a46829772c0e6030b7607_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied4367d37c7141298cb4fdc3adef842d_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07c3c76ed88d4612a15d8daf5874486b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab9c0e490e5b409f818ad1fd0ba564a7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d8921ae00644e968ea3b39b44e5e6be_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bfdee030cbc49baadf91413f3bd72b9_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1342fc470d44486822d04a68d8d00ec_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3b235e18a384746bae631a4c9642be1_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id08aa391f2684371a6971aa72bb4521a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a86230afa1e4a6cad4c6e87b5261ff7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbe1f9d829d845418d0507a31d92c4d0_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0e3cb79b02940e3afc4af2a5a631cd9_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00778b10e5af4bc791d1e8bbdd2bc204_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacbdfe154b164f529f2e69136f05274f_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3304f9e4e7c4ee8b06281744d7d29d5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i661a37b39e8c487aa2f3ff704761f5d2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1a4981a319243a488072bbdd896bf56_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia27aa4eb532a45a799170754ae5ed161_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e557585fa834313b8b97ce7709070a9_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i949f6e0a191b4f4eb7c2781bbac7d13f_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idca63bfd34644ba5bc55002b5b4d5a8e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2be122533f1424399fcc358654c4c3c_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92e59ba1db31451aa3a8f14eb7816088_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i234ad40879c94cc2969e46faf33c17cc_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3d9dccc5c584c4980e7a904d8a983bf_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3253049e290946cd8a51612d31bcd76b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i273e42d494bc4b7eb94a87f9d5987d1f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6368f09f9b35486ea7cba69aacb7e3b0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i275015b2876d4c6d8fcb7fcdbd81df65_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f3e3713f381473f97efa9d195f99ffc_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98f25d91afdc48968db8d33b505ba457_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d48dd9d0d814bbca1d1b0419263f649_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefd23a50dc7c42fcb55115309d6d6cb5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54751f70883943a59eb320c03774cc90_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if904c809a5cc47d7b5470bf8066c13bc_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11256befd90346248d26afa528551f9f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7ccd3dcadf64c67aceef9eec40f6b84_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0409bf3aaf47499c862aca1869e89dc5_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e8300916c9f4f18862cbda08e5f8057_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i092132d8bdf1497aa5fa557713c95b5f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4425ca9af5e64e22ac69aa3be800b66a_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21660177d3cf4725a1adfee86587c410_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa74aa704e1a4c00aa265ccc209e1380_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i066cce25039f4a8caa66512b868996f8_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0af309f3267d40c3b42203456d5ad2d9_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84982e9d6460466bb3d6705abbfb2f69_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea0e3ef3419b4d75adf175b93648c1b6_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08a1d8e556c2462dbffb82954114233c_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i449dac796d2545b3b9f5d700d9bc735e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a9c0705fde748bebf4dc83c4526eedc_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67279a229f6346a78562ee616f898161_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd6421c05ae448adb09f10e096aa875a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i222491a1b870418a91eeb762d8d1eee8_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d7dc7d7e32844b18dadac4c73fcc43d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icff33641613a4644b8764afca4e5e006_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40f24e02fa214e8ca63a5dc798f5aa78_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb35b47d312946dabc1007fce8107f34_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib15659c9d6514a6f8707334b438bf18b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e80c257552240eeb8c38ce4765cb32d_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id65abc97d55744b0b397e09a73a60cb2_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8149a55d6d9e44f08db766c017d527a4_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d3a78039e7f4b40946cc088fba95f07_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i870d2071335a4c349e9bdf6c5dd8d221_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfabb85d57ed4e6e887596a521298fb6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd907d3be6c6488b96c02cf61fe58ae2_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic800efd413714d9d8a60516ca5f7d6ee_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cc24ee69c5e41af8566a1fcd0f833bc_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2509eddc1f545e09f38e5e2b4414e6b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i028b50c377714c899ae9c599c83171a0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66dd731836ac479eae5b91d919a1282b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ef2752fd1b046dbba1e17488a65f77c_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i926ba91f36ef48a68fe6266e71d6869a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4e5ad3b9bd24320b4d78a6d53743649_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff991be03a2b4d159d3a77225971b22b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib476ce85857e4f488b4ac69194703bb8_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf5c33d3be83417685f6d8ce5f603a71_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6386cedfeef4e04b42dfa0d05731d11_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41f47282388e46edaf2c190bca1a05f3_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fff9f5f7b7143e383cbb939bdf7ad11_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i708657b70522407092d787ab45a8beb0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5b9bb0bcfc4462ba8d103cb379d694b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic23bf00a30e04ba28d25d34bb814c35e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65b6178ffad3411eb9697a130c03e546_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b4a5583c6aa48ceacfd7cb8304fe30c_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07875b0557b747c1817c640f15714392_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia502d9d60b7a47f6a866b6d2e0e7126f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58017869d1b24f54bed182c8572366f0_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd9ab20dc83c431fbee3c5fe6720e9f8_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aebbc77b14247239abf6a5e633c97fd_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1c87e0aa1f746979a526054fc431766_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida08580984a943569bd4235ee5579e20_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i542883a564ac49d99d576a6b19e782b4_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6ffed65f4a64a30906e469a8d768eb0_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d5630eefc3e4b02942a364b65337f88_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2ee8524f73941a28f36ded1f0ae9694_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b9faf917d1049188734075ab026d41d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08a55e3eca274722b79aa4b030bf30ff_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d8c1b87d69949739491c09dd1df4a3e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41d128ea214b4e15bed9dcde7d5f5996_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84f072c0693846e9987d24a6f8158c06_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic11d6e0c7a594cc58857314068a88853_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fc205a8aa4348dabb8157a34a1f17e6_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c942d86e2b2405fba98d51d0541433d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibff7c2542e2e46b386cc5c9b9e43ed68_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie56b8a3a16e2475b9f30017cd504ca86_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f314714a5bd4eb3b5976682016d9f0d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ffa3bbb13054be0b90f9be2fe0a69de_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a4ad3308fb2433ab4bb66f0ed570ddf_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i161c8b4e12a84317ab8397b42ebcbd69_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf6748ed9caa4723bfd8c2a5895eb586_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5d16014da004533a78f87eb30d1bbdb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd6a6522853c4fd39a5c2f6393777cda_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfec35f176a949e19fc22a208824eaf9_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43234b4b84a444a9add41d11cc2a72e9_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89612e90f2314e95be21fae3c19c58e6_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dde3b1fc1c140b7b975e1257746af2a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie55616146f624252916d67d0fb6270a3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1329742ce6594bfc9eddf10d9e6e6d1b_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic66ee5c432fb43989fab14ab0949bd32_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0eaa56b37ca45d6be7c0ae8cc029a05_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12c344a819924cb3abc49e0e78326cb5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86027318c21946418cf4bac6b9766a4a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if180dfc034c94229b3b69b27873c5523_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6d295d1a9e8463fae253f66cb1dd8c9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2d14c5a6d394ef9a183cc124fa5a80a_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9002b75b28cf45caa22c4976168c7b62_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i192b54c044b440f48ee211083347803e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4eab92d733042da922500164d7a49b1_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia624c75d38284ec6a2ec845b2560bce2_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2be65f500ff545279a1db64b6247c724_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8f488e3ce82400e9d20999f51bfd957_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i684ab47875044db597f5dfe5c54f245d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibffd9ab5bd7e43d2bdabc0050f445bbc_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53bf7c2112b84b558b199f49dd38db16_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0df24236c7145dea99c2071261ac7b9_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cdc558e3419463e9447cf921a59d40e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7b52918f61f47df92b761c6d628e9dd_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b4e08a0ee17422a8c214d277d942d69_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91c7274c6de64cad9ae9f5f8d47e3a03_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8caaafd1850845b59365f8e185f8173c_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3b5a13cbe6b4786982dea5ebe78b704_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if99789229d014c78a17d5f4a81bbfa36_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30ec518ef4e84aff82c8baa7363b31de_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe41c007f8e74211896f3015a2132bd1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25b4bc0c83d64827aac46f72ea370c2b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59011837e8e74865818d7c6e22573da3_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84ff03e41df948aea3483799d1cbea10_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dd8d7d4f2d84befa81f6c55d1286f96_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b01d17f27cf45d1be57134c670e1e36_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc662de37ec34428972835cc3abf9da7_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96b4301ec6a748738bcd3da3c58a855d_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ActelionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74b5f6e37afe4a4db8b8e7f9fdd0b2ef_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:AdvancedSterilizationProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dcfe72e83d94e7f84475a87d6457756_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ff6ac9a46e741ebb0af1c793cb24164_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad866650cbf4417d988e0b72205283fc_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab994f6e28264437bf740f3cb576b596_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c5552cc49964c378bbb9b282742a62d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c4338357956452382a3b4130bcd7e7e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:A2020AcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0305d06bfd34bdfb74072845ac023d4_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic56891ab2cd6480ba37ea1ceb033b908_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if085f95b01a24cb5b37a6f4a5c06c613_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i652360a76ef04b59bdc669400214e356_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab3ebcc4c2ae4fe293b17a266c45d8fb_D20220128-20220128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-28</xbrli:startDate><xbrli:endDate>2022-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4dfe20935d14ee3bdc74b4b396d04be_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:VerbSurgicalIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38342c75b72a472b9fd00cc1e1df9f64_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5ee7cee5c044dc895e1060a81eb1b2b_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dc89baa93fd48229b56fd011dd9c983_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafbc6103989b414a84c18b6479a23d0b_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i657d184bcd08449dbbd5a6d436f9a8f6_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c34dca13b3246238c5245124b592b5c_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:A2019AcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if156d32e424b440faf1f0d3e777e112b_D20190117-20190117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-17</xbrli:startDate><xbrli:endDate>2019-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:context id="i31c41bc161bd4282b210e004dbeb91e5_I20190116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief3cab3c65b84702aa8c68b0beb5654a_D20181231-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia63d28caef88416ba2d4d20a17561867_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bb9d754278d494ea4868d3a7a6440d8_D20200928-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-28</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27523630f0dc4c789b10d08289448d52_D20190401-20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf01140629ce4b44992bec25a4d0157b_I20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4958dd807d8c42a3b81c7c535df76aae_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91459e999e794e2a864d95b8eb009680_D20200629-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b6fbd9b80d84153817595caadafdadd_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9f9f41fdfe94421ada2b29f1eda2e7d_I20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic68faf24908f44f48cafea31ccd53622_I20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie12611a8a0b5457b8429c851c4a1acb1_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12d629a6349442e1bcd3b89fd1744c17_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="chf"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit><xbrli:context id="i0028bc7fe5bc4af89fae762f116f5492_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96cb437b61cd4edc8359b3f5f09fa26c_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fed2deb8c9147eb8ff44239290a9c54_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c2687a93cd147aa9d8a4fba7100335e_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:AdvancedSterilizationProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fb558e71971413fb73765983f5dcf7c_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:AdvancedSterilizationProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1293b88bd90d458eac2d0d6a7b850b0d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claimant"><xbrli:measure>jnj:claimant</xbrli:measure></xbrli:unit><xbrli:context id="i16e6e6646c3b4d109123795d9c7df84e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb4e5502065243778f8d181c244dd324_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9d5ee581ec640ec80ed1f8d2ef956fe_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4378318856543098e6cf32dbe8237ca_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ac530b2a8144cd796fa1d12ee757dfa_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7be14aefb4947a6870ffa19e0bf31ca_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:InvokanaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb92b728ef4e453193b6bc673799a78b_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55464ad945a643baa712e791b033c1ed_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a3b65d9882f4457b2a58709975f0f58_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cases"><xbrli:measure>jnj:cases</xbrli:measure></xbrli:unit><xbrli:context id="i09cbeb4b729f4746a9c451af63dd91c7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1cc0378da84475bbc08a06b2a879405_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cd3b425c568464d84bffc5929d955ac_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6133d5a7101f441a9444db674a47b348_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8473134a97db464ab939bcb0bb98f418_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i659974d043fe4a37b83a80d13bc59d65_D20200601-20200628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if17dccaaceb943739755c40b7c59083d_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifba96edcac3c4389a3b0bb8b2c90cd45_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb58c35946ea47c2a018ec31bb2540d3_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c3dc4fb3ece45fdbc810c1cbca8eab7_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="jnj:LegalJurisdictionAxis">jnj:StateLevelJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60459746fbf841b59219889ad727de9f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="jnj:LegalJurisdictionAxis">jnj:FederalLevelJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia204f8664a9d4e17b4e9da7fc3db9fc3_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9e9d5c5c1ab4177a2b9d89bb136c5e3_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d6e9afb25e04fc1adbd653da6d9243e_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07cc6e7b5efd42c9b9d122106a692420_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ec18e9e128b4bcb867c217e36034665_D20200120-20200120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-20</xbrli:startDate><xbrli:endDate>2020-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15323762d4454d4fa681a2ea0ef1eab5_I20150430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ContactLensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>jnj:claim</xbrli:measure></xbrli:unit><xbrli:context id="i9040c31d4c1748199785beebbd0586ea_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f2a0b2a8ead42e18de0ad368f5442fb_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd48c767309c46d8a8d98cc62c7d4f0e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f942e7d06b448759571f02f4385e4ca_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a7d77bec63f4ec9ba629e605fa7f760_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4742330f4c264777a98ea1c8e9843989_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i070444329d4348a7b9c8aebe5a9aa3c9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf61a7957d2e4fbf85c40c9d23a9297e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49ac509f65b740f7bf421ae80e274e2a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7cc0a51e3df46baa43c1b66bf2a029e_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5c2f9e6ae2646e49bca2879436ed3ed_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54a04675fe8142f985b33a5c678e172f_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i125634f59e794aada3577c9ee8b1c64b_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id60a51c9ec914539bb291a40e2bd0afd_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46179c58ccf9458a966c4f2d2c9cb18a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcec504d9dde41a1b752577a2c9939c5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdd89adfa0f0484b84b07f77e48731a8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2327edec83cc47c299891dc7c339c323_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i872fb39f2b694b7b97a09c5a2b7bfa67_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i531752ccd3b04bb4bd2ee5442e9d418a_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01b7633b6f6a47ac92f6869a755469fb_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8f0b1a408074a8f9ca58bbfea6c3348_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia09f9acab5bd428d86b7dafd5dd2f6bc_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie50addf0e3d44897a0a2e867211ed920_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i918a4b3733da4e56bf9e7e5969d09d95_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91a2f9eb45f44e87b7a3dd02889d98b3_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b09fb038985486b93ffe0bcfbe958f1_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if116a595b26043caaadde3e9d3b3c0a2_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i01be8f8f216a4c39adb513a606bfe937_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODQx_27b1bd73-0611-415b-b65f-810c46c70a5c">10-K</ix:nonNumeric> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6YmFiMTIzYzM3Nzg0NGEwN2EzMDJjMDk0NmM3NGE5MmEvdGFibGVyYW5nZTpiYWIxMjNjMzc3ODQ0YTA3YTMwMmMwOTQ2Yzc0YTkyYV8wLTAtMS0xLTI5NzI2_de183da4-8c09-46ed-ad79-02643363a1fb">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18xMTY_9fcb31af-3c34-470e-b0e8-446c26bac89b"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18xMTY_b6260daf-ab1c-4c31-8767-ba20b89e8769">January 2</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6ZGNjMDgwMjc4OTAwNGIxMWIyMTZhZjMyNjQyZTYxZDYvdGFibGVyYW5nZTpkY2MwODAyNzg5MDA0YjExYjIxNmFmMzI2NDJlNjFkNl8wLTAtMS0xLTI5NzI2_583b511a-f608-45fa-928e-91298757719f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transition Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934<br/>for the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODUx_a66e230e-b1ae-4a46-a865-773e4ec2eb1e">1-3215</ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODUy_8082e1e7-779d-4196-aac6-6295cedc80d1">JOHNSON &amp; JOHNSON</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.489%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6ZjM4YzVlZmQzMWViNDY2NGFkYTlkZDc1ZWYwMmIyYzEvdGFibGVyYW5nZTpmMzhjNWVmZDMxZWI0NjY0YWRhOWRkNzVlZjAyYjJjMV8wLTAtMS0xLTI5NzI2_6042dabb-0bbc-400d-b14e-aa5b8a5580ef">New Jersey</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6ZjM4YzVlZmQzMWViNDY2NGFkYTlkZDc1ZWYwMmIyYzEvdGFibGVyYW5nZTpmMzhjNWVmZDMxZWI0NjY0YWRhOWRkNzVlZjAyYjJjMV8wLTItMS0xLTI5NzI2_b8c9d46e-cdd0-44ab-9323-eed568fbdc04">22-1024240</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">One Johnson&#160;&amp; Johnson Plaza<br/>New Brunswick, New Jersey</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">08933</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODQ3_5a7a0c66-423e-40e0-bbdf-952fe1846aaa">One Johnson &amp; Johnson Plaza</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODQ4_df38dbca-4e73-415f-b5b7-353760df4724">New Brunswick</ix:nonNumeric>, <ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODQ5_a9b92aaa-8fbb-41ff-932b-dd82794356e0">New Jersey</ix:nonNumeric> <ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODQz_72bd6cd9-56f3-460f-8544-0ff31ec91880">08933</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODUz_977c298c-f44c-49dd-8218-fea36773b7fb">732</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODQy_500b02c0-7380-4f2b-805d-b6c5d4931240">524-0400</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(b) OF THE ACT</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i358cc237f97d4810a1abd5b9de60ad85_D20210104-20220102" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV8xLTAtMS0xLTI5NzI2_37e7dd42-9c86-4b75-adea-524866205a4c">Common Stock, Par Value $1.00</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i358cc237f97d4810a1abd5b9de60ad85_D20210104-20220102" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV8xLTEtMS0xLTI5NzI2_ff5ce16d-5e85-4e21-918b-07e05b3f832a">JNJ</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i358cc237f97d4810a1abd5b9de60ad85_D20210104-20220102" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV8xLTItMS0xLTI5NzI2_6c388257-ecda-4350-8936-05f0c5daec80">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idab25bcb2e7e45a48ac378b27f9146f5_D20210104-20220102" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV8zLTAtMS0xLTI5NzI2_efbe23be-6620-49e5-97a5-6fab6f75d3e1">0.650% Notes Due May 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idab25bcb2e7e45a48ac378b27f9146f5_D20210104-20220102" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV8zLTEtMS0xLTI5NzI2_c45a87a0-2354-41c5-aed6-8cd79ab393ec">JNJ24C</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idab25bcb2e7e45a48ac378b27f9146f5_D20210104-20220102" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV8zLTItMS0xLTI5NzI2_24feae56-83a4-4bbc-91a1-0b30855807e4">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i392be2e4ae3149e8afab760b8a03cf5a_D20210104-20220102" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV80LTAtMS0xLTI5NzI2_f3ccd581-45da-4286-9934-4941a5a385d2">5.50% Notes Due November 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i392be2e4ae3149e8afab760b8a03cf5a_D20210104-20220102" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV80LTEtMS0xLTI5NzI2_bc38934a-24b2-473a-8a05-d13b59e6f0bd">JNJ24BP</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i392be2e4ae3149e8afab760b8a03cf5a_D20210104-20220102" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV80LTItMS0xLTI5NzI2_5700f1c5-d64f-4c2e-9783-d6d03962fc8c">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i72f05d226e504140b886d1d1d2e1240e_D20210104-20220102" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV81LTAtMS0xLTI5NzI2_e59d3345-c11b-4a92-9f7c-ebfaaf1934a0">1.150% Notes Due November 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i72f05d226e504140b886d1d1d2e1240e_D20210104-20220102" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV81LTEtMS0xLTI5NzI2_4d12fbe9-f966-46de-9b2a-1741c03da5d3">JNJ28</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i72f05d226e504140b886d1d1d2e1240e_D20210104-20220102" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV81LTItMS0xLTI5NzI2_2807bfce-2511-45de-a2ed-c3540e2ae1d6">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4245bb20b07345a4913a280495de0ce9_D20210104-20220102" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV82LTAtMS0xLTI5NzI2_340e468d-965b-4ae0-94dc-afb58948a5e2">1.650% Notes Due May 2035</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4245bb20b07345a4913a280495de0ce9_D20210104-20220102" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV82LTEtMS0xLTI5NzI2_0ecd040a-1626-44d6-b71f-1a0d2763f0fd">JNJ35</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4245bb20b07345a4913a280495de0ce9_D20210104-20220102" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV82LTItMS0xLTI5NzI2_500f9d56-0c5d-4541-9e3c-7b7b959dfbc3">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;<ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODU0_250055b7-e056-4201-876b-65ff47a729e7">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act.&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODQ0_9d0cb4e7-e28e-4c4d-a24e-444da91e2f39">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Exchange Act during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;<ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODU1_39980524-dfb4-4591-bdd7-f8950dcec4eb">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODUw_f68deef9-1aea-451c-96ce-b1d8115e5cfb">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6MTdlYTYxZmRkNjQxNDcxOTkzN2M4OGVkZDMwNWQ4YTMvdGFibGVyYW5nZToxN2VhNjFmZGQ2NDE0NzE5OTM3Yzg4ZWRkMzA1ZDhhM18wLTEtMS0xLTI5NzI2_c4ff9a9d-3736-4a67-866c-0f00b188d99f">Large accelerated filer</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6MTdlYTYxZmRkNjQxNDcxOTkzN2M4OGVkZDMwNWQ4YTMvdGFibGVyYW5nZToxN2VhNjFmZGQ2NDE0NzE5OTM3Yzg4ZWRkMzA1ZDhhM18xLTQtMS0xLTI5NzI2_47bc666f-f840-4850-85b3-16551642c2bb">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6MTdlYTYxZmRkNjQxNDcxOTkzN2M4OGVkZDMwNWQ4YTMvdGFibGVyYW5nZToxN2VhNjFmZGQ2NDE0NzE5OTM3Yzg4ZWRkMzA1ZDhhM18yLTItMS0xLTI5NzI2_e3e60bd5-e61b-40da-bee6-62b76ab9e1ff">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes&#160;<ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODQ1_847e993e-c14b-4597-ae5c-26154298a655">&#9745;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODQ2_94f153de-968c-41c3-9aab-67450eb840f7">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the Common Stock held by non-affiliates computed by reference to the price at which the Common Stock was last sold as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was approximately $<ix:nonFraction unitRef="usd" contextRef="ic57d5f238fed45668d8b43777b0d8cec_I20210704" decimals="-9" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yNzI4_a253a88a-bcc6-4c3d-bb1d-f4e3acd20ed2">445</ix:nonFraction> billion.</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i90afe5d53fd9474bad9a6c64ad556568_I20220210" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yNzY1_8a91337f-9222-4b1a-83db-3b45b66a0ddb">2,629,268,158</ix:nonFraction> shares of Common Stock outstanding.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Parts I and III:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portions of registrant&#8217;s proxy statement for its 2022 annual meeting of shareholders filed within 120&#160;days after the close of the registrant&#8217;s fiscal year (the &#8220;Proxy Statement&#8221;), are incorporated by reference to this report on Form 10-K (this &#8220;Report&#8221;).</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Item</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_13">PART&#160;I</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_19">General</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_22">Segments of Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_22">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_25">Geographic Areas</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_25">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_28">Raw Materials</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_28">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_31">Patents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_31">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_34">Trademarks</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_37">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_37">Seasonality</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_37">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_40">Competition</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_40">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_43">Environment</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_43">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_46">Regulation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_46">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_49">Employees and Human Capital Management</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_49">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_52">Available Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_52">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_55">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_55">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_58">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_58">15</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_61">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_61">16</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_64">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_64">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_67">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_67">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_70">Executive Officers of the Registrant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_70">17</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_73">PART&#160;II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_76">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_76">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_79">(Reserved)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_79">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_85">Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_85">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_106">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_106">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_109">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_109">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_241">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_241">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_244">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_244">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_247">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_247">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_2652">Disclosures Regarding Foreign Jurisdictions That Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_2652">108</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_250">PART&#160;III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_253">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_253">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_256">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_256">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_259">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_259">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_262">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_262">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_265">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_265">109</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_268">PART&#160;IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_271">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_271">110</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_274">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_274">110</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_277">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_277">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_280">Exhibit&#160;Index</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_280">113</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_10"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K </span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Johnson &amp; Johnson&#8217;s other publicly available documents contain &#8220;forward-looking statements&#8221; within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson &amp; Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements do not relate strictly to historical or current facts and reflect management&#8217;s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;will,&#8221; &#8220;anticipates,&#8221; &#8220;estimates&#8221; and other words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating results and financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives, including associated cost savings and other benefits; the planned separation of the Company&#8217;s Consumer Health business; the Company&#8217;s strategy for growth; product development activities; regulatory approvals; market position and expenditures.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company&#8217;s control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company&#8217;s actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Product Development, Market Success and Competition</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company&#8217;s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Challenges to the Company&#8217;s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Increasingly aggressive and frequent challenges to the Company&#8217;s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Allegations that the Company&#8217;s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company&#8217;s ability to sell the products in question and require the payment of money damages and future royalties.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Product Liability, Litigation and Regulatory Activity</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Increased scrutiny of the healthcare industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Failure to meet compliance obligations in compliance agreements with governments or government agencies, which could result in significant sanctions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Compliance with local regulations and laws that may restrict the Company&#8217;s ability to manufacture or sell its products in relevant markets, including requirements to comply with medical device reporting regulations and other requirements such as the European Union&#8217;s Medical Devices Regulation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Changes in domestic and international tax laws and regulations, increasing audit scrutiny by tax authorities around the world and exposures to additional tax liabilities potentially in excess of existing reserves; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to the Company&#8217;s Strategic Initiatives, Healthcare Market Trends and the Planned Separation of the Company&#8217;s Consumer Health Business</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Challenges to the Company&#8217;s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company&#8217;s ability to consummate the planned separation of the Company&#8217;s Consumer Health business on a timely basis or at all;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Company&#8217;s ability to successfully separate the Company&#8217;s Consumer Health business and realize the anticipated benefits from the planned separation; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The New Consumer Health Company&#8217;s ability to succeed as a standalone publicly traded company.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Economic Conditions, Financial Markets and Operating Internationally</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of global public health crises and pandemics, including the novel coronavirus (COVID-19) pandemic;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Changes to global climate, extreme weather and natural disasters that could affect demand for the Company&#8217;s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company&#8217;s products and operations; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Supply Chain and Operations </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Interruptions and breaches of the Company&#8217;s information technology systems or those of the Company&#8217;s vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company&#8217;s products; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The potential that the expected benefits and opportunities related to restructuring actions contemplated for the global supply chain may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors also should carefully read the Risk Factors described in Item 1A of this Annual Report on Form 10-K for a description of certain risks that could, among other things, cause the Company&#8217;s actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above and in Item 1A to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_16"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">BUSINESS</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_19"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Johnson&#160;&amp; Johnson and its subsidiaries (the Company) have approximately 141,700&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson&#160;&amp; Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company&#8217;s primary focus is products related to human health and well-being. Johnson&#160;&amp; Johnson was incorporated in the State of New Jersey in 1887.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Executive Committee of Johnson&#160;&amp; Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company. This Committee oversees and coordinates the activities of the Company's three business segments: Consumer Health, Pharmaceutical and Medical Devices. Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies. Each subsidiary within the business segments is, with limited exceptions, managed by residents of the country where located.</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_22"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segments of Business</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company is organized into three business segments: Consumer Health, Pharmaceutical and Medical Devices. Additional information required by this item is incorporated herein by reference to the narrative and tabular descriptions of segments and operating results under: &#8220;Item 7. Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition&#8221; of this Report; and Note&#160;17 &#8220;Segments of Business and Geographic Areas&#8221; of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consumer Health</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;The Consumer Health segment includes a broad range of products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women&#8217;s Health and Wound Care markets. Major brands in Skin Health/Beauty include the AVEENO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">; CLEAN&#160;&amp; CLEAR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">; DR. CI:LABO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">; NEUTROGENA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and OGX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> product lines. Over-the-Counter (OTC) medicines include the broad family of TYLENOL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> acetaminophen products; SUDAFED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> cold, flu and allergy products; BENADRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and ZYRTEC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> allergy products; MOTRIN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> IB ibuprofen products; NICORETTE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> smoking cessation products outside the U.S.; ZARBEE&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> products, inspired by nature, and the PEPCID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> line of acid reflux products. Baby Care includes the JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and AVEENO Baby</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> line of products. Oral Care includes the LISTERINE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> product line. Major brands in Women&#8217;s Health outside of North America are STAYFREE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and CAREFREE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> sanitary pads and o.b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> tampon brands. Wound Care brands include the BAND-AID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Brand Adhesive Bandages and NEOSPORIN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> First Aid product lines. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">               In November 2021, the Company announced its intention to separate the Company&#8217;s Consumer Health business, with the intention to create a new, publicly traded company. The Company is targeting completion of the planned separation in 18 to 24 months after initial announcement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;The Pharmaceutical segment is focused on six therapeutic areas: Immunology (e.g., rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis), Infectious Diseases (e.g., HIV/AIDS and COVID-19), Neuroscience (e.g., mood disorders, neurodegenerative disorders and schizophrenia), Oncology (e.g., prostate cancer, hematologic malignancies, lung cancer and bladder cancer), Cardiovascular and Metabolism (e.g., thrombosis, diabetes and macular degeneration) and Pulmonary Hypertension (e.g., Pulmonary Arterial Hypertension). Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. Key products in the Pharmaceutical segment include: REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis and active polyarticular juvenile idiopathic arthritis (pJIA) in people 2 years of age and older; STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ustekinumab), a treatment for adults and children with moderate to severe plaque psoriasis, for adults with active psoriatic arthritis, for adults with moderately to severely active Crohn's disease and treatment of moderately to severely active ulcerative colitis; TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (guselkumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; the Janssen COVID-19 vaccine, authorized for use under Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older; EDURANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (rilpivirine), PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (darunavir) and PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (darunavir/cobicistat), antiretroviral medicines for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral products and SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), a once-daily single tablet regimen for the treatment of HIV; CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (methylphenidate HCl) extended-release tablets CII, a treatment </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for attention deficit hyperactivity disorder; INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (paliperidone palmitate), for the treatment of schizophrenia and schizoaffective disorder in adults; INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (paliperidone palmitate), for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for at least four months; RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (risperidone long-acting injection), for the treatment of schizophrenia and the maintenance treatment of Bipolar 1 Disorder in adults; ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (abiraterone acetate), a treatment for patients with prostate cancer; ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer; IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ibrutinib), a treatment for certain B-cell malignancies, or blood cancers and chronic graft versus host disease; DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (daratumumab), a treatment for multiple myeloma; DARZALEX FASPRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (daratumumab and hyaluronidase-fihj), a treatment for multiple myeloma and light chain (AL) Amyloidosis;  PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (epoetin alfa), a treatment for chemotherapy-induced anemia and patients with chronic kidney disease; XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment and reduction of risk of recurrence of DVT and PE to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) and peripheral artery disease (PAD), for the treatment and secondary prevention of thromboembolism in pediatric patients, and for thromboprophylaxis in pediatric patients following the Fontan procedure; INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (canagliflozin), for the treatment of adults with type 2 diabetes; INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/VOKANAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (canagliflozin/metformin HCl), a combination therapy of fixed doses of canagliflozin and metformin hydrochloride for the treatment of adults with type 2 diabetes; and INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> XR (canagliflozin/metformin hydrochloride extended-release), a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release, for the treatment of adults with type 2 diabetes; OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (macitentan) as monotherapy or in combination, indicated for the long-term treatment of pulmonary arterial hypertension (PAH); UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (selexipag), the only approved oral and intravenous, selective IP receptor agonist targeting a prostacyclin pathway in PAH. Many of these medicines were developed in collaboration with strategic partners or are licensed from other companies and maintain active lifecycle development programs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Devices </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;The Medical Devices segment includes a broad range of products used in the Interventional Solutions, Orthopaedics, Surgery, and Vision fields. Medical Devices in Interventional Solutions include Electrophysiology products (Biosense Webster) to treat cardiovascular diseases, Neurovascular care (Cerenovus) that treats hemorrhagic and ischemic stroke; the Orthopaedics portfolio (DePuy Synthes) is comprised of products in support of Hips, Knees, Trauma, and Spine, Sports &amp; Other; the Surgery portfolios include advanced and general surgery offerings (Ethicon), solutions that focus on Breast Aesthetics (Mentor) and Ear, Nose and Throat (Acclarent) procedures; and Johnson &amp; Johnson Vision products such as ACUVUE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Brand disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. These products are distributed to wholesalers, hospitals and retailers, and used predominantly in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. Beginning in the fiscal first quarter of 2022, the Medical Devices segment will be referred to as the MedTech segment.</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_25"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Areas</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Johnson&#160;&amp; Johnson and its subsidiaries (the Company) have approximately 141,700&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world with the primary focus on products related to human health and well-being.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The products made and sold in the international business include many of those described above under &#8220;&#8211;&#160;Segments of Business&#160;&#8211; Consumer Health,&#8221; &#8220;&#8211;&#160;Pharmaceutical&#8221; and &#8220;&#8211;&#160;Medical Devices.&#8221; However, the principal markets, products and methods of distribution in the international business vary with the country and the culture. The products sold in international business include those developed in the U.S. and by subsidiaries abroad.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S.&#160;activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_28"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Raw Materials</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Raw materials essential to the Company's business are generally readily available from multiple sources.  Where there are exceptions, the temporary unavailability of those raw materials would not likely have a material adverse effect on the financial results of the Company.</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_31"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's subsidiaries have made a practice of obtaining patent protection on their products and processes where possible. They own, or are licensed under, a significant number of patents in the U.S. and other countries relating to their products, product uses, formulations and manufacturing processes, which in the aggregate are believed to be of material importance to the Company in the operation of its businesses. The Company&#8217;s subsidiaries face patent challenges from third parties, including challenges seeking to manufacture and market generic and biosimilar versions of the Company's key pharmaceutical products prior to expiration of the applicable patents covering those products. Significant legal proceedings and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">claims involving the Company's patent and other intellectual property are described in Note 19, &#8220;Legal Proceedings&#8212;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual Property&#8221; of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">              Sales of the Company&#8217;s largest product, STELARA</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> (ustekinumab), accounted for approximately 9.7% of the Company's total revenues for fiscal 2021. Accordingly, the patents related to this product are believed to be material to the Company.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Janssen Biotech, Inc., a wholly-owned subsidiary of Johnson &amp; Johnson, owns patents specifically related to STELARA</span><span style="color:#000000;font-family:'Palatino Linotype',sans-serif;font-size:7.8pt;font-weight:400;line-height:107%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Palatino Linotype',sans-serif;font-size:12pt;font-weight:400;line-height:107%">.</span><span style="color:#000000;font-family:'Palatino Linotype',sans-serif;font-size:7.8pt;font-weight:400;line-height:107%;position:relative;top:-4.2pt;vertical-align:baseline">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The latest expiring United States composition of matter patent expires in 2023. The latest expiring European composition of matter patent expires in 2024. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Sales of the Company&#8217;s second largest product, collectively DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> (daratumumab) and DARZALEX FASPRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> (daratumumab and hyaluronidase-fihj), accounted for approximately 6.4% of the Company's total revenues for fiscal 2021. Accordingly, the patents related to this product are believed to be material to the Company.  Genmab A/S owns two patent families related to DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, and Janssen Biotech, Inc. has an exclusive license to those patent families. The two patent families both expire in the United States in 2029. The latest expiring licensed European patent expires in 2032. Janssen Biotech, Inc. owns a separate patent portfolio related to DARZALEX FASPRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span></div><div id="i01be8f8f216a4c39adb513a606bfe937_34"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company&#8217;s subsidiaries have made a practice of selling their products under trademarks and of obtaining protection for these trademarks by all available means. These trademarks are protected by registration in the U.S. and other countries where such products are marketed. The Company considers these trademarks in the aggregate to be of material importance in the operation of its businesses.</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_37"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Worldwide sales do not reflect any significant degree of seasonality; however, spending has been heavier in the fourth quarter of each year than in other quarters. This reflects increased spending decisions, principally for advertising and research and development activity.</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In all of their product lines, the Company's subsidiaries compete with companies both locally and globally. Competition exists in all product lines without regard to the number and size of the competing companies involved. Competition in research, both internally and externally sourced, involving the development and the improvement of new and existing products and processes, is particularly significant. The development of new and innovative products, as well as protecting the underlying intellectual property of the Company&#8217;s product portfolio, is important to the Company's success in all areas of its business. The competitive environment requires substantial investments in continuing research. In addition, the development and maintenance of customer demand for the Company&#8217;s consumer products involve significant expenditures for advertising and promotion.</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company is subject to a variety of U.S.&#160;and international environmental protection measures. The Company believes that its operations comply in all material respects with applicable environmental laws and regulations. The Company&#8217;s compliance with these requirements is not expected to have a material effect upon its capital expenditures, cash flows, earnings or competitive position.</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company&#8217;s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation and enforcement. The Company is subject to costly and complex U.S. and foreign laws and governmental regulations and any adverse regulatory action may materially adversely affect the Company's financial condition and business operations. In the U.S., the drug, device and cosmetic industries have long been subject to regulation by various federal and state agencies, primarily as to product safety, efficacy, manufacturing, advertising, labeling and safety reporting. The exercise of broad regulatory powers by the U.S. Food and Drug Administration (the U.S. FDA) continues to result in increases in the amounts of testing and documentation required for U.S. FDA approval of new drugs and devices and a corresponding increase in the expense of product introduction. Similar trends are also evident in major markets outside of the U.S.  The new medical device regulatory framework and the new privacy regulations in Europe and in other countries are examples of such increased regulation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The regulatory agencies under whose purview the Company operates have administrative powers that may subject it to actions such as product withdrawals, recalls, seizure of products and other civil and criminal sanctions. In some cases, the Company&#8217;s subsidiaries may deem it advisable to initiate product recalls.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The U.S. FDA and regulatory agencies around the globe are also increasing their enforcement activities. If the U.S. FDA were to conclude that we are not in compliance with applicable laws or regulations, or that any of our drugs or medical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">devices are ineffective or pose an unreasonable health risk, the U.S. FDA could ban such products, detain or seize adulterated or misbranded products, order a recall, repair, replacement, or refund of such products, refuse to grant pending applications for marketing authorization or require certificates of foreign governments for exports, and/or require us to notify health professionals and others that the products present unreasonable risks of substantial harm to the public health. The U.S. FDA may also assess civil or criminal penalties against us, our officers or employees and impose operating restrictions on a company-wide basis, or enjoin and/or restrain certain conduct resulting in violations of applicable law. The U.S. FDA may also recommend prosecution to the U.S. Department of Justice. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively marketing and selling our products and limit our ability to obtain future clearances or approvals, and could result in a substantial modification to our business practices and operations. Equivalent enforcement mechanisms exist in different countries in which we conduct business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The costs of human healthcare have been and continue to be a subject of study, investigation and regulation by governmental agencies and legislative bodies around the world. In the U.S., attention has been focused by states, regulatory agencies and congress on drug prices and profits and programs that encourage doctors to write prescriptions for particular drugs, or to recommend, use or purchase particular medical devices. Laws and regulations have been enacted to require adherence to strict compliance standards and prevent fraud and abuse in the healthcare industry.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There is increased focus on interactions and financial relationships between healthcare companies and healthcare providers. Various transparency laws and regulations require disclosures of payments and other transfers of value made to physicians and teaching hospitals and, beginning with disclosures in 2022, to certain non-physician practitioners. Federal and foreign laws governing international business practices require strict compliance with anti-bribery standards and certain prohibitions with respect to payments to any foreign government official. Payers have become a more potent force in the market place and increased attention is being paid to drug and medical device pricing, appropriate drug and medical device utilization and the quality and costs of healthcare generally.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. government actors continue efforts to repeal, modify, or invalidate provisions of the Patient Protection and Affordable Care Act (the ACA) which passed in 2010. For example, federal legislation repealed the ACA&#8217;s individual mandate tax penalty as well as the tax on generous employer-sponsored healthcare plans; the Center for Medicare &amp; Medicaid Services (CMS) began permitting states to impose work requirements on persons covered by Medicaid expansion plans; certain federal subsidies to insurers have ended; and certain short-term insurance plans not offering the full array of ACA benefits have been allowed to extend in duration.  Some of these changes are being challenged in U.S. courts and so their long-term impact remains uncertain. The ACA has also been subject to judicial challenge. In November 2020, the U.S. Supreme Court heard argument in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Texas v. Azar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which challenges the constitutionality of the ACA. Pending resolution of the litigation, all of the ACA but the individual mandate to buy health insurance remains in effect.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The U.S. government also continues to propose and implement changes to the Medicare Part D benefit including the size of manufacturer discounts in the coverage gap and catastrophic phases of the benefit.  There are a number of additional bills pending in Congress and healthcare reform proposals at the state level that would affect drug pricing in the Medicare and Medicaid programs. This changing federal landscape has both positive and negative impacts on the U.S. healthcare industry with much remaining uncertain as to how various provisions of federal law, and potential modification or repeal of these laws, will ultimately affect the industry.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;In addition, business practices in the healthcare industry have come under increased scrutiny, particularly in the U.S., by government agencies and state attorneys general, and resulting investigations and prosecutions carry the risk of significant civil and criminal penalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Further, the Company relies on global supply chains, and production and distribution processes, that are complex, are subject to increasing regulatory requirements, and may be faced with unexpected changes such as those resulting from the COVID-19 pandemic and Brexit that may affect sourcing, supply and pricing of materials used in the Company's products.  These processes also are subject to complex and lengthy regulatory approvals.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The global regulatory landscape is also subject to change as the COVID-19 pandemic continues to affect the U.S. and global economies. The U.S. FDA and other health authorities have shifted resources and priorities to meet the many challenges presented by the pandemic. Pandemic-related disruptions could negatively impact the processing of regulatory submissions and slow agency review times necessary for the approval or clearance of new drugs and devices. The duration and severity of the COVID-19 pandemic is unpredictable and difficult to assess.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Human Capital Management </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of January 2, 2022 and January 3, 2021, the number of employees were approximately:</span></div><div style="padding-left:56.25pt;padding-right:56.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.368%"><tr><td style="width:1.0%"></td><td style="width:52.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,300&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,400&#160;</span></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full-time equivalent (FTE) positions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,700&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,500&#160;</span></td><td style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:112.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:107%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">&#8220;Employee&#8221; is defined as an individual working full-time or part-time, excluding fixed term employees, interns and co-op employees. Employee data may not include full population from more recently acquired companies and individuals on long-term disability are excluded. Contingent workers, contractors and subcontractors are also excluded.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:107%;position:relative;top:-2.8pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%"> FTE represents the total number of full-time equivalent positions and does not reflect the total number of individual employees as some work part-time.</span></div><div style="text-indent:30.35pt"><span><br/></span></div><div style="text-indent:126pt"><img src="jnj-20220102_g1.jpg" alt="jnj-20220102_g1.jpg" style="height:269px;margin-bottom:5pt;vertical-align:text-bottom;width:341px"/></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Strategy </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company believes that its employees are critical to its continued success and are an essential element of its long-term strategy. Management is responsible for ensuring that its policies and processes reflect and reinforce the Company's desired corporate culture, including policies and processes related to strategy, risk management, and ethics and compliance. The Company&#8217;s human capital management strategy is built on three fundamental focus areas:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Attracting and recruiting the best talent </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developing and retaining talent </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Empowering and inspiring talent</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Underpinning these focus areas are ongoing efforts to cultivate and foster a culture built on diversity, equity and inclusion (DEI), innovation, health, well-being and safety, where the Company's employees are encouraged to succeed both professionally and personally while helping the Company achieve its business goals.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Culture and Employee Engagement </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At Johnson &amp; Johnson, employees are guided by Our Credo which sets forth the Company's responsibilities to patients, consumers, customers, healthcare professionals, employees, communities and shareholders. Employees worldwide are further guided by the Company&#8217;s Code of Business Conduct which sets basic requirements for business conduct and serves as a foundation for the Company policies, procedures and guidelines, all of which provide additional guidance on expected employee behaviors in every market where it operates. The Company conducts global surveys that offer its employees the ability to provide feedback and valuable insight to help address potential human resources risks and identify opportunities to improve. In 2021, 91% of global employees across 77 countries participated in Our Voice Survey which was offered in 36 languages.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Growth and Development </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To continue to lead in the changing healthcare landscape, it is crucial that the Company continue to attract and retain top talent. The Company believes that its employees must be equipped with the right knowledge and skills and be provided with opportunities to grow and develop in their careers. Accordingly, professional development programs and educational resources</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.565%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.565%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.972%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">are available to all employees. The Company's objective is to foster a learning culture that helps shape each person&#8217;s unique career path while creating a robust pipeline of talent to deliver on the Company&#8217;s long-term strategies. In furtherance of this objective, the Company deploys a global approach to ensure development is for everyone, regardless of where they are on their career journey. In 2021, 45.8% of employees in Manager and above job categories took advantage of career opportunities by moving across functions, country or business segment lines (including upward promotion or lateral transfer and excluding employees in the research and development organizations). The Company's voluntary turnover rate was 8%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity, Equity, and Inclusion (DEI)</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is committed to workplace diversity and to cultivating, fostering, and advancing a culture of equity and inclusion. Enabling employees to perform at their best while being themselves is fundamental to the Company's continued success. The Company&#8217;s DEI vision is: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Be yourself, change the world</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company's DEI strategy focuses on three pillars that reflect the strategic priorities identified to enable the Company to address the challenges and opportunities presented by this evolving understanding of diversity: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Accelerate the Company&#8217;s efforts to advance a culture of inclusion and innovation </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Build a diverse workforce for the future </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enhance business results and reputation </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's DEI strategy is guided by internal and external insights, global best practices and continual employee feedback which remind the Company that while diversity changes by location, inclusion is the same everywhere. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Benefits </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Company's total rewards philosophy, the Company offers competitive compensation and benefits to attract and retain top talent. The Company is committed to fairness and equitable treatment in its compensation and benefits for employees at all levels. The Company observes legal minimum wage provisions and exceeds them where possible. The Company's total rewards offerings include an array of programs to support its employees' financial, physical, and mental well-being, including annual performance incentive opportunities, pension and retirement savings programs, health and welfare benefits, paid time off, leave programs, flexible work schedules and employee assistance programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health, Wellness and Safety </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s investment in employee health, well-being and safety is built on its conviction that advancing health for humanity starts with advancing the health of its employees. With the right awareness, focus, practices and tools, the Company ensures that all its employees around the world, as well as temporary contractors and visitors to the Company's sites, can work safely. The Company has continuously expanded health and well-being programs throughout the Company and across the globe, incorporating new thinking and technologies to keep its offerings best-in-class and to help employees achieve their personal health goals. The programs and practices the Company advances for total health&#8212;physical, mental, emotional and financial&#8212;help ensure employee health protection from emerging health risks.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Safety and COVID-19 Pandemic Response</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Protecting and supporting our employees during the COVID-19 pandemic continues to be a top priority and our approach includes: keeping employees informed of local COVID-19 transmission rates and corresponding risk levels; promoting the health and safety of our employees in the workplace through robust layers of protection; enhanced cleaning and access to cleaning supplies and personal protective equipment; supporting employees with pay continuity, benefits and well-being tools; and recognizing extraordinary employee contributions at work and in our communities. In 2021, in recognition of the new way of working, we initiated J&amp;J Flex, a hybrid model that empowers our office-based employees to find the right productivity and balance of in-person and remote work. This model allows for work to happen seamlessly across a variety of workplaces and is enabled by an array of enhanced collaboration tools and technology to optimize productivity and connection. J&amp;J Flex rolled out in fourth quarter 2021 globally, and will continue deployment through 2022 as protocol and requirements related to the COVID-19 pandemic allow. The Company is evaluating flexible work strategies for its on-site workforce, such as virtual on-boarding and training, to help our employees balance their personal and professional lives. Also, we continued to enhance our benefits offerings with access to wellness tools, on-site vaccine clinics, mental health support resources and delivery of at-home testing kits. In addition, as COVID-19 vaccines were broadly distributed and administered in 2021, including the one developed by Johnson &amp; Johnson, we adopted policies in the U.S., Puerto Rico, and certain other countries to require proof of vaccination from Johnson &amp; Johnson employees and contingent workers, in order to return to our sites, where permitted by local law and regulation. In the U.S. and Puerto Rico, this requirement took effect on October 4, 2021, with processes established for granting accommodations to those with medical or religious needs. Select manufacturing and distribution employees and contractors in the U.S. and Puerto Rico, as well as certain additional countries, are adopting similar policies through early 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company&#8217;s main corporate website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.jnj.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All of the Company&#8217;s SEC filings are also available on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.investor.jnj.com/sec.cfm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as soon as reasonably practicable after having been electronically filed or furnished to the SEC. All SEC filings are also available at the SEC&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Investors and the public should note that the Company also announces information at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.factsaboutourprescriptionopioids.com,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.factsabouttalc.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.LTLManagementInformation.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use these websites to communicate with investors and the public about our products, litigation and other matters. It is possible that the information we post to these websites could be deemed to be material information. Therefore, we encourage investors and others interested in the Company to review the information posted to these websites in conjunction with www.jnj.com, the Company's SEC filings, press releases, public conference calls and webcasts.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;In addition, the Amended and Restated Certificate of Incorporation, By-Laws, the written charters of the Audit Committee, the Compensation&#160;&amp; Benefits Committee, the Nominating&#160;&amp; Corporate Governance Committee, the Regulatory Compliance Committee, the Science, Technology &amp; Sustainability Committee and any special committee of the Board of Directors and the Company&#8217;s Principles of Corporate Governance, Code of Business Conduct (for employees), Code of Business Conduct&#160;&amp; Ethics for Members of the Board of Directors and Executive Officers, and other corporate governance materials, are available at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">www.investor.jnj.com/gov.cfm </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the Company's website and will be provided without charge to any shareholder submitting a written request, as provided above.  The information on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">www.jnj.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">www.factsaboutourprescriptionopioids.com,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">www.factsabouttalc.com </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">www.LTLManagementInformation.com </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">is not, and will not be deemed, a part of this Report or incorporated into any other filings the Company makes with the SEC.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investment in the Company&#8217;s common stock or debt securities involves risks and uncertainties. The Company seeks to identify, manage and mitigate risks to our business, but uncertainties and risks are difficult to predict and many are outside of the Company&#8217;s control and cannot therefore be eliminated. In addition to the other information in this report and the Company&#8217;s other filings with the SEC, investors should consider carefully the factors set forth below. Investors should be aware that it is not possible to predict or identify all such factors and that the following is not meant to be a complete discussion of all potential risks or uncertainties. If known or unknown risks or uncertainties materialize, the Company&#8217;s business, results of operations or financial condition could be adversely affected, potentially in a material way.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Business, Industry and Operations </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company&#8217;s businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company&#8217;s earnings.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company faces substantial competition in all three operating segments and in all geographic markets. The Company&#8217;s businesses compete with companies of all sizes on the basis of cost-effectiveness, technological innovations, intellectual property rights, product performance, real or perceived product advantages, pricing and availability and rate of reimbursement. The Company also competes with other market participants in securing rights to acquisitions, collaborations and licensing agreements with third parties. Competition for rights to product candidates and technologies may result in significant investment and acquisition costs and onerous agreement terms for the Company. Competitors&#8217; development of more effective or less costly products, and/or their ability to secure patent and other intellectual property rights and successfully market products ahead of the Company, could negatively impact sales of the Company&#8217;s existing products as well as its ability to bring new products to market despite significant prior investment in the related product development. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s Pharmaceutical businesses, loss of patent exclusivity for a product often is followed by a substantial reduction in sales as competitors gain regulatory approval for generic and other competing products and enter the market. Similar competition can be triggered by the loss of exclusivity for a biological product. For the Company&#8217;s Medical Devices businesses, technological innovation, product quality, reputation and customer service are especially important to competitiveness. Development by other companies of new or improved products, processes and technologies could threaten to make the Company&#8217;s products or technologies less desirable, less economical or obsolete. The Company&#8217;s Consumer Health businesses face intense competition from other branded products and retailers&#8217; private-label brands. If the Company fails to sufficiently differentiate and market its brand name consumer products, this could adversely affect revenues and profitability of those products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interruptions and delays in manufacturing operations could adversely affect the Company&#8217;s business, sales and reputation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s manufacture of products requires the timely delivery of sufficient amounts of complex, high-quality components and materials. The Company&#8217;s subsidiaries operate 85 manufacturing facilities as well as sourcing from thousands of suppliers around the world. The Company has in the past, and may in the future, face unanticipated interruptions and delays in manufacturing through its internal or external supply chain. Manufacturing disruptions can occur for many reasons including regulatory action, production quality deviations or safety issues, labor disputes, labor shortages, site-specific incidents (such as fires), natural disasters such as hurricanes and other severe weather events, raw material shortages, political unrest, terrorist attacks and epidemics or pandemics. Such delays and difficulties in manufacturing can result in product shortages, declines in sales and reputational impact as well as significant remediation and related costs associated with addressing the shortage. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company relies on third parties to manufacture certain of our products. Any failure by or loss of a third-party manufacturer could result in delays and increased costs, which may adversely affect our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on third parties to manufacture certain of our products. We depend on these third-party manufacturers to allocate to us a portion of their manufacturing capacity sufficient to meet our needs, to produce products of acceptable quality and at acceptable manufacturing yields and to deliver those products to us on a timely basis and at acceptable prices. However, we cannot guarantee that these third-party manufacturers will be able to meet our near-term or long-term manufacturing requirements, which could result in lost sales and have an adverse effect on our business. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks associated with our reliance on third parties to manufacture these products include reliance on the third party for regulatory compliance and quality assurance, misappropriation of the Company&#8217;s intellectual property, limited ability to manage our inventory, possible breach of the manufacturing agreement by the third party and the possible termination or nonrenewal of the manufacturing agreement by the third party at a time that is costly or inconvenient for us. Moreover, if any of our third-party manufacturers suffers any damage to facilities, loses benefits under material agreements, experiences power outages, encounters financial difficulties, is unable to secure necessary raw materials from its suppliers or suffers any other reduction in efficiency, the Company may experience significant business disruption. In the event of any such disruption, the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company would need to seek and source other qualified third-party manufacturers, likely resulting in further delays and increased costs which could affect our business adversely.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Counterfeit versions of our products could harm our patients and have a negative impact on our revenues, earnings, reputation and business. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our industry continues to be challenged by the vulnerability of distribution channels to illegal counterfeiting and the presence of counterfeit products in a growing number of markets and over the Internet. Third parties may illegally distribute and sell counterfeit versions of our products, which do not meet our rigorous manufacturing and testing standards. To distributors and patients, counterfeit products may be visually indistinguishable from the authentic version. Counterfeit medicines pose a risk to patient health and safety because of the conditions under which they are manufactured </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">&#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">often in unregulated, unlicensed, uninspected and unsanitary sites </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">&#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as well as the lack of regulation of their contents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The industry&#8217;s failure to mitigate the threat of counterfeit medicines could adversely impact our business and reputation by impacting patient confidence in our authentic products, potentially resulting in lost sales, product recalls, and an increased threat of litigation. In addition, diversion of our products from their authorized market into other channels may result in reduced revenues and negatively affect our profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The COVID-19 pandemic has adversely impacted certain aspects of the Company&#8217;s business and could cause disruptions or future impact to the Company&#8217;s business, results of operations and financial condition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks associated with global health crises, epidemics and pandemics, including the global outbreak of coronavirus and its variants (COVID-19). The COVID-19 pandemic has adversely impacted, and is expected to continue to adversely impact, certain aspects of the Company&#8217;s business, results of operations and financial condition, including lower sales and reduced customer demand and usage of certain of our products. The spread of COVID-19 has caused the Company to modify its business practices (including instituting remote work for many of the Company&#8217;s employees), and the Company may take further actions as may be required by government authorities or as the Company determines are in the best interests of our patients, customers, employees and business partners. The Company continues to monitor the situation and while we have robust business continuity plans in place across our global supply chain network to help mitigate the impact of COVID-19, these efforts may not completely prevent our business from being adversely affected and future impacts remain uncertain. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While the U.S. and other countries have begun or will begin to reopen their economies, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the extent to which COVID-19 will impact the Company&#8217;s future operations will depend on many factors which cannot be predicted with confidence, including the duration of the outbreak and impact of variants. Any resurgence in COVID-19 could result in the imposition of new mandates and prolonged restrictive measures implemented in order to control the spread of the disease. The continued global spread of COVID-19 could adversely impact the Company&#8217;s operations, including, among other things, our manufacturing operations, supply chain, including third-party suppliers, sales and marketing and clinical trial operations. Any of these factors could adversely affect the Company&#8217;s business, financial results, and global economic conditions generally.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face uncertainties related to our COVID-19 vaccine, including uncertainties related to the risk that our continued development programs may not be successful, commercially viable or receive approval from regulatory authorities; risks associated with clinical trial and real-world data, including further analyses of its efficacy, safety and durability; the risk that data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by national immunization technical advisory groups (NITAGs) and regulatory authorities; disruptions in the relationships between us, our third-party suppliers and external manufacturers; the risk that other companies may produce superior or competitive products; the risk that demand for any products we may develop may no longer exist; risks related to the availability of raw materials to manufacture any such products; the risk that we may not be able to recoup costs associated with our R&amp;D and manufacturing efforts and risks associated with any changes in the way we approach or provide additional research funding for potential drug development related to COVID-19; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis, that we may continue to experience manufacturing delays once a manufacturing site is activated, or have access to logistics or supply channels commensurate with global demand for any potential approved vaccine or product candidate, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods indicated, and other challenges and risks associated with the pace of our vaccine development program; and pricing and access challenges for such products, including in the U.S.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, to the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section and those incorporated by reference herein, i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ncluding risks relating to the Company&#8217;s effective tax rate as a result of changes in consumption as well as changes in laws relating to supply of the Company&#8217;s products</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given that developments concerning the COVID-19 pandemic have been constantly evolving, additional impacts and risks may arise, including litigation, that are not presently known to the Company. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Government Regulation and Legal Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global sales in the Company&#8217;s Pharmaceutical and Medical Devices segments may be negatively impacted by healthcare reforms and increasing pricing pressures.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s Pharmaceutical and Medical Devices products are significantly affected by reimbursements by third-party payers such as government healthcare programs, private insurance plans and managed care organizations. As part of various efforts to contain healthcare costs, these payers are putting downward pressure on prices at which products will be reimbursed. In the U.S., increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, in part due to continued consolidation among healthcare providers, could result in further pricing pressures. In addition, increased political scrutiny could result in additional pricing pressures. Outside the U.S., numerous major markets, including the EU, United Kingdom, Japan and China, have pervasive government involvement in funding healthcare and, in that regard, directly or indirectly impose price controls, limit access to, or reimbursement for, the Company&#8217;s products, or reduce the value of its intellectual property protection.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational damage.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the ordinary course of business, Johnson &amp; Johnson and its subsidiaries are subject to numerous claims and lawsuits involving various issues such as product liability, patent disputes and claims that their product sales, marketing and pricing practices violate various antitrust, unfair trade practices and/or consumer protection laws. The Company&#8217;s more significant legal proceedings are described in Note 19, &#8220;Legal Proceedings&#8221; under Notes to the Consolidated Financial Statements included in Item 8 of this Report. Litigation, in general, and securities, derivative action, class action and multi-district litigation, in particular, can be expensive and disruptive. Some of these matters may include thousands of plaintiffs, may involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. For example, the Company is a defendant in numerous lawsuits arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Baby Powder, and the Company&#8217;s sale, manufacturing and marketing of opioids.</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While the Company believes it has substantial defenses in these matters, it is not feasible to predict the ultimate outcome of litigation. The Company could in the future be required to pay significant amounts as a result of settlements or judgments in these matters, potentially in excess of accruals, including matters where the Company could be held jointly and severally liable among other defendants. The resolution of, or increase in accruals for, one or more of these matters in any reporting period could have a material adverse effect on the Company&#8217;s results of operations and cash flows for that period. The Company does not purchase third-party product liability insurance; however, the Company utilizes a wholly owned captive insurance company subject to certain limits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Product reliability, safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concerns about product safety, whether raised internally or by litigants, regulators or consumer advocates, and whether or not based on scientific evidence, can result in safety alerts, product recalls, governmental investigations, regulatory action on the part of the U.S. Food and Drug Administration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(or its counterpart in other countries), private claims and lawsuits, payment of fines and settlements, declining sales and reputational damage. These circumstances can also result in damage to brand image, brand equity and consumer trust in the Company&#8217;s products. Product recalls have in the past, and could in the future, prompt government investigations and inspections, the shutdown of manufacturing facilities, continued product shortages and related sales declines, significant remediation costs, reputational damage, possible civil penalties and criminal prosecution. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company faces significant regulatory scrutiny, which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Like other companies in the healthcare industry, the Company is subject to extensive regulation, investigations and legal action by national, state and local government agencies in the U.S. and other countries in which it operates. Regulatory issues regarding compliance with current Good Manufacturing Practices (cGMP) (and comparable quality regulations in foreign countries) by manufacturers of drugs, devices and consumer products can lead to fines and penalties, product recalls, product shortages, interruptions in production, delays in new product approvals and litigation. In addition, the marketing, pricing and sale of the Company&#8217;s products are subject to regulation, investigations and legal actions including under the Federal Food, Drug, and Cosmetic Act, the Medicaid Rebate Program, federal and state false claims acts, state unfair trade practices acts and consumer protection laws. Scrutiny of healthcare industry business practices by government agencies and state attorneys general in the U.S., and any resulting investigations and prosecutions, carry risk of significant civil and criminal penalties including, but not limited to, debarment from participation in government healthcare programs. Any such debarment could have a material adverse effect on the Company&#8217;s business and results of operations. The most significant current investigations and litigation brought by government agencies are described in Note 19, &#8220;Legal Proceedings&#8212;Government Proceedings&#8221; under Notes to the Consolidated Financial Statements included in Item 8 of this Report. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company&#8217;s operating results.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in tax laws or regulations around the world, including in the U.S. and as led by the Organization for Economic Cooperation and Development, could negatively impact the Company&#8217;s effective tax rate and results of operations. A change in statutory tax rate or certain international tax provisions in any country would result in the revaluation of the Company&#8217;s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the Company&#8217;s Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to tax laws or regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;Income Taxes&#8221; under Notes to the Consolidated Financial Statements included in Item 8 of this Report for additional information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company conducts business and files tax returns in numerous countries and is addressing tax audits and disputes with many tax authorities. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. The Company regularly assesses the likely outcomes of its tax audits and disputes to determine the appropriateness of its tax reserves. However, any tax authority could take a position on tax treatment that is contrary to the Company&#8217;s expectations, which could result in tax liabilities in excess of reserves.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Intellectual Property </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company faces increased challenges to intellectual property rights central to its business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns or licenses a significant number of patents and other proprietary rights relating to its products and manufacturing processes. These rights are essential to the Company&#8217;s businesses and materially important to the Company&#8217;s results of operations. Public policy, both within and outside the U.S., has become increasingly unfavorable toward intellectual property rights. The Company cannot be certain that it will obtain adequate patent protection for new products and technologies in the United States and other important markets or that such protections, once granted, will last as long as originally anticipated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Competitors routinely challenge the validity or extent of the Company&#8217;s owned or licensed patents and proprietary rights through litigation, interferences, oppositions and other proceedings, such as inter partes review (IPR) proceedings before the United States Patent &amp; Trademark Office (USPTO). These proceedings absorb resources and can be protracted as well as unpredictable. In addition, challenges that the Company&#8217;s products infringe the patents of third parties could result in an injunction and/or the need to pay past damages and future royalties and adversely affect the competitive position and sales of the products in question. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has faced increasing patent challenges from third parties seeking to manufacture and market generic and biosimilar versions of the Company&#8217;s key pharmaceutical products prior to expiration of the applicable patents covering those products. In the U.S., manufacturers of generic versions of innovative human pharmaceutical products may challenge the validity, or claim non-infringement, of innovator products through the Abbreviated New Drug Application, or ANDA, process with the U.S. FDA and related ANDA litigation. The Biologics Price Competition and Innovation Act (BPCIA), enacted in 2010, which created a new regulatory pathway for the approval by the U.S. FDA of biosimilar alternatives to innovator-developed biological products, also created mechanisms for biosimilar applicants to challenge the patents on the innovator biologics. The IPR process with the USPTO is also being used by competitors to challenge patents asserted in litigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the Company is not successful in defending its patents against such challenges, or upon the &#8220;at-risk&#8221; launch by the generic or biosimilar firm of its product, the Company can lose a major portion of revenues for the referenced product in a very short period of time. Current legal proceedings involving the Company&#8217;s patents and other intellectual property rights are described in Note 19, &#8220;Legal Proceedings&#8212;Intellectual Property&#8221; under Notes to the Consolidated Financial Statements included in Item 8 of this Report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Product Development, Regulatory Approval and Commercialization</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant challenges or delays in the Company&#8217;s innovation and development of new products, technologies and indications could have an adverse impact on the Company&#8217;s long-term success.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s continued growth and success depends on its ability to innovate and develop new and differentiated products and services that address the evolving healthcare needs of patients, providers and consumers. Development of successful </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products and technologies is also necessary to offset revenue losses when the Company&#8217;s existing products lose market share due to various factors such as competition and loss of patent exclusivity. New products introduced within the past five years accounted for approximately 25% of 2021 sales. The Company cannot be certain when or whether it will be able to develop, license or otherwise acquire companies, products and technologies, whether particular product candidates will be granted regulatory approval, and, if approved, whether the products will be commercially successful.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company pursues product development through internal research and development as well as through collaborations, acquisitions, joint ventures and licensing or other arrangements with third parties. In all of these contexts, developing new products, particularly pharmaceutical and biotechnology products and medical devices, requires significant investment of resources over many years. Only a very few biopharmaceutical research and development programs result in commercially viable products. The process depends on many factors including the ability to: discern patients&#8217; and healthcare providers&#8217; future needs; develop promising new compounds, strategies and technologies; achieve successful clinical trial results; secure effective intellectual property protection; obtain regulatory approvals on a timely basis; and, if and when they reach the market, successfully differentiate the Company&#8217;s products from competing products and approaches to treatment. New products or enhancements to existing products may not be accepted quickly or significantly in the marketplace due to product and price competition, changes in customer preferences or healthcare purchasing patterns, resistance by healthcare providers or uncertainty over third-party reimbursement. Even following initial regulatory approval, the success of a product can be adversely impacted by safety and efficacy findings in larger real-world patient populations, as well as market entry of competitive products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Financial and Economic Market Conditions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company faces a variety of financial, economic, legal, social and political risks associated with conducting business internationally</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s extensive operations and business activity throughout the world are accompanied by certain financial, economic, legal, social and political risks, including those listed below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In fiscal 2021, approximately 50% of the Company&#8217;s sales occurred outside of the U.S., with approximately 25% in Europe, 6% in the Western Hemisphere, excluding the U.S., and 19%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Asia-Pacific and Africa region. Changes in non-U.S. currencies relative to the U.S. dollar impact the Company&#8217;s revenues and expenses. While the Company uses financial instruments to mitigate the impact of fluctuations in currency exchange rates on its cash flows, unhedged exposures continue to be subject to currency fluctuations. In addition, the weakening or strengthening of the U.S. dollar may result in significant favorable or unfavorable translation effects when the operating results of the Company&#8217;s non-U.S. business activity are translated into U.S. dollars. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflation and Currency Devaluation Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company faces challenges in maintaining profitability of operations in economies experiencing high inflation rates. The Company has accounted for operations in Argentina and Venezuela as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. While the Company strives to maintain profit margins in these areas through cost reduction programs, productivity improvements and periodic price increases, it might experience operating losses as a result of continued inflation. In addition, the impact of currency devaluations in countries experiencing high inflation rates or significant currency exchange fluctuations could negatively impact the Company&#8217;s operating results. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Illegal Importation of Pharmaceutical Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The illegal importation of pharmaceutical products from countries where government price controls or other market dynamics result in lower prices may adversely affect the Company&#8217;s sales and profitability in the U.S. and other countries in which the Company operates. With the exception of limited quantities of prescription drugs for personal use, foreign imports of pharmaceutical products are illegal under current U.S. law. However, the volume of illegal imports continues to rise as the ability of patients and other customers to obtain the lower-priced imports has grown significantly.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-Bribery and Other Regulations: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to various federal and foreign laws that govern its international business practices with respect to payments to government officials. Those laws include the U.S. Foreign Corrupt Practices Act (FCPA), which prohibits U.S. publicly traded companies from promising, offering, or giving anything of value to foreign officials with the corrupt intent of influencing the foreign official for the purpose of helping the Company obtain or retain business or gain any improper advantage. The Company&#8217;s business is heavily regulated and therefore involves significant interaction with foreign officials. Also, in many countries outside the U.S., the healthcare providers who prescribe human pharmaceuticals are employed by the government and the purchasers of human pharmaceuticals are government entities; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therefore, the Company&#8217;s interactions with these prescribers and purchasers are subject to regulation under the FCPA. In addition to the U.S. application and enforcement of the FCPA, various jurisdictions in which the Company operates have laws and regulations, including the U.K. Bribery Act 2010, aimed at preventing and penalizing corrupt and anticompetitive behavior. Enforcement activities under these laws could subject the Company to additional administrative and legal proceedings and actions, which could include claims for civil penalties, criminal sanctions, and administrative remedies, including exclusion from healthcare programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial, Economic, Legal, Social and Political Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Other risks inherent in conducting business globally include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">local and regional economic environments and policies in the markets that we serve, including interest rates, monetary policy, inflation, economic growth, recession, commodity prices, and currency controls or other limitations on the ability to expatriate cash; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">protective economic policies taken by governments, such as trade protection measures and import/export licensing requirements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">compliance with local regulations and laws including, in some countries, regulatory requirements restricting the Company&#8217;s ability to manufacture or sell its products in the relevant market; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">diminished protection of intellectual property and contractual rights in certain jurisdictions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">potential nationalization or expropriation of the Company&#8217;s foreign assets; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">political or social upheavals, economic instability, repression, or human rights issues; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">geopolitical events, including natural disasters, disruptions to markets due to war, armed conflict, terrorism, epidemics or pandemics.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to maintain a satisfactory credit rating could adversely affect our liquidity, capital position, borrowing costs and access to capital markets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently maintain investment grade credit ratings with Moody&#8217;s Investors Service and Standard &amp; Poor&#8217;s Ratings Services. Rating agencies routinely evaluate us, and their ratings of our long-term and short-term debt are based on a number of factors. Any downgrade of our credit ratings by a credit rating agency, whether as a result of our actions or factors which are beyond our control, can increase the cost of borrowing under any indebtedness we may incur, reduce market capacity for our commercial paper or require the posting of additional collateral under our derivative contracts. There can be no assurance that we will be able to maintain our credit ratings, and any additional actual or anticipated changes or downgrades in our credit ratings, including any announcement that our ratings are under review for a downgrade, may have a negative impact on our liquidity, capital position and access to capital markets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to the Planned Separation of our Consumer Health Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The planned separation of the Company&#8217;s Consumer Health business may not be completed on the terms or timeline currently contemplated, if at all, and may not achieve the expected results.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, the Company announced its intention to separate the Company&#8217;s Consumer Health business, with the intention to create a new, publicly traded company. The planned separation is intended to qualify as a tax-free transaction for U.S. federal income tax purposes. The Company is targeting completion of the planned separation in 18 to 24 months after initial announcement. Completion of the planned separation will be subject to the satisfaction of certain conditions, including, among others, consultations with works councils and other employee representative bodies, as required, final approval of the Company&#8217;s Board of Directors, receipt of a favorable opinion and Internal Revenue Service (&#8220;IRS&#8221;) ruling with respect to the tax-free nature of the transaction, and the receipt of other regulatory approvals. There can be no assurance regarding the ultimate timing of the planned separation or that such separation will be completed. Unanticipated developments could delay, prevent or otherwise adversely affect the planned separation, including but not limited to disruptions in general or financial market conditions or potential problems or delays in obtaining various regulatory and tax approvals or clearances.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The costs to complete the planned separation will be significant. In addition, the Company may be unable to achieve some or all of the strategic and financial benefits that it expects to achieve from the planned separation of the Company&#8217;s Consumer Health business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company will incur significant expenses in connection with the planned separation. In addition, the Company may not be able to achieve the full strategic and financial benefits that are expected to result from the planned separation. The anticipated benefits of the planned separation are based on a number of assumptions, some of which may prove incorrect.</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Following the planned separation, the price of shares of the Company&#8217;s common stock may fluctuate significantly.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company cannot predict the effect of the planned separation on the trading price of shares of its common stock, and the market value of shares of its common stock may be less than, equal to or greater than the market value of shares of its common stock prior to the planned separation. In addition, the price of the Company&#8217;s common stock may be more volatile around the time of the planned separation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The planned separation could result in substantial tax liability.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company intends to obtain an opinion from its U.S. tax advisors and a ruling from the IRS as to the tax-free nature of the planned separation under the U.S. Internal Revenue Code of 1986, as amended. The opinion and ruling will be based on, among other things, various factual assumptions and representations that the Company and the New Consumer Health Company will make regarding the past and future conduct of the companies&#8217; respective businesses and other matters. If any of these assumptions or representations are, or become, inaccurate or incomplete, reliance on the opinion and ruling may be jeopardized. If subsequent to the planned separation it is determined that the transaction does not qualify for tax-free treatment for U.S. federal income tax purposes, the resulting tax liability to the Company and its shareholders could be substantial.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The planned separation may also not qualify for tax-free treatment in other countries around the world, and as a result may trigger substantial tax liability to the Company.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Risks </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business depends on our ability to recruit and retain talented, highly skilled employees and a diverse workforce. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our continued growth requires us to recruit and retain talented employees representing diverse backgrounds, experiences, and skill sets. The market for highly skilled workers and leaders in our industry is extremely competitive and our ability to compete depends on our ability to hire, develop and motivate highly skilled personnel in all areas of our organization. Maintaining our brand and reputation, as well as a diverse, equitable and inclusive work environment enables us to attract top talent. If we are less successful in our recruiting efforts, or if we cannot retain highly skilled workers and key leaders, our ability to develop and deliver successful products and services may be adversely affected. In addition, effective succession planning is important to our long-term success. Any unsuccessful implementation of our succession plans or failure to ensure effective transfer of knowledge and smooth transitions involving key employees could</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adversely affect our business, financial condition, or results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Climate change resulting from increased concentrations of carbon dioxide and other greenhouse gases in the atmosphere could present risks to our operations, including an adverse impact on global temperatures, weather patterns and the frequency and severity of extreme weather and natural disasters. Natural disasters and extreme weather conditions, such as a hurricane, tornado, earthquake, wildfire or flooding, may pose physical risks to our facilities and disrupt the operation of our supply chain. The impacts of the changing climate on water resources may result in water scarcity, limiting our ability to access sufficient high-quality water in certain locations, which may increase operational costs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concern over climate change may also result in new or additional legal or regulatory requirements designed to reduce greenhouse gas emissions and/or mitigate the effects of climate change on the environment. If such laws or regulations are more stringent than current legal or regulatory obligations, we may experience disruption in, or an increase in the costs associated with sourcing, manufacturing and distribution of our products, which may adversely affect our business, results of operations or financial condition. Further, the impacts of climate change have an influence on customer preferences, and failure to provide climate-friendly products could potentially result in loss of market share.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An information security incident, including a cybersecurity breach, could have a negative impact to the Company&#8217;s business or reputation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet business objectives, the Company relies on both internal information technology (IT) systems and networks, and those of third parties and their vendors, to process and store sensitive data, including confidential research, business plans, financial information, intellectual property, and personal data that may be subject to legal protection, and ensure the continuity of the Company&#8217;s supply chain. The extensive information security and cybersecurity threats, which affect companies globally, pose a risk to the security and availability of these systems and networks, and the confidentiality, integrity, and availability of the Company&#8217;s sensitive data. The Company continually assesses these threats and makes investments to increase internal protection, detection, and response capabilities, as well as ensure the Company&#8217;s third-party providers have required capabilities and controls, to address this risk</span><span style="color:#00b050;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not experienced any material impact to the business or operations resulting from information or cybersecurity attacks; however, because of the frequently changing attack techniques, along with the increased volume and sophistication of the attacks, there is the potential for the Company to be adversely </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impacted. This impact could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action. The Company maintains cybersecurity insurance in the event of an information security or cyber incident; however, the coverage may not be sufficient to cover all financial, legal, business or reputational losses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">A breach of privacy laws or unauthorized access, loss or misuse of personal data could have a negative impact to the Company&#8217;s business or reputation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is subject to privacy and data protection laws across the globe that impose broad compliance obligations on the collection, use, storage, access, transfer and protection of personal data. Breach of such requirements could result in substantial fines, penalties, private right of actions, claims and damage to our reputation and business. New privacy laws are expected in other territories, together with greater privacy enforcement by governmental authorities globally, particularly on data localization requirements and international data flows. The Company has established privacy compliance programs and controls that our businesses worldwide are required to comply with, but with many technology and data-driven initiatives being prioritized across the Company and involving multiple vendors and third parties, there are potential risks of controls imposed on cross border data flows, unauthorized access, and loss of personal data through internal and external threats that could impact our business operations and research activities. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:36pt;text-indent:18pt"><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_58"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.36pt">UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Not applicable.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_61"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.02pt">PROPERTIES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's subsidiaries operate 85 manufacturing facilities occupying approximately 15.0&#160;million square feet of floor space. The manufacturing facilities are used by the industry segments of the Company&#8217;s business approximately as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:81.916%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Segment</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Square Feet<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,987&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Within the U.S., four facilities are used by the Consumer Health segment, five by the Pharmaceutical segment and 17 by the Medical Devices segment. Outside of the U.S., 23 facilities are used by the Consumer Health segment, 13 by the Pharmaceutical segment and 23 by the Medical Devices segment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The locations of the manufacturing facilities by major geographic areas of the world are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Geographic Area</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Facilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Square Feet<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,233&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Africa, Asia and Pacific</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,987&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition to the manufacturing facilities discussed above, the Company maintains numerous office and warehouse facilities throughout the world. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's subsidiaries generally seek to own, rather than lease, their manufacturing facilities, although some, principally in non-U.S. locations, are leased. Office and warehouse facilities are often leased. The Company also engages contract manufacturers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company is committed to maintaining all of its properties in good operating condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;McNEIL-PPC, Inc. (now Johnson &amp; Johnson Consumer Inc.) (McNEIL-PPC) operated under a consent decree, signed in 2011 with the U.S. FDA, which governed certain McNeil Consumer Healthcare manufacturing operations, and required McNEIL-PPC to remediate the facilities it operates in Lancaster, Pennsylvania, Fort Washington, Pennsylvania, and Las Piedras, Puerto Rico (the &#8220;Consent Decree&#8221;). Following U.S. FDA inspections McNEIL-PPC received notifications from the U.S FDA that all three manufacturing facilities were in conformity with applicable laws and regulations, and commercial production restarted in 2015. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">            Under the Consent Decree, after receiving notice from the U.S. FDA of being in compliance with applicable laws and regulations, each of the three facilities was subject to a five-year audit period by a third-party cGMP expert. A third-party expert continued to reassess the sites at various times through 2020. U.S. FDA inspections of the facilities which have been delayed due to COVID-19 were completed and the Consent Decree was vacated in July of 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;Segment information on additions to property, plant and equipment is contained in Note&#160;17 &#8220;Segments of Business and Geographic Areas&#8221; of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:54pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to the information set forth in Note&#160;19 &#8220;Legal Proceedings&#8221; of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_67"></div><div style="padding-left:54pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.52pt">MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_70"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE OFFICERS OF THE REGISTRANT</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Listed below are the executive officers of the Company. There are no family relationships between any of the executive officers, and there is no arrangement or understanding between any executive officer and any other person pursuant to which the executive officer was selected. At the annual meeting of the Board of Directors, the executive officers are elected by the Board to hold office for one year and until their respective successors are elected and qualified, or until earlier resignation or removal.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with regard to the directors of the Company is incorporated herein by reference to the material captioned &#8220;Item 1. Election of Directors&#8221; in the Proxy Statement.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:33.701%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Position</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vanessa Broadhurst</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Global Corporate Affairs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joaquin Duato</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer; Chairman, Executive Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter M. Fasolo, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Chief Human Resources Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William N. Hait, M.D., Ph. D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Chief External Innovation, Medical Safety and Global Public Health Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mathai Mammen, Ph. D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Pharmaceuticals, R&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ashley McEvoy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Worldwide Chairman, Medical Devices</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thibaut Mongon</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee, Executive Vice President, Worldwide Chairman, Consumer Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Swanson</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Chief Information Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer L. Taubert</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Worldwide Chairman, Pharmaceuticals</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael H. Ullmann</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, General Counsel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(j)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn E. Wengel</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Chief Global Supply Chain Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(k)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Chief Financial Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(l)</span></div></td></tr></table></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Ms. V. Broadhurst joined the Company in 2005 as Worldwide Vice President, Anemia &amp; Oncology Supportive Care. She then went on to become Vice President of the Cardiovascular &amp; Institutional Franchise in 2008, and President of Janssen Therapeutics in 2011 before becoming U.S. President, Internal Medicine in 2012. From 2013 to 2017, she held General Manager roles at Amgen in Inflammation &amp; Cardiovascular, and Cardiovascular &amp; Bone. In 2017, Ms. Broadhurst rejoined Johnson &amp; Johnson as U.S. President, Cardiovascular &amp; Metabolism and a member of the Janssen Americas Leadership Team. In this role she also provided operational oversight of the full portfolio of Janssen medicines in Puerto Rico and Canada. In 2018, she was appointed Company Group Chairman, Global Commercial Strategy Organization. In 2022, Ms. Broadhurst was named Executive Vice President, Global Corporate Affairs and a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">member of the Executive Committee, leading the Company's global marketing, communication, design and philanthropy functions.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Mr. J. Duato became Chief Executive Officer and Chairman of the Executive Committee and joined the Board of Directors in January 2022. He joined the Company in 1989 with Janssen-Farmaceutica S.A. (Spain), a subsidiary of the Company, and held executive positions of increasing responsibility in all business sectors and across multiple geographies and functions. In 2009, he was named Company Group Chairman, Pharmaceuticals, and in 2011, he was named Worldwide Chairman, Pharmaceuticals. In 2016, Mr. Duato became a member of the Executive Committee and was named Executive Vice President, Worldwide Chairman, Pharmaceuticals. In July 2018, Mr. Duato was promoted to Vice Chairman of the Executive Committee, where he provided strategic direction for the Pharmaceutical and Consumer Health sectors and oversaw both the Global Supply Chain, Information Technology and Health &amp; Wellness teams.  As a dual citizen of Spain and the United States, Mr. Duato's international perspective and global lens gives him a deep appreciation of diverse thoughts and opinions.  </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Dr.&#160;P. M. Fasolo joined the Company in 2004 as Worldwide Vice President, Human Resources in the Medical Devices segment, and subsequently served as the Company&#8217;s Chief Talent Officer. He left Johnson &amp; Johnson in 2007 to join Kohlberg Kravis Roberts &amp; Co. as Chief Talent Officer. Dr. Fasolo returned to the Company in 2010 as the Vice President, Global Human Resources, and in 2011, he became a member of the Executive Committee. In April 2016, he was named Executive Vice President, Chief Human Resources Officer. Dr. Fasolo has responsibility for global talent, recruiting, diversity, compensation benefits, employee relations and all aspects of the human resources agenda for the Company. He also serves on the Boards of the Human Resources Policy Association, Tufts University and Save the Children and was named a Fellow of the National Academy of Human Resources in 2017.  </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Dr. W. Hait joined the Company in 2007 as Senior Vice President, Worldwide Head of Oncology Research. He then served as the first Global Therapeutic Area Head for Oncology from 2009 to 2011, and then as Global Head, Janssen Research &amp; Development from 2011 through 2018. From 2018 to 2022, he was Global Head, Johnson &amp; Johnson Global External Innovation. In 2022, he became Executive Vice President, Chief External Innovation, Medical Safety and Global Public Health Officer, and a member of the Executive Committee. He is responsible for leading external sourcing and creation of transformational innovation to help Johnson &amp; Johnson achieve its mission to improve human health utilizing the Company&#8217;s excellence in pharmaceuticals, medical devices and consumer products. He also has oversight over Global Public Health and the Office of the Chief Medical Officer.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Dr. M. Mammen joined the Company in 2017 as Global Head of R&amp;D at the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. Prior to joining Janssen in June 2017, Dr. Mammen was Senior Vice President at Merck Research Laboratories, responsible for research in the areas of Cardiovascular, Metabolic and Renal Diseases, Oncology/lmmuno-Oncology and Immunology. Prior to Merck, he led R&amp;D at Theravance, a company he co-founded in the San Francisco Bay Area in 1997 based on his work at Harvard University. In 2022, he was named as Executive Vice President, Pharmaceuticals R&amp;D, and a member of the Executive Committee. He is responsible for a team whose mission is to make transformational medicines with unequivocal benefit for patients worldwide, working across a wide range of therapeutic areas and biological pathways in the areas of: Oncology, Cardiovascular and Metabolic Disease, Retinal Disease, Pulmonary Hypertension, Immunology, Neuroscience and Infectious Disease and Vaccines. These Therapeutic Areas are fueled by world-class Global Functions in Discovery Sciences and Manufacturing, Regulatory Affairs, Development Operations and Data Science.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">Ms. A. McEvoy joined the Company in 1996 as Assistant Brand Manager of McNeil Consumer Health, a subsidiary of the Company, advancing through positions of increasing responsibilities until she was appointed Company Group Chairman, Vision Care in 2012, followed by Company Group Chairman, Consumer Medical Devices in 2014. In July 2018, Ms. McEvoy was promoted to Executive Vice President, Worldwide Chairman, Medical Devices, and became a member of the Executive Committee. Ms. McEvoy has responsibility for the surgery, orthopaedics, interventional solutions and eye health businesses across Ethicon, DePuy Synthes, Biosense Webster and Johnson &amp; Johnson Vision.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.18pt">Mr. T. Mongon joined the Company in 2000 as Director of Marketing for the Vision Care group in France and subsequently held positions of increasing responsibility until he transitioned to the Pharmaceutical sector in 2012, as the Global Commercial Strategy Leader for the Neuroscience therapeutic area. In 2014, he joined the Consumer Health sector as Company Group Chairman Asia-Pacific. In 2019, he was promoted to Executive Vice President and Worldwide Chairman, Consumer Health, and became a member of the Executive Committee. Mr. Mongon has responsibility for  the global development of Johnson &amp; Johnson&#8217;s health and wellness products and solutions in beauty, OTC, oral care, baby care, women&#8217;s health, and wound care.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Mr. J. Swanson rejoined the Company in 2019 as Chief Information Officer of Johnson &amp; Johnson from Bayer Crop Science, where he served as a member of the Executive Leadership Team and as CIO and Head of Digital Transformation. From 1996 to 2005, Mr. Swanson held positions of increasing responsibility at the Company, including Project Manager, Director IT, Sr. Director IT and Vice President, Chief Information Officer. Mr. Swanson is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">responsible for enhancing Johnson &amp; Johnson&#8217;s business impact and shaping its direction through the strategic use of technology. Mr. Swanson, Executive Vice President, Chief Information Officer, joined the Executive Committee effective January 3, 2022.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Ms. J. L. Taubert joined the Company in 2005 as Worldwide Vice President, and she held several executive positions of increasing responsibility in the Pharmaceutical sector. In 2012, she was appointed Company Group Chairman, North America Pharmaceuticals, and in 2015 became Company Group Chairman, The Americas, Pharmaceuticals. In July 2018, Ms. Taubert was promoted to Executive Vice President, Worldwide Chairman, Pharmaceuticals, and became a member of the Executive Committee. Ms. Taubert is responsible for the Pharmaceutical sector globally, including shaping the company&#8217;s strategy of transformational medical innovation and for successfully bringing to market critical new medicines that significantly improve the lives of patients living with cancer, immune-related diseases, cardiovascular disease, infectious diseases, pulmonary hypertension and serious mental illness. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Mr. M. H. Ullmann joined the Company in 1989 as a corporate attorney in the Law Department.&#160;He was appointed Corporate Secretary in 1998 and served in that role until 2006.&#160; During that time, he also held various management positions in the Law Department.&#160; In 2006, he was named General Counsel, Medical Devices and Diagnostics and was appointed Vice President, General Counsel and became a member of the Executive Committee in 2012. In April 2016, Mr. Ullmann was named Executive Vice President, General Counsel. Mr. Ullmann has worldwide responsibility for legal, government affairs &amp; policy, global security, aviation, healthcare compliance, global brand protection and privacy.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Ms. K. E. Wengel joined the Company in 1988 as Project Engineer and Engineering Supervisor at Janssen, a subsidiary of the Company. During her tenure with the Company, she has held a variety of strategic leadership and executive positions across the global enterprise, in roles within operations, quality, engineering, new products, information technology, and other technical and business functions. In 2010, Ms. Wengel became the first Chief Quality Officer of the Company. In 2014, she was promoted to Vice President, Johnson &amp; Johnson Supply Chain. In July 2018, she was promoted to Executive Vice President, Chief Global Supply Chain Officer, and became a member of the Executive Committee. Ms. Wengel has enterprise-wide responsibilities for Supply Chain, Quality &amp; Compliance, Procurement, Engineering &amp; Property Services, Environmental Health &amp; Safety and Sustainability.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(l)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Mr. J. J. Wolk joined the Company in 1998 as Finance Manager, Business Development for Ortho-McNeil, a subsidiary of the Company, and through the years held a variety of senior leadership roles in several segments and functions across the Company's subsidiaries, in Pharmaceuticals, Medical Devices and Supply Chain. From 2014 to 2016, he served as Vice President, Finance and Chief Financial Officer of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. In 2016, Mr. Wolk became the Vice President, Investor Relations. In July 2018, he was appointed Executive Vice President, Chief Financial Officer and became a member of the Executive Committee. Mr. Wolk plays a strategic role in the overall management of the Company, and leads the development and execution of the Company's global long-term financial strategy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_76"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of February 10, 2022, there were 127,899 record holders of common stock of the Company. Additional information called for by this item is incorporated herein by reference to the following sections of this Report: Note&#160;16 &#8220;Common Stock, Stock Option Plans and Stock Compensation Agreements&#8221; of the Notes to Consolidated Financial Statements included in Item 8; and Item&#160;12 &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#160;&#8211; Equity Compensation Plan Information.&#8221;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities  </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information with respect to common stock purchases by the Company during the fiscal fourth quarter of 2021. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company&#8217;s compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal fourth quarter.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:42.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.936%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Shares Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Avg. Price<br/>Paid Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 4, 2021 through October 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2021 through November 28, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 29, 2021 through January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,391,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;During the fiscal fourth quarter of 2021, the Company repurchased an aggregate of 6,041,024 shares of Johnson &amp; Johnson Common Stock in open-market transactions, all of which were purchased in open-market transactions as part of a systematic plan to meet the needs of the Company&#8217;s compensation programs.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Reserved</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_88"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and Business Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Description of the Company and Business Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson&#160;&amp; Johnson and its subsidiaries (the Company) have approximately 141,700&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world with the primary focus on products related to human health and well-being.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is organized into three business segments: Consumer Health, Pharmaceutical and Medical Devices. The Consumer Health segment includes a broad range of products used in the Baby Care, Oral Care, Skin Health/Beauty, Over-the-Counter pharmaceutical, Women&#8217;s Health and Wound Care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on six therapeutic areas, including Immunology, Infectious diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The Medical Devices segment includes a broad range of products used in the Orthopaedic, Surgery, Interventional Solutions (cardiovascular and neurovascular) and Vision fields.  These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Executive Committee of Johnson&#160;&amp; Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company. This Committee oversees and coordinates the activities of the Consumer Health, Pharmaceutical and Medical Devices business segments.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In all of its product lines, the Company competes with other companies both locally and globally, throughout the world. Competition exists in all product lines without regard to the number and size of the competing companies involved. Competition in research, involving the development and the improvement of new and existing products and processes, is particularly significant. The development of new and innovative products, as well as protecting the underlying intellectual property of the Company's product portfolio, is important to the Company&#8217;s success in all areas of its business. The competitive environment requires substantial investments in continuing research. In addition, the development and maintenance of customer demand for the Company&#8217;s consumer products involves significant expenditures for advertising and promotion.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Objectives </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With &#8220;Our Credo&#8221; as the foundation, the Company&#8217;s purpose is to blend heart, science and ingenuity to profoundly change the trajectory of health for humanity. The Company is committed to bringing its full breadth and depth to ensure health for people today and for future generations. United around this common ambition, the Company is poised to fulfill its purpose and successfully meet the demands of the rapidly evolving markets in which it competes. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is broadly based in human healthcare, and is committed to creating value by developing accessible, high quality, innovative products and services. New products introduced within the past five years accounted for approximately 25% of 2021 sales. In 2021, $14.7 billion was invested in research and development reflecting management&#8217;s commitment to create life-enhancing innovations and to create value through partnerships that will profoundly change the trajectory of health for humanity. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A critical driver of the Company&#8217;s success is the diversity of its 141,700 employees worldwide. Employees are empowered and inspired to lead with the Company&#8217;s Our Credo and purpose as guides. This allows every employee to use the Company&#8217;s reach and size to advance the Company's purpose, and to also lead with agility and urgency. Leveraging the extensive resources across the enterprise enables the Company to innovate and execute with excellence. This ensures the Company can remain focused on addressing the unmet needs of society every day and invest for an enduring impact, ultimately delivering value to its patients, consumers and healthcare professionals, employees, communities and shareholders.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:center"><img src="jnj-20220102_g2.jpg" alt="jnj-20220102_g2.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:180px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><img src="jnj-20220102_g3.jpg" alt="jnj-20220102_g3.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:180px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><img src="jnj-20220102_g4.jpg" alt="jnj-20220102_g4.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:181px"/></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Analysis of Consolidated Sales</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For discussion on results of operations and financial condition pertaining to the fiscal years 2020 and 2019 see the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021, Item 7. Management's Discussion and Analysis of Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, worldwide sales increased 13.6% to $93.8&#160;billion as compared to an increase of 0.6% in 2020. These sales changes consisted of the following:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"></td><td style="width:62.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.028%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sales increase/(decrease) due to:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volume</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net impact of acquisitions and divestitures on the worldwide sales growth was a negative impact of 0.6% in 2021 and a negative impact of 0.3% in 2020. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales by U.S.&#160;companies were $47.2&#160;billion in 2021 and $43.1&#160;billion in 2020. This represents increases of 9.3% in 2021 and 2.5% in 2020. Sales by international companies were $46.6&#160;billion in 2021 and $39.5&#160;billion in 2020. This represents an increase of 18.2% in 2021 and a decrease of 1.3% in 2020.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The five-year compound annual growth rates for worldwide, U.S.&#160;and international sales were 5.5%, 4.5% and 6.5%, respectively. The ten-year compound annual growth rates for worldwide, U.S.&#160;and international sales were 3.7%, 5.0% and 2.6%, respectively.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, sales by companies in Europe achieved growth of 24.3% as compared to the prior year, which included operational growth of 20.7% and a positive currency impact of 3.6%. Sales by companies in the Western Hemisphere (excluding the U.S.) achieved growth of 7.8% as compared to the prior year, which included operational growth of 7.3% and a positive currency impact of 0.5%. Sales by companies in the Asia-Pacific, Africa region achieved growth of 14.1% as compared to the prior year, including operational growth of 11.4% and a positive currency impact of 2.7%.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company estimated that the inclusion of a 53rd week in the fiscal year 2020 results negatively impacted the 2021 comparative sales growth by approximately 1.0%. (See Note 1 to the Consolidated Financial Statements for Annual Closing Date details). While the additional week added a few days to sales, it also added a full week's worth of operating costs; therefore, the net earnings impact was negligible.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company utilized three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0% and 11.0% of the total consolidated revenues. In 2020, the Company had three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0% and 12.0% of the total consolidated revenues. </span></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><img src="jnj-20220102_g5.jpg" alt="jnj-20220102_g5.jpg" style="height:269px;margin-bottom:5pt;vertical-align:text-bottom;width:350px"/><img src="jnj-20220102_g6.jpg" alt="jnj-20220102_g6.jpg" style="height:269px;margin-bottom:5pt;vertical-align:text-bottom;width:320px"/></div><div><span><br/></span></div><div style="padding-left:180pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: values may have been rounded</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                               </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Analysis of Sales by Business Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer Health segment sales in 2021 were $14.6 billion, an increase of 4.1% from 2020, which included 2.8% operational growth and a positive currency impact of 1.3%.  U.S.&#160;Consumer Health segment sales were $6.5 billion, an increase of 2.4%. International sales were $8.1 billion, an increase of 5.6%, which included 3.1% operational growth and a positive currency impact of 2.5%. In 2021, acquisitions and divestitures had a net negative impact of 1.0% on the operational sales growth of the worldwide Consumer Health segment. </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Consumer Health Franchise Sales:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:51.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8217;21 vs. &#8217;20</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Consumer Health  Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,635</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,053</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OTC franchise sales of $5.2 billion increased 8.4% as compared to the prior year. Growth was primarily attributable to Analgesics, TYLENOL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MOTRIN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, digestive health and the hydration benefit offering (ORSL).</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Skin Health/Beauty franchise sales of $4.5 billion increased 2.0% as compared to the prior year. Growth was primarily due to COVID-19 recovery, strong performance of NEUTROGENA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and AVEENO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and eCommerce acceleration partially offset by the divestiture of DR. CI:LABO - Sedona business in Asia Pacific and external supply constraints. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oral Care franchise sales of $1.6 billion increased 0.2% as compared to the prior year. Market growth in the U.S. along with strong performance in the Asia Pacific region due to successful brand building and promotional campaigns and the positive impact of currency offset the negative impact of the floss divestiture and U.S. external supply constraints. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Baby Care franchise sales of $1.6 billion increased 3.2% compared to the prior year. Growth was driven by AVEENO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Asia Pacific eCommerce strength, innovation and COVID-19 recovery.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Women&#8217;s Health franchise sales of $0.9 billion increased 1.8% as compared to the prior year primarily driven by COVID-19 market recovery, favorable price and strong brand building in Asia Pacific partially offset by disruptions in Europe due to flooding.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Wound Care/Other franchise sales of $0.7 billion increased 2.6% as compared to the prior year. Growth was due to strong performance of BAND-AID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Brand Adhesive Bandages in the U.S. partially offset by product discontinuations and competitive pressures in Asia Pacific.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company announced its intention to separate the Company&#8217;s Consumer Health business, with the intention to create a new, publicly traded company. The Company is targeting completion of the planned separation in 18 to 24 months after initial announcement.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment sales in 2021 were $52.1 billion, an increase of 14.3% from 2020, which included operational growth of 13.1% and a positive currency impact of 1.2%.  U.S.&#160;sales were $28.0 billion, an increase of 8.6%. International sales were $24.1 billion, an increase of 21.6%, which included 18.8% operational growth and a positive currency impact of 2.8%. In 2021, acquisitions and divestitures had a net negative impact of 0.5% on the operational sales growth of the worldwide Pharmaceutical segment. Adjustments to previous sales reserve estimates were approximately $0.7 billion and $0.6 billion in fiscal years 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Pharmaceutical Therapeutic Area Sales*:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:57.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.801%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.204%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8217;21 vs. &#8217;20</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,055</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;SIMPONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,861</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,574</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;COVID-19 VACCINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;EDURANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/ PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,011</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,548</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/methylphenidate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,548</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,367</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> /abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Pulmonary Hypertension </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,450</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,148</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,460</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,878</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Pharmaceutical Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52,080</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,572</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of VELCADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunology products achieved sales of $16.8 billion in 2021, representing an increase of 11.3% as compared to the prior year driven by strong uptake of STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ustekinumab) in Crohn's disease and Ulcerative Colitis and strength in TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(guselkumab) in Psoriasis and uptake in Psoriatic Arthritis. This was partially offset by lower sales of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(infliximab) due to biosimilar competition.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilar versions of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been introduced in the United States and certain markets outside the United States and additional competitors continue to enter the market. Continued infliximab biosimilar competition will result in a further reduction in sales of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The latest expiring United States patent for STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ustekinumab) will expire in September 2023. STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ustekinumab) U.S. sales in fiscal 2021 were approximately $5.9 billion. The expiration of a product patent or loss of market exclusivity is likely to result in a reduction in sales.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infectious disease products achieved sales of $5.9 billion in 2021, representing an increase of 64.0% as compared to the prior year. Growth was primarily driven by the contribution of the COVID-19 vaccine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This was partially offset by lower sales of PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (darunavir/cobicistat) due to increased competition and loss of exclusivity of PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in certain countries outside the U.S.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuroscience products achieved sales of $7.0 billion, representing an increase of 7.1% as compared to the prior year. Paliperidone long-acting injectables growth was driven by sales of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (paliperidone palmitate) and INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from new patient starts and persistence as well as the launch of INVEGA HAFYERA&#8482;. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology products achieved sales of $14.5 billion in 2021, representing an increase of 17.6% as compared to the prior year. Contributors to the growth were strong sales of DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (daratumumab) driven by continued strong market growth, share gains in all regions and solid uptake of the subcutaneous formulation launched in 2020; the continued global launch uptake of ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (apalutamide) and IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ibrutinib) growth primarily driven by market and continued share leadership. The growth of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ibrutinib) was partially offset by competitive pressures from novel oral agents and COVID-19 related market dynamics including delays in new patient starts.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pulmonary Hypertension products achieved sales of $3.5 billion, representing an increase of 9.6% as compared to the prior year. Sales growth of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (macitentan) and UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (selexipag) were due to continued share gains and market growth.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiovascular/Metabolism/Other products sales were $4.5 billion, a decline of 8.6% as compared to the prior year. The decline was primarily attributable to lower sales of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (canagliflozin) due to share erosion and PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/ EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(epoetin alfa) due to biosimilar competition.  </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company advanced its pipeline with several regulatory submissions and approvals for new drugs and additional indications for existing drugs as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product Name          (Chemical Name)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US  Approval</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EU  Approval</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US Filing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EU Filing</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BYANNLI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maintenance Treatment of Schizophrenia in Adults</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABENUVA (rilpivirine and cabotegravir)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HIV treatment for use every two months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 Vaccine </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 Emergency Use</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 Vaccine Booster Shot</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 Emergency Use</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(daratumumab)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subcutaneous (SC) formulation Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis and Gains an Additional Approval in Pre-Treated Multiple Myeloma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DARZALEX FASPRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (daratumumab and hyaluronidase-fihj)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INVEGA HAFYERA (paliperidone palmitate)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First and Only Twice-Yearly Treatment for Adults with Schizophrenia</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PONVORY (Ponesimod)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PONVORY (Ponesimod)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral Treatment for Adults with Relapsing Multiple Sclerosis </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RYBREVANT (amivantamab-vmjw)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SPRAVATO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (esketamine)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rapid reduction of depressive symptoms in a psychiatric emergency for patients with major depressive disorder</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (ustekinumab)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of Pediatric Patients with Juvenille Psoriatic Arthritis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teclistamab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of Patients with Relapsed or Refractory Multiple Myeloma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(selexipag)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH)<br/></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (rivaroxaban)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Help Prevent and Treat Blood Clots in Pediatric Patients<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (rivaroxaban)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expanded Peripheral Artery Disease (PAD) Indication to Include Patients After Lower-Extremity Revascularization (LER)<br/></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical Devices Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medical Devices segment sales in 2021 were $27.1 billion, an increase of 17.9% from 2020, which included operational growth of 16.2% and a positive currency impact of 1.7%. U.S.&#160;sales were $12.7 billion, an increase of 14.9% as compared to the prior year. International sales were $14.4 billion, an increase of 20.6% as compared to the prior year, which included operational growth of 17.3% and a positive currency impact of 3.3%. In 2021, the net impact of acquisitions and divestitures on the Medical Devices segment worldwide operational sales growth was a negative 0.6% primarily due to the divestiture of Advanced Sterilization Products (ASP). The Company has seen a market recovery in global procedural volumes in the Medical Devices segment as compared to the prior year which had significant negative impacts from COVID-19. This procedural volume recovery is the primary driver of sales and earnings growth as compared to the prior year. </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Medical Devices Franchise Sales:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:53.403%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.344%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8217;21 vs. &#8217;20</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,812</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,232</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Advanced</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;General</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,588</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,763</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Hips</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Knees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trauma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Spine, Sports &amp; Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,688</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,919</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contact Lenses/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Surgical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,971</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medical Devices Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,060</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,959</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Surgery franchise achieved sales of $9.8 billion in 2021 representing an increase of 19.2% from 2020. The growth in Advanced Surgery was primarily driven by Endocutter, Biosurgery and Energy products attributable to market recovery, market expansion and the success of new products offsetting competitive pressures in the U.S. The growth in General Surgery was primarily driven by market recovery and the continued strength of the suture portfolio partially offset by the impact of the ASP divestiture in the prior year.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Orthopaedics franchise achieved sales of $8.6 billion in 2021, representing an increase of 10.6% from 2020. The growth in hips reflects the market recovery combined with continued strength of the portfolio including the ACTIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> stem and enabling technologies &#8211; KINCISE&#8482; and VELYS&#8482; Hip Navigation. The growth in knees was primarily driven by procedure recovery and new product introductions. The growth in Trauma was driven by global market recovery and uptake of new products. The growth in Spine, Sports &amp; Other was primarily driven by procedure recovery and new product introductions.    </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Vision franchise achieved sales of $4.7 billion in 2021, representing an increase of 19.6% from 2020. The Contact Lenses/Other operational growth was due to market recovery and market share gains from new products. Surgical Vision operational growth was primarily due to market recovery and uptake of recently launched products.   </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Interventional Solutions franchise achieved sales of $4.0 billion in 2021, an increase of 30.4% from 2020. Growth in the electrophysiology and stroke businesses were driven by market recovery and success of new products and commercial strategies. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in the fiscal first quarter of 2022, the Medical Devices segment will be referred to as the MedTech segment.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Analysis of Consolidated Earnings Before Provision for Taxes on Income</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated earnings before provision for taxes on income was $22.8 billion and $16.5 billion for the years 2021 and 2020, respectively. As a percent to sales, consolidated earnings before provision for taxes on income was 24.3% and 20.0%, in 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div style="text-align:center"><img src="jnj-20220102_g7.jpg" alt="jnj-20220102_g7.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:350px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Products Sold and Selling, Marketing and Administrative Expenses:</span></div><div><span><br/></span></div><div style="text-align:center"><img src="jnj-20220102_g8.jpg" alt="jnj-20220102_g8.jpg" style="height:201px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/><img src="jnj-20220102_g9.jpg" alt="jnj-20220102_g9.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold decreased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">Non-recurring prior year COVID-19 production related slow-downs and related inventory impacts</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Fixed cost deleveraging in the Medical Devices business in the fiscal 2020</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Favorable mix within the Pharmaceutical business as well as at the enterprise level with a higher percentage of sales coming from the Pharmaceutical business</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Supply chain efficiencies in the Consumer Health segment </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The intangible asset amortization expense included in cost of products sold was $4.7 billion for both fiscal years 2021 and 2020.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, Marketing and Administrative Expenses decreased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Leveraging in the Medical Devices business resulting from the recovery of sales from the prior years impact of COVID-19</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased brand marketing expenses in the Consumer Health business</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Research and Development Expense: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense by segment of business was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:47.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.868%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Sales*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Sales*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,714&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,159&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent increase/(decrease) over the prior year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*As a percent to segment sales </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities represent a significant part of the Company's business. These expenditures relate to the processes of discovering, testing and developing new products, upfront payments and developmental milestones, improving existing products, as well as ensuring product efficacy and regulatory compliance prior to launch. The Company remains committed to investing in research and development with the aim of delivering high quality and innovative products. </span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development increased as a percent to sales primarily driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">General portfolio progression in the Pharmaceutical business</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">COVID-19 vaccine expenses, net of governmental reimbursements</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-Process Research and Development (IPR&amp;D): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2021, the Company recorded a partial IPR&amp;D charge of $0.9 billion primarily related to expected development delays in the general surgery digital robotics platform (Ottava) acquired with the Auris Health acquisition in 2019. The impairment charge was calculated based on revisions to the discounted cash flow valuation model reflecting a delay of first in human procedures of approximately two years from the initial acquisition model assumption of the second half of 2022. The Company will continue to monitor the remaining $1.5 billion Ottava platform intangible asset as development program activities are ongoing. In fiscal year 2020, the Company recorded an IPR&amp;D charge of $0.2 billion primarily related to a partial impairment due to timing and progression of one of the digital surgery platforms acquired with the Auris Health acquisition.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 28, 2022, subsequent to the fiscal year 2021, additional information regarding efficacy became available which led the Company to the decision to terminate the development of bermekimab for Atopic Dermatitis (AD). The Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of AD and Hidradenitis Suppurativa (HS). The impairment charge is related to the AD indication and is a nonrecognized subsequent event and will be reflected in the first quarter 2022 financial statements. The Company acquired all rights to bermekimab from XBiotech, Inc. in fiscal year 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Other (Income) Expense, Net:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson &amp; Johnson Innovation - JJDC, Inc. (JJDC), unrealized gains and losses on investments, income and losses associated with certain employee benefit programs, gains and losses on divestitures, certain transactional currency gains and losses, acquisition-related costs, litigation accruals and settlements, as well as royalty income. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income)&#160;expense, net for the fiscal year 2021 was favorable by $2.4 billion as compared to the prior year primarily due to the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:49.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.146%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in Billions)(Income)/Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition, Integration and Divestiture related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gains)/losses on securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit plan related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other (Income) Expense, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2021 is primarily related to talc and Risperdal. 2020 is primarily related to talc and the opioid litigation settlement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is p</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">rimarily related to divestiture gains of two pharmaceutical brands outside the U.S. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">   2020 is primarily driven by a contingent consideration reversal of approximately $1.1 billion related to the timing of certain developmental milestones associated with the Auris Health acquisition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2021 includes Consumer Health separation costs of $0.1 billion. Costs in future years are expected to be significantly higher. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Interest (Income) Expense:&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fiscal year 2021 included net interest expense of $130 million as compared to $90 million net interest expense in the fiscal year 2020. This was primarily due to lower rates of interest earned on cash balances and a higher average debt balance, partially offset by the benefit from net investment hedging. Cash, cash equivalents and marketable securities totaled $31.6&#160;billion at the end of 2021, and averaged $28.4&#160;billion as compared to the cash, cash equivalents and marketable securities total of $25.2&#160;billion and $22.2&#160;billion average cash balance in 2020. The total debt balance at the end of 2021 was $33.8&#160;billion with an average debt balance of $34.5&#160;billion as compared to $35.3&#160;billion at the end of 2020 and an average debt balance of $31.5 billion. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Before Tax by Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before tax by segment of business were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:38.212%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.018%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.018%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.321%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Before Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Segment Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent of Segment Sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,064)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,848&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,775&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,584&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net expense not allocated to segments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before provision for taxes on income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,776&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,497&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,775&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.43pt">See Note&#160;17 to the Consolidated Financial Statements for more details.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health Segment: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Consumer Health segment income before tax as a percent of sales was 8.8% versus a loss before tax of 7.6% in 2020. The increase in the income before tax as a percent of sales was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">2021 litigation expense includes $1.6 billion of talc expenses; 2020 includes $3.9 billion of talc expenses </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Supply chain efficiencies</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Increased brand marketing expenses and commodity inflation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Pharmaceutical segment income before tax as a percent to sales was 34.9% versus 33.9% in 2020.&#160;The increase in the income before tax as a percent of sales was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Divestiture gains of $0.6 billion related to two pharmaceutical brands outside the U.S. in fiscal 2021</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">2021 litigation expense includes $0.6 billion primarily related to Risperdal; 2020 includes $0.8 billion primarily related to the opioid litigation settlement</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Research &amp; Development investment in the COVID-19 vaccine net of governmental reimbursements and general portfolio progression </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical Devices Segment:&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Medical Devices segment income before tax as a percent to sales was 16.2% versus 13.3% in 2020. The increase in the income before tax as a percent to sales was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Recovery of prior year COVID-19 production related slow downs and related inventory impacts</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Overall expense leveraging resulting from the Medical Devices sales recovery</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Litigation expense of $0.1 billion in 2021 vs. $0.3 billion in 2020 </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">A contingent consideration reversal of approximately $1.1 billion in the fiscal 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">A higher IPR&amp;D charge of $0.7 billion ($0.9 billion in 2021 related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Restructuring:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;In the fiscal second quarter of 2018, the Company announced plans to implement actions across its Global Supply Chain that are intended to enable the Company to focus resources and increase investments in critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio of the future, enhance agility and drive growth. The Company expects these supply chain actions will include expanding its use of strategic collaborations, and bolstering its initiatives to reduce complexity, improving cost-competitiveness, enhancing capabilities and optimizing its network.&#160; Discussions regarding specific future actions are ongoing and are subject to all relevant consultation requirements before they are finalized. In total, the Company expects these actions to generate approximately $0.6 to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by the end of 2022. The Company expects to record pre-tax restructuring charges of approximately $2.1 to $2.3 billion. The Company estimates that approximately 70% of the cumulative pre-tax costs will result in cash outlays.&#160;In 2021, the Company recorded a pre-tax charge of $0.5 billion, which is included on the following lines of the Consolidated Statement of Earnings, $0.3 billion in restructuring, $0.1 billion in other (income) expense and $0.1 billion in cost of products sold. Total project costs of approximately $1.8 billion have been recorded since the restructuring was announced. The program is set to be completed at the end of 2022.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;20 to the Consolidated Financial Statements for additional details related to the restructuring programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for Taxes on Income:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The worldwide effective income tax rate was 8.3% in 2021 and 10.8% in 2020. </span></div><div><span><br/></span></div><div style="margin-top:2.7pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For discussion related to the fiscal 2021 provision for taxes refer to Note&#160;8 to the Consolidated Financial Statements. </span></div><div style="margin-bottom:8pt;margin-top:2.7pt;text-indent:18pt"><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_100"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity&#160;&amp; Cash Flows</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents were $14.5&#160;billion at the end of 2021 as compared to $14.0&#160;billion at the end of 2020. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary sources and uses of cash that contributed to the $0.5&#160;billion increase were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:21.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q4 2020 Cash and cash equivalents balance</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cash generated from operating activities</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net cash used by investing activities</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net cash used by financing activities</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">effect of exchange rate and rounding</span></td></tr><tr><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q4 2021 Cash and cash equivalents balance</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company had $17.1 billion in marketable securities at the end of fiscal year 2021 and $11.2 billion at the end of fiscal year 2020. See Note&#160;1 to the Consolidated Financial Statements for additional details on cash, cash equivalents and marketable securities.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow from operations of $23.4&#160;billion was the result of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Earnings</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation and asset write-downs partially offset by the deferred tax provision, net gain on sale of assets/businesses and credit losses and accounts receivable allowances</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a decrease in current and non-current liabilities</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">an increase in accounts payable and accrued liabilities </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">an increase in accounts receivable, inventories and other current and non-current assets</span></td></tr><tr><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Flow from operations</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities use of $8.7 billion of cash was primarily used for:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">additions to property, plant and equipment</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net purchases of investments</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">proceeds from the disposal of assets/businesses, net</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;acquisitions </span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">other (primarily licenses and milestones) and rounding</span></td></tr><tr><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for investing activities</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities use of $14.0 billion of cash was primarily used for: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">dividends to shareholders </span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">repurchase of common stock for employee share programs</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net repayment from short and long term debt</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">proceeds from stock options exercised/employee withholding tax on stock awards, net</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">other and rounding</span></td></tr><tr><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for financing activities</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of January 2, 2022, the Company's notes payable and long-term debt was in excess of cash, cash equivalents and marketable securities. As of January 2, 2022, the net debt position was $2.1 billion as compared to the prior year of $10.1 billion. There was a decrease in the net debt position due to repayment of debt and an increase in cash, cash equivalents, and marketable securities generating from operations. The debt balance at the end of 2021 was $33.8 billion as compared to $35.3 billion in 2020. Considering recent market conditions and the on-going COVID-19 crisis, the Company has evaluated its operating cash flows and liquidity profile and does not foresee any significant incremental risk. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Company's approximate $1.1 billion in contractual supply commitments associated with its development of the COVID-19 vaccine, the opioid litigation settlement for $5.0 billion and the establishment of the $2.0 billion trust for talc related liabilities (See Note 19 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable. Effective beginning in fiscal 2022, the U.S. Tax Cuts and Job Act of 2017 currently requires the Company to deduct U.S. and international research and development expenditures for tax purposes over 5 to 15 years, instead of in the current fiscal year. As a result, the Company is expecting an increase in annual cash tax payments to the U.S Treasury of an incremental $1.0 to 1.5 billion beginning in fiscal 2022. The Company will concurrently record a deferred tax benefit for the future amortization of the research and development (R&amp;D) for tax purposes and therefore, the Company is not expecting a significant impact to its effective tax rate related to this change. The requirement to expense R&amp;D as incurred is unchanged for U.S. GAAP purposes and the impact to pre-tax R&amp;D expense is not affected by this provision.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, as a result of the Tax Cuts and Jobs Act (TCJA), the Company has access to its cash outside the U.S. at a significantly reduced cost. During the fiscal third quarter of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2021, in accordance with the terms of the agreement associated with the acquisition of Actelion, the Company's undrawn credit facility with Idorsia was terminated. </span></div><div style="margin-top:4pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s material contractual obligations and their aggregate maturities as of January&#160;2, 2022: To satisfy these obligations, the Company intends to use cash from operations.  </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:28.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.002%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax Legislation (TCJA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest on<br/>Debt Obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,852&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,536&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,899</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,116</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,964</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,979</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For tax matters, see Note&#160;8 to the Consolidated Financial Statements. The table does not include activity related to business combinations or the Company&#8217;s approximate $1.1 billion in contractual supply commitments associated with its development of a COVID-19 vaccine. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing and Market Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses financial instruments to manage the impact of foreign exchange rate changes on cash flows. Accordingly, the Company enters into forward foreign exchange contracts to protect the value of certain foreign currency assets and liabilities and to hedge future foreign currency transactions primarily related to product costs. Gains or losses on these contracts are offset by the gains or losses on the underlying transactions. A 10% appreciation of the U.S.&#160;Dollar from the January 2, 2022 market rates would increase the unrealized value of the Company&#8217;s forward contracts by $0.1 billion.  Conversely, a 10% depreciation of the U.S.&#160;Dollar from the January&#160;2, 2022 market rates would decrease the unrealized value of the Company&#8217;s forward contracts by $0.1&#160;billion. In either scenario, the gain or loss on the forward contract would be offset by the gain or loss on the underlying transaction, and therefore, would have no impact on future anticipated earnings and cash flows.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company hedges the exposure to fluctuations in currency exchange rates, and the effect on certain assets and liabilities in foreign currency, by entering into currency swap contracts. A 1% change in the spread between U.S.&#160;and foreign interest rates on the Company&#8217;s interest rate sensitive financial instruments would either increase or decrease the unrealized value of the Company&#8217;s swap contracts by approximately $2.2 billion. In either scenario, at maturity, the gain or loss on the swap contract would be offset by the gain or loss on the underlying transaction, and therefore, would have no impact on future anticipated cash flows.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an investment grade credit rating. The counterparties to these contracts are major financial institutions and there is no significant concentration of exposure with any one counterparty. Management believes the risk of loss is remote. The Company entered into credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. See Note&#160;6 to the Consolidated Financial Statements for additional details on credit support agreements.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in both fixed rate and floating rate interest earning securities which carry a degree of interest rate risk. The fair market value of fixed rate securities may be adversely impacted due to a rise in interest rates, while floating rate securities may produce less income than predicted if interest rates fall. A 1% (100 basis points) change in spread on the Company&#8217;s interest rate sensitive investments would either increase or decrease the unrealized value of cash equivalents and current marketable securities by approximately $0.1 billion. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has access to substantial sources of funds at numerous banks worldwide. In September 2021, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10&#160;billion, which expires on September&#160;8, 2022.  Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreement are not material.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total borrowings at the end of 2021 and 2020 were $33.8&#160;billion and $35.3&#160;billion, respectively. The decrease in borrowings was due to the repayment of debt. In 2021, net debt (cash and current marketable securities, net of debt) was $2.1&#160;billion compared to net debt of $10.1 billion in 2020. Total debt represented 31.3% of total capital (shareholders&#8217; equity and total debt) in 2021 and 35.8% of total capital in 2020. Shareholders&#8217; equity per share at the end of 2021 was $28.16 compared to $24.04 at year-end 2020.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of borrowings can be found in Note&#160;7 to the Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company increased its dividend in 2021 for the 59th&#160;consecutive year. Cash dividends paid were $4.19 per share in 2021 and $3.98 per share in 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2022, the Board of Directors declared a regular cash dividend of $1.06 per share, payable on March 8, 2022 to shareholders of record as of February 22, 2022.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i01be8f8f216a4c39adb513a606bfe937_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of results of operations and financial condition are based on the Company&#8217;s consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the U.S.&#160;(GAAP). The preparation of these financial statements requires that management make estimates and assumptions that affect the amounts reported for revenues, expenses, assets, liabilities and other related disclosures. Actual results may or may not differ from these estimates. The Company believes that the understanding of certain key accounting policies and estimates are essential in achieving more insight into the Company&#8217;s operating results and financial condition.  These key accounting policies include revenue recognition, income taxes, legal and self-insurance contingencies, valuation of long-lived assets, assumptions used to determine the amounts recorded for pensions and other employee benefit plans and accounting for stock based awards.</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to, the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of January 2, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the year ended January 2, 2022, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#8217;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#8217;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during the fiscal years&#160;2021 and&#160;2020.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements of certain products, which are included in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales to customers. For all years presented, profit-share payments were less than 3.0% of the total revenues and are included in sales to customers.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company enters into collaboration arrangements that contain multiple revenue generating activities.   Amounts due from collaborative partners for these arrangements are recognized as each activity is performed or delivered, based on the relative selling price. Upfront fees received as part of these arrangements are deferred and recognized over the performance period. See Note&#160;1 to the Consolidated Financial Statements for additional disclosures on collaborations.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reasonably likely changes to assumptions used to calculate the accruals for rebates, returns and promotions are not anticipated to have a material effect on the financial statements. The Company currently discloses the impact of changes to assumptions in the quarterly or annual filing in which there is a material financial statement impact. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below are tables that show the progression of accrued rebates, returns, promotions, reserve for doubtful accounts and reserve for cash discounts by segment of business for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health Segment</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.935%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments/Credits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>End of     Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(895)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued promotions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,999)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,987&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,030)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,247)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(788)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued promotions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,047)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,919&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,960)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for doubtful accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,169)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes reserve for customer rebates of $80&#160;million at January&#160;2, 2022 and $66&#160;million at January&#160;3, 2021, recorded as a contra asset.</span></div><div style="margin-top:13pt"><span><br/></span></div><div style="margin-top:13pt"><span><br/></span></div><div style="margin-top:13pt"><span><br/></span></div><div style="margin-top:13pt"><span><br/></span></div><div style="margin-top:13pt"><span><br/></span></div><div style="margin-top:13pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:45.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments/Credits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>End of       Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued promotions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,729)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,425&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,461&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,888)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,998&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued promotions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,518&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,658&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,873)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,303&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for doubtful accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,029)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,619&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,716&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,910)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,425&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes reserve for customer rebates of $218&#160;million at January&#160;2, 2022 and $174&#160;million at January&#160;3, 2021, recorded as a contra asset. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes prior period adjustments</span></div><div style="margin-top:13pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical Devices Segment</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:45.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments/Credits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>End of       Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,670)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued promotions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,371)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,532)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,983)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(558)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued promotions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,840&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,653)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for doubtful accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,790)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,575&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes reserve for customer rebates of $845&#160;million at January&#160;2, 2022 and $707&#160;million at January&#160;3, 2021, recorded as a contra asset.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $0.7 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 1 and Note 8 to the Consolidated Financial Statements for further information regarding income taxes.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal and Self Insurance Contingencies:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company records accruals for various contingencies, including legal proceedings and product liability claims as these arise in the normal course of business. The accruals are based on management&#8217;s judgment as to the probability of losses and, where applicable, actuarially determined estimates. The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated. </span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. </span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes 1 and 19 to the Consolidated Financial Statements for further information regarding product liability and legal proceedings.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-Lived and Intangible Assets:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company assesses changes, both qualitatively and quantitatively, in economic conditions and makes assumptions regarding estimated future cash flows in evaluating the value of the Company&#8217;s property, plant and equipment, goodwill and intangible assets.  As these assumptions and estimates may change over time, it may or may not be necessary for the Company to record impairment charges.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Benefit Plans:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. These plans are based on assumptions for the discount rate, expected return on plan assets, mortality rates, expected salary increases, healthcare cost trend rates and attrition rates. See Note&#160;10 to the Consolidated Financial Statements for further details on these rates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company recognizes compensation expense associated with the issuance of equity instruments to employees for their services. Based on the type of equity instrument, the fair value is estimated on the date of grant using either the Black-Scholes option valuation model or a combination of both the Black-Scholes option valuation model and Monte Carlo valuation model, and is expensed in the financial statements over the service period. The input assumptions used in determining fair value are the expected life, expected volatility, risk-free rate and expected dividend yield. Prior to fiscal 2020, for performance share units, the fair market value was calculated for each of the three component goals at the date of grant: operational sales, adjusted operational earnings per share and relative total shareholder return. Beginning in fiscal 2020, for performance share units, the fair market value is calculated for the two component goals at the date of grant: adjusted operational earnings per share and relative total shareholder return. &#160;The fair values for the earnings per share goal of each performance share unit was estimated on the date of grant using the fair market value of the shares at the time of the award, discounted for dividends, which are not paid on the performance share units during the vesting period.&#160;The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model. See Note&#160;16 to the Consolidated Financial Statements for additional information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note&#160;1 to the Consolidated Financial Statements for recently adopted accounting pronouncements and recently issued accounting pronouncements not yet adopted as of January&#160;2, 2022.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Economic and Market Factors</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 considerations and business continuity</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has considered various internal and external factors in assessing the potential impact of COVID-19 on its business and financial results based upon information available at this time, as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Operating Model: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a diversified business model across the healthcare industry with flexibility designed into its manufacturing, research and development clinical operations and commercial capabilities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Supply Chain: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to leverage its global manufacturing footprint and dual-source capabilities while closely monitoring and maintaining critical inventory at major distribution centers away from high-risk areas to help ensure adequate and effective distribution. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Business Continuity: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The robust, active business continuity plans across the Company's network have been instrumental in preparing the Company for events like COVID-19 and the ability to meet the majority of patient and consumer needs remains uninterrupted.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Workforce: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has put procedures in place to protect its essential workforce in manufacturing, distribution, commercial and research operations while ensuring appropriate remote working protocols have been established for other employees. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Liquidity:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's high-quality credit rating allows the Company superior access to the financial capital markets for the foreseeable future. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Domestic and Foreign Legislation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will continue to assess and evaluate the on-going global legislative efforts to combat the COVID-19 impact on economies and the sectors in which it participates. Currently, the recent legislative acts put in place are not expected to have a material impact on the Company&#8217;s operations. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In fiscal 2020 and 2021, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.1 billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to evaluate and monitor both its internal and external supply arrangements, including its contract with Emergent BioSolutions and related production activities at its Bayview, Maryland facility. The Company has established a global vaccine supply network, where, in addition to its internal manufacturing site in Leiden, the Netherlands, ten other manufacturing sites will be involved in the production of vaccine across different countries and continents. The Company does not believe that a disruption at a vaccine manufacturing site, or the resulting delay would have a material financial impact on the Company&#8217;s consolidated financial statements or results.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is aware that its products are used in an environment where, for more than a decade, policymakers, consumers and businesses have expressed concerns about the rising cost of healthcare.  In response to these concerns, the Company has a long-standing policy of pricing products responsibly. For the period 2011&#160;- 2021, in the U.S., the weighted average compound annual growth rate of the Company&#8217;s net price increases for healthcare products (prescription and over-the-counter drugs, hospital and professional products) was below the U.S.&#160;Consumer Price Index (CPI).</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate. The Company has accounted for operations in Argentina and Venezuela as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. This did not have a material impact to the Company's results in the period. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company is exposed to fluctuations in currency exchange rates. A 1% change in the value of the U.S.&#160;Dollar as compared to all foreign currencies in which the Company had sales, income or expense in 2021 would have increased or decreased the translation of foreign sales by approximately $0.5&#160;billion and net income by approximately $0.2&#160;billion.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. A change in statutory tax rate in any country would result in the revaluation of the Company&#8217;s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted.&#160; This change would result in an expense or benefit recorded to the Company&#8217;s Consolidated Statement of Earnings.&#160; The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company faces various worldwide healthcare changes that may continue to result in pricing pressures that include healthcare cost containment and government legislation relating to sales, promotions and reimbursement of healthcare products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing healthcare insurance coverage, as a result of the current global economic downturn, may continue to impact the Company&#8217;s businesses.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also operates in an environment increasingly hostile to intellectual property rights. Firms have filed Abbreviated New Drug Applications or Biosimilar Biological Product Applications with the U.S. FDA or otherwise challenged the coverage and/or validity of the Company's patents, seeking to market generic or biosimilar forms of many of the Company&#8217;s key pharmaceutical products prior to expiration of the applicable patents covering those products. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue will be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also a risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place.  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial, employment, indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of business.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of January&#160;2, 2022, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;19 to the Consolidated Financial Statements included in Item 8 of this report for further information regarding legal proceedings.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Common Stock is listed on the New York Stock Exchange under the symbol JNJ. As of February 10, 2022, there were 127,899 record holders of Common Stock of the Company. </span></div><div style="text-align:center"><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_106"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.8pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to &#8220;Item 7. Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition&#160;- Liquidity and Capital Resources - Financing and Market Risk&#8221; of this Report; and Note&#160;1 &#8220;Summary of Significant Accounting Policies&#160;- Financial Instruments&#8221; of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. &#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Index to Audited Consolidated Financial Statements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_112">41</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_112">Consolidated Balance Sheets</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_118">42</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_118">Consolidated Statements of Earnings</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_121">43</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_121">Consolidated Statements of Comprehensive Income </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_127">44</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_127">Consolidated Statements of Equity</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_133">45</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_133">Consolidated Statements of Cash Flows</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_136">47</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_136">Notes to Consolidated Financial Statements</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_229">103</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_229">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID <ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMDkvZnJhZzozNDdjNGY0MWUwZGY0ZDYzYTBhYmFhOGMxNmNiYzQxZi90YWJsZTo4MmJjYmI0OWU5ZWQ0NDNmYjEwZmFhY2IwOThiMjM0MS90YWJsZXJhbmdlOjgyYmNiYjQ5ZTllZDQ0M2ZiMTBmYWFjYjA5OGIyMzQxXzctMS0xLTEtNTEyMjUvdGV4dHJlZ2lvbjo5YWUzZTE2OWM3YmI0NGE0YTY4MWY2NGJlNzAzMjdjM182NTk3MDY5NzY2NzM1_d503d707-1061-468d-b9ae-b18d6b33a357">238</ix:nonNumeric>)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_232">106</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01be8f8f216a4c39adb513a606bfe937_232">Management&#8217;s Report on Internal Control Over Financial Reporting</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOHNSON&#160;&amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> CONSOLIDATED BALANCE SHEETS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At January&#160;2, 2022 and January&#160;3, 2021 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Millions Except Share and Per Share Amounts) (Note&#160;1)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents (Notes&#160;1 and 2)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzMtMS0xLTEtMjk3MjY_48b17659-0204-44b5-9656-f9a6f5f682c6">14,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzMtMy0xLTEtMjk3MjY_2840c495-590d-41f8-9f55-0fc1cec41dc9">13,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities (Notes&#160;1 and 2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzQtMS0xLTEtMjk3MjY_2a1bc963-ff02-4a3b-9b78-18bc1bcbaf47">17,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzQtMy0xLTEtMjk3MjY_9971dd86-f3fe-4ef9-a9e2-b7668adb2f30">11,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable trade, less allowances for doubtful accounts $<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzUtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjoxMTMxNWVhM2NkYzc0MGM0YjQ4OGU5ZDQyZWQ2ZGI3Y183MA_35d0e655-5881-4a5d-8b6a-1e0b7511f862">230</ix:nonFraction> (2020, $<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzUtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjoxMTMxNWVhM2NkYzc0MGM0YjQ4OGU5ZDQyZWQ2ZGI3Y184MQ_5537a794-8008-4b54-b994-3124daa0d3f1">293</ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzUtMS0xLTEtMjk3MjY_8cd1432a-3706-4653-b4e2-3e6dfee173cd">15,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzUtMy0xLTEtMjk3MjY_1f4f21ec-9f95-4db9-9ffe-b40a43b2aec9">13,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories (Notes&#160;1 and 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzYtMS0xLTEtMjk3MjY_112564ed-a1fa-4daf-bd37-56d8010cc222">10,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzYtMy0xLTEtMjk3MjY_6e87cd29-fd8d-487a-b96c-3603e0b91a7e">9,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzgtMS0xLTEtMjk3MjY_e7a5bd29-402f-4d49-b562-ff5ba8fbb880">3,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzgtMy0xLTEtMjk3MjY_302e954d-4738-47df-962b-5edbee963e62">3,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzEwLTEtMS0xLTI5NzI2_f10eedb4-826f-43b2-9cd7-90d5cb820c34">60,979</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzEwLTMtMS0xLTI5NzI2_9cfcf9be-8009-47a2-b750-a1dab0160ed5">51,237</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net (Notes&#160;1 and 4)</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzExLTEtMS0xLTI5NzI2_448b1b42-cefc-4c9b-98b7-c7a4f7556116">18,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzExLTMtMS0xLTI5NzI2_ad6e31ab-c241-495a-8daf-433607cf9137">18,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net (Notes&#160;1 and 5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzEyLTEtMS0xLTI5NzI2_4b5af859-dd55-48ec-944a-ce565540d5de">46,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzEyLTMtMS0xLTI5NzI2_1ddb0e57-d58a-4af5-a230-cfbafa97fc04">53,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill (Notes&#160;1 and 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzEzLTEtMS0xLTI5NzI2_3680d9a7-b8af-4207-b518-e193c6124f0c">35,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzEzLTMtMS0xLTI5NzI2_858f258d-da9a-4078-ab3f-d0a6b0142141">36,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes on income (Note 8)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzE0LTEtMS0xLTI5NzI2_6997292b-db55-4e3c-9e3a-83213b1fad4b">10,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzE0LTMtMS0xLTI5NzI2_a4a69b04-e2ea-4d49-b4a0-732b00c8e6f7">8,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzE1LTEtMS0xLTI5NzI2_665ce8e5-b724-4110-9d71-a9210718c986">10,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzE1LTMtMS0xLTI5NzI2_78093e63-f0b9-49f1-8ab4-970a836a967e">6,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzE2LTEtMS0xLTI5NzI2_7f2a612c-529a-4dfe-801c-900ed2605357">182,018</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzE2LTMtMS0xLTI5NzI2_a5be1890-1a0c-412c-a986-53c0e9389577">174,894</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans and notes payable (Note&#160;7)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzE5LTEtMS0xLTI5NzI2_63b7e40d-c6ef-4dbf-8998-1a69546a2fa9">3,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzE5LTMtMS0xLTI5NzI2_b724e1f2-b917-48bb-99de-a354e33f65ca">2,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzIwLTEtMS0xLTI5NzI2_84cbee1f-7c69-49a2-9944-67ca75ca28eb">11,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzIwLTMtMS0xLTI5NzI2_a7ba9b58-7d18-49f3-a9c7-ddac0c2e86d8">9,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzIxLTEtMS0xLTI5NzI2_cc7eb195-f1be-4d2b-bdf3-e7df5bc8b69b">13,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzIxLTMtMS0xLTI5NzI2_eb7f1194-3487-49d8-9128-2573cfc16486">13,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates, returns and promotions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="jnj:AccruedRebatesReturnsAndPromotions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzIyLTEtMS0xLTI5NzI2_0160afec-7644-49fb-9157-ee293b189371">12,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="jnj:AccruedRebatesReturnsAndPromotions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzIyLTMtMS0xLTI5NzI2_6fd10492-180e-4e5e-b205-a5cd22e14571">11,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee related obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzIzLTEtMS0xLTI5NzI2_bd8b422d-1ce8-4a9e-8948-243d2b90957c">3,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzIzLTMtMS0xLTI5NzI2_8344321d-119e-48e0-ac9b-395860b8f660">3,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes on income (Note 8)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI0LTEtMS0xLTI5NzI2_d36080ac-e808-4dbd-8937-8e9f4ad3c167">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI0LTMtMS0xLTI5NzI2_0cfba561-3b04-440c-be96-18a4be129eda">1,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI1LTEtMS0xLTI5NzI2_c7069afd-7c07-4acb-a94f-8c614a2679ac">45,226</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI1LTMtMS0xLTI5NzI2_afb56fc7-ed7f-4408-b289-2b28e8877669">42,493</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt (Note&#160;7)</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI2LTEtMS0xLTI5NzI2_012cfa33-30b8-4de0-a268-1ebbe41fbc8b">29,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI2LTMtMS0xLTI5NzI2_7050595c-1b25-44a4-82e9-05059b38c42c">32,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes on income (Note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI3LTEtMS0xLTI5NzI2_135e08aa-aa75-42e0-a786-9b79b53cf2a9">7,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI3LTMtMS0xLTI5NzI2_504cd34b-2674-4deb-8406-c18c3ef05618">7,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations (Notes&#160;9 and 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI4LTEtMS0xLTI5NzI2_684011a5-bcfd-4bd3-afa3-12da94219d4f">8,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI4LTMtMS0xLTI5NzI2_ac7a5ac6-92e8-4c56-ab26-105a13582d3b">10,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term taxes payable (Note 1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI5LTEtMS0xLTI5NzI2_e128b2bc-87fa-436c-93b2-4b806256c8d7">5,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI5LTMtMS0xLTI5NzI2_dbfa5906-321c-46f1-8182-e9590fc5c2fa">6,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzMwLTEtMS0xLTI5NzI2_b3e0ce70-e5f9-4bf4-9755-e54cce3f817e">10,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzMwLTMtMS0xLTI5NzI2_3f0d2001-2c73-43f7-afd4-51d682b4314f">11,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzMxLTEtMS0xLTI5NzI2_b94f3340-4fce-481c-9c78-1b05bd2fe358">107,995</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzMxLTMtMS0xLTI5NzI2_8e10aaaa-3197-4bee-92c5-e674e1624b00">111,616</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies (Note 19)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzMxLTEtMS0xLTUyOTY3_f32dac7c-fd4a-4cfc-bcd4-05437b73be37"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzMxLTMtMS0xLTUyOTY5_f673bca5-2f0a-442c-b4c3-49de86a2def2"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock&#160;&#8212; without par value (authorized and unissued <ix:nonFraction unitRef="shares" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM0LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MTUzYjcyYWEzNzIyNDMxMDhkYzljMWM5YTk1YzM1ZGFfNjU_74b0b8af-1e5d-42f0-88a9-792e473deb61"><ix:nonFraction unitRef="shares" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM0LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MTUzYjcyYWEzNzIyNDMxMDhkYzljMWM5YTk1YzM1ZGFfNjU_b8f564e0-17ee-4c10-801a-e2f2e004edec">2,000,000</ix:nonFraction></ix:nonFraction>&#160;shares)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM0LTEtMS0xLTI5NzI2_440a16e9-c345-4bbc-8090-f93524b6247d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM0LTMtMS0xLTI5NzI2_505fc1b0-6e57-49e6-8310-950616f81766">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#160;&#8212; par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDc2OWMzZjM2ZjAxNGJmMzkwNzA4MGJkNzIxNjdiODRfMzA_0c80bc19-5858-4247-90da-e92642f7f012"><ix:nonFraction unitRef="usdPerShare" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDc2OWMzZjM2ZjAxNGJmMzkwNzA4MGJkNzIxNjdiODRfMzA_378b6c3a-54b2-43b0-a4fd-ec6ad172a820">1.00</ix:nonFraction></ix:nonFraction> per share (Note&#160;12) (authorized <ix:nonFraction unitRef="shares" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDc2OWMzZjM2ZjAxNGJmMzkwNzA4MGJkNzIxNjdiODRfNjU_6180cff2-3af0-43b6-bde8-521a1eba84c8"><ix:nonFraction unitRef="shares" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDc2OWMzZjM2ZjAxNGJmMzkwNzA4MGJkNzIxNjdiODRfNjU_ce7fe11a-9c00-49b4-b20f-16ba585bc8ef">4,320,000,000</ix:nonFraction></ix:nonFraction>&#160;shares; issued <ix:nonFraction unitRef="shares" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDc2OWMzZjM2ZjAxNGJmMzkwNzA4MGJkNzIxNjdiODRfODM_795c70b2-779b-4c4d-819d-e2425afcdba0"><ix:nonFraction unitRef="shares" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDc2OWMzZjM2ZjAxNGJmMzkwNzA4MGJkNzIxNjdiODRfODM_c63e2f3e-58ef-467b-be83-b78d62d48841">3,119,843,000</ix:nonFraction></ix:nonFraction>&#160;shares)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM1LTEtMS0xLTI5NzI2_bf8b82cd-ec60-4da7-88fb-3b5f03b30b1a">3,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM1LTMtMS0xLTI5NzI2_6cb4dc1d-adde-4463-bfab-f13da48b5557">3,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss) (Note&#160;13)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM2LTEtMS0xLTI5NzI2_eef6fbe1-f220-420f-90ca-29a3071e1e44">13,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM2LTMtMS0xLTI5NzI2_a7515e19-b18f-4289-966b-573fcc1bd7eb">15,242</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM3LTEtMS0xLTI5NzI2_19c14cb6-cd88-4f7f-bb81-1aed45e270ec">123,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM3LTMtMS0xLTI5NzI2_d4b5e5b1-28c6-41c8-a5ee-e1fe480dc6a9">113,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:StockholdersEquityBeforeTreasuryStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM4LTEtMS0xLTI5NzI2_63091a4a-64e0-4407-8b42-07cd1de4d57a">113,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:StockholdersEquityBeforeTreasuryStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM4LTMtMS0xLTI5NzI2_89a5c10a-cb24-4aad-8081-151a2ca3a304">101,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: common stock held in treasury, at cost (Note&#160;12) (<ix:nonFraction unitRef="shares" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM5LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MjdhMjJlN2FhMWUxNDY5MDk4ZmNjZGE3YmZjODRiYjZfNjA_1bf057a2-f978-44df-984f-6cfd1d79f0d2">490,878,000</ix:nonFraction>&#160;shares and <ix:nonFraction unitRef="shares" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM5LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MjdhMjJlN2FhMWUxNDY5MDk4ZmNjZGE3YmZjODRiYjZfNzQ_fa75b33d-5ec5-41a7-a55c-df5a0d4a1086">487,331,000</ix:nonFraction>&#160;shares)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM5LTEtMS0xLTI5NzI2_17684634-be01-42c5-abfc-a38852906f00">39,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM5LTMtMS0xLTI5NzI2_62ad8d6e-f573-4312-84df-09aa8d7ff61b">38,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzQwLTEtMS0xLTI5NzI2_e376468f-a6c5-4d50-88b8-34d94a2dc4b8">74,023</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzQwLTMtMS0xLTI5NzI2_fea5bff2-5f69-465c-b928-735f9423037e">63,278</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzQxLTEtMS0xLTI5NzI2_727730eb-74ef-4498-a816-800bf47361c8">182,018</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzQxLTMtMS0xLTI5NzI2_fd144760-3ce7-437f-92a7-54db804db18b">174,894</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOHNSON&#160;&amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EARNINGS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars and Shares in Millions Except Per Share Amounts) (Note&#160;1)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:63.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to customers</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEtMS0xLTEtMjk3MjY_ab529d60-1618-45d0-99c3-aa6ca01ac9b1">93,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEtMy0xLTEtMjk3MjY_01a348f2-1f14-4fe7-8663-51d363aa2c46">82,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEtNS0xLTEtMjk3MjY_d74441ff-5fbd-44a3-b004-03531e7f0315">82,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzItMS0xLTEtMjk3MjY_ea8a0e92-9b12-4ecb-8863-403543a85330">29,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzItMy0xLTEtMjk3MjY_34f921c0-f66c-413f-b287-f69d519f7919">28,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzItNS0xLTEtMjk3MjY_4f8a5330-d21e-4ec6-8642-0a2b759d7120">27,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzMtMS0xLTEtMjk3MjY_909accf0-7bee-4c88-ad75-44758eec9afe">63,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzMtMy0xLTEtMjk3MjY_6618fb6c-acf6-4371-bd68-193660e8e7f8">54,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzMtNS0xLTEtMjk3MjY_15f681bf-1b3f-4abd-9d40-bf6f3ecdef19">54,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, marketing and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzQtMS0xLTEtMjk3MjY_e435ac47-400d-44a1-8607-a35df3fd9c24">24,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzQtMy0xLTEtMjk3MjY_ced10d8d-8091-42a1-9cf5-c229decd89f7">22,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzQtNS0xLTEtMjk3MjY_9eeb0426-522b-400f-ac8c-65128881475f">22,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzUtMS0xLTEtMjk3MjY_bd0ca7ad-5636-40a3-a00d-e1b521c2e3f3">14,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzUtMy0xLTEtMjk3MjY_3eb07dec-82f8-4529-9409-0188d27d08fc">12,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzUtNS0xLTEtMjk3MjY_19c7e53c-12c6-4c87-ad2e-67a359c12ab6">11,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development (Note 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzYtMS0xLTEtMjk3MjY_09335fb8-03bc-44c7-ac0f-28263ac00a4e">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzYtMy0xLTEtMjk3MjY_888cfdfe-6e99-40c5-87a1-276e7e9e0cf7">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzYtNS0xLTEtMjk3MjY_66a95e91-9562-4652-bea0-aab44950eb7d">890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzctMS0xLTEtMjk3MjY_cd524c75-b434-4fb2-a4ee-5663ad1f8979">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzctMy0xLTEtMjk3MjY_cdfee8ad-2c06-444f-af07-a93fb969c27b">111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzctNS0xLTEtMjk3MjY_6905e13d-3e79-4c73-89c9-cf69696c9ffc">357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net of portion capitalized (Note&#160;4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzgtMS0xLTEtMjk3MjY_23365afe-5435-4fe2-b7af-8e229e3b77ec">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzgtMy0xLTEtMjk3MjY_c7de60d7-977f-4cd6-98bf-87c5f60a3047">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzgtNS0xLTEtMjk3MjY_2617971e-61c7-4bcd-96bc-632820954c9e">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzktMS0xLTEtMjk3MjY_68d7c683-20dd-4304-bf52-6221215d84fd">489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzktMy0xLTEtMjk3MjY_5c227758-63c8-49c1-b80e-89ca5c066da8">2,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzktNS0xLTEtMjk3MjY_1e6b20fd-a4e9-4452-9c73-33939457ecf6">2,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring (Note 20)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEwLTEtMS0xLTI5NzI2_49899cfa-2612-47c2-a581-88f14996ab4b">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEwLTMtMS0xLTI5NzI2_67f3e0b3-ba94-4288-b707-d1c7a6bc1cf5">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEwLTUtMS0xLTI5NzI2_100cd858-a63a-49b9-b97e-6e2d6ae868af">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before provision for taxes on income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzExLTEtMS0xLTI5NzI2_7995301b-e17a-4e00-a068-5d6c03774854">22,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzExLTMtMS0xLTI5NzI2_50cce635-0fdb-4c3e-b9cc-0dbd1fde0831">16,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzExLTUtMS0xLTI5NzI2_24dbbd56-6ea6-4e13-8102-9e9f00bbee34">17,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for taxes on income (Note&#160;8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEyLTEtMS0xLTI5NzI2_27b49939-33f6-4cf5-ac47-39f950e0c060">1,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEyLTMtMS0xLTI5NzI2_39541dea-3c6c-44f2-b138-75d1fb720173">1,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEyLTUtMS0xLTI5NzI2_9d02ef4e-ad2a-4c7a-b0d1-4a552d64d7d2">2,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net earnings</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEzLTEtMS0xLTI5NzI2_d95ec3c5-a122-4dcf-81ed-8c0910132632">20,878</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEzLTMtMS0xLTI5NzI2_477ed28b-fb6d-4c49-b37a-367c0e8b13bc">14,714</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEzLTUtMS0xLTI5NzI2_0b8e2506-4ea7-4349-9fd2-89e85ae8b979">15,119</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net earnings per share (Notes 1 and 15)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzE2LTEtMS0xLTI5NzI2_e40f2da3-2912-43b7-811d-71f31be44954">7.93</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzE2LTMtMS0xLTI5NzI2_73832526-fa47-4360-836a-f422f7664bb2">5.59</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzE2LTUtMS0xLTI5NzI2_233b4834-76ef-4a76-989b-168b555d75b7">5.72</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Diluted </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzE3LTEtMS0xLTI5NzI2_cb2d9fa0-dc00-404e-ac76-b9ba30500c54">7.81</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzE3LTMtMS0xLTI5NzI2_743d9624-63f2-4eaf-a54d-13a0038aade8">5.51</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzE3LTUtMS0xLTI5NzI2_d5ebdca1-71f1-491e-9c13-cced8a36bca3">5.63</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average shares outstanding (Notes 1 and 15)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzE5LTEtMS0xLTI5NzI2_e25dbae9-b3b8-4414-b278-7ef3f8f70378">2,632.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzE5LTMtMS0xLTI5NzI2_e5f61934-6861-46bc-b1de-8e398cc087e3">2,632.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzE5LTUtMS0xLTI5NzI2_617786f8-c390-46b5-b8c1-a767b562d360">2,645.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzIwLTEtMS0xLTI5NzI2_47156813-c0f0-4338-924c-4fabbc4e193e">2,674.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzIwLTMtMS0xLTI5NzI2_8d8a9ce9-00d2-47f4-b2ec-352f549e1a47">2,670.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzIwLTUtMS0xLTI5NzI2_a6801d3a-fc8d-4512-aca8-d0de97131881">2,684.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Millions) (Note&#160;1)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:56.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzEtMS0xLTEtMjk3MjY_5b0f3c9b-91b6-46f7-ba82-52cdda712969">20,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzEtMy0xLTEtMjk3MjY_3270e9d3-51ef-4f60-b7b8-16e1f98dc1c2">14,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzEtNS0xLTEtMjk3MjY_7fbf5bd0-2e4f-4da5-8756-51a847ce5dcf">15,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzQtMS0xLTEtMjk3MjY_1eeb1ba2-300c-4123-b059-97f1882ca100">1,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzQtMy0xLTEtMjk3MjY_c90f98bd-1ebe-47bd-b84e-9d55d4f98a6b">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzQtNS0xLTEtMjk3MjY_e2a99b8c-df74-4548-9198-337cd6140e88">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unrealized holding gain (loss) arising during period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzctMS0xLTEtMjk3MjY_625037ea-f29a-4737-a4f1-ab433f4553b3">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzctMy0xLTEtMjk3MjY_11b06376-5ca5-4005-b7b7-e8af9c92a62e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzctNS0xLTEtMjk3MjY_4a5b1192-8ca0-4680-a4a8-ce6da677c6f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Reclassifications to earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzgtMS0xLTEtMjk3MjY_ce478faa-fb13-48b9-96a9-afe98cd542bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzgtMy0xLTEtMjk3MjY_72a01396-f83d-4dd7-913b-2aa99cbd9270">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzgtNS0xLTEtMjk3MjY_27caad73-ac55-4d43-a8cd-a42bce612bf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzktMS0xLTEtMjk3MjY_c9cc99aa-5ebc-492f-93fb-33b136513625">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzktMy0xLTEtMjk3MjY_0b13daf7-09d9-47c3-9f6f-2e3b1ba94c3c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzktNS0xLTEtMjk3MjY_351df772-a399-49da-aa96-336707bf7db9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Employee benefit plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prior service credit (cost), net of amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzEyLTEtMS0xLTI5NzI2_2ee72bc3-9b41-462e-9030-cadf8b1d281c">169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzEyLTMtMS0xLTI5NzI2_c8f22681-a99c-47e7-bc25-3739f19898cf">1,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzEyLTUtMS0xLTI5NzI2_ba94e443-fe89-4d85-aaf7-151d44b1eb61">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gain (loss), net of amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzEzLTEtMS0xLTI5NzI2_b7644c57-764f-4c20-a46d-926aa15e88f5">4,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzEzLTMtMS0xLTI5NzI2_082a1c63-ed75-4218-a374-6b98a0a901d5">1,135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzEzLTUtMS0xLTI5NzI2_d94f4372-f3b7-4611-90df-6bdf03e3faf1">714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Effect of exchange rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE0LTEtMS0xLTI5NzI2_88c72a35-3d65-409a-a6dd-de90e8f0cca5">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE0LTMtMS0xLTI5NzI2_74410623-2cae-4fb6-928b-23a3b6bd32f3">229</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE0LTUtMS0xLTI5NzI2_33008e8b-0740-46f1-8e67-bf7708c5f92a">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE1LTEtMS0xLTI5NzI2_e530865f-3e58-480c-b2f2-2704d43da505">4,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE1LTMtMS0xLTI5NzI2_0aebe1d3-7610-4b0e-97eb-5acf33ebc7d9">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE1LTUtMS0xLTI5NzI2_ef5eb551-84b2-4ce5-ad2d-34550851e46c">733</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Derivatives &amp; hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unrealized gain (loss) arising during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE4LTEtMS0xLTI5NzI2_2c576823-4ad1-4772-a121-f20eaf56d037">199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE4LTMtMS0xLTI5NzI2_6a2fedd2-2c1d-43a3-a7b1-190732d1ec25">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE4LTUtMS0xLTI5NzI2_7d0080c8-a8d8-47bf-b848-6e9d0fcd5758">107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Reclassifications to earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE5LTEtMS0xLTI5NzI2_c619de52-95bc-483c-8828-22ae34ba3d6a">789</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE5LTMtMS0xLTI5NzI2_83a43e8b-090e-4b6b-a909-66bd8e971445">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE5LTUtMS0xLTI5NzI2_cbeb6233-e3fa-4a71-9002-591b284acab4">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzIwLTEtMS0xLTI5NzI2_c7820b16-82b0-4dec-9f7d-00368483a14d">988</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzIwLTMtMS0xLTI5NzI2_e7b37d3a-f6aa-487f-9bce-690c6b5b5704">947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzIwLTUtMS0xLTI5NzI2_333108ef-1730-4d5f-8d7d-ec1fca118f9e">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzIyLTEtMS0xLTI5NzI2_35a12603-2a82-4fe9-852e-f9404ce1e538">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzIyLTMtMS0xLTI5NzI2_ad46ea46-2de1-4f3f-9b0b-d8c61f5745b2">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzIyLTUtMS0xLTI5NzI2_5673d3c2-f614-45a7-b6af-87339e13602a">669</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzI0LTEtMS0xLTI5NzI2_2590b93e-feb7-4d0c-a394-6c6717122ebe">23,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzI0LTMtMS0xLTI5NzI2_6dea4173-cd89-4305-8cdc-fa9b89625066">15,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzI0LTUtMS0xLTI5NzI2_80af5aeb-37dd-403f-aebb-ab83b76ebec2">14,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The tax effects in other comprehensive income for the fiscal years 2021, 2020 and 2019 respectively: Foreign Currency Translation; $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY18xMzY_bc74488a-7797-4aeb-8ca5-e7fd19b5713f">346</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY18xNDk_4238add3-f9af-4489-9abb-bdeaca3b4bf9">536</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY18xNjU_decb6a37-ac72-442b-abcd-82112e9bc7db">19</ix:nonFraction> million; Securities: $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY182NTk3MDY5NzY3MDYy_d3ffab35-04a6-45ce-befc-9bb04f0dfe11">1</ix:nonFraction> million in 2021, Employee Benefit Plans: $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY18yMDI_1608d158-6146-4cb6-8965-fbf761ea0d07">1,198</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY18yMTU_54b8fa40-b80e-4fe6-8000-49f66f7eabcf">21</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY18yMzE_8ecff339-ae63-41a5-a326-5b4fcdf0f2a1">222</ix:nonFraction> million, Derivatives &amp; Hedges: $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY18yNjY_32855123-cb8a-44e0-a715-df4d61eee7ba">263</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY18yNzk_08b3fd26-f072-4a6e-bb7a-6abc01735c52">252</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY18yOTU_13c1dcd4-5063-429c-af29-58f6a469a98d">27</ix:nonFraction> million.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOHNSON&#160;&amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Millions) (Note&#160;1)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:34.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 30, 2018</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2087646dc6744a28755f382fc0a83c8_I20181230" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEtMS0xLTEtMjk3MjY_2c4f9f16-7510-4799-8485-61e20175a6af">59,752</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37828c53082f418d82b181eca97c9828_I20181230" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEtMy0xLTEtMjk3MjY_e6469dc5-a31e-461f-a785-57272b0549e7">106,216</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8503a818334a40a588f1d51c6b02cbdd_I20181230" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEtNS0xLTEtMjk3MjY_32c1d5d6-9f7f-4c22-8cdf-69b6052c04f1">15,222</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9eaed1449a745b293b614e71ca57f4e_I20181230" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEtNy0xLTEtMjk3MjY_871b37dc-e145-44da-a20f-e958d790c698">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ad9ecbc1c9a4fc99c00bdc33b0042a9_I20181230" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEtOS0xLTEtMjk3MjY_6737533d-99e6-4cc9-8b7e-d8fba483b443">34,362</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net earnings </span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzMtMS0xLTEtMjk3MjY_d0ac73e9-b155-4fd3-9b3d-d90f3eb981f3">15,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7363031583c4556a56c66f8230d2edb_D20181231-20191229" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzMtMy0xLTEtMjk3MjY_21ec4559-74d1-4113-a1e7-8389024672c8">15,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzQtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozZDBhMzNmZTRlZDk0Y2JmOTJjY2MyN2M3NGI0ZmYxNV8yNg_f35a61d6-89ee-48d8-9930-936954187940">3.75</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzQtMS0xLTEtMjk3MjY_ca01924e-92b8-4a92-a14a-5c58ee7d62bc">9,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7363031583c4556a56c66f8230d2edb_D20181231-20191229" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzQtMy0xLTEtMjk3MjY_dee20016-8b32-4c35-b40f-72aeedfa282b">9,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzUtMS0xLTEtMjk3MjY_769ffffd-ee65-4d04-9c48-119ba3842e12">1,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7363031583c4556a56c66f8230d2edb_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzUtMy0xLTEtMjk3MjY_182a70d0-5b10-452c-b577-bae04c21e14d">758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i506f1bb3ec9a4c2fa89004c3dc9d077b_D20181231-20191229" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzUtOS0xLTEtMjk3MjY_f1dacd24-7895-4362-9513-5eb81f449c3c">2,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzYtMS0xLTEtMjk3MjY_3e40588b-8f68-47fe-8856-d281da1525f2">6,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i506f1bb3ec9a4c2fa89004c3dc9d077b_D20181231-20191229" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzYtOS0xLTEtMjk3MjY_633f60b8-2d10-498e-8ff9-b04ef1d617d1">6,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzctMS0xLTEtMjk3MjY_2a315f15-9f56-49b8-bca0-50f8b89bf024">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7363031583c4556a56c66f8230d2edb_D20181231-20191229" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzctMy0xLTEtMjk3MjY_241a4687-d50e-4199-9810-420f28d0ac2e">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzgtMS0xLTEtMjk3MjY_c8e521de-d2eb-4770-bf35-380b5f4870d8">669</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f88c24f46d04306b18b2052c29a8b77_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzgtNS0xLTEtMjk3MjY_5445adec-a135-4e83-b2d0-1fa5c81788e1">669</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 29, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzktMS0xLTEtMjk3MjY_1385c261-3961-43d5-9220-5c1084230931">59,471</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70ed7bf48d664a018365719e86ad0f9b_I20191229" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzktMy0xLTEtMjk3MjY_c1117a6a-7f82-44ef-8855-8048214024ca">110,659</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c3c777d14a94558a9524c8d48022809_I20191229" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzktNS0xLTEtMjk3MjY_5fa2ab01-a36c-4acf-87e8-f7bc40574b42">15,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d93b4bd07f45c5b3b285162b1f7ac1_I20191229" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzktNy0xLTEtMjk3MjY_707d6e1d-b163-4716-8f9a-a909115472ef">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32714d4caccf4a978d06df9c559c7342_I20191229" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzktOS0xLTEtMjk3MjY_96eaa855-e6cb-4cd6-9b2b-715af5b8c5fd">38,417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzExLTEtMS0xLTI5NzI2_29cc54dd-511d-4842-841a-0c1e18a40438">14,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbfa2026c924048a41d1a2e7ab20fe2_D20191230-20210103" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzExLTMtMS0xLTI5NzI2_f31fbccf-445c-4707-9088-6eb2383f4b51">14,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEyLTAtMS0xLTI5NzI2L3RleHRyZWdpb246ZWQ1ZjRlY2JmMjNmNGRkODkzZTlkZjIxMThjYWZkMGFfMjY_9bfb4154-5cc3-4da5-ae75-d5e8e5001b6d">3.98</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEyLTEtMS0xLTI5NzI2_8cf3d9e8-e6a1-4f76-9616-328f1b6e9101">10,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbfa2026c924048a41d1a2e7ab20fe2_D20191230-20210103" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEyLTMtMS0xLTI5NzI2_72512645-33bc-4fbc-a780-37052b90eb98">10,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEzLTEtMS0xLTI5NzI2_3be31bcd-3626-4c95-b1bb-62c30124a20e">2,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbfa2026c924048a41d1a2e7ab20fe2_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEzLTMtMS0xLTI5NzI2_ec1cfb09-1ecc-4b30-98b4-b8ea5a894105">931</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if090847b243c45b38f83514b26483411_D20191230-20210103" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEzLTktMS0xLTI5NzI2_1b37190b-e344-4d20-bf61-ac25389a679b">3,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE0LTEtMS0xLTI5NzI2_38135f5d-6b60-4131-a4c9-26b282baea16">3,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if090847b243c45b38f83514b26483411_D20191230-20210103" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE0LTktMS0xLTI5NzI2_b974e49d-e42a-4637-8773-46c5d4e2cb57">3,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE1LTEtMS0xLTI5NzI2_224f0835-6de2-495f-ad29-f0402d2877b9">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbfa2026c924048a41d1a2e7ab20fe2_D20191230-20210103" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE1LTMtMS0xLTI5NzI2_e14fadd8-05f4-4270-bb6f-99bdf20cb28e">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE2LTEtMS0xLTI5NzI2_a40f446a-ae6b-40f2-9678-22de15f33edd">649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa270dceb439ab74cfc1fa351ade8_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE2LTUtMS0xLTI5NzI2_3d4845c4-6600-4b1d-9775-8eb4168bd2a0">649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 3, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE3LTEtMS0xLTI5NzI2_22c378f7-7b3d-4f2e-898a-1eac34421c49">63,278</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5986c2c6f01d4f0ba394a6d7cad02794_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE3LTMtMS0xLTI5NzI2_48705a74-eeb2-4c3b-aea7-86aff001bc3c">113,890</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2264aac360274fdbb45a327357031ad9_I20210103" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE3LTUtMS0xLTI5NzI2_a9a1371a-49cb-4b72-80bb-958c135575c1">15,242</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice303ba3fb57401c902937dcecc85b8a_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE3LTctMS0xLTI5NzI2_afdbd07c-73b2-4b97-ba66-f64d1f143c9b">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice5631336113469c8d53050918b83329_I20210103" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE3LTktMS0xLTI5NzI2_7b64130e-5c37-4a08-94b2-6344b4ec4ab4">38,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net earnings </span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE5LTEtMS0xLTI5NzI2_e42a6e7b-8da6-4b95-82a7-2e8ed972e796">20,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3fc6829cad467cbb53b7a1fe81a50a_D20210104-20220102" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE5LTMtMS0xLTI5NzI2_f1d73549-02a7-4506-8c2a-e3169a581b6a">20,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzIwLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MTg2MzQ0MDFlYjJmNGZkZGI1MTgyNzM1NzBiZDEzYmRfMjY_4f1f47bd-02ba-4440-ab7a-f1a0184e6b3b">4.19</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzIwLTEtMS0xLTI5NzI2_b6de4016-a0c4-42c1-b8b2-fc3195fb179c">11,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a3fc6829cad467cbb53b7a1fe81a50a_D20210104-20220102" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzIwLTMtMS0xLTI5NzI2_2c8118ab-5e1a-4057-942f-42f982d28a2e">11,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzIxLTEtMS0xLTI5NzI2_81ca41d7-1778-4248-8985-98f3258c7819">2,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a3fc6829cad467cbb53b7a1fe81a50a_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzIxLTMtMS0xLTI5NzI2_8b4addd1-b249-4189-8632-e1f61296d5ef">676</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5f195a7f1f400580767c19f5aada99_D20210104-20220102" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzIxLTktMS0xLTI5NzI2_983e9e27-251e-40a6-855b-2cceb8fb66a3">2,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzIyLTEtMS0xLTI5NzI2_90f3abb7-57ef-4b59-a3b9-bf33cde8c26a">3,456</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5f195a7f1f400580767c19f5aada99_D20210104-20220102" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzIyLTktMS0xLTI5NzI2_d485660d-eac8-4438-8699-c6083b6b341b">3,456</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzI0LTEtMS0xLTI5NzI2_fb6792d6-d1e9-49ab-9802-fbb367998ceb">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91696814d2cc4ce18c1ad6fe530463f4_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzI0LTUtMS0xLTI5NzI2_d981db58-9e96-433f-86bb-5412be4ea018">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 2, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzI1LTEtMS0xLTI5NzI2_6b33b669-a890-4830-8c35-79869dee8294">74,023</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i456831c91d5b4616a6190fa546fd617b_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzI1LTMtMS0xLTI5NzI2_6ee36eda-cf67-4e03-88ff-378bd5ef5c32">123,060</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i857ac21d217c4940938fa16c01722dcd_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzI1LTUtMS0xLTI5NzI2_2b33a45c-1e71-4eb3-9a0d-a98dcba03395">13,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864da61d817849afadab2a86db4b41cb_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzI1LTctMS0xLTI5NzI2_0f0821fb-a933-4184-a8b1-cff31ead388a">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32f1b367b80b48e593609d66c7aa128c_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzI1LTktMS0xLTI5NzI2_df126bef-75bf-4f3a-90b5-22069fa3fcb0">39,099</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> CONSOLIDATED STATEMENTS OF CASH FLOWS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Millions) (Note 1)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:61.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.851%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net earnings</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzItMS0xLTEtMjk3MjY_1a4e3228-7ebd-4469-be59-c9b0b4671439">20,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzItMy0xLTEtMjk3MjY_7473f685-e52c-4c89-b9aa-dffd38623f1a">14,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzItNS0xLTEtMjk3MjY_41e3a64b-c57f-477b-81e6-5abeb7563757">15,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings to cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization of property and intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQtMS0xLTEtMjk3MjY_4df7a077-0abc-4096-b799-44981ba738d9">7,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQtMy0xLTEtMjk3MjY_e492809c-abf1-43f4-a9d1-3ee1e1986419">7,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQtNS0xLTEtMjk3MjY_2448a6ee-5489-4809-9680-683d748f90d1">7,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzUtMS0xLTEtMjk3MjY_5f546c3c-de02-427f-8439-d5d4b9e93d5f">1,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzUtMy0xLTEtMjk3MjY_ebb019c6-0f98-4252-b27b-00ca93c834fd">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzUtNS0xLTEtMjk3MjY_b6ecd27a-c844-4224-8104-7c9595941818">977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset write-downs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzctMS0xLTEtMjk3MjY_6d2fc922-f1aa-4788-b9b8-4de2e98cef0a">989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzctMy0xLTEtMjk3MjY_9dce6cc8-d871-416f-b270-5f84ec548ad2">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzctNS0xLTEtMjk3MjY_346b3755-1013-4a36-846e-24d0dbfc9695">1,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration reversal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzgtMS0xLTEtMjk3MjY_f64af6e0-f2d9-4025-95a4-f7af37ed0e48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzgtMy0xLTEtMjk3MjY_09458da0-7e70-45f9-a5a0-ee623d869dae">1,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzgtNS0xLTEtMjk3MjY_7b1c82f4-63f6-4bfd-878c-a9f84547f960">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net gain on sale of assets/businesses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzktMS0xLTEtMjk3MjY_ee4c4cda-11c0-4c4f-b491-4526b088ac1a">617</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzktMy0xLTEtMjk3MjY_f455b289-dbb5-4d47-84e8-3c9a0482a409">111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzktNS0xLTEtMjk3MjY_8b2944d8-e96b-4d85-9008-9bef1637a92a">2,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzExLTEtMS0xLTI5NzI2_ac04cb96-0895-4c1e-be23-661377c0a6d4">2,079</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzExLTMtMS0xLTI5NzI2_b3f3eedb-e3da-447f-935d-f2d55bf6bed7">1,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzExLTUtMS0xLTI5NzI2_08dde179-e31c-4c6d-bea9-2be6fb590db4">2,476</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit losses and accounts receivable allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzEyLTEtMS0xLTI5NzI2_8dfc5c82-6ce6-4346-a11a-ad9364aed634">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzEyLTMtMS0xLTI5NzI2_37246538-843a-419f-b6a2-87681047566e">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzEyLTUtMS0xLTI5NzI2_fa512007-e4e7-467c-a062-5a40ef39d502">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Increase)/Decrease in accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE0LTEtMS0xLTI5NzI2_64799808-812d-4299-a2b8-629d8d43a74c">2,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE0LTMtMS0xLTI5NzI2_d47f5244-239a-4c5e-8f72-b765ec1ae573">774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE0LTUtMS0xLTI5NzI2_7c5265b1-d88c-4123-a74d-b71f02c6e714">289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE1LTEtMS0xLTI5NzI2_a94249f9-d08c-4d40-afe7-c1aa37636ace">1,248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE1LTMtMS0xLTI5NzI2_7026920f-3bb7-41ab-894d-b8d40eca3baa">265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE1LTUtMS0xLTI5NzI2_1bc0967b-4427-4b3e-818e-82052eaa77af">277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE2LTEtMS0xLTI5NzI2_c522e0c1-64ac-43f0-984a-4e8f7652a7db">2,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE2LTMtMS0xLTI5NzI2_f64f1e4d-56ad-4385-8aec-9f198505a720">5,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE2LTUtMS0xLTI5NzI2_91dcde38-0845-41cb-9e48-bce5da71139a">4,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in other current and non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE3LTEtMS0xLTI5NzI2_acba46b5-06ce-4dc0-ba21-bd2da2556de7">1,964</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE3LTMtMS0xLTI5NzI2_50ac6a1c-a8a2-46d6-b4ca-fb89997a850c">3,704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE3LTUtMS0xLTI5NzI2_44cf8264-7c53-4be1-9a11-c7d31dffa597">1,054</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Decrease)/Increase in other current and non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE4LTEtMS0xLTI5NzI2_110483de-05a9-4d0d-849e-48909f4d3819">1,061</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE4LTMtMS0xLTI5NzI2_491d8f05-1b8b-405f-a82b-75ca52870256">744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE4LTUtMS0xLTI5NzI2_220c0de2-d9ee-4bf2-8498-bfb8e17b54ba">1,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash flows from operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE5LTEtMS0xLTI5NzI2_3d67475e-a346-4df4-9a40-884c45a52323">23,410</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE5LTMtMS0xLTI5NzI2_92380605-a725-4a84-8e36-3eda026024e4">23,536</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE5LTUtMS0xLTI5NzI2_12854f16-9fc4-4bfe-8252-290ebe0fee97">23,416</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions to property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzIxLTEtMS0xLTI5NzI2_4f20cff2-b7e8-480a-b45d-2ab14a0cc34b">3,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzIxLTMtMS0xLTI5NzI2_26281358-d883-48c5-9763-f848e27f9816">3,347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzIxLTUtMS0xLTI5NzI2_e195c6e4-b8b2-4b5c-8446-731f380d8a6e">3,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the disposal of assets/businesses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzIyLTEtMS0xLTI5NzI2_28b77ac2-1a5a-42b6-b0ff-ef6e608ea207">711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzIyLTMtMS0xLTI5NzI2_a5cc252a-5c7d-4836-bf1e-5c05b5cf1899">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzIyLTUtMS0xLTI5NzI2_34410055-510d-4bd2-9e64-8108e69da70f">3,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions, net of cash acquired (Note&#160;18)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzIzLTEtMS0xLTI5NzI2_2d3e0922-c957-4dbc-b35b-2acea2bc6f64">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzIzLTMtMS0xLTI5NzI2_be663a32-ae67-491f-8c54-e2786ea644e3">7,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzIzLTUtMS0xLTI5NzI2_9bc6a1e0-ee53-4685-9bee-558ac0897b9b">5,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI0LTEtMS0xLTI5NzI2_db7421b6-8a65-4afc-9907-4bfd60f40448">30,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI0LTMtMS0xLTI5NzI2_c7875c45-49e2-4d16-b5af-dc558ae1fa8f">21,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI0LTUtMS0xLTI5NzI2_4eeaa0dc-57f3-4a6f-97da-c4044c51f4d3">3,920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI1LTEtMS0xLTI5NzI2_4cb14f77-2054-4f51-8d99-98c25e3f0fb3">25,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI1LTMtMS0xLTI5NzI2_b4b8d88f-92c9-4411-a302-0185bfb9d97e">12,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI1LTUtMS0xLTI5NzI2_955cdabe-c047-41fc-a96c-cef8fc8a9a37">3,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI2LTEtMS0xLTI5NzI2_c70ad05c-f8b2-45fb-9c6c-c4859c489780">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" sign="-" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI2LTMtMS0xLTI5NzI2_efdd781e-e77c-423d-9d3c-72394c2481a4">987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI2LTUtMS0xLTI5NzI2_f908ca00-d11a-4768-8f74-83b3ee9da35f">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (primarily licenses and milestones)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI3LTEtMS0xLTI5NzI2_48352e94-fe50-46ff-8e74-90320f3688d2">508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI3LTMtMS0xLTI5NzI2_334ab26e-ebe7-4d50-a10f-eabcd6a049e9">521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI3LTUtMS0xLTI5NzI2_cd2d2c51-00e5-4132-9d66-2ae4b2b6b9fe">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash used by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI4LTEtMS0xLTI5NzI2_49746f9d-db41-4c16-90b8-286e9d48f6f2">8,683</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI4LTMtMS0xLTI5NzI2_61c22f24-929b-4017-917f-cbd46357638f">20,825</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI4LTUtMS0xLTI5NzI2_356d6c7e-de7b-4aa0-9ec0-b0f2409c1fea">6,194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends to shareholders</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMwLTEtMS0xLTI5NzI2_282e325d-2f12-4004-bff7-c2dfb83eebc8">11,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMwLTMtMS0xLTI5NzI2_2abb9144-4668-423f-9c55-c4395d7c5cbd">10,481</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMwLTUtMS0xLTI5NzI2_93af165c-223a-4e23-b187-3b62ebe3c9fa">9,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMxLTEtMS0xLTI5NzI2_5343d432-ee25-45bc-8672-e74e12db7fd2">3,456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMxLTMtMS0xLTI5NzI2_75ce441f-1aea-47b2-9285-9f24cdf96289">3,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMxLTUtMS0xLTI5NzI2_2a372809-9b71-47b8-9442-555a943c7e16">6,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from short-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMyLTEtMS0xLTI5NzI2_68e71ee4-2050-4699-8714-3517ae5e1ff6">1,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMyLTMtMS0xLTI5NzI2_b58978e5-5b05-4514-9739-1afdb0264703">3,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMyLTUtMS0xLTI5NzI2_625687e7-a5c7-4744-90fa-3e712c8182ea">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of short-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMzLTEtMS0xLTI5NzI2_84320525-d4fc-4e70-9730-ff0d443fc20a">1,190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMzLTMtMS0xLTI5NzI2_c6f07919-c678-4a86-a08c-6074b9799788">2,663</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMzLTUtMS0xLTI5NzI2_843a5e86-9a51-4ab4-a2da-c1c01664c325">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from long-term debt, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM0LTEtMS0xLTI5NzI2_9e2ae773-781c-4402-8833-ad99dfdc14ac">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM0LTMtMS0xLTI5NzI2_0115afd1-6973-4c0e-a6ee-2853f4917162">7,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM0LTUtMS0xLTI5NzI2_7dc16b49-009a-4361-abc4-482abddf49ae">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM1LTEtMS0xLTI5NzI2_7efb490c-bfa6-464c-ab24-86b4248856cc">1,802</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM1LTMtMS0xLTI5NzI2_4bd04ec3-b90c-4a66-a4dc-04a05409dc19">1,064</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM1LTUtMS0xLTI5NzI2_0b7e4871-cafc-49a5-9bfc-054bf806f1de">2,823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM2LTEtMS0xLTI5NzI2_625682d5-922a-499f-9894-9e9a598d91a4">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM2LTMtMS0xLTI5NzI2_e4c7db6e-8515-4043-a9ce-5671c7f5f635">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM2LTUtMS0xLTI5NzI2_3d1ed05f-b6e6-4994-b9be-ccaf522f03da">954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM3LTEtMS0xLTI5NzI2_300a0739-8047-4e22-aa49-403391b10782">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" sign="-" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM3LTMtMS0xLTI5NzI2_85e95f79-1d0f-40a2-8467-159af4e8421f">333</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM3LTUtMS0xLTI5NzI2_690ce44c-c8c6-4905-be03-d27bb58b8ee8">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM4LTEtMS0xLTI5NzI2_c9dd73d8-10ed-4b90-9af6-daf2deaa2e76">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM4LTMtMS0xLTI5NzI2_df5cfefb-0895-4ac1-8a85-6c8b0c1e51f4">294</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM4LTUtMS0xLTI5NzI2_cdab6f93-7ebd-4b33-a478-d3ecc63a7842">475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash used by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM5LTEtMS0xLTI5NzI2_b411f18b-e083-4336-aa47-a89b6f243111">14,047</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM5LTMtMS0xLTI5NzI2_e4bc9e0a-06c5-4633-8344-79dcd0f76ce7">6,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM5LTUtMS0xLTI5NzI2_871965bb-bdd5-47af-8ee0-060fc64a7b46">18,015</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQwLTEtMS0xLTI5NzI2_9969119a-5ad2-45b2-9919-dfe345f1fba6">178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQwLTMtMS0xLTI5NzI2_c3fad9f4-b311-4120-ac7a-b7d5b871dcc3">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQwLTUtMS0xLTI5NzI2_0412adb1-bff9-426d-b26d-56f0be609d04">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase/(Decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQxLTEtMS0xLTI5NzI2_28bc0dcf-0268-4441-b8b1-2514e9e3d744">502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQxLTMtMS0xLTI5NzI2_d5801e2e-c5c7-48f4-81c9-87f2877fcaed">3,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQxLTUtMS0xLTI5NzI2_8f335752-adf8-4b32-bfab-0d7b9af94090">802</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of year (Note&#160;1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQyLTEtMS0xLTI5NzI2_38c98703-1d00-426b-b091-52dce989eb98">13,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQyLTMtMS0xLTI5NzI2_ef3148cc-1cd4-4ec5-8c62-533cb9b697fd">17,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2087646dc6744a28755f382fc0a83c8_I20181230" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQyLTUtMS0xLTI5NzI2_c9433189-6de2-427a-89c5-673bafd581a2">18,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of year (Note&#160;1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQzLTEtMS0xLTI5NzI2_631e1e7f-cc73-4420-87ea-c1842595eb45">14,487</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQzLTMtMS0xLTI5NzI2_8d8589ce-00e3-4546-a20d-edbbadd21354">13,985</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQzLTUtMS0xLTI5NzI2_616121e7-2b3a-4cf1-9634-5f00605456b0">17,305</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental cash flow data</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid during the year for:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:InterestPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQ3LTEtMS0xLTI5NzI2_b0151cf0-d41e-43c5-aca9-6a54d244c733">990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:InterestPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQ3LTMtMS0xLTI5NzI2_e3b8f076-b14a-429b-9447-09bfa72129ee">904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:InterestPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQ3LTUtMS0xLTI5NzI2_84b28a47-21cd-425c-90a1-2115709b9ef8">995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest, net of amount capitalized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQ4LTEtMS0xLTI5NzI2_7413bdab-6920-4a29-95c8-b99edb4ea2cd">941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQ4LTMtMS0xLTI5NzI2_83628638-22c3-475b-bc9d-6901522da4b9">841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQ4LTUtMS0xLTI5NzI2_99d5bf83-25a8-4a54-a7bd-c57151175dff">925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQ5LTEtMS0xLTI5NzI2_9a043dba-b00f-40a6-9fce-4616e0d70305">4,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQ5LTMtMS0xLTI5NzI2_f2147b6b-f5ff-44b4-b91d-95caf099d9d2">4,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQ5LTUtMS0xLTI5NzI2_5e2c4522-b563-43ea-81fd-c362a477bfcc">4,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:38pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:61.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.851%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental schedule of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzUyLTEtMS0xLTI5NzI2_88b13ed7-4551-487b-8dff-379a4d32f816">1,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzUyLTMtMS0xLTI5NzI2_8147b34e-f343-4af3-bd41-ad4b5bf963d3">1,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzUyLTUtMS0xLTI5NzI2_be170f46-74a0-439c-bcbe-f9e626b29d4f">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzUzLTEtMS0xLTI5NzI2_625a6984-3fd0-4f02-95a8-440f20651e85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzUzLTMtMS0xLTI5NzI2_79c88237-4810-485c-b478-b58b1beec489">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzUzLTUtMS0xLTI5NzI2_a65e4831-f4aa-4910-824d-529d85411b2c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzU2LTEtMS0xLTI5NzI2_653f9fe7-4c3b-4027-8d97-832748a3119a">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzU2LTMtMS0xLTI5NzI2_3328ce27-7762-4200-a6c6-385e83ac188e">7,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzU2LTUtMS0xLTI5NzI2_1de24905-b20d-4c93-979a-3b87f49abc04">7,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of liabilities assumed and noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzU3LTEtMS0xLTI5NzI2_26be08bd-97c5-4d4f-be69-783fbaab8a91">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzU3LTMtMS0xLTI5NzI2_b2525b28-ef53-4e32-ab40-e7a58478c00f">432</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzU3LTUtMS0xLTI5NzI2_065f2428-62c9-4693-bae6-d4961c060bc6">1,418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash paid for acquisitions (Note 18)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzU4LTEtMS0xLTI5NzI2_06b225da-11c7-431d-bf29-8c877472d654">60</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzU4LTMtMS0xLTI5NzI2_71282c1a-442f-4458-bb59-0fa16c2889f2">7,323</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzU4LTUtMS0xLTI5NzI2_d73d3013-20a1-4d4a-9da7-db529f2f9e55">5,810</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_139"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzY1OTcwNjk4MjE0MzU_93ff29ca-8893-4b8d-831f-1bad62915176" continuedAt="idec29c5d3bef4edb907daefdb7011426" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="idec29c5d3bef4edb907daefdb7011426" continuedAt="idc08f82752654af6b5e808db9b9748b0"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODY0_7cf5e221-c61e-4819-a85b-df1580f0e995" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Johnson&#160;&amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTIy_cd361460-6d5d-44f1-a46e-87767bec70ff" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of the Company and Business Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has approximately <ix:nonFraction unitRef="employee" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-2" name="jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzQ1NA_0c59a766-461c-4cba-8c54-8f069418173c">141,700</ix:nonFraction>&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is organized into <ix:nonFraction unitRef="segment" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzc3MQ_881238ae-32f2-42c1-a1f0-dc5208b77d46">three</ix:nonFraction> business segments: Consumer Health, Pharmaceutical and Medical Devices. The Consumer Health segment includes a broad range of products used in the Baby Care, Oral Care, Skin Health/Beauty, Over-the-Counter pharmaceutical, Women&#8217;s Health and Wound Care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on six therapeutic areas, including Immunology, Infectious diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The Medical Devices segment includes a broad range of products used in the Orthopaedic, Surgery, Interventional Solutions (cardiovascular and neurovascular) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company announced its intention to separate the Company&#8217;s Consumer Health business, with the intention to create a new, publicly traded company. The Company is targeting completion of the planned separation in 18 to 24 months after initial announcement.</span></div></ix:nonNumeric><div style="margin-top:3pt"><span><br/></span></div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTQ2_6416aba8-dd2c-4e74-8c54-f8c175ab033d" continuedAt="i64fd5720274e4e69a90dc78d5f6b7d08" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in fiscal 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Adopted as of January 2, 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. There were no new material accounting standards issued in fiscal 2021 that impacted the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASU 2021-01: Reference Rate Reform </span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i64fd5720274e4e69a90dc78d5f6b7d08">In mid- 2017, the Financial Conduct Authority (FCA) announced that it will no longer require banks to submit rates for the London Interbank Offered Rate (LIBOR) after 2021 hence market participants should work to transition to alternative reference rates (Reference Rate Reform) and should not rely on LIBOR being available after the end of 2021. Reference rate reform is the term used to refer to the efforts that have been undertaken by regulators and other market participants to introduce new reference rates that are based on a larger and more liquid population of observable transactions. The Company evaluated the implications of reference rate reform and applicable financial reporting guidance in ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting on its key financial and commercial contracts that referenced LIBOR including any hedging relationships. Most contracts reviewed will mature prior to the termination of LIBOR or will be modified to apply a new reference rate (primarily the Secured Overnight Financing Rate &#8220;SOFR&#8221; where applicable). The company also applied available practical expedients under ASC 848 to in scope financial and commercial contracts that previously referenced LIBOR when applicable. As a result, the Company's implementation of any reference rate reform provisions to commercial and financial contracts did not result in any material change for the Company.</ix:continuation>  </span><span style="color:#1f3864;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </span></div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTA5_04a09443-87cc-40bb-9323-75ab12987dfc" continuedAt="i2fbd878828764aa4a1453d142fcb8085" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idc08f82752654af6b5e808db9b9748b0" continuedAt="icca7a162d7e64d1aa6ceb21852373100"><ix:continuation id="i2fbd878828764aa4a1453d142fcb8085"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at least an investment grade credit rating.  The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than <ix:nonFraction unitRef="number" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="INF" name="jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzUzNTQ_0941b941-2234-4acb-a64a-4a13cf4a7862">102</ix:nonFraction>% of their value.  The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at <ix:nonFraction unitRef="number" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="INF" name="jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzU3Mjc_9aeb75c3-7754-4695-bcfe-9651e5a10506">102</ix:nonFraction>% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.</span></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODY1_6f107230-336b-4d28-ba28-f93906011398" continuedAt="i5ab1f9db0c354a8e8384361e46d6c345" escape="true">Investments</ix:nonNumeric></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5ab1f9db0c354a8e8384361e46d6c345">Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.</ix:continuation>&#160;</span></div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODc0_138cd3f7-0299-40e2-8c65-b44f0cd47bda" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment and Depreciation</span></div><div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="jnj:EstimatedUsefulLivesOfAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODM1_02968779-91a6-434d-9739-9895e2e4379d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:86.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i43031434703546208388df65cfb38be8_D20210104-20220102" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90YWJsZToyY2E3YTE0MGJmYWI0NDE0YWM4Yzc3ODJmZmFmMzFkOS90YWJsZXJhbmdlOjJjYTdhMTQwYmZhYjQ0MTRhYzhjNzc4MmZmYWYzMWQ5XzAtMS0xLTEtMjk3MjYvdGV4dHJlZ2lvbjpjZWVmZjgyNGJmYzA0OTM4YWIyMzA0YjY5YjNkMzc5ZF80_488d08d1-8c14-4ec2-9116-39f6b0706862">20</ix:nonNumeric>&#160;- <ix:nonNumeric contextRef="i014ba6f3e80849a28122f5bc50cd0d40_D20210104-20220102" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90YWJsZToyY2E3YTE0MGJmYWI0NDE0YWM4Yzc3ODJmZmFmMzFkOS90YWJsZXJhbmdlOjJjYTdhMTQwYmZhYjQ0MTRhYzhjNzc4MmZmYWYzMWQ5XzAtMS0xLTEtMjk3MjYvdGV4dHJlZ2lvbjpjZWVmZjgyNGJmYzA0OTM4YWIyMzA0YjY5YjNkMzc5ZF85_cf817473-25b8-49c9-bed2-9844fe81e51d">30</ix:nonNumeric>&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id99da0671adc429480c2f2f9dfd88fcc_D20210104-20220102" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90YWJsZToyY2E3YTE0MGJmYWI0NDE0YWM4Yzc3ODJmZmFmMzFkOS90YWJsZXJhbmdlOjJjYTdhMTQwYmZhYjQ0MTRhYzhjNzc4MmZmYWYzMWQ5XzEtMS0xLTEtMjk3MjYvdGV4dHJlZ2lvbjowOTk0NTk1MWI5Y2Y0OGU5OTkwNjY1MDk3NmIzZWQyNV80_23aff49a-e7b6-43b7-ba11-1f1e073a2e87">10</ix:nonNumeric>&#160;- <ix:nonNumeric contextRef="i698e54dd726c4d32801340b6a2864ac6_D20210104-20220102" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90YWJsZToyY2E3YTE0MGJmYWI0NDE0YWM4Yzc3ODJmZmFmMzFkOS90YWJsZXJhbmdlOjJjYTdhMTQwYmZhYjQ0MTRhYzhjNzc4MmZmYWYzMWQ5XzEtMS0xLTEtMjk3MjYvdGV4dHJlZ2lvbjowOTk0NTk1MWI5Y2Y0OGU5OTkwNjY1MDk3NmIzZWQyNV85_afde01e5-4181-48cd-8aeb-1a3ad5035ac2">20</ix:nonNumeric>&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia09026d98ab54d0ab3a6818b803f2d60_D20210104-20220102" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90YWJsZToyY2E3YTE0MGJmYWI0NDE0YWM4Yzc3ODJmZmFmMzFkOS90YWJsZXJhbmdlOjJjYTdhMTQwYmZhYjQ0MTRhYzhjNzc4MmZmYWYzMWQ5XzItMS0xLTEtMjk3MjYvdGV4dHJlZ2lvbjo3MGJlOGM1ZWY3NjI0ZjY2OWY0MDQ0OTRkNTkxNTI1Yl80_0c897137-7de6-44ab-b695-57f9e8ac5b8b">2</ix:nonNumeric>&#160;- <ix:nonNumeric contextRef="i7bd54d7094d64fd0b19d0a1281d9b700_D20210104-20220102" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90YWJsZToyY2E3YTE0MGJmYWI0NDE0YWM4Yzc3ODJmZmFmMzFkOS90YWJsZXJhbmdlOjJjYTdhMTQwYmZhYjQ0MTRhYzhjNzc4MmZmYWYzMWQ5XzItMS0xLTEtMjk3MjYvdGV4dHJlZ2lvbjo3MGJlOGM1ZWY3NjI0ZjY2OWY0MDQ0OTRkNTkxNTI1Yl85_50b45c53-0e0f-499d-b8b4-f9eed479a02c">13</ix:nonNumeric>&#160;years</span></div></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from <ix:nonNumeric contextRef="ia0ad24090c2d488cb2a8dadbaca511fa_D20210104-20220102" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzcyMzM_c53845f4-499e-434f-aecf-402f1e2ab972">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i28f696c1c6874735a62135bedd0cf600_D20210104-20220102" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzcyMzk_7dd027c5-6c30-4c75-88ab-da131e537b90">8</ix:nonNumeric>&#160;years.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#8217;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODE4_3ff70e78-fa33-4f92-943c-cd9f5b88bab0" continuedAt="i9a95d177fe234664b5b234632612901b" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Managed Care, Medicare and Medicaid programs, which amounted to $<ix:nonFraction unitRef="usd" contextRef="i19a5a3c7ee35405ba80137bf84570da6_I20220102" decimals="-8" name="jnj:AccruedRebatesReturnsAndPromotions" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzg5OTE_723c208c-7d0d-4180-8319-b393eebbc4c9">7.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ib90b59b163b542a1adf97f356be068eb_I20210103" decimals="-8" name="jnj:AccruedRebatesReturnsAndPromotions" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzg5OTg_9cb06134-769f-4660-8ab1-13726b17ad2e">7.2</ix:nonFraction> billion as of January&#160;2, 2022 and January&#160;3, 2021, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#8217;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#8217;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icca7a162d7e64d1aa6ceb21852373100" continuedAt="i503c2474bd0a4a70a0211d612ae6280d"><ix:continuation id="i9a95d177fe234664b5b234632612901b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately <ix:nonFraction unitRef="number" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="3" name="jnj:SalesReturnReserve" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzEwNTM0_0402de88-4b59-42d4-ac26-6d92d78a1d10"><ix:nonFraction unitRef="number" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="3" name="jnj:SalesReturnReserve" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzEwNTM0_7df76798-3905-4814-942c-a09d04c15da1"><ix:nonFraction unitRef="number" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="3" name="jnj:SalesReturnReserve" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzEwNTM0_c22fd06c-16e8-46d0-81d9-7315c0908a5a">1.0</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of annual net trade sales during each of the fiscal years&#160;2021,&#160;2020&#160;and&#160;2019.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. For all years presented, profit-share payments were less than <ix:nonFraction unitRef="number" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="3" name="jnj:ProfitLossPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzExNDI0_0106fb8d-d7a7-4e81-990d-8f9a6a4deca1"><ix:nonFraction unitRef="number" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="3" name="jnj:ProfitLossPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzExNDI0_646ac5b4-6d9f-41af-8bb4-6bcc8f64154b"><ix:nonFraction unitRef="number" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="3" name="jnj:ProfitLossPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzExNDI0_afbb7540-da97-4d5e-891f-b1d811b36e39">3.0</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the total revenues and are included in sales to customers.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.</span></div></ix:continuation><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ShippingAndHandlingCostPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTMz_1dffb8b5-1363-43c5-a6f0-72bb7d7ef43f" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs incurred were $<ix:nonFraction unitRef="usd" contextRef="i460777456be14637947184c662627b8b_D20210104-20220102" decimals="-8" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzExNjQ1_18881b25-c447-4126-895b-2d6ff986718a">1.1</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i9624c6a1bedd497c80dbb2352574e47f_D20191230-20210103" decimals="-8" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzExNjQ5_118e6e83-fbc8-474c-b671-c83c03d06af0">1.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i093d06247d2c44aa8f18996fcd289352_D20181231-20191229" decimals="-8" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzExNjU2_99f3b1c2-bbba-4899-8607-faae83ff2983">1.0</ix:nonFraction> billion in fiscal years 2021, 2020 and 2019, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than <ix:nonFraction unitRef="number" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="3" name="jnj:ShippingandHandlingCostsasaPercentofSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzExODQx_2e8d4def-cfb6-4e4d-84c6-2dcd4f7189fe"><ix:nonFraction unitRef="number" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="3" name="jnj:ShippingandHandlingCostsasaPercentofSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzExODQx_c0281ca5-b274-4f13-929c-681ca21db445"><ix:nonFraction unitRef="number" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="3" name="jnj:ShippingandHandlingCostsasaPercentofSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzExODQx_e65d58ae-4b54-4dc6-825f-c4275cf06c97">0.5</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of sales to customers for all periods presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTM0_8236dbb4-664d-4abd-bacb-000ca93a9128" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODc2_c36eca7a-9b02-46c8-a807-d52be9122e01" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2021 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions.  See Note&#160;5 for further details on Intangible Assets and Goodwill.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODU1_c6e45f46-e0d6-490a-9e01-8ad810a3e18c" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value.  Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#8217;s impact on the Company&#8217;s financial performance; (2)&#160;protect the Company&#8217;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODI4_45526e87-8e3c-48f3-95a6-594111826ee8" continuedAt="i760342e622be42409b1cf8e3dd471b54" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTI0_2cce01d2-b420-436a-93e5-bea5f12e0c78"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTI0_dee6b310-adcd-43bf-a063-cd1559b71416">Other assets</span></span>, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODU5_5e9c1949-8e21-4631-bf9f-ba8181485230"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTM2_2dbaf7d6-873f-4b21-881f-1b610527d361">Accrued liabilities</span></span>, and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODgz_5fa03461-5e24-4b61-b8c9-f2468f3220fb"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODgz_8dab58da-7c04-4417-a1bc-72271f9a3a36">Other liabilities</span></span> on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i503c2474bd0a4a70a0211d612ae6280d" continuedAt="i6d06303e790047bbbab9b17dab7270bd"><ix:continuation id="i760342e622be42409b1cf8e3dd471b54"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-8" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE2MjA5_a7887645-2b20-4619-bdba-7d308219b21a">0.9</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-8" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE2MjE2_3956ad1f-bf74-4431-aeef-9eeeceb092fb">1.0</ix:nonFraction>&#160;billion in 2021 and 2020, respectively. The lease liability was $<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-8" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE2Mjc1_ff535cbc-d8ca-4ca7-8e7b-3fbc9afc8160">1.0</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-8" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE2Mjgy_81235d1b-c13e-46c7-934f-309596d68b12">1.1</ix:nonFraction>&#160;billion in 2021and 2020, respectively. The operating lease costs were $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-8" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE2MzQ4_614f8af6-2b14-4be1-86bb-322a9585b96c">0.3</ix:nonFraction>&#160;billion, $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-8" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE2MzUy_fa99ae69-6e5c-48e5-8deb-fb68938d01c0">0.3</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-8" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE2MzU5_8dcae0da-438b-4241-8ed7-f8502c39afe2">0.3</ix:nonFraction>&#160;billion in 2021, 2020 and 2019, respectively. Cash paid for amounts included in the measurement of lease liabilities were $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-8" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE2NDc2_6d4fe5e0-2e44-4442-a1f7-238493b46ef6">0.3</ix:nonFraction>&#160;billion, $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-8" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE2NDgz_a49a461e-8ff1-4c7a-a997-5be5bb2f10c8">0.3</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-8" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzU0OTc1NTgxOTMzMDE_873ef49f-2539-4d89-ab4e-b1f4f56d5da9">0.3</ix:nonFraction>&#160;billion in 2021, 2020 and 2019, respectively.</span></div></ix:continuation><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="jnj:ProductLiabilityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODMy_d9041113-5333-4a62-a6b6-2a71f28e5601" continuedAt="ieeb2720406964631ae620e45c002e670" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Product Liability</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div></ix:nonNumeric><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ieeb2720406964631ae620e45c002e670"> The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.</ix:continuation> </span></div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODg0_8ac9023a-bb37-45ea-943c-c368d6c056ff" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development.  Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product.  Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#8217;s operations. In general, the income statement presentation for these collaborations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nature/Type of Collaboration</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Earnings Presentation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third-party sale of product &amp; profit share payments received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to customers</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties/milestones paid to collaborative partner (post-regulatory approval)*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties received from collaborative partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payments&#160;&amp; milestones paid to collaborative partner (pre-regulatory approval)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development payments to collaborative partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development payments received from collaborative partner or government entity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all years presented, there was no individual project that represented greater than <ix:nonFraction unitRef="number" contextRef="ic2ccb55418494f0c9e1a4c75f0b03e66_D20210104-20220102" decimals="INF" name="jnj:ConcentrationRiskThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE5MjQ5_1006ff07-af51-4c87-937c-7a0ca0ab1409"><ix:nonFraction unitRef="number" contextRef="if755ebb14d5b4945b2b45f2055df1f4d_D20181231-20191229" decimals="INF" name="jnj:ConcentrationRiskThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE5MjQ5_46050c12-4323-4140-a7b8-276814f18219"><ix:nonFraction unitRef="number" contextRef="i2214ef047a294d0ca9d41d06ad0fb607_D20191230-20210103" decimals="INF" name="jnj:ConcentrationRiskThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE5MjQ5_ceaa9e52-5205-4c82-b852-22c1bd2ab8c7">5</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the total annual consolidated research and development expense.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, co-developed with Bayer HealthCare AG and IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, licensed from Genmab A/S.</span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODM4_4e6986aa-b09c-4fb0-a1f8-b4c0d8156d27" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE5OTc4_489bd204-26b5-41ee-a36d-f85b048f6086">2.7</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE5OTgy_f379ade7-0d76-4ff3-8c1c-a24203c11ce3">2.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE5OTg5_f6fb8db9-ec6a-477b-8dd8-77922dfed803">2.2</ix:nonFraction> billion in fiscal years 2021, 2020 and 2019, respectively.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6d06303e790047bbbab9b17dab7270bd" continuedAt="i018a78f07dee46a89621dff8276ea63b"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODQ5_056ca1ba-a3a6-40ac-ac81-eda584d0b1f9" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from <ix:nonFraction unitRef="number" contextRef="i13202586bd644a6e92b8bfdf9c3a4ede_D20170102-20171231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzIxMTk3_f3bba072-b7eb-43a3-b1c2-e8d6eec54e8f">35</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i90352e12079c4d1fb386797dfa54f1b7_D20180101-20181230" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzIxMjAz_c6aba3b9-b1bf-4e8c-bba5-b4ea980dc4b6">21</ix:nonFraction>%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of <ix:nonFraction unitRef="number" contextRef="i90352e12079c4d1fb386797dfa54f1b7_D20180101-20181230" decimals="3" name="jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzIxNDU4_d54b827a-0ced-468d-a45c-50d68875048d">15.5</ix:nonFraction>% and all other earnings were taxed at a rate of <ix:nonFraction unitRef="number" contextRef="i90352e12079c4d1fb386797dfa54f1b7_D20180101-20181230" decimals="3" name="jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzIxNTA4_c5d680e6-e3fe-4b40-96c1-e72f0a5e8cb8">8.0</ix:nonFraction>%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2021 was approximately $<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-8" name="jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzIxNjk5_af3d661a-0ecb-4cbc-9a88-b771099a34bf">6.9</ix:nonFraction>&#160;billion, of which $<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-8" name="jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzIxNzEy_903dd59e-480e-44ba-b50c-936b907a4df3">6.1</ix:nonFraction>&#160;billion is classified as noncurrent and reflected as &#8220;Long-term taxes payable&#8221; on the Company&#8217;s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI).  GILTI is described as the excess of a U.S. shareholder&#8217;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#8220;period cost&#8221;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., &#8220;deferred method&#8221;). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-8" name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzIzNTM0_859d778e-3883-4576-9f6f-602a2e6c1335">0.7</ix:nonFraction> billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">See Note 8 to the Consolidated Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">for further information regarding income taxes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTQx_e60adc56-e726-4047-8476-1158c4190f0e" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Earnings Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODY3_e7eb8c6e-99b9-4b42-aa01-252ada84ee6a" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of January 2, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#8217;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the fiscal year ended January 2, 2022, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i018a78f07dee46a89621dff8276ea63b"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="jnj:FiscalPeriodPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODQy_516ef94d-e2b4-433e-9dea-61c247d90750" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Closing Date</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODU2_56e0ef4b-c701-4d93-9d8b-c877af9e3877" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_145"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90ZXh0cmVnaW9uOjZiN2ZjYzZmYjA4NjQ5OGFiMGE4MjMwOGZkZDgwZjNjXzEwOTU_9746d2fa-7d8f-4b90-a2ee-226d064f9aa2" continuedAt="i6023bd2b18d64bf18ceca2e78a7746b4" escape="true">Cash, Cash Equivalents and Current Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="i6023bd2b18d64bf18ceca2e78a7746b4" continuedAt="ia314ed09957343e2b53ddf2628bf597e"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90ZXh0cmVnaW9uOjZiN2ZjYzZmYjA4NjQ5OGFiMGE4MjMwOGZkZDgwZjNjXzEwODg_1256febe-dc89-41a0-87ca-ebfda85ddedc" escape="true"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the fiscal year 2021 and 2020, cash, cash equivalents and current marketable securities were comprised of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.615%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.056%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.219%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Loss</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0d9084821448c9b54197410a611a82_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzItMi0xLTEtMjk3MjY_5ae299a3-8d6f-4c0d-9df1-5817b448d221">2,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0d9084821448c9b54197410a611a82_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzItNi0xLTEtMjk3MjY_ae5ada8f-c25f-483d-84ec-b509f55c6903">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0d9084821448c9b54197410a611a82_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzItOC0xLTEtMjk3MjY_81a985eb-1de5-4e5d-8fde-5a1564159bd6">2,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0d9084821448c9b54197410a611a82_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzItMTAtMS0xLTI5NzI2_45072976-054d-49c7-9dfe-9f483ada15c9">2,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0d9084821448c9b54197410a611a82_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzItMTItMS0xLTI5NzI2_7058adf5-c07f-4428-9b94-169dede6ab54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied5749f9adf2410da151a894ff6b6ef6_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzQtMi0xLTEtMjk3MjY_229aea46-432e-42ee-b414-ffdea38dc08b">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied5749f9adf2410da151a894ff6b6ef6_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzQtNi0xLTEtMjk3MjY_d9464523-c276-45ac-883b-bd4d58c1df0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied5749f9adf2410da151a894ff6b6ef6_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzQtOC0xLTEtMjk3MjY_4b0be5ca-2df4-49ae-8dd9-e5729eee6a14">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied5749f9adf2410da151a894ff6b6ef6_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzQtMTAtMS0xLTI5NzI2_b20226ab-6249-440e-bc4c-8f3b9a8d1a12">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied5749f9adf2410da151a894ff6b6ef6_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzQtMTItMS0xLTI5NzI2_248c590b-fee0-4471-a38d-4a51c212e3b1">916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252e4b54420c4dde85f5fd67aa0422b4_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzUtMi0xLTEtMjk3MjY_25038257-7d0a-4433-85c7-94a265900ebc">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252e4b54420c4dde85f5fd67aa0422b4_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzUtNi0xLTEtMjk3MjY_2b1b8b56-c1da-4e09-bce7-456618ae9c92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252e4b54420c4dde85f5fd67aa0422b4_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzUtOC0xLTEtMjk3MjY_3d312071-1920-45b3-8d35-02b574e3b03b">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252e4b54420c4dde85f5fd67aa0422b4_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzUtMTAtMS0xLTI5NzI2_0bee8270-b6a7-4271-9d5d-82f64d6b5d91">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252e4b54420c4dde85f5fd67aa0422b4_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzUtMTItMS0xLTI5NzI2_160aa922-bd15-4f6b-b574-d9fc6b1ed223">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i452410a40d07461f83a08316f634a401_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzctMi0xLTEtMjk3MjY_5edc3b46-bd32-45f4-a5a3-ae196322817e">3,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i452410a40d07461f83a08316f634a401_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzctNi0xLTEtMjk3MjY_f79cf6f1-a32a-4eef-845a-e6800eaee35b">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i452410a40d07461f83a08316f634a401_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzctOC0xLTEtMjk3MjY_85989d8a-2ea1-4fb2-bedd-ff6f19c11af8">3,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i452410a40d07461f83a08316f634a401_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzctMTAtMS0xLTI5NzI2_92dc30bf-0d8b-4345-9bd0-3243063b8ba2">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i452410a40d07461f83a08316f634a401_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzctMTItMS0xLTI5NzI2_b7db61d4-8a61-4a7c-99cb-2ead233ef61b">3,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e8bf5abffa4483b11b26ea2161affe_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzgtMi0xLTEtMjk3MjY_b82e10e6-9238-461f-afd4-590fd221bf96">1,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e8bf5abffa4483b11b26ea2161affe_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzgtNi0xLTEtMjk3MjY_40bb6935-5aac-442a-8a0d-d2248086f537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e8bf5abffa4483b11b26ea2161affe_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzgtOC0xLTEtMjk3MjY_38c98ca5-f37e-4dba-923f-5ef93bb097dc">1,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e8bf5abffa4483b11b26ea2161affe_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzgtMTAtMS0xLTI5NzI2_06a90dc2-65b6-4127-ab5b-14d072ff9fde">1,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e8bf5abffa4483b11b26ea2161affe_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzgtMTItMS0xLTI5NzI2_deb9fb21-6193-4634-882a-b6a6119e9e38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if52d136488484e92a32ea314340d972c_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzktMi0xLTEtMjk3MjY_e4764190-49f1-4b26-9940-e7a6b7cf799b">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if52d136488484e92a32ea314340d972c_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzktNi0xLTEtMjk3MjY_19759346-1315-48fc-9768-fd99b8ec6145">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if52d136488484e92a32ea314340d972c_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzktOC0xLTEtMjk3MjY_6878e92d-a64e-4932-bb06-296478763f44">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if52d136488484e92a32ea314340d972c_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzktMTAtMS0xLTI5NzI2_812a5fae-d3b9-4df4-a2be-897236d2b4ff">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if52d136488484e92a32ea314340d972c_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzktMTItMS0xLTI5NzI2_59698640-2a11-482a-b352-7595348ad47d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Subtotal </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb97dbd3891498f92976302fc99a0ec_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEwLTItMS0xLTI5NzI2_b7c7ad37-ceac-4a34-b265-1320f95c128b">11,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb97dbd3891498f92976302fc99a0ec_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEwLTYtMS0xLTI5NzI2_e263bc16-9c13-45ee-9a6b-5a5a50088d89">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb97dbd3891498f92976302fc99a0ec_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEwLTgtMS0xLTI5NzI2_6bf23c99-4d49-4f6a-9876-8c3c529c200e">11,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb97dbd3891498f92976302fc99a0ec_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEwLTEwLTEtMS0yOTcyNg_e9843c08-ef7b-4f8c-a29e-bedec61a7353">7,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb97dbd3891498f92976302fc99a0ec_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEwLTEyLTEtMS0yOTcyNg_55f57d8a-d32e-46dd-b75d-8064587ee232">4,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id14a4eca31dd4e00a85267ec8f40ec78_I20220102" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEyLTItMS0xLTI5NzI2_5b53e09c-dc60-44ff-b4b3-e61ead57f962">19,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id14a4eca31dd4e00a85267ec8f40ec78_I20220102" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEyLTYtMS0xLTI5NzI2_8bdfae22-65ac-4e12-8ec0-79626b765c12">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id14a4eca31dd4e00a85267ec8f40ec78_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEyLTgtMS0xLTI5NzI2_aa5c6f99-385d-4aec-9358-03b741bbe355">19,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id14a4eca31dd4e00a85267ec8f40ec78_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEyLTEwLTEtMS0yOTcyNg_6de8381b-f9c2-49e9-bd01-cbd3ace66ce3">6,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id14a4eca31dd4e00a85267ec8f40ec78_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEyLTEyLTEtMS0yOTcyNg_60338d2f-b2a4-43a3-86e9-aba0c6243db3">12,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Sovereign Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf6e725073c14b38991908baa96e1d7d_I20220102" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEzLTItMS0xLTI5NzI2_55b8bb6a-f0dc-4b53-883a-a45938f441de">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf6e725073c14b38991908baa96e1d7d_I20220102" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEzLTYtMS0xLTI5NzI2_ef5bab9e-3471-48eb-b940-c977349fed79">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf6e725073c14b38991908baa96e1d7d_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEzLTgtMS0xLTI5NzI2_018ec2dc-f174-47dc-aa0e-9a449c6b82ac">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf6e725073c14b38991908baa96e1d7d_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEzLTEwLTEtMS0yOTcyNg_4089a6f5-7c14-400f-ac23-eccc8d5e5d4c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf6e725073c14b38991908baa96e1d7d_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEzLTEyLTEtMS0yOTcyNg_298f2ea6-e20c-428e-86ca-8e25d127f4da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ea071f45f34fd7ba90322c1178679b_I20220102" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE0LTItMS0xLTI5NzI2_c85b1d09-cce3-4bae-b5a9-bdbcc8359ea5">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ea071f45f34fd7ba90322c1178679b_I20220102" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE0LTYtMS0xLTI5NzI2_9c4782cf-e5cc-4507-bc70-b8a5d159e399">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ea071f45f34fd7ba90322c1178679b_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE0LTgtMS0xLTI5NzI2_1f9c7bbf-dda8-4181-904b-8f8694643489">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ea071f45f34fd7ba90322c1178679b_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE0LTEwLTEtMS0yOTcyNg_5b15c3e4-9df5-4509-975a-d0b4eaff58c6">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ea071f45f34fd7ba90322c1178679b_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE0LTEyLTEtMS0yOTcyNg_ba986952-162b-40d3-9dfd-d1eaeb76012e">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Subtotal available for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9cfb292ef54c7a93d6ee930b4c18b6_I20220102" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE2LTItMS0xLTI5NzI2_63a6c2bd-f9a4-4dfd-ac55-2c1aa57c552f">19,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica9cfb292ef54c7a93d6ee930b4c18b6_I20220102" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE2LTYtMS0xLTI5NzI2_73ec889d-d139-4920-a7e5-d98fb2659ddb">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9cfb292ef54c7a93d6ee930b4c18b6_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE2LTgtMS0xLTI5NzI2_49aca93a-0720-43f4-9631-78ab60b14ccd">19,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9cfb292ef54c7a93d6ee930b4c18b6_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE2LTEwLTEtMS0yOTcyNg_269c83b2-c866-4493-89f5-4dd625e49cb6">6,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9cfb292ef54c7a93d6ee930b4c18b6_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE2LTEyLTEtMS0yOTcyNg_800fd79d-5f17-43b1-b7c3-a82d280bf720">12,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE4LTEwLTEtMS0yOTcyNg_6ddcc9fa-beca-4848-8467-8bb220ab9737">14,487</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE4LTEyLTEtMS0yOTcyNg_34e0c792-e2c7-4e67-85af-c670951fc605">17,121</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.287%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Gain</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22c801516ef3458cb70b9d6768e94cc8_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzItMi0xLTEtMjk3MjY_176e139a-2adf-4f7f-9656-afefc13c6d93">2,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22c801516ef3458cb70b9d6768e94cc8_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzItNC0xLTEtMjk3MjY_40f2651e-8787-459c-8393-809a043d8206">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22c801516ef3458cb70b9d6768e94cc8_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzItOC0xLTEtMjk3MjY_d30bcec1-f51c-47a3-9b53-4239c412af59">2,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22c801516ef3458cb70b9d6768e94cc8_I20210103" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzItMTAtMS0xLTI5NzI2_5ae8d6e4-23d6-4206-bcac-358b0a3e34d9">2,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22c801516ef3458cb70b9d6768e94cc8_I20210103" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzItMTItMS0xLTI5NzI2_8c875d50-eb8e-4181-928d-c5869866df5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f498cef62e47498c8115a8257a7f5c_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzQtMi0xLTEtMjk3MjY_719f5994-80c4-4027-9eeb-257b22faf3de">690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f498cef62e47498c8115a8257a7f5c_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzQtNC0xLTEtMjk3MjY_ccd180d2-53db-4418-b25a-1dc0695cbd4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f498cef62e47498c8115a8257a7f5c_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzQtOC0xLTEtMjk3MjY_25a410b2-d067-4589-a38e-ff8448b580cd">690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f498cef62e47498c8115a8257a7f5c_I20210103" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzQtMTAtMS0xLTI5NzI2_1ce5f145-63b1-4803-91a1-2ea0ad2df127">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f498cef62e47498c8115a8257a7f5c_I20210103" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzQtMTItMS0xLTI5NzI2_3342f958-946c-4507-b516-016f99a37a01">690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d7e47ac51a74794aa5dd2b7dddcbc9a_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzUtMi0xLTEtMjk3MjY_0d73699f-8f9a-494d-ae4b-35cde0b2ddfe">1,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d7e47ac51a74794aa5dd2b7dddcbc9a_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzUtNC0xLTEtMjk3MjY_14548fa5-4fc9-4b61-b371-b364d8a4f04b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d7e47ac51a74794aa5dd2b7dddcbc9a_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzUtOC0xLTEtMjk3MjY_2e3b123f-61cf-4eaa-8d28-f89df668765f">1,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d7e47ac51a74794aa5dd2b7dddcbc9a_I20210103" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzUtMTAtMS0xLTI5NzI2_af2148f8-3d18-45b9-8e2f-9bb6e63dec43">1,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d7e47ac51a74794aa5dd2b7dddcbc9a_I20210103" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzUtMTItMS0xLTI5NzI2_09eafca4-5d58-4b45-bede-173c5daaae0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dda7dc33acb494ab90787cb95a42bd6_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzctMi0xLTEtMjk3MjY_74d6d83d-71f0-4e62-a399-e920b9d4a95b">2,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dda7dc33acb494ab90787cb95a42bd6_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzctNC0xLTEtMjk3MjY_22191a82-d65c-4434-ae39-3b16c5c2ac04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dda7dc33acb494ab90787cb95a42bd6_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzctOC0xLTEtMjk3MjY_4900fc58-9d52-4ccf-baa2-4d6510d4def0">2,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dda7dc33acb494ab90787cb95a42bd6_I20210103" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzctMTAtMS0xLTI5NzI2_954166b2-492f-4835-9fd1-123f3b35fdff">1,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dda7dc33acb494ab90787cb95a42bd6_I20210103" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzctMTItMS0xLTI5NzI2_e656c38c-1ef5-4862-86fb-36c2262c5092">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec8bdf1492e47008be52fa4584b89b6_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzgtMi0xLTEtMjk3MjY_f4ea7e7d-766f-4715-b8a7-38e82982b8d6">2,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec8bdf1492e47008be52fa4584b89b6_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzgtNC0xLTEtMjk3MjY_11469a1b-d204-40db-b1d8-6af596f7767a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec8bdf1492e47008be52fa4584b89b6_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzgtOC0xLTEtMjk3MjY_c5a36e5e-6cac-4bed-92ff-e743a24d95d6">2,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec8bdf1492e47008be52fa4584b89b6_I20210103" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzgtMTAtMS0xLTI5NzI2_ec4020fb-b763-410b-b159-97d39c33324d">2,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec8bdf1492e47008be52fa4584b89b6_I20210103" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzgtMTItMS0xLTI5NzI2_667dcc53-915e-4b30-8386-6524e2edd539">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f3e3e39127c4af6809fdfd339d25195_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzktMi0xLTEtMjk3MjY_b0d45f9a-1a1c-48eb-985d-45ed5174553a">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f3e3e39127c4af6809fdfd339d25195_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzktNC0xLTEtMjk3MjY_51725f49-0c62-4135-8d00-71c20d70a62c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f3e3e39127c4af6809fdfd339d25195_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzktOC0xLTEtMjk3MjY_25a7918e-6a02-4589-83ed-e187a851d40a">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f3e3e39127c4af6809fdfd339d25195_I20210103" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzktMTAtMS0xLTI5NzI2_64a5217a-7efe-4473-8c85-5530f5d417b7">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f3e3e39127c4af6809fdfd339d25195_I20210103" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzktMTItMS0xLTI5NzI2_7037bf52-2807-42e5-8a7b-0a5aacd73bee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Subtotal </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d963d3b70ad451fab86f669cf84769c_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEwLTItMS0xLTI5NzI2_a485954c-145c-4a45-a3c4-30be7d592c18">11,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d963d3b70ad451fab86f669cf84769c_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEwLTQtMS0xLTI5NzI2_2ec62409-e86b-4a12-b2a7-500dd68fbd7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d963d3b70ad451fab86f669cf84769c_I20210103" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEwLTgtMS0xLTI5NzI2_be93c2f8-8332-4960-8bde-ac32f3a9d270">11,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d963d3b70ad451fab86f669cf84769c_I20210103" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEwLTEwLTEtMS0yOTcyNg_b66ebfa4-2073-444a-926c-562a0c4702ba">9,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d963d3b70ad451fab86f669cf84769c_I20210103" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEwLTEyLTEtMS0yOTcyNg_0998d82e-b78e-43c1-ba9f-457cdb6061ae">1,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gov't Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ee19fc5a38645fd8e5d2c3bde0c13ae_I20210103" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEyLTItMS0xLTI5NzI2_aec311b9-7f6b-452b-b4c3-1da68ffac798">13,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ee19fc5a38645fd8e5d2c3bde0c13ae_I20210103" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEyLTQtMS0xLTI5NzI2_636d9ead-0004-4c01-8803-6477776109f0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ee19fc5a38645fd8e5d2c3bde0c13ae_I20210103" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEyLTgtMS0xLTI5NzI2_2df29372-60ea-451a-ac25-ef5eea069bbc">13,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ee19fc5a38645fd8e5d2c3bde0c13ae_I20210103" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEyLTEwLTEtMS0yOTcyNg_806a3fc5-1757-4d6e-bc3f-ff1354e3f465">4,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ee19fc5a38645fd8e5d2c3bde0c13ae_I20210103" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEyLTEyLTEtMS0yOTcyNg_f659fd69-4d89-4652-aced-e9f694712d1d">9,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Sovereign Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2732aa7ddf3c4fc584a545a80ed55496_I20210103" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEzLTItMS0xLTI5NzI2_1143f34f-b64e-46b2-9ab2-53686e37a4c1">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2732aa7ddf3c4fc584a545a80ed55496_I20210103" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEzLTQtMS0xLTI5NzI2_796fe1d5-bae6-4666-919b-65ca0a68f05a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2732aa7ddf3c4fc584a545a80ed55496_I20210103" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEzLTgtMS0xLTI5NzI2_98a612f1-8064-4694-b473-8efb012c6d17">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2732aa7ddf3c4fc584a545a80ed55496_I20210103" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEzLTEwLTEtMS0yOTcyNg_b4c20af4-deb5-4d54-9dee-6c0169e79bd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2732aa7ddf3c4fc584a545a80ed55496_I20210103" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEzLTEyLTEtMS0yOTcyNg_d0bc8dd6-432d-4ecc-928f-a4443d9c7508">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b07805351ce42b98b594c790d5114ee_I20210103" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE0LTItMS0xLTI5NzI2_dd0a080e-b987-43a1-b882-157dbadd4d50">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b07805351ce42b98b594c790d5114ee_I20210103" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE0LTQtMS0xLTI5NzI2_08df7b2f-5c2a-4097-9d9d-b30e0c00bd0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b07805351ce42b98b594c790d5114ee_I20210103" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE0LTgtMS0xLTI5NzI2_f26f31f7-81cf-407a-8232-76e34b8a2c09">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b07805351ce42b98b594c790d5114ee_I20210103" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE0LTEwLTEtMS0yOTcyNg_1c7559cb-0411-4893-807c-e64d6bf0ca77">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b07805351ce42b98b594c790d5114ee_I20210103" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE0LTEyLTEtMS0yOTcyNg_ecf5829a-0505-455a-bbb2-7c313a8cf6a7">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Subtotal available for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c6300a66b9a4b979eb41526a4c94fb3_I20210103" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE2LTItMS0xLTI5NzI2_15963110-8e84-428e-846f-0aa10faab043">14,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c6300a66b9a4b979eb41526a4c94fb3_I20210103" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE2LTQtMS0xLTI5NzI2_789b8eeb-4ec9-4678-8962-0037d3e47681">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c6300a66b9a4b979eb41526a4c94fb3_I20210103" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE2LTgtMS0xLTI5NzI2_abde620c-285d-49b6-873b-8c8fae49136e">14,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c6300a66b9a4b979eb41526a4c94fb3_I20210103" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE2LTEwLTEtMS0yOTcyNg_5b004d4d-d755-4f0f-bdee-9a3b53925498">4,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c6300a66b9a4b979eb41526a4c94fb3_I20210103" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE2LTEyLTEtMS0yOTcyNg_a980458d-f455-4adc-9f5c-71544c967001">9,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE4LTEwLTEtMS0yOTcyNg_b48d6ba5-ceb1-4ac4-a7b0-f11fbbb1bdc0">13,985</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE4LTEyLTEtMS0yOTcyNg_1e43086a-b043-48cc-9b45-b514a3356d0e">11,200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia314ed09957343e2b53ddf2628bf597e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90ZXh0cmVnaW9uOjZiN2ZjYzZmYjA4NjQ5OGFiMGE4MjMwOGZkZDgwZjNjXzEwOTM_6e2c5590-cff3-4963-8a42-562e8365d32a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale debt securities at January&#160;2, 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"></td><td style="width:43.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTozZmY4ODdjZmI3N2Q0MDZiYTlkYWQ3ZDgxMzNmN2IyZi90YWJsZXJhbmdlOjNmZjg4N2NmYjc3ZDQwNmJhOWRhZDdkODEzM2Y3YjJmXzEtMi0xLTEtMjk3MjY_1662b487-4bfb-4c64-adee-d16fe355001d">19,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTozZmY4ODdjZmI3N2Q0MDZiYTlkYWQ3ZDgxMzNmN2IyZi90YWJsZXJhbmdlOjNmZjg4N2NmYjc3ZDQwNmJhOWRhZDdkODEzM2Y3YjJmXzEtNC0xLTEtMjk3MjY_5e96bda5-1288-4286-b054-edc1d2899c96">19,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTozZmY4ODdjZmI3N2Q0MDZiYTlkYWQ3ZDgxMzNmN2IyZi90YWJsZXJhbmdlOjNmZjg4N2NmYjc3ZDQwNmJhOWRhZDdkODEzM2Y3YjJmXzItMi0xLTEtMjk3MjY_93d886c5-1d13-4201-8157-c000275abce9">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTozZmY4ODdjZmI3N2Q0MDZiYTlkYWQ3ZDgxMzNmN2IyZi90YWJsZXJhbmdlOjNmZjg4N2NmYjc3ZDQwNmJhOWRhZDdkODEzM2Y3YjJmXzItNC0xLTEtMjk3MjY_ca33fb0b-4587-4106-8f66-15d4eee60bbe">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTozZmY4ODdjZmI3N2Q0MDZiYTlkYWQ3ZDgxMzNmN2IyZi90YWJsZXJhbmdlOjNmZjg4N2NmYjc3ZDQwNmJhOWRhZDdkODEzM2Y3YjJmXzMtMi0xLTEtMjk3MjY_1465e11f-2d51-475e-aeb0-6b0968365956">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTozZmY4ODdjZmI3N2Q0MDZiYTlkYWQ3ZDgxMzNmN2IyZi90YWJsZXJhbmdlOjNmZjg4N2NmYjc3ZDQwNmJhOWRhZDdkODEzM2Y3YjJmXzMtNC0xLTEtMjk3MjY_0247f7db-9626-4201-8774-c9d92772ec85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTozZmY4ODdjZmI3N2Q0MDZiYTlkYWQ3ZDgxMzNmN2IyZi90YWJsZXJhbmdlOjNmZjg4N2NmYjc3ZDQwNmJhOWRhZDdkODEzM2Y3YjJmXzQtMi0xLTEtMjk3MjY_7be0cd0f-aeb1-4c39-8ab5-fad73cbb5c14">19,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTozZmY4ODdjZmI3N2Q0MDZiYTlkYWQ3ZDgxMzNmN2IyZi90YWJsZXJhbmdlOjNmZjg4N2NmYjc3ZDQwNmJhOWRhZDdkODEzM2Y3YjJmXzQtNC0xLTEtMjk3MjY_dffce029-a890-4216-9526-7e40cff55b43">19,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.</span></div></ix:continuation><div><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_148"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90ZXh0cmVnaW9uOmJjMzI5OWJhNDZiYjQwZjg4ZjcxNGMwMDdmYTU4OGQxXzMxNA_cf90943e-0a91-45ed-821b-6f346146c935" continuedAt="ieddab292278544d9be35b4e2578b0882" escape="true">Inventories</ix:nonNumeric></span></div><div><ix:continuation id="ieddab292278544d9be35b4e2578b0882"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90ZXh0cmVnaW9uOmJjMzI5OWJhNDZiYjQwZjg4ZjcxNGMwMDdmYTU4OGQxXzMxOQ_34ef9f1e-c2a9-40ee-a73f-d78f637ec029" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2021 and 2020, inventories were comprised of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:66.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90YWJsZTplNTNmMzVmMGE4MmY0NGE1OTU3NDc5ZjkyZjNlYWE4Ni90YWJsZXJhbmdlOmU1M2YzNWYwYTgyZjQ0YTU5NTc0NzlmOTJmM2VhYTg2XzEtMi0xLTEtMjk3MjY_00ac7173-e820-40b2-b44b-a9f7d85f9caf">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90YWJsZTplNTNmMzVmMGE4MmY0NGE1OTU3NDc5ZjkyZjNlYWE4Ni90YWJsZXJhbmdlOmU1M2YzNWYwYTgyZjQ0YTU5NTc0NzlmOTJmM2VhYTg2XzEtNC0xLTEtMjk3MjY_2a07b88d-7ec7-4f8f-a40f-db275bf84f40">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90YWJsZTplNTNmMzVmMGE4MmY0NGE1OTU3NDc5ZjkyZjNlYWE4Ni90YWJsZXJhbmdlOmU1M2YzNWYwYTgyZjQ0YTU5NTc0NzlmOTJmM2VhYTg2XzItMi0xLTEtMjk3MjY_f8ae7c90-d052-4d7a-b660-47500a60abe2">2,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90YWJsZTplNTNmMzVmMGE4MmY0NGE1OTU3NDc5ZjkyZjNlYWE4Ni90YWJsZXJhbmdlOmU1M2YzNWYwYTgyZjQ0YTU5NTc0NzlmOTJmM2VhYTg2XzItNC0xLTEtMjk3MjY_8f2b89a3-c72b-4f50-accf-f39966892312">2,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90YWJsZTplNTNmMzVmMGE4MmY0NGE1OTU3NDc5ZjkyZjNlYWE4Ni90YWJsZXJhbmdlOmU1M2YzNWYwYTgyZjQ0YTU5NTc0NzlmOTJmM2VhYTg2XzMtMi0xLTEtMjk3MjY_c696857e-95d7-49ea-93d5-ff6f914d46f3">6,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90YWJsZTplNTNmMzVmMGE4MmY0NGE1OTU3NDc5ZjkyZjNlYWE4Ni90YWJsZXJhbmdlOmU1M2YzNWYwYTgyZjQ0YTU5NTc0NzlmOTJmM2VhYTg2XzMtNC0xLTEtMjk3MjY_ec4b6fd4-1728-469a-8c07-590966c0be0a">5,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90YWJsZTplNTNmMzVmMGE4MmY0NGE1OTU3NDc5ZjkyZjNlYWE4Ni90YWJsZXJhbmdlOmU1M2YzNWYwYTgyZjQ0YTU5NTc0NzlmOTJmM2VhYTg2XzQtMi0xLTEtMjk3MjY_d6539fca-4d6f-4f51-a9c4-bacaf1aeae78">10,387</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90YWJsZTplNTNmMzVmMGE4MmY0NGE1OTU3NDc5ZjkyZjNlYWE4Ni90YWJsZXJhbmdlOmU1M2YzNWYwYTgyZjQ0YTU5NTc0NzlmOTJmM2VhYTg2XzQtNC0xLTEtMjk3MjY_7cc46025-e9b8-46e5-87ee-e9ad3324c7ef">9,344</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_151"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90ZXh0cmVnaW9uOmFjMzZlZDZhNDM3ZjQ2ZTA5ODIyYjcyODU0YWU3YmQ2XzEwMDY_d0d62adb-91a2-4c80-a589-37d766090368" continuedAt="i034be0ac963349218162dd1e230a0968" escape="true">Property, Plant and Equipment</ix:nonNumeric></span></div><ix:continuation id="i034be0ac963349218162dd1e230a0968"><div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90ZXh0cmVnaW9uOmFjMzZlZDZhNDM3ZjQ2ZTA5ODIyYjcyODU0YWU3YmQ2XzEwMDI_06ea828e-bf0f-451b-8415-f827edcb3a65" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2021 and 2020, property, plant and equipment at cost and accumulated depreciation were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:67.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.307%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a7352ca619841d79bdbb2c6ab3f2250_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzEtMi0xLTEtMjk3MjY_1c5420aa-02da-477f-985e-2c6970215685">884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib364b47fe9454f339d85cae2d78e751e_I20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzEtNC0xLTEtMjk3MjY_ab9991fd-b8f2-4c87-8c1b-39b99c7fc0bd">882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0f4b2d54b954ffba9bb73844eeb14ce_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzItMi0xLTEtMjk3MjY_b09117d8-f4e7-41cb-964c-3c788616673e">12,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b324b449f448d9b34e40182d15e032_I20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzItNC0xLTEtMjk3MjY_f14b9761-8e2f-490c-9cef-f621d607a9c3">12,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f40ebb739fb428985cccbc8ef38df17_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzMtMi0xLTEtMjk3MjY_b10703ca-d846-4dd5-a52c-f37536b9607d">29,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia56c56468be347ee80d5f33b118fa31d_I20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzMtNC0xLTEtMjk3MjY_a4f747a2-6352-447f-9011-5490b936d455">29,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ed4936b7ad042b8b7e83fda8d3b4873_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzQtMi0xLTEtMjk3MjY_f19223ac-b133-4b25-b018-d1e5eef0db7d">4,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1204533ce0a4d7aaffb4e685bdbfa57_I20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzQtNC0xLTEtMjk3MjY_4039f700-df31-41d8-94f2-8a499d560b5a">4,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzUtMi0xLTEtMjk3MjY_a651af25-633a-47cf-9134-73fd81307def">47,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzUtNC0xLTEtMjk3MjY_34d84fc1-8ab4-414e-be09-93d39129f00f">46,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzYtMi0xLTEtMjk3MjY_c38fde3a-57e9-4669-9a28-22bf0f528829">28,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzYtNC0xLTEtMjk3MjY_63ffcb2d-618e-46ab-8bb9-e652bc25e7b4">28,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzctMi0xLTEtMjk3MjY_c36cdfd1-522c-4abc-8bda-f986d2914a23">18,962</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzctNC0xLTEtMjk3MjY_b007caee-5a5f-4931-a922-d2d0f8a2aaee">18,766</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in fiscal years 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90ZXh0cmVnaW9uOmFjMzZlZDZhNDM3ZjQ2ZTA5ODIyYjcyODU0YWU3YmQ2XzUxNA_d90a0f68-7aa8-407f-91ae-d808f598a1e6">49</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90ZXh0cmVnaW9uOmFjMzZlZDZhNDM3ZjQ2ZTA5ODIyYjcyODU0YWU3YmQ2XzUxOA_dffd9323-0499-4b6d-8095-7806cc6f6ca4">63</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90ZXh0cmVnaW9uOmFjMzZlZDZhNDM3ZjQ2ZTA5ODIyYjcyODU0YWU3YmQ2XzUyNQ_3ec3246f-6731-4477-87bd-3b0d5db49f2b">70</ix:nonFraction> million, respectively.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense, including the amortization of capitalized interest in fiscal years 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-8" name="jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90ZXh0cmVnaW9uOmFjMzZlZDZhNDM3ZjQ2ZTA5ODIyYjcyODU0YWU3YmQ2XzY1MA_4b1908db-4715-401a-97ea-3a1cbe9f818c">2.7</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-8" name="jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90ZXh0cmVnaW9uOmFjMzZlZDZhNDM3ZjQ2ZTA5ODIyYjcyODU0YWU3YmQ2XzY1NA_021341ac-408e-4bea-8c24-6e19ec6c07e1">2.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-8" name="jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90ZXh0cmVnaW9uOmFjMzZlZDZhNDM3ZjQ2ZTA5ODIyYjcyODU0YWU3YmQ2XzY2MQ_84d5b08f-cf37-4cc5-8333-c0bcf69c199c">2.5</ix:nonFraction> billion, respectively. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_154"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzEyNTg_61fd065d-6fb3-4a89-a542-5f0bba5cd510" continuedAt="i3ea38a1ac3f44c969a07353e84dcc94b" escape="true">Intangible Assets and Goodwill</ix:nonNumeric></span></div><ix:continuation id="i3ea38a1ac3f44c969a07353e84dcc94b"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzEyNjA_b26a0411-f6aa-4b36-ba5b-1e523357cbc8" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2021 and 2020, the gross and net amounts of intangible assets were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks&#160;&#8212; gross</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ae060052d4740af8581a0a0eb3df2c9_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzItMi0xLTEtMjk3MjY_0d6b3e7a-6c4e-4c2a-b6ad-b4dc67beca37">38,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48cb4cc5378a4a059f9b5fdc68b7045f_I20210103" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzItNC0xLTEtMjk3MjY_b1a1969c-6916-4ef3-b8fb-a61b6efea4bf">39,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ae060052d4740af8581a0a0eb3df2c9_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzMtMi0xLTEtMjk3MjY_1cb7cc51-42b1-4596-8655-b0cda24fe0ba">20,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48cb4cc5378a4a059f9b5fdc68b7045f_I20210103" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzMtNC0xLTEtMjk3MjY_7c3b00ad-2d3d-4816-9ac5-447bb662cabe">17,618</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks&#160;&#8212; net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ae060052d4740af8581a0a0eb3df2c9_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzQtMi0xLTEtMjk3MjY_fd50bd16-00fb-4f53-9eac-d4e72e25ead5">18,484</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48cb4cc5378a4a059f9b5fdc68b7045f_I20210103" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzQtNC0xLTEtMjk3MjY_87906089-0544-43c7-85fd-b6fc92380249">22,372</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2ea168b3aa471788ebf1eb8f662c13_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzUtMi0xLTEtMjk3MjY_45143b89-d0db-4bbb-8b68-58391c6cfc8a">23,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i663b04fe910b4db3913be35f413b1086_I20210103" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzUtNC0xLTEtMjk3MjY_e53ecccd-3d91-4a73-96ea-55efabc51c91">22,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc2ea168b3aa471788ebf1eb8f662c13_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzYtMi0xLTEtMjk3MjY_9bab8703-7c3c-4b8a-8687-9db62c74b61c">11,925</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i663b04fe910b4db3913be35f413b1086_I20210103" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzYtNC0xLTEtMjk3MjY_27dc09ff-acb1-4f93-99d8-c75da1add30c">10,912</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2ea168b3aa471788ebf1eb8f662c13_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzctMi0xLTEtMjk3MjY_68c36051-43b5-4ae5-8c6d-6e77f9fd2c77">11,086</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i663b04fe910b4db3913be35f413b1086_I20210103" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzctNC0xLTEtMjk3MjY_dc7b107f-5882-46e6-9ec5-0a6ce751080d">11,986</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee8c7d3f6c6c4979b1116a020a60940f_I20220102" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzktMi0xLTEtMjk3MjY_94ee59ed-c5f1-45d6-bbfb-d48a7ad1f805">6,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic27bd4dd176844408f1e04f435bb2a53_I20210103" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzktNC0xLTEtMjk3MjY_95a14c09-8f27-443b-ab73-a92d4f74a8cf">7,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07a8e81747cd49fdb8dd11022b941933_I20220102" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzEwLTItMS0xLTI5NzI2_495b406a-ab9e-44ed-9cce-04bb1d09f2a1">9,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabc2d103024d42f6b18c1c1e3fead71d_I20210103" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzEwLTQtMS0xLTI5NzI2_7b86fe19-bdb1-4aeb-b9cf-71bb6a9d47c5">11,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzExLTItMS0xLTI5NzI2_91360bd7-ac71-4b05-b3f3-adef5c5755a9">16,822</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzExLTQtMS0xLTI5NzI2_5c11b1f7-f3ed-42c8-bc36-22bfe13f696a">19,044</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets&#160;&#8212; net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzEyLTItMS0xLTI5NzI2_d9617bcd-fb38-42ae-bf0a-14711a125c79">46,392</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzEyLTQtMS0xLTI5NzI2_b888d556-6df6-4d82-8c02-1c6bb6882f43">53,402</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In fiscal 2021, the Company recorded a partial IPR&amp;D impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i6c822c4eb5ed4bbcb5d13167c9341beb_D20210104-20220102" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzU0OTc1NTgxNDE0MzQ_f775f42c-6bbe-4269-9129-d9a0342dbfe0">0.9</ix:nonFraction>&#160;billion primarily related to expected development delays in the general surgery digital robotics platform (Ottava) acquired with the Auris Health acquisition in 2019. The impairment charge was calculated based on revisions to the discounted cash flow valuation model reflecting a delay of first in human procedures of approximately two years from the initial acquisition model assumption of the second half of 2022. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzEyNTA_d9b874f8-b1e2-42c7-8b7a-3fa38f187ab9" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of January&#160;2, 2022 and January&#160;3, 2021, as allocated by segment of business, was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:33.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical Devices</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7efc7098a12d46b8a4268c1f5f6471f0_I20191229" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzEtMi0xLTEtMjk3MjY_bc5db28b-3fe4-4b23-bf26-24047cb5002b">9,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b8d65d037cb434ebb1aab6adcf3472e_I20191229" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzEtNC0xLTEtMjk3MjY_f998f646-11c9-49a9-bfdc-f04b66f7baf6">9,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7e98efb6dee498ba2fde96801469678_I20191229" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzEtNi0xLTEtMjk3MjY_76674877-c0a2-4cf8-836f-75b04a165d00">14,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzEtOC0xLTEtMjk3MjY_4a233338-25bd-43bc-adec-58078907cf8d">33,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43f753e349c40788db498a0b8a5fe34_D20191230-20210103" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzItMi0xLTEtMjk3MjY_8d69d99f-5a6f-4f0a-abf8-ef087467f5d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9f7770a07704889bef20acb8a0c5220_D20191230-20210103" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzItNC0xLTEtMjk3MjY_aa0f51c5-66f9-4f9d-a1bc-01e9042171d4">1,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ddb5ada6e24683aa7c697889661250_D20191230-20210103" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzItNi0xLTEtMjk3MjY_1670a120-373e-488f-b79f-83437aab0b49">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzItOC0xLTEtMjk3MjY_c64d16d9-76d1-4221-a110-22e29e5df720">1,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43f753e349c40788db498a0b8a5fe34_D20191230-20210103" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzQtMi0xLTEtMjk3MjY_23b5de9e-adc5-43a2-aa02-9b66c23423c3">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9f7770a07704889bef20acb8a0c5220_D20191230-20210103" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzQtNC0xLTEtMjk3MjY_a9250d42-33c9-44b5-89b9-b86192bca356">618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ddb5ada6e24683aa7c697889661250_D20191230-20210103" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzQtNi0xLTEtMjk3MjY_077e244c-29a6-4eef-9545-450fa781d821">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzQtOC0xLTEtMjk3MjY_841acfc4-b9c9-4572-9380-3c332efdddbd">1,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ca486a39254f2e9a23c4f2f015bf3a_I20210103" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzUtMi0xLTEtMjk3MjY_f932c66f-c816-4346-bf3e-eec486b0eab1">10,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib90b59b163b542a1adf97f356be068eb_I20210103" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzUtNC0xLTEtMjk3MjY_71de13eb-4fd0-46ce-8f7f-8b73009f3b93">11,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bd00e52fe1e423e8c220d276d67dac9_I20210103" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzUtNi0xLTEtMjk3MjY_8fddca1c-815f-492c-b469-2dcfa180c6ba">15,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzUtOC0xLTEtMjk3MjY_f5d082c6-d9b4-4058-8e7a-e64197cf7e55">36,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1198f98bdb8f4597b4a10112426c5f06_D20210104-20220102" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzYtMi0xLTEtMjk3MjY_0f5d9910-997f-4c7c-a351-2029ebc059fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzYtNC0xLTEtMjk3MjY_13ff1907-03d8-4559-bfba-f09a057c1d3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzYtNi0xLTEtMjk3MjY_03298460-29eb-438f-87fe-44b13554fe75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzYtOC0xLTEtMjk3MjY_43261806-7c68-4aa0-b8bf-a4a7e73f5cea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to divestitures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1198f98bdb8f4597b4a10112426c5f06_D20210104-20220102" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzctMi0xLTEtMjk3MjY_499c0d05-3eaf-40a9-aa31-b4d815962725">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzctNC0xLTEtMjk3MjY_be4660eb-2646-4f6c-9783-d5f2516a10f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzctNi0xLTEtMjk3MjY_ba1b105b-a266-4d72-a163-e32625a4b1c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzctOC0xLTEtNDE2Njc_c3cf57e3-b06f-4cc1-b3f3-bc727493577b">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1198f98bdb8f4597b4a10112426c5f06_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzgtMi0xLTEtMjk3MjY_e704438d-1659-49cb-8185-c4b6b8636933">517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzgtNC0xLTEtMjk3MjY_d5f3c80d-1231-438a-aeb0-99cfbf5f2d3f">429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzgtNi0xLTEtMjk3MjY_b1b6d1e1-94ee-4a3b-80de-6e9183b50fa2">192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzgtOC0xLTEtMjk3MjY_483cea30-2b6f-4ee1-bccd-79fb776c140a">1,138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98801c17d85a449bba4c52f12426dc9a_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzktMi0xLTEtMjk3MjY_abf340c4-deb9-4a91-9923-eb123ea9fb15">9,810</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a5a3c7ee35405ba80137bf84570da6_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzktNC0xLTEtMjk3MjY_af0ab462-55e5-486e-b3ac-99d5807832c1">10,580</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i795ce14783b64a95bab66ad564c35fe9_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzktNi0xLTEtMjk3MjY_823c1405-f2bf-43c5-8451-c0143b5f2631">14,856</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzktOC0xLTEtMjk3MjY_fb6a9f22-d2d0-40bd-acaa-f368f098a3d6">35,246</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average amortization period for patents and trademarks is <ix:nonNumeric contextRef="i44e7c974360849d3ba8c0295bf5a75f9_D20210104-20220102" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzY2MA_859cf60a-c506-4c17-bbe4-1169117f22ae">12</ix:nonNumeric> years. The weighted average amortization period for customer relationships and other intangible assets is <ix:nonNumeric contextRef="i003dc23bbef8425a95b799e88c2ea3cc_D20210104-20220102" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzc2Mw_dc9612c3-7275-4933-9009-bc4286ca71cb">21</ix:nonNumeric> years. The amortization expense of amortizable assets included in Cost of products sold was $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzg1Mg_6be6463e-a86c-490d-8050-8a50582b6055">4.7</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzg1Ng_f1aa89d0-7978-44b4-9652-4656a5876b69">4.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzg2Mw_17fe9414-462d-4e58-ad4d-430f32a730ab">4.5</ix:nonFraction> billion before tax, for the fiscal years ended January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019, respectively. Intangible asset write-downs are included in Other (income) expense, net.</span></div><div><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzEyNTI_4d8883b3-46c3-48c3-abb3-7cc60256f864" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"></td><td style="width:18.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToyZWE5YjJhOTgzMDg0Y2IwOThlMGU3Y2U2MzZjYjU4Ny90YWJsZXJhbmdlOjJlYTliMmE5ODMwODRjYjA5OGUwZTdjZTYzNmNiNTg3XzItMC0xLTEtMjk3MjY_69be8c7b-4896-4c64-9716-1455f21c7bc9">4,600</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToyZWE5YjJhOTgzMDg0Y2IwOThlMGU3Y2U2MzZjYjU4Ny90YWJsZXJhbmdlOjJlYTliMmE5ODMwODRjYjA5OGUwZTdjZTYzNmNiNTg3XzItMi0xLTEtMjk3MjY_446f95cd-a08f-42a2-96ac-fcdba596ce4e">4,600</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToyZWE5YjJhOTgzMDg0Y2IwOThlMGU3Y2U2MzZjYjU4Ny90YWJsZXJhbmdlOjJlYTliMmE5ODMwODRjYjA5OGUwZTdjZTYzNmNiNTg3XzItNC0xLTEtMjk3MjY_889c7b87-cae2-4846-b44e-e4718937b2b6">4,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToyZWE5YjJhOTgzMDg0Y2IwOThlMGU3Y2U2MzZjYjU4Ny90YWJsZXJhbmdlOjJlYTliMmE5ODMwODRjYjA5OGUwZTdjZTYzNmNiNTg3XzItNi0xLTEtMjk3MjY_c718f7c9-18b2-4f7e-b133-ecdb8ad862a0">3,600</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToyZWE5YjJhOTgzMDg0Y2IwOThlMGU3Y2U2MzZjYjU4Ny90YWJsZXJhbmdlOjJlYTliMmE5ODMwODRjYjA5OGUwZTdjZTYzNmNiNTg3XzItOC0xLTEtMjk3MjY_5ec367ea-76ee-4141-995e-854a276f9bc2">3,000</ix:nonFraction></span></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div></ix:continuation><div><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_157"></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5Xzk4NTY_e41282ba-8c70-4d08-83eb-a126b049473c" continuedAt="i843b21914cc446529e59f3d9e34afec9" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i843b21914cc446529e59f3d9e34afec9" continuedAt="iee6bf6cdb7b84eaa9f2db374ce88db2d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements.  As of January&#160;2, 2022, the total amount of cash collateral paid by the Company under the CSA amounted to $<ix:nonFraction unitRef="usd" contextRef="i481d55d4f8994158a9674ef0152c9f10_I20220102" decimals="-6" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzE2NDc_575a5b8b-5adf-42a3-a09f-3bd94b97f39a">570</ix:nonFraction> million net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of January&#160;2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="i481d55d4f8994158a9674ef0152c9f10_I20220102" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzIyOTc_84858a05-dce5-4792-a5e2-a46234c98972">45.8</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="ide40f8c8eeea4d2e8f7770aabdc662ff_I20220102" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzIzMDQ_d2df5401-bee6-4c9a-bf12-20704afc0869">37.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ife54767ac5ea4ca28081964675153a39_I20220102" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzMyOTg1MzQ4OTMyOTA_8a033c0f-6f6b-4c4a-96c4-5a2127a8f500">10.0</ix:nonFraction> billion, respectively. As of January&#160;3, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="ifd2d53c5c93540bc8d713ea6f655ed74_I20210103" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzI0NTg_d0b61395-f3b0-4448-9e6b-7407de77a360">37.8</ix:nonFraction> billion and  $<ix:nonFraction unitRef="usd" contextRef="i84703fb2bb5c49cabc6f3a6a621d65b8_I20210103" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzI0NjY_511ad652-aa12-40c3-9d5a-35539eae602b">30.6</ix:nonFraction> billion, respectively.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings.&#160;Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedge are accounted through the currency translation account within accumulated other comprehensive income.&#160;The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of January&#160;2, 2022, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzQ2NjE_44222f3c-7366-4f87-8920-b9bbe6dd0668">336</ix:nonFraction> million&#160;after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note&#160;13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the <ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzQ5MjA_a5265257-daf9-4e18-8106-d7a238f72311">next 12 months</ix:nonNumeric> as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is <ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzUwODE_6636dd39-3d55-40b9-aa5c-08be6537bbe5">18</ix:nonNumeric> months, excluding interest rate contracts and net investment hedges. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iee6bf6cdb7b84eaa9f2db374ce88db2d" continuedAt="i39c2daf28deb4bb490a1f8fba989128d"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5Xzk4MzY_e8786929-0c49-4840-8b33-8888b8419650" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021, net of tax:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income) Expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808995d91a27460c9150c476dd1da392_D20210104-20220102" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtMS0xLTEtNTMyMjk_bb95b50b-a4d7-4cbf-9e61-fa1f4f1713c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0192bf715a243bf91d01442328393a5_D20210104-20220102" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtMi0xLTEtNTMyMjk_1afb9afe-3b53-4cde-9434-a1ed0b8ce378">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id60bdb5b63a8467fa3b6eeb112fbe483_D20210104-20220102" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtMy0xLTEtNTMyMjk_2f654d23-36ee-45b4-bcc3-8ec466bbffdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b7e0a2b5849409ca6652a1b1d9009f8_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtNC0xLTEtMjk3MjY_c84d5242-ac0f-4f85-8517-87b608f42066">109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c3d3ec9cd0343bea423885018d25702_D20210104-20220102" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtNS0xLTEtNTMyMjk_b1744438-ad4f-4fad-b5c3-e2553950e678">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c38412ef9e6497482c4931bff7adc40_D20191230-20210103" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtNi0xLTEtNTMyMjk_daf00d71-dfb0-42b2-86bc-5323eabbefbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a92a1966c547b5b282d744cb467936_D20191230-20210103" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtNy0xLTEtNTMyMjk_82e37962-a6cb-41de-a541-cbcd40aad83c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6100225b54fc4ad197e03ca829ba928d_D20191230-20210103" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtOC0xLTEtNTMyMjk_a4d9f260-ad1d-4ea1-ba83-ef8e1cd3724a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib720add8d11a4684b8b6655ee5659b4c_D20191230-20210103" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtOS0xLTEtMjk3MjY_76fb37f9-e4b3-4335-9004-6d6e9cbc402f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i106b831f4ff540dab0212fc0f723cb2f_D20191230-20210103" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtMTAtMS0xLTUzMjI5_987c752d-08df-403e-9816-ce1f6e8a16c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808995d91a27460c9150c476dd1da392_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktMS0xLTEtNTMyMjk_52dfd201-6247-44a5-bdba-4e69a87547b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0192bf715a243bf91d01442328393a5_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktMi0xLTEtNTMyMjk_19424602-ec60-4c1c-b285-22df09cc6cea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id60bdb5b63a8467fa3b6eeb112fbe483_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktMy0xLTEtNTMyMjk_1678e2d7-53a6-4769-ad3d-99f3c14a7142">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b7e0a2b5849409ca6652a1b1d9009f8_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktNC0xLTEtMjk3MjY_cfef8833-551a-436b-b7c2-39b74fcc5d78">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c3d3ec9cd0343bea423885018d25702_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktNS0xLTEtNTMyMjk_bc28bbf9-2f13-46a6-ae44-ccb6dc0f178f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c38412ef9e6497482c4931bff7adc40_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktNi0xLTEtNTMyMjk_9b08b181-c7c1-4f84-9096-7e5e85539983">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a92a1966c547b5b282d744cb467936_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktNy0xLTEtNTMyMjk_a512e5e8-1306-4f42-809f-37fd9652130f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6100225b54fc4ad197e03ca829ba928d_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktOC0xLTEtNTMyMjk_03e20faf-a031-4a29-bb20-3135ddfe79e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib720add8d11a4684b8b6655ee5659b4c_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktOS0xLTEtMjk3MjY_d5f26286-b44c-471c-827f-c205ee978730">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i106b831f4ff540dab0212fc0f723cb2f_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktMTAtMS0xLTUzMjI5_5e33c297-eb01-408c-8ef3-cc47f8208fa0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52a259e92c5049eda0dbf8c42cea6804_D20210104-20220102" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTEtMS0xLTI5NzI2_032ed5a8-cd01-425c-bcf2-495839c4481f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id786d862a5f04ff48bcbb29805518774_D20210104-20220102" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTItMS0xLTI5NzI2_ae1b725e-1021-4aa2-8018-dfcab9364f01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i985b96ccd9484a66b346bc504f80d0a1_D20210104-20220102" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTMtMS0xLTI5NzI2_d1fd6bd3-c275-4921-8478-6184ace08cc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbc1cc0cc71418babaecbd428b53b3b_D20210104-20220102" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTQtMS0xLTI5NzI2_24fbf105-eb03-4a85-9ed2-14b340367b4b">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ec2a313be1445888459a2cb95ec031b_D20210104-20220102" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTUtMS0xLTI5NzI2_cdaa8c92-f10c-4f1b-abfd-943bd4025a08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d672893c8cc417db3f3cd8f14697306_D20191230-20210103" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTYtMS0xLTI5NzI2_dc3c5309-9dec-4cf6-a90c-91435e839b87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd978faac464658a1798c339c543b0a_D20191230-20210103" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTctMS0xLTI5NzI2_0f864b82-09db-457f-95d0-cb501d2a855c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if14f023407364aa181f33d20d53b160b_D20191230-20210103" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTgtMS0xLTI5NzI2_8cf4da97-6928-4288-be7e-6301bb0a4e2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c166abab67452688a30d1ef04d16f1_D20191230-20210103" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTktMS0xLTI5NzI2_e02440ef-b420-45e1-a9ee-16e874bfaa1e">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5665ea9b95743bf9c890aefaf80d04a_D20191230-20210103" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTEwLTEtMS0yOTcyNg_89a73c37-c4e3-471e-9210-e5b9175b8a01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52a259e92c5049eda0dbf8c42cea6804_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTEtMS0xLTI5NzI2_0fcaf1bb-edb3-4e19-bb9c-63feaaee6945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id786d862a5f04ff48bcbb29805518774_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTItMS0xLTI5NzI2_fdd48d4d-5c95-4652-a6bf-823754bd97b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i985b96ccd9484a66b346bc504f80d0a1_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTMtMS0xLTI5NzI2_56b52f88-698b-4c07-8b54-103ca8b2318e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbc1cc0cc71418babaecbd428b53b3b_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTQtMS0xLTI5NzI2_46cb1279-19ef-4b80-8ab8-ee3e1c1db049">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ec2a313be1445888459a2cb95ec031b_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTUtMS0xLTI5NzI2_c06cf6a4-560f-4e2c-8839-70549bfa37c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d672893c8cc417db3f3cd8f14697306_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTYtMS0xLTI5NzI2_485fba9a-6091-4796-8b01-9be6ad5f2764">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd978faac464658a1798c339c543b0a_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTctMS0xLTI5NzI2_7b2052da-6a3c-4ede-b6d8-5c01626a8ee0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if14f023407364aa181f33d20d53b160b_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTgtMS0xLTI5NzI2_1480d0f7-7404-46c0-82d1-99040ae06456">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c166abab67452688a30d1ef04d16f1_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTktMS0xLTI5NzI2_2f26c7ce-1dbb-4312-86b6-393c1613825d">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5665ea9b95743bf9c890aefaf80d04a_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTEwLTEtMS0yOTcyNg_65dadc45-2c9c-4091-96e7-54848a23565c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b31f531f8d1475f88bdb4724aace2fd_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTEtMS0xLTI5NzI2_efe1a884-007e-45f7-ab7d-0d0f295c9d4c">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92c7f67b422f4287a1a96e34cff07706_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTItMS0xLTI5NzI2_7d1832a7-e79b-4a21-9a8e-b40cca95a4c1">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0446032e1785439f985c59f1a7df1bcc_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTMtMS0xLTI5NzI2_496a2196-cd4b-4a53-9a4c-e7a9a57e55d3">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c2845f743f49b9b13f7ad7d5f81f15_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTQtMS0xLTI5NzI2_56c27bc7-80af-4793-830b-051d63e26edd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia828ba075e524e7090012a4cdc4a5662_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTUtMS0xLTI5NzI2_04baaaa2-cc7e-4238-8c79-024022925fa9">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d7cbac295a4d9d8247f5d8e6c2cdaa_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTYtMS0xLTI5NzI2_980eeabb-a3cb-4094-8194-f3181a986d63">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78f4b6c63cab436a8845f1c2ac4c66f9_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTctMS0xLTI5NzI2_1939296d-d29b-40c4-b3d5-1c0d7edc0f0d">329</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i848c6b8efe174f4e9f95b5f1dd159ef4_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTgtMS0xLTI5NzI2_1c3d142d-bfe6-423d-96a3-39ad001d7412">137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07bde8491d87476ca7b9ebedfa820539_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTktMS0xLTI5NzI2_9b02220e-c2a2-4005-9aa4-4506df09da30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i634edb5f28be4c3db07ca7a3116c19fb_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTEwLTEtMS0yOTcyNg_2c1b3069-af57-403e-a4e6-d681e7264b1f">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b31f531f8d1475f88bdb4724aace2fd_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTEtMS0xLTI5NzI2_dbfa8944-0e47-44f7-b5ee-44b6f27b6dcb">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92c7f67b422f4287a1a96e34cff07706_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTItMS0xLTI5NzI2_8be74a3e-388a-44b0-abe9-3546a665b131">557</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0446032e1785439f985c59f1a7df1bcc_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTMtMS0xLTI5NzI2_0a86b4d3-55db-4489-9fcb-a499e091e218">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c2845f743f49b9b13f7ad7d5f81f15_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTQtMS0xLTI5NzI2_adab5875-6843-48d3-be6c-e396b2f34b76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia828ba075e524e7090012a4cdc4a5662_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTUtMS0xLTI5NzI2_98487c2d-d3af-48b9-867a-fbba27a2fc6e">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d7cbac295a4d9d8247f5d8e6c2cdaa_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTYtMS0xLTI5NzI2_b5a51cbf-118b-4b71-a64f-294b7dbc8fd0">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78f4b6c63cab436a8845f1c2ac4c66f9_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTctMS0xLTI5NzI2_2f2612b9-dc42-4058-a438-2948e2626ec2">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i848c6b8efe174f4e9f95b5f1dd159ef4_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTgtMS0xLTI5NzI2_d71829bb-69e5-4c26-9f32-e0982bc051f9">91</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07bde8491d87476ca7b9ebedfa820539_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTktMS0xLTI5NzI2_e23433f8-ee04-4d6a-8830-88fc902764dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i634edb5f28be4c3db07ca7a3116c19fb_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTEwLTEtMS0yOTcyNg_30e6bacc-f6c4-4b8c-894e-7fa1f3f8e545">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0123bf3fb024b76ae1885d1761a5b82_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTEtMS0xLTI5NzI2_e91fc067-2d73-4ce3-87fc-e43b689f9264">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd790bc28d74dff8d098e4985e0db53_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTItMS0xLTI5NzI2_3672dd62-b5c5-4b0f-9441-40e3c5f4c9aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae16c703b374886a06975f54aceaedc_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTMtMS0xLTI5NzI2_d894ca95-0a74-44a6-88e3-848468066b6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d4ccba4445542b791db72cb4a2b0c5e_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTQtMS0xLTI5NzI2_b423a639-9dc8-46b4-b4e9-cd80d8ce71b2">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb2552df8fe44b0a4e1444a56e55504_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTUtMS0xLTI5NzI2_f4e0d9e4-de99-4f91-b6b2-ec15ef027ab8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i032a01d82e6b46aca1a6b8385c458f94_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTYtMS0xLTI5NzI2_3a388636-7418-41c6-a1d4-b739b9a8b121">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9affd553b7d74c819ed99f3018b801a6_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTctMS0xLTI5NzI2_07caab3e-8179-4b2a-af2c-97eee447e653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief391a34b2eb4d2d8fe2aaaff100ce78_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTgtMS0xLTI5NzI2_2b035be8-3240-4237-8131-8ecb9f298310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if28f0b8b33504b4f9f89e9d449f06cb6_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTktMS0xLTI5NzI2_05be0a18-8c48-4698-bde9-dfa0e3ca6d53">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa5a045453b74d8195dd434da3e842f7_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTEwLTEtMS0yOTcyNg_bfb6fbc3-2654-4be7-a95d-8df93164920e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0123bf3fb024b76ae1885d1761a5b82_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTEtMS0xLTI5NzI2_bdaa458e-3d64-47c3-a5a6-41881503364b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd790bc28d74dff8d098e4985e0db53_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTItMS0xLTI5NzI2_c0b11fe2-2ed1-4ad5-8f0b-f3e83417073d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae16c703b374886a06975f54aceaedc_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTMtMS0xLTI5NzI2_b5727fc7-e0f1-4109-a1f6-d902de233469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d4ccba4445542b791db72cb4a2b0c5e_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTQtMS0xLTI5NzI2_a3de5386-b9f2-476b-b642-90717d6e3dda">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb2552df8fe44b0a4e1444a56e55504_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTUtMS0xLTI5NzI2_d7ac445e-724a-4c6e-9fea-101ed238a68e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i032a01d82e6b46aca1a6b8385c458f94_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTYtMS0xLTI5NzI2_efd22941-3ed3-4fc4-b394-5c090454dcb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9affd553b7d74c819ed99f3018b801a6_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTctMS0xLTI5NzI2_c2a725f9-85d4-4894-ab8f-d856026db5d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief391a34b2eb4d2d8fe2aaaff100ce78_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTgtMS0xLTI5NzI2_4b99a4cc-a345-4c92-9f95-bb77c8fc52df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if28f0b8b33504b4f9f89e9d449f06cb6_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTktMS0xLTI5NzI2_fb6d0793-8dd7-42b3-b9ad-fe9777b4abba">748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa5a045453b74d8195dd434da3e842f7_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTEwLTEtMS0yOTcyNg_470d3798-efde-4710-bc2f-efdcf790aa36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 2, 2022 and January 3, 2021, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:30.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if076b21d69e44a83b09033d94b086ac3_I20220102" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmNGQ0Mjg4MDliZWY0YTRkYTYwOWIzM2M1OTc2Njc3Zi90YWJsZXJhbmdlOmY0ZDQyODgwOWJlZjRhNGRhNjA5YjMzYzU5NzY2NzdmXzQtMi0xLTEtMzUzMDg_9a205fc1-785a-43e5-8da4-39b34ff1d887">9,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52546e6d078c45f7ac9bd5ced9ab7cf3_I20210103" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmNGQ0Mjg4MDliZWY0YTRkYTYwOWIzM2M1OTc2Njc3Zi90YWJsZXJhbmdlOmY0ZDQyODgwOWJlZjRhNGRhNjA5YjMzYzU5NzY2NzdmXzQtNC0xLTEtMzUzMzE_5efdbe2a-bb89-4b01-9b68-9d6d145a178b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if076b21d69e44a83b09033d94b086ac3_I20220102" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmNGQ0Mjg4MDliZWY0YTRkYTYwOWIzM2M1OTc2Njc3Zi90YWJsZXJhbmdlOmY0ZDQyODgwOWJlZjRhNGRhNjA5YjMzYzU5NzY2NzdmXzQtNi0xLTEtMzUzNDk_083bd0cf-8b4e-448d-9553-d9c4f9d89ed4">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52546e6d078c45f7ac9bd5ced9ab7cf3_I20210103" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmNGQ0Mjg4MDliZWY0YTRkYTYwOWIzM2M1OTc2Njc3Zi90YWJsZXJhbmdlOmY0ZDQyODgwOWJlZjRhNGRhNjA5YjMzYzU5NzY2NzdmXzQtOC0xLTEtMzUzNjQ_3d70991a-4096-4250-883a-02f6325c7993">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i39c2daf28deb4bb490a1f8fba989128d" continuedAt="ic18fb4f53a6c403fac04507ef8da5945"><div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5Xzk4Njk_6a5eb062-d7aa-4587-90a6-c5e960c73918" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:37.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.532%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92e2a8e7af49412bbc0f28e465623b6f_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo4ZWI0MGU0N2RmZGY0NDEyYmMwYmY4ZjY2NmJkNDc4My90YWJsZXJhbmdlOjhlYjQwZTQ3ZGZkZjQ0MTJiYzBiZjhmNjY2YmQ0NzgzXzItNC0xLTEtMjk3MjY_c6e47788-a523-46ec-aacd-d36a4c5df4fa">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i174a527600c44ee8992a7b48db2a0f80_D20191230-20210103" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo4ZWI0MGU0N2RmZGY0NDEyYmMwYmY4ZjY2NmJkNDc4My90YWJsZXJhbmdlOjhlYjQwZTQ3ZGZkZjQ0MTJiYzBiZjhmNjY2YmQ0NzgzXzItNi0xLTEtMjk3MjY_ea7792ce-f3d0-4e21-b440-ae9494beccb5">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5Xzk4NTE_d930707a-da81-4739-ae9d-f1a795c28cd7" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following table is the effect of net investment hedges for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:20.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)           Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmMTdkYTZhM2EyZTM0ZDEzOWMxMjdkNzE0NjRjOTk5Ny90YWJsZXJhbmdlOmYxN2RhNmEzYTJlMzRkMTM5YzEyN2Q3MTQ2NGM5OTk3XzItMi0xLTEtMjk3MjY_c07a82cd-0479-4f36-bd63-98595b6d0a3b">387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmMTdkYTZhM2EyZTM0ZDEzOWMxMjdkNzE0NjRjOTk5Ny90YWJsZXJhbmdlOmYxN2RhNmEzYTJlMzRkMTM5YzEyN2Q3MTQ2NGM5OTk3XzItNC0xLTEtMjk3MjY_abac0c5b-e7f5-47ef-b196-2c080686a657">473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense<br/></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie117c70d8dab414e86a30cd9df792971_D20211004-20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmMTdkYTZhM2EyZTM0ZDEzOWMxMjdkNzE0NjRjOTk5Ny90YWJsZXJhbmdlOmYxN2RhNmEzYTJlMzRkMTM5YzEyN2Q3MTQ2NGM5OTk3XzItOC0xLTEtMjk3MjY_0936d8ac-cae6-4734-8fb7-bd6da456c561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a9a8b7f5c64483bd4a1030ddd50c04_D20200928-20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmMTdkYTZhM2EyZTM0ZDEzOWMxMjdkNzE0NjRjOTk5Ny90YWJsZXJhbmdlOmYxN2RhNmEzYTJlMzRkMTM5YzEyN2Q3MTQ2NGM5OTk3XzItMTAtMS0xLTI5NzI2_95d94286-97c2-468e-849e-387eddc948e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd102efd0d744d738ffe8f80c0ea4d4f_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmMTdkYTZhM2EyZTM0ZDEzOWMxMjdkNzE0NjRjOTk5Ny90YWJsZXJhbmdlOmYxN2RhNmEzYTJlMzRkMTM5YzEyN2Q3MTQ2NGM5OTk3XzMtMi0xLTEtMjk3MjY_3cd0caef-54bf-4a12-8b76-0ef0d62160a6">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8082b83eab643a19df9232e909a1570_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmMTdkYTZhM2EyZTM0ZDEzOWMxMjdkNzE0NjRjOTk5Ny90YWJsZXJhbmdlOmYxN2RhNmEzYTJlMzRkMTM5YzEyN2Q3MTQ2NGM5OTk3XzMtNC0xLTEtMjk3MjY_c03e9f4f-aa16-4b54-8dec-fb994381a1cf">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i223217fcf82c4c9fbd27757bd7ab98f3_D20211004-20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmMTdkYTZhM2EyZTM0ZDEzOWMxMjdkNzE0NjRjOTk5Ny90YWJsZXJhbmdlOmYxN2RhNmEzYTJlMzRkMTM5YzEyN2Q3MTQ2NGM5OTk3XzMtOC0xLTEtMjk3MjY_0cc2430e-6c7b-4ae9-b0be-fda5e961449a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf5fca83f72e4903ab75e0c5be5d0b90_D20200928-20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmMTdkYTZhM2EyZTM0ZDEzOWMxMjdkNzE0NjRjOTk5Ny90YWJsZXJhbmdlOmYxN2RhNmEzYTJlMzRkMTM5YzEyN2Q3MTQ2NGM5OTk3XzMtMTAtMS0xLTI5NzI2_ecaeddd3-596b-43e1-b76b-00c3dfaaaa3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company measures equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5Xzk4NzA_5263f7ed-fcca-406c-99f5-97def9994969" escape="true"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:25.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.143%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales/ Purchases/Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba88d1e19f44fdeb865036ee60e1e26_I20210103" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzItMi0xLTEtMjk3MjY_c2ba3f03-1047-4fbd-ba8a-378d8d6aace6">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i039392ea3c3b403db051bc1af156bce0_D20210104-20220102" decimals="-6" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzItNC0xLTEtMjk3MjY_888522e7-d446-4ce6-a769-12bf00c2537e">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i039392ea3c3b403db051bc1af156bce0_D20210104-20220102" decimals="-6" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzItNi0xLTEtMjk3MjY_b7e2d299-4e9d-4627-9b14-3d6951ac4143">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ded06cef625444b86727e06867cbda7_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzItOC0xLTEtMjk3MjY_9e2101b1-2e89-49d8-94a2-c3d9e72e99d4">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ded06cef625444b86727e06867cbda7_I20220102" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzItMTAtMS0xLTI5NzI2_b2e89544-e83f-4bbc-9be6-983f4f0d324e">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0a4bb0a45cf4321a078221f082dc745_I20210103" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzQtMi0xLTEtMjk3MjY_b5b9c35e-df66-43a4-bc52-215231319ec8">738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb81f8d839b475bac63d7d23d05d99b_D20210104-20220102" decimals="-6" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzQtNC0xLTEtMjk3MjY_cb00fc3e-1344-45bf-a726-11fe59851f5a">394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb81f8d839b475bac63d7d23d05d99b_D20210104-20220102" decimals="-6" sign="-" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzQtNi0xLTEtMjk3MjY_a6e6dce2-c862-49e6-be3c-5c5c9305cf78">632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87a7804b1f44de484b175a96356f43f_I20220102" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzQtOC0xLTEtMjk3MjY_ef57f0ff-61a3-4a1f-8eaf-8ba119f5ee3b">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87a7804b1f44de484b175a96356f43f_I20220102" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzQtMTAtMS0xLTI5NzI2_d18d34f8-fcc9-4a7b-a08c-6381bf086a2c">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:25.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.143%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales/ Purchases/Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bbf538e3b42487aabaada415c912f2b_I20191229" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzItMi0xLTEtMjk3MjY_1a1c23de-663c-4acf-8846-e779c73c3a83">1,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec68da81f3f4ed78748a512faa1b83a_D20191230-20210103" decimals="-6" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzItNC0xLTEtMjk3MjY_6ae6385f-e675-49f9-9b7e-b4dfdbdc933d">527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaec68da81f3f4ed78748a512faa1b83a_D20191230-20210103" decimals="-6" sign="-" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzItNi0xLTEtMjk3MjY_6ba217de-983f-46f2-850c-18883dcf4535">194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba88d1e19f44fdeb865036ee60e1e26_I20210103" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzItOC0xLTEtMjk3MjY_d9e5d71e-2c74-4b0f-980e-8a6ec73dd1e1">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba88d1e19f44fdeb865036ee60e1e26_I20210103" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzItMTAtMS0xLTI5NzI2_c0b1c0b4-2466-4cbd-a8a5-f305562a1bfa">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e2c57afbb094c14a7064ef903706da7_I20191229" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzQtMi0xLTEtMjk3MjY_2c47ddc5-b631-42de-9bdf-3a83abd90e54">712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i904861e4f8ed471381dbacfc8e3ab52e_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzQtNC0xLTEtMjk3MjY_77da4878-6e1d-4003-a855-a6b74bb3ef5f">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i904861e4f8ed471381dbacfc8e3ab52e_D20191230-20210103" decimals="-6" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzQtNi0xLTEtMjk3MjY_f26679ab-f390-45bc-bc19-98b4cbd65d3e">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0a4bb0a45cf4321a078221f082dc745_I20210103" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzQtOC0xLTEtMjk3MjY_cd4fafaa-6751-4978-99a4-43701ec0260b">738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0a4bb0a45cf4321a078221f082dc745_I20210103" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzQtMTAtMS0xLTI5NzI2_e7c651f9-8951-41e8-8b31-7e1e862854c8">738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic18fb4f53a6c403fac04507ef8da5945" continuedAt="i177b0ffb57094ff2abeaae991bd60ddb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021 for equity investments without readily determinable market values, $<ix:nonFraction unitRef="usd" contextRef="i5bb81f8d839b475bac63d7d23d05d99b_D20210104-20220102" decimals="-6" sign="-" name="jnj:EquityFairValueAdjustmentImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzY0MzE_6e536945-c81c-4f3f-85df-e3ae6b981f5a">28</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i904861e4f8ed471381dbacfc8e3ab52e_D20191230-20210103" decimals="-6" sign="-" name="jnj:EquityFairValueAdjustmentImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzY0Mzg_1e694f91-1e9f-4353-8b84-5f18f8c14d10">76</ix:nonFraction> million, respectively, of the changes in fair value reflected in net income were the result of impairments. There were offsetting impacts of  $<ix:nonFraction unitRef="usd" contextRef="i5bb81f8d839b475bac63d7d23d05d99b_D20210104-20220102" decimals="-6" name="jnj:EquityFairValueAdjustmentChangeinObservablePrices" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzY1NTI_2023e1e7-145d-47f2-a567-23d809f25648">422</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i904861e4f8ed471381dbacfc8e3ab52e_D20191230-20210103" decimals="-6" name="jnj:EquityFairValueAdjustmentChangeinObservablePrices" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzY1NTk_c561c9aa-d877-4189-979b-40de605bb227">21</ix:nonFraction> million, respectively, of changes in fair value reflected in net income due to changes in observable prices and gains on the disposal of investments. The impact in fiscal 2021 was driven by the gain on disposal of the Grail investment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability.  In accordance with ASC 820, a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S.&#160;Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level&#160;1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following three levels of inputs are used to measure fair value:</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#160;&#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#160;&#8212; Significant other observable inputs.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#160;&#8212; Significant unobservable inputs.</span></div><div style="margin-top:7pt"><span><br/></span></div><div style="margin-top:7pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5Xzk4MzE_26d99c5a-54e6-45f9-b9f5-fb1ae0465d8e" continuedAt="i2a5c20234c8e42d5bca5998eaa238109" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of the fiscal year ended January&#160;2, 2022 and January&#160;3, 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.218%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c8d98bc79544f2796d5f14b04f588e5_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzQtMi0xLTEtMjk3MjY_e4061ed9-78c8-4374-8dd1-31919bec6f1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc765a63065f4fc7a9606b02f261afad_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzQtNC0xLTEtMjk3MjY_3ff4ea1a-e8f6-4302-9fc8-b7769913a86e">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071cfab120ae4af6b209509a7218091d_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzQtNi0xLTEtMjk3MjY_3db67b6c-260b-410a-9b2c-337e0daa7014">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i481d55d4f8994158a9674ef0152c9f10_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzQtOC0xLTEtMjk3MjY_2ab27984-05a6-47cb-8673-935a5d3d453b">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4babc1d42ff4632a1e3e6b5c723c86f_I20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzQtMTAtMS0xLTI5NzI2_25752e89-30d4-4fdc-b401-ae8ad922ac99">849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b06190f006c4dce9af3c9f28a239d36_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzUtMi0xLTEtMjk3MjY_03fe783a-88e0-4506-a58e-f8bce83303b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcee04e7edb6498692d55fa0db8bfab5_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzUtNC0xLTEtMjk3MjY_4cb175aa-ff39-44c3-a004-dbb1b4df546a">796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3713ead11f41faa96420921c930eba_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzUtNi0xLTEtMjk3MjY_5264aec2-e745-42f6-b9dc-745bb5692aef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieab28e9d35ce41f88040fcdf057e21e4_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzUtOC0xLTEtMjk3MjY_02b3cf3a-c987-4c93-a8e0-570e114d64db">796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6fce32d455546de8f77cd04c86b5dd7_I20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzUtMTAtMS0xLTI5NzI2_5fd0a4d7-bafe-4bc8-bfec-9e8e8e800c1c">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i769b6005fa4c4532801176ab7112c4aa_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzctMi0xLTEtMjk3MjY_b2a23edb-e838-462f-8fcb-c8377510e1fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed3758031c041a586a6a2d9b7ea4c75_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzctNC0xLTEtMjk3MjY_d68f8088-7718-4104-8451-a68608ca2277">1,336</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac6290a59e7c45c899a410f1f0e2c835_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzctNi0xLTEtMjk3MjY_76163be4-e28c-4c06-a4db-d642a7259a80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzctOC0xLTEtMjk3MjY_a263da74-7811-4ad7-bbb8-2372223cb6d8">1,336</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2707e7b5d243d78d1b3c5313fcea06_I20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzctMTAtMS0xLTI5NzI2_4c504b64-15d8-46b1-897a-238a2126aaa2">1,089</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c8d98bc79544f2796d5f14b04f588e5_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzktMi0xLTEtMjk3MjY_119461e9-ce2b-4593-bcb3-24dc31ea748c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc765a63065f4fc7a9606b02f261afad_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzktNC0xLTEtMjk3MjY_5cbc5df1-24fb-4a3c-9107-21f373309277">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071cfab120ae4af6b209509a7218091d_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzktNi0xLTEtMjk3MjY_3bacd2b3-0f51-4e0d-a30c-4c2a6ff6ff8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i481d55d4f8994158a9674ef0152c9f10_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzktOC0xLTEtMjk3MjY_bf675cf1-0753-4fc7-b28c-14e1d93f6c52">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4babc1d42ff4632a1e3e6b5c723c86f_I20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzktMTAtMS0xLTI5NzI2_16550927-2b77-4c43-981e-14e51507880c">702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b06190f006c4dce9af3c9f28a239d36_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEwLTItMS0xLTI5NzI2_9466fd99-ad4a-4490-8c80-75d1c581c9b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcee04e7edb6498692d55fa0db8bfab5_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEwLTQtMS0xLTI5NzI2_707f10ac-924b-4aaa-9aa7-fda5c4cc7aac">979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3713ead11f41faa96420921c930eba_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEwLTYtMS0xLTI5NzI2_10fc3d0b-d0a1-4f00-b3e4-54bb89629de4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieab28e9d35ce41f88040fcdf057e21e4_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEwLTgtMS0xLTI5NzI2_76360966-12d1-4172-89e5-13d125524ba5">979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6fce32d455546de8f77cd04c86b5dd7_I20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEwLTEwLTEtMS0yOTcyNg_f608be36-f73a-47fb-ba90-148623c030d2">1,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i769b6005fa4c4532801176ab7112c4aa_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEzLTItMS0xLTI5NzI2_f9f66964-9f1b-4d72-a7bb-af43e66387ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed3758031c041a586a6a2d9b7ea4c75_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEzLTQtMS0xLTI5NzI2_cba1b85b-39a5-4d81-b9b3-0faf6ce234a6">1,860</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac6290a59e7c45c899a410f1f0e2c835_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEzLTYtMS0xLTI5NzI2_0896d774-29ef-4f2e-8ae4-eca79d541683">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEzLTgtMS0xLTI5NzI2_f498388c-a30a-4136-b788-f520921a8ee7">1,860</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2707e7b5d243d78d1b3c5313fcea06_I20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEzLTEwLTEtMS0yOTcyNg_004379ae-5d78-4fc6-9949-6f107c266032">2,271</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c8d98bc79544f2796d5f14b04f588e5_I20220102" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE2LTItMS0xLTI5NzI2_792a42f1-c4b3-4493-bed0-dd8cf6646411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc765a63065f4fc7a9606b02f261afad_I20220102" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE2LTQtMS0xLTI5NzI2_1bf51ba1-e0bd-4643-a304-1802b29e5741">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071cfab120ae4af6b209509a7218091d_I20220102" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE2LTYtMS0xLTI5NzI2_1589de23-52c8-4737-b7ac-2d6fa66c380d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i481d55d4f8994158a9674ef0152c9f10_I20220102" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE2LTgtMS0xLTI5NzI2_7a6d3635-42bd-4446-a299-7bde5be4ba23">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4babc1d42ff4632a1e3e6b5c723c86f_I20210103" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE2LTEwLTEtMS0yOTcyNg_f0950be4-afc7-42a6-b74a-ccc5d87dbc7e">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c8d98bc79544f2796d5f14b04f588e5_I20220102" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE4LTItMS0xLTI5NzI2_93faa8f1-02c0-4b4e-843a-6782440c8eef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc765a63065f4fc7a9606b02f261afad_I20220102" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE4LTQtMS0xLTI5NzI2_b9935422-9e6e-4b15-b6f8-1c1db92dedc2">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071cfab120ae4af6b209509a7218091d_I20220102" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE4LTYtMS0xLTI5NzI2_9b3b435c-8515-4463-92a1-16a7986431ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i481d55d4f8994158a9674ef0152c9f10_I20220102" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE4LTgtMS0xLTI5NzI2_f37a369f-05c9-49bd-bb01-bd23130a530f">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4babc1d42ff4632a1e3e6b5c723c86f_I20210103" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE4LTEwLTEtMS0yOTcyNg_e89c88bb-010e-4a5d-bbdf-7d698a7afacd">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Available For Sale Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i769b6005fa4c4532801176ab7112c4aa_I20220102" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIwLTItMS0xLTI5NzI2_d3ee73e5-1781-4bec-8a0f-06cc1bbf1f0d">1,884</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed3758031c041a586a6a2d9b7ea4c75_I20220102" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIwLTQtMS0xLTI5NzI2_2f932078-d9fd-48d4-a3ec-7b73b2ec4b68">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac6290a59e7c45c899a410f1f0e2c835_I20220102" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIwLTYtMS0xLTI5NzI2_4bdece4c-9f67-4e88-98dc-5761cb382a9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIwLTgtMS0xLTI5NzI2_421da651-0fb0-42d9-b101-49246659411d">1,884</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIwLTEwLTEtMS0yOTcyNg_69517408-9b90-488e-94e4-2486b4708599">1,481</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i769b6005fa4c4532801176ab7112c4aa_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIxLTItMS0xLTI5NzI2_bf29f004-2139-4171-bac9-26825ac4f507">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed3758031c041a586a6a2d9b7ea4c75_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIxLTQtMS0xLTI5NzI2_717b778d-2f47-450f-b53d-69cc02275f4a">19,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac6290a59e7c45c899a410f1f0e2c835_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIxLTYtMS0xLTI5NzI2_ff92bd90-f04e-4963-9806-46b19cec167b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIxLTgtMS0xLTI5NzI2_ea398c6d-179a-4aef-81e8-c6c03b254c3b">19,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIxLTEwLTEtMS0yOTcyNg_798de2e5-4035-4bc2-9f65-e41b950bc0e8">14,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac6290a59e7c45c899a410f1f0e2c835_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIzLTYtMS0xLTI5NzI2_52026e2f-7a8d-4ce5-8228-56f2f320379e">533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIzLTgtMS0xLTI5NzI2_75e4e3aa-686a-404b-9645-17a98dc17ee7">533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIzLTEwLTEtMS0yOTcyNg_6983f031-0df0-4441-b4f3-000caf1e428c">633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i177b0ffb57094ff2abeaae991bd60ddb"><ix:continuation id="i2a5c20234c8e42d5bca5998eaa238109"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.409%"><tr><td style="width:1.0%"></td><td style="width:53.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzItMi0xLTEtMjk3MjY_7270d315-79bc-4096-a65b-9975e33bff9b">1,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzItNC0xLTEtMjk3MjY_3cb9801b-a576-43f5-a32b-980ac36725f7">1,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzMtMi0xLTEtMjk3MjY_0468558a-c1da-4cac-ade3-4f7bcb022ec6">1,285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzMtNC0xLTEtMjk3MjY_f0698fd9-6128-468d-b1df-2bd6a8bfa0b9">1,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzQtMi0xLTEtMjk3MjY_3b93f5d5-8c93-46c3-9f16-7ed4d9cace78">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzQtNC0xLTEtMjk3MjY_3a3fbe03-5319-4a01-8100-d3a4126cd1eb">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzYtMi0xLTEtMjk3MjY_b5df05c5-47e4-4239-9ef0-58113ba3a144">1,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzYtNC0xLTEtMjk3MjY_9b0de8a4-c248-4b47-9878-7208d6fbfcf7">2,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzctMi0xLTEtMjk3MjY_a14d69ec-293d-43e8-b532-51ac9cf8ac2f">1,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzctNC0xLTEtMjk3MjY_649c93e8-38f7-4d87-8cfe-c05962ff19e6">2,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzgtMi0xLTEtMjk3MjY_35a72178-342c-4ce5-8e75-efe943bb46fa">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzgtNC0xLTEtMjk3MjY_6462e505-d27e-43d7-b679-7bf43e8b470d">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzItMy0xLTEtMjk3MjY_0a45a993-afb2-47fd-b668-994a0ba01ae4">633</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzItNC0xLTEtMjk3MjY_7bf046a1-5593-4f95-903a-2767eff7e96b">1,715</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2087646dc6744a28755f382fc0a83c8_I20181230" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzItNS0xLTEtMjk3MjY_00b8fc58-f6ce-4798-b517-bfbe3df57d57">397</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzMtMy0xLTEtMjk3MjY_3b47caf8-ec46-4029-b5b3-306b109a2323">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" sign="-" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzMtNC0xLTEtMjk3MjY_24eb4a44-90c1-4b5a-9cc3-51398d0f35c3">1,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzMtNS0xLTEtMjk3MjY_6da90b55-0c08-4c76-ac29-df775a8c1eb0">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzQtMy0xLTEtMjk3MjY_04b335f6-677d-4117-97c8-473b66efe4ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzQtNC0xLTEtMjk3MjY_d1a26198-dc97-4088-95a3-8148ebe984b3">106</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzQtNS0xLTEtMjk3MjY_9af8d0f3-7d7e-4929-9db0-8fd9faef4d11">1,246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzUtMy0xLTEtMjk3MjY_976e7453-1674-45fe-8ce0-88ecd06e4555">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzUtNC0xLTEtMjk3MjY_00d39006-c330-423c-a47c-019df3918ff7">99</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzUtNS0xLTEtMjk3MjY_e2164dd0-d197-4830-9a9e-21359f0bc7d8">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzYtMy0xLTEtMjk3MjY_ef5ebc8f-eea6-43fd-a859-6ab65e4a04de">533</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzYtNC0xLTEtMjk3MjY_479ad611-3baa-430f-a9f7-c21d05df3068">633</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzYtNS0xLTEtMjk3MjY_aa5b1bb8-c2aa-49c5-9a7b-b9ce1a5a600a">1,715</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2020 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $<ix:nonFraction unitRef="usd" contextRef="ic7b9bae4686a473695740b6d4c2202f6_I20210103" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5Xzg4MTg_3706e12d-27e4-4fc7-a750-5f9e74d38a63">1,481</ix:nonFraction> million, which are classified as Level&#160;1 and contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i81f3450daac144e3af1b7a08f181808b_I20210103" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5Xzg4ODY_1537b5fe-1924-479c-9214-7f640bec275a">633</ix:nonFraction> million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes cross currency interest rate swaps and interest rate swaps.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Classified as non-current other assets.  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Classified as cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes $<ix:nonFraction unitRef="usd" contextRef="i5254374306bb4a078614cffdec9aabe0_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzkxNDM_49238704-0945-43cd-94a7-b8a587a49e5f">520</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i093bf273c79847d989c1c903a61b7968_I20210103" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzkxNDc_85289b90-eb9a-4441-8f9a-f42582d86a1f">594</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia24860d7401b457eba3d9b0be9935de4_I20191229" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzkxOTA_de0344bd-ffd2-4e86-bf51-b2f5e9330df7">1,631</ix:nonFraction> million, classified as non-current other liabilities as of January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019, respectively. Includes $<ix:nonFraction unitRef="usd" contextRef="i1d16f4e3e01647648ac49ed4c2dda9b8_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzkyODI_6a9b7df5-56d8-4f43-becc-e7719823f17e">13</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3965bff979ef4a58b0bbda03ce593630_I20210103" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzkyODk_5cda9459-4be6-4275-95fd-84a3504cad01">39</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ieb6f78322e8048bd9abad306b8359695_I20191229" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzMyOTg1MzQ4OTM2MjM_09441f96-a0e9-4dc4-8f00-315f415c73ae">84</ix:nonFraction>&#160;million classified as current liabilities as of January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019, respectively.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt">Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense.  The Company recorded a contingent consideration reversal of $<ix:nonFraction unitRef="usd" contextRef="if923e101b65a4eb9b85820250bc20ec0_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5Xzk1MTY_18b1580c-fd32-4bfe-a76c-6dd80e95e5b7">1,148</ix:nonFraction>&#160;million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense.</span></div></ix:continuation><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes&#160;2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzE5NjY_790ae9a1-b0fc-403c-b29f-2ada5ce97525" continuedAt="ida1d72613db645b581aac46161e16ded" escape="true">Borrowings</ix:nonNumeric></span></div><div><ix:continuation id="ida1d72613db645b581aac46161e16ded" continuedAt="i54b58ca3e8ee4917ac6c1343466bbe72"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzE5Nzc_8123259e-ef27-467e-a54b-aa114bbf207a" continuedAt="i1270320337da476ca9b9a4a635e1b287" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term debt are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Rate %</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Rate %</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id163764cde774d6e9f3063f4dd81d013_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjpiOWRlNjZiYjk5OWE0OWZlODhjYTRlYzY1ZGZkMDg4NF80_0537ac07-f829-4b42-b61a-52f397cd10a9">3.55</ix:nonFraction>% Notes due 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id163764cde774d6e9f3063f4dd81d013_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQtMi0xLTEtMjk3MjY_26469b2b-2e5c-4861-913e-431e643e550f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id163764cde774d6e9f3063f4dd81d013_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQtNC0xLTEtMjk3MjY_9c2e3dc2-de77-456d-ae79-5cafc974a738">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5edd790b7e564a90a840e7e6dc7e272b_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQtNi0xLTEtMjk3MjY_6d246e5b-189e-47e5-99c3-d1ac743da91b">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5edd790b7e564a90a840e7e6dc7e272b_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQtOC0xLTEtMjk3MjY_6ca9534e-cbe4-4e5f-9905-6db6710319dd">3.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a7fe279402746beaab8e640a5291e42_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzUtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjoyZGI1MzRjMjk4ZjQ0Zjg4YmRkNGVhY2E5ZDgxYjkzY180_1e545c2e-fe86-4ca4-9a69-7731a6aac4e3">2.45</ix:nonFraction>% Notes due 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7fe279402746beaab8e640a5291e42_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzUtMi0xLTEtMjk3MjY_006e0ea8-a8f9-4fa7-9d63-82ae481d6bc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a7fe279402746beaab8e640a5291e42_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzUtNC0xLTEtMjk3MjY_6a1c8bbd-6fc6-4bbe-be52-969b7dd1f1e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1abb55e4e6ba4d30a5bddbb2e70b1191_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzUtNi0xLTEtMjk3MjY_dd1f503b-4647-4ceb-8eb9-bfe133e8006f">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1abb55e4e6ba4d30a5bddbb2e70b1191_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzUtOC0xLTEtMjk3MjY_a4410427-75e0-4e46-ad80-beca549ab80d">2.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a0bea261b2440189c3155cacb540621_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzYtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjoxMmM3NDY3NDYxYWQ0NWJjOWY5YjJhNDZmZjI4NmNhNl80_8d211c39-9328-4882-92eb-4d3ae1730742">1.65</ix:nonFraction>% Notes due 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a0bea261b2440189c3155cacb540621_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzYtMi0xLTEtMjk3MjY_e4e3d791-b501-47ae-ab95-ccd4fa17631c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a0bea261b2440189c3155cacb540621_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzYtNC0xLTEtMjk3MjY_f0407678-1038-4130-8d5e-30bda8ea7e1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i904410fb32534db6ae296a0c7b27b0ca_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzYtNi0xLTEtMjk3MjY_d400f234-b64c-4553-b9d3-551c7a6e91ab">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i904410fb32534db6ae296a0c7b27b0ca_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzYtOC0xLTEtMjk3MjY_71f54c02-47b9-422c-ae60-919bfc6dbc7e">1.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69182c330b4b414e89f02252079a1706_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzctMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozODFlMWYyMmQ2NTA0MTQyYjA2M2Y5YmJlYmUzZTM5N180_a5a3527e-dd89-4cef-b53b-74256bbfa899">0.250</ix:nonFraction>% Notes due 2022                                                        (<ix:nonFraction unitRef="eur" contextRef="i69182c330b4b414e89f02252079a1706_I20220102" decimals="-9" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzctMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozODFlMWYyMmQ2NTA0MTQyYjA2M2Y5YmJlYmUzZTM5N183OA_bb346d20-123a-4eb7-a917-3bab6a7f316a">1</ix:nonFraction>B Euro <ix:nonFraction unitRef="number" contextRef="i69182c330b4b414e89f02252079a1706_I20220102" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzctMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozODFlMWYyMmQ2NTA0MTQyYjA2M2Y5YmJlYmUzZTM5N184Nw_42579e0a-26f0-43d6-9630-0e516c7031ae">1.1311</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(<ix:nonFraction unitRef="eur" contextRef="if497493118ae4cde8380f3ccac17ff11_I20210103" decimals="-9" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzctMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozODFlMWYyMmQ2NTA0MTQyYjA2M2Y5YmJlYmUzZTM5N185NQ_8df48b27-303d-4444-b89a-1cfc92b64159">1</ix:nonFraction>B Euro <ix:nonFraction unitRef="number" contextRef="if497493118ae4cde8380f3ccac17ff11_I20210103" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzctMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozODFlMWYyMmQ2NTA0MTQyYjA2M2Y5YmJlYmUzZTM5N18xMDQ_7057e40d-d0a9-411e-ac20-6c16a2cd1999">1.2281</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69182c330b4b414e89f02252079a1706_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzctMi0xLTEtMjk3MjY_0e361adf-2dc4-4f7c-8573-3ab7026ce2c9">1,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69182c330b4b414e89f02252079a1706_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzctNC0xLTEtMjk3MjY_f672af8c-cd18-4bc9-b6a7-334b3b5c7b94">0.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if497493118ae4cde8380f3ccac17ff11_I20210103" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzctNi0xLTEtMjk3MjY_bc1ab45e-320e-4e52-a83b-cb6f7454a176">1,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if497493118ae4cde8380f3ccac17ff11_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzctOC0xLTEtMjk3MjY_e52ca744-46a5-467b-8d7d-ab28af78b0b2">0.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i550e73b82fa342f982d286fe29ff7070_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzgtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjplZjFiNzFmMWM5ODE0MjdmODI5YjQ4NmYxM2QwYjkzOF80_ee593cad-1e15-4fcc-86b9-880073de0314">2.25</ix:nonFraction>% Notes due 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i550e73b82fa342f982d286fe29ff7070_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzgtMi0xLTEtMjk3MjY_206538aa-2844-430f-a233-123354253a1b">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i550e73b82fa342f982d286fe29ff7070_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzgtNC0xLTEtMjk3MjY_d81c3e7a-cbe8-4520-9fdf-1e9a5409ab48">2.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90668084b50c4dd2ba37011a73641c3e_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzgtNi0xLTEtMjk3MjY_0d30587a-2b91-4565-a443-dd6a1acb2363">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i90668084b50c4dd2ba37011a73641c3e_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzgtOC0xLTEtMjk3MjY_887bad84-512c-4702-b0a1-d4442d094f32">2.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i813c37b3fb784cd4be0ce6ef143587ab_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzktMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjplMzBkMWM2YzI3NjY0ZGM5YjQ0MzBkNDc1MmViNTJlZF80_c0588070-a92c-4fb3-9acd-5677bb1a07f2">6.73</ix:nonFraction>%&#160;Debentures due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i813c37b3fb784cd4be0ce6ef143587ab_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzktMi0xLTEtMjk3MjY_1f99d57f-9f34-41db-8fdd-c99b8d3e79c9">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i813c37b3fb784cd4be0ce6ef143587ab_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzktNC0xLTEtMjk3MjY_8ef4e7e1-c7d6-4559-86fc-8fc1d1b1062b">6.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d636f7f126a4235961db45e96929aee_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzktNi0xLTEtMjk3MjY_26825f63-0194-4048-acd9-f8fc881261fe">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d636f7f126a4235961db45e96929aee_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzktOC0xLTEtMjk3MjY_b7807d09-4918-4c01-afce-f7b2ca8de177">6.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c3b7af038464a8783ea5368d254f51b_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEwLTAtMS0xLTI5NzI2L3RleHRyZWdpb246NDgxNmE1ZjU3YjM3NGUwNGIxYTk4NjQ2NTg4NmZiODlfNA_cb946713-895e-48a4-af6b-7f1457a2d21f">3.375</ix:nonFraction>% Notes due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c3b7af038464a8783ea5368d254f51b_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEwLTItMS0xLTI5NzI2_053b7757-366a-4865-b76f-39ab7931c137">802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c3b7af038464a8783ea5368d254f51b_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEwLTQtMS0xLTI5NzI2_ccc838db-0f04-4011-a559-5f7f8a220fa8">3.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6319e5cd14e849fb9bc1d26f55976e25_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEwLTYtMS0xLTI5NzI2_7f141bbb-759a-46a2-8c57-62edb74f612d">803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6319e5cd14e849fb9bc1d26f55976e25_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEwLTgtMS0xLTI5NzI2_09032ea9-998d-44c8-b672-184b595a0be7">3.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i46c00efd504548b0a772f17dfaaf31a4_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzExLTAtMS0xLTI5NzI2L3RleHRyZWdpb246YjJmOTU4NDMyNDllNDY2ZGI4ODk4ZjQyOTkyNDZhZGRfNA_8c713664-d274-47f4-a012-099e85757ad4">2.05</ix:nonFraction>% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46c00efd504548b0a772f17dfaaf31a4_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzExLTItMS0xLTI5NzI2_1bb57273-97ec-4905-baa7-5634ec331d1f">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i46c00efd504548b0a772f17dfaaf31a4_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzExLTQtMS0xLTI5NzI2_972d5c39-7522-4834-86ae-22a924469edc">2.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaad724dc80d4d528b251ff223f924c3_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzExLTYtMS0xLTI5NzI2_1e50c8b5-31a4-4cbf-b49f-9c43b1fb14e8">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaaad724dc80d4d528b251ff223f924c3_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzExLTgtMS0xLTI5NzI2_582bfe44-c6a5-4466-adb3-abcea4abd01e">2.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie52eb5fe20d44487a51c329a11aaefdb_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEyLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MmE0NTUzNDdmNTg5NDZkZDgwZmI3OTRiNmQwMzI2YzZfNA_4ee9e1ad-fa1e-418a-a461-36d5fb0c0e45">0.650</ix:nonFraction>% Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="ie52eb5fe20d44487a51c329a11aaefdb_I20220102" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEyLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MmE0NTUzNDdmNTg5NDZkZDgwZmI3OTRiNmQwMzI2YzZfMjQ_878fa749-66b7-4ab2-9941-e9143b4d24a3">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="ie52eb5fe20d44487a51c329a11aaefdb_I20220102" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEyLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MmE0NTUzNDdmNTg5NDZkZDgwZmI3OTRiNmQwMzI2YzZfMzQ_b2c68464-243b-4630-bccd-06f1f4c3b55a">1.1311</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(<ix:nonFraction unitRef="eur" contextRef="i35d501ad10624baf887280017b6b88cf_I20210103" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEyLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MmE0NTUzNDdmNTg5NDZkZDgwZmI3OTRiNmQwMzI2YzZfNDI_e42e832f-9b83-4229-a2a9-10ce45e80bc7">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="i35d501ad10624baf887280017b6b88cf_I20210103" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEyLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MmE0NTUzNDdmNTg5NDZkZDgwZmI3OTRiNmQwMzI2YzZfNTI_62f5bf45-f4bb-4f89-a0f2-b2f1a72438c0">1.2281</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie52eb5fe20d44487a51c329a11aaefdb_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEyLTItMS0xLTI5NzI2_30d8e518-669c-4754-bf03-cfe97da4e810">847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie52eb5fe20d44487a51c329a11aaefdb_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEyLTQtMS0xLTI5NzI2_37ed8daf-d046-4b73-b4f0-887b64569c14">0.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35d501ad10624baf887280017b6b88cf_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEyLTYtMS0xLTI5NzI2_b96fb1f8-ab08-44dd-8348-5fdd6bd99b8a">919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i35d501ad10624baf887280017b6b88cf_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEyLTgtMS0xLTI5NzI2_f5a9d1d4-b431-4a1a-a3c8-600f15512b93">0.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic325e42974444401b43cd0f7a06ca840_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEzLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MjFkNGMzNGJiM2ZkNDU2ZTg5M2I3Zjc5MDQ1ZTljNzJfNA_6878ad46-68cb-4406-8ae4-6345d7ca9fc0">5.50</ix:nonFraction>%&#160;Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="gbp" contextRef="ic325e42974444401b43cd0f7a06ca840_I20220102" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEzLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MjFkNGMzNGJiM2ZkNDU2ZTg5M2I3Zjc5MDQ1ZTljNzJfMjQ_902a5dfe-465a-4563-a65c-5f5366c466fe">500</ix:nonFraction>MM <ix:nonFraction unitRef="number" contextRef="ic325e42974444401b43cd0f7a06ca840_I20220102" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEzLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MjFkNGMzNGJiM2ZkNDU2ZTg5M2I3Zjc5MDQ1ZTljNzJfMjk_77f0ad1c-944b-4bff-a79f-59dbd59191ef">1.3485</ix:nonFraction> GBP )</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(<ix:nonFraction unitRef="gbp" contextRef="i23ebbe6c25ea4f94a4f7a79af3ae380c_I20210103" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEzLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MjFkNGMzNGJiM2ZkNDU2ZTg5M2I3Zjc5MDQ1ZTljNzJfNDI_77d9630c-bc9a-4060-8de2-e927c087fea0">500</ix:nonFraction>MM GBP <ix:nonFraction unitRef="number" contextRef="i23ebbe6c25ea4f94a4f7a79af3ae380c_I20210103" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEzLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MjFkNGMzNGJiM2ZkNDU2ZTg5M2I3Zjc5MDQ1ZTljNzJfNTE_fe9b2f9a-c9e2-4f8e-911c-c59ce927abf1">1.3654</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic325e42974444401b43cd0f7a06ca840_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEzLTItMS0xLTI5NzI2_5f497021-cf5f-47db-a4e9-810832191b09">672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic325e42974444401b43cd0f7a06ca840_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEzLTQtMS0xLTI5NzI2_a58a421e-9e26-4451-926c-2bbbe5435862">6.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23ebbe6c25ea4f94a4f7a79af3ae380c_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEzLTYtMS0xLTI5NzI2_3443b9a9-5ac0-4933-82dc-d712e2063bf6">679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23ebbe6c25ea4f94a4f7a79af3ae380c_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEzLTgtMS0xLTI5NzI2_daa91d9c-e32b-4e6c-9534-90226fdd1eb4">6.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id03e49fef75f4ad086ee0152d3b7896f_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE0LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MWVmYTU3NGVlMmQ5NGQ5MjgwOTFlNTVkNTA5ZjAwOWVfNA_f6461db1-f07c-4a1a-996e-ed569e9e1c49">2.625</ix:nonFraction>% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03e49fef75f4ad086ee0152d3b7896f_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE0LTItMS0xLTI5NzI2_affd0393-a064-4d43-a85d-8eb430975b01">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id03e49fef75f4ad086ee0152d3b7896f_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE0LTQtMS0xLTI5NzI2_50c76873-e50f-43d0-9be2-ae6b7bccba48">2.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7856d21e578e46b9b1070fee609a0e37_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE0LTYtMS0xLTI5NzI2_cc963076-8840-4fa2-b278-da9bf1cb2853">748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7856d21e578e46b9b1070fee609a0e37_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE0LTgtMS0xLTI5NzI2_69940cf0-dca2-40be-8613-1f33d4d93be9">2.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice544b21d87b4663b518b0e214c4294b_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246NjE3OTMyYWQ5ZjJmNDJiMGFjZDQ0ZGVjYTIwZTY5ODJfNA_27115619-2d8f-44f8-90b2-1bd326c33bf8">0.55</ix:nonFraction>% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice544b21d87b4663b518b0e214c4294b_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE1LTItMS0xLTI5NzI2_e88885f2-7dc9-4210-9d72-3670952611d0">983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice544b21d87b4663b518b0e214c4294b_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE1LTQtMS0xLTI5NzI2_626fd4b6-55b9-4a76-90d6-ad59211e1655">0.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib04d55053c914695966b620bbf97d8eb_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE1LTYtMS0xLTI5NzI2_6bec302c-cbf6-40f1-8b91-674ea1ea5cfc">996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib04d55053c914695966b620bbf97d8eb_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE1LTgtMS0xLTI5NzI2_0530b67e-884c-4852-9e7b-fc7369ecbea6">0.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff56df08a53e4e72b5ba1d8f127ae174_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE2LTAtMS0xLTI5NzI2L3RleHRyZWdpb246NGVkOTQxMDlhNzZkNDRmMmI2YTFlYzE5ODA1OWM0NTFfNA_ef908604-6cab-42d2-ab0b-a76fcc20f0a6">2.45</ix:nonFraction>% Notes due 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff56df08a53e4e72b5ba1d8f127ae174_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE2LTItMS0xLTI5NzI2_22098f12-b431-41e1-b7b9-d9cf731b7d88">1,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff56df08a53e4e72b5ba1d8f127ae174_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE2LTQtMS0xLTI5NzI2_ad57faf6-378f-4444-bc96-9fdea3089a84">2.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739863a8ea5642299f1ea5847ac97114_I20210103" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE2LTYtMS0xLTI5NzI2_fc4e7fc2-2725-4b7e-8de0-e94007089e65">1,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i739863a8ea5642299f1ea5847ac97114_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE2LTgtMS0xLTI5NzI2_22574c69-911a-4365-938d-09f06885fc98">2.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie1a46192ec1b4ed09aaafc90b80400a3_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE3LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDg4ZGZiOWQzMTM2NGQxM2JmMzNhY2FjMmM4YmY4YWJfNA_2e4e56c2-7c15-4dca-9091-05154e15c270">2.95</ix:nonFraction>% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1a46192ec1b4ed09aaafc90b80400a3_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE3LTItMS0xLTI5NzI2_5b5d2a3c-0f02-4aa6-ae3c-5fb2770742ee">978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie1a46192ec1b4ed09aaafc90b80400a3_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE3LTQtMS0xLTI5NzI2_93feae64-1758-4b4d-b6d1-69fbe51e964c">2.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1831bd89995549639d1c19d6d216a958_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE3LTYtMS0xLTI5NzI2_2795afc7-b667-4188-9c5f-45aadf61add8">997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1831bd89995549639d1c19d6d216a958_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE3LTgtMS0xLTI5NzI2_2f1249f0-bd9c-4455-99f8-1271bd7de04f">2.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i972bf884bfea41ffb590c5a7eac07cd4_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE4LTAtMS0xLTI5NzI2L3RleHRyZWdpb246YzdlNmU0NWM4YWYwNDQ0ZWFkZDkwN2Q4ZDllODhlMDVfNA_9d192c1f-df4f-4f83-9657-ebefe9bd8c14">0.95</ix:nonFraction>% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972bf884bfea41ffb590c5a7eac07cd4_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE4LTItMS0xLTI5NzI2_95411435-7741-4f5f-9e61-7e8143b6eceb">1,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i972bf884bfea41ffb590c5a7eac07cd4_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE4LTQtMS0xLTI5NzI2_d0ca83c3-b4f0-4085-88ad-6941a39de162">0.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i205cddf8beb44dffb12b506c83e24428_I20210103" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE4LTYtMS0xLTI5NzI2_ea174b37-be21-4697-92cb-6fc40d4d31ee">1,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i205cddf8beb44dffb12b506c83e24428_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE4LTgtMS0xLTI5NzI2_744f8dc0-5a4a-4f38-801d-b7d77d4e604f">0.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7fa3f9944b0c403d9f46170a329df816_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE5LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MzNmMTBhMjkzMjc1NGZkZTllZTQzN2VjMGNjMGZhNDNfNA_f4aafe94-3c12-4010-890d-e6595592cea1">1.150</ix:nonFraction>% Notes due 2028                                                (<ix:nonFraction unitRef="eur" contextRef="i7fa3f9944b0c403d9f46170a329df816_I20220102" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE5LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MzNmMTBhMjkzMjc1NGZkZTllZTQzN2VjMGNjMGZhNDNfNzA_7b6e264a-06a4-49b6-86f8-c3c170f81302">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="i7fa3f9944b0c403d9f46170a329df816_I20220102" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE5LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MzNmMTBhMjkzMjc1NGZkZTllZTQzN2VjMGNjMGZhNDNfODA_45093f8d-a096-4d54-a6e6-1419860b92b5">1.1311</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(<ix:nonFraction unitRef="eur" contextRef="i1c5bee0e48bf4e4099a183bdeee52392_I20210103" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE5LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MzNmMTBhMjkzMjc1NGZkZTllZTQzN2VjMGNjMGZhNDNfODg_93f65a6f-9449-4bbf-bdfd-ead12c788d4b">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="i1c5bee0e48bf4e4099a183bdeee52392_I20210103" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE5LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MzNmMTBhMjkzMjc1NGZkZTllZTQzN2VjMGNjMGZhNDNfOTg_d39cb758-b931-4112-a36d-3b311ee36823">1.2281</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fa3f9944b0c403d9f46170a329df816_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE5LTItMS0xLTI5NzI2_30b1ab15-5b62-4db6-bd93-814e6b7d6c9f">843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7fa3f9944b0c403d9f46170a329df816_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE5LTQtMS0xLTI5NzI2_a44b486f-8a11-4319-bf10-b87af154a03e">1.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5bee0e48bf4e4099a183bdeee52392_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE5LTYtMS0xLTI5NzI2_c1c045b4-1a6b-4548-8fbd-cf6b0190c6d6">915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c5bee0e48bf4e4099a183bdeee52392_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE5LTgtMS0xLTI5NzI2_673083e3-8b32-480a-8cb8-8f3df6e25544">1.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5cf895e15ef54040bfac0247f96946b9_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIwLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MzI2YjcyMmZiODVmNDNiNmFiNGQ3ZjZkMTg0NmY2NDlfNA_08b704dc-c8c8-48d6-ba86-3f07603b4013">2.90</ix:nonFraction>%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cf895e15ef54040bfac0247f96946b9_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIwLTItMS0xLTI5NzI2_c6c7f9d4-0646-4eb5-a8e6-acae8a47f895">1,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5cf895e15ef54040bfac0247f96946b9_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIwLTQtMS0xLTI5NzI2_bb04999f-2aec-46f0-bf9e-d70ebc521532">2.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37d3ee2aa4344396b0069afab5218f8a_I20210103" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIwLTYtMS0xLTI5NzI2_e01f39e2-54ba-41e1-9838-99b9c70fc7e4">1,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i37d3ee2aa4344396b0069afab5218f8a_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIwLTgtMS0xLTI5NzI2_0be7f4eb-7d7d-49ba-873e-d9c0a60df4f6">2.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bbfeb41492140249fab5192b682546a_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIxLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDE4MDY0ZjU4OGEyNGMwNjk3MTEzM2IwMDllODJjMmNfNA_101cc1fd-3488-4605-bbff-048bc0c23362">6.95</ix:nonFraction>%&#160;Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbfeb41492140249fab5192b682546a_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIxLTItMS0xLTI5NzI2_8f7fa660-1134-4038-a77a-4d78b4a2a703">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bbfeb41492140249fab5192b682546a_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIxLTQtMS0xLTI5NzI2_05cdd92d-2399-48b4-b60c-5a770f0cdcf9">7.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i658f3103f74c4c7fbb7b36c491a45202_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIxLTYtMS0xLTI5NzI2_7888b1f1-51aa-4852-9c18-6cc0fd60181a">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i658f3103f74c4c7fbb7b36c491a45202_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIxLTgtMS0xLTI5NzI2_4f169ac6-bb40-4902-95ba-66a30baec286">7.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i57a48838d3bc409fbed2cc1936c123cd_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIyLTAtMS0xLTI5NzI2L3RleHRyZWdpb246OWZhM2FhODdiNjRjNGYzNWI5Njk4MzlmZDhlMzdjNjRfNA_9d984f40-323f-49c0-ba1b-6e9c0d30ef22">1.30</ix:nonFraction>% Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57a48838d3bc409fbed2cc1936c123cd_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIyLTItMS0xLTI5NzI2_814c60be-101a-454e-b5b3-70a6e077b6bd">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i57a48838d3bc409fbed2cc1936c123cd_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIyLTQtMS0xLTI5NzI2_15f11666-f772-490f-87f6-016b84ef1697">1.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0408738fa2104741b459f57515ad3ab1_I20210103" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIyLTYtMS0xLTI5NzI2_20dbf01c-3f3c-4f9c-b58f-318404ccaed9">1,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0408738fa2104741b459f57515ad3ab1_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIyLTgtMS0xLTI5NzI2_ddacce34-593f-46a5-931a-3b6fa7a74a95">1.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i17953ea1893e452cb3c1c9dd6916994c_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIzLTAtMS0xLTI5NzI2L3RleHRyZWdpb246YWNkMDlmY2Q1MzFiNDY4MzkyMmM1NTgwMGY1Yzk3YTZfNA_609450f0-6f5a-4d0f-9dff-ad5aad0beb1a">4.95</ix:nonFraction>%&#160;Debentures due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17953ea1893e452cb3c1c9dd6916994c_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIzLTItMS0xLTI5NzI2_88634876-3c7a-43a3-8bda-6583d4685145">498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i17953ea1893e452cb3c1c9dd6916994c_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIzLTQtMS0xLTI5NzI2_a12933f4-e6a3-4ed0-8e55-d815003303e6">4.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c0880f1340c45b89ff33b5be547b0ce_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIzLTYtMS0xLTI5NzI2_2b368ffe-eee4-429c-9f44-1743bfa360e9">498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c0880f1340c45b89ff33b5be547b0ce_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIzLTgtMS0xLTI5NzI2_74d6f659-db3f-4be1-a995-337c9b73281a">4.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2976154beffb47c4be5a474bc8db9894_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI0LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MzU2MWQ0ZTMxODJiNDcwZTgxOWI4NDAwYzk4ZTliY2JfNA_d264bbf9-cb95-4f88-b470-3798bfd1ba32">4.375</ix:nonFraction>% Notes due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2976154beffb47c4be5a474bc8db9894_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI0LTItMS0xLTI5NzI2_274401ab-373f-4a8b-bcaf-69b851c930fd">854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2976154beffb47c4be5a474bc8db9894_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI0LTQtMS0xLTI5NzI2_04735a42-de0f-46ad-b3ca-a9e2e8fcd8e8">4.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d27e50b0964bbcb629a108b11c7420_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI0LTYtMS0xLTI5NzI2_afc1d9f2-bc77-46e5-bd51-2b81ff763b90">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5d27e50b0964bbcb629a108b11c7420_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI0LTgtMS0xLTI5NzI2_4460382b-bf17-49ef-9d29-9f792582a700">4.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae7e9316990b44f98989c64c67ff0c10_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246NjFjYzg0NTEyMDU3NGEyMGE2NDc3OTE0MjdlZDIzMGJfNA_b1cd2f48-2a2c-49c9-8fa5-bf37a49f3227">1.650</ix:nonFraction>% Notes due 2035                                                     (<ix:nonFraction unitRef="eur" contextRef="iae7e9316990b44f98989c64c67ff0c10_I20220102" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246NjFjYzg0NTEyMDU3NGEyMGE2NDc3OTE0MjdlZDIzMGJfNzU_26ba0104-8cf4-4fd8-8e42-5c4bb948f191">1.5</ix:nonFraction>B Euro <ix:nonFraction unitRef="number" contextRef="iae7e9316990b44f98989c64c67ff0c10_I20220102" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246NjFjYzg0NTEyMDU3NGEyMGE2NDc3OTE0MjdlZDIzMGJfODQ_a61bd701-592c-46e6-ba8f-a4d002e212ec">1.1311</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(<ix:nonFraction unitRef="eur" contextRef="i2685a9e688f94a75a231df74311feb24_I20210103" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246NjFjYzg0NTEyMDU3NGEyMGE2NDc3OTE0MjdlZDIzMGJfOTI_cf4cca1f-3e14-47bc-be8a-70a1e4e66005">1.5</ix:nonFraction>B Euro <ix:nonFraction unitRef="number" contextRef="i2685a9e688f94a75a231df74311feb24_I20210103" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246NjFjYzg0NTEyMDU3NGEyMGE2NDc3OTE0MjdlZDIzMGJfMTAx_99a38f65-5aaf-4381-8597-cc47fda0afa9">1.2281</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae7e9316990b44f98989c64c67ff0c10_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI1LTItMS0xLTI5NzI2_a1b1d334-37b2-41a3-9bbd-8b9396066402">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae7e9316990b44f98989c64c67ff0c10_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI1LTQtMS0xLTI5NzI2_04dc27ae-5b98-42c2-a943-805ed0d26fbe">1.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2685a9e688f94a75a231df74311feb24_I20210103" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI1LTYtMS0xLTI5NzI2_762f7a96-9625-4c18-becc-d9416f848a5a">1,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2685a9e688f94a75a231df74311feb24_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI1LTgtMS0xLTI5NzI2_3114717a-0b7b-4168-92e3-7da7fd801315">1.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie17e8d053df0468983d5b9c5221888e5_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI2LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDI2ZTlkOTAzMzAxNDI1Yjk3MDNhMWVjYmNmYjAzNTVfNA_5d324507-ede2-4b59-b500-aa9ee3577692">3.55</ix:nonFraction>% Notes due 2036</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie17e8d053df0468983d5b9c5221888e5_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI2LTItMS0xLTI5NzI2_fd5ace8a-f9ea-4c7f-88f3-5d07960df109">974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie17e8d053df0468983d5b9c5221888e5_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI2LTQtMS0xLTI5NzI2_cb0f7178-2ff6-4d98-8562-49b2f1233011">3.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if74440cec8d14911a94f8cbf380782ef_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI2LTYtMS0xLTI5NzI2_ec1c53df-8929-4b67-8ea3-232a30b1c836">989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if74440cec8d14911a94f8cbf380782ef_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI2LTgtMS0xLTI5NzI2_0b211b24-f333-44ec-ae98-44e8075c1066">3.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0adb5ffb62d14519a2797379c107d86e_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI3LTAtMS0xLTI5NzI2L3RleHRyZWdpb246OGI4MDM0ZjY2ZmRhNDIwNzk0ZWY2ZmFkMGU1OGJkY2JfNA_d96b26cc-abce-46c5-b18a-57eea0a27f6b">5.95</ix:nonFraction>%&#160;Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0adb5ffb62d14519a2797379c107d86e_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI3LTItMS0xLTI5NzI2_a28daccf-8e8a-4311-94a6-ba8d465fa393">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0adb5ffb62d14519a2797379c107d86e_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI3LTQtMS0xLTI5NzI2_5e876ea4-987f-4e28-a829-30a15864be3c">5.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b9c1e7af3946a08254176836ec29a7_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI3LTYtMS0xLTI5NzI2_2da710a2-c94a-47d6-ba63-7175a4d23070">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i47b9c1e7af3946a08254176836ec29a7_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI3LTgtMS0xLTI5NzI2_8f17b495-639b-4dcb-b6fa-a68b03e8f7aa">5.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ed9c4f37ce1466fa53ccf042656f5d6_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI4LTAtMS0xLTI5NzI2L3RleHRyZWdpb246ZWI1M2VhMDdiNjFjNDBkNGIyZGEyZGE3MWE4OTIxZTlfNA_ed3eb9ea-2b08-420c-9aea-4c108548a4e0">3.625</ix:nonFraction>% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ed9c4f37ce1466fa53ccf042656f5d6_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI4LTItMS0xLTI5NzI2_c41b7f6e-f741-4af7-b2ab-3be45f8f9278">1,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ed9c4f37ce1466fa53ccf042656f5d6_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI4LTQtMS0xLTI5NzI2_3ca8666e-56de-49b2-83e9-5b7402863d76">3.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83c020a1a4849fb88e0231815c8866d_I20210103" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI4LTYtMS0xLTI5NzI2_817ee777-d9ee-41df-8df5-e94951d96f51">1,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia83c020a1a4849fb88e0231815c8866d_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI4LTgtMS0xLTI5NzI2_7b98b900-5121-405d-9fea-4b446602c157">3.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0118c5eed732427f9cf06f31486fc01c_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI5LTAtMS0xLTI5NzI2L3RleHRyZWdpb246NjliYzgzYmU4MDRlNGE5NGIzM2JjMmQ4ZTJkZGI2YWVfNA_a97e2e97-37fb-455b-ab7e-e43adde303a1">5.85</ix:nonFraction>%&#160;Debentures due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0118c5eed732427f9cf06f31486fc01c_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI5LTItMS0xLTI5NzI2_213b4408-41ae-488b-8539-57d27f6c1312">696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0118c5eed732427f9cf06f31486fc01c_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI5LTQtMS0xLTI5NzI2_34e1e457-0aa2-4e39-974c-c8c33aafb6f6">5.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife7c692d97564c858b7b4ed1c803b286_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI5LTYtMS0xLTI5NzI2_17cb4c3a-0deb-430f-81c8-6830d39ea673">696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife7c692d97564c858b7b4ed1c803b286_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI5LTgtMS0xLTI5NzI2_5b2f0722-0229-4625-a32a-417baea73074">5.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic38bc0786162462d9877b064a6a205e6_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMwLTAtMS0xLTI5NzI2L3RleHRyZWdpb246NDM1YTVmYTIxYjY0NDY1MWJjYmZiOWM5ZjIwM2M4Y2NfNA_bf9b5672-738c-4d8a-b058-8339378d6e84">3.400</ix:nonFraction>%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic38bc0786162462d9877b064a6a205e6_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMwLTItMS0xLTI5NzI2_dd1dc6cc-0287-469e-9ea9-0f61dbe00c1f">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic38bc0786162462d9877b064a6a205e6_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMwLTQtMS0xLTI5NzI2_67326c83-6ef2-4f2b-9aa9-95eec8ca74a5">3.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i726718a28d4d4e549a41a17182d08fe6_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMwLTYtMS0xLTI5NzI2_f63163b5-0108-4c1e-94a2-6e0b953c88d3">991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i726718a28d4d4e549a41a17182d08fe6_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMwLTgtMS0xLTI5NzI2_ceb7d8e9-04ea-458a-86c4-124ecc84e916">3.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53a8fedc553f4f0f9de5d0a709173803_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMxLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MzQ4MGQzMzRjNzFkNDJlNThmM2E5ZTFhNTVlYzljZmFfNA_737e7da7-eb3b-47a9-839b-afbad5ba4f1d">4.50</ix:nonFraction>%&#160;Debentures due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a8fedc553f4f0f9de5d0a709173803_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMxLTItMS0xLTI5NzI2_9ddb1caf-df8f-4d07-b910-150d34da82c0">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53a8fedc553f4f0f9de5d0a709173803_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMxLTQtMS0xLTI5NzI2_848a6c05-3dc1-444d-af48-94970836f167">4.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b1dedd1b83419bb98c00b29d60b882_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMxLTYtMS0xLTI5NzI2_00427609-5f3e-4ebb-9e6c-b661305b5c07">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i62b1dedd1b83419bb98c00b29d60b882_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMxLTgtMS0xLTI5NzI2_7c02dc41-21ac-4c03-a15f-a4b4a105c51e">4.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8bd1c41b5d0d42c69a6f96b89a46e668_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMyLTAtMS0xLTI5NzI2L3RleHRyZWdpb246YWExNzhjYzU2NWJkNDY5MTkyZjEyNDZjMGRkMGZhNWZfNA_0ee6c613-51d0-4f81-abc4-721cfbe8e1d3">2.10</ix:nonFraction>% Notes due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bd1c41b5d0d42c69a6f96b89a46e668_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMyLTItMS0xLTI5NzI2_981979ee-7bbf-4c7b-9a43-d82d3d02db87">974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8bd1c41b5d0d42c69a6f96b89a46e668_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMyLTQtMS0xLTI5NzI2_da22082c-9cc0-4f0b-a9bf-92ffbaad34fe">2.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5eb48543498494ca45ded9c606d3d15_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMyLTYtMS0xLTI5NzI2_1426d40e-1321-449c-a88e-5ec17b0481c1">986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib5eb48543498494ca45ded9c606d3d15_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMyLTgtMS0xLTI5NzI2_edbd0288-23c2-4c09-bd66-56337228fc23">2.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib69f13bfa815433e85d3e00eef71fedf_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMzLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MjczNzg5MTZlMGMwNGZiZThmZDExY2NiYTAzZjg1MWNfNA_57bc6cb3-3097-4c76-b981-3f4bba0a3e26">4.85</ix:nonFraction>% Notes due 2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib69f13bfa815433e85d3e00eef71fedf_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMzLTItMS0xLTI5NzI2_ef266dc5-6c48-451b-8c46-54d093b48330">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib69f13bfa815433e85d3e00eef71fedf_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMzLTQtMS0xLTI5NzI2_e2eb425b-60de-44a3-bb3b-c1b58e100b4e">4.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8d56c9e88f342bea407c38d6cd7e55f_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMzLTYtMS0xLTI5NzI2_696e8612-7418-4b14-855f-469068a3c523">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie8d56c9e88f342bea407c38d6cd7e55f_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMzLTgtMS0xLTI5NzI2_b6f4df65-a741-4e2a-863a-91a995fec589">4.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfa4a27c5acc457f8dfe7f024890432d_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM0LTAtMS0xLTI5NzI2L3RleHRyZWdpb246NDgyZTVjNGI0ZmQ4NDUxM2I4OWQ3NWMwODZlOTIyZmRfNA_44f92617-dd22-44ee-b973-e645a29ad68d">4.50</ix:nonFraction>% Notes due 2043</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa4a27c5acc457f8dfe7f024890432d_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM0LTItMS0xLTI5NzI2_e02d0f48-9bde-4150-a46e-64990631a51e">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfa4a27c5acc457f8dfe7f024890432d_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM0LTQtMS0xLTI5NzI2_2e0eb975-5427-49ba-8df7-1f49fa6ac989">4.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if36ddad29b164d53899d8ee23f080abd_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM0LTYtMS0xLTI5NzI2_349a4f0e-ad7d-4fce-b4b8-81d7999defa5">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if36ddad29b164d53899d8ee23f080abd_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM0LTgtMS0xLTI5NzI2_4b80858e-1260-435f-93d1-87efd2a382bb">4.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i11c0c665fc394565a535f0b2c5c1317b_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MzVkODZhNmIxNmYwNGI1NTkyOGQwZjE0ZjgxYzlmMDBfNA_64d789b9-c3c3-4dbf-8cac-dab462afdcd3">3.70</ix:nonFraction>% Notes due 2046</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c0c665fc394565a535f0b2c5c1317b_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM1LTItMS0xLTI5NzI2_f745af9a-ca7f-4521-a87b-db6ecc4dbfe6">1,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i11c0c665fc394565a535f0b2c5c1317b_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM1LTQtMS0xLTI5NzI2_7fe4ef59-d79c-4368-9707-edf59c5d9b48">3.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54250135a56c4cd5be1d66d5f63431cf_I20210103" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM1LTYtMS0xLTI5NzI2_bc43e013-37a4-4497-8313-e17930537050">1,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54250135a56c4cd5be1d66d5f63431cf_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM1LTgtMS0xLTI5NzI2_36bd475c-bcd6-4f6e-8026-5313abbf2c7e">3.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i50afe1be5edb4180890a7b5b27e4d27a_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM2LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MTgzOTgwZjQ0MTc1NGUyNmFkODg4YjkzNzFlNjkxYTRfNA_930a78f0-794a-4208-b51f-cc9d0ca25855">3.75</ix:nonFraction>% Notes due 2047</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50afe1be5edb4180890a7b5b27e4d27a_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM2LTItMS0xLTI5NzI2_4e7041df-0077-48ed-867f-b19d8d6ea3be">971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i50afe1be5edb4180890a7b5b27e4d27a_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM2LTQtMS0xLTI5NzI2_e24dc118-e450-4c2b-bd8d-a2b881c02733">3.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3faf3f90111144d7a940a9a2c71d768d_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM2LTYtMS0xLTI5NzI2_64eeca44-31bf-4a32-bde9-4ed5e19be5c5">991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3faf3f90111144d7a940a9a2c71d768d_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM2LTgtMS0xLTI5NzI2_9d66ef39-cff2-4b5c-8620-46c1d2534e25">3.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e28fa051d454297b4accf2668e5f29a_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM3LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDUyMGQ0ZDJiZTE3NDBmMjhlMzA5OWRmZjk4ZWVjMTdfNA_f8abb625-a4dc-4ab3-a394-8bd4a721d6e9">3.500</ix:nonFraction>% Notes due 2048</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e28fa051d454297b4accf2668e5f29a_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM3LTItMS0xLTI5NzI2_3662dd74-6776-426f-ac1b-ef7589e11871">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e28fa051d454297b4accf2668e5f29a_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM3LTQtMS0xLTI5NzI2_bae24664-9711-4548-9dd1-39c912bf1480">3.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbd71c42f6294b2fbf205f288d70c25a_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM3LTYtMS0xLTI5NzI2_836f039c-3b86-49d5-98cd-a605431bbd59">742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icbd71c42f6294b2fbf205f288d70c25a_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM3LTgtMS0xLTI5NzI2_2020780f-6987-439d-9149-c59e37cbf92a">3.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i168b47008a8445648dc5777fadae1587_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM4LTAtMS0xLTI5NzI2L3RleHRyZWdpb246ODA2MmE0ZGI5NzNhNDdlNWJmNTAyZDFmN2ZmOWMzMzVfNA_9061a763-3a5c-4492-83d3-83d4032d67ec">2.250</ix:nonFraction>% Notes due 2050</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i168b47008a8445648dc5777fadae1587_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM4LTItMS0xLTI5NzI2_c125b8b1-adaa-4768-88ad-f9bc60964518">983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i168b47008a8445648dc5777fadae1587_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM4LTQtMS0xLTI5NzI2_fc6fc105-ec57-4e01-966c-7765c5c77d57">2.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7aefbac28e2470ea9d6063671ef8da1_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM4LTYtMS0xLTI5NzI2_ad75a7bc-f27d-4108-81b7-7ce377af477f">984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id7aefbac28e2470ea9d6063671ef8da1_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM4LTgtMS0xLTI5NzI2_9ff19ec8-d22e-47cf-b269-89393a48082f">2.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03664ec5ebbe4d8da845ff31701a77f2_I20220102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM5LTAtMS0xLTI5NzI2L3RleHRyZWdpb246OTUxN2JhNjcwMTczNGZjMmJmODRmNDdmZDllYjg3YzZfNA_066a7fce-5f34-450d-8733-a9d33f74dcd0">2.450</ix:nonFraction>% Notes due 2060</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03664ec5ebbe4d8da845ff31701a77f2_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM5LTItMS0xLTI5NzI2_ae11c634-ce1b-4622-8319-6d460c6617a5">1,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03664ec5ebbe4d8da845ff31701a77f2_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM5LTQtMS0xLTI5NzI2_28b96e9f-aa88-41c2-9bf3-69fc9aea39fe">2.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd4a9a1de87b4f128a0bb747c7a11f74_I20210103" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM5LTYtMS0xLTI5NzI2_39baf271-d61b-4d71-bdf8-cc95d39ca102">1,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd4a9a1de87b4f128a0bb747c7a11f74_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM5LTgtMS0xLTI5NzI2_f20c00df-5025-4332-bc56-eab55304a6fd">2.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aa10255024e47998e73466dc7e568bc_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQwLTItMS0xLTI5NzI2_c464fc4c-0351-45b6-a72f-ba21be2ec415">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6aa10255024e47998e73466dc7e568bc_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQwLTQtMS0xLTI5NzI2_16329aa6-0b8c-4ff3-9696-7c0626e062be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec495cbb0c2c4cedbd4600d7d89a94d8_I20210103" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQwLTYtMS0xLTI5NzI2_b2555111-085e-4a25-be20-f8a7776b89a3">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iec495cbb0c2c4cedbd4600d7d89a94d8_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQwLTgtMS0xLTI5NzI2_37e5525d-d1f9-4ae2-8327-a367f8877db0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQxLTItMS0xLTI5NzI2_6b34250e-ee3b-4b63-898b-378507507eab">32,116</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQxLTQtMS0xLTI5NzI2_6d5029c7-c6a1-48cb-8173-f3b76333de6e">2.89</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQxLTYtMS0xLTI5NzI2_ad0ba312-c7c6-4950-846a-e098b0b210e4">34,434</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQxLTgtMS0xLTI5NzI2_f5039092-52cc-4075-8249-5dd70d3fef3a">2.85</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQyLTItMS0xLTI5NzI2_e90d86ec-d20b-4d96-ba31-fabf3f345bda">2,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQyLTYtMS0xLTI5NzI2_19f25162-05e6-4f6d-9894-c88fc4d489fa">1,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQzLTItMS0xLTI5NzI2_7a4699a8-0981-40e3-9972-ba00a7d5a0c4">29,985</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQzLTYtMS0xLTI5NzI2_84905b47-8dd0-4d00-a358-5771af89fd78">32,635</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i54b58ca3e8ee4917ac6c1343466bbe72"><ix:continuation id="i1270320337da476ca9b9a4a635e1b287"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Weighted average effective rate.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Translation rate at January&#160;2, 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Translation rate at January&#160;3, 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The excess of the fair value over the carrying value of debt was $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-8" name="jnj:ExcessOfFairValueOverCarryingValueOfDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzIxNg_de18f223-4462-4abe-9543-42241fce1d66">3.2</ix:nonFraction> billion at the end of fiscal year 2021 and $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-8" name="jnj:ExcessOfFairValueOverCarryingValueOfDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzI1Mg_b5f95211-b068-418a-a049-44f9ff39f55f">5.4</ix:nonFraction> billion at the end of fiscal year 2020.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has access to substantial sources of funds at numerous banks worldwide. In September 2021, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $<ix:nonFraction unitRef="usd" contextRef="ied2f6ed477eb4ce6ad7d7bfaa6f716d3_I20210930" decimals="-9" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzczNA_d57be58f-d52d-4649-aa53-02cc87edc006">10</ix:nonFraction> billion, which expires on September&#160;8, 2022. Interest charged on borrowings under the credit line agreement is based on either the Term SOFR Reference Rate or other applicable market rates as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreements are not material.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Throughout fiscal years 2021 and 2020, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-8" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzEzMDE_1337476f-6544-463b-84a4-0aa16a83a7dc">3.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-8" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzEwOTk1MTE2MzExOTE_30730433-bd12-46a4-81d4-bae87093cb2c">2.6</ix:nonFraction> billion at the end of fiscal years 2021 and 2020, respectively. The current portion of the long term debt was $<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-8" name="us-gaap:LongTermCommercialPaperCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzEzNDM_f66fda4e-db8e-4431-8c5c-d7fdb380718d">2.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-8" name="us-gaap:LongTermCommercialPaperCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzE3MzQ_09e10629-77f5-4df8-ae39-0af1e97b0f5d">1.8</ix:nonFraction> billion in 2021 and 2020, respectively, and the remainder is commercial paper and local borrowing by international subsidiaries. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The current debt balance as of January&#160;2, 2022 includes $<ix:nonFraction unitRef="usd" contextRef="i64bd5e8b71f34e13ac4ffb87991525cb_I20220102" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzU0OTc1NTgxNDMzMzY_126f4962-d2c9-4f4f-ac7e-52e615dc961d">1.6</ix:nonFraction>&#160;billion of commercial paper which has a weighted average interest rate of <ix:nonFraction unitRef="number" contextRef="i64bd5e8b71f34e13ac4ffb87991525cb_I20220102" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzU0OTc1NTgxNDMzNTQ_03378004-e32c-495c-98b9-9486a1b1ca0d">0.11</ix:nonFraction>% and a weighted average maturity of approximately <ix:nonNumeric contextRef="ie196b853653742808afbef735bb258c5_D20210104-20220102" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzU0OTc1NTgxNDMzODU_fdfcf27d-d47f-47a6-a1ad-427c0e8f2af1">three months</ix:nonNumeric>.</span></div><div style="text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzE5NzQ_0d9db74e-88ad-41f1-8537-92592e5f76c7" escape="true"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate maturities of long-term debt obligations commencing in 2022 are:</span></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:15.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">After 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTpjMDkxMGQ0MjA0N2I0OTdmOTgyZjgzNjZlNzJjYWRkZC90YWJsZXJhbmdlOmMwOTEwZDQyMDQ3YjQ5N2Y5ODJmODM2NmU3MmNhZGRkXzItMC0xLTEtMjk3MjY_9a32ed94-136e-473b-98e7-12bcc3da1602">2,131</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTpjMDkxMGQ0MjA0N2I0OTdmOTgyZjgzNjZlNzJjYWRkZC90YWJsZXJhbmdlOmMwOTEwZDQyMDQ3YjQ5N2Y5ODJmODM2NmU3MmNhZGRkXzItMi0xLTEtMjk3MjY_0e989ae5-b921-4548-b6fe-8631fe82012c">1,551</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTpjMDkxMGQ0MjA0N2I0OTdmOTgyZjgzNjZlNzJjYWRkZC90YWJsZXJhbmdlOmMwOTEwZDQyMDQ3YjQ5N2Y5ODJmODM2NmU3MmNhZGRkXzItNC0xLTEtMjk3MjY_a7dd77cc-3728-4a11-a2a7-97c78f2d5b7f">1,518</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTpjMDkxMGQ0MjA0N2I0OTdmOTgyZjgzNjZlNzJjYWRkZC90YWJsZXJhbmdlOmMwOTEwZDQyMDQ3YjQ5N2Y5ODJmODM2NmU3MmNhZGRkXzItNi0xLTEtMjk3MjY_72b0b7d7-dfb3-4da1-a447-b79bfe2c4363">1,732</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTpjMDkxMGQ0MjA0N2I0OTdmOTgyZjgzNjZlNzJjYWRkZC90YWJsZXJhbmdlOmMwOTEwZDQyMDQ3YjQ5N2Y5ODJmODM2NmU3MmNhZGRkXzItOC0xLTEtMjk3MjY_d4295256-5255-4c66-92c3-f203095f0f56">1,995</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTpjMDkxMGQ0MjA0N2I0OTdmOTgyZjgzNjZlNzJjYWRkZC90YWJsZXJhbmdlOmMwOTEwZDQyMDQ3YjQ5N2Y5ODJmODM2NmU3MmNhZGRkXzItMTAtMS0xLTI5NzI2_b1bded58-c4fd-48d5-865c-01a2927405a8">23,189</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_169"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNTc1_8cfd6906-41f5-43a9-a636-df54f29ac251" continuedAt="if52983e832104e7faa3c47270f7463d2" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><ix:continuation id="if52983e832104e7faa3c47270f7463d2" continuedAt="i7888ccf252cb4060b96987805af3c269"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNTc4_42368869-2325-4fda-a1f7-a2eaa9891b68" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for taxes on income consists of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:50.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.003%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currently payable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzItMi0xLTEtMjk3MjY_6de60cdb-2c2b-460f-9536-1dd366455dc2">1,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzItNC0xLTEtMjk3MjY_ec0768f5-a8a5-487c-88a8-8e71b8b20701">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzItNi0xLTEtMjk3MjY_42f0b057-da7e-4fc3-8080-e4178ca65524">1,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzQtMi0xLTEtMjk3MjY_537c697b-4f21-4769-b986-7be1293ce065">2,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzQtNC0xLTEtMjk3MjY_2ad49bd3-3b02-46a3-9de8-39029668413c">1,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzQtNi0xLTEtMjk3MjY_7ea7622f-0533-4dc6-b34e-1ca34fdd8afa">2,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total currently payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzUtMi0xLTEtMjk3MjY_06defaed-4a09-4c87-9835-ef48c0025ec5">3,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzUtNC0xLTEtMjk3MjY_57225879-39fd-48f2-8df9-28daae6204bf">2,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzUtNi0xLTEtMjk3MjY_31ee1dfb-7f66-4ada-95d1-17b7a68b7106">4,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzctMi0xLTEtMjk3MjY_4eb7e788-d8c2-4d06-a325-7059b73d66df">583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzctNC0xLTEtMjk3MjY_d8ee6b91-7f42-41c6-8347-59f0343f655a">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzctNi0xLTEtMjk3MjY_6e5b28d5-f163-467e-8077-7ad3bb3f0701">814</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzktMi0xLTEtMjk3MjY_df3a8c3e-04aa-420f-9507-730c9f46cab0">2,662</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzktNC0xLTEtMjk3MjY_8fa81b15-5007-4897-b581-6f0fb24f757c">1,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzktNi0xLTEtMjk3MjY_90c12e9b-7f10-40a5-967a-d080a7afd634">1,662</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzEwLTItMS0xLTI5NzI2_255c498f-857e-47cb-86b4-684a39680d86">2,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzEwLTQtMS0xLTI5NzI2_4a6c3a1d-93a0-4eb0-be93-83d37af1aad8">1,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzEwLTYtMS0xLTI5NzI2_b390f25a-d076-4a08-8de7-f6299d987acd">2,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Provision for taxes on income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzExLTItMS0xLTI5NzI2_a21be182-6b9c-4703-b1f1-976d37dc40f0">1,898</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzExLTQtMS0xLTI5NzI2_5b884d95-67e3-45eb-8c90-0cc10baad710">1,783</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzExLTYtMS0xLTI5NzI2_c641abf2-e9d8-43e9-ad98-5697550ce1db">2,209</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7888ccf252cb4060b96987805af3c269" continuedAt="i92058636e33649e1976b92f79a87b9ad"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNTY2_d258b8b6-414d-4344-ad8d-d69e1cdad254" continuedAt="i138e47fa9bf54a368474caa9b33e4512" escape="true"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A comparison of income tax expense at the U.S.&#160;statutory rate of <ix:nonFraction unitRef="number" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzIzNw_35001ae2-f803-4591-81af-8ddd55998e4c"><ix:nonFraction unitRef="number" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzIzNw_ae84e403-869d-4593-8326-5da351efb219">21</ix:nonFraction></ix:nonFraction>% in fiscal years 2021, 2020 and 2019, to the Company&#8217;s effective tax rate is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:48.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzEtMi0xLTEtMjk3MjY_1431248e-25a2-42ce-8dea-83ddc13bcd7e">6,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzEtNC0xLTEtMjk3MjY_794460e6-fb17-460a-8d50-a480290602ba">4,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzEtNi0xLTEtMjk3MjY_68313247-8fb6-411f-b81f-3c84c58d55ef">3,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzItMi0xLTEtMjk3MjY_bee04e5a-a6b5-4b12-916f-b2bb778438d8">16,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzItNC0xLTEtMjk3MjY_885c88cf-3d03-49ab-b5a8-1a854582941b">12,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzItNi0xLTEtMjk3MjY_c54964f6-3021-4bd5-a6f1-c870c9dbc232">13,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes on income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzMtMi0xLTEtMjk3MjY_e21a1e51-8c94-4289-8f8b-6aed7e85cc8f">22,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzMtNC0xLTEtMjk3MjY_fbbf1807-c7dc-41f8-9d8e-3444c28389a3">16,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzMtNi0xLTEtMjk3MjY_ebef13bd-91df-420f-bc67-2b9675b0f636">17,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rates:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzUtMi0xLTEtMjk3MjY_939a0feb-b902-40a8-9847-d86b24d83942">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzUtNC0xLTEtMjk3MjY_441e85c9-7989-4753-85e9-a00bd77f6d3f">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzUtNi0xLTEtMjk3MjY_0844b689-637c-4c24-9d49-75bbd97b4df5">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzYtMi0xLTEtMjk3MjY_f54e2733-fdf2-492b-b22b-1e514751e3c2">16.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzYtNC0xLTEtMjk3MjY_921111e2-e992-4890-a775-c42ced42186d">9.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzYtNi0xLTEtMjk3MjY_fe043229-71bf-4ac4-a806-d55d51c9d2ab">5.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes on international income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzEwLTItMS0xLTI5NzI2_53af6c32-255e-49f1-a169-e7827c1d683c">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzEwLTQtMS0xLTI5NzI2_ef76c985-56dd-4d7a-864a-a8f5874b3a0c">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzEwLTYtMS0xLTI5NzI2_68f1965a-6c19-4916-8adf-4d6bca201c2e">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefits from loss on capital assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="3" sign="-" name="jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzExLTItMS0xLTI5NzI2_accc8478-eb33-461f-9203-e7bfed5ae470">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="3" sign="-" name="jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzExLTQtMS0xLTI5NzI2_0d9bff24-3b5c-43c9-873d-d18af50958b1">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="3" sign="-" name="jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzExLTYtMS0xLTI5NzI2_f8d9466b-23de-41c0-bb6f-bbe57b9d7cdf">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefits on share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzEyLTItMS0xLTI5NzI2_0fc3b033-dc53-41a3-b743-08611fa8c5ee">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzEyLTQtMS0xLTI5NzI2_946d8890-bf79-4cf2-b336-237af7c43535">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzEyLTYtMS0xLTI5NzI2_2afe26a6-0f95-4585-91db-55a708fc021b">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TCJA and related impacts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="rate" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzE0LTItMS0xLTI5NzI2_41069f60-18cb-47ef-82cc-6a11f9c907a6">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="rate" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzE0LTQtMS0xLTI5NzI2_26146a66-fe58-4240-a16a-53ccdd717760">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="rate" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzE0LTYtMS0xLTI5NzI2_9e235eec-fba8-4aaa-80a3-03e25b76bb2e">3.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzE1LTItMS0xLTI5NzI2_bcf04aef-a571-4f62-a214-d077a2d87a13">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzE1LTQtMS0xLTI5NzI2_4f3f7b37-842f-4d1d-8f8e-30b4f0a7d40e">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzE1LTYtMS0xLTI5NzI2_7a0c299d-0b40-4d8e-a0dd-000b90a07cab">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzE2LTItMS0xLTI5NzI2_77d73955-f779-4d9f-8b29-e47b9cc94900">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzE2LTQtMS0xLTI5NzI2_17007844-533a-4179-96cd-9fba0a21a5b8">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzE2LTYtMS0xLTI5NzI2_721d41a8-b9b4-42e9-8a24-c30b1cf47ae7">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflects the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2021 amounts include the reorganization of international subsidiaries; the 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. The 2021 amounts include the reorganization of international subsidiaries; the 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, both of which is further described below. </span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i138e47fa9bf54a368474caa9b33e4512">(3) Represents impact of adjustments to balances originally recorded as part of the 2017 TCJA provisional tax charge. Further information provided below.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fiscal year 2021 tax rate decreased by <ix:nonFraction unitRef="number" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="3" sign="-" name="jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEyOTY_8eb4d543-9522-4d93-aecf-fb5ca6ffce0a">2.5</ix:nonFraction>% compared to the fiscal year 2020 tax rate, which was primarily driven by the following items. In fiscal year 2021, the Company reorganized the ownership structure of certain wholly-owned international subsidiaries. As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with applicable local regulations. The net impact of this restructuring was approximately $<ix:nonFraction unitRef="usd" contextRef="i8cd6b32233734c51bca233601a3752ae_I20220102" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNTc1MTY_b03e911a-a8c7-44cc-b932-e6efeb229570">0.6</ix:nonFraction>&#160;billion net benefit or <ix:nonFraction unitRef="number" contextRef="icf0d50ada4f346ffb63114cb3d32ba28_D20210104-20220102" decimals="3" name="jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNTc1MDk_af9dee68-b3d2-4636-93c5-4411e5ab292a">2.7</ix:nonFraction>% benefit to the Company&#8217;s annual effective tax rate, comprised of the following items: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="jnj:DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNTg1Njc_b5cf4389-6c62-42d9-892e-47812073715b">2.3</ix:nonFraction>&#160;billion of local deferred tax assets to record the remeasurement of the tax basis of these assets to fair value, this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="jnj:IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNTg1ODE_eb959b63-417b-4500-8506-9b26d67e4958">1.7</ix:nonFraction>&#160;billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of these deferred tax assets. This expense has been reflected as &#8220;U.S. tax on international income&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Also, in the fiscal fourth quarter of 2021, the Company recognized a loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2021 tax rate by approximately <ix:nonFraction unitRef="number" contextRef="i2f79758b58cf409fb7e5e1f32144e7f6_D20211004-20220102" decimals="3" sign="-" name="jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNjAzMzQ_dd74ad76-695c-4434-a93b-0e180f83f728">1.3</ix:nonFraction>% which is reflected as a &#8220;Tax benefits from loss on capital assets&#8221; on the effective tax rate reconciliation. Additionally other fiscal 2021 impacts to the rate were primarily driven by litigation and acquisition related items as follows:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company accrued additional legal expenses, of approximately $<ix:nonFraction unitRef="usd" contextRef="i7b0c1ad768954c3cb5d973a4cb0b4f0d_D20210104-20220102" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNjAyNzE_4ed79bf6-69a3-470b-831d-6ccebf718d38">1.6</ix:nonFraction>&#160;billion for talc at an effective tax rate of <ix:nonFraction unitRef="number" contextRef="i7b0c1ad768954c3cb5d973a4cb0b4f0d_D20210104-20220102" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNjAyODU_00fff484-f3af-4d6d-9a39-a10233a42d18">23.5</ix:nonFraction>% and $<ix:nonFraction unitRef="usd" contextRef="i161f67e1e8fc4b20952f5d16b610a1cc_D20210104-20220102" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNjAyOTI_a95e3f4d-c27f-4799-af00-13b0c9e2495c">0.8</ix:nonFraction>&#160;billion for Risperdal settlements at an effective tax rate of <ix:nonFraction unitRef="number" contextRef="i161f67e1e8fc4b20952f5d16b610a1cc_D20210104-20220102" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNjAzMDY_15f0e7fd-9a77-4d3d-ab97-f2fbe27155bc">16.4</ix:nonFraction>% (See Note 19 to the Consolidated Financial Statements for more details).</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company recorded a partial IPR&amp;D charge of $<ix:nonFraction unitRef="usd" contextRef="i8aa69bd5ba1f43b3b6d5887ae14e8e86_D20211004-20220102" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNjAzMTM_df5742d9-b286-4be4-bad4-9e49499d708e">0.9</ix:nonFraction>&#160;billion for the Ottava intangible asset (acquired with the Auris Health acquisition in 2019) at an effective rate of <ix:nonFraction unitRef="number" contextRef="i8aa69bd5ba1f43b3b6d5887ae14e8e86_D20211004-20220102" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNjAzMjc_de900e08-c7a8-4486-8c59-325b5f163090">22.4</ix:nonFraction>% (See Notes 5 and 18 to the Consolidated Financial Statements for more details).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The fiscal year 2020 tax rate decreased by <ix:nonFraction unitRef="number" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="3" name="jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNjIwMTQ_04872d55-f745-45f6-a610-47e9c87d4fc6">1.9</ix:nonFraction>% compared to the fiscal year 2019 tax rate. which was primarily driven by the following items. In fiscal year 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF) which became effective on January 1, 2020. The Federal transitional provisions of TRAF allow companies, under certain conditions, to adjust the tax basis in certain assets to fair value (i.e., &#8220;step-up&#8221;) to be depreciated and amortized resulting in an incremental Swiss tax deduction over the transitional period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">TRAF also provides for parameters which enable the Swiss cantons to establish localized tax rates and regulations for companies. The new cantonal tax parameters include favorable tax benefits for patents and additional research and development </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i92058636e33649e1976b92f79a87b9ad" continuedAt="id8deddbb1f21411d849f4a837afcf8c2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">tax deductions. The cantonal transitional provisions of TRAF allowed companies to elect either 1) tax basis step-up similar to the Federal transition benefit or 2) alternative statutory tax rate for a period not to exceed 5 years. The Company currently has operations located in various Swiss cantons. During the fiscal year 2019, as described in further detail below, the Company recorded the impacts of the TRAF that were enacted in that period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">During the fiscal year 2020, the final canton where the Company maintains significant operations enacted TRAF legislation. Additionally, the Company received rulings from the Swiss Federal and cantonal tax authorities in the remaining jurisdictions where it has significant operations. These rulings resulted in the Company revising its estimate on the tax basis adjustment (i.e., &#8220;step-up&#8221;) for its assets and as a result, the Company recorded additional deferred tax benefits in 2020. The Company recognized a net benefit in the fiscal year 2020 for Swiss Tax Reform of approximately $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="jnj:FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzMwODY_059c84c8-267d-44ab-a4ca-d0e35c42654c">0.4</ix:nonFraction>&#160;billion or <ix:nonFraction unitRef="number" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="3" name="jnj:EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzMwOTI_56a4fe24-bf16-4c38-aeca-4a04d3c1a875">2.6</ix:nonFraction>% benefit to the Company&#8217;s annual effective tax rate, comprised of the following items: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-8" name="jnj:FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzMxOTg_d28eb514-d72e-4c9f-a1f3-31c4b113f679">0.3</ix:nonFraction> billion tax benefit relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred in the fiscal year 2020; this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzM1MDk_bb478821-a369-481d-98b0-2540218121c9">450</ix:nonFraction> million deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company&#8217;s Swiss subsidiaries&#8217; assets as described above; this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-8" name="jnj:FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzM3ODY_24e27d8f-4687-4ce2-8360-f8294edf7254">0.3</ix:nonFraction> billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities in the fiscal year 2020. This benefit has been reflected as &#8220;U.S. tax on international income&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company does not expect to receive future rulings regarding the transitional provisions of TRAF. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Also, in the fiscal year 2020, the Company recognized a capital loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2020 tax rate by approximately <ix:nonFraction unitRef="number" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzQ0MjQ_44ddff9a-6c87-489c-921a-195e93f377ad">1.2</ix:nonFraction>% which is reflected as a &#8220;Tax benefits from loss on capital assets&#8221; on the effective tax rate reconciliation. In addition, in the fiscal year 2020, the Company had lower income in higher tax jurisdictions, primarily driven by:       </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the accrual of litigation costs related to talc for $<ix:nonFraction unitRef="usd" contextRef="i5b5fd248c6fa4b22b336af4f57cb8a47_D20191230-20210103" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzQ3MTQ_253eb461-11f4-4943-8ead-b8c46d3ba47d">4.0</ix:nonFraction>&#160;billion which reduced the U.S. earnings before taxes at an effective tax rate of <ix:nonFraction unitRef="number" contextRef="if70cf172b8f449b8bb218775e0fcb014_D20191230-20210103" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzQ3OTA_87c5deb6-95b3-4b2f-be6a-5d1eb467ec4f">23.5</ix:nonFraction>%;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accrual of additional legal costs, including an additional $<ix:nonFraction unitRef="usd" contextRef="i063d308c5d8f4797bb4e17583565d9b7_D20191230-20210103" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzQ4NTc_389063b3-02bd-4d86-9f82-8a33d8e39ca1">1.0</ix:nonFraction>&#160;billion associated with a revised agreement in principle to settle opioid litigation at an effective tax rate of <ix:nonFraction unitRef="number" contextRef="i4882989be8b64ae0bf4ca80baf92c148_D20191230-20210103" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzQ5NjU_e3caf9c8-ea1a-47a1-aab2-b8234ccbb7db">21.4</ix:nonFraction>% </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also reduced the contingent consideration liability related to the Auris Health acquisition (see Note 18) and reversed of some of its unrecognized tax benefits due to the completion of several years of tax examinations in certain jurisdictions during the fiscal year 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In fiscal year 2019, the Company reorganized the ownership structure of certain wholly-owned international subsidiaries in the fiscal fourth quarter of 2019, which resulted in a reduction of certain withholding and local taxes that it had previously recognized as part of the provisional Tax Cuts and Jobs Act (TCJA) tax charge in the fiscal year 2017 and finalized in the fiscal year 2018. Following the completion of this restructuring and approval by the applicable local authorities, the Company reversed a deferred tax liability of  $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-8" name="jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzYwOTA_d394d274-2bc2-4227-99b6-2727c07c82d0">0.6</ix:nonFraction> billion and a related deferred tax asset of $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-8" name="jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzYxMjk_cfd0705e-0902-4845-8a9d-f5c544e7abab">0.2</ix:nonFraction> billion for U.S. foreign tax credits, for a net deferred tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-8" sign="-" name="jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzYxOTY_7f8d56b6-e566-46e3-99cb-fa484fb2503a">0.4</ix:nonFraction> billion decreasing the annual effective tax rate by <ix:nonFraction unitRef="number" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="3" sign="-" name="jnj:EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzYyNDM_0361ccb7-ea30-4090-be0e-586d1d72d1f1">2.2</ix:nonFraction>%. This benefit has been reflected as &#8220;TCJA and related impacts&#8221; on the Company&#8217;s effective tax rate reconciliation. The following items also impacted the fiscal year 2019 effective tax rate: </span></div><div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of the agreement in principle to settle opioid litigation for $<ix:nonFraction unitRef="usd" contextRef="i7f6076db24f64e8b8d695cf2700ed061_I20191031" decimals="-9" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzY0MzQ_2e2b10c8-29b6-4829-aabb-25b5f4eb7998">4</ix:nonFraction> billion (see Note 19 to the Consolidated Financial Statements) which reduced the U.S. earnings before taxes at an effective tax rate of <ix:nonFraction unitRef="number" contextRef="ia9954ad68ee94f408f19784fd44dc96b_D20191001-20191229" decimals="3" sign="-" name="jnj:IncreaseDecreaseInEarningsBeforeTaxesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzY1NjU_9c71545a-58b6-4ca2-bf90-6b71716511b0">23.5</ix:nonFraction>% and decreased the Company&#8217;s annual effective tax rate by approximately <ix:nonFraction unitRef="number" contextRef="ia9954ad68ee94f408f19784fd44dc96b_D20191001-20191229" decimals="3" sign="-" name="jnj:EffectiveTaxRateReconciliationLitigationSettlementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzY2Mzk_4bd17616-ad54-4bab-ae3e-dfd7809f76a2">2.1</ix:nonFraction>%. </span></div><div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December of fiscal year 2019, the U.S. Treasury issued final foreign tax credit regulations, which resulted in the Company revising the amount of foreign tax credits that were initially recorded in the fiscal year 2017 as part of the provisional TCJA tax charge. As a result, the Company recorded an increased deferred tax asset related to these foreign tax credits of approximately $<ix:nonFraction unitRef="usd" contextRef="i7a80321fb97a41e480b2b933fde2af82_D20191201-20191229" decimals="-8" name="jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzcwMzA_1728aaa8-0f7c-4862-9ba4-a8ded2bec729">0.3</ix:nonFraction> billion or <ix:nonFraction unitRef="number" contextRef="i7a80321fb97a41e480b2b933fde2af82_D20191201-20191229" decimals="3" name="jnj:EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzcwMzY_9bfe9ac5-d98f-4153-88da-d10282ef37a3">1.7</ix:nonFraction>% to the annual effective tax rate.  This benefit has been reflected as &#8220;TCJA and related impacts&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company reassessed its uncertain tax positions related to the current IRS audit and increased its unrecognized tax benefit by $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-8" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzczMTg_48d7abfb-fa01-4f92-b240-25caabc154d3">0.3</ix:nonFraction> billion liability which increased the annual effective tax rate by approximately <ix:nonFraction unitRef="number" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="3" name="jnj:EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzczOTQ_98909458-9141-487d-b6e5-9291c2f13b81">1.5</ix:nonFraction>% (see section on Unrecognized Tax Benefits for additional information). As these positions were related to uncertain tax regarding international transfer pricing, this expense has been classified as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation. </span></div></ix:continuation><div style="padding-right:4.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id8deddbb1f21411d849f4a837afcf8c2" continuedAt="ibae0cad0cfb84a5db5434ef565735101"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described above for the Swiss tax legislation, in the fiscal year 2019, the Company recorded a net tax expense of $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="jnj:FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzgzOTg_2a44c42b-4083-4928-bff6-4f187b5a10c3">0.1</ix:nonFraction>&#160;billion which increased the effective tax rate for the fiscal year 2019 by approximately <ix:nonFraction unitRef="number" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="3" name="jnj:EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzg0ODI_c637ebfc-bfbf-48fc-88a0-5a3c3972cda4">0.6</ix:nonFraction>%. This net tax expense related to federal and certain cantonal enactments in the fiscal year 2019 consisting of the following provisions:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-8" name="jnj:FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzg2Mzg_bc36d224-ae17-4694-8402-76a2e90b1acd">0.6</ix:nonFraction>&#160;billion tax expense relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred by December 29, 2019; this expense has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-8" name="jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzg5NDY_42b54399-6859-4994-a383-b26e94b8de0d">0.9</ix:nonFraction>&#160;billion deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company&#8217;s Swiss subsidiaries&#8217; assets; this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="jnj:FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzkyMDQ_9a8c71c8-16d7-483d-b406-744cbf898d7a">450</ix:nonFraction>&#160;million of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities and the new deferred tax asset for the Federal step-up. This benefit has been reflected as &#8220;U.S. tax on international income&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-right:4.5pt"><span><br/></span></div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNTkx_0b1437bf-b74b-4e4b-af9c-7f97b16550bc" continuedAt="i3a61404115644edd835cb644c9507eec" escape="true"><div style="margin-bottom:9.9pt;margin-top:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Temporary differences and carryforwards at the end of fiscal years 2021 and 2020 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 Deferred Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Deferred Tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzItMi0xLTEtMjk3MjY_4565d83a-3422-402c-9601-ca4dafc19c91">1,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzItNi0xLTEtMjk3MjY_1896fea4-8ba0-4f0b-b8ec-f21d40ca825a">2,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzMtMi0xLTEtMjk3MjY_07aa146e-8b44-47da-b868-4cb1bf380daf">679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzMtNi0xLTEtMjk3MjY_00f6980e-7c82-4f4a-ae9b-605a3b7900f5">627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation of property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzQtNC0xLTEtMjk3MjY_d12a9429-cd12-4bf5-8afc-d119c235ad18">876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzQtOC0xLTEtMjk3MjY_f6779aca-a061-427a-856d-a7057138f6d0">823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzUtNC0xLTEtMjk3MjY_24cf43e6-0795-43b7-832a-4bad8a18e749">2,659</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzUtOC0xLTEtMjk3MjY_365fabd4-3cb8-4da3-a4b7-7858072ae637">5,023</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D capitalized for tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzYtMi0xLTEtMjk3MjY_453b7b6c-2eef-4c9d-95af-dc061fbe5f7a">1,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzYtNi0xLTEtMjk3MjY_5a9e7698-0dab-41c4-8326-97f94b62c301">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves&#160;&amp; liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzctMi0xLTEtMjk3MjY_1d459f8d-a4d8-46ea-9dde-2ede43079566">2,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzctNi0xLTEtMjk3MjY_a9b9f8bc-d4c4-4b7d-85be-2ed016a6d807">3,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income reported for tax purposes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzgtMi0xLTEtMjk3MjY_705bab5c-4464-4dd4-b91e-e964083c7f60">2,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzgtNi0xLTEtMjk3MjY_7db1fa76-0ab5-4315-989b-28ea27bcf0d7">1,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realizable operating loss carryforward</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzktMi0xLTEtMjk3MjY_7087bb87-0102-4813-b9f8-cf45add039a6">1,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzktNi0xLTEtMjk3MjY_40ec774c-3929-49ff-861c-c88d85d0cb77">990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undistributed foreign earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="jnj:DeferredTaxAssetsUndistributedForeignEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEwLTItMS0xLTI5NzI2_842fa246-3c9a-4ecf-8d4d-053c7d1a9762">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEwLTQtMS0xLTI5NzI2_dece6f2c-4e27-4b67-8c54-39443a5aa963">1,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="jnj:DeferredTaxAssetsUndistributedForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEwLTYtMS0xLTI5NzI2_6407b035-45e9-40d1-bdd9-116fe4c202f7">812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEwLTgtMS0xLTI5NzI2_a2768e2b-af0f-4cd8-bc21-30cc0f429b5d">1,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global intangible low-taxed income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzExLTQtMS0xLTI5NzI2_517d8154-c688-4819-a893-155d27faca2d">4,853</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzExLTgtMS0xLTI5NzI2_49590af2-a7e4-43fc-9470-594842a57325">3,606</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous international</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEyLTItMS0xLTI5NzI2_693ae5d8-b265-4d53-942d-d6b0ee14a9df">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEyLTQtMS0xLTI5NzI2_4d5e3145-7606-468a-8981-aa5f53225db1">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEyLTYtMS0xLTI5NzI2_02051953-bf9a-4034-b43c-31c0cf3f8ae0">854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEyLTgtMS0xLTI5NzI2_f5330d6f-772f-4e23-8fa5-64550604faff">211</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="jnj:DeferredTaxAssetsOtherDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEzLTItMS0xLTI5NzI2_c105388d-2b85-4f8a-a355-b5f2cfffb305">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="jnj:DeferredTaxLiabilitiesOtherDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEzLTgtMS0xLTI5NzI2_81066d19-0ee4-4f68-ad6e-335bc1d2d24c">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzE0LTItMS0xLTI5NzI2_0cccc343-5579-4869-8aa5-f24f9febc078">12,624</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzE0LTQtMS0xLTI5NzI2_0fcb849a-dd00-4334-9e9a-bb040f0f6bd7">9,888</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzE0LTYtMS0xLTI5NzI2_a4234aa4-4434-4982-96e2-4760525b99ee">12,477</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzE0LTgtMS0xLTI5NzI2_6ff235fa-71f3-4832-b656-968753e6ab8a">11,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to current year presentation</span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"><ix:continuation id="i3a61404115644edd835cb644c9507eec" continuedAt="i2d53caf155bb4637aadba2c35dc45a5f">(2)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i2d53caf155bb4637aadba2c35dc45a5f">Amount is inclusive of the $<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="jnj:DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEwOTk1MTE2MzA3OTky_055dbf51-8422-41cc-accb-418f001ea71d">2.3</ix:nonFraction>&#160;billion deferred tax asset established as part of the reorganized ownership structure of certain wholly-owned international subsidiaries, as previously described.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has wholly-owned international subsidiaries that have cumulative net losses. The Company believes that it is more likely than not that these subsidiaries will generate future taxable income sufficient to utilize these deferred tax assets. However, in certain jurisdictions, valuation allowances have been recorded against deferred tax assets for loss carryforwards that are not more likely than not to be realized. Such valuation allowances are not material.</span></div><div style="margin-top:4pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNTky_feca309a-799f-4049-8bbb-0a740c0dffc1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to unrecognized tax benefits:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:50.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.495%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzEtMi0xLTEtMjk3MjY_a0435dbf-d884-4577-a570-7b10f0da0723">3,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzEtNC0xLTEtMjk3MjY_dfeab324-adce-4ec6-9611-2ec13f327839">3,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2087646dc6744a28755f382fc0a83c8_I20181230" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzEtNi0xLTEtMjk3MjY_47abe825-02e4-4de0-8968-8f1313f0112d">3,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzItMi0xLTEtMjk3MjY_fd4dac62-8892-4193-9f46-04fdb81a01a7">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzItNC0xLTEtMjk3MjY_c836c440-4a35-4ab9-9f98-3e6f5c03bc69">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzItNi0xLTEtMjk3MjY_7a1e698f-3667-4622-ae6d-99ec5a9effb6">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to prior period tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzMtMi0xLTEtMjk3MjY_b2ba78b2-fb44-428b-b41d-8dbc5791b0e7">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzMtNC0xLTEtMjk3MjY_94b7ddc8-8c9a-4b86-a396-3eecbcc76281">668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzMtNi0xLTEtMjk3MjY_5fef84ee-6c79-4196-90f0-9a80c935af70">408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to prior period tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzQtMi0xLTEtMjk3MjY_81b8210b-00ca-48dd-b6c0-fb29d240438d">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzQtNC0xLTEtMjk3MjY_ad092b1c-9b2d-4a0e-bf9c-870ef800179a">551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzQtNi0xLTEtMjk3MjY_23bb5ba2-5545-4765-91b2-2925c6da140a">105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzUtMi0xLTEtMjk3MjY_3ea02fef-a82c-4b7f-9a90-1b7468c2fade">187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzUtNC0xLTEtMjk3MjY_1dbb9bb9-d6ae-439c-b735-230e23c1b025">839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzUtNi0xLTEtMjk3MjY_b7d092c8-cafe-49d1-812a-f50e5480c5e9">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzYtMi0xLTEtMjk3MjY_c8376ae9-6a5d-47d9-8b46-7ebbb369ad89">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzYtNC0xLTEtMjk3MjY_35b32306-ecd7-4599-b297-1cc698ad5800">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzYtNi0xLTEtMjk3MjY_1afa3f40-36cf-4d42-8c7b-de1eaa637d36">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzctMi0xLTEtMjk3MjY_f9bcc8f4-7e9f-47d2-8dec-365b6dd3a953">3,323</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzctNC0xLTEtMjk3MjY_3f87113c-81e2-468d-a2b4-f7098b04bd40">3,373</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzctNi0xLTEtMjk3MjY_54cb5690-e860-401a-bf81-451962ca2c3e">3,853</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibae0cad0cfb84a5db5434ef565735101"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzExODQy_953b7ffa-ee34-47ea-816f-67c81cf4522b">3.3</ix:nonFraction> billion at January&#160;2, 2022, if recognized, would affect the Company&#8217;s annual effective tax rate. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. In the fiscal year 2020, the Company made its final payments for approximately$<ix:nonFraction unitRef="usd" contextRef="ieb7ecccc89964876b8660c4b222156cc_D20191230-20210103" decimals="-8" name="jnj:UnrecognizedTaxBenefitLiabilityPayment" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEyNDg3_9b4901b4-7d3a-4471-a89c-4eec11cbeef1">0.7</ix:nonFraction> billion to the U.S. Treasury related to the final settlement of 2010-2012 tax audit liability.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities, except as previously noted on amounts related to the current United States IRS audit. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNDE0_dfa822c8-7885-42c5-9adf-bba9b3ea87ae">44</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNDE4_b57e1176-cc12-4b25-b1e2-fb5e9a10ea05">32</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNDI1_46acecae-a585-4468-bc75-cbcf12a345f2">50</ix:nonFraction> million in fiscal years 2021, 2020 and 2019, respectively. The total amount of accrued interest was $<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNTE0_7b5188e4-f8f1-4031-820b-7bd3b9b61ef9">512</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNTIx_3abb4f8e-57ac-46ff-bd20-e6ba32920d1c">468</ix:nonFraction> million in fiscal years 2021 and 2020, respectively.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_175"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:CompensationRelatedCostsGeneralTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90ZXh0cmVnaW9uOjQ2ODU5MjYzMTNmMjQ3ZjBiMjMwYjliMjQzZjkxODIzXzMwNA_85104835-8c20-4c2b-a5b7-49e30ecd93d4" continuedAt="ieaeeb5cdd705433b87402cd3ac83d7ac" escape="true">Employee Related Obligations</ix:nonNumeric></span></div><ix:continuation id="ieaeeb5cdd705433b87402cd3ac83d7ac"><div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="jnj:EmployeeRelatedObligationsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90ZXh0cmVnaW9uOjQ2ODU5MjYzMTNmMjQ3ZjBiMjMwYjliMjQzZjkxODIzXzMxMA_a500fd58-a56d-47fa-89e1-4d43c2cd6329" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal 2021 and fiscal 2020, employee related obligations recorded on the Consolidated Balance Sheets were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzEtMi0xLTEtMjk3MjY_70c5c1ae-b3d9-4e9c-838a-2c03a3ec9d88">4,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzEtNC0xLTEtMjk3MjY_4a1878bb-556c-4865-9dcb-2d957cfde665">5,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postretirement benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzItMi0xLTEtMjk3MjY_a4a897a1-602e-459c-856c-3604694246dc">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzItNC0xLTEtMjk3MjY_b583da27-7302-44ab-856f-416022f6ea1b">2,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postemployment benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzMtMi0xLTEtMjk3MjY_d8d413ef-f7a3-4521-9671-3afcf6cb4ed3">3,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzMtNC0xLTEtMjk3MjY_ad35841f-b6f1-4fc7-bd61-169c7a588341">3,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzQtMi0xLTEtMjk3MjY_a7ddb0df-c2c1-478f-815b-1cda237c097b">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzQtNC0xLTEtMjk3MjY_c4e9c0b0-5f78-4b33-a423-bd200b20ebdf">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total employee obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="jnj:EmployeeObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzUtMi0xLTEtMjk3MjY_7af71a24-08fd-44e7-b8a2-9d26bbebf2d9">9,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="jnj:EmployeeObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzUtNC0xLTEtMjk3MjY_02d8baa7-d04b-4724-92d1-64393e29ecf4">11,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current benefits payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzYtMi0xLTEtMjk3MjY_05786698-18b7-474a-8c18-63a7a70dcf91">557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzYtNC0xLTEtMjk3MjY_37d1ef1f-6433-45d0-b2d6-30d05d30b119">547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations&#160;&#8212; non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzctMi0xLTEtMjk3MjY_4ab91fe4-07d5-4ed3-96c3-bd26ad5d053c">8,898</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzctNC0xLTEtMjk3MjY_67bdc3ea-2189-4f1e-b7bd-95daf77ae384">10,771</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid employee related obligations of $<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90ZXh0cmVnaW9uOjQ2ODU5MjYzMTNmMjQ3ZjBiMjMwYjliMjQzZjkxODIzXzE5Ng_2c32a027-4cbf-434c-b543-aa3f72ab5225">4,436</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90ZXh0cmVnaW9uOjQ2ODU5MjYzMTNmMjQ3ZjBiMjMwYjliMjQzZjkxODIzXzIwMw_839c6a2b-4d6c-4c0f-8827-b95be9a3a552">656</ix:nonFraction> million for 2021 and 2020, respectively, are included in Other assets on the Consolidated Balance Sheets.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_178"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODY1_3632f357-fa70-4cc3-a10c-546fc1fe3d78" continuedAt="i48b0da9ffb734389aba7dc5c27ed540f" escape="true">Pensions and Other Benefit Plans</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i48b0da9ffb734389aba7dc5c27ed540f" continuedAt="i6bd2c87862364b48b8260c3e9d1985a7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily healthcare, to all eligible U.S.&#160;retired employees and their dependents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many international employees are covered by government-sponsored programs and the cost to the Company is not significant.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S, non-union pension benefits for employees hired before January 1, 2015 are primarily based on the employee&#8217;s compensation during the last <ix:nonNumeric contextRef="ie6a7535dcc684ff5971979c84c966ae9_D20210104-20220102" name="jnj:EmployeeCompensationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzYyNw_7675f936-414a-43db-a30f-3d38c5fc9e81">five years</ix:nonNumeric> before retirement and the number of years of service (the Final Average Pay formula). U.S. pension benefits for employees hired after 2014, are calculated using a different formula based on employee compensation over total years of service (the Retirement Value formula).</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees,</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accrued under the Final Average Pay formula for service before January 1, 2026. The impact of this change decreases the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projected Benefit Obligation as of January 3, 2021 by approximately $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEzMDQ_3d7be2fb-dc49-4113-aa8c-d70e905b3d6b">1.8</ix:nonFraction>&#160;billion and is included in the &#8220;Amendments&#8221; line in the Change in Benefit Obligation.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not fund retiree healthcare benefits in advance and has the right to modify these plans in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 and 2020 the Company used December 31, 2021 and December 31, 2020, respectively, as the measurement date for all U.S.&#160;and international retirement and other benefit plans.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODY2_52a0e139-174f-44a8-91b5-7a57d8b535d5" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans for 2021, 2020 and 2019 include the following components:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzItMi0xLTEtMjk3MjY_b2768c63-99f1-4645-b249-dbeed6dd2702">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzItNC0xLTEtMjk3MjY_35f89fe7-bcdd-471e-aa18-4d07d024d323">1,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzItNi0xLTEtMjk3MjY_0b3eec7a-2f8d-4a25-b586-0cf42576c3da">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzItOC0xLTEtMjk3MjY_4e6c6415-09a0-4710-9855-fe3634759798">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzItMTAtMS0xLTI5NzI2_8ea70533-e021-4fe3-900a-fbe097acbadf">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzItMTItMS0xLTI5NzI2_32e67553-eb83-4623-b552-8ea14a503d46">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzMtMi0xLTEtMjk3MjY_aaf48701-5132-4483-9913-e318800ad038">770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzMtNC0xLTEtMjk3MjY_44a2496b-013d-4177-b9c8-b947f672f831">955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzMtNi0xLTEtMjk3MjY_e22554cc-a4cf-4333-a891-73fbf85aabef">1,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzMtOC0xLTEtMjk3MjY_77a6588f-2fdf-4dd3-bad7-8686855bbe32">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzMtMTAtMS0xLTI5NzI2_105db3ca-f790-446d-8113-74b6b4de51e3">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzMtMTItMS0xLTI5NzI2_61cd2b01-f0db-4d50-b3fa-62210137d439">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzQtMi0xLTEtMjk3MjY_992d57e5-660f-428f-acd3-9735ea323a9a">2,645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzQtNC0xLTEtMjk3MjY_b8c2b984-6618-4943-b8ef-5fcb84355bb3">2,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzQtNi0xLTEtMjk3MjY_8067acda-6311-4127-af7d-db2d6454797d">2,322</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzQtOC0xLTEtMjk3MjY_c12776d3-277e-4562-b0cf-c7a3a41e8c87">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzQtMTAtMS0xLTI5NzI2_dfb836ba-b7b4-4973-81d9-807ef79d5d14">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzQtMTItMS0xLTI5NzI2_6f9a92bb-85b8-40bb-808b-6157b306f9d6">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzUtMi0xLTEtMjk3MjY_dd1a778f-3ecc-42f7-a7ec-639bedf9ccc7">181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzUtNC0xLTEtMjk3MjY_2d48ee77-b5c2-4715-8a7a-7b5f7df7ebff">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzUtNi0xLTEtMjk3MjY_e309a9bf-09ba-47e3-83aa-90ee9789459e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzUtOC0xLTEtMjk3MjY_1cda5009-cf2f-4baf-b556-b1f99237f967">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzUtMTAtMS0xLTI5NzI2_96da5722-1b49-41e5-9594-f44b67c22bbf">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzUtMTItMS0xLTI5NzI2_ce60a89e-1558-4213-8940-602fa9292920">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzctMi0xLTEtMjk3MjY_f278fb44-f659-47e5-95f3-f0a776a8e728">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzctNC0xLTEtMjk3MjY_d814ddb4-6c50-4358-aa9d-a5c7d1ffc61f">891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzctNi0xLTEtMjk3MjY_44877d63-1080-4479-968a-b747566504ff">579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzctOC0xLTEtMjk3MjY_74ed2c08-3df6-45b5-819c-b61960dafbae">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzctMTAtMS0xLTI5NzI2_ea340f96-e5aa-4797-b67a-548a5eee6d9f">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzctMTItMS0xLTI5NzI2_bce1f87e-3d30-45ea-8d59-eb3cadff836d">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzgtMi0xLTEtMjk3MjY_f401a6cf-6038-43f7-8ce4-65143d34c7db">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzgtNC0xLTEtMjk3MjY_a04ee517-b742-45ed-a629-19bdde0947ab">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzgtNi0xLTEtMjk3MjY_7c14ea05-3106-4239-99c6-ccca6571ea3b">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzgtOC0xLTEtMjk3MjY_afefd409-52bb-485a-a2e0-5cd2c6ffa99a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzgtMTAtMS0xLTI5NzI2_674b0167-6cd9-497a-adab-896523d108a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzgtMTItMS0xLTI5NzI2_c61d4905-2ec7-4426-b433-303f6c12f793">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzktMi0xLTEtMjk3MjY_40abb03c-dd43-40a9-b20b-8c0109544570">623</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzktNC0xLTEtMjk3MjY_ef2fcbdf-81da-4db6-bc5b-5dbd38c884d2">790</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzktNi0xLTEtMjk3MjY_dceb1f4d-862b-4088-b05f-1210d9af6179">593</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzktOC0xLTEtMjk3MjY_af7c5e04-8e72-44cb-bb87-98807c239206">503</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzktMTAtMS0xLTI5NzI2_c0f3d9dc-7376-4672-9d0d-3da72e41e32f">524</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzktMTItMS0xLTI5NzI2_f10c66c6-be43-4d6b-b772-61ba3d28c9d5">551</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized gains and losses for the U.S.&#160;pension plans are amortized over the average remaining future service for each plan.  For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S.&#160;benefit plans is determined by using a <ix:nonFraction unitRef="number" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="2" name="jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzIyOTA_bc29512a-cf1b-4345-89b9-1fed612972c9">10</ix:nonFraction>% corridor of the greater of the market value of assets or the accumulated postretirement benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior service costs/benefits for the U.S.&#160;pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S.&#160;benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><ix:continuation id="i6bd2c87862364b48b8260c3e9d1985a7" continuedAt="i267c7bc7e9a640f283f7d1509e6b7489"><div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODIw_bc5f9966-a027-4a52-90f2-882ba6752e31" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average actuarial assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:39.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Worldwide Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Periodic Benefit Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzMtMi0xLTEtMjk3MjY_4fa4a877-c33c-4e51-b703-dbba1a60e9e5">2.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzMtNC0xLTEtMjk3MjY_a7e315dd-1808-4ace-9848-d463f06f114c">2.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzMtNi0xLTEtMjk3MjY_2d49436c-71f1-4720-bbf8-b0da9f5db42f">3.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzMtOC0xLTEtMjk3MjY_ea9ba5fa-5f68-490e-b5dc-1ff2503b52b4">2.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzMtMTAtMS0xLTI5NzI2_9aa4e89b-9e6d-4f10-99a7-90ec7aef1496">3.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzMtMTItMS0xLTI5NzI2_60ff8447-1fbe-47e1-9750-e97b59c3b778">4.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzQtMi0xLTEtMjk3MjY_ed1bfb2d-6411-4578-a5f4-940f048efb13">2.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzQtNC0xLTEtMjk3MjY_b8a26bc1-2af2-4cd3-963f-e8ee42ff4ced">3.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzQtNi0xLTEtMjk3MjY_4354cc62-2d69-433a-8aa9-1032c155c2fd">4.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzQtOC0xLTEtMjk3MjY_1d51b9cc-dc53-4e48-89ef-5cea5aa36590">2.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzQtMTAtMS0xLTI5NzI2_82207509-8a14-4a35-b6d4-1f05b9370b61">3.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzQtMTItMS0xLTI5NzI2_3fee2d46-8526-4938-8622-f5bacd2ee7d5">4.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of increase in compensation levels</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzUtMi0xLTEtMjk3MjY_5b03c718-fca9-40c0-8610-cd9c6ed05b43">4.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzUtNC0xLTEtMjk3MjY_1a0ad94a-f662-442a-a238-fa1eb8f25c16">4.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzUtNi0xLTEtMjk3MjY_cdf9ba35-e5a7-4bf8-8f82-024eb62d229a">3.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzUtOC0xLTEtMjk3MjY_fe1d7918-4f2b-4101-beef-2cf2b626d6a1">4.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzUtMTAtMS0xLTI5NzI2_f6d38675-a38a-41cb-8677-612fb3f4e256">4.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzUtMTItMS0xLTI5NzI2_5ad76eb4-e607-480c-b790-1ba1b8e966c0">4.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzYtMi0xLTEtMjk3MjY_a46b9c05-fc77-4d23-bd47-f581ab237532">7.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzYtNC0xLTEtMjk3MjY_f96b77f8-e96c-44a5-aed4-e605b36ea674">8.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzYtNi0xLTEtMjk3MjY_e0ca3fbb-0cda-49c3-a1ba-84a077fe8d30">8.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzktMi0xLTEtMjk3MjY_771b47c4-11c2-4ce9-8072-d79e52c2ed83">2.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzktNC0xLTEtMjk3MjY_f0dea56c-ff09-415a-a493-ee11fb3946c1">2.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20e1360ceda342bdac619fa006a12c36_I20191229" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzktNi0xLTEtMjk3MjY_b3eb33ed-0118-49f3-85f6-9ace553be359">2.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzktOC0xLTEtMjk3MjY_253ea0c0-ef75-41a2-86c3-37d3180b7b7f">2.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzktMTAtMS0xLTI5NzI2_9896f25c-4cfb-4cb3-bdff-eba53ec47cac">2.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4cf76105357f41648e3142ea1703f16a_I20191229" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzktMTItMS0xLTI5NzI2_a87750c5-e796-4549-b800-2581c136332a">3.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of increase in compensation levels</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzEwLTItMS0xLTI5NzI2_5dd8a96f-d802-4b4a-8194-9225b3eebfb6">4.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzEwLTQtMS0xLTI5NzI2_5db86987-44c1-4a7b-a235-4490bf251953">4.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20e1360ceda342bdac619fa006a12c36_I20191229" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzEwLTYtMS0xLTI5NzI2_c09d1f00-e2a7-4aed-90ae-449f1e0ad5f3">4.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzEwLTgtMS0xLTI5NzI2_4b14bd8c-29e6-48b4-936d-85b3bb2b28b0">4.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzEwLTEwLTEtMS0yOTcyNg_3db821cf-02c3-44f6-8d22-849a3b5aa203">4.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4cf76105357f41648e3142ea1703f16a_I20191229" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzEwLTEyLTEtMS0yOTcyNg_0c4bea58-5d7b-4fff-bbe2-f5a616d724c7">4.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. The Company's methodology in determining service and interest cost uses duration specific spot rates along that yield curve to the plans' liability cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market. </span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODEz_5eecebd2-ec2d-4853-b520-b8c415850c5a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the assumed healthcare cost trend rates, for all individuals:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:71.313%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.946%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Healthcare Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare cost trend rate assumed for next year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="4" name="us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo4MjgwZTFmY2I4Njc0NzFhODE2OTI3ODZhZWNjNTZhMC90YWJsZXJhbmdlOjgyODBlMWZjYjg2NzQ3MWE4MTY5Mjc4NmFlY2M1NmEwXzEtMi0xLTEtMjk3MjY_1c331f8c-3ee0-4618-99b5-79eff8b1f16c">5.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="4" name="us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo4MjgwZTFmY2I4Njc0NzFhODE2OTI3ODZhZWNjNTZhMC90YWJsZXJhbmdlOjgyODBlMWZjYjg2NzQ3MWE4MTY5Mjc4NmFlY2M1NmEwXzEtNC0xLTEtMjk3MjY_bc486edd-5a2b-4fe7-be73-67bb082a6da7">5.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline (ultimate trend)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="4" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo4MjgwZTFmY2I4Njc0NzFhODE2OTI3ODZhZWNjNTZhMC90YWJsZXJhbmdlOjgyODBlMWZjYjg2NzQ3MWE4MTY5Mjc4NmFlY2M1NmEwXzItMi0xLTEtMjk3MjY_6b511762-895c-4a03-821f-e228c5c5df31">3.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="4" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo4MjgwZTFmY2I4Njc0NzFhODE2OTI3ODZhZWNjNTZhMC90YWJsZXJhbmdlOjgyODBlMWZjYjg2NzQ3MWE4MTY5Mjc4NmFlY2M1NmEwXzItNC0xLTEtMjk3MjY_49b32010-b7dc-49ac-b861-98b785fd6952">4.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year the rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo4MjgwZTFmY2I4Njc0NzFhODE2OTI3ODZhZWNjNTZhMC90YWJsZXJhbmdlOjgyODBlMWZjYjg2NzQ3MWE4MTY5Mjc4NmFlY2M1NmEwXzMtMi0xLTEtMjk3MjY_5ced3980-1bc2-4f51-8e7b-bff7d1a336c8">2046</ix:nonNumeric>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" name="us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo4MjgwZTFmY2I4Njc0NzFhODE2OTI3ODZhZWNjNTZhMC90YWJsZXJhbmdlOjgyODBlMWZjYjg2NzQ3MWE4MTY5Mjc4NmFlY2M1NmEwXzMtNC0xLTEtMjk3MjY_7e5f68a3-6520-4536-920f-166ac27fd84a">2040</ix:nonNumeric>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-top:3pt"><ix:continuation id="i267c7bc7e9a640f283f7d1509e6b7489" continuedAt="iae4749729d694928af9adf39896c975f"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfNetFundedStatusTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODcx_f9ed0e51-202d-46e7-b855-ac188cde2348" continuedAt="i17b118a98042456da7b405b4822f213a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2021 and 2020 for the Company&#8217;s defined benefit retirement plans and other post-retirement plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation&#160;&#8212; beginning of year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMtMi0xLTEtMjk3MjY_59874dc4-a0c7-4d5e-ad4a-0c6fe28311a9">43,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e1360ceda342bdac619fa006a12c36_I20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMtNC0xLTEtMjk3MjY_8c266286-eecf-476b-875e-49838d60a210">37,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMtNi0xLTEtMjk3MjY_63e8dc2e-ddbf-40ac-965f-5b9c53177266">5,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cf76105357f41648e3142ea1703f16a_I20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMtOC0xLTEtMjk3MjY_e4f62e37-cedd-4d61-8078-89af0036fc4f">5,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQtMi0xLTEtMjk3MjY_62a29a41-653c-48b9-a0c4-1527916bf0b8">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQtNC0xLTEtMjk3MjY_fcbcb471-56b5-47f3-8be6-8703fac4f8c8">1,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQtNi0xLTEtMjk3MjY_c4ddb0c2-793e-48c0-a203-ba6f4fefa930">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQtOC0xLTEtMjk3MjY_65192530-2fe6-4d3b-8aca-43b533241032">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzUtMi0xLTEtMjk3MjY_d59fbc13-32aa-4f87-ab5a-efb9e6f69bcd">770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzUtNC0xLTEtMjk3MjY_ce817f2e-ff92-4ba2-8b10-06d9cc5ca883">955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzUtNi0xLTEtMjk3MjY_53188fd1-d74e-4b4c-92ef-ccd8fa47377d">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzUtOC0xLTEtMjk3MjY_4d572846-8237-42bc-a513-62d70aaec2f9">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzYtMi0xLTEtMjk3MjY_0a7b3be5-0278-431c-a223-36633f530900">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzYtNC0xLTEtMjk3MjY_5111ed23-dcdb-4b64-8940-c252065477bd">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzYtNi0xLTEtMjk3MjY_602886b0-ba30-43ec-9f57-bcc75ac42aac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzYtOC0xLTEtMjk3MjY_e813eec9-2cba-4be6-b05b-7bb4df5baadc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzctMi0xLTEtMjk3MjY_ec9bda1b-3765-4e0b-a156-76bdf0e9a47b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzctNC0xLTEtMjk3MjY_30efdc62-aa54-43b7-b080-624b5b9ed022">1,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzctNi0xLTEtMjk3MjY_f8f62458-0a53-4279-afaa-cf89a70bf6b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzctOC0xLTEtMjk3MjY_4bd58e59-77a6-4ad9-98ab-14112eae8c40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains) losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzgtMi0xLTEtMjk3MjY_c5750910-bbcb-4f4f-a192-0f7097076946">2,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzgtNC0xLTEtMjk3MjY_e14506ca-4b14-4733-8878-e8663edb1ec0">5,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzgtNi0xLTEtMjk3MjY_6fc8fa09-bc3d-4374-9142-d6595e14c33a">188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzgtOC0xLTEtMjk3MjY_db0d10d7-394e-4b1b-a0e8-6aeae7cff341">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures&#160;&amp; acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzktMi0xLTEtMjk3MjY_f945a179-c654-4b6e-8407-76c90c3685eb">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzktNC0xLTEtMjk3MjY_92880c9f-4bb8-4dad-b010-d5a801b3fa82">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzktNi0xLTEtMjk3MjY_a7cb09cc-db4e-48ee-ac60-70f07656dd29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzktOC0xLTEtMjk3MjY_4f9858f9-3173-46ec-96ce-b58430f321b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments, settlements&#160;&amp; restructuring</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="jnj:CurtailmentsAndSettlementsAndRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEwLTItMS0xLTI5NzI2_42606f29-e2fb-4d05-b2ed-46731f5b4ec0">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="jnj:CurtailmentsAndSettlementsAndRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEwLTQtMS0xLTI5NzI2_60993dc7-6d48-4269-871c-ebd4de0e4d8d">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="jnj:CurtailmentsAndSettlementsAndRestructuring" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEwLTYtMS0xLTI5NzI2_11acae10-a4d8-482d-a594-75fd43bdcc7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="jnj:CurtailmentsAndSettlementsAndRestructuring" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEwLTgtMS0xLTI5NzI2_2b353d6a-b658-42dd-9251-5aae585edc08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid from plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzExLTItMS0xLTI5NzI2_7763c6fe-81f7-4e24-a0e1-236841cce119">1,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzExLTQtMS0xLTI5NzI2_28d289c0-e634-42f6-8331-d94e85b10dd2">1,111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzExLTYtMS0xLTI5NzI2_b73ba4f6-36ad-4408-ac36-84c7bbf114d6">348</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzExLTgtMS0xLTI5NzI2_d79f18eb-9757-4a44-924f-ae1396b32639">396</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEyLTItMS0xLTI5NzI2_020ede9e-ce22-4c04-b43f-4cfde23a9776">683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEyLTQtMS0xLTI5NzI2_c0c742a3-bc8a-4f7f-a03d-70ab9e795261">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEyLTYtMS0xLTI5NzI2_95de8753-4015-442e-93a5-59ddced41a8b">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEyLTgtMS0xLTI5NzI2_9c3d9164-6078-45dc-b337-8cc8508e2291">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEzLTItMS0xLTI5NzI2_64baea35-7b6f-41b2-a2a5-14fe90f7fc94">41,582</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEzLTQtMS0xLTI5NzI2_291b268f-b622-4544-bf99-91d58382251c">43,300</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEzLTYtMS0xLTI5NzI2_899b043f-cd46-4b12-9349-364c8ef7b026">4,878</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEzLTgtMS0xLTI5NzI2_311e1445-5f29-43f7-83d7-98073aaf5257">5,028</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value&#160;&#8212; beginning of year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE1LTItMS0xLTI5NzI2_c924e0bd-db42-4e80-b268-d5fd44a4bd2b">38,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e1360ceda342bdac619fa006a12c36_I20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE1LTQtMS0xLTI5NzI2_0d8bf734-e4b3-4988-a9a5-101e184d0277">32,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE1LTYtMS0xLTI5NzI2_d80f41bc-f58b-4b77-91bd-93cc768acf1d">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cf76105357f41648e3142ea1703f16a_I20191229" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE1LTgtMS0xLTI5NzI2_455cb84f-3edf-45bb-83c3-e678ff58b2b6">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE2LTItMS0xLTI5NzI2_a1e2f8f1-2d18-46ee-b637-9dbe1f7d27b3">4,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE2LTQtMS0xLTI5NzI2_1cb66b3e-0360-4f9b-92ae-55b5d92ddb94">5,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE2LTYtMS0xLTI5NzI2_62e13806-8463-4255-bccf-5796769e6343">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE2LTgtMS0xLTI5NzI2_1a1a430c-b8b6-4215-8a07-43f7ab44ce31">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE3LTItMS0xLTI5NzI2_680b7ac0-8c14-4682-bf83-01a306cc030c">969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE3LTQtMS0xLTI5NzI2_53c3631e-f27a-46ab-9caa-62cd2e3c3e45">870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE3LTYtMS0xLTI5NzI2_1ff68ace-6303-42cb-a580-77e638330c56">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE3LTgtMS0xLTI5NzI2_43028c87-6ba4-43be-9b10-50e0e8d2054d">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE4LTItMS0xLTI5NzI2_1ff74c02-ea0a-4c63-9bc4-03a70331e799">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE4LTQtMS0xLTI5NzI2_77968673-eec8-4204-a740-ea357ba5686f">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE4LTYtMS0xLTI5NzI2_af2f69ba-bfc5-4023-945c-5e90caff1713">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE4LTgtMS0xLTI5NzI2_a80b106f-a73b-4982-973c-fa396ae7b636">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE5LTItMS0xLTI5NzI2_7368820c-2c20-4d87-8c55-ad752149b735">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE5LTQtMS0xLTI5NzI2_3dbf7fa7-3545-45c9-a174-a06248839b81">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE5LTYtMS0xLTI5NzI2_74a81dce-4929-44d5-938f-14f4f3bb853d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE5LTgtMS0xLTI5NzI2_b339d921-2623-4ae0-a45d-85820e4decd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures&#160;&amp; acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIwLTItMS0xLTI5NzI2_f4fd2a6b-d59a-4870-b3ff-c1acb13c1378">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIwLTQtMS0xLTI5NzI2_76af1318-9054-4b48-bfb6-b5be06b07a7b">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIwLTYtMS0xLTI5NzI2_c53f55c9-c126-49ed-a0af-ac448f19c448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIwLTgtMS0xLTI5NzI2_1396a694-d75f-489a-94d3-2cb933ddb8f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid from plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIxLTItMS0xLTI5NzI2_9d61fe28-6e77-4863-9922-9a157ffeecb0">1,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIxLTQtMS0xLTI5NzI2_3e55ee20-7a19-49ee-98af-2272a135ffec">1,111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIxLTYtMS0xLTI5NzI2_da85c531-165b-4a73-9a82-47d8b257b249">348</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIxLTgtMS0xLTI5NzI2_174cf22a-7345-4067-8182-101a6da2f343">396</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIyLTItMS0xLTI5NzI2_85c1baae-bc03-482e-b0c4-2d459b5335f1">574</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIyLTQtMS0xLTI5NzI2_3f680de0-9563-4350-8b0f-451ea9e3eb4a">747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIyLTYtMS0xLTI5NzI2_52415688-1c7a-49e7-b8e5-aa675b70b3fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIyLTgtMS0xLTI5NzI2_2b41d29f-0472-4002-93be-470660e58781">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIzLTItMS0xLTI5NzI2_ea7977c8-f1cb-4aa3-a43e-3675656aa998">41,930</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIzLTQtMS0xLTI5NzI2_c8177486-40d0-4cdb-ae2f-edc662295aa6">38,195</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIzLTYtMS0xLTI5NzI2_bbf89f77-e62a-40b1-8033-4130c3e7c5ae">102</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIzLTgtMS0xLTI5NzI2_8850789c-adb1-48fa-b984-1ad68bd01d3d">90</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status &#8212; end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI0LTItMS0xLTI5NzI2_6d73b970-4cb8-428b-91bc-59243e863c12">348</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI0LTQtMS0xLTI5NzI2_cf2331ae-d405-4772-835c-879a5dced81c">5,105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI0LTYtMS0xLTI5NzI2_9f45ac7b-13f4-45e4-9b3a-1c88196de836">4,776</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI0LTgtMS0xLTI5NzI2_d51f35e0-e89e-48e9-9115-f7ea031c502a">4,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI2LTItMS0xLTI5NzI2_4ad9ffb9-7df4-4acc-a73f-4e2321efb62e">4,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI2LTQtMS0xLTI5NzI2_4bc814a1-591b-4422-a42e-ce280f751747">656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI2LTYtMS0xLTI5NzI2_63b61eb5-9cd1-4337-a0d8-9f52816f7f63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI2LTgtMS0xLTI5NzI2_ecb8e794-7a42-4c69-8ce1-bf32f474ba05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI3LTItMS0xLTI5NzI2_1b854ec8-ce3c-4ebc-852d-245149d0eebd">115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI3LTQtMS0xLTI5NzI2_ac61bf39-4da9-4b44-ae64-49fbdb6110a1">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI3LTYtMS0xLTI5NzI2_7fbac882-ca40-49db-8257-8926f5a02d75">438</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI3LTgtMS0xLTI5NzI2_385ed932-4a94-4672-bef5-6b290b9babbf">418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI4LTItMS0xLTI5NzI2_74587f31-4eee-4e61-9c9f-59a8e2f65e09">3,973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI4LTQtMS0xLTI5NzI2_fc68f3f8-e747-4858-8394-d57c234a3617">5,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI4LTYtMS0xLTI5NzI2_f11403d5-9fde-4e13-8a76-1e455c96329b">4,338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI4LTgtMS0xLTI5NzI2_65728470-31a8-4a67-a224-acaa3b98f65c">4,520</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI5LTItMS0xLTI5NzI2_bdd034d2-381e-4cfb-9585-df314e87ba71">348</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI5LTQtMS0xLTI5NzI2_e8bb03fa-d15d-474f-a0d5-7f5c66b78fb5">5,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI5LTYtMS0xLTI5NzI2_6ea9fb6f-ab2c-4887-b7ff-3a7d37f07711">4,776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI5LTgtMS0xLTI5NzI2_a035a809-bb9a-48e0-b440-1d1b526a6f2f">4,938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMxLTItMS0xLTI5NzI2_f197d502-c483-419e-9e68-ea6f1a9b2d40">5,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMxLTQtMS0xLTI5NzI2_b7e42af5-a9d5-46e1-8fcd-0b546c2aef2c">10,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMxLTYtMS0xLTI5NzI2_bc3192af-ef04-446d-9e5f-f979ce4489fe">1,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMxLTgtMS0xLTI5NzI2_43fd7f6e-bed3-48a5-97dc-ce2ab0204f00">1,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMyLTItMS0xLTI5NzI2_63f03570-e8ca-4b91-a915-27d0c2b66716">1,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMyLTQtMS0xLTI5NzI2_8231edf3-356c-497f-bfde-e78b1690e8a2">1,797</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMyLTYtMS0xLTI5NzI2_9358f4d3-7b0f-44e1-9a82-05b87b84740e">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMyLTgtMS0xLTI5NzI2_8c718539-3128-4f68-8a47-f571dfbe28c0">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net transition obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMzLTItMS0xLTI5NzI2_2d8bef37-c2e2-413f-aa92-3fb502ca740d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMzLTQtMS0xLTI5NzI2_4e04d799-cd17-44fb-b41d-05439084973f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMzLTYtMS0xLTI5NzI2_fe637d67-3a83-4d5c-b38c-a3252f4a2c3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMzLTgtMS0xLTI5NzI2_90f5852c-f91a-49a0-82f9-3cce3088e50e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax effects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzM0LTItMS0xLTI5NzI2_30fcd810-f5f8-4d32-83f2-2da89978b369">3,929</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzM0LTQtMS0xLTI5NzI2_cc3cee0a-2d5f-4e86-9137-aa317b85c3c3">9,063</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzM0LTYtMS0xLTI5NzI2_2c84d070-c0ac-469d-a10b-deaf1e413012">1,100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzM0LTgtMS0xLTI5NzI2_9e59b225-dd9b-401f-b1f2-be45a5275742">1,419</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligations&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzM2LTItMS0xLTI5NzI2_9c322b50-e99b-47f4-b590-e33c128cbec5">39,049</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzM2LTQtMS0xLTI5NzI2_7ad86b55-47f0-4396-8544-be206db99bd9">40,356</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The actuarial gain for retirement plans in 2021 was primarily related to increases in discount rates; the actuarial losses for retirement plans in 2020 were primarily related to decreases in discount rates.</span></div></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iae4749729d694928af9adf39896c975f" continuedAt="if31df7b272ec4539b11e7c8d891fd002"><div style="margin-top:3pt"><ix:continuation id="i17b118a98042456da7b405b4822f213a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQyLTItMS0xLTI5NzI2_a01847da-fc34-4f38-8198-d1312a134748">623</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQyLTQtMS0xLTI5NzI2_7149b967-c275-48e0-a4cb-b4df5df1f125">790</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQyLTYtMS0xLTI5NzI2_a4c3d09e-f2ba-4fda-a83f-1c90585eee16">503</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQyLTgtMS0xLTI5NzI2_3c3bf348-4808-4ba8-a348-9e07260e479b">524</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial (gain) loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQzLTItMS0xLTI5NzI2_63a39209-04a7-44f6-b986-3be9dd576d7b">3,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQzLTQtMS0xLTI5NzI2_4d0f7d76-dab2-4f4d-83c3-c6c6f2b1b4bc">2,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQzLTYtMS0xLTI5NzI2_d68cf0f2-18f0-433f-9d58-6550bce6e70f">199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQzLTgtMS0xLTI5NzI2_91f511ce-145d-4020-91a3-141c4c1e7b0a">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ0LTItMS0xLTI5NzI2_c9ab92fc-b6c6-4ffd-8b1b-d233391f7664">1,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ0LTQtMS0xLTI5NzI2_57a344a2-2d69-4d40-aa1e-f5025b152d05">891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ0LTYtMS0xLTI5NzI2_99d9a5fc-6d29-4e47-ae43-2ce36e04286d">151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ0LTgtMS0xLTI5NzI2_fe69caca-54c0-467c-816e-23f54119b3f2">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ1LTItMS0xLTI5NzI2_720cecbc-a785-402b-ad70-28b12eabfebc">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ1LTQtMS0xLTI5NzI2_f8865e47-9aeb-48b6-87d5-807d0707c1da">1,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ1LTYtMS0xLTI5NzI2_f0f584a6-3d63-43a1-bc05-affcd2ad166a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ1LTgtMS0xLTI5NzI2_0f8332ec-edee-4e63-b473-25a3f80be608">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (cost) credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ2LTItMS0xLTI5NzI2_48763032-acd3-4ef2-9808-7281ebd9223d">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ2LTQtMS0xLTI5NzI2_2dcddbb5-5ed5-4db8-a13a-8c80e95e9c69">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ2LTYtMS0xLTI5NzI2_e91e2a2b-f9f4-4e61-883e-2463dbce2dff">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ2LTgtMS0xLTI5NzI2_0d695808-458d-4d5d-98bb-fc057a3dd5eb">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" sign="-" name="jnj:EffectOfExchangeRates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ3LTItMS0xLTI5NzI2_6ae10998-2fe5-4fe4-b6ea-ecd9b964f5a6">136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="jnj:EffectOfExchangeRates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ3LTQtMS0xLTI5NzI2_c03764b5-4880-4244-b8d3-8f58749069a5">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="jnj:EffectOfExchangeRates" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ3LTYtMS0xLTI5NzI2_1b270da7-fd72-4baf-b51a-d576a3edca13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="jnj:EffectOfExchangeRates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ3LTgtMS0xLTI5NzI2_30a9024e-88ff-4af9-a4b3-da3826e56242">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total loss/(income) recognized in other comprehensive income, before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ4LTItMS0xLTI5NzI2_3bbca482-6f51-43d2-aabf-862f9f889f19">5,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ4LTQtMS0xLTI5NzI2_f684e52d-a3cd-4cf3-a5d9-e31f9e918a1c">236</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ4LTYtMS0xLTI5NzI2_1541bb96-0258-440d-a703-c4ececf531f5">319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ4LTgtMS0xLTI5NzI2_ce4f0085-0f40-4ad7-b6d6-bc2c48c1d90d">191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in net periodic benefit cost and other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ5LTItMS0xLTI5NzI2_8aee5b1a-e0c6-48d4-9189-4efe453cb92a">4,511</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103" decimals="-6" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ5LTQtMS0xLTI5NzI2_02489647-3dac-46f6-b2dc-9dbca9cd7c9b">1,026</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102" decimals="-6" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ5LTYtMS0xLTI5NzI2_ec656c0a-547e-4a64-a5ed-41304435e3ca">184</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103" decimals="-6" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ5LTgtMS0xLTI5NzI2_b76515a1-260b-462d-a042-635899c5a6e7">333</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company contributed $<ix:nonFraction unitRef="usd" contextRef="i58b503af83254025807546f7f976450b_D20210104-20220102" decimals="-6" name="us-gaap:PensionContributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzQ1MjI_3f4ddf1c-710a-4087-8ed1-386bd5413aff">102</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5a1c5e25bdb6461788f20271b3996e97_D20210104-20220102" decimals="-6" name="us-gaap:PensionContributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzQ1Mjk_c837f27d-6cd4-4813-9e28-c80066285a7b">867</ix:nonFraction> million to its U.S.&#160;and international pension plans, respectively.</span></div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODI4_5321e1bb-113e-4668-9c53-2909f0407d8a" escape="true"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the funded status of the Company's U.S. Qualified &amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2021 and December&#160;31, 2020, respectively:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plans</span></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Qualified Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Qualified Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unfunded Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f88b3066f8425fb8a00e6f0f402f0c_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzMtMS0xLTEtMjk3MjY_66c798c0-cc56-4df1-971b-66b6061d99d9">27,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8d176ee39d4902bc1ae66d486ece07_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzMtMi0xLTEtMjk3MjY_d36ece34-7f44-40a6-a3cb-c67cadd2dd2b">25,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia15acadd24374bdd89b9144660681aac_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzMtMy0xLTEtMjk3MjY_79b39619-29fd-4221-a92a-4f2acb5f48a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e0e58ded464efe87df57667936575e_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzMtNC0xLTEtMjk3MjY_95c49945-d83f-457e-a8d8-7f2ba6a69ff5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib54b3dfabff34851a1673d1bd91d3667_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzMtNS0xLTEtMjk3MjY_73c7979e-a373-441a-bfbf-4ee30df44c4e">13,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie541284941f54eb39c0cdd62a5aff1ac_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzMtNi0xLTEtMjk3MjY_70159aba-c6b4-4ddc-81a1-2a3432e27f3f">12,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1605c791bdd4560a2228fadfa81e2c5_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzMtNy0xLTEtMjk3MjY_d29bbf5f-45f7-4572-a477-e821b09466b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7fcbc33c13a41e8885b35d3df83c640_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzMtOC0xLTEtMjk3MjY_08249f96-0360-4e8d-a661-5d5bfae7277b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Benefit Obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f88b3066f8425fb8a00e6f0f402f0c_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzQtMS0xLTEtMjk3MjY_42793617-c9dc-4e9c-8fa4-6268970d364e">25,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8d176ee39d4902bc1ae66d486ece07_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzQtMi0xLTEtMjk3MjY_d07d1a5c-d941-479c-9776-a213acd2571f">25,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia15acadd24374bdd89b9144660681aac_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzQtMy0xLTEtMjk3MjY_78b5cf20-8d4b-4b0a-a2a0-4caedaba2b79">2,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e0e58ded464efe87df57667936575e_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzQtNC0xLTEtMjk3MjY_19cfa5e0-7c64-44ce-9196-d22f878adc82">2,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib54b3dfabff34851a1673d1bd91d3667_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzQtNS0xLTEtMjk3MjY_19a6d3da-c09b-4fc6-ac61-6d435d2c36f7">13,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie541284941f54eb39c0cdd62a5aff1ac_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzQtNi0xLTEtMjk3MjY_b3ea6cc0-806e-4bb2-9c99-9ba7a070e94b">14,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1605c791bdd4560a2228fadfa81e2c5_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzQtNy0xLTEtMjk3MjY_00088ed5-7676-40ab-bcae-0250031ce6b5">410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7fcbc33c13a41e8885b35d3df83c640_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzQtOC0xLTEtMjk3MjY_7c610ff2-c9c9-438c-a834-68dcdd82af49">545</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Benefit Obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f88b3066f8425fb8a00e6f0f402f0c_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzUtMS0xLTEtMjk3MjY_1d8cd45b-1d2f-49e4-a536-3c91cefbf3ce">23,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8d176ee39d4902bc1ae66d486ece07_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzUtMi0xLTEtMjk3MjY_3a42fa64-287d-4c49-ba51-3c509837145c">24,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia15acadd24374bdd89b9144660681aac_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzUtMy0xLTEtMjk3MjY_b687af34-55c2-4b86-ad7f-1c07d7ebb8d0">2,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e0e58ded464efe87df57667936575e_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzUtNC0xLTEtMjk3MjY_a6cdea8c-8471-4fcb-9703-f0bec0cfd10b">2,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib54b3dfabff34851a1673d1bd91d3667_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzUtNS0xLTEtMjk3MjY_651f80b1-39ce-4d0a-a157-52a095130968">12,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie541284941f54eb39c0cdd62a5aff1ac_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzUtNi0xLTEtMjk3MjY_2e37bbbe-70bf-4ccd-963a-0f1b60342670">13,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1605c791bdd4560a2228fadfa81e2c5_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzUtNy0xLTEtMjk3MjY_5471ad68-394e-450e-af78-486f9494962d">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7fcbc33c13a41e8885b35d3df83c640_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzUtOC0xLTEtMjk3MjY_7c3ad552-c26d-451b-8dfd-d3a764babb97">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over (Under) Funded Status</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Benefit Obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f88b3066f8425fb8a00e6f0f402f0c_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzctMS0xLTEtMjk3MjY_f624e12f-de54-4b24-a5cd-0acc67fd8f1d">2,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8d176ee39d4902bc1ae66d486ece07_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzctMi0xLTEtMjk3MjY_9e3e790c-e83f-4305-824d-83e3bdb14d55">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia15acadd24374bdd89b9144660681aac_I20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzctMy0xLTEtMjk3MjY_9ef5f338-41b0-4dff-9c98-7be21f7ad858">2,703</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e0e58ded464efe87df57667936575e_I20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzctNC0xLTEtMjk3MjY_0fc72ac3-e2c7-4292-8ac6-95d133030cef">2,748</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib54b3dfabff34851a1673d1bd91d3667_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzctNS0xLTEtMjk3MjY_d46b6fd6-1189-4d8f-8319-dae3fc1d8534">558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie541284941f54eb39c0cdd62a5aff1ac_I20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzctNi0xLTEtMjk3MjY_d0f5679c-ba26-44ea-ab7d-2234bc7552a5">1,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1605c791bdd4560a2228fadfa81e2c5_I20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzctNy0xLTEtMjk3MjY_dd7ca895-c107-47e4-b9aa-d903a56cc282">410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7fcbc33c13a41e8885b35d3df83c640_I20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzctOC0xLTEtMjk3MjY_62dad0af-72eb-4c38-b917-195e5ed42905">545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Benefit Obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f88b3066f8425fb8a00e6f0f402f0c_I20220102" decimals="-6" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzgtMS0xLTEtMjk3MjY_ad83bfee-30b2-4e5f-afaf-2dd2544b89fb">3,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8d176ee39d4902bc1ae66d486ece07_I20210103" decimals="-6" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzgtMi0xLTEtMjk3MjY_211e07ce-4609-4656-a857-a2b2bc090376">1,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia15acadd24374bdd89b9144660681aac_I20220102" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzgtMy0xLTEtMjk3MjY_185781ce-eeb3-4b02-80cc-3add5082e96d">2,479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e0e58ded464efe87df57667936575e_I20210103" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzgtNC0xLTEtMjk3MjY_7f258594-49c8-445d-8d56-af64dc03138a">2,495</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib54b3dfabff34851a1673d1bd91d3667_I20220102" decimals="-6" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzgtNS0xLTEtMjk3MjY_e962bc4c-cab7-4135-ae83-a51465aaa1dc">1,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie541284941f54eb39c0cdd62a5aff1ac_I20210103" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzgtNi0xLTEtMjk3MjY_3e29ec32-ef06-4560-9258-1e5aedb95979">569</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1605c791bdd4560a2228fadfa81e2c5_I20220102" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzgtNy0xLTEtMjk3MjY_598a3289-35a7-4937-a531-25a0d8cf60e5">373</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7fcbc33c13a41e8885b35d3df83c640_I20210103" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzgtOC0xLTEtMjk3MjY_b34c0f63-d2b4-4111-ae22-45a1258b5208">493</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-8" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzQ5Njk_2d604456-2f36-462b-8c2c-1247c54f17bd">3.9</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-8" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzQ5NzM_f16d36a7-fa32-40d5-8af2-717a3d378e9c">4.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-8" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzQ5ODA_2fd033c8-14be-4982-bb5e-6b66d2fa486d">0.3</ix:nonFraction> billion, respectively, at the end of 2021, and $<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-8" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzUwMjA_77ff044b-e1ea-4b53-997d-422d6cc08f92">8.8</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-8" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzUwMjQ_315e8724-ebc1-4f09-8313-72062214314d">9.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-8" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzUwMzE_d30a972f-76f1-4a97-a352-d88ab934b2c0">4.4</ix:nonFraction> billion, respectively, at the end of 2020.</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODYy_d6a9d481-275a-48f1-aa04-8c1342c6d0a9" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the projected future benefit payments from the Company&#8217;s retirement and other benefit plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:35.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.803%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027-2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected future benefit payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzItMi0xLTEtMjk3MjY_bd06eb27-4a53-4997-a39e-a0e857bc975a">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzItNC0xLTEtMjk3MjY_05fa750c-0722-4373-9490-3b9621bd6e35">1,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzItNi0xLTEtMjk3MjY_8abc65db-f7ff-4230-834d-5f5cf8dca98d">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzItOC0xLTEtMjk3MjY_873e63c6-f171-445a-ae6c-6aae40a1f699">1,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzItMTAtMS0xLTI5NzI2_1c33a008-859d-484a-bafd-33b47d4ca296">1,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if217fbfb3878426eba07b1762dc50833_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzItMTItMS0xLTI5NzI2_41a3fa08-5199-4a7a-9b55-a38ea9be74f4">9,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other benefit plans&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzUtMi0xLTEtMjk3MjY_3fb4f0e9-05fd-47c9-ba9a-d925d754c087">447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzUtNC0xLTEtMjk3MjY_2f4081bb-da6f-4e49-8040-88cbf31d6843">459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzUtNi0xLTEtMjk3MjY_3727f4b5-fd87-42ad-8979-f1e02b5f9f86">472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzUtOC0xLTEtMjk3MjY_407e62fc-1209-437d-a587-6eb14382ed9e">485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzUtMTAtMS0xLTI5NzI2_8e46d634-2406-4e27-a0b8-15141d0b9346">434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzUtMTItMS0xLTI5NzI2_cc755141-4c90-4e95-993f-2504b61c4e7a">2,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODM2_d70ecc80-1f77-470e-a536-133680fbdc3d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the projected future minimum contributions to the unfunded retirement plans.  These amounts do not include any discretionary contributions that the Company may elect to make in the future.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:35.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.803%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027-2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected future contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo3MjNiMWQ1MThlZWQ0ZmU3YjQwNjk1MDgxOGI4MDhmZS90YWJsZXJhbmdlOjcyM2IxZDUxOGVlZDRmZTdiNDA2OTUwODE4YjgwOGZlXzEtMi0xLTEtMjk3MjY_62623718-1930-48b9-9263-f4c24192380a">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo3MjNiMWQ1MThlZWQ0ZmU3YjQwNjk1MDgxOGI4MDhmZS90YWJsZXJhbmdlOjcyM2IxZDUxOGVlZDRmZTdiNDA2OTUwODE4YjgwOGZlXzEtNC0xLTEtMjk3MjY_d2cb328d-ddda-45dd-8619-362fd21043ff">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo3MjNiMWQ1MThlZWQ0ZmU3YjQwNjk1MDgxOGI4MDhmZS90YWJsZXJhbmdlOjcyM2IxZDUxOGVlZDRmZTdiNDA2OTUwODE4YjgwOGZlXzEtNi0xLTEtMjk3MjY_1338c66f-11bf-436e-9ee2-a4f67f5c4359">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo3MjNiMWQ1MThlZWQ0ZmU3YjQwNjk1MDgxOGI4MDhmZS90YWJsZXJhbmdlOjcyM2IxZDUxOGVlZDRmZTdiNDA2OTUwODE4YjgwOGZlXzEtOC0xLTEtMjk3MjY_4e3be636-a005-4ea8-8712-b5513b725991">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo3MjNiMWQ1MThlZWQ0ZmU3YjQwNjk1MDgxOGI4MDhmZS90YWJsZXJhbmdlOjcyM2IxZDUxOGVlZDRmZTdiNDA2OTUwODE4YjgwOGZlXzEtMTAtMS0xLTI5NzI2_a7419415-e47c-4d08-8a3d-a3d441d06f99">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo3MjNiMWQ1MThlZWQ0ZmU3YjQwNjk1MDgxOGI4MDhmZS90YWJsZXJhbmdlOjcyM2IxZDUxOGVlZDRmZTdiNDA2OTUwODE4YjgwOGZlXzEtMTItMS0xLTI5NzI2_2e723e40-7704-4d51-b9ed-542eef675cca">794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if31df7b272ec4539b11e7c8d891fd002" continuedAt="i355a834db2d340e5bc01094e28125547"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company&#8217;s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds.  </span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODY5_f5dba70e-e42d-441a-b392-75bc4eb8af54" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s retirement plan asset allocation at the end of 2021 and 2020 and target allocations for 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:58.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.755%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent of<br/>Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Target<br/>Allocation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Worldwide Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i52c49a8c4db34117958d49e77780d7e7_I20220102" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxYjkxYzgzMmNjMWE0ODc5OTdhNjliYWY4ZjE1NDBhNi90YWJsZXJhbmdlOjFiOTFjODMyY2MxYTQ4Nzk5N2E2OWJhZjhmMTU0MGE2XzMtMi0xLTEtMjk3MjY_5761b211-d592-40ea-bc13-4cf9fa8f37aa">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b45609e47e840bd9bc2b4829a2dfa26_I20210103" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxYjkxYzgzMmNjMWE0ODc5OTdhNjliYWY4ZjE1NDBhNi90YWJsZXJhbmdlOjFiOTFjODMyY2MxYTQ4Nzk5N2E2OWJhZjhmMTU0MGE2XzMtNC0xLTEtMjk3MjY_ece145c7-e62c-4fb8-960c-5be0d515dcf3">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i52c49a8c4db34117958d49e77780d7e7_I20220102" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxYjkxYzgzMmNjMWE0ODc5OTdhNjliYWY4ZjE1NDBhNi90YWJsZXJhbmdlOjFiOTFjODMyY2MxYTQ4Nzk5N2E2OWJhZjhmMTU0MGE2XzMtNi0xLTEtMjk3MjY_cc4e2f08-1de3-43df-aa8b-40cd446166a1">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5c7a5058f0d4ea482b056a1543610b3_I20220102" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxYjkxYzgzMmNjMWE0ODc5OTdhNjliYWY4ZjE1NDBhNi90YWJsZXJhbmdlOjFiOTFjODMyY2MxYTQ4Nzk5N2E2OWJhZjhmMTU0MGE2XzQtMi0xLTEtMjk3MjY_0bbc3de5-32da-4579-aaf4-6c8aa9e66509">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie47761f8002e45c199053ae0a267c678_I20210103" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxYjkxYzgzMmNjMWE0ODc5OTdhNjliYWY4ZjE1NDBhNi90YWJsZXJhbmdlOjFiOTFjODMyY2MxYTQ4Nzk5N2E2OWJhZjhmMTU0MGE2XzQtNC0xLTEtMjk3MjY_716e8d8e-0447-4e17-8bf4-3a7d2ae14d07">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5c7a5058f0d4ea482b056a1543610b3_I20220102" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxYjkxYzgzMmNjMWE0ODc5OTdhNjliYWY4ZjE1NDBhNi90YWJsZXJhbmdlOjFiOTFjODMyY2MxYTQ4Nzk5N2E2OWJhZjhmMTU0MGE2XzQtNi0xLTEtMjk3MjY_814bd2be-d5dd-4e04-b9cd-e3f557886662">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxYjkxYzgzMmNjMWE0ODc5OTdhNjliYWY4ZjE1NDBhNi90YWJsZXJhbmdlOjFiOTFjODMyY2MxYTQ4Nzk5N2E2OWJhZjhmMTU0MGE2XzUtMi0xLTEtMjk3MjY_4f1b61c3-c032-41fc-98b2-85d51296b3ae">100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxYjkxYzgzMmNjMWE0ODc5OTdhNjliYWY4ZjE1NDBhNi90YWJsZXJhbmdlOjFiOTFjODMyY2MxYTQ4Nzk5N2E2OWJhZjhmMTU0MGE2XzUtNC0xLTEtMjk3MjY_ab23779a-5766-4f89-abce-e748db85357d">100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxYjkxYzgzMmNjMWE0ODc5OTdhNjliYWY4ZjE1NDBhNi90YWJsZXJhbmdlOjFiOTFjODMyY2MxYTQ4Nzk5N2E2OWJhZjhmMTU0MGE2XzUtNi0xLTEtMjk3MjY_8579182a-925d-47d8-8b56-937d07d271a8">100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Determination of Fair Value of Plan Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan has an established and well-documented process for determining fair values.  Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation Hierarchy</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       The Net Asset Value (NAV) is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial instrument&#8217;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a description of the valuation methodologies used for the investments measured at fair value.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Short-term investment funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the NAV provided by the administrator of the fund. The NAV is a quoted price in a market that is not active and classified as Level&#160;2.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Government and agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level&#160;1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level&#160;2.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Debt instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level&#160;1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level&#160;2. Level&#160;3 debt instruments are priced based on unobservable inputs.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level&#160;1 of the valuation hierarchy.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commingled funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; These investment vehicles are valued using the NAV provided by the fund administrator. Assets in the Level&#160;2 category have a quoted market price.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i355a834db2d340e5bc01094e28125547" continuedAt="i2497d8527203432c968ae2bff5af86b8"><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Other assets are represented primarily by limited partnerships. These investment vehicles are valued using the NAV provided by the fund administrator. Other assets that are exchange listed and actively traded are classified as Level&#160;1, while inactively traded assets are classified as Level&#160;2. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODQ1_e9d96d63-9585-4349-aac2-566ab58b0b87" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2021 and December&#160;31, 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:18.235%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.161%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaafdd23d13d0493891e7d7ac9afa2c86_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzMtMi0xLTEtMjk3MjY_8115dead-d2aa-4bf5-af71-a94080218355">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c80cbf0e584468d8ffebcfcd75988d6_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzMtNC0xLTEtMjk3MjY_773ce8c5-1760-4a01-8eae-67edf0470b09">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe30c736fe24e1ca4d36fc6c3007110_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzMtNi0xLTEtMjk3MjY_e332e838-baa4-4f09-9cc4-bb803d7632b8">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4dd9dc19e6149b88426c05b99e85df6_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzMtOC0xLTEtMjk3MjY_dfdab624-e16a-4274-b9b5-f92c70e98c5b">763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id064b00e4ce442d3ab5bb43fe94a8111_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzMtMTAtMS0xLTI5NzI2_bc16b609-6945-4715-9c5c-f60431e93807">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1a29cf707e4f78a4258d452faef951_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzMtMTItMS0xLTI5NzI2_83601093-f8d0-4b6b-b925-72e838a9dda5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6980acd8ab1348a7a9d21340b15bbad1_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzMtMTgtMS0xLTI5NzI2_de76ca35-f373-433c-bcd9-1484274f7e9d">1,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i547106227f34401da5bb7b68702b3644_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzMtMjAtMS0xLTI5NzI2_658ec67b-a616-40b9-a356-53de62c86eab">890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government and agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f22835beae34a80914d14a3e622b9b6_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzQtMi0xLTEtMjk3MjY_fbc87741-93a8-405d-aa84-5955b97c5ba8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc5fd4a09af04cc889161a3e85ab6ebb_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzQtNC0xLTEtMjk3MjY_3fde126b-5609-43f9-9007-4eecf94e7afc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedb15225c1b941948e9771dbfe0bec89_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzQtNi0xLTEtMjk3MjY_5f382625-84ca-4ef1-a5f5-4763dfa365a8">7,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93af333b5f5246b98690e521de9166f3_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzQtOC0xLTEtMjk3MjY_54dad198-69ca-4d7b-b707-6f079ee70b5a">5,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3af6ce2fee94f8b8ad34e9cbe4c2959_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzQtMTAtMS0xLTI5NzI2_da4bd7bf-8239-4381-8fa2-3c3f4dd39053">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id97dc2bfbc6b4c75a3fda94dda89b30d_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzQtMTItMS0xLTI5NzI2_ebd5dc39-baa4-44e8-8b9d-e5df677a5e0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6398c3336be94b3782104a66be75812c_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzQtMTgtMS0xLTI5NzI2_ad59fd0b-4e8a-4824-96ac-5c76df7e587a">7,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa9057e6eac45ea8abc150ad50bb903_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzQtMjAtMS0xLTI5NzI2_f5d14b3d-6d45-4b76-8655-9468d59b2d9d">5,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bae6b71cd68453fb9432e997b2ec281_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzUtMi0xLTEtMjk3MjY_98650f50-b1d5-4a33-bb66-84a33dd6cb38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99cb936201fa4622b0837f8dfecd6b89_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzUtNC0xLTEtMjk3MjY_8b90b99a-a601-43c4-968a-7952b836a21a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic774cb65db23481fa83313228c547f8e_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzUtNi0xLTEtMjk3MjY_a992c7be-c0c9-4fbc-aaad-984f0c1151c8">3,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc8a4ada79bb4caea9c29a70213afbb9_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzUtOC0xLTEtMjk3MjY_66637edf-20aa-4a31-a292-acb999a4743d">3,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f76e7653f5d4d2aa16e4e2b1264054d_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzUtMTAtMS0xLTI5NzI2_dda7fb8d-aaca-460e-b393-6ffcefb85d0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibee6b63499d74ba8843e5919b699a3d5_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzUtMTItMS0xLTI5NzI2_d6424451-f227-489a-96c1-f2c4fec65691">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2811f795aee94f61a4b7ca5101e1bb88_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzUtMTgtMS0xLTI5NzI2_9b52bec0-1047-4726-9fb7-51d1f91b51d0">3,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb935c546f034a40abf2db76a024a9ce_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzUtMjAtMS0xLTI5NzI2_a85d3a87-6490-4387-96d9-7c621c2a07ab">3,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d95f694324341bc841a0a7101ef54b5_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzYtMi0xLTEtMjk3MjY_b3c39fff-c294-4f17-a9ca-aef4a8b40595">14,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie917ced662c542a288e1c9403b69f779_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzYtNC0xLTEtMjk3MjY_48d620b2-741d-412a-a94d-94f4c67cab4f">14,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5498d11f3d2542428717838316f8244c_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzYtNi0xLTEtMjk3MjY_92c25f9f-b316-4512-8a3a-22ef694d5a02">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b5e7375ea064e46babac18112aa607e_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzYtOC0xLTEtMjk3MjY_d34879fa-bbf7-411d-bc45-25179985f87f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7140a79533384965ad078f1d35179c5d_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzYtMTAtMS0xLTI5NzI2_808612ec-d127-4319-9532-98194d2a7060">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b431efe4f564593ae595088e0d47426_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzYtMTItMS0xLTI5NzI2_658157fb-b33a-45f7-82c8-d00f2040fd71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7c92fe0ae4748908db33019e0c4de42_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzYtMTgtMS0xLTI5NzI2_2a80b707-5112-4779-bd2f-8dc470438cd3">14,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5a1066842f549089f6164c20f388be6_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzYtMjAtMS0xLTI5NzI2_9b1c22c4-094c-4328-b6ce-59bc0da7a238">14,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i783e5becfec34efabd5b62b1ed29b447_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctMi0xLTEtMjk3MjY_71a3245b-6aca-469e-b34a-d464a6e06e91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a34f28344246b3b17696830a6b62bb_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctNC0xLTEtMjk3MjY_9a04bb82-d65f-475d-ae77-ea359c966065">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica3bf1a545d84c639cb2f963349213d2_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctNi0xLTEtMjk3MjY_cc88aece-287c-4371-b2d4-652021218fc3">5,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc20ad9303354673b2fc373f330c597f_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctOC0xLTEtMjk3MjY_76cc14ba-11ee-4eb1-8532-a98519ee2d94">4,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d0542bd36b04ade9a1445e4d2bd9293_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctMTAtMS0xLTI5NzI2_e1ed0b58-c9a4-4ee5-99fc-61a8c72d777e">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dab0c78d2044636b1b0795ffb41ceba_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctMTItMS0xLTI5NzI2_fc55f464-f100-4057-8af7-826373b51cfd">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05353447c3f44422a85c9a643c4158e7_I20220102" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctMTQtMS0xLTI5NzI2_e5e72ef8-5761-4d22-9aad-a781ed443a28">8,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9481f72b68741a38d64130564e80f8b_I20210103" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctMTYtMS0xLTI5NzI2_1d9e7c01-726f-4e53-9a29-b7ea2b5b664c">8,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05353447c3f44422a85c9a643c4158e7_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctMTgtMS0xLTI5NzI2_49e982ce-1026-43b8-bd26-da67547413e2">14,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9481f72b68741a38d64130564e80f8b_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctMjAtMS0xLTI5NzI2_24da01b4-5749-461d-a383-f3d7227a1b1e">13,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9ef3d78b9964c72bc181499fe2a8a48_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktMi0xLTEtMjk3MjY_106bc5b8-648d-4b41-a2b8-b901bc170a16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8663f2154b743c0a9082ef7ef48c04c_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktNC0xLTEtMjk3MjY_f2b59ab4-10c9-44d6-b293-9601fb5503b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib44c796f51604beeb234f0a74a350c2f_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktNi0xLTEtMjk3MjY_fc5575d8-2b6f-4596-9443-df6d394ad846">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic90e615b8bd94bd0bd916ce166a2e1a5_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktOC0xLTEtMjk3MjY_a2ecca88-ae09-4283-beae-b62ab6aef184">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia206a3f6344d4adb8fd0339224dd9315_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktMTAtMS0xLTI5NzI2_e5497dfb-63a3-4ccd-8021-52731035ed2a">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice03248f0c7342dd9422615211a7ce92_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktMTItMS0xLTI5NzI2_bd708cf6-d39e-4810-86e7-686a9248fd5c">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic68aa1aedc3b40c5b7b80e1388117a04_I20220102" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktMTQtMS0xLTI5NzI2_c2662588-85ad-45a5-b0e4-02dfb74232e9">1,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f74ff9d83eb4bff80eca87771ac8af3_I20210103" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktMTYtMS0xLTI5NzI2_f359440e-1f69-4804-9aac-474f4c367e2a">856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic68aa1aedc3b40c5b7b80e1388117a04_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktMTgtMS0xLTI5NzI2_1fff820f-8f3a-42f2-af91-35fc67b45cc5">1,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f74ff9d83eb4bff80eca87771ac8af3_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktMjAtMS0xLTI5NzI2_32aa8392-5ccd-49ce-bdd7-2d264c1c654d">888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investments at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic288cd72530f4cd2842d023a50460e18_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTItMS0xLTI5NzI2_de38bd53-1cc2-4c1c-9bb9-c0da1d834e59">14,209</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia30f04104b444cd3b652b8554c878f2c_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTQtMS0xLTI5NzI2_62b9ee1a-7367-426e-b67c-11b1c89e0f03">14,502</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic047ffb5ebe44765a2e2ca57b1137125_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTYtMS0xLTI5NzI2_75711a62-1058-4eb6-8735-e919ac28f922">17,086</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52201b2d7c81445d9be675a280747548_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTgtMS0xLTI5NzI2_758b2bba-a4f1-4afc-805e-550a90249883">14,420</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a16fd18d26435eb42b51c0b3b1b851_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTEwLTEtMS0yOTcyNg_0831b39a-27c4-413d-8cae-611c25cf7d2a">120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20eeda577995420193ec4dd9d63bba01_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTEyLTEtMS0yOTcyNg_f7de2029-7397-49e1-a3ae-4763e1fdbf5a">181</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65cf763a87bd4988a9339426e416baea_I20220102" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTE0LTEtMS0yOTcyNg_56ef2ce2-0758-4f22-b9ad-f80763425eaa">10,515</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i011f2815be9247198ea2477163de1299_I20210103" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTE2LTEtMS0yOTcyNg_2a7243cc-0c2e-4505-85d4-2c442a5b118e">9,092</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65cf763a87bd4988a9339426e416baea_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTE4LTEtMS0yOTcyNg_3e316c92-c42d-4071-a3d8-2320b9d60d53">41,930</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i011f2815be9247198ea2477163de1299_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTIwLTEtMS0yOTcyNg_66691b0f-953d-46ee-b190-888a7606a43c">38,195</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The activity for the Level 3 assets is not significant for all years presented.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Other Benefit Plans are unfunded except for U.S.&#160;commingled funds (Level 2) of $<ix:nonFraction unitRef="usd" contextRef="ia84d82cf676c42178e9d4fe5cfa9c970_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwNDgx_02edb717-6857-4120-b1b9-6aa3e759d1b1">102</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7161773f423d4d04b3b04039512ea242_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwNDg4_c320e1d6-0225-4a93-8714-6c3e297f27de">90</ix:nonFraction> million at December&#160;31, 2021 and December&#160;31, 2020, respectively. </span></div></ix:continuation><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2497d8527203432c968ae2bff5af86b8">The fair value of Johnson&#160;&amp; Johnson Common Stock directly held in plan assets was $<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwNzA2_c9b2f96e-6d22-4825-a4ed-aef8835b5a76">385</ix:nonFraction> million (<ix:nonFraction unitRef="number" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="3" name="jnj:PercentageOfCompanysCommonStockToPlanAsset" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwNzEw_a26d755b-868b-48d4-bf57-7b7343a10c46">0.9</ix:nonFraction>% of total plan assets) at December&#160;31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwNzYw_f1b8edd8-6967-4dd5-8ea0-6f62dfd011cb">946</ix:nonFraction> million (<ix:nonFraction unitRef="number" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="3" name="jnj:PercentageOfCompanysCommonStockToPlanAsset" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwNzY0_d1ebfe02-ade8-40da-b850-b91333d6fbae">2.5</ix:nonFraction>% of total plan assets) at December&#160;31, 2020.</ix:continuation> </span></div><div><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_184"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="jnj:SavingsPlanTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODQvZnJhZzpiZGYxZjYwZTgxMTE0M2U3OTk3ZDM2MDVkNGM2YWVlNi90ZXh0cmVnaW9uOmJkZjFmNjBlODExMTQzZTc5OTdkMzYwNWQ0YzZhZWU2XzQwNQ_67fdaa53-f9c1-43c7-bd68-ce4ba13c6f97" continuedAt="i6984a2fbc4a74acc8083c071985f7b18" escape="true">Savings Plan</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6984a2fbc4a74acc8083c071985f7b18">The Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee&#8217;s contributions consistent with the provisions of the plan for which he/she is eligible. Total Company matching contributions to the plans were $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODQvZnJhZzpiZGYxZjYwZTgxMTE0M2U3OTk3ZDM2MDVkNGM2YWVlNi90ZXh0cmVnaW9uOmJkZjFmNjBlODExMTQzZTc5OTdkMzYwNWQ0YzZhZWU2XzM0Mg_4edf0df4-23fa-4dd8-8ea1-7919da72a643">256</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODQvZnJhZzpiZGYxZjYwZTgxMTE0M2U3OTk3ZDM2MDVkNGM2YWVlNi90ZXh0cmVnaW9uOmJkZjFmNjBlODExMTQzZTc5OTdkMzYwNWQ0YzZhZWU2XzM0Ng_566d96d0-b691-4315-a30a-af91a8a017b8">243</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODQvZnJhZzpiZGYxZjYwZTgxMTE0M2U3OTk3ZDM2MDVkNGM2YWVlNi90ZXh0cmVnaW9uOmJkZjFmNjBlODExMTQzZTc5OTdkMzYwNWQ0YzZhZWU2XzM1Mw_a1d4013b-640a-47db-ba5f-1972632687cf">235</ix:nonFraction> million in fiscal years 2021, 2020 and 2019, respectively.</ix:continuation></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:TreasuryStockTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzc3Ng_453a30b4-4c22-4b99-8d54-c78bb5b8974e" continuedAt="ie56bf75f7df447fd9881b264f3661321" escape="true">Capital and Treasury Stock</ix:nonNumeric></span></div><ix:continuation id="ie56bf75f7df447fd9881b264f3661321"><div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="jnj:ChangesInTreasuryStockTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzc2Nw_fa884284-c984-4de2-87e6-e9040f5a71ca" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in treasury stock were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in Millions Except Treasury Stock Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia2087646dc6744a28755f382fc0a83c8_I20181230" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzItMi0xLTEtMjk3MjY_c7cfe4f9-521d-4738-ad16-7c44d1da7c79">457,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2087646dc6744a28755f382fc0a83c8_I20181230" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzItNC0xLTEtMjk3MjY_33f375f6-be9a-4dd0-bb76-efc7aa5972c8">34,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzMtMi0xLTEtMjk3MjY_c861fae1-8e12-4f93-ae54-34f4d5e3a075">20,053</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzMtNC0xLTEtMjk3MjY_23dabf9d-2745-4dc8-bdff-1b2d0cd30bb9">2,691</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i506f1bb3ec9a4c2fa89004c3dc9d077b_D20181231-20191229" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzQtMi0xLTEtMjk3MjY_46d5e4f1-55c5-48b4-8601-63c4f468211f">49,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i506f1bb3ec9a4c2fa89004c3dc9d077b_D20181231-20191229" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzQtNC0xLTEtMjk3MjY_dd71afdf-68e7-4223-848d-6786f80e388a">6,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzUtMi0xLTEtMjk3MjY_5301c6ad-f0d9-4e5f-befd-a05a1bf8e179">487,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzUtNC0xLTEtMjk3MjY_75ed6cda-eecb-40cc-bc4a-e60d66b5b23f">38,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzYtMi0xLTEtMjk3MjY_913ee169-57dd-447a-b532-8d13610403cf">21,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzYtNC0xLTEtMjk3MjY_32212f39-afc8-44d2-b80b-e2fd004a19d7">3,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if090847b243c45b38f83514b26483411_D20191230-20210103" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzctMi0xLTEtMjk3MjY_e0ff4df1-fd31-4887-ad80-13e0adfb1c44">21,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if090847b243c45b38f83514b26483411_D20191230-20210103" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzctNC0xLTEtMjk3MjY_c35ecf57-be13-4ca8-adf1-276e2024ca44">3,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzgtMi0xLTEtMjk3MjY_5e2b8042-0fcb-4fb9-a5cd-d393d62231cf">487,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzgtNC0xLTEtMjk3MjY_a2cfa328-f5f7-44ad-821b-56c13a772040">38,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzktMi0xLTEtMjk3MjY_e9d0649c-69f4-49e8-93b4-8e3fee5c8248">17,399</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzktNC0xLTEtMjk3MjY_81ee0d70-7eb4-4c4d-a6c4-2985780853d3">2,847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide5f195a7f1f400580767c19f5aada99_D20210104-20220102" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzEwLTItMS0xLTI5NzI2_8bd727b0-d9ca-443c-bbd9-966c49a91d27">20,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5f195a7f1f400580767c19f5aada99_D20210104-20220102" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzEwLTQtMS0xLTI5NzI2_5b1b8a94-fe2a-4d71-8ab3-2566125f4c1a">3,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzExLTItMS0xLTI5NzI2_75c2f725-3f6c-4157-962c-2ab6ce2a797a">490,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzExLTQtMS0xLTI5NzI2_0b7b939f-ad52-4dea-a39a-8af9c637be1c">39,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate shares of common stock issued were approximately <ix:nonFraction unitRef="shares" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzEyNw_4beb959b-e4d9-4047-90db-cc54ca805112"><ix:nonFraction unitRef="shares" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzEyNw_5135bc06-7550-4e0c-8d5f-10314f249e72"><ix:nonFraction unitRef="shares" contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzEyNw_61732a38-15b4-4150-806b-9bed290e6e30">3,119,843,000</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares at the end of fiscal years 2021, 2020 and 2019.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash dividends paid were $<ix:nonFraction unitRef="usdPerShare" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzIwNQ_ede7e57d-ee7e-4e31-b314-1d2c4767a0e3">4.19</ix:nonFraction> per share in fiscal year 2021, compared with dividends of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzI2NA_445ef538-2590-4341-83b7-d412f7802c71">3.98</ix:nonFraction> per share in fiscal year 2020, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzMwMA_96ec704d-2813-4a5d-80f2-d9a083a65e96">3.75</ix:nonFraction> per share in fiscal year 2019. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2022, the Board of Directors declared a regular cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="id8c97df697f946a4a28e06f21b923b40_D20220104-20220104" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzQxMg_193ac7c9-f7b9-46fa-bf64-fc95744bc97c">1.06</ix:nonFraction> per share, payable on March 8, 2022 to shareholders of record as of February 22, 2022.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2018, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $<ix:nonFraction unitRef="usd" contextRef="i7122062f1c554f58bcf1918e884a09af_I20181217" decimals="-8" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzY1Mw_0d7a914e-4b43-4244-84e9-55ca562af097">5.0</ix:nonFraction> billion of the Company's shares of common stock. This share repurchase program was completed as of September 29, 2019.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_193"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90ZXh0cmVnaW9uOjA0YTA0NDQ0YTYyZTQzMzRhMzlhZjVhZTgzMjRiYzJmXzk4NA_37b4749d-90bc-4880-9d34-d58cfb2681dc" continuedAt="i651ae52a20224f899c259d7790ab7488" escape="true">Accumulated Other Comprehensive Income (Loss)</ix:nonNumeric></span></div><ix:continuation id="i651ae52a20224f899c259d7790ab7488"><div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90ZXh0cmVnaW9uOjA0YTA0NDQ0YTYyZTQzMzRhMzlhZjVhZTgzMjRiYzJmXzk3Mw_9ec1bcf5-0013-4a7f-b577-5532069e8458" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign<br/>Currency Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss) On Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/<br/>(Loss) On<br/>Derivatives &amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia54143af8e294de8a878b870cb6ea183_I20181230" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEtMi0xLTEtMjk3MjY_cd18818f-bec5-4b68-91a3-3c3023bc6030">8,869</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4f8e689cd0845169580efef9b726eb8_I20181230" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEtNC0xLTEtMjk3MjY_b3365ba9-89af-4883-920e-461117e69e67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfa5021c9521460ea844d42abe8a5aeb_I20181230" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEtNi0xLTEtMjk3MjY_79be6963-f3f4-45e6-a199-145f4ae99735">6,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i484c2311f67440a3876482adeb22ccb3_I20181230" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEtOC0xLTEtMjk3MjY_e278c725-dcb7-4f6c-9bb8-3892b9578b76">195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8503a818334a40a588f1d51c6b02cbdd_I20181230" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEtMTAtMS0xLTI5NzI2_bb5dbffa-9d94-4932-bafc-fbe5ffbdb8c7">15,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2019 changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b3e5218e47b4138b803ab86e37ed163_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzMtMi0xLTEtMjk3MjY_c449eaaa-19f2-4577-8ce5-b49cf8baafbb">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dadf43537624342b93174d221447d45_D20181231-20191229" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzMtNC0xLTEtMjk3MjY_2e674a4a-41b1-4155-8da7-df092a36d717">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d10b1357d4345dabd40e640f459d595_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzMtNi0xLTEtMjk3MjY_2c17c276-beab-4fc9-92e4-f44f369e4cec">733</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb2239aebff9499e9a34c274aaeb6c7f_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzMtOC0xLTEtMjk3MjY_79ce8f1e-24bd-4f5c-9750-751cf871c44d">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f88c24f46d04306b18b2052c29a8b77_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzMtMTAtMS0xLTI5NzI2_fa47b6b3-9e2e-43d4-b39b-ffff5812177b">669</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09358b98b87140529a0feb97fb9db596_I20191229" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzQtMi0xLTEtMjk3MjY_086c4426-e24e-470a-8e7d-861cb0970959">8,705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51768edbfc634fdda12f4209d23a3fe8_I20191229" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzQtNC0xLTEtMjk3MjY_ac670724-93c0-4b5f-a53f-e170dc2b6fcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40dc9b8885b14646ad4ca14020da2020_I20191229" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzQtNi0xLTEtMjk3MjY_1b44e32a-6dc2-47ad-bf04-1c654d3aa48a">6,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia91a8b98474c492b93ac66dd2c441f86_I20191229" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzQtOC0xLTEtMjk3MjY_a03dc9bd-8438-4dfd-908b-8919cb871f0f">295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c3c777d14a94558a9524c8d48022809_I20191229" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzQtMTAtMS0xLTI5NzI2_d7928896-eac1-422a-9028-5ca0cda0f959">15,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2020 changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i491bbfb299144dc0a55fa842720b7ce9_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzYtMi0xLTEtMjk3MjY_9a4fbf83-4821-4f55-9d3a-a10d4ec73d94">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb17cd90126f48b89e2321d3bacf6a95_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzYtNC0xLTEtMjk3MjY_53d67138-1b69-4043-a8db-bdbbae7e9c38">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c595eaa21f3452191aa3045d9aaf15e_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzYtNi0xLTEtMjk3MjY_cefcd61f-6a50-49d3-9947-06b3eddceb2b">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d84caefa07e483fb905ffb4ad67b125_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzYtOC0xLTEtMjk3MjY_3099e46a-f30a-47f4-8296-5c9398bd0fa7">947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa270dceb439ab74cfc1fa351ade8_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzYtMTAtMS0xLTI5NzI2_0124a7a7-9494-409c-bd30-2c3cc42bebc7">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i803bbc6136dd4d39b64cf980705d6a38_I20210103" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzctMi0xLTEtMjk3MjY_03ef234d-75cd-4db2-a40b-680926fdaa97">8,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc1c4f9ce70e4d3ebe6058b0e4183d02_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzctNC0xLTEtMjk3MjY_688cd65c-a286-49de-847d-73f54b8fc795">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21cfba8b0adc47c8a606f3009b7f1da4_I20210103" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzctNi0xLTEtMjk3MjY_95e0812c-1b5a-44c3-b0eb-352785ec8fe5">6,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b43e493bfda4958aafcf54a1f7de911_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzctOC0xLTEtMjk3MjY_2c30c943-3be9-424c-8497-bafc86292081">652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2264aac360274fdbb45a327357031ad9_I20210103" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzctMTAtMS0xLTI5NzI2_b9701583-8e29-4a98-b0d9-a32cd2b3dd6b">15,242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2021 changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf4efa66d2f54bfe8f36fb497d4ba3c0_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzktMi0xLTEtMjk3MjY_2a3fcaca-d86e-4996-b998-289c4e578c38">1,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9de3dfaa4b2047e3b29dfc3f5c5f3140_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzktNC0xLTEtMjk3MjY_3f5fd8f5-3ad1-47fb-bc09-95f7b34e8dc0">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fddeabd9fa049fe9b79fddca48ac307_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzktNi0xLTEtMjk3MjY_9326e91a-85f8-4b21-83c2-3390a846d083">4,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bb21536fb564a0d91048d2a7f920ea4_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzktOC0xLTEtMjk3MjY_c36f9eeb-8e2a-4505-a1fb-e4ae6be11978">988</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91696814d2cc4ce18c1ad6fe530463f4_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzktMTAtMS0xLTI5NzI2_76012344-2a28-4a29-a1a9-3e3e5b9227cb">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2e15d2205eb426fb0faa00095711ac7_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEwLTItMS0xLTI5NzI2_13dd10a9-aa77-4dbb-be7b-c170d704fb1f">10,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aa9d5da1c0d4119a4ea3ab746d49fa9_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEwLTQtMS0xLTI5NzI2_c846888e-890e-4101-9571-9e3644dfcc11">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50338dbd5c54672ae5cc0b8d7addd69_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEwLTYtMS0xLTI5NzI2_0cbced30-2d0b-4f2a-8462-902a324f5a41">2,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief6a4d3a16fb4a8695e2f75ad4fe9856_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEwLTgtMS0xLTI5NzI2_df0dac80-08a4-421d-add5-89814cb948a7">336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i857ac21d217c4940938fa16c01722dcd_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEwLTEwLTEtMS0yOTcyNg_b3efbbbf-71b9-4880-8f81-e9ac6353b41d">13,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details.</span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction.  See Note 6 for additional details.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_196"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ForeignCurrencyDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTYvZnJhZzo2MDI4YTM2M2NmNGM0YWM5YTZiYjI4YjlkNDJhYWFjYS90ZXh0cmVnaW9uOjYwMjhhMzYzY2Y0YzRhYzlhNmJiMjhiOWQ0MmFhYWNhXzE1MjA_339ccb55-944f-404f-8704-aa4006a71177" continuedAt="i1a7a4aa4b4e84d31b93baade3e0920a3" escape="true">International Currency Translation</ix:nonNumeric></span></div><ix:continuation id="i1a7a4aa4b4e84d31b93baade3e0920a3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For translation of its subsidiaries operating in non-U.S.&#160;Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency. For the majority of the Company's subsidiaries the local currency is the functional currency. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. The other current and non-current assets line within the Statement of Cash flows includes the impact of foreign currency translation. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies, (Argentina and Venezuela). The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the changes during fiscal years 2021, 2020 and 2019 for foreign currency translation adjustments is included in Note&#160;13. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net currency transaction gains and losses included in Other (income) expense were losses of $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTYvZnJhZzo2MDI4YTM2M2NmNGM0YWM5YTZiYjI4YjlkNDJhYWFjYS90ZXh0cmVnaW9uOjYwMjhhMzYzY2Y0YzRhYzlhNmJiMjhiOWQ0MmFhYWNhXzE0NTc_eb1bff38-f897-4916-bf17-b48f2b6ddb44">236</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTYvZnJhZzo2MDI4YTM2M2NmNGM0YWM5YTZiYjI4YjlkNDJhYWFjYS90ZXh0cmVnaW9uOjYwMjhhMzYzY2Y0YzRhYzlhNmJiMjhiOWQ0MmFhYWNhXzE0NjE_678de814-37fa-4a42-b533-a9b0ad8a5074">209</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTYvZnJhZzo2MDI4YTM2M2NmNGM0YWM5YTZiYjI4YjlkNDJhYWFjYS90ZXh0cmVnaW9uOjYwMjhhMzYzY2Y0YzRhYzlhNmJiMjhiOWQ0MmFhYWNhXzE0Njg_ec4ab126-b2c8-494a-9174-378182aca733">267</ix:nonFraction> million in fiscal years 2021, 2020 and 2019, respectively.</span></div></ix:continuation><div><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_199"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90ZXh0cmVnaW9uOjk2YTg0NTQwMTQxYzQ2YTk5Mjc0ZDY2YWYyMzRiNmFlXzEyOTI_6f51c52c-3424-42e8-995a-4a1f00c8bbf3" continuedAt="id84547baa47c4473bc4ea5653c349571" escape="true">Earnings Per Share</ix:nonNumeric></span></div><ix:continuation id="id84547baa47c4473bc4ea5653c349571"><div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90ZXh0cmVnaW9uOjk2YTg0NTQwMTQxYzQ2YTk5Mjc0ZDY2YWYyMzRiNmFlXzEyODg_df89801f-1e2b-4251-ade3-c4d78d2d04d4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions Except Per Share Amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzEtMi0xLTEtMjk3MjY_13391024-52c3-4200-8932-88b401c53d8a">7.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzEtNC0xLTEtMjk3MjY_11240899-b900-4174-aa95-56c76f905d5f">5.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzEtNi0xLTEtMjk3MjY_8c813b3d-83a2-4bcd-81a3-25cb8b43a489">5.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding&#160;&#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzItMi0xLTEtMjk3MjY_27d9d0ce-e0f5-4a8f-bf56-20b54d17fb24">2,632.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzItNC0xLTEtMjk3MjY_9bf55f61-083d-4190-9365-e25f3cb4037a">2,632.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzItNi0xLTEtMjk3MjY_770113e4-e9e9-4c67-9259-3e7236d55c7c">2,645.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-5" name="jnj:PotentialSharesExercisableUnderStockOptionPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzMtMi0xLTEtMjk3MjY_f5dfa00f-1355-490c-b386-95626bb99800">138.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-5" name="jnj:PotentialSharesExercisableUnderStockOptionPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzMtNC0xLTEtMjk3MjY_91398e3e-edcb-4039-91e3-f85ee2ccd6a9">118.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-5" name="jnj:PotentialSharesExercisableUnderStockOptionPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzMtNi0xLTEtMjk3MjY_13155acd-30b6-44e2-815e-9c22676bebec">136.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzQtMi0xLTEtMjk3MjY_2d798aff-3eb8-4baa-95ee-8ee78ea9f51a">96.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzQtNC0xLTEtMjk3MjY_a6425e0f-76bb-41b1-b93f-98f81177b931">80.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzQtNi0xLTEtMjk3MjY_ff42050e-a369-4c9d-8ac0-6fba3443ee8e">97.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzUtMi0xLTEtMjk3MjY_dde521ef-6075-4af8-b23b-c4f8e8a20f96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzUtNC0xLTEtMjk3MjY_122207e3-af69-47f6-920f-b758ee0b3392">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzUtNi0xLTEtMjk3MjY_a14d20d0-fdcd-4827-ac63-c63cd2c38a6b">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted average shares outstanding&#160;&#8212; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzYtMi0xLTEtMjk3MjY_fcd6e890-2765-4166-a97a-643c89f74828">2,674.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzYtNC0xLTEtMjk3MjY_11899dc4-6d46-4e62-8a3b-c3a1f366e2de">2,670.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzYtNi0xLTEtMjk3MjY_8892c556-d9de-4acc-894a-419cc302c4f6">2,684.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzctMi0xLTEtMjk3MjY_43af21fb-d815-4ca8-99bb-8447853dc5ff">7.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzctNC0xLTEtMjk3MjY_f5e0a04a-d7d2-47d2-8d8a-ae1bdeb5f6d9">5.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzctNi0xLTEtMjk3MjY_c536bd61-bb91-4700-8202-3472c8a42297">5.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The diluted net earnings per share calculation for fiscal year 2021 included all shares related to stock options, as the exercise price of these options was less than the average market value of the Company's stock. As of January 2, 2022, the Company did not have convertible debt. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The diluted net earnings per share calculation for fiscal year 2020 excluded <ix:nonFraction unitRef="shares" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90ZXh0cmVnaW9uOjk2YTg0NTQwMTQxYzQ2YTk5Mjc0ZDY2YWYyMzRiNmFlXzI0Nw_72040611-5bc0-4b77-bc10-5a91751ab905">18</ix:nonFraction> million shares related to stock options, as the exercise price of these options was greater than the average market value of the Company's stock. As of January 3, 2021, the Company did not have convertible debt. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The diluted net earnings per share calculation for fiscal year 2019 excluded an insignificant number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company&#8217;s stock. The diluted net earnings per share calculation for fiscal year 2019 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense of $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:InterestOnConvertibleDebtNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90ZXh0cmVnaW9uOjk2YTg0NTQwMTQxYzQ2YTk5Mjc0ZDY2YWYyMzRiNmFlXzg1OA_3979de3d-9aa0-4639-9f66-7ab07caf2d51">1</ix:nonFraction> million after-tax.</span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_205"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzYwNDc_aee6bcfe-aca7-4ac1-bbf5-e113975938d1" continuedAt="i8db560d359954855852089f56c0ab6ef" escape="true">Common Stock, Stock Option Plans and Stock Compensation Agreements</ix:nonNumeric></span></div><ix:continuation id="i8db560d359954855852089f56c0ab6ef" continuedAt="ic78bdc8f69df4080beb98da76cbb83a8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January&#160;2, 2022, the Company had <ix:nonFraction unitRef="stockbasedcompensationplans" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="0" name="jnj:NumberOfStockBasedCompensationPlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4Xzk2_8bfc9953-7cad-4c63-8729-ef942bc33f80">2</ix:nonFraction> stock-based compensation plans. The shares outstanding are for contracts under the Company's 2005 Long-Term Incentive Plan and the 2012 Long-Term Incentive Plan. The 2005 Long-Term Incentive Plan expired April 26, 2012. All options and restricted shares granted subsequent to that date were under the 2012 Long-Term Incentive Plan. Under the 2012 Long-Term Incentive Plan, the Company may issue up to <ix:nonFraction unitRef="shares" contextRef="ibac73284db3c4555ab751fa7712d96fa_I20220102" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzUwMQ_559916bd-eec6-46e9-bc4e-4983e5263505">650</ix:nonFraction> million shares of common stock, plus any shares canceled, expired, forfeited, or not issued from the 2005 Long-Term Incentive Plan subsequent to April 26, 2012. Shares available for future grants under the 2012 Long-Term Incentive Plan were <ix:nonFraction unitRef="shares" contextRef="ibac73284db3c4555ab751fa7712d96fa_I20220102" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzczOA_e0514005-0af5-4c70-a264-d2f565389f89">240</ix:nonFraction> million at the end of fiscal year 2021.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation cost that has been charged against income for these plans was $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4Xzg1MA_b33a9c07-0cdd-4e69-a70a-95ff0376f901">1,135</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4Xzg1NA_18846259-8d51-49a1-811f-ab265e82e1d1">1,005</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4Xzg2MQ_8e4186db-fed2-42ec-b49a-37a69921f2f5">977</ix:nonFraction> million for fiscal years 2021, 2020 and 2019, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzEwMTM_fcacdba8-6171-464b-ac54-374e67f931f0">218</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzEwMTc_25780636-38b8-40ab-849a-323e67437d6a">210</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzEwMjQ_750a38d1-994d-437d-8884-c18017d1c946">227</ix:nonFraction> million for fiscal years 2021, 2020 and 2019, respectively. The Company also recognized additional income tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzExMzU_03a94771-9a2e-4961-8b77-575cb5f07bc1">223</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzExMzk_3ab91dc0-0a05-4473-bfe1-96167c46d048">248</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzExNDY_89c03a86-f02c-4054-92d6-d41c86f4bb97">209</ix:nonFraction>&#160;million for fiscal years 2021, 2020 and 2019, respectively, for which options were exercised or restricted shares were vested. The total unrecognized compensation cost was $<ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzEzMTM_b7001e97-bbf2-47aa-8576-8a304bb6e749">862</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzEzMTc_1b5ca670-1b74-4e14-8e6f-e529d54116f8">804</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzEzMjQ_f4d28c86-0673-42e7-9ea5-a0a97b9da370">823</ix:nonFraction> million for fiscal years 2021, 2020 and 2019, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic78bdc8f69df4080beb98da76cbb83a8" continuedAt="i50396ac224534ae78a0ed57f97a7783f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively.  The weighted average period for this cost to be recognized was <ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzE0Mzc_4e90e6a3-0705-4e14-b8ad-20ae8f0eba2a">1.78</ix:nonNumeric>&#160;years, <ix:nonNumeric contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzE0NDc_0562826e-5481-418c-86a9-b54d8747c70f">1.76</ix:nonNumeric>&#160;years and <ix:nonNumeric contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzE0NjA_0e56c1fe-7813-4925-b889-4967ca34c8d4">1.71</ix:nonNumeric>&#160;years for fiscal years 2021, 2020, and 2019, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished through market purchases throughout the year for the number of shares used to settle employee benefit equity issuances. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options expire <ix:nonNumeric contextRef="i878c87afdf46469b95b60a72ffa60b1f_D20210104-20220102" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzE4Nzk_d800c3a2-03d8-4f7d-9122-8070ac259dd3">10</ix:nonNumeric>&#160;years from the date of grant and vest over service periods that range from <ix:nonNumeric contextRef="i67642e6fd25c46c7b9f6124eab76fddc_D20210104-20220102" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzE5NTc_1e05ae93-2e23-494f-888f-2d1261c3bb3c">6</ix:nonNumeric> months to <ix:nonNumeric contextRef="ife1e770bea9143ada35c3572dfd2a7ec_D20210104-20220102" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzE5NjM_41529066-4734-4844-8951-8f6e73196242">4</ix:nonNumeric> years.  All options are granted at the average of the high and low prices of the Company&#8217;s Common Stock on the New York Stock Exchange on the date of grant. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. For 2021, 2020 and 2019 grants, expected volatility represents a blended rate of 10-year weekly historical overall volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson&#160;&amp; Johnson options with a life of 2&#160;years. For all grants, historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S.&#160;Treasury yield curve in effect at the time of grant.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzYwNTQ_efeeea0b-b466-4b47-8f86-6b3839976ce6" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average fair value of options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzI3NzU_861081d7-2826-4cb8-9ec4-c6e800d79bac">20.86</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzI3Nzk_ed3419f0-2362-49b9-acf9-f60a0d6f244b">16.42</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzI3ODY_4c1b8949-ffe0-45d1-a7aa-50d2c565f5a1">17.80</ix:nonFraction>, in fiscal years 2021, 2020 and 2019, respectively.  The fair value was estimated based on the weighted average assumptions of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:56.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzEtMS0xLTEtMjk3MjY_cd130965-2ef3-4c95-9ac9-99793e77ca18">0.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzEtMy0xLTEtMjk3MjY_a8169d4c-5e48-40be-85ac-f48a8be4e7ae">1.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzEtNS0xLTEtMjk3MjY_17b80761-bd5c-4872-8557-9570e8e610a0">2.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzItMS0xLTEtMjk3MjY_cf9890be-b880-45ff-af66-c104aa76dc30">18.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzItMy0xLTEtMjk3MjY_73f39df8-d734-45af-adfb-cd4e047815ab">15.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzItNS0xLTEtMjk3MjY_c00ac0cc-f24c-4b75-953c-bd2b99a3d6df">16.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzMtMS0xLTEtMjk3MjY_846586a2-8ba8-4901-b674-bd999fd30b6e">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzMtMy0xLTEtMjk3MjY_5079beff-4f37-4937-9786-ba6f4e0bacf2">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzMtNS0xLTEtMjk3MjY_15813da4-6c25-4d28-bef4-5110d2b92855">7.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzQtMS0xLTEtMjk3MjY_72143cb6-6096-4484-8664-8f25cadf2bdd">2.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzQtMy0xLTEtMjk3MjY_90137b80-07aa-4ef4-bbbf-0a1fdb202a79">2.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzQtNS0xLTEtMjk3MjY_1c671f2f-ca3e-4650-a509-5db679e5cbcd">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzYwNDQ_03a6388e-8abf-4da1-9778-7009a5cac737" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the Plan as of January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019, and changes during the years ending on those dates is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:47.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(Dollars in Millions) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia2087646dc6744a28755f382fc0a83c8_I20181230" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEtMi0xLTEtMjk3MjY_fb6d9a10-d94d-4e46-bd18-b3cf7373bcb9">109,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia2087646dc6744a28755f382fc0a83c8_I20181230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEtNC0xLTEtMjk3MjY_2b6fdabb-6295-417e-92c3-83aef6dfc514">98.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2087646dc6744a28755f382fc0a83c8_I20181230" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEtNi0xLTEtMjk3MjY_ce2e1048-c114-4327-8280-a9e519f83228">3,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzItMi0xLTEtMjk3MjY_e2e49246-d6a1-4531-88bb-4918023b3756">19,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzItNC0xLTEtMjk3MjY_71a355d8-9516-4dc8-b709-f7cfe1f0e567">131.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzMtMi0xLTEtMjk3MjY_258b58fd-cef0-4978-8de4-094e0082c152">14,785</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzMtNC0xLTEtMjk3MjY_f4a83bdc-1266-47e4-8f25-86d75c32f49b">82.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzQtMi0xLTEtMjk3MjY_b53afc52-0756-4302-890e-b54ecbe4c890">2,975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzQtNC0xLTEtMjk3MjY_0cd3e14c-9dde-4877-a1d3-bad795ec35cd">125.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzUtMi0xLTEtMjk3MjY_aa50f412-f87b-4705-9e6c-18245fe533ca">111,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzUtNC0xLTEtMjk3MjY_bb85c629-c903-477c-9e03-af7b58744077">105.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzUtNi0xLTEtMjk3MjY_b65a9804-5b78-487e-b9f5-b073bb5abc4c">4,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzYtMi0xLTEtMjk3MjY_0b78f974-e90a-479a-95aa-11857653e196">20,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzYtNC0xLTEtMjk3MjY_eb0db9eb-a5b5-4169-9eaa-cf62699c551a">151.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzctMi0xLTEtMjk3MjY_4f1248d7-34e3-42e5-9343-55c8e1e5b847">16,275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzctNC0xLTEtMjk3MjY_69fa6021-35c4-4c72-b0b9-0f8ccacc81a1">86.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzgtMi0xLTEtMjk3MjY_8d8f4f7d-d9f9-47b1-9de8-f9a2f7d2f6db">1,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzgtNC0xLTEtMjk3MjY_1ffb24c4-7f51-497d-9710-a6163571e6f2">137.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzktMi0xLTEtMjk3MjY_3af3159a-c58b-4a50-abab-922675c7dec2">114,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzktNC0xLTEtMjk3MjY_21cc75bf-7e76-4b14-a8cd-eac0307536af">116.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzktNi0xLTEtMjk3MjY_56b2124a-e51c-47ed-b227-1506faba08ed">4,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEwLTItMS0xLTI5NzI2_6357f7af-3799-4a58-87ec-875dd427b5f6">18,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEwLTQtMS0xLTI5NzI2_4df83da1-2653-4ec7-9d7b-509869dbd362">164.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzExLTItMS0xLTI5NzI2_427b2f9d-c601-44d9-a86d-c89acc54e8fb">13,248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzExLTQtMS0xLTI5NzI2_9676c017-917b-456a-aa4c-575c2c08d3ab">97.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEyLTItMS0xLTI5NzI2_525dc7e1-657a-4011-bb54-cf155aa39404">2,166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEyLTQtMS0xLTI5NzI2_d51376cd-48cb-4ef6-bf2b-9c4d81a7699c">149.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEzLTItMS0xLTI5NzI2_784cc260-ac3d-4d66-94fa-8bf81bf7a337">117,361</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEzLTQtMS0xLTI5NzI2_fdd5d6f5-f1bc-42f6-b994-52d36410459d">125.36</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEzLTYtMS0xLTI5NzI2_3d624c8b-f84b-44cd-a46a-3d54abf7cc3d">5,364</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzMxMDQ_dc828100-0096-48d9-9b0b-99ec6b6bdc1c">919</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzMxMDg_f0634d56-4ecb-48ad-90c6-e525cdbeb578">1,021</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzMxMTU_298d9709-6162-4c9b-8fce-ffcb7b70075a">807</ix:nonFraction> million in fiscal years 2021, 2020 and 2019, respectively.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i50396ac224534ae78a0ed57f97a7783f" continuedAt="i373e3718ee974843be092abd1761c2f2"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzYwMzY_ec86824b-e43c-43db-9404-13f4092d70d8" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock options outstanding and exercisable at January&#160;2, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"></td><td style="width:29.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.168%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="idd89ef5ec708419d83c0f50bd2e3f33a_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjo4ZmI4ZDMxOGFhMDE0NDdmOGU1MjcwYzdkMzkwNmIyZF81_87c7624c-9629-4850-8f12-d849eb5ce820">65.08</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="idd89ef5ec708419d83c0f50bd2e3f33a_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjo4ZmI4ZDMxOGFhMDE0NDdmOGU1MjcwYzdkMzkwNmIyZF85_c53d0cee-aa15-4557-b8f0-1822d4b2fa64">90.44</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1cd5b16b5eb54677834e76fbba9c913b_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzItMi0xLTEtMjk3MjY_689d2e20-ec7a-4c0f-a38d-c8a1d3043c6f">16,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idd89ef5ec708419d83c0f50bd2e3f33a_D20210104-20220102" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzItNC0xLTEtMjk3MjY_af700b6f-e452-4148-8aea-2142b3039b4a">1.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1cd5b16b5eb54677834e76fbba9c913b_I20220102" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzItNi0xLTEtMjk3MjY_2b258751-03fa-4650-9b06-934b9eb02651">81.92</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1cd5b16b5eb54677834e76fbba9c913b_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzItOC0xLTEtMjk3MjY_c4686dd0-3ab2-4380-84df-2dc0bacbc944">16,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1cd5b16b5eb54677834e76fbba9c913b_I20220102" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzItMTAtMS0xLTI5NzI2_a41fa241-8d3d-4ebd-9be6-3ced15ce1d27">81.92</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="idec9b1a5f62642c0b966a067f115c2f0_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzMtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjpiMTk0ODc1YTViYjI0Yjg2OTg5MzIzYjhlYThiNWY2Nl81_a98bba42-1293-4051-bbd5-1a4c2e330e7c">100.06</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="idec9b1a5f62642c0b966a067f115c2f0_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzMtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjpiMTk0ODc1YTViYjI0Yjg2OTg5MzIzYjhlYThiNWY2Nl85_73cdbf39-07fd-4482-a0fa-cf08513d0b2d">101.87</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie82cdef29cc04363906a567a9d6829fd_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzMtMi0xLTEtMjk3MjY_16ae7f3e-b297-4520-8205-b43f39414b1b">22,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idec9b1a5f62642c0b966a067f115c2f0_D20210104-20220102" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzMtNC0xLTEtMjk3MjY_92a3a841-6a38-4dd7-bf0d-f4eb8f306a7c">3.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ie82cdef29cc04363906a567a9d6829fd_I20220102" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzMtNi0xLTEtMjk3MjY_2db892fc-3d94-4640-945f-6eba46f265f4">101.07</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie82cdef29cc04363906a567a9d6829fd_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzMtOC0xLTEtMjk3MjY_3d22e7ba-c926-41db-99bc-c93feedd2b86">22,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ie82cdef29cc04363906a567a9d6829fd_I20220102" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzMtMTAtMS0xLTI5NzI2_79947038-646e-4bb4-aef5-a419fdc01374">101.07</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i8082802da5c34e03b65215fbc1747020_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzQtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjplYzg3ZDI5NTEzZDY0OWU2OTAwOTE0NzRkYzNkYTVkZF81_6b009c49-2351-4884-a6b6-7415be6fa9aa">115.67</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i8082802da5c34e03b65215fbc1747020_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzQtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjplYzg3ZDI5NTEzZDY0OWU2OTAwOTE0NzRkYzNkYTVkZF85_de407e8a-5880-4748-8ccd-a5b2aff75eb0">129.51</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i53a0b42ef8b740cb82bebc7e9ad442e7_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzQtMi0xLTEtMjk3MjY_e4b2f29f-69ee-4b38-8e9d-2e68666c1aad">24,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8082802da5c34e03b65215fbc1747020_D20210104-20220102" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzQtNC0xLTEtMjk3MjY_9a54834c-1667-4405-a714-e077dcac91df">5.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i53a0b42ef8b740cb82bebc7e9ad442e7_I20220102" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzQtNi0xLTEtMjk3MjY_f23a95dc-bf4a-48fb-93cf-c9cddbec94de">122.59</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i53a0b42ef8b740cb82bebc7e9ad442e7_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzQtOC0xLTEtMjk3MjY_33deb237-eb2f-498e-b2bc-2e8b7f45eb3d">23,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i53a0b42ef8b740cb82bebc7e9ad442e7_I20220102" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzQtMTAtMS0xLTI5NzI2_472f131a-dffe-4b22-af02-f3b7b13c1e32">122.43</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i42e155106ee54d669ceeb882529be05f_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzUtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjo4YThhZGM5YjMzZTM0NzllOWMyZmJiYWJlMDVmZTAwN181_f5f43bbf-8a9d-4581-91b4-8cea8707a74b">131.94</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i42e155106ee54d669ceeb882529be05f_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzUtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjo4YThhZGM5YjMzZTM0NzllOWMyZmJiYWJlMDVmZTAwN185_6caa095e-5a12-4b0c-beb8-022518f925fb">151.41</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id67bcb0b84aa42ffbafbcc561a13093e_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzUtMi0xLTEtMjk3MjY_d83def95-2a7b-4909-acbe-290f551aefef">36,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i42e155106ee54d669ceeb882529be05f_D20210104-20220102" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzUtNC0xLTEtMjk3MjY_f7aacfcf-1627-447a-a562-48ed6ed8eeb7">7.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id67bcb0b84aa42ffbafbcc561a13093e_I20220102" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzUtNi0xLTEtMjk3MjY_063caa18-0a3f-41b2-a1d7-7be22db55374">142.23</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id67bcb0b84aa42ffbafbcc561a13093e_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzUtOC0xLTEtMjk3MjY_35525814-847e-4924-a584-911263201335">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id67bcb0b84aa42ffbafbcc561a13093e_I20220102" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzUtMTAtMS0xLTI5NzI2_c0812314-16cf-4337-8762-9b34fdf0b79e">140.72</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic399470ff9944abebce0ebbbfc9f95be_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzYtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjplOTQwYTE3YmJjYjQ0YmQ3OTExYTFjMGIyM2U4NmRlY181_4ce6feed-61da-49c0-ad63-e6cb5fb4822d">151.42</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="ic399470ff9944abebce0ebbbfc9f95be_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzYtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjplOTQwYTE3YmJjYjQ0YmQ3OTExYTFjMGIyM2U4NmRlY185_deb825ff-d4da-4bab-bfb8-4f1c2a57cb57">164.62</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i239ccf8862324768acca0b6dd0899121_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzYtMi0xLTEtMjk3MjY_20936a40-08ad-4b97-8a8d-0b26581db90e">17,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic399470ff9944abebce0ebbbfc9f95be_D20210104-20220102" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzYtNC0xLTEtMjk3MjY_c2cf94e6-f78c-46cd-82b0-84b1dfd25725">9.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i239ccf8862324768acca0b6dd0899121_I20220102" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzYtNi0xLTEtMjk3MjY_812e539c-3293-4623-89d6-1129e1f60b8c">164.62</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i239ccf8862324768acca0b6dd0899121_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzYtOC0xLTEtMjk3MjY_22ded970-ce47-4403-81db-dc6e2c171249">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i239ccf8862324768acca0b6dd0899121_I20220102" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzYtMTAtMS0xLTI5NzI2_d9da795d-a4c7-439c-b26b-bd51deb29117">164.62</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzctMi0xLTEtMjk3MjY_985f427a-6e8f-4138-a8f1-31732efa7a4d">117,361</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzctNC0xLTEtMjk3MjY_6c75e472-d649-49ef-b83c-5f006b731293">5.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzctNi0xLTEtMjk3MjY_4ad80d75-e390-4c79-8218-61d8e474c4db">125.36</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzctOC0xLTEtMjk3MjY_3c98956d-2adb-4876-8ed0-37d999de29c9">62,742</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzctMTAtMS0xLTI5NzI2_0df9e58f-df4f-4fbf-819a-7506d20a40bd">104.42</ix:nonFraction></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Average contractual life remaining in years.</span></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding at January&#160;3, 2021 and December&#160;29, 2019 were <ix:nonFraction unitRef="shares" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzMzNDE_963d148a-4e3d-4d2a-a993-1c4a7745e2a3">114,250</ix:nonFraction> and an average life of <ix:nonNumeric contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzMzNjc_504d49be-7bf9-42e1-ae60-56c56bd000f1">6.0</ix:nonNumeric> years and <ix:nonFraction unitRef="shares" contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzMzODA_0a69f83d-235c-4311-9c74-3d4b17d885b6">111,637</ix:nonFraction> and an average life of <ix:nonNumeric contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzM0MDY_c0de2f5a-e6e6-4190-b70e-906c84536a6e">6.0</ix:nonNumeric>&#160;years, respectively. Stock options exercisable at January&#160;3, 2021 and December&#160;29, 2019 were <ix:nonFraction unitRef="shares" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzM0NzQ_cd2bf4b0-a813-4126-b09a-9efb58ba03fb">61,289</ix:nonFraction> at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzM1MDA_85e3cf1c-f762-4f7f-bf2e-fa9da15958ce">96.97</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzM1MDc_07b9771d-7d37-44d3-b08e-6a39868e74e3">60,761</ix:nonFraction> at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzM1MzM_fc0e99ab-4838-4baa-b89e-e0cfcd82bcba">88.88</ix:nonFraction>, respectively. </span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Share Units and Performance Share Units</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company grants restricted share units which vest over service periods that range from <ix:nonNumeric contextRef="ib2ff139955b84bebb659527301f2d7f3_D20210104-20220102" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzM2OTM_dd562ba6-acde-443a-83ab-346c8f661322">6</ix:nonNumeric> months to <ix:nonNumeric contextRef="i6608a73388e94a39a929181aeaf3e2ea_D20210104-20220102" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzM2OTk_304c95ba-1a47-4653-9d89-c29cef69ae15">3</ix:nonNumeric> years. The Company also grants performance share units, which are paid in shares of Johnson &amp; Johnson Common Stock after the end of a <ix:nonNumeric contextRef="i7982e382a8c642f3ab7e8d233cd63f23_D20210104-20220102" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzYwNTA_ca0a1beb-83f2-4bce-8002-d5baa855a6d7">three-year</ix:nonNumeric> performance period. Whether any performance share units vest, and the amount that does vest, is tied to the completion of service periods that range from <ix:nonNumeric contextRef="i9cf80e986c6a49168d7e1239ef86064b_D20210104-20220102" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzM5OTI_6eb840d9-c7b0-4013-a86d-310583b36d52">6</ix:nonNumeric> months to <ix:nonNumeric contextRef="ic8597ec09b7848ea847316c99dd326ef_D20210104-20220102" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzM5OTg_602b66bb-9a2b-45f1-883e-9fdc7b61d2f7">3</ix:nonNumeric> years and the achievement, over a <ix:nonNumeric contextRef="i7982e382a8c642f3ab7e8d233cd63f23_D20210104-20220102" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzYwNjE_10035172-61bc-4e0f-ab7d-c1b6a6146109">three-year</ix:nonNumeric> period, of three equally-weighted goals that directly align with or help drive long-term total shareholder return: operational sales, adjusted operational earnings per share, and relative total shareholder return. Beginning in fiscal 2020, performance shares were granted with two equally-weighted goals that directly align with or help drive long-term total shareholder return: adjusted operational earnings per share and relative total shareholder return. The number of shares actually earned at the end of the <ix:nonNumeric contextRef="i7982e382a8c642f3ab7e8d233cd63f23_D20210104-20220102" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzYwMzc_8e9ca1a1-ba6e-446f-b0bc-dcab0f7ff14e">three-year</ix:nonNumeric> period will vary, based only on actual performance, from <ix:nonFraction unitRef="number" contextRef="i9cf80e986c6a49168d7e1239ef86064b_D20210104-20220102" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzQ2MTU_262e0efd-4407-473b-807c-5bfaa47849a9">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ic8597ec09b7848ea847316c99dd326ef_D20210104-20220102" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzQ2MjE_8e35eec8-993d-4bcf-83c2-7c899815b9dc">200</ix:nonFraction>% of the target number of performance share units granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzYwMzM_278123ff-ba25-48c5-a3f6-ae00bcef6b86" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the restricted share units and performance share units activity under the Plans as of January&#160;2, 2022 is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"></td><td style="width:55.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Performance Share Units</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7038702487ec4c45a376b222a0a20d05_I20210103" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzktMi0xLTEtMjk3MjY_5648acb1-484b-44de-a13a-184765057f35">14,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31cd18cf81d841f5a062c0c4dff7e8d9_I20210103" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzktNC0xLTEtMjk3MjY_beaa3c08-2f9b-4876-92ad-7e06ea311a00">2,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i164575311ea140df89ecfa92b9b8b764_D20210104-20220102" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzEwLTItMS0xLTI5NzI2_f1cf4b3f-b491-43ce-a68a-7acadbcb5e36">4,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7982e382a8c642f3ab7e8d233cd63f23_D20210104-20220102" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzEwLTQtMS0xLTI5NzI2_f0ddcf0c-db60-4de7-a7d6-cb560c3e28d7">741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i164575311ea140df89ecfa92b9b8b764_D20210104-20220102" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzExLTItMS0xLTI5NzI2_7b259cfb-52c6-406f-8e1d-8804359b9759">5,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7982e382a8c642f3ab7e8d233cd63f23_D20210104-20220102" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzExLTQtMS0xLTI5NzI2_eed18761-b9e8-48c0-828b-a8ae078d4264">610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited/adjusted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i164575311ea140df89ecfa92b9b8b764_D20210104-20220102" decimals="-3" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzEyLTItMS0xLTI5NzI2_15bb5ff0-77b3-41b7-a110-5a8268c5e343">756</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7982e382a8c642f3ab7e8d233cd63f23_D20210104-20220102" decimals="-3" sign="-" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzEyLTQtMS0xLTI5NzI2_43b0bd6a-97d0-4c98-a828-8ace2d6611d3">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia84f3c7aa69a4e3ca4e10cee006b35d6_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzEzLTItMS0xLTI5NzI2_d9782a0a-7d34-4620-8ca8-69c7fd534d10">14,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a880d0282e64618a404c4e5c8cda751_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzEzLTQtMS0xLTI5NzI2_d70ea796-6308-4f53-8305-98f019d1780c">2,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average fair value of the restricted share units granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i164575311ea140df89ecfa92b9b8b764_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzQ4NzI_8ac69559-e405-44dc-b6ec-c94d5c74433f">152.62</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="iaa26f4b3444e4c15a4078dc66b339b0d_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzQ4NzY_b6775266-8490-493b-bff9-8e09ab7daf67">139.58</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i7364abb0a14f4216bcad7a962281ebf6_D20181231-20191229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzQ4ODM_125c87f8-4186-4ab2-a9ba-610083b6918f">121.31</ix:nonFraction> in fiscal years 2021, 2020 and 2019, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $<ix:nonFraction unitRef="usd" contextRef="i164575311ea140df89ecfa92b9b8b764_D20210104-20220102" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzUxODA_4e927c75-7260-4586-bbbe-89f475f31bcf">611</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="iaa26f4b3444e4c15a4078dc66b339b0d_D20191230-20210103" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzUxODQ_3f33d1d1-eeca-45dd-b459-a89c5b7dab52">650</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7364abb0a14f4216bcad7a962281ebf6_D20181231-20191229" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzUxOTE_b05a7dcb-e364-473e-99d6-213aae1c8fc0">586</ix:nonFraction> million in 2021, 2020 and 2019, respectively.</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value of the performance share units granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i7982e382a8c642f3ab7e8d233cd63f23_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzUzMDE_68db7fa2-67ff-4fd6-84bb-79644176b533">179.35</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7ed28ab7d2664b82bbdff0bc1302e139_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzUzMDU_600057b0-acc4-48e9-b7b1-da41c0e52605">160.54</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="if7b0fdaa9d9e46c9afcb09b831c329a4_D20181231-20191229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzUzMTI_7f6172ea-cde3-47b0-9547-1afe424eabb5">124.67</ix:nonFraction> in fiscal years 2021, 2020 and 2019, calculated using the weighted average fair market value for each of the component goals at the date of grant.&#160; </span></div></ix:continuation><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i373e3718ee974843be092abd1761c2f2">The fair values for the sales and earnings per share goals of each performance share unit were estimated on the date of grant using the fair market value of the shares at the time of the award discounted for dividends, which are not paid on the performance share units during the vesting period.&#160;The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model.&#160;The fair value of performance share units issued was $<ix:nonFraction unitRef="usd" contextRef="i7982e382a8c642f3ab7e8d233cd63f23_D20210104-20220102" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzU5NzQ_a62b9d72-8b9a-4f27-8eb8-3429267e813f">83</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7ed28ab7d2664b82bbdff0bc1302e139_D20191230-20210103" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzU5Nzg_c4b6a808-bdec-4c85-a834-26163c422fc2">91</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if7b0fdaa9d9e46c9afcb09b831c329a4_D20181231-20191229" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzU5ODU_4a1d3470-4b96-46e6-b1c5-5f83e1a4a7e1">119</ix:nonFraction> million in fiscal years 2021, 2020 and 2019, respectively.</ix:continuation> </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_211"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzM0NDQ_37d27699-8500-4b17-9428-74d7ad6554ff" continuedAt="i4908a2825e0b4de5bda1d35775a9ab37" escape="true">Segments of Business* and Geographic Areas</ix:nonNumeric></span></div><div><ix:continuation id="i4908a2825e0b4de5bda1d35775a9ab37" continuedAt="i0c89da56c8914935845d531d9e7e700a"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="jnj:SalesBySegmentOfBusinessTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzM0MzI_57b56d7f-8c46-4943-a602-88d675b724bf" continuedAt="if2ac038a58d641cea939c0357ac8a372" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:34.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217;21 vs. &#8217;20</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217;20 vs. &#8217;19</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192bc4de755f43dea6fc766f7aea65d0_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUtMi0xLTEtMjk3MjY_b50d1f20-b43d-494c-9d74-aab34bf6b122">2,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb82aff41a04d54b8471dfaef55cbfb_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUtNC0xLTEtMjk3MjY_34ae80e7-191d-4987-80dc-a3f01ccb537e">2,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9131515b36de452dba77389706d7cf68_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUtNi0xLTEtMjk3MjY_9fed1999-3d5e-4ddf-a87e-33b0444af98c">2,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i192bc4de755f43dea6fc766f7aea65d0_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUtOC0xLTEtMjk3MjY_51b2ed51-90ba-4e37-8d17-c11e983fd645">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iffb82aff41a04d54b8471dfaef55cbfb_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUtMTAtMS0xLTI5NzI2_0ba7ca04-4efe-4d22-ad9b-3c47a4839863">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd0fc1997c54c228fd7a7bd70bf4aac_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYtMi0xLTEtMjk3MjY_fc6a0712-4964-4155-9e1f-45caefffd484">2,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icebbd7181a854a83b106002262a3f05a_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYtNC0xLTEtMjk3MjY_d27f5cc1-38d5-42bc-8022-b83d771e8367">2,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d99e38809f24798a6aa6262467560c6_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYtNi0xLTEtMjk3MjY_7e97e3d4-5e23-46c3-888b-4b5f367e1b48">2,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibcd0fc1997c54c228fd7a7bd70bf4aac_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYtOC0xLTEtMjk3MjY_851a5a62-1bfb-4ad2-97f8-49b4d25312c0">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icebbd7181a854a83b106002262a3f05a_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYtMTAtMS0xLTI5NzI2_6788aaf8-41f1-43af-ba8f-f39c16ff6210">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c63ea6850a74252ba3d49fa9fe7b74a_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzctMi0xLTEtMjk3MjY_39a3ea7b-3c76-46c1-bfc8-8585674122c4">5,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ba444b93d124ce393b5b3f193a70f2f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzctNC0xLTEtMjk3MjY_9ae85f77-5fdb-4867-808c-702e73a66342">4,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94f3652f4af1446da52491a28d5ec451_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzctNi0xLTEtMjk3MjY_9ce52388-d9da-4768-84ac-a26142cfd6bb">4,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c63ea6850a74252ba3d49fa9fe7b74a_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzctOC0xLTEtMjk3MjY_263d6e97-515c-4143-b2f2-5bb40c52ddc0">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ba444b93d124ce393b5b3f193a70f2f_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzctMTAtMS0xLTI5NzI2_3e3da999-8ab5-4170-93c9-f284eb41be8e">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d10f0f5f973460c82f6e46d69e2962a_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzktMi0xLTEtMjk3MjY_2cee6a52-ab95-4384-8a4b-4329b22a8b57">2,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief6f2ac5fd8f4812a89cc848a4c1df06_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzktNC0xLTEtMjk3MjY_49b426c9-ad82-4df0-a39d-cb19b62c73e7">2,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32966c9a84284da0b58c8d0ae0faa3c8_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzktNi0xLTEtMjk3MjY_853a7628-dbec-441b-924e-3063d9c0868a">2,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d10f0f5f973460c82f6e46d69e2962a_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzktOC0xLTEtMjk3MjY_9aa19d3e-f34f-4cb4-8c6c-556abddbe46b">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ief6f2ac5fd8f4812a89cc848a4c1df06_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzktMTAtMS0xLTI5NzI2_ce421e5d-0e62-4c80-9c91-c234a864f610">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3128d308ffe4613906d97816a65e9bd_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwLTItMS0xLTI5NzI2_cd1adb89-db0a-4422-86f5-1b816a467d4e">2,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a561bfd58ec4ccabd2025a6e7cf9bd5_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwLTQtMS0xLTI5NzI2_fd24e785-5c22-4f45-8f40-3ecc161d9e80">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i400f84b397df414cbbedb7f3a7926c43_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwLTYtMS0xLTI5NzI2_171a963b-5ef4-45ee-a266-7a7fefe360c3">2,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3128d308ffe4613906d97816a65e9bd_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwLTgtMS0xLTI5NzI2_a860a3e8-ad88-46ec-bdd6-4de8b9babfe5">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2a561bfd58ec4ccabd2025a6e7cf9bd5_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwLTEwLTEtMS0yOTcyNg_c3b1a034-1346-4d88-b39b-1adb56c2f4d3">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3d80b5dc4e343d19875dae1cb177ef0_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExLTItMS0xLTI5NzI2_ae57d04c-ad51-4cd2-b94d-0c7b78a14486">4,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ac3647e660b4922bcde7ec55782e160_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExLTQtMS0xLTI5NzI2_f096b994-1276-4487-93c9-c6d0f99299d6">4,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdb4bd463a34c9fa3b35815b52e6ef3_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExLTYtMS0xLTI5NzI2_181f158f-d1b3-4e0e-ad06-2a89b14e5251">4,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3d80b5dc4e343d19875dae1cb177ef0_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExLTgtMS0xLTI5NzI2_61a6d9b5-bba5-47b2-ba70-dddb00fa2f52">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0ac3647e660b4922bcde7ec55782e160_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExLTEwLTEtMS0yOTcyNg_290ef07c-2a6a-473c-ad01-cc76e53cecb0">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadd4ee8352f9426fae8e6bdc7fe52372_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzLTItMS0xLTI5NzI2_1b10898b-a2d9-4cca-8768-f89db6cbea44">637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1577281a68942e6b6973a3973d33136_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzLTQtMS0xLTI5NzI2_dabecca3-8f9e-4c32-82fe-1e24060a1391">683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8cfdad6d51e400e8669811b1b2b4267_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzLTYtMS0xLTI5NzI2_af1b84b2-0d48-45db-b693-1fd8996ca811">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iadd4ee8352f9426fae8e6bdc7fe52372_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzLTgtMS0xLTI5NzI2_cb54534b-e3e7-4ebf-9448-96549f7ffffd">6.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1577281a68942e6b6973a3973d33136_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzLTEwLTEtMS0yOTcyNg_7f72a1c9-032f-40db-ae36-e303f9f877e3">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35d06bb332e74e4982e637a9ca92913d_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0LTItMS0xLTI5NzI2_47735993-177b-419e-b7cc-db851cec6fb4">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc75eb155004e52844ffebf7174bbd0_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0LTQtMS0xLTI5NzI2_bfabc1fc-d4c9-4121-8790-369a49b078af">958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375d3135400b433096c8e5dab3fa38a1_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0LTYtMS0xLTI5NzI2_d07ce67f-3a9f-4595-aa79-07c3f909a9d0">906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i35d06bb332e74e4982e637a9ca92913d_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0LTgtMS0xLTI5NzI2_6e06bfc2-eb6e-4202-9078-e8f3fe8d61a1">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dc75eb155004e52844ffebf7174bbd0_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0LTEwLTEtMS0yOTcyNg_a8c3287b-3b0e-4503-8726-302c4b601358">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6952a648640445fbdd6cdd36431a750_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1LTItMS0xLTI5NzI2_2d6c7b0f-e33b-48be-bd13-e6785647f2cb">1,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07542366df9243c6abac2d16b1dfb58b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1LTQtMS0xLTI5NzI2_38e1a832-cb75-4bcb-9812-3454e784309c">1,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i064e7c0f8fa548429b040cde3913d49f_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1LTYtMS0xLTI5NzI2_acd6dd62-1e94-4f33-96f0-1f875318802c">1,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6952a648640445fbdd6cdd36431a750_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1LTgtMS0xLTI5NzI2_f2f41c17-e832-4fd0-b5e5-76911cb9bcc3">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07542366df9243c6abac2d16b1dfb58b_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1LTEwLTEtMS0yOTcyNg_5af4746b-3c5a-4169-8789-9e5df5fee6f5">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77b6cd743a414007b81cd6a3d310ef78_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE3LTItMS0xLTI5NzI2_bd008ff4-33fa-4137-95f0-deebbff98b7a">378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2fafb4659f34a019ee6e466fc04640f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE3LTQtMS0xLTI5NzI2_b940cc66-b976-43af-8334-9d2b56c4b4f3">376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdbca246df0847e9a8c4c4c568f2f273_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE3LTYtMS0xLTI5NzI2_0a498fab-3002-45f2-afbd-7c425f7d514e">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i77b6cd743a414007b81cd6a3d310ef78_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE3LTgtMS0xLTI5NzI2_7c06ca87-a4e5-48a0-b716-5cdec52c173c">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib2fafb4659f34a019ee6e466fc04640f_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE3LTEwLTEtMS0yOTcyNg_5d1fbe50-33d8-42c4-a1da-dfb53abbd3af">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i022c563362694b598da5b24ae2277042_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4LTItMS0xLTI5NzI2_ccb3c334-af08-44bf-9f4a-c4389702b3e3">1,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9241b397d581403bba8152c090405eca_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4LTQtMS0xLTI5NzI2_d54e7a51-023c-45aa-8330-d22e15648abd">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6771db02e5f8466e9669560f1ce16529_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4LTYtMS0xLTI5NzI2_d9ce14b1-69a6-4227-b9df-a89419c8d1f6">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i022c563362694b598da5b24ae2277042_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4LTgtMS0xLTI5NzI2_2c5d8cfa-cf25-46ca-8ccd-616901b03e5b">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9241b397d581403bba8152c090405eca_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4LTEwLTEtMS0yOTcyNg_a3234bd5-a472-45a5-b921-6f3a1047c24e">13.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84e86bd12edd4e36b8b1f925a62c221d_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5LTItMS0xLTI5NzI2_8e65f7cb-42b8-4b2b-a199-a72277f6f625">1,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f3c558885324ba1953b737d2adc0dd0_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5LTQtMS0xLTI5NzI2_75aff1fe-992b-4301-b166-53d5d276c16d">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2db5485b4bd4b42a522def325281378_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5LTYtMS0xLTI5NzI2_01c8bf68-0f1b-4de8-ac07-9bd09f89864e">1,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i84e86bd12edd4e36b8b1f925a62c221d_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5LTgtMS0xLTI5NzI2_dc5aaed9-e496-414a-bd76-35db4a4134fd">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4f3c558885324ba1953b737d2adc0dd0_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5LTEwLTEtMS0yOTcyNg_3049ea97-1ec6-4bdf-b862-9f7de9ab4b4b">9.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f56f359990241d3a0b4c60663ba73e8_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxLTItMS0xLTI5NzI2_221506c1-3a2b-49a8-881d-3aa9208b7737">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050c5285c0d645479744c7f00e88de1a_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxLTQtMS0xLTI5NzI2_a99459f6-8e04-416e-a422-c637c508fb18">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb9f8fb040f4aa586cf78caa70caec0_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxLTYtMS0xLTI5NzI2_6f81bd41-0bd2-496c-a6c3-184a7d840495">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6f56f359990241d3a0b4c60663ba73e8_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxLTgtMS0xLTI5NzI2_3a7ae271-6623-4d27-8d09-4fe4938fbe52">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i050c5285c0d645479744c7f00e88de1a_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxLTEwLTEtMS0yOTcyNg_0b0a59cf-1bf7-4873-87f8-a4fdc139c0e6">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23807e0c5b084f52943e64733569f8b6_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyLTItMS0xLTI5NzI2_55919f8f-9251-423b-97d4-5376b8158c2f">905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eefeafc846f4408a7e000284e1799b2_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyLTQtMS0xLTI5NzI2_67f58cae-b1bf-43d3-af68-174c2f7b9787">888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbbbd6fc37c4d11acae7021cffb7cfd_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyLTYtMS0xLTI5NzI2_58d7a746-c5f1-4440-9eda-d3f0e15d8795">974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23807e0c5b084f52943e64733569f8b6_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyLTgtMS0xLTI5NzI2_3ea0acb2-a6da-46b2-998b-d07be46148c9">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2eefeafc846f4408a7e000284e1799b2_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyLTEwLTEtMS0yOTcyNg_6fc06837-9cd5-477d-b7e2-aab05aa04ea1">8.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad865eab405c42688b73a15ad42a8b8d_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzLTItMS0xLTI5NzI2_b81727e4-1bb4-4540-a07b-8922eccba276">917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifef895456d614fdabb4ee70a7406be36_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzLTQtMS0xLTI5NzI2_6c336e29-ad66-4f17-849a-7fc6a154d91d">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieda9b733b51a4ce4b729836ac29a9802_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzLTYtMS0xLTI5NzI2_92cfb9ae-8009-452f-9ddc-43237d63ecf4">986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iad865eab405c42688b73a15ad42a8b8d_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzLTgtMS0xLTI5NzI2_1a6d0d43-366a-45e0-be9d-6be3ce239f08">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifef895456d614fdabb4ee70a7406be36_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzLTEwLTEtMS0yOTcyNg_8f09b9ae-169c-4053-a3bf-a1f2a6450487">8.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6576ad6b7f6341ec9b085c6461df5f80_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI1LTItMS0xLTI5NzI2_49c74143-9c29-4e86-8fd5-86d5b822448c">495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65ba73df1e8b4801b72d2316d8a633c3_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI1LTQtMS0xLTI5NzI2_aaf42550-9b1b-4456-9e35-c756bd3c1b55">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i615e942c7fdf4b2f990bb45b5b38934e_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI1LTYtMS0xLTI5NzI2_d9fd4269-b40c-4ba1-8f1e-408a5363452c">441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6576ad6b7f6341ec9b085c6461df5f80_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI1LTgtMS0xLTI5NzI2_02837cb0-3810-4e2e-917d-4a954fb673e8">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i65ba73df1e8b4801b72d2316d8a633c3_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI1LTEwLTEtMS0yOTcyNg_e325a1d6-8823-44a6-b38d-522f6ec311ad">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4735078cb2534ea1aac702a26e874601_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI2LTItMS0xLTI5NzI2_402974e2-e7d9-4717-a867-f5fb3b4ce60d">243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08b088a9453b40469d5f8fbb460e6662_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI2LTQtMS0xLTI5NzI2_a91d7efb-78a1-42da-9465-a73f00bb2f78">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffdc846cb23b49548ae67d105477e7ca_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI2LTYtMS0xLTI5NzI2_87ed8b9e-9963-44b1-bc75-f826320ff92a">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4735078cb2534ea1aac702a26e874601_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI2LTgtMS0xLTI5NzI2_cf670c4f-febd-4246-9e78-57f9b045bf42">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08b088a9453b40469d5f8fbb460e6662_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI2LTEwLTEtMS0yOTcyNg_138c9ae5-9ce8-46de-a274-b9fd63b31ec9">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75581ba7e91e4e2680d33c3738c407a9_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI3LTItMS0xLTI5NzI2_8f873564-7a78-4fc1-8198-968d030fe50f">739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id405ef4ec29047a392666ca100c5896f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI3LTQtMS0xLTI5NzI2_f66f759a-d04d-41d1-b3ef-4965449323ab">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44c0cd51f839449b841b58440ac22a33_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI3LTYtMS0xLTI5NzI2_95ea5d8c-5893-426b-aa91-50d61a202f25">671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i75581ba7e91e4e2680d33c3738c407a9_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI3LTgtMS0xLTI5NzI2_8a61680b-6447-40b2-a4f3-fe44ac456a8b">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id405ef4ec29047a392666ca100c5896f_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI3LTEwLTEtMS0yOTcyNg_6364031b-ff10-44bd-91e7-62ad1457f53c">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cd93ab841884a5493587a7b877c5d6b_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI5LTItMS0xLTI5NzI2_14170a05-5f0a-4f17-873a-cc6985b1aeb0">6,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9be280a895e24bc2b461be2b202dc790_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI5LTQtMS0xLTI5NzI2_b1b3be0f-5803-4cbe-bc0d-1ae2076c6030">6,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a50b9c81baf410eace82766e4ac78e0_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI5LTYtMS0xLTI5NzI2_2419e7f7-0d61-4816-bec9-b2dcff3657ec">5,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5cd93ab841884a5493587a7b877c5d6b_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI5LTgtMS0xLTI5NzI2_964ead42-5965-4942-93f7-fb051814e217">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9be280a895e24bc2b461be2b202dc790_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI5LTEwLTEtMS0yOTcyNg_125457a6-02c8-4c3c-8a8d-b5e32d5d6036">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea74d1c2c27413fad7f2b508f4aa451_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMwLTItMS0xLTI5NzI2_a0e2d36e-3bc1-43b9-b83e-937650cfd13a">8,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5d8bff62eea4ed39c39a6731f599a92_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMwLTQtMS0xLTI5NzI2_6dee1eb9-192c-42db-af93-988fd7d1f86c">7,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4495a7b68b684dcc8ad8b2dd0d0cb678_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMwLTYtMS0xLTI5NzI2_53c5e65b-e14d-467b-b1a9-e807d9ebeec6">8,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1ea74d1c2c27413fad7f2b508f4aa451_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMwLTgtMS0xLTI5NzI2_34332763-92d8-4c25-a803-8ff491c76a0f">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib5d8bff62eea4ed39c39a6731f599a92_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMwLTEwLTEtMS0yOTcyNg_b84e5972-5401-45bb-816b-c3ace9c2ed11">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1198f98bdb8f4597b4a10112426c5f06_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMxLTItMS0xLTI5NzI2_82280380-dfbd-44e3-a279-661f479e4e23">14,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43f753e349c40788db498a0b8a5fe34_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMxLTQtMS0xLTI5NzI2_781cc6fb-5015-487a-b5e6-821077a75429">14,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63ccacb9faa4b73878a9057b0fd6b30_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMxLTYtMS0xLTI5NzI2_22eaa077-f922-4d5e-8d66-efbd7eba120f">13,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1198f98bdb8f4597b4a10112426c5f06_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMxLTgtMS0xLTI5NzI2_a3bb8bc7-1b0d-48c1-808e-8ae3383a078d">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if43f753e349c40788db498a0b8a5fe34_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMxLTEwLTEtMS0yOTcyNg_c3483510-ebc0-44e2-ac97-e418959ffe36">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:189pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><ix:continuation id="i0c89da56c8914935845d531d9e7e700a" continuedAt="id034a45e93814496bea4f140162926e1"><ix:continuation id="if2ac038a58d641cea939c0357ac8a372" continuedAt="i2ca66f5ea19f4e38a028220289f060ca"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:34.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00834d1d0411420090b5c1edf63e1dfa_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM1LTItMS0xLTI5NzI2_c43e3fb4-4003-4316-b9a5-6df24530e21e">10,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6071637def043888bf3deb3a4c15799_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM1LTQtMS0xLTI5NzI2_657d0a21-f812-41f0-8968-286a240a6632">10,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f5ca4ce57845c5b53fc4f1d13397db_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM1LTYtMS0xLTI5NzI2_e9933207-42c0-4c56-9092-b303ebd92974">9,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00834d1d0411420090b5c1edf63e1dfa_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM1LTgtMS0xLTI5NzI2_8150f62b-f63a-49e4-ba63-be19fe8db3ef">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie6071637def043888bf3deb3a4c15799_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM1LTEwLTEtMS0yOTcyNg_488e866b-bd9c-4d22-abcb-f00bef4d1483">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba87799cace4d7ea02ee1f5e0a4d031_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM2LTItMS0xLTI5NzI2_79aa8199-b57f-40a1-8a32-5482907bf991">5,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c52e9cc9c14137918169f0b8a1bdb5_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM2LTQtMS0xLTI5NzI2_ba7da21b-a490-4ed1-90b1-e4cd376a1ef4">4,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedf0e8d371a6458193259414109945a4_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM2LTYtMS0xLTI5NzI2_f3171dc6-21d3-437b-ba32-df7ed480a10e">4,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icba87799cace4d7ea02ee1f5e0a4d031_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM2LTgtMS0xLTI5NzI2_9ecd5a74-317a-48b5-a383-3438c744c2ca">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib5c52e9cc9c14137918169f0b8a1bdb5_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM2LTEwLTEtMS0yOTcyNg_b9a159bf-aa90-4e42-b294-9fb04aca57e1">13.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23071b0ab3d54897a0d5dd7749feafe6_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM3LTItMS0xLTI5NzI2_f43c3262-0b13-492c-b2f8-b536c70a3f2c">16,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i931a1c9f97ec484da90098853ca3c244_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM3LTQtMS0xLTI5NzI2_0c27426b-3c30-4ba8-8abc-f6c4b3888de9">15,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c2e9c0297b447e93e02db4e79afb3c_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM3LTYtMS0xLTI5NzI2_62d3ae92-34b2-441a-9338-29a873cdd607">13,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23071b0ab3d54897a0d5dd7749feafe6_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM3LTgtMS0xLTI5NzI2_a0d0f379-113f-456a-a2bb-52d0db895f5d">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i931a1c9f97ec484da90098853ca3c244_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM3LTEwLTEtMS0yOTcyNg_f919920a-adc5-4157-a677-680ee649983c">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07618356beec49e9917628c554e15b4b_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM5LTItMS0xLTI5NzI2_98970269-7377-4824-bd43-dd958eade71e">2,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6280e9e226a04001a209231428e7818e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM5LTQtMS0xLTI5NzI2_c2f7bbd6-344f-42cd-a2b1-d303644667bf">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaf44ff1272d49ce93687c31a2fcd512_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM5LTYtMS0xLTI5NzI2_85c73cd4-f720-42e7-9405-2deaaf8e1a0d">3,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i07618356beec49e9917628c554e15b4b_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM5LTgtMS0xLTI5NzI2_ced60dc3-da23-4492-9561-f0cb681b43e2">19.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6280e9e226a04001a209231428e7818e_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM5LTEwLTEtMS0yOTcyNg_5d473514-58a8-4371-831d-50fff5c1b77a">18.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f4796c099b4277b9207e1042e91c37_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQwLTItMS0xLTI5NzI2_bfbad8f1-210f-4286-81eb-6882606d85e4">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ab4cfd32f2b4e75a6eb344b3faa7585_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQwLTQtMS0xLTI5NzI2_14bd58f8-09d5-44e6-812f-67cabe5d241b">346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i128aea28460a455aaf7714a32b5ec211_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQwLTYtMS0xLTI5NzI2_8128c3ac-cd23-43fd-a7c7-0c7c74c5c216">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i00f4796c099b4277b9207e1042e91c37_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQwLTgtMS0xLTI5NzI2_db93da8e-cfe2-42db-8814-4e32df145d78">31.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ab4cfd32f2b4e75a6eb344b3faa7585_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQwLTEwLTEtMS0yOTcyNg_08348f39-6897-47e2-9b65-aa5f152f2c16">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied68b4d63a6e47f99762e52306477051_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQxLTItMS0xLTI5NzI2_a9995093-93ec-4171-bd42-fc9f34c85bb6">935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78385204266240099fc582cb7e7fbd51_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQxLTQtMS0xLTI5NzI2_32d057d0-5aa8-4e38-93ac-a1f571327235">893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iced1449a3371463397b9b7085addc2d0_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQxLTYtMS0xLTI5NzI2_a2bc2ae2-3c54-41f6-98e3-905b7ec242ce">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ied68b4d63a6e47f99762e52306477051_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQxLTgtMS0xLTI5NzI2_d29e70cb-6679-4df9-ac5a-5ae216fe6a3e">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i78385204266240099fc582cb7e7fbd51_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQxLTEwLTEtMS0yOTcyNg_6a10a304-a1a0-4b63-a28f-2c3ae905d370">11.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i650a133233af49bfaee6ed4af066a9d6_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQyLTItMS0xLTI5NzI2_ee154a01-8044-4ccf-92b2-2d0d01eea839">3,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3e283c3e9214f85ae2918d74ac3d82d_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQyLTQtMS0xLTI5NzI2_8c4cb02f-3a0d-46fa-8426-b432f3ac2472">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ce48e00f8545ec8e7a84f01797b22c_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQyLTYtMS0xLTI5NzI2_81bd23e8-dc24-492c-91f8-b778f3688de7">4,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i650a133233af49bfaee6ed4af066a9d6_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQyLTgtMS0xLTI5NzI2_f5609cbc-6739-4c05-bfe3-1282a4f2f759">14.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie3e283c3e9214f85ae2918d74ac3d82d_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQyLTEwLTEtMS0yOTcyNg_675d2f0e-5340-4a1d-b65e-675e78b8bd3f">14.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d4bf4b9e3694ef285c9c31b956b677e_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ0LTItMS0xLTI5NzI2_46cdcae8-f92e-457f-be8c-35f18f4464e6">1,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd06b502c49a4f488fc11fb2c3838ef3_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ0LTQtMS0xLTI5NzI2_4b594d1e-1124-479b-b50f-26506188eacc">1,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233cf7fe392245428889ea57e0fc2d22_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ0LTYtMS0xLTI5NzI2_52881d0f-1183-47e6-af6f-e09ef1ea313c">1,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2d4bf4b9e3694ef285c9c31b956b677e_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ0LTgtMS0xLTI5NzI2_398146f2-fc8d-4c9d-bad8-87b2cacc7bdc">2.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idd06b502c49a4f488fc11fb2c3838ef3_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ0LTEwLTEtMS0yOTcyNg_811ccda3-44ec-40b6-a59c-0830a1c54ba5">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c61950fc8949c5b32766ec79d02eaf_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ1LTItMS0xLTI5NzI2_876f8134-533b-42c2-a9e6-afda83987b37">1,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebf3d76775d644ba97bdf492a1dd1267_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ1LTQtMS0xLTI5NzI2_9e83a937-ad72-4ec8-b77a-37ba72d5f215">1,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a8ae6b440b4b81b32f6a052e5a8558_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ1LTYtMS0xLTI5NzI2_bdad626c-38ab-479a-9f44-7c7e0f40974a">1,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id4c61950fc8949c5b32766ec79d02eaf_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ1LTgtMS0xLTI5NzI2_7037d691-3232-4725-91bb-758115c0291c">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebf3d76775d644ba97bdf492a1dd1267_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ1LTEwLTEtMS0yOTcyNg_84c5cf64-3ae0-4854-9a95-0843f92b8f20">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i875c8735b8514e90bad447aeb6eadbc2_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ2LTItMS0xLTI5NzI2_35e67a4b-a4a5-4e9a-b13f-5524a95b54f3">2,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f3798ee8de34093a99e42ecc9db1ecd_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ2LTQtMS0xLTI5NzI2_86045eb8-1fcb-4f5c-b39e-716625d38e5b">2,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a3f22a534874f458fb9c7bdc05cb65c_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ2LTYtMS0xLTI5NzI2_66683293-4d2c-4366-aaff-a525211263ac">2,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i875c8735b8514e90bad447aeb6eadbc2_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ2LTgtMS0xLTI5NzI2_9387a535-f8d2-488d-b886-3a85d5782676">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f3798ee8de34093a99e42ecc9db1ecd_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ2LTEwLTEtMS0yOTcyNg_35034253-4305-4528-8499-094bb2e327c9">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i387f05cfe3524712bad1d9f54eb5cccd_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ4LTItMS0xLTI5NzI2_66919be4-dcf9-4d94-a340-011df4a51f00">5,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia62cfbf9f33d4aa284727311f21d634e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ4LTQtMS0xLTI5NzI2_6352767e-8c98-4d89-8590-9fcc8cb6c3be">5,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15b688eb12f54afc92d5afd59ea3c706_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ4LTYtMS0xLTI5NzI2_b85dc8f4-a8c2-4207-b588-c48e7d9b51cf">4,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i387f05cfe3524712bad1d9f54eb5cccd_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ4LTgtMS0xLTI5NzI2_91b8f184-6075-4fd6-bbb9-7b1e1bcf4120">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia62cfbf9f33d4aa284727311f21d634e_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ4LTEwLTEtMS0yOTcyNg_f81ed3d8-1c7b-44de-897c-1a9c7367426c">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ff56877211249dd8ac926ef0d64f13b_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ5LTItMS0xLTI5NzI2_9705b34e-c47b-42c2-ace9-8897048029d1">3,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i522f8a96ab7444c9b0a072059a13e972_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ5LTQtMS0xLTI5NzI2_824d6251-c5da-47c7-b754-021b4690356f">2,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27123f6e396341619661b5c3adc7e7d7_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ5LTYtMS0xLTI5NzI2_f9af9d0d-bc81-46e2-b77a-cf3c66c7f67f">2,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ff56877211249dd8ac926ef0d64f13b_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ5LTgtMS0xLTI5NzI2_9b2593b1-6fe8-473a-8cc7-6175056c5c75">29.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i522f8a96ab7444c9b0a072059a13e972_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ5LTEwLTEtMS0yOTcyNg_f888fc44-6fb0-4211-9d95-9e3389e862a7">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7809d87d5c845608f30c8285db41530_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUwLTItMS0xLTI5NzI2_5ebb4210-dcd5-4f7d-a173-ec8a156e8677">9,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f1a5560e5b14f0893f3ee125948348a_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUwLTQtMS0xLTI5NzI2_192a5f87-4879-4e77-8ba4-03dfc72b4834">7,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd59309ca0944688a41953f08782f58_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUwLTYtMS0xLTI5NzI2_14a1b5ba-c816-43fa-81f9-5a353cc1d6c1">6,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic7809d87d5c845608f30c8285db41530_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUwLTgtMS0xLTI5NzI2_f64e1e9f-025b-4221-9a83-2c2583ac45f9">18.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f1a5560e5b14f0893f3ee125948348a_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUwLTEwLTEtMS0yOTcyNg_ecba3bc1-d1d0-4ad3-9583-dca9c2fde42c">21.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b9271bf3d148c1862fbcdce1ca1e53_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUyLTItMS0xLTI5NzI2_fc7e0d33-c737-479e-916a-e6590fb1cc2e">1,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc8570ebb01c438ea0f57235642eacc7_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUyLTQtMS0xLTI5NzI2_a7d0b3f2-cb22-4851-8dac-5484937152c7">926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e5920e5bf6749e2a8feab5aaad9c855_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUyLTYtMS0xLTI5NzI2_25b77eb5-e5a2-4625-9c3a-d7f278551326">764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25b9271bf3d148c1862fbcdce1ca1e53_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUyLTgtMS0xLTI5NzI2_5793b05c-76b0-4362-920a-411fe743ee16">62.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icc8570ebb01c438ea0f57235642eacc7_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUyLTEwLTEtMS0yOTcyNg_4ff06f2e-fa82-4160-bbaa-06c9fafc2b8e">21.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia490b063eb8a46d3bdd2ff016e7d7783_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUzLTItMS0xLTI5NzI2_2def00aa-e591-47a4-8be6-e76e77be36b4">624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4565c280598049f3aa2278617178658f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUzLTQtMS0xLTI5NzI2_24118bbf-90fb-42a7-bb41-c4990c071e9c">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8317c263da5445e96ef10c57d87335e_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUzLTYtMS0xLTI5NzI2_b2d0ff54-ee13-4761-b8ac-d1cb4c62a615">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia490b063eb8a46d3bdd2ff016e7d7783_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUzLTgtMS0xLTI5NzI2_60bb8705-4672-4ef5-b0d7-58eff11d3501">48.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4565c280598049f3aa2278617178658f_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUzLTEwLTEtMS0yOTcyNg_762215cd-105b-4d12-829c-ee360be3c9c0">69.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a754bdc99b4589aafca7079db10c80_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU0LTItMS0xLTI5NzI2_d7d5dfab-6736-469b-b1b2-0e086d71aa04">2,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfe65f5fd84478bfecb83176d8cf1a_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU0LTQtMS0xLTI5NzI2_05e7f87e-e6bc-4c69-9176-0a8a802d0f52">1,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61a8303dc0bc4b82b4eb802262faa800_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU0LTYtMS0xLTI5NzI2_bc813a37-954a-4a98-8cdb-b61ba7daa32d">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08a754bdc99b4589aafca7079db10c80_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU0LTgtMS0xLTI5NzI2_477bcf77-ff6d-4f81-be9c-e4dab369dcf2">57.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i82dfe65f5fd84478bfecb83176d8cf1a_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU0LTEwLTEtMS0yOTcyNg_89cf8c16-3f20-4879-b1a3-268835d65ee4">33.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5106140dfc9c442095b0f77e74bd6ab5_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU2LTItMS0xLTI5NzI2_031451da-440a-43cf-9a49-80340121cd3d">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92703c0c3b7349978b612c21f233b393_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU2LTQtMS0xLTI5NzI2_51a94357-e6c1-4dc3-8d66-e390717d62e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590ff19ce91142bcb3863bd2c6e2f069_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU2LTYtMS0xLTI5NzI2_d82b7532-c4ce-4745-bb03-5f89915c9bfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i92703c0c3b7349978b612c21f233b393_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU2LTEwLTEtMS0yOTcyNg_907079c8-539d-45d0-97e1-4d59562102ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f224616f5a463b8f804675e284a7d3_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU3LTItMS0xLTI5NzI2_2913489e-4a15-4e0d-8d6c-e1911066ecf8">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife046f7abde54338b2b69413c736da26_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU3LTQtMS0xLTI5NzI2_8172e38e-8c13-4ec8-9a73-dcd819e439af">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83e3aa3c5f51435b93d1dbe65ac91d90_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU3LTYtMS0xLTI5NzI2_c0294fc7-3b02-45a5-9d10-8eec965a37d5">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic9f224616f5a463b8f804675e284a7d3_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU3LTgtMS0xLTI5NzI2_2170b076-c612-4d25-b04c-8db208010297">73.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife046f7abde54338b2b69413c736da26_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU3LTEwLTEtMS0yOTcyNg_2fda7b1b-c167-4795-a7fc-16d829d36e85">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5465f74052f34acfb49d0e1a25300dc8_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU4LTItMS0xLTI5NzI2_d94714e3-f644-4ec5-981b-aad213fe03f1">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie74fbb87373b4b59ab055d2fff965e07_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU4LTQtMS0xLTI5NzI2_d1f2477f-b00e-46aa-9986-318fe2ed4611">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3530f8c2ec644b0780f82d2251ffd602_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU4LTYtMS0xLTI5NzI2_429840eb-c762-4d4f-bad1-6994a2e047e8">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie74fbb87373b4b59ab055d2fff965e07_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU4LTEwLTEtMS0yOTcyNg_74de71d8-9ef3-48c0-8547-130eb35fa3cf">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf363f3dae664585a3f17f32b6970829_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYxLTItMS0xLTI5NzI2_89abced4-7572-4834-b007-12543f81da6e">2,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40eda5c751a24278a262d5a7707bbf96_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYxLTQtMS0xLTI5NzI2_ec3baff3-67c7-46b2-85ca-c1e9077d883b">1,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69b0b0d154c1422f9d32b3d2082d49eb_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYxLTYtMS0xLTI5NzI2_bd007b75-df15-4d99-aacb-32f7b14046f6">1,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icf363f3dae664585a3f17f32b6970829_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYxLTgtMS0xLTI5NzI2_93a06b87-63a4-4e2c-99a3-215609010513">29.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i40eda5c751a24278a262d5a7707bbf96_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYxLTEwLTEtMS0yOTcyNg_f932c62a-37ec-48ec-b038-f1722e4e91ff">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2db3c45977049f1acbf33a46b8f1197_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYyLTItMS0xLTI5NzI2_10e88b36-07b6-4196-a57c-a223e2834531">3,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b2cef1544584a32a4606c9be98a902b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYyLTQtMS0xLTI5NzI2_6e514d03-cbf9-43d0-8f0a-a2263db61539">1,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib308904527464b1f9f083c28369a2106_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYyLTYtMS0xLTI5NzI2_4e2419f9-a91c-4053-85b0-b8282592b34a">1,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia2db3c45977049f1acbf33a46b8f1197_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYyLTgtMS0xLTI5NzI2_e102f698-ff86-4397-b066-49952ba239d7">96.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b2cef1544584a32a4606c9be98a902b_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYyLTEwLTEtMS0yOTcyNg_b7e073eb-c918-409f-bae9-33796e6f0ae9">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id02c8176e6b54fbd95f6a63b9d32b50f_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYzLTItMS0xLTI5NzI2_03884669-c6fa-4eed-afeb-c2c00692edd2">5,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1ededb6af34beeb2892f0c47c60708_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYzLTQtMS0xLTI5NzI2_75a84e7d-ed83-4aa5-9072-0e7f35f2be47">3,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c7e3cb454244e8fbcbbac2736af573a_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYzLTYtMS0xLTI5NzI2_332566b4-7c1f-47f9-9dab-fa1920e42494">3,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id02c8176e6b54fbd95f6a63b9d32b50f_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYzLTgtMS0xLTI5NzI2_03a97e6b-75fa-452a-aa22-6083b363c079">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee1ededb6af34beeb2892f0c47c60708_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYzLTEwLTEtMS0yOTcyNg_ea5bc54a-2b04-4304-8948-27c6e2080514">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddc954bdfca40e5b84a70e77aa5b0ff_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY1LTItMS0xLTM2OTg1_9db979d2-5266-4b2f-8e54-0650c6ec20e3">634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d8535a6c304a3ca7e7a68a08f5c836_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY1LTQtMS0xLTM2OTg1_ff2a7465-aa9c-492d-aeca-b985b1202216">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18a2c82e5bd42faa30e52df5f67d0f1_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY1LTYtMS0xLTM2OTg1_3386cc98-7f40-4f2c-a681-5c7fe612eda0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bea3a5e88f4153ac03408e384f810b_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY2LTItMS0xLTM2OTg1_f4cd2be2-f8f8-4e16-a0e3-47db352a2570">1,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fa30ec743194334be89aabe3830b90b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY2LTQtMS0xLTM2OTg1_65576f6e-dcdc-493f-8c9d-f9caa9af606a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08d85765adf1424dbaac0219f0177c84_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY2LTYtMS0xLTM2OTg1_26ea622a-3d07-48f5-8a4d-ecc245101564">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb2fe12284743f396b4f94eba5b3803_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY3LTItMS0xLTM2OTg1_0d1e4186-20aa-4453-9c30-2d73fa242c7d">2,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idff0f007396e4810b440aabe3054aef9_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY3LTQtMS0xLTM2OTg1_19f229b3-5480-4da5-aba1-368af2ffd5fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i789f89f97ffa47c7b42b23eb088f0422_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY3LTYtMS0xLTM2OTg1_0be9e461-a7ba-4de4-9b18-5ef070f103ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / rilpivirine</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id21042f6fd3244f6887b53a8d4813430_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY1LTItMS0xLTI5NzI2_25b0d866-8616-4d5e-a9f1-d5d74c795613">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf047bcbe355467c8f65460dba57e264_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY1LTQtMS0xLTI5NzI2_2aa94921-f94c-4684-b4fb-270127e87610">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8bc791af8b648d782365c72c1a39a7c_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY1LTYtMS0xLTI5NzI2_ea36709a-b5fb-4ea3-a196-bd956060f40c">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id21042f6fd3244f6887b53a8d4813430_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY1LTgtMS0xLTI5NzI2_0086b092-c71a-46f9-97fb-022b80d57102">7.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibf047bcbe355467c8f65460dba57e264_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY1LTEwLTEtMS0yOTcyNg_cbe82e8b-bc7b-431c-8b70-5afd7111ad59">11.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4861e2b2aeb543fbb746c4b4f1195f46_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY2LTItMS0xLTI5NzI2_db37870e-9c6d-458b-8535-e92e05c13f3b">953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b56e952fcde4c7e91401eb5a85ca321_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY2LTQtMS0xLTI5NzI2_89bd6f63-1312-469c-a6ae-b2dbb4d10351">920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1625d21dd2242ec893225588e77f1b9_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY2LTYtMS0xLTI5NzI2_0fb19327-a649-4935-ac0a-5036649f0dbb">812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4861e2b2aeb543fbb746c4b4f1195f46_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY2LTgtMS0xLTI5NzI2_f3bfdcbe-e02c-47e3-a476-5f35bb7a4b59">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b56e952fcde4c7e91401eb5a85ca321_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY2LTEwLTEtMS0yOTcyNg_aedce388-a063-4bd1-9679-0e03be461fb9">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i805f444f9b4f4b78a5e115f7da23f40b_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY3LTItMS0xLTI5NzI2_255fb96a-49cf-46c3-8b17-aceca53072c8">994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a0e2e227a4493a886e7e12cc63281f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY3LTQtMS0xLTI5NzI2_07508a32-034f-4d74-9f31-77ae76932130">964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb4f242ab4b94ba3bb07fea9dbb6f194_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY3LTYtMS0xLTI5NzI2_ebdf2453-176b-49d9-81ac-37823f3397d2">861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i805f444f9b4f4b78a5e115f7da23f40b_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY3LTgtMS0xLTI5NzI2_0184a408-b6f5-4169-a3a1-a59847471d8e">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i67a0e2e227a4493a886e7e12cc63281f_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY3LTEwLTEtMS0yOTcyNg_7b81fcfc-faa8-4ce1-b1fb-c32a4e660baa">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> /                                              </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d93d7178a424340b255ab8cc1671993_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY5LTItMS0xLTI5NzI2_7b1c90de-e3f8-40ba-a23d-acb261d0c9e8">1,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50a2f88597bb4e56babe220ec155c933_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY5LTQtMS0xLTI5NzI2_167ca83b-6b8a-406b-9f3e-72ffb5db192b">1,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba7b86a3b9b4ffc8203367aff4b1f12_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY5LTYtMS0xLTI5NzI2_6fa89f91-0571-4c7a-ac70-99687d021de8">1,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9d93d7178a424340b255ab8cc1671993_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY5LTgtMS0xLTI5NzI2_ca2f7db8-d966-4cc9-8a8f-ee98cd3bfd61">4.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i50a2f88597bb4e56babe220ec155c933_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY5LTEwLTEtMS0yOTcyNg_2dccaa78-8541-4371-a4b6-6e66c067d7fd">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ca4566672f4e21b57db409f2ca399b_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcwLTItMS0xLTI5NzI2_743cee9f-1541-456c-b607-1045e9eb0ee2">575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72fd0da598264bf58922963c2e268f9f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcwLTQtMS0xLTI5NzI2_ee81fe0c-0267-4f95-a4a5-38697379401e">597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68dfc09b6cc74b269337c9823085c75d_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcwLTYtMS0xLTI5NzI2_c5ca654c-66fd-4d07-b2b1-5cc9dd088801">689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i00ca4566672f4e21b57db409f2ca399b_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcwLTgtMS0xLTI5NzI2_31fa7e65-96c9-4a7f-8fa6-be235f573a31">3.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i72fd0da598264bf58922963c2e268f9f_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcwLTEwLTEtMS0yOTcyNg_52baf13a-f11d-466c-9634-4f44efd81e51">13.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0dbfabf4ce84c5dadfb5096deb252aa_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcxLTItMS0xLTI5NzI2_98ed78bc-cfed-4916-9fc4-dae11c9f9134">2,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a5ddf6505c49959a39142a4734937d_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcxLTQtMS0xLTI5NzI2_d5224eac-0f9f-48b5-a3e5-55a07fbceaa8">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7eef150a18e4e7c9fb366789c95e51b_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcxLTYtMS0xLTI5NzI2_0f7eccfd-73cd-4089-bcae-7f32d4a25938">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie0dbfabf4ce84c5dadfb5096deb252aa_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcxLTgtMS0xLTI5NzI2_f2d2248c-9e2a-40d0-a065-37c856e52e45">4.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i71a5ddf6505c49959a39142a4734937d_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcxLTEwLTEtMS0yOTcyNg_90ec5e73-54dd-41e1-9d35-e6bec767f8a2">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844da3be083d4b0991bcf4a93b302f05_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzczLTItMS0xLTI5NzI2_373a00e9-9ce6-464a-ab27-291f58cfc82d">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f0f46a5f794204849d8974443208af_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzczLTQtMS0xLTI5NzI2_18e46fc1-cf5d-4af8-9511-8beb1d64da61">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c3bc420ba184db5b0c0a09e582ba601_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzczLTYtMS0xLTI5NzI2_508d83ad-98ef-4b8f-9433-3567a941565f">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i844da3be083d4b0991bcf4a93b302f05_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzczLTgtMS0xLTI5NzI2_584a4ad0-7001-47d2-9956-c52c2b8bcd5d">36.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i93f0f46a5f794204849d8974443208af_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzczLTEwLTEtMS0yOTcyNg_0809aabb-3266-4b15-81d9-7faebb9912fa">17.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90a6c337bc74400ead0814dfe3ded9ac_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc0LTItMS0xLTI5NzI2_73d30a8d-cccb-4e3a-8e96-1a2162548a4e">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d256c783ba14651b3deabb6dbca6ac3_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc0LTQtMS0xLTI5NzI2_30a37d90-637e-4e74-98c3-678d9711d9f1">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23065d742db5456abc56ab20b4266dea_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc0LTYtMS0xLTI5NzI2_61ccefe2-c336-4e9f-869e-bcb7cb4af695">315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i90a6c337bc74400ead0814dfe3ded9ac_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc0LTgtMS0xLTI5NzI2_f39395e3-4843-4702-841c-7b6d2d4a94a9">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d256c783ba14651b3deabb6dbca6ac3_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc0LTEwLTEtMS0yOTcyNg_96556f4b-6c41-470f-af13-5bdbf29c98cb">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if55330cd78f747a88fbccd460f0ec00f_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc1LTItMS0xLTI5NzI2_141286de-6b08-4420-b4bc-1c3dfa693098">399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d1488ec3e3c4b168ab09734e1cb2ef9_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc1LTQtMS0xLTI5NzI2_60b21115-e4f4-4460-b63b-22c8cef23727">427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1b7f8f06d9d4045bbceff6b94ee3210_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc1LTYtMS0xLTI5NzI2_18b13db4-6089-440f-be05-c361f6c43500">441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if55330cd78f747a88fbccd460f0ec00f_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc1LTgtMS0xLTI5NzI2_61155370-e1fb-4691-bcc7-1f1541dce412">6.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2d1488ec3e3c4b168ab09734e1cb2ef9_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc1LTEwLTEtMS0yOTcyNg_7e37da9a-002b-4f59-ac2f-577ff9fa82a2">3.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><ix:continuation id="id034a45e93814496bea4f140162926e1" continuedAt="i62f5d7d64cf74a90a733191e167f6d4d"><ix:continuation id="i2ca66f5ea19f4e38a028220289f060ca" continuedAt="i1ba8055d178e457ebf6f20c70e090489"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:34.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb742dc6f1a14657ade44dbb3734869a_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc4LTItMS0xLTI5NzI2_2b20d9af-3087-446f-b0f4-1ee4e7678660">3,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b5d7e03ed1438bb2eb5544aa5e51a0_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc4LTQtMS0xLTI5NzI2_5629d986-66f5-4fde-a3e9-99ab3a12d198">3,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3ecc659932b4e20a391e656b1cf4600_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc4LTYtMS0xLTI5NzI2_12345e8b-5e0e-46e1-a383-cba5a41df8cf">2,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb742dc6f1a14657ade44dbb3734869a_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc4LTgtMS0xLTI5NzI2_f7bf3457-5bb0-4ced-94ab-827503ff2261">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia7b5d7e03ed1438bb2eb5544aa5e51a0_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc4LTEwLTEtMS0yOTcyNg_9627bc06-7169-4cee-811f-080ea48b72b5">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e82f975ef30440e880e83c96d9d5a6d_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc5LTItMS0xLTI5NzI2_0f6fe67e-ba39-46ce-8ba0-59d590a05870">3,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7172a6f847d4499da4684dd32ff6587d_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc5LTQtMS0xLTI5NzI2_76a2220d-ee6f-4582-892a-1923805d68a5">3,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47c5bf1c0fe4beb961f5f32232ec895_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc5LTYtMS0xLTI5NzI2_e69424b0-c5f7-41a3-b9f1-36130ebf188e">3,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e82f975ef30440e880e83c96d9d5a6d_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc5LTgtMS0xLTI5NzI2_6332c6e9-36b7-4f61-a76a-807198748519">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7172a6f847d4499da4684dd32ff6587d_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc5LTEwLTEtMS0yOTcyNg_c813b266-de51-459d-b265-f0c8fc6955a8">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8d54437eaba48faad57862e220ec9ba_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgwLTItMS0xLTI5NzI2_16d94a62-a317-44b7-aa46-0c315a59e22a">7,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic172a5b3e234408b904ca83aea199d14_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgwLTQtMS0xLTI5NzI2_2853b567-67f0-40f5-96a9-63098ffd309f">6,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716ef7913074441580f76f25ff473db3_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgwLTYtMS0xLTI5NzI2_c6d459d9-e9b5-438a-b0e6-8990640ce4d5">6,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie8d54437eaba48faad57862e220ec9ba_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgwLTgtMS0xLTI5NzI2_1cb87612-1a58-4b74-bfcd-bdcb1d69a824">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic172a5b3e234408b904ca83aea199d14_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgwLTEwLTEtMS0yOTcyNg_a4247c93-4a32-4fba-bbc3-564eaf71f0a1">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / methylphenidate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i045f6bb81e3d4317b32f42c7864f0ce5_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgyLTItMS0xLTI5NzI2_57938330-f118-431c-931f-be2b41af433a">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeea74059fd94beeac322670b9baabca_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgyLTQtMS0xLTI5NzI2_18b6e885-12d4-428c-9a13-003e7726aa45">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f7304198142471ca4e3ba8d2b8b2dbb_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgyLTYtMS0xLTI5NzI2_033ea001-4807-4f39-b9c0-196026abbbec">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i045f6bb81e3d4317b32f42c7864f0ce5_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgyLTgtMS0xLTI5NzI2_447b1a84-f31e-4768-9681-9a7aeaa1f8cc">5.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ieeea74059fd94beeac322670b9baabca_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgyLTEwLTEtMS0yOTcyNg_073cb283-064e-4942-a391-93c650a52434">21.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62a4d2b818ce406f90793b13460001fb_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgzLTItMS0xLTI5NzI2_cf55acad-d523-4871-8539-c1fbb43477b3">495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f347c3391bc41aa85bcd9845a2709af_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgzLTQtMS0xLTI5NzI2_5075c0a8-8139-47cc-9f8f-5dedfc6c8a3e">439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec40c04f9d454e2f8463d169e94a0db7_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgzLTYtMS0xLTI5NzI2_73f2d2e9-864e-44c0-8f90-bb4c54f96c9e">463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i62a4d2b818ce406f90793b13460001fb_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgzLTgtMS0xLTI5NzI2_487c363d-a19c-4ea2-abf8-ebd7012d4bde">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1f347c3391bc41aa85bcd9845a2709af_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgzLTEwLTEtMS0yOTcyNg_9d90b767-7e54-42b3-9146-95413906c6ee">5.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib20ac18affec473182fcb58284b62b0e_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg0LTItMS0xLTI5NzI2_1ed156ff-17f1-4ad7-8034-b1f035daf6d7">667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9073991f08b1465283d39628e414f9d0_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg0LTQtMS0xLTI5NzI2_8314d803-1b12-418a-88de-e3cfdcef323b">622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icffef1f5716b4b64b0f0bdfba755b0e7_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg0LTYtMS0xLTI5NzI2_6570014a-43cc-4dc5-8352-758397102f71">696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib20ac18affec473182fcb58284b62b0e_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg0LTgtMS0xLTI5NzI2_13cf9d13-1eba-421d-9938-dba530084954">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9073991f08b1465283d39628e414f9d0_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg0LTEwLTEtMS0yOTcyNg_ed877325-4fd1-4f56-93e1-fcdf7e858294">10.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e1c17df3e194f1e91c5e45244f1f77c_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg2LTItMS0xLTI5NzI2_5f76b94c-53e6-4ae8-b3a4-f568c441598f">2,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaeef50117a46faa8df83f358a7edea_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg2LTQtMS0xLTI5NzI2_31807650-f919-45c7-a358-1c8be92de6d6">2,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70636291997f49208bb484bc59053d07_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg2LTYtMS0xLTI5NzI2_837181b6-66a7-409a-beb1-532387b3a275">2,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4e1c17df3e194f1e91c5e45244f1f77c_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg2LTgtMS0xLTI5NzI2_12d478df-04d0-4444-ba5d-96c23e4d75e7">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7eaeef50117a46faa8df83f358a7edea_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg2LTEwLTEtMS0yOTcyNg_b48de9ad-2fef-4f40-9ff5-51dbeb45bdfd">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd513a7d62984d5f9d3b9a8b8e403e60_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg3LTItMS0xLTI5NzI2_df0a2472-399d-43fc-8cab-68a704119ae8">1,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04a63eca2254a59a36cde0f40f8f746_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg3LTQtMS0xLTI5NzI2_2ada2779-46ab-4a78-8ec2-94dcade2abd2">1,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf8ef533f70c490d94f9db77743e9b87_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg3LTYtMS0xLTI5NzI2_50495490-dd46-4324-8c21-b6959fb2e2a4">1,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibd513a7d62984d5f9d3b9a8b8e403e60_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg3LTgtMS0xLTI5NzI2_85706ace-f1a0-418a-b175-d774fe48e31f">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia04a63eca2254a59a36cde0f40f8f746_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg3LTEwLTEtMS0yOTcyNg_af452516-b404-488c-b29c-63f9c2614539">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cc68bd95fc3478a9e77570132e953cf_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg4LTItMS0xLTI5NzI2_81df342d-2212-4bdc-acc9-071b30c45714">4,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2255cd9d9c44cf8a9e8c1c315f656b6_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg4LTQtMS0xLTI5NzI2_0a436aed-3f00-4038-b285-7f320b74fc08">3,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e4b54306a4415da8f707b8ded967a0_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg4LTYtMS0xLTI5NzI2_3d5a38e4-df45-40a5-a321-300df577647b">3,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7cc68bd95fc3478a9e77570132e953cf_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg4LTgtMS0xLTI5NzI2_66f11ef4-855f-4957-80e7-42159bc9f932">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie2255cd9d9c44cf8a9e8c1c315f656b6_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg4LTEwLTEtMS0yOTcyNg_e84e65f5-1d25-456b-853e-e19406cad737">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814ea4ac6baf497f8b3622d1588dd4fe_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkwLTItMS0xLTI5NzI2_b3a53e57-f1a7-4e94-9a02-65ee682b2bb4">287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib635c2bb6a9c4682b88d93ff9e2e12c6_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkwLTQtMS0xLTI5NzI2_a09f253d-edf6-4eeb-95b9-b7712ca9efa0">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i370e769b4db246bf866de99ce8aec22c_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkwLTYtMS0xLTI5NzI2_742b05c0-32d7-4b01-802b-05312a69923c">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i814ea4ac6baf497f8b3622d1588dd4fe_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkwLTgtMS0xLTI5NzI2_840a2f93-298c-4592-a23f-9ffaca6701f9">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib635c2bb6a9c4682b88d93ff9e2e12c6_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkwLTEwLTEtMS0yOTcyNg_26225049-b64d-4a41-bf7b-238d4d3b7fa7">5.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc879599c5a46cdbbdff6a01666beef_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkxLTItMS0xLTI5NzI2_1fc84e04-5aa4-4ca5-acf2-620e1f0f4cfe">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5dec1e00694287b6044e170dc592de_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkxLTQtMS0xLTI5NzI2_a4ee5d35-c03e-4891-904f-688e5c6633e8">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8d79f0300124a3fb9fc87ac1735b564_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkxLTYtMS0xLTI5NzI2_2f077f0a-1272-4fcd-b33e-eefe9a096269">374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7dc879599c5a46cdbbdff6a01666beef_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkxLTgtMS0xLTI5NzI2_4a735cb4-727c-484d-a4eb-4118197ab1b4">11.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7d5dec1e00694287b6044e170dc592de_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkxLTEwLTEtMS0yOTcyNg_ffc47a3a-66cb-467c-b850-a48375a81bac">7.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic94160fb0a474a0687f27b40423f5cb5_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkyLTItMS0xLTI5NzI2_0e2a11ca-c49a-4b20-a2e7-935ef0d91ee5">592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4222851f7d5c417c83afe973ae5d0159_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkyLTQtMS0xLTI5NzI2_d3d75d48-d76b-4823-b6e7-186b1dcd16a7">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de04364812e434785d220fe797cd119_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkyLTYtMS0xLTI5NzI2_e69dc72a-79d7-47da-b285-4fd591ef7e0b">688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic94160fb0a474a0687f27b40423f5cb5_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkyLTgtMS0xLTI5NzI2_e59d07a4-ee77-490b-8dab-f53faa023eb8">7.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4222851f7d5c417c83afe973ae5d0159_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkyLTEwLTEtMS0yOTcyNg_d500b82f-2a58-4ca0-811a-b87fddd4613b">6.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c934290591045e6af2df7d8b360299f_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk0LTItMS0xLTI5NzI2_1f09c85e-3a37-4936-888a-46b40ca9705a">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc793642dc34fb8bc13264db3c2b910_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk0LTQtMS0xLTI5NzI2_b5098821-8f85-4c46-8337-b39046f4c550">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08089cf711014f1e98f6d9a9cdf4e5a6_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk0LTYtMS0xLTI5NzI2_684a5870-b117-4299-bb32-93b76f5aac46">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c934290591045e6af2df7d8b360299f_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk0LTgtMS0xLTI5NzI2_052aebf8-8637-455d-a9e8-92ca270dfcb7">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2dc793642dc34fb8bc13264db3c2b910_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk0LTEwLTEtMS0yOTcyNg_d491091f-4d37-4c69-a466-821e2ed300ba">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48aeb94da2f440daa0044b9d1b46d05_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk1LTItMS0xLTI5NzI2_fd24f640-6ed9-4092-ab82-6cc04dc67362">1,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dabbfb12da541ddb881aa0135400f3b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk1LTQtMS0xLTI5NzI2_61f797c6-d77e-425c-97ec-112335508574">1,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabe57c96bf62464fa90fd751cdaa6812_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk1LTYtMS0xLTI5NzI2_423701ba-794d-48a8-85fb-257a5eafa29b">1,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib48aeb94da2f440daa0044b9d1b46d05_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk1LTgtMS0xLTI5NzI2_74afe2bf-a47a-4a61-95e0-d2eb6d9bc49c">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0dabbfb12da541ddb881aa0135400f3b_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk1LTEwLTEtMS0yOTcyNg_fbbb750f-1d06-4f7c-9bfc-cfc605e875ae">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if16b1050a2ea4ac38b8dbfa679f48f95_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk2LTItMS0xLTI5NzI2_4fad34ce-490a-4e8b-8b71-143f0764aedc">1,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56944bb518044ff2b8fd31922efe406c_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk2LTQtMS0xLTI5NzI2_0797ccad-986d-492c-8eeb-30da1e166b92">1,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2d0a9ad27884389aa902fa95d666252_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk2LTYtMS0xLTI5NzI2_99012220-498a-43a9-a44d-95978d25dea1">1,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if16b1050a2ea4ac38b8dbfa679f48f95_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk2LTgtMS0xLTI5NzI2_9f2bbbe4-59d5-4dfb-86b3-9a298f007ff8">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i56944bb518044ff2b8fd31922efe406c_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk2LTEwLTEtMS0yOTcyNg_d366899b-90d8-4195-bbb9-2f2edd960ea2">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5923e8e2b04e40f0b40227e5c5493fbc_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk5LTItMS0xLTI5NzI2_013524fe-8fe8-48cd-8d5f-cf7bce1f806d">5,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e85127952964447a44873c81135f105_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk5LTQtMS0xLTI5NzI2_08a4a009-df23-4a1e-bf29-1d72d808d6ce">5,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0167f5d01f2e48d5bf9bf67a240ff929_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk5LTYtMS0xLTI5NzI2_ce213365-1088-4669-9476-1aa9124197bd">4,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5923e8e2b04e40f0b40227e5c5493fbc_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk5LTgtMS0xLTI5NzI2_f9bbe109-79dd-4375-b078-1ca12c22dcd0">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7e85127952964447a44873c81135f105_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk5LTEwLTEtMS0yOTcyNg_03c3d8b3-e194-4696-8d4a-11a087a82794">18.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8677e4e7312c443d8f02f7836a90e787_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMC0yLTEtMS0yOTcyNg_fa08d4cd-45fc-4e42-9b5f-f23fcfbc2091">8,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12482888cede42db9e124e85eb782d12_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMC00LTEtMS0yOTcyNg_b0f706bd-4d4e-4d35-82e1-52875b60a3b0">7,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic22cf04ce4d04163abd28d1680da2cc6_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMC02LTEtMS0yOTcyNg_0f18e9bb-c312-433d-926b-8aa64e79ba75">6,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8677e4e7312c443d8f02f7836a90e787_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMC04LTEtMS0yOTcyNg_902296ac-36b2-4254-b589-709d858e853f">18.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12482888cede42db9e124e85eb782d12_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMC0xMC0xLTEtMjk3MjY_b5355113-81b7-4294-a12d-bd0246929f71">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95a87c453d545bd97f71c7a6e370768_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMS0yLTEtMS0yOTcyNg_9adc1fcf-8b10-4dbc-af58-9658347975fe">14,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf575c6968d644f098e6c4cd687f9282_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMS00LTEtMS0yOTcyNg_ee6aae14-86a6-4bc3-9a91-ee18e8bc5cfb">12,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4feb8a8b5d184238a0d534cd46a60f1b_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMS02LTEtMS0yOTcyNg_0d40d75c-f5fb-4e1a-b1ef-06fd35959826">10,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia95a87c453d545bd97f71c7a6e370768_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMS04LTEtMS0yOTcyNg_a95e436e-6a49-4ebd-8332-d767903524cb">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idf575c6968d644f098e6c4cd687f9282_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMS0xMC0xLTEtMjk3MjY_f51806a6-fdd1-4122-869a-714f2364f6ca">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b56ab9b20b540b0827829a4d1b8215c_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMy0yLTEtMS0yOTcyNg_b9fa0591-857e-4b53-860f-7260abfdab82">3,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7815787e2f468c9ad07ae016d7952f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMy00LTEtMS0yOTcyNg_b4ade27f-18cb-4f05-902e-933d4b503a8a">2,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f9d60e84a26463286cb9128b46e9bf0_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMy02LTEtMS0yOTcyNg_ee298e86-8164-4c82-ab05-385cef7abeeb">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b56ab9b20b540b0827829a4d1b8215c_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMy04LTEtMS0yOTcyNg_98e595ac-4cb9-424b-a692-2f91d3a16efd">42.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icf7815787e2f468c9ad07ae016d7952f_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMy0xMC0xLTEtMjk3MjY_7887487f-0341-4c17-ad9a-81052bfbe63d">42.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e6ad08ba3564fa58b0dd76578714f7c_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNC0yLTEtMS0yOTcyNg_29a79e00-b5fb-4386-9f61-dbce539b1118">2,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb9d9b491866496f84b91c1509866032_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNC00LTEtMS0yOTcyNg_8eb01cc4-3199-48b1-ba81-29081518aaed">1,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30dae1e51bed48feafdb469324840549_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNC02LTEtMS0yOTcyNg_94ec6bf3-8988-43c0-a215-f5a995ddf708">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7e6ad08ba3564fa58b0dd76578714f7c_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNC04LTEtMS0yOTcyNg_271c648c-1a92-4721-9aaf-2ff96db8b4ee">45.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb9d9b491866496f84b91c1509866032_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNC0xMC0xLTEtMjk3MjY_39fd9069-46fc-4303-b843-8ed1137846d2">36.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ea090a5dab4707b69bb4be8924ab82_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNS0yLTEtMS0yOTcyNg_0e472c88-9dc0-47f0-95d3-3c5b17bef2b6">6,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e6f8b6cb1d43a5be16680ce48b6661_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNS00LTEtMS0yOTcyNg_3289f7aa-33ce-4140-a3e7-377b3a0dc892">4,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ecec90ffdef42469fcadfbe71238277_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNS02LTEtMS0yOTcyNg_ad5cc596-eebf-445b-93fa-1ae3bb6ec70f">2,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08ea090a5dab4707b69bb4be8924ab82_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNS04LTEtMS0yOTcyNg_64a2e269-e20b-4d06-a18d-86df305a2d52">43.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i40e6f8b6cb1d43a5be16680ce48b6661_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNS0xMC0xLTEtMjk3MjY_b5b80726-17a5-4f94-87e7-f26a9ba58723">39.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3085b2c60dfb4078a65276bee9eeeb4f_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNy0yLTEtMS0yOTcyNg_8ed508a6-42a9-497c-95fb-173cee7304e5">813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f25409391b04e50bb4df4caaef16032_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNy00LTEtMS0yOTcyNg_28c5dc34-424e-45b4-bd21-c33512ccd2a0">583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0083624867b449aeaf811f3a98d73be4_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNy02LTEtMS0yOTcyNg_3a5c12a8-a122-40e8-8e8d-7f4e36d67ab5">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3085b2c60dfb4078a65276bee9eeeb4f_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNy04LTEtMS0yOTcyNg_ba181cdb-b71c-4cc8-97bc-14f3a4967160">39.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f25409391b04e50bb4df4caaef16032_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNy0xMC0xLTEtMjk3MjY_ec71af30-d8b0-4412-a24b-39c18d7ccb87">96.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84eb225252644245a3b20653e29a4713_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwOC0yLTEtMS0yOTcyNg_309f13e9-08b4-4d00-abff-a4edde592fcb">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855fb40e563f4b2f99bad8082fb5326e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwOC00LTEtMS0yOTcyNg_9fe058b8-84d0-4abc-944b-56a695f0b085">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f5f8e7f36e4be19b1b70e62c43a23a_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwOC02LTEtMS0yOTcyNg_dddcd9c6-f806-4212-835d-067ac4be4882">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* *</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb5c6e054854c3fb2c00e7bcc0e2daa_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwOS0yLTEtMS0yOTcyNg_f8e8c00d-8827-4ed5-94c8-c9c88ab065fe">1,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416100c083414a9baae7c6d73ede58a3_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwOS00LTEtMS0yOTcyNg_bea6771e-a851-4d20-9a23-b9344284692c">760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f73cee4bf7345c49d627dffc1663c72_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwOS02LTEtMS0yOTcyNg_c77b0cb6-0174-4dca-8f07-efa8fdd6627c">332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9fb5c6e054854c3fb2c00e7bcc0e2daa_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwOS04LTEtMS0yOTcyNg_e5c60c9b-93ab-4e2a-b62b-e6cf13cbb7d1">70.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* *</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26ad055634a14d8ab152b50284444586_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMS0yLTEtMS0yOTcyNg_f947c3e5-4b41-4c85-9ac5-25c950eb7c29">1,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaf78fa003384e408fb12bf4bd5f741e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMS00LTEtMS0yOTcyNg_b1a233e9-1cd6-4e84-adee-1b1da3f37fb5">1,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bc205f26e72447cb7d40dbcea60293e_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMS02LTEtMS0yOTcyNg_ad5fbc1d-c0ec-4e46-8e16-9a45ac2fbc6f">1,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i26ad055634a14d8ab152b50284444586_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMS04LTEtMS0yOTcyNg_5ce260d4-0dc7-422c-9bdc-578601701731">4.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaaf78fa003384e408fb12bf4bd5f741e_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMS0xMC0xLTEtMjk3MjY_348e43f6-c858-4ae1-998c-b0a57dc2842f">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69934e81fab444219448ad5bb5307afa_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMi0yLTEtMS0yOTcyNg_5cffec84-18a8-4bc5-ba71-d103a1ae6b90">2,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife0fe4d393c848648fc39692c666de5d_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMi00LTEtMS0yOTcyNg_8850c4a7-fbd6-4dd0-aaea-71506536fe99">2,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b8d232b64864d51b020808f0bad00c3_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMi02LTEtMS0yOTcyNg_42a85892-d7e7-45d2-b7f9-b35bdd0865db">1,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69934e81fab444219448ad5bb5307afa_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMi04LTEtMS0yOTcyNg_ccbf2ce0-df07-4bf6-8f8c-ced399eca26d">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife0fe4d393c848648fc39692c666de5d_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMi0xMC0xLTEtMjk3MjY_bd71d8bb-8f29-4902-b740-8ea780f5cb43">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib916361cb7fa43a59ebd580516312c23_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMy0yLTEtMS0yOTcyNg_9bbfc46f-9eaa-4835-85d4-afd73e0b3565">4,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7977fec0d5a6435aa250b1252dbcb344_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMy00LTEtMS0yOTcyNg_e0d3d006-8d5f-45b3-853e-97b62fc197ea">4,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i508045fb141245bebe09d1c312027357_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMy02LTEtMS0yOTcyNg_a0399181-3c3f-42d1-96ed-6afeed111c96">3,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib916361cb7fa43a59ebd580516312c23_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMy04LTEtMS0yOTcyNg_1ccfbf43-a510-4d1f-b7c7-5ff247fb1054">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7977fec0d5a6435aa250b1252dbcb344_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMy0xMC0xLTEtMjk3MjY_86a7b048-e91f-4c57-9c77-a2042c815093">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2492cd00dc6a41f19230bb05436b06c3_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExOS0yLTEtMS0yOTcyNg_bd6f2957-2d47-4f9a-892b-c04f48d97b5f">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb3e5d251b9a41f0974af3234b4d0c1e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExOS00LTEtMS0yOTcyNg_c79d81b9-d03c-4725-888a-abce155eb2c7">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d5d82a3078b4b23af81af36ccc607cc_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExOS02LTEtMS0yOTcyNg_d78e8f67-53af-41e9-af1b-2311301aaf56">810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2492cd00dc6a41f19230bb05436b06c3_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExOS04LTEtMS0yOTcyNg_372f1432-7d46-4b5b-8b9d-fe94aa1154e5">68.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idb3e5d251b9a41f0974af3234b4d0c1e_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExOS0xMC0xLTEtMjk3MjY_fd7bb53d-0503-4221-8d1f-404b2bfe45f1">54.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c61c8c074234f0789152b71643a576c_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMC0yLTEtMS0yOTcyNg_a3a26551-599a-402d-b642-fabb43704941">2,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64bb03a2c1e24381b5b0b4ede7a5b34b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMC00LTEtMS0yOTcyNg_b7e3de17-4691-4b5f-b66e-921dcecc075f">2,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ba710a9effd497494383ecca075e6ba_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMC02LTEtMS0yOTcyNg_0d3efaab-33a3-434f-ac3a-9d557bdaa8e8">1,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c61c8c074234f0789152b71643a576c_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMC04LTEtMS0yOTcyNg_58d2c0e9-ae65-4f50-b81d-227411bb331a">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i64bb03a2c1e24381b5b0b4ede7a5b34b_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMC0xMC0xLTEtMjk3MjY_362ea968-0abf-4913-913a-5413807f98b6">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacd5e055a14f4fb6a23943dca90aaf64_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMS0yLTEtMS0yOTcyNg_e420336a-6470-48cf-952a-b37fde2ef414">2,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id445257ea7744bfd9a8983407adc2143_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMS00LTEtMS0yOTcyNg_1c6ab187-4c00-45df-b99b-2ca258680806">2,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia936a49b95f0497a8473b15cdbbce2ae_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMS02LTEtMS0yOTcyNg_07b8e4fc-4b55-45fc-80f3-8e23e561bd61">2,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iacd5e055a14f4fb6a23943dca90aaf64_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMS04LTEtMS0yOTcyNg_2bb91847-b923-4052-9a43-81555ee9a477">7.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id445257ea7744bfd9a8983407adc2143_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMS0xMC0xLTEtMjk3MjY_9ecfebba-b832-41d4-9046-26ad579d700b">11.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec35270655784d61a34b51b61a34c955_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNC0yLTEtMS0yOTcyNg_85995fb3-e265-4f46-a32b-da6e242fa9ba">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e5cdc0c9e3484eb182d85a7402eb77_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNC00LTEtMS0yOTcyNg_88c3ab5e-c579-4b42-a505-1c2cadcbfcfc">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd1c0392a134aa99e761b2f95847293_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNC02LTEtMS0yOTcyNg_deea1f0c-c0ca-4a35-bfe9-a58c31c84134">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iec35270655784d61a34b51b61a34c955_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNC04LTEtMS0yOTcyNg_beffdc99-0df6-4065-8fae-49c416675847">31.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i97e5cdc0c9e3484eb182d85a7402eb77_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNC0xMC0xLTEtMjk3MjY_c2487e6e-bed1-4126-b94b-27a0f18fb9ee">18.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9318604febe14a94af81eecc0a785bb1_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNS0yLTEtMS0yOTcyNg_65c19d7c-dd70-42d8-b919-554b444a80ad">458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if25ceca79c15413b8f30df32f846e465_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNS00LTEtMS0yOTcyNg_209bbd6c-a5ae-479f-8271-6b5b7dfa1b38">738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9ac0f5fe82940299f1a331d5d44bd02_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNS02LTEtMS0yOTcyNg_eb55912e-6bd1-43a9-b5da-d48c719965ab">1,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9318604febe14a94af81eecc0a785bb1_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNS04LTEtMS0yOTcyNg_90f2ea15-f61b-4791-a5e8-ed41705d93d4">37.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if25ceca79c15413b8f30df32f846e465_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNS0xMC0xLTEtMjk3MjY_1e7e2357-d9d6-423e-a62b-25c1ab876012">32.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4829eb8419034125807a23e98d8ee355_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNi0yLTEtMS0yOTcyNg_1ac4b0ce-797c-4780-9a04-87728672197c">568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43084feb39e24663ad525e292889d8d8_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNi00LTEtMS0yOTcyNg_7314646f-bed8-467f-924f-d3395df8d4ad">821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09244b74cab94aa2a7ad31bd955792cc_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNi02LTEtMS0yOTcyNg_72e0ad17-92df-43b1-988a-889295ec11b4">1,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4829eb8419034125807a23e98d8ee355_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNi04LTEtMS0yOTcyNg_7946db24-42ed-4cbf-b72e-9f1211b018ab">30.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i43084feb39e24663ad525e292889d8d8_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNi0xMC0xLTEtMjk3MjY_dea27c80-0047-4457-930f-62dfdd188318">29.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><ix:continuation id="i62f5d7d64cf74a90a733191e167f6d4d" continuedAt="i5a34b452f68841279043343721f484bf"><ix:continuation id="i1ba8055d178e457ebf6f20c70e090489" continuedAt="i6cce5a361f4847a589e249c0bbfc7b71"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:34.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b994b9bb38d4894bcf7722b7dd244de_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyOS0yLTEtMS0yOTcyNg_b81ad496-40ae-4f85-805b-a7d53c91f1ba">2,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07925528b3644a4e9e4ed3e3b71c3c9d_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyOS00LTEtMS0yOTcyNg_e9b476bd-0124-4ddf-9ab1-13f29ad2f5fb">2,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5efd22e32d44db38c958a3060f57dba_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyOS02LTEtMS0yOTcyNg_7866a412-590f-4e35-b6ad-e6cbaed4ba0d">1,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b994b9bb38d4894bcf7722b7dd244de_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyOS04LTEtMS0yOTcyNg_08ca7de5-5072-4ba2-9069-235ae425e9af">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07925528b3644a4e9e4ed3e3b71c3c9d_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyOS0xMC0xLTEtMjk3MjY_7eccf52f-1ee1-40b4-8bc1-02adfbc56172">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d7442d0ab6421c845a0cfc7bee4bef_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMC0yLTEtMS0yOTcyNg_1b5d6ea5-b558-476d-aec1-0cb68c9539ac">1,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie18c8a66affb47e294a84056ff86c0fb_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMC00LTEtMS0yOTcyNg_98e309a3-71ad-4463-ae51-ab81d2ae2711">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i271b0b2860ef4bc48fe0bb5645096466_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMC02LTEtMS0yOTcyNg_d53aa066-6ac2-4bba-b900-cb12f342dfea">939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i87d7442d0ab6421c845a0cfc7bee4bef_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMC04LTEtMS0yOTcyNg_24b78292-29d0-4562-8017-e28b77ec09fe">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie18c8a66affb47e294a84056ff86c0fb_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMC0xMC0xLTEtMjk3MjY_f104f663-8579-447f-9c7b-f2c96fcfdd37">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16bab441088648eeac5e89da18478b3d_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMS0yLTEtMS0yOTcyNg_d52cf378-cc57-48b9-bfbe-5a58b45e5a69">3,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i281b34eb0d124b8090359d19f5649c26_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMS00LTEtMS0yOTcyNg_1130b53f-c63f-47ea-bf14-9b5b8444b310">3,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21c2f4162852419f9469e508c07e9f59_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMS02LTEtMS0yOTcyNg_0de5b095-5793-4dff-b174-9e95dc860e47">2,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i16bab441088648eeac5e89da18478b3d_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMS04LTEtMS0yOTcyNg_57a68f4b-baa3-4098-b0a8-89e967e9237c">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i281b34eb0d124b8090359d19f5649c26_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMS0xMC0xLTEtMjk3MjY_704ee6a6-1be4-4165-936c-41fe68c4998f">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bdc57ec26d64526a8a02e0b5eefbdce_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMy0yLTEtMS0yOTcyNg_693707a2-a1ae-483c-962e-52f1e90f0dec">1,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75393431ba4b43ec999c0c626b97a85a_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMy00LTEtMS0yOTcyNg_27969005-22bc-43a5-a4fe-347041f9cee9">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24ed0f45654143e7bd119e8dba14a248_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMy02LTEtMS0yOTcyNg_e912b466-5540-44aa-a68e-39c6378a0b06">766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7bdc57ec26d64526a8a02e0b5eefbdce_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMy04LTEtMS0yOTcyNg_f7389ab8-5259-446a-b874-bff6838cd379">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i75393431ba4b43ec999c0c626b97a85a_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMy0xMC0xLTEtMjk3MjY_623370a4-8eae-43a5-aac1-8459b47d38a5">31.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00781dd599394b27a4548a96fdf47dcd_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNC0yLTEtMS0yOTcyNg_d7592a23-36fb-4d36-a1db-5f4ff3328247">672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5285c14317334dcdb114e8f542b05e55_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNC00LTEtMS0yOTcyNg_99934777-4de8-4ada-acbb-459daddc3e24">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0142ba4580f9403e859c146d50423865_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNC02LTEtMS0yOTcyNg_7822a9f9-10e5-43bb-90c3-29549c5ad0ba">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00781dd599394b27a4548a96fdf47dcd_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNC04LTEtMS0yOTcyNg_d8301771-a704-4a93-aec3-0e11610536b4">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5285c14317334dcdb114e8f542b05e55_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNC0xMC0xLTEtMjk3MjY_6140a102-a872-45f4-9003-2a3ab5317520">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c0c0ffc4f67453684f177809b84b6d1_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNS0yLTEtMS0yOTcyNg_674cec9c-d215-4791-beaf-e872c25cb628">1,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i603a5b11ffb34e64b886e811464da6d1_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNS00LTEtMS0yOTcyNg_4791ccb8-0035-45da-bd93-2a499c457e98">1,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33e35fd935b449cd87da860775063b45_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNS02LTEtMS0yOTcyNg_1a303e10-da5f-4057-81ba-e82ce0b31085">1,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c0c0ffc4f67453684f177809b84b6d1_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNS04LTEtMS0yOTcyNg_3a5e9b4c-882b-4956-aecf-63739f3ac755">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i603a5b11ffb34e64b886e811464da6d1_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNS0xMC0xLTEtMjk3MjY_1ade08a9-971d-4caa-b726-dea90bbe4999">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff8555c708a43078ad2afecb67d66e6_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNy0yLTEtMS0yOTcyNg_551ef3c4-36df-4934-995d-10117132ba6b">1,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766c492cc7c9493e81c043bab5ce0792_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNy00LTEtMS0yOTcyNg_5c767f94-21c1-45f5-b135-e63231dd3624">955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63014d356cf948fb90cbd74710d1a00f_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNy02LTEtMS0yOTcyNg_e30da035-4708-434f-8fd2-4b586548df41">714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icff8555c708a43078ad2afecb67d66e6_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNy04LTEtMS0yOTcyNg_bca1acce-d543-45f4-8717-183a84237198">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i766c492cc7c9493e81c043bab5ce0792_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNy0xMC0xLTEtMjk3MjY_e0890856-7e5f-4daf-aabc-95ee2a09b61b">33.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c41d11433d64accb3db5ddb31b09a77_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOC0yLTEtMS0yOTcyNg_d7198975-0ff5-46e0-8245-2666ac25f8d1">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d1ffed8e4c846e99dc9439de4ed307b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOC00LTEtMS0yOTcyNg_4cc4b7eb-422b-4d0e-87d1-f0da8c929f7e">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7944381e57ad429a8fcb8c4561513ca1_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOC02LTEtMS0yOTcyNg_26882cf1-a323-4f17-9479-c7132d7fcf2c">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c41d11433d64accb3db5ddb31b09a77_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOC04LTEtMS0yOTcyNg_895c8e24-fa3b-45b4-b84b-7424874a74df">31.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6d1ffed8e4c846e99dc9439de4ed307b_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOC0xMC0xLTEtMjk3MjY_aceffb59-026a-4a73-a9fb-50ba4a314fcd">30.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44edb1d49d2f465e924c4e1e880b74a1_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOS0yLTEtMS0yOTcyNg_a7b7609c-dcd2-4fa8-971c-717e545a5039">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c87e25c87c4e1a9a1aaed707a48369_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOS00LTEtMS0yOTcyNg_f678beca-7862-4b87-be38-22f135328b2a">1,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3120cc75a64c70b1146e4c34e24ae6_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOS02LTEtMS0yOTcyNg_586fbe34-d030-48b6-a449-a1a714eab65c">819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i44edb1d49d2f465e924c4e1e880b74a1_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOS04LTEtMS0yOTcyNg_a6d80ee6-7b4c-44c5-9e81-92a866534a35">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i57c87e25c87c4e1a9a1aaed707a48369_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOS0xMC0xLTEtMjk3MjY_87ff2297-2815-4ff0-94ba-fe33c6431d39">33.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3dd0bb1f6a24599b7fae40ad2e6e3a1_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0MS0yLTEtMS0yOTcyNg_c4317430-5a60-4f2d-b7f9-6548979d83ed">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5969e842241246218b535a59d92380f8_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0MS00LTEtMS0yOTcyNg_4cc6e5f5-8094-41bc-8ae3-f2facda71edd">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4064a0928a04ccbbdd9885f05ec28ca_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0MS02LTEtMS0yOTcyNg_68db0da7-ced0-4f56-b48a-f8ca6ca80867">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if3dd0bb1f6a24599b7fae40ad2e6e3a1_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0MS04LTEtMS0yOTcyNg_ba48f0db-391e-4cd2-9517-36910cfcc87e">3.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5969e842241246218b535a59d92380f8_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0MS0xMC0xLTEtMjk3MjY_8189d2eb-112f-45b7-8243-d3d3a1c71e31">17.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd90a7b4fb61410a89aeeeaaa41f4305_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Mi0yLTEtMS0yOTcyNg_5ca4d565-3c0f-4d5c-ac3c-0bf3dbc0bc0c">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ff91543c3e8429f958c8e05d94d0522_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Mi00LTEtMS0yOTcyNg_74d01f68-ed60-4148-b0b5-fd8a9915932d">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93d13747093f4c91ad73a481a62db2a5_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Mi02LTEtMS0yOTcyNg_3fc643ca-3a94-4f7a-85cc-2c944a8d28e7">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idd90a7b4fb61410a89aeeeaaa41f4305_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Mi04LTEtMS0yOTcyNg_7ce5206f-bbed-41de-9aa4-c2d532b16091">5.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3ff91543c3e8429f958c8e05d94d0522_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Mi0xMC0xLTEtMjk3MjY_3e317f15-a471-4c20-9aed-1c4ee63d6b09">9.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic61250cfcef0490b8e1042b72907be02_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0My0yLTEtMS0yOTcyNg_e1fd5ff6-f7ca-4afc-8fc4-b10511231ca7">395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19796a0c1cd4f1b8e7233548fdde432_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0My00LTEtMS0yOTcyNg_42635171-71fc-4b96-a1cc-71fbf4b5ecdf">416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1a20fa60764b468728eb227dfcf93f_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0My02LTEtMS0yOTcyNg_44e7a7ed-dc0e-42bf-9836-39143f63280f">476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic61250cfcef0490b8e1042b72907be02_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0My04LTEtMS0yOTcyNg_6c10bb3f-a329-49aa-abdc-442d20a33fcd">5.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if19796a0c1cd4f1b8e7233548fdde432_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0My0xMC0xLTEtMjk3MjY_ab642f52-6578-4a7a-ae97-093c5344746e">12.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaab1d242f57c4857bc07508d3fef7f57_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0NS0yLTEtMS0yOTcyNg_df2f0804-f229-4bac-8091-d5a971698d23">3,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675381e27e8e4f8c92cf3dee1a9f85e1_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0NS00LTEtMS0yOTcyNg_a49d1867-59f4-4a14-bc9e-c9111154eb95">3,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c624bba8b9c43b0aff6e81143910b91_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0NS02LTEtMS0yOTcyNg_40626360-7d17-449f-a2f2-e3812bc79c46">3,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iaab1d242f57c4857bc07508d3fef7f57_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0NS04LTEtMS0yOTcyNg_2b006191-ae79-40da-ab7f-07543be91cf4">9.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i675381e27e8e4f8c92cf3dee1a9f85e1_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0NS0xMC0xLTEtMjk3MjY_863da83a-8f87-4db0-8571-570e20321bf2">6.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4abe8cd280bc4dc38415f6a54595a59e_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ni0yLTEtMS0yOTcyNg_093fdcdc-a6b6-4334-94c2-4d4962118cfa">1,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c16bc456bd940bb901d164807f45809_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ni00LTEtMS0yOTcyNg_2d0cbc26-0c85-4698-9d7c-2be61a150fe2">1,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5243c3d264ac40d09b1366108f2813a5_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ni02LTEtMS0yOTcyNg_d6ed486d-7cd2-4087-a093-63b4b44767a5">1,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4abe8cd280bc4dc38415f6a54595a59e_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ni04LTEtMS0yOTcyNg_e971c30a-dee8-463a-b24d-b1626840fd3f">7.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5c16bc456bd940bb901d164807f45809_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ni0xMC0xLTEtMjk3MjY_e90c0398-2530-4689-bb13-57b996c29ce1">6.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297695ea47c64a8ab41165f4e8cd24ca_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ny0yLTEtMS0yOTcyNg_a7d95de3-b17e-43b3-9195-b6a6d213e00e">4,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09d261dd66bc4a6fa3474295db120684_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ny00LTEtMS0yOTcyNg_7301a3c9-943d-40c5-bb3d-bbed5e69ed02">4,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6585c5f17b5243029be20ef4718f4ea1_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ny02LTEtMS0yOTcyNg_178478cc-36fb-4cea-a425-0cf2989f0802">5,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i297695ea47c64a8ab41165f4e8cd24ca_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ny04LTEtMS0yOTcyNg_b8128353-fcf6-4eee-9d94-dedfb1df8aad">8.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i09d261dd66bc4a6fa3474295db120684_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ny0xMC0xLTEtMjk3MjY_1e959de1-c464-4498-b837-48e09d4abd4a">6.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84ccf738ed9a45f9bbe93e37729899b0_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0OS0yLTEtMS0yOTcyNg_295718b7-812f-4b02-b628-2ef725df8c50">2,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i211d1d903be349e7b8c4d90c4d8e7ea8_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0OS00LTEtMS0yOTcyNg_613ee501-a58b-4837-ad52-54f175224563">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic41939995d744557b2fadc86190eb309_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0OS02LTEtMS0yOTcyNg_5b0bb66b-8966-443c-b6ab-dee945a6f75e">2,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i84ccf738ed9a45f9bbe93e37729899b0_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0OS04LTEtMS0yOTcyNg_1025763c-bc8b-4402-909b-142faad4ece5">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i211d1d903be349e7b8c4d90c4d8e7ea8_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0OS0xMC0xLTEtMjk3MjY_e4eaf273-ed6d-40cb-89ae-77c5481e2f50">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59cfc473af604a8da15221699e4b413a_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MC0yLTEtMS0yOTcyNg_ebfaece3-dfbe-4929-903e-db5966da7f62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b7e2f978c5475796d2aeac43f69af0_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MC00LTEtMS0yOTcyNg_1c4ba13a-d3f5-4b5e-b834-5d90279bb5a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i258c4fd8ba0447d5964abdb213044818_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MC02LTEtMS0yOTcyNg_564810bc-3692-4d3b-81b4-ad4eb951df9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i59cfc473af604a8da15221699e4b413a_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MC04LTEtMS0yOTcyNg_142b0381-6770-441f-b7d2-04b66b014faa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i67b7e2f978c5475796d2aeac43f69af0_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MC0xMC0xLTEtMjk3MjY_e39249c4-fbf2-4730-9bdd-1cfa3ce59841">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e04698c0f76437fa764204c1042ea2a_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MS0yLTEtMS0yOTcyNg_994d3298-fea8-433a-979a-23fa862f57fc">2,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15858ed4ab2a40ba98560ad9c345f601_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MS00LTEtMS0yOTcyNg_78c15a31-0065-46b2-885f-81bdc6f6346e">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d2d7a4b4074a02adf791b11dbeea4b_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MS02LTEtMS0yOTcyNg_6896af98-4be0-4908-adc9-d410a4183c0d">2,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e04698c0f76437fa764204c1042ea2a_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MS04LTEtMS0yOTcyNg_ed6cabc8-c4da-4aef-b8df-e0a44ed81833">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15858ed4ab2a40ba98560ad9c345f601_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MS0xMC0xLTEtMjk3MjY_e703709c-37c7-400b-a3c9-33a761caffe2">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cb15999bd6c4c56a5291296be65bdc9_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1My0yLTEtMS0yOTcyNg_7fbd1991-ddad-4297-a2c4-385682dad36b">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic841ebde283e4fe69105c52901291b20_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1My00LTEtMS0yOTcyNg_92cf4868-ea04-40a2-ada3-5cfe9ab81f6e">564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ed18e2587674e6bb9e55bb50d6174e6_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1My02LTEtMS0yOTcyNg_372d8da0-8319-45c1-ab2d-c4fb80833eb6">536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9cb15999bd6c4c56a5291296be65bdc9_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1My04LTEtMS0yOTcyNg_e32976c9-ebec-4618-9a51-63de559982fa">45.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic841ebde283e4fe69105c52901291b20_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1My0xMC0xLTEtMjk3MjY_3c86680d-67e9-4c2c-bfa8-1df98bbaa145">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ebc2042874040a2b7bab4e67bea27e1_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NC0yLTEtMS0yOTcyNg_12155ad6-2632-49a6-b40c-89c49e65e2f8">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1242f0ab963e4cdebfae1b38000d1c0e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NC00LTEtMS0yOTcyNg_8cce744b-817d-459e-9024-895aa7ddfe6b">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88046ddeac01478aae7aa3b6fd4cd0f2_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NC02LTEtMS0yOTcyNg_aee5f8be-617d-4504-aece-adad6a5c9e72">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ebc2042874040a2b7bab4e67bea27e1_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NC04LTEtMS0yOTcyNg_2748b65e-74ad-4a0d-b6f6-bc44128da82e">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1242f0ab963e4cdebfae1b38000d1c0e_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NC0xMC0xLTEtMjk3MjY_dde90bbf-de5b-4759-bc10-d704d5754b8f">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fd4aec56fe4857881bc9ca6e2ebc28_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NS0yLTEtMS0yOTcyNg_e5a7dae9-6027-4f46-ac99-e5341792cea6">563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f3a036d977f4825a3d6b45499f1bf73_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NS00LTEtMS0yOTcyNg_beb57644-95ec-4591-b98c-b2415e8236d7">795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i545bab733e4f449cafdf90c3798807d7_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NS02LTEtMS0yOTcyNg_50482c29-2a32-4237-be9a-d0dd3217f66d">735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib6fd4aec56fe4857881bc9ca6e2ebc28_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NS04LTEtMS0yOTcyNg_f4d789a9-72d5-4f51-b1f1-ccc34af7a343">29.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f3a036d977f4825a3d6b45499f1bf73_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NS0xMC0xLTEtMjk3MjY_5d489ef6-a787-4311-b2fb-3c0acb3647bc">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a2648c41e074ca5a9b6e8509a34ba69_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1Ny0yLTEtMS0yOTcyNg_86300d24-eaa8-4f7d-9b6f-67092b8e26b1">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida37c995a07f44bdb1293caa0b49b88f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1Ny00LTEtMS0yOTcyNg_072af17b-379d-4081-94c0-d90d9d0a88ab">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830c2e05cc524c80a9769de9a4ecc07f_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1Ny02LTEtMS0yOTcyNg_cbbfbe88-bd2d-45fe-ab69-58d74a69a78b">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9a2648c41e074ca5a9b6e8509a34ba69_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1Ny04LTEtMS0yOTcyNg_20f58b29-ed40-448d-b507-e7d4b4827154">19.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ida37c995a07f44bdb1293caa0b49b88f_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1Ny0xMC0xLTEtMjk3MjY_58355704-d6ec-4a80-9fb6-240343b2f543">45.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a015a3eee243aaba77cfdb4761746f_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OC0yLTEtMS0yOTcyNg_cee67b53-4701-4c24-bc1c-a030db8f003e">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib761e394f720484e86bb1215c1c4a5d7_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OC00LTEtMS0yOTcyNg_43b18815-8c8a-4f44-8263-dbb28875200f">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i128f3aaa257a46b78b36a2dfb202715e_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OC02LTEtMS0yOTcyNg_ef972f83-fc8f-4271-87bf-6878b4713183">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i65a015a3eee243aaba77cfdb4761746f_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OC04LTEtMS0yOTcyNg_e13f2d96-7068-4c3f-9ddc-36a1966ebb55">6.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib761e394f720484e86bb1215c1c4a5d7_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OC0xMC0xLTEtMjk3MjY_7fc15e77-021e-4268-b485-f38d9a19c8eb">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876ae032ad75425dbf80231e9170bcbc_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OS0yLTEtMS0yOTcyNg_bfe2359e-9c16-44d3-ac9b-88dafcae635b">479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7ab917ab8b04eda955e8203c8814bad_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OS00LTEtMS0yOTcyNg_2909cf13-6a24-42ed-9773-2256ca6ad16e">552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de6312edbab4fc1b98af49b4891a217_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OS02LTEtMS0yOTcyNg_efa18d65-f535-4ffe-807d-19ee64ec62fe">790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i876ae032ad75425dbf80231e9170bcbc_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OS04LTEtMS0yOTcyNg_486c92a7-a3c2-4383-a4d3-e422de9a53c3">13.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic7ab917ab8b04eda955e8203c8814bad_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OS0xMC0xLTEtMjk3MjY_6c7ab4e9-1bc7-41ce-b100-1d0eb99641a1">30.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ad086a689a4494b8f7603e98b20bf80_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2MS0yLTEtMS0yOTcyNg_1f6c3c91-255f-4b87-a293-6c3e3af0a009">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf56df821a7c433d8bce9033b393786f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2MS00LTEtMS0yOTcyNg_9cf6c5c0-a928-41a8-ba82-1edc0b0b05b9">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia277734b806943c9a73e6ecb6dbe0eef_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2MS02LTEtMS0yOTcyNg_b529aad4-bcd5-48c4-967b-c26ba6254fe2">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8ad086a689a4494b8f7603e98b20bf80_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2MS04LTEtMS0yOTcyNg_ac310779-0739-49cf-acde-4cebb48eed5c">31.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iaf56df821a7c433d8bce9033b393786f_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2MS0xMC0xLTEtMjk3MjY_cb7f0a56-1253-464f-abaf-f788cc7d7c70">15.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1daa11474a049bdaebda77832fe66e0_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Mi0yLTEtMS0yOTcyNg_ee55cb24-f7e4-4a35-9c37-cc0e9f0f0d4b">758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e24ec61f60841539515b9dad3105f4d_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Mi00LTEtMS0yOTcyNg_c9eb20fc-fc53-4c61-98af-1790bd0ff0a6">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b6cac63b0c4cb4af1c8513a38855bd_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Mi02LTEtMS0yOTcyNg_b14974ba-474a-4702-ba77-57c39e6e02a2">974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id1daa11474a049bdaebda77832fe66e0_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Mi04LTEtMS0yOTcyNg_7d67e279-dcb3-480b-bffe-05fb8ec595ec">12.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4e24ec61f60841539515b9dad3105f4d_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Mi0xMC0xLTEtMjk3MjY_1ae546ec-4695-4a3c-a6f9-55dce7e61b27">11.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f3da552d44fe9c15d7efd001a255_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2My0yLTEtMS0yOTcyNg_94e1cb4e-c9de-48a5-8006-b777e2662801">981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e6d423063d240c680e574f22c368d85_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2My00LTEtMS0yOTcyNg_bd5919c9-1fc1-4255-abee-396f705470a2">1,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39fe54bd882c4e64976ec42f3c86ea0d_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2My02LTEtMS0yOTcyNg_f0578e2d-db10-4b56-a0d0-7088237a1d9b">1,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9df7f3da552d44fe9c15d7efd001a255_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2My04LTEtMS0yOTcyNg_8d8fb542-70db-4dd9-9e62-58e2870bfe59">17.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7e6d423063d240c680e574f22c368d85_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2My0xMC0xLTEtMjk3MjY_361dbaa0-6df4-48a1-bb25-34c01d8c378a">12.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67be3029faf745a8adc9589c55128db4_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ni0yLTEtMS0yOTcyNg_c8201f05-c50e-476b-b4f6-b8b3d4a3ae0f">27,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9efd22575fd4bcfbf17627fcfa7cbd2_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ni00LTEtMS0yOTcyNg_2bacdcee-bcc1-49d9-87c4-6c70e8e481af">25,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i443b2dc23fbc4bb9b95e55dbe54d0032_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ni02LTEtMS0yOTcyNg_19e35242-1dd2-4e96-a40a-1aef9fe342e2">23,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i67be3029faf745a8adc9589c55128db4_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ni04LTEtMS0yOTcyNg_c3bd277d-3a17-4e1f-bc74-f6676940d52e">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib9efd22575fd4bcfbf17627fcfa7cbd2_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ni0xMC0xLTEtMjk3MjY_8c29b385-dfa8-44cc-9409-91873f26f525">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65dfeabf7bf04ff3b9e4a50912b6534e_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ny0yLTEtMS0yOTcyNg_a59ea948-309c-43ae-adfc-7e3cab0b8cc5">24,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if74ce695258e4192a81f8bd943d68de8_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ny00LTEtMS0yOTcyNg_f96b2083-8c59-4d77-acd0-5f1e1585cba7">19,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed80240aaab4a27988be21654755b5a_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ny02LTEtMS0yOTcyNg_1e5af828-9315-4a05-99c2-c05783d845fc">18,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i65dfeabf7bf04ff3b9e4a50912b6534e_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ny04LTEtMS0yOTcyNg_dc3735bb-bc8c-4616-8be6-c8b07bd60942">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if74ce695258e4192a81f8bd943d68de8_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ny0xMC0xLTEtMjk3MjY_ab65f66b-42fe-46f2-bf8d-6c3b7746f42f">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2OC0yLTEtMS0yOTcyNg_139633be-49db-4dd4-b9dc-6cb2b66fb433">52,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9f7770a07704889bef20acb8a0c5220_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2OC00LTEtMS0yOTcyNg_52d2d0ea-81b0-46de-aff3-a19be88ad744">45,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cf37c66bfb4ef5bce478f5333fb5df_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2OC02LTEtMS0yOTcyNg_f7d5ac07-52d3-4832-969f-b95be4a22567">42,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2OC04LTEtMS0yOTcyNg_24e21388-87d4-40bb-8afe-591db42ab87c">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9f7770a07704889bef20acb8a0c5220_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2OC0xMC0xLTEtMjk3MjY_47a590ac-81f2-4b80-95bb-a87de2213eb4">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:57pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><ix:continuation id="i5a34b452f68841279043343721f484bf" continuedAt="i246b7eb237324ec28b8e952a40024831"><ix:continuation id="i6cce5a361f4847a589e249c0bbfc7b71" continuedAt="i6fc8cf47c0364e71a171f44859c4192c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:34.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60ed8921747044c5a0cacb0bdbb61ee5_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4MS0yLTEtMS0yOTcyNg_30dcfa67-2107-4a99-a5bc-0b749011f6d1">1,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e5877a920f4ed5b8884f48704c60dd_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4MS00LTEtMS0yOTcyNg_54a589dd-6d44-4085-a2b5-12e2c1d40d4c">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d312ed9a008438aafe8e2616054ee50_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4MS02LTEtMS0yOTcyNg_abff8c5c-5422-4d62-88d5-f88ab828e9ba">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60ed8921747044c5a0cacb0bdbb61ee5_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4MS04LTEtMS0yOTcyNg_18d46887-af79-43b8-b84e-7d6845659b73">26.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14e5877a920f4ed5b8884f48704c60dd_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4MS0xMC0xLTEtMjk3MjY_483f51ee-eaaa-4033-8a03-773038c2ec23">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8a398a171a24a8498a76f0430bf01d8_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Mi0yLTEtMS0yOTcyNg_cd5a7e95-05b9-4659-9b68-08603130642e">2,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice5069a97d424275971a265d90db25f2_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Mi00LTEtMS0yOTcyNg_71eca803-140b-4002-93af-1a333141baf7">1,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6664751dc074f608b93f8348f757b2b_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Mi02LTEtMS0yOTcyNg_b6bdd993-79ec-477e-b85e-72b71bfeeed9">1,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib8a398a171a24a8498a76f0430bf01d8_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Mi04LTEtMS0yOTcyNg_5786a93c-b261-48f8-91f2-ed43f5a90ee1">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice5069a97d424275971a265d90db25f2_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Mi0xMC0xLTEtMjk3MjY_bf264f10-2c88-4681-8b04-7c0bffd562fb">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47511162d73d4b6d9f5256e85c7e0459_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4My0yLTEtMS0yOTcyNg_fdc415ae-9d9a-4bda-80da-ad33b70ffc50">3,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i643aacdc85d74fc88245ec3722a90e65_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4My00LTEtMS0yOTcyNg_460f9214-4f65-4011-8e5f-896a874ebb86">3,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0d5c2adced94c5db905a0ccc543024b_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4My02LTEtMS0yOTcyNg_a29490c1-a7e1-4b8c-9434-b7a0b8ceb07f">2,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i47511162d73d4b6d9f5256e85c7e0459_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4My04LTEtMS0yOTcyNg_7ac9564e-89c8-44fc-a848-a40a0912963a">30.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i643aacdc85d74fc88245ec3722a90e65_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4My0xMC0xLTEtMjk3MjY_bc9cfc8a-f9de-42ac-bec6-14201250ea21">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i636b39044d77475baa810025fccb74fc_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4NS0yLTEtMS0yOTcyNg_5189000e-63c1-42e9-84e1-f5b237eb89d2">5,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i106843425fe24320805510bfc4532f23_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4NS00LTEtMS0yOTcyNg_884bce91-6fad-4fdd-9d5e-48440d726d3a">4,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib806ab041535413685cecd33d2128890_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4NS02LTEtMS0yOTcyNg_633c53a9-d7bc-4c1b-9857-fd4b86320a1f">5,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i636b39044d77475baa810025fccb74fc_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4NS04LTEtMS0yOTcyNg_1fc166ba-48d4-4b20-8d0b-91d4ceeaa90d">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i106843425fe24320805510bfc4532f23_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4NS0xMC0xLTEtMjk3MjY_67c7675f-1d81-428b-84cd-02dca80f2537">10.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64dc60886f8947f0b033db2e2d716436_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ni0yLTEtMS0yOTcyNg_ba2e2494-a5bd-4785-9aaf-6963f99d5585">3,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie402bd95c7f249bcb616b6d175dbf07b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ni00LTEtMS0yOTcyNg_ab2abffa-89fd-4366-8934-2c545cee00db">2,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fa0825611594020b2fe056c0e4efae8_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ni02LTEtMS0yOTcyNg_68bd6f9e-d7f9-4fd1-9ac8-a351d574e237">3,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i64dc60886f8947f0b033db2e2d716436_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ni04LTEtMS0yOTcyNg_df6a5c53-ed61-42ee-9121-8b8a9a713f11">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie402bd95c7f249bcb616b6d175dbf07b_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ni0xMC0xLTEtMjk3MjY_18aa607a-10fe-44b9-a7f8-6026e3639f7f">15.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f0fac6b04c84b689a79771f385713c2_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ny0yLTEtMS0yOTcyNg_c54af3b3-f26b-4af7-a9e5-2dc2dcef2536">8,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816f338852d14f0fb2d6dfbdc728effd_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ny00LTEtMS0yOTcyNg_d22b034a-6132-49d9-bbdc-b41c82e18668">7,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46440e9fa084f209298e0c8b233ad13_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ny02LTEtMS0yOTcyNg_2a8946be-75fc-4249-a419-5274ee23083c">8,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f0fac6b04c84b689a79771f385713c2_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ny04LTEtMS0yOTcyNg_ceba8200-fa95-4ded-9717-c807ddfbcf1a">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i816f338852d14f0fb2d6dfbdc728effd_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ny0xMC0xLTEtMjk3MjY_1cd9e76e-bc93-47d0-bfc1-4aca8581e666">12.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e39d41add6463b9092b617f971b75f_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4OS0yLTEtMS0yOTcyNg_835718e0-e8eb-47fa-90da-c999a1374374">883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice66c64ac61048f19a21734cafb5097d_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4OS00LTEtMS0yOTcyNg_7e60c73c-f211-45a4-8dce-b356723c8828">793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib72662fc19e040589f8f2ec556ad1d4c_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4OS02LTEtMS0yOTcyNg_e4c2e36b-c108-418d-b521-183058106cf0">863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i51e39d41add6463b9092b617f971b75f_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4OS04LTEtMS0yOTcyNg_7969e9db-e2fd-471b-8df8-42ffb0e144d5">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ice66c64ac61048f19a21734cafb5097d_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4OS0xMC0xLTEtMjk3MjY_2f0a51d5-2d05-4bf3-ac90-c5c0c8f8bc1e">8.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75c9d64349fb47d0be110ff26bce965f_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MC0yLTEtMS0yOTcyNg_e1712eff-e963-4057-ac69-bc519cc25c97">602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d4d5a35e0264fa3a59ab55f6e08dc1b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MC00LTEtMS0yOTcyNg_8da6e4d1-814c-441e-83c6-531521ee5714">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dfb56f1cc3472b91d0ad823df8d237_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MC02LTEtMS0yOTcyNg_5982c2fa-03a8-431e-b2f3-1533a326134d">575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i75c9d64349fb47d0be110ff26bce965f_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MC04LTEtMS0yOTcyNg_0eccc706-8eaf-4461-8a77-08e24007f7d4">23.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3d4d5a35e0264fa3a59ab55f6e08dc1b_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MC0xMC0xLTEtMjk3MjY_0bfe9ee5-98fb-4274-9fa8-a93fa6153d01">15.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id20b1d22e77a4da4a5261a8d5004c3d7_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MS0yLTEtMS0yOTcyNg_a8d98535-832d-4f72-bd8f-9d7a7e4c8a05">1,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6ff7e9dc76409ab4354387f1f95d6e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MS00LTEtMS0yOTcyNg_8f641bba-3a9b-4ff8-9449-d2a416c1c955">1,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0f0d1cba3e4983876bb49c63f4d22f_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MS02LTEtMS0yOTcyNg_ab77930d-84ea-489d-833c-b1aee38e97ca">1,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id20b1d22e77a4da4a5261a8d5004c3d7_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MS04LTEtMS0yOTcyNg_9d0e9c15-dd96-4778-b385-20ac6221010a">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4a6ff7e9dc76409ab4354387f1f95d6e_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MS0xMC0xLTEtMjk3MjY_3d655d0b-ee99-4be1-9497-952d33842fea">11.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1865f77461f6431495acc8c63093e96f_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5My0yLTEtMS0yOTcyNg_844442ce-9152-4524-b1ee-5428a917cd85">787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie347616036fd4a74b6a373520ba980d7_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5My00LTEtMS0yOTcyNg_2c0445b3-0d7d-4898-bdb6-038e3a5053fa">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b643a5b78824e2497a25c62b3737d1e_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5My02LTEtMS0yOTcyNg_e3c4e1be-7c7d-425b-af7b-91b1690c3482">889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1865f77461f6431495acc8c63093e96f_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5My04LTEtMS0yOTcyNg_e8889806-102d-45b3-99c1-04c5ca06d4f2">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie347616036fd4a74b6a373520ba980d7_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5My0xMC0xLTEtMjk3MjY_54bb1241-386e-4266-be4f-c3110184fd5f">16.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7196fd596c74749bad40acfaea1b70a_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NC0yLTEtMS0yOTcyNg_571a59cf-40ad-4695-9620-91f91664cebc">538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64ccbb362945429fac924633eba5f320_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NC00LTEtMS0yOTcyNg_9f6c8de8-35ad-4af6-bc2a-70ed3f96f117">427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ce06e19cb740a191f99093f0e41f93_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NC02LTEtMS0yOTcyNg_274b5f65-065e-48b7-8ff3-80b576ddc110">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia7196fd596c74749bad40acfaea1b70a_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NC04LTEtMS0yOTcyNg_f37c3dea-176f-4a52-a4dd-235d625c321d">26.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i64ccbb362945429fac924633eba5f320_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NC0xMC0xLTEtMjk3MjY_106181c4-1895-466b-a8b2-aab1be9f23a7">27.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0420b48e154a40cd94667e4f7c079b72_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NS0yLTEtMS0yOTcyNg_55343f83-02ae-481b-a736-d1f770042790">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id844326b0acb41a7b4c00cb04e75dcc9_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NS00LTEtMS0yOTcyNg_8608464a-d7c8-47b3-ab33-571743c02874">1,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34d26533be64f5db220b79da72535d4_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NS02LTEtMS0yOTcyNg_4c43dc87-d1a5-4a06-b7b4-39cf7127e234">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0420b48e154a40cd94667e4f7c079b72_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NS04LTEtMS0yOTcyNg_e0728ea8-14c9-4c73-af4e-ad8e2c4f215f">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id844326b0acb41a7b4c00cb04e75dcc9_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NS0xMC0xLTEtMjk3MjY_3e31e5ef-cb8e-490f-a3f3-c51f966fea79">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e00c0c4a5a54349a215833e43d01f5c_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5Ny0yLTEtMS0yOTcyNg_66d3732e-e31f-451c-acd3-4a2cf922eaaf">1,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eac76a3b41a46829772c0e6030b7607_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5Ny00LTEtMS0yOTcyNg_eae2234a-25f0-4ae7-9aa5-eb17f6384172">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied4367d37c7141298cb4fdc3adef842d_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5Ny02LTEtMS0yOTcyNg_bb999bc2-350c-4558-b9ae-8ebc80d8a5a9">1,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e00c0c4a5a54349a215833e43d01f5c_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5Ny04LTEtMS0yOTcyNg_688e4c37-ac24-45fe-a37f-9b6a3800df14">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9eac76a3b41a46829772c0e6030b7607_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5Ny0xMC0xLTEtMjk3MjY_80f0e51d-3662-4045-a55d-989c043c5c75">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c3c76ed88d4612a15d8daf5874486b_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OC0yLTEtMS0yOTcyNg_852cd255-2a9a-4a78-89f8-c8d04f26ca32">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab9c0e490e5b409f818ad1fd0ba564a7_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OC00LTEtMS0yOTcyNg_a20cce70-c16a-4bde-bbcb-025340ce50a5">966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d8921ae00644e968ea3b39b44e5e6be_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OC02LTEtMS0yOTcyNg_8601a907-c23e-46f1-b040-e22024d484fd">1,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07c3c76ed88d4612a15d8daf5874486b_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OC04LTEtMS0yOTcyNg_f15f34b1-22e3-4ae6-a9a2-f3453bc54e40">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iab9c0e490e5b409f818ad1fd0ba564a7_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OC0xMC0xLTEtMjk3MjY_eea999b4-4d87-43ee-863e-0006cbe6ab62">9.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfdee030cbc49baadf91413f3bd72b9_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OS0yLTEtMS0yOTcyNg_f0d5c8f5-f7a3-4f7c-814d-99ce9c4acfc3">2,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1342fc470d44486822d04a68d8d00ec_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OS00LTEtMS0yOTcyNg_8508f165-971e-442d-bebe-59d55e25bfab">2,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b235e18a384746bae631a4c9642be1_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OS02LTEtMS0yOTcyNg_4a363290-6e3c-45a0-ae14-71643051798e">2,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9bfdee030cbc49baadf91413f3bd72b9_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OS04LTEtMS0yOTcyNg_26c434dd-55c0-404d-84af-fe268f485488">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie1342fc470d44486822d04a68d8d00ec_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OS0xMC0xLTEtMjk3MjY_b6ac5cf2-5a88-4e38-a57e-249b445537a7">3.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08aa391f2684371a6971aa72bb4521a_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMS0yLTEtMS0yOTcyNg_e5613b60-3134-441e-952e-b177d783f49a">1,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a86230afa1e4a6cad4c6e87b5261ff7_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMS00LTEtMS0yOTcyNg_599d56b7-94f2-43af-bf43-cf58db5aef26">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbe1f9d829d845418d0507a31d92c4d0_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMS02LTEtMS0yOTcyNg_6f48b106-7b53-4d21-a976-d0a62d6327ec">1,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id08aa391f2684371a6971aa72bb4521a_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMS04LTEtMS0yOTcyNg_e751a691-ba57-4fb4-94cb-8297daec9fa1">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9a86230afa1e4a6cad4c6e87b5261ff7_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMS0xMC0xLTEtMjk3MjY_3010fe84-29f3-4715-9cac-2c69a3286e08">16.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e3cb79b02940e3afc4af2a5a631cd9_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMi0yLTEtMS0yOTcyNg_a292322a-1d54-4a4b-ba8b-df33ff7f1914">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00778b10e5af4bc791d1e8bbdd2bc204_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMi00LTEtMS0yOTcyNg_4af3897d-0f09-4a19-bbb7-aa29663903fd">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacbdfe154b164f529f2e69136f05274f_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMi02LTEtMS0yOTcyNg_14fbdbf8-0f31-42dd-a379-bdfb00829b37">1,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib0e3cb79b02940e3afc4af2a5a631cd9_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMi04LTEtMS0yOTcyNg_dcdb3290-9c7f-4d65-b6d8-57295bc12bd9">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i00778b10e5af4bc791d1e8bbdd2bc204_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMi0xMC0xLTEtMjk3MjY_215b44f6-4662-4f22-8095-a25179767fea">14.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3304f9e4e7c4ee8b06281744d7d29d5_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMy0yLTEtMS0yOTcyNg_9ce4dca2-8b38-47c2-8236-cc26502050a5">2,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i661a37b39e8c487aa2f3ff704761f5d2_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMy00LTEtMS0yOTcyNg_0ba3e6ba-ea7c-4222-a80c-56ca2ff73f0e">2,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1a4981a319243a488072bbdd896bf56_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMy02LTEtMS0yOTcyNg_6e8388b7-f78a-46e9-af1a-f2a1641c30fb">3,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie3304f9e4e7c4ee8b06281744d7d29d5_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMy04LTEtMS0yOTcyNg_aca02d06-ce0a-4ad6-8172-5903b0dac902">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i661a37b39e8c487aa2f3ff704761f5d2_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMy0xMC0xLTEtMjk3MjY_2213698b-d0c0-40f8-ad5b-67b1933c2948">15.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia27aa4eb532a45a799170754ae5ed161_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNS0yLTEtMS0yOTcyNg_1ddb62be-007d-4f2c-8c89-894712a53f6f">3,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e557585fa834313b8b97ce7709070a9_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNS00LTEtMS0yOTcyNg_dab2fda8-2359-4dfe-a54c-288d9decf03a">3,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i949f6e0a191b4f4eb7c2781bbac7d13f_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNS02LTEtMS0yOTcyNg_a6099767-e437-47bc-a02b-62f9d0c9ef84">3,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia27aa4eb532a45a799170754ae5ed161_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNS04LTEtMS0yOTcyNg_55706c4d-fdd8-4d17-8714-c038672cff5d">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8e557585fa834313b8b97ce7709070a9_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNS0xMC0xLTEtMjk3MjY_48d17627-96d0-4533-ad2e-470f6a630ee1">15.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idca63bfd34644ba5bc55002b5b4d5a8e_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNi0yLTEtMS0yOTcyNg_8026057b-0fd6-4e5b-b3f8-62c22c28c24b">5,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2be122533f1424399fcc358654c4c3c_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNi00LTEtMS0yOTcyNg_54ace91d-fb5b-4fc3-8fbf-668e2ec7b1c7">4,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92e59ba1db31451aa3a8f14eb7816088_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNi02LTEtMS0yOTcyNg_35955df6-7c00-478c-b784-aabc9a3f9f87">5,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idca63bfd34644ba5bc55002b5b4d5a8e_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNi04LTEtMS0yOTcyNg_9c0b21be-77e1-43ad-9f31-bb615b52bf26">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia2be122533f1424399fcc358654c4c3c_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNi0xMC0xLTEtMjk3MjY_5b8ee6a2-02c5-43b0-9d21-5298630c8a11">12.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i234ad40879c94cc2969e46faf33c17cc_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNy0yLTEtMS0yOTcyNg_516c332b-1f90-4a08-9acd-e7aac8b51425">9,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3d9dccc5c584c4980e7a904d8a983bf_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNy00LTEtMS0yOTcyNg_56327337-ab04-4f61-a390-3e8d6f328fc0">8,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3253049e290946cd8a51612d31bcd76b_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNy02LTEtMS0yOTcyNg_14e3d2c7-ddb3-4937-8775-8bcd363fede0">9,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i234ad40879c94cc2969e46faf33c17cc_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNy04LTEtMS0yOTcyNg_71622b98-8b6e-45b7-9243-ff07abdff9f6">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie3d9dccc5c584c4980e7a904d8a983bf_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNy0xMC0xLTEtMjk3MjY_f74ad438-6ea9-44b1-b959-45c691362c4f">13.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i273e42d494bc4b7eb94a87f9d5987d1f_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwOS0yLTEtMS0yOTcyNg_2c6cee31-733d-427f-9001-48838cf714c8">1,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6368f09f9b35486ea7cba69aacb7e3b0_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwOS00LTEtMS0yOTcyNg_deb274f3-cee6-4eb0-94e5-f3b89815fea8">1,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i275015b2876d4c6d8fcb7fcdbd81df65_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwOS02LTEtMS0yOTcyNg_7f89b7e0-50fa-4948-b897-aec2bc859c1f">1,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i273e42d494bc4b7eb94a87f9d5987d1f_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwOS04LTEtMS0yOTcyNg_a5ffd6f4-24e1-4440-954e-ab8d2858fb94">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6368f09f9b35486ea7cba69aacb7e3b0_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwOS0xMC0xLTEtMjk3MjY_8409dd9a-8363-4292-815b-8de138f6b817">6.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f3e3713f381473f97efa9d195f99ffc_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMC0yLTEtMS0yOTcyNg_244e5f64-9242-4327-819d-5c39bcb1ed08">2,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f25d91afdc48968db8d33b505ba457_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMC00LTEtMS0yOTcyNg_b950b2d3-a5ef-4af5-b85a-2157f1b91542">2,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d48dd9d0d814bbca1d1b0419263f649_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMC02LTEtMS0yOTcyNg_931fe3a3-a39a-4e2f-aaf7-39e5ba566c8f">2,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6f3e3713f381473f97efa9d195f99ffc_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMC04LTEtMS0yOTcyNg_71f63355-bbaf-4d54-954e-850539af146c">24.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i98f25d91afdc48968db8d33b505ba457_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMC0xMC0xLTEtMjk3MjY_82c143d3-3820-43a1-92b2-f68198e9071d">6.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefd23a50dc7c42fcb55115309d6d6cb5_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMS0yLTEtMS0yOTcyNg_ef2f7850-403c-4a68-98e4-837adc80f11d">4,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54751f70883943a59eb320c03774cc90_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMS00LTEtMS0yOTcyNg_08088740-429a-4abc-a8c3-ac0f14739311">3,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if904c809a5cc47d7b5470bf8066c13bc_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMS02LTEtMS0yOTcyNg_dabfc1fb-2151-44cb-848f-b31333248432">4,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iefd23a50dc7c42fcb55115309d6d6cb5_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMS04LTEtMS0yOTcyNg_3125261b-937e-420f-8f72-2331ade05028">20.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i54751f70883943a59eb320c03774cc90_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMS0xMC0xLTEtMjk3MjY_48a3b8f8-bd23-4785-952b-a2cf4b02ed48">6.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11256befd90346248d26afa528551f9f_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMy0yLTEtMS0yOTcyNg_e4a8627d-2ed0-4347-a3b5-64b3607d4aea">2,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ccd3dcadf64c67aceef9eec40f6b84_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMy00LTEtMS0yOTcyNg_5d0020fd-37eb-41a8-af47-e21090c7b424">1,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0409bf3aaf47499c862aca1869e89dc5_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMy02LTEtMS0yOTcyNg_12b6d16d-096a-4bae-a88a-41df96a5a7b7">2,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i11256befd90346248d26afa528551f9f_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMy04LTEtMS0yOTcyNg_fee1989e-f9f3-4b96-a3ad-37d9b6950425">22.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie7ccd3dcadf64c67aceef9eec40f6b84_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMy0xMC0xLTEtMjk3MjY_c7d08ea0-d094-446a-ab89-19a5f815e3bb">21.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e8300916c9f4f18862cbda08e5f8057_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNC0yLTEtMS0yOTcyNg_00240299-8c73-4820-9396-66ac58d86689">3,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092132d8bdf1497aa5fa557713c95b5f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNC00LTEtMS0yOTcyNg_5d4cdc33-a78f-43b9-899a-7826939e578c">2,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4425ca9af5e64e22ac69aa3be800b66a_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNC02LTEtMS0yOTcyNg_c6c0df68-3157-4aa2-95ee-5deb32818aa8">3,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e8300916c9f4f18862cbda08e5f8057_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNC04LTEtMS0yOTcyNg_9b39a9ca-62d8-4c83-8e04-13f2adfa8213">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i092132d8bdf1497aa5fa557713c95b5f_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNC0xMC0xLTEtMjk3MjY_37c09da9-4323-48e8-854c-9936627129af">16.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21660177d3cf4725a1adfee86587c410_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNS0yLTEtMS0yOTcyNg_ed624b42-feb7-464e-91b0-342e20d063ce">5,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa74aa704e1a4c00aa265ccc209e1380_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNS00LTEtMS0yOTcyNg_03ef82bc-254c-44f6-b773-8883c70969ad">4,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066cce25039f4a8caa66512b868996f8_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNS02LTEtMS0yOTcyNg_46601363-c0a4-42a7-bf97-6d5e48a84beb">5,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i21660177d3cf4725a1adfee86587c410_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNS04LTEtMS0yOTcyNg_69ca57b7-96b4-4e3a-89f1-a7564408a007">18.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iaa74aa704e1a4c00aa265ccc209e1380_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNS0xMC0xLTEtMjk3MjY_14c669ac-bbd3-42a7-956b-3528a11097de">18.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0af309f3267d40c3b42203456d5ad2d9_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNy0yLTEtMS0yOTcyNg_e32f2ef7-5d9b-4ba6-9e41-73f3208fedf7">1,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84982e9d6460466bb3d6705abbfb2f69_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNy00LTEtMS0yOTcyNg_f8ed24dd-6621-421f-9cd7-3c2edfe9a150">1,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0e3ef3419b4d75adf175b93648c1b6_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNy02LTEtMS0yOTcyNg_b85adcf7-c1d6-41b6-bc66-1162c0da7f49">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0af309f3267d40c3b42203456d5ad2d9_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNy04LTEtMS0yOTcyNg_54b2600b-9e92-4cc7-8ba6-6bf659695d41">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i84982e9d6460466bb3d6705abbfb2f69_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNy0xMC0xLTEtMjk3MjY_146b0a9e-5559-4b7f-899d-bea7bb17621d">13.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a1d8e556c2462dbffb82954114233c_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOC0yLTEtMS0yOTcyNg_434d9011-2057-4781-ade0-1f40b0b470c5">2,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449dac796d2545b3b9f5d700d9bc735e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOC00LTEtMS0yOTcyNg_f0befe95-48e7-4ebd-a542-5a604d080158">2,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9c0705fde748bebf4dc83c4526eedc_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOC02LTEtMS0yOTcyNg_4ea715c0-d498-4a84-b003-304fc6de9c93">2,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08a1d8e556c2462dbffb82954114233c_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOC04LTEtMS0yOTcyNg_5b84aa11-9394-48d7-a73d-a4d7b57b1e01">19.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i449dac796d2545b3b9f5d700d9bc735e_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOC0xMC0xLTEtMjk3MjY_2126f8f4-3d17-49b9-a069-a652da6c4458">16.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67279a229f6346a78562ee616f898161_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOS0yLTEtMS0yOTcyNg_a889ec72-0a43-4c8b-9756-a3d04b9945b2">4,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6421c05ae448adb09f10e096aa875a_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOS00LTEtMS0yOTcyNg_fa62ef71-d644-4cc3-be71-c8516f07d98e">3,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i222491a1b870418a91eeb762d8d1eee8_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOS02LTEtMS0yOTcyNg_bc5a56d9-5371-411a-8352-e25d3a439a11">4,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i67279a229f6346a78562ee616f898161_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOS04LTEtMS0yOTcyNg_3eedf428-2f3a-4f36-ab6c-db488e6382cc">19.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifd6421c05ae448adb09f10e096aa875a_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOS0xMC0xLTEtMjk3MjY_c7121bfa-ccaa-445c-8432-f2545181a246">15.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7dc7d7e32844b18dadac4c73fcc43d_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMi0yLTEtMS0yOTcyNg_b1d913c6-12ff-482d-b8ed-3992fdab4022">1,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff33641613a4644b8764afca4e5e006_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMi00LTEtMS0yOTcyNg_ca4ebc1e-86b0-4f06-b9e5-8680dbedee5c">1,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40f24e02fa214e8ca63a5dc798f5aa78_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMi02LTEtMS0yOTcyNg_d59f7e45-e4f3-4388-b6aa-cb9918831a27">1,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0d7dc7d7e32844b18dadac4c73fcc43d_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMi04LTEtMS0yOTcyNg_803274f4-e068-4fe0-bd5e-2970461e7f76">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icff33641613a4644b8764afca4e5e006_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMi0xMC0xLTEtMjk3MjY_dd214a35-3477-4fe6-a970-d4936118c62d">7.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb35b47d312946dabc1007fce8107f34_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMy0yLTEtMS0yOTcyNg_3c07d868-5ea7-4765-95b7-de2dc6b5503c">2,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib15659c9d6514a6f8707334b438bf18b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMy00LTEtMS0yOTcyNg_f313060a-22d5-4c25-b196-9016ff4f191d">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e80c257552240eeb8c38ce4765cb32d_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMy02LTEtMS0yOTcyNg_b2b34876-6adb-4eee-b63f-d9fb1d971639">2,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb35b47d312946dabc1007fce8107f34_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMy04LTEtMS0yOTcyNg_b780ea81-8add-48b1-83b9-cee8e24f2177">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib15659c9d6514a6f8707334b438bf18b_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMy0xMC0xLTEtMjk3MjY_8e2d4aa9-78b6-45ba-828f-f670c72111d2">14.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id65abc97d55744b0b397e09a73a60cb2_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNC0yLTEtMS0yOTcyNg_9235aea8-5816-4aba-ba70-69930c19190e">3,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8149a55d6d9e44f08db766c017d527a4_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNC00LTEtMS0yOTcyNg_48ffa8d3-9b4b-4a37-81f9-7ef8c2aabee2">2,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d3a78039e7f4b40946cc088fba95f07_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNC02LTEtMS0yOTcyNg_cff4ce10-34f1-4bec-999b-a150c89df1bf">3,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id65abc97d55744b0b397e09a73a60cb2_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNC04LTEtMS0yOTcyNg_f4acc83c-127b-44b5-8c53-cf5de053b47f">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8149a55d6d9e44f08db766c017d527a4_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNC0xMC0xLTEtMjk3MjY_d7f85a5a-88df-4114-a2ca-fbcb5b73fbcc">11.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i246b7eb237324ec28b8e952a40024831" continuedAt="ieab9782fe8de46c69aa70629e38ada4a"><ix:continuation id="i6fc8cf47c0364e71a171f44859c4192c"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:34.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870d2071335a4c349e9bdf6c5dd8d221_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNi0yLTEtMS0yOTcyNg_03b0cf9e-9226-4b06-929e-26e594103303">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfabb85d57ed4e6e887596a521298fb6_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNi00LTEtMS0yOTcyNg_00de787d-b756-477d-b2ad-e83b1c54e6bb">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd907d3be6c6488b96c02cf61fe58ae2_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNi02LTEtMS0yOTcyNg_ffdd02cf-90fb-479a-ac21-d49961d47acc">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i870d2071335a4c349e9bdf6c5dd8d221_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNi04LTEtMS0yOTcyNg_6a2cdd18-4c81-42aa-ae5d-769f6eeac1ff">33.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icfabb85d57ed4e6e887596a521298fb6_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNi0xMC0xLTEtMjk3MjY_08e15a84-9753-4ef4-b48e-2991180e74a5">29.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic800efd413714d9d8a60516ca5f7d6ee_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNy0yLTEtMS0yOTcyNg_0292d574-a14b-4cb3-858f-e43186e471c3">788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cc24ee69c5e41af8566a1fcd0f833bc_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNy00LTEtMS0yOTcyNg_fd5afa88-6f5b-4af5-9d70-bcda5c0bf739">581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2509eddc1f545e09f38e5e2b4414e6b_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNy02LTEtMS0yOTcyNg_dca7653b-ef74-494b-9ee0-7907503475ed">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic800efd413714d9d8a60516ca5f7d6ee_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNy04LTEtMS0yOTcyNg_82700450-db58-44bd-9d89-859809daf7c8">35.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7cc24ee69c5e41af8566a1fcd0f833bc_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNy0xMC0xLTEtMjk3MjY_9dbe600f-4395-49c1-9a53-6cfac170d66f">21.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028b50c377714c899ae9c599c83171a0_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyOC0yLTEtMS0yOTcyNg_0d836a59-5124-4613-9e4f-94db880e6e77">1,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66dd731836ac479eae5b91d919a1282b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyOC00LTEtMS0yOTcyNg_a30e18c5-d624-4311-a7c4-458332cd8c94">925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ef2752fd1b046dbba1e17488a65f77c_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyOC02LTEtMS0yOTcyNg_a2a1c916-86dd-45a1-9809-ce8f87e7f182">1,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i028b50c377714c899ae9c599c83171a0_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyOC04LTEtMS0yOTcyNg_eba30d0a-f6df-467e-9ccc-9a0f9dc042c0">34.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i66dd731836ac479eae5b91d919a1282b_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyOC0xMC0xLTEtMjk3MjY_0c0c937d-ea5e-4ba3-a374-62d7b462b71a">24.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926ba91f36ef48a68fe6266e71d6869a_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMS0yLTEtMS0yOTcyNg_e80f7771-0902-42d9-8736-be2443b8fcc7">12,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4e5ad3b9bd24320b4d78a6d53743649_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMS00LTEtMS0yOTcyNg_830f831e-0a36-4f53-a7dc-a160f23931a4">11,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff991be03a2b4d159d3a77225971b22b_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMS02LTEtMS0yOTcyNg_5c12dd2b-1f1e-482e-a5f5-9769a79306cc">12,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i926ba91f36ef48a68fe6266e71d6869a_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMS04LTEtMS0yOTcyNg_f3ed1c09-1538-4be7-ade1-6c180c902a27">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id4e5ad3b9bd24320b4d78a6d53743649_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMS0xMC0xLTEtMjk3MjY_ac2e1370-b774-4b4f-b297-8dc79e1d22ae">10.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib476ce85857e4f488b4ac69194703bb8_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMi0yLTEtMS0yOTcyNg_06d7613c-bd02-44e3-b59b-3f162f900ac3">14,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf5c33d3be83417685f6d8ce5f603a71_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMi00LTEtMS0yOTcyNg_7e528cb9-4476-4b4c-98c8-7bb2cede0b57">11,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6386cedfeef4e04b42dfa0d05731d11_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMi02LTEtMS0yOTcyNg_0f252c1f-ddd7-4d3d-a712-9fcb1f9752d7">13,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib476ce85857e4f488b4ac69194703bb8_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMi04LTEtMS0yOTcyNg_d7b11306-ea86-4308-8946-7db4c4f3cd37">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iaf5c33d3be83417685f6d8ce5f603a71_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMi0xMC0xLTEtMjk3MjY_56bb3a3c-b5d0-420a-967e-8e5f59f22ca6">12.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMy0yLTEtMS0yOTcyNg_c195e9a2-f51f-4a40-ad6b-a4c95640a2e1">27,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ddb5ada6e24683aa7c697889661250_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMy00LTEtMS0yOTcyNg_4deed2aa-21d8-46a5-9ad0-eb9f3b56dd06">22,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f47282388e46edaf2c190bca1a05f3_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMy02LTEtMS0yOTcyNg_56a7f796-d885-49d2-bfa9-1f1e146a346c">25,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMy04LTEtMS0yOTcyNg_ccf40389-59c4-4563-a59d-05638ef816a2">17.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i86ddb5ada6e24683aa7c697889661250_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMy0xMC0xLTEtMjk3MjY_da2e99c8-2db3-487f-86e0-4215756073d8">11.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fff9f5f7b7143e383cbb939bdf7ad11_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNi0yLTEtMS0yOTcyNg_029c5688-2b42-4ab0-bf67-be5b7da79068">47,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i708657b70522407092d787ab45a8beb0_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNi00LTEtMS0yOTcyNg_c16671d3-d355-477e-b03c-86b34e3cf533">43,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5b9bb0bcfc4462ba8d103cb379d694b_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNi02LTEtMS0yOTcyNg_b694490c-5e8e-4921-9233-76f354724afb">42,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4fff9f5f7b7143e383cbb939bdf7ad11_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNi04LTEtMS0yOTcyNg_05f9310d-f831-4e37-b0c0-c8274e5769c6">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i708657b70522407092d787ab45a8beb0_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNi0xMC0xLTEtMjk3MjY_39ec1aa0-054f-4566-9a09-574b544e598e">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic23bf00a30e04ba28d25d34bb814c35e_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNy0yLTEtMS0yOTcyNg_efe9bdc9-ade3-49db-b196-2fdea39cb96b">46,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65b6178ffad3411eb9697a130c03e546_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNy00LTEtMS0yOTcyNg_f987add6-fde5-4dce-8a22-0880ce4541ca">39,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b4a5583c6aa48ceacfd7cb8304fe30c_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNy02LTEtMS0yOTcyNg_b3986bee-dfad-4fa0-b1f8-f47724fcef21">39,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic23bf00a30e04ba28d25d34bb814c35e_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNy04LTEtMS0yOTcyNg_fdd54b8e-fcd4-45b9-802d-3ae839e6ea8d">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i65b6178ffad3411eb9697a130c03e546_D20191230-20210103" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNy0xMC0xLTEtMjk3MjY_28648985-e7e9-4711-8546-3b20facf1110">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzOC0yLTEtMS0yOTcyNg_a0f72eeb-1ded-4d3f-a5b3-9923511a8c0e">93,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzOC00LTEtMS0yOTcyNg_3388bee2-c04d-4e26-9f11-68a698c4b718">82,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzOC02LTEtMS0yOTcyNg_1c94192f-2fed-45e6-8469-23a02c21610f">82,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzOC04LTEtMS0yOTcyNg_f044720e-3f88-4016-b12e-f927fcf5e14c">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzOC0xMC0xLTEtMjk3MjY_e8287230-e17e-49e3-b070-13efb505e2d7">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**Percentage greater than 100% or not meaningful</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzM0MjU_a1a92abf-e868-4c9a-986f-b3631f9cf3a5" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (Loss) Before Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07875b0557b747c1817c640f15714392_D20210104-20220102" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzItMi0xLTEtMjk3MjY_200df569-31af-4b3e-aaff-f8ab775cd478">1,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia502d9d60b7a47f6a866b6d2e0e7126f_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzItNC0xLTEtMjk3MjY_65421e09-e151-4747-98e2-95b3dcd13532">1,064</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58017869d1b24f54bed182c8572366f0_D20181231-20191229" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzItNi0xLTEtMjk3MjY_d7a9b4bb-38a7-458c-a688-9d47d6abebf1">2,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd9ab20dc83c431fbee3c5fe6720e9f8_I20220102" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzItOC0xLTEtMjk3MjY_24783a4e-683a-4ae7-bd2b-7b94495b4f60">25,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aebbc77b14247239abf6a5e633c97fd_I20210103" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzItMTAtMS0xLTI5NzI2_ce740799-905d-4a42-b127-a8e8ea291de5">27,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1c87e0aa1f746979a526054fc431766_D20210104-20220102" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzMtMi0xLTEtMjk3MjY_8c1598c7-16a5-4d7c-a1f5-9bf67890cf91">18,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida08580984a943569bd4235ee5579e20_D20191230-20210103" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzMtNC0xLTEtMjk3MjY_4f22944f-cccb-4694-8a60-a05813ee295b">15,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i542883a564ac49d99d576a6b19e782b4_D20181231-20191229" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzMtNi0xLTEtMjk3MjY_ea1fe425-e83b-473b-9095-6c1e30c2a3a6">8,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ffed65f4a64a30906e469a8d768eb0_I20220102" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzMtOC0xLTEtMjk3MjY_6ec383b0-b7c1-4869-9431-681b58e723e6">64,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d5630eefc3e4b02942a364b65337f88_I20210103" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzMtMTAtMS0xLTI5NzI2_6ded1ef9-db62-4626-af94-810502119547">66,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ee8524f73941a28f36ded1f0ae9694_D20210104-20220102" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzQtMi0xLTEtMjk3MjY_14b4fec6-3648-432a-8b86-7ca1660139cb">4,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b9faf917d1049188734075ab026d41d_D20191230-20210103" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzQtNC0xLTEtMjk3MjY_eca71265-4fa0-4e06-a1bb-3b0d298568f7">3,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a55e3eca274722b79aa4b030bf30ff_D20181231-20191229" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzQtNi0xLTEtMjk3MjY_731c38fc-7bee-4034-8e81-5240f9ef2997">7,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d8c1b87d69949739491c09dd1df4a3e_I20220102" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzQtOC0xLTEtMjk3MjY_1d7eba55-d70d-4be9-9acc-8660526870d1">53,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41d128ea214b4e15bed9dcde7d5f5996_I20210103" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzQtMTAtMS0xLTI5NzI2_a1ed7b87-4843-41d7-835f-11ffec73f430">49,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f072c0693846e9987d24a6f8158c06_D20210104-20220102" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzUtMi0xLTEtMjk3MjY_4c42b44d-f8de-46ba-9f61-2f108a44c86f">23,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic11d6e0c7a594cc58857314068a88853_D20191230-20210103" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzUtNC0xLTEtMjk3MjY_821fdbda-f447-4474-8e90-196c7acdb0c1">17,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fc205a8aa4348dabb8157a34a1f17e6_D20181231-20191229" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzUtNi0xLTEtMjk3MjY_799f9121-4109-429b-86a9-6b95f7fdb2c0">18,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c942d86e2b2405fba98d51d0541433d_I20220102" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzUtOC0xLTEtMjk3MjY_2774bcf0-571e-48d2-b26b-b095347e4b78">142,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibff7c2542e2e46b386cc5c9b9e43ed68_I20210103" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzUtMTAtMS0xLTI5NzI2_6669c6c0-e121-4b76-8845-f14227f8e0c6">143,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie56b8a3a16e2475b9f30017cd504ca86_D20210104-20220102" decimals="-6" name="jnj:ExpenseNotAllocatedToSegments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzYtMi0xLTEtMjk3MjY_f7fd4fc1-9e8d-41eb-bfec-e74aace4e08c">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f314714a5bd4eb3b5976682016d9f0d_D20191230-20210103" decimals="-6" name="jnj:ExpenseNotAllocatedToSegments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzYtNC0xLTEtMjk3MjY_7bf44c52-341e-4b56-90a4-4dd5896a5638">945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ffa3bbb13054be0b90f9be2fe0a69de_D20181231-20191229" decimals="-6" name="jnj:ExpenseNotAllocatedToSegments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzYtNi0xLTEtMjk3MjY_91ac8e8c-d164-4aa4-a156-1381396685a3">835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a4ad3308fb2433ab4bb66f0ed570ddf_I20220102" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzctOC0xLTEtMjk3MjY_1fce997d-a00f-407a-87d1-b3e5239bf974">39,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161c8b4e12a84317ab8397b42ebcbd69_I20210103" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzctMTAtMS0xLTI5NzI2_8b9bb670-6f48-4d34-a10f-459cea60787b">31,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzgtMi0xLTEtMjk3MjY_50de66ba-e124-49bd-ab79-3941c7e3fe83">22,776</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzgtNC0xLTEtMjk3MjY_6fc38b08-0573-4b52-93d6-4cbccbb713b4">16,497</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzgtNi0xLTEtMjk3MjY_e22bcd9f-e9c5-487a-9192-c0fd96eb25e5">17,328</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzgtOC0xLTEtMjk3MjY_be61c009-74a1-4799-918c-e475ea8aef68">182,018</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzgtMTAtMS0xLTI5NzI2_badcf5ce-b4ad-47a0-b89a-a00fd05c90fd">174,894</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions to Property,<br/>Plant &amp; Equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation and<br/>Amortization</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07875b0557b747c1817c640f15714392_D20210104-20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzItMi0xLTEtMjk3MjY_5dd53a7a-7747-477f-a966-0f068761ab6c">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia502d9d60b7a47f6a866b6d2e0e7126f_D20191230-20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzItNC0xLTEtMjk3MjY_a7e283ae-c30d-4f3b-b54a-cb27d707f1c1">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58017869d1b24f54bed182c8572366f0_D20181231-20191229" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzItNi0xLTEtMjk3MjY_540b36fc-b8aa-4df3-b144-c5277cfabc43">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07875b0557b747c1817c640f15714392_D20210104-20220102" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzItOC0xLTEtMjk3MjY_cc18b51f-f3d3-40c4-9b06-35d224739f19">759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia502d9d60b7a47f6a866b6d2e0e7126f_D20191230-20210103" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzItMTAtMS0xLTI5NzI2_57f29536-b662-4267-bbf1-6e5917d021b0">785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58017869d1b24f54bed182c8572366f0_D20181231-20191229" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzItMTItMS0xLTI5NzI2_70798105-cd0f-486f-9063-55e974051248">765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1c87e0aa1f746979a526054fc431766_D20210104-20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzMtMi0xLTEtMjk3MjY_f06bef64-cb93-4f3a-9f05-49b68acc618b">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida08580984a943569bd4235ee5579e20_D20191230-20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzMtNC0xLTEtMjk3MjY_660bdd19-ca7f-4589-bcc7-00c079bd624e">863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i542883a564ac49d99d576a6b19e782b4_D20181231-20191229" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzMtNi0xLTEtMjk3MjY_b343d347-24ce-4d9a-aa6d-21a44e3ed864">950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1c87e0aa1f746979a526054fc431766_D20210104-20220102" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzMtOC0xLTEtMjk3MjY_81db2060-e1cc-407d-86eb-4776fb5b7259">4,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida08580984a943569bd4235ee5579e20_D20191230-20210103" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzMtMTAtMS0xLTI5NzI2_0d5dd57a-c6b6-4861-b063-9457d1c92616">4,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i542883a564ac49d99d576a6b19e782b4_D20181231-20191229" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzMtMTItMS0xLTI5NzI2_15d6118e-536e-49d2-a871-5e318fdd3c34">3,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ee8524f73941a28f36ded1f0ae9694_D20210104-20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzQtMi0xLTEtMjk3MjY_6fdef2be-7da5-47ad-b19e-b768c3d04b5d">1,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b9faf917d1049188734075ab026d41d_D20191230-20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzQtNC0xLTEtMjk3MjY_41682cb7-7614-4069-accf-aceb2cc8e85b">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a55e3eca274722b79aa4b030bf30ff_D20181231-20191229" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzQtNi0xLTEtMjk3MjY_c4b13fc4-ce3d-4338-8fdb-434b14ed794a">1,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ee8524f73941a28f36ded1f0ae9694_D20210104-20220102" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzQtOC0xLTEtMjk3MjY_eaf2f7cc-21b3-449a-8155-e050ab120cda">2,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b9faf917d1049188734075ab026d41d_D20191230-20210103" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzQtMTAtMS0xLTI5NzI2_022dd515-9df6-4ec4-9721-f83209e0d1a2">2,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a55e3eca274722b79aa4b030bf30ff_D20181231-20191229" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzQtMTItMS0xLTI5NzI2_ff23bf2a-c76a-439a-9930-a059483141cc">2,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segments total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf6748ed9caa4723bfd8c2a5895eb586_D20210104-20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzUtMi0xLTEtMjk3MjY_9b749ae5-3fe0-40de-a916-ad28b8642462">3,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5d16014da004533a78f87eb30d1bbdb_D20191230-20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzUtNC0xLTEtMjk3MjY_2b8805d0-ee0a-467f-9ef7-6ad92d228419">3,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6a6522853c4fd39a5c2f6393777cda_D20181231-20191229" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzUtNi0xLTEtMjk3MjY_00f5b399-4931-40a5-882b-53fcf6d863b9">3,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf6748ed9caa4723bfd8c2a5895eb586_D20210104-20220102" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzUtOC0xLTEtMjk3MjY_75bffa85-34e3-47cf-94d7-58e4108006ba">7,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5d16014da004533a78f87eb30d1bbdb_D20191230-20210103" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzUtMTAtMS0xLTI5NzI2_431b4ecc-3e78-4900-bcd2-3162f9b223d6">6,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6a6522853c4fd39a5c2f6393777cda_D20181231-20191229" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzUtMTItMS0xLTI5NzI2_99057a43-9850-459f-bee0-2b66bf103cc4">6,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfec35f176a949e19fc22a208824eaf9_D20210104-20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzYtMi0xLTEtMjk3MjY_718c967c-5c63-4d1d-8857-45f64d87106e">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43234b4b84a444a9add41d11cc2a72e9_D20191230-20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzYtNC0xLTEtMjk3MjY_3edbf2ca-2137-4182-abeb-23929a5f128b">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89612e90f2314e95be21fae3c19c58e6_D20181231-20191229" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzYtNi0xLTEtMjk3MjY_c810716e-e546-44c6-872c-beef9fbb3667">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfec35f176a949e19fc22a208824eaf9_D20210104-20220102" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzYtOC0xLTEtMjk3MjY_a96f38f9-e72a-4aee-a851-c56cbad04092">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43234b4b84a444a9add41d11cc2a72e9_D20191230-20210103" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzYtMTAtMS0xLTI5NzI2_180e5976-613d-4d4f-adce-2fc0ee1e6e75">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89612e90f2314e95be21fae3c19c58e6_D20181231-20191229" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzYtMTItMS0xLTI5NzI2_cf656c5d-4342-4b1f-b8b9-6c15c65b27ca">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzctMi0xLTEtMjk3MjY_a94037ee-d108-47cf-8a5f-caea67dcc72e">3,652</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzctNC0xLTEtMjk3MjY_fde45f1b-9766-4753-bd3f-4e5b7182e08b">3,347</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzctNi0xLTEtMjk3MjY_f39bba5b-f6a5-449a-9bfd-ade6bcbb6d36">3,498</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzctOC0xLTEtMjk3MjY_ad192cde-259c-4405-b4af-a96f51cb5d0b">7,390</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzctMTAtMS0xLTI5NzI2_fe3ac21e-a6de-4132-857e-584bb61e3fb6">7,231</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzctMTItMS0xLTI5NzI2_76d8b7e3-4494-484a-800e-4d1b07bb0b31">7,009</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzM0Mjc_e2705d41-9d9e-46cb-85e2-c10bef5edd4f" continuedAt="iae72746622a041b3aae4f0ba837b5d5b" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-Lived Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dde3b1fc1c140b7b975e1257746af2a_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzItMi0xLTEtMjk3MjY_f5ce6d9e-a939-4cd7-b95a-77cfda1784fb">47,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie55616146f624252916d67d0fb6270a3_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzItNC0xLTEtMjk3MjY_6708344d-c631-4e5a-b11d-a8b77da3077f">43,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329742ce6594bfc9eddf10d9e6e6d1b_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzItNi0xLTEtMjk3MjY_619b8fdf-fffc-4390-afbe-9acd2e37cf57">42,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic66ee5c432fb43989fab14ab0949bd32_I20220102" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzItOC0xLTEtMjk3MjY_291ed013-282a-4c79-bde3-02b0a3310470">48,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0eaa56b37ca45d6be7c0ae8cc029a05_I20210103" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzItMTAtMS0xLTI5NzI2_ee73fb59-1c84-42e1-88bf-5b9c42985077">49,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12c344a819924cb3abc49e0e78326cb5_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzMtMi0xLTEtMjk3MjY_5ba47c64-ae2f-4e7b-9ca8-1993000f40aa">23,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86027318c21946418cf4bac6b9766a4a_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzMtNC0xLTEtMjk3MjY_217a24ff-1087-4ebd-a78e-e7913bb0d527">18,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if180dfc034c94229b3b69b27873c5523_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzMtNi0xLTEtMjk3MjY_00503af0-b517-480d-a053-0d58f985f3d0">18,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6d295d1a9e8463fae253f66cb1dd8c9_I20220102" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzMtOC0xLTEtMjk3MjY_ce0cfa68-631d-48db-b4b8-20a74f8dfd80">43,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2d14c5a6d394ef9a183cc124fa5a80a_I20210103" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzMtMTAtMS0xLTI5NzI2_e038b2a4-3b8f-481e-84d3-df1277663c04">49,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere excluding U.S.&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9002b75b28cf45caa22c4976168c7b62_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzQtMi0xLTEtMjk3MjY_d4eff0cc-865a-4cc5-9647-8388fbf2e767">5,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192b54c044b440f48ee211083347803e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzQtNC0xLTEtMjk3MjY_c1f0b6d5-207b-4865-ba30-ec9af6f09371">5,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4eab92d733042da922500164d7a49b1_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzQtNi0xLTEtMjk3MjY_5e3712b0-3d26-492b-b0fa-dd7b1b5b2dd9">5,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia624c75d38284ec6a2ec845b2560bce2_I20220102" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzQtOC0xLTEtMjk3MjY_4be6bfb3-cc7c-4298-b021-32a6fad04605">2,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2be65f500ff545279a1db64b6247c724_I20210103" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzQtMTAtMS0xLTI5NzI2_a62bd078-9c1c-46e1-a0e7-f290113aece3">2,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f488e3ce82400e9d20999f51bfd957_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzUtMi0xLTEtMjk3MjY_5ae7dd7f-4b4a-4894-8fe2-634c10d32ce5">17,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i684ab47875044db597f5dfe5c54f245d_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzUtNC0xLTEtMjk3MjY_e96fd8e3-3d26-4818-a256-66fe6e6111ff">15,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffd9ab5bd7e43d2bdabc0050f445bbc_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzUtNi0xLTEtMjk3MjY_980d021b-5612-466e-a326-17f19492fe45">15,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53bf7c2112b84b558b199f49dd38db16_I20220102" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzUtOC0xLTEtMjk3MjY_09827880-42f9-406f-9ece-f25924d2f588">5,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df24236c7145dea99c2071261ac7b9_I20210103" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzUtMTAtMS0xLTI5NzI2_4fe4f584-41ca-4f4f-b895-a9e33d661762">5,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segments total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f072c0693846e9987d24a6f8158c06_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzYtMi0xLTEtMjk3MjY_e7ad530b-f528-4352-9211-7f2f6fde94c2">93,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic11d6e0c7a594cc58857314068a88853_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzYtNC0xLTEtMjk3MjY_f4afd3e3-a71b-423b-97f4-faeb79754db2">82,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fc205a8aa4348dabb8157a34a1f17e6_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzYtNi0xLTEtMjk3MjY_608e6b07-b1ba-49e5-9b0d-c1d99d7e3cd7">82,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cdc558e3419463e9447cf921a59d40e_I20220102" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzYtOC0xLTEtMjk3MjY_bc3d248e-dd81-4f88-ab36-a896d97e7dee">99,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7b52918f61f47df92b761c6d628e9dd_I20210103" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzYtMTAtMS0xLTI5NzI2_c2b848d4-1a4c-4c49-80d4-0bccdc565891">107,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a4ad3308fb2433ab4bb66f0ed570ddf_I20220102" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzctOC0xLTEtMjk3MjY_603f99aa-24e1-485e-a0a8-8be2ea89a6d1">1,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161c8b4e12a84317ab8397b42ebcbd69_I20210103" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzctMTAtMS0xLTI5NzI2_6921ffb8-d61e-4c47-ae82-4bb01762ed20">1,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non long-lived assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b4e08a0ee17422a8c214d277d942d69_I20220102" decimals="-6" name="jnj:OtherNonLongLivedAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzgtOC0xLTEtMjk3MjY_c9b0d8c9-c1b6-42b1-bb87-20d1e6911a7b">81,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91c7274c6de64cad9ae9f5f8d47e3a03_I20210103" decimals="-6" name="jnj:OtherNonLongLivedAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzgtMTAtMS0xLTI5NzI2_1a6cfb78-605a-4d2c-9634-cb4c66c116da">66,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzktMi0xLTEtMjk3MjY_bb538a78-085f-4e29-b956-e293771a178f">93,775</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzktNC0xLTEtMjk3MjY_588bbb49-4342-4a26-affb-7a7955067f49">82,584</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzktNi0xLTEtMjk3MjY_fea7a282-7878-40dc-a939-cb08c7b0b748">82,059</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzktOC0xLTEtMjk3MjY_0efe0fe7-af82-46ac-9083-a88cd109f8ea">182,018</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzktMTAtMS0xLTI5NzI2_a8342e1d-1de1-4781-b468-9c799a2b2f02">174,894</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;1 for a description of the segments in which the Company operates. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ieab9782fe8de46c69aa70629e38ada4a" continuedAt="i5cc676fae7be4236893f38a31d9dab7c"><ix:continuation id="iae72746622a041b3aae4f0ba837b5d5b" continuedAt="iafc6813dea5645698e12417000f77774"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Export sales are not significant. In fiscal year 2021, the Company utilized three wholesalers distributing products for all <ix:nonFraction unitRef="segment" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzQ0NQ_e93ab160-cc72-46c2-9c82-c81858431e26">three</ix:nonFraction> segments that represented approximately <ix:nonFraction unitRef="number" contextRef="i8caaafd1850845b59365f8e185f8173c_D20210104-20220102" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzQ4OA_078f88b2-2061-45fa-a1e4-312b71a5dfa1">14.0</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="id3b5a13cbe6b4786982dea5ebe78b704_D20210104-20220102" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzQ5Mg_16fb4dde-c678-4482-b121-88d030fd0329">11.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if99789229d014c78a17d5f4a81bbfa36_D20210104-20220102" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzQ5OQ_23ac3ec2-af68-4918-b818-174a8c568998">11.0</ix:nonFraction>% of the total consolidated revenues. In fiscal year 2020, the Company had three wholesalers distributing products for all <ix:nonFraction unitRef="segment" contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzYyMQ_e93ab160-cc72-46c2-9c82-c81858431e26">three</ix:nonFraction> segments that represented approximately <ix:nonFraction unitRef="number" contextRef="i30ec518ef4e84aff82c8baa7363b31de_D20191230-20210103" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzY2NA_bac8c584-ba78-4276-9d1d-ae0c2a700c01">16.0</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ibe41c007f8e74211896f3015a2132bd1_D20191230-20210103" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzY2OA_11eebcf6-8d5c-4ffc-b497-7478b51a3176">12.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i25b4bc0c83d64827aac46f72ea370c2b_D20191230-20210103" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzY3NQ_828fde59-832d-4d7b-9a21-9d69d92d6c5c">12.0</ix:nonFraction>% of the total consolidated revenues. In fiscal year 2019, the Company had three wholesalers distributing products for all <ix:nonFraction unitRef="segment" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0Xzc5Nw_e46ca588-3660-42f6-a9fb-fbef5ff4f7ce">three</ix:nonFraction> segments that represented approximately <ix:nonFraction unitRef="number" contextRef="i59011837e8e74865818d7c6e22573da3_D20181231-20191229" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0Xzg0MA_2b4d4d59-cea6-4812-867f-efc7e9ef9a5a">15.0</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i84ff03e41df948aea3483799d1cbea10_D20181231-20191229" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0Xzg0NA_692ea272-1d8f-45b3-8e2a-8d480fbea8ab">12.0</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="i9dd8d7d4f2d84befa81f6c55d1286f96_D20181231-20191229" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0Xzg1Mg_bc10cec6-bcf4-4177-baa7-78db7899fd84">11.0</ix:nonFraction>% of the total consolidated revenues. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">General corporate includes cash, cash equivalents and marketable securities.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="i1198f98bdb8f4597b4a10112426c5f06_D20210104-20220102" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDQ5NTE_09a19424-67da-4501-8474-13fb40583edd">1.6</ix:nonFraction>&#160;billion, primarily talc related reserves</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="i1198f98bdb8f4597b4a10112426c5f06_D20210104-20220102" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDQ5NjU_71c272f2-be24-4756-8ee3-8c86ab79cf33">0.1</ix:nonFraction>&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDQ5Nzk_97a25dc7-720f-440a-b2bb-3077b5896303">0.6</ix:nonFraction>&#160;billion, primarily related to Risperdal </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Divestiture gains of $<ix:nonFraction unitRef="usd" contextRef="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102" decimals="-8" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDQ5OTM_00da5b21-15e7-48d1-96c7-24ddf7f1a1b5">0.6</ix:nonFraction>&#160;billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Gains on securities of $<ix:nonFraction unitRef="usd" contextRef="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102" decimals="-8" name="us-gaap:MarketableSecuritiesRealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDUwMDc_eb35aedc-20bb-464a-b90a-f894f3b33381">0.5</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDUwMjE_91f23763-2def-4df6-b632-c43401d2b880">0.1</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDUwMzU_55919dba-3039-40f5-b1d5-089c041abda0">0.3</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $<ix:nonFraction unitRef="usd" contextRef="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102" decimals="-8" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDUwNDk_809b5757-3114-4da3-abec-86c98727c287">0.9</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A Medical Device Regulation charge of $<ix:nonFraction unitRef="usd" contextRef="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102" decimals="-8" name="jnj:RegulationCharge" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDUwNjM_48e9576d-fdf9-42b2-8f3b-49663a66c7e3">0.2</ix:nonFraction>&#160;billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDUwNzc_83080604-af47-4252-b1f6-f32cf66dec7c">0.1</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="if43f753e349c40788db498a0b8a5fe34_D20191230-20210103" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzExMjc_2a246e41-1d28-460e-9079-ddb2defd5016">3.9</ix:nonFraction>&#160;billion, primarily talc related reserves and certain settlements.</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="ia9f7770a07704889bef20acb8a0c5220_D20191230-20210103" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzEyMzU_e6a7331f-b33c-4c95-89df-60068887964d">0.8</ix:nonFraction>&#160;billion, primarily related to the agreement in principle to settle opioid litigation </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An unrealized gain on securities of $<ix:nonFraction unitRef="usd" contextRef="ida08580984a943569bd4235ee5579e20_D20191230-20210103" decimals="-8" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzEzNTI_0534ddf9-c9d3-4bff-9965-d00a5f19f3ed">0.5</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="ia9f7770a07704889bef20acb8a0c5220_D20191230-20210103" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzEzOTA_e0b99685-c66a-4e32-a46e-5239a1cd4352">0.1</ix:nonFraction>&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A contingent consideration reversal of $<ix:nonFraction unitRef="usd" contextRef="i2b01d17f27cf45d1be57134c670e1e36_D20191230-20210103" decimals="-8" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE0NTg_46b9c8f5-0a90-4a8b-9717-6ae6242f1e07">1.1</ix:nonFraction>&#160;billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="i86ddb5ada6e24683aa7c697889661250_D20191230-20210103" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE1ODg_c51b088c-2108-462c-bcbf-20739046c185">0.3</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="i86ddb5ada6e24683aa7c697889661250_D20191230-20210103" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE2MjY_6526b578-0a82-4bd9-81b6-cf102c9819a1">0.3</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $<ix:nonFraction unitRef="usd" contextRef="i86ddb5ada6e24683aa7c697889661250_D20191230-20210103" decimals="-8" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE2ODA_7c209f6a-fec1-4d62-8430-b83d7c580c20">0.2</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A Medical Device Regulation charge of $<ix:nonFraction unitRef="usd" contextRef="i86ddb5ada6e24683aa7c697889661250_D20191230-20210103" decimals="-8" name="jnj:RegulationCharge" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE3MjI_eed0b33f-dd1b-416b-bc8e-2d5e936d379c">0.1</ix:nonFraction>&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $<ix:nonFraction unitRef="usd" contextRef="ibc662de37ec34428972835cc3abf9da7_D20181231-20191229" decimals="-8" name="us-gaap:GainLossOnSaleOfEquityInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE3NjU_e081bf23-36bf-4d3e-adfa-c7dcc0aae434">0.3</ix:nonFraction> billion related to the Company's previously held equity investment in DR. CI:LABO</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="ib63ccacb9faa4b73878a9057b0fd6b30_D20181231-20191229" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE4NjQ_0a63694c-f4c8-422a-a1ed-0d2e66641127">0.4</ix:nonFraction> billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="ib63ccacb9faa4b73878a9057b0fd6b30_D20181231-20191229" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE5MDI_3ce290bc-d780-4a8a-932c-02e9329f473d">0.1</ix:nonFraction> billion </span></div><div style="margin-top:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="ib2cf37c66bfb4ef5bce478f5333fb5df_D20181231-20191229" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE5NTM_58cf8318-b429-416e-9202-8ee71184fd99">4.3</ix:nonFraction> billion of which $<ix:nonFraction unitRef="usd" contextRef="i7f6076db24f64e8b8d695cf2700ed061_I20191031" decimals="-8" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE5NjU_122c3a6f-56c9-47d9-ab11-13a2aa8d55a9">4.0</ix:nonFraction> billion is related to the agreement in principle to settle opioid litigation</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $<ix:nonFraction unitRef="usd" contextRef="ib2cf37c66bfb4ef5bce478f5333fb5df_D20181231-20191229" decimals="-8" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzIwODc_56690ea6-fbe9-4e7d-a232-17a1104ac06d">0.9</ix:nonFraction> billion related to the Alios asset</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A research and development expense of $<ix:nonFraction unitRef="usd" contextRef="ib2cf37c66bfb4ef5bce478f5333fb5df_D20181231-20191229" decimals="-8" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzIxNTU_230424f3-c67c-48e0-b274-c6c34d64c67f">0.3</ix:nonFraction> billion for an upfront payment related to argenx </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An unrealized gain on securities of $<ix:nonFraction unitRef="usd" contextRef="i542883a564ac49d99d576a6b19e782b4_D20181231-20191229" decimals="-8" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzIyMzY_0d1d66d2-ca43-48b6-9b49-408d07bc0749">0.6</ix:nonFraction> billion </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5cc676fae7be4236893f38a31d9dab7c"><ix:continuation id="iafc6813dea5645698e12417000f77774"><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Actelion acquisition and integration related costs of $<ix:nonFraction unitRef="usd" contextRef="i96b4301ec6a748738bcd3da3c58a855d_D20181231-20191229" decimals="-8" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzIyOTQ_63b3986a-7c29-4543-88ad-049c851665e5">0.2</ix:nonFraction> billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring charge of $<ix:nonFraction unitRef="usd" contextRef="ib2cf37c66bfb4ef5bce478f5333fb5df_D20181231-20191229" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzIzMjQ_d13a03ea-16f7-433a-9b51-f5d2bdb0c87c">0.1</ix:nonFraction> billion</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Medical Devices includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $<ix:nonFraction unitRef="usd" contextRef="i74b5f6e37afe4a4db8b8e7f9fdd0b2ef_D20181231-20191229" decimals="-8" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzIzNjM_bdcce145-9d78-4b3f-b166-4fa3e9cc30c9">2.0</ix:nonFraction> billion from the divestiture of the ASP business</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="i41f47282388e46edaf2c190bca1a05f3_D20181231-20191229" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzI0NDE_34975f1b-c4fd-4404-a4be-0e7fa204fbfe">0.4</ix:nonFraction> billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="i41f47282388e46edaf2c190bca1a05f3_D20181231-20191229" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzI0Njc_3914d19c-a943-42f8-9138-d7d679fb35f3">0.4</ix:nonFraction> billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Auris Health acquisition and integration related costs of $<ix:nonFraction unitRef="usd" contextRef="i5dcfe72e83d94e7f84475a87d6457756_D20181231-20191229" decimals="-8" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzI1Mjk_862d8308-4684-4342-a9cd-2a847776fa1a">0.1</ix:nonFraction> billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Long-lived assets include property, plant and equipment, net for fiscal years 2021, and 2020 of $<ix:nonFraction unitRef="usd" contextRef="i6ff6ac9a46e741ebb0af1c793cb24164_I20220102" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzMyODg_50e0a8e0-5af8-4f86-8c3f-539e0cfce28d">18,962</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iad866650cbf4417d988e0b72205283fc_I20210103" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzMyOTU_a921da6c-5812-4451-9381-f16f6541e3d0">18,766</ix:nonFraction>, respectively, and intangible assets and goodwill, net for fiscal years 2021 and 2020 of $<ix:nonFraction unitRef="usd" contextRef="iab994f6e28264437bf740f3cb576b596_I20220102" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzMzODM_4ec916e2-23ab-4eff-ac7a-fa476a9ca203">81,638</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7c5552cc49964c378bbb9b282742a62d_I20210103" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzMzOTA_6958e8fd-7793-4134-9425-532f8a7ebc22">89,795</ix:nonFraction>, respectively.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_214"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEwNjAx_9acc3303-b5f9-4b6b-8b2f-37909a830e7b" continuedAt="ide6704a2185c46a0b340a4e266f51a23" escape="true">Acquisitions and Divestitures</ix:nonNumeric></span></div><ix:continuation id="ide6704a2185c46a0b340a4e266f51a23" continuedAt="id0da0a6bdab04907be9ce714c83bc991"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During fiscal year 2021, the Company did not make any material acquisitions. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During fiscal year 2020, certain businesses were acquired for $<ix:nonFraction unitRef="usd" contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzc1_d7e20394-a1e4-4e4f-b774-555446e070cc">7.3</ix:nonFraction>&#160;billion in cash and $<ix:nonFraction unitRef="usd" contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzkw_ac874c07-2e1b-485a-ae34-796cfcf74640">0.4</ix:nonFraction>&#160;billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $<ix:nonFraction unitRef="usd" contextRef="i6c4338357956452382a3b4130bcd7e7e_I20210103" decimals="-8" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzQzOA_714825ad-0369-4cc9-9ea1-798430b853fa">7.5</ix:nonFraction>&#160;billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fiscal year 2020 acquisitions primarily included: all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc. (XBiotech), Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases and the outstanding shares in Verb Surgical Inc., a company with significant  robotics and data science capabilities.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="id0305d06bfd34bdfb74072845ac023d4_D20191230-20200329" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEyNTQ_d763ccc3-f389-4451-9d34-cc98e1a79ff3">0.8</ix:nonFraction>&#160;billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $<ix:nonFraction unitRef="usd" contextRef="ic56891ab2cd6480ba37ea1ceb033b908_I20200329" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEzNzU_9e2796d2-5bb3-41a9-bb06-d8d7b3881a08">0.8</ix:nonFraction>&#160;billion applying a probability of success factor that ranged from <ix:nonFraction unitRef="number" contextRef="if085f95b01a24cb5b37a6f4a5c06c613_I20200329" decimals="1" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzE0MzY_ea54440e-cb85-4d1b-bb9f-bd7a8bd12995">20</ix:nonFraction>% to  <ix:nonFraction unitRef="number" contextRef="i652360a76ef04b59bdc669400214e356_I20200329" decimals="1" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzE0NDM_39444ff5-1266-4032-be48-139493888e06">60</ix:nonFraction>% to reflect inherent development, regulatory and commercial risk for the different indications. The discount rate applied was approximately <ix:nonFraction unitRef="number" contextRef="ic56891ab2cd6480ba37ea1ceb033b908_I20200329" decimals="2" name="jnj:BusinessAcquisitionDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzE1ODU_f6b91629-f85e-4cb9-9268-ef65910b7df0">16</ix:nonFraction>%.  XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. On January 28, 2022, subsequent to the fiscal year 2021, additional information regarding efficacy became available which led the Company to the decision to terminate the development of bermekimab for Atopic Dermatitis (AD). The Company recorded an intangible asset impairment charge of approximately $<ix:nonFraction unitRef="usd" contextRef="iab3ebcc4c2ae4fe293b17a266c45d8fb_D20220128-20220128" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEwOTk1MTE2NDc0Mzc_c2c0dcaf-ff98-43c8-99f5-e9cfb98fa434">0.6</ix:nonFraction>&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of AD and Hidradenitis Suppurativa (HS). The impairment charge is related to the AD indication and is a nonrecognized subsequent event and will be reflected in the first quarter 2022 financial statements. The Company acquired all rights to bermekimab from XBiotech, Inc. in fiscal year 2020.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in the fiscal first quarter of 2020, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with significant robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the Medical Devices segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $<ix:nonFraction unitRef="usd" contextRef="ie4dfe20935d14ee3bdc74b4b396d04be_I20200329" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzIyOTA_c767ea10-183e-466d-90ea-75193c0e0f61">0.4</ix:nonFraction>&#160;billion, goodwill for $<ix:nonFraction unitRef="usd" contextRef="ie4dfe20935d14ee3bdc74b4b396d04be_I20200329" decimals="-8" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzIzMDc_30b46716-4338-4576-8454-ec5e33525235">0.2</ix:nonFraction>&#160;billion, other assets of $<ix:nonFraction unitRef="usd" contextRef="ie4dfe20935d14ee3bdc74b4b396d04be_I20200329" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzIzMjc_b599792d-dfc1-4dcb-a51e-78501dbc47db">0.2</ix:nonFraction>&#160;billion and liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="ie4dfe20935d14ee3bdc74b4b396d04be_I20200329" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzIzNTc_3f1672ba-0970-48e5-9b3d-c73fb01657b0">0.3</ix:nonFraction>&#160;billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $<ix:nonFraction unitRef="usd" contextRef="ie4dfe20935d14ee3bdc74b4b396d04be_I20200329" decimals="-8" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzI0NTM_bf6a3662-dc43-4f81-8f98-ae19b2d50f70">0.4</ix:nonFraction>&#160;billion. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 1, 2020, the Company completed the acquisition of Momenta for a purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="i38342c75b72a472b9fd00cc1e1df9f64_D20201001-20201001" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzI1NjU_d0549a27-1ad7-4e0d-a17c-7c421190351d">6.1</ix:nonFraction>&#160;billion, net of cash acquired. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets (IPR&amp;D) of $<ix:nonFraction unitRef="usd" contextRef="ic5ee7cee5c044dc895e1060a81eb1b2b_I20201001" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzI2OTc_6ca07869-17ba-4426-b826-967b70a8bc6c">6.0</ix:nonFraction>&#160;billion, goodwill of $<ix:nonFraction unitRef="usd" contextRef="i3dc89baa93fd48229b56fd011dd9c983_I20201001" decimals="-8" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzI3MTM_06745105-58a2-4e9a-a2c5-bb0cce09f98d">1.2</ix:nonFraction>&#160;billion, other assets of $<ix:nonFraction unitRef="usd" contextRef="i3dc89baa93fd48229b56fd011dd9c983_I20201001" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzI3MzM_b3a957ba-f006-4217-aac7-5378e504e1fc">0.5</ix:nonFraction>&#160;billion and liabilities of $<ix:nonFraction unitRef="usd" contextRef="i3dc89baa93fd48229b56fd011dd9c983_I20201001" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzI3NTU_0640b44c-c973-49f1-bdcf-a58d55b959ca">1.6</ix:nonFraction>&#160;billion. The assets acquired are intended to address substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Depending on the asset, probability of success factors ranging from <ix:nonFraction unitRef="number" contextRef="iafbc6103989b414a84c18b6479a23d0b_I20201001" decimals="1" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzMwMTQ_f3c849c3-0024-4b74-9e7e-adbd6efda56c">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i657d184bcd08449dbbd5a6d436f9a8f6_I20201001" decimals="2" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzMwMjA_970ebab6-0944-43a8-b9cd-2ebae7bad1e5">77</ix:nonFraction>% were used in the fair value calculation to reflect inherent development and regulatory risk of the IPR&amp;D. The discount rate applied was approximately <ix:nonFraction unitRef="number" contextRef="i3dc89baa93fd48229b56fd011dd9c983_I20201001" decimals="2" name="jnj:BusinessAcquisitionDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzMxNzM_000e9577-9a9e-4c16-910f-f658986b50c2">13</ix:nonFraction>%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. The transaction was accounted for as a business combination and included in the Pharmaceutical segment.                   </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2019 certain businesses were acquired for $<ix:nonFraction unitRef="usd" contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzM1MTY_0eee7be8-7470-412b-94a9-70607078ca07">5.8</ix:nonFraction> billion in cash and $<ix:nonFraction unitRef="usd" contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzM1MzE_ea2284b9-130c-42be-9977-5b0ad4fa72d9">1.4</ix:nonFraction> billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $<ix:nonFraction unitRef="usd" contextRef="i1c34dca13b3246238c5245124b592b5c_I20191229" decimals="-8" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzM4NTY_30c550da-1fb1-436f-9394-b83aa856002b">6.8</ix:nonFraction>&#160;billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fiscal year 2019 acquisitions primarily included DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products and Auris Health, Inc. a </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id0da0a6bdab04907be9ce714c83bc991" continuedAt="ia2bc9349053d40d2b1e5f2591c3ca213"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">privately held developer of robotic technologies, initially focused in lung cancer, with an U.S. FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 17, 2019, the Company acquired DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products for a total purchase price of approximately &#165;<ix:nonFraction unitRef="jpy" contextRef="if156d32e424b440faf1f0d3e777e112b_D20190117-20190117" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzQ2MTI_237b648a-d236-40cd-8cf1-8e76ddcb38a6">230</ix:nonFraction> billion, which equates to approximately $<ix:nonFraction unitRef="usd" contextRef="if156d32e424b440faf1f0d3e777e112b_D20190117-20190117" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzQ2NDc_4a63ce1e-4ee2-4900-b642-38582f9088d9">2.1</ix:nonFraction> billion, using the exchange rate of <ix:nonFraction unitRef="number" contextRef="i31c41bc161bd4282b210e004dbeb91e5_I20190116" decimals="2" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzQ2Nzg_8cf41967-abe9-49cc-ba0c-b42d41a43d1d">109.06</ix:nonFraction> Japanese Yen to each U.S. Dollar on January 16, 2019. Additionally, in the fiscal first quarter of 2019, the Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $<ix:nonFraction unitRef="usd" contextRef="ief3cab3c65b84702aa8c68b0beb5654a_D20181231-20190331" decimals="-8" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzQ4ODI_5a4681bc-14ee-4dfc-b596-be2b635c4d19">0.3</ix:nonFraction> billion related to the Company's previously held equity investment in DR. CI:LABO. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company treated this transaction as a business combination and included it in the Consumer Health segment.  During the fiscal first quarter of 2020, the Company finalized the purchase price allocation. The final fair value of the acquisition was allocated primarily to amortizable intangible assets for $<ix:nonFraction unitRef="usd" contextRef="ia63d28caef88416ba2d4d20a17561867_I20200329" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzUyNjg_e73d7bf4-06a1-4c50-9a4f-1f36a2ebcf79">1.5</ix:nonFraction> billion, goodwill for $<ix:nonFraction unitRef="usd" contextRef="ia63d28caef88416ba2d4d20a17561867_I20200329" decimals="-8" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzUyODU_49259ada-e086-4cb8-99a3-2044b3219cb4">1.2</ix:nonFraction> billion and liabilities of $<ix:nonFraction unitRef="usd" contextRef="ia63d28caef88416ba2d4d20a17561867_I20200329" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzUzMDc_b09c29a5-b181-445e-bf95-3c437af8995b">0.4</ix:nonFraction> billion. The amortizable intangible assets were comprised of brand/trademarks and customer relationships with a weighted average life of <ix:nonNumeric contextRef="i7bb9d754278d494ea4868d3a7a6440d8_D20200928-20210103" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzU0Mzk_1f7820d8-5090-46a7-a15f-66d85a5cb045">15.3</ix:nonNumeric> years. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 1, 2019 the Company&#160;completed the acquisition of Auris Health, Inc. for approximately $<ix:nonFraction unitRef="usd" contextRef="i27523630f0dc4c789b10d08289448d52_D20190401-20190401" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzU2OTI_f9841983-9abd-4f7d-96fe-1c76266d931a">3.4</ix:nonFraction> billion, net of cash acquired. Additional contingent payments of up to $<ix:nonFraction unitRef="usd" contextRef="idf01140629ce4b44992bec25a4d0157b_I20190401" decimals="-7" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzU3NTg_e6b62e6c-6d3b-4296-99a2-907495ef294c">2.35</ix:nonFraction> billion, in the aggregate, may be payable upon reaching certain predetermined milestones. Auris Health was a privately held developer of robotic technologies, initially focused in lung cancer, with a U.S. FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. The Company treated this transaction as a business combination and included it in the Medical Devices segment. The fair value of the acquisition was allocated primarily to amortizable and non-amortizable intangible assets, primarily IPR&amp;D for $<ix:nonFraction unitRef="usd" contextRef="idf01140629ce4b44992bec25a4d0157b_I20190401" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzYyODk_4801f926-99a1-4798-b782-1a86479d0d98">3.0</ix:nonFraction> billion, goodwill for $<ix:nonFraction unitRef="usd" contextRef="idf01140629ce4b44992bec25a4d0157b_I20190401" decimals="-8" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzYzMDY_abbe65ba-6cb3-4815-8a11-e4549c610829">2.0</ix:nonFraction> billion, marketable securities of $<ix:nonFraction unitRef="usd" contextRef="idf01140629ce4b44992bec25a4d0157b_I20190401" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzYzMzU_b1561cd2-c9a6-47cd-b516-963f12430b21">0.2</ix:nonFraction> billion and liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="idf01140629ce4b44992bec25a4d0157b_I20190401" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzYzNjU_f7f3e028-4237-41a5-82df-eca8b4e96651">1.8</ix:nonFraction> billion, which includes the fair value of the contingent payments mentioned above. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. During the fiscal second quarter of 2020, the Company finalized the purchase price allocation. During fiscal 2020, the Company recorded Other income of approximately $<ix:nonFraction unitRef="usd" contextRef="i4958dd807d8c42a3b81c7c535df76aae_I20210103" decimals="-8" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzY2MDk_f4515db9-60f3-4586-bdf1-85300dc3f5ff">1.1</ix:nonFraction>&#160;billion for the reversal of all of the contingent consideration related to the timing of certain developmental and commercial milestones, which are not expected to be met based on the Company&#8217;s current timelines. During the fiscal third quarter of 2020, the Company recorded a partial IPR&amp;D impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i91459e999e794e2a864d95b8eb009680_D20200629-20200927" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzY5MTY_820c01c9-5c6b-4333-96e5-a0e3f96f7dcc">0.1</ix:nonFraction>&#160;billion related to timing and progression of the digital surgery platforms. In the fiscal third quarter of 2021, the Company recorded a partial IPR&amp;D charge of $<ix:nonFraction unitRef="usd" contextRef="i2b6fbd9b80d84153817595caadafdadd_D20210705-20211003" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEwOTk1MTE2Mjk4NDE3_e7e07178-28de-4e7e-98e2-e9d1706c1c0b">0.9</ix:nonFraction>&#160;billion primarily related to expected development delays in the general surgery digital robotics platform (Ottava). A probability of success factor ranging from <ix:nonFraction unitRef="number" contextRef="if9f9f41fdfe94421ada2b29f1eda2e7d_I20190401" decimals="2" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzcwMzI_b98015c1-bc7f-42d1-b513-9f9216a596b3">18</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ic68faf24908f44f48cafea31ccd53622_I20190401" decimals="2" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzcwMzg_f4294bb8-ee94-49a0-a849-220f38a7d037">66</ix:nonFraction>% across Ottava sub-platforms, was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&amp;D. The discount rate applied was approximately <ix:nonFraction unitRef="number" contextRef="idf01140629ce4b44992bec25a4d0157b_I20190401" decimals="3" name="jnj:BusinessAcquisitionDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzcyMTM_dcbb2424-7c35-4026-a32b-4a492b3e5863">9.5</ix:nonFraction>%.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with U.S.&#160;GAAP standards related to business combinations, and goodwill and other intangible assets, supplemental pro forma information for fiscal years 2021, 2020 and 2019 is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company&#8217;s results of operations, cash flows or financial position.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestitures</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During fiscal year 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately  $<ix:nonFraction unitRef="usd" contextRef="ie12611a8a0b5457b8429c851c4a1acb1_D20210104-20220102" decimals="-7" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzg0Mjg_b6e9c6de-0f34-45f7-9889-0249595da999">0.6</ix:nonFraction>&#160;billion. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i12d629a6349442e1bcd3b89fd1744c17_D20191230-20210103" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzg1NTc_35b26396-a576-4917-b21e-1de0b7c9a1a3">11.8</ix:nonFraction>&#160;million shares of Idorsia LTD (Idorsia), or its <ix:nonFraction unitRef="number" contextRef="i12d629a6349442e1bcd3b89fd1744c17_D20191230-20210103" decimals="3" name="us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzg2MDA_34bec073-2a6d-4d0b-bfe4-3daea2b867fa">8.3</ix:nonFraction>% ownership in the company at that time. The transaction resulted in gross proceeds of approximately CHF <ix:nonFraction unitRef="chf" contextRef="i12d629a6349442e1bcd3b89fd1744c17_D20191230-20210103" decimals="-6" name="us-gaap:ProceedsFromSaleOfInterestInCorporateUnit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzg2OTM_91711bd2-7343-4ba3-a54f-9844d7864e97">337</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i12d629a6349442e1bcd3b89fd1744c17_D20191230-20210103" decimals="-6" name="us-gaap:ProceedsFromSaleOfInterestInCorporateUnit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzg2OTc_756e5d54-1b1f-4977-86a1-91883502a6f0">357</ix:nonFraction>&#160;million) based on a sales price of CHF <ix:nonFraction unitRef="usdPerShare" contextRef="i0028bc7fe5bc4af89fae762f116f5492_I20210103" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzg3MzE_45326c88-1a80-4926-a40f-d97da8adc493">28.55</ix:nonFraction>/share and resulted in an immaterial net loss. At the end of fiscal 2020, the Company had rights to approximately <ix:nonFraction unitRef="shares" contextRef="i12d629a6349442e1bcd3b89fd1744c17_D20191230-20210103" decimals="-5" name="jnj:ConvertibleNoteEquityInterestNumberOfShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEwOTk1MTE2Mjk4NDMx_8e7ab85f-3c2d-4da6-99e5-7c7a36a9482d">38.7</ix:nonFraction>&#160;million shares through a convertible loan with a principal amount of CHF <ix:nonFraction unitRef="chf" contextRef="i96cb437b61cd4edc8359b3f5f09fa26c_I20210103" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEwOTk1MTE2Mjk4NDQ1_70af0d0d-96a6-46a8-a4b3-601e3cd68da4">445</ix:nonFraction>&#160;million (due June 2027). During fiscal year 2021, the Company converted CHF <ix:nonFraction unitRef="chf" contextRef="i9fed2deb8c9147eb8ff44239290a9c54_D20210104-20220102" decimals="-6" name="jnj:DebtInstrumentConvertibleAmountOfLoanConverted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEwOTk1MTE2Mjk4NDcx_73b6728f-3b97-43df-acad-70ea660fb7be">110</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i9fed2deb8c9147eb8ff44239290a9c54_D20210104-20220102" decimals="-6" name="jnj:DebtInstrumentConvertibleAmountOfLoanConverted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEwOTk1MTE2Mjk4NDg0_9b40f039-5867-47cb-93cf-cc0f93f6cda2">120</ix:nonFraction>&#160;million) of this loan into approximately <ix:nonFraction unitRef="shares" contextRef="i9fed2deb8c9147eb8ff44239290a9c54_D20210104-20220102" decimals="-5" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEwOTk1MTE2Mjk4NDU4_0e373eaa-5122-4e2e-bd3b-3e6a03e8bfff">9.6</ix:nonFraction>&#160;million shares of Idorsia which were reflected at fair value as of January 2, 2022. During the fiscal third quarter of 2021, the Company's undrawn credit facility with Idorsia was terminated. </span></div></ix:continuation><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia2bc9349053d40d2b1e5f2591c3ca213">During fiscal year 2019, the Company divested its ASP business to Fortive Corporation for an aggregate value of approximately $<ix:nonFraction unitRef="usd" contextRef="i1c2687a93cd147aa9d8a4fba7100335e_I20191229" decimals="-8" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzkyNTE_a3ac1e7c-d488-4fbf-a6ac-ca6f14fa6bfd">2.8</ix:nonFraction> billion, consisting of $<ix:nonFraction unitRef="usd" contextRef="i1c2687a93cd147aa9d8a4fba7100335e_I20191229" decimals="-8" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCash" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzkyNjk_33bbc1ce-83b9-4c9b-813e-f3c691b3d663">2.7</ix:nonFraction> billion of cash proceeds and $<ix:nonFraction unitRef="usd" contextRef="i1c2687a93cd147aa9d8a4fba7100335e_I20191229" decimals="-8" name="jnj:DisposalGroupIncludingDiscontinuedOperationReceivablesRetained" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzkyOTM_6486eff0-4d9a-46b1-8f41-b63be9e07231">0.1</ix:nonFraction> billion of retained net receivables. The Company recognized a pre-tax gain recorded in Other ( income) expense, net, of approximately $<ix:nonFraction unitRef="usd" contextRef="i5fb558e71971413fb73765983f5dcf7c_D20181231-20191229" decimals="-8" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzk0MjI_8478910b-68a1-452e-b16b-6e125e59cf7a">2.0</ix:nonFraction> billion.</ix:continuation> </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i01be8f8f216a4c39adb513a606bfe937_217"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2Xzg4NDI3_9151385d-7683-44f4-9516-9c0f94f4bf76" continuedAt="id5bdb610b7104c90b4259009405ae0f6" escape="true">Legal Proceedings</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id5bdb610b7104c90b4259009405ae0f6" continuedAt="i0569c0d969a94efe9727b0e1edf3fb39">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. Due to the ongoing impacts of the COVID-19 pandemic, certain trials have been rescheduled or delayed. The Company continues to monitor its legal proceedings as the situation evolves and in person trials resume.</ix:continuation></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0569c0d969a94efe9727b0e1edf3fb39" continuedAt="i02e4381fb16f4cd7bdebc53eb4037bbf"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of January&#160;2, 2022, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company&#8217;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#8217;s balance sheet, is not expected to have a material adverse effect on the Company&#8217;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#8217;s results of operations and cash flows for that period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PRODUCT LIABILITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The most significant of these cases include: the DePuy ASR&#8482; XL Acetabular System and DePuy ASR&#8482; Hip Resurfacing System; the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Acetabular Cup System; pelvic meshes; RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">; XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">; body powders containing talc, primarily JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Baby Powder; INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">; and ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Flexible Composite Mesh. As of January&#160;2, 2022, in the United States there were approximately <ix:nonFraction unitRef="claimant" contextRef="i1293b88bd90d458eac2d0d6a7b850b0d_I20220102" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzQ1NTM_fac0ebb1-4f81-43ab-a5b1-e8666cd68d92">250</ix:nonFraction> plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR&#8482; XL Acetabular System and DePuy ASR&#8482; Hip Resurfacing System; <ix:nonFraction unitRef="claimant" contextRef="i16e6e6646c3b4d109123795d9c7df84e_I20220102" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzQ3MTc_cf17c795-13c0-4ac4-9da6-f0ecb82b18ce">5,300</ix:nonFraction> with respect to the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Acetabular Cup System; <ix:nonFraction unitRef="claimant" contextRef="idb4e5502065243778f8d181c244dd324_I20220102" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzQ3NzM_904557c1-0b01-4f88-95fd-213b7fd3ef09">10,100</ix:nonFraction> with respect to pelvic meshes; <ix:nonFraction unitRef="claimant" contextRef="ic9d5ee581ec640ec80ed1f8d2ef956fe_I20220102" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzQ4MDc_274ac128-a67f-4f5a-b056-cd846afd2e12">8,800</ix:nonFraction> with respect to RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">; <ix:nonFraction unitRef="claimant" contextRef="ia4378318856543098e6cf32dbe8237ca_I20220102" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzQ4Mzg_61a8a3d6-b5f9-466c-8b54-512df166c083">5,500</ix:nonFraction> with respect to XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">; <ix:nonFraction unitRef="claimant" contextRef="i7ac530b2a8144cd796fa1d12ee757dfa_I20220102" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzQ4Njc_f298d91d-baa9-497a-9876-4bea9cf3d3a5">40,400</ix:nonFraction> with respect to body powders containing talc; <ix:nonFraction unitRef="claimant" contextRef="ie7be14aefb4947a6870ffa19e0bf31ca_I20220102" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzQ5MTY_09b98891-435f-4cda-8090-932062719aef">100</ix:nonFraction> with respect to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and <ix:nonFraction unitRef="claimant" contextRef="ieb92b728ef4e453193b6bc673799a78b_I20220102" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzQ5NTA_8ece3776-2499-4409-b3de-1d0822905411">4,700</ix:nonFraction> with respect to ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Flexible Composite Mesh. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> XL Acetabular System and DePuy ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp; Johnson. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than <ix:nonFraction unitRef="claimant" contextRef="i55464ad945a643baa712e791b033c1ed_I20220102" decimals="0" name="jnj:Numberofpatientsinsettlement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYzNDA_2b7f69f9-2133-4bba-aaa9-6abad309af7f">10,000</ix:nonFraction>  claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle </span><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the class actions filed in that country</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company continues to receive information with respect to potential additional </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i02e4381fb16f4cd7bdebc53eb4037bbf" continuedAt="i7baddce199b3430bb50c28075dcd5f13"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp; Johnson (collectively, DePuy) relating to the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation also has been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System and the related settlement program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson arising out of Ethicon&#8217;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#8217;s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#8217;s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands and class actions in Israel, Australia and Canada. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021, and the High Court heard oral argument on the application in November 2021. Special leave was refused. While this brings an end to the appellate process, there will now be an individual case assessment process for the remaining group member claims. The parties currently are in discussions with the Court to determine the form and mechanism of that individual case assessment process. The next hearing is scheduled for late February 2022. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently negotiating the wording and some of the terms thereof and once finalized, the settlement will be subject to court approval. The parties are due to update the court on the status of the finalization of the settlement negotiations by the end of February 2022. The Company has established accruals with respect to product liability litigation associated with Ethicon&#8217;s pelvic mesh products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately <ix:nonFraction unitRef="cases" contextRef="i8a3b65d9882f4457b2a58709975f0f58_I20210531" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzY1OTcwNzAxNzE0MDY_d61a19f6-61e5-4538-b0e4-bf3fddbb5ac7">3,600</ix:nonFraction> Physiomesh cases (covering approximately <ix:nonFraction unitRef="claimant" contextRef="i8a3b65d9882f4457b2a58709975f0f58_I20210531" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYwNDczMTQwNzE2NzE_12b6d541-6555-4beb-a84a-8b7f6d4854de">4,300</ix:nonFraction> plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes <ix:nonFraction unitRef="cases" contextRef="i09cbeb4b729f4746a9c451af63dd91c7_I20210930" decimals="0" name="jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYwNDczMTQwNzU5Mzg_98cdad4b-2bb4-4e4b-868d-3059e7338b6c">3,729</ix:nonFraction> cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. The deadline for issuance of Individual Allocation amounts by the Special Master is March 2022. The costs associated with this proposed settlement are reflected in the Company&#8217;s accruals. Post-Settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of February 2022, there are approximately <ix:nonFraction unitRef="cases" contextRef="ib1cc0378da84475bbc08a06b2a879405_I20220228" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYwNDczMTQwNzU5NDU_b587507f-76b8-4559-8a36-16ae6085c91e">90</ix:nonFraction> active cases subject to these orders which are being reviewed and evaluated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">Claims have also been filed against Ethicon and Johnson &amp; Johnson alleging personal injuries arising from the PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"> Mesh and PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"> Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. Discovery is underway in the MCL proceedings. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i7baddce199b3430bb50c28075dcd5f13" continuedAt="iec8e58539b684734b2e7c03eac98d065"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ethicon and Johnson &amp; Johnson also have been subject to claims for personal injuries arising from the PROLENE&#8482; Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Flexible Composite Mesh, PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Mesh and PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Ventral Patch, and PROLENE&#8482; Polypropylene Hernia System products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson arising out of the use of RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $<ix:nonFraction unitRef="usd" contextRef="i5cd3b425c568464d84bffc5929d955ac_D20191001-20191031" decimals="-9" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzEzMzEx_79be0016-f7b7-4b31-bcaa-a52ae6882ce7">8.0</ix:nonFraction>&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $<ix:nonFraction unitRef="usd" contextRef="i6133d5a7101f441a9444db674a47b348_D20200101-20200131" decimals="-5" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzEzNDE2_cf08dc22-db56-4a83-8d5b-f47e579c60c3">6.8</ix:nonFraction>&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury arising out of the use of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp; Johnson; and JPI&#8217;s collaboration partner for XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Bayer Healthcare AG, and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson &amp; Johnson announced an agreement in principle to settle the XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp; Johnson Consumer Inc. and Johnson &amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase through fiscal year 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of  $<ix:nonFraction unitRef="usd" contextRef="i8473134a97db464ab939bcb0bb98f418_D20180701-20180731" decimals="-8" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzE2MzQ4_91743db1-4b4b-4a1a-a335-df3214d7e037">4.7</ix:nonFraction>&#160;billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham v. Johnson &amp; Johnson, et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No. ED 207476 (Mo. App.), reducing the overall award to $<ix:nonFraction unitRef="usd" contextRef="i659974d043fe4a37b83a80d13bc59d65_D20200601-20200628" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzE2NDQ3_b6281cfb-1077-4029-8a5b-a88506f1daf0">2.1</ix:nonFraction>&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $<ix:nonFraction unitRef="usd" contextRef="if17dccaaceb943739755c40b7c59083d_D20210601-20210630" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzE2NTU1_5f86d0a9-0f3a-4eb5-8a6c-cfbb059d8368">2.5</ix:nonFraction>&#160;billion. The facts and circumstances, including the terms of the award, were unique to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, Johnson &amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#8217;s direct parent, Johnson &amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#8217;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#8217; compensation statute or act (the Talc-Related Liabilities). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, notwithstanding the Company&#8217;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). As a result of the LTL Bankruptcy Case, the Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iec8e58539b684734b2e7c03eac98d065" continuedAt="id7e6a81e499c461a8ecb8bafd091f887"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, Johnson &amp; Johnson, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court subsequently extended the PI through the end of February 2022. Claimants have filed a motion to dismiss the LTL Bankruptcy Case. The court commenced a hearing on February 14, 2022 regarding the motion to dismiss and on whether the PI should be extended. While the PI effectively stays all of the Company&#8217;s talc-related personal injury litigation, LTL has agreed to lift the automatic stay on a small number of appeals where appeal bonds have been filed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has agreed to provide funding to LTL for the payment of amounts the Bankruptcy Court determines are owed by LTL through the establishment of a $<ix:nonFraction unitRef="usd" contextRef="ifba96edcac3c4389a3b0bb8b2c90cd45_D20211001-20211031" decimals="-9" name="jnj:LossContingencyReserveEstablishedWithinTrust" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYwNDczMTQwOTE1ODc_e145726d-c113-423d-8013-a673da075dca">2</ix:nonFraction>&#160;billion trust in furtherance of this purpose. The Company has established a reserve for approximately $<ix:nonFraction unitRef="usd" contextRef="ifba96edcac3c4389a3b0bb8b2c90cd45_D20211001-20211031" decimals="-9" name="jnj:LossContingencyReserveEstablishedWithinTrust" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYwNDczMTQwOTE1NzU_12875cb5-a5ac-432a-ae4c-7efd013a3eab">2</ix:nonFraction>&#160;billion in connection with the aforementioned trust. Subsequent to the fiscal third quarter of 2021, the Company de-consolidated LTL, which is a related party, as a result of the bankruptcy filing. The impact of the de-consolidation is not material to the Company. The parties have not yet been able to reach a resolution of all matters related to talc, and while certain amounts under various scenarios have recently been referred to in testimony as part of the LTL bankruptcy proceedings, the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217;s potential liability for personal injury from exposure to talcum powder sold by Imerys (Talc Claims). In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants&#8217; Committee (TCC), and the Future Claimants&#8217; Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent&#8217;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan. The Company challenged certain improprieties with respect to portions of the vote and sought to disqualify those votes. In October 2021, the Bankruptcy Court issued a ruling deeming thousands of votes as withdrawn as improperly voted. In October 2021, Imerys cancelled the confirmation hearing on the Plan. Imerys, the TCC, the FCR, and certain of Imerys&#8217;s insurers (the Mediation Parties) have since agreed to engage in mediation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys adversary proceeding). The Imerys adversary proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company&#8217;s talc liabilities from its other assets. The Bankruptcy Court denied the motion. The Company thereafter filed a motion to dismiss the adversary proceeding. The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Imerys adversary proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2020, Cyprus Mines Corporation and its parent (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus adversary proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan. The Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against Talc Claims asserted against it. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the TCC and FCR appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus adversary proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2021, several of the Company&#8217;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Coverage Action.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id7e6a81e499c461a8ecb8bafd091f887" continuedAt="i3bb214ce2fae439b8cccec2341a7f41a"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2018, a securities class action lawsuit was filed against Johnson &amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Baby Powder, and that purchasers of Johnson &amp; Johnson&#8217;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, the Company answered the complaint. In April 2021, briefing on Plaintiffs&#8217; motion for class certification was completed. In July 2021, the Company filed a notice of supplemental authority in opposition to Plaintiff&#8217;s motion for class certification, and Plaintiff filed a response. In December 2021, the Company filed a motion to supplement the class certification record, and in January 2022, Plaintiff responded. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson &amp; Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. In February 2022, the Court granted Johnson &amp; Johnson's cross motion to dismiss. In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Baby Powder, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2020, a report was delivered to the Company&#8217;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues and demanding that suit be brought against certain Directors. Four of the shareholders who sent demands are plaintiffs in th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp; Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson &amp; Johnson&#8217;s motion to dismiss pending a decision on Plaintiff&#8217;s motion for discovery. In November 2021, at the Court&#8217;s request, the parties submitted supplemental briefing on Plaintiff&#8217;s motion for discovery. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp; Johnson Savings Plan against Johnson &amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp; Johnson stock as a Johnson &amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#8217; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#8217; motion was complete. In February 2021, the Court granted Defendants&#8217; motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice. In May 2021, Plaintiffs filed a notice of appeal with the Third Circuit. In July 2021, Plaintiffs filed their opening brief in the Third Circuit and in September 2021, Defendants filed their response brief, and in October 2021, Plaintiffs filed their reply brief. In January 2022, the Third Circuit heard oral argument.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#8217;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Baby Powder. In that lawsuit, the plaintiffs allege that Johnson &amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#8217;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. In October 2021, Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit. A bankruptcy stay was imposed in December 2021, and the Court held the reply deadline in abeyance.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters, including from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice, the Subcommittee on Economic and Consumer Policy of the House Committee on Oversight and Reform, the Senate </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3bb214ce2fae439b8cccec2341a7f41a" continuedAt="id2b77a1dce0c4049b64b4c4948818a33"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Committee on the Judiciary, the House Committee on Oversight and Reform, and individual Members of Congress. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases also have been filed in various state courts. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> related product liability litigation.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">INTELLECTUAL PROPERTY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain subsidiaries of Johnson &amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#8217;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medical Devices</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that Acclarent&#8217;s RELIEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Spin and RELIEVEA SpinPlus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> products infringe U.S. Patent No. 9,011,412. Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of Acclarent&#8217;s U.S. Patent No. 8,414,473. Trial began in October 2021, and shortly thereafter, the parties reached an agreement to settle the case. Plaintiff&#8217;s motion to dismiss with prejudice was filed in October 2021. The case was dismissed with prejudice in November 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (&#8217;200); 6,491,701 (&#8217;701); 6,522,906 (&#8217;906); 6,800,056 (&#8217;056); 8,142,447 (&#8217;447); 8,620,473 (&#8217;473); 8,801,601 (&#8217;601); and 9,452,276 (&#8217;276) based on Auris&#8217; Monarch&#8482; Platform. Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the &#8217;200, &#8217;056, &#8217;601 &#8217;701, &#8217;447, &#8217;276 and &#8217;906 patents. Intuitive subsequently dropped the &#8217;200, &#8217;473 and &#8217;701 patents from the suit. In December 2019, the USPTO instituted review of the &#8217;601 patent and denied review of the &#8217;056 patent. In February and March 2020, the USPTO instituted review of the &#8217;200, &#8217;447, &#8217;701 and &#8217;906 patents and denied review of the &#8217;276 patent. In December 2020, the USPTO declared all of the challenged claims in the &#8217;601 patent to be invalid. Intuitive has appealed that decision. In March 2021, the USPTO ruled that the challenged claims of the &#8217;447 and &#8217;906 patents are not invalid. Auris has appealed that decision. Auris filed a request for reexamination of the &#8217;276 patent in November 2021, and in January 2022, the USPTO granted the reexamination request. Trial is scheduled to begin in January 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in the United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 and 9,713,537 by one or more of the following products:  ZERO-P-VA&#8482; Spacer, ZERO-P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Spacer, ZERO-P NATURAL&#8482; Plate, SYNFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> LR Spacer and SYNFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Evolution System. RSB Spine seeks </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id2b77a1dce0c4049b64b4c4948818a33" continuedAt="i41294ab563594dd5acc3e2f9279b5ad0"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. A stay that had been entered pending Inter Partes Review at the U.S. Patent &amp; Trademark Office has been lifted, and trial is scheduled to begin in December 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2020, Osteoplastics, LLC filed a patent infringement suit against DePuy Synthes, Inc., DePuy Synthes Products, Inc., Medical Device Business Services, Inc., and Synthes, Inc. (collectively, DePuy Synthes) in the United States District Court for the District of Delaware. In the suit, Osteoplastics alleges willful infringement of U.S. Patent Nos. 8,781,557; 9,929,920; 9,330,206; 9,626,756; 9,672,617; 9,672,302; and 9,275,191 based on the PROPLAN CMF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Virtual Surgical Planning Services and the TruMatch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> CMF Personalize Solutions. In April 2020, Osteoplastics filed an amended complaint to substitute U.S. Patent No. 9,292,920 for U.S. Patent No. 9,929,920. Osteoplastics seeks monetary damages and injunctive relief. In June 2020, DePuy Synthes filed a motion to dismiss the complaint. In October 2020, the Court dismissed Medical Device Business Services, Inc. from the case but otherwise denied the motion. In June 2021, Osteoplastics admitted that the PROPLAN CMF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Virtual Surgical Planning Services do not infringe any asserted patents. Trial was scheduled for October 2022. In October 2021, the case was settled and dismissed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Rasmussen Instruments, LLC (Rasmussen) filed a patent infringement suit against DePuy Synthes Products, Inc., DePuy Synthes Sales, Inc. and Medical Device Business Services, Inc. (collectively, DePuy) in the United States District Court for the District of Massachusetts. Rasmussen alleges that DePuy willfully infringes U.S. Patent Nos. 9,492,180 and 10,517,583 (&#8217;583) by making and selling the Attune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Balanced Sizer. In April 2021, Rasmussen sought permission to amend its infringement contentions to allege that DePuy also willfully infringes the &#8217;583 patent by making and selling the Attune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Balancing Blocks. Rasmussen seeks treble damages for willful infringement. Trial is scheduled for February 2022.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmaceutical</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes lawsuits the Company&#8217;s subsidiaries have brought against generic companies that have filed ANDAs with the U.S. FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. In the event the Company&#8217;s subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the generic companies involved would have the ability, upon approval of the U.S. FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#8217;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in January 2019, Janssen Inc. and Janssen Oncology, Inc. (collectively, Janssen) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex Inc. (Apotex), Pharmascience Inc. (Pharmascience) and Dr. Reddy&#8217;s Laboratories Ltd. and Dr. Reddy&#8217;s Laboratories, Inc. (collectively, DRL) in response to those parties&#8217; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before the expiration of the Canadian Patent No. 2,661,422 (&#8217;422). The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#8217;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of U.S. Patent No. 10,828,310 (&#8217;310). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories, Ltd. which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;310 patent.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i41294ab563594dd5acc3e2f9279b5ad0" continuedAt="i523102f2d1d24862bf4afc6ad8e25d2c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc. (collectively, Taro) which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;310 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;310 patent. In August 2021, the court entered a joint stipulation dismissing Teva Pharmaceutical Industries Ltd.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the court consolidated the Delaware lawsuits for all purposes, including trial. Trial for the consolidated Delaware lawsuits is scheduled to begin in May 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan Pharmaceuticals Inc. and Mylan Inc. which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;310 patent. In August 2021, JPI and Bayer filed a motion before the United States Judicial Panel on Multidistrict Litigation (the MDL panel) to transfer this lawsuit to the United States District Court for the District of Delaware for coordinated and consolidated pretrial proceedings. In December 2021, the MDL panel granted the motion. No trial date has been set in this lawsuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In each of these lawsuits, JPI and Bayer are seeking an order enjoining defendants from marketing their generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before the expiration of the &#8217;310 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, Janssen Pharmaceuticals, Inc., Janssen Research &amp; Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories Ltd (DRL), who filed an ANDA seeking approval to market a generic version of INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before expiration of MTPC&#8217;s United States Patent No. 7,943,788 (&#8217;788) relating to INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In January 2021, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before expiration of MTPC&#8217;s United States Patent Nos. 7,943,582 (&#8217;582) and/or 8,513,202 (&#8217;202) relating to INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">In each of these U.S. lawsuits, Janssen and MTPC are seeking an order enjoining the defendant from marketing their generic versions of INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"> and/or, INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, Janssen Inc., Janssen Pharmaceutica NV and MTPC initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the Canadian Patent Nos. 2,799,204, 2,534,024 and 2,671,357. Janssen Inc., Janssen Pharmaceutica NV and MTPC are seeking an order enjoining Sandoz from marketing its generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents. The trial is scheduled to begin in August 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2020, Janssen Inc. (Janssen) and Actelion Pharmaceuticals Ltd (Actelion) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of Canadian Patent No. 2,659,770 (&#8217;770). Trial is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the &#8217;770 patent. Trial is scheduled to begin in February 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (JAMP) in Canada in response to JAMP&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg before the expiration of the &#8217;770 patent and Canadian Patent No. 2,621,273 (&#8217;273). Trial is scheduled to begin in April 2022. </span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i523102f2d1d24862bf4afc6ad8e25d2c" continuedAt="idef5b21ad0274d989e4841e5e6ec78c5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before the expiration of United States Patent No. 9,439,906 (&#8217;906). Trial concluded in October 2020. In October 2021, the court issued a decision in Janssen&#8217;s favor. Teva has appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;906 patent. Pursuant to an agreement by the parties, judgment in favor of Janssen was entered in December 2021. Mylan has filed an appeal. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Tolmar, Inc., Tolmar Therapeutics, Inc., Tolmar Pharmaceuticals, Inc. and Tolmar Holding, Inc. (collectively, Tolmar), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of Canadian Patent Nos. 2,309,629 (&#8217;629) and 2,655,335 (&#8217;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#8217;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#8217;s generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if approved, would infringe certain claims of the &#8217;335 patent and that the claims of the &#8217;335 patent are not invalid for obviousness. Teva Canada appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in November 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. A trial on the issue of validity is scheduled to begin in July 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in December 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Apotex has not contested validity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LLC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (546 mg) before expiration of United States Patent No. 10,143,693 (&#8217;693) relating to INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(546 mg). Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before the expiration of the &#8217;693 patent. Trial is scheduled to begin in October 2022. </span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idef5b21ad0274d989e4841e5e6ec78c5" continuedAt="i1bdcc1fa10e544d09dcfda13745c2656"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(819 mg) before expiration of the &#8217;693 patent. Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (819 mg) before the expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (273 mg and 410 mg) before expiration of the &#8217;693 patent. Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (273 mg and 410 mg) before the expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the court consolidated the three cases into the case filed in September 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, asserting infringement of United States Patent Nos. 7,514,444; 8,003,309; 8,476,284; 8,497,277; 8,697,711; 8,753,403; 8,754,090; 8,754,091; 8,952,015; 8,957,079; 9,181,257; 9,296,753; 9,655,857; 9,725,455; 10,010,507; 10,106,548; and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386. Pharmacyclics and JBI are seeking an order enjoining the defendants from marketing generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trial against Alvogen took place in October 2020. In August 2021, the District Court issued a decision in favor of Pharmacyclics and Janssen finding the asserted claims against Alvogen to be infringed and not invalid. Alvogen has appealed that decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2021, Pharmacyclics and Janssen Inc. (Janssen Canada) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco Pharma (Canada) Inc. (Natco) in response to Natco&#8217;s filing of two ANDSs seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">capsules before the expiration of Canadian Patent Nos. 2,663,116; 2,928,721; 2,800,913; 3,007,787; 3,007,788; 2,875,986; and 3,022,256. The trial is scheduled to begin in July 2023. Pharmacyclics and Janssen are seeking an order enjoining Natco from marketing its generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2020, Actelion Pharmaceuticals Ltd (Actelion) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Zydus Pharmaceuticals (USA), Inc. and Zydus Worldwide DMCC (collectively, Zydus), who filed an ANDA seeking approval to market a generic version of UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">before expiration of Nippon Shinyaku&#8217;s United States Patent Nos. 7,205,302 (&#8217;302); relating to UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Actelion is the exclusive licensee of the &#8217;302 patent. In January 2022, Actelion, Nippon Shinyaku and Zydus entered into a confidential settlement agreement and the lawsuit was dismissed.</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GOVERNMENT PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Average Wholesale Price (AWP) Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1bdcc1fa10e544d09dcfda13745c2656" continuedAt="i0899445885864961aace0aee5a03ce32"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;J AWP Defendants were ultimately dismissed. The J&amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp; Johnson and ALZA Corporation. All other cases have been resolved.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Opioid Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in 2014 and continuing to the present, Johnson &amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in approximately <ix:nonFraction unitRef="claimant" contextRef="ieb58c35946ea47c2a018ec31bb2540d3_I20220102" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzU3Mjg1_7cfd2fd1-0b06-40c9-a5d4-b915a378ccb8">3,400</ix:nonFraction> lawsuits related to the marketing of opioids, including DURAGESIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, NUCYNTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and NUCYNTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including Johnson &amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The Government of Puerto Rico filed suit in Superior Court of San Juan. There are over <ix:nonFraction unitRef="claimant" contextRef="i9c3dc4fb3ece45fdbc810c1cbca8eab7_I20220102" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzY1OTcwNzAxNzE0MjA_2bf08ee4-c00d-4fe7-97ad-0bbbcfd4360b">380</ix:nonFraction> cases pending in various state courts. There are close to <ix:nonFraction unitRef="claimant" contextRef="i60459746fbf841b59219889ad727de9f_I20220102" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzY1OTcwNzAxNzE0MTM_16f45659-12b6-4338-ba6d-63d063b68a92">3,000</ix:nonFraction> federal cases coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio. In addition, the Province of British Columbia filed suit against Johnson &amp; Johnson and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against Johnson &amp; Johnson and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. In October 2019, an antitrust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2019, the trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp; Johnson and JPI in the amount of $<ix:nonFraction unitRef="usd" contextRef="ia204f8664a9d4e17b4e9da7fc3db9fc3_D20181231-20191229" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYwMjE2_2d1a75d7-f44a-456c-bf4a-4096f6cc33b1">465</ix:nonFraction>&#160;million. Johnson &amp; Johnson and JPI appealed the judgment, and in November 2021, the Oklahoma Supreme Court reversed the trial court&#8217;s judgment. In October 2019 Johnson &amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against Johnson &amp; Johnson and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial concluded in October 2021, and in December 2021, the Court entered a final trial judgment in favor of Defendants on all claims. In February 2022, Plaintiffs' motion to set aside and vacate the judgment was denied.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Johnson &amp; Johnson received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. In September 2019, Johnson &amp; Johnson received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums. In September 2020, the Company learned that NYDFS filed a statement of charges related to this investigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2021, the Company and JPI announced a settlement agreement with the State of New York and its participating subdivisions, including Nassau County and Suffolk County, resolving their opioid-related claims against the Company on terms consistent with the Company&#8217;s previously announced agreement in principle to contribute up to $<ix:nonFraction unitRef="usd" contextRef="ie9e9d5c5c1ab4177a2b9d89bb136c5e3_D20210601-20210630" decimals="-9" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYxMDkx_f0ed82a3-aaa6-4a92-9352-483cbfbeefeb">5</ix:nonFraction>&#160;billion to all-in settlement of opioid-related claims by states, cities, counties, and tribal governments. The settlement provides New York and its participating subdivisions with up to $<ix:nonFraction unitRef="usd" contextRef="ie9e9d5c5c1ab4177a2b9d89bb136c5e3_D20210601-20210630" decimals="-6" name="jnj:LossContingencyDamagesAwardedAdditionalReimbursementValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYxMTk2_dfe192e6-30c9-48fc-a5a0-72c3694ea7e1">263</ix:nonFraction>&#160;million to address opioid-related issues, reimburses attorney fees and costs, and removes the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0899445885864961aace0aee5a03ce32" continuedAt="i4bd2430c9203471d924855213b54000d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Company and Janssen from a multi-defendant trial of opioid-related claims that commenced in Suffolk County in June 2021. In exchange, the Company and JPI receive releases from the claims asserted by New York and the participating parties, including NYDFS.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the Company and JPI announced a settlement agreement with the State of Texas and its participating subdivisions, including Dallas County, Bexar County, and Tarrant County, resolving their opioid-related claims against the Company on terms consistent with the Company&#8217;s previously announced agreement to contribute up to $<ix:nonFraction unitRef="usd" contextRef="i0d6e9afb25e04fc1adbd653da6d9243e_D20211001-20211031" decimals="-9" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzY1OTcwNzAxNzE0MjU_b4eddceb-f767-41a0-9eff-f419b6aaa242">5</ix:nonFraction>&#160;billion to all-in settlement of opioid-related claims by states, cities, counties, and tribal governments. The settlement provides Texas and its participating subdivisions with up to $<ix:nonFraction unitRef="usd" contextRef="i0d6e9afb25e04fc1adbd653da6d9243e_D20211001-20211031" decimals="-6" name="jnj:LossContingencyDamagesAwardedAdditionalReimbursementValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzY1OTcwNzAxNzE0Mzc_bb691326-b7f0-4459-8625-ab22ad1ba35b">297</ix:nonFraction>&#160;million to address opioid-related issues and reimburse attorney fees and costs, and removes the Company and Janssen from multi-defendant bellwether trials of opioid-related claims scheduled to commence in Texas state courts in early 2022. In exchange, the Company and JPI will receive releases from the claims asserted by Texas and the participating subdivisions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Johnson &amp; Johnson, JPI and other pharmaceutical companies have also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#8217;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $<ix:nonFraction unitRef="usd" contextRef="i7f6076db24f64e8b8d695cf2700ed061_I20191031" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYwNDczMTQxODcwNjk_385722e1-2a3d-42a3-8ea4-aae8984a6c7e">4</ix:nonFraction>&#160;billion as settlement of these matters. In October 2020, the Company agreed to contribute up to an additional $<ix:nonFraction unitRef="usd" contextRef="i07cc6e7b5efd42c9b9d122106a692420_I20201031" decimals="-9" name="jnj:LossContingencyEstimateOfAdditionalPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzY1OTcwNzAxNzE0NTE_43677cfa-cfd5-42e7-8857-27d10f793f20">1</ix:nonFraction>&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of $<ix:nonFraction unitRef="usd" contextRef="i07cc6e7b5efd42c9b9d122106a692420_I20201031" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYwNDczMTQxODcwODE_f890b44d-3a89-4a1b-9c6f-76280be2e892">5</ix:nonFraction>&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement in principle is not an admission of liability or wrong-doing. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims have been finalized and up to one-third of the all-in settlement is expected to be paid within the next 12 months, depending upon the level of participation by the states and their subdivisions. The terms provide a period of time for states to elect to participate in the agreement and, thereafter, a period for the subdivisions of the participating states to opt-in. As of January 2022, 45 states, five territories, and the District of Columbia had elected to participate in the settlement. The subdivision opt-in period expired in January 2022. The Company retains the right to opt-out of the agreement until late February 2022 if, in its sole discretion, there is insufficient participation. Based on expected participation, the Company has committed in advance to proceed with the settlement in five of the participating states (New York, Texas, Florida, Nevada, and New Mexico) and with tribal governments, whose cases were scheduled for trial in 2021, 2022, or 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From June 2017 through December 2019, the Company&#8217;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In May 2020, the shareholder filed an amended complaint challenging the Board&#8217;s rejection of his demand. In August 2020, Johnson &amp; Johnson moved to dismiss the amended complaint. In February 2021, the Court held oral argument on Johnson &amp; Johnson&#8217;s motion. In February 2022, the Court granted Johnson &amp; Johnson&#8217;s motion to dismiss the amended complaint. In August 2020, another shareholder who sent a demand filed a separate derivative complaint in the same court making similar allegations. In October 2020, the Court granted defendants&#8217; request to reassign the second-filed case to the division where the first-filed case is pending. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2019, two additional shareholders who sent demands filed two separate derivative complaints making similar allegations against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the United States District for the District of New Jersey. In April 2020, the two federal cases were consolidated into a single action captioned</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> In re Johnson &amp; Johnson Opioid Stockholder Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In July 2020, the shareholders filed a consolidated complaint. In September 2020, Johnson &amp; Johnson moved to dismiss the consolidated complaint, and in December 2020, the shareholders opposed Johnson &amp; Johnson&#8217;s motion. Johnson &amp; Johnson filed its reply in February 2021. In July 2020, an additional shareholder who sent a demand filed a derivative complaint in the same federal court making similar allegations against the same defendants named in the consolidated action. In January 2021, pursuant to an order in the consolidated action, the third case was consolidated into the consolidated action. In February 2021, the Court granted the shareholders motion to voluntarily dismiss the consolidated action without prejudice, and the shareholders&#8217; counsel then filed a notice of association in the first-filed derivative action pending in the Superior Court of New Jersey. </span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4bd2430c9203471d924855213b54000d" continuedAt="iebdd078d69804c2bbad72b4059da5f81"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney&#8217;s Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR&#8482; XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#8217; motion to dismiss with prejudice, unsealed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint, and denied the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators&#8217; request for leave to file a further amended complaint. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#8217;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#8217; request to file a third amended complaint. In March 2021, DePuy filed its motion to strike and dismiss the relators&#8217; second amended complaint; the District Court denied DePuy&#8217;s motion to strike and dismiss in July 2021. DePuy filed a motion for reconsideration of the District Court&#8217;s July 2021 ruling. In November 2021, the District Court granted DePuy&#8217;s motion for reconsideration and dismissed the case with prejudice. The District Court&#8217;s order was unsealed in December 2021. The Relators filed several post-dismissal motions, including a January 2022 omnibus motion for reconsideration. Following the District Court&#8217;s order dismissing the case with prejudice, DePuy filed a December 2021 motion seeking the recovery of attorneys&#8217; fees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2012, Johnson &amp; Johnson was contacted by the California Attorney General&#8217;s office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp; Johnson&#8217;s subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp; Johnson and Ethicon settled the Washington case. The California case started trial in July 2019 and concluded in September 2019. In October 2019, Johnson &amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $<ix:nonFraction unitRef="usd" contextRef="i3ec18e9e128b4bcb867c217e36034665_D20200120-20200120" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzY4MDEx_f7f09c61-481c-4716-9f45-ef7b23bbbf25">344</ix:nonFraction>&#160;million. In April 2020, the Court in California denied the Company&#8217;s motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of  $<ix:nonFraction unitRef="usd" contextRef="i3ec18e9e128b4bcb867c217e36034665_D20200120-20200120" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzY4MTc1_0c3fc25a-5197-491a-8290-111fe9b24684">344</ix:nonFraction>&#160;million, but denied the Attorney General&#8217;s request for injunctive relief. The Company is appealing the penalty judgment. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon. Trial in the Kentucky matter is scheduled for May 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp; Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers&#8217; use of talc contained in JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Baby Powder and JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. Johnson &amp; Johnson and JJCI moved for summary judgment on the grounds that the State&#8217;s claim was barred by preemption, which the trial court denied. The Mississippi Supreme Court granted Johnson &amp; Johnson and JJCI&#8217;s request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Briefing and oral argument were completed. Thereafter, the Court rejected the interlocutory appeal in April 2021 and remanded the matter to the trial court. Thereafter, the State moved for a trial setting. JJCI objected to any trial setting due to the LTL Bankruptcy and that any decision on whether the stay applied should be deferred to the LTL Bankruptcy court. The State opposed any stay and argued that the trial court should decide issues concerning the stay. The motion for trial setting and JJCI&#8217;s objections were heard in November 2021 and in January 2022, the Court granted plaintiff&#8217;s motion for trial setting and directed the parties to consult with the Court administrator to secure a trial date. That process is underway. In August 2021, JJCI filed a Petition for Writ of Certiorari in the United States Supreme Court as to the Mississippi Supreme Court&#8217;s ruling of April 2021, the State responded to the Petition for Writ of Certiorari in November 2021, the JJCI filed a reply in November 2021, and the United States Supreme Court denied the Petition for Writ of Certiorari in December 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. The Company made its first document production in February 2021 and discovery is currently scheduled to close on April 25, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forty-two states and the District of Columbia have commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iebdd078d69804c2bbad72b4059da5f81" continuedAt="i4949c16983cb46d7901818e98d277190"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, Janssen Pharmaceuticals, Inc. (JPI) received a Civil Investigative Demand from the United States Attorney&#8217;s Office for the Southern District of New York related to JPI&#8217;s contractual relationships with pharmacy benefit managers over the period from January 1, 2006 to the present with regard to certain of JPI&#8217;s pharmaceutical products. The demand was issued in connection with an investigation under the False Claims Act. The Company has provided documents in response to the demand. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2016, Johnson &amp; Johnson and Janssen Products LP were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and INTELENCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Daubert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April and September 2017, Johnson &amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, OLYSIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, SIMPONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The subpoenas also seek documents relating to Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, Johnson &amp; Johnson received a subpoena from the United States Attorney&#8217;s Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc.(DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these hospitals. Johnson &amp; Johnson and DePuy have produced documents in response to the subpoena and are fully cooperating with the government&#8217;s investigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp; Johnson to cooperate with these inquiries by producing the requested information.</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL LITIGATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April 2015, over <ix:nonFraction unitRef="claim" contextRef="i15323762d4454d4fa681a2ea0ef1eab5_I20150430" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzY1OTcwNzAxNzE0NjM_89efcbb4-1a4b-48ca-968f-84ff4ce1145e">30</ix:nonFraction> putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. Discovery and pre-trial motion practice are complete. Trial is scheduled to begin in March 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The cases were consolidated for pre-trial purposes as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4949c16983cb46d7901818e98d277190" continuedAt="i98ea2346d6294bcca113e3d8f11e7dea"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Antitrust Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in United States District Court for the Eastern District of Pennsylvania. The consolidated complaint seeks damages and injunctive relief. Discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, Walgreen Co. and Kroger Co., filed an antitrust complaint against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The complaint seeks damages and injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#8217;s decision. This matter was settled in January 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp; Johnson in connection with its investigation of whether Janssen&#8217;s REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#8217;s decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. TRACLEER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In October 2019, the Court granted Actelion&#8217;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. Discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint filed on behalf of the United States, 28 states, and the District of Columbia. The complaint, which was filed in December 2017 in United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to the government in connection with direct government sales and government-funded drug reimbursement programs. At this time, the federal and state governments have declined to intervene. The case has been transferred to United States District Court for the District of New Jersey. Janssen&#8217;s motion to dismiss was denied in December 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2019, a class action antitrust complaint was filed against Janssen R&amp;D Ireland (Janssen) and Johnson &amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#8217; motions to dismiss. Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint. In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. In December 2021, several insurance companies and other payers filed individual &#8220;Opt-Out&#8221; complaints containing allegations similar to the original complaint. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#8217;s business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. In August 2020, the Court granted in part and denied in part BWI&#8217;s motion to dismiss. In December 2021, BWI filed a motion for summary judgment. The trial is set for April 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, Johnson &amp; Johnson received a demand for indemnification from Pfizer Inc., pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp; Johnson Inc. received a demand for indemnification from Sanofi Consumer Health, Inc., pursuant to the 2016 Asset Purchase Agreement between Johnson &amp; Johnson Inc. and Sanofi. In January 2020, Johnson &amp; Johnson received a demand for indemnification from </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i98ea2346d6294bcca113e3d8f11e7dea"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boehringer Ingelheim Pharmaceuticals, Inc., pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim. The notices seek indemnification for legal claims related to over-the-counter ZANTAC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#8217; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in May 2021, multiple </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">putative </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">class actions were filed in state and federal courts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(California, Florida, New York, and New Jersey)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> against various Johnson &amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and the affirmative promotion of those products as &#8220;safe&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; and, in at least one case, alleging a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strict liability manufacturing defect and failure to warn </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">claims, asserting that the named plaintiffs</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> suffered unspecified injuries as a result of alleged exposure to benzene.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability case and one case pending in New Jersey state court, in the United States District Court for the Southern District of Florida, Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court. In December 2021, plaintiffs in the consolidated actions filed a motion for preliminary approval of a nationwide class settlement.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson (subsequently substituted by Johnson &amp; Johnson Consumer Inc. (JJCI)) along with more than 120 other companies, is a defendant in a cost recovery and contribution action brought by Occidental Chemical Corporation in June 2018 in the United States District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson or its subsidiaries are also parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_220"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20. <ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzI2NTU_9e14ed9c-ea95-418f-8c64-7c05831b8dcb" continuedAt="ic7df775e0725435ba5d49d3bc33692cd" escape="true">Restructuring</ix:nonNumeric></span></div><ix:continuation id="ic7df775e0725435ba5d49d3bc33692cd" continuedAt="ib94ab06de78b46399404d7718ae623c4"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal second quarter of 2018, the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In fiscal year 2021, the Company recorded a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i9040c31d4c1748199785beebbd0586ea_D20210104-20220102" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzc5NQ_67827444-9e45-43f9-acec-c9f0269829de">0.5</ix:nonFraction> billion, which is included on the following lines of the Consolidated Statement of Earnings, $<ix:nonFraction unitRef="usd" contextRef="i7f2a0b2a8ead42e18de0ad368f5442fb_D20210104-20220102" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzg4Mw_ae6ae96c-6dda-49bc-9cd1-8975b6b729f7">0.3</ix:nonFraction> billion in restructuring, $<ix:nonFraction unitRef="usd" contextRef="ifd48c767309c46d8a8d98cc62c7d4f0e_D20210104-20220102" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzkwNA_4e67fef6-6100-4f4d-ac7e-1b746a3ca9a1">0.1</ix:nonFraction> billion in other (income) expense and $<ix:nonFraction unitRef="usd" contextRef="i9f942e7d06b448759571f02f4385e4ca_D20210104-20220102" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzkzNw_cccde1e8-5f2e-4462-8450-a7dccdd771b7">0.1</ix:nonFraction> billion in cost of products sold. Total project costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i6a7d77bec63f4ec9ba629e605fa7f760_I20220102" decimals="-8" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzEwMDM_a01e5908-d7fa-44af-86d8-47cf68f80d06">1.8</ix:nonFraction> billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In total, the Company expects the Global Supply Chain actions to generate approximately $<ix:nonFraction unitRef="usd" contextRef="i4742330f4c264777a98ea1c8e9843989_I20220102" decimals="-8" name="jnj:RestructuringandRelatedCostExpectedFutureSavings" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzEyMzA_76b1f572-e626-442a-8b3a-48f74b29a6a5">0.6</ix:nonFraction> billion to $<ix:nonFraction unitRef="usd" contextRef="i070444329d4348a7b9c8aebe5a9aa3c9_I20220102" decimals="-8" name="jnj:RestructuringandRelatedCostExpectedFutureSavings" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzEyMzY_ac528153-fcce-42c8-a71b-ba1b679cd992">0.8</ix:nonFraction> billion in annual pre-tax cost savings that will be substantially delivered by the end of 2022. The program is set to be completed at the end of 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company expects to record pre-tax restructuring charges of approximately $<ix:nonFraction unitRef="usd" contextRef="i4742330f4c264777a98ea1c8e9843989_I20220102" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzEzOTM_0e713ef1-ab92-4b9f-86ff-c21b2160d6bc">2.1</ix:nonFraction> billion to $<ix:nonFraction unitRef="usd" contextRef="i070444329d4348a7b9c8aebe5a9aa3c9_I20220102" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzEzOTk_76f5ed60-57dc-4d9f-b6d3-534af764f27f">2.3</ix:nonFraction> billion, over the <ix:nonNumeric contextRef="iaf61a7957d2e4fbf85c40c9d23a9297e_D20210104-20220102" name="jnj:RestructuringandRelatedCostDurationofRestructuringPlan" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzE0MTI_e7807ae8-6827-459f-8d71-33eb5225d8a4">4</ix:nonNumeric> to <ix:nonNumeric contextRef="i49ac509f65b740f7bf421ae80e274e2a_D20210104-20220102" name="jnj:RestructuringandRelatedCostDurationofRestructuringPlan" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzE0MTg_f93c0039-198b-4256-ba8c-aacc8c67fc69">5</ix:nonNumeric> year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzI2NTE_408525e8-2a90-4568-a61c-d1195b757be4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2021: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs/Sales </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, December&#160;29, 2019</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7cc0a51e3df46baa43c1b66bf2a029e_I20191229" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzE4LTEtMS0xLTI5NzI2_c31be8a0-5505-458d-9e19-afa51b762450">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c2f9e6ae2646e49bca2879436ed3ed_I20191229" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzE4LTItMS0xLTI5NzI2_50fc2276-47c2-4ea5-9891-a4718eb7138f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54a04675fe8142f985b33a5c678e172f_I20191229" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzE4LTQtMS0xLTI5NzI2_1a7eb55e-c35b-43df-8123-9cec96d6d560">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i125634f59e794aada3577c9ee8b1c64b_I20191229" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzE4LTYtMS0xLTI5NzI2_e760e9a0-1f56-480f-a364-adaadd4dec77">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id60a51c9ec914539bb291a40e2bd0afd_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzIwLTEtMS0xLTI5NzI2_57dd34c5-792d-4066-a69d-c01978e224ea">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46179c58ccf9458a966c4f2d2c9cb18a_D20191230-20210103" decimals="-6" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzIwLTItMS0xLTI5NzI2_0073eece-1423-421c-b277-ca4d23d9632f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcec504d9dde41a1b752577a2c9939c5_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzIwLTQtMS0xLTI5NzI2_5e03dc2b-e0f5-4dac-80f7-bddefee88ff6">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdd89adfa0f0484b84b07f77e48731a8_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzIwLTYtMS0xLTI5NzI2_27e8aad3-016d-4f56-80f4-abc1920a40f1">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January&#160;3, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2327edec83cc47c299891dc7c339c323_I20210103" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzIyLTEtMS0xLTI5NzI2_23fae20c-f7c5-45c7-b95d-b6f087e42123">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872fb39f2b694b7b97a09c5a2b7bfa67_I20210103" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzIyLTItMS0xLTI5NzI2_7409a2af-ca23-4336-bd8f-592e3cd7d917">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531752ccd3b04bb4bd2ee5442e9d418a_I20210103" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzIyLTQtMS0xLTI5NzI2_4eed61e2-ab69-4ae1-93db-522b4def8fb8">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01b7633b6f6a47ac92f6869a755469fb_I20210103" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzIyLTYtMS0xLTI5NzI2_32fcc143-c674-448c-80e9-5d3f9d30697c">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8f0b1a408074a8f9ca58bbfea6c3348_D20210104-20220102" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI1LTEtMS0xLTI5NzI2_3448f968-327f-43c7-8778-7aae4e62bdcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia09f9acab5bd428d86b7dafd5dd2f6bc_D20210104-20220102" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI1LTItMS0xLTI5NzI2_8fb560ae-9028-4e31-9adb-1b4786de57ec">53</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie50addf0e3d44897a0a2e867211ed920_D20210104-20220102" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI1LTQtMS0xLTI5NzI2_2c25694b-fe18-4ea1-a873-9a225aa9379b">420</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9040c31d4c1748199785beebbd0586ea_D20210104-20220102" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI1LTYtMS0xLTI5NzI2_cd2393d9-16e4-418e-a0d3-e1f2116273e7">473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8f0b1a408074a8f9ca58bbfea6c3348_D20210104-20220102" decimals="-6" name="jnj:GainOnSaleOfAnAssetPaymentForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI2LTEtMS0xLTI5NzI2_e1c17459-dd74-4d6a-93e3-a95476fbf84f">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia09f9acab5bd428d86b7dafd5dd2f6bc_D20210104-20220102" sign="-" xsi:nil="true" name="jnj:GainOnSaleOfAnAssetPaymentForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI2LTItMS0xLTI5NzI2_9cde4f38-25dc-4819-b5d1-5016be6c31ac"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie50addf0e3d44897a0a2e867211ed920_D20210104-20220102" decimals="-6" name="jnj:GainOnSaleOfAnAssetPaymentForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI2LTQtMS0xLTI5NzI2_05e3286e-9881-495a-a874-2d5fc23bc206">404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9040c31d4c1748199785beebbd0586ea_D20210104-20220102" decimals="-6" name="jnj:GainOnSaleOfAnAssetPaymentForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI2LTYtMS0xLTI5NzI2_9bf116c2-5e5e-4d83-9696-777094d17a2e">427</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8f0b1a408074a8f9ca58bbfea6c3348_D20210104-20220102" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI3LTEtMS0xLTI5NzI2_40cf01df-b328-4dd7-8091-1c5f808ab0de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia09f9acab5bd428d86b7dafd5dd2f6bc_D20210104-20220102" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI3LTItMS0xLTI5NzI2_a1052955-ae38-48af-90e7-ce694684ebac">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie50addf0e3d44897a0a2e867211ed920_D20210104-20220102" sign="-" xsi:nil="true" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI3LTQtMS0xLTI5NzI2_c13c3fb0-82e5-4b7d-b526-80008d3c4492"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9040c31d4c1748199785beebbd0586ea_D20210104-20220102" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI3LTYtMS0xLTI5NzI2_1cca0990-e0c3-4bb0-9df7-900183959def">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January&#160;2, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i918a4b3733da4e56bf9e7e5969d09d95_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI4LTEtMS0xLTI5NzI2_a5f26fe0-2a5f-4708-8f18-5507eaa5bafc">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a2f9eb45f44e87b7a3dd02889d98b3_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI4LTItMS0xLTI5NzI2_431a3378-905d-4b5b-af7a-99415fd5a56a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b09fb038985486b93ffe0bcfbe958f1_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI4LTQtMS0xLTI5NzI2_5af558fe-04d0-451a-adf0-2554e76a663c">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if116a595b26043caaadde3e9d3b3c0a2_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI4LTYtMS0xLTI5NzI2_b0ffaec0-48d4-4ffe-9102-99cf02c81602">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Cash outlays for severance are expected to be substantially paid out over the next year in accordance with the Company's plans and local laws. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib94ab06de78b46399404d7718ae623c4">The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_229"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the Board of Directors and Shareholders of Johnson &amp; Johnson</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated balance sheets of Johnson &amp; Johnson and its subsidiaries (the &#8220;Company&#8221;) as of January 2, 2022 and January 3, 2021, and the related consolidated statements of earnings, of comprehensive income, of equity and of cash flows for each of the three fiscal years in the period ended January 2, 2022, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company's internal control over financial reporting as of January 2, 2022, based on criteria established in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of January 2, 2022 and January 3, 2021, and the results of its operations and its cash flows for each of the three fiscal years in the period ended January 2, 2022 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of January 2, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (2013) issued by the COSO.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis for Opinions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="text-indent:5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-indent:5pt"><span><br/></span></div><div style="text-indent:5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Critical Audit Matters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">U.S. Pharmaceutical Rebate Reserves &#8211; Managed Care, Medicare and Medicaid</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in Note 1 to the consolidated financial statements, the Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied. Rebates and discounts provided to customers are accounted for as variable consideration and recorded as a reduction in sales. The liability for such rebates and discounts is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet. A significant portion of the liability related to rebates is from the sale of pharmaceutical goods within the U.S., primarily the Managed Care, Medicare and Medicaid programs, which amounted to $7.7 billion as of January 2, 2022. For significant rebate programs, which include the U.S. Managed Care, Medicare and Medicaid rebate programs, rebates and discounts estimated by management are based on contractual terms, historical experience, patient outcomes, trend analysis, and projected market conditions in the U.S. pharmaceutical market. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The principal considerations for our determination that performing procedures relating to U.S. pharmaceutical rebate reserves - Managed Care, Medicare and Medicaid is a critical audit matter are the significant judgment by management due to the significant measurement uncertainty involved in developing these reserves and the high degree of auditor judgment, subjectivity and audit effort in performing procedures and evaluating the assumptions related to contractual terms, historical experience, patient outcomes, trend analysis, and projected market conditions in the U.S. pharmaceutical market. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to U.S. pharmaceutical rebate reserves - Managed Care, Medicare and Medicaid, including controls over the assumptions used to estimate these rebates. These procedures also included, among others, (i) developing an independent estimate of the rebates by utilizing third party information on price and market conditions in the U.S. pharmaceutical market, the terms of the specific rebate programs, and the historical experience and trend analysis of actual rebate claims paid; (ii) testing rebate claims processed by the Company, including evaluating those claims for consistency with the contractual and mandated terms of the Company&#8217;s rebate arrangements; and (iii) comparing the independent estimates to management&#8217;s estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Litigation Contingencies &#8211; Talc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in Notes 1 and 19 to the consolidated financial statements, the Company records accruals for loss contingencies associated with legal matters, including talc, when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. To the extent adverse awards, judgments, or verdicts have been rendered against the Company, management does not record an accrual until a loss is determined to be probable and can be reasonably estimated. For these matters, management is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors, including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. Management continues to believe that the Company has strong legal grounds to contest the talc verdicts it has appealed. Notwithstanding management&#8217;s confidence in the safety of the Company&#8217;s talc products, in certain circumstances the Company has settled cases. In October 2021, Johnson &amp; Johnson Consumer Inc. (Old JJCI), a wholly-owned subsidiary of Johnson &amp; Johnson, implemented a corporate restructuring and created a subsidiary, LTL Management LLC (LTL), which became solely responsible for the talc-related liabilities, and another subsidiary, New JJCI, which became responsible for the remaining business of Old JJCI. LTL filed a voluntary petition, seeking relief under chapter 11 of the Bankruptcy Code. As a result of the LTL bankruptcy case, the Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, Johnson &amp; Johnson, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties. Claimants have filed a motion to dismiss the LTL bankruptcy case. The court commenced a hearing on February 14, 2022 regarding the motion to dismiss and on whether the PI should be extended. The Company has agreed to provide funding to LTL for the payment of amounts the Bankruptcy Court determines are owed by LTL through the establishment of a $2 billion trust in furtherance of this purpose. The Company has established a reserve for approximately $2 billion in connection with the aforementioned trust. The parties have not yet been able to reach a resolution of all matters related to talc, and while certain amounts under various scenarios have recently been referred to in testimony as part of the LTL bankruptcy proceedings, the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The principal considerations for our determination that performing procedures relating to the talc litigation is a critical audit matter are the significant judgment by management when assessing the likelihood of a loss being incurred and when determining whether a reasonable estimate of the loss or range of loss for the future and existing talc claims can be made, which in turn led to a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating management&#8217;s assessment of the loss contingencies associated with this litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management&#8217;s evaluation of the talc litigation, including controls over determining whether a loss is probable and whether the amount of loss can be reasonably estimated, as well as financial statement disclosures. These procedures also included, among others, (i) gaining an understanding of the Company&#8217;s process around the accounting and reporting for the talc litigation; (ii) discussing the status of significant known actual and potential litigation and the ongoing LTL bankruptcy proceedings with the Company&#8217;s in-house legal counsel, as well as external counsel when deemed necessary; (iii) obtaining and evaluating the letters of audit inquiry with internal and external legal counsel for significant litigation; (iv) evaluating the reasonableness of management&#8217;s assessment regarding whether an unfavorable outcome is reasonably possible or probable and reasonably estimable; and (v) evaluating the sufficiency of the Company&#8217;s litigation contingencies disclosures.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Litigation &#8211; Opioids</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in Notes 1 and 19 to the consolidated financial statements, the Company records accruals for loss contingencies associated with legal matters, including opioids, when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. To the extent adverse awards, judgments, or verdicts have been rendered against the Company, management does not record an accrual until a loss is determined to be probable and can be reasonably estimated. For these matters, management is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors, including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. The Company has been named in numerous lawsuits brought by certain state and local governments, including tribal governments, related to opioids matters. In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $4 billion as settlement of the matters. In October 2020, the Company agreed to contribute up to an additional $1 billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of $5 billion. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims have been finalized, depending upon the level of participation by the various parties. The terms provide a period of time for states to elect to participate in the agreement and, thereafter, a period for the subdivisions of the participating states to opt-in. The subdivision opt-in period expired in January 2022. The Company retains the right to opt-out of the agreement until late February 2022 if, in its sole discretion, there is insufficient participation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The principal considerations for our determination that performing procedures relating to the opioids litigation is a critical audit matter are the significant judgment by management when determining whether a reasonable estimate of the range of loss for the agreement to settle the opioids litigation can be made, which in turn led to a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating management&#8217;s assessment of the loss contingencies associated with this litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management&#8217;s evaluation of the opioid litigation, including controls over determining whether a loss is probable and whether the amount of loss can be reasonably estimated, as well as financial statement disclosures. These procedures also included, among others, (i) gaining an understanding of the Company&#8217;s process around the accounting and reporting for the opioids litigation; (ii) discussing the status of significant known actual and potential litigation and ongoing settlement negotiations with the Company&#8217;s in-house legal counsel, as well as external counsel when deemed necessary; (iii) obtaining and evaluating the letters of audit inquiry with internal and external legal counsel for significant litigation; (iv) evaluating the reasonableness of management&#8217;s assessment regarding whether an unfavorable outcome is reasonably possible or probable and reasonably estimable; and (v) evaluating the sufficiency of the Company&#8217;s litigation contingencies disclosures.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ <ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjkvZnJhZzpiOTQxMmIwMzlhNzg0OWQzYTQxZmRmYTM0N2U4OThmZi90ZXh0cmVnaW9uOmI5NDEyYjAzOWE3ODQ5ZDNhNDFmZGZhMzQ3ZTg5OGZmXzEwOTk1MTE2Mjk1NTI5_29fde36f-c12a-4b23-814d-42267a86759d">PricewaterhouseCoopers LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjkvZnJhZzpiOTQxMmIwMzlhNzg0OWQzYTQxZmRmYTM0N2U4OThmZi90ZXh0cmVnaW9uOmI5NDEyYjAzOWE3ODQ5ZDNhNDFmZGZhMzQ3ZTg5OGZmXzEwOTk1MTE2Mjk1NTMx_872654e9-e865-4e12-a0f9-d9d04df5ccaf">Florham Park, New Jersey</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 17, 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company&#8217;s auditor since at least 1920. We have not been able to determine the specific year we began serving as auditor of the Company.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_232"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section&#160;404 of the Sarbanes-Oxley Act of 2002, management is required to assess the effectiveness of the Company&#8217;s internal control over financial reporting as of the end of each fiscal year and report, based on that assessment, whether the Company&#8217;s internal control over financial reporting is effective.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting.  The Company&#8217;s internal control over financial reporting is designed to provide reasonable assurance as to the reliability of the Company&#8217;s financial reporting and the preparation of external financial statements in accordance with generally accepted accounting principles.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal controls over financial reporting, no matter how well designed, have inherent limitations.  Therefore, internal control over financial reporting determined to be effective can provide only reasonable assurance with respect to financial statement preparation and may not prevent or detect all misstatements.  Moreover, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management has assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of January 2, 2022.  In making this assessment, the Company used the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in &#8220;Internal Control-Integrated Framework (2013).&#8221;  These criteria are in the areas of control environment, risk assessment, control activities, information and communication, and monitoring.  The Company&#8217;s assessment included extensive documenting, evaluating and testing the design and operating effectiveness of its internal controls over financial reporting.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s processes and assessment, as described above, management has concluded that, as of January 2, 2022, the Company&#8217;s internal control over financial reporting was effective.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of the Company&#8217;s internal control over financial reporting as of January 2, 2022 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report, which appears herein.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;&#160;J. Duato</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Joseph J. Wolk</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joaquin Duato</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_238"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Return Performance Graphs </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below are line graphs comparing the cumulative total shareholder return on the Company&#8217;s Common Stock for periods of five years and ten years ending January&#160;2, 2022, against the cumulative total return of the Standard&#160;&amp; Poor&#8217;s 500 Stock Index, the Standard&#160;&amp; Poor&#8217;s Pharmaceutical Index and the Standard&#160;&amp; Poor&#8217;s Healthcare Equipment Index. The graphs and tables assume that $100 was invested on December&#160;31, 2016 and December&#160;31, 2011 in each of the Company&#8217;s Common Stock, the Standard&#160;&amp; Poor&#8217;s 500 Stock Index, the Standard&#160;&amp; Poor&#8217;s Pharmaceutical Index and the Standard&#160;&amp; Poor&#8217;s Healthcare Equipment Index and that all dividends were reinvested.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5 Year Shareholder Return Performance J&amp;J vs. Indices</span></div><div style="margin-top:9pt"><img src="jnj-20220102_g10.jpg" alt="jnj-20220102_g10.jpg" style="height:233px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$124.40</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$118.02</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$137.15</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$152.03</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$169.43</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P 500 Index</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$121.82</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$116.47</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$153.13</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$181.29</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$233.28</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P Pharmaceutical Index</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$112.57</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$121.68</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$140.04</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$150.58</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$189.36</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P Healthcare Equipment Index</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$130.90</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$152.15</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$196.77</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$231.46</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$276.26</span></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10 Year Shareholder Return Performance J&amp;J vs. Indices</span></div><div style="margin-top:18pt"><img src="jnj-20220102_g11.jpg" alt="jnj-20220102_g11.jpg" style="height:230px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2011</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2012</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2013</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2014</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2015</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$110.83</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$149.19</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$175.05</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$177.08</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$204.21</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$254.05</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$241.00</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$280.07</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$310.46</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$346.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P 500 Index</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$115.99</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$153.55</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$174.55</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$176.95</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$198.10</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$241.33</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$230.73</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$303.35</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$359.13</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$462.13</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P Pharmaceutical Index</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$114.43</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$154.74</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$189.12</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$200.06</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$196.93</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$221.69</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$239.63</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$275.78</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$296.54</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$372.90</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P Healthcare Equipment Index</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$117.27</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$149.74</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$189.09</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$200.39</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$213.38</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$279.31</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$324.67</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$419.87</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$493.90</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$589.48</span></td></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_241"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Not applicable.</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_244"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.8pt">CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Disclosure Controls and Procedures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;At the end of the period covered by this Report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Company&#8217;s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer, and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs.&#160;Duato and Wolk concluded that, as of the end of the period covered by this Report, the Company&#8217;s disclosure controls and procedures were effective.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Reports on Internal Control Over Financial Reporting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The information called for by this item is incorporated herein by reference to &#8220;Management&#8217;s Report on Internal Control Over Financial Reporting&#8221;, and the attestation regarding internal controls over financial reporting included in the &#8220;Report of Independent Registered Public Accounting Firm&#8221; included in Item 8 of this Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Changes in Internal Control Over Financial Reporting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;During the fiscal quarter ended January 2, 2022, there were no changes in the Company&#8217;s internal control over financial reporting identified in connection with the evaluation required under Rules&#160;13a-15 and 15d-15 under the Exchange Act that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company has not experienced any material impact to its internal controls over financial reporting despite the fact that many of its employees have worked remotely due to the COVID-19 pandemic. The Company proactively took actions to re-evaluate and refine its financial reporting process through additional monitoring controls to provide reasonable assurance that the financial results are reported accurately and timely. The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is implementing a multi-year, enterprise-wide initiative to integrate, simplify and standardize processes and systems for the human resources, information technology, procurement, supply chain and finance functions. These are enhancements to support the growth of the Company&#8217;s financial shared service capabilities and standardize financial systems. This initiative is not in response to any identified deficiency or weakness in the Company&#8217;s internal control over financial reporting. In response to this initiative, the Company has and will continue to align and streamline the design and operation of its financial control environment.</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_247"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.36pt">OTHER INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Not applicable.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_2652"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C.       DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">              Not applicable.</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_250"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_253"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to the discussion of the Audit Committee under the caption &#8220;Item 1. Election of Directors - Board Committees&#8221;; and the material under the captions &#8220;Item 1. Election of Directors&#8221; and, if applicable, &#8220;Stock Ownership and Section 16 Compliance &#8211; Delinquent Section&#160;16(a) Reports&#8221; in the Proxy Statement; and the material under the caption &#8220;Executive Officers of the Registrant&#8221; in Part&#160;I of this Report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company&#8217;s Code of Business Conduct, which covers all employees (including the Chief Executive Officer, Chief Financial Officer and Controller), meets the requirements of the SEC rules promulgated under Section&#160;406 of the Sarbanes-Oxley Act of 2002. The Code of Business Conduct is available on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.jnj.com/code-of-business-conduct</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and copies are available to shareholders without charge upon written request to the Secretary at the Company&#8217;s principal executive offices. Any substantive amendment to the Code of Business Conduct or any waiver of the Code granted to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Chief Executive Officer, the Chief Financial Officer or the Controller will be posted on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.investor.jnj.com/gov.cfm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within five business days (and retained on the website for at least one year).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, the Company has adopted a Code of Business Conduct&#160;&amp; Ethics for Members of the Board of Directors and Executive Officers. The Code of Business Conduct&#160;&amp; Ethics for Members of the Board of Directors and Executive Officers is available on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.investor.jnj.com/gov/boardconduct.cfm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and copies are available to shareholders without charge upon written request to the Secretary at the Company&#8217;s principal executive offices. Any substantive amendment to the Code or any waiver of the Code granted to any member of the Board of Directors or any executive officer will be posted on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.investor.jnj.com/gov.cfm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within five business days (and retained on the website for at least one year).</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_256"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">EXECUTIVE COMPENSATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to the material under the captions &#8220;Item 1. Election of Directors &#8211; Director Compensation,&#8221; and &#8220;Item 2. Compensation &amp; Benefits Committee Report,&#8221; &#8220;Compensation Discussion and Analysis&#8221; and &#8220;Executive Compensation Tables&#8221; in the Proxy Statement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The material incorporated herein by reference to the material under the caption &#8220;Compensation &amp; Benefits Committee Report&#8221; in the Proxy Statement shall be deemed furnished, and not filed, in this Report and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, as a result of this furnishing, except to the extent that the Company specifically incorporates it by reference.</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_259"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to the material under the caption &#8220;Item 1. Stock Ownership and Section&#160;16 Compliance&#8221; in the Proxy Statement; and Note&#160;16 &#8220;Common Stock, Stock Option Plans and Stock Compensation Agreements&#8221; of the Notes to Consolidated Financial Statements in Item 8 of this Report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table provides certain information as of January 2, 2022 concerning the shares of the Company&#8217;s Common Stock that may be issued under existing equity compensation plans.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Securities to<br/>be Issued Upon Exercise of<br/>Outstanding Options and  Rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price of<br/>Outstanding Options and Rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Securities</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Available for</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Future Issuance Under Equity Compensation Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Compensation Plans Approved by Security Holders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,794,708&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$109.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,344,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Compensation Plans Not Approved by Security Holders</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,794,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$109.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,344,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Included in this category are the following equity compensation plans which have been approved by the Company&#8217;s shareholders: 2005 Long-Term Incentive Plan and 2012 Long-Term Incentive Plan.</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">This column excludes shares reflected under the column &#8220;Number of Securities to be Issued Upon Exercise of Outstanding Options and Rights.&#8221;</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The 2005 Long-Term Incentive Plan expired April 26, 2012.  All options and restricted shares granted subsequent to that date were under the 2012 Long-Term Incentive Plan.</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_262"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to the material under the captions &#8220;Item 1. Election of Directors&#160;- Director Independence&#8221; and &#8220;Related Person Transactions&#8221; in the Proxy Statement.</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_265"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to the material under the caption &#8220;Item 3. Ratification of Appointment of Independent Registered Public Accounting Firm&#8221; in the Proxy Statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_268"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div id="i01be8f8f216a4c39adb513a606bfe937_271"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">EXHIBITS&#160;AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as part of this report:</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements</span></div><div style="margin-top:5pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Consolidated Balance Sheets at end of Fiscal Years 2021 and 2020</span></div><div style="margin-top:5pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Consolidated Statements of Earnings for Fiscal Years 2021, 2020 and 2019&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Consolidated Statements of Comprehensive Income for Fiscal Years 2021, 2020 and 2019</span></div><div style="margin-top:5pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Consolidated Statements of Equity for Fiscal Years 2021, 2020 and 2019</span></div><div style="margin-top:5pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Consolidated Statements of Cash Flows for Fiscal Years 2021, 2020 and 2019</span></div><div style="margin-top:5pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notes to Consolidated Financial Statements</span></div><div style="margin-top:5pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:9pt;padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All schedules are omitted because they are not applicable or the required information is included in the financial statements or notes.</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Required</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> to be Filed by Item&#160;60l of Regulation&#160;S-K</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this item is incorporated herein by reference to the Exhibit&#160;Index in this Report.</span></div><div style="margin-top:5pt;text-indent:45pt"><span><br/></span></div><div id="i01be8f8f216a4c39adb513a606bfe937_274"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.    FORM 10-K SUMMARY</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. The Company has elected not to include such summary information.</span></div><div style="padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_277"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:19pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date:   February 17, 2022</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.192%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JOHNSON&#160;&amp; JOHNSON</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr></table></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.631%"><tr><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;J. Duato</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Duato, Director<br/>and Chief Executive Officer</span></td></tr></table></div><div style="text-align:center;text-indent:324pt"><span><br/></span></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:34.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.918%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;J. Duato</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Duato</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer <br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;J. J. Wolk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. J. Wolk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;R. J. Decker Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controller and Chief Accounting Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. J. Decker Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ A. Gorsky</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Chairman, Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. Gorsky</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ M. C. Beckerle</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M. C. Beckerle</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;D. S. Davis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D. S. Davis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;I. E. L. Davis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I. E. L. Davis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;J. A. Doudna</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. A. Doudna</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:36.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ M. A. Hewson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M. A. Hewson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ H. Joly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">H. Joly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ M. B. McClellan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M. B. McClellan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;A. M. Mulcahy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. M. Mulcahy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;C. Prince</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C. Prince</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;A. E. Washington</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. E. Washington</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;M. A. Weinberger</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M. A. Weinberger</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ N.Y. West</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N. Y. West</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;R. A. Williams</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. A. Williams</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112</span></div></td></tr></table></div></div></div><div id="i01be8f8f216a4c39adb513a606bfe937_280"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:19pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;INDEX</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reg. S-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Table</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Item No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Exhibit</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040616000071/exhibit3i-restatedcertific.htm">3(i)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restated Certificate of Incorporation effective February 19, 2016&#160;&#8212; Incorporated herein by reference to Exhibit 3(i) of the Registrant&#8217;s Form 10-K Annual Report for the fiscal year ended January 3, 2016.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040620000034/ex31amendmenttocoi.htm">3(ii)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment to the Certificate of Incorporation of Johnson &amp; Johnson effective April 30, 2020 &#160;&#8212; Incorporated herein by reference to Exhibit 3.1 of the Registrant's Form 8-K Current Report filed April 29, 2020.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040620000039/ex31amendmenttoby-laws.htm">3(iii)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By-Laws of the Company, as amended effective June 9, 2020&#160;&#8212; Incorporated herein by reference to Exhibit 3.1 of the Registrant&#8217;s Form 8-K Current Report filed June 10, 2020.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon the request of the Securities and Exchange Commission, the Registrant will furnish a copy of all instruments defining the rights of holders of long-term debt of the Registrant.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040620000052/aug12exhibit41.htm">4(b)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 &#160;&#8212; Incorporated herein by reference to Exhibit 4.1 of the Registrant&#8217;s Form 8-K Current Report filed August 12, 2020.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040605000088/ltipexhibitfour.txt">10(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2005 Long-Term Incentive Plan&#160;&#8212; Incorporated herein by reference to Exhibit 4 of the Registrant&#8217;s S-8 Registration Statement filed on May 10, 2005 (file no. 333-124785).*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040612000006/tenoneformofcertificatesto.htm">10(b)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Option Certificate under the 2005 Long-Term Incentive Plan&#160;&#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Form 8-K Current Report filed January 13, 2012.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040617000015/a2017jnjproxy.htm">10(c)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2012 Long-Term Incentive Plan&#160;&#8212; Incorporated herein by reference to Appendix A of the Registrant&#8217;s Proxy Statement filed on March 15, 2017.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040612000081/0000200406-12-000081-index.htm">10(d)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Option Certificate, Restricted Share Unit Certificate and Performance Share Unit Certificate under the 2012 Long-Term Incentive Plan&#160;&#8212; Incorporated herein by reference to Exhibits 10.2, 10.3 and 10.4 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended April 1, 2012.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040618000019/0000200406-18-000019-index.htm">10(e)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global NonQualified Stock Option Award Agreement, Global Restricted Share Unit Award Agreement and Global Performance Share Unit Award Agreement under the 2012 Long-Term Incentive Plan&#160;&#8212; Incorporated herein by reference to Exhibits  10.1, 10.2 and 10.3 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended April 1, 2018.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040619000033/a201910-q1qexhibit10ajjexe.htm">10(f)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Johnson &amp; Johnson Executive Incentive Plan (Amended as of November 28, 2018)&#160;&#8212; Incorporated herein by reference to Exhibit 10(a) of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended March 31, 2019.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000095012304003155/y94471exv10wg.txt">10(g)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Deferred Compensation (Certificate of Extra Compensation) Plan&#160;&#8212; Incorporated herein by reference to Exhibit 10(g) of the Registrant&#8217;s Form 10-K Annual Report for the year ended December 28, 2003.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000095012309003187/y74152exv10wj.htm">10(h)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendments to the Certificate of Extra Compensation Plan effective as of January 1, 2009&#160;&#8212; Incorporated herein by reference to Exhibit 10(j) of the Registrant&#8217;s Form 10-K Annual Report for the year ended December 28, 2008.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000095012309057624/y79425exv10w1.htm">10(i)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2009 Certificates of Long-Term Performance Plan&#160;&#8212; Incorporated herein by reference to Exhibit&#160;10.1 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended September 27, 2009.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000119312512075565/d281803dex10k.htm">10(j)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Deferred Fee Plan for Directors&#160;(Amended as of January 17, 2012) &#8212; Incorporated herein by reference to Exhibit 10(k) of the Registrant's Form 10-K Annual Report for the fiscal year ended January 1, 2012.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040612000140/exhibit101.htm">10(k)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Johnson &amp; Johnson Executive Income Deferral Plan Amended and Restated Effective January 1, 2010&#160;&#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended September 30, 2012.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/0000950123-97-002843-index.html">10(l)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess Savings Plan&#160;(Effective as of January 1, 1996) &#8212; Incorporated herein by reference to Exhibit 10(j) of the Registrant&#8217;s Form 10-K Annual Report for the fiscal year ended December 29, 1996.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000095012309003187/y74152exv10wp.htm">10(m)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendments to the Johnson &amp; Johnson Excess Savings Plan effective as of January 1, 2009&#160;&#8212; Incorporated herein by reference to Exhibit 10(p) of the Registrant&#8217;s Form 10-K Annual Report for the fiscal year ended December 28, 2008.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/200406/000020040621000008/ex31-jjexcessplanx2020rest.htm">10(n)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Amended and Restated Excess Benefit Plan of Johnson &amp; Johnson and Affiliated Companies (Amended and restated effective January 1, 2020, except as otherwise provided) incorporated herein by reference to Exhibit 10(n) of the Registrant's Form 10-K Annual Report for the fiscal year ended January 3, 2021*</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10(o)**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Life Plan Agreement&#160;&#8212; Incorporated herein by reference to Exhibit 10(i) of the Registrant&#8217;s Form 10-K Annual Report for the fiscal year ended January 3, 1993.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040615000019/a201510-q1qexhibit101execu.htm">10(p)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Life Plan Agreement&#160;Closure Letter &#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended March 29, 2015.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040612000140/exhibit102.htm">10(q)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement for Dr. Paulus Stoffels - Incorporated herein by reference to Exhibit 10.2 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended September 30, 2012.*</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reg. S-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Table</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Item No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040614000097/a201410-q3qexhibit101sever.htm">10(r)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance Pay Plan of Johnson &amp; Johnson and U.S. Affiliated Companies, Amended and Restated as of October 1, 2014 &#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant's Form 10-Q Quarterly Report for the quarter ended September 28, 2014.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040615000044/exhibit101severancepayplan.htm">10(s)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Amendment to the Severance Pay Plan of Johnson &amp; Johnson and U.S. Affiliated Companies (as amended and restated effective October 1, 2014) &#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant's Form 10-Q Quarterly Report for the quarter ended June 28, 2015.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040616000071/exhibit10x-secondamendment.htm">10(t)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Amendment to the Severance Pay Plan of Johnson &amp; Johnson and U.S. Affiliated Companies (as amended and restated effective October 1, 2014) &#8212; Incorporated herein by reference to Exhibit 10(x) of the Registrant's Form 10-K Annual Report for the fiscal year ended January 3, 2016.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex21-subsidiariesxform10xk.htm">21</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subsidiaries &#8212; Filed with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex23-pwcconsentxform10xkx2.htm">23</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of Independent Registered Public Accounting Firm&#160;&#8212; Filed with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex311-302certofceoxform10x.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act&#160;&#8212; Filed with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex312-302certofcfoxform10x.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act&#160;&#8212; Filed with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex321-906certofceoxform10x.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act&#160;&#8212; Furnished with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex322-906certofcfoxform10x.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act&#160;&#8212; Furnished with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 101:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 104:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File&#8211;&#8211;the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:2.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plan.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paper filing.</span></td></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of any of the Exhibits listed above will be provided without charge to any shareholder submitting a written request specifying the desired exhibit(s) to the Secretary at the principal executive offices of the Company. Pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, the Company has not filed as exhibits to this Form 10-K certain long-term debt instruments, including indentures, under which the total amount of securities authorized does not exceed 10% of the total assets of the Company and its subsidiaries on a consolidated basis. The Company hereby agrees to furnish a copy of any such instrument to the SEC upon request.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:4pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114</span></div></td></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>2
<FILENAME>ex21-subsidiariesxform10xk.htm
<DESCRIPTION>EX-21 SUBSIDIARIES
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8fd8663f50f647dab6ee6c9aeaf319e7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;21</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson&#160;&#38; Johnson, a New Jersey corporation, had the U.S. and international subsidiaries shown below as of January&#160;2,&#160;2022. Johnson &#38; Johnson is not a subsidiary of any other entity. </font></div><div><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Subsidiaries&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acclarent, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Pharmaceuticals US, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Akros Medical, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Albany Street LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ALZA Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alza Land Management, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Development, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Manufacturing USA, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Nominee Holdings, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Sales and Service, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Spain Holdings, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO U.K. Holdings, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anakuria Therapeutics, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animas Diabetes Care, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animas LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animas Technologies LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AorTx, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aragon Pharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific Holdings, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Atrionix, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AUB Holdings LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Auris Health, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BeneVir BioPharm, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BioMedical Enterprises, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biosense Webster, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Calibra Medical LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Centocor Biologics, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Centocor Research &#38; Development, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cerenovus, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ci&#58;Labo USA, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coherex Medical, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company Store.com, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cordis International Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoTherix Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CSATS, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Washington</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Mitek, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Orthopaedics, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Products, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Spine, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Synthes Institute, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Synthes Products, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Synthes Sales, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Synthes, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dutch Holding LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ECL7, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon Endo-Surgery, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon Endo-Surgery, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon US, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hansen Medical International, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hansen Medical, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hickory Merger Sub, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">I.D. Acquisition Corp.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Innovative Surgical Solutions, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen BioPharma, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Biotech, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Diagnostics, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Global Services, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Oncology, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Ortho LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Products, LP</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Research &#38; Development, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Scientific Affairs, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Supply Group, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Manufacturing, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jevco Holding, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJHC, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ International Investment LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Middle East) Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Enterprise Innovation Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Finance Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Gateway, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Health and Wellness Solutions, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Health Care Systems Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Innovation - JJDC, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Innovation LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson International</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Devices &#38; Diagnostics Group - Latin America, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson S.E., Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Services, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Surgical Vision, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Urban Renewal Associates</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Vision Care, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JOM Pharmaceutical Services, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LTL Management LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Consumer Pharmaceuticals Co.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Healthcare LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil LA LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNEIL MMP, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Nutritionals, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Device Business Services, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices &#38; Diagnostics Global Services, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices International LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MegaDyne Medical Products, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Utah</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor Partnership Holding Company I, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor Texas GP LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor Texas L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor Worldwide LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Micrus Endovascular LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Middlesex Assurance Company Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vermont</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Momenta Pharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NeoStrata Company, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands Holding Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NeuWave Medical, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novira Therapeutics, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NuVera Medical, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OMJ Pharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Omrix Biopharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ortho Biologics LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ortho Biotech Holding LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ortho-McNeil Pharmaceutical, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patriot Pharmaceuticals, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Peninsula Pharmaceuticals, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Percivia LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Princeton Laboratories, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pulsar Vascular, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Regency Urban Renewal Associates</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty A&#38;M LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rutan Realty LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scios LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sightbox, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SterilMed, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes USA Products, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes USA, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TARIS Biomedical LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TearScience, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Anspach Effort, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Vision Care Institute, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tibotec, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Torax Medical, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Verb Surgical Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vogue International LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vogue International Trading, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WH4110 Development Company, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zarbee's, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Subsidiaries&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3Dintegrated ApS</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Pharmaceuticals Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Pharmaceuticals Trading (Shanghai) Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Treasury Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO (Hangzhou) Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO (Shanghai) Medical Devices Trading Co., Ltd Beijing Branch</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO (Shanghai) Medical Devices Trading Co., Ltd Guangzhou Branch</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO (Shanghai) Medical Devices Trading Co., Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO ASIA LIMITED</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Asia Limited (Korea Branch)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea, Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Asia Limited Taiwan Branch (Hong Kong)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taiwan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Australia Pty Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Australia Pty Limited (New Zealand Branch)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Canada Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Denmark ApS</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO France</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Germany GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Groningen B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO International Holdings Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Ireland</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Ireland, Ireland Branch</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Italy SRL</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Japan K.K.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Netherlands BV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Norway AS</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Norway</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Puerto Rico Manufacturing, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Singapore Pte. Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Switzerland GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO United Kingdom, Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Uppsala AB</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Apsis</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Backsvalan 2 Aktiebolag</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Backsvalan 6 Handelsbolag</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beijing Dabao Cosmetics Co., Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Berna Rhein B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biosense Webster (Israel) Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Branch of Johnson &#38; Johnson LLC (RU) in Kazakhstan</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kazakhstan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">C Consumer Products Denmark ApS</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Campus-Foyer Apotheke GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carlo Erba OTC S.r.l.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ChromaGenics B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ci&#58;Labo Customer Marketing Co., Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ci&#58;z. Labo Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag AG</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag GmbH International</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag Holding AG</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag Holding Treasury Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag-Biotech, S.L.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ColBar LifeScience Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cordis de Mexico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corimmun GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debs-Vogue Corporation (Proprietary) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Hellas SA</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy International Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Ireland Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Mexico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Synthes Gorgan Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Synthes Leto SARL</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EES Holdings de Mexico, S. de R.L. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EES, S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EIT Emerging Implant Technologies GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon Endo-Surgery (Europe) GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon PR Holdings Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon Sarl</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon Women's Health &#38; Urology Sarl</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethnor (Proprietary) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethnor del Istmo S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Panama</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethnor Farmaceutica, S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venezuela, Bolivarian Republic of</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury (Development) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury (Instruments) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury Medical Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury Orthopaedics International Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury Orthopaedics Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FMS Future Medical System SA</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GH Biotech Holdings Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global Investment Participation B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GMED Healthcare BV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GMED Healthcare BV (Branch)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Guangzhou Bioseal Biotech Co., Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hansen Medical Deutschland GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hansen Medical UK Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Healthcare Services (Shanghai) Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Innomedic Gesellschaft f&#252;r innovative Medizintechnik und Informatik mbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J &#38; J Company West Africa Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nigeria</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J&#38;J Pension Trustees Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J.C. General Services BV</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Alzheimer Immunotherapy (Holding) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Biologics (Ireland) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Biologics B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Cilag Farmaceutica S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Cilag S.p.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Cilag SPA</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Algeria</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Cilag, C.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venezuela, Bolivarian Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Development Finance Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Egypt LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Farmaceutica Portugal Lda</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Holding GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Irish Finance Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Korea Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea, Republic of</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceutica (Proprietary) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceutica NV</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceutica S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Peru</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceutical K.K.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceutical Sciences Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceutical Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Janssen Pharmaceuticals, Inc., Japan Branch</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen R&#38;D Ireland Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Sciences Ireland Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Vaccines &#38; Prevention B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Vaccines Corp.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea, Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Vaccines, Branch of Cilag GmbH International</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag (New Zealand) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag A&#47;S</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag AG</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Aktiebolag</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag AS</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Norway</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag de Mexico S. de R.L. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Farmaceutica Lda.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Farmaceutica Ltda.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag International NV</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Kft.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Kft. Branch Office</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag NV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag OY</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Pharma GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Pharmaceutical S.A.C.I.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Polska, Sp. z o.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Pty Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Pty Ltd (Branch)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Colombia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag s.r.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag, S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag, S.A. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Pharma, S.L.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J-C Health Care Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJ Surgical Vision Spain, S.L.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJC Acquisition Company B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV Belgium BV</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV Manufacturing Malaysia SDN. BHD.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV Norden AB</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV Produtos Oticos Ltda.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ Global Business Services s.r.o.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ Holding EMEA B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J-C Health Care Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJ Surgical Vision Spain, S.L.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJC Acquisition Company B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV Belgium BV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV Manufacturing Malaysia SDN. BHD.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV Norden AB</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV Produtos Oticos Ltda.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ Global Business Services s.r.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ Holding EMEA B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson - Societa' Per Azioni</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Angola), Limitada</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Angola</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (China) Investment Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (China) Investment Ltd. Beijing Branch</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Egypt) S.A.E.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Hong Kong) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Ireland) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Jamaica) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jamaica</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Kenya) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kenya</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Middle East) Inc. Service Center (DAFZA Branch)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Middle East), Inc. (DHCC Branch)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Middle East), Inc. (JAFZA Branch)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Mozambique), Limitada</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mozambique</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Namibia) (Proprietary) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Namibia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (New Zealand) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Philippines), Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Private) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zimbabwe</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Thailand) Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Trinidad) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trinidad and Tobago</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Vietnam) Co., Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vietnam</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson AB</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson AB Eesti filiaal (Branch)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Estonia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson AG</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson AG (Zuchwil Branch)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Belgium Finance Company BV</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Bulgaria EOOD</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bulgaria</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson China Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer (Hong Kong) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer (Thailand) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer Health Care Switzerland, Branch of Janssen-Cilag AG</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer Holdings France</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer NV</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer Saudi Arabia Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Saudi Arabia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer Services EAME Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer, Inc. (Dominican Republic Branch)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dominican Republic</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson d.o.o.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Slovenia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Argentina S.A.C. e. I.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Chile Limitada</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chile</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Chile S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chile</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Colombia S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Colombia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Mexico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Uruguay S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Uruguay</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Venezuela, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venezuela, Bolivarian Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson del Ecuador, S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ecuador</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Del Paraguay, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Paraguay</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson del Peru S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Peru</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson do Brasil Industria E Comercio de Produtos Para Saude Ltda.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Dominicana, S.A.S.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dominican Republic</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson European Treasury Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Finance Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Financial Services GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Financial Services GmbH (Branch Office)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson for Export and Import LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Gesellschaft m.b.H.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Guatemala, S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Guatemala</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Johnson &#38; Johnson Hellas Commercial and Industrial S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Hellas Consumer Products Commercial Societe Anonyme</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Hemisferica S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Puerto Rico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Holding GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Industrial Ltda.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Innovation Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson International (Belgian Branch) (European Logistics Center)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson International (Singapore) Pte. Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson International (Singapore) Pte. Ltd. (Branch)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson International Financial Services Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson K.K.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Kft.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Korea Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea, Republic of</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Korea Selling &#38; Distribution LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea, Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Limited (Sri Lanka Branch)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sri Lanka</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Russian Federation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Luxembourg Finance Company Sarl</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Management Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical (China) Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical (Proprietary) Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical (Shanghai) Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical (Shanghai) Ltd. Beijing Branch</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical (Suzhou) Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Korea Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea, Republic of</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Mexico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical NV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Products GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Pty Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical S.p.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical SAS</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Saudi Arabia Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Saudi Arabia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Taiwan Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taiwan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical, S.C.S.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venezuela, Bolivarian Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medikal Sanayi ve Ticaret Limited Sirketi</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medikal Sanayi ve Ticaret Limited Sirketi (Ankara Branch)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medikal Sanayi ve Ticaret Limited Sirketi (Izmir Branch)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Middle East - Scientific Office</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Middle East FZ - LLC (Lebanese Branch)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lebanon</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Middle East FZ-LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Middle East FZ-LLC (Ghana Branch)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ghana</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Middle East FZ-LLC (Kenya Branch)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kenya</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Middle East FZ-LLC Branch (TSO) (Saudi Arabia Branch)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Saudi Arabia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Morocco Societe Anonyme</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Morocco</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson NCB (Belgian Branch)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Nordic AB</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Pacific Pty Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Pakistan (Private) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pakistan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Panama, S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Panama</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Personal Care (Chile) S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chile</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Johnson &#38; Johnson Poland Sp. z o.o.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Poland sp. z o.o. oddzial w Warszawie &#34;Consumer&#34;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Private Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Pte. Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Pte. Ltd. Korea Branch</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea, Republic of</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Pty. Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Romania S.R.L.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Romania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson S.E. d.o.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Croatia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Sante Beaute France</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson SDN. BHD.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Surgical Vision India Private Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Taiwan Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taiwan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson UK Treasury Company Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Ukraine LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ukraine</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Vision Care (Shanghai) Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Vision Care Ireland Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson, Lda</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson, S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson, s.r.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson, s.r.o.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Slovakia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson and Johnson (Proprietary) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson and Johnson Sihhi Malzeme Sanayi Ve Ticaret Limited Sirketi</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson Y Johnson de Costa Rica, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costa Rica</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">La Concha Land Investment Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latam International Investment Company Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Legal Entity Name</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Country</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil AB</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Denmark ApS</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Healthcare (Ireland) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Healthcare (UK) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Iberica S.L.U.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Panama, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Panama</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Products Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Sweden AB</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MDS Co. Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medos International Sarl</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medos International S&#224;rl, succursale de Neuch&#226;tel (Branch)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medos Sarl</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Menlo Care De Mexico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor Deutschland GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor Medical Systems B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Momenta Ireland Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NeoStrata UG (haftungsbeschr&#228;nkt)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuravi Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Obtech Medical Mexico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OBTECH Medical Sarl</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OGX Beauty Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OMJ Holding GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OMJ Ireland Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Omrix Biopharmaceuticals Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Omrix Biopharmaceuticals NV</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orthospin Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orthotaxy</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Pharmadirect Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmedica Laboratories (Proprietary) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Productos de Cuidado Personal y de La Salud de Bolivia S.R.L.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bolivia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proleader S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Uruguay</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PT Integrated Healthcare Indonesia</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indonesia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PT. Johnson &#38; Johnson Indonesia</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indonesia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RespiVert Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RoC International</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sedona Singapore International Pte. Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sedona Thai International Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Serhum S.A. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shanghai Elsker For Mother &#38; Baby Co., Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shanghai Elsker Mother &#38; Baby Co., Ltd Minghang Branch</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shanghai Johnson &#38; Johnson Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shanghai Johnson &#38; Johnson Pharmaceuticals Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sodiac ESV</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spectrum Vision Limited Liability Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Russian Federation</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spectrum Vision Limited Liability Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ukraine</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spectrum Vision Limited Liability Partnership</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kazakhstan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Process Institute Deutschland GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Costa Rica S.C.R., Limitada</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costa Rica</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SYNTHES GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Holding AG</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Holding Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SYNTHES Medical Immobilien GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Medical Surgical Equipment &#38; Instruments Trading LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Produktions GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Proprietary Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes S.M.P., S. de R.L. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Tuttlingen GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UAB &#34;Johnson &#38; Johnson&#34;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lithuania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UAB Johnson &#38; Johnson Eesti Filiaal (Estonian Branch)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Estonia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vania Expansion</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vision Care Finance Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xian Janssen Pharmaceutical Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xian-Janssen Pharmaceutical Ltd. Beijing Branch Office</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xian-Janssen Pharmaceutical Ltd. Shanghai Branch Office</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XO1 Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>3
<FILENAME>ex23-pwcconsentxform10xkx2.htm
<DESCRIPTION>EX-23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ibd118e82759c4ad298dbfd282d32b495_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;23</font></div><div style="margin-top:19pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-top:7pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-211250, 333-181092, 333-163857, 333-129542, and 333-124785) and Form S-3 (No. 333-236499) of Johnson &#38; Johnson of our report dated February 17, 2022 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47;PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Florham Park, NJ </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 17, 2022</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex311-302certofceoxform10x.htm
<DESCRIPTION>EX-31.1 CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5e38dd71ca8e45579bca0620bde1708a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;31.1</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joaquin Duato, certify that&#58;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;I have reviewed this Annual Report on Form 10-K for the fiscal year ended January 2, 2022 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#8220;Company&#8221;)&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;The Company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the Company and have&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(c) Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(d) Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company&#8217;s most recent fiscal quarter (the Company&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;The Company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joaquin Duato</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joaquin Duato</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February 17, 2022</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex312-302certofcfoxform10x.htm
<DESCRIPTION>EX-31.2 CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i75e7611dc5264c7abdd455bbb344cd7e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 31.2</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph J. Wolk certify that&#58;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;I have reviewed this Annual Report on Form 10-K for the fiscal year ended January 2, 2022 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#8220;Company&#8221;)&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;The Company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the Company and have&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(c) Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(d) Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company&#8217;s most recent fiscal quarter (the Company&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;The Company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph J. Wolk</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February 17, 2022 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex321-906certofceoxform10x.htm
<DESCRIPTION>EX-32.1 CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i114ba8d482e340ee94b0f07752bce38b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned, Joaquin Duato, the Chief Executive Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the Company's Annual Report on Form 10-K for the fiscal year ended January 2, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joaquin Duato</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joaquin Duato</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February 17, 2022</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is being furnished to the SEC with this Report on Form 10-K pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.</font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ex322-906certofcfoxform10x.htm
<DESCRIPTION>EX-32.2 CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i398367d24d1d4e4a819230cd191fd356_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned, Joseph J. Wolk, the Chief Financial Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the Company's Annual Report on Form 10-K for the fiscal year ended January 2, 2022 (the &#8220;Report&#34;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph J. Wolk</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February 17, 2022</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is being furnished to the SEC with this Report on Form 10-K pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>jnj-20220102.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2ac3ec12-1a04-4290-8adc-1ec251a989dd,g:c9588643-da6b-4c23-b331-47586e9dc1a5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:jnj="http://www.jnj.com/20220102" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.jnj.com/20220102">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20220102_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20220102_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20220102_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20220102_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.jnj.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.jnj.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEarnings" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings">
        <link:definition>1003005 - Statement - Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1004006 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical">
        <link:definition>1005007 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity">
        <link:definition>1006008 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquityParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical">
        <link:definition>1007009 - Statement - Consolidated Statements of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1008010 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2303301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2404401 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandCurrentMarketableSecurities" roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities">
        <link:definition>2106102 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandCurrentMarketableSecuritiesTables" roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables">
        <link:definition>2307302 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails" roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails">
        <link:definition>2408403 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails">
        <link:definition>2409404 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.jnj.com/role/Inventories">
        <link:definition>2110103 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.jnj.com/role/InventoriesTables">
        <link:definition>2311303 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.jnj.com/role/InventoriesDetails">
        <link:definition>2412405 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.jnj.com/role/PropertyPlantandEquipment">
        <link:definition>2113104 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentTables" roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentTables">
        <link:definition>2314304 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails">
        <link:definition>2415406 - Disclosure - Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNarrativeDetails" roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails">
        <link:definition>2416407 - Disclosure - Property, Plant and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill">
        <link:definition>2117105 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>2318305 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails">
        <link:definition>2419408 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillGoodwillDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails">
        <link:definition>2420409 - Disclosure - Intangible Assets and Goodwill - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillNarrativeDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails">
        <link:definition>2421410 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails">
        <link:definition>2422411 - Disclosure - Intangible Assets and Goodwill - Estimated Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.jnj.com/role/FairValueMeasurements">
        <link:definition>2123106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.jnj.com/role/FairValueMeasurementsTables">
        <link:definition>2324306 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2425412 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofDerivativeActivityDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails">
        <link:definition>2426413 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails">
        <link:definition>2427414 - Disclosure - Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails">
        <link:definition>2428415 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails">
        <link:definition>2429416 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails">
        <link:definition>2430417 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails">
        <link:definition>2431418 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://www.jnj.com/role/Borrowings">
        <link:definition>2132107 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://www.jnj.com/role/BorrowingsTables">
        <link:definition>2333307 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofLongtermDebtInstrumentsDetails" roleURI="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails">
        <link:definition>2434419 - Disclosure - Borrowings - Schedule of Long-term Debt Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://www.jnj.com/role/BorrowingsNarrativeDetails">
        <link:definition>2435420 - Disclosure - Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsAggregateMaturitiesofLongTermObligationsDetails" roleURI="http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails">
        <link:definition>2436421 - Disclosure - Borrowings - Aggregate Maturities of Long Term Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.jnj.com/role/IncomeTaxes">
        <link:definition>2137108 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.jnj.com/role/IncomeTaxesTables">
        <link:definition>2338308 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionforIncomeTaxesDetails" roleURI="http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails">
        <link:definition>2439422 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" roleURI="http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails">
        <link:definition>2440423 - Disclosure - Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.jnj.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2441424 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTemporaryDifferencesandCarryforwardsDetails" roleURI="http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails">
        <link:definition>2442425 - Disclosure - Income Taxes - Temporary Differences and Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" roleURI="http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails">
        <link:definition>2443426 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRelatedObligations" roleURI="http://www.jnj.com/role/EmployeeRelatedObligations">
        <link:definition>2144109 - Disclosure - Employee Related Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRelatedObligationsTables" roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsTables">
        <link:definition>2345309 - Disclosure - Employee Related Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRelatedObligationsEmployeeRelatedObligationsDetails" roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails">
        <link:definition>2446427 - Disclosure - Employee Related Obligations - Employee Related Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1" roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1">
        <link:definition>2446427 - Disclosure - Employee Related Obligations - Employee Related Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRelatedObligationsNarrativeDetails" roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails">
        <link:definition>2447428 - Disclosure - Employee Related Obligations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlans" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans">
        <link:definition>2148110 - Disclosure - Pensions and Other Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansTables" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables">
        <link:definition>2349310 - Disclosure - Pensions and Other Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansNarrativeDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails">
        <link:definition>2450429 - Disclosure - Pensions and Other Benefit Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>2451430 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails">
        <link:definition>2452431 - Disclosure - Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails">
        <link:definition>2453432 - Disclosure - Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails">
        <link:definition>2454433 - Disclosure - Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails">
        <link:definition>2455434 - Disclosure - Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails">
        <link:definition>2456435 - Disclosure - Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails">
        <link:definition>2457436 - Disclosure - Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails">
        <link:definition>2458437 - Disclosure - Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails">
        <link:definition>2459438 - Disclosure - Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SavingsPlan" roleURI="http://www.jnj.com/role/SavingsPlan">
        <link:definition>2160111 - Disclosure - Savings Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SavingsPlanNarrativeDetails" roleURI="http://www.jnj.com/role/SavingsPlanNarrativeDetails">
        <link:definition>2461439 - Disclosure - Savings Plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalandTreasuryStock" roleURI="http://www.jnj.com/role/CapitalandTreasuryStock">
        <link:definition>2162112 - Disclosure - Capital and Treasury Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalandTreasuryStockTables" roleURI="http://www.jnj.com/role/CapitalandTreasuryStockTables">
        <link:definition>2363311 - Disclosure - Capital and Treasury Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalandTreasuryStockChangesinTreasuryStockDetails" roleURI="http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails">
        <link:definition>2464440 - Disclosure - Capital and Treasury Stock - Changes in Treasury Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalandTreasuryStockNarrativeDetails" roleURI="http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails">
        <link:definition>2465441 - Disclosure - Capital and Treasury Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss">
        <link:definition>2166113 - Disclosure - Accumulated Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2367312 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2468442 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InternationalCurrencyTranslation" roleURI="http://www.jnj.com/role/InternationalCurrencyTranslation">
        <link:definition>2169114 - Disclosure - International Currency Translation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InternationalCurrencyTranslationNarrativeDetails" roleURI="http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails">
        <link:definition>2470443 - Disclosure - International Currency Translation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.jnj.com/role/EarningsPerShare">
        <link:definition>2171115 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.jnj.com/role/EarningsPerShareTables">
        <link:definition>2372313 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" roleURI="http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails">
        <link:definition>2473444 - Disclosure - Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareNarrativeDetails" roleURI="http://www.jnj.com/role/EarningsPerShareNarrativeDetails">
        <link:definition>2474445 - Disclosure - Earnings Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreements" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements">
        <link:definition>2175116 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreementsTables" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables">
        <link:definition>2376314 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails">
        <link:definition>2477446 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails">
        <link:definition>2478447 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails">
        <link:definition>2479448 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails">
        <link:definition>2480449 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails">
        <link:definition>2481450 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreas" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas">
        <link:definition>2182117 - Disclosure - Segments of Business and Geographic Areas</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasTables" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables">
        <link:definition>2383315 - Disclosure - Segments of Business and Geographic Areas (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails">
        <link:definition>2484451 - Disclosure - Segments of Business and Geographic Areas - Sales by Segment of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails">
        <link:definition>2485452 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitures" roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures">
        <link:definition>2186118 - Disclosure - Acquisitions and Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresNarrativeDetails" roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails">
        <link:definition>2487453 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedings" roleURI="http://www.jnj.com/role/LegalProceedings">
        <link:definition>2188119 - Disclosure - Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsDetails" roleURI="http://www.jnj.com/role/LegalProceedingsDetails">
        <link:definition>2489454 - Disclosure - Legal Proceedings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.jnj.com/role/Restructuring">
        <link:definition>2190120 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.jnj.com/role/RestructuringTables">
        <link:definition>2391316 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativeDetails" roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails">
        <link:definition>2492455 - Disclosure - Restructuring - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails" roleURI="http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails">
        <link:definition>2493456 - Disclosure - Restructuring - Summary of Severance Charges and Associated Spending (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" abstract="false" name="PercentageOfCorridorOfGreaterOfMarketValueOfAssets" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_SkinHealthBeautyMember" abstract="true" name="SkinHealthBeautyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_Wholesaler2Member" abstract="true" name="Wholesaler2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_HIPSMember" abstract="true" name="HIPSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_RegulationCharge" abstract="false" name="RegulationCharge" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_Wholesaler1Member" abstract="true" name="Wholesaler1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_BabyPowderMember" abstract="true" name="BabyPowderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_UnfundedPlansMember" abstract="true" name="UnfundedPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ExercisePriceRangeFiveMember" abstract="true" name="ExercisePriceRangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SegmentsTotalMember" abstract="true" name="SegmentsTotalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ExpenseNotAllocatedToSegments" abstract="false" name="ExpenseNotAllocatedToSegments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_PotentialSharesExercisableUnderStockOptionPlans" abstract="false" name="PotentialSharesExercisableUnderStockOptionPlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_LegalProceedingTextualsAbstract" abstract="true" name="LegalProceedingTextualsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" abstract="false" name="EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A6.73Debenturesdue2023Member" abstract="true" name="A6.73Debenturesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" abstract="false" name="DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_SalesBySegmentOfBusinessTableTextBlock" abstract="false" name="SalesBySegmentOfBusinessTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" abstract="false" name="EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_MomentaMember" abstract="true" name="MomentaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset" abstract="false" name="TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.95Notesdue2027Member" abstract="true" name="A2.95Notesdue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PatentsAndTrademarksMember" abstract="true" name="PatentsAndTrademarksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" abstract="true" name="PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FederalLevelJurisdictionMember" abstract="true" name="FederalLevelJurisdictionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset" abstract="false" name="TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" abstract="false" name="DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_PhysiomeshMember" abstract="true" name="PhysiomeshMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OpiodsMember" abstract="true" name="OpiodsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PROCRITEPREXMember" abstract="true" name="PROCRITEPREXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit" abstract="false" name="TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ProfitLossPercentToSales" abstract="false" name="ProfitLossPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_StelaraMember" abstract="true" name="StelaraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LegalJurisdictionDomain" abstract="true" name="LegalJurisdictionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" abstract="false" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ChangesInTreasuryStockTableTextBlock" abstract="false" name="ChangesInTreasuryStockTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_NonQualifiedPlansMember" abstract="true" name="NonQualifiedPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" abstract="false" name="EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_VerbSurgicalIncMember" abstract="true" name="VerbSurgicalIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SupplyChainMember" abstract="true" name="SupplyChainMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" abstract="false" name="FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_GeneralCorporateMember" abstract="true" name="GeneralCorporateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CommingledFundsMember" abstract="true" name="CommingledFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" abstract="false" name="EstimatedUsefulLivesOfAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_ChangesInTreasuryStockRollForward" abstract="true" name="ChangesInTreasuryStockRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_AdvancedSterilizationProductsMember" abstract="true" name="AdvancedSterilizationProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TRAUMAMember" abstract="true" name="TRAUMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DeferredTaxAssetsOtherDomestic" abstract="false" name="DeferredTaxAssetsOtherDomestic" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" abstract="false" name="ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_A3.375Notesdue2023Member" abstract="true" name="A3.375Notesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A1.150NotesDue2028Member" abstract="true" name="A1.150NotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" abstract="false" name="DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_RisperdalMember" abstract="true" name="RisperdalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_BusinessAcquisitionDiscountRate" abstract="false" name="BusinessAcquisitionDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A0.650NotesDue2024Member" abstract="true" name="A0.650NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2019AcquisitionsMember" abstract="true" name="A2019AcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.500Notesdue2048Member" abstract="true" name="A3.500Notesdue2048Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OpioidMember" abstract="true" name="OpioidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SimponiSimponiAriaMember" abstract="true" name="SimponiSimponiAriaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ErleadaMember" abstract="true" name="ErleadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.50Debenturesdue2040Member" abstract="true" name="A4.50Debenturesdue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" abstract="true" name="OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_INVOKANAINVOKAMETMember" abstract="true" name="INVOKANAINVOKAMETMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" abstract="true" name="INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.85Notesdue2041Member" abstract="true" name="A4.85Notesdue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SPINESPORTSOTHERMember" abstract="true" name="SPINESPORTSOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LossContingencyReserveEstablishedWithinTrust" abstract="false" name="LossContingencyReserveEstablishedWithinTrust" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" abstract="true" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_LandAndLeaseholdImprovementsMember" abstract="true" name="LandAndLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.70Notesdue2046Member" abstract="true" name="A3.70Notesdue2046Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ZYTIGAMember" abstract="true" name="ZYTIGAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ConcentrationRiskThresholdPercentage" abstract="false" name="ConcentrationRiskThresholdPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="jnj_ChangesinTreasuryStockSharesOutstandingRollForward" abstract="true" name="ChangesinTreasuryStockSharesOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" abstract="false" name="FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" abstract="false" name="LossContingencyNumberOfClaimsWithinSettlementAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" abstract="false" name="IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ImmunologyMember" abstract="true" name="ImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2020AcquisitionsMember" abstract="true" name="A2020AcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CONTACTLENSESOTHERMember" abstract="true" name="CONTACTLENSESOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LitigationSettlementByCompaniesAxis" abstract="true" name="LitigationSettlementByCompaniesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_A5.50NotesDue2024Member" abstract="true" name="A5.50NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue" abstract="false" name="LossContingencyDamagesAwardedAdditionalReimbursementValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_XareltoMember" abstract="true" name="XareltoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DebtInstrumentConvertibleAmountOfLoanConverted" abstract="false" name="DebtInstrumentConvertibleAmountOfLoanConverted" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" abstract="false" name="TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A2.25Notesdue2022Member" abstract="true" name="A2.25Notesdue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EquityFairValueAdjustmentChangeinObservablePrices" abstract="false" name="EquityFairValueAdjustmentChangeinObservablePrices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" abstract="true" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_EquityInvestmentswithReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.45Notesdue2021Member" abstract="true" name="A2.45Notesdue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_RemicadeMember" abstract="true" name="RemicadeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherInfectiousDiseasesMember" abstract="true" name="OtherInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" abstract="false" name="OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_IMBRUVICAMember" abstract="true" name="IMBRUVICAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InterestIncomeExpenseNetMember" abstract="true" name="InterestIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CardiovascularMetabolismOtherMember" abstract="true" name="CardiovascularMetabolismOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_WomensHealthMember" abstract="true" name="WomensHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PulmonaryHypertensionMember" abstract="true" name="PulmonaryHypertensionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AssetWriteoffMember" abstract="true" name="AssetWriteoffMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PercentageOfCompanysCommonStockToPlanAsset" abstract="false" name="PercentageOfCompanysCommonStockToPlanAsset" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A5.85Debenturesdue2038Member" abstract="true" name="A5.85Debenturesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ConsumerMember" abstract="true" name="ConsumerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherNonLongLivedAssets" abstract="false" name="OtherNonLongLivedAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_WesternHemisphereExcludingUSMember" abstract="true" name="WesternHemisphereExcludingUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OTCMember" abstract="true" name="OTCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_RISPERDALCONSTAMember" abstract="true" name="RISPERDALCONSTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.45Notesdue2026Member" abstract="true" name="A2.45Notesdue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SurgicalMeshProductsMarketingMember" abstract="true" name="SurgicalMeshProductsMarketingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LegalJurisdictionAxis" abstract="true" name="LegalJurisdictionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_DePuyASRU.S.Member" abstract="true" name="DePuyASRU.S.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SavingsPlanAbstract" abstract="true" name="SavingsPlanAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_OtherOncologyMember" abstract="true" name="OtherOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" abstract="false" name="DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_BermekimabMember" abstract="true" name="BermekimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" abstract="false" name="FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A3.55Notesdue2036Member" abstract="true" name="A3.55Notesdue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithoutReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" abstract="false" name="MinimumCollateralValueasaPercentReverseRepurchaseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" abstract="false" name="FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_MedicalDevicesMember" abstract="true" name="MedicalDevicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InvokanaMember" abstract="true" name="InvokanaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherIncomeExpenseNetMember" abstract="true" name="OtherIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" abstract="false" name="EffectiveIncomeTaxRateReconciliationCapitalLoss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_RestructuringandRelatedCostDurationofRestructuringPlan" abstract="false" name="RestructuringandRelatedCostDurationofRestructuringPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jnj_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" abstract="false" name="TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A210NotesDue2040Member" abstract="true" name="A210NotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PurchasedInProcessResearchAndDevelopmentMember" abstract="true" name="PurchasedInProcessResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CurtailmentsAndSettlementsAndRestructuring" abstract="false" name="CurtailmentsAndSettlementsAndRestructuring" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ProductLiabilityPolicyTextBlock" abstract="false" name="ProductLiabilityPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_Numberofpatientsinsettlement" abstract="false" name="Numberofpatientsinsettlement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_VisionMember" abstract="true" name="VisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.75Notesdue2047Member" abstract="true" name="A3.75Notesdue2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AsrMember" abstract="false" name="AsrMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" abstract="false" name="ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A055NotesDue2025Member" abstract="true" name="A055NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EDURANTrilpivirineMember" abstract="true" name="EDURANTrilpivirineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DARZALEXMember" abstract="true" name="DARZALEXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" abstract="false" name="TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EmployeeRelatedObligationsTableTextBlock" abstract="false" name="EmployeeRelatedObligationsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" abstract="false" name="NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_SavingsPlanTextBlock" abstract="false" name="SavingsPlanTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_A2.05Notesdue2023Member" abstract="true" name="A2.05Notesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PercentageChangeInSalesBySegmentOfBusiness" abstract="false" name="PercentageChangeInSalesBySegmentOfBusiness" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A3.400Notesdue2038Member" abstract="true" name="A3.400Notesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent" abstract="false" name="IncreaseDecreaseInEarningsBeforeTaxesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_OralCareMember" abstract="true" name="OralCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.50Notesdue2043Member" abstract="true" name="A4.50Notesdue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SURGICALMember" abstract="true" name="SURGICALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AccruedRebatesReturnsAndPromotions" abstract="false" name="AccruedRebatesReturnsAndPromotions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_PinnacleAcetabularCupSystemMember" abstract="false" name="PinnacleAcetabularCupSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AurisHealthMember" abstract="true" name="AurisHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InterventionalSolutionsMember" abstract="true" name="InterventionalSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_WoundCareandOtherMember" abstract="true" name="WoundCareandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherImmunologyMember" abstract="true" name="OtherImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A130NotesDue2030Member" abstract="true" name="A130NotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DeferredTaxLiabilitiesOtherDomestic" abstract="false" name="DeferredTaxLiabilitiesOtherDomestic" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A6.95Notesdue2029Member" abstract="true" name="A6.95Notesdue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherSovereignSecuritiesMember" abstract="true" name="OtherSovereignSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" abstract="false" name="OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ExercisePriceRangeOneMember" abstract="true" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DeferredTaxAssetsUndistributedForeignEarnings" abstract="false" name="DeferredTaxAssetsUndistributedForeignEarnings" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A2.900Notesdue2028Member" abstract="true" name="A2.900Notesdue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CizHoldingsCo.Ltd.Member" abstract="true" name="CizHoldingsCo.Ltd.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_StateLevelJurisdictionMember" abstract="true" name="StateLevelJurisdictionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OTHERNEUROSCIENCEMember" abstract="true" name="OTHERNEUROSCIENCEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SurgeryMember" abstract="true" name="SurgeryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ShippingandHandlingCostsasaPercentofSales" abstract="false" name="ShippingandHandlingCostsasaPercentofSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_ProductLiabilityContingencyNumberOfClaimant" abstract="false" name="ProductLiabilityContingencyNumberOfClaimant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_GainOnSaleOfAnAssetPaymentForRestructuring" abstract="false" name="GainOnSaleOfAnAssetPaymentForRestructuring" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A4.95Debenturesdue2033Member" abstract="true" name="A4.95Debenturesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationReceivablesRetained" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" abstract="false" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_NumberOfStockBasedCompensationPlans" abstract="false" name="NumberOfStockBasedCompensationPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_OrthopaedicsMember" abstract="true" name="OrthopaedicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ContactLensesMember" abstract="true" name="ContactLensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_UnrecognizedTaxBenefitLiabilityPayment" abstract="false" name="UnrecognizedTaxBenefitLiabilityPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_LossContingencyEstimateOfAdditionalPossibleLoss" abstract="false" name="LossContingencyEstimateOfAdditionalPossibleLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ExcessOfFairValueOverCarryingValueOfDebt" abstract="false" name="ExcessOfFairValueOverCarryingValueOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ShortTermInvestmentFundsMember" abstract="true" name="ShortTermInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A095NotesDue2027Member" abstract="true" name="A095NotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OPSUMITMember" abstract="true" name="OPSUMITMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ActelionMember" abstract="true" name="ActelionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CashPaidDuringTheYearAbstract" abstract="true" name="CashPaidDuringTheYearAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="jnj_KNEESMember" abstract="true" name="KNEESMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TalcMember" abstract="true" name="TalcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EmployeeObligations" abstract="false" name="EmployeeObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" abstract="false" name="TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_WholesalerConcentrationRiskMember" abstract="true" name="WholesalerConcentrationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ADVANCEDMember" abstract="true" name="ADVANCEDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.55Notesdue2021Member" abstract="true" name="A3.55Notesdue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_RestructuringandRelatedCostExpectedFutureSavings" abstract="false" name="RestructuringandRelatedCostExpectedFutureSavings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_BabyCareMember" abstract="true" name="BabyCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A5.95Notesdue2037Member" abstract="true" name="A5.95Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LitigationSettlementByCompaniesDomain" abstract="true" name="LitigationSettlementByCompaniesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability" abstract="false" name="TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" abstract="false" name="DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" abstract="false" name="ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" abstract="false" name="DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_InfectiousDiseasesMember" abstract="true" name="InfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_UPTRAVIMember" abstract="true" name="UPTRAVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SalesReturnReserve" abstract="false" name="SalesReturnReserve" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" abstract="true" name="ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_QualifiedPlansMember" abstract="true" name="QualifiedPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" abstract="false" name="InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" abstract="false" name="EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A2012LongTermIncentivePlanMember" abstract="true" name="A2012LongTermIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FiscalPeriodPolicyTextBlock" abstract="false" name="FiscalPeriodPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" abstract="false" name="SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent" abstract="false" name="EffectiveTaxRateReconciliationLitigationSettlementPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_GENERALMember" abstract="true" name="GENERALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_IdorsiaMember" abstract="true" name="IdorsiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PelvicMeshesMember" abstract="false" name="PelvicMeshesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" abstract="false" name="DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_Wholesaler3Member" abstract="true" name="Wholesaler3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2450NotesDue2060Member" abstract="true" name="A2450NotesDue2060Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent" abstract="false" name="EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A4.375Notesdue2033Member" abstract="true" name="A4.375Notesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CONCERTAMethylphenidateMember" abstract="true" name="CONCERTAMethylphenidateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EffectOfExchangeRates" abstract="false" name="EffectOfExchangeRates" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_UNITEDSTATESExportsMember" abstract="true" name="UNITEDSTATESExportsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ConvertibleNoteEquityInterestNumberOfShares" abstract="false" name="ConvertibleNoteEquityInterestNumberOfShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_FundedPlansMember" abstract="true" name="FundedPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A0.250NotesDue2022Member" abstract="true" name="A0.250NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A1.65Notesdue2021Member" abstract="true" name="A1.65Notesdue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" abstract="false" name="FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" abstract="false" name="TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_BusinessCombinationProbabilityOfSuccessFactor" abstract="false" name="BusinessCombinationProbabilityOfSuccessFactor" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanOverUnderFundedStatusABO" abstract="false" name="DefinedBenefitPlanOverUnderFundedStatusABO" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" abstract="true" name="ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_A3.625Notesdue2037Member" abstract="true" name="A3.625Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AsiaPacificAfricaMember" abstract="true" name="AsiaPacificAfricaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" abstract="false" name="EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_December172018ShareRepurchaseProgramMember" abstract="true" name="December172018ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentRollForward" abstract="true" name="EquityInvestmentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_A2.625Notesdue2025Member" abstract="true" name="A2.625Notesdue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" abstract="false" name="DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EquityFairValueAdjustmentImpairmentLoss" abstract="false" name="EquityFairValueAdjustmentImpairmentLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EmployeeCompensationPeriod" abstract="false" name="EmployeeCompensationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jnj_ConcentrationOfCreditRiskTable" abstract="true" name="ConcentrationOfCreditRiskTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_A2250NotesDue2050Member" abstract="true" name="A2250NotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EvraAndDoxilMember" abstract="true" name="EvraAndDoxilMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ConcentrationOfCreditRiskLineItems" abstract="true" name="ConcentrationOfCreditRiskLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_A1.650NotesDue2035Member" abstract="true" name="A1.650NotesDue2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TremfyaMember" abstract="true" name="TremfyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>jnj-20220102_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2ac3ec12-1a04-4290-8adc-1ec251a989dd,g:c9588643-da6b-4c23-b331-47586e9dc1a5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20220102.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8e4ac2f1-87e8-47bc-99c8-525cfcf04f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5162fcd9-7a5a-4c82-bd6e-c777efa248fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8e4ac2f1-87e8-47bc-99c8-525cfcf04f2d" xlink:to="loc_us-gaap_LiabilitiesCurrent_5162fcd9-7a5a-4c82-bd6e-c777efa248fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d2f1e34c-d29e-455a-9e5a-5f01ade62ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8e4ac2f1-87e8-47bc-99c8-525cfcf04f2d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d2f1e34c-d29e-455a-9e5a-5f01ade62ed6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8a65ebde-6ca4-4b42-8f73-5128461b2eac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8e4ac2f1-87e8-47bc-99c8-525cfcf04f2d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8a65ebde-6ca4-4b42-8f73-5128461b2eac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_84361715-96d7-4e9a-9435-d731e0d6a6da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8e4ac2f1-87e8-47bc-99c8-525cfcf04f2d" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_84361715-96d7-4e9a-9435-d731e0d6a6da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_e07a6f8a-4079-402b-b08f-e46b3debb254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8e4ac2f1-87e8-47bc-99c8-525cfcf04f2d" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_e07a6f8a-4079-402b-b08f-e46b3debb254" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_936d2bd4-9ccf-4cd2-8b78-10475b271604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8e4ac2f1-87e8-47bc-99c8-525cfcf04f2d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_936d2bd4-9ccf-4cd2-8b78-10475b271604" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ffd31011-b9c5-4f36-ba93-7be533224b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_10357c93-bb76-4bf4-b1c8-1badf32dcbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ffd31011-b9c5-4f36-ba93-7be533224b8e" xlink:to="loc_us-gaap_Liabilities_10357c93-bb76-4bf4-b1c8-1badf32dcbfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7c7e45d3-cef6-4932-a276-dd25411906a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ffd31011-b9c5-4f36-ba93-7be533224b8e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7c7e45d3-cef6-4932-a276-dd25411906a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b855ab97-8972-42a5-88cc-221344380a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ffd31011-b9c5-4f36-ba93-7be533224b8e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b855ab97-8972-42a5-88cc-221344380a6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_bec445ef-e258-48ef-a684-58709ad0448c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e59cebde-0153-41fb-8095-bce6e5b1e6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_bec445ef-e258-48ef-a684-58709ad0448c" xlink:to="loc_us-gaap_AssetsCurrent_e59cebde-0153-41fb-8095-bce6e5b1e6b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f5aab36e-8e86-4750-ad1b-aa8c970b0f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_bec445ef-e258-48ef-a684-58709ad0448c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f5aab36e-8e86-4750-ad1b-aa8c970b0f44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9407dd7b-f767-40d4-a735-9a74da64a62a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_bec445ef-e258-48ef-a684-58709ad0448c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9407dd7b-f767-40d4-a735-9a74da64a62a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7b5437b3-3831-494e-bb99-ab2755b83346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_bec445ef-e258-48ef-a684-58709ad0448c" xlink:to="loc_us-gaap_Goodwill_7b5437b3-3831-494e-bb99-ab2755b83346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_9b6bace1-c83a-48a1-baaa-10d46ffc2ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_bec445ef-e258-48ef-a684-58709ad0448c" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_9b6bace1-c83a-48a1-baaa-10d46ffc2ee8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd1f3ca4-491b-4901-9c12-cf702c8ee39c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_bec445ef-e258-48ef-a684-58709ad0448c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd1f3ca4-491b-4901-9c12-cf702c8ee39c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_2db9b97d-3184-44a0-9755-a22de5165ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f4933a9f-a215-42db-a175-bcd4099ecbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_2db9b97d-3184-44a0-9755-a22de5165ab5" xlink:to="loc_us-gaap_PreferredStockValue_f4933a9f-a215-42db-a175-bcd4099ecbf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_af16f1a0-a24a-4c3c-abe0-ac262b7a215a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_2db9b97d-3184-44a0-9755-a22de5165ab5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_af16f1a0-a24a-4c3c-abe0-ac262b7a215a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4e367f47-3e7d-45e0-b361-2e267f3dd0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_2db9b97d-3184-44a0-9755-a22de5165ab5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4e367f47-3e7d-45e0-b361-2e267f3dd0ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1669f1cc-a5f2-4cc3-a8dc-5a26abd93456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_2db9b97d-3184-44a0-9755-a22de5165ab5" xlink:to="loc_us-gaap_CommonStockValue_1669f1cc-a5f2-4cc3-a8dc-5a26abd93456" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_94812044-3c81-45d9-bc91-223af0ed8992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_120b374c-3dc2-4e1c-b4fd-1acfda66ac22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_94812044-3c81-45d9-bc91-223af0ed8992" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_120b374c-3dc2-4e1c-b4fd-1acfda66ac22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d74fc349-50e6-4b11-b038-b7aa38a7d6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_94812044-3c81-45d9-bc91-223af0ed8992" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d74fc349-50e6-4b11-b038-b7aa38a7d6eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_208320a1-4969-48d5-b76e-29dd9265807f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_94812044-3c81-45d9-bc91-223af0ed8992" xlink:to="loc_us-gaap_CommonStockValue_208320a1-4969-48d5-b76e-29dd9265807f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_c0c719d8-ed28-4e93-8cf9-86aeacd4425e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_94812044-3c81-45d9-bc91-223af0ed8992" xlink:to="loc_us-gaap_TreasuryStockValue_c0c719d8-ed28-4e93-8cf9-86aeacd4425e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8b8dae54-1c63-425f-a504-7fbc8625be2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_82647248-d6b5-4641-9859-8c5844657692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8b8dae54-1c63-425f-a504-7fbc8625be2a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_82647248-d6b5-4641-9859-8c5844657692" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_bc8b24a0-08df-4a5f-9839-061fe522e182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8b8dae54-1c63-425f-a504-7fbc8625be2a" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_bc8b24a0-08df-4a5f-9839-061fe522e182" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f432283f-1d62-4a72-aa82-2565aad513fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8b8dae54-1c63-425f-a504-7fbc8625be2a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f432283f-1d62-4a72-aa82-2565aad513fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0c51da0d-f5b0-4a94-af4d-5856effdf1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8b8dae54-1c63-425f-a504-7fbc8625be2a" xlink:to="loc_us-gaap_InventoryNet_0c51da0d-f5b0-4a94-af4d-5856effdf1d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9d95a9dc-7831-4636-a1e6-91f4f6075d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8b8dae54-1c63-425f-a504-7fbc8625be2a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9d95a9dc-7831-4636-a1e6-91f4f6075d4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2e1ab36f-a9f4-4b10-bb25-e525616e1f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_66d22065-26da-4ded-8beb-ccbd70bf4108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2e1ab36f-a9f4-4b10-bb25-e525616e1f8b" xlink:to="loc_us-gaap_ShortTermBorrowings_66d22065-26da-4ded-8beb-ccbd70bf4108" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1fe2b644-6063-4ad5-82e5-440b981d72cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2e1ab36f-a9f4-4b10-bb25-e525616e1f8b" xlink:to="loc_us-gaap_AccountsPayableCurrent_1fe2b644-6063-4ad5-82e5-440b981d72cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6ad70d29-1891-4d19-a193-7004f647455d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2e1ab36f-a9f4-4b10-bb25-e525616e1f8b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_6ad70d29-1891-4d19-a193-7004f647455d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_ff0f72db-cce2-4563-8ee0-cc3263db3400" xlink:href="jnj-20220102.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2e1ab36f-a9f4-4b10-bb25-e525616e1f8b" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_ff0f72db-cce2-4563-8ee0-cc3263db3400" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6acd5133-a85f-4827-98aa-dfee6197b73a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2e1ab36f-a9f4-4b10-bb25-e525616e1f8b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6acd5133-a85f-4827-98aa-dfee6197b73a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_bc472c45-79bb-4b9c-9926-328d30915e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2e1ab36f-a9f4-4b10-bb25-e525616e1f8b" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_bc472c45-79bb-4b9c-9926-328d30915e91" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20220102.xsd#ConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_a2d3b42d-aa48-44f5-ba02-fff4a64f67cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fae5af9e-405f-470a-98aa-5eeca3c84ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_a2d3b42d-aa48-44f5-ba02-fff4a64f67cb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fae5af9e-405f-470a-98aa-5eeca3c84ccf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6e17a0df-cf94-4ac0-9abe-07154b349cde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_a2d3b42d-aa48-44f5-ba02-fff4a64f67cb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6e17a0df-cf94-4ac0-9abe-07154b349cde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9709a289-cdf6-4a81-b761-ef6038aef583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_ce7a1c6c-b0a1-4a2d-9a67-0d0b000e164e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9709a289-cdf6-4a81-b761-ef6038aef583" xlink:to="loc_us-gaap_GrossProfit_ce7a1c6c-b0a1-4a2d-9a67-0d0b000e164e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ecd39ba8-4935-4a97-85fa-237e99b58093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9709a289-cdf6-4a81-b761-ef6038aef583" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ecd39ba8-4935-4a97-85fa-237e99b58093" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_25e996af-d7bd-45be-8b63-b060b48d80bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9709a289-cdf6-4a81-b761-ef6038aef583" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_25e996af-d7bd-45be-8b63-b060b48d80bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_b71cdc50-0392-4d24-8bd8-75d465d88888" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9709a289-cdf6-4a81-b761-ef6038aef583" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_b71cdc50-0392-4d24-8bd8-75d465d88888" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_0f261787-4b5a-4f92-8933-744c78afa58d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9709a289-cdf6-4a81-b761-ef6038aef583" xlink:to="loc_us-gaap_InvestmentIncomeInterest_0f261787-4b5a-4f92-8933-744c78afa58d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_997b4cad-5628-41a4-a066-085b5c8f0aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9709a289-cdf6-4a81-b761-ef6038aef583" xlink:to="loc_us-gaap_InterestExpense_997b4cad-5628-41a4-a066-085b5c8f0aa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_91e0eacf-db4e-403c-a549-aac438233e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9709a289-cdf6-4a81-b761-ef6038aef583" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_91e0eacf-db4e-403c-a549-aac438233e6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e3c9a308-4033-4b27-a308-b5942b7a4be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9709a289-cdf6-4a81-b761-ef6038aef583" xlink:to="loc_us-gaap_RestructuringCharges_e3c9a308-4033-4b27-a308-b5942b7a4be5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7da7ea75-b4bf-495c-be8b-eda2af35bcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3653ba4c-af80-461c-b849-e811a9bd08e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7da7ea75-b4bf-495c-be8b-eda2af35bcdf" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3653ba4c-af80-461c-b849-e811a9bd08e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_19eeec09-8eaa-4150-92dd-a21e6216c485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7da7ea75-b4bf-495c-be8b-eda2af35bcdf" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_19eeec09-8eaa-4150-92dd-a21e6216c485" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20220102.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_74793e7b-682e-42a4-b86b-8bcd2848d72b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_3d4436b6-7e80-4255-ba0a-e2e37832f459" xlink:href="jnj-20220102.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_74793e7b-682e-42a4-b86b-8bcd2848d72b" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_3d4436b6-7e80-4255-ba0a-e2e37832f459" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_5c479d2b-e5f4-4290-a79c-a96af6ea5b9c" xlink:href="jnj-20220102.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_74793e7b-682e-42a4-b86b-8bcd2848d72b" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_5c479d2b-e5f4-4290-a79c-a96af6ea5b9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_3e8e4203-34ef-4136-ba8b-682a69900a23" xlink:href="jnj-20220102.xsd#jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_74793e7b-682e-42a4-b86b-8bcd2848d72b" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_3e8e4203-34ef-4136-ba8b-682a69900a23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_66c574fe-61b9-4250-a73f-fd5ca86a974e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_b5af3903-4f4e-4c44-81d3-8bf97a623799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_66c574fe-61b9-4250-a73f-fd5ca86a974e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_b5af3903-4f4e-4c44-81d3-8bf97a623799" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_6897a838-a296-4ad4-8144-6f6cbfaf7b02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_66c574fe-61b9-4250-a73f-fd5ca86a974e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_6897a838-a296-4ad4-8144-6f6cbfaf7b02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6eae2d3d-231b-4cba-9fa4-482fbace28fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_98605e90-0bcd-4f0d-b0db-3275019bf91f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6eae2d3d-231b-4cba-9fa4-482fbace28fb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_98605e90-0bcd-4f0d-b0db-3275019bf91f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_16ed80cc-fe55-4ad2-8ef4-b1302479295b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6eae2d3d-231b-4cba-9fa4-482fbace28fb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_16ed80cc-fe55-4ad2-8ef4-b1302479295b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d7e08021-963d-43ef-804e-438e27c2239c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_bcc6a337-7f33-4a53-8230-24d0792884ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d7e08021-963d-43ef-804e-438e27c2239c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_bcc6a337-7f33-4a53-8230-24d0792884ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_10d5472a-5c43-4148-8071-d3e787423d54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d7e08021-963d-43ef-804e-438e27c2239c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_10d5472a-5c43-4148-8071-d3e787423d54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_96ed3d5f-f92d-4c9c-b60a-aad2d77ddcab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d7e08021-963d-43ef-804e-438e27c2239c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_96ed3d5f-f92d-4c9c-b60a-aad2d77ddcab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_8119dad9-e594-4758-b4c6-6fa699ca5c67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d7e08021-963d-43ef-804e-438e27c2239c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_8119dad9-e594-4758-b4c6-6fa699ca5c67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f4dfa177-1afd-43f6-9833-702c5532e473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d69650a3-fd31-4fc9-a97d-52d84abb1fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f4dfa177-1afd-43f6-9833-702c5532e473" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d69650a3-fd31-4fc9-a97d-52d84abb1fb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1abd0f64-0ce1-4af0-9547-dec4725ca99f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f4dfa177-1afd-43f6-9833-702c5532e473" xlink:to="loc_us-gaap_NetIncomeLoss_1abd0f64-0ce1-4af0-9547-dec4725ca99f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20220102.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_984d8bca-2f60-48c6-a25a-2434b97dc9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_961f8f1b-0681-40ce-b2a0-b2fca3b81620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_984d8bca-2f60-48c6-a25a-2434b97dc9b7" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_961f8f1b-0681-40ce-b2a0-b2fca3b81620" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_7c4b4d4d-6e96-4e05-8eaa-60b1b22e62f9" xlink:href="jnj-20220102.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_984d8bca-2f60-48c6-a25a-2434b97dc9b7" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_7c4b4d4d-6e96-4e05-8eaa-60b1b22e62f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_75623e16-460d-4c10-a4d0-dfc6c7c87f73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_984d8bca-2f60-48c6-a25a-2434b97dc9b7" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_75623e16-460d-4c10-a4d0-dfc6c7c87f73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_478a568f-5f5b-4555-8184-1411fca13c28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_984d8bca-2f60-48c6-a25a-2434b97dc9b7" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_478a568f-5f5b-4555-8184-1411fca13c28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_c6b75785-a282-43c1-b33d-3b4bf9b7862b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_984d8bca-2f60-48c6-a25a-2434b97dc9b7" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_c6b75785-a282-43c1-b33d-3b4bf9b7862b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_04ddb701-39e8-47ed-9816-7310676a254b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_984d8bca-2f60-48c6-a25a-2434b97dc9b7" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_04ddb701-39e8-47ed-9816-7310676a254b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7f3b6d9e-904a-4b16-b566-507e9d0bd176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_984d8bca-2f60-48c6-a25a-2434b97dc9b7" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7f3b6d9e-904a-4b16-b566-507e9d0bd176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d21542db-8cca-4f9e-9df5-c3d58a6778ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_984d8bca-2f60-48c6-a25a-2434b97dc9b7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d21542db-8cca-4f9e-9df5-c3d58a6778ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_087c0b9f-84c6-428e-9cec-6ef0fb909c12" xlink:href="jnj-20220102.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_984d8bca-2f60-48c6-a25a-2434b97dc9b7" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_087c0b9f-84c6-428e-9cec-6ef0fb909c12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_4518cf0c-077e-439c-b330-e024c14fce4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_0ed4ba43-a42f-434a-b8a1-b4bca650905e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_4518cf0c-077e-439c-b330-e024c14fce4e" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_0ed4ba43-a42f-434a-b8a1-b4bca650905e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_76d8bfef-5e12-4774-b5da-a625bb31593e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_4518cf0c-077e-439c-b330-e024c14fce4e" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_76d8bfef-5e12-4774-b5da-a625bb31593e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_846e5e40-13ca-4382-9296-abdce4295208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f2a04ad-a6c8-4b3b-bc80-f537e0666ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_846e5e40-13ca-4382-9296-abdce4295208" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f2a04ad-a6c8-4b3b-bc80-f537e0666ed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a2a17268-f4dd-4197-8640-211627c63afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_846e5e40-13ca-4382-9296-abdce4295208" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a2a17268-f4dd-4197-8640-211627c63afa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d04a2ab-9629-4e0d-8198-b44d149c80e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_846e5e40-13ca-4382-9296-abdce4295208" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d04a2ab-9629-4e0d-8198-b44d149c80e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e653d9c3-f31e-48d1-b932-ca37cc249955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_846e5e40-13ca-4382-9296-abdce4295208" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e653d9c3-f31e-48d1-b932-ca37cc249955" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb7d868e-ee2b-4f80-90e0-5536990e4a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ae540e25-9d12-49c7-9735-5c7b7bd93923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb7d868e-ee2b-4f80-90e0-5536990e4a24" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ae540e25-9d12-49c7-9735-5c7b7bd93923" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0bd9bd5c-4006-437b-be66-bf86e24c3b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb7d868e-ee2b-4f80-90e0-5536990e4a24" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0bd9bd5c-4006-437b-be66-bf86e24c3b9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f2bac56e-0267-44fc-a507-5fffa4577571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb7d868e-ee2b-4f80-90e0-5536990e4a24" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f2bac56e-0267-44fc-a507-5fffa4577571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1b52e404-fb14-44ab-a054-5d9f3b9b1737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb7d868e-ee2b-4f80-90e0-5536990e4a24" xlink:to="loc_us-gaap_ShareBasedCompensation_1b52e404-fb14-44ab-a054-5d9f3b9b1737" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_54651d55-d839-45a6-8bc4-03494ebbf508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb7d868e-ee2b-4f80-90e0-5536990e4a24" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_54651d55-d839-45a6-8bc4-03494ebbf508" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bf52a231-5e4e-49ed-8525-273221da0cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb7d868e-ee2b-4f80-90e0-5536990e4a24" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bf52a231-5e4e-49ed-8525-273221da0cdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7e3cb996-67f7-47ea-9e3d-6f66883d8d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb7d868e-ee2b-4f80-90e0-5536990e4a24" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7e3cb996-67f7-47ea-9e3d-6f66883d8d8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_df0c095b-f9ee-4113-b84c-b8556e7c9098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb7d868e-ee2b-4f80-90e0-5536990e4a24" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_df0c095b-f9ee-4113-b84c-b8556e7c9098" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ed92fa92-792c-4e2a-ada5-033fb6d59790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb7d868e-ee2b-4f80-90e0-5536990e4a24" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ed92fa92-792c-4e2a-ada5-033fb6d59790" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5fa3a4e8-70a4-4452-a5d5-2824b32d971b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb7d868e-ee2b-4f80-90e0-5536990e4a24" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5fa3a4e8-70a4-4452-a5d5-2824b32d971b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a925c199-1de6-4249-b4ee-9fb0b84d04f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb7d868e-ee2b-4f80-90e0-5536990e4a24" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a925c199-1de6-4249-b4ee-9fb0b84d04f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ce379aeb-761c-4fe7-a1c8-cd2209c96b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb7d868e-ee2b-4f80-90e0-5536990e4a24" xlink:to="loc_us-gaap_NetIncomeLoss_ce379aeb-761c-4fe7-a1c8-cd2209c96b42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_ba88b200-c22f-4c2a-95fa-59f709fab116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb7d868e-ee2b-4f80-90e0-5536990e4a24" xlink:to="loc_us-gaap_AssetImpairmentCharges_ba88b200-c22f-4c2a-95fa-59f709fab116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7eafcfa-9c9d-43f5-a903-e45f5d2a8c95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0c11085b-658e-4175-86e6-640512bf531c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7eafcfa-9c9d-43f5-a903-e45f5d2a8c95" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0c11085b-658e-4175-86e6-640512bf531c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_81885a36-cae3-42af-b8e5-f88f73ddb1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7eafcfa-9c9d-43f5-a903-e45f5d2a8c95" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_81885a36-cae3-42af-b8e5-f88f73ddb1cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_bb76796b-6c34-4f37-9895-49107d88f5df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7eafcfa-9c9d-43f5-a903-e45f5d2a8c95" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_bb76796b-6c34-4f37-9895-49107d88f5df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_ee27d2bd-bf11-4fc7-b182-a5fb288ca55c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7eafcfa-9c9d-43f5-a903-e45f5d2a8c95" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_ee27d2bd-bf11-4fc7-b182-a5fb288ca55c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1782f4f2-e5e0-4b9e-8ee1-c6d8f50dac53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7eafcfa-9c9d-43f5-a903-e45f5d2a8c95" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1782f4f2-e5e0-4b9e-8ee1-c6d8f50dac53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f267d2e5-86d7-416b-890b-fabb7845f81d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7eafcfa-9c9d-43f5-a903-e45f5d2a8c95" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f267d2e5-86d7-416b-890b-fabb7845f81d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_78ec0623-5283-4931-99f9-a84645a53d25" xlink:href="jnj-20220102.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7eafcfa-9c9d-43f5-a903-e45f5d2a8c95" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_78ec0623-5283-4931-99f9-a84645a53d25" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_721356e9-823d-444b-8b02-fcf5e1349feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_0ba7b1cc-f3e4-4e93-9158-1c223ab259b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_721356e9-823d-444b-8b02-fcf5e1349feb" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_0ba7b1cc-f3e4-4e93-9158-1c223ab259b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ae95d4c9-23a2-45c1-b178-a94fd714aaab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_721356e9-823d-444b-8b02-fcf5e1349feb" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ae95d4c9-23a2-45c1-b178-a94fd714aaab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2c387796-17b4-45c2-a594-e486f8372191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_721356e9-823d-444b-8b02-fcf5e1349feb" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2c387796-17b4-45c2-a594-e486f8372191" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e3d77009-c18c-425e-a6ca-00dbef3e4122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fd8c44c1-16cf-449c-9503-16a98ed37cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e3d77009-c18c-425e-a6ca-00dbef3e4122" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fd8c44c1-16cf-449c-9503-16a98ed37cd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3409e129-09a5-481a-b77c-d8d70da084bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e3d77009-c18c-425e-a6ca-00dbef3e4122" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3409e129-09a5-481a-b77c-d8d70da084bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9b383ab7-c9c7-43da-aa08-97d3bcf4a45f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a78624f3-1b62-425b-81c2-22bfe4d0cdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9b383ab7-c9c7-43da-aa08-97d3bcf4a45f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a78624f3-1b62-425b-81c2-22bfe4d0cdf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9c274b5d-f66c-4323-97e8-42dd67f234a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9b383ab7-c9c7-43da-aa08-97d3bcf4a45f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9c274b5d-f66c-4323-97e8-42dd67f234a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_82732012-81d6-4568-af0d-03b093c1c7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8bcb6625-7699-4d92-85b1-c4481b3e95f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_82732012-81d6-4568-af0d-03b093c1c7d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8bcb6625-7699-4d92-85b1-c4481b3e95f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_164f9729-da92-4841-ad7c-61715d4bd969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_82732012-81d6-4568-af0d-03b093c1c7d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_164f9729-da92-4841-ad7c-61715d4bd969" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_887dd0e6-30d0-4e3d-9cd7-ec3b9c392eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_242caf23-72fd-4348-8846-134943d23205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_887dd0e6-30d0-4e3d-9cd7-ec3b9c392eef" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_242caf23-72fd-4348-8846-134943d23205" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_e43bea25-6297-49b0-93ae-082a472f167d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_887dd0e6-30d0-4e3d-9cd7-ec3b9c392eef" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_e43bea25-6297-49b0-93ae-082a472f167d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_a3ee6b5d-f3a0-4745-93b9-39061413ebeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7f5143d2-bbb5-4b07-8e5f-2c0b4bf50c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_a3ee6b5d-f3a0-4745-93b9-39061413ebeb" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7f5143d2-bbb5-4b07-8e5f-2c0b4bf50c17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_871f1b82-b310-4bf0-94fd-d762a66b2a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_a3ee6b5d-f3a0-4745-93b9-39061413ebeb" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_871f1b82-b310-4bf0-94fd-d762a66b2a34" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#BorrowingsScheduleofLongtermDebtInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e1dd87a1-8cca-4f6f-811f-6cc513a2c1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ac4db886-1c6c-45fd-94b0-504dbafeb0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e1dd87a1-8cca-4f6f-811f-6cc513a2c1cc" xlink:to="loc_us-gaap_LongTermDebtCurrent_ac4db886-1c6c-45fd-94b0-504dbafeb0b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b5c9c718-47eb-4b3c-bb66-acfb0a98f6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e1dd87a1-8cca-4f6f-811f-6cc513a2c1cc" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_b5c9c718-47eb-4b3c-bb66-acfb0a98f6d7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b16988d8-e05c-40d8-8641-2ee4d011dfdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_99d9486a-fe4a-474d-86e5-845f174ab9af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b16988d8-e05c-40d8-8641-2ee4d011dfdc" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_99d9486a-fe4a-474d-86e5-845f174ab9af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4cd25e4f-c07d-4b80-8375-b61ee61797df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b16988d8-e05c-40d8-8641-2ee4d011dfdc" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4cd25e4f-c07d-4b80-8375-b61ee61797df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0e530a55-ffc1-4b60-8bd1-13358051443c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bc0a9c24-10e1-4cd5-b4c7-34ae6c2475d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0e530a55-ffc1-4b60-8bd1-13358051443c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bc0a9c24-10e1-4cd5-b4c7-34ae6c2475d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c0d27e67-8bb5-40e6-8510-ae5989107754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0e530a55-ffc1-4b60-8bd1-13358051443c" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c0d27e67-8bb5-40e6-8510-ae5989107754" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9c74a223-ad72-4e86-bdf0-b1ea618ae8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e2a3b62c-d11d-48c7-b163-618aa9cb4bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9c74a223-ad72-4e86-bdf0-b1ea618ae8c5" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e2a3b62c-d11d-48c7-b163-618aa9cb4bca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6f38a310-9451-4662-8108-8fc1a0fe8044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9c74a223-ad72-4e86-bdf0-b1ea618ae8c5" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6f38a310-9451-4662-8108-8fc1a0fe8044" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_73047194-4ad3-4caf-b2f3-688456e0d4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e36aeab6-ac06-45b5-82f9-1e62ca447ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_73047194-4ad3-4caf-b2f3-688456e0d4f5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e36aeab6-ac06-45b5-82f9-1e62ca447ad2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_80deba49-b4eb-45f4-a0b3-8160f4c07653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_73047194-4ad3-4caf-b2f3-688456e0d4f5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_80deba49-b4eb-45f4-a0b3-8160f4c07653" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f33b8eb1-d9ce-44e3-8bad-574e925de3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b0406125-608b-4db7-b6c8-7a700e9478fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f33b8eb1-d9ce-44e3-8bad-574e925de3c8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b0406125-608b-4db7-b6c8-7a700e9478fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_56cb1e47-b50a-451e-aa3b-174d1f5c1c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f33b8eb1-d9ce-44e3-8bad-574e925de3c8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_56cb1e47-b50a-451e-aa3b-174d1f5c1c4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_92f56d69-c54c-474c-94de-9e699ed5db50" xlink:href="jnj-20220102.xsd#jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f33b8eb1-d9ce-44e3-8bad-574e925de3c8" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_92f56d69-c54c-474c-94de-9e699ed5db50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_56a6e05e-11c6-4c80-ad0b-a2abae4b7002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f33b8eb1-d9ce-44e3-8bad-574e925de3c8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_56a6e05e-11c6-4c80-ad0b-a2abae4b7002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_309297f5-79fa-4db2-adb2-699a8c1b3712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f33b8eb1-d9ce-44e3-8bad-574e925de3c8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_309297f5-79fa-4db2-adb2-699a8c1b3712" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_b047e208-a219-4b5a-bddb-746a2223cccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f33b8eb1-d9ce-44e3-8bad-574e925de3c8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_b047e208-a219-4b5a-bddb-746a2223cccd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_6e32ded9-cfc9-4b06-bea7-96c012ebafb2" xlink:href="jnj-20220102.xsd#jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f33b8eb1-d9ce-44e3-8bad-574e925de3c8" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_6e32ded9-cfc9-4b06-bea7-96c012ebafb2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_aa532004-7654-44cd-8893-086cd94816f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_10efba44-a0c9-4617-8779-8ebf22d3b3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_aa532004-7654-44cd-8893-086cd94816f6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_10efba44-a0c9-4617-8779-8ebf22d3b3c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_448d2396-b304-46bc-871a-87bf3c6e37ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_aa532004-7654-44cd-8893-086cd94816f6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_448d2396-b304-46bc-871a-87bf3c6e37ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_317c365f-32fb-4e64-bb81-73199be7f23d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_aa532004-7654-44cd-8893-086cd94816f6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_317c365f-32fb-4e64-bb81-73199be7f23d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_f0f92d39-887e-4c71-bb67-20a5c80ef94e" xlink:href="jnj-20220102.xsd#jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_aa532004-7654-44cd-8893-086cd94816f6" xlink:to="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_f0f92d39-887e-4c71-bb67-20a5c80ef94e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_2c1add0a-14a8-4d3a-b01a-e265adbb57c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_aa532004-7654-44cd-8893-086cd94816f6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_2c1add0a-14a8-4d3a-b01a-e265adbb57c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilitiesOtherDomestic_4c47869e-077f-46f9-b28d-04ae4379bded" xlink:href="jnj-20220102.xsd#jnj_DeferredTaxLiabilitiesOtherDomestic"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_aa532004-7654-44cd-8893-086cd94816f6" xlink:to="loc_jnj_DeferredTaxLiabilitiesOtherDomestic_4c47869e-077f-46f9-b28d-04ae4379bded" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c61b209a-05e5-4082-b25f-57ffb8c571e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6add1b4f-f2ee-4094-9982-79f8283105a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c61b209a-05e5-4082-b25f-57ffb8c571e8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6add1b4f-f2ee-4094-9982-79f8283105a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_bfd56fbe-9d21-4fd0-b4af-56366dca9bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c61b209a-05e5-4082-b25f-57ffb8c571e8" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_bfd56fbe-9d21-4fd0-b4af-56366dca9bac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_fcc322ea-5689-4ba6-ba65-ae7f0ef1d7df" xlink:href="jnj-20220102.xsd#jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c61b209a-05e5-4082-b25f-57ffb8c571e8" xlink:to="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_fcc322ea-5689-4ba6-ba65-ae7f0ef1d7df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_d7341121-53df-4183-b7b9-84da1a2ef550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c61b209a-05e5-4082-b25f-57ffb8c571e8" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_d7341121-53df-4183-b7b9-84da1a2ef550" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_7f169750-05c9-4e1c-b6c5-9ad3a6bd648d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c61b209a-05e5-4082-b25f-57ffb8c571e8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_7f169750-05c9-4e1c-b6c5-9ad3a6bd648d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_10886ad0-8800-4a16-976c-1faae3381afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c61b209a-05e5-4082-b25f-57ffb8c571e8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_10886ad0-8800-4a16-976c-1faae3381afd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings_6c3baa81-c4b3-430d-9f3f-f484ae0b74ce" xlink:href="jnj-20220102.xsd#jnj_DeferredTaxAssetsUndistributedForeignEarnings"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c61b209a-05e5-4082-b25f-57ffb8c571e8" xlink:to="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings_6c3baa81-c4b3-430d-9f3f-f484ae0b74ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_5ba49c9d-d2d6-426d-a830-95f468b662d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c61b209a-05e5-4082-b25f-57ffb8c571e8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_5ba49c9d-d2d6-426d-a830-95f468b662d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsOtherDomestic_8c9f2a64-621c-4353-8ad5-c71ecaf85c74" xlink:href="jnj-20220102.xsd#jnj_DeferredTaxAssetsOtherDomestic"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c61b209a-05e5-4082-b25f-57ffb8c571e8" xlink:to="loc_jnj_DeferredTaxAssetsOtherDomestic_8c9f2a64-621c-4353-8ad5-c71ecaf85c74" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeObligations_3e3296df-9e57-49b8-88a3-4e4f59ba4881" xlink:href="jnj-20220102.xsd#jnj_EmployeeObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_8257330a-268e-48de-a8ab-3dacb214f9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_3e3296df-9e57-49b8-88a3-4e4f59ba4881" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_8257330a-268e-48de-a8ab-3dacb214f9ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_923176cd-b28c-4106-8b28-132a90d216ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_3e3296df-9e57-49b8-88a3-4e4f59ba4881" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_923176cd-b28c-4106-8b28-132a90d216ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_db93a0ba-9ac3-43b5-9d5e-fc6ad74750b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_3e3296df-9e57-49b8-88a3-4e4f59ba4881" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_db93a0ba-9ac3-43b5-9d5e-fc6ad74750b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_44c0b71c-579c-4e83-b7a3-5daf4e57ee8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_3e3296df-9e57-49b8-88a3-4e4f59ba4881" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_44c0b71c-579c-4e83-b7a3-5daf4e57ee8f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1" xlink:type="simple" xlink:href="jnj-20220102.xsd#EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeObligations_3532fef6-9930-4c7d-8455-0b197dba0ce7" xlink:href="jnj-20220102.xsd#jnj_EmployeeObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_41404a18-0677-4308-a311-5bf68c4aae1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_3532fef6-9930-4c7d-8455-0b197dba0ce7" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_41404a18-0677-4308-a311-5bf68c4aae1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_83a10527-4626-4032-ad06-e7ca649bb6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_3532fef6-9930-4c7d-8455-0b197dba0ce7" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_83a10527-4626-4032-ad06-e7ca649bb6bd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6b94bbbb-8384-4ded-b3b4-5cd228d45782" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_903ff634-914f-4fcc-9ce4-7c2b427b3806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6b94bbbb-8384-4ded-b3b4-5cd228d45782" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_903ff634-914f-4fcc-9ce4-7c2b427b3806" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_6593940b-478e-4d24-b70c-80a53a62498f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6b94bbbb-8384-4ded-b3b4-5cd228d45782" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_6593940b-478e-4d24-b70c-80a53a62498f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_11afe634-6e7d-4fe7-a59d-fb7a85526ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6b94bbbb-8384-4ded-b3b4-5cd228d45782" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_11afe634-6e7d-4fe7-a59d-fb7a85526ac5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_fdb4b4b3-a859-47e9-a992-0d0f103bd6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6b94bbbb-8384-4ded-b3b4-5cd228d45782" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_fdb4b4b3-a859-47e9-a992-0d0f103bd6b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_fb4a7cab-4bac-4f84-a8fa-8982cc9da765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6b94bbbb-8384-4ded-b3b4-5cd228d45782" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_fb4a7cab-4bac-4f84-a8fa-8982cc9da765" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_ddb97023-4dc4-434a-9ca5-41d2b0011b35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6b94bbbb-8384-4ded-b3b4-5cd228d45782" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_ddb97023-4dc4-434a-9ca5-41d2b0011b35" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_7c595d3f-4abb-4f6e-80f9-df504455c204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_62b64d73-23b1-44d7-8b34-0e458fabf45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_7c595d3f-4abb-4f6e-80f9-df504455c204" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_62b64d73-23b1-44d7-8b34-0e458fabf45c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_979fe923-5590-4842-8b7c-68f86d3de89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_7c595d3f-4abb-4f6e-80f9-df504455c204" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_979fe923-5590-4842-8b7c-68f86d3de89b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_e32b5486-1ac4-4e1c-95e2-d16ff887fc98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_e04faa1a-6241-4fe0-9c3f-d83bfada4ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_e32b5486-1ac4-4e1c-95e2-d16ff887fc98" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_e04faa1a-6241-4fe0-9c3f-d83bfada4ac7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_136cc877-0f9f-4a2a-bc5d-422d0b5233e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_e32b5486-1ac4-4e1c-95e2-d16ff887fc98" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_136cc877-0f9f-4a2a-bc5d-422d0b5233e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_eea638e0-58eb-445b-8521-6b7916828e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_e32b5486-1ac4-4e1c-95e2-d16ff887fc98" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_eea638e0-58eb-445b-8521-6b7916828e6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_6e9da396-19d7-45db-8155-f2d28bb7fbcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_a6a430f7-2478-46c2-b205-e6a4f444a8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_6e9da396-19d7-45db-8155-f2d28bb7fbcb" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_a6a430f7-2478-46c2-b205-e6a4f444a8a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_3049ff12-7526-409a-8fde-7f706f27bd09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_6e9da396-19d7-45db-8155-f2d28bb7fbcb" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_3049ff12-7526-409a-8fde-7f706f27bd09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_55aec491-fde9-49ff-9031-bc1ae9535858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_6e9da396-19d7-45db-8155-f2d28bb7fbcb" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_55aec491-fde9-49ff-9031-bc1ae9535858" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_91037c6b-3170-4914-a6ed-219b50e173b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e2c30651-547b-495f-867b-faf9866173a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_91037c6b-3170-4914-a6ed-219b50e173b0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e2c30651-547b-495f-867b-faf9866173a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PotentialSharesExercisableUnderStockOptionPlans_8f0be3e6-79a8-4730-9830-b8879fb34243" xlink:href="jnj-20220102.xsd#jnj_PotentialSharesExercisableUnderStockOptionPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_91037c6b-3170-4914-a6ed-219b50e173b0" xlink:to="loc_jnj_PotentialSharesExercisableUnderStockOptionPlans_8f0be3e6-79a8-4730-9830-b8879fb34243" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_b3c339ca-e26b-4290-9dae-08ae059e834c" xlink:href="jnj-20220102.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_91037c6b-3170-4914-a6ed-219b50e173b0" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_b3c339ca-e26b-4290-9dae-08ae059e834c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_5d1550dd-9cff-40f5-91bf-46d6564f623a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_91037c6b-3170-4914-a6ed-219b50e173b0" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_5d1550dd-9cff-40f5-91bf-46d6564f623a" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>jnj-20220102_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2ac3ec12-1a04-4290-8adc-1ec251a989dd,g:c9588643-da6b-4c23-b331-47586e9dc1a5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CoverPage" xlink:type="simple" xlink:href="jnj-20220102.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CoverPage" xlink:type="extended" id="i3a6b2067f6d041e18fb1807c1b51600a_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3975e5cc-0cca-4d47-8e28-79534d167473" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_DocumentType_3975e5cc-0cca-4d47-8e28-79534d167473" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_a1dff4da-1110-4650-9a87-6121fd81b324" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_DocumentAnnualReport_a1dff4da-1110-4650-9a87-6121fd81b324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5a68e64f-4a33-4ab4-a96b-4a0049b7fab5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_DocumentPeriodEndDate_5a68e64f-4a33-4ab4-a96b-4a0049b7fab5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_bd83228a-ed7a-4411-b107-c558466f4273" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_DocumentTransitionReport_bd83228a-ed7a-4411-b107-c558466f4273" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_95bec8c0-ab71-4cba-9266-93b579be7bef" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityFileNumber_95bec8c0-ab71-4cba-9266-93b579be7bef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_641ff387-1daa-49c4-921b-82eef3ab4da6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityRegistrantName_641ff387-1daa-49c4-921b-82eef3ab4da6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8d1765a1-7fa5-4333-96ee-ddeeb1b729ea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8d1765a1-7fa5-4333-96ee-ddeeb1b729ea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ff66b0c9-77bf-4cd8-ab06-db77f11f912b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityTaxIdentificationNumber_ff66b0c9-77bf-4cd8-ab06-db77f11f912b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e3f13a41-5fce-45f0-b3c8-bfb78e6bff49" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityAddressAddressLine1_e3f13a41-5fce-45f0-b3c8-bfb78e6bff49" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e4d1f90a-5898-4b5f-8948-bfc404f314b1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityAddressCityOrTown_e4d1f90a-5898-4b5f-8948-bfc404f314b1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a649ef91-edae-46e1-9b06-ba39aaa0f0b2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityAddressStateOrProvince_a649ef91-edae-46e1-9b06-ba39aaa0f0b2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1d651bf1-11e3-4681-b127-362c9f08d620" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityAddressPostalZipCode_1d651bf1-11e3-4681-b127-362c9f08d620" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8ce0e278-f240-422c-bbf7-4f20a84a4619" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_CityAreaCode_8ce0e278-f240-422c-bbf7-4f20a84a4619" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_03b09cee-a8f0-4296-a861-b3357ae9d9d2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_LocalPhoneNumber_03b09cee-a8f0-4296-a861-b3357ae9d9d2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e6e193de-78c9-4e4b-bbbd-7155f5fc856d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_Security12bTitle_e6e193de-78c9-4e4b-bbbd-7155f5fc856d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b8d3cac9-f381-41c7-87ed-77cdafabe331" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_TradingSymbol_b8d3cac9-f381-41c7-87ed-77cdafabe331" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e921b37c-0bf5-4fa7-8c18-b3d53c3a5767" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_SecurityExchangeName_e921b37c-0bf5-4fa7-8c18-b3d53c3a5767" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_f1ff7c63-795e-4148-b5b4-0f36aeb17bfa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_f1ff7c63-795e-4148-b5b4-0f36aeb17bfa" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_4ba22fdd-5516-406c-ad73-33a75a764b61" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityVoluntaryFilers_4ba22fdd-5516-406c-ad73-33a75a764b61" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2605b2a1-bfcd-4717-a358-906c34d47211" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityCurrentReportingStatus_2605b2a1-bfcd-4717-a358-906c34d47211" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c04790e7-0bf0-4503-8c35-2f0ce4526335" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityInteractiveDataCurrent_c04790e7-0bf0-4503-8c35-2f0ce4526335" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_cd691512-05fc-442d-b870-e7d6f0688722" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityFilerCategory_cd691512-05fc-442d-b870-e7d6f0688722" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3e7a3b4c-214b-449b-a479-769e83e3adbf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityEmergingGrowthCompany_3e7a3b4c-214b-449b-a479-769e83e3adbf" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a00ae9d9-3865-420d-99d1-aa48cdd748ad" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntitySmallBusiness_a00ae9d9-3865-420d-99d1-aa48cdd748ad" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_b027f5e1-99f6-453b-a413-e6b96727a096" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_IcfrAuditorAttestationFlag_b027f5e1-99f6-453b-a413-e6b96727a096" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_328920ee-7c3e-492e-9b90-23b3fe790bd4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityShellCompany_328920ee-7c3e-492e-9b90-23b3fe790bd4" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_f2724806-00af-4812-b684-4a7068ce7088" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityPublicFloat_f2724806-00af-4812-b684-4a7068ce7088" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8b1bae8e-64e9-4f66-b387-c395e2b82ab7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8b1bae8e-64e9-4f66-b387-c395e2b82ab7" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_541c6917-cfc3-49ac-bc75-ed400c71704a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityCentralIndexKey_541c6917-cfc3-49ac-bc75-ed400c71704a" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e6f02546-9e64-4191-9282-ddc2285f5ef6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_CurrentFiscalYearEndDate_e6f02546-9e64-4191-9282-ddc2285f5ef6" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f574de2c-00e7-41c9-90af-2fee5046775e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_DocumentFiscalYearFocus_f574de2c-00e7-41c9-90af-2fee5046775e" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1501adee-e3fd-41cc-a21a-ee0467800975" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1501adee-e3fd-41cc-a21a-ee0467800975" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d01be743-6023-48a3-afa0-94422763d940" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_AmendmentFlag_d01be743-6023-48a3-afa0-94422763d940" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_727ccf8e-1867-45cd-92a6-02f5f4e00518" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_DocumentInformationTable_727ccf8e-1867-45cd-92a6-02f5f4e00518" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9acd6f26-a647-467c-9599-4f9f46ef6af4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_727ccf8e-1867-45cd-92a6-02f5f4e00518" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9acd6f26-a647-467c-9599-4f9f46ef6af4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9acd6f26-a647-467c-9599-4f9f46ef6af4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9acd6f26-a647-467c-9599-4f9f46ef6af4" xlink:to="loc_us-gaap_ClassOfStockDomain_9acd6f26-a647-467c-9599-4f9f46ef6af4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c864a51b-0785-460f-8f73-bf30992ec9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9acd6f26-a647-467c-9599-4f9f46ef6af4" xlink:to="loc_us-gaap_ClassOfStockDomain_c864a51b-0785-460f-8f73-bf30992ec9b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4ac2bde9-0f4f-4853-b4de-002800013ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c864a51b-0785-460f-8f73-bf30992ec9b5" xlink:to="loc_us-gaap_CommonStockMember_4ac2bde9-0f4f-4853-b4de-002800013ab2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_b3da5c3d-50f6-4e4e-8de4-f0692b3330ac" xlink:href="jnj-20220102.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c864a51b-0785-460f-8f73-bf30992ec9b5" xlink:to="loc_jnj_A0.650NotesDue2024Member_b3da5c3d-50f6-4e4e-8de4-f0692b3330ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_c7a30b62-4534-4bed-9c2a-ccd8d898658f" xlink:href="jnj-20220102.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c864a51b-0785-460f-8f73-bf30992ec9b5" xlink:to="loc_jnj_A5.50NotesDue2024Member_c7a30b62-4534-4bed-9c2a-ccd8d898658f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_4a56b272-19ba-469e-a72e-495f9e7594d7" xlink:href="jnj-20220102.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c864a51b-0785-460f-8f73-bf30992ec9b5" xlink:to="loc_jnj_A1.150NotesDue2028Member_4a56b272-19ba-469e-a72e-495f9e7594d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_89b829b1-1bcb-4c86-a33d-84e292feb215" xlink:href="jnj-20220102.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c864a51b-0785-460f-8f73-bf30992ec9b5" xlink:to="loc_jnj_A1.650NotesDue2035Member_89b829b1-1bcb-4c86-a33d-84e292feb215" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20220102.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended" id="ib06fa169167145688ae10832ccbb0574_ConsolidatedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ce65a349-5399-4faa-909b-2921dcf23a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a4b33248-98e6-4bf2-a432-e5c48868e05d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ce65a349-5399-4faa-909b-2921dcf23a17" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a4b33248-98e6-4bf2-a432-e5c48868e05d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b02f1b80-84d8-4572-bc68-4afdd437c5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ce65a349-5399-4faa-909b-2921dcf23a17" xlink:to="loc_us-gaap_NetIncomeLoss_b02f1b80-84d8-4572-bc68-4afdd437c5cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_5f06b60d-5eb4-4b3b-a521-2b150a68749d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ce65a349-5399-4faa-909b-2921dcf23a17" xlink:to="loc_us-gaap_DividendsCommonStockCash_5f06b60d-5eb4-4b3b-a521-2b150a68749d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_befa74ff-e9e4-4499-9e1b-fd422b60e81f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ce65a349-5399-4faa-909b-2921dcf23a17" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_befa74ff-e9e4-4499-9e1b-fd422b60e81f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_511de337-86e4-4718-b145-2cd24a4f7706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ce65a349-5399-4faa-909b-2921dcf23a17" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_511de337-86e4-4718-b145-2cd24a4f7706" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_2be2dd46-19ce-4b52-ad2b-13486eb71325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ce65a349-5399-4faa-909b-2921dcf23a17" xlink:to="loc_us-gaap_StockholdersEquityOther_2be2dd46-19ce-4b52-ad2b-13486eb71325" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_714da56d-5bda-4184-97bb-257563f2b531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ce65a349-5399-4faa-909b-2921dcf23a17" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_714da56d-5bda-4184-97bb-257563f2b531" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_792c803f-ddf4-4c30-a464-2b9b7952695c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2c882a81-ebf4-4b75-96a2-8394a329de09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ce65a349-5399-4faa-909b-2921dcf23a17" xlink:to="loc_us-gaap_StatementTable_2c882a81-ebf4-4b75-96a2-8394a329de09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_63174556-8dba-496c-bb98-5a53e2e51b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2c882a81-ebf4-4b75-96a2-8394a329de09" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_63174556-8dba-496c-bb98-5a53e2e51b7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_63174556-8dba-496c-bb98-5a53e2e51b7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_63174556-8dba-496c-bb98-5a53e2e51b7d" xlink:to="loc_us-gaap_EquityComponentDomain_63174556-8dba-496c-bb98-5a53e2e51b7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5faa5a9f-28d3-41ab-a956-b27abe15d540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_63174556-8dba-496c-bb98-5a53e2e51b7d" xlink:to="loc_us-gaap_EquityComponentDomain_5faa5a9f-28d3-41ab-a956-b27abe15d540" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ba752ecd-d730-49da-93bc-175dc3e8b4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5faa5a9f-28d3-41ab-a956-b27abe15d540" xlink:to="loc_us-gaap_RetainedEarningsMember_ba752ecd-d730-49da-93bc-175dc3e8b4ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_91e7b10e-0b28-41af-9625-39f395e196ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5faa5a9f-28d3-41ab-a956-b27abe15d540" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_91e7b10e-0b28-41af-9625-39f395e196ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9a3b9fc9-09f1-43ce-a30d-a4e5d2402e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5faa5a9f-28d3-41ab-a956-b27abe15d540" xlink:to="loc_us-gaap_CommonStockMember_9a3b9fc9-09f1-43ce-a30d-a4e5d2402e6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_92252371-ac28-4a72-b83a-b3cecb396239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5faa5a9f-28d3-41ab-a956-b27abe15d540" xlink:to="loc_us-gaap_TreasuryStockMember_92252371-ac28-4a72-b83a-b3cecb396239" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i3a68c26a01b949ab8b13d1255940c6c2_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:href="jnj-20220102.xsd#jnj_ConcentrationOfCreditRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_086a6b69-bf64-48d0-bc64-f63f8100165c" xlink:href="jnj-20220102.xsd#jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_086a6b69-bf64-48d0-bc64-f63f8100165c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_b0bb83b1-1494-46ee-bd3b-989aacaa2e47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_NumberOfReportableSegments_b0bb83b1-1494-46ee-bd3b-989aacaa2e47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_c0636a48-a6da-4016-ad43-4a1defc91a92" xlink:href="jnj-20220102.xsd#jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_c0636a48-a6da-4016-ad43-4a1defc91a92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_20d0ae49-0df8-4bb5-8ce2-08968d9964f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_20d0ae49-0df8-4bb5-8ce2-08968d9964f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_5d95eb5a-d835-4d33-aae5-1c7f2a0894fb" xlink:href="jnj-20220102.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_5d95eb5a-d835-4d33-aae5-1c7f2a0894fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesReturnReserve_9cbf6593-9c6a-4cce-9606-b4478471be1a" xlink:href="jnj-20220102.xsd#jnj_SalesReturnReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_SalesReturnReserve_9cbf6593-9c6a-4cce-9606-b4478471be1a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProfitLossPercentToSales_e0b097d4-9b5d-4f84-868c-535fdb81869f" xlink:href="jnj-20220102.xsd#jnj_ProfitLossPercentToSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_ProfitLossPercentToSales_e0b097d4-9b5d-4f84-868c-535fdb81869f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_47f599e6-c964-434e-b4a8-aed9b8202b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_47f599e6-c964-434e-b4a8-aed9b8202b8a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShippingandHandlingCostsasaPercentofSales_ca88b18c-11bd-4547-87f7-d5333ae90fb7" xlink:href="jnj-20220102.xsd#jnj_ShippingandHandlingCostsasaPercentofSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_ShippingandHandlingCostsasaPercentofSales_ca88b18c-11bd-4547-87f7-d5333ae90fb7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_844397e8-2a05-46e3-b26b-dfc1ba6230a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_844397e8-2a05-46e3-b26b-dfc1ba6230a8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_580effa7-65d1-42ba-bd41-f602a418352b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_580effa7-65d1-42ba-bd41-f602a418352b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_d421016d-cdbb-4e69-8e45-311011d12584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_d421016d-cdbb-4e69-8e45-311011d12584" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2595b624-c596-4221-968a-687816c763c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2595b624-c596-4221-968a-687816c763c9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0771abb4-91b7-4f5f-ae5f-3da44247cfc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_OperatingLeaseLiability_0771abb4-91b7-4f5f-ae5f-3da44247cfc0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_d23029da-54d7-4de8-ba88-865043cbd70e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_OperatingLeaseCost_d23029da-54d7-4de8-ba88-865043cbd70e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_03a260d8-566c-4efc-a96d-6e3389bc11dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_OperatingLeasePayments_03a260d8-566c-4efc-a96d-6e3389bc11dc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationRiskThresholdPercentage_50c82758-0c2c-44b2-81a2-7a34ce065eb0" xlink:href="jnj-20220102.xsd#jnj_ConcentrationRiskThresholdPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_ConcentrationRiskThresholdPercentage_50c82758-0c2c-44b2-81a2-7a34ce065eb0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_2f1c0e4e-5497-4063-bd42-d6dc8d41ef8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_AdvertisingExpense_2f1c0e4e-5497-4063-bd42-d6dc8d41ef8b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_af74dba0-74e6-41fc-84ae-6a99a6a29fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_af74dba0-74e6-41fc-84ae-6a99a6a29fdc" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_854fa16d-bac7-4423-9619-36f5778cc29d" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_854fa16d-bac7-4423-9619-36f5778cc29d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_25f6963a-2615-4bcc-8c81-9fc898ff1c03" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_25f6963a-2615-4bcc-8c81-9fc898ff1c03" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_5b229e9f-6d9b-47cb-bac8-66c3060a8e87" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_5b229e9f-6d9b-47cb-bac8-66c3060a8e87" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_10278406-64f2-4a4d-8371-891b2ef885ed" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_10278406-64f2-4a4d-8371-891b2ef885ed" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_9690921b-680a-4e65-b59b-9aa8cb311988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_9690921b-680a-4e65-b59b-9aa8cb311988" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskTable_5eb50d29-1bea-4074-ba5b-2acfe4fb5244" xlink:href="jnj-20220102.xsd#jnj_ConcentrationOfCreditRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_ConcentrationOfCreditRiskTable_5eb50d29-1bea-4074-ba5b-2acfe4fb5244" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9035a417-51ce-4711-8cdd-cf927c86ad43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_5eb50d29-1bea-4074-ba5b-2acfe4fb5244" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9035a417-51ce-4711-8cdd-cf927c86ad43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9035a417-51ce-4711-8cdd-cf927c86ad43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9035a417-51ce-4711-8cdd-cf927c86ad43" xlink:to="loc_us-gaap_SegmentDomain_9035a417-51ce-4711-8cdd-cf927c86ad43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_96d99343-c042-4860-ae21-35a8cc8bb0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9035a417-51ce-4711-8cdd-cf927c86ad43" xlink:to="loc_us-gaap_SegmentDomain_96d99343-c042-4860-ae21-35a8cc8bb0e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_683a276d-9f8d-4be0-bedc-96daa802f84c" xlink:href="jnj-20220102.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_96d99343-c042-4860-ae21-35a8cc8bb0e2" xlink:to="loc_jnj_PharmaceuticalMember_683a276d-9f8d-4be0-bedc-96daa802f84c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d0bb137c-b0d6-48d5-b173-643310e4657b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_5eb50d29-1bea-4074-ba5b-2acfe4fb5244" xlink:to="loc_srt_ProductOrServiceAxis_d0bb137c-b0d6-48d5-b173-643310e4657b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d0bb137c-b0d6-48d5-b173-643310e4657b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d0bb137c-b0d6-48d5-b173-643310e4657b" xlink:to="loc_srt_ProductsAndServicesDomain_d0bb137c-b0d6-48d5-b173-643310e4657b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a39feb88-c62f-49f0-a467-5065b859b621" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d0bb137c-b0d6-48d5-b173-643310e4657b" xlink:to="loc_srt_ProductsAndServicesDomain_a39feb88-c62f-49f0-a467-5065b859b621" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_43038d5d-1b07-4a20-b855-39f8b4c07b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a39feb88-c62f-49f0-a467-5065b859b621" xlink:to="loc_us-gaap_ShippingAndHandlingMember_43038d5d-1b07-4a20-b855-39f8b4c07b8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4033b0a0-8b19-4309-a171-ce2fbfe3d660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_5eb50d29-1bea-4074-ba5b-2acfe4fb5244" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4033b0a0-8b19-4309-a171-ce2fbfe3d660" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4033b0a0-8b19-4309-a171-ce2fbfe3d660_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4033b0a0-8b19-4309-a171-ce2fbfe3d660" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4033b0a0-8b19-4309-a171-ce2fbfe3d660_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0574081d-c3da-4498-952d-fefda6e115bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4033b0a0-8b19-4309-a171-ce2fbfe3d660" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0574081d-c3da-4498-952d-fefda6e115bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e23298ac-eb26-4510-810d-50ca07e376d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0574081d-c3da-4498-952d-fefda6e115bc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e23298ac-eb26-4510-810d-50ca07e376d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e5134fa5-aab5-4972-91f7-5c95ad589d95" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_5eb50d29-1bea-4074-ba5b-2acfe4fb5244" xlink:to="loc_srt_RangeAxis_e5134fa5-aab5-4972-91f7-5c95ad589d95" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e5134fa5-aab5-4972-91f7-5c95ad589d95_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e5134fa5-aab5-4972-91f7-5c95ad589d95" xlink:to="loc_srt_RangeMember_e5134fa5-aab5-4972-91f7-5c95ad589d95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ed54fb0-9fd7-4f7a-ba91-00d8bcbc2c2b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e5134fa5-aab5-4972-91f7-5c95ad589d95" xlink:to="loc_srt_RangeMember_3ed54fb0-9fd7-4f7a-ba91-00d8bcbc2c2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fb9b20f3-035a-4cb3-9360-6deac2069f5f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3ed54fb0-9fd7-4f7a-ba91-00d8bcbc2c2b" xlink:to="loc_srt_MinimumMember_fb9b20f3-035a-4cb3-9360-6deac2069f5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8b637f4c-c057-4c5c-92aa-10dcf3b8ce7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3ed54fb0-9fd7-4f7a-ba91-00d8bcbc2c2b" xlink:to="loc_srt_MaximumMember_8b637f4c-c057-4c5c-92aa-10dcf3b8ce7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fb0ca561-133d-45f2-b037-ed33e0d0426d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_5eb50d29-1bea-4074-ba5b-2acfe4fb5244" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fb0ca561-133d-45f2-b037-ed33e0d0426d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fb0ca561-133d-45f2-b037-ed33e0d0426d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fb0ca561-133d-45f2-b037-ed33e0d0426d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fb0ca561-133d-45f2-b037-ed33e0d0426d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6876a26f-ca9e-4200-bced-ba278cd7d50e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fb0ca561-133d-45f2-b037-ed33e0d0426d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6876a26f-ca9e-4200-bced-ba278cd7d50e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_ae45d1c1-b210-4864-97e8-fdc790408c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6876a26f-ca9e-4200-bced-ba278cd7d50e" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_ae45d1c1-b210-4864-97e8-fdc790408c1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e4057aae-9fef-4c0b-a9e5-2846dbe3008d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_5eb50d29-1bea-4074-ba5b-2acfe4fb5244" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e4057aae-9fef-4c0b-a9e5-2846dbe3008d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e4057aae-9fef-4c0b-a9e5-2846dbe3008d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e4057aae-9fef-4c0b-a9e5-2846dbe3008d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e4057aae-9fef-4c0b-a9e5-2846dbe3008d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fe63bd84-defa-4acc-9a37-242e6d2aa6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e4057aae-9fef-4c0b-a9e5-2846dbe3008d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fe63bd84-defa-4acc-9a37-242e6d2aa6ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_d988b03c-cb19-4428-ae87-1dba40d2cc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_fe63bd84-defa-4acc-9a37-242e6d2aa6ef" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_d988b03c-cb19-4428-ae87-1dba40d2cc7a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails" xlink:type="extended" id="i8d8b8b5910294a99948a4c30f27829c3_SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_09d3e62e-1ad1-4e25-bb34-02dc4029933e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_261aae80-e241-427c-bc88-ee45924c793c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_09d3e62e-1ad1-4e25-bb34-02dc4029933e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_261aae80-e241-427c-bc88-ee45924c793c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb14d088-c656-4438-9201-a58aeaf4dcaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_09d3e62e-1ad1-4e25-bb34-02dc4029933e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb14d088-c656-4438-9201-a58aeaf4dcaa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_94ce0def-581e-4419-960b-618ab06352b3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb14d088-c656-4438-9201-a58aeaf4dcaa" xlink:to="loc_srt_RangeAxis_94ce0def-581e-4419-960b-618ab06352b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_94ce0def-581e-4419-960b-618ab06352b3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_94ce0def-581e-4419-960b-618ab06352b3" xlink:to="loc_srt_RangeMember_94ce0def-581e-4419-960b-618ab06352b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6d7920ab-c072-46d2-a63d-b69ad46d612b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_94ce0def-581e-4419-960b-618ab06352b3" xlink:to="loc_srt_RangeMember_6d7920ab-c072-46d2-a63d-b69ad46d612b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6a51f502-ba8f-4597-9f14-494779e2c238" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6d7920ab-c072-46d2-a63d-b69ad46d612b" xlink:to="loc_srt_MinimumMember_6a51f502-ba8f-4597-9f14-494779e2c238" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c3817a52-7257-4419-a428-22d4f1fe9a40" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6d7920ab-c072-46d2-a63d-b69ad46d612b" xlink:to="loc_srt_MaximumMember_c3817a52-7257-4419-a428-22d4f1fe9a40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_913b6390-04fb-45f9-95b8-fb213e532792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb14d088-c656-4438-9201-a58aeaf4dcaa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_913b6390-04fb-45f9-95b8-fb213e532792" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_913b6390-04fb-45f9-95b8-fb213e532792_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_913b6390-04fb-45f9-95b8-fb213e532792" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_913b6390-04fb-45f9-95b8-fb213e532792_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e3b46b9b-933f-4a57-9fab-a9f7bd53ebca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_913b6390-04fb-45f9-95b8-fb213e532792" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e3b46b9b-933f-4a57-9fab-a9f7bd53ebca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_a7d20137-75e4-4d93-bb20-f7f691f54555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e3b46b9b-933f-4a57-9fab-a9f7bd53ebca" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_a7d20137-75e4-4d93-bb20-f7f691f54555" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LandAndLeaseholdImprovementsMember_da4b12a2-d60b-41f2-807e-48e19fd2b527" xlink:href="jnj-20220102.xsd#jnj_LandAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e3b46b9b-933f-4a57-9fab-a9f7bd53ebca" xlink:to="loc_jnj_LandAndLeaseholdImprovementsMember_da4b12a2-d60b-41f2-807e-48e19fd2b527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_e1df7fbc-1075-4f9f-80e8-056cf88d6bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e3b46b9b-933f-4a57-9fab-a9f7bd53ebca" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_e1df7fbc-1075-4f9f-80e8-056cf88d6bf4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails" xlink:type="extended" id="ibdb981c5e6e3411bbba6ef05c3cb2bf8_CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_7a348de8-aac4-464a-844b-100a0c42cfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_7a348de8-aac4-464a-844b-100a0c42cfe1" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_93fe2d2c-7fc2-464d-a7eb-a267614184d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_HeldToMaturitySecurities_93fe2d2c-7fc2-464d-a7eb-a267614184d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a5bbd53a-b273-40c8-86b8-869d2834761c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a5bbd53a-b273-40c8-86b8-869d2834761c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_d6677ce9-0f33-4f07-9c0d-5ed4f6fc5788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_d6677ce9-0f33-4f07-9c0d-5ed4f6fc5788" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_34bd4a0a-167e-4b4e-a23a-517f8037915b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_34bd4a0a-167e-4b4e-a23a-517f8037915b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f375deef-a0f8-4041-b3a2-81649ec9711f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f375deef-a0f8-4041-b3a2-81649ec9711f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_539a69fa-8437-48f0-a40f-f63ff4a4701b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_539a69fa-8437-48f0-a40f-f63ff4a4701b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_81f3cfb1-54ce-4157-9100-810c742c69fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_81f3cfb1-54ce-4157-9100-810c742c69fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5d98c66e-d843-4ce5-95ce-d92bde229303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5d98c66e-d843-4ce5-95ce-d92bde229303" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_cf91211d-9ee1-49cb-b8c2-e14a238ae30a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_cf91211d-9ee1-49cb-b8c2-e14a238ae30a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0c394fe0-3bfb-4094-a1bc-7f01bfb1d764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0c394fe0-3bfb-4094-a1bc-7f01bfb1d764" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8f1fabc3-7b18-4297-8ed5-01264b74ff18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_7a348de8-aac4-464a-844b-100a0c42cfe1" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8f1fabc3-7b18-4297-8ed5-01264b74ff18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_39a88903-dc1f-4ca5-9ef6-05f652600ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8f1fabc3-7b18-4297-8ed5-01264b74ff18" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_39a88903-dc1f-4ca5-9ef6-05f652600ba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_39a88903-dc1f-4ca5-9ef6-05f652600ba9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_39a88903-dc1f-4ca5-9ef6-05f652600ba9" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_39a88903-dc1f-4ca5-9ef6-05f652600ba9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_24b7ed8d-c873-490f-ada7-c34ae625f976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_39a88903-dc1f-4ca5-9ef6-05f652600ba9" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_24b7ed8d-c873-490f-ada7-c34ae625f976" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_04035dda-a0fd-434c-bac4-3b442c5a3a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_24b7ed8d-c873-490f-ada7-c34ae625f976" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_04035dda-a0fd-434c-bac4-3b442c5a3a34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_4580a9dd-f82e-4e31-b576-aa080febabdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_24b7ed8d-c873-490f-ada7-c34ae625f976" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_4580a9dd-f82e-4e31-b576-aa080febabdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_5f4d35f2-3605-4331-89bd-98011d9930cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8f1fabc3-7b18-4297-8ed5-01264b74ff18" xlink:to="loc_us-gaap_InvestmentTypeAxis_5f4d35f2-3605-4331-89bd-98011d9930cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5f4d35f2-3605-4331-89bd-98011d9930cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_5f4d35f2-3605-4331-89bd-98011d9930cd" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5f4d35f2-3605-4331-89bd-98011d9930cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_5f4d35f2-3605-4331-89bd-98011d9930cd" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_484e1b4e-0141-414c-9ada-f79d39f292d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:to="loc_us-gaap_CashMember_484e1b4e-0141-414c-9ada-f79d39f292d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_e961e9b8-1e21-419c-a484-caea14244950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_e961e9b8-1e21-419c-a484-caea14244950" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_cd2f2a59-7ab4-4178-8211-47d0e76efcb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_cd2f2a59-7ab4-4178-8211-47d0e76efcb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_56aca57f-ad5a-4704-8479-e5c9ed5aa53e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_56aca57f-ad5a-4704-8479-e5c9ed5aa53e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_6bd6b029-600f-42c5-a2c1-3900a5166bce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_6bd6b029-600f-42c5-a2c1-3900a5166bce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_2b9d2b79-71fe-406e-b17c-c4356743604b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:to="loc_us-gaap_BankTimeDepositsMember_2b9d2b79-71fe-406e-b17c-c4356743604b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_b4669046-5176-48c5-bed6-ec10dd59587e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_b4669046-5176-48c5-bed6-ec10dd59587e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherSovereignSecuritiesMember_f5763c44-0997-4900-bb2e-5b80e674b5ec" xlink:href="jnj-20220102.xsd#jnj_OtherSovereignSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:to="loc_jnj_OtherSovereignSecuritiesMember_f5763c44-0997-4900-bb2e-5b80e674b5ec" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="extended" id="iee4d9c07b9be4183aabc11a908ceb49f_PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8712825-1808-4c80-811f-6efbfe00f2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b2a60c67-fffd-4cc1-96d5-5e5a7c13484d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8712825-1808-4c80-811f-6efbfe00f2ec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b2a60c67-fffd-4cc1-96d5-5e5a7c13484d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fbfa3b03-d89f-4751-8b11-1e851603249a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8712825-1808-4c80-811f-6efbfe00f2ec" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fbfa3b03-d89f-4751-8b11-1e851603249a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_be5ef988-f781-4a13-8976-ec8515534f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8712825-1808-4c80-811f-6efbfe00f2ec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_be5ef988-f781-4a13-8976-ec8515534f57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bdc59a4f-279b-4c1d-bf4f-c3e0b15b3768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8712825-1808-4c80-811f-6efbfe00f2ec" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bdc59a4f-279b-4c1d-bf4f-c3e0b15b3768" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f594324-9949-4efb-b296-60b6a2b48393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bdc59a4f-279b-4c1d-bf4f-c3e0b15b3768" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f594324-9949-4efb-b296-60b6a2b48393" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f594324-9949-4efb-b296-60b6a2b48393_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f594324-9949-4efb-b296-60b6a2b48393" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f594324-9949-4efb-b296-60b6a2b48393_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f1450dd-a83b-4432-a1d0-5066572f484f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f594324-9949-4efb-b296-60b6a2b48393" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f1450dd-a83b-4432-a1d0-5066572f484f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LandAndLeaseholdImprovementsMember_1c248d16-e26e-4f14-92a6-6ed2a797258b" xlink:href="jnj-20220102.xsd#jnj_LandAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f1450dd-a83b-4432-a1d0-5066572f484f" xlink:to="loc_jnj_LandAndLeaseholdImprovementsMember_1c248d16-e26e-4f14-92a6-6ed2a797258b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_55791192-c1dc-4dd1-a1c0-532cf7558e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f1450dd-a83b-4432-a1d0-5066572f484f" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_55791192-c1dc-4dd1-a1c0-532cf7558e02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_76b9fb65-468f-45a0-8645-e10b6e21b8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f1450dd-a83b-4432-a1d0-5066572f484f" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_76b9fb65-468f-45a0-8645-e10b6e21b8f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_cdc1993e-9e38-46aa-aad1-a2a065db824c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f1450dd-a83b-4432-a1d0-5066572f484f" xlink:to="loc_us-gaap_ConstructionInProgressMember_cdc1993e-9e38-46aa-aad1-a2a065db824c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="extended" id="i5e29c9563f304762802a1e127f810d7b_IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1a826f07-dad1-483d-a0ec-12b0f9ca4b44" xlink:href="jnj-20220102.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_f7a527fc-badc-4565-9d82-6b0cc0cb6da2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1a826f07-dad1-483d-a0ec-12b0f9ca4b44" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_f7a527fc-badc-4565-9d82-6b0cc0cb6da2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_9826cbb1-4fee-4b05-8a7c-98a49742bc17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_f7a527fc-badc-4565-9d82-6b0cc0cb6da2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_9826cbb1-4fee-4b05-8a7c-98a49742bc17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_be8d171b-dc37-4381-ab13-7fe50e70ed5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_9826cbb1-4fee-4b05-8a7c-98a49742bc17" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_be8d171b-dc37-4381-ab13-7fe50e70ed5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5286024e-5807-45c4-b5ce-8c2c4aa4298f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_9826cbb1-4fee-4b05-8a7c-98a49742bc17" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5286024e-5807-45c4-b5ce-8c2c4aa4298f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f74def34-0ea4-4aed-97ee-7e33a28a8689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_9826cbb1-4fee-4b05-8a7c-98a49742bc17" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f74def34-0ea4-4aed-97ee-7e33a28a8689" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_07452004-367d-429a-9ec8-2c49e5fce907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_f7a527fc-badc-4565-9d82-6b0cc0cb6da2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_07452004-367d-429a-9ec8-2c49e5fce907" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1b957188-2b66-4151-9746-069237fba76c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_07452004-367d-429a-9ec8-2c49e5fce907" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1b957188-2b66-4151-9746-069237fba76c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3ced8a31-cbfe-455a-9f5b-91bd35ba321a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_07452004-367d-429a-9ec8-2c49e5fce907" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3ced8a31-cbfe-455a-9f5b-91bd35ba321a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_a6065b15-7a1a-4841-a862-4ecd27e4b8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1a826f07-dad1-483d-a0ec-12b0f9ca4b44" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_a6065b15-7a1a-4841-a862-4ecd27e4b8a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_9dec3905-2154-49a7-a567-f311ad1ab615" xlink:href="jnj-20220102.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1a826f07-dad1-483d-a0ec-12b0f9ca4b44" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_9dec3905-2154-49a7-a567-f311ad1ab615" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d0dd92c7-9bd2-469c-b2d7-b2c12cc5e0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_9dec3905-2154-49a7-a567-f311ad1ab615" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d0dd92c7-9bd2-469c-b2d7-b2c12cc5e0ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0dd92c7-9bd2-469c-b2d7-b2c12cc5e0ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d0dd92c7-9bd2-469c-b2d7-b2c12cc5e0ad" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0dd92c7-9bd2-469c-b2d7-b2c12cc5e0ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5d2fc7f8-c89d-4336-b45e-6aca3fc221ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d0dd92c7-9bd2-469c-b2d7-b2c12cc5e0ad" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5d2fc7f8-c89d-4336-b45e-6aca3fc221ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_1d09e84a-83e2-4c1f-a6ad-bb253d731dfd" xlink:href="jnj-20220102.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5d2fc7f8-c89d-4336-b45e-6aca3fc221ef" xlink:to="loc_jnj_AurisHealthMember_1d09e84a-83e2-4c1f-a6ad-bb253d731dfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3ccce5bf-3432-43c9-9f82-1d5459db4db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_9dec3905-2154-49a7-a567-f311ad1ab615" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3ccce5bf-3432-43c9-9f82-1d5459db4db1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3ccce5bf-3432-43c9-9f82-1d5459db4db1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3ccce5bf-3432-43c9-9f82-1d5459db4db1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3ccce5bf-3432-43c9-9f82-1d5459db4db1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5e7ec265-5001-4bf8-b1a8-1e25fec71de7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3ccce5bf-3432-43c9-9f82-1d5459db4db1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5e7ec265-5001-4bf8-b1a8-1e25fec71de7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_19569439-23ff-4533-904a-afefb16d2684" xlink:href="jnj-20220102.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5e7ec265-5001-4bf8-b1a8-1e25fec71de7" xlink:to="loc_jnj_PatentsAndTrademarksMember_19569439-23ff-4533-904a-afefb16d2684" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_551291cd-6096-4832-9c85-4530b44bd01a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5e7ec265-5001-4bf8-b1a8-1e25fec71de7" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_551291cd-6096-4832-9c85-4530b44bd01a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_cd6e380d-0dbc-490e-8c51-9bb3dd90ce82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5e7ec265-5001-4bf8-b1a8-1e25fec71de7" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_cd6e380d-0dbc-490e-8c51-9bb3dd90ce82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ac0c7dbf-27f2-4769-b20e-7916142a545f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_9dec3905-2154-49a7-a567-f311ad1ab615" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ac0c7dbf-27f2-4769-b20e-7916142a545f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ac0c7dbf-27f2-4769-b20e-7916142a545f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ac0c7dbf-27f2-4769-b20e-7916142a545f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ac0c7dbf-27f2-4769-b20e-7916142a545f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_48ee9bf3-7574-41c2-89ae-0cf79cfa42a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ac0c7dbf-27f2-4769-b20e-7916142a545f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_48ee9bf3-7574-41c2-89ae-0cf79cfa42a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_0c54fc7c-341f-45fe-936f-d3584692a8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_48ee9bf3-7574-41c2-89ae-0cf79cfa42a0" xlink:to="loc_us-gaap_TrademarksMember_0c54fc7c-341f-45fe-936f-d3584692a8d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_73c883fa-6449-4568-8089-494c933b575a" xlink:href="jnj-20220102.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_48ee9bf3-7574-41c2-89ae-0cf79cfa42a0" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_73c883fa-6449-4568-8089-494c933b575a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_b29b7caa-dd6f-4de3-942a-e2b064af3684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_48ee9bf3-7574-41c2-89ae-0cf79cfa42a0" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_b29b7caa-dd6f-4de3-942a-e2b064af3684" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#IntangibleAssetsandGoodwillGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails" xlink:type="extended" id="i7bd2c8fe4b0a43e7b7ae92e7198bfe0c_IntangibleAssetsandGoodwillGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_c2dedc40-4d19-413f-9c45-245befc76347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_d3a7ac06-2b62-4a4f-b45d-85ba8cfedb63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_c2dedc40-4d19-413f-9c45-245befc76347" xlink:to="loc_us-gaap_GoodwillRollForward_d3a7ac06-2b62-4a4f-b45d-85ba8cfedb63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_089c87b3-3c51-41b5-b68b-ac8bea838bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_d3a7ac06-2b62-4a4f-b45d-85ba8cfedb63" xlink:to="loc_us-gaap_Goodwill_089c87b3-3c51-41b5-b68b-ac8bea838bcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_0cdd0414-7e7d-410b-954b-2fa640cb09a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_d3a7ac06-2b62-4a4f-b45d-85ba8cfedb63" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_0cdd0414-7e7d-410b-954b-2fa640cb09a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_42213366-4efd-460f-84f3-7efaae79bad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_d3a7ac06-2b62-4a4f-b45d-85ba8cfedb63" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_42213366-4efd-460f-84f3-7efaae79bad8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_61114e5a-b6ab-4ef9-bf26-0bbe6aa741c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_d3a7ac06-2b62-4a4f-b45d-85ba8cfedb63" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_61114e5a-b6ab-4ef9-bf26-0bbe6aa741c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7b6d88d8-f6a5-4c76-b53e-ab0c7b914000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_0346a5e4-55f8-4477-9354-33af21113529" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_c2dedc40-4d19-413f-9c45-245befc76347" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_0346a5e4-55f8-4477-9354-33af21113529" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f2219c9d-cbf6-403d-95b9-18a38096e7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_0346a5e4-55f8-4477-9354-33af21113529" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f2219c9d-cbf6-403d-95b9-18a38096e7b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f2219c9d-cbf6-403d-95b9-18a38096e7b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f2219c9d-cbf6-403d-95b9-18a38096e7b0" xlink:to="loc_us-gaap_SegmentDomain_f2219c9d-cbf6-403d-95b9-18a38096e7b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_81dee365-40df-435f-8a1a-43256010daa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f2219c9d-cbf6-403d-95b9-18a38096e7b0" xlink:to="loc_us-gaap_SegmentDomain_81dee365-40df-435f-8a1a-43256010daa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_af771109-6fec-4fb4-bbdb-8b925f80149b" xlink:href="jnj-20220102.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_81dee365-40df-435f-8a1a-43256010daa9" xlink:to="loc_jnj_ConsumerMember_af771109-6fec-4fb4-bbdb-8b925f80149b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_b83b32ce-1219-408a-a02e-2ce9fa5ef688" xlink:href="jnj-20220102.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_81dee365-40df-435f-8a1a-43256010daa9" xlink:to="loc_jnj_PharmaceuticalMember_b83b32ce-1219-408a-a02e-2ce9fa5ef688" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_6b4d81a7-7287-41fd-88e7-7df77f8d0a10" xlink:href="jnj-20220102.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_81dee365-40df-435f-8a1a-43256010daa9" xlink:to="loc_jnj_MedicalDevicesMember_6b4d81a7-7287-41fd-88e7-7df77f8d0a10" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended" id="ibe6c1c37faaa49f1a4d76837a42b6808_IntangibleAssetsandGoodwillNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ea7122c7-4059-4860-8ba3-81f57b6207bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_23162e1c-ff5b-4c51-afec-2789b6a96ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ea7122c7-4059-4860-8ba3-81f57b6207bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_23162e1c-ff5b-4c51-afec-2789b6a96ee2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2accd86e-7e4a-40c5-9796-b75035d4ac84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ea7122c7-4059-4860-8ba3-81f57b6207bc" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2accd86e-7e4a-40c5-9796-b75035d4ac84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_44d460a5-559f-46ed-a038-78e895805e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ea7122c7-4059-4860-8ba3-81f57b6207bc" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_44d460a5-559f-46ed-a038-78e895805e82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_77a50c56-27b7-4831-ac41-dd17afc2e906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_44d460a5-559f-46ed-a038-78e895805e82" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_77a50c56-27b7-4831-ac41-dd17afc2e906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77a50c56-27b7-4831-ac41-dd17afc2e906_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_77a50c56-27b7-4831-ac41-dd17afc2e906" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77a50c56-27b7-4831-ac41-dd17afc2e906_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_880ebd4e-11cc-43d6-865d-db69a50e0491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_77a50c56-27b7-4831-ac41-dd17afc2e906" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_880ebd4e-11cc-43d6-865d-db69a50e0491" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_14f4b21a-76b2-4e2e-b7e9-a2b7efe6966c" xlink:href="jnj-20220102.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_880ebd4e-11cc-43d6-865d-db69a50e0491" xlink:to="loc_jnj_PatentsAndTrademarksMember_14f4b21a-76b2-4e2e-b7e9-a2b7efe6966c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_0f8d6abe-134b-4205-9ca8-c86a4f06c2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_880ebd4e-11cc-43d6-865d-db69a50e0491" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_0f8d6abe-134b-4205-9ca8-c86a4f06c2d5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i828831a6332843919d4a73a68c75a420_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_36b7f8cc-1328-43e1-b2a2-46c40c58494e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_4a140f6f-7888-4016-837c-af47906dda8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_36b7f8cc-1328-43e1-b2a2-46c40c58494e" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_4a140f6f-7888-4016-837c-af47906dda8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_11bf4b80-99ad-40fa-a5f6-418a47020298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_36b7f8cc-1328-43e1-b2a2-46c40c58494e" xlink:to="loc_us-gaap_DerivativeNotionalAmount_11bf4b80-99ad-40fa-a5f6-418a47020298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_9421c292-23d7-427f-849c-6ddeb9418862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_36b7f8cc-1328-43e1-b2a2-46c40c58494e" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_9421c292-23d7-427f-849c-6ddeb9418862" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_0c2f3089-63f9-4b42-8bcd-abfc8fa6137f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_36b7f8cc-1328-43e1-b2a2-46c40c58494e" xlink:to="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_0c2f3089-63f9-4b42-8bcd-abfc8fa6137f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_cc39c25a-7cd5-4bdf-a090-083a34d3e8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_36b7f8cc-1328-43e1-b2a2-46c40c58494e" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_cc39c25a-7cd5-4bdf-a090-083a34d3e8a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_dcec157e-38a7-45a8-95e1-8101b2e96058" xlink:href="jnj-20220102.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_36b7f8cc-1328-43e1-b2a2-46c40c58494e" xlink:to="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_dcec157e-38a7-45a8-95e1-8101b2e96058" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices_2b292945-6022-4cdd-b04f-95c4413b5075" xlink:href="jnj-20220102.xsd#jnj_EquityFairValueAdjustmentChangeinObservablePrices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_36b7f8cc-1328-43e1-b2a2-46c40c58494e" xlink:to="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices_2b292945-6022-4cdd-b04f-95c4413b5075" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_434e5a0e-7fde-4182-9a5f-b483f2aa1198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_36b7f8cc-1328-43e1-b2a2-46c40c58494e" xlink:to="loc_us-gaap_DerivativeTable_434e5a0e-7fde-4182-9a5f-b483f2aa1198" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1f01c2ef-e5d7-4fef-801e-a03722779f46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_434e5a0e-7fde-4182-9a5f-b483f2aa1198" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1f01c2ef-e5d7-4fef-801e-a03722779f46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1f01c2ef-e5d7-4fef-801e-a03722779f46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1f01c2ef-e5d7-4fef-801e-a03722779f46" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1f01c2ef-e5d7-4fef-801e-a03722779f46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1940764b-39b6-4869-b1f3-566356b53055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1f01c2ef-e5d7-4fef-801e-a03722779f46" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1940764b-39b6-4869-b1f3-566356b53055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_eebf2d06-fc47-4d54-aa58-a487087b6d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1940764b-39b6-4869-b1f3-566356b53055" xlink:to="loc_us-gaap_EquitySecuritiesMember_eebf2d06-fc47-4d54-aa58-a487087b6d6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4b201820-cfd3-4ba5-ad80-471c94afece2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_434e5a0e-7fde-4182-9a5f-b483f2aa1198" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4b201820-cfd3-4ba5-ad80-471c94afece2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_4b201820-cfd3-4ba5-ad80-471c94afece2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4b201820-cfd3-4ba5-ad80-471c94afece2" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_4b201820-cfd3-4ba5-ad80-471c94afece2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f9bad65b-326b-4a81-9b36-b5fe53d0d78b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4b201820-cfd3-4ba5-ad80-471c94afece2" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f9bad65b-326b-4a81-9b36-b5fe53d0d78b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_e88126da-bb83-4882-8557-3e9226e774e8" xlink:href="jnj-20220102.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f9bad65b-326b-4a81-9b36-b5fe53d0d78b" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_e88126da-bb83-4882-8557-3e9226e774e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0bcb3fde-9470-40de-b7fb-0a581b267918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_434e5a0e-7fde-4182-9a5f-b483f2aa1198" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0bcb3fde-9470-40de-b7fb-0a581b267918" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0bcb3fde-9470-40de-b7fb-0a581b267918_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0bcb3fde-9470-40de-b7fb-0a581b267918" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0bcb3fde-9470-40de-b7fb-0a581b267918_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b02f0d5f-e52d-43ce-b72f-29ff910484df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0bcb3fde-9470-40de-b7fb-0a581b267918" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b02f0d5f-e52d-43ce-b72f-29ff910484df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_45aa2f78-25c4-4c53-ae43-b05e81c0159e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b02f0d5f-e52d-43ce-b72f-29ff910484df" xlink:to="loc_us-gaap_ForeignExchangeContractMember_45aa2f78-25c4-4c53-ae43-b05e81c0159e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_5ecf9e28-4219-43ba-ac1f-34e23ea6913a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b02f0d5f-e52d-43ce-b72f-29ff910484df" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_5ecf9e28-4219-43ba-ac1f-34e23ea6913a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_6f2aa3b6-2059-4b7d-bc90-33569a2d81a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b02f0d5f-e52d-43ce-b72f-29ff910484df" xlink:to="loc_us-gaap_InterestRateSwapMember_6f2aa3b6-2059-4b7d-bc90-33569a2d81a2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended" id="i2893ee5f8ac940cdb7b2005a6dc7d7ff_FairValueMeasurementsSummaryofDerivativeActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b1ecb7ec-1681-44b4-8840-89653e6752d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_16dec9cb-ddf6-4531-92ee-c692fb8dbc42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b1ecb7ec-1681-44b4-8840-89653e6752d1" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_16dec9cb-ddf6-4531-92ee-c692fb8dbc42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_a0e9e1e3-97b5-4425-bd70-2fd8711bc0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b1ecb7ec-1681-44b4-8840-89653e6752d1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_a0e9e1e3-97b5-4425-bd70-2fd8711bc0fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_8e209caa-a49e-4f00-83b7-8e623ac2fe60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b1ecb7ec-1681-44b4-8840-89653e6752d1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_8e209caa-a49e-4f00-83b7-8e623ac2fe60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_a4e47b6b-f265-4165-97cc-e8b052c54cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b1ecb7ec-1681-44b4-8840-89653e6752d1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_a4e47b6b-f265-4165-97cc-e8b052c54cba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4cfe9152-eb33-46fe-8edb-310de3745183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b1ecb7ec-1681-44b4-8840-89653e6752d1" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4cfe9152-eb33-46fe-8edb-310de3745183" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3b937648-e27f-4b3b-91b9-b7ec97dc30a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4cfe9152-eb33-46fe-8edb-310de3745183" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3b937648-e27f-4b3b-91b9-b7ec97dc30a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3b937648-e27f-4b3b-91b9-b7ec97dc30a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3b937648-e27f-4b3b-91b9-b7ec97dc30a2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3b937648-e27f-4b3b-91b9-b7ec97dc30a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bc3e515f-e4a7-49f5-9503-967ddc8ffd00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3b937648-e27f-4b3b-91b9-b7ec97dc30a2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bc3e515f-e4a7-49f5-9503-967ddc8ffd00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_a9e504ca-8410-4c1b-b6b5-cbe31bec5e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bc3e515f-e4a7-49f5-9503-967ddc8ffd00" xlink:to="loc_us-gaap_SalesMember_a9e504ca-8410-4c1b-b6b5-cbe31bec5e5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6ff25c8b-d7b3-4616-b5c7-5d6cc823b6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bc3e515f-e4a7-49f5-9503-967ddc8ffd00" xlink:to="loc_us-gaap_CostOfSalesMember_6ff25c8b-d7b3-4616-b5c7-5d6cc823b6c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0b063aa4-55e4-41c0-aecc-d0ac43876a31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bc3e515f-e4a7-49f5-9503-967ddc8ffd00" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0b063aa4-55e4-41c0-aecc-d0ac43876a31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_03c4dd11-3291-42dc-8c3c-bc1f3ef80a07" xlink:href="jnj-20220102.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bc3e515f-e4a7-49f5-9503-967ddc8ffd00" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_03c4dd11-3291-42dc-8c3c-bc1f3ef80a07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_d010c116-0220-4107-bdf5-cc19327380d4" xlink:href="jnj-20220102.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bc3e515f-e4a7-49f5-9503-967ddc8ffd00" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_d010c116-0220-4107-bdf5-cc19327380d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_bfabf382-f9de-4489-ab5c-06479311de56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4cfe9152-eb33-46fe-8edb-310de3745183" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_bfabf382-f9de-4489-ab5c-06479311de56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bfabf382-f9de-4489-ab5c-06479311de56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bfabf382-f9de-4489-ab5c-06479311de56" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bfabf382-f9de-4489-ab5c-06479311de56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_240e8851-1eb0-47b7-afd2-1aa4d796cbac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bfabf382-f9de-4489-ab5c-06479311de56" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_240e8851-1eb0-47b7-afd2-1aa4d796cbac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b4507ee9-4d88-466e-8712-1289826edf4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_240e8851-1eb0-47b7-afd2-1aa4d796cbac" xlink:to="loc_us-gaap_InterestRateSwapMember_b4507ee9-4d88-466e-8712-1289826edf4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_3d3f6023-404b-4f67-a466-13d23080aeda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_240e8851-1eb0-47b7-afd2-1aa4d796cbac" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_3d3f6023-404b-4f67-a466-13d23080aeda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f32d687f-d78f-446f-8f1e-7f527387b4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_240e8851-1eb0-47b7-afd2-1aa4d796cbac" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f32d687f-d78f-446f-8f1e-7f527387b4ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a68a463e-b4ec-4ca1-84cc-82a97a415437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4cfe9152-eb33-46fe-8edb-310de3745183" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a68a463e-b4ec-4ca1-84cc-82a97a415437" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_a68a463e-b4ec-4ca1-84cc-82a97a415437_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a68a463e-b4ec-4ca1-84cc-82a97a415437" xlink:to="loc_us-gaap_HedgingRelationshipDomain_a68a463e-b4ec-4ca1-84cc-82a97a415437_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f55f01bb-51bf-453a-9705-6d846260cbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a68a463e-b4ec-4ca1-84cc-82a97a415437" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f55f01bb-51bf-453a-9705-6d846260cbfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_c343f8c3-5316-4c59-a5e6-c6f8e821b0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f55f01bb-51bf-453a-9705-6d846260cbfd" xlink:to="loc_us-gaap_FairValueHedgingMember_c343f8c3-5316-4c59-a5e6-c6f8e821b0bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_c0a744ae-0afc-4b0c-b6d0-c354d7f42a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f55f01bb-51bf-453a-9705-6d846260cbfd" xlink:to="loc_us-gaap_CashFlowHedgingMember_c0a744ae-0afc-4b0c-b6d0-c354d7f42a69" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" xlink:type="extended" id="i5bcaabaa56f94c63918b67bd343dd22a_FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a54adf2c-9129-49c2-8f7d-4ba86af5177e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_74bad6c4-045c-48ab-8989-bce5e965039a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a54adf2c-9129-49c2-8f7d-4ba86af5177e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_74bad6c4-045c-48ab-8989-bce5e965039a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_10e74871-9f26-41e9-b52c-9007c14957f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a54adf2c-9129-49c2-8f7d-4ba86af5177e" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_10e74871-9f26-41e9-b52c-9007c14957f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f2d69e6f-a6b7-4e15-8ad1-f90b7a80b4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a54adf2c-9129-49c2-8f7d-4ba86af5177e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f2d69e6f-a6b7-4e15-8ad1-f90b7a80b4f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a4a5b993-f9eb-4d37-b246-b413309956f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f2d69e6f-a6b7-4e15-8ad1-f90b7a80b4f3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a4a5b993-f9eb-4d37-b246-b413309956f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a4a5b993-f9eb-4d37-b246-b413309956f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a4a5b993-f9eb-4d37-b246-b413309956f4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a4a5b993-f9eb-4d37-b246-b413309956f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0de3ab89-69c5-41b1-b1f6-578d9db5258e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a4a5b993-f9eb-4d37-b246-b413309956f4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0de3ab89-69c5-41b1-b1f6-578d9db5258e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_9eeee69c-d8b9-4e40-aabd-f6130f23fc38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0de3ab89-69c5-41b1-b1f6-578d9db5258e" xlink:to="loc_us-gaap_LongTermDebtMember_9eeee69c-d8b9-4e40-aabd-f6130f23fc38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_1406ec9b-f0fa-45e2-a29c-b2778855e901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f2d69e6f-a6b7-4e15-8ad1-f90b7a80b4f3" xlink:to="loc_us-gaap_HedgingDesignationAxis_1406ec9b-f0fa-45e2-a29c-b2778855e901" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_1406ec9b-f0fa-45e2-a29c-b2778855e901_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_1406ec9b-f0fa-45e2-a29c-b2778855e901" xlink:to="loc_us-gaap_HedgingDesignationDomain_1406ec9b-f0fa-45e2-a29c-b2778855e901_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_feed4173-ef01-44b6-bcb7-2782b1cf4401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_1406ec9b-f0fa-45e2-a29c-b2778855e901" xlink:to="loc_us-gaap_HedgingDesignationDomain_feed4173-ef01-44b6-bcb7-2782b1cf4401" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_20b16e9e-b075-405d-8a3f-651132e287d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_feed4173-ef01-44b6-bcb7-2782b1cf4401" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_20b16e9e-b075-405d-8a3f-651132e287d4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="i194572996c3f46d9b559b0ca9861ccbc_FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_510f7aa2-e555-465a-b076-94c994049a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_60a5c7d8-dbb4-49ee-8738-8e778d64801d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_510f7aa2-e555-465a-b076-94c994049a0a" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_60a5c7d8-dbb4-49ee-8738-8e778d64801d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_78ca1c98-c4d2-48b2-a6af-fb81b21e3dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_510f7aa2-e555-465a-b076-94c994049a0a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_78ca1c98-c4d2-48b2-a6af-fb81b21e3dc8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_802bb44d-1e4c-4edc-838b-8d4920adfbef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_78ca1c98-c4d2-48b2-a6af-fb81b21e3dc8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_802bb44d-1e4c-4edc-838b-8d4920adfbef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_802bb44d-1e4c-4edc-838b-8d4920adfbef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_802bb44d-1e4c-4edc-838b-8d4920adfbef" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_802bb44d-1e4c-4edc-838b-8d4920adfbef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b5e3de95-2059-4370-89db-309c1e315da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_802bb44d-1e4c-4edc-838b-8d4920adfbef" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b5e3de95-2059-4370-89db-309c1e315da1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_79ef6dd1-4dea-4467-a23e-92ab04166a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b5e3de95-2059-4370-89db-309c1e315da1" xlink:to="loc_us-gaap_ForeignExchangeContractMember_79ef6dd1-4dea-4467-a23e-92ab04166a76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_33b7c4ae-965f-4824-aa8c-2ed9cbf5353f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_78ca1c98-c4d2-48b2-a6af-fb81b21e3dc8" xlink:to="loc_us-gaap_HedgingDesignationAxis_33b7c4ae-965f-4824-aa8c-2ed9cbf5353f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_33b7c4ae-965f-4824-aa8c-2ed9cbf5353f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_33b7c4ae-965f-4824-aa8c-2ed9cbf5353f" xlink:to="loc_us-gaap_HedgingDesignationDomain_33b7c4ae-965f-4824-aa8c-2ed9cbf5353f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c9f7fbcb-2799-4327-a87c-7cd5483fe4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_33b7c4ae-965f-4824-aa8c-2ed9cbf5353f" xlink:to="loc_us-gaap_HedgingDesignationDomain_c9f7fbcb-2799-4327-a87c-7cd5483fe4a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_bd622fbb-af16-4e72-9c6c-9d5d9885294e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_c9f7fbcb-2799-4327-a87c-7cd5483fe4a6" xlink:to="loc_us-gaap_NondesignatedMember_bd622fbb-af16-4e72-9c6c-9d5d9885294e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_09ca80e0-a73d-4a9e-8391-dca5075cbba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_78ca1c98-c4d2-48b2-a6af-fb81b21e3dc8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_09ca80e0-a73d-4a9e-8391-dca5075cbba5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_09ca80e0-a73d-4a9e-8391-dca5075cbba5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_09ca80e0-a73d-4a9e-8391-dca5075cbba5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_09ca80e0-a73d-4a9e-8391-dca5075cbba5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b41df3bc-9f13-4e7d-b6a6-caca06cd3aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_09ca80e0-a73d-4a9e-8391-dca5075cbba5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b41df3bc-9f13-4e7d-b6a6-caca06cd3aef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_19cf62a7-5fc2-4c02-a62e-d12d89af0e29" xlink:href="jnj-20220102.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b41df3bc-9f13-4e7d-b6a6-caca06cd3aef" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_19cf62a7-5fc2-4c02-a62e-d12d89af0e29" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended" id="i03db285f0eb6422e8b6f6b6a3ff7e430_FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_713f7b11-7441-45b7-822a-48b344a28d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_aacc4aee-f50f-4f6a-928e-4676f8a10e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_713f7b11-7441-45b7-822a-48b344a28d96" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_aacc4aee-f50f-4f6a-928e-4676f8a10e40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_0c798669-48f3-41ae-91f2-38926cabe8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_713f7b11-7441-45b7-822a-48b344a28d96" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_0c798669-48f3-41ae-91f2-38926cabe8fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e86c32b2-343b-478a-9505-97466ea60e23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_713f7b11-7441-45b7-822a-48b344a28d96" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e86c32b2-343b-478a-9505-97466ea60e23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_32c0e54f-7980-4594-82ae-313ed5095203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e86c32b2-343b-478a-9505-97466ea60e23" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_32c0e54f-7980-4594-82ae-313ed5095203" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_32c0e54f-7980-4594-82ae-313ed5095203_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_32c0e54f-7980-4594-82ae-313ed5095203" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_32c0e54f-7980-4594-82ae-313ed5095203_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_db74cdc5-cd0e-4a40-ad5d-5a374cf55550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_32c0e54f-7980-4594-82ae-313ed5095203" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_db74cdc5-cd0e-4a40-ad5d-5a374cf55550" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_a622bec7-9c43-4994-a75a-4f1403bb5c64" xlink:href="jnj-20220102.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db74cdc5-cd0e-4a40-ad5d-5a374cf55550" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_a622bec7-9c43-4994-a75a-4f1403bb5c64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d1d31e65-3b10-4bab-b065-2e9eb9a4a172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e86c32b2-343b-478a-9505-97466ea60e23" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d1d31e65-3b10-4bab-b065-2e9eb9a4a172" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d1d31e65-3b10-4bab-b065-2e9eb9a4a172_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d1d31e65-3b10-4bab-b065-2e9eb9a4a172" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d1d31e65-3b10-4bab-b065-2e9eb9a4a172_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_83a5befb-a2e6-4b19-90ec-fea45d307d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d1d31e65-3b10-4bab-b065-2e9eb9a4a172" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_83a5befb-a2e6-4b19-90ec-fea45d307d2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_f3437eed-e5a1-4d4b-b20a-7ac16a78f75c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_83a5befb-a2e6-4b19-90ec-fea45d307d2f" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_f3437eed-e5a1-4d4b-b20a-7ac16a78f75c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended" id="i3927ea2bc0434afd8661eda3ea69b5e4_FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a0fc6dd2-4595-419c-848a-89fe81b93d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_75d6fc96-5b2a-4813-bc45-dcd5e783ac68" xlink:href="jnj-20220102.xsd#jnj_EquityInvestmentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a0fc6dd2-4595-419c-848a-89fe81b93d3f" xlink:to="loc_jnj_EquityInvestmentRollForward_75d6fc96-5b2a-4813-bc45-dcd5e783ac68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_712cb729-ab8e-4bf7-aa41-329cef77f0db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_75d6fc96-5b2a-4813-bc45-dcd5e783ac68" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_712cb729-ab8e-4bf7-aa41-329cef77f0db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_b30c082d-0e4f-46cb-b092-d3b7ac60b642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_75d6fc96-5b2a-4813-bc45-dcd5e783ac68" xlink:to="loc_us-gaap_EquityFairValueAdjustment_b30c082d-0e4f-46cb-b092-d3b7ac60b642" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_0ff52991-0964-4c50-a8f3-c11cdb582456" xlink:href="jnj-20220102.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_75d6fc96-5b2a-4813-bc45-dcd5e783ac68" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_0ff52991-0964-4c50-a8f3-c11cdb582456" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_087b86b9-a1b5-44cd-9c1c-7fdd98cd5d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_75d6fc96-5b2a-4813-bc45-dcd5e783ac68" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_087b86b9-a1b5-44cd-9c1c-7fdd98cd5d09" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_0c6e6963-a453-4dac-b915-61d6f8e153e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_75d6fc96-5b2a-4813-bc45-dcd5e783ac68" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_0c6e6963-a453-4dac-b915-61d6f8e153e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_043effd3-c0c8-461c-a43c-830882969703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a0fc6dd2-4595-419c-848a-89fe81b93d3f" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_043effd3-c0c8-461c-a43c-830882969703" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_601a5a59-7d24-4e60-af29-0a8af9231511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_043effd3-c0c8-461c-a43c-830882969703" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_601a5a59-7d24-4e60-af29-0a8af9231511" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_601a5a59-7d24-4e60-af29-0a8af9231511_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_601a5a59-7d24-4e60-af29-0a8af9231511" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_601a5a59-7d24-4e60-af29-0a8af9231511_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3b30151e-0ac2-4066-9565-ab14765661e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_601a5a59-7d24-4e60-af29-0a8af9231511" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3b30151e-0ac2-4066-9565-ab14765661e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_7decf201-3605-486b-98d1-95870e4d8214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3b30151e-0ac2-4066-9565-ab14765661e7" xlink:to="loc_us-gaap_EquitySecuritiesMember_7decf201-3605-486b-98d1-95870e4d8214" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a1d67706-96dd-4d13-88f4-0fe0c045d48f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_043effd3-c0c8-461c-a43c-830882969703" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a1d67706-96dd-4d13-88f4-0fe0c045d48f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_a1d67706-96dd-4d13-88f4-0fe0c045d48f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a1d67706-96dd-4d13-88f4-0fe0c045d48f" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_a1d67706-96dd-4d13-88f4-0fe0c045d48f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_0a985555-c2f9-479f-abab-49970eadc5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a1d67706-96dd-4d13-88f4-0fe0c045d48f" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_0a985555-c2f9-479f-abab-49970eadc5b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_b4f244f7-aa98-4efa-b191-ca677604cf96" xlink:href="jnj-20220102.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_0a985555-c2f9-479f-abab-49970eadc5b2" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_b4f244f7-aa98-4efa-b191-ca677604cf96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_9bd3d280-c9bd-42e2-a7ba-4bb2fb871d3e" xlink:href="jnj-20220102.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_0a985555-c2f9-479f-abab-49970eadc5b2" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_9bd3d280-c9bd-42e2-a7ba-4bb2fb871d3e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended" id="ibc1e37fb1eff4e6091bcfe0d13909eb2_FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_598c133f-ccc4-4d79-8516-2892ba035e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_598c133f-ccc4-4d79-8516-2892ba035e97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_7b821279-f091-4727-b7df-6530f0d44188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_598c133f-ccc4-4d79-8516-2892ba035e97" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_7b821279-f091-4727-b7df-6530f0d44188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_ef789731-6ac0-4e4e-9132-33e165f8aee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_598c133f-ccc4-4d79-8516-2892ba035e97" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_ef789731-6ac0-4e4e-9132-33e165f8aee2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_8a0a5b7a-77b0-4ce3-9028-5ad6461a2ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_598c133f-ccc4-4d79-8516-2892ba035e97" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_8a0a5b7a-77b0-4ce3-9028-5ad6461a2ed0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_6d639127-a6cc-42a4-8326-95ebb7c358ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_598c133f-ccc4-4d79-8516-2892ba035e97" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_6d639127-a6cc-42a4-8326-95ebb7c358ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_046fcc87-69f3-49dc-8b84-106a71f5e5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_598c133f-ccc4-4d79-8516-2892ba035e97" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_046fcc87-69f3-49dc-8b84-106a71f5e5a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7679d04b-c7de-4612-b082-87a18d639489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_598c133f-ccc4-4d79-8516-2892ba035e97" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7679d04b-c7de-4612-b082-87a18d639489" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6f1447bf-6f15-4f5e-a024-4469786c296e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_598c133f-ccc4-4d79-8516-2892ba035e97" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6f1447bf-6f15-4f5e-a024-4469786c296e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2879cce5-25d6-46e8-8c24-fcdfff6af8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2879cce5-25d6-46e8-8c24-fcdfff6af8a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_843176fb-c187-4c0a-b4ee-d6a4c2542282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_843176fb-c187-4c0a-b4ee-d6a4c2542282" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_4948293c-5023-4935-92c4-04bf5acb4d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_DerivativeAssets_4948293c-5023-4935-92c4-04bf5acb4d4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_4271dfce-bf03-49dc-a749-b8b5d6def00f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_4271dfce-bf03-49dc-a749-b8b5d6def00f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_fef645fa-3088-4f5a-968a-827db8f512b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_fef645fa-3088-4f5a-968a-827db8f512b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_0c29f7d3-359c-4297-9491-40feffc36461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_DerivativeLiabilities_0c29f7d3-359c-4297-9491-40feffc36461" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a313adfa-4bb6-4999-b391-5cddd52b3d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a313adfa-4bb6-4999-b391-5cddd52b3d0b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_bb416a1d-0265-4259-81f7-e3ebe873d248" xlink:href="jnj-20220102.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_bb416a1d-0265-4259-81f7-e3ebe873d248" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_325e050f-e0e4-407d-b82c-fc8fefba1648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_325e050f-e0e4-407d-b82c-fc8fefba1648" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_f9434482-9fdf-452f-8b1d-c40edf870724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_f9434482-9fdf-452f-8b1d-c40edf870724" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_23b4d9ca-dd4f-43dc-9bea-0dafee59cc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_32ee53b5-41d2-4e48-b69e-40a25cc8343a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_32ee53b5-41d2-4e48-b69e-40a25cc8343a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_537ab408-0e90-4ca1-885e-51e05122ea6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_537ab408-0e90-4ca1-885e-51e05122ea6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_5645d90c-0ea0-4fc0-afa9-3aef10aefa2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_537ab408-0e90-4ca1-885e-51e05122ea6a" xlink:to="loc_us-gaap_HedgingDesignationAxis_5645d90c-0ea0-4fc0-afa9-3aef10aefa2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_5645d90c-0ea0-4fc0-afa9-3aef10aefa2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_5645d90c-0ea0-4fc0-afa9-3aef10aefa2c" xlink:to="loc_us-gaap_HedgingDesignationDomain_5645d90c-0ea0-4fc0-afa9-3aef10aefa2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_55d854ad-73ab-46e9-ac11-5fdf826369f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_5645d90c-0ea0-4fc0-afa9-3aef10aefa2c" xlink:to="loc_us-gaap_HedgingDesignationDomain_55d854ad-73ab-46e9-ac11-5fdf826369f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_5ed56639-4211-49f6-aed8-6d100065ba87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_55d854ad-73ab-46e9-ac11-5fdf826369f2" xlink:to="loc_us-gaap_NondesignatedMember_5ed56639-4211-49f6-aed8-6d100065ba87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a40fff43-13b9-460f-8f9f-e1be7be735f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_537ab408-0e90-4ca1-885e-51e05122ea6a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a40fff43-13b9-460f-8f9f-e1be7be735f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a40fff43-13b9-460f-8f9f-e1be7be735f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a40fff43-13b9-460f-8f9f-e1be7be735f5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a40fff43-13b9-460f-8f9f-e1be7be735f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_08c4d003-53f9-428e-84f0-9389fa27678e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a40fff43-13b9-460f-8f9f-e1be7be735f5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_08c4d003-53f9-428e-84f0-9389fa27678e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_daf7dfb7-c7e9-4a50-b414-56749e91e7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_08c4d003-53f9-428e-84f0-9389fa27678e" xlink:to="loc_us-gaap_InterestRateContractMember_daf7dfb7-c7e9-4a50-b414-56749e91e7b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_79239312-1350-4eaf-843c-af63da7e2e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_08c4d003-53f9-428e-84f0-9389fa27678e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_79239312-1350-4eaf-843c-af63da7e2e99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_28d6d0d1-ca81-40ed-84f4-b28ac0575668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_537ab408-0e90-4ca1-885e-51e05122ea6a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_28d6d0d1-ca81-40ed-84f4-b28ac0575668" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_28d6d0d1-ca81-40ed-84f4-b28ac0575668_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_28d6d0d1-ca81-40ed-84f4-b28ac0575668" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_28d6d0d1-ca81-40ed-84f4-b28ac0575668_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1fccce53-a7f7-40eb-9ec2-f37f51b5698e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_28d6d0d1-ca81-40ed-84f4-b28ac0575668" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1fccce53-a7f7-40eb-9ec2-f37f51b5698e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6970202b-7588-4fd7-a837-ed3d14d32319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1fccce53-a7f7-40eb-9ec2-f37f51b5698e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6970202b-7588-4fd7-a837-ed3d14d32319" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b52c1777-257b-42e8-a841-6f4951ee5674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1fccce53-a7f7-40eb-9ec2-f37f51b5698e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b52c1777-257b-42e8-a841-6f4951ee5674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3f88a8f3-b609-4829-a4e4-9d21563efc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1fccce53-a7f7-40eb-9ec2-f37f51b5698e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3f88a8f3-b609-4829-a4e4-9d21563efc1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_3c9cb2ab-39d7-46c9-beb4-1731376aee97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_537ab408-0e90-4ca1-885e-51e05122ea6a" xlink:to="loc_us-gaap_InvestmentTypeAxis_3c9cb2ab-39d7-46c9-beb4-1731376aee97" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_3c9cb2ab-39d7-46c9-beb4-1731376aee97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_3c9cb2ab-39d7-46c9-beb4-1731376aee97" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_3c9cb2ab-39d7-46c9-beb4-1731376aee97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4801c3d7-7b42-48f3-baf9-67ffcdf8cbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_3c9cb2ab-39d7-46c9-beb4-1731376aee97" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4801c3d7-7b42-48f3-baf9-67ffcdf8cbd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_bffb9454-202c-4537-9a0c-a60751152326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4801c3d7-7b42-48f3-baf9-67ffcdf8cbd1" xlink:to="loc_us-gaap_EquitySecuritiesMember_bffb9454-202c-4537-9a0c-a60751152326" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0c435b47-0e33-4f7a-b232-48737e6d8494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_537ab408-0e90-4ca1-885e-51e05122ea6a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0c435b47-0e33-4f7a-b232-48737e6d8494" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c435b47-0e33-4f7a-b232-48737e6d8494_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0c435b47-0e33-4f7a-b232-48737e6d8494" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c435b47-0e33-4f7a-b232-48737e6d8494_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d16a33f9-f1cb-468d-b7b7-a980a8556d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0c435b47-0e33-4f7a-b232-48737e6d8494" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d16a33f9-f1cb-468d-b7b7-a980a8556d99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_eeec04e8-5659-416d-b762-1b5833ca081d" xlink:href="jnj-20220102.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d16a33f9-f1cb-468d-b7b7-a980a8556d99" xlink:to="loc_jnj_AurisHealthMember_eeec04e8-5659-416d-b762-1b5833ca081d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_299b7cbe-d073-4f79-9a42-f96197ab3d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_537ab408-0e90-4ca1-885e-51e05122ea6a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_299b7cbe-d073-4f79-9a42-f96197ab3d14" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_299b7cbe-d073-4f79-9a42-f96197ab3d14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_299b7cbe-d073-4f79-9a42-f96197ab3d14" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_299b7cbe-d073-4f79-9a42-f96197ab3d14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_01379b83-d789-47ec-9293-adee183db6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_299b7cbe-d073-4f79-9a42-f96197ab3d14" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_01379b83-d789-47ec-9293-adee183db6a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8a9bf6b5-00cc-400c-8ed0-41ce11db7b85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_01379b83-d789-47ec-9293-adee183db6a7" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8a9bf6b5-00cc-400c-8ed0-41ce11db7b85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_aeb30546-0062-48ad-8da6-9f6c4a552e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_01379b83-d789-47ec-9293-adee183db6a7" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_aeb30546-0062-48ad-8da6-9f6c4a552e64" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#BorrowingsScheduleofLongtermDebtInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="extended" id="i144f890c2a144426b03422f073b16982_BorrowingsScheduleofLongtermDebtInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3d469cd2-f1ad-436b-90fb-fe747d42c005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3d469cd2-f1ad-436b-90fb-fe747d42c005" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_fcb781bf-ed2a-45c5-86cb-55d423149675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:to="loc_us-gaap_LongTermDebt_fcb781bf-ed2a-45c5-86cb-55d423149675" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b340d042-afd1-4554-837f-93b2f1665ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:to="loc_us-gaap_LongTermDebtCurrent_b340d042-afd1-4554-837f-93b2f1665ca8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_aa4a2a65-bea4-4148-9671-ce068456fe95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_aa4a2a65-bea4-4148-9671-ce068456fe95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_04080bdd-ee79-4972-942f-fb77d71eb333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_04080bdd-ee79-4972-942f-fb77d71eb333" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_37717576-35ec-425e-a7b3-0ae4ba84e12b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_37717576-35ec-425e-a7b3-0ae4ba84e12b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_aeceaf14-5c70-4899-bf7e-aec88b48f4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_aeceaf14-5c70-4899-bf7e-aec88b48f4a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_ac88b29a-0d1b-4669-8559-b02bd15aae6a" xlink:href="jnj-20220102.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:to="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_ac88b29a-0d1b-4669-8559-b02bd15aae6a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7b55daf2-5138-4b7a-a282-0ee0ec59fb20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:to="loc_us-gaap_DebtInstrumentTable_7b55daf2-5138-4b7a-a282-0ee0ec59fb20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_88274a2a-7fcc-48ed-93c7-10f31a818ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7b55daf2-5138-4b7a-a282-0ee0ec59fb20" xlink:to="loc_us-gaap_DebtInstrumentAxis_88274a2a-7fcc-48ed-93c7-10f31a818ce0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_88274a2a-7fcc-48ed-93c7-10f31a818ce0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_88274a2a-7fcc-48ed-93c7-10f31a818ce0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_88274a2a-7fcc-48ed-93c7-10f31a818ce0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_88274a2a-7fcc-48ed-93c7-10f31a818ce0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2021Member_632ae5ae-803d-40fd-a550-f0519fe38106" xlink:href="jnj-20220102.xsd#jnj_A3.55Notesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A3.55Notesdue2021Member_632ae5ae-803d-40fd-a550-f0519fe38106" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2021Member_8aa68abd-8171-42d4-a1cc-23ec5a2a3544" xlink:href="jnj-20220102.xsd#jnj_A2.45Notesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A2.45Notesdue2021Member_8aa68abd-8171-42d4-a1cc-23ec5a2a3544" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.65Notesdue2021Member_eb705b57-01c7-42fc-aa3f-5cdc30cd1909" xlink:href="jnj-20220102.xsd#jnj_A1.65Notesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A1.65Notesdue2021Member_eb705b57-01c7-42fc-aa3f-5cdc30cd1909" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.250NotesDue2022Member_59fe0348-fbb0-425c-ba5e-81d6f5a5c787" xlink:href="jnj-20220102.xsd#jnj_A0.250NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A0.250NotesDue2022Member_59fe0348-fbb0-425c-ba5e-81d6f5a5c787" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.25Notesdue2022Member_df78cabc-242e-4bf0-a289-d152ea571ee7" xlink:href="jnj-20220102.xsd#jnj_A2.25Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A2.25Notesdue2022Member_df78cabc-242e-4bf0-a289-d152ea571ee7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member_cdbab93c-0dbe-441e-9e94-c2bb94a91826" xlink:href="jnj-20220102.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A6.73Debenturesdue2023Member_cdbab93c-0dbe-441e-9e94-c2bb94a91826" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member_aafbeb93-1a8d-44b6-847f-29b6d2ba243c" xlink:href="jnj-20220102.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A3.375Notesdue2023Member_aafbeb93-1a8d-44b6-847f-29b6d2ba243c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.05Notesdue2023Member_d6d2308f-744b-42ce-a293-1025bfdc8c0e" xlink:href="jnj-20220102.xsd#jnj_A2.05Notesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A2.05Notesdue2023Member_d6d2308f-744b-42ce-a293-1025bfdc8c0e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_2f771544-d1c3-4466-bb66-b7779934ee75" xlink:href="jnj-20220102.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A0.650NotesDue2024Member_2f771544-d1c3-4466-bb66-b7779934ee75" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_1756521b-d09f-4bef-861a-671162139c1f" xlink:href="jnj-20220102.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A5.50NotesDue2024Member_1756521b-d09f-4bef-861a-671162139c1f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_18300166-61d6-426d-8fb3-b2b5aff9ae8b" xlink:href="jnj-20220102.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A2.625Notesdue2025Member_18300166-61d6-426d-8fb3-b2b5aff9ae8b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A055NotesDue2025Member_b9e0b1ff-8c35-47d6-9350-fbef2e02e64c" xlink:href="jnj-20220102.xsd#jnj_A055NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A055NotesDue2025Member_b9e0b1ff-8c35-47d6-9350-fbef2e02e64c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_bac4216f-b861-499f-ba1d-32f31cfc1155" xlink:href="jnj-20220102.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A2.45Notesdue2026Member_bac4216f-b861-499f-ba1d-32f31cfc1155" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_3547e848-1bd0-436e-b64b-5edcb6100019" xlink:href="jnj-20220102.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A2.95Notesdue2027Member_3547e848-1bd0-436e-b64b-5edcb6100019" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_c6d94159-67ad-4a89-b477-0b9208b89625" xlink:href="jnj-20220102.xsd#jnj_A095NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A095NotesDue2027Member_c6d94159-67ad-4a89-b477-0b9208b89625" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_170e72aa-4313-42a3-84ae-94fadc915404" xlink:href="jnj-20220102.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A1.150NotesDue2028Member_170e72aa-4313-42a3-84ae-94fadc915404" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_adaea4ec-dcd6-42dd-b760-a8370e341353" xlink:href="jnj-20220102.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A2.900Notesdue2028Member_adaea4ec-dcd6-42dd-b760-a8370e341353" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_ea87dc38-1718-41bd-a8e9-2cfcd4432149" xlink:href="jnj-20220102.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A6.95Notesdue2029Member_ea87dc38-1718-41bd-a8e9-2cfcd4432149" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A130NotesDue2030Member_50542be9-2e08-433c-8670-798dd9ac01a2" xlink:href="jnj-20220102.xsd#jnj_A130NotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A130NotesDue2030Member_50542be9-2e08-433c-8670-798dd9ac01a2" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_9855d2d8-8817-46ff-bfef-e286b88cd1cd" xlink:href="jnj-20220102.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_9855d2d8-8817-46ff-bfef-e286b88cd1cd" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_10b48cf7-7fa5-4c3d-a0ff-398b7bd37ec6" xlink:href="jnj-20220102.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A4.375Notesdue2033Member_10b48cf7-7fa5-4c3d-a0ff-398b7bd37ec6" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_07c12ea6-cacf-4777-9d5c-8a42acf19376" xlink:href="jnj-20220102.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A1.650NotesDue2035Member_07c12ea6-cacf-4777-9d5c-8a42acf19376" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_337cacf7-d4f3-4814-b4b4-10c603f69862" xlink:href="jnj-20220102.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A3.55Notesdue2036Member_337cacf7-d4f3-4814-b4b4-10c603f69862" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_d51d904f-0bda-445d-a482-f2b5ae4aeced" xlink:href="jnj-20220102.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A5.95Notesdue2037Member_d51d904f-0bda-445d-a482-f2b5ae4aeced" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_adc6d887-d8cb-402b-87de-c69feeb3ecda" xlink:href="jnj-20220102.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A3.625Notesdue2037Member_adc6d887-d8cb-402b-87de-c69feeb3ecda" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_73f970dd-741d-4576-a816-52b6cab85291" xlink:href="jnj-20220102.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_73f970dd-741d-4576-a816-52b6cab85291" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_a82cf6af-c9fa-411b-a6e7-c13bfb74d6f4" xlink:href="jnj-20220102.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A3.400Notesdue2038Member_a82cf6af-c9fa-411b-a6e7-c13bfb74d6f4" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_2c677ea2-576a-44a9-a0ac-c20d032ab388" xlink:href="jnj-20220102.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_2c677ea2-576a-44a9-a0ac-c20d032ab388" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_f5328793-1d0d-45ef-839b-23df750a17a0" xlink:href="jnj-20220102.xsd#jnj_A210NotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A210NotesDue2040Member_f5328793-1d0d-45ef-839b-23df750a17a0" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_d7eb6dff-89f6-48fe-be18-8f5df098bc14" xlink:href="jnj-20220102.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A4.85Notesdue2041Member_d7eb6dff-89f6-48fe-be18-8f5df098bc14" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_3c206bfa-e1ae-442d-8171-c4f46cee0ed9" xlink:href="jnj-20220102.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A4.50Notesdue2043Member_3c206bfa-e1ae-442d-8171-c4f46cee0ed9" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_1891e93c-feeb-43c8-9c84-023e3a029e03" xlink:href="jnj-20220102.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A3.70Notesdue2046Member_1891e93c-feeb-43c8-9c84-023e3a029e03" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_a31b3f19-8cd1-41dd-9549-74e4c0ed3a5e" xlink:href="jnj-20220102.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A3.75Notesdue2047Member_a31b3f19-8cd1-41dd-9549-74e4c0ed3a5e" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_7350171a-9d89-4711-948c-300f7dae82c6" xlink:href="jnj-20220102.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A3.500Notesdue2048Member_7350171a-9d89-4711-948c-300f7dae82c6" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_1bb1abd5-b893-44e6-9182-da72e7f33ce5" xlink:href="jnj-20220102.xsd#jnj_A2250NotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A2250NotesDue2050Member_1bb1abd5-b893-44e6-9182-da72e7f33ce5" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_9e1d62e5-a1e6-4e9c-a4d1-77b64ce135df" xlink:href="jnj-20220102.xsd#jnj_A2450NotesDue2060Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A2450NotesDue2060Member_9e1d62e5-a1e6-4e9c-a4d1-77b64ce135df" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_6f76c6cf-b3b0-47a5-adc9-816f3b6fd10b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_6f76c6cf-b3b0-47a5-adc9-816f3b6fd10b" xlink:type="arc" order="36"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/BorrowingsNarrativeDetails" xlink:type="extended" id="i28af3d1e03604cc9924ce740004accdb_BorrowingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_7635b8cb-6286-4445-99fd-0f0961e44b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_1b32f436-df61-44bb-ad16-be493a205251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7635b8cb-6286-4445-99fd-0f0961e44b56" xlink:to="loc_us-gaap_ShortTermBorrowings_1b32f436-df61-44bb-ad16-be493a205251" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_91dc9046-7924-4937-982e-28d4da205a08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7635b8cb-6286-4445-99fd-0f0961e44b56" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_91dc9046-7924-4937-982e-28d4da205a08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_a623a52b-ce9e-4e7d-81d2-a00a1cb07ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7635b8cb-6286-4445-99fd-0f0961e44b56" xlink:to="loc_us-gaap_DebtInstrumentTerm_a623a52b-ce9e-4e7d-81d2-a00a1cb07ec0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_602b2b36-c6f9-4f3f-955d-2a69ce2b00b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7635b8cb-6286-4445-99fd-0f0961e44b56" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_602b2b36-c6f9-4f3f-955d-2a69ce2b00b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1ef9b2ae-da5e-4cfb-aec5-78ae3a68b7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_602b2b36-c6f9-4f3f-955d-2a69ce2b00b6" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1ef9b2ae-da5e-4cfb-aec5-78ae3a68b7d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1ef9b2ae-da5e-4cfb-aec5-78ae3a68b7d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1ef9b2ae-da5e-4cfb-aec5-78ae3a68b7d7" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1ef9b2ae-da5e-4cfb-aec5-78ae3a68b7d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_a1d0e64e-0a0a-4861-b1fc-2465505021e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1ef9b2ae-da5e-4cfb-aec5-78ae3a68b7d7" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_a1d0e64e-0a0a-4861-b1fc-2465505021e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8d632002-0eb4-4c91-927c-cbd4db668c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_a1d0e64e-0a0a-4861-b1fc-2465505021e1" xlink:to="loc_us-gaap_CommercialPaperMember_8d632002-0eb4-4c91-927c-cbd4db668c10" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i1bffc466fbbf4bd7994bde0334991cc7_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_632fead9-63f7-4895-8f8f-09c296424f2d" xlink:href="jnj-20220102.xsd#jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_632fead9-63f7-4895-8f8f-09c296424f2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_fea04f41-24c0-43dd-98fa-6a5db723613a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_fea04f41-24c0-43dd-98fa-6a5db723613a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_d3b70981-5ce5-43fa-831e-992d042629b1" xlink:href="jnj-20220102.xsd#jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_d3b70981-5ce5-43fa-831e-992d042629b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_7c091ff8-4e3c-4f32-b925-d9827c1a99c2" xlink:href="jnj-20220102.xsd#jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_7c091ff8-4e3c-4f32-b925-d9827c1a99c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_c84cee5e-b2be-41cc-b593-7d90d94316e0" xlink:href="jnj-20220102.xsd#jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_c84cee5e-b2be-41cc-b593-7d90d94316e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_1822ad17-13a9-47d6-8120-d5fbba5dc8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_LitigationSettlementExpense_1822ad17-13a9-47d6-8120-d5fbba5dc8f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_693c16e5-32d4-430c-8c8a-253d25ab9714" xlink:href="jnj-20220102.xsd#jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_693c16e5-32d4-430c-8c8a-253d25ab9714" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e83e26e3-9a72-450b-adcf-007e1f1f2303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e83e26e3-9a72-450b-adcf-007e1f1f2303" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_d6b32ae6-385c-491d-8a44-b167adcb7cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_d6b32ae6-385c-491d-8a44-b167adcb7cb7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_c6906ce0-5ce9-4758-b3da-5e2e79045c19" xlink:href="jnj-20220102.xsd#jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_c6906ce0-5ce9-4758-b3da-5e2e79045c19" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_cd669a44-d9cb-4f71-bcb2-d70b43e95a0c" xlink:href="jnj-20220102.xsd#jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_cd669a44-d9cb-4f71-bcb2-d70b43e95a0c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_54c613be-ed56-4293-901a-f38285690d1e" xlink:href="jnj-20220102.xsd#jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_54c613be-ed56-4293-901a-f38285690d1e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_360101d5-61e4-4e5b-ba6e-685f143eb2f6" xlink:href="jnj-20220102.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_360101d5-61e4-4e5b-ba6e-685f143eb2f6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_5acee826-00db-405b-9193-89e9360aeed2" xlink:href="jnj-20220102.xsd#jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_5acee826-00db-405b-9193-89e9360aeed2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_146685f7-c589-4888-a137-c326025c9739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_146685f7-c589-4888-a137-c326025c9739" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent_ddf27dc0-00ce-4d02-a395-382b24d8a96c" xlink:href="jnj-20220102.xsd#jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent_ddf27dc0-00ce-4d02-a395-382b24d8a96c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability_52cb3fa3-0f7c-4788-b19f-8bb9422fd740" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability_52cb3fa3-0f7c-4788-b19f-8bb9422fd740" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset_0084e957-58c2-46c8-8988-e095e4900776" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset_0084e957-58c2-46c8-8988-e095e4900776" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit_f520bee3-d754-4ef6-9e62-008101cfffb2" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit_f520bee3-d754-4ef6-9e62-008101cfffb2" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent_3c722055-06c9-4d71-be6f-8fd5042027e8" xlink:href="jnj-20220102.xsd#jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent_3c722055-06c9-4d71-be6f-8fd5042027e8" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_cbb53078-c7d0-4a38-b208-15b64f2f3f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_cbb53078-c7d0-4a38-b208-15b64f2f3f9a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent_3830412a-0a83-4952-9fc6-4a1df1710e2e" xlink:href="jnj-20220102.xsd#jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent_3830412a-0a83-4952-9fc6-4a1df1710e2e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset_eb53f995-717c-4262-b449-4a2ad7759a75" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset_eb53f995-717c-4262-b449-4a2ad7759a75" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_fc914607-a0dc-45f6-b8fe-b66c36d31ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_fc914607-a0dc-45f6-b8fe-b66c36d31ff6" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent_d0638ba0-f696-43bc-bfcb-1a48649f6471" xlink:href="jnj-20220102.xsd#jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent_d0638ba0-f696-43bc-bfcb-1a48649f6471" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_5239159f-9d05-49aa-a01f-ceb4350442cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_5239159f-9d05-49aa-a01f-ceb4350442cc" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment_2c19a98a-f530-41ae-a061-8d46ada025d5" xlink:href="jnj-20220102.xsd#jnj_UnrecognizedTaxBenefitLiabilityPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment_2c19a98a-f530-41ae-a061-8d46ada025d5" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_03bfda43-a55a-46bd-b62c-b6318b7b9a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_03bfda43-a55a-46bd-b62c-b6318b7b9a63" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_8a5d5f5e-9e24-40bf-bf74-37761a8329df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_8a5d5f5e-9e24-40bf-bf74-37761a8329df" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_1b99ae03-a893-40d0-8e4b-832d5f825b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_1b99ae03-a893-40d0-8e4b-832d5f825b78" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_6685cbe7-c7e6-4b2c-8797-538b6fb3ab86" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1b99ae03-a893-40d0-8e4b-832d5f825b78" xlink:to="loc_srt_LitigationCaseAxis_6685cbe7-c7e6-4b2c-8797-538b6fb3ab86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6685cbe7-c7e6-4b2c-8797-538b6fb3ab86_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_6685cbe7-c7e6-4b2c-8797-538b6fb3ab86" xlink:to="loc_srt_LitigationCaseTypeDomain_6685cbe7-c7e6-4b2c-8797-538b6fb3ab86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_3fcf819e-f2da-424a-810d-517d492751cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_6685cbe7-c7e6-4b2c-8797-538b6fb3ab86" xlink:to="loc_srt_LitigationCaseTypeDomain_3fcf819e-f2da-424a-810d-517d492751cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_15279079-8774-4048-a78d-e5939e19cef9" xlink:href="jnj-20220102.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_3fcf819e-f2da-424a-810d-517d492751cd" xlink:to="loc_jnj_TalcMember_15279079-8774-4048-a78d-e5939e19cef9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_950e1639-99ca-43df-a238-f9144cb34443" xlink:href="jnj-20220102.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_3fcf819e-f2da-424a-810d-517d492751cd" xlink:to="loc_jnj_RisperdalMember_950e1639-99ca-43df-a238-f9144cb34443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpiodsMember_e48dc568-0032-440c-b976-3383458e63fe" xlink:href="jnj-20220102.xsd#jnj_OpiodsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_3fcf819e-f2da-424a-810d-517d492751cd" xlink:to="loc_jnj_OpiodsMember_e48dc568-0032-440c-b976-3383458e63fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_38e153d0-17fd-4fd8-b786-621d9e767a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1b99ae03-a893-40d0-8e4b-832d5f825b78" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_38e153d0-17fd-4fd8-b786-621d9e767a5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_38e153d0-17fd-4fd8-b786-621d9e767a5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_38e153d0-17fd-4fd8-b786-621d9e767a5f" xlink:to="loc_us-gaap_SegmentDomain_38e153d0-17fd-4fd8-b786-621d9e767a5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_560def66-ecb1-4ede-b671-b1f583f9ebcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_38e153d0-17fd-4fd8-b786-621d9e767a5f" xlink:to="loc_us-gaap_SegmentDomain_560def66-ecb1-4ede-b671-b1f583f9ebcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_27ec73f5-628d-4bff-8e8c-b669da235639" xlink:href="jnj-20220102.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_560def66-ecb1-4ede-b671-b1f583f9ebcd" xlink:to="loc_jnj_ConsumerMember_27ec73f5-628d-4bff-8e8c-b669da235639" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_11a041b0-3608-4ba2-baf7-3bade6dc51bf" xlink:href="jnj-20220102.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_560def66-ecb1-4ede-b671-b1f583f9ebcd" xlink:to="loc_jnj_PharmaceuticalMember_11a041b0-3608-4ba2-baf7-3bade6dc51bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_899cc345-4ae7-4fb9-9e8a-a97ee56b04fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1b99ae03-a893-40d0-8e4b-832d5f825b78" xlink:to="loc_us-gaap_LitigationStatusAxis_899cc345-4ae7-4fb9-9e8a-a97ee56b04fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_899cc345-4ae7-4fb9-9e8a-a97ee56b04fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_899cc345-4ae7-4fb9-9e8a-a97ee56b04fa" xlink:to="loc_us-gaap_LitigationStatusDomain_899cc345-4ae7-4fb9-9e8a-a97ee56b04fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_057febda-5b22-45a5-8c29-7336d339bfbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_899cc345-4ae7-4fb9-9e8a-a97ee56b04fa" xlink:to="loc_us-gaap_LitigationStatusDomain_057febda-5b22-45a5-8c29-7336d339bfbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_9e96b377-3ab9-4fbc-8204-57f11b0b46c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_057febda-5b22-45a5-8c29-7336d339bfbf" xlink:to="loc_us-gaap_PendingLitigationMember_9e96b377-3ab9-4fbc-8204-57f11b0b46c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_93463bc3-286d-4b67-97e9-8cac45c08a40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1b99ae03-a893-40d0-8e4b-832d5f825b78" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_93463bc3-286d-4b67-97e9-8cac45c08a40" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_93463bc3-286d-4b67-97e9-8cac45c08a40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_93463bc3-286d-4b67-97e9-8cac45c08a40" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_93463bc3-286d-4b67-97e9-8cac45c08a40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_2ed07614-9f03-4138-87d7-51e77f9dc973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_93463bc3-286d-4b67-97e9-8cac45c08a40" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_2ed07614-9f03-4138-87d7-51e77f9dc973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_1e5dce04-dc9d-4c62-9a41-eed20ab6c986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_2ed07614-9f03-4138-87d7-51e77f9dc973" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_1e5dce04-dc9d-4c62-9a41-eed20ab6c986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c6e88849-6b5a-405d-9503-5f6fac4393d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1b99ae03-a893-40d0-8e4b-832d5f825b78" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c6e88849-6b5a-405d-9503-5f6fac4393d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c6e88849-6b5a-405d-9503-5f6fac4393d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c6e88849-6b5a-405d-9503-5f6fac4393d9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c6e88849-6b5a-405d-9503-5f6fac4393d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6af69b7-5374-4643-b1b6-58a0d65774e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c6e88849-6b5a-405d-9503-5f6fac4393d9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6af69b7-5374-4643-b1b6-58a0d65774e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_d754c405-f96c-40cf-aaf4-d19b13479abf" xlink:href="jnj-20220102.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6af69b7-5374-4643-b1b6-58a0d65774e6" xlink:to="loc_jnj_AurisHealthMember_d754c405-f96c-40cf-aaf4-d19b13479abf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_304a354f-6f56-439f-bb07-ee3e65e46e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1b99ae03-a893-40d0-8e4b-832d5f825b78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_304a354f-6f56-439f-bb07-ee3e65e46e77" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_304a354f-6f56-439f-bb07-ee3e65e46e77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_304a354f-6f56-439f-bb07-ee3e65e46e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_304a354f-6f56-439f-bb07-ee3e65e46e77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f6db525-aa97-4d9f-9d2b-c1729a4576be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_304a354f-6f56-439f-bb07-ee3e65e46e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f6db525-aa97-4d9f-9d2b-c1729a4576be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_fe76a65d-766f-4aa2-b082-26ac46384819" xlink:href="jnj-20220102.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f6db525-aa97-4d9f-9d2b-c1729a4576be" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_fe76a65d-766f-4aa2-b082-26ac46384819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_ed0734a6-26b6-43c3-83cf-d7a983b98466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1b99ae03-a893-40d0-8e4b-832d5f825b78" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_ed0734a6-26b6-43c3-83cf-d7a983b98466" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ed0734a6-26b6-43c3-83cf-d7a983b98466_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ed0734a6-26b6-43c3-83cf-d7a983b98466" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ed0734a6-26b6-43c3-83cf-d7a983b98466_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_51139e74-c9a0-4bde-84d3-46d669cfa9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ed0734a6-26b6-43c3-83cf-d7a983b98466" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_51139e74-c9a0-4bde-84d3-46d669cfa9fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f6f70008-3103-4429-89af-e2c3d4d306f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_51139e74-c9a0-4bde-84d3-46d669cfa9fc" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f6f70008-3103-4429-89af-e2c3d4d306f0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails" xlink:type="extended" id="i66aac1b04ce6424385c7987a7c173ce9_PensionsandOtherBenefitPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeCompensationPeriod_b69640aa-cf98-4317-ae86-c3908f717e90" xlink:href="jnj-20220102.xsd#jnj_EmployeeCompensationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_jnj_EmployeeCompensationPeriod_b69640aa-cf98-4317-ae86-c3908f717e90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_7f3ea1a2-9cdc-4ea8-a196-078975741a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_7f3ea1a2-9cdc-4ea8-a196-078975741a0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_dc061b0b-8f36-4856-b0d5-e8695fdf2ede" xlink:href="jnj-20220102.xsd#jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_dc061b0b-8f36-4856-b0d5-e8695fdf2ede" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_64d64a95-f386-4100-b251-5d05a97977cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_us-gaap_PensionContributions_64d64a95-f386-4100-b251-5d05a97977cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_25680176-4240-408d-a649-80593db3762a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_25680176-4240-408d-a649-80593db3762a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_e35dd13f-6485-40d0-ad90-f49fdcb3b1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_e35dd13f-6485-40d0-ad90-f49fdcb3b1ee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_38b0524d-7b34-41ba-bae4-55dd17165641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_38b0524d-7b34-41ba-bae4-55dd17165641" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_d4ea3fb3-ce55-4a77-a773-0908494d347f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_d4ea3fb3-ce55-4a77-a773-0908494d347f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_06226fc2-4733-4b8e-bfbb-54856ffc64ee" xlink:href="jnj-20220102.xsd#jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_06226fc2-4733-4b8e-bfbb-54856ffc64ee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCompanysCommonStockToPlanAsset_cb499293-674d-4396-a22b-4a482cf07bf6" xlink:href="jnj-20220102.xsd#jnj_PercentageOfCompanysCommonStockToPlanAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_jnj_PercentageOfCompanysCommonStockToPlanAsset_cb499293-674d-4396-a22b-4a482cf07bf6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0682614c-de72-49d0-88a7-c451aabf08de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0682614c-de72-49d0-88a7-c451aabf08de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c50d4e57-b9cf-4b19-a6d8-39543ae2eada" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0682614c-de72-49d0-88a7-c451aabf08de" xlink:to="loc_srt_RangeAxis_c50d4e57-b9cf-4b19-a6d8-39543ae2eada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c50d4e57-b9cf-4b19-a6d8-39543ae2eada_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c50d4e57-b9cf-4b19-a6d8-39543ae2eada" xlink:to="loc_srt_RangeMember_c50d4e57-b9cf-4b19-a6d8-39543ae2eada_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d5895047-3a6f-44e5-a152-32fa6be7a398" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c50d4e57-b9cf-4b19-a6d8-39543ae2eada" xlink:to="loc_srt_RangeMember_d5895047-3a6f-44e5-a152-32fa6be7a398" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fb7cac5f-a806-485b-b6fa-d6f75abc8b73" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d5895047-3a6f-44e5-a152-32fa6be7a398" xlink:to="loc_srt_MaximumMember_fb7cac5f-a806-485b-b6fa-d6f75abc8b73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d2b0ca93-b3c1-4cb4-b9c0-7ba81a6e20eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0682614c-de72-49d0-88a7-c451aabf08de" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d2b0ca93-b3c1-4cb4-b9c0-7ba81a6e20eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_d2b0ca93-b3c1-4cb4-b9c0-7ba81a6e20eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d2b0ca93-b3c1-4cb4-b9c0-7ba81a6e20eb" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_d2b0ca93-b3c1-4cb4-b9c0-7ba81a6e20eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_ccdb8580-c00d-41a6-b94d-1659cef6f0db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d2b0ca93-b3c1-4cb4-b9c0-7ba81a6e20eb" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_ccdb8580-c00d-41a6-b94d-1659cef6f0db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember_1f06899a-f5e1-4c62-be43-08eeaef8a23c" xlink:href="jnj-20220102.xsd#jnj_CommingledFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ccdb8580-c00d-41a6-b94d-1659cef6f0db" xlink:to="loc_jnj_CommingledFundsMember_1f06899a-f5e1-4c62-be43-08eeaef8a23c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b4b74733-fdfc-495f-9cc1-a606edd55a43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0682614c-de72-49d0-88a7-c451aabf08de" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b4b74733-fdfc-495f-9cc1-a606edd55a43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4b74733-fdfc-495f-9cc1-a606edd55a43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b4b74733-fdfc-495f-9cc1-a606edd55a43" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4b74733-fdfc-495f-9cc1-a606edd55a43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0b8e9003-c424-4a25-8b64-6d332c2de1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b4b74733-fdfc-495f-9cc1-a606edd55a43" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0b8e9003-c424-4a25-8b64-6d332c2de1c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5d688907-d789-40fe-bcde-ca880ca147cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0b8e9003-c424-4a25-8b64-6d332c2de1c6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5d688907-d789-40fe-bcde-ca880ca147cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_f6870790-1c09-4cc6-9f01-914fd939af6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0682614c-de72-49d0-88a7-c451aabf08de" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_f6870790-1c09-4cc6-9f01-914fd939af6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_f6870790-1c09-4cc6-9f01-914fd939af6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f6870790-1c09-4cc6-9f01-914fd939af6a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_f6870790-1c09-4cc6-9f01-914fd939af6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_6b991303-f6dd-4a96-b8c0-3fae32ba28bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f6870790-1c09-4cc6-9f01-914fd939af6a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_6b991303-f6dd-4a96-b8c0-3fae32ba28bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_3ed6cee9-21e8-468d-9b91-5e4e2a6dab1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6b991303-f6dd-4a96-b8c0-3fae32ba28bf" xlink:to="loc_us-gaap_DomesticPlanMember_3ed6cee9-21e8-468d-9b91-5e4e2a6dab1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3a82cba7-28c3-4c76-b661-428e6998c721" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_3ed6cee9-21e8-468d-9b91-5e4e2a6dab1f" xlink:to="loc_country_US_3a82cba7-28c3-4c76-b661-428e6998c721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_9e2668a9-dedb-4dbf-bc23-27ec660000b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6b991303-f6dd-4a96-b8c0-3fae32ba28bf" xlink:to="loc_us-gaap_ForeignPlanMember_9e2668a9-dedb-4dbf-bc23-27ec660000b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_562235c8-5e4e-442f-ac32-9ae19dfcc21a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0682614c-de72-49d0-88a7-c451aabf08de" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_562235c8-5e4e-442f-ac32-9ae19dfcc21a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_562235c8-5e4e-442f-ac32-9ae19dfcc21a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_562235c8-5e4e-442f-ac32-9ae19dfcc21a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_562235c8-5e4e-442f-ac32-9ae19dfcc21a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8bdd295b-62eb-45b7-9a2f-5214bbed27ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_562235c8-5e4e-442f-ac32-9ae19dfcc21a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8bdd295b-62eb-45b7-9a2f-5214bbed27ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_3d87b228-6bca-45f6-8f10-a7c4e1a647a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8bdd295b-62eb-45b7-9a2f-5214bbed27ef" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_3d87b228-6bca-45f6-8f10-a7c4e1a647a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0533ba34-a909-47e6-82b4-fd018c0d573e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8bdd295b-62eb-45b7-9a2f-5214bbed27ef" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0533ba34-a909-47e6-82b4-fd018c0d573e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="i374630ef89b54443a8ebfb71d8467f97_PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b71b186-f70b-42bf-9ace-0f9f09d12dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_493e781e-0f38-4103-b651-8e7c4985b422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b71b186-f70b-42bf-9ace-0f9f09d12dc8" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_493e781e-0f38-4103-b651-8e7c4985b422" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_86bb80d3-a440-423d-8daf-d71d3b8387bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b71b186-f70b-42bf-9ace-0f9f09d12dc8" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_86bb80d3-a440-423d-8daf-d71d3b8387bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_9b6f6b5c-d6d6-497a-aff4-8463dacfd8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b71b186-f70b-42bf-9ace-0f9f09d12dc8" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_9b6f6b5c-d6d6-497a-aff4-8463dacfd8cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_40104f49-a886-42bd-a2c4-9894e4d3b7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b71b186-f70b-42bf-9ace-0f9f09d12dc8" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_40104f49-a886-42bd-a2c4-9894e4d3b7f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_e51fe7c6-133c-44ab-90e2-7605f68ecb77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b71b186-f70b-42bf-9ace-0f9f09d12dc8" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_e51fe7c6-133c-44ab-90e2-7605f68ecb77" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_b7f16320-27a4-4af3-93da-310bea563a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b71b186-f70b-42bf-9ace-0f9f09d12dc8" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_b7f16320-27a4-4af3-93da-310bea563a16" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_259a3f30-23d0-4dae-8b8e-736f9ffd35cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b71b186-f70b-42bf-9ace-0f9f09d12dc8" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_259a3f30-23d0-4dae-8b8e-736f9ffd35cc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7a63bf23-85cf-4530-8de7-51c2e518ce50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b71b186-f70b-42bf-9ace-0f9f09d12dc8" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7a63bf23-85cf-4530-8de7-51c2e518ce50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_61c81836-da07-425c-8b09-9ab9a493438f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7a63bf23-85cf-4530-8de7-51c2e518ce50" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_61c81836-da07-425c-8b09-9ab9a493438f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_61c81836-da07-425c-8b09-9ab9a493438f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_61c81836-da07-425c-8b09-9ab9a493438f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_61c81836-da07-425c-8b09-9ab9a493438f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8b4a2a6b-441b-4877-b536-56e2515714c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_61c81836-da07-425c-8b09-9ab9a493438f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8b4a2a6b-441b-4877-b536-56e2515714c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_2f615b41-92f4-4290-96b7-dec1ddbe0556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8b4a2a6b-441b-4877-b536-56e2515714c0" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_2f615b41-92f4-4290-96b7-dec1ddbe0556" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_84fb42a0-47c4-472b-82d3-995e0c5bbc19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8b4a2a6b-441b-4877-b536-56e2515714c0" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_84fb42a0-47c4-472b-82d3-995e0c5bbc19" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" xlink:type="extended" id="ic3e558c3220940e6b37f724507226baf_PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ec2826aa-dbb7-4671-b248-7bf680e5a894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_ffab0d71-4277-4076-b6a1-78fa22179ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ec2826aa-dbb7-4671-b248-7bf680e5a894" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_ffab0d71-4277-4076-b6a1-78fa22179ec2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_1505030d-2688-4daf-89b3-656a04983c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_ffab0d71-4277-4076-b6a1-78fa22179ec2" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_1505030d-2688-4daf-89b3-656a04983c79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_c195be78-bec9-4c82-9249-7ac39bd44052" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_ffab0d71-4277-4076-b6a1-78fa22179ec2" xlink:to="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_c195be78-bec9-4c82-9249-7ac39bd44052" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_484a5a93-31e3-4cce-bf3c-944c67dd182b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_ffab0d71-4277-4076-b6a1-78fa22179ec2" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_484a5a93-31e3-4cce-bf3c-944c67dd182b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_362d4f86-e575-48ec-b204-89f464799df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_ffab0d71-4277-4076-b6a1-78fa22179ec2" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_362d4f86-e575-48ec-b204-89f464799df9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_51d64dca-5a6b-4cfa-9f18-7f7aec79c402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ec2826aa-dbb7-4671-b248-7bf680e5a894" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_51d64dca-5a6b-4cfa-9f18-7f7aec79c402" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_8f505918-add7-4e3a-89fb-3942d1e6b9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_51d64dca-5a6b-4cfa-9f18-7f7aec79c402" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_8f505918-add7-4e3a-89fb-3942d1e6b9f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_ba79e350-125f-40a8-a0f6-9a897f146ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_51d64dca-5a6b-4cfa-9f18-7f7aec79c402" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_ba79e350-125f-40a8-a0f6-9a897f146ce7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7c0e4566-1f03-4585-9c64-f7eb1c62907f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ec2826aa-dbb7-4671-b248-7bf680e5a894" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7c0e4566-1f03-4585-9c64-f7eb1c62907f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_0771ce81-1d8f-442d-ad74-52d9fa958cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7c0e4566-1f03-4585-9c64-f7eb1c62907f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_0771ce81-1d8f-442d-ad74-52d9fa958cb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_0771ce81-1d8f-442d-ad74-52d9fa958cb3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_0771ce81-1d8f-442d-ad74-52d9fa958cb3" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_0771ce81-1d8f-442d-ad74-52d9fa958cb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2966ee9f-84e8-40c0-9bb6-d8f5f7360667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_0771ce81-1d8f-442d-ad74-52d9fa958cb3" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2966ee9f-84e8-40c0-9bb6-d8f5f7360667" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_7f61ce93-0f94-46fb-9393-229b7c20dde8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2966ee9f-84e8-40c0-9bb6-d8f5f7360667" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_7f61ce93-0f94-46fb-9393-229b7c20dde8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_744bcc60-35a9-48c1-a319-107c248f5d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2966ee9f-84e8-40c0-9bb6-d8f5f7360667" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_744bcc60-35a9-48c1-a319-107c248f5d87" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" xlink:type="extended" id="if83ccad83ae243c4814248efc433b006_PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f5584753-20e7-45f8-975a-7ccb83872ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f5584753-20e7-45f8-975a-7ccb83872ffa" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_740f2e7d-e3eb-47f0-8042-ce3bef6c121d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_740f2e7d-e3eb-47f0-8042-ce3bef6c121d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_027dddd5-5668-4367-9c77-a7a9c4f1f4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_027dddd5-5668-4367-9c77-a7a9c4f1f4b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_b96ac309-dae0-42fd-8996-b4a46a08d28d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_b96ac309-dae0-42fd-8996-b4a46a08d28d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_c19441fc-7a77-47b1-8f14-158f2cc6f294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_c19441fc-7a77-47b1-8f14-158f2cc6f294" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_317c6873-1d0b-4fa1-934f-29e5cc0600b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_317c6873-1d0b-4fa1-934f-29e5cc0600b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_e9b9ead2-7f02-4063-a50f-4e10afafda89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_e9b9ead2-7f02-4063-a50f-4e10afafda89" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_46f52ae7-4f1b-4c3e-946e-59efbd0c7ba6" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_46f52ae7-4f1b-4c3e-946e-59efbd0c7ba6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CurtailmentsAndSettlementsAndRestructuring_faeba6a3-dab9-4b62-8901-55c448de01b5" xlink:href="jnj-20220102.xsd#jnj_CurtailmentsAndSettlementsAndRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_jnj_CurtailmentsAndSettlementsAndRestructuring_faeba6a3-dab9-4b62-8901-55c448de01b5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_dc83c867-c115-42a2-9bd9-9734f99a9453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_dc83c867-c115-42a2-9bd9-9734f99a9453" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_c4239b9f-0343-43ef-af30-f6b9ead1133d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_c4239b9f-0343-43ef-af30-f6b9ead1133d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_a14edc3f-3d77-49d2-bc6d-6424e067a6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f5584753-20e7-45f8-975a-7ccb83872ffa" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_509ddaf6-d42d-442a-bf57-c53d26d72a74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_509ddaf6-d42d-442a-bf57-c53d26d72a74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_9825fbea-0c77-49af-be56-4233a532e7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_9825fbea-0c77-49af-be56-4233a532e7a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_939d1747-4267-4ebe-9437-ddb1758aaaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_939d1747-4267-4ebe-9437-ddb1758aaaa9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_dab48414-dd22-4fcc-a6c5-4ff2ef55c0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_dab48414-dd22-4fcc-a6c5-4ff2ef55c0f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_20f9fcc3-4d3a-4cc9-bf09-caa986da34d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_20f9fcc3-4d3a-4cc9-bf09-caa986da34d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_b0049907-3a54-4a5b-9333-2981a2999a48" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:to="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_b0049907-3a54-4a5b-9333-2981a2999a48" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_0ecf9ada-d3de-4a61-902f-164bd603f9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_0ecf9ada-d3de-4a61-902f-164bd603f9d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_d38c9998-eb21-47d3-9a12-432beb6a8f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_d38c9998-eb21-47d3-9a12-432beb6a8f06" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_a9d5381b-d09f-41d6-ad79-7bed768b735e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_63b68dd8-8b04-4cc6-a5bb-654e2e752db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_63b68dd8-8b04-4cc6-a5bb-654e2e752db1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_964f564d-1a0e-4f0d-bf5b-a2872e510835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f5584753-20e7-45f8-975a-7ccb83872ffa" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_964f564d-1a0e-4f0d-bf5b-a2872e510835" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_3e43d347-55e4-4a82-bd6c-71b55014edb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_964f564d-1a0e-4f0d-bf5b-a2872e510835" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_3e43d347-55e4-4a82-bd6c-71b55014edb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_0f02b61d-d210-4a0a-858e-8c77ba954b93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_964f564d-1a0e-4f0d-bf5b-a2872e510835" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_0f02b61d-d210-4a0a-858e-8c77ba954b93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3d333a83-d1c4-426f-83cf-10f09e3581a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_964f564d-1a0e-4f0d-bf5b-a2872e510835" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3d333a83-d1c4-426f-83cf-10f09e3581a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_4252707b-00ff-48d8-9d6b-14ab0466d47a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_964f564d-1a0e-4f0d-bf5b-a2872e510835" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_4252707b-00ff-48d8-9d6b-14ab0466d47a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_e3f2e5ec-3459-42dd-8665-97cd27188bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f5584753-20e7-45f8-975a-7ccb83872ffa" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_e3f2e5ec-3459-42dd-8665-97cd27188bf1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_91b6e22e-1104-448d-ac8f-3052ce2e1761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_e3f2e5ec-3459-42dd-8665-97cd27188bf1" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_91b6e22e-1104-448d-ac8f-3052ce2e1761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_b216ed99-9ad7-4f70-812e-f024012a372f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_e3f2e5ec-3459-42dd-8665-97cd27188bf1" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_b216ed99-9ad7-4f70-812e-f024012a372f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_cbfb289e-4d40-4fbe-9c40-1121ea362775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_e3f2e5ec-3459-42dd-8665-97cd27188bf1" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_cbfb289e-4d40-4fbe-9c40-1121ea362775" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_ab06c72a-38dc-483b-b83a-bb4a0a8df8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_e3f2e5ec-3459-42dd-8665-97cd27188bf1" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_ab06c72a-38dc-483b-b83a-bb4a0a8df8ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_6160ed18-d8fe-452a-90fa-fb4fb8a7ae6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_e3f2e5ec-3459-42dd-8665-97cd27188bf1" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_6160ed18-d8fe-452a-90fa-fb4fb8a7ae6b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_bc90e7c5-03d8-4264-8918-d8f676b61912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_e3f2e5ec-3459-42dd-8665-97cd27188bf1" xlink:to="loc_us-gaap_PensionContributions_bc90e7c5-03d8-4264-8918-d8f676b61912" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f5584753-20e7-45f8-975a-7ccb83872ffa" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8b226e5e-27b8-436b-bf57-698aa2ae2446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8b226e5e-27b8-436b-bf57-698aa2ae2446" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_189b2554-c9cb-4ef8-b3f5-22d16ee709b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_189b2554-c9cb-4ef8-b3f5-22d16ee709b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_4a3c6834-0103-4cb8-a830-1843383e8f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_4a3c6834-0103-4cb8-a830-1843383e8f72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_c75cf074-06ae-451d-a36c-6623881cd7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_c75cf074-06ae-451d-a36c-6623881cd7e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_43ac39a4-d928-44c2-a82f-09ef3afc6ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_43ac39a4-d928-44c2-a82f-09ef3afc6ae4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectOfExchangeRates_a1fde505-e125-404e-b081-d0032f4c7dea" xlink:href="jnj-20220102.xsd#jnj_EffectOfExchangeRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:to="loc_jnj_EffectOfExchangeRates_a1fde505-e125-404e-b081-d0032f4c7dea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_247b2e8c-84db-4cf3-bd79-20d742d682bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_247b2e8c-84db-4cf3-bd79-20d742d682bf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_37cf02d1-ef18-4f0e-a4d2-f07c9f7e8aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_37cf02d1-ef18-4f0e-a4d2-f07c9f7e8aee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1658aef3-ed33-429c-8a45-d763451fb80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f5584753-20e7-45f8-975a-7ccb83872ffa" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1658aef3-ed33-429c-8a45-d763451fb80f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_61cf5a41-705f-4f02-b1db-5b0a5a049665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1658aef3-ed33-429c-8a45-d763451fb80f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_61cf5a41-705f-4f02-b1db-5b0a5a049665" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_61cf5a41-705f-4f02-b1db-5b0a5a049665_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_61cf5a41-705f-4f02-b1db-5b0a5a049665" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_61cf5a41-705f-4f02-b1db-5b0a5a049665_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_bb8dfce8-9b60-4466-beee-b54b0844028e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_61cf5a41-705f-4f02-b1db-5b0a5a049665" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_bb8dfce8-9b60-4466-beee-b54b0844028e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_76bca262-1656-443b-827e-e0790ffb568f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_bb8dfce8-9b60-4466-beee-b54b0844028e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_76bca262-1656-443b-827e-e0790ffb568f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4761826b-c9df-4a49-989c-3032ef93d64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_bb8dfce8-9b60-4466-beee-b54b0844028e" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4761826b-c9df-4a49-989c-3032ef93d64b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" xlink:type="extended" id="i72d5259f3c7a46f6a7e9703658b4c58a_PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_97b49c39-c366-4d02-a6db-ba37c372df18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e1ee5abd-930e-4838-a383-f295e3d61bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_97b49c39-c366-4d02-a6db-ba37c372df18" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e1ee5abd-930e-4838-a383-f295e3d61bc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5f72a2db-1cae-479e-b8db-f8bf9d1bb9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_97b49c39-c366-4d02-a6db-ba37c372df18" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5f72a2db-1cae-479e-b8db-f8bf9d1bb9a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_a2f4dee9-e1eb-426c-8e94-ae74f313fbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_97b49c39-c366-4d02-a6db-ba37c372df18" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_a2f4dee9-e1eb-426c-8e94-ae74f313fbc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_e4c57dab-72b6-4cdf-b88c-26f7c8cc0f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_97b49c39-c366-4d02-a6db-ba37c372df18" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_e4c57dab-72b6-4cdf-b88c-26f7c8cc0f98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_ea1d7ca6-26dc-4115-8daf-ab0456fc2ac0" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanOverUnderFundedStatusABO"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_97b49c39-c366-4d02-a6db-ba37c372df18" xlink:to="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_ea1d7ca6-26dc-4115-8daf-ab0456fc2ac0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f13bc819-98cc-4815-9506-c8afe552bf36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_97b49c39-c366-4d02-a6db-ba37c372df18" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f13bc819-98cc-4815-9506-c8afe552bf36" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d36a6e81-fda2-4a98-8170-85257899efe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f13bc819-98cc-4815-9506-c8afe552bf36" xlink:to="loc_us-gaap_PlanNameAxis_d36a6e81-fda2-4a98-8170-85257899efe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d36a6e81-fda2-4a98-8170-85257899efe4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d36a6e81-fda2-4a98-8170-85257899efe4" xlink:to="loc_us-gaap_PlanNameDomain_d36a6e81-fda2-4a98-8170-85257899efe4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1cb391ce-12ae-4137-81ec-85f2ba2d1b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d36a6e81-fda2-4a98-8170-85257899efe4" xlink:to="loc_us-gaap_PlanNameDomain_1cb391ce-12ae-4137-81ec-85f2ba2d1b42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_QualifiedPlansMember_1f9c021b-13e6-4737-9b82-6b888c3cc39d" xlink:href="jnj-20220102.xsd#jnj_QualifiedPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1cb391ce-12ae-4137-81ec-85f2ba2d1b42" xlink:to="loc_jnj_QualifiedPlansMember_1f9c021b-13e6-4737-9b82-6b888c3cc39d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonQualifiedPlansMember_7c797302-ea24-4465-9e12-cf0416e19750" xlink:href="jnj-20220102.xsd#jnj_NonQualifiedPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1cb391ce-12ae-4137-81ec-85f2ba2d1b42" xlink:to="loc_jnj_NonQualifiedPlansMember_7c797302-ea24-4465-9e12-cf0416e19750" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FundedPlansMember_2e667bf7-f91e-4408-a628-27aaa0c2d22e" xlink:href="jnj-20220102.xsd#jnj_FundedPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1cb391ce-12ae-4137-81ec-85f2ba2d1b42" xlink:to="loc_jnj_FundedPlansMember_2e667bf7-f91e-4408-a628-27aaa0c2d22e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnfundedPlansMember_2ce4ef06-d7fa-4cfe-afcd-cef4049a83c0" xlink:href="jnj-20220102.xsd#jnj_UnfundedPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1cb391ce-12ae-4137-81ec-85f2ba2d1b42" xlink:to="loc_jnj_UnfundedPlansMember_2ce4ef06-d7fa-4cfe-afcd-cef4049a83c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_4a241f8c-7971-424c-a15c-d162effd8cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f13bc819-98cc-4815-9506-c8afe552bf36" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_4a241f8c-7971-424c-a15c-d162effd8cfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_4a241f8c-7971-424c-a15c-d162effd8cfb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_4a241f8c-7971-424c-a15c-d162effd8cfb" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_4a241f8c-7971-424c-a15c-d162effd8cfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_d693c5dc-ec5f-44d3-be68-9087d4a89995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_4a241f8c-7971-424c-a15c-d162effd8cfb" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_d693c5dc-ec5f-44d3-be68-9087d4a89995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_c9c10b62-b34b-4155-907a-831b792962e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_d693c5dc-ec5f-44d3-be68-9087d4a89995" xlink:to="loc_us-gaap_DomesticPlanMember_c9c10b62-b34b-4155-907a-831b792962e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_abccec6b-5711-4e96-b6a9-b7f551f2c08b" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_c9c10b62-b34b-4155-907a-831b792962e9" xlink:to="loc_country_US_abccec6b-5711-4e96-b6a9-b7f551f2c08b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_d12ed96a-f6ad-45b4-90c5-b7f84d056192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_d693c5dc-ec5f-44d3-be68-9087d4a89995" xlink:to="loc_us-gaap_ForeignPlanMember_d12ed96a-f6ad-45b4-90c5-b7f84d056192" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" xlink:type="extended" id="if84a35c17f234b309b9dbbb4498d1a00_PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b0ca8e7d-026a-4535-a46d-48b8a1e02a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_38eb4cb2-48c6-4b2f-beeb-bc96c66f1686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b0ca8e7d-026a-4535-a46d-48b8a1e02a52" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_38eb4cb2-48c6-4b2f-beeb-bc96c66f1686" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_00047b34-c12d-4825-a80b-e36a4152047b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b0ca8e7d-026a-4535-a46d-48b8a1e02a52" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_00047b34-c12d-4825-a80b-e36a4152047b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_bb9b5531-ac7b-4e10-b664-931d7f3fea02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b0ca8e7d-026a-4535-a46d-48b8a1e02a52" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_bb9b5531-ac7b-4e10-b664-931d7f3fea02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_f3443a4e-c540-4948-97ec-d097c3e8aac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b0ca8e7d-026a-4535-a46d-48b8a1e02a52" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_f3443a4e-c540-4948-97ec-d097c3e8aac9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_ce5240a6-5431-4711-8d0c-105697c86603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b0ca8e7d-026a-4535-a46d-48b8a1e02a52" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_ce5240a6-5431-4711-8d0c-105697c86603" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_249dc01c-d53a-471b-a82a-8d5244f4fee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b0ca8e7d-026a-4535-a46d-48b8a1e02a52" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_249dc01c-d53a-471b-a82a-8d5244f4fee1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7151a771-2d7c-4be4-a6b4-b0ba4da4e456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b0ca8e7d-026a-4535-a46d-48b8a1e02a52" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7151a771-2d7c-4be4-a6b4-b0ba4da4e456" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_de8a9a36-d12d-4661-87f4-46beed3a517a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7151a771-2d7c-4be4-a6b4-b0ba4da4e456" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_de8a9a36-d12d-4661-87f4-46beed3a517a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_de8a9a36-d12d-4661-87f4-46beed3a517a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_de8a9a36-d12d-4661-87f4-46beed3a517a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_de8a9a36-d12d-4661-87f4-46beed3a517a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7d4fe1e7-7063-4d67-ab08-8e2e02bccc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_de8a9a36-d12d-4661-87f4-46beed3a517a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7d4fe1e7-7063-4d67-ab08-8e2e02bccc1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_9279acea-af10-4d51-a4c4-ab84842d991a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_7d4fe1e7-7063-4d67-ab08-8e2e02bccc1c" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_9279acea-af10-4d51-a4c4-ab84842d991a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_ebcf1212-0213-4da7-9dca-af8cf1d6b4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_7d4fe1e7-7063-4d67-ab08-8e2e02bccc1c" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_ebcf1212-0213-4da7-9dca-af8cf1d6b4ee" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" xlink:type="extended" id="ief6ba0fbf7e94eb29989a1b93d83a4d6_PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ce873a6e-8a84-48bf-8fc5-ff24b697dc70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_f5468745-7ac3-4fe6-872d-d8928c216be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ce873a6e-8a84-48bf-8fc5-ff24b697dc70" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_f5468745-7ac3-4fe6-872d-d8928c216be5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_cef1e93c-b966-4731-96dd-ab0eb1b3f3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ce873a6e-8a84-48bf-8fc5-ff24b697dc70" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_cef1e93c-b966-4731-96dd-ab0eb1b3f3e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0e9a9f34-8e00-4ddd-9456-73de7755674b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ce873a6e-8a84-48bf-8fc5-ff24b697dc70" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0e9a9f34-8e00-4ddd-9456-73de7755674b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_89cd64e6-b723-4181-817c-26d8de07da74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0e9a9f34-8e00-4ddd-9456-73de7755674b" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_89cd64e6-b723-4181-817c-26d8de07da74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_89cd64e6-b723-4181-817c-26d8de07da74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_89cd64e6-b723-4181-817c-26d8de07da74" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_89cd64e6-b723-4181-817c-26d8de07da74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_f4f10bd6-7257-4f7e-8644-e7040e5aa821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_89cd64e6-b723-4181-817c-26d8de07da74" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_f4f10bd6-7257-4f7e-8644-e7040e5aa821" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_02eb8dcd-bdcc-4770-840f-faac63c02d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f10bd6-7257-4f7e-8644-e7040e5aa821" xlink:to="loc_us-gaap_EquitySecuritiesMember_02eb8dcd-bdcc-4770-840f-faac63c02d98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_c43560e4-16b8-48c2-ad46-56aa873e3a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f10bd6-7257-4f7e-8644-e7040e5aa821" xlink:to="loc_us-gaap_DebtSecuritiesMember_c43560e4-16b8-48c2-ad46-56aa873e3a09" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails" xlink:type="extended" id="i30cd471cb593459ea326001884ca6f02_PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_df9564d7-0398-430d-a715-f0af4a381805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e69a89ae-cb6e-4ef6-b75f-b37adb886550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_df9564d7-0398-430d-a715-f0af4a381805" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e69a89ae-cb6e-4ef6-b75f-b37adb886550" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_1b81b8da-6228-4047-80b4-bdbaf169682b" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_df9564d7-0398-430d-a715-f0af4a381805" xlink:to="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_1b81b8da-6228-4047-80b4-bdbaf169682b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_079d9d57-1ef2-482c-a17f-07d9a0e4bc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_df9564d7-0398-430d-a715-f0af4a381805" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_079d9d57-1ef2-482c-a17f-07d9a0e4bc6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd694abb-d340-4103-902b-9560ca47e0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_079d9d57-1ef2-482c-a17f-07d9a0e4bc6e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd694abb-d340-4103-902b-9560ca47e0ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_cd694abb-d340-4103-902b-9560ca47e0ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd694abb-d340-4103-902b-9560ca47e0ed" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_cd694abb-d340-4103-902b-9560ca47e0ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ddea0521-7823-43d5-90b4-6a9915d7286d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd694abb-d340-4103-902b-9560ca47e0ed" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ddea0521-7823-43d5-90b4-6a9915d7286d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cfa482bd-055c-47ad-9485-64aa3200fd94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ddea0521-7823-43d5-90b4-6a9915d7286d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cfa482bd-055c-47ad-9485-64aa3200fd94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_ebb41ada-f956-4054-ab48-a5bfe27cbfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_079d9d57-1ef2-482c-a17f-07d9a0e4bc6e" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_ebb41ada-f956-4054-ab48-a5bfe27cbfc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ebb41ada-f956-4054-ab48-a5bfe27cbfc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ebb41ada-f956-4054-ab48-a5bfe27cbfc5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ebb41ada-f956-4054-ab48-a5bfe27cbfc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8ad4b0d9-e4f3-487a-b85c-3e5485e44f81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ebb41ada-f956-4054-ab48-a5bfe27cbfc5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8ad4b0d9-e4f3-487a-b85c-3e5485e44f81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_bc10b2b4-f1e7-4857-be1c-1c41254ee53e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8ad4b0d9-e4f3-487a-b85c-3e5485e44f81" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_bc10b2b4-f1e7-4857-be1c-1c41254ee53e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_468adf7a-9a16-43e5-9a2b-29ddc2756d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_079d9d57-1ef2-482c-a17f-07d9a0e4bc6e" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_468adf7a-9a16-43e5-9a2b-29ddc2756d3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_468adf7a-9a16-43e5-9a2b-29ddc2756d3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_468adf7a-9a16-43e5-9a2b-29ddc2756d3e" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_468adf7a-9a16-43e5-9a2b-29ddc2756d3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_8f13563d-2280-4855-9528-53dc3344179c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_468adf7a-9a16-43e5-9a2b-29ddc2756d3e" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_8f13563d-2280-4855-9528-53dc3344179c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShortTermInvestmentFundsMember_97bf597f-53e6-4c08-ac03-35f601356bcc" xlink:href="jnj-20220102.xsd#jnj_ShortTermInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8f13563d-2280-4855-9528-53dc3344179c" xlink:to="loc_jnj_ShortTermInvestmentFundsMember_97bf597f-53e6-4c08-ac03-35f601356bcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_ce02f9e2-29d7-4b11-86de-8a4586124b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8f13563d-2280-4855-9528-53dc3344179c" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_ce02f9e2-29d7-4b11-86de-8a4586124b43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_d4fd9da5-ef50-4374-a0e4-667fb8ebca70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8f13563d-2280-4855-9528-53dc3344179c" xlink:to="loc_us-gaap_DebtSecuritiesMember_d4fd9da5-ef50-4374-a0e4-667fb8ebca70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_270ff53a-2219-42a0-bcd1-8e47d68fc104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8f13563d-2280-4855-9528-53dc3344179c" xlink:to="loc_us-gaap_EquitySecuritiesMember_270ff53a-2219-42a0-bcd1-8e47d68fc104" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember_61c165c3-593a-4dac-82ce-0ca45ec1c422" xlink:href="jnj-20220102.xsd#jnj_CommingledFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8f13563d-2280-4855-9528-53dc3344179c" xlink:to="loc_jnj_CommingledFundsMember_61c165c3-593a-4dac-82ce-0ca45ec1c422" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_ed78cd60-59dc-456f-882c-418e6b21ba7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8f13563d-2280-4855-9528-53dc3344179c" xlink:to="loc_us-gaap_OtherAssetsMember_ed78cd60-59dc-456f-882c-418e6b21ba7e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fb46a2f0-9250-4262-8145-b36def95b76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_079d9d57-1ef2-482c-a17f-07d9a0e4bc6e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fb46a2f0-9250-4262-8145-b36def95b76b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fb46a2f0-9250-4262-8145-b36def95b76b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fb46a2f0-9250-4262-8145-b36def95b76b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fb46a2f0-9250-4262-8145-b36def95b76b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_084fa4b6-1bbe-4218-b7c2-79d2dfd062ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fb46a2f0-9250-4262-8145-b36def95b76b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_084fa4b6-1bbe-4218-b7c2-79d2dfd062ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1927d959-1497-4833-8df1-eb5fe73bdce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_084fa4b6-1bbe-4218-b7c2-79d2dfd062ee" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1927d959-1497-4833-8df1-eb5fe73bdce4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_feabcf9b-2ae7-4e01-b31d-20e7013fa453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_084fa4b6-1bbe-4218-b7c2-79d2dfd062ee" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_feabcf9b-2ae7-4e01-b31d-20e7013fa453" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_48f21684-6fd7-4126-8fec-190dfb019fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_084fa4b6-1bbe-4218-b7c2-79d2dfd062ee" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_48f21684-6fd7-4126-8fec-190dfb019fbe" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#CapitalandTreasuryStockChangesinTreasuryStockDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails" xlink:type="extended" id="i0beb6ac921d14763bc38dda57e9cec69_CapitalandTreasuryStockChangesinTreasuryStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9b85989d-a52f-46b7-b664-78b0a8aaa514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e2ffb7be-3daf-46e2-abff-629c6f45856c" xlink:href="jnj-20220102.xsd#jnj_ChangesinTreasuryStockSharesOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9b85989d-a52f-46b7-b664-78b0a8aaa514" xlink:to="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e2ffb7be-3daf-46e2-abff-629c6f45856c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_11462bcf-d496-45a3-88ee-3d3078d7083c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e2ffb7be-3daf-46e2-abff-629c6f45856c" xlink:to="loc_us-gaap_TreasuryStockShares_11462bcf-d496-45a3-88ee-3d3078d7083c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_7333c102-fa42-490c-90d1-bc2d8e9cb1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e2ffb7be-3daf-46e2-abff-629c6f45856c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_7333c102-fa42-490c-90d1-bc2d8e9cb1b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_3ec8b268-c665-4d0f-ba9f-273c6de74931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e2ffb7be-3daf-46e2-abff-629c6f45856c" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_3ec8b268-c665-4d0f-ba9f-273c6de74931" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_f5367d98-7db1-4c32-a3f6-359795f3ea01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockRollForward_fe489b4c-ef8f-480f-9545-fe51d81614b8" xlink:href="jnj-20220102.xsd#jnj_ChangesInTreasuryStockRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9b85989d-a52f-46b7-b664-78b0a8aaa514" xlink:to="loc_jnj_ChangesInTreasuryStockRollForward_fe489b4c-ef8f-480f-9545-fe51d81614b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_89f92cdb-da26-426a-b0b0-a69f7d5c048f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_fe489b4c-ef8f-480f-9545-fe51d81614b8" xlink:to="loc_us-gaap_TreasuryStockValue_89f92cdb-da26-426a-b0b0-a69f7d5c048f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_82a8c3d9-a31a-4540-bed6-fee19ffc6528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_fe489b4c-ef8f-480f-9545-fe51d81614b8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_82a8c3d9-a31a-4540-bed6-fee19ffc6528" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c4e03f1c-dd8d-4bc3-9b8c-ae1717a821fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_fe489b4c-ef8f-480f-9545-fe51d81614b8" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c4e03f1c-dd8d-4bc3-9b8c-ae1717a821fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_f5ea8278-0306-4c4a-93e0-d3b64cf35530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_fbccf097-61d1-4181-a24f-60b99ce0ea29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9b85989d-a52f-46b7-b664-78b0a8aaa514" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_fbccf097-61d1-4181-a24f-60b99ce0ea29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d285773b-9198-4ab4-938c-1cf2bd0dd6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_fbccf097-61d1-4181-a24f-60b99ce0ea29" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d285773b-9198-4ab4-938c-1cf2bd0dd6f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d285773b-9198-4ab4-938c-1cf2bd0dd6f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d285773b-9198-4ab4-938c-1cf2bd0dd6f8" xlink:to="loc_us-gaap_EquityComponentDomain_d285773b-9198-4ab4-938c-1cf2bd0dd6f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6b1925ae-2fa8-42d4-ac90-52f5995faa42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d285773b-9198-4ab4-938c-1cf2bd0dd6f8" xlink:to="loc_us-gaap_EquityComponentDomain_6b1925ae-2fa8-42d4-ac90-52f5995faa42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_69cc47c1-bd1d-47e5-a0ec-916af545258a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6b1925ae-2fa8-42d4-ac90-52f5995faa42" xlink:to="loc_us-gaap_TreasuryStockMember_69cc47c1-bd1d-47e5-a0ec-916af545258a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#CapitalandTreasuryStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails" xlink:type="extended" id="i8feeedb44ed34fcca2d970556eb2c192_CapitalandTreasuryStockNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b12cb2b3-11bd-4299-a4ab-5f4fcc02ae14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d07eaed6-48fa-4d7f-8cea-d22aa9639c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b12cb2b3-11bd-4299-a4ab-5f4fcc02ae14" xlink:to="loc_us-gaap_CommonStockSharesIssued_d07eaed6-48fa-4d7f-8cea-d22aa9639c0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_ca987faf-6383-4501-acb0-c47ce9a00769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b12cb2b3-11bd-4299-a4ab-5f4fcc02ae14" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_ca987faf-6383-4501-acb0-c47ce9a00769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1e171d83-1800-45a3-a78f-050d7bfecaba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b12cb2b3-11bd-4299-a4ab-5f4fcc02ae14" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1e171d83-1800-45a3-a78f-050d7bfecaba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_512ca25a-58f3-4175-b745-d413269a48b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b12cb2b3-11bd-4299-a4ab-5f4fcc02ae14" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_512ca25a-58f3-4175-b745-d413269a48b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_360871e0-86cd-4bb6-baac-3697af48aba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b12cb2b3-11bd-4299-a4ab-5f4fcc02ae14" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_360871e0-86cd-4bb6-baac-3697af48aba9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_fb8ddf3b-e4ec-4223-8e27-3af8024587f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_360871e0-86cd-4bb6-baac-3697af48aba9" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_fb8ddf3b-e4ec-4223-8e27-3af8024587f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_fb8ddf3b-e4ec-4223-8e27-3af8024587f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_fb8ddf3b-e4ec-4223-8e27-3af8024587f7" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_fb8ddf3b-e4ec-4223-8e27-3af8024587f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_df62eda4-75b5-4713-8046-13dd2172a10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_fb8ddf3b-e4ec-4223-8e27-3af8024587f7" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_df62eda4-75b5-4713-8046-13dd2172a10a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_December172018ShareRepurchaseProgramMember_d9371433-b265-4ef0-a334-82ab4ba45bda" xlink:href="jnj-20220102.xsd#jnj_December172018ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_df62eda4-75b5-4713-8046-13dd2172a10a" xlink:to="loc_jnj_December172018ShareRepurchaseProgramMember_d9371433-b265-4ef0-a334-82ab4ba45bda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a662fd8b-559f-4389-9a00-bfcfe1e6d3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_360871e0-86cd-4bb6-baac-3697af48aba9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a662fd8b-559f-4389-9a00-bfcfe1e6d3d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a662fd8b-559f-4389-9a00-bfcfe1e6d3d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a662fd8b-559f-4389-9a00-bfcfe1e6d3d8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a662fd8b-559f-4389-9a00-bfcfe1e6d3d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d2af6935-743b-48b5-86a8-808b9f8c23bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a662fd8b-559f-4389-9a00-bfcfe1e6d3d8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d2af6935-743b-48b5-86a8-808b9f8c23bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_fad2cb43-4522-44c0-ad67-0a2cc9eb59a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d2af6935-743b-48b5-86a8-808b9f8c23bd" xlink:to="loc_us-gaap_SubsequentEventMember_fad2cb43-4522-44c0-ad67-0a2cc9eb59a1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="iaf87f0a759994e53ac1955515862ac21_AccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e8da221-90dd-48f1-a0f2-456708cd217c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_25d102e3-a73a-4058-b23b-cd8a6b0861bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e8da221-90dd-48f1-a0f2-456708cd217c" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_25d102e3-a73a-4058-b23b-cd8a6b0861bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1256680f-e37f-4260-8014-66846000ce5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_25d102e3-a73a-4058-b23b-cd8a6b0861bc" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1256680f-e37f-4260-8014-66846000ce5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e2b5ea38-6e0c-4a41-8867-bcb7fa245e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_25d102e3-a73a-4058-b23b-cd8a6b0861bc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e2b5ea38-6e0c-4a41-8867-bcb7fa245e46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aa515e75-a4a4-4e8a-8837-691df01aa08b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_631f1d92-7c18-4f38-aee2-59f26438bf64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e8da221-90dd-48f1-a0f2-456708cd217c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_631f1d92-7c18-4f38-aee2-59f26438bf64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7e128e51-8229-440f-8544-242e56500fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_631f1d92-7c18-4f38-aee2-59f26438bf64" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7e128e51-8229-440f-8544-242e56500fd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7e128e51-8229-440f-8544-242e56500fd0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7e128e51-8229-440f-8544-242e56500fd0" xlink:to="loc_us-gaap_EquityComponentDomain_7e128e51-8229-440f-8544-242e56500fd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0d20e35a-3cb7-4ca1-831a-e1f931d8030b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7e128e51-8229-440f-8544-242e56500fd0" xlink:to="loc_us-gaap_EquityComponentDomain_0d20e35a-3cb7-4ca1-831a-e1f931d8030b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_e72383d0-f049-40e4-bd6d-af750478e805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0d20e35a-3cb7-4ca1-831a-e1f931d8030b" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_e72383d0-f049-40e4-bd6d-af750478e805" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8f696e51-db72-49e3-803b-8e0f08e0ae75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0d20e35a-3cb7-4ca1-831a-e1f931d8030b" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8f696e51-db72-49e3-803b-8e0f08e0ae75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b2a64f6e-7a30-42fc-9a14-629be59f4426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0d20e35a-3cb7-4ca1-831a-e1f931d8030b" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b2a64f6e-7a30-42fc-9a14-629be59f4426" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_91d581f7-f4f0-4179-a00b-2c6ef5a15957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0d20e35a-3cb7-4ca1-831a-e1f931d8030b" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_91d581f7-f4f0-4179-a00b-2c6ef5a15957" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3aac60fd-6d06-4897-9aa0-06a5ae8388a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0d20e35a-3cb7-4ca1-831a-e1f931d8030b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3aac60fd-6d06-4897-9aa0-06a5ae8388a4" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails" xlink:type="extended" id="ie7f40ad338ae483ca9d7ecb6a4b6d341_CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfStockBasedCompensationPlans_30c91225-7dcd-4f29-9422-aa2a9789b744" xlink:href="jnj-20220102.xsd#jnj_NumberOfStockBasedCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_jnj_NumberOfStockBasedCompensationPlans_30c91225-7dcd-4f29-9422-aa2a9789b744" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_62fed785-614e-4760-8e1f-debd42c0498e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_62fed785-614e-4760-8e1f-debd42c0498e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_07e6eb03-280b-44bd-88f9-d228e44d09db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_07e6eb03-280b-44bd-88f9-d228e44d09db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c34327c0-fc9e-4e00-9d07-08548c0fd914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c34327c0-fc9e-4e00-9d07-08548c0fd914" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_76efac1c-5bfe-4c07-9f7f-b3a25c329464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_76efac1c-5bfe-4c07-9f7f-b3a25c329464" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_0b26febc-adaf-4091-9358-6d2f06511e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_0b26febc-adaf-4091-9358-6d2f06511e5e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a2705571-3228-4c48-ab3e-cc58449b847a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a2705571-3228-4c48-ab3e-cc58449b847a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4ae685fc-f7f5-4dba-8d57-21d75d42cde5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4ae685fc-f7f5-4dba-8d57-21d75d42cde5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8634f5da-4e78-4d68-9904-a06cdfc48e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8634f5da-4e78-4d68-9904-a06cdfc48e17" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dcd3c7fc-0ec8-49db-bc5d-6077988714c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dcd3c7fc-0ec8-49db-bc5d-6077988714c8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dfd0fec9-49a4-4913-879e-487dede7faa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dfd0fec9-49a4-4913-879e-487dede7faa9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_37873ba6-1f3a-47fd-8daa-55c65146802f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_37873ba6-1f3a-47fd-8daa-55c65146802f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_359c4852-6d5e-4a83-8297-601a5b786507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_359c4852-6d5e-4a83-8297-601a5b786507" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_3e2b3cf5-9267-47e5-8efb-77dbdb196b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_3e2b3cf5-9267-47e5-8efb-77dbdb196b17" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_888834bc-73fe-45e3-835c-1d16ecdccc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_888834bc-73fe-45e3-835c-1d16ecdccc6a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1f80b5ce-70e6-4aea-aaa0-4eed6bec9e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1f80b5ce-70e6-4aea-aaa0-4eed6bec9e7c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e0b7dd7a-0759-4950-8c28-742b6c181d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e0b7dd7a-0759-4950-8c28-742b6c181d5b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9d67d782-52e3-4563-92b9-388dad3b0ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9d67d782-52e3-4563-92b9-388dad3b0ccb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9ffcbed2-055d-4604-b36d-575eb73ca4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9ffcbed2-055d-4604-b36d-575eb73ca4a7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5a779d0-45fe-4626-8f21-88f73d0258ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5a779d0-45fe-4626-8f21-88f73d0258ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_e7927db6-7f9e-4af6-bc99-c4613656ae68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5a779d0-45fe-4626-8f21-88f73d0258ba" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_e7927db6-7f9e-4af6-bc99-c4613656ae68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_e7927db6-7f9e-4af6-bc99-c4613656ae68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_e7927db6-7f9e-4af6-bc99-c4613656ae68" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_e7927db6-7f9e-4af6-bc99-c4613656ae68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_651c4d57-3868-45f7-9d2c-de4aa1218ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_e7927db6-7f9e-4af6-bc99-c4613656ae68" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_651c4d57-3868-45f7-9d2c-de4aa1218ca0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2012LongTermIncentivePlanMember_19feef8a-ddcf-4114-a50f-76170a33d391" xlink:href="jnj-20220102.xsd#jnj_A2012LongTermIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_651c4d57-3868-45f7-9d2c-de4aa1218ca0" xlink:to="loc_jnj_A2012LongTermIncentivePlanMember_19feef8a-ddcf-4114-a50f-76170a33d391" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_598bb284-225d-42d7-8679-00b29a3bcbe7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5a779d0-45fe-4626-8f21-88f73d0258ba" xlink:to="loc_srt_RangeAxis_598bb284-225d-42d7-8679-00b29a3bcbe7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_598bb284-225d-42d7-8679-00b29a3bcbe7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_598bb284-225d-42d7-8679-00b29a3bcbe7" xlink:to="loc_srt_RangeMember_598bb284-225d-42d7-8679-00b29a3bcbe7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5fb3d636-be4f-464c-9976-32cc3bfaa7e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_598bb284-225d-42d7-8679-00b29a3bcbe7" xlink:to="loc_srt_RangeMember_5fb3d636-be4f-464c-9976-32cc3bfaa7e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9ed7836d-2cd7-425a-b0ea-70352a9868db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5fb3d636-be4f-464c-9976-32cc3bfaa7e4" xlink:to="loc_srt_MinimumMember_9ed7836d-2cd7-425a-b0ea-70352a9868db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_408735e5-8136-4fba-a9f5-74024721d240" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5fb3d636-be4f-464c-9976-32cc3bfaa7e4" xlink:to="loc_srt_MaximumMember_408735e5-8136-4fba-a9f5-74024721d240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b08ed20c-6076-44a6-99a0-c3eb4391b77d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5a779d0-45fe-4626-8f21-88f73d0258ba" xlink:to="loc_us-gaap_AwardTypeAxis_b08ed20c-6076-44a6-99a0-c3eb4391b77d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b08ed20c-6076-44a6-99a0-c3eb4391b77d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b08ed20c-6076-44a6-99a0-c3eb4391b77d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b08ed20c-6076-44a6-99a0-c3eb4391b77d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_821e3a21-027d-4388-8147-6ed919f9fc46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b08ed20c-6076-44a6-99a0-c3eb4391b77d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_821e3a21-027d-4388-8147-6ed919f9fc46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c47bff87-0a3a-4879-9d7f-892d7bcc0329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_821e3a21-027d-4388-8147-6ed919f9fc46" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c47bff87-0a3a-4879-9d7f-892d7bcc0329" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_34c59b3c-5329-467e-b5b6-0491f956c90b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_821e3a21-027d-4388-8147-6ed919f9fc46" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_34c59b3c-5329-467e-b5b6-0491f956c90b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_725bf1cb-6140-4ebc-b4e7-7f53d1038320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_821e3a21-027d-4388-8147-6ed919f9fc46" xlink:to="loc_us-gaap_PerformanceSharesMember_725bf1cb-6140-4ebc-b4e7-7f53d1038320" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails" xlink:type="extended" id="i1034c21d55874afc9caf29ed04a2090a_CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_52e50713-9939-4d79-bb7b-6bc961dbcbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_debf45ab-14e1-460d-ab4d-b577a2042512" xlink:href="jnj-20220102.xsd#jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_52e50713-9939-4d79-bb7b-6bc961dbcbbc" xlink:to="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_debf45ab-14e1-460d-ab4d-b577a2042512" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_f60c65ba-711d-4026-9150-4c85537c57d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_debf45ab-14e1-460d-ab4d-b577a2042512" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_f60c65ba-711d-4026-9150-4c85537c57d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_0c0c52ea-3892-43d4-a05a-38dfdba940bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_debf45ab-14e1-460d-ab4d-b577a2042512" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_0c0c52ea-3892-43d4-a05a-38dfdba940bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_d0e73812-f5e0-4f5f-a17f-460c04026b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_debf45ab-14e1-460d-ab4d-b577a2042512" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_d0e73812-f5e0-4f5f-a17f-460c04026b7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_c626390d-243e-4bdf-8a2b-48993c9fd049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_debf45ab-14e1-460d-ab4d-b577a2042512" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_c626390d-243e-4bdf-8a2b-48993c9fd049" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_56ee6758-af09-493d-8f3a-c09a76df84d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_debf45ab-14e1-460d-ab4d-b577a2042512" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_56ee6758-af09-493d-8f3a-c09a76df84d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_382e296d-507e-49c9-a1b5-c87647dc65e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_debf45ab-14e1-460d-ab4d-b577a2042512" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_382e296d-507e-49c9-a1b5-c87647dc65e1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_e2f743ae-bc16-427a-9727-20dabf5423a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_debf45ab-14e1-460d-ab4d-b577a2042512" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_e2f743ae-bc16-427a-9727-20dabf5423a1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_06e479c2-9a16-4b40-8cb3-437ffa9429ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_52e50713-9939-4d79-bb7b-6bc961dbcbbc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_06e479c2-9a16-4b40-8cb3-437ffa9429ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2ed6c11e-db3a-4a98-999e-445a46324b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_06e479c2-9a16-4b40-8cb3-437ffa9429ca" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2ed6c11e-db3a-4a98-999e-445a46324b1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2ed6c11e-db3a-4a98-999e-445a46324b1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2ed6c11e-db3a-4a98-999e-445a46324b1f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2ed6c11e-db3a-4a98-999e-445a46324b1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3956bd29-d8f6-4ff9-a9f2-f42c29417cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2ed6c11e-db3a-4a98-999e-445a46324b1f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3956bd29-d8f6-4ff9-a9f2-f42c29417cd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeOneMember_fa43e8cc-8d84-4280-991e-0ffcbe34ae00" xlink:href="jnj-20220102.xsd#jnj_ExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3956bd29-d8f6-4ff9-a9f2-f42c29417cd3" xlink:to="loc_jnj_ExercisePriceRangeOneMember_fa43e8cc-8d84-4280-991e-0ffcbe34ae00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeTwoMember_2cabfc1d-f70e-4321-b717-731a6afcf38a" xlink:href="jnj-20220102.xsd#jnj_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3956bd29-d8f6-4ff9-a9f2-f42c29417cd3" xlink:to="loc_jnj_ExercisePriceRangeTwoMember_2cabfc1d-f70e-4321-b717-731a6afcf38a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeThreeMember_4e3253a4-c464-4527-b5ed-d28a8b62e269" xlink:href="jnj-20220102.xsd#jnj_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3956bd29-d8f6-4ff9-a9f2-f42c29417cd3" xlink:to="loc_jnj_ExercisePriceRangeThreeMember_4e3253a4-c464-4527-b5ed-d28a8b62e269" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFourMember_218771bc-df0f-418c-bb51-8c9b0a7eb9c4" xlink:href="jnj-20220102.xsd#jnj_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3956bd29-d8f6-4ff9-a9f2-f42c29417cd3" xlink:to="loc_jnj_ExercisePriceRangeFourMember_218771bc-df0f-418c-bb51-8c9b0a7eb9c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFiveMember_76884699-1528-4ae6-af05-1a02928d98bb" xlink:href="jnj-20220102.xsd#jnj_ExercisePriceRangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3956bd29-d8f6-4ff9-a9f2-f42c29417cd3" xlink:to="loc_jnj_ExercisePriceRangeFiveMember_76884699-1528-4ae6-af05-1a02928d98bb" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails" xlink:type="extended" id="ie1cdf40ce31549df9aed58f0b02b284a_CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2042abd1-0f21-4d2a-84f6-f828f72802f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_29cd24ef-c56b-4134-9f40-39a47128af99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2042abd1-0f21-4d2a-84f6-f828f72802f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_29cd24ef-c56b-4134-9f40-39a47128af99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9056f3bb-89e9-4791-bd9a-d47ad8ea53f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_29cd24ef-c56b-4134-9f40-39a47128af99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9056f3bb-89e9-4791-bd9a-d47ad8ea53f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7097cb22-04ae-42b4-ba86-8307d0328bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9056f3bb-89e9-4791-bd9a-d47ad8ea53f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7097cb22-04ae-42b4-ba86-8307d0328bd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ccb12b44-5c7c-4bcd-aca9-2121f4bcc253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9056f3bb-89e9-4791-bd9a-d47ad8ea53f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ccb12b44-5c7c-4bcd-aca9-2121f4bcc253" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_426cb757-b470-4baa-9ff7-fb537adda9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9056f3bb-89e9-4791-bd9a-d47ad8ea53f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_426cb757-b470-4baa-9ff7-fb537adda9b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_51f6748d-cd1e-4757-8a9f-65ee0db55369" xlink:href="jnj-20220102.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9056f3bb-89e9-4791-bd9a-d47ad8ea53f2" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_51f6748d-cd1e-4757-8a9f-65ee0db55369" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f3a0fa1b-f694-443c-a54d-3a85aca86c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6fc2dc7-beeb-4508-88ad-1207e812d0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2042abd1-0f21-4d2a-84f6-f828f72802f7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6fc2dc7-beeb-4508-88ad-1207e812d0b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_31ac8ada-425b-4a9b-a0fd-c2a7632cc8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6fc2dc7-beeb-4508-88ad-1207e812d0b4" xlink:to="loc_us-gaap_AwardTypeAxis_31ac8ada-425b-4a9b-a0fd-c2a7632cc8a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31ac8ada-425b-4a9b-a0fd-c2a7632cc8a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_31ac8ada-425b-4a9b-a0fd-c2a7632cc8a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31ac8ada-425b-4a9b-a0fd-c2a7632cc8a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8571caea-11ff-4495-8b79-1f9353991158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_31ac8ada-425b-4a9b-a0fd-c2a7632cc8a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8571caea-11ff-4495-8b79-1f9353991158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_669c2fbb-551d-4fdf-94d6-2f36ee94492f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8571caea-11ff-4495-8b79-1f9353991158" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_669c2fbb-551d-4fdf-94d6-2f36ee94492f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6353170a-b2fd-4505-836d-8a02497e8190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8571caea-11ff-4495-8b79-1f9353991158" xlink:to="loc_us-gaap_PerformanceSharesMember_6353170a-b2fd-4505-836d-8a02497e8190" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" xlink:type="extended" id="ie7db1a92276742f1b2b785d7dc370e4b_SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c5dc9ab2-d99c-474f-ad57-dec021b97ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9b8ea337-087e-462d-9247-fc012f5a0d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c5dc9ab2-d99c-474f-ad57-dec021b97ac1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9b8ea337-087e-462d-9247-fc012f5a0d71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_1e00c1b6-357d-4003-abcc-b351fe09c031" xlink:href="jnj-20220102.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c5dc9ab2-d99c-474f-ad57-dec021b97ac1" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_1e00c1b6-357d-4003-abcc-b351fe09c031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_147367e5-c24f-4005-b31b-7a0b13ef4ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c5dc9ab2-d99c-474f-ad57-dec021b97ac1" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_147367e5-c24f-4005-b31b-7a0b13ef4ecc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_bbd97f9c-73b5-4d7a-aebd-ae1b58932874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_147367e5-c24f-4005-b31b-7a0b13ef4ecc" xlink:to="loc_us-gaap_LitigationStatusAxis_bbd97f9c-73b5-4d7a-aebd-ae1b58932874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_bbd97f9c-73b5-4d7a-aebd-ae1b58932874_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_bbd97f9c-73b5-4d7a-aebd-ae1b58932874" xlink:to="loc_us-gaap_LitigationStatusDomain_bbd97f9c-73b5-4d7a-aebd-ae1b58932874_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_9166e095-dbdb-474e-8f44-975c480cb568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_bbd97f9c-73b5-4d7a-aebd-ae1b58932874" xlink:to="loc_us-gaap_LitigationStatusDomain_9166e095-dbdb-474e-8f44-975c480cb568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_06ef5537-bd5d-4c80-a9eb-bc3a7a3911e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_9166e095-dbdb-474e-8f44-975c480cb568" xlink:to="loc_us-gaap_PendingLitigationMember_06ef5537-bd5d-4c80-a9eb-bc3a7a3911e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a321b9d2-8bd5-47fc-96fd-03e383a751b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_147367e5-c24f-4005-b31b-7a0b13ef4ecc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a321b9d2-8bd5-47fc-96fd-03e383a751b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a321b9d2-8bd5-47fc-96fd-03e383a751b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a321b9d2-8bd5-47fc-96fd-03e383a751b4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a321b9d2-8bd5-47fc-96fd-03e383a751b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_260034c1-104e-4569-837c-f3360bd423a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a321b9d2-8bd5-47fc-96fd-03e383a751b4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_260034c1-104e-4569-837c-f3360bd423a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_28e5c97d-02f8-43a5-9165-7ecb0a477dc3" xlink:href="jnj-20220102.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_260034c1-104e-4569-837c-f3360bd423a4" xlink:to="loc_jnj_AurisHealthMember_28e5c97d-02f8-43a5-9165-7ecb0a477dc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e42fb96c-0a96-4339-a683-280e6662115a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_147367e5-c24f-4005-b31b-7a0b13ef4ecc" xlink:to="loc_srt_StatementGeographicalAxis_e42fb96c-0a96-4339-a683-280e6662115a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e42fb96c-0a96-4339-a683-280e6662115a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e42fb96c-0a96-4339-a683-280e6662115a" xlink:to="loc_srt_SegmentGeographicalDomain_e42fb96c-0a96-4339-a683-280e6662115a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6d44f825-fea9-4d26-8767-dfd83519764e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e42fb96c-0a96-4339-a683-280e6662115a" xlink:to="loc_srt_SegmentGeographicalDomain_6d44f825-fea9-4d26-8767-dfd83519764e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_70e20403-e59a-48eb-84f6-56fa587f9c7f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6d44f825-fea9-4d26-8767-dfd83519764e" xlink:to="loc_country_US_70e20403-e59a-48eb-84f6-56fa587f9c7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_4c5dbd5d-f8a8-4904-8a34-2b0990606170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6d44f825-fea9-4d26-8767-dfd83519764e" xlink:to="loc_us-gaap_NonUsMember_4c5dbd5d-f8a8-4904-8a34-2b0990606170" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_41c666e0-ee62-4b7c-a5bc-9114139b6a6c" xlink:href="jnj-20220102.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6d44f825-fea9-4d26-8767-dfd83519764e" xlink:to="loc_jnj_UNITEDSTATESExportsMember_41c666e0-ee62-4b7c-a5bc-9114139b6a6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0f7611aa-94cf-49af-aee5-6d44447415bd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_147367e5-c24f-4005-b31b-7a0b13ef4ecc" xlink:to="loc_srt_ProductOrServiceAxis_0f7611aa-94cf-49af-aee5-6d44447415bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0f7611aa-94cf-49af-aee5-6d44447415bd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0f7611aa-94cf-49af-aee5-6d44447415bd" xlink:to="loc_srt_ProductsAndServicesDomain_0f7611aa-94cf-49af-aee5-6d44447415bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0f7611aa-94cf-49af-aee5-6d44447415bd" xlink:to="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_9b2f271d-fef7-456e-a59a-ee6a1e5c195f" xlink:href="jnj-20220102.xsd#jnj_OTCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_OTCMember_9b2f271d-fef7-456e-a59a-ee6a1e5c195f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SkinHealthBeautyMember_812e41e6-0612-44d2-9a12-18600f8ee89c" xlink:href="jnj-20220102.xsd#jnj_SkinHealthBeautyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_SkinHealthBeautyMember_812e41e6-0612-44d2-9a12-18600f8ee89c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_9cb6648d-a4aa-4882-b7e7-8ab6144af262" xlink:href="jnj-20220102.xsd#jnj_OralCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_OralCareMember_9cb6648d-a4aa-4882-b7e7-8ab6144af262" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_ec09e638-62e0-42ba-9303-9aebe71c7907" xlink:href="jnj-20220102.xsd#jnj_BabyCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_BabyCareMember_ec09e638-62e0-42ba-9303-9aebe71c7907" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember_f4197ae7-e749-4e18-bdb6-3e62a8278f89" xlink:href="jnj-20220102.xsd#jnj_WomensHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_WomensHealthMember_f4197ae7-e749-4e18-bdb6-3e62a8278f89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember_d9eefbe1-da2d-4cbb-b340-5c2a7bdf0317" xlink:href="jnj-20220102.xsd#jnj_WoundCareandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_WoundCareandOtherMember_d9eefbe1-da2d-4cbb-b340-5c2a7bdf0317" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_12fa329a-d249-4316-af06-d07210b2d312" xlink:href="jnj-20220102.xsd#jnj_RemicadeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_RemicadeMember_12fa329a-d249-4316-af06-d07210b2d312" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_2d1f04e0-6bb6-4091-9be2-6fa0bcf7e712" xlink:href="jnj-20220102.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_SimponiSimponiAriaMember_2d1f04e0-6bb6-4091-9be2-6fa0bcf7e712" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_c6f7d91c-8ffa-48cc-b834-3d96f12777fe" xlink:href="jnj-20220102.xsd#jnj_StelaraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_StelaraMember_c6f7d91c-8ffa-48cc-b834-3d96f12777fe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_8be61d63-ecc5-4d10-b89e-eb19519e8949" xlink:href="jnj-20220102.xsd#jnj_TremfyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_TremfyaMember_8be61d63-ecc5-4d10-b89e-eb19519e8949" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_4772d9bf-dc7b-48c0-b462-7a56018dac56" xlink:href="jnj-20220102.xsd#jnj_OtherImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_OtherImmunologyMember_4772d9bf-dc7b-48c0-b462-7a56018dac56" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member_261caf24-7d43-446d-9c53-28417050c402" xlink:href="jnj-20220102.xsd#jnj_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_COVID19Member_261caf24-7d43-446d-9c53-28417050c402" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_622d4ea8-153a-47b7-a280-6764da89dae4" xlink:href="jnj-20220102.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_EDURANTrilpivirineMember_622d4ea8-153a-47b7-a280-6764da89dae4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_87815bcf-2240-4391-9b48-38bb4fd81124" xlink:href="jnj-20220102.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_87815bcf-2240-4391-9b48-38bb4fd81124" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_8d650c0c-e7ee-4fa2-ae61-57bed043a943" xlink:href="jnj-20220102.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_8d650c0c-e7ee-4fa2-ae61-57bed043a943" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_4ddfcb7f-60ff-4fd9-91af-7819c36f00f6" xlink:href="jnj-20220102.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_4ddfcb7f-60ff-4fd9-91af-7819c36f00f6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_c2bafc5b-4582-43af-a345-afb92be26efe" xlink:href="jnj-20220102.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_c2bafc5b-4582-43af-a345-afb92be26efe" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember_28754b39-2426-4541-869e-addb7783fd3e" xlink:href="jnj-20220102.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_RISPERDALCONSTAMember_28754b39-2426-4541-869e-addb7783fd3e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_704d7cc7-37a3-4bf6-9335-0524d7bb4ccd" xlink:href="jnj-20220102.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_704d7cc7-37a3-4bf6-9335-0524d7bb4ccd" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_40ee56e7-65a2-485f-b947-c271d67bd601" xlink:href="jnj-20220102.xsd#jnj_DARZALEXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_DARZALEXMember_40ee56e7-65a2-485f-b947-c271d67bd601" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ErleadaMember_1d9b2ea6-0dfe-47ed-a402-34f9bbe2ec8c" xlink:href="jnj-20220102.xsd#jnj_ErleadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_ErleadaMember_1d9b2ea6-0dfe-47ed-a402-34f9bbe2ec8c" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_df081a24-0238-4a9b-901e-637f3597137e" xlink:href="jnj-20220102.xsd#jnj_IMBRUVICAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_IMBRUVICAMember_df081a24-0238-4a9b-901e-637f3597137e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_6e777624-688f-4e76-9e9a-b34ab869dc9a" xlink:href="jnj-20220102.xsd#jnj_ZYTIGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_ZYTIGAMember_6e777624-688f-4e76-9e9a-b34ab869dc9a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_2778060c-9427-4a21-a1c2-5b6250897797" xlink:href="jnj-20220102.xsd#jnj_OtherOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_OtherOncologyMember_2778060c-9427-4a21-a1c2-5b6250897797" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_6b321631-5d2a-4bdc-8d2c-acd6565653f9" xlink:href="jnj-20220102.xsd#jnj_OPSUMITMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_OPSUMITMember_6b321631-5d2a-4bdc-8d2c-acd6565653f9" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_5a82cd4e-6d35-4655-8285-1f3d2f3f3145" xlink:href="jnj-20220102.xsd#jnj_UPTRAVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_UPTRAVIMember_5a82cd4e-6d35-4655-8285-1f3d2f3f3145" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_c8583e40-dac4-43dd-9fad-d45a8e95c816" xlink:href="jnj-20220102.xsd#jnj_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_OtherMember_c8583e40-dac4-43dd-9fad-d45a8e95c816" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_0731547e-ac4d-42ce-8d43-87b1c4d1118e" xlink:href="jnj-20220102.xsd#jnj_XareltoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_XareltoMember_0731547e-ac4d-42ce-8d43-87b1c4d1118e" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember_527a6bc8-0b27-41fc-9b66-31afa7aa6591" xlink:href="jnj-20220102.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_INVOKANAINVOKAMETMember_527a6bc8-0b27-41fc-9b66-31afa7aa6591" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PROCRITEPREXMember_cac1b266-788c-48e4-b55e-3d02c7a388b4" xlink:href="jnj-20220102.xsd#jnj_PROCRITEPREXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_PROCRITEPREXMember_cac1b266-788c-48e4-b55e-3d02c7a388b4" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_11d818a7-abc7-444d-b907-2475c50b6829" xlink:href="jnj-20220102.xsd#jnj_HIPSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_HIPSMember_11d818a7-abc7-444d-b907-2475c50b6829" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_150a7a0e-04bf-43e6-9cbe-6c6b3476ebac" xlink:href="jnj-20220102.xsd#jnj_KNEESMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_KNEESMember_150a7a0e-04bf-43e6-9cbe-6c6b3476ebac" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_a1e1aa32-0024-46f5-a31e-7dbea5c5138f" xlink:href="jnj-20220102.xsd#jnj_TRAUMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_TRAUMAMember_a1e1aa32-0024-46f5-a31e-7dbea5c5138f" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINESPORTSOTHERMember_5ab45f14-306c-402b-b9dc-4d4e51838af1" xlink:href="jnj-20220102.xsd#jnj_SPINESPORTSOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_SPINESPORTSOTHERMember_5ab45f14-306c-402b-b9dc-4d4e51838af1" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_bdf56529-8661-4ed2-ae58-e263a08ce8e0" xlink:href="jnj-20220102.xsd#jnj_ADVANCEDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_ADVANCEDMember_bdf56529-8661-4ed2-ae58-e263a08ce8e0" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_44e9b292-59ce-438c-8af1-27095bd675d6" xlink:href="jnj-20220102.xsd#jnj_GENERALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_GENERALMember_44e9b292-59ce-438c-8af1-27095bd675d6" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_697527f7-39bc-4ea2-bb78-3b4b8ba2c158" xlink:href="jnj-20220102.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_697527f7-39bc-4ea2-bb78-3b4b8ba2c158" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_8634cfce-65f3-418e-ac50-b2899041532f" xlink:href="jnj-20220102.xsd#jnj_SURGICALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_SURGICALMember_8634cfce-65f3-418e-ac50-b2899041532f" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_49e7963b-5c58-4977-acbc-929eb10a9e49" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_147367e5-c24f-4005-b31b-7a0b13ef4ecc" xlink:to="loc_srt_ConsolidationItemsAxis_49e7963b-5c58-4977-acbc-929eb10a9e49" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_49e7963b-5c58-4977-acbc-929eb10a9e49_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_49e7963b-5c58-4977-acbc-929eb10a9e49" xlink:to="loc_srt_ConsolidationItemsDomain_49e7963b-5c58-4977-acbc-929eb10a9e49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_6ac18646-3ce1-4205-9fd1-9b2904bd211d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_49e7963b-5c58-4977-acbc-929eb10a9e49" xlink:to="loc_srt_ConsolidationItemsDomain_6ac18646-3ce1-4205-9fd1-9b2904bd211d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8a8e59a3-7f4e-4809-94d6-6be735dc84ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_147367e5-c24f-4005-b31b-7a0b13ef4ecc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8a8e59a3-7f4e-4809-94d6-6be735dc84ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8a8e59a3-7f4e-4809-94d6-6be735dc84ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8a8e59a3-7f4e-4809-94d6-6be735dc84ce" xlink:to="loc_us-gaap_SegmentDomain_8a8e59a3-7f4e-4809-94d6-6be735dc84ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_105ec90a-1aa3-4f30-98a3-d94b8952156e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8a8e59a3-7f4e-4809-94d6-6be735dc84ce" xlink:to="loc_us-gaap_SegmentDomain_105ec90a-1aa3-4f30-98a3-d94b8952156e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_0aa39418-f174-43a2-b4aa-829cc6b1efd3" xlink:href="jnj-20220102.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_105ec90a-1aa3-4f30-98a3-d94b8952156e" xlink:to="loc_jnj_ConsumerMember_0aa39418-f174-43a2-b4aa-829cc6b1efd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_3f27af5c-71a6-46a9-a8b9-cd5dc470d43e" xlink:href="jnj-20220102.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_105ec90a-1aa3-4f30-98a3-d94b8952156e" xlink:to="loc_jnj_PharmaceuticalMember_3f27af5c-71a6-46a9-a8b9-cd5dc470d43e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_8c3e05c4-f81f-4800-a336-ad05c2f0579f" xlink:href="jnj-20220102.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_105ec90a-1aa3-4f30-98a3-d94b8952156e" xlink:to="loc_jnj_MedicalDevicesMember_8c3e05c4-f81f-4800-a336-ad05c2f0579f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_c403bf8a-d42c-4162-a863-a197ed0fcd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_147367e5-c24f-4005-b31b-7a0b13ef4ecc" xlink:to="loc_us-gaap_SubsegmentsAxis_c403bf8a-d42c-4162-a863-a197ed0fcd5f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_c403bf8a-d42c-4162-a863-a197ed0fcd5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_c403bf8a-d42c-4162-a863-a197ed0fcd5f" xlink:to="loc_us-gaap_SubsegmentsDomain_c403bf8a-d42c-4162-a863-a197ed0fcd5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_c403bf8a-d42c-4162-a863-a197ed0fcd5f" xlink:to="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_219ae4cd-683f-419a-9296-24b8bc8fa837" xlink:href="jnj-20220102.xsd#jnj_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_ImmunologyMember_219ae4cd-683f-419a-9296-24b8bc8fa837" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_b1556862-4b42-4284-a8da-180ddd7727db" xlink:href="jnj-20220102.xsd#jnj_InfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_InfectiousDiseasesMember_b1556862-4b42-4284-a8da-180ddd7727db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_0b2fa3c0-5035-4d49-82ed-0178970217a5" xlink:href="jnj-20220102.xsd#jnj_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_NeuroscienceMember_0b2fa3c0-5035-4d49-82ed-0178970217a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_8ec0ea58-2d4d-4474-86e0-abfedf663637" xlink:href="jnj-20220102.xsd#jnj_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_OncologyMember_8ec0ea58-2d4d-4474-86e0-abfedf663637" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_a1c56043-a0e7-472c-9fb1-6868c2040787" xlink:href="jnj-20220102.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_PulmonaryHypertensionMember_a1c56043-a0e7-472c-9fb1-6868c2040787" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_0e9d6059-647c-4d0f-9128-68b8c073a873" xlink:href="jnj-20220102.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_0e9d6059-647c-4d0f-9128-68b8c073a873" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_2921cfb4-4e39-4763-ace2-4361c590bb6a" xlink:href="jnj-20220102.xsd#jnj_InterventionalSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_InterventionalSolutionsMember_2921cfb4-4e39-4763-ace2-4361c590bb6a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_ecb2eca6-9590-4490-b992-63adaac15d51" xlink:href="jnj-20220102.xsd#jnj_OrthopaedicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_OrthopaedicsMember_ecb2eca6-9590-4490-b992-63adaac15d51" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_818b3009-eaf6-4fbb-8020-80efb44209bc" xlink:href="jnj-20220102.xsd#jnj_SurgeryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_SurgeryMember_818b3009-eaf6-4fbb-8020-80efb44209bc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_d3aa1207-720e-49d7-bc13-e41ec5f9d2a2" xlink:href="jnj-20220102.xsd#jnj_VisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_VisionMember_d3aa1207-720e-49d7-bc13-e41ec5f9d2a2" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" xlink:type="extended" id="ib3fb4e1662ca4c37a338fdd5850c66de_SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1c834141-20ab-4efc-a5e8-0d5dfd425d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1c834141-20ab-4efc-a5e8-0d5dfd425d48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExpenseNotAllocatedToSegments_17cc43a5-65a5-4535-8e5f-791165482b40" xlink:href="jnj-20220102.xsd#jnj_ExpenseNotAllocatedToSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_jnj_ExpenseNotAllocatedToSegments_17cc43a5-65a5-4535-8e5f-791165482b40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_126cd655-eef3-4bea-8108-5d2986b464e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_Assets_126cd655-eef3-4bea-8108-5d2986b464e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_541ab24c-8edd-414f-8c86-f5a94bf58f11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_541ab24c-8edd-414f-8c86-f5a94bf58f11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_01ab0d36-2c91-4313-bb28-db10f3171e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_01ab0d36-2c91-4313-bb28-db10f3171e3a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_722e315f-7ab6-419b-b8b5-7ab211ed14ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_722e315f-7ab6-419b-b8b5-7ab211ed14ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_f4614bc7-00d7-4c16-b9f9-79a0fe06c200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_NoncurrentAssets_f4614bc7-00d7-4c16-b9f9-79a0fe06c200" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonLongLivedAssets_69d69abd-15ee-4e53-851b-040633a36760" xlink:href="jnj-20220102.xsd#jnj_OtherNonLongLivedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_jnj_OtherNonLongLivedAssets_69d69abd-15ee-4e53-851b-040633a36760" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b7fd6498-c806-4a2c-a30c-06622a76ef0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b7fd6498-c806-4a2c-a30c-06622a76ef0e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_012aaf69-0cdf-4cde-8036-2c83b88ce68f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_NumberOfOperatingSegments_012aaf69-0cdf-4cde-8036-2c83b88ce68f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_93013be2-f83c-460c-8fae-f3771673717e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_LitigationSettlementExpense_93013be2-f83c-460c-8fae-f3771673717e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_46579bf2-efdc-4b6d-bec4-bce86535f8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_RestructuringCharges_46579bf2-efdc-4b6d-bec4-bce86535f8e7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_7031a851-f238-491e-af90-00d5183f2c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_7031a851-f238-491e-af90-00d5183f2c0d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_788f24d8-d8fb-4bbe-8d52-8c9315a4c70e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_788f24d8-d8fb-4bbe-8d52-8c9315a4c70e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_64c5bd15-baaf-4219-bcbb-23df6c7ce810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_64c5bd15-baaf-4219-bcbb-23df6c7ce810" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RegulationCharge_4c39f1c7-6be9-4de7-9f2b-2138b5d32624" xlink:href="jnj-20220102.xsd#jnj_RegulationCharge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_jnj_RegulationCharge_4c39f1c7-6be9-4de7-9f2b-2138b5d32624" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_55c7f224-5b1f-4c9f-98fe-10aeca1c5f03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_55c7f224-5b1f-4c9f-98fe-10aeca1c5f03" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_120e2aab-b964-4c1b-abba-6f08bdb402e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_120e2aab-b964-4c1b-abba-6f08bdb402e1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfEquityInvestments_785a2cc3-c99e-4359-8245-ca9bd7ec59d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_GainLossOnSaleOfEquityInvestments_785a2cc3-c99e-4359-8245-ca9bd7ec59d0" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_47be4a72-f4dc-41e1-adaa-ed0e9ef1624f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_47be4a72-f4dc-41e1-adaa-ed0e9ef1624f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_18b3e5cc-3376-493d-83cd-c67f5b64a4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_18b3e5cc-3376-493d-83cd-c67f5b64a4eb" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_42684399-82b6-4896-8ee5-e916637dc833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_42684399-82b6-4896-8ee5-e916637dc833" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_8f30f70e-2e46-4413-aa24-b22efcb892a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_us-gaap_SubsegmentsAxis_8f30f70e-2e46-4413-aa24-b22efcb892a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_8f30f70e-2e46-4413-aa24-b22efcb892a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_8f30f70e-2e46-4413-aa24-b22efcb892a7" xlink:to="loc_us-gaap_SubsegmentsDomain_8f30f70e-2e46-4413-aa24-b22efcb892a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_f45f9877-b3bf-46cf-a590-bcf84f326331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_8f30f70e-2e46-4413-aa24-b22efcb892a7" xlink:to="loc_us-gaap_SubsegmentsDomain_f45f9877-b3bf-46cf-a590-bcf84f326331" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_33828dec-2069-454c-90e8-a8768a9b91ce" xlink:href="jnj-20220102.xsd#jnj_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_f45f9877-b3bf-46cf-a590-bcf84f326331" xlink:to="loc_jnj_ImmunologyMember_33828dec-2069-454c-90e8-a8768a9b91ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_41f44034-8d52-4287-a872-066d6fa466ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_srt_ConsolidationItemsAxis_41f44034-8d52-4287-a872-066d6fa466ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_41f44034-8d52-4287-a872-066d6fa466ed_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_41f44034-8d52-4287-a872-066d6fa466ed" xlink:to="loc_srt_ConsolidationItemsDomain_41f44034-8d52-4287-a872-066d6fa466ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ee9c2903-a756-43f9-92bd-27b158953d1d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_41f44034-8d52-4287-a872-066d6fa466ed" xlink:to="loc_srt_ConsolidationItemsDomain_ee9c2903-a756-43f9-92bd-27b158953d1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_57412fc4-4179-40e0-a2b1-1c55057d3802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ee9c2903-a756-43f9-92bd-27b158953d1d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_57412fc4-4179-40e0-a2b1-1c55057d3802" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_3a7a4a9f-ceec-4754-acc2-31bfc36429f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ee9c2903-a756-43f9-92bd-27b158953d1d" xlink:to="loc_us-gaap_OperatingSegmentsMember_3a7a4a9f-ceec-4754-acc2-31bfc36429f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_70ebb1e9-a8b8-4a49-b16a-cee962f6f612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_70ebb1e9-a8b8-4a49-b16a-cee962f6f612" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_70ebb1e9-a8b8-4a49-b16a-cee962f6f612_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_70ebb1e9-a8b8-4a49-b16a-cee962f6f612" xlink:to="loc_us-gaap_SegmentDomain_70ebb1e9-a8b8-4a49-b16a-cee962f6f612_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_96a19212-fd62-4b60-97fe-ef2aabdea56b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_70ebb1e9-a8b8-4a49-b16a-cee962f6f612" xlink:to="loc_us-gaap_SegmentDomain_96a19212-fd62-4b60-97fe-ef2aabdea56b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GeneralCorporateMember_c9247cf1-b6a9-415c-a662-f4c2a1ed9bd3" xlink:href="jnj-20220102.xsd#jnj_GeneralCorporateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_96a19212-fd62-4b60-97fe-ef2aabdea56b" xlink:to="loc_jnj_GeneralCorporateMember_c9247cf1-b6a9-415c-a662-f4c2a1ed9bd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_d12f5692-fefd-461f-9484-21ecc64cd743" xlink:href="jnj-20220102.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_96a19212-fd62-4b60-97fe-ef2aabdea56b" xlink:to="loc_jnj_ConsumerMember_d12f5692-fefd-461f-9484-21ecc64cd743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_d0bd3044-6743-4cce-a612-800000b8dd97" xlink:href="jnj-20220102.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_96a19212-fd62-4b60-97fe-ef2aabdea56b" xlink:to="loc_jnj_PharmaceuticalMember_d0bd3044-6743-4cce-a612-800000b8dd97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_5e322cac-8581-49d6-b5f7-c505c1af97f6" xlink:href="jnj-20220102.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_96a19212-fd62-4b60-97fe-ef2aabdea56b" xlink:to="loc_jnj_MedicalDevicesMember_5e322cac-8581-49d6-b5f7-c505c1af97f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SegmentsTotalMember_d9095ab2-f7ca-4cea-acf8-c54d14f10421" xlink:href="jnj-20220102.xsd#jnj_SegmentsTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_96a19212-fd62-4b60-97fe-ef2aabdea56b" xlink:to="loc_jnj_SegmentsTotalMember_d9095ab2-f7ca-4cea-acf8-c54d14f10421" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cc2b82ae-3e7a-4966-9c84-bdab6b0e7a31" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_srt_StatementGeographicalAxis_cc2b82ae-3e7a-4966-9c84-bdab6b0e7a31" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cc2b82ae-3e7a-4966-9c84-bdab6b0e7a31_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_cc2b82ae-3e7a-4966-9c84-bdab6b0e7a31" xlink:to="loc_srt_SegmentGeographicalDomain_cc2b82ae-3e7a-4966-9c84-bdab6b0e7a31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c7c80bd7-af03-46d8-a3b4-3bf7659baca0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_cc2b82ae-3e7a-4966-9c84-bdab6b0e7a31" xlink:to="loc_srt_SegmentGeographicalDomain_c7c80bd7-af03-46d8-a3b4-3bf7659baca0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ac0d685c-dc99-44e0-9647-a1dd71197f6e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c7c80bd7-af03-46d8-a3b4-3bf7659baca0" xlink:to="loc_country_US_ac0d685c-dc99-44e0-9647-a1dd71197f6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_5cf18cef-4488-424c-9ecb-bc478ff999d9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c7c80bd7-af03-46d8-a3b4-3bf7659baca0" xlink:to="loc_srt_EuropeMember_5cf18cef-4488-424c-9ecb-bc478ff999d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_29904e72-098c-40b2-a147-c1de5258d205" xlink:href="jnj-20220102.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c7c80bd7-af03-46d8-a3b4-3bf7659baca0" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_29904e72-098c-40b2-a147-c1de5258d205" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_ea9c7d4a-4949-4e38-8853-ee93daee15cf" xlink:href="jnj-20220102.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c7c80bd7-af03-46d8-a3b4-3bf7659baca0" xlink:to="loc_jnj_AsiaPacificAfricaMember_ea9c7d4a-4949-4e38-8853-ee93daee15cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e507cd4b-11f8-4220-bb25-90f8cdd5594a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_srt_MajorCustomersAxis_e507cd4b-11f8-4220-bb25-90f8cdd5594a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e507cd4b-11f8-4220-bb25-90f8cdd5594a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_e507cd4b-11f8-4220-bb25-90f8cdd5594a" xlink:to="loc_srt_NameOfMajorCustomerDomain_e507cd4b-11f8-4220-bb25-90f8cdd5594a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_342c91b5-d467-4583-b4f4-0070bfe41848" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_e507cd4b-11f8-4220-bb25-90f8cdd5594a" xlink:to="loc_srt_NameOfMajorCustomerDomain_342c91b5-d467-4583-b4f4-0070bfe41848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler1Member_38274501-efab-4700-9cf4-0f919112dda0" xlink:href="jnj-20220102.xsd#jnj_Wholesaler1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_342c91b5-d467-4583-b4f4-0070bfe41848" xlink:to="loc_jnj_Wholesaler1Member_38274501-efab-4700-9cf4-0f919112dda0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler2Member_eb21bb89-408c-424e-8dae-d4a53e8e1de0" xlink:href="jnj-20220102.xsd#jnj_Wholesaler2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_342c91b5-d467-4583-b4f4-0070bfe41848" xlink:to="loc_jnj_Wholesaler2Member_eb21bb89-408c-424e-8dae-d4a53e8e1de0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler3Member_a30eb59c-657e-44f3-b25d-a044aa7920b0" xlink:href="jnj-20220102.xsd#jnj_Wholesaler3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_342c91b5-d467-4583-b4f4-0070bfe41848" xlink:to="loc_jnj_Wholesaler3Member_a30eb59c-657e-44f3-b25d-a044aa7920b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1e7be757-893b-4853-863f-6ad3ce262784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1e7be757-893b-4853-863f-6ad3ce262784" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1e7be757-893b-4853-863f-6ad3ce262784_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1e7be757-893b-4853-863f-6ad3ce262784" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1e7be757-893b-4853-863f-6ad3ce262784_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c6d6e9d8-dffa-4028-980a-13daf0717800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1e7be757-893b-4853-863f-6ad3ce262784" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c6d6e9d8-dffa-4028-980a-13daf0717800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_de576785-8f4b-475c-95f1-1c4294900f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c6d6e9d8-dffa-4028-980a-13daf0717800" xlink:to="loc_us-gaap_SalesRevenueNetMember_de576785-8f4b-475c-95f1-1c4294900f21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dcbf6a39-70cc-49f0-a461-cbdb960b6f70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dcbf6a39-70cc-49f0-a461-cbdb960b6f70" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcbf6a39-70cc-49f0-a461-cbdb960b6f70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dcbf6a39-70cc-49f0-a461-cbdb960b6f70" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcbf6a39-70cc-49f0-a461-cbdb960b6f70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68179b48-d406-4471-ba57-5b1c1786eb04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dcbf6a39-70cc-49f0-a461-cbdb960b6f70" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68179b48-d406-4471-ba57-5b1c1786eb04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_74dcb29a-e396-44a4-b95f-2b83364981a2" xlink:href="jnj-20220102.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68179b48-d406-4471-ba57-5b1c1786eb04" xlink:to="loc_jnj_AurisHealthMember_74dcb29a-e396-44a4-b95f-2b83364981a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CizHoldingsCo.Ltd.Member_670c64f5-4882-497a-85c8-29f97dd27f7b" xlink:href="jnj-20220102.xsd#jnj_CizHoldingsCo.Ltd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68179b48-d406-4471-ba57-5b1c1786eb04" xlink:to="loc_jnj_CizHoldingsCo.Ltd.Member_670c64f5-4882-497a-85c8-29f97dd27f7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ActelionMember_c3db2a14-0b8d-4b17-a0db-b4242102c788" xlink:href="jnj-20220102.xsd#jnj_ActelionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68179b48-d406-4471-ba57-5b1c1786eb04" xlink:to="loc_jnj_ActelionMember_c3db2a14-0b8d-4b17-a0db-b4242102c788" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2a079afb-2669-46be-ba9f-f6522900d98a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2a079afb-2669-46be-ba9f-f6522900d98a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2a079afb-2669-46be-ba9f-f6522900d98a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2a079afb-2669-46be-ba9f-f6522900d98a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2a079afb-2669-46be-ba9f-f6522900d98a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7ad17812-59fb-43a9-b508-f20c6ab17814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2a079afb-2669-46be-ba9f-f6522900d98a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7ad17812-59fb-43a9-b508-f20c6ab17814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember_a9335944-c9a8-40ec-96ad-71332597a8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7ad17812-59fb-43a9-b508-f20c6ab17814" xlink:to="loc_us-gaap_OtherIncomeMember_a9335944-c9a8-40ec-96ad-71332597a8e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_761e74aa-927a-4d08-b513-f38626619bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_us-gaap_LitigationStatusAxis_761e74aa-927a-4d08-b513-f38626619bea" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_761e74aa-927a-4d08-b513-f38626619bea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_761e74aa-927a-4d08-b513-f38626619bea" xlink:to="loc_us-gaap_LitigationStatusDomain_761e74aa-927a-4d08-b513-f38626619bea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_bdcf9f3d-1b5e-49c4-a47d-da8949bde29e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_761e74aa-927a-4d08-b513-f38626619bea" xlink:to="loc_us-gaap_LitigationStatusDomain_bdcf9f3d-1b5e-49c4-a47d-da8949bde29e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_1879cf56-ac51-47a8-b89b-cb300539963b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_bdcf9f3d-1b5e-49c4-a47d-da8949bde29e" xlink:to="loc_us-gaap_PendingLitigationMember_1879cf56-ac51-47a8-b89b-cb300539963b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_96aa312a-c745-4fa6-8edd-46cca2bd8184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_96aa312a-c745-4fa6-8edd-46cca2bd8184" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96aa312a-c745-4fa6-8edd-46cca2bd8184_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_96aa312a-c745-4fa6-8edd-46cca2bd8184" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96aa312a-c745-4fa6-8edd-46cca2bd8184_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bc3e24d-4c83-4268-b0fb-045f0147e980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_96aa312a-c745-4fa6-8edd-46cca2bd8184" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bc3e24d-4c83-4268-b0fb-045f0147e980" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_0253a666-f19b-47c1-95b1-5610230e7843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bc3e24d-4c83-4268-b0fb-045f0147e980" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_0253a666-f19b-47c1-95b1-5610230e7843" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_7eca21e0-35c0-4bca-921e-d44c6e8f67f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bc3e24d-4c83-4268-b0fb-045f0147e980" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_7eca21e0-35c0-4bca-921e-d44c6e8f67f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6ef629b0-d2c1-459d-b3ba-bcd791db3087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6ef629b0-d2c1-459d-b3ba-bcd791db3087" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6ef629b0-d2c1-459d-b3ba-bcd791db3087_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6ef629b0-d2c1-459d-b3ba-bcd791db3087" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6ef629b0-d2c1-459d-b3ba-bcd791db3087_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f12219ab-4ebb-4b96-80ef-1f2e04b93b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6ef629b0-d2c1-459d-b3ba-bcd791db3087" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f12219ab-4ebb-4b96-80ef-1f2e04b93b28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AdvancedSterilizationProductsMember_60f1b1b9-1a4c-4ffc-a240-19ddb2a8a777" xlink:href="jnj-20220102.xsd#jnj_AdvancedSterilizationProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f12219ab-4ebb-4b96-80ef-1f2e04b93b28" xlink:to="loc_jnj_AdvancedSterilizationProductsMember_60f1b1b9-1a4c-4ffc-a240-19ddb2a8a777" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f9dccad2-27a4-4ec0-80cc-27e538d14b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f9dccad2-27a4-4ec0-80cc-27e538d14b73" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f9dccad2-27a4-4ec0-80cc-27e538d14b73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f9dccad2-27a4-4ec0-80cc-27e538d14b73" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f9dccad2-27a4-4ec0-80cc-27e538d14b73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e7551c60-30bc-4783-98e9-cafd949e5127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f9dccad2-27a4-4ec0-80cc-27e538d14b73" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e7551c60-30bc-4783-98e9-cafd949e5127" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WholesalerConcentrationRiskMember_3ed01175-f37f-43dc-9c8c-cb240c93ff59" xlink:href="jnj-20220102.xsd#jnj_WholesalerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e7551c60-30bc-4783-98e9-cafd949e5127" xlink:to="loc_jnj_WholesalerConcentrationRiskMember_3ed01175-f37f-43dc-9c8c-cb240c93ff59" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended" id="i45172facbaf04f8ead3b5a2e5e6e3a3c_AcquisitionsandDivestituresNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_78f1c1f6-a9c2-4812-bd5b-381d86b9d5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_78f1c1f6-a9c2-4812-bd5b-381d86b9d5fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_dedcdaff-af1b-42a9-bf23-269a3dde7c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_dedcdaff-af1b-42a9-bf23-269a3dde7c58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_7c3cfdd8-2a52-48b6-a266-60cfeb35e21b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_7c3cfdd8-2a52-48b6-a266-60cfeb35e21b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_80bb8390-8a6c-4468-8202-074fdcdd2379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_80bb8390-8a6c-4468-8202-074fdcdd2379" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_3d00e4e1-d51a-46ce-a8c3-207deff4fbb7" xlink:href="jnj-20220102.xsd#jnj_BusinessCombinationProbabilityOfSuccessFactor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_3d00e4e1-d51a-46ce-a8c3-207deff4fbb7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessAcquisitionDiscountRate_4732d9a4-35c2-42f0-9029-c7ab01762860" xlink:href="jnj-20220102.xsd#jnj_BusinessAcquisitionDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_jnj_BusinessAcquisitionDiscountRate_4732d9a4-35c2-42f0-9029-c7ab01762860" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_89af83b0-c008-4bf2-b010-2f6dfe30a984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_89af83b0-c008-4bf2-b010-2f6dfe30a984" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d9b28e8e-3f38-4295-95d9-1e158066b8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_Goodwill_d9b28e8e-3f38-4295-95d9-1e158066b8e5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_0502d98b-a2a2-43e6-bc83-74415c9934f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_0502d98b-a2a2-43e6-bc83-74415c9934f0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_41db5c89-e517-4ac4-8412-beb93bc001a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_41db5c89-e517-4ac4-8412-beb93bc001a1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c9f0c86a-3b7a-4f7b-9d76-49bbbba600cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c9f0c86a-3b7a-4f7b-9d76-49bbbba600cd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_a86ae3a8-efb7-4cb8-bab3-b654823e9812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_a86ae3a8-efb7-4cb8-bab3-b654823e9812" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7e66dc43-68d3-43ca-8748-2e762e23881e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7e66dc43-68d3-43ca-8748-2e762e23881e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4835e4bd-c184-4022-a94d-d340d21b3fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4835e4bd-c184-4022-a94d-d340d21b3fdf" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f2fe4424-5f43-4d09-a702-e7468413292e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f2fe4424-5f43-4d09-a702-e7468413292e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_16c64e8d-9212-43e3-bfbe-0e321db22567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_16c64e8d-9212-43e3-bfbe-0e321db22567" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_9f7b2c3e-a162-40f6-8bf5-bc96f0349996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_9f7b2c3e-a162-40f6-8bf5-bc96f0349996" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a8009ed6-70ea-4ade-acb9-494fc0c8d7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a8009ed6-70ea-4ade-acb9-494fc0c8d7ee" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_165dd177-8398-4b2b-ad5d-2e3bd9572409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_165dd177-8398-4b2b-ad5d-2e3bd9572409" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_5fc8e35b-714c-4856-9d35-ffc1450f6e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfInterestInCorporateUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_5fc8e35b-714c-4856-9d35-ffc1450f6e5e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c64aecd0-b8e6-44f2-aaea-fff94d7e20c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c64aecd0-b8e6-44f2-aaea-fff94d7e20c4" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConvertibleNoteEquityInterestNumberOfShares_82a40fd8-6e0a-464d-b5dd-2bfd2e97fb9e" xlink:href="jnj-20220102.xsd#jnj_ConvertibleNoteEquityInterestNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_jnj_ConvertibleNoteEquityInterestNumberOfShares_82a40fd8-6e0a-464d-b5dd-2bfd2e97fb9e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_de3b8095-1707-41e8-a028-a639d3f37abc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_LongTermDebt_de3b8095-1707-41e8-a028-a639d3f37abc" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DebtInstrumentConvertibleAmountOfLoanConverted_c915adb6-4d4e-40cb-af2a-e1b629d77110" xlink:href="jnj-20220102.xsd#jnj_DebtInstrumentConvertibleAmountOfLoanConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_jnj_DebtInstrumentConvertibleAmountOfLoanConverted_c915adb6-4d4e-40cb-af2a-e1b629d77110" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_e2514ccf-2e2d-41f9-9225-d79d484fd222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_e2514ccf-2e2d-41f9-9225-d79d484fd222" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_a16d5cc0-b378-4fea-a134-122088f261ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_a16d5cc0-b378-4fea-a134-122088f261ee" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_a4d40508-8e25-4573-a548-e8bc51442bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_a4d40508-8e25-4573-a548-e8bc51442bbc" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained_e3237279-0ed1-4d08-b9c7-0787a16467d1" xlink:href="jnj-20220102.xsd#jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained_e3237279-0ed1-4d08-b9c7-0787a16467d1" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_8c50f642-bc16-4ccc-85dd-e466ff3d756f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_8c50f642-bc16-4ccc-85dd-e466ff3d756f" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3a86f2e-6a40-4be4-b02d-d0879910f1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3a86f2e-6a40-4be4-b02d-d0879910f1e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_906ad015-47e6-4cec-b5c6-66bc47c20b21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3a86f2e-6a40-4be4-b02d-d0879910f1e4" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_906ad015-47e6-4cec-b5c6-66bc47c20b21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_906ad015-47e6-4cec-b5c6-66bc47c20b21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_906ad015-47e6-4cec-b5c6-66bc47c20b21" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_906ad015-47e6-4cec-b5c6-66bc47c20b21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_508d59de-6bc4-441d-8968-da0c1e7dfb18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_906ad015-47e6-4cec-b5c6-66bc47c20b21" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_508d59de-6bc4-441d-8968-da0c1e7dfb18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_468a5895-af9d-467f-b32d-72c7b1be03e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_508d59de-6bc4-441d-8968-da0c1e7dfb18" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_468a5895-af9d-467f-b32d-72c7b1be03e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_22b0311e-1cb7-4788-80b7-8946783a0308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3a86f2e-6a40-4be4-b02d-d0879910f1e4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_22b0311e-1cb7-4788-80b7-8946783a0308" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_22b0311e-1cb7-4788-80b7-8946783a0308_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_22b0311e-1cb7-4788-80b7-8946783a0308" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_22b0311e-1cb7-4788-80b7-8946783a0308_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7d54f4c0-d196-4e27-bb79-a1a42c600735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_22b0311e-1cb7-4788-80b7-8946783a0308" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7d54f4c0-d196-4e27-bb79-a1a42c600735" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AdvancedSterilizationProductsMember_aed86c36-8882-49d6-bd04-3465641010e3" xlink:href="jnj-20220102.xsd#jnj_AdvancedSterilizationProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7d54f4c0-d196-4e27-bb79-a1a42c600735" xlink:to="loc_jnj_AdvancedSterilizationProductsMember_aed86c36-8882-49d6-bd04-3465641010e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember_3f5e3a46-14e9-4ab2-bc64-9bbdab58a763" xlink:href="jnj-20220102.xsd#jnj_EvraAndDoxilMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7d54f4c0-d196-4e27-bb79-a1a42c600735" xlink:to="loc_jnj_EvraAndDoxilMember_3f5e3a46-14e9-4ab2-bc64-9bbdab58a763" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_65a278db-9e7a-49ae-8911-f7ddb5f41bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3a86f2e-6a40-4be4-b02d-d0879910f1e4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_65a278db-9e7a-49ae-8911-f7ddb5f41bba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_65a278db-9e7a-49ae-8911-f7ddb5f41bba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_65a278db-9e7a-49ae-8911-f7ddb5f41bba" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_65a278db-9e7a-49ae-8911-f7ddb5f41bba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0cfecf51-e562-4530-bcd2-52e1c3e63583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_65a278db-9e7a-49ae-8911-f7ddb5f41bba" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0cfecf51-e562-4530-bcd2-52e1c3e63583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_f7166773-9521-49b3-a063-ade3569b0ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0cfecf51-e562-4530-bcd2-52e1c3e63583" xlink:to="loc_us-gaap_ConvertibleDebtMember_f7166773-9521-49b3-a063-ade3569b0ddc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f349f8d-64ba-47ec-86f6-b463efc64f7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3a86f2e-6a40-4be4-b02d-d0879910f1e4" xlink:to="loc_srt_RangeAxis_2f349f8d-64ba-47ec-86f6-b463efc64f7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2f349f8d-64ba-47ec-86f6-b463efc64f7d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2f349f8d-64ba-47ec-86f6-b463efc64f7d" xlink:to="loc_srt_RangeMember_2f349f8d-64ba-47ec-86f6-b463efc64f7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ab65969e-36bb-4300-abc4-c2dce46e3136" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2f349f8d-64ba-47ec-86f6-b463efc64f7d" xlink:to="loc_srt_RangeMember_ab65969e-36bb-4300-abc4-c2dce46e3136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_342845d9-79b4-4012-a920-9a514211ad9b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ab65969e-36bb-4300-abc4-c2dce46e3136" xlink:to="loc_srt_MaximumMember_342845d9-79b4-4012-a920-9a514211ad9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1f913e55-1d96-4718-8f20-6e5c6f492c1d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ab65969e-36bb-4300-abc4-c2dce46e3136" xlink:to="loc_srt_MinimumMember_1f913e55-1d96-4718-8f20-6e5c6f492c1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2b24a01a-2115-4f37-accb-19b379e31091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3a86f2e-6a40-4be4-b02d-d0879910f1e4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2b24a01a-2115-4f37-accb-19b379e31091" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b24a01a-2115-4f37-accb-19b379e31091_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2b24a01a-2115-4f37-accb-19b379e31091" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b24a01a-2115-4f37-accb-19b379e31091_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2b24a01a-2115-4f37-accb-19b379e31091" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2019AcquisitionsMember_88e021fd-e05d-4565-9eab-0cbfc73bc058" xlink:href="jnj-20220102.xsd#jnj_A2019AcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:to="loc_jnj_A2019AcquisitionsMember_88e021fd-e05d-4565-9eab-0cbfc73bc058" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_673eaf8f-45d7-4550-8955-4f2f9628b9ce" xlink:href="jnj-20220102.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:to="loc_jnj_AurisHealthMember_673eaf8f-45d7-4550-8955-4f2f9628b9ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CizHoldingsCo.Ltd.Member_6fb48f99-4b2e-493a-9cc7-ac7dd5c3b0ef" xlink:href="jnj-20220102.xsd#jnj_CizHoldingsCo.Ltd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:to="loc_jnj_CizHoldingsCo.Ltd.Member_6fb48f99-4b2e-493a-9cc7-ac7dd5c3b0ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IdorsiaMember_e06d7ea2-3d8e-44fb-a135-16f6afcf8404" xlink:href="jnj-20220102.xsd#jnj_IdorsiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:to="loc_jnj_IdorsiaMember_e06d7ea2-3d8e-44fb-a135-16f6afcf8404" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MomentaMember_022c2732-c14e-478f-9e6e-a2a59ea89648" xlink:href="jnj-20220102.xsd#jnj_MomentaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:to="loc_jnj_MomentaMember_022c2732-c14e-478f-9e6e-a2a59ea89648" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2020AcquisitionsMember_b65e89c6-ec0e-4dce-b915-19f91854389a" xlink:href="jnj-20220102.xsd#jnj_A2020AcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:to="loc_jnj_A2020AcquisitionsMember_b65e89c6-ec0e-4dce-b915-19f91854389a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_70feba96-5b34-4bbb-b982-0cf93d431285" xlink:href="jnj-20220102.xsd#jnj_BermekimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:to="loc_jnj_BermekimabMember_70feba96-5b34-4bbb-b982-0cf93d431285" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VerbSurgicalIncMember_eb4728a3-b3ad-40cf-96ff-419787773d3b" xlink:href="jnj-20220102.xsd#jnj_VerbSurgicalIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:to="loc_jnj_VerbSurgicalIncMember_eb4728a3-b3ad-40cf-96ff-419787773d3b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_267905ae-40a9-4dec-9985-7f82928a31ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3a86f2e-6a40-4be4-b02d-d0879910f1e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_267905ae-40a9-4dec-9985-7f82928a31ea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_267905ae-40a9-4dec-9985-7f82928a31ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_267905ae-40a9-4dec-9985-7f82928a31ea" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_267905ae-40a9-4dec-9985-7f82928a31ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0bb541ad-4851-4f8a-b105-cf77a1a8bd34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_267905ae-40a9-4dec-9985-7f82928a31ea" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0bb541ad-4851-4f8a-b105-cf77a1a8bd34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2ab3139b-9c1d-45a2-8701-1ff223e58042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0bb541ad-4851-4f8a-b105-cf77a1a8bd34" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_2ab3139b-9c1d-45a2-8701-1ff223e58042" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4b18603e-780b-4f75-91e6-0d9991679ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3a86f2e-6a40-4be4-b02d-d0879910f1e4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4b18603e-780b-4f75-91e6-0d9991679ffd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4b18603e-780b-4f75-91e6-0d9991679ffd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4b18603e-780b-4f75-91e6-0d9991679ffd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4b18603e-780b-4f75-91e6-0d9991679ffd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_047e726f-7ce6-40ae-a39e-f25ccd1d22e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4b18603e-780b-4f75-91e6-0d9991679ffd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_047e726f-7ce6-40ae-a39e-f25ccd1d22e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_62c8352b-dbbb-430f-9fd0-d7d83418b925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_047e726f-7ce6-40ae-a39e-f25ccd1d22e8" xlink:to="loc_us-gaap_SubsequentEventMember_62c8352b-dbbb-430f-9fd0-d7d83418b925" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#LegalProceedingsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended" id="i1af34e1946da4d63bf8e83aba825e1fa_LegalProceedingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_e20999f5-8c88-4374-99c2-83f4bc3da6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:href="jnj-20220102.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e20999f5-8c88-4374-99c2-83f4bc3da6d6" xlink:to="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_a5e55a86-4816-4745-ae2e-915c8accf258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_a5e55a86-4816-4745-ae2e-915c8accf258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_7b942071-fcb9-4e38-91f4-e9e264284fde" xlink:href="jnj-20220102.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_7b942071-fcb9-4e38-91f4-e9e264284fde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_50b494bd-b0a3-4065-9b61-dc9ba6da6caa" xlink:href="jnj-20220102.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_50b494bd-b0a3-4065-9b61-dc9ba6da6caa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_fe6b63d4-dfa5-4ad7-9f45-5863e7d97619" xlink:href="jnj-20220102.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_jnj_Numberofpatientsinsettlement_fe6b63d4-dfa5-4ad7-9f45-5863e7d97619" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_a46b8651-19ff-4359-8ecc-f5c55a951201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_a46b8651-19ff-4359-8ecc-f5c55a951201" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue_04720082-de06-4d4e-a52f-9afeee65d57e" xlink:href="jnj-20220102.xsd#jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue_04720082-de06-4d4e-a52f-9afeee65d57e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_ddc50c08-7eb2-469e-aac7-4ca5ff2ac4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_ddc50c08-7eb2-469e-aac7-4ca5ff2ac4fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_d45d5afe-2867-4e0b-9197-78ed8f6c4ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_d45d5afe-2867-4e0b-9197-78ed8f6c4ee2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust_5aad8abb-cb3b-46a6-a435-3b7c1b81e375" xlink:href="jnj-20220102.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_jnj_LossContingencyReserveEstablishedWithinTrust_5aad8abb-cb3b-46a6-a435-3b7c1b81e375" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_5fb03f22-e5e0-4e91-a0d3-ef92f6ce347f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_5fb03f22-e5e0-4e91-a0d3-ef92f6ce347f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_f2297021-c8cf-460a-ad5b-4bde2454851e" xlink:href="jnj-20220102.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_f2297021-c8cf-460a-ad5b-4bde2454851e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_7982e945-daa5-45f1-8c41-a9e1714789b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_e20999f5-8c88-4374-99c2-83f4bc3da6d6" xlink:to="loc_us-gaap_LossContingenciesTable_7982e945-daa5-45f1-8c41-a9e1714789b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d61d610a-1770-449c-a539-05a50308dadd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7982e945-daa5-45f1-8c41-a9e1714789b2" xlink:to="loc_srt_LitigationCaseAxis_d61d610a-1770-449c-a539-05a50308dadd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d61d610a-1770-449c-a539-05a50308dadd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_d61d610a-1770-449c-a539-05a50308dadd" xlink:to="loc_srt_LitigationCaseTypeDomain_d61d610a-1770-449c-a539-05a50308dadd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2857825b-c8f0-41b0-92f7-8c4d06e9ad1f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_d61d610a-1770-449c-a539-05a50308dadd" xlink:to="loc_srt_LitigationCaseTypeDomain_2857825b-c8f0-41b0-92f7-8c4d06e9ad1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_9ca44d41-077e-45e8-aee1-88ba1221c92b" xlink:href="jnj-20220102.xsd#jnj_DePuyASRU.S.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2857825b-c8f0-41b0-92f7-8c4d06e9ad1f" xlink:to="loc_jnj_DePuyASRU.S.Member_9ca44d41-077e-45e8-aee1-88ba1221c92b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_e7b5db57-e93e-421d-8f54-824a2e774f19" xlink:href="jnj-20220102.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2857825b-c8f0-41b0-92f7-8c4d06e9ad1f" xlink:to="loc_jnj_RisperdalMember_e7b5db57-e93e-421d-8f54-824a2e774f19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_94e5c854-9bab-4fab-9291-0b87ee8863b3" xlink:href="jnj-20220102.xsd#jnj_BabyPowderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2857825b-c8f0-41b0-92f7-8c4d06e9ad1f" xlink:to="loc_jnj_BabyPowderMember_94e5c854-9bab-4fab-9291-0b87ee8863b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_4d613aca-65d8-435e-ab02-df9c3da3dadc" xlink:href="jnj-20220102.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2857825b-c8f0-41b0-92f7-8c4d06e9ad1f" xlink:to="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_4d613aca-65d8-435e-ab02-df9c3da3dadc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember_acad771d-d8d1-41bb-b57e-d0ec73db7d27" xlink:href="jnj-20220102.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2857825b-c8f0-41b0-92f7-8c4d06e9ad1f" xlink:to="loc_jnj_SurgicalMeshProductsMarketingMember_acad771d-d8d1-41bb-b57e-d0ec73db7d27" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_a33d6fe6-3e8f-4003-ba6f-48acaaa0a759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7982e945-daa5-45f1-8c41-a9e1714789b2" xlink:to="loc_us-gaap_LitigationStatusAxis_a33d6fe6-3e8f-4003-ba6f-48acaaa0a759" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_a33d6fe6-3e8f-4003-ba6f-48acaaa0a759_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_a33d6fe6-3e8f-4003-ba6f-48acaaa0a759" xlink:to="loc_us-gaap_LitigationStatusDomain_a33d6fe6-3e8f-4003-ba6f-48acaaa0a759_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_f38dabd9-0064-4b90-91f7-ddd23a569ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_a33d6fe6-3e8f-4003-ba6f-48acaaa0a759" xlink:to="loc_us-gaap_LitigationStatusDomain_f38dabd9-0064-4b90-91f7-ddd23a569ceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_8a8f7768-5c3e-47ed-940f-b8a6cd1d11e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_f38dabd9-0064-4b90-91f7-ddd23a569ceb" xlink:to="loc_us-gaap_SettledLitigationMember_8a8f7768-5c3e-47ed-940f-b8a6cd1d11e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_36989a8a-1e0a-40dd-aadb-ae22b24ac313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_JudicialRulingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_f38dabd9-0064-4b90-91f7-ddd23a569ceb" xlink:to="loc_us-gaap_JudicialRulingMember_36989a8a-1e0a-40dd-aadb-ae22b24ac313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_28b6bc9a-f22c-48d1-ac43-49504329ad08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_f38dabd9-0064-4b90-91f7-ddd23a569ceb" xlink:to="loc_us-gaap_PendingLitigationMember_28b6bc9a-f22c-48d1-ac43-49504329ad08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_df1b4662-3dba-428a-a7a9-9152e974633e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7982e945-daa5-45f1-8c41-a9e1714789b2" xlink:to="loc_srt_ProductOrServiceAxis_df1b4662-3dba-428a-a7a9-9152e974633e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_df1b4662-3dba-428a-a7a9-9152e974633e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_df1b4662-3dba-428a-a7a9-9152e974633e" xlink:to="loc_srt_ProductsAndServicesDomain_df1b4662-3dba-428a-a7a9-9152e974633e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_df1b4662-3dba-428a-a7a9-9152e974633e" xlink:to="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_da92a80c-1f5a-479d-8737-ed4974930845" xlink:href="jnj-20220102.xsd#jnj_AsrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_AsrMember_da92a80c-1f5a-479d-8737-ed4974930845" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_37474a61-4993-4fe8-bf6c-a3655034cad4" xlink:href="jnj-20220102.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_37474a61-4993-4fe8-bf6c-a3655034cad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_d2ab89bd-55ea-41f7-8c20-2f822fe9cf6d" xlink:href="jnj-20220102.xsd#jnj_PelvicMeshesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_PelvicMeshesMember_d2ab89bd-55ea-41f7-8c20-2f822fe9cf6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_b0ac8a3e-e754-4f40-8183-13def033eddd" xlink:href="jnj-20220102.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_RisperdalMember_b0ac8a3e-e754-4f40-8183-13def033eddd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_7cddc59c-f627-40ad-aeb1-fd76b3b8f2d9" xlink:href="jnj-20220102.xsd#jnj_XareltoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_XareltoMember_7cddc59c-f627-40ad-aeb1-fd76b3b8f2d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_7e1ef8c9-282f-4ac9-a006-97c0a466be72" xlink:href="jnj-20220102.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_TalcMember_7e1ef8c9-282f-4ac9-a006-97c0a466be72" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember_0dcbf5e0-7228-473b-b52c-6e28872e5007" xlink:href="jnj-20220102.xsd#jnj_InvokanaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_InvokanaMember_0dcbf5e0-7228-473b-b52c-6e28872e5007" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_f7700ec3-6608-4314-97a2-0cb8b8c1bac7" xlink:href="jnj-20220102.xsd#jnj_PhysiomeshMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_PhysiomeshMember_f7700ec3-6608-4314-97a2-0cb8b8c1bac7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember_8286a093-93f3-4893-b616-bb30c9195eef" xlink:href="jnj-20220102.xsd#jnj_OpioidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_OpioidMember_8286a093-93f3-4893-b616-bb30c9195eef" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ContactLensesMember_ddb2de12-7077-4a5b-a3fb-4a3ac61773b8" xlink:href="jnj-20220102.xsd#jnj_ContactLensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_ContactLensesMember_ddb2de12-7077-4a5b-a3fb-4a3ac61773b8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis_d5f4a937-deba-4437-b4b1-e655c23ecf34" xlink:href="jnj-20220102.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7982e945-daa5-45f1-8c41-a9e1714789b2" xlink:to="loc_jnj_LitigationSettlementByCompaniesAxis_d5f4a937-deba-4437-b4b1-e655c23ecf34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_d5f4a937-deba-4437-b4b1-e655c23ecf34_default" xlink:href="jnj-20220102.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_d5f4a937-deba-4437-b4b1-e655c23ecf34" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_d5f4a937-deba-4437-b4b1-e655c23ecf34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_32b5201d-f882-43d9-bcc4-faeee29ddbe8" xlink:href="jnj-20220102.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_d5f4a937-deba-4437-b4b1-e655c23ecf34" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_32b5201d-f882-43d9-bcc4-faeee29ddbe8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_54441bf6-4eb4-4be1-a2a8-4acf768dc67c" xlink:href="jnj-20220102.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain_32b5201d-f882-43d9-bcc4-faeee29ddbe8" xlink:to="loc_jnj_RisperdalMember_54441bf6-4eb4-4be1-a2a8-4acf768dc67c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_addde7f7-20ed-4afb-8747-1d7f94926e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7982e945-daa5-45f1-8c41-a9e1714789b2" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_addde7f7-20ed-4afb-8747-1d7f94926e78" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_addde7f7-20ed-4afb-8747-1d7f94926e78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_addde7f7-20ed-4afb-8747-1d7f94926e78" xlink:to="loc_us-gaap_LossContingencyNatureDomain_addde7f7-20ed-4afb-8747-1d7f94926e78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_2afe09bb-2356-4ef3-877c-ad845e7b4a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_addde7f7-20ed-4afb-8747-1d7f94926e78" xlink:to="loc_us-gaap_LossContingencyNatureDomain_2afe09bb-2356-4ef3-877c-ad845e7b4a32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_1516272c-7461-44ef-aedd-72b55105a8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_2afe09bb-2356-4ef3-877c-ad845e7b4a32" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_1516272c-7461-44ef-aedd-72b55105a8a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalJurisdictionAxis_c949a845-7bca-4294-a91d-db1548a8cf7c" xlink:href="jnj-20220102.xsd#jnj_LegalJurisdictionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7982e945-daa5-45f1-8c41-a9e1714789b2" xlink:to="loc_jnj_LegalJurisdictionAxis_c949a845-7bca-4294-a91d-db1548a8cf7c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalJurisdictionDomain_c949a845-7bca-4294-a91d-db1548a8cf7c_default" xlink:href="jnj-20220102.xsd#jnj_LegalJurisdictionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_jnj_LegalJurisdictionAxis_c949a845-7bca-4294-a91d-db1548a8cf7c" xlink:to="loc_jnj_LegalJurisdictionDomain_c949a845-7bca-4294-a91d-db1548a8cf7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalJurisdictionDomain_04b301f7-1884-4682-b3f9-65fa4d4481e2" xlink:href="jnj-20220102.xsd#jnj_LegalJurisdictionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_jnj_LegalJurisdictionAxis_c949a845-7bca-4294-a91d-db1548a8cf7c" xlink:to="loc_jnj_LegalJurisdictionDomain_04b301f7-1884-4682-b3f9-65fa4d4481e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StateLevelJurisdictionMember_222c3383-c3f7-41ca-9fc8-89a62ba7c268" xlink:href="jnj-20220102.xsd#jnj_StateLevelJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalJurisdictionDomain_04b301f7-1884-4682-b3f9-65fa4d4481e2" xlink:to="loc_jnj_StateLevelJurisdictionMember_222c3383-c3f7-41ca-9fc8-89a62ba7c268" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalLevelJurisdictionMember_97d42dac-ffed-478d-b5d2-abd6aa5d0f27" xlink:href="jnj-20220102.xsd#jnj_FederalLevelJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalJurisdictionDomain_04b301f7-1884-4682-b3f9-65fa4d4481e2" xlink:to="loc_jnj_FederalLevelJurisdictionMember_97d42dac-ffed-478d-b5d2-abd6aa5d0f27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c3d6cb90-b874-4b51-9f7d-007c9901134f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7982e945-daa5-45f1-8c41-a9e1714789b2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c3d6cb90-b874-4b51-9f7d-007c9901134f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c3d6cb90-b874-4b51-9f7d-007c9901134f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c3d6cb90-b874-4b51-9f7d-007c9901134f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c3d6cb90-b874-4b51-9f7d-007c9901134f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f9d98f43-06c2-46c8-9749-70a52fade9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c3d6cb90-b874-4b51-9f7d-007c9901134f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f9d98f43-06c2-46c8-9749-70a52fade9ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_76bb509e-ecd2-49e4-b6ac-d61fdc77fb12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f9d98f43-06c2-46c8-9749-70a52fade9ef" xlink:to="loc_us-gaap_SubsequentEventMember_76bb509e-ecd2-49e4-b6ac-d61fdc77fb12" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#RestructuringNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended" id="ide8a967e1fba41318a607fb7b1d230b5_RestructuringNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_3b8ed519-61fd-4383-ade5-d0d2e9b57892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_94c8eb8d-802d-44e1-a516-acd403f795a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b8ed519-61fd-4383-ade5-d0d2e9b57892" xlink:to="loc_us-gaap_RestructuringCharges_94c8eb8d-802d-44e1-a516-acd403f795a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_54d6199b-cf71-4e40-a047-5df486a372c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b8ed519-61fd-4383-ade5-d0d2e9b57892" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_54d6199b-cf71-4e40-a047-5df486a372c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_9c372e70-0134-4c82-ab12-2ccaf00e7ec7" xlink:href="jnj-20220102.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b8ed519-61fd-4383-ade5-d0d2e9b57892" xlink:to="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_9c372e70-0134-4c82-ab12-2ccaf00e7ec7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_b7d9acca-4bb2-4a90-ac0c-ee770f945160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b8ed519-61fd-4383-ade5-d0d2e9b57892" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_b7d9acca-4bb2-4a90-ac0c-ee770f945160" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_191a9e83-c1db-4bcf-872d-2e5c79fac3e2" xlink:href="jnj-20220102.xsd#jnj_RestructuringandRelatedCostDurationofRestructuringPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b8ed519-61fd-4383-ade5-d0d2e9b57892" xlink:to="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_191a9e83-c1db-4bcf-872d-2e5c79fac3e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b977c165-8ccb-4e5a-814d-c4044b5599d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b8ed519-61fd-4383-ade5-d0d2e9b57892" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b977c165-8ccb-4e5a-814d-c4044b5599d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_b6bd741e-2730-4ada-82ff-7fcddf80819e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b977c165-8ccb-4e5a-814d-c4044b5599d6" xlink:to="loc_us-gaap_RestructuringPlanAxis_b6bd741e-2730-4ada-82ff-7fcddf80819e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_b6bd741e-2730-4ada-82ff-7fcddf80819e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_b6bd741e-2730-4ada-82ff-7fcddf80819e" xlink:to="loc_us-gaap_RestructuringPlanDomain_b6bd741e-2730-4ada-82ff-7fcddf80819e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_5cf49177-b1c0-46be-bdab-7ebf4829a589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_b6bd741e-2730-4ada-82ff-7fcddf80819e" xlink:to="loc_us-gaap_RestructuringPlanDomain_5cf49177-b1c0-46be-bdab-7ebf4829a589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_b12b9091-a4d0-4327-a8fd-2f45af84636d" xlink:href="jnj-20220102.xsd#jnj_SupplyChainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_5cf49177-b1c0-46be-bdab-7ebf4829a589" xlink:to="loc_jnj_SupplyChainMember_b12b9091-a4d0-4327-a8fd-2f45af84636d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9fe0c326-7bbb-471a-b873-667932c83030" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b977c165-8ccb-4e5a-814d-c4044b5599d6" xlink:to="loc_srt_RangeAxis_9fe0c326-7bbb-471a-b873-667932c83030" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9fe0c326-7bbb-471a-b873-667932c83030_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9fe0c326-7bbb-471a-b873-667932c83030" xlink:to="loc_srt_RangeMember_9fe0c326-7bbb-471a-b873-667932c83030_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52d5d599-d499-477f-9fba-8f530fcf52c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9fe0c326-7bbb-471a-b873-667932c83030" xlink:to="loc_srt_RangeMember_52d5d599-d499-477f-9fba-8f530fcf52c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fbc7f6f5-fcc2-4e78-bc1a-6c83d6098a5b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_52d5d599-d499-477f-9fba-8f530fcf52c8" xlink:to="loc_srt_MinimumMember_fbc7f6f5-fcc2-4e78-bc1a-6c83d6098a5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6cca8ba4-c902-4082-9438-2a0b6308b16a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_52d5d599-d499-477f-9fba-8f530fcf52c8" xlink:to="loc_srt_MaximumMember_6cca8ba4-c902-4082-9438-2a0b6308b16a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2d43c0f8-b562-459a-a5e7-4f19b9a91f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b977c165-8ccb-4e5a-814d-c4044b5599d6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2d43c0f8-b562-459a-a5e7-4f19b9a91f10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2d43c0f8-b562-459a-a5e7-4f19b9a91f10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2d43c0f8-b562-459a-a5e7-4f19b9a91f10" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2d43c0f8-b562-459a-a5e7-4f19b9a91f10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ad0960ae-6b0c-4416-a3e0-92ae1b37c1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2d43c0f8-b562-459a-a5e7-4f19b9a91f10" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ad0960ae-6b0c-4416-a3e0-92ae1b37c1a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_d24692ae-5834-44b2-afda-7a0a5be68021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad0960ae-6b0c-4416-a3e0-92ae1b37c1a3" xlink:to="loc_us-gaap_RestructuringChargesMember_d24692ae-5834-44b2-afda-7a0a5be68021" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_23d84c12-99fb-4734-bd31-57c17e94fe58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad0960ae-6b0c-4416-a3e0-92ae1b37c1a3" xlink:to="loc_us-gaap_CostOfSalesMember_23d84c12-99fb-4734-bd31-57c17e94fe58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_c7b445cb-94b0-4aba-a09d-a16d9094bf8c" xlink:href="jnj-20220102.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad0960ae-6b0c-4416-a3e0-92ae1b37c1a3" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_c7b445cb-94b0-4aba-a09d-a16d9094bf8c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails" xlink:type="extended" id="i06e541079f224da58738172254d47432_RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_aa26c795-ebe9-4d68-afb2-2d837c776f20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_7210c446-6c4a-4f2f-975c-54845811673b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_aa26c795-ebe9-4d68-afb2-2d837c776f20" xlink:to="loc_us-gaap_RestructuringReserveRollForward_7210c446-6c4a-4f2f-975c-54845811673b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_727cb457-fc23-461b-9a8c-52dbbc101650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7210c446-6c4a-4f2f-975c-54845811673b" xlink:to="loc_us-gaap_RestructuringReserve_727cb457-fc23-461b-9a8c-52dbbc101650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_96a00e46-9043-4d72-aef9-438cd075e7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7210c446-6c4a-4f2f-975c-54845811673b" xlink:to="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_96a00e46-9043-4d72-aef9-438cd075e7c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ee864ecd-ee3c-4bce-b394-25ae01592f93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7210c446-6c4a-4f2f-975c-54845811673b" xlink:to="loc_us-gaap_RestructuringCharges_ee864ecd-ee3c-4bce-b394-25ae01592f93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_e1994b2c-3356-4e10-a116-279d5b006e28" xlink:href="jnj-20220102.xsd#jnj_GainOnSaleOfAnAssetPaymentForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7210c446-6c4a-4f2f-975c-54845811673b" xlink:to="loc_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_e1994b2c-3356-4e10-a116-279d5b006e28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_a6b8daf0-6cb2-4a32-a6a6-db410a536e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7210c446-6c4a-4f2f-975c-54845811673b" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_a6b8daf0-6cb2-4a32-a6a6-db410a536e8d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_b4b32a2f-4b3d-41c2-9586-9a9810f33c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6b288e59-64a9-4bb3-b1c1-9293b3ba0fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_aa26c795-ebe9-4d68-afb2-2d837c776f20" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6b288e59-64a9-4bb3-b1c1-9293b3ba0fc2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_dfa324d3-d345-46d3-aada-9e9cf1a1ecc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6b288e59-64a9-4bb3-b1c1-9293b3ba0fc2" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_dfa324d3-d345-46d3-aada-9e9cf1a1ecc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_dfa324d3-d345-46d3-aada-9e9cf1a1ecc0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_dfa324d3-d345-46d3-aada-9e9cf1a1ecc0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_dfa324d3-d345-46d3-aada-9e9cf1a1ecc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_7c8461c1-0a3e-41ac-a117-ab7e2e18b8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_dfa324d3-d345-46d3-aada-9e9cf1a1ecc0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_7c8461c1-0a3e-41ac-a117-ab7e2e18b8a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_e1481304-546e-417f-a196-14355266826f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7c8461c1-0a3e-41ac-a117-ab7e2e18b8a3" xlink:to="loc_us-gaap_EmployeeSeveranceMember_e1481304-546e-417f-a196-14355266826f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember_1de59062-d4ca-4a55-8db6-e9c664faa68a" xlink:href="jnj-20220102.xsd#jnj_AssetWriteoffMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7c8461c1-0a3e-41ac-a117-ab7e2e18b8a3" xlink:to="loc_jnj_AssetWriteoffMember_1de59062-d4ca-4a55-8db6-e9c664faa68a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_723dbe6f-56cb-4f2f-942d-7f3244a2baab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7c8461c1-0a3e-41ac-a117-ab7e2e18b8a3" xlink:to="loc_us-gaap_OtherRestructuringMember_723dbe6f-56cb-4f2f-942d-7f3244a2baab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_37438d20-6380-451d-b996-e5c9f5bea2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6b288e59-64a9-4bb3-b1c1-9293b3ba0fc2" xlink:to="loc_us-gaap_RestructuringPlanAxis_37438d20-6380-451d-b996-e5c9f5bea2a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_37438d20-6380-451d-b996-e5c9f5bea2a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_37438d20-6380-451d-b996-e5c9f5bea2a0" xlink:to="loc_us-gaap_RestructuringPlanDomain_37438d20-6380-451d-b996-e5c9f5bea2a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_d2db3186-555f-456c-85ce-0e0e2cc63869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_37438d20-6380-451d-b996-e5c9f5bea2a0" xlink:to="loc_us-gaap_RestructuringPlanDomain_d2db3186-555f-456c-85ce-0e0e2cc63869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_e9ecdd9a-766c-4fc8-8135-e579185da1fb" xlink:href="jnj-20220102.xsd#jnj_SupplyChainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_d2db3186-555f-456c-85ce-0e0e2cc63869" xlink:to="loc_jnj_SupplyChainMember_e9ecdd9a-766c-4fc8-8135-e579185da1fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_697a07b5-789d-45e7-bf4f-e273a7b37f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6b288e59-64a9-4bb3-b1c1-9293b3ba0fc2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_697a07b5-789d-45e7-bf4f-e273a7b37f5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_697a07b5-789d-45e7-bf4f-e273a7b37f5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_697a07b5-789d-45e7-bf4f-e273a7b37f5c" xlink:to="loc_us-gaap_SegmentDomain_697a07b5-789d-45e7-bf4f-e273a7b37f5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ad50b66e-38d2-4e43-a311-9701d4fdffa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_697a07b5-789d-45e7-bf4f-e273a7b37f5c" xlink:to="loc_us-gaap_SegmentDomain_ad50b66e-38d2-4e43-a311-9701d4fdffa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_e39a5726-dc4b-474e-a911-cd39078ea3d9" xlink:href="jnj-20220102.xsd#jnj_SupplyChainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ad50b66e-38d2-4e43-a311-9701d4fdffa6" xlink:to="loc_jnj_SupplyChainMember_e39a5726-dc4b-474e-a911-cd39078ea3d9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>jnj-20220102_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2ac3ec12-1a04-4290-8adc-1ec251a989dd,g:c9588643-da6b-4c23-b331-47586e9dc1a5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_75726ec0-129a-4c73-83d8-caca54b3ec54_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_9a66b961-d620-464e-b590-2de2e407b061_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow data</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_29cb77fc-357c-4815-8707-47e44ebf667d_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_66411f60-d91e-4b0d-9589-8dbd0620f4ef_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) On Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_92fd9e7a-d262-4a8e-b1ba-9df47d2053c8_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceedings</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_6181c9a3-3b71-42d7-a41d-43e058b1efc5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gains) losses(2)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_8875dbf5-4a6a-497b-8b29-5f024074ec4b_terseLabel_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI</link:label>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_label_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]</link:label>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_documentation_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:href="jnj-20220102.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:to="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BabyPowderMember_78a2b049-d5ce-4ef9-8228-41a0eb845ab7_terseLabel_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder</link:label>
    <link:label id="lab_jnj_BabyPowderMember_label_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:label id="lab_jnj_BabyPowderMember_documentation_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember" xlink:href="jnj-20220102.xsd#jnj_BabyPowderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BabyPowderMember" xlink:to="lab_jnj_BabyPowderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1ec75461-eba6-4fb3-81c8-a76e34b6f5d9_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings_ceecc721-2530-424c-b239-87621c85c092_terseLabel_en-US" xlink:label="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed foreign earnings</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings_label_en-US" xlink:label="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Undistributed Foreign Earnings</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings_documentation_en-US" xlink:label="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:href="jnj-20220102.xsd#jnj_DeferredTaxAssetsUndistributedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:to="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConsumerMember_2f085c88-4811-49d7-aa06-576ff22355a3_terseLabel_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Health</link:label>
    <link:label id="lab_jnj_ConsumerMember_label_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer [Member]</link:label>
    <link:label id="lab_jnj_ConsumerMember_documentation_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember" xlink:href="jnj-20220102.xsd#jnj_ConsumerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConsumerMember" xlink:to="lab_jnj_ConsumerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_63108184-25e5-4e84-8302-83a0231b757e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeFiveMember_ca6f9b11-2aa4-4aa9-9224-fc2267b0c23a_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$151.42-$164.62</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeFiveMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeFiveMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFiveMember" xlink:href="jnj-20220102.xsd#jnj_ExercisePriceRangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeFiveMember" xlink:to="lab_jnj_ExercisePriceRangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_6ff39d0b-000c-433b-898d-53bb3f7e8f5a_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities at fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument Detail [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_244b534f-dcef-4dc8-bb80-ac3b13c8bb56_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships and other intangible assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_d6f0d7a8-a5b5-4a99-8e34-735c685cdf32_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_32dd1c77-f316-454a-855e-2eb98f5787a5_terseLabel_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense recorded related to TRAF</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" xlink:href="jnj-20220102.xsd#jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" xlink:to="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_7a04ba43-7620-442d-a198-0b0103258f3a_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ADVANCEDMember_3e5a8b40-ac17-4306-9614-3511c73ffc22_terseLabel_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_label_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_documentation_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember" xlink:href="jnj-20220102.xsd#jnj_ADVANCEDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ADVANCEDMember" xlink:to="lab_jnj_ADVANCEDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_f363794d-70fb-428b-a7d7-f947e3dacf46_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ae4aeb7d-ecf5-4e8e-a01d-d7736771fb56_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_75b4fe5b-4e72-453d-abe9-e49e8104756b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_0262245a-ec81-4cec-b054-d026ab866fe9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments, fair value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_84986c2e-3230-4881-ac16-90e0712d56c1_terseLabel_en-US" xlink:label="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of company's common stock directly held in plan assets</link:label>
    <link:label id="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_label_en-US" xlink:label="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Company's Common Stock Directly Held In Plan Assets</link:label>
    <link:label id="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_documentation_en-US" xlink:label="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of company's common stock directly held in plan assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:href="jnj-20220102.xsd#jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:to="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_92dabb16-dc34-4582-9646-cefc36aa5918_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_5c3d572f-1371-4033-8660-3e99af4c66e1_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments : Liabilities</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_465abe26-f953-4e5f-a93c-ff5111b4ab3e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled/forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_ac1fabe6-c216-4dc8-8192-955b4376a1ee_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of basic net earnings per share to diluted net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_b1a019a6-e4c9-410d-b2d1-b3b87f8d85c7_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current benefits payable</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_f5b8206f-85ca-44be-8e42-57a78860c78d_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a260e766-8d3a-462b-9e7d-a4d4dc6e674b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2020AcquisitionsMember_c98563cf-0458-4de5-8f91-02d030dd2bdc_terseLabel_en-US" xlink:label="lab_jnj_A2020AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Acquisitions</link:label>
    <link:label id="lab_jnj_A2020AcquisitionsMember_label_en-US" xlink:label="lab_jnj_A2020AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Acquisitions [Member]</link:label>
    <link:label id="lab_jnj_A2020AcquisitionsMember_documentation_en-US" xlink:label="lab_jnj_A2020AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2020AcquisitionsMember" xlink:href="jnj-20220102.xsd#jnj_A2020AcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2020AcquisitionsMember" xlink:to="lab_jnj_A2020AcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_d92d4165-0005-4d88-b9cf-962a82c6f80c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c2a4fce6-2099-4e75-b49c-1342319f2fb3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future grants under long-term incentive plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_739cd274-dfd9-4c18-8199-dded67be7260_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_910eafe9-256b-4ac0-9029-3c8f34d8080a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase/(Decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_af4aa95e-0b9b-4ad9-b181-8cc1b529cf8d_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_8148c9bf-cd7f-404c-bfe8-c605c8d3f48a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, number of equity instruments (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3408a4c3-9b17-446c-ae1f-e5efb36f6595_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1d90fd14-313d-4c29-84db-e8d97bc67086_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_938aa9bf-1958-4374-9f96-634b01e0ea1a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6e8759df-63aa-4bea-8ca6-03f323ec2795_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_5aa43601-aab0-4205-ad55-f82371f6b41d_terseLabel_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_label_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_documentation_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember" xlink:href="jnj-20220102.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONTACTLENSESOTHERMember" xlink:to="lab_jnj_CONTACTLENSESOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LegalJurisdictionAxis_280fda1f-d395-4598-beef-882b11cd6185_terseLabel_en-US" xlink:label="lab_jnj_LegalJurisdictionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Jurisdiction [Axis]</link:label>
    <link:label id="lab_jnj_LegalJurisdictionAxis_label_en-US" xlink:label="lab_jnj_LegalJurisdictionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Jurisdiction [Axis]</link:label>
    <link:label id="lab_jnj_LegalJurisdictionAxis_documentation_en-US" xlink:label="lab_jnj_LegalJurisdictionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Jurisdiction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalJurisdictionAxis" xlink:href="jnj-20220102.xsd#jnj_LegalJurisdictionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LegalJurisdictionAxis" xlink:to="lab_jnj_LegalJurisdictionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_683a98d5-a91a-4489-89b0-2f8e6e878db3_terseLabel_en-US" xlink:label="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D capitalized for tax</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_label_en-US" xlink:label="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets International Research And Development Capitalized</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_documentation_en-US" xlink:label="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets international research and development capitalized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:href="jnj-20220102.xsd#jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:to="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_0ff2c91b-b030-4c1a-9a37-28e7bdb84839_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_162a494d-d2e3-4fc1-af5b-488795b58b0d_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures&#160;&amp; acquisitions</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:to="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_c0190e7d-f369-4ec9-b420-05dc3ab76ba6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_0275b1c5-4a7d-48a4-b574-81a851095001_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Range, Minimum (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SkinHealthBeautyMember_636515d7-933e-4363-ab33-cc1e574abbc1_terseLabel_en-US" xlink:label="lab_jnj_SkinHealthBeautyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skin health/Beauty</link:label>
    <link:label id="lab_jnj_SkinHealthBeautyMember_label_en-US" xlink:label="lab_jnj_SkinHealthBeautyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skin health/Beauty [Member]</link:label>
    <link:label id="lab_jnj_SkinHealthBeautyMember_documentation_en-US" xlink:label="lab_jnj_SkinHealthBeautyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skin health/Beauty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SkinHealthBeautyMember" xlink:href="jnj-20220102.xsd#jnj_SkinHealthBeautyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SkinHealthBeautyMember" xlink:to="lab_jnj_SkinHealthBeautyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_010991ca-6442-4623-8e7c-4f1a3338d91c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_83e0b913-c892-4929-98dc-b4ce8ad138a7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_HIPSMember_078f567a-d239-4e71-b302-b9d3593bbdba_terseLabel_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS</link:label>
    <link:label id="lab_jnj_HIPSMember_label_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS [Member]</link:label>
    <link:label id="lab_jnj_HIPSMember_documentation_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember" xlink:href="jnj-20220102.xsd#jnj_HIPSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_HIPSMember" xlink:to="lab_jnj_HIPSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_52bccd60-2b98-402e-8d37-fae3fd2d30a7_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense of amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_53435974-6c14-4af1-8cc9-1a0c88e2c004_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Severance Charges and Associated Spending</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_c11576e9-1236-401a-a195-78277b3c3cf6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5853d01a-2ef5-4b16-acef-2ec40b7940ef_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average useful life of acquired intangibles</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UnfundedPlansMember_edea4f98-81a5-4ac6-b7e5-1153be662c73_terseLabel_en-US" xlink:label="lab_jnj_UnfundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded Plans</link:label>
    <link:label id="lab_jnj_UnfundedPlansMember_label_en-US" xlink:label="lab_jnj_UnfundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded Plans [Member]</link:label>
    <link:label id="lab_jnj_UnfundedPlansMember_documentation_en-US" xlink:label="lab_jnj_UnfundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnfundedPlansMember" xlink:href="jnj-20220102.xsd#jnj_UnfundedPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UnfundedPlansMember" xlink:to="lab_jnj_UnfundedPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_521c284a-c4a6-4613-b8ed-abd099daff68_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to prior period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_8123f224-9bd8-4705-a42c-f1964c9cf5e3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cd6cdcc7-7921-4a95-be48-d4ecdbcf7718_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_37b0423b-a40d-4cae-ade4-0698e9f54757_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_c165ffad-13e5-4046-b750-28627dc85ff8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskTable_2b3606fa-29b5-4509-9b77-2157eebaf366_terseLabel_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk [Table]</link:label>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskTable_label_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk [Table]</link:label>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskTable_documentation_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskTable" xlink:href="jnj-20220102.xsd#jnj_ConcentrationOfCreditRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable" xlink:to="lab_jnj_ConcentrationOfCreditRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_6a91edf6-b98e-4c7c-ae6b-e315049baa54_verboseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due May 2035</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_7ecde21d-2ad2-4581-a74f-5ee5b85ac582_terseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes due 2035 (1.5B Euro 1.1311)(2)/(1.5B Euro 1.2281)(3)</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_label_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_documentation_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member" xlink:href="jnj-20220102.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.650NotesDue2035Member" xlink:to="lab_jnj_A1.650NotesDue2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WholesalerConcentrationRiskMember_95814b19-af94-4b1f-bbde-9636bb4fbe67_terseLabel_en-US" xlink:label="lab_jnj_WholesalerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler Concentration Risk</link:label>
    <link:label id="lab_jnj_WholesalerConcentrationRiskMember_label_en-US" xlink:label="lab_jnj_WholesalerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler Concentration Risk [Member]</link:label>
    <link:label id="lab_jnj_WholesalerConcentrationRiskMember_documentation_en-US" xlink:label="lab_jnj_WholesalerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler Concentration Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WholesalerConcentrationRiskMember" xlink:href="jnj-20220102.xsd#jnj_WholesalerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WholesalerConcentrationRiskMember" xlink:to="lab_jnj_WholesalerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_10d8deab-f672-4d3b-a8d5-03dddfe126fa_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_bef6fab3-058a-498b-baa0-0ab8bf94bd5d_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:href="jnj-20220102.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_77f2a26a-5551-42cd-a6d7-e9f1ade9e144_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_17131861-bee2-48d8-921f-14faced940f1_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims within settlement agreement</link:label>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_label_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Claims within Settlement Agreement</link:label>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_documentation_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Claims within Settlement Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:href="jnj-20220102.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:to="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentRollForward_c8b613e7-bef2-414c-8f35-6876c1b4d963_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_label_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward" xlink:href="jnj-20220102.xsd#jnj_EquityInvestmentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentRollForward" xlink:to="lab_jnj_EquityInvestmentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_3744010e-76fa-45b7-93ba-0668b98bdfbf_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_2016edce-0b30-49a2-a2a9-b898c6894ce6_terseLabel_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_label_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_documentation_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember" xlink:href="jnj-20220102.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OTHERNEUROSCIENCEMember" xlink:to="lab_jnj_OTHERNEUROSCIENCEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_a72d70ea-cb5e-4fe8-94f0-2597c2bc94c0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_74ba6cdf-e9aa-482a-bcdb-674bef612eb3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7705138b-7b0f-47d7-bf76-a14a7ef858aa_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_cdf23db1-d482-46d8-90a4-2ba5a3171060_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Equity Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_0f9e8d8b-9ec9-4499-ae23-f9579e46c928_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PhysiomeshMember_67f73a87-f918-4601-9b64-4b7ccb842ee0_terseLabel_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_label_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_documentation_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember" xlink:href="jnj-20220102.xsd#jnj_PhysiomeshMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PhysiomeshMember" xlink:to="lab_jnj_PhysiomeshMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d8eecbbc-9a19-42b0-9871-199c670e8ad0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of option activity under the Plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4a7ce20d-84da-43a4-afd4-3e1307a952c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_0432c619-b1d3-4a24-be1e-d0c98d8b2389_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized actuarial losses (gains)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A055NotesDue2025Member_9078a940-ddc9-40bd-ab42-729da0d54675_terseLabel_en-US" xlink:label="lab_jnj_A055NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.55% Notes due 2025</link:label>
    <link:label id="lab_jnj_A055NotesDue2025Member_label_en-US" xlink:label="lab_jnj_A055NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.55% Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A055NotesDue2025Member_documentation_en-US" xlink:label="lab_jnj_A055NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.55% Notes due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A055NotesDue2025Member" xlink:href="jnj-20220102.xsd#jnj_A055NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A055NotesDue2025Member" xlink:to="lab_jnj_A055NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7ca27e34-5619-4611-900a-ae52a0a504b7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_57558328-0bdd-44e4-81c1-932c0e37b60f_terseLabel_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95%&#160;Notes due 2029</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_label_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_documentation_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member" xlink:href="jnj-20220102.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A6.95Notesdue2029Member" xlink:to="lab_jnj_A6.95Notesdue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_cb3c1c45-7026-49a1-8fae-a2e6a28a7862_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock&#160;&#8212; without par value (authorized and unissued 2,000,000&#160;shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_3f7e3cde-9476-4cfb-9752-d87f494c52a1_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_d9f9acf2-33ed-478f-a9a0-257223bf01a0_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with readily determinable value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:href="jnj-20220102.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_b07d6b05-df20-4da8-bb9d-5c39dc39e704_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_82e066bc-cd4f-4e38-b04c-0940cbda3bf2_terseLabel_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere excluding U.S.&#160;</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_label_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_documentation_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember" xlink:href="jnj-20220102.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WesternHemisphereExcludingUSMember" xlink:to="lab_jnj_WesternHemisphereExcludingUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_eab8d3fc-28bd-4b49-aed2-8bba0381807e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_918e7283-ceb3-4ae4-a35f-9211267775a5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_cf4b76b5-5c5f-4513-aa2b-f33755fbc526_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instruments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ErleadaMember_d0d1bfab-1c3d-42fa-8ed0-12ac2aebedea_terseLabel_en-US" xlink:label="lab_jnj_ErleadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA</link:label>
    <link:label id="lab_jnj_ErleadaMember_label_en-US" xlink:label="lab_jnj_ErleadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erleada [Member]</link:label>
    <link:label id="lab_jnj_ErleadaMember_documentation_en-US" xlink:label="lab_jnj_ErleadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erleada</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ErleadaMember" xlink:href="jnj-20220102.xsd#jnj_ErleadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ErleadaMember" xlink:to="lab_jnj_ErleadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionContributions_7437666e-4384-4f5f-b4d5-a24b60e7356a_terseLabel_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution to pension plans</link:label>
    <link:label id="lab_us-gaap_PensionContributions_label_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionContributions" xlink:to="lab_us-gaap_PensionContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9ad2b67b-f7d3-493e-9646-245b796214ee_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase)/Decrease in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_6edd77e7-71c4-465a-9b6a-8b4a129aeeab_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, held-to-maturity</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_51956cee-dc0d-47e6-83ac-3a76abe638e3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_0cd69bd4-9c14-486e-aa64-f463f26e6d72_terseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits from loss on capital assets</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_a519e81e-350d-4a07-bde9-9f56afcfe286_negatedTerseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits from loss on capital assets</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Capital Loss</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Capital Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:href="jnj-20220102.xsd#jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_303f9644-e34a-40d4-853d-5430cd209e9f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_1e69b371-93f4-4279-bb07-fe03b8cdd927_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_fa5ad283-a68f-421b-bdfd-7280df66d813_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4c49d5fe-2110-458d-bb67-cb16cae54973_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_c4ef00ad-a12c-4858-8646-1827e4bef89b_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of short-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_157edc71-1939-4d31-be92-2ae89757c2c0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_1f46c6a2-8280-4733-ab03-cc809bcc1109_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_a86d1e3a-9c79-43e8-abe7-419113fac024_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e1bb6f9a-7658-42b5-8863-08945a013e8d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ed5aa554-de8c-4e97-ab44-67e2883bdf63_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ee6a0c50-6b17-4ae9-839a-25f21e706ed2_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_48468609-0c92-4eca-9e11-2ed3ce7e1908_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeOneMember_1b25b751-adba-4501-a09a-bbee5c066474_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$65.08-$90.44</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeOneMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One Member</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeOneMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeOneMember" xlink:href="jnj-20220102.xsd#jnj_ExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeOneMember" xlink:to="lab_jnj_ExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_bfd3a323-90af-4cab-bd86-7dec85f8e5ab_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_eed247d4-7a8b-47f4-815c-72ceeaea6cda_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1d9333ff-90e8-45da-88a1-d11582601582_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DePuyASRU.S.Member_0d68a6fe-897a-48be-87f0-078f558eac35_terseLabel_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S.</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_label_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_documentation_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member" xlink:href="jnj-20220102.xsd#jnj_DePuyASRU.S.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DePuyASRU.S.Member" xlink:to="lab_jnj_DePuyASRU.S.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A095NotesDue2027Member_4919642e-8d3f-4105-a9f8-24dc90d85cc2_terseLabel_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_label_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_documentation_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member" xlink:href="jnj-20220102.xsd#jnj_A095NotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A095NotesDue2027Member" xlink:to="lab_jnj_A095NotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_2d11f42b-ac60-4967-9d3c-4cb050497bed_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid employee related obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_edbbd863-4720-42a8-870a-29270d274872_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_2b0c1540-ba20-42ee-854d-6e2a9782d684_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SupplyChainMember_55776d8b-f477-41f0-a6cd-cf553b151fc1_terseLabel_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain</link:label>
    <link:label id="lab_jnj_SupplyChainMember_label_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain [Member]</link:label>
    <link:label id="lab_jnj_SupplyChainMember_documentation_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember" xlink:href="jnj-20220102.xsd#jnj_SupplyChainMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SupplyChainMember" xlink:to="lab_jnj_SupplyChainMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_bc03feed-6128-48c3-8e91-dbf44ff95d33_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_660cfa1f-a504-4579-a86f-3dbd50bb4a36_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_227ab267-a6e0-4036-ac82-10eabf46ebc9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gross Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_58541fc9-46eb-48ce-a8fa-03d5a9e3e2d0_terseLabel_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member" xlink:href="jnj-20220102.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.375Notesdue2033Member" xlink:to="lab_jnj_A4.375Notesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_d04051a4-85fd-4a26-b255-f5d3834e670c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_1e51ebd2-d223-4b99-9c7d-57e2de10745b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_94f4a2d8-ff20-4b52-8b37-f8807f6759db_negatedLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities assumed and noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfEquityInvestments_0f1cd71b-37b6-4898-bf53-84da97f9b72c_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on sale of equity investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfEquityInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfEquityInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfEquityInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_50d7c8ad-b405-4a39-9747-34e6bc67b691_terseLabel_en-US" xlink:label="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans</link:label>
    <link:label id="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_label_en-US" xlink:label="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Estimated Future Employer Contributions [Table Text Block]</link:label>
    <link:label id="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_documentation_en-US" xlink:label="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated future employer contributions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:href="jnj-20220102.xsd#jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:to="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_abaed9cf-7f6d-4e7e-99e0-d0d58d03a0b6_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_c58c175c-340f-4676-9330-be54f48efafd_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesReturnReserve_0f3513c2-3688-4253-abac-3285218f18e9_terseLabel_en-US" xlink:label="lab_jnj_SalesReturnReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales return reserve (as a percent)</link:label>
    <link:label id="lab_jnj_SalesReturnReserve_label_en-US" xlink:label="lab_jnj_SalesReturnReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Return Reserve</link:label>
    <link:label id="lab_jnj_SalesReturnReserve_documentation_en-US" xlink:label="lab_jnj_SalesReturnReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales return reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesReturnReserve" xlink:href="jnj-20220102.xsd#jnj_SalesReturnReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesReturnReserve" xlink:to="lab_jnj_SalesReturnReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_f15109a8-5001-42f7-8959-da5db9930c5a_terseLabel_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing</link:label>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_label_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing [Member]</link:label>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_documentation_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember" xlink:href="jnj-20220102.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SurgicalMeshProductsMarketingMember" xlink:to="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_85cbffba-3bba-4e1f-8ac9-3e1126318e3f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_71bd72b3-507d-47b1-a73e-3b956d32955f_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_94b1358c-cf6e-41ad-9c4f-7012eccd0283_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_58e63dad-0322-41e1-884d-f84b4282a912_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4fd5841a-c850-45c9-bb58-32ad7da6fe5f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_86f6b7f6-06a2-4a33-9899-132e57fdc756_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_cddeafbc-5367-43bc-b320-0b4de05ea33b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_13b5364d-04b7-4e22-93ca-873335e01414_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation of foreign earnings amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:to="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ad33044e-4735-452e-a3a5-d7cde51cc3b6_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_524b9263-ac46-4afc-94c8-1a3a57cc1c58_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_139f8ec7-0c17-46b0-b38b-5320aac5256d_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_d145d1b5-d69b-49ce-ac02-882b27f7f393_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments : Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Assets, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_ca26391d-1d82-438c-b98d-8b36c6dddbc6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_ccc1c5b7-33a7-41fd-84c0-82ae09528933_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_56359ed3-c910-4d89-b063-8da0aae1ab83_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_373a64e2-10eb-4ae3-97ba-8c365c81c629_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_03ff48ed-79d4-469b-a6f2-6bf8313dd5f3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LandAndLeaseholdImprovementsMember_f68a5316-88e9-4f0b-b6e2-e1935f401055_terseLabel_en-US" xlink:label="lab_jnj_LandAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and leasehold improvements</link:label>
    <link:label id="lab_jnj_LandAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_jnj_LandAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land And Leasehold Improvements [Member]</link:label>
    <link:label id="lab_jnj_LandAndLeaseholdImprovementsMember_documentation_en-US" xlink:label="lab_jnj_LandAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and leasehold improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LandAndLeaseholdImprovementsMember" xlink:href="jnj-20220102.xsd#jnj_LandAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LandAndLeaseholdImprovementsMember" xlink:to="lab_jnj_LandAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_4615ae95-895e-4c66-bf68-c3ae79e926a2_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year Two</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_dc6131d9-9f2e-43ec-8355-1a62f0668c5f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_b31a3c0f-696b-452e-91ff-14f1fd86923b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After 2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_94647fc0-040b-4577-89d7-5ef4fc6a799d_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service credit (cost), net of amortization</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:href="jnj-20220102.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1e19ffae-27a1-42f1-b3a7-610c7f37e094_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_3f7fd92a-791c-4a4f-bac1-5d273f50a374_terseLabel_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_label_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_documentation_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:href="jnj-20220102.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:to="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_a389e7a3-366b-4d06-a2e5-ee6d3c7e5b3c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_5c18a784-8869-4463-8445-4f50a7843b85_terseLabel_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular Cup System</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_label_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular Cup System [Member]</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_documentation_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular cup system.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:href="jnj-20220102.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:to="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_00daefaf-f6d7-47b9-a189-2b09fe57e948_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration reversal</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_18c2135b-839b-47e0-9b37-901f4848c0b3_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities (Notes&#160;1 and 2)</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_88b2e8a9-7b4c-4308-8193-fcd0dd425672_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_9da7d6a1-8bb7-43f9-b024-ccebfeee6ad7_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_75a24000-d8ab-4458-82e3-ea783b404c3c_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TCJA, provisional liability</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_07e6415f-6b42-4146-86ee-3e8be0d9c1a1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_a61b23fa-5086-4225-94b6-71e74664024a_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_bcd9b5a3-f2f8-490e-9a4b-f81bcc6e7550_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_36cfdabd-9544-41b8-945a-3e06b669c9e6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_bc966fe0-6b01-4ac0-a20b-907df67081f0_terseLabel_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50%&#160;Debentures due 2040</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_label_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_documentation_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member" xlink:href="jnj-20220102.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Debenturesdue2040Member" xlink:to="lab_jnj_A4.50Debenturesdue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_332f3bce-9bad-465b-9d4e-42d8d6d57197_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3f84d9cd-6a95-42ee-ad9a-5ad4ca67a712_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, unrecognized gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c285e435-3907-4028-98ac-b44800385c89_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_ab48a224-3bc7-4a17-a25f-874e3774012a_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve balance beginning</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_033ccb20-29c4-4fac-b383-bc767f0b05da_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve balance ending</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityBeforeTreasuryStock_8e44e848-0da8-4df3-b10e-f903ef7b45f1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity before Treasury Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityBeforeTreasuryStock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity before Treasury Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:to="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_1a1513b4-c064-43f0-adbf-ba5385bb83f2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation contingency</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Wholesaler3Member_5306613d-21d6-41c8-8d47-b750417df184_terseLabel_en-US" xlink:label="lab_jnj_Wholesaler3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 3</link:label>
    <link:label id="lab_jnj_Wholesaler3Member_label_en-US" xlink:label="lab_jnj_Wholesaler3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 3 [Member]</link:label>
    <link:label id="lab_jnj_Wholesaler3Member_documentation_en-US" xlink:label="lab_jnj_Wholesaler3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler3Member" xlink:href="jnj-20220102.xsd#jnj_Wholesaler3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Wholesaler3Member" xlink:to="lab_jnj_Wholesaler3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_da0aabfe-cc38-4174-9c09-f839dba31cd4_terseLabel_en-US" xlink:label="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, tax basis increase of certain assets due to reorganization</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_label_en-US" xlink:label="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_documentation_en-US" xlink:label="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:href="jnj-20220102.xsd#jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:to="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_af717201-3730-4080-8328-a4c6df8da4bc_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes on income (Note&#160;8)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_81875a5d-687b-43c6-bd48-061416d448ab_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShippingandHandlingCostsasaPercentofSales_c4d8816b-81bb-4221-b360-c7e8f824df86_terseLabel_en-US" xlink:label="lab_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and handling costs as a percent of sales</link:label>
    <link:label id="lab_jnj_ShippingandHandlingCostsasaPercentofSales_label_en-US" xlink:label="lab_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling Costs as a Percent of Sales</link:label>
    <link:label id="lab_jnj_ShippingandHandlingCostsasaPercentofSales_documentation_en-US" xlink:label="lab_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling Costs as a Percent of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:href="jnj-20220102.xsd#jnj_ShippingandHandlingCostsasaPercentofSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:to="lab_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_910666a1-a00f-44c4-94bd-db2b9d1b333e_terseLabel_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_label_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_documentation_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember" xlink:href="jnj-20220102.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SimponiSimponiAriaMember" xlink:to="lab_jnj_SimponiSimponiAriaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_0d09d523-fd1f-49fe-8025-9013b4dce704_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_a3aafa44-71f9-4004-888d-95ca034bd089_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_126bd689-6f33-4f2c-9c5c-866a0137fcc0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options average price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_707e194b-03fc-4f09-bd8f-8183aee3edde_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled non cash</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Settled without Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:to="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_XareltoMember_16a05bcb-3fba-4112-9bf3-5a4b01471f3c_terseLabel_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XARELTO</link:label>
    <link:label id="lab_jnj_XareltoMember_label_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:label id="lab_jnj_XareltoMember_documentation_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember" xlink:href="jnj-20220102.xsd#jnj_XareltoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_XareltoMember" xlink:to="lab_jnj_XareltoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_fec3c83a-61a0-49e9-902c-833a1b0d666f_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_284b6d19-cd32-4039-b2ad-0292e62f51e0_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_4f4b6b3d-5170-42bb-9dd7-796bfb68a2ff_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_7f2675fb-8ca9-42c4-97c5-58cad487514d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_fc059b6d-39f3-4b0e-bf0b-05d2c15b15bf_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_414792ad-20ff-41e2-82a3-c3922531c325_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_19adc194-c0cc-4576-9bbc-3e71f3eb1954_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year Three</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_4b4d5f6d-c76c-49fd-80a8-10bce06928ab_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_ccbe5fe2-4b99-4879-bd7a-b2a21f2b9359_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Current Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_c99a3841-9692-470d-8ab1-9bb13e2967d4_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. taxes</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_4df9abb8-ce63-4171-a752-95d0a6f5e848_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_ee3c8fe0-d125-4bdd-9386-6749b530ce50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits on share-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_01ed71f7-2dab-40f1-8869-d0c3080080c2_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_fb496892-2523-4596-8ac2-ce9305e5c3be_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#160;&#8212; par value $1.00 per share (Note&#160;12) (authorized 4,320,000,000&#160;shares; issued 3,119,843,000&#160;shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a91d70d7-c785-44f2-ac5e-8b58643d917e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period for total compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_626ca6e4-ba50-4ce0-ac3f-282379e6fb20_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded status - end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_dcbd8c28-179b-4170-978a-e206dc72fa6b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_e8c87833-0e57-407f-b643-ff2950d96500_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Divestitures</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_b3b145c9-97f6-4e6b-8ae1-b9f0d7601053_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3f07f0f9-ce77-47eb-b6cc-c469908d772b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ZYTIGAMember_4ec44265-67fd-46b2-9a86-8d02e54ab77e_terseLabel_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA/abiraterone acetate</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_label_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_documentation_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember" xlink:href="jnj-20220102.xsd#jnj_ZYTIGAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ZYTIGAMember" xlink:to="lab_jnj_ZYTIGAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_85eb1073-0903-406b-bd47-2b90d5a183c9_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_375f4128-df7c-4e57-8a71-3225ef155518_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_db6e085f-f2e2-480b-a9c3-303f9f929fe0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives &amp; hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_25702ffb-e701-416f-809d-3315e6ebad4c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service cost (credit)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_cc693a69-24d7-460a-a304-37290748ea6a_verboseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:href="jnj-20220102.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:to="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a3dd70c7-fa23-4181-97ab-080e4a7766a5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International taxes</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_a63845e1-dbc2-4e76-a1bf-cf7adbaf5dff_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_d71873f4-46f9-4ab2-911e-18a32f242b4a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare cost trend rate assumed for next year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_7d471a7a-482a-4dd3-ab9a-f1459553e87b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_b94c1b55-b5d8-4c48-9b8f-d6e1b4f227c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments and settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherNonLongLivedAssets_0da4bd46-1c3e-4266-8bf7-247174ff337d_terseLabel_en-US" xlink:label="lab_jnj_OtherNonLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non Long Lived Assets</link:label>
    <link:label id="lab_jnj_OtherNonLongLivedAssets_label_en-US" xlink:label="lab_jnj_OtherNonLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non Long Lived Assets</link:label>
    <link:label id="lab_jnj_OtherNonLongLivedAssets_documentation_en-US" xlink:label="lab_jnj_OtherNonLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non long lived assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonLongLivedAssets" xlink:href="jnj-20220102.xsd#jnj_OtherNonLongLivedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherNonLongLivedAssets" xlink:to="lab_jnj_OtherNonLongLivedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_88a4c0ed-6e6e-43ab-baae-cb018ed34d4f_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without readily determinable value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:href="jnj-20220102.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_d8bf0109-58c3-43ea-bcf3-d435ca320b6a_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_703cdb8b-cf72-4f93-bf9c-8a8f2b1cd5cd_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_966dfabd-5d5d-4d1e-a8d4-e10ed7ea4cd2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_cec3a41f-ccd6-4f43-9e8e-8f7b2531f543_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goods in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_84a4babe-0610-489c-98df-7d4d285d02cb_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other receivables</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_7f80d8f5-2bd0-4e50-a754-8400691cb3ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_ee5ce1f6-48b6-46b7-b77f-def5659b8ac8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a7d0f1f9-ab5f-4067-890c-982fc97df7ef_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_664d1593-0d4a-40ed-98dd-6e7a2f7dc3f3_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_13fc6c44-b466-40ae-8b6f-c853da8f7b20_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to Customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ff9dc6a7-d6f6-4ec3-8a4f-6e2b2c9a2936_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_VerbSurgicalIncMember_b95099dd-8a3c-4d90-af9a-09028aaca2f6_terseLabel_en-US" xlink:label="lab_jnj_VerbSurgicalIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verb Surgical Inc.</link:label>
    <link:label id="lab_jnj_VerbSurgicalIncMember_label_en-US" xlink:label="lab_jnj_VerbSurgicalIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verb Surgical Inc. [Member]</link:label>
    <link:label id="lab_jnj_VerbSurgicalIncMember_documentation_en-US" xlink:label="lab_jnj_VerbSurgicalIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verb Surgical Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VerbSurgicalIncMember" xlink:href="jnj-20220102.xsd#jnj_VerbSurgicalIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_VerbSurgicalIncMember" xlink:to="lab_jnj_VerbSurgicalIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_aafa2a68-634f-4c76-8984-376d0bd209f6_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SurgeryMember_5f7a4eb2-873a-4522-af50-04a764e8b2da_terseLabel_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery</link:label>
    <link:label id="lab_jnj_SurgeryMember_label_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery [Member]</link:label>
    <link:label id="lab_jnj_SurgeryMember_documentation_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember" xlink:href="jnj-20220102.xsd#jnj_SurgeryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SurgeryMember" xlink:to="lab_jnj_SurgeryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1f919ed4-8541-4429-b1c9-1e2a7e825251_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_0c1e60e6-29d8-4370-9ca4-705fcfb299af_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_9907e4ef-09ec-49ae-8ead-feb832627470_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_636cd4e8-4070-4e8f-a8b9-4b8404873178_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_420581c7-578a-4ddc-a7a5-64257cc57b1b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EmployeeCompensationPeriod_1f7ebcbe-6edf-45df-9b72-7d4de69d9ffc_terseLabel_en-US" xlink:label="lab_jnj_EmployeeCompensationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement plan benefits Employee compensation Period</link:label>
    <link:label id="lab_jnj_EmployeeCompensationPeriod_label_en-US" xlink:label="lab_jnj_EmployeeCompensationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Compensation Period</link:label>
    <link:label id="lab_jnj_EmployeeCompensationPeriod_documentation_en-US" xlink:label="lab_jnj_EmployeeCompensationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Compensation Period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeCompensationPeriod" xlink:href="jnj-20220102.xsd#jnj_EmployeeCompensationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EmployeeCompensationPeriod" xlink:to="lab_jnj_EmployeeCompensationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_e44808e9-438e-4555-8afa-a0742f27b8dd_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments of Business and Geographic Areas</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f5e2f2b1-fc23-4dee-9d80-d08a8def0ff4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2df8d82c-0082-439a-bb43-8585a1b94dfa_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_0dd8777d-f7f8-4ecd-811c-c294c92203bc_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_3919bbfa-3585-4573-bff7-7dc2ba0c10c5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_b6736a98-c23d-4ccb-9af9-e3b7fd96ab9d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027-2031</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_ca0322ec-dda6-4720-8359-46c281d31929_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_a66c8c9f-4a1d-4cf6-abb7-e4f2951a89a1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_553eb7ae-87ec-420c-b075-8e35a38d73ea_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_VisionMember_c3385c5c-59a1-416b-9905-0c00ab06294f_terseLabel_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision</link:label>
    <link:label id="lab_jnj_VisionMember_label_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision [Member]</link:label>
    <link:label id="lab_jnj_VisionMember_documentation_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember" xlink:href="jnj-20220102.xsd#jnj_VisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_VisionMember" xlink:to="lab_jnj_VisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_02a0b413-9811-4a66-9ccf-51a12c0cb900_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_cd5ce301-a926-4d16-9428-b6c22f675bec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_1c5b7985-6d9c-49ec-9b06-ef372ee62d68_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ebcb5895-7a00-4fe4-80fd-d7c0db8005ba_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease)/Increase in other current and non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_6850ec80-1061-444c-a0e0-c3dbe19e1afa_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year Four</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_82d71331-b81e-4d08-95a1-e897b9ac92ed_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (primarily licenses and milestones)</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_8f1b7a4a-0b27-4b15-8e65-f013c51e8dc1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income reported for tax purposes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_1dbeed0a-7533-42a6-a524-c93245ec57ef_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d60b71fc-b5e7-42db-92a0-6f98362d2d99_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_acec9326-4d6a-49e4-bf3c-4759c59e9813_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax rates:</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_d280d320-6cd4-42e1-932f-28c8633505bb_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2ede6352-0c27-43f4-aeaa-03714b954234_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_ead53513-8eb8-4dfc-a901-6b3b4017b54d_terseLabel_en-US" xlink:label="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in deferred tax liabilities, global intangible low-taxed income (GILTI)</link:label>
    <link:label id="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_label_en-US" xlink:label="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)</link:label>
    <link:label id="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_documentation_en-US" xlink:label="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:href="jnj-20220102.xsd#jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:to="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GENERALMember_af597202-f973-47db-a961-2b9ff2e5f95a_terseLabel_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL</link:label>
    <link:label id="lab_jnj_GENERALMember_label_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:label id="lab_jnj_GENERALMember_documentation_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember" xlink:href="jnj-20220102.xsd#jnj_GENERALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GENERALMember" xlink:to="lab_jnj_GENERALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_df875fc2-81e3-4452-8706-ea02ced0f32c_terseLabel_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total recognized in net periodic benefit cost and other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:to="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_7b20df0e-8624-437b-afc6-e2a55144dad0_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2f4c29fc-d7e5-4b1b-a099-6bf9cdc5b7ac_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_97ba9b43-1e36-4591-befc-8081ad2efff5_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f6e44205-1513-4ec7-8cae-5daffaaffd30_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShortTermInvestmentFundsMember_3b714081-4d40-4510-9427-d357d60a62f9_terseLabel_en-US" xlink:label="lab_jnj_ShortTermInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investment funds</link:label>
    <link:label id="lab_jnj_ShortTermInvestmentFundsMember_label_en-US" xlink:label="lab_jnj_ShortTermInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Investment Funds [Member]</link:label>
    <link:label id="lab_jnj_ShortTermInvestmentFundsMember_documentation_en-US" xlink:label="lab_jnj_ShortTermInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShortTermInvestmentFundsMember" xlink:href="jnj-20220102.xsd#jnj_ShortTermInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShortTermInvestmentFundsMember" xlink:to="lab_jnj_ShortTermInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_568dfe9a-9a7f-46e1-a46e-85e95281b15a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_6fc68a2a-21d2-48a3-8b9d-23b14b123c86_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0a0256fd-8345-400f-b845-728f6d747e8d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_dc3426eb-2bad-4e0d-b3e2-afe7e25d3140_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of debt</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_99005257-4b28-4a02-9b03-c03dc484b6c8_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity, unrecognized gain</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestOnConvertibleDebtNetOfTax_f5bc4ba8-e9b1-483d-ab83-00225dccce82_terseLabel_en-US" xlink:label="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense convertible debt</link:label>
    <link:label id="lab_us-gaap_InterestOnConvertibleDebtNetOfTax_label_en-US" xlink:label="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on Convertible Debt, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:to="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_e3f205be-7fa2-4667-a1a4-d28dd41d5174_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_c2400e94-634c-4d28-bdea-20549d80eb15_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives of the assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_941fa558-a300-4a27-a814-9fbaacefd529_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_360eaeb5-8261-4c38-8cd2-f0d28ee67842_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_c44003cf-7212-4681-9a7f-3949f0239fd8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EmployeeObligations_fc4b74a2-8a64-4ef2-a18b-00c1256c98c0_totalLabel_en-US" xlink:label="lab_jnj_EmployeeObligations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total employee obligations</link:label>
    <link:label id="lab_jnj_EmployeeObligations_label_en-US" xlink:label="lab_jnj_EmployeeObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Obligations</link:label>
    <link:label id="lab_jnj_EmployeeObligations_documentation_en-US" xlink:label="lab_jnj_EmployeeObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total employee obligations current and non current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeObligations" xlink:href="jnj-20220102.xsd#jnj_EmployeeObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EmployeeObligations" xlink:to="lab_jnj_EmployeeObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_9dd267a5-b528-4662-a568-cfa4484c61f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent_b293bcfe-ebb2-4cee-b9d7-4b555e1f0828_terseLabel_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate reconciliation, litigation settlement, percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent_label_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Litigation Settlement, Percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent_documentation_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Litigation Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent" xlink:href="jnj-20220102.xsd#jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent" xlink:to="lab_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_34a81a87-38e1-4200-b209-6abcc6a740b1_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total currently payable</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_b73333db-f897-4b4f-8e17-a5c332dbf777_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_a780b75b-e3b5-46f7-9730-41b7c69d7ebe_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_cce3f1dd-7a6d-4f00-8f92-e3308d866f53_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset_6f670910-707f-4c4f-97fe-30d018f94b2d_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of deferred tax asset</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Asset</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_3e1fc1d5-6354-4a93-a944-171f39bd268f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from short-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_90b53283-61a8-44dc-b39f-9a2e78af6c71_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax benefit recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ImmunologyMember_32e27395-c316-4b4d-8005-bad76030a79a_terseLabel_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology</link:label>
    <link:label id="lab_jnj_ImmunologyMember_label_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:label id="lab_jnj_ImmunologyMember_documentation_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember" xlink:href="jnj-20220102.xsd#jnj_ImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ImmunologyMember" xlink:to="lab_jnj_ImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_bfa2fcde-32a3-406f-8e9f-8834b6b3696e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock_b327f1a9-a0bd-4a20-8089-19b82dd27f87_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Related Obligations</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, General [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_ccfcf96c-1cc7-4d94-9c20-0a91895018bf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_454f9a59-88dd-4c48-ad54-5fe4affeb6ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_ced9a009-668e-477a-9ca9-e9211d54d949_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_4a57f36b-b3d1-436a-a9d6-0b2699170966_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_c581ecf9-57ed-435a-99c8-79b0dc79b5a2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan with accumulated benefit obligation in excess of plan assets, plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_1c1d4d70-02d5-4a18-a674-ac05dbb6a4e1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_8c8fe689-e47d-4038-87c5-d08ae06925a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_89108649-c9a9-4be3-9cbc-8edf5daf1f6f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_184aa6be-b9a9-4c2e-8057-8fff427cb97d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d66d2faf-756b-4bf9-bfbf-4ce1ca53e027_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_592afeec-ae3f-4b1e-8107-f46a40d655aa_terseLabel_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:href="jnj-20220102.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_121a7014-e878-4676-8ea5-5922dea9acbc_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_f213c1c0-65bf-4934-bf21-d8b1683d9bca_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_61df95e7-037a-4a0b-b5be-5285712fe184_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan participant contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_6c88cea5-4378-4eba-a7f2-215722316172_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProfitLossPercentToSales_dd2a99cf-c223-4a75-a6b9-6df684a2629e_terseLabel_en-US" xlink:label="lab_jnj_ProfitLossPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of profit share payments (less than)</link:label>
    <link:label id="lab_jnj_ProfitLossPercentToSales_label_en-US" xlink:label="lab_jnj_ProfitLossPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Loss Percent To Sales</link:label>
    <link:label id="lab_jnj_ProfitLossPercentToSales_documentation_en-US" xlink:label="lab_jnj_ProfitLossPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit loss percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProfitLossPercentToSales" xlink:href="jnj-20220102.xsd#jnj_ProfitLossPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProfitLossPercentToSales" xlink:to="lab_jnj_ProfitLossPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_94301789-d225-413c-a758-fc37fb5c8b00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled/forfeited, average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3f8aab84-2f93-4f1b-b303-e012c9feab82_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for taxes on income (Note&#160;8)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_319aeb1f-9ed9-4122-98bd-eff37a85dc3b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_0aff160c-c108-4c28-b9fb-972698ac66bb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation/other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeFourMember_80feb48f-3985-41b1-a2f4-12a356b76e38_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$131.94-$151.41</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFourMember" xlink:href="jnj-20220102.xsd#jnj_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeFourMember" xlink:to="lab_jnj_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_5221fd60-8abf-4e68-a93d-fb79e59a0d47_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9271f2bc-4173-4e7c-a5c9-5d1726b57b21_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable trade, less allowances for doubtful accounts $230 (2020, $293)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1a46ae49-30e6-4b74-9763-9d92b521d868_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_a62cfbb1-15cc-441b-9458-3fa385ee4393_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalent Composition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_45bfff79-5d2a-417d-b8d5-a5ee70223dfd_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_b4a8126a-e146-40f3-8508-9bacd329336f_verboseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due May 2024</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_3c706a73-c0e8-4d79-8563-7d323f0fa3a0_terseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes due 2024 (750MM Euro 1.1311)(2)/(750MM Euro 1.2281)(3)</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member" xlink:href="jnj-20220102.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0.650NotesDue2024Member" xlink:to="lab_jnj_A0.650NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_d592a2b9-8fca-4e3d-9eb7-0d47b7b3bc83_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_fbdaeca6-236b-4695-bbdc-96921994f468_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0fa6f054-ad78-470a-b632-cb67cf3cfc98_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_972e911f-6b00-45b5-a730-3f362ce5ab83_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_72809556-293a-463a-93a1-d312dec1012f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_ed0b69da-b6ce-4242-95e7-cd3408f7c71e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_c6fb3f7e-0748-401f-92ba-19776a398460_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) reclassified from AOCI into income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WomensHealthMember_0f37ae58-aa1e-4d95-8901-9bb5e6a65d34_terseLabel_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health</link:label>
    <link:label id="lab_jnj_WomensHealthMember_label_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health [Member]</link:label>
    <link:label id="lab_jnj_WomensHealthMember_documentation_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember" xlink:href="jnj-20220102.xsd#jnj_WomensHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WomensHealthMember" xlink:to="lab_jnj_WomensHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_aaa8e0d1-ed7c-4b47-b76d-a5e7ce7b1fdb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_8aecffef-305f-41e2-9d4f-2b6d74d0d80f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor_78a4ab90-bc84-4ad5-a669-1c27f7bae029_terseLabel_en-US" xlink:label="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of success factor</link:label>
    <link:label id="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor_label_en-US" xlink:label="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Probability Of Success Factor</link:label>
    <link:label id="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor_documentation_en-US" xlink:label="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Probability Of Success Factor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:href="jnj-20220102.xsd#jnj_BusinessCombinationProbabilityOfSuccessFactor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:to="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_da395123-1e77-4638-b9d2-3293eff7fbfd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_18f4fe69-91bc-439c-9603-2b04b907a058_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_f61170e5-9518-41c2-9921-dd2e98f6274c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_038a4497-f696-436f-bd8b-8fc2931aa7c7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_a8f89099-fe15-4837-979f-70e7588880eb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_f0cf44c1-4a69-473b-97aa-6eb3cb3c81a4_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_73bb372d-6dd6-4178-b7ed-02146ec94b1c_terseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding and exercisable</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Abstract]</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation shares authorized under stock option plans by exercise price range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:href="jnj-20220102.xsd#jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:to="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5be0b9df-f6d8-4259-9433-2dc40b902b07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average fair value of option granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_eeebf862-44a6-4367-b1a6-7dd6d97292bc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_4e02d4e9-b3e9-4a0c-98b5-fbef7c88eb8d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_25e7a131-aa25-42b1-9f59-96920e574575_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OPSUMITMember_15293642-26a3-4e27-8bd4-8fe016bbdd7a_terseLabel_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT</link:label>
    <link:label id="lab_jnj_OPSUMITMember_label_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:label id="lab_jnj_OPSUMITMember_documentation_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember" xlink:href="jnj-20220102.xsd#jnj_OPSUMITMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OPSUMITMember" xlink:to="lab_jnj_OPSUMITMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a6bd9d5d-21bd-4592-ba3a-007478647a19_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_94831095-73b5-46bf-8287-76a90fb2778d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_4ce3bd1e-0034-4f8d-b3ab-f9862c2ce5b3_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, noncurrent</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_7d114028-fc9d-4be6-8420-d408bcae2f00_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_02259d57-0813-40a6-9b7a-8c1c46636914_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_0ab3c79d-dcda-4d47-abf4-8c4b3e9f4da2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_5ec39379-c761-4fa8-a3b9-4df0f8913012_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0.250NotesDue2022Member_cc0e25ed-e42d-4995-a6fd-dcda67801ad1_terseLabel_en-US" xlink:label="lab_jnj_A0.250NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.250% Notes due 2022 (1B Euro 1.1311)(2)/(1B Euro 1.2281)(3)</link:label>
    <link:label id="lab_jnj_A0.250NotesDue2022Member_label_en-US" xlink:label="lab_jnj_A0.250NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.250% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_jnj_A0.250NotesDue2022Member_documentation_en-US" xlink:label="lab_jnj_A0.250NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.250% Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.250NotesDue2022Member" xlink:href="jnj-20220102.xsd#jnj_A0.250NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0.250NotesDue2022Member" xlink:to="lab_jnj_A0.250NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_ec3c2153-8dec-4f83-a391-28e35ce20a65_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_977ca7d9-7a7a-4deb-8354-f832d0ea5635_terseLabel_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90%&#160;Notes due 2028</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_label_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_documentation_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member" xlink:href="jnj-20220102.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.900Notesdue2028Member" xlink:to="lab_jnj_A2.900Notesdue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_c7e5a441-883f-456a-ba11-5f6989cd048d_terseLabel_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_label_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_documentation_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember" xlink:href="jnj-20220102.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UNITEDSTATESExportsMember" xlink:to="lab_jnj_UNITEDSTATESExportsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FederalLevelJurisdictionMember_62e1a25f-b5a1-4546-a061-54c2cce9b7c4_terseLabel_en-US" xlink:label="lab_jnj_FederalLevelJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Level Jurisdiction</link:label>
    <link:label id="lab_jnj_FederalLevelJurisdictionMember_label_en-US" xlink:label="lab_jnj_FederalLevelJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Level Jurisdiction [Member]</link:label>
    <link:label id="lab_jnj_FederalLevelJurisdictionMember_documentation_en-US" xlink:label="lab_jnj_FederalLevelJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Level Jurisdiction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalLevelJurisdictionMember" xlink:href="jnj-20220102.xsd#jnj_FederalLevelJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FederalLevelJurisdictionMember" xlink:to="lab_jnj_FederalLevelJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_771767df-5023-464e-9898-a21798560fef_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_66c622e6-dad3-4257-9fe6-e25d2559575f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company' Retirement Plan Asset Allocation and Target Allocations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1fa1dd69-cb44-4e0e-b11a-5ded7843de30_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_3377b57f-e72d-4620-a661-29e9164bb1b5_terseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. taxes on international income</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Related To Domestic Tax On International Income</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation related to domestic tax on international income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:href="jnj-20220102.xsd#jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9f8d5d3a-e9c3-4d32-9752-4d46996e54ae_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_31a1f8fe-8511-4325-9015-f68e091e90b9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_fc5126c2-c29d-4c98-bed2-abff4ef510de_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_026cdb22-3dc1-41bf-81be-bad640b94553_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_065b10b5-0f40-4c4e-9f8e-6167c4cf9fdf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Recognized In Income on Derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_81ae6e7f-f552-4f6d-8047-cc3870af0df3_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_d256f87c-ea23-48ef-99a8-38812d77c49e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_8fdc4d4e-4512-41fa-a055-e45a8711cee5_terseLabel_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of fair value over carrying value of debt</link:label>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_label_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Of Fair Value Over Carrying Value Of Debt</link:label>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_documentation_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of fair value over carrying value of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:href="jnj-20220102.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:to="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ecf55872-b781-410d-b77a-0ab4c3ce7cfe_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_82fa87cd-b168-4295-a02e-1bf0b169dad8_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_768e05b2-7c48-47e4-9240-8fd1788b5adf_terseLabel_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95%&#160;Debentures due 2033</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member" xlink:href="jnj-20220102.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.95Debenturesdue2033Member" xlink:to="lab_jnj_A4.95Debenturesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_2474f339-ca81-4334-bf10-70f42ea4ba2a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_KNEESMember_9d29fc9f-cd08-48e4-903d-2e3d5e56efe4_terseLabel_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES</link:label>
    <link:label id="lab_jnj_KNEESMember_label_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES [Member]</link:label>
    <link:label id="lab_jnj_KNEESMember_documentation_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember" xlink:href="jnj-20220102.xsd#jnj_KNEESMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_KNEESMember" xlink:to="lab_jnj_KNEESMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0f1204d8-3533-4e60-b47f-26539b04c9ae_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e3f28e78-e459-4fe2-8d2b-b718b103879d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTranslationAbstract_d6bee3ae-a9ce-4737-b45a-5ca356bb651c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTranslationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation [Abstract]</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTranslationAbstract_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTranslationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTranslationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTranslationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTranslationAbstract" xlink:to="lab_us-gaap_ForeignCurrencyTranslationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_024801cb-5208-4dfa-bb0f-2daf3cbfa261_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Benefit Obligation</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Over (Under) Funded Status ABO</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan over (under) funded status ABO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanOverUnderFundedStatusABO"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:to="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3c30bed5-1357-41dd-a749-f1c832604a8b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_67b5a476-55f2-40f5-a5b5-c25a4ccf3f1a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_be73e5c7-80ad-41b1-a4f2-3c3886f5bbef_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherSovereignSecuritiesMember_b5676768-d742-4180-a4d5-068045aaaa98_terseLabel_en-US" xlink:label="lab_jnj_OtherSovereignSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sovereign Securities</link:label>
    <link:label id="lab_jnj_OtherSovereignSecuritiesMember_label_en-US" xlink:label="lab_jnj_OtherSovereignSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sovereign Securities [Member]</link:label>
    <link:label id="lab_jnj_OtherSovereignSecuritiesMember_documentation_en-US" xlink:label="lab_jnj_OtherSovereignSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sovereign Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherSovereignSecuritiesMember" xlink:href="jnj-20220102.xsd#jnj_OtherSovereignSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherSovereignSecuritiesMember" xlink:to="lab_jnj_OtherSovereignSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_4df20cf9-afec-4f4f-931e-9abb84907071_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_301ec1a1-012c-4c0b-86f0-745a11c46d0d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_cf0e6d66-3a08-4990-aa54-f9af2ac6cfeb_terseLabel_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability contingency, number of claimants</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_label_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Contingency Number Of Claimant</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_documentation_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability contingency number of claimant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:href="jnj-20220102.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:to="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6268e682-4d66-4302-95d1-8109b2d7e843_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f49fddd8-d7fc-4c1c-8ff3-a508449acf49_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_a9457a0d-35b4-4158-b290-4060f690d2df_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_725027b8-7757-4e0b-ac7f-704261ad4af0_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember" xlink:to="lab_us-gaap_RepurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_bbf2fb25-fdda-4ca7-ab7d-cd4d337d0d18_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed foreign earnings</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_48b5821a-7826-4ed2-b2b0-3f123bc03b70_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_e3cec9b8-8c54-4f7a-996a-ef841158ecf9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_87608e93-a5b5-4d73-bbeb-49f58eda37fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_6af211f9-3e39-4f80-9804-1929a342441b_terseLabel_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA/INVOKAMET</link:label>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_label_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA/INVOKAMET [Member]</link:label>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_documentation_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA/INVOKAMET [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember" xlink:href="jnj-20220102.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_INVOKANAINVOKAMETMember" xlink:to="lab_jnj_INVOKANAINVOKAMETMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_d308cf6d-abe2-42fa-b292-f53d0ff4b43f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_46786cb3-a859-4a38-904e-55496f0c4837_terseLabel_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400%&#160;Notes due 2038</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_label_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member" xlink:href="jnj-20220102.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.400Notesdue2038Member" xlink:to="lab_jnj_A3.400Notesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset_40b58a03-635a-494d-ad44-29d5abdb51af_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TCJA, increase (decrease) in deferred tax asset</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Increase (Decrease) In Deferred Tax Asset</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Increase (Decrease) In Deferred Tax Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_a46c777f-210b-4df9-b73a-be1956702f09_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8bf1d05b-b10f-49e7-b146-45ee1a8f958d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_6d9861f6-ec73-442b-83c0-67a666764cf6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Excluded Component, Gain (Loss), Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:to="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_bd22df98-35a7-4ad8-9f7e-7c5b7b5eb6a8_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_6dcc0912-df9c-4794-a599-a290f7ad6efb_terseLabel_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense related to TRAF</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:href="jnj-20220102.xsd#jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:to="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_5ddace74-a2b0-4c7f-a980-628290632721_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4031a2b6-582e-42a3-876a-dcd494c82b3d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9fc9b2cb-cfea-4567-bf6f-3ec904b75d04_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_f4da321a-b617-402e-af20-6737661285e0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TCJA and related impacts</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_2f613cf3-5ab7-4795-a369-dba17693bedb_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service (cost) credit</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_f528270c-546a-4b39-8dca-8c06359a7538_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit_2d2fae64-0e19-4138-a434-f925b44f373e_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, foreign tax credits, net deferred tax expense (benefit)</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Net Deferred Tax Expense (Benefit)</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Net Deferred Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_b3eb58a1-ef9d-4169-a076-1b88e4a6d01f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_c809fa3e-0a09-44f8-81e5-f6d3700b1801_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: common stock held in treasury, at cost (Note&#160;12) (490,878,000&#160;shares and 487,331,000&#160;shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_631c7539-d605-467a-b19c-93ddfc47a01d_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Balance</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_80ac8c71-9c6e-49de-abb3-441afb76208c_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Ending Balance</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1b9a7302-7f36-4fc3-8f65-04f00356832a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding (Notes 1 and 15)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_8a81cb82-d8cc-46fe-850a-53abf1b8c317_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, including discontinued operation, cash</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_78323612-4e6a-455e-a064-e1b5e4e5dbd0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_b488e451-4556-46f9-9e47-d7d8a43beb15_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_595d3da4-e69e-468d-8ed6-7534a973d2e2_verboseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due November 2024</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_122d6a43-c3d5-4245-bee6-0886a871f08c_terseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50%&#160;Notes due 2024 (500MM 1.3485 GBP )(2)/(500MM GBP 1.3654)(3)</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member" xlink:href="jnj-20220102.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.50NotesDue2024Member" xlink:to="lab_jnj_A5.50NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_955cdd2e-cdb8-4e9f-90b6-1f545ba2b3ef_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring (Note 20)</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_93aa8490-2d66-4bb2-a45a-c12ce5cacacb_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_467d0775-8b90-4305-9374-5450478a6fab_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RisperdalMember_1ef0c535-03a5-404f-880f-4372a965bbb9_terseLabel_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal</link:label>
    <link:label id="lab_jnj_RisperdalMember_label_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal [Member]</link:label>
    <link:label id="lab_jnj_RisperdalMember_documentation_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember" xlink:href="jnj-20220102.xsd#jnj_RisperdalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RisperdalMember" xlink:to="lab_jnj_RisperdalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e00ac180-018b-40e7-b6b8-4a726bd528c3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_55dd3a90-efba-4565-aa1c-7d6f1063e4b2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_3473f1ac-0148-4ff1-9dca-ce200e406ea1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherOncologyMember_545a0fbf-bd33-44c6-8ab7-dfa755a78223_terseLabel_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_label_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_documentation_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember" xlink:href="jnj-20220102.xsd#jnj_OtherOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherOncologyMember" xlink:to="lab_jnj_OtherOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_32c263af-db12-4df0-9691-deaa6b4fe3b9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_df3e3fae-e2b0-494a-bd2c-353b3b0ac0e2_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_aa9116ea-bc0b-4a8b-a0f2-0a00a8159d73_terseLabel_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73%&#160;Debentures due 2023</link:label>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_label_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member" xlink:href="jnj-20220102.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A6.73Debenturesdue2023Member" xlink:to="lab_jnj_A6.73Debenturesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_721d34cf-958b-4854-a2aa-245557daa787_terseLabel_en-US" xlink:label="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense, including the amortization of capitalized interest</link:label>
    <link:label id="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_label_en-US" xlink:label="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation Expense Including Amortization Of Capitalized Interest</link:label>
    <link:label id="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_documentation_en-US" xlink:label="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense including the amortization of capitalized interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:href="jnj-20220102.xsd#jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:to="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_edea73ff-b75e-4136-afc3-eab3a8e8e3fd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_f6a6c2de-b5e0-4fb0-81eb-366a6aefc471_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation, unfunded plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_586a1ac4-2e9a-485a-a9e9-69a2cb2303be_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fa12031d-9926-4c89-9546-5fe9a08d0d84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_4047c6f0-6e62-4d59-a230-81f219fbcbfe_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment at Cost and Accumulated Depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_a95bb4d9-d85d-4a0c-87f2-c311bcee34ae_negatedTerseLabel_en-US" xlink:label="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global intangible low-taxed income</link:label>
    <link:label id="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_label_en-US" xlink:label="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability, Global Intangible Low-Taxed Income</link:label>
    <link:label id="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_documentation_en-US" xlink:label="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability, Global Intangible Low-Taxed Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:href="jnj-20220102.xsd#jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:to="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_d1f118da-9fe9-4bf5-a12b-f18bd793e96c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_7e554941-2269-4df6-b5dd-7e53d4d7b65d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_76d2739b-b8d4-4042-8ad3-b7a629242950_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental schedule of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BermekimabMember_491db001-26a3-4e78-bbf3-1bdfd6d15092_terseLabel_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab</link:label>
    <link:label id="lab_jnj_BermekimabMember_label_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab [Member]</link:label>
    <link:label id="lab_jnj_BermekimabMember_documentation_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember" xlink:href="jnj-20220102.xsd#jnj_BermekimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BermekimabMember" xlink:to="lab_jnj_BermekimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_aa36f989-d6cc-4a55-a8ac-ee0bb0e4414d_terseLabel_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA</link:label>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_label_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA [Member]</link:label>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_documentation_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember" xlink:href="jnj-20220102.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RISPERDALCONSTAMember" xlink:to="lab_jnj_RISPERDALCONSTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c62f42ae-3158-4f25-9a41-b9cfa3068db2_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net (Notes&#160;1 and 4)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5ba1d738-05a7-4674-80fc-9568c2a65e0a_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_61181cb4-92a5-4e9d-b771-615a43e06c36_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_37709929-4065-4995-92a5-afd5ec02b0f0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings per share (Notes 1 and 15)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_43ed81dd-23d1-4659-8481-8ccefeb9565b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ChangesInTreasuryStockRollForward_4549a31f-65f7-4610-a35c-90a317cb307b_terseLabel_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in treasury stock</link:label>
    <link:label id="lab_jnj_ChangesInTreasuryStockRollForward_label_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Treasury Stock [Roll Forward]</link:label>
    <link:label id="lab_jnj_ChangesInTreasuryStockRollForward_documentation_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in treasury stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockRollForward" xlink:href="jnj-20220102.xsd#jnj_ChangesInTreasuryStockRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward" xlink:to="lab_jnj_ChangesInTreasuryStockRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_b5b7ad48-1ec6-4473-8490-345d4153e278_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeTwoMember_6cf35adf-887c-42fb-8687-390e4f41555e_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$100.06-$101.87</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeTwoMember" xlink:href="jnj-20220102.xsd#jnj_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeTwoMember" xlink:to="lab_jnj_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_d0d088fc-fb1e-4537-b97c-a7d71e10ccca_terseLabel_en-US" xlink:label="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives of Assets</link:label>
    <link:label id="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_label_en-US" xlink:label="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives Of Assets [Table Text Block]</link:label>
    <link:label id="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_documentation_en-US" xlink:label="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives of the assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:href="jnj-20220102.xsd#jnj_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:to="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_ea935b87-0094-41d3-bf0c-28d914ad9598_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_9ba5e77c-ebd8-4b88-a856-96cf04b74930_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_d11d61c3-1cf9-4464-a470-f9b415ec04bd_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_cd123164-b9d7-4602-b58e-b29cce6be35e_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward foreign exchange contracts:</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent_dd20272f-b68a-4682-90f3-e4a7826ff56f_terseLabel_en-US" xlink:label="lab_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in earnings before taxes, percent</link:label>
    <link:label id="lab_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent_label_en-US" xlink:label="lab_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Earnings Before Taxes, Percent</link:label>
    <link:label id="lab_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent_documentation_en-US" xlink:label="lab_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Earnings Before Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent" xlink:href="jnj-20220102.xsd#jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent" xlink:to="lab_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5beb8432-c2cf-4586-8bcf-e029dc24deaf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercise price beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2b071ac8-3298-4f00-8284-45feb95af1d4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercise price end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_ba250301-e554-4e8e-a061-d98b7e3f3929_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NonQualifiedPlansMember_f38b7c47-e42a-49e3-99ee-3aabcee0bbe6_terseLabel_en-US" xlink:label="lab_jnj_NonQualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Qualified Plans</link:label>
    <link:label id="lab_jnj_NonQualifiedPlansMember_label_en-US" xlink:label="lab_jnj_NonQualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Qualified Plans [Member]</link:label>
    <link:label id="lab_jnj_NonQualifiedPlansMember_documentation_en-US" xlink:label="lab_jnj_NonQualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non qualified plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonQualifiedPlansMember" xlink:href="jnj-20220102.xsd#jnj_NonQualifiedPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NonQualifiedPlansMember" xlink:to="lab_jnj_NonQualifiedPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_e7383287-e3cc-47f0-b122-a3963e062186_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year Five</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year five.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_1afd63a0-a6a1-4b92-8de6-c90f0bbbbb05_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f4c61c87-2892-40d2-8dc0-2ab71873c349_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b8aa5c41-e81b-4307-add0-aa6797c71536_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1f03dc91-5d27-464e-8007-10eadd94198d_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets at fair value&#160;&#8212; beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_d3cb459d-80d2-4fb9-a3e8-c49f17522429_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets at fair value&#160;- End of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GeneralCorporateMember_90718d56-aece-42f3-b995-c6bc377cff8f_terseLabel_en-US" xlink:label="lab_jnj_GeneralCorporateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Corporate</link:label>
    <link:label id="lab_jnj_GeneralCorporateMember_label_en-US" xlink:label="lab_jnj_GeneralCorporateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Corporate [Member]</link:label>
    <link:label id="lab_jnj_GeneralCorporateMember_documentation_en-US" xlink:label="lab_jnj_GeneralCorporateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General corporate member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GeneralCorporateMember" xlink:href="jnj-20220102.xsd#jnj_GeneralCorporateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GeneralCorporateMember" xlink:to="lab_jnj_GeneralCorporateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_03a88f64-9cd5-4c74-9231-509da3e0bf8d_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_00c22190-2bf4-426a-972b-00aae4c9c499_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, estimate of possible loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.65Notesdue2021Member_8ccea4eb-de58-45c7-84ad-e1cfdd6f930d_terseLabel_en-US" xlink:label="lab_jnj_A1.65Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Notes due 2021</link:label>
    <link:label id="lab_jnj_A1.65Notesdue2021Member_label_en-US" xlink:label="lab_jnj_A1.65Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Notes due 2021 [Member]</link:label>
    <link:label id="lab_jnj_A1.65Notesdue2021Member_documentation_en-US" xlink:label="lab_jnj_A1.65Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Notes due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.65Notesdue2021Member" xlink:href="jnj-20220102.xsd#jnj_A1.65Notesdue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.65Notesdue2021Member" xlink:to="lab_jnj_A1.65Notesdue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_f76ecb00-52ca-475d-9766-fcfadb2568aa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_ee31614b-c271-4b04-990e-f18f6b72db49_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings and the current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_d85acf3b-ea30-4502-ab69-62c5eedb08d1_terseLabel_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_label_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_documentation_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member" xlink:href="jnj-20220102.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.85Notesdue2041Member" xlink:to="lab_jnj_A4.85Notesdue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_1811f8a0-d5a5-4e33-8eb2-6decfa8ed06e_terseLabel_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate reconciliation, net increase (decrease) in tax rate, percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_label_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_documentation_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:href="jnj-20220102.xsd#jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:to="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans_ee8b1c58-2310-4eeb-82b1-2e3861f70862_terseLabel_en-US" xlink:label="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential shares exercisable under stock option plans (in shares)</link:label>
    <link:label id="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans_label_en-US" xlink:label="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Shares Exercisable Under Stock Option Plans</link:label>
    <link:label id="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans_documentation_en-US" xlink:label="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Shares Exercisable Under Stock Option Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PotentialSharesExercisableUnderStockOptionPlans" xlink:href="jnj-20220102.xsd#jnj_PotentialSharesExercisableUnderStockOptionPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PotentialSharesExercisableUnderStockOptionPlans" xlink:to="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_84690aaa-3ab3-47cd-ab03-8422e6c430b5_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and stock option plans (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_f1e737d7-8bcc-445c-81e5-88e6cf2c9497_terseLabel_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Sovereign Securities</link:label>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sovereign Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:to="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_41f5d895-934f-4bff-bc48-8cc7f792eac7_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Plans</link:label>
    <link:label id="lab_country_US_a3ca2869-88a6-43e6-b7d2-f40919f096dc_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_bd301f77-4385-474e-987c-d41064b70d78_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_22431a25-996d-46ee-a10a-76f21480d77b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_3bde88fa-4fd6-42f9-b7e8-6e5ec019d293_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to Property, Plant &amp; Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c96c30de-ed31-4c57-a0af-6a40aa2fbd23_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TRAUMAMember_861e92ef-78dd-4372-b15d-9e53e574e475_terseLabel_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA</link:label>
    <link:label id="lab_jnj_TRAUMAMember_label_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:label id="lab_jnj_TRAUMAMember_documentation_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember" xlink:href="jnj-20220102.xsd#jnj_TRAUMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TRAUMAMember" xlink:to="lab_jnj_TRAUMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_74473eae-2617-4430-8695-bae3a4c6c44c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_a9af2675-4d1e-4cc5-9ffa-8858f7b0126c_terseLabel_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Expense</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_51a55d1f-a2da-45f8-b43b-7a6b66ebe2e1_verboseLabel_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember" xlink:href="jnj-20220102.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherIncomeExpenseNetMember" xlink:to="lab_jnj_OtherIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0ec02a19-5392-423e-8826-532bf51b7ec4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2cf23060-bcfd-40c8-a899-eded56af00a2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4ecdfdd5-27b7-4857-a5b6-b56b8af0bdd1_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e7345f31-e31f-4b17-baf3-210963469680_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.&#160;</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FundedPlansMember_7640f831-462c-4c34-b685-0032ad0315a5_terseLabel_en-US" xlink:label="lab_jnj_FundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded Plans</link:label>
    <link:label id="lab_jnj_FundedPlansMember_label_en-US" xlink:label="lab_jnj_FundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded Plans [Member]</link:label>
    <link:label id="lab_jnj_FundedPlansMember_documentation_en-US" xlink:label="lab_jnj_FundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FundedPlansMember" xlink:href="jnj-20220102.xsd#jnj_FundedPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FundedPlansMember" xlink:to="lab_jnj_FundedPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_86f09966-254e-40b5-94a5-d9fb1b8f626c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_cc53fb41-1fab-438a-be33-77b4f6e1bad9_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OTCMember_2b2a9451-6f79-4a68-abb0-4f72b58bdbec_terseLabel_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC</link:label>
    <link:label id="lab_jnj_OTCMember_label_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:label id="lab_jnj_OTCMember_documentation_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember" xlink:href="jnj-20220102.xsd#jnj_OTCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OTCMember" xlink:to="lab_jnj_OTCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_e79a571d-cad4-48a2-a778-68dbc3bfd416_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_048306f9-828d-4575-9699-eaeb1603a408_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability_da330275-d26a-4f20-bfaf-18cceafdd720_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of deferred tax liability</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Liability</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_c35c6cd6-12f6-4998-8dc8-5cfb8642b7cd_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_b727edb3-047b-4b3b-bdc9-f88733662517_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_20cd5b67-d19d-466b-9c6b-b53de29d383f_terseLabel_en-US" xlink:label="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of corridor of greater of market value of assets</link:label>
    <link:label id="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_label_en-US" xlink:label="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Corridor Of Greater Of Market Value Of Assets</link:label>
    <link:label id="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_documentation_en-US" xlink:label="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of corridor of greater of market value of assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:href="jnj-20220102.xsd#jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:to="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment_e73b96c2-26f7-4d73-8152-8ca296e248b6_terseLabel_en-US" xlink:label="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment on unrecognized tax benefit liability</link:label>
    <link:label id="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment_label_en-US" xlink:label="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefit Liability, Payment</link:label>
    <link:label id="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment_documentation_en-US" xlink:label="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefit Liability, Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:href="jnj-20220102.xsd#jnj_UnrecognizedTaxBenefitLiabilityPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:to="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_9a52d9e8-71a3-444c-92d1-8adfd8a73427_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_20497abd-2d0f-4f58-b805-c2f7b4785701_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7ff00b64-ce4b-4a9b-a071-98613b4fa365_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_20dcf637-9196-4344-a2d6-c2b66a28fb9e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_cf57c785-e84a-49d2-a9c2-4aadf7ae72a5_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_df3b5860-b4b6-4ac1-9438-866f829e2ba0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_66bbc856-97cd-4817-b0c9-eb73219fe0e2_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_08b8e298-4497-44ee-8c12-e396e13d5ff9_terseLabel_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset recorded related to TRAF</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_label_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_documentation_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:href="jnj-20220102.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:to="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_fb334612-3874-4e75-b594-bccd2d1947f2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, fair value adjustment</link:label>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueAdjustment" xlink:to="lab_us-gaap_EquityFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_4b93477e-20c2-4151-85c9-3decaf4319ff_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_babc75eb-da19-4db0-b64c-1c402dfe4682_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9724ee78-1f67-415e-981d-0783b37cc38a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8e03b075-b4a8-4610-8f1e-c3ccbcd86831_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_7eb9f986-b4f7-410e-95e6-62648c3df870_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_75cd26e5-71c9-4361-85e9-c3d788ded4f8_terseLabel_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_label_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies [Domain]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_documentation_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement by companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain" xlink:href="jnj-20220102.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain" xlink:to="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_0188d1a5-d525-4189-8635-1bf266caefb4_terseLabel_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_label_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_documentation_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember" xlink:href="jnj-20220102.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONCERTAMethylphenidateMember" xlink:to="lab_jnj_CONCERTAMethylphenidateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_StelaraMember_cf400f24-ab6e-4ba5-b8fd-ab733f05bb94_terseLabel_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara</link:label>
    <link:label id="lab_jnj_StelaraMember_label_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara [Member]</link:label>
    <link:label id="lab_jnj_StelaraMember_documentation_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember" xlink:href="jnj-20220102.xsd#jnj_StelaraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_StelaraMember" xlink:to="lab_jnj_StelaraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_4d23e6bb-9d24-4ba9-a30a-f405b39ae50d_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_ff166442-130d-4d44-b2f9-2576940e9b66_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained_a5ccc863-332a-40eb-942d-66660afa78c5_terseLabel_en-US" xlink:label="lab_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, including discontinued operation, receivables retained</link:label>
    <link:label id="lab_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained_label_en-US" xlink:label="lab_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Receivables Retained</link:label>
    <link:label id="lab_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained_documentation_en-US" xlink:label="lab_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Receivables Retained</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained" xlink:href="jnj-20220102.xsd#jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained" xlink:to="lab_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a8181136-9e29-4f04-b96b-15b344f6a312_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OrthopaedicsMember_87610d8d-7a99-49b7-b573-bf3d4899c1ea_terseLabel_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_label_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_documentation_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember" xlink:href="jnj-20220102.xsd#jnj_OrthopaedicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OrthopaedicsMember" xlink:to="lab_jnj_OrthopaedicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_316c027f-1914-4723-9e58-c3c04daf677c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_d174b082-6c57-4917-82eb-6515bae74ae7_terseLabel_en-US" xlink:label="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of reclassification of cash flow hedge gain (loss)</link:label>
    <link:label id="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_label_en-US" xlink:label="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Reclassification of Cash Flow Hedge Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:to="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_1bfa6d15-b5f0-4c1f-918b-a9cb4755dafb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CurtailmentsAndSettlementsAndRestructuring_407072ef-fe74-4dc7-a7d0-373ab28d189e_negatedTerseLabel_en-US" xlink:label="lab_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments, settlements&#160;&amp; restructuring</link:label>
    <link:label id="lab_jnj_CurtailmentsAndSettlementsAndRestructuring_label_en-US" xlink:label="lab_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments And Settlements And Restructuring</link:label>
    <link:label id="lab_jnj_CurtailmentsAndSettlementsAndRestructuring_documentation_en-US" xlink:label="lab_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of increase or decrease related to curtailments, settlements and restructuring.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:href="jnj-20220102.xsd#jnj_CurtailmentsAndSettlementsAndRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:to="lab_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_bbe88570-1ded-4934-9bbf-2b6f3b8f162d_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b0b72cc6-df6f-4bf3-a982-6116e3ace7e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_8b7e6524-5ca4-44b0-8ec8-768b05cf022d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated benefit obligation unfunded plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d200badd-739e-474f-bf61-484af6ff979b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_f5827e05-ce5a-4efa-b451-063560c06d10_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous international</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_d82543a5-f4ba-4a9b-a750-d0a849c99070_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b3638f28-a50f-4733-92dc-cb1b63ff5520_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average assumptions of fair value of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c24659ca-45bf-4df9-8e69-39b534a32f0a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total compensation cost not yet recognized for option</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_f0531a64-c3e5-4d69-abb6-b2c42b2a67bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Derivatives not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_3a248430-af7f-4296-a282-a9cba4c895cc_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_feff0d88-27d5-4b45-8ef4-a76ff6ffc0c1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_f62df9f1-4c4d-4644-b4dd-34e0917ece7d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net realizable operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_3a6b2129-d1ba-4d5e-a6de-bcb4ad5afa9b_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible assets net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_06c108eb-a103-4c9e-a0b7-011776af60fc_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill (Notes&#160;1 and 5)</link:label>
    <link:label id="lab_us-gaap_Goodwill_da421adc-3a41-43a4-94f9-bc26710119e3_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_2b9921da-64f9-443c-be53-d3c251ba8483_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_b86bb65c-8b4c-4914-8016-18dc222243f3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1ad2a46d-2e8c-439d-822b-8dbed2d71baa_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International operations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_c55bbb2c-ed08-4c21-af95-9c75993b203a_terseLabel_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_label_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_documentation_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember" xlink:href="jnj-20220102.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsiaPacificAfricaMember" xlink:to="lab_jnj_AsiaPacificAfricaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_b2616444-396c-42f0-92d9-6409fde64dd5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17e16598-b7a9-4950-ab2a-eb6b6ed07d82_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings to cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_c47e512e-7c56-4f63-aad1-bae2a7d11f24_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_e0af7d23-6210-481a-a046-ce7f3171d04a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_98a6bcbe-b6ae-4566-ac4d-4e0a8e3d1f77_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CizHoldingsCo.Ltd.Member_7826218d-b25f-491c-9c3f-948566ac54ef_terseLabel_en-US" xlink:label="lab_jnj_CizHoldingsCo.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ci:z Holdings Co. Ltd.</link:label>
    <link:label id="lab_jnj_CizHoldingsCo.Ltd.Member_label_en-US" xlink:label="lab_jnj_CizHoldingsCo.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ci:z Holdings Co. Ltd. [Member]</link:label>
    <link:label id="lab_jnj_CizHoldingsCo.Ltd.Member_documentation_en-US" xlink:label="lab_jnj_CizHoldingsCo.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ci:z Holdings Co. Ltd. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CizHoldingsCo.Ltd.Member" xlink:href="jnj-20220102.xsd#jnj_CizHoldingsCo.Ltd.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CizHoldingsCo.Ltd.Member" xlink:to="lab_jnj_CizHoldingsCo.Ltd.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_d1c41778-9738-4a39-af79-47faa78741d8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SegmentsTotalMember_8cd391e0-be9f-4af6-acdf-e6d48b92dd37_terseLabel_en-US" xlink:label="lab_jnj_SegmentsTotalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments Total</link:label>
    <link:label id="lab_jnj_SegmentsTotalMember_label_en-US" xlink:label="lab_jnj_SegmentsTotalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments Total [Member]</link:label>
    <link:label id="lab_jnj_SegmentsTotalMember_documentation_en-US" xlink:label="lab_jnj_SegmentsTotalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SegmentsTotalMember" xlink:href="jnj-20220102.xsd#jnj_SegmentsTotalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SegmentsTotalMember" xlink:to="lab_jnj_SegmentsTotalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ContactLensesMember_b983b0b7-14d8-47e1-bbeb-f3e9871a1822_terseLabel_en-US" xlink:label="lab_jnj_ContactLensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Lenses</link:label>
    <link:label id="lab_jnj_ContactLensesMember_label_en-US" xlink:label="lab_jnj_ContactLensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Lenses [Member]</link:label>
    <link:label id="lab_jnj_ContactLensesMember_documentation_en-US" xlink:label="lab_jnj_ContactLensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Lenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ContactLensesMember" xlink:href="jnj-20220102.xsd#jnj_ContactLensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ContactLensesMember" xlink:to="lab_jnj_ContactLensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_268f4c1f-f7d5-4a0d-a485-6827c41488bb_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_a1dd3c34-86df-4618-9055-b656dad78346_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_cc4c7f14-ce0f-4ded-b27e-a7ec087c38fb_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_7a677b52-ac31-4951-83d4-ba2acbaceea0_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_ef08a7be-ddac-4dfd-b99e-025fbbbad973_negatedTerseLabel_en-US" xlink:label="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settlements</link:label>
    <link:label id="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_label_en-US" xlink:label="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Sale of an Asset (Payment) for Restructuring</link:label>
    <link:label id="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_documentation_en-US" xlink:label="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Sale of an Asset (Payment) for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GainOnSaleOfAnAssetPaymentForRestructuring" xlink:href="jnj-20220102.xsd#jnj_GainOnSaleOfAnAssetPaymentForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GainOnSaleOfAnAssetPaymentForRestructuring" xlink:to="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_475a9e6c-f821-4c5c-b912-5ecccffc3188_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_99e9b5a2-84ca-4abc-ae5c-1e530bf8d05f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_4d4cf175-fe47-42d7-b4d2-d07117bd027e_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ccdae79d-5cff-44e8-a6f4-0ccc83b9b9bc_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d2081089-fbbd-4ef6-92eb-ce469a0aa2f1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_3544493b-8b3d-4ae0-b7a3-62937e5d3986_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_baa45067-0c32-4005-af0f-822b089947a4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_cf19951e-9f91-439f-bbc2-c7b7784ac2bc_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_444a8a2e-16ba-4d17-b3ed-6f915ee2a4e2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_6f024ec3-b9d8-4047-97e4-afeeae66c93a_terseLabel_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimated fair value</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_label_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_documentation_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:href="jnj-20220102.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:to="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_1d87c64c-c0e1-4af0-883d-7e95825717f5_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_65e2082b-e28d-4922-a703-122bfacad508_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_9858d852-3e7d-40d6-b802-7a0d05a11bf7_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee related obligations</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_a0b22f70-8230-4380-9402-4388b7cf7b4d_terseLabel_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and related cost, duration of restructuring plan</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_label_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Duration of Restructuring Plan</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_documentation_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Duration of Restructuring Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:href="jnj-20220102.xsd#jnj_RestructuringandRelatedCostDurationofRestructuringPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:to="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_c19e02a0-5206-46b5-9444-8b7c916f5ca1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps contracts:</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_a63ed596-72f3-46e5-970d-9f71ba2d12cd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DARZALEXMember_68f240fc-75d9-4eaa-98b6-62225391114a_terseLabel_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX</link:label>
    <link:label id="lab_jnj_DARZALEXMember_label_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:label id="lab_jnj_DARZALEXMember_documentation_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember" xlink:href="jnj-20220102.xsd#jnj_DARZALEXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DARZALEXMember" xlink:to="lab_jnj_DARZALEXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_6cf2a291-89a1-4dff-ae02-07b443502f35_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange rate, translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_77d9d46b-c5ee-49bc-acc9-7a73808e707e_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_2a3bc821-b205-4256-a3ad-bfef52256536_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_33edd5b4-432e-4a6a-9d3b-7bfc69d27344_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Maturities of Long Term Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_f55e1d9f-a014-42f8-8379-afa34e287434_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of the Company And Business Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_a319788f-106a-4b46-a24b-e8abb13845e8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, including discontinued operation, consideration</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1ea8c58d-ddbc-4369-b8db-7c5ee568648b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_0ed65595-71e2-43a1-990c-74c44cce7ae2_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets, excluding goodwill</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_023f3d28-680f-4197-a19a-6b5bb4e977e9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c6cf12ce-e95d-470a-8d52-11f9a91ad4f6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ef86bc66-0f0b-438e-b03b-503d422068cf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets, noncurrent</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_ad15a4ef-0eaf-4dfb-a728-fe72f4dc8c75_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate to which the cost trend rate is assumed to decline (ultimate trend)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Ultimate Health Care Cost Trend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:to="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_af8643ce-a5d8-41d2-8375-4f280627cb5c_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_3b859f71-1304-4a8c-8a31-14ad5f695fee_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_c4abb0d2-40ca-4dae-be73-dc9101b0087e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c96f9271-4903-4c81-935d-52dee91dcff2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_0f37b98c-423b-44d0-8d59-e98996d6ef98_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_3f3e116c-d564-4f94-abe3-a45adfde0fab_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_cde2511a-3fc5-4ec1-8d2f-3690359e16c3_terseLabel_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_label_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_documentation_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member" xlink:href="jnj-20220102.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.75Notesdue2047Member" xlink:to="lab_jnj_A3.75Notesdue2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_bf9489ff-3c32-4bb2-b07c-3adbb25115e5_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_db09e920-dcba-4ec3-810c-9541cb6ce504_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and stock option plans</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_84ff88d7-c922-4db7-995c-1e591a1fbb8e_terseLabel_en-US" xlink:label="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information Related to the Benefit Obligation and the Fair Value of Plan Assets</link:label>
    <link:label id="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information Related To Benefit Obligation And Fair Value Of Plan Assets [Table Text Block]</link:label>
    <link:label id="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_documentation_en-US" xlink:label="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to the benefit obligation and the fair value of plan assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:href="jnj-20220102.xsd#jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_12658395-ff3d-4c4d-ac55-d3d57052dbb6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Maturities of Available for Sale Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_79b5a4cc-e306-4340-9d31-ed9450f9cbc7_negatedTerseLabel_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: shares repurchased under treasury stock method (in shares)</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_label_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Which Could Be Repurchased Under Treasury Stock Method</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_documentation_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:href="jnj-20220102.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:to="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_27cf6498-b5fa-456b-871b-972c1435184e_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_c353bfe2-4b5c-4489-a4d0-e24d6cf87bf8_totalLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid for acquisitions (Note 18)</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_03cf4812-d357-4fa8-a501-108c9aaa9388_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt shares (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_1cc931b1-0014-45bc-8078-e2d4c5885759_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related obligations</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_26be3ee8-4ce5-4537-b110-7e1ad1fce173_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_1cf731c5-792f-46d4-9c5b-22632681471c_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Held-for-sale or Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9662ad77-1d93-4588-8d07-a3e62d2fef27_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of RSU or PSU units settled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e11c8b07-329e-421a-a751-a7368ca3b617_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average fair value of RSU's and PSU's granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_6459be55-a277-4fcd-946b-9af5ca9e12d6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1c1f90d5-8813-487c-bd2d-bcb5689e7d4b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5a433f2b-146c-40d8-bc22-c32717596aa0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_eb6aae07-0fda-4439-9082-ed69bd2d0540_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related obligations (Notes&#160;9 and 10)</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_ac454108-efa9-49b0-b719-75fcc0750231_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related obligations&#160;&#8212; non-current</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_cb54f4a4-aa8b-42a2-902e-db0f69671dc6_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A130NotesDue2030Member_aa0e3b98-7fb5-476c-ae4d-cc602c982e3c_terseLabel_en-US" xlink:label="lab_jnj_A130NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.30% Notes due 2030</link:label>
    <link:label id="lab_jnj_A130NotesDue2030Member_label_en-US" xlink:label="lab_jnj_A130NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.30% Notes due 2030 [Member]</link:label>
    <link:label id="lab_jnj_A130NotesDue2030Member_documentation_en-US" xlink:label="lab_jnj_A130NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.30% Notes due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A130NotesDue2030Member" xlink:href="jnj-20220102.xsd#jnj_A130NotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A130NotesDue2030Member" xlink:to="lab_jnj_A130NotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dd003c77-b8d9-44da-8b66-5592450dc559_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_c9a3ea62-d007-4796-9c27-c035f9485753_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_fb07445d-1f57-43bc-9dd2-503320cabf93_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_d4817f55-7bdf-4f9b-b995-7f29d6a08c0e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_December172018ShareRepurchaseProgramMember_16609326-3b43-4533-a96c-2576138936be_terseLabel_en-US" xlink:label="lab_jnj_December172018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 17, 2018 Share Repurchase Program</link:label>
    <link:label id="lab_jnj_December172018ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_jnj_December172018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 17, 2018 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_jnj_December172018ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_jnj_December172018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 17, 2018 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_December172018ShareRepurchaseProgramMember" xlink:href="jnj-20220102.xsd#jnj_December172018ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_December172018ShareRepurchaseProgramMember" xlink:to="lab_jnj_December172018ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_62609c41-947f-4c4c-aafb-705fb2de069a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_97dd3152-cdb7-48ce-b079-29fad648799f_terseLabel_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_label_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_documentation_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement" xlink:href="jnj-20220102.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Numberofpatientsinsettlement" xlink:to="lab_jnj_Numberofpatientsinsettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent_bc96a06d-1b78-48a6-96df-5baed18f4a73_terseLabel_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate reconciliation, unrecognized tax benefits, percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent_label_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Unrecognized Tax Benefits, Percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent_documentation_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Unrecognized Tax Benefits, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent" xlink:href="jnj-20220102.xsd#jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent" xlink:to="lab_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ChangesInTreasuryStockTableTextBlock_8ff2e49b-5014-490d-aec1-59a29fc8921b_terseLabel_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Treasury Stock</link:label>
    <link:label id="lab_jnj_ChangesInTreasuryStockTableTextBlock_label_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Treasury Stock [Table Text Block]</link:label>
    <link:label id="lab_jnj_ChangesInTreasuryStockTableTextBlock_documentation_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in treasury stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockTableTextBlock" xlink:href="jnj-20220102.xsd#jnj_ChangesInTreasuryStockTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ChangesInTreasuryStockTableTextBlock" xlink:to="lab_jnj_ChangesInTreasuryStockTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6ba4a125-9042-4edc-9eb7-7c4265fb9be9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0cf2d503-df69-4a94-864b-e6809923d58b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_1460be3b-1a0f-438b-bcfb-244c1fabd9ae_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_2ed91b47-e7ff-4228-ae07-7f7a3f3c220c_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_24174ae7-4a4d-49cf-b0b9-5b2d9c78b9d6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment and Depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ea10defc-0267-421d-b79d-3631db061399_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding beginning of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b145cb13-c21f-4739-bc8c-fba6f219f7b2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InvokanaMember_f928b715-9cc5-461a-882b-4c019232b140_terseLabel_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana</link:label>
    <link:label id="lab_jnj_InvokanaMember_label_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana [Member]</link:label>
    <link:label id="lab_jnj_InvokanaMember_documentation_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember" xlink:href="jnj-20220102.xsd#jnj_InvokanaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InvokanaMember" xlink:to="lab_jnj_InvokanaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_66c9301a-42f6-4e54-b09d-088f5fb6ddc3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_2ef2e374-6c70-4b23-8ca0-7d922160afb9_terseLabel_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities</link:label>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:to="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2b8c788d-2a8d-4a8a-9ae0-8042ecbd631e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_c520bd8e-0e11-416f-82be-b07e30e6c204_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives &amp; hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_9e42cf90-ea40-4b8b-b721-d048be6cae1f_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectOfExchangeRates_722977b2-67e6-4eb1-8977-1a7e2b83bcc7_terseLabel_en-US" xlink:label="lab_jnj_EffectOfExchangeRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates</link:label>
    <link:label id="lab_jnj_EffectOfExchangeRates_label_en-US" xlink:label="lab_jnj_EffectOfExchangeRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect Of Exchange Rates</link:label>
    <link:label id="lab_jnj_EffectOfExchangeRates_documentation_en-US" xlink:label="lab_jnj_EffectOfExchangeRates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect Of Exchange Rates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectOfExchangeRates" xlink:href="jnj-20220102.xsd#jnj_EffectOfExchangeRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectOfExchangeRates" xlink:to="lab_jnj_EffectOfExchangeRates" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.45Notesdue2021Member_8b071960-807e-404b-8ac0-c993f6650a32_terseLabel_en-US" xlink:label="lab_jnj_A2.45Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2021</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2021Member_label_en-US" xlink:label="lab_jnj_A2.45Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2021 [Member]</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2021Member_documentation_en-US" xlink:label="lab_jnj_A2.45Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2021Member" xlink:href="jnj-20220102.xsd#jnj_A2.45Notesdue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.45Notesdue2021Member" xlink:to="lab_jnj_A2.45Notesdue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_StateLevelJurisdictionMember_d4eacfd6-6efa-44b0-b1af-976925f68eb5_terseLabel_en-US" xlink:label="lab_jnj_StateLevelJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Level Jurisdiction</link:label>
    <link:label id="lab_jnj_StateLevelJurisdictionMember_label_en-US" xlink:label="lab_jnj_StateLevelJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Level Jurisdiction [Member]</link:label>
    <link:label id="lab_jnj_StateLevelJurisdictionMember_documentation_en-US" xlink:label="lab_jnj_StateLevelJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Level Jurisdiction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StateLevelJurisdictionMember" xlink:href="jnj-20220102.xsd#jnj_StateLevelJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_StateLevelJurisdictionMember" xlink:to="lab_jnj_StateLevelJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_1692a578-7746-42ff-a406-849fad27a1bd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends to shareholders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:to="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExpenseNotAllocatedToSegments_3abb431b-3b2d-48e5-9cfa-649a7766d1a5_terseLabel_en-US" xlink:label="lab_jnj_ExpenseNotAllocatedToSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Expense not allocated to segments</link:label>
    <link:label id="lab_jnj_ExpenseNotAllocatedToSegments_label_en-US" xlink:label="lab_jnj_ExpenseNotAllocatedToSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Not Allocated To Segments</link:label>
    <link:label id="lab_jnj_ExpenseNotAllocatedToSegments_documentation_en-US" xlink:label="lab_jnj_ExpenseNotAllocatedToSegments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense not allocated to segments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExpenseNotAllocatedToSegments" xlink:href="jnj-20220102.xsd#jnj_ExpenseNotAllocatedToSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExpenseNotAllocatedToSegments" xlink:to="lab_jnj_ExpenseNotAllocatedToSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_67997617-cdaa-44d4-8195-4e2642f5070a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest on income tax expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_7be54fe2-162c-436d-9cb0-e1588b13b1ed_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d767748a-9bbb-43ce-b222-f4b20c1f0280_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Differences and Carryforwards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_81c4d5c5-c403-41f4-8401-65041ad913fb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6ade1828-4611-4645-9008-ee6f31e75049_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_9ec8987e-4e3c-4c8e-901b-c377ea45dee9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target Allocation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_65d293b7-6253-4ef2-892e-2b9b726e8bbc_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net actuarial (gain) loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d6493f79-7dea-4521-aaa4-d2fa229770dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_241d967c-29a9-462c-96e4-3b328e22039c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_63d60190-5268-4b57-a07c-fb00e539711b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_5f784eb5-85aa-4140-8687-dbc4101515ff_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments : Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Liabilities, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_d8860bd0-8259-45f6-8aa6-f0bffe8e0e7a_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on divestiture</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_COVID19Member_b5fe8fdc-0761-4a6f-879c-927ad3b355b5_terseLabel_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_jnj_COVID19Member_label_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_jnj_COVID19Member_documentation_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member" xlink:href="jnj-20220102.xsd#jnj_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_COVID19Member" xlink:to="lab_jnj_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_2b0fe435-cb17-40d7-af97-e4b0393b7574_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of pending claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_51066618-ce22-4804-b7eb-a64b0e722c2a_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_de336598-42b5-43d9-85e6-8f52b8239dbe_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_781705f6-5c56-4f41-996c-98461ade1b53_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Gov't Securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.25Notesdue2022Member_1850b3d7-14dd-449e-bdec-3f6e671268c2_terseLabel_en-US" xlink:label="lab_jnj_A2.25Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes due 2022</link:label>
    <link:label id="lab_jnj_A2.25Notesdue2022Member_label_en-US" xlink:label="lab_jnj_A2.25Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes due 2022 [Member]</link:label>
    <link:label id="lab_jnj_A2.25Notesdue2022Member_documentation_en-US" xlink:label="lab_jnj_A2.25Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.25Notesdue2022Member" xlink:href="jnj-20220102.xsd#jnj_A2.25Notesdue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.25Notesdue2022Member" xlink:to="lab_jnj_A2.25Notesdue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_79351c22-2685-4f09-8155-deb500ef1dc8_terseLabel_en-US" xlink:label="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards</link:label>
    <link:label id="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_label_en-US" xlink:label="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Issued For Employee Compensation And Stock Option Plans Net Of Cash Proceeds</link:label>
    <link:label id="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_documentation_en-US" xlink:label="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock issued for employee compensation and stock option plans, net of cash proceeds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:href="jnj-20220102.xsd#jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:to="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_7132f052-7e57-4ac4-bb94-0434d8174112_terseLabel_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023</link:label>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_label_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member" xlink:href="jnj-20220102.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.375Notesdue2023Member" xlink:to="lab_jnj_A3.375Notesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_407ef041-fc8d-4f84-b860-deef967aa8fb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_1192f001-2b97-4d13-a46f-dceba8ea5313_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matching contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_6405a860-e360-48d0-9944-146044788612_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingMember" xlink:to="lab_us-gaap_ShippingAndHandlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_4b3334cf-5a7b-4b04-8ca7-f426fdb7b6be_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_93a7b7b2-2fae-4794-b650-fcb0ccdfa2a7_terseLabel_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_label_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_documentation_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:href="jnj-20220102.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:to="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_60ddf2f3-92ec-4e22-8ac9-907d302e8d80_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Reclassified From Accumulated OCI Into Income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4baea370-83a3-4cdc-ac1a-b22626488098_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized for issuance under long-term incentive plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_60001777-e097-449a-b962-daa26e85b55c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_0a791d4d-eaca-472f-aac5-7efd9afc82b6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equity interests</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Interest in Corporate Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfInterestInCorporateUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:to="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_a3383acc-e258-421f-93c5-3e80dc6694af_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_fd7597b4-dde1-4e05-a948-02680644ab27_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_79115b9f-3a6b-42dd-b76e-6b05df166ffa_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit losses and accounts receivable allowances</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_eab86525-b10e-4dee-b2d1-392076106882_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_97296eea-b4ab-4aeb-ae3b-039a27bcce77_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TCJA, undistributed foreign earnings percent related to cash and cash equivalents</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Wholesaler1Member_4cdcfbd0-b2d8-40a5-89cd-189a8518af78_terseLabel_en-US" xlink:label="lab_jnj_Wholesaler1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 1</link:label>
    <link:label id="lab_jnj_Wholesaler1Member_label_en-US" xlink:label="lab_jnj_Wholesaler1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 1 [Member]</link:label>
    <link:label id="lab_jnj_Wholesaler1Member_documentation_en-US" xlink:label="lab_jnj_Wholesaler1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler1Member" xlink:href="jnj-20220102.xsd#jnj_Wholesaler1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Wholesaler1Member" xlink:to="lab_jnj_Wholesaler1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NumberOfStockBasedCompensationPlans_41c45212-9eb7-455b-9d7f-1b7c96ed3b5c_terseLabel_en-US" xlink:label="lab_jnj_NumberOfStockBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock-based compensation plans</link:label>
    <link:label id="lab_jnj_NumberOfStockBasedCompensationPlans_label_en-US" xlink:label="lab_jnj_NumberOfStockBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Stock Based Compensation Plans</link:label>
    <link:label id="lab_jnj_NumberOfStockBasedCompensationPlans_documentation_en-US" xlink:label="lab_jnj_NumberOfStockBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock-based compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfStockBasedCompensationPlans" xlink:href="jnj-20220102.xsd#jnj_NumberOfStockBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NumberOfStockBasedCompensationPlans" xlink:to="lab_jnj_NumberOfStockBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_71e1c7d8-d7a3-4dce-95ce-1966b5bb5b29_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_9867647a-a81d-4c47-8fb4-ca4c6dbb2473_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital and Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_label_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockTextBlock" xlink:to="lab_us-gaap_TreasuryStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_f01d31d3-1ac0-4d3f-b129-bf2abe577509_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_JudicialRulingMember_a5e3880a-8a98-4fe9-bb3b-45821459466f_terseLabel_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling</link:label>
    <link:label id="lab_us-gaap_JudicialRulingMember_label_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_JudicialRulingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_JudicialRulingMember" xlink:to="lab_us-gaap_JudicialRulingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_667f59b6-b332-4bf7-a0d5-c03de0bd5301_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e51d0215-de91-440c-b7f4-44a57c351e91_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_bda2535d-c3f9-4e5f-b0b0-9871c0ff679b_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BusinessAcquisitionDiscountRate_ec5a38f8-3ec3-4a41-9166-ad50ee1370ec_terseLabel_en-US" xlink:label="lab_jnj_BusinessAcquisitionDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_jnj_BusinessAcquisitionDiscountRate_label_en-US" xlink:label="lab_jnj_BusinessAcquisitionDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Discount Rate</link:label>
    <link:label id="lab_jnj_BusinessAcquisitionDiscountRate_documentation_en-US" xlink:label="lab_jnj_BusinessAcquisitionDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessAcquisitionDiscountRate" xlink:href="jnj-20220102.xsd#jnj_BusinessAcquisitionDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BusinessAcquisitionDiscountRate" xlink:to="lab_jnj_BusinessAcquisitionDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_636e40de-2c2d-4830-81aa-0bb16c47dd51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised, average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_dfda6737-bb6a-41e3-9b19-0ffac1611f37_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid from plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_84601369-f568-4e16-9467-c908d357d7f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_163f2a6c-3d41-4049-8855-b69943e5cad8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options, tax benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_90481f93-c394-4a86-9f2e-87055cb3f26c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_3d2a4727-1f01-48d1-9c7b-577d8eb26dd6_terseLabel_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_label_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_documentation_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember" xlink:href="jnj-20220102.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CardiovascularMetabolismOtherMember" xlink:to="lab_jnj_CardiovascularMetabolismOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_a222ca98-e5a2-4384-874e-a35f38e6e5b6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_1d30b06c-f379-4bd4-bb43-9ccdf5946612_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_8673d261-9173-4658-bc92-6550a947d32a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_d2fa6ca2-b1bb-4a9b-9510-1e14fa7db8ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OpiodsMember_3f9a6a2c-e1f9-4e3c-beb7-127f81c07dd4_terseLabel_en-US" xlink:label="lab_jnj_OpiodsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opiods</link:label>
    <link:label id="lab_jnj_OpiodsMember_label_en-US" xlink:label="lab_jnj_OpiodsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opiods [Member]</link:label>
    <link:label id="lab_jnj_OpiodsMember_documentation_en-US" xlink:label="lab_jnj_OpiodsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opiods [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpiodsMember" xlink:href="jnj-20220102.xsd#jnj_OpiodsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OpiodsMember" xlink:to="lab_jnj_OpiodsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_890d49db-eb0e-4a32-920e-f60e5ae14f30_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_ce037619-1f51-4bb0-ba57-b69349fba1d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_cfa18e6e-ff4e-4c98-a876-121cd174e3b4_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_b401ed74-4534-4e59-b2b3-ecf1317433b6_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Plans</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_83843f2e-c96a-4a3f-b832-92b7caf43eca_terseLabel_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding (Textuals)</link:label>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_label_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding (Textuals) [Abstract]</link:label>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_documentation_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding Textuals Abstract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract" xlink:href="jnj-20220102.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LegalProceedingTextualsAbstract" xlink:to="lab_jnj_LegalProceedingTextualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_9c5b5e0e-e995-41dc-83fb-72b5c6c7b797_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_78dd4344-1dfa-4d41-bee7-21dc1355478e_verboseLabel_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates, returns and promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_49da93d3-6696-45bd-ba6e-1338817066bf_terseLabel_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates Returns And Promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_label_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates Returns And Promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_documentation_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:href="jnj-20220102.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:to="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_0da471eb-d483-48f0-aec5-7663d6eb92fe_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_bf53ae57-0789-464e-aa38-3b2da38fa8b2_verboseLabel_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased in-process research and development</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_3c805a73-29dd-481a-9ae4-8516b17b8b6a_terseLabel_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased in-process research and development(1)</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:href="jnj-20220102.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:to="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BabyCareMember_111db139-234b-430c-84d5-a2272181bde3_terseLabel_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care</link:label>
    <link:label id="lab_jnj_BabyCareMember_label_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care [Member]</link:label>
    <link:label id="lab_jnj_BabyCareMember_documentation_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember" xlink:href="jnj-20220102.xsd#jnj_BabyCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BabyCareMember" xlink:to="lab_jnj_BabyCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease_15f48758-03bc-4b15-bb2d-af8cfe09a4fa_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity during the period</link:label>
    <link:label id="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:to="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_82f928ac-baba-4164-a055-c688e2f3bba6_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b1e38609-73dc-4038-a4a3-40b065efea22_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_c8bdf2d5-af81-47cc-b835-28eef4e78209_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, marketing and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7c08232d-dcbd-4fe5-8be6-4322327e7bfd_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_844d687f-def2-4df2-b28f-4f4b7f3b6547_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_84379746-ed6a-4a47-8865-02a3f4b8dcf2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_f33c3666-ebab-4a27-8264-fd4dc1e7a4f8_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the disposal of assets/businesses, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_d56a3af8-0d70-4fb6-abac-21a000d820ed_terseLabel_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_label_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_documentation_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member" xlink:href="jnj-20220102.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.55Notesdue2036Member" xlink:to="lab_jnj_A3.55Notesdue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_e28f452c-5bcd-4526-826d-d32de2ce2e79_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year One</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_72a5c88a-7dd1-43d2-82c8-f2edbf537fbf_terseLabel_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]</link:label>
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_label_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:to="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TalcMember_9e6a2a84-5458-41f2-87f2-73a920aca331_terseLabel_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc</link:label>
    <link:label id="lab_jnj_TalcMember_label_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc [Member]</link:label>
    <link:label id="lab_jnj_TalcMember_documentation_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember" xlink:href="jnj-20220102.xsd#jnj_TalcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TalcMember" xlink:to="lab_jnj_TalcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_03ebecec-dd98-4544-96cb-98d559aadfc2_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost discount rate</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:to="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_cc80ee1c-f54d-48bf-8b96-b341093dc517_terseLabel_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85%&#160;Debentures due 2038</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_label_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member" xlink:href="jnj-20220102.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.85Debenturesdue2038Member" xlink:to="lab_jnj_A5.85Debenturesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_cbf5f975-d5de-4104-8b66-b93c5c8c399a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_920467ef-23d5-4b24-aa6f-c0bc900335eb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PelvicMeshesMember_e43e1034-f63d-477d-90b8-2144dfab4ed1_terseLabel_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic Meshes</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_label_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic Meshes [Member]</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_documentation_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic meshes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember" xlink:href="jnj-20220102.xsd#jnj_PelvicMeshesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PelvicMeshesMember" xlink:to="lab_jnj_PelvicMeshesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4e6bf631-f654-43fd-a697-4b5e64206b95_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, net of cash acquired (Note&#160;18)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ad307ea0-4fcb-41e6-b0ef-4684a350dc78_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_e5617ff1-74e6-47cd-88b6-7b8c3a255002_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_e0e48860-b48b-42f4-85bd-6647bad073e4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_90d16ccb-bf7e-4bfd-9fca-46fc78595ccc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_1a19247d-8b1e-4b1f-8510-a36039acc62c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_fe916d1e-aeb1-4408-8311-1995d33e5db2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_aaf309fc-c6c5-46e9-be3b-43f7f57a6a20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable number of Options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f4a25054-a4db-439c-93ba-7f6fe4941879_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Stock Option Plans and Stock Compensation Agreements</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7336468a-1630-4d96-a808-3946b12f86aa_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_9a567fc8-5147-4f93-bb84-c6c78c288dd3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares_9f6867be-763f-4ed6-be31-2b0708fd16c5_terseLabel_en-US" xlink:label="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note, equity Interest (in shares)</link:label>
    <link:label id="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares_label_en-US" xlink:label="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Note, Equity Interest, number of shares</link:label>
    <link:label id="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares_documentation_en-US" xlink:label="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Note, Equity Interest, number of shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConvertibleNoteEquityInterestNumberOfShares" xlink:href="jnj-20220102.xsd#jnj_ConvertibleNoteEquityInterestNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConvertibleNoteEquityInterestNumberOfShares" xlink:to="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_ebbdab15-4a4d-4f13-b239-fc25db5f9e91_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EmployeeRelatedObligationsTableTextBlock_77022618-9d6d-460c-a415-7e4efcdd096c_terseLabel_en-US" xlink:label="lab_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Related Obligations</link:label>
    <link:label id="lab_jnj_EmployeeRelatedObligationsTableTextBlock_label_en-US" xlink:label="lab_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Related Obligations [Table Text Block]</link:label>
    <link:label id="lab_jnj_EmployeeRelatedObligationsTableTextBlock_documentation_en-US" xlink:label="lab_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:href="jnj-20220102.xsd#jnj_EmployeeRelatedObligationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:to="lab_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_e0570332-d59b-431c-8f65-577208470310_terseLabel_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_label_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_documentation_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member" xlink:href="jnj-20220102.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.45Notesdue2026Member" xlink:to="lab_jnj_A2.45Notesdue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8093e8f2-e923-42a8-9042-bfaf63fb0e9a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency transaction gain (loss), before tax</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_6ae004ad-5fe1-4a4c-83f9-be67e27add4c_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_538a94c1-98f3-4ef9-9297-cb4debc81ed6_terseLabel_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_label_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_documentation_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member" xlink:href="jnj-20220102.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Notesdue2043Member" xlink:to="lab_jnj_A4.50Notesdue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_5f8d551a-5648-4032-9aef-dee82a0f19c7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, related to acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_2b3be55d-48da-4af4-bd4b-2267836c3312_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_ceafd118-eeee-4474-83a8-20083629820a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_f093762a-17db-4283-b366-ce467f0bb5fd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other benefit plans&#160;</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_9d41fa79-9d56-40e5-a52f-56f87b6ca2f7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 19)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_7b73acf9-9417-4524-a1a4-af1365bdd9e5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate maturities of long-term obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_484cdbb9-c59b-4fe6-bb07-58371827402f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ff46631a-1158-4337-ba60-d25fe75bb33d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss) (Note&#160;13)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_42335d63-f01c-4aa8-ba72-a9d40510be8b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_fc0f39d7-4c5f-4f59-9c4d-7cbbef8260e1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1e086daf-a2e3-472b-acab-b7eed459b217_verboseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_919ef2bc-2288-44ae-8146-782b9199f5e9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term taxes payable (Note 1)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDisclosureTextBlock_599d69a8-ea55-4f45-a8de-a71e997dd3b6_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Currency Transalation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_03e05bbd-6180-4ed1-bb8b-0e3f2f58547c_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments, increase (decrease) from acquisition (sale) during period</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_label_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:href="jnj-20220102.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:to="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_6168ac52-0e73-40ce-95bc-85b3801b6255_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RegulationCharge_9ee28b84-c763-444e-b420-12a945f29189_terseLabel_en-US" xlink:label="lab_jnj_RegulationCharge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulation charge</link:label>
    <link:label id="lab_jnj_RegulationCharge_label_en-US" xlink:label="lab_jnj_RegulationCharge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulation charge</link:label>
    <link:label id="lab_jnj_RegulationCharge_documentation_en-US" xlink:label="lab_jnj_RegulationCharge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulation charge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RegulationCharge" xlink:href="jnj-20220102.xsd#jnj_RegulationCharge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RegulationCharge" xlink:to="lab_jnj_RegulationCharge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_c16c7549-9c18-4cdb-82ee-42dcffa6ba25_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation, nondeductible expense, impairment losses, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_cc1e0d9d-ad14-4d06-824d-03bb15281dad_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_fda16389-6187-4115-8d40-76fb9818479a_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_8ddcbb32-8e42-4015-a7fe-d767c246d418_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_573c7416-5706-4b49-98a0-2c7aeeeba9c5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_95486232-21ef-4fc0-a939-1f7a3453b1b0_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_3f157fa8-a782-404a-8b9f-8d0f6ff4e197_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_0aa24521-4c8f-4334-a856-69daa67da193_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_c2ac1a2f-c5e1-4a03-b0ea-7f3bda74b24e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of increase in compensation levels</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_51b01d5a-ae4f-4317-99c8-220950d785b1_terseLabel_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_label_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies [Axis]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_documentation_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement by companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis" xlink:href="jnj-20220102.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis" xlink:to="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PharmaceuticalMember_ec7bc693-b1a8-426e-b9f3-0705609994be_verboseLabel_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_9b6f3ba7-7164-4d2e-b4aa-51bccb1bc4fc_terseLabel_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_label_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_documentation_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember" xlink:href="jnj-20220102.xsd#jnj_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PharmaceuticalMember" xlink:to="lab_jnj_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_b7fadbf4-7b8d-407a-9a59-9eac7c7b0b4d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_023d6d63-48f6-449d-b103-74172b0425b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_4310db2b-4649-4906-a3ef-877f67743416_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option average life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_46d8e736-42be-43f8-86fd-fcbd6085f4ce_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Average Life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SavingsPlanTextBlock_7c65f605-5cde-478f-9c2e-d3bc2427a27e_terseLabel_en-US" xlink:label="lab_jnj_SavingsPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Savings Plan</link:label>
    <link:label id="lab_jnj_SavingsPlanTextBlock_label_en-US" xlink:label="lab_jnj_SavingsPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Savings Plan [Text Block]</link:label>
    <link:label id="lab_jnj_SavingsPlanTextBlock_documentation_en-US" xlink:label="lab_jnj_SavingsPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Savings Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanTextBlock" xlink:href="jnj-20220102.xsd#jnj_SavingsPlanTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SavingsPlanTextBlock" xlink:to="lab_jnj_SavingsPlanTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SPINESPORTSOTHERMember_ee8cb9a7-dd81-46d8-b785-54db75042fe2_terseLabel_en-US" xlink:label="lab_jnj_SPINESPORTSOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE,SPORTS &amp; OTHER</link:label>
    <link:label id="lab_jnj_SPINESPORTSOTHERMember_label_en-US" xlink:label="lab_jnj_SPINESPORTSOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE, SPORTS &amp; OTHER [Member]</link:label>
    <link:label id="lab_jnj_SPINESPORTSOTHERMember_documentation_en-US" xlink:label="lab_jnj_SPINESPORTSOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE &amp; OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINESPORTSOTHERMember" xlink:href="jnj-20220102.xsd#jnj_SPINESPORTSOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SPINESPORTSOTHERMember" xlink:to="lab_jnj_SPINESPORTSOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9a3d9a2f-26a9-43bc-84b4-f33f5b267b53_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currently payable:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_5a0851ff-482b-44c7-b1fb-14e98708857c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments : Assets</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_54e67daa-7f78-4903-b762-9a08751af9bf_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RemicadeMember_6cea50b9-3516-45a0-9b25-3e26c6bccd8a_terseLabel_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade</link:label>
    <link:label id="lab_jnj_RemicadeMember_label_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:label id="lab_jnj_RemicadeMember_documentation_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember" xlink:href="jnj-20220102.xsd#jnj_RemicadeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RemicadeMember" xlink:to="lab_jnj_RemicadeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_3416f3c7-fa4e-4139-9e21-fea0c1889294_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity, unrecognized loss</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ActelionMember_02003001-6f89-4218-a312-a1590f41e71c_terseLabel_en-US" xlink:label="lab_jnj_ActelionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actelion</link:label>
    <link:label id="lab_jnj_ActelionMember_label_en-US" xlink:label="lab_jnj_ActelionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actelion [Member]</link:label>
    <link:label id="lab_jnj_ActelionMember_documentation_en-US" xlink:label="lab_jnj_ActelionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actelion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ActelionMember" xlink:href="jnj-20220102.xsd#jnj_ActelionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ActelionMember" xlink:to="lab_jnj_ActelionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TremfyaMember_3d36ca66-c4f1-46fb-b343-9f9b02b66af3_terseLabel_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya</link:label>
    <link:label id="lab_jnj_TremfyaMember_label_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya [Member]</link:label>
    <link:label id="lab_jnj_TremfyaMember_documentation_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfaya</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember" xlink:href="jnj-20220102.xsd#jnj_TremfyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TremfyaMember" xlink:to="lab_jnj_TremfyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_573e2362-96c5-472f-b0b3-7bfd9afeb3af_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c3f4f54a-79b8-4851-97a0-fd265c49606b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par Value $1.00</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_282ade4a-a198-401c-8143-cf351794b7dd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issued Amount</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_967f453e-e5e3-498b-9cf7-222ed75edc61_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NeuroscienceMember_333e1997-5268-4b81-af81-0ffb72bb17c5_terseLabel_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_label_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_documentation_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember" xlink:href="jnj-20220102.xsd#jnj_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NeuroscienceMember" xlink:to="lab_jnj_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a5b70366-375e-4247-bc96-85e0c01c63c6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, unrecognized loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_cae1a672-097c-43fb-9054-90cb08412543_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5eef5f0d-664c-4016-9af0-211f4b3210ea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeThreeMember_3b033b38-5d77-4e88-b954-2efb9a700bef_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$115.67-$129.51</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeThreeMember" xlink:href="jnj-20220102.xsd#jnj_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeThreeMember" xlink:to="lab_jnj_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_da70ca06-3ac9-4551-bcc0-ecbe0888e342_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_8d8bd62e-6270-48d8-be07-452c497af41d_terseLabel_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense related to change in tax rate from TRAF</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Change In Tax Rate, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Change In Tax Rate, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" xlink:href="jnj-20220102.xsd#jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" xlink:to="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_f981727b-3c27-450c-a3fd-d90c532689dd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_72f2e4f2-177f-4508-b748-305ed5036a6c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_3e12c5f1-fbd3-4bc6-9e57-ee914eb6ebd4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_74525fa0-90a6-46f0-977e-3cdb112fcf20_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents (Notes&#160;1 and 2)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5126ac2b-3976-41d7-8443-d6ae7b45201f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash &amp; Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_29dfe200-ed4b-423f-81e1-33830a6f9f01_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Amount</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_d942f80c-76d3-4a39-b7bb-085e4128045f_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_6cabfcde-060f-4662-a480-1ee7c72a2d84_terseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation, litigation settlement, percent</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Litigation Settlement, Percent</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Litigation Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" xlink:href="jnj-20220102.xsd#jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_bf565cc2-ce37-4f80-ae2b-c919878d8384_terseLabel_en-US" xlink:label="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum reverse repurchase agreement collateral (as a percent)</link:label>
    <link:label id="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_label_en-US" xlink:label="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Collateral Value as a Percent, Reverse Repurchase Agreement</link:label>
    <link:label id="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_documentation_en-US" xlink:label="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Collateral Value as a Percent, Reverse Repurchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:href="jnj-20220102.xsd#jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:to="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_9a3f3829-22ff-4221-ab3e-246b362ec485_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_ffec3c65-4f36-4ded-b044-98595f72ca6b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset write-downs</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_8fba3cc9-72a7-444e-8e29-ead9fdb8765d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_69c913ee-ea34-4324-9cde-b76d0d57008e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_82eccac5-6563-4eab-b716-db83d0226467_terseLabel_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_label_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_177375ac-2b1b-413f-bbb5-3c562c4107b6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid from plan</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AuditorInformationAbstract_label_en-US" xlink:label="lab_jnj_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_jnj_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_jnj_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AuditorInformationAbstract" xlink:href="jnj-20220102.xsd#jnj_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AuditorInformationAbstract" xlink:to="lab_jnj_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_dc71e640-737c-482c-b5dc-f649ac40c51b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_34e8fe59-5661-4eb9-baef-2b7db2cb3dfa_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_ebe4e03f-95f5-4446-990b-80d5583bd184_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_22da74e5-5c7b-47e0-bb5b-76ed5d8dcfef_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_94da07b1-f416-4d62-b6e5-74d1a2b52876_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_072fb317-ff67-4855-b024-682a0300e392_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_2a5f3fff-0425-4dd8-b71c-0ebdb95bf72b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_f8a2b960-3869-49d7-8a44-d96846cb27c3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_03411e1c-e3fe-4164-91a8-7ef1b46801ee_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b0b3a4e6-ebf1-497a-a0c7-3bae776c9146_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted, average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3ef101c4-e730-4be5-97a8-29f64e2302ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_faaf123e-884d-45d7-be7d-9e95728a5ed2_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_3d45c8c2-539d-4c86-bf36-977995f9484d_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_24088b4a-7fd0-4a17-9e27-a047b404fd84_terseLabel_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_label_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_documentation_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member" xlink:href="jnj-20220102.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.500Notesdue2048Member" xlink:to="lab_jnj_A3.500Notesdue2048Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5fff9869-dad2-47c1-b7ea-0f22b802bccb_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2142fcfb-b2e4-499d-bb7c-ab0298aaa9d3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_6d08685f-c17a-4cda-a75f-0ddb16235898_terseLabel_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, fair value adjustment, impairment loss</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_label_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Impairment Loss</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_documentation_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:href="jnj-20220102.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:to="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_42848d22-857e-407d-818b-bd916c8ef8ce_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total before tax effects</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IdorsiaMember_ef28e740-ca96-4d56-95f3-e13c70a5403b_terseLabel_en-US" xlink:label="lab_jnj_IdorsiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia</link:label>
    <link:label id="lab_jnj_IdorsiaMember_label_en-US" xlink:label="lab_jnj_IdorsiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia [Member]</link:label>
    <link:label id="lab_jnj_IdorsiaMember_documentation_en-US" xlink:label="lab_jnj_IdorsiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IdorsiaMember" xlink:href="jnj-20220102.xsd#jnj_IdorsiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IdorsiaMember" xlink:to="lab_jnj_IdorsiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_a354f04b-cefc-4f6c-91f0-53d402557d8b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total loss/(income) recognized in other comprehensive income, before tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_1d6f431b-1bf7-4482-be3f-af46a9c8a69b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c2feb9ca-34ae-4d62-a5b3-5cf1e4c2b8e6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2019AcquisitionsMember_2b80c34c-a709-4d75-8ce8-d521417257d2_terseLabel_en-US" xlink:label="lab_jnj_A2019AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Acquisitions</link:label>
    <link:label id="lab_jnj_A2019AcquisitionsMember_label_en-US" xlink:label="lab_jnj_A2019AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Acquisitions [Member]</link:label>
    <link:label id="lab_jnj_A2019AcquisitionsMember_documentation_en-US" xlink:label="lab_jnj_A2019AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Acquisitions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2019AcquisitionsMember" xlink:href="jnj-20220102.xsd#jnj_A2019AcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2019AcquisitionsMember" xlink:to="lab_jnj_A2019AcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_96be7d9d-f2e8-4a45-9c4b-0b9cb5931a25_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense capitalized</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_81fcf8fa-05c0-46e3-a264-032327eaa6c6_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027-2031</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Five Fiscal Years Thereafter</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan expected future benefit contribution in five fiscal years thereafter.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_928f59a6-3c6e-4bf9-995b-fc0b872bdfcc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_be3bdd5b-4c76-4dad-a9ea-c240dfca3411_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_9bc79815-77e0-46bc-a3c9-b636a62dd4fc_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_a80a73bb-67b2-4e24-8c26-72f989a3ba00_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_ad7c3525-17be-4284-9f89-00c7d76986ba_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_bb57c455-0bec-4c7f-bfa4-c15e58d87980_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_9a1bb6d5-1cd8-4715-92d5-cdab921103eb_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss), net of amortization</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:href="jnj-20220102.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AdvancedSterilizationProductsMember_e21eb12b-b00d-4d61-bca3-0e5a770ef9b7_terseLabel_en-US" xlink:label="lab_jnj_AdvancedSterilizationProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AdvancedSterilizationProducts</link:label>
    <link:label id="lab_jnj_AdvancedSterilizationProductsMember_label_en-US" xlink:label="lab_jnj_AdvancedSterilizationProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AdvancedSterilizationProducts [Member]</link:label>
    <link:label id="lab_jnj_AdvancedSterilizationProductsMember_documentation_en-US" xlink:label="lab_jnj_AdvancedSterilizationProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AdvancedSterilizationProducts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AdvancedSterilizationProductsMember" xlink:href="jnj-20220102.xsd#jnj_AdvancedSterilizationProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AdvancedSterilizationProductsMember" xlink:to="lab_jnj_AdvancedSterilizationProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_4c17e2f0-9935-40af-b6a3-fbb0824422a3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_579a9c33-25b0-44a2-bd64-409ae6d6982a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net of portion capitalized (Note&#160;4)</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_a6f6b2cf-fcbd-4e1e-ba6e-3ab9265c8b30_terseLabel_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAF effect on tax rate</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_label_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Federal Act On Tax Reform And AHV Financing, Percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_documentation_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Federal Act On Tax Reform And AHV Financing, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" xlink:href="jnj-20220102.xsd#jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" xlink:to="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_d8d9ee12-6ef5-4981-92b2-ea9797424790_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected long-term rate of return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2a8df557-7578-4de5-9578-113d6dd974f3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d95165dc-c654-401a-889b-0d60344dfa69_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_003f6bba-6fee-4b75-88dc-6ea73a10a78f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_765f10c1-77c7-40a2-b756-305af7ce3a33_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5a507163-c6c6-4684-bc76-859bfe765cbd_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_42e36ed1-ee14-4f09-86a7-9902e4dc4919_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_6f6ac156-2570-4501-b1e2-87409768b72e_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4b90f6e6-0d2c-42c1-a51e-dcf629cb4a14_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f16558c8-90bb-450d-a593-4e67a6109d17_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_515fa3a6-1ba6-4369-a1ef-e46261879043_verboseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross currency interest rate swaps</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_0f985d5f-dca7-40f4-b702-a3c422ed66a0_terseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross currency interest rate swaps contracts:</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e35753bf-2184-41ee-b3d6-593743b9568e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_6d3c91d1-6f58-4f83-9549-0f345a7c898b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Derivative Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_bfd3511b-f4c9-403a-a12c-83a71d332626_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_623181ee-c039-4494-9c55-47d3152a435f_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:href="jnj-20220102.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_0ee5012c-d8bd-4415-8262-36acb437e3d3_verboseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due November 2028</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_a794d1cb-7323-4aa7-b005-6fac1ce1bcc4_terseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes due 2028 (750MM Euro 1.1311)(2)/(750MM Euro 1.2281)(3)</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_label_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_documentation_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member" xlink:href="jnj-20220102.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.150NotesDue2028Member" xlink:to="lab_jnj_A1.150NotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_badcaf2d-69ab-4dfe-9337-3e88fdcb36e5_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_adfba0f3-e290-4b84-8fa3-8c485da6ef07_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_90fab190-001f-4ee6-8569-07e079cac75d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_da963fb2-4b2d-4c9a-91fe-2b4f6f77bf16_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a039f204-b5f7-4fe7-a97c-36b861257a6a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_129792dc-6e1f-4259-be9e-d9969fd7937c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_c5664d9f-6e95-44ad-ae34-07eefab58f2d_terseLabel_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_label_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_documentation_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember" xlink:href="jnj-20220102.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EDURANTrilpivirineMember" xlink:to="lab_jnj_EDURANTrilpivirineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_4d58e2fe-9f4c-456b-b329-549d57750464_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long-term debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_b1799dc2-ec87-4c00-9fad-9bed4fd81f50_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_97f848bf-accb-4ed1-a2fa-77adc2c96100_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_e6642a55-0766-4585-a8d6-f39a5a13b06e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_9eba92d8-ca15-4c91-91ec-0e9f8bbc7a45_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, estimate of additional possible loss</link:label>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_label_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Additional Possible Loss</link:label>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_documentation_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Additional Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:href="jnj-20220102.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:to="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_c7b28aea-9658-4d70-b7bb-9fb6d0b86a58_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_72893c66-e76a-47ae-bb59-bcad16f3afaa_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of Plan Assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_506391ac-c529-4050-823a-02d0f7877b0b_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories (Notes&#160;1 and 3)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_8822c040-f7e4-45db-9545-03f9733e6167_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_6b4cf269-d686-47fa-a6b9-760e9b285b0a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_08484f16-471d-4822-9e9d-995637951c2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8c4e18e8-37b6-41f0-81a0-dae128935633_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. taxes</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_bf170314-f0c2-48e4-9702-ee80fe5799ac_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IMBRUVICAMember_47813ce8-824c-4168-9f14-6b419bf8f265_terseLabel_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_label_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_documentation_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember" xlink:href="jnj-20220102.xsd#jnj_IMBRUVICAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IMBRUVICAMember" xlink:to="lab_jnj_IMBRUVICAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_5b2aeb49-7744-4a3d-8ada-f1213e1cba31_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2250NotesDue2050Member_0f02b278-e85c-4523-95b6-9db777036693_terseLabel_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_label_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050 [Member]</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_documentation_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member" xlink:href="jnj-20220102.xsd#jnj_A2250NotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2250NotesDue2050Member" xlink:to="lab_jnj_A2250NotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_338b1c87-515f-4a58-90d4-975e87a92c64_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_7c9d5d2b-50ff-4073-a65b-ff630558a001_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities without readily determinable fair value, amount</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_5a280431-ee05-4fcc-a981-cc4a9808f530_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OralCareMember_4fe9314a-9277-42e8-8b46-c3dde8285862_terseLabel_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care</link:label>
    <link:label id="lab_jnj_OralCareMember_label_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care [Member]</link:label>
    <link:label id="lab_jnj_OralCareMember_documentation_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember" xlink:href="jnj-20220102.xsd#jnj_OralCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OralCareMember" xlink:to="lab_jnj_OralCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_16a0d070-e019-4bcc-9ffa-74adb5e11dbd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Funded Status</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Funded Status [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetFundedStatusTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_d232421e-f7cb-4d78-8265-53d78e1c548e_terseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:href="jnj-20220102.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_019571a8-391b-42c3-97b5-a5dd869ab06b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_b5ca8d91-f065-406a-b657-93e3d6e55b67_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves&#160;&amp; liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e1bc3c7a-2314-4d1b-b740-d88f07411ec7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_8970337f-54bf-4df1-a4ae-a1f67b827ef5_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermCommercialPaperCurrent_c7dcaa20-42a9-42c2-8cea-e233d3ddd2f1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermCommercialPaperCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowed under the commercial paper program</link:label>
    <link:label id="lab_us-gaap_LongTermCommercialPaperCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermCommercialPaperCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Commercial Paper, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermCommercialPaperCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermCommercialPaperCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermCommercialPaperCurrent" xlink:to="lab_us-gaap_LongTermCommercialPaperCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ffa09850-51f3-406e-a0f6-c87a44f724dd_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1358ecfc-d710-4937-90c9-78ff02c29616_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AssetWriteoffMember_0f0da351-b9a0-41ad-ac76-1284ae7eb691_terseLabel_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-offs/Sales</link:label>
    <link:label id="lab_jnj_AssetWriteoffMember_label_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-off [Member]</link:label>
    <link:label id="lab_jnj_AssetWriteoffMember_documentation_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-off [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember" xlink:href="jnj-20220102.xsd#jnj_AssetWriteoffMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AssetWriteoffMember" xlink:to="lab_jnj_AssetWriteoffMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_70b81257-89ef-4994-8f6a-3176706e5dd1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Wholesaler2Member_2d53169f-3b93-4436-b08e-924bcafebe30_terseLabel_en-US" xlink:label="lab_jnj_Wholesaler2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 2</link:label>
    <link:label id="lab_jnj_Wholesaler2Member_label_en-US" xlink:label="lab_jnj_Wholesaler2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 2 [Member]</link:label>
    <link:label id="lab_jnj_Wholesaler2Member_documentation_en-US" xlink:label="lab_jnj_Wholesaler2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler2Member" xlink:href="jnj-20220102.xsd#jnj_Wholesaler2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Wholesaler2Member" xlink:to="lab_jnj_Wholesaler2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_6592a99d-a2b4-423f-9488-843f6631950f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Health Care Cost Trend Rates</link:label>
    <link:label id="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Health Care Cost Trend Rates [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_044bf320-af55-47a8-aef8-fdd2b667596a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsrMember_0c591a53-2a96-431a-82b8-f4ff8072e7fa_terseLabel_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR</link:label>
    <link:label id="lab_jnj_AsrMember_label_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR [Member]</link:label>
    <link:label id="lab_jnj_AsrMember_documentation_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember" xlink:href="jnj-20220102.xsd#jnj_AsrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsrMember" xlink:to="lab_jnj_AsrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_81400a15-82a6-41c7-958f-6ad0b5883e00_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_d31f85b0-ceea-4f35-8ab0-5e9aa1ecaf9b_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve established</link:label>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_label_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established within Trust</link:label>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_documentation_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established within Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:href="jnj-20220102.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:to="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_ac949a7c-eb89-4390-b41a-bf8bd23c8b55_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_2bf02934-a35f-4f55-be15-50392aec9358_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_f4cab54d-b660-4efb-abe2-6c4f5cc2c9ce_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), pension and other, effects of exchange rate net of tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">other comprehensive income loss, pension and other , effects of exchange rate net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:href="jnj-20220102.xsd#jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_f2afac63-a6af-4600-814e-fbc26422626a_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensions and Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cbfa8d15-2b15-4a3a-89fc-72e2a08025c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock_eda7454a-4c8a-4b4b-bd09-63bc84abdab3_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling Cost, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_80c640e3-8124-4aa7-bcb1-ff32478c2768_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest on income taxes accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_747501b5-0b76-47d7-aff4-2333a51b3a0d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_f86f704e-0e4c-40e2-8c11-dc90b63078b5_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_fa75d8c9-a44e-47cf-a273-a045e2e211b7_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures&#160;&amp; acquisitions</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:to="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_27c5d2c4-c7a2-487b-ac25-751be63cb79c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, related to divestitures</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_4435a6f6-7489-422d-a907-b232f671fb3c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d9ba9b7e-241c-4dd3-bdb1-cd208fd86552_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_76fffd62-643b-46d8-821f-cc257d0a8057_verboseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_0c5099b7-7678-46e6-a487-89c1c7b66b05_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_f08e7714-bbdf-436b-a987-311953cc2f8a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest, net of amount capitalized</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_5b49104d-c0ef-4865-903c-5ae2d888f194_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DebtInstrumentConvertibleAmountOfLoanConverted_1a9dd4aa-ea6e-4c63-a6f8-f300dada2999_terseLabel_en-US" xlink:label="lab_jnj_DebtInstrumentConvertibleAmountOfLoanConverted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt, amount of loan converted</link:label>
    <link:label id="lab_jnj_DebtInstrumentConvertibleAmountOfLoanConverted_label_en-US" xlink:label="lab_jnj_DebtInstrumentConvertibleAmountOfLoanConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Amount of Loan Converted</link:label>
    <link:label id="lab_jnj_DebtInstrumentConvertibleAmountOfLoanConverted_documentation_en-US" xlink:label="lab_jnj_DebtInstrumentConvertibleAmountOfLoanConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Amount of Loan Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DebtInstrumentConvertibleAmountOfLoanConverted" xlink:href="jnj-20220102.xsd#jnj_DebtInstrumentConvertibleAmountOfLoanConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DebtInstrumentConvertibleAmountOfLoanConverted" xlink:to="lab_jnj_DebtInstrumentConvertibleAmountOfLoanConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_b4adcbd6-3408-4a3b-9a8c-7b1e423ecf93_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_211776fd-4076-4ff1-ae29-4b5de0241b95_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_3b3a9621-6787-47b1-bee8-ebb4d22c21ce_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service cost (credit)(1)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_32a71b8f-ba83-4b18-b1de-482016e73568_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_848d0d2c-9fac-42a4-8915-7b6b4dc72063_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_dd4eb96f-3fe8-40c4-b5cb-9318f1d0bd8b_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_244bead2-9a51-43b4-99a2-46c9c727c117_terseLabel_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment benefits</link:label>
    <link:label id="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_baa6183c-1d64-4dd8-a272-b405b3f175ee_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_0c0fbdc8-e243-4b13-90f0-64760013be6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans and notes payable (Note&#160;7)</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_863d365c-b83b-4136-a85a-a25faae981c9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans and notes payable</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_676ad25d-1c3c-4667-a012-be8545a7c865_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_572628a2-1645-419c-bd85-d86dc634a385_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development (Note 5)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_3afe764f-6942-455b-aec4-51d8ca3e0516_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_f3915d3a-855c-4e75-929c-4b93e2cd0833_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_3bde9b5b-f189-4f19-801e-214048c81848_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.05Notesdue2023Member_f3e01da4-9f7e-41bc-89b3-7271616fe5e2_terseLabel_en-US" xlink:label="lab_jnj_A2.05Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.05% Notes due 2023</link:label>
    <link:label id="lab_jnj_A2.05Notesdue2023Member_label_en-US" xlink:label="lab_jnj_A2.05Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.05% Notes due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A2.05Notesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A2.05Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.05% Notes due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.05Notesdue2023Member" xlink:href="jnj-20220102.xsd#jnj_A2.05Notesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.05Notesdue2023Member" xlink:to="lab_jnj_A2.05Notesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9e73ef8a-cf40-44f5-a3c1-0b12614823b9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_56984768-15a0-4044-b2e0-a9227847e75d_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding&#160;&#8212; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_90787a60-677d-4de5-8c27-ea653246f81f_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_71f3c875-794c-4bd4-bfa3-9bd588034d9b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_a076d5e6-0afc-48df-b66a-b7db2463278f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskLineItems_c6db4452-b714-4026-b27a-70cc4aefd981_terseLabel_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk [Line Items]</link:label>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskLineItems_label_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk [Line Items]</link:label>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskLineItems_documentation_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of credit risk.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskLineItems" xlink:href="jnj-20220102.xsd#jnj_ConcentrationOfCreditRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems" xlink:to="lab_jnj_ConcentrationOfCreditRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_b132e5e1-73f5-43c0-a4ff-76c5c2291c48_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_8bb23914-7423-4979-899d-ede0087f6851_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_0d8a5eb4-5649-443a-a12c-5fa2f1efd198_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AurisHealthMember_b06dfde5-ec85-4e72-b893-09874eb287ed_terseLabel_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health</link:label>
    <link:label id="lab_jnj_AurisHealthMember_label_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health [Member]</link:label>
    <link:label id="lab_jnj_AurisHealthMember_documentation_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember" xlink:href="jnj-20220102.xsd#jnj_AurisHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AurisHealthMember" xlink:to="lab_jnj_AurisHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_bf82ff00-b103-4638-ac71-8580f87d0d4b_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net actuarial loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_9645d928-484f-420a-9adc-8d7fdcc96d4a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Recognized In Accumulated OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_4c1fd5ee-b97e-41a8-b518-31221a981a5a_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_5d8d5961-795b-44ef-87d0-135c46f979d2_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2fd81806-5b0c-41d6-b749-479d6ddc7b08_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_1d8e8d5b-07b8-40db-9b55-f3fa4f0a4252_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_b01020f8-0786-46fe-82d6-5ec5569c7415_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net (Notes&#160;1 and 5)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_e2cb3911-2f7b-4c6f-a5f0-57f64a4fe4b9_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets - net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_a55b9eac-b6b3-49f5-a5d6-dc9f583f3262_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_de861218-0359-41dc-a58b-a3d707f9a104_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:to="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f678a8f3-148c-49fc-8581-06ef49f06bed_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_fc13b72a-a387-4f0e-b020-bd1783bdfa2d_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with indefinite lives:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_be746363-8dc9-4de0-ba4f-1944fd12b4f0_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes on income (Note 8)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_8c18d1c0-9fe2-44c3-a970-9dd4c6684f9f_terseLabel_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Sales by Segment of Business</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_label_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales By Segment Of Business [Table Text Block]</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_documentation_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:href="jnj-20220102.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:to="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_94b987b5-2103-49cf-8fdb-bd7cbf2ebdb0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_c300f1db-8854-408b-a6ae-7499bb4fb264_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral paid</link:label>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_label_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:to="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1beebcc7-cd60-41d8-936d-d45a9ef023ae_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_930a61c6-a5ee-4347-8f7d-82bcd41e9bb3_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_842a99a7-197c-482b-a4ff-799fbcb60c91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_404615fb-a88f-4e44-893b-49045a05f8b5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_11d508e3-244e-42f1-879e-1b88904e5e19_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_1882447e-b5fb-49e4-bb95-532103ef8892_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of property and intangibles</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_88727cc6-caff-4feb-ac44-50244bdb47d3_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProductLiabilityPolicyTextBlock_872720c2-3f33-43b1-a28b-c54804063f7e_terseLabel_en-US" xlink:label="lab_jnj_ProductLiabilityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:label id="lab_jnj_ProductLiabilityPolicyTextBlock_label_en-US" xlink:label="lab_jnj_ProductLiabilityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability [Policy Text Block]</link:label>
    <link:label id="lab_jnj_ProductLiabilityPolicyTextBlock_documentation_en-US" xlink:label="lab_jnj_ProductLiabilityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityPolicyTextBlock" xlink:href="jnj-20220102.xsd#jnj_ProductLiabilityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProductLiabilityPolicyTextBlock" xlink:to="lab_jnj_ProductLiabilityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_d834ce3a-1eeb-4c29-8715-61da844d0433_terseLabel_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_label_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_documentation_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member" xlink:href="jnj-20220102.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.70Notesdue2046Member" xlink:to="lab_jnj_A3.70Notesdue2046Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices_74ce2cb9-f3c5-4dd8-b9a1-5467ddaff757_terseLabel_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, fair value adjustment, change in observable prices</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices_label_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Change in Observable Prices</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices_documentation_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Change in Observable Prices</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:href="jnj-20220102.xsd#jnj_EquityFairValueAdjustmentChangeinObservablePrices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:to="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxAssetsOtherDomestic_2375d815-833a-4c9c-8f57-141360f7497e_terseLabel_en-US" xlink:label="lab_jnj_DeferredTaxAssetsOtherDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous U.S.&#160;</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsOtherDomestic_label_en-US" xlink:label="lab_jnj_DeferredTaxAssetsOtherDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Other Domestic</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsOtherDomestic_documentation_en-US" xlink:label="lab_jnj_DeferredTaxAssetsOtherDomestic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets other domestic.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsOtherDomestic" xlink:href="jnj-20220102.xsd#jnj_DeferredTaxAssetsOtherDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxAssetsOtherDomestic" xlink:to="lab_jnj_DeferredTaxAssetsOtherDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConcentrationRiskThresholdPercentage_7c77524f-fcef-4f3b-8290-d29d28a5d98c_terseLabel_en-US" xlink:label="lab_jnj_ConcentrationRiskThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, threshold percentage (as a percent)</link:label>
    <link:label id="lab_jnj_ConcentrationRiskThresholdPercentage_label_en-US" xlink:label="lab_jnj_ConcentrationRiskThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Threshold Percentage</link:label>
    <link:label id="lab_jnj_ConcentrationRiskThresholdPercentage_documentation_en-US" xlink:label="lab_jnj_ConcentrationRiskThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Threshold Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationRiskThresholdPercentage" xlink:href="jnj-20220102.xsd#jnj_ConcentrationRiskThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConcentrationRiskThresholdPercentage" xlink:to="lab_jnj_ConcentrationRiskThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8b6aabf1-4989-4e1b-8193-1f634c4d3282_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_fcf7664a-ad6d-44e5-8d66-319ee77d4cde_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_MedicalDevicesMember_6ad42f4f-15b7-4ddb-bc42-f0d05e4d3154_terseLabel_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_9eeee1ba-34b8-4826-a52b-fa11a64412c0_verboseLabel_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_label_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices [Member]</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_documentation_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember" xlink:href="jnj-20220102.xsd#jnj_MedicalDevicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_MedicalDevicesMember" xlink:to="lab_jnj_MedicalDevicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_2b089666-118f-487b-906d-97adad29fcfd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit plans:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_644f9c0e-5aeb-4ca3-b4cd-18223ec7f91f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_2ad1ca85-bb40-4374-88d0-27ba34272dcc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sale of assets/businesses</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_ebee9816-a305-4391-a9fa-526e2f9f4ca3_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_348eecc9-12b0-44f2-b9a9-24ba828b0ebd_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_b537fa00-9aa0-4627-8fb8-4440e26b19bc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestiture of brands</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_64ced7bd-477c-4254-b97c-a9d62e32e3f3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_2cbfc723-687c-4287-bb00-90143708022a_terseLabel_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_label_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_documentation_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember" xlink:href="jnj-20220102.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PatentsAndTrademarksMember" xlink:to="lab_jnj_PatentsAndTrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2012LongTermIncentivePlanMember_4b54f924-9af2-44ad-942e-a0f82d44f252_terseLabel_en-US" xlink:label="lab_jnj_A2012LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Long-Term Incentive Plan</link:label>
    <link:label id="lab_jnj_A2012LongTermIncentivePlanMember_label_en-US" xlink:label="lab_jnj_A2012LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Long-Term Incentive Plan [Member]</link:label>
    <link:label id="lab_jnj_A2012LongTermIncentivePlanMember_documentation_en-US" xlink:label="lab_jnj_A2012LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Long-Term Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2012LongTermIncentivePlanMember" xlink:href="jnj-20220102.xsd#jnj_A2012LongTermIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2012LongTermIncentivePlanMember" xlink:to="lab_jnj_A2012LongTermIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_4dea22cf-7678-42bb-b815-8ed092223678_terseLabel_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member" xlink:href="jnj-20220102.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.625Notesdue2037Member" xlink:to="lab_jnj_A3.625Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset_3b357baa-99f2-4753-a790-ed959e64e0fd_terseLabel_en-US" xlink:label="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of company's common stock to plan asset</link:label>
    <link:label id="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset_label_en-US" xlink:label="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Company's Common Stock To Plan Asset</link:label>
    <link:label id="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset_documentation_en-US" xlink:label="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of the company's common stock to the total plan asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCompanysCommonStockToPlanAsset" xlink:href="jnj-20220102.xsd#jnj_PercentageOfCompanysCommonStockToPlanAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageOfCompanysCommonStockToPlanAsset" xlink:to="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_61974d01-fd31-4d22-94d0-e1cd09614f5f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_248870f7-62ed-420c-aa3d-03a856010cb3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Range, Maximum (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherImmunologyMember_a8c58862-0326-47e4-bc49-aa559f4c4ecd_terseLabel_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_label_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_documentation_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember" xlink:href="jnj-20220102.xsd#jnj_OtherImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherImmunologyMember" xlink:to="lab_jnj_OtherImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_1035cf17-93dd-4385-a004-608a97a73f1f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases related to prior period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_4178aeba-3fdf-4633-b101-6ed7c3124f62_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FiscalPeriodPolicyTextBlock_1ad32408-3adc-4d9f-8211-c91241187125_terseLabel_en-US" xlink:label="lab_jnj_FiscalPeriodPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Closing Date</link:label>
    <link:label id="lab_jnj_FiscalPeriodPolicyTextBlock_label_en-US" xlink:label="lab_jnj_FiscalPeriodPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period [Policy Text Block]</link:label>
    <link:label id="lab_jnj_FiscalPeriodPolicyTextBlock_documentation_en-US" xlink:label="lab_jnj_FiscalPeriodPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal period policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiscalPeriodPolicyTextBlock" xlink:href="jnj-20220102.xsd#jnj_FiscalPeriodPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FiscalPeriodPolicyTextBlock" xlink:to="lab_jnj_FiscalPeriodPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CommingledFundsMember_706e0741-ce08-4924-b9f8-91c280b1f7a6_terseLabel_en-US" xlink:label="lab_jnj_CommingledFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commingled funds</link:label>
    <link:label id="lab_jnj_CommingledFundsMember_label_en-US" xlink:label="lab_jnj_CommingledFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commingled Funds [Member]</link:label>
    <link:label id="lab_jnj_CommingledFundsMember_documentation_en-US" xlink:label="lab_jnj_CommingledFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commingled funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember" xlink:href="jnj-20220102.xsd#jnj_CommingledFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CommingledFundsMember" xlink:to="lab_jnj_CommingledFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsAbstract_8b8fa0e9-9b53-4f89-b577-193216929c57_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract" xlink:to="lab_us-gaap_CompensationRelatedCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_f6d2a60e-5838-49af-9d22-9baaa22105ab_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7113a2e6-ce85-429c-a17c-cdbf8e56df02_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_dcbd7f69-28ba-4318-9433-0136edbd9488_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EvraAndDoxilMember_27787da7-9c9d-4b7f-8754-c02ab70bc5ef_terseLabel_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil</link:label>
    <link:label id="lab_jnj_EvraAndDoxilMember_label_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil [Member]</link:label>
    <link:label id="lab_jnj_EvraAndDoxilMember_documentation_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember" xlink:href="jnj-20220102.xsd#jnj_EvraAndDoxilMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EvraAndDoxilMember" xlink:to="lab_jnj_EvraAndDoxilMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_b3e5d2c4-ff37-43a6-bd4e-ebdb6cfb77b5_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation - beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_e9455450-c06b-403f-88ac-b19834a306f9_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation - end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_50d1cade-8938-473d-95cd-9497f2541640_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_8d0276d6-2758-481a-9eca-5f20eb456dbc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Support Agreement (CSA)</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DamagesFromProductDefectsMember_8e1b69d1-8a3a-4384-9058-41d9dc66bb3e_terseLabel_en-US" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages from Product Defects</link:label>
    <link:label id="lab_us-gaap_DamagesFromProductDefectsMember_label_en-US" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages from Product Defects [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DamagesFromProductDefectsMember" xlink:to="lab_us-gaap_DamagesFromProductDefectsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeMember_08e50219-e10a-49d0-b307-488a1bc92e83_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income</link:label>
    <link:label id="lab_us-gaap_OtherIncomeMember_label_en-US" xlink:label="lab_us-gaap_OtherIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeMember" xlink:to="lab_us-gaap_OtherIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_a40842a5-104e-4d22-ac93-7cc3369631c7_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum length of time for hedging transaction exposure</link:label>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_label_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Length of Time, Foreign Currency Cash Flow Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:to="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_e5952d03-3734-4eee-a354-ff0f7ef3dc96_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_e2896a3b-87af-47b4-9c96-33ad4732e9c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_5cc1bae8-04b3-42d2-9889-9c5b2e28cdf4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_30b7a31f-9f08-4896-88f2-5332f971ec9e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_13c1cb1f-230f-49c6-9c77-315794dca060_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterventionalSolutionsMember_a5646ded-a277-4a63-9b4b-98d244f04a1b_terseLabel_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions</link:label>
    <link:label id="lab_jnj_InterventionalSolutionsMember_label_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions [Member]</link:label>
    <link:label id="lab_jnj_InterventionalSolutionsMember_documentation_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember" xlink:href="jnj-20220102.xsd#jnj_InterventionalSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterventionalSolutionsMember" xlink:to="lab_jnj_InterventionalSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_9df20d1b-5691-4f99-8cf7-9923ad46c0cb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous international</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_e5d7a509-d2af-4dea-a579-389918c1e2fb_terseLabel_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred net losses (gains) on derivatives included in accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_label_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:to="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_db49568e-6102-4ca8-9034-2bcb9ae6cacb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_526ea495-6f41-4068-a528-2323b6501899_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Support Agreement (CSA)</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_410a053f-679b-45a8-bc5b-1335b6c98542_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_7a59a00b-4656-4f1b-9c52-f07fef177b2a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of net actuarial loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_21006b8f-2a12-4752-b7f8-f463ee8fd61d_verboseLabel_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_label_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_documentation_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:href="jnj-20220102.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:to="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_777a9cca-f4a9-463f-bd45-268f858a1dbf_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_8bb5c6d0-f7d9-43f5-aa6f-0201052e6239_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TJCA , provisional liability, non-current</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Noncurrent</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_cb6a7f8c-82b8-46c8-86d6-532aea7e0f38_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan participant contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_8659cfd6-37ac-4b39-ac83-9ce9049d62ed_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt (Note&#160;7)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_6a2f2091-8d64-46e9-9c76-9f2d7f4c0517_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_e8c4e831-5e9a-4992-b87c-edead9a635ef_terseLabel_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_label_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_documentation_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member" xlink:href="jnj-20220102.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.95Notesdue2027Member" xlink:to="lab_jnj_A2.95Notesdue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_42554da5-fbe9-41cc-9190-08c8f4ff06d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_3cf753e3-6c91-40f9-8d55-6f546ac9ee5c_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and stock option plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c2462b18-8912-45e4-9c97-f592fe53ef77_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation cost charged for Long term incentive plan</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_53e60526-02a7-4393-b186-8ecce09a9966_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_76c53968-1257-423e-b3c6-a9d1cd45f6cd_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price over fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_f3534ade-06eb-4220-a224-2d09eb1303d7_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_74c5faef-af7f-4fd0-afc4-145cf2204533_terseLabel_en-US" xlink:label="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_label_en-US" xlink:label="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Employees Engaged In Company Activities Worldwide</link:label>
    <link:label id="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_documentation_en-US" xlink:label="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees engaged in company activities worldwide.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:href="jnj-20220102.xsd#jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:to="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_e3f063fa-601f-4e9f-b32b-911b09c259fa_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, percentage of ownership before transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership before Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OpioidMember_d14d7403-e34d-41d4-af4c-e33a284c8972_terseLabel_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid</link:label>
    <link:label id="lab_jnj_OpioidMember_label_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">opioid [Member]</link:label>
    <link:label id="lab_jnj_OpioidMember_documentation_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember" xlink:href="jnj-20220102.xsd#jnj_OpioidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OpioidMember" xlink:to="lab_jnj_OpioidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_570e181e-9977-4e15-9022-1f830cbb30b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2450NotesDue2060Member_386b6a64-390b-46c6-a998-7503ccce9ff1_terseLabel_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_label_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060 [Member]</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_documentation_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member" xlink:href="jnj-20220102.xsd#jnj_A2450NotesDue2060Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2450NotesDue2060Member" xlink:to="lab_jnj_A2450NotesDue2060Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_9a4d19df-7a64-4192-922f-39895eb15764_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_987d4098-4593-438d-9167-d513fc4fa5e3_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7ba1d2bd-165a-48bd-b37e-d34a74403540_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of year (Note&#160;1)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a6559f1b-61bd-4bea-91d0-48eaa7b5a86e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of year (Note&#160;1)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherMember_0e571feb-2c3f-45d5-a27c-7e460036be90_terseLabel_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_jnj_OtherMember_label_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_jnj_OtherMember_documentation_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember" xlink:href="jnj-20220102.xsd#jnj_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherMember" xlink:to="lab_jnj_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_43742d4b-f318-4f2f-aa5e-a64cba3ddf4d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0789cc1e-0081-4e3d-b5e6-f8e5437fe027_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_c343fcd0-c16e-4494-829c-d992e8d78b19_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ca816f08-83cb-496a-8bcf-475b9aacea37_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6e86cb9e-acb2-4040-998d-e361890c9024_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_f4e3003f-c9fa-4139-b6c5-7caf85f9afc8_terseLabel_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (Income) Expense</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense Net Member</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense Net Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember" xlink:href="jnj-20220102.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterestIncomeExpenseNetMember" xlink:to="lab_jnj_InterestIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CashPaidDuringTheYearAbstract_862e3aa6-4407-4681-9eb1-c4ef6eeb55a2_terseLabel_en-US" xlink:label="lab_jnj_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the year for:</link:label>
    <link:label id="lab_jnj_CashPaidDuringTheYearAbstract_label_en-US" xlink:label="lab_jnj_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During The Year [Abstract]</link:label>
    <link:label id="lab_jnj_CashPaidDuringTheYearAbstract_documentation_en-US" xlink:label="lab_jnj_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During The Year [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashPaidDuringTheYearAbstract" xlink:href="jnj-20220102.xsd#jnj_CashPaidDuringTheYearAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CashPaidDuringTheYearAbstract" xlink:to="lab_jnj_CashPaidDuringTheYearAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_a8ae5544-5fa0-42bd-ae8d-dad016e0a2c9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LegalJurisdictionDomain_0fa9f052-5d63-4e84-b6bc-1a2ef547ff58_terseLabel_en-US" xlink:label="lab_jnj_LegalJurisdictionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Jurisdiction [Domain]</link:label>
    <link:label id="lab_jnj_LegalJurisdictionDomain_label_en-US" xlink:label="lab_jnj_LegalJurisdictionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Jurisdiction [Domain]</link:label>
    <link:label id="lab_jnj_LegalJurisdictionDomain_documentation_en-US" xlink:label="lab_jnj_LegalJurisdictionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalJurisdictionDomain" xlink:href="jnj-20220102.xsd#jnj_LegalJurisdictionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LegalJurisdictionDomain" xlink:to="lab_jnj_LegalJurisdictionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_6bad2b93-1da3-4525-bf11-26e2330173f7_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Measured at Net Asset Value</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:to="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_a54f9cfa-2ce5-4782-a7a7-469c3e5eda86_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible assets gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_9e7d1d7e-be85-4c99-8416-64bdb4e018b4_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with definite lives:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_6edcb6f2-9ec8-4e61-9531-2445965b5ac4_terseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled/forfeited/adjusted (in shares)</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:href="jnj-20220102.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:to="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_12756522-c55e-479a-bead-75fe4fc6b40a_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS)</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_64ef1132-6322-43a3-a32c-72b728541ba8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8c1c5f9c-bf0f-44db-9479-fcc367a101d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3f2a5a1d-8601-4ff5-ac1f-6e7ddfb036e6_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_04fdaf2b-5c1f-4d7a-8f61-c6819d5c6131_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_956b4973-e827-46b5-8d19-d9fc6fb5c1a6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_a93ec6ba-8b52-4771-9b7a-ca46c8d7d02b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OncologyMember_c69a2a44-581a-4752-a0bf-3728a1b8da3f_terseLabel_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology</link:label>
    <link:label id="lab_jnj_OncologyMember_label_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_jnj_OncologyMember_documentation_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember" xlink:href="jnj-20220102.xsd#jnj_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OncologyMember" xlink:to="lab_jnj_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_4039f5bc-c63f-4053-a636-b217cfa9f1ad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement benefits</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Other Postretirement Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_QualifiedPlansMember_b0058384-14c2-48a6-a61e-41ea700da520_terseLabel_en-US" xlink:label="lab_jnj_QualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified Plans</link:label>
    <link:label id="lab_jnj_QualifiedPlansMember_label_en-US" xlink:label="lab_jnj_QualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified Plans [Member]</link:label>
    <link:label id="lab_jnj_QualifiedPlansMember_documentation_en-US" xlink:label="lab_jnj_QualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_QualifiedPlansMember" xlink:href="jnj-20220102.xsd#jnj_QualifiedPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_QualifiedPlansMember" xlink:to="lab_jnj_QualifiedPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_1c396993-59a5-4ce1-a406-aba7eb7791cb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_89fe1e58-e4ad-4338-bc2a-3046783cf800_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/ (Loss) On Derivatives &amp; Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_b00f07e8-443f-4943-bd08-a1ed33a0238b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SavingsPlanAbstract_e5d88eb2-b34f-464e-b0ad-803024f469f1_terseLabel_en-US" xlink:label="lab_jnj_SavingsPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Savings Plan [Abstract]</link:label>
    <link:label id="lab_jnj_SavingsPlanAbstract_label_en-US" xlink:label="lab_jnj_SavingsPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Savings Plan [Abstract]</link:label>
    <link:label id="lab_jnj_SavingsPlanAbstract_documentation_en-US" xlink:label="lab_jnj_SavingsPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Savings Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanAbstract" xlink:href="jnj-20220102.xsd#jnj_SavingsPlanAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SavingsPlanAbstract" xlink:to="lab_jnj_SavingsPlanAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_dd07e452-8d44-4731-895b-d45c623237e6_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_1b2cbf1d-5316-4867-adf5-1312bf532551_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, realized gain (loss)</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_4a4954b6-c0f0-485b-a970-21e2d157b410_terseLabel_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95%&#160;Notes due 2037</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member" xlink:href="jnj-20220102.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.95Notesdue2037Member" xlink:to="lab_jnj_A5.95Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_481cff5e-84fc-45cf-b897-a54051f89b3b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_68c3801d-63fa-4909-bc70-3e3d9ae12ffd_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_5a7ea899-6b9d-496b-86ea-63439263cf97_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and building equipment</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5c66b341-50cc-4400-b24a-1c92932b07a5_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_7c25c26a-24c7-4855-a0ea-ace01b1d8751_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount, held-to-maturity</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.55Notesdue2021Member_597aad22-13ac-49e3-86f3-be23f56d83ff_terseLabel_en-US" xlink:label="lab_jnj_A3.55Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2021</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2021Member_label_en-US" xlink:label="lab_jnj_A3.55Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2021 [Member]</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2021Member_documentation_en-US" xlink:label="lab_jnj_A3.55Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2021Member" xlink:href="jnj-20220102.xsd#jnj_A3.55Notesdue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.55Notesdue2021Member" xlink:to="lab_jnj_A3.55Notesdue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_70f731df-f433-40d4-8a11-1b912ef370b3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PROCRITEPREXMember_f3595b4d-a377-4af2-ae17-fb107d9d9201_terseLabel_en-US" xlink:label="lab_jnj_PROCRITEPREXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROCRIT/EPREX</link:label>
    <link:label id="lab_jnj_PROCRITEPREXMember_label_en-US" xlink:label="lab_jnj_PROCRITEPREXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROCRIT/EPREX [Member]</link:label>
    <link:label id="lab_jnj_PROCRITEPREXMember_documentation_en-US" xlink:label="lab_jnj_PROCRITEPREXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROCRIT/EPREX [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PROCRITEPREXMember" xlink:href="jnj-20220102.xsd#jnj_PROCRITEPREXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PROCRITEPREXMember" xlink:to="lab_jnj_PROCRITEPREXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_681d07e1-8976-439b-83ce-26f9d490abcf_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation, deduction</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A210NotesDue2040Member_ed048855-065b-4eb6-a350-889766f5dfa3_terseLabel_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_label_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_documentation_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member" xlink:href="jnj-20220102.xsd#jnj_A210NotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A210NotesDue2040Member" xlink:to="lab_jnj_A210NotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_94d6f9b3-20e1-46a1-99fd-cc5a2ffd551e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing capacity under credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SURGICALMember_2af0fcc4-c0c8-469b-8430-60e7ef44202e_terseLabel_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL</link:label>
    <link:label id="lab_jnj_SURGICALMember_label_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:label id="lab_jnj_SURGICALMember_documentation_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember" xlink:href="jnj-20220102.xsd#jnj_SURGICALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SURGICALMember" xlink:to="lab_jnj_SURGICALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent_baeaedd1-af2a-48f7-be66-d06c7843fc69_terseLabel_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TJCA, foreign tax credit percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent_label_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent_documentation_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" xlink:href="jnj-20220102.xsd#jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" xlink:to="lab_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_11f9f0f2-9020-4110-898c-1c4c13139793_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_2fe61ebc-4e13-4504-b981-02f3c8974ebc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized net transition obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Transition Asset (Obligation), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_e197e32e-6540-4b87-b56b-e3bfc3d2e263_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension benefits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Pension Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:to="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_45c86a8c-6d10-4c08-bb29-5589a6c4730f_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InfectiousDiseasesMember_7e09789e-494e-4f36-a852-63bff68e0b23_terseLabel_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember" xlink:href="jnj-20220102.xsd#jnj_InfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InfectiousDiseasesMember" xlink:to="lab_jnj_InfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_ac68c8c4-ca63-40fa-a5d3-4fdefbbfdcce_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_7140c1e7-4a48-4648-bfdc-9c16b3ca23a4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_ff7d0a45-ea6e-4114-92b6-0a1d475b7d6c_terseLabel_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_label_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_documentation_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember" xlink:href="jnj-20220102.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PulmonaryHypertensionMember" xlink:to="lab_jnj_PulmonaryHypertensionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_c564bcd0-de8b-49cc-a86b-adb010dc27c5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_a87a223e-97ee-4017-89af-d7b5a22174d5_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_87b62886-5840-4c7a-9e9b-96401f497ab8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of increase in compensation levels</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_6ac1e57f-4ea3-4a43-8994-81c506ff5ccd_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_fdfb1e98-af9d-4e41-ba6b-5d75220fa62c_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_27dd299a-fdb6-4d92-97f1-857e22dc9ab9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs incurred since announced</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_MomentaMember_b1801b6d-f58d-4b9e-baf0-6c6e5e4ec5e6_terseLabel_en-US" xlink:label="lab_jnj_MomentaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Momenta</link:label>
    <link:label id="lab_jnj_MomentaMember_label_en-US" xlink:label="lab_jnj_MomentaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Momenta [Member]</link:label>
    <link:label id="lab_jnj_MomentaMember_documentation_en-US" xlink:label="lab_jnj_MomentaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Momenta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MomentaMember" xlink:href="jnj-20220102.xsd#jnj_MomentaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_MomentaMember" xlink:to="lab_jnj_MomentaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_22b0f343-f120-46c7-9565-2d997b00ca1e_terseLabel_en-US" xlink:label="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Treasury Stock Shares Outstanding [Roll Forward]</link:label>
    <link:label id="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_label_en-US" xlink:label="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Treasury Stock Shares Outstanding [Roll Forward]</link:label>
    <link:label id="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_documentation_en-US" xlink:label="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Treasury Stock Shares Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:href="jnj-20220102.xsd#jnj_ChangesinTreasuryStockSharesOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:to="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxLiabilitiesOtherDomestic_3528b904-9035-4843-8598-f31f02855883_negatedTerseLabel_en-US" xlink:label="lab_jnj_DeferredTaxLiabilitiesOtherDomestic" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous U.S.&#160;</link:label>
    <link:label id="lab_jnj_DeferredTaxLiabilitiesOtherDomestic_label_en-US" xlink:label="lab_jnj_DeferredTaxLiabilitiesOtherDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other Domestic</link:label>
    <link:label id="lab_jnj_DeferredTaxLiabilitiesOtherDomestic_documentation_en-US" xlink:label="lab_jnj_DeferredTaxLiabilitiesOtherDomestic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilitiesOtherDomestic" xlink:href="jnj-20220102.xsd#jnj_DeferredTaxLiabilitiesOtherDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxLiabilitiesOtherDomestic" xlink:to="lab_jnj_DeferredTaxLiabilitiesOtherDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_7a1785f6-e0b9-40b5-bd92-e3052c8ada3c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of the Hedged Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_b6e05148-b32e-4074-bc53-99f36230f923_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gross Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue_522b32bb-4e8a-4297-8400-d5921c8255c7_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded, including settlement for related issues, reimbursement for legal fees, and removal from related claims</link:label>
    <link:label id="lab_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue_label_en-US" xlink:label="lab_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Additional Reimbursement, Value</link:label>
    <link:label id="lab_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue_documentation_en-US" xlink:label="lab_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Additional Reimbursement, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue" xlink:href="jnj-20220102.xsd#jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue" xlink:to="lab_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_c5dbea5f-72bc-454f-aac5-cf88d07136fa_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Segment Of Business</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_label_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Segment Of Business</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:href="jnj-20220102.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:to="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_ba0c2f18-1d08-4c18-bba8-70c142bbabc0_terseLabel_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625% Notes due 2025</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_label_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_documentation_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member" xlink:href="jnj-20220102.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.625Notesdue2025Member" xlink:to="lab_jnj_A2.625Notesdue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_bd8c77fe-7409-4fb2-84c1-556ba0b49375_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_90ee5a05-933f-485a-8684-61033f376c59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding number of Options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_674d0902-b0eb-42f3-943d-6b538e856636_terseLabel_en-US" xlink:label="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract</link:label>
    <link:label id="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_label_en-US" xlink:label="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract</link:label>
    <link:label id="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_documentation_en-US" xlink:label="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comparison of income tax expense at the Statutory rate and Company's tax rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:href="jnj-20220102.xsd#jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:to="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_6eee333e-010d-47d5-9481-c4c01d638d42_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Products Sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_e6ba0303-93d1-4e45-896a-1e72f2f65f3d_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_11d47cb9-fb81-44ca-b6c1-5a32a63ab6ab_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes on income (Note 8)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_d62144b4-8277-4bd2-a280-ce272128aa1c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UPTRAVIMember_44e21510-76b7-4236-8ab9-e477c58428d8_terseLabel_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_label_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_documentation_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember" xlink:href="jnj-20220102.xsd#jnj_UPTRAVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UPTRAVIMember" xlink:to="lab_jnj_UPTRAVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_0bacd672-fd24-4f34-824e-d2ef13af117b_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International taxes</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_8f223b0a-d34d-4dbc-9b6d-74824f372894_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_b2349950-40b6-4444-9174-58b7952f9d75_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WoundCareandOtherMember_f96e6b0b-9f4d-4907-9393-ad0487cfd6c2_terseLabel_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other</link:label>
    <link:label id="lab_jnj_WoundCareandOtherMember_label_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other [Member]</link:label>
    <link:label id="lab_jnj_WoundCareandOtherMember_documentation_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember" xlink:href="jnj-20220102.xsd#jnj_WoundCareandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WoundCareandOtherMember" xlink:to="lab_jnj_WoundCareandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_79d76aae-701d-4753-8233-e654078ab309_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_f368f032-36ac-4596-b8ac-9890e3804e65_terseLabel_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember" xlink:href="jnj-20220102.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherInfectiousDiseasesMember" xlink:to="lab_jnj_OtherInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_cdd73c2b-134c-4b7f-ac32-2b702709d998_terseLabel_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and related cost, expected future savings</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_label_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Future Savings</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_documentation_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Future Savings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:href="jnj-20220102.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:to="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_3bef6e18-90ce-4a5d-84f6-2dd4bc247e13_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d64933ad-f706-475b-88e7-9df383f9dc24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>jnj-20220102_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2ac3ec12-1a04-4290-8adc-1ec251a989dd,g:c9588643-da6b-4c23-b331-47586e9dc1a5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/CoverPage" xlink:type="simple" xlink:href="jnj-20220102.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_88ac12e4-4b3f-4d00-89ec-683d934ebbd5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_727ccf8e-1867-45cd-92a6-02f5f4e00518" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_88ac12e4-4b3f-4d00-89ec-683d934ebbd5" xlink:to="loc_dei_DocumentInformationTable_727ccf8e-1867-45cd-92a6-02f5f4e00518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9acd6f26-a647-467c-9599-4f9f46ef6af4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_727ccf8e-1867-45cd-92a6-02f5f4e00518" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9acd6f26-a647-467c-9599-4f9f46ef6af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c864a51b-0785-460f-8f73-bf30992ec9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9acd6f26-a647-467c-9599-4f9f46ef6af4" xlink:to="loc_us-gaap_ClassOfStockDomain_c864a51b-0785-460f-8f73-bf30992ec9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4ac2bde9-0f4f-4853-b4de-002800013ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c864a51b-0785-460f-8f73-bf30992ec9b5" xlink:to="loc_us-gaap_CommonStockMember_4ac2bde9-0f4f-4853-b4de-002800013ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_b3da5c3d-50f6-4e4e-8de4-f0692b3330ac" xlink:href="jnj-20220102.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c864a51b-0785-460f-8f73-bf30992ec9b5" xlink:to="loc_jnj_A0.650NotesDue2024Member_b3da5c3d-50f6-4e4e-8de4-f0692b3330ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_c7a30b62-4534-4bed-9c2a-ccd8d898658f" xlink:href="jnj-20220102.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c864a51b-0785-460f-8f73-bf30992ec9b5" xlink:to="loc_jnj_A5.50NotesDue2024Member_c7a30b62-4534-4bed-9c2a-ccd8d898658f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_4a56b272-19ba-469e-a72e-495f9e7594d7" xlink:href="jnj-20220102.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c864a51b-0785-460f-8f73-bf30992ec9b5" xlink:to="loc_jnj_A1.150NotesDue2028Member_4a56b272-19ba-469e-a72e-495f9e7594d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_89b829b1-1bcb-4c86-a33d-84e292feb215" xlink:href="jnj-20220102.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c864a51b-0785-460f-8f73-bf30992ec9b5" xlink:to="loc_jnj_A1.650NotesDue2035Member_89b829b1-1bcb-4c86-a33d-84e292feb215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_727ccf8e-1867-45cd-92a6-02f5f4e00518" xlink:to="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3975e5cc-0cca-4d47-8e28-79534d167473" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_DocumentType_3975e5cc-0cca-4d47-8e28-79534d167473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_a1dff4da-1110-4650-9a87-6121fd81b324" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_DocumentAnnualReport_a1dff4da-1110-4650-9a87-6121fd81b324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5a68e64f-4a33-4ab4-a96b-4a0049b7fab5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_DocumentPeriodEndDate_5a68e64f-4a33-4ab4-a96b-4a0049b7fab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_bd83228a-ed7a-4411-b107-c558466f4273" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_DocumentTransitionReport_bd83228a-ed7a-4411-b107-c558466f4273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_95bec8c0-ab71-4cba-9266-93b579be7bef" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityFileNumber_95bec8c0-ab71-4cba-9266-93b579be7bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_641ff387-1daa-49c4-921b-82eef3ab4da6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityRegistrantName_641ff387-1daa-49c4-921b-82eef3ab4da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8d1765a1-7fa5-4333-96ee-ddeeb1b729ea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8d1765a1-7fa5-4333-96ee-ddeeb1b729ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ff66b0c9-77bf-4cd8-ab06-db77f11f912b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityTaxIdentificationNumber_ff66b0c9-77bf-4cd8-ab06-db77f11f912b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e3f13a41-5fce-45f0-b3c8-bfb78e6bff49" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityAddressAddressLine1_e3f13a41-5fce-45f0-b3c8-bfb78e6bff49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e4d1f90a-5898-4b5f-8948-bfc404f314b1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityAddressCityOrTown_e4d1f90a-5898-4b5f-8948-bfc404f314b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a649ef91-edae-46e1-9b06-ba39aaa0f0b2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityAddressStateOrProvince_a649ef91-edae-46e1-9b06-ba39aaa0f0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1d651bf1-11e3-4681-b127-362c9f08d620" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityAddressPostalZipCode_1d651bf1-11e3-4681-b127-362c9f08d620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8ce0e278-f240-422c-bbf7-4f20a84a4619" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_CityAreaCode_8ce0e278-f240-422c-bbf7-4f20a84a4619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_03b09cee-a8f0-4296-a861-b3357ae9d9d2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_LocalPhoneNumber_03b09cee-a8f0-4296-a861-b3357ae9d9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e6e193de-78c9-4e4b-bbbd-7155f5fc856d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_Security12bTitle_e6e193de-78c9-4e4b-bbbd-7155f5fc856d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b8d3cac9-f381-41c7-87ed-77cdafabe331" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_TradingSymbol_b8d3cac9-f381-41c7-87ed-77cdafabe331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e921b37c-0bf5-4fa7-8c18-b3d53c3a5767" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_SecurityExchangeName_e921b37c-0bf5-4fa7-8c18-b3d53c3a5767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_f1ff7c63-795e-4148-b5b4-0f36aeb17bfa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_f1ff7c63-795e-4148-b5b4-0f36aeb17bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_4ba22fdd-5516-406c-ad73-33a75a764b61" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityVoluntaryFilers_4ba22fdd-5516-406c-ad73-33a75a764b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2605b2a1-bfcd-4717-a358-906c34d47211" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityCurrentReportingStatus_2605b2a1-bfcd-4717-a358-906c34d47211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c04790e7-0bf0-4503-8c35-2f0ce4526335" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityInteractiveDataCurrent_c04790e7-0bf0-4503-8c35-2f0ce4526335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_cd691512-05fc-442d-b870-e7d6f0688722" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityFilerCategory_cd691512-05fc-442d-b870-e7d6f0688722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3e7a3b4c-214b-449b-a479-769e83e3adbf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityEmergingGrowthCompany_3e7a3b4c-214b-449b-a479-769e83e3adbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a00ae9d9-3865-420d-99d1-aa48cdd748ad" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntitySmallBusiness_a00ae9d9-3865-420d-99d1-aa48cdd748ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_b027f5e1-99f6-453b-a413-e6b96727a096" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_IcfrAuditorAttestationFlag_b027f5e1-99f6-453b-a413-e6b96727a096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_328920ee-7c3e-492e-9b90-23b3fe790bd4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityShellCompany_328920ee-7c3e-492e-9b90-23b3fe790bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_f2724806-00af-4812-b684-4a7068ce7088" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityPublicFloat_f2724806-00af-4812-b684-4a7068ce7088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8b1bae8e-64e9-4f66-b387-c395e2b82ab7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8b1bae8e-64e9-4f66-b387-c395e2b82ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_541c6917-cfc3-49ac-bc75-ed400c71704a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_EntityCentralIndexKey_541c6917-cfc3-49ac-bc75-ed400c71704a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e6f02546-9e64-4191-9282-ddc2285f5ef6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_CurrentFiscalYearEndDate_e6f02546-9e64-4191-9282-ddc2285f5ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f574de2c-00e7-41c9-90af-2fee5046775e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_DocumentFiscalYearFocus_f574de2c-00e7-41c9-90af-2fee5046775e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1501adee-e3fd-41cc-a21a-ee0467800975" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1501adee-e3fd-41cc-a21a-ee0467800975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d01be743-6023-48a3-afa0-94422763d940" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a7134dbe-e132-4452-b90e-f18f10152ecb" xlink:to="loc_dei_AmendmentFlag_d01be743-6023-48a3-afa0-94422763d940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AuditInformation" xlink:type="simple" xlink:href="jnj-20220102.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AuditorInformationAbstract_f1857b2d-6772-44ee-ab9a-aaf150e4d90d" xlink:href="jnj-20220102.xsd#jnj_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_9716b62d-2bcb-4ab8-b250-23f79250e8c2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_AuditorInformationAbstract_f1857b2d-6772-44ee-ab9a-aaf150e4d90d" xlink:to="loc_dei_AuditorName_9716b62d-2bcb-4ab8-b250-23f79250e8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_b1e07fe5-8354-4f5d-b8cc-ff520dd0deac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_AuditorInformationAbstract_f1857b2d-6772-44ee-ab9a-aaf150e4d90d" xlink:to="loc_dei_AuditorLocation_b1e07fe5-8354-4f5d-b8cc-ff520dd0deac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_0c28f611-a547-4457-8481-aa74f56b9231" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_AuditorInformationAbstract_f1857b2d-6772-44ee-ab9a-aaf150e4d90d" xlink:to="loc_dei_AuditorFirmId_0c28f611-a547-4457-8481-aa74f56b9231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20220102.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_290392f5-9918-4348-92f5-c98d2e55690f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1f6d4efe-3653-4f59-8717-f58b16c9c2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_290392f5-9918-4348-92f5-c98d2e55690f" xlink:to="loc_us-gaap_AssetsAbstract_1f6d4efe-3653-4f59-8717-f58b16c9c2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3b298730-da78-4ec4-a2da-f56f143a81a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1f6d4efe-3653-4f59-8717-f58b16c9c2d2" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3b298730-da78-4ec4-a2da-f56f143a81a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_091c9217-2b4a-496f-9bc7-d75a0b334e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3b298730-da78-4ec4-a2da-f56f143a81a7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_091c9217-2b4a-496f-9bc7-d75a0b334e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_017facba-3993-4269-bfda-be4e2b6964b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3b298730-da78-4ec4-a2da-f56f143a81a7" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_017facba-3993-4269-bfda-be4e2b6964b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1fbf77bc-f1ab-4a11-833c-59395785d2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3b298730-da78-4ec4-a2da-f56f143a81a7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1fbf77bc-f1ab-4a11-833c-59395785d2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d0baaeb0-6d84-49b5-99d9-3d2a6ffd8618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3b298730-da78-4ec4-a2da-f56f143a81a7" xlink:to="loc_us-gaap_InventoryNet_d0baaeb0-6d84-49b5-99d9-3d2a6ffd8618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c434a9c0-018c-4f61-9b12-6a7ad31e35ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3b298730-da78-4ec4-a2da-f56f143a81a7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c434a9c0-018c-4f61-9b12-6a7ad31e35ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_181cb43b-6d16-4135-87cc-da27e6496e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3b298730-da78-4ec4-a2da-f56f143a81a7" xlink:to="loc_us-gaap_AssetsCurrent_181cb43b-6d16-4135-87cc-da27e6496e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_67401da9-3837-4a7d-bcc0-095eeec77634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1f6d4efe-3653-4f59-8717-f58b16c9c2d2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_67401da9-3837-4a7d-bcc0-095eeec77634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1ea726ed-2252-410c-be0c-84fa93723803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1f6d4efe-3653-4f59-8717-f58b16c9c2d2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1ea726ed-2252-410c-be0c-84fa93723803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_32e1d8ab-d356-44a7-b322-d9a0af06e471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1f6d4efe-3653-4f59-8717-f58b16c9c2d2" xlink:to="loc_us-gaap_Goodwill_32e1d8ab-d356-44a7-b322-d9a0af06e471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_6fbc927b-276f-43e7-b476-46a5c13a158f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1f6d4efe-3653-4f59-8717-f58b16c9c2d2" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_6fbc927b-276f-43e7-b476-46a5c13a158f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7b553508-4b17-440c-afe2-ebe12e3c1942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1f6d4efe-3653-4f59-8717-f58b16c9c2d2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7b553508-4b17-440c-afe2-ebe12e3c1942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_75347aa2-ae26-4de8-bbe7-872964219598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1f6d4efe-3653-4f59-8717-f58b16c9c2d2" xlink:to="loc_us-gaap_Assets_75347aa2-ae26-4de8-bbe7-872964219598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a15b47bd-ac82-4d35-a303-b2d5080df830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_290392f5-9918-4348-92f5-c98d2e55690f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a15b47bd-ac82-4d35-a303-b2d5080df830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_dc9bfc2b-8c53-4294-80cd-80ca3e38a65c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a15b47bd-ac82-4d35-a303-b2d5080df830" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_dc9bfc2b-8c53-4294-80cd-80ca3e38a65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_25ff1334-aa56-4cad-ac7f-2f56aae411df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dc9bfc2b-8c53-4294-80cd-80ca3e38a65c" xlink:to="loc_us-gaap_ShortTermBorrowings_25ff1334-aa56-4cad-ac7f-2f56aae411df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4f61f48e-ba25-42a8-8a6a-b7e6b95db7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dc9bfc2b-8c53-4294-80cd-80ca3e38a65c" xlink:to="loc_us-gaap_AccountsPayableCurrent_4f61f48e-ba25-42a8-8a6a-b7e6b95db7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cb7f7a07-b0db-4a5a-8450-96ff67960b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dc9bfc2b-8c53-4294-80cd-80ca3e38a65c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cb7f7a07-b0db-4a5a-8450-96ff67960b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_f8ebb819-9b10-4e31-bf09-bbce2b78a110" xlink:href="jnj-20220102.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dc9bfc2b-8c53-4294-80cd-80ca3e38a65c" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_f8ebb819-9b10-4e31-bf09-bbce2b78a110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cccab478-6b5d-4948-b152-b66b936ff51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dc9bfc2b-8c53-4294-80cd-80ca3e38a65c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cccab478-6b5d-4948-b152-b66b936ff51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_40f090c5-be37-459d-bde0-b48f58ab22d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dc9bfc2b-8c53-4294-80cd-80ca3e38a65c" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_40f090c5-be37-459d-bde0-b48f58ab22d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c2a79f0c-6ae5-49bf-bea2-b6ef45441bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dc9bfc2b-8c53-4294-80cd-80ca3e38a65c" xlink:to="loc_us-gaap_LiabilitiesCurrent_c2a79f0c-6ae5-49bf-bea2-b6ef45441bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fbe9f354-6b8c-4296-9374-c9f0342bf506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a15b47bd-ac82-4d35-a303-b2d5080df830" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fbe9f354-6b8c-4296-9374-c9f0342bf506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_dcc80a5b-bc0a-4d22-abe3-5e7a183c1bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a15b47bd-ac82-4d35-a303-b2d5080df830" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_dcc80a5b-bc0a-4d22-abe3-5e7a183c1bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_df4b9acf-52a0-459f-9599-1ce24be23b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a15b47bd-ac82-4d35-a303-b2d5080df830" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_df4b9acf-52a0-459f-9599-1ce24be23b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_3adcbb07-d3ac-4a27-b085-53f33e26fb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a15b47bd-ac82-4d35-a303-b2d5080df830" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_3adcbb07-d3ac-4a27-b085-53f33e26fb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_646cc22b-3634-414d-b6a1-86895385dbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a15b47bd-ac82-4d35-a303-b2d5080df830" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_646cc22b-3634-414d-b6a1-86895385dbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_645091be-4f7f-426a-a7cb-dba16a6deb99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a15b47bd-ac82-4d35-a303-b2d5080df830" xlink:to="loc_us-gaap_Liabilities_645091be-4f7f-426a-a7cb-dba16a6deb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_90e59bf3-0ea6-44e8-971a-27600608eb85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a15b47bd-ac82-4d35-a303-b2d5080df830" xlink:to="loc_us-gaap_CommitmentsAndContingencies_90e59bf3-0ea6-44e8-971a-27600608eb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_edfb1ef1-c92d-4159-8b8f-dc90efd63650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a15b47bd-ac82-4d35-a303-b2d5080df830" xlink:to="loc_us-gaap_StockholdersEquityAbstract_edfb1ef1-c92d-4159-8b8f-dc90efd63650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8367fca6-82c3-411f-b014-1932d0fb774d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edfb1ef1-c92d-4159-8b8f-dc90efd63650" xlink:to="loc_us-gaap_PreferredStockValue_8367fca6-82c3-411f-b014-1932d0fb774d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b68f170a-e1b3-44f6-9dd2-843790407deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edfb1ef1-c92d-4159-8b8f-dc90efd63650" xlink:to="loc_us-gaap_CommonStockValue_b68f170a-e1b3-44f6-9dd2-843790407deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e0fff63a-7f5e-4656-920e-7fc866b7bd53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edfb1ef1-c92d-4159-8b8f-dc90efd63650" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e0fff63a-7f5e-4656-920e-7fc866b7bd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_772d227e-a1ab-4096-84e6-d28418981229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edfb1ef1-c92d-4159-8b8f-dc90efd63650" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_772d227e-a1ab-4096-84e6-d28418981229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_1625f798-a1f2-48ce-97b8-72fb835e4961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edfb1ef1-c92d-4159-8b8f-dc90efd63650" xlink:to="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_1625f798-a1f2-48ce-97b8-72fb835e4961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_89c2b1c4-f249-4e9f-b507-9324cee3c259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edfb1ef1-c92d-4159-8b8f-dc90efd63650" xlink:to="loc_us-gaap_TreasuryStockValue_89c2b1c4-f249-4e9f-b507-9324cee3c259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e909b30d-cc44-4abe-aa4b-abe72be56727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edfb1ef1-c92d-4159-8b8f-dc90efd63650" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e909b30d-cc44-4abe-aa4b-abe72be56727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_62eddfd4-3b07-4738-a13b-d8ff0c723e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a15b47bd-ac82-4d35-a303-b2d5080df830" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_62eddfd4-3b07-4738-a13b-d8ff0c723e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="jnj-20220102.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2fd76e4f-8ff4-4f17-93eb-70ef6a02c6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_550cad48-a880-4da7-819e-5fbfdfd4f4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2fd76e4f-8ff4-4f17-93eb-70ef6a02c6f2" xlink:to="loc_us-gaap_AssetsCurrentAbstract_550cad48-a880-4da7-819e-5fbfdfd4f4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7a812575-772e-40d6-82a3-0625710d4d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_550cad48-a880-4da7-819e-5fbfdfd4f4a6" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7a812575-772e-40d6-82a3-0625710d4d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e60aab96-155d-41ab-94a4-d360cc9d0a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2fd76e4f-8ff4-4f17-93eb-70ef6a02c6f2" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e60aab96-155d-41ab-94a4-d360cc9d0a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_93c804fa-7f8d-436b-9608-987ff09a3588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e60aab96-155d-41ab-94a4-d360cc9d0a1b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_93c804fa-7f8d-436b-9608-987ff09a3588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c80cf3b2-9ccc-476e-a3dd-c6eecbee80fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e60aab96-155d-41ab-94a4-d360cc9d0a1b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c80cf3b2-9ccc-476e-a3dd-c6eecbee80fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0d8b0c09-f1e7-4229-9a1a-6715fec7b9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e60aab96-155d-41ab-94a4-d360cc9d0a1b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0d8b0c09-f1e7-4229-9a1a-6715fec7b9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a7ea8856-08d3-45f0-8fe7-2886f5635615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e60aab96-155d-41ab-94a4-d360cc9d0a1b" xlink:to="loc_us-gaap_CommonStockSharesIssued_a7ea8856-08d3-45f0-8fe7-2886f5635615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_13776939-62bb-450d-b7c1-6111db473560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e60aab96-155d-41ab-94a4-d360cc9d0a1b" xlink:to="loc_us-gaap_TreasuryStockShares_13776939-62bb-450d-b7c1-6111db473560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20220102.xsd#ConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a69b8b5a-ed63-4d8f-86f8-520f3f3ffc28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bf1fa63d-7faf-4201-9286-0644e60236e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a69b8b5a-ed63-4d8f-86f8-520f3f3ffc28" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bf1fa63d-7faf-4201-9286-0644e60236e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e7fb5bd1-b44f-4580-83fa-df4ccc04b2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a69b8b5a-ed63-4d8f-86f8-520f3f3ffc28" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e7fb5bd1-b44f-4580-83fa-df4ccc04b2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_bc84fbd8-bb64-4a5c-b33a-3125ea7dc4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a69b8b5a-ed63-4d8f-86f8-520f3f3ffc28" xlink:to="loc_us-gaap_GrossProfit_bc84fbd8-bb64-4a5c-b33a-3125ea7dc4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fcb853fb-c17a-4075-b056-dc547855fddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a69b8b5a-ed63-4d8f-86f8-520f3f3ffc28" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fcb853fb-c17a-4075-b056-dc547855fddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_af03cc8a-2c3d-40ef-a194-e4087383686e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a69b8b5a-ed63-4d8f-86f8-520f3f3ffc28" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_af03cc8a-2c3d-40ef-a194-e4087383686e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_0c4ce448-bfe4-495f-bd40-3fb13032f28a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a69b8b5a-ed63-4d8f-86f8-520f3f3ffc28" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_0c4ce448-bfe4-495f-bd40-3fb13032f28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_de1d6693-7950-4753-aea3-14f6ca4d2662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a69b8b5a-ed63-4d8f-86f8-520f3f3ffc28" xlink:to="loc_us-gaap_InvestmentIncomeInterest_de1d6693-7950-4753-aea3-14f6ca4d2662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_891598db-3741-4d59-979a-14b953433ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a69b8b5a-ed63-4d8f-86f8-520f3f3ffc28" xlink:to="loc_us-gaap_InterestExpense_891598db-3741-4d59-979a-14b953433ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_32ded6a7-c3a1-464d-9818-194efe17fb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a69b8b5a-ed63-4d8f-86f8-520f3f3ffc28" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_32ded6a7-c3a1-464d-9818-194efe17fb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9d65713a-9603-41b7-b594-b447059b08a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a69b8b5a-ed63-4d8f-86f8-520f3f3ffc28" xlink:to="loc_us-gaap_RestructuringCharges_9d65713a-9603-41b7-b594-b447059b08a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_63e127a0-ca49-4f43-8696-cedbb7ca9a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a69b8b5a-ed63-4d8f-86f8-520f3f3ffc28" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_63e127a0-ca49-4f43-8696-cedbb7ca9a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8a31453b-8157-468f-8a0a-cb565de47dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a69b8b5a-ed63-4d8f-86f8-520f3f3ffc28" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8a31453b-8157-468f-8a0a-cb565de47dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_015599f6-f7f4-4b42-8175-146153eeaaef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a69b8b5a-ed63-4d8f-86f8-520f3f3ffc28" xlink:to="loc_us-gaap_NetIncomeLoss_015599f6-f7f4-4b42-8175-146153eeaaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f2a7d29b-6dcc-4084-9181-1c3f2548ae55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a69b8b5a-ed63-4d8f-86f8-520f3f3ffc28" xlink:to="loc_us-gaap_EarningsPerShareAbstract_f2a7d29b-6dcc-4084-9181-1c3f2548ae55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b7ffe0af-a5a9-4a9f-bc50-f6bdd2f2a46d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f2a7d29b-6dcc-4084-9181-1c3f2548ae55" xlink:to="loc_us-gaap_EarningsPerShareBasic_b7ffe0af-a5a9-4a9f-bc50-f6bdd2f2a46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_df3e3aa9-48bf-4c59-9666-4fbb4f633a08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f2a7d29b-6dcc-4084-9181-1c3f2548ae55" xlink:to="loc_us-gaap_EarningsPerShareDiluted_df3e3aa9-48bf-4c59-9666-4fbb4f633a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_23457e0c-a18b-405f-9d21-5e2e649175d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a69b8b5a-ed63-4d8f-86f8-520f3f3ffc28" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_23457e0c-a18b-405f-9d21-5e2e649175d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4512ac62-41b3-4de3-8e38-0034af218fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_23457e0c-a18b-405f-9d21-5e2e649175d3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4512ac62-41b3-4de3-8e38-0034af218fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6f7b0b0c-c987-41f0-a523-a9d5424c4a25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_23457e0c-a18b-405f-9d21-5e2e649175d3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6f7b0b0c-c987-41f0-a523-a9d5424c4a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20220102.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_09a16b19-8f89-4ad3-847c-30b6a5e40bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_76725937-340d-419e-9a8c-8cce8d0687b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_09a16b19-8f89-4ad3-847c-30b6a5e40bd3" xlink:to="loc_us-gaap_NetIncomeLoss_76725937-340d-419e-9a8c-8cce8d0687b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ffde64aa-bb22-44f5-b4b3-dc6e0eaf9835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_09a16b19-8f89-4ad3-847c-30b6a5e40bd3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ffde64aa-bb22-44f5-b4b3-dc6e0eaf9835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_d0cd0a82-aed6-4512-a302-27f19fdf11ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ffde64aa-bb22-44f5-b4b3-dc6e0eaf9835" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_d0cd0a82-aed6-4512-a302-27f19fdf11ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_4d55d560-902e-40a1-a599-063158aba9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ffde64aa-bb22-44f5-b4b3-dc6e0eaf9835" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_4d55d560-902e-40a1-a599-063158aba9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1689e063-a94b-415c-b7f9-dd464347d751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_4d55d560-902e-40a1-a599-063158aba9ce" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1689e063-a94b-415c-b7f9-dd464347d751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_73c21c54-92d0-464b-939f-2da1b5eea600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_4d55d560-902e-40a1-a599-063158aba9ce" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_73c21c54-92d0-464b-939f-2da1b5eea600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e5a3ce2f-9dc2-47ab-83e6-fbf48985d61f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_4d55d560-902e-40a1-a599-063158aba9ce" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e5a3ce2f-9dc2-47ab-83e6-fbf48985d61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_f2722131-b9b9-4fe4-9468-48e98ab21c51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ffde64aa-bb22-44f5-b4b3-dc6e0eaf9835" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_f2722131-b9b9-4fe4-9468-48e98ab21c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_20b26d0b-384b-488b-aee7-8388721bc3b2" xlink:href="jnj-20220102.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_f2722131-b9b9-4fe4-9468-48e98ab21c51" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_20b26d0b-384b-488b-aee7-8388721bc3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_159e1dcb-5b61-4842-ad3f-92ee556d864c" xlink:href="jnj-20220102.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_f2722131-b9b9-4fe4-9468-48e98ab21c51" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_159e1dcb-5b61-4842-ad3f-92ee556d864c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_552a5b6d-c9fe-48aa-99f4-4d7941848804" xlink:href="jnj-20220102.xsd#jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_f2722131-b9b9-4fe4-9468-48e98ab21c51" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_552a5b6d-c9fe-48aa-99f4-4d7941848804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_af6fcac8-a85c-4e85-ad7d-a066cc287d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_f2722131-b9b9-4fe4-9468-48e98ab21c51" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_af6fcac8-a85c-4e85-ad7d-a066cc287d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_a730fec4-3f55-4ed5-a73c-6f076b893cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ffde64aa-bb22-44f5-b4b3-dc6e0eaf9835" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_a730fec4-3f55-4ed5-a73c-6f076b893cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_e249d5b3-f20e-45bc-97b9-6eefb6c61bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_a730fec4-3f55-4ed5-a73c-6f076b893cc3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_e249d5b3-f20e-45bc-97b9-6eefb6c61bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_bbda221f-bd5a-4480-94ce-4f96a9622104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_a730fec4-3f55-4ed5-a73c-6f076b893cc3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_bbda221f-bd5a-4480-94ce-4f96a9622104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_8402fe71-6db6-43c2-90f0-f5f8af9797b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_a730fec4-3f55-4ed5-a73c-6f076b893cc3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_8402fe71-6db6-43c2-90f0-f5f8af9797b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ef851880-744e-4332-97e7-27f89ca097f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_09a16b19-8f89-4ad3-847c-30b6a5e40bd3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ef851880-744e-4332-97e7-27f89ca097f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_13d33d8f-55b5-4cbf-9361-b95c62083dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_09a16b19-8f89-4ad3-847c-30b6a5e40bd3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_13d33d8f-55b5-4cbf-9361-b95c62083dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="jnj-20220102.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5d8df6b9-5f44-4fff-93a8-d36bc6334e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_e72c7479-d14a-4344-945c-3aa6331abbd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5d8df6b9-5f44-4fff-93a8-d36bc6334e78" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_e72c7479-d14a-4344-945c-3aa6331abbd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_9c231bfd-a481-4b90-bb1f-9d3564778862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5d8df6b9-5f44-4fff-93a8-d36bc6334e78" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_9c231bfd-a481-4b90-bb1f-9d3564778862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_f58fe134-4106-413f-b8f0-2f76c7405e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5d8df6b9-5f44-4fff-93a8-d36bc6334e78" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_f58fe134-4106-413f-b8f0-2f76c7405e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_4c665558-006b-4be5-8737-81f6afed813c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5d8df6b9-5f44-4fff-93a8-d36bc6334e78" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_4c665558-006b-4be5-8737-81f6afed813c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20220102.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6beef41c-a4d0-4bd0-9912-3c12da089ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2c882a81-ebf4-4b75-96a2-8394a329de09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6beef41c-a4d0-4bd0-9912-3c12da089ec3" xlink:to="loc_us-gaap_StatementTable_2c882a81-ebf4-4b75-96a2-8394a329de09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_63174556-8dba-496c-bb98-5a53e2e51b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2c882a81-ebf4-4b75-96a2-8394a329de09" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_63174556-8dba-496c-bb98-5a53e2e51b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5faa5a9f-28d3-41ab-a956-b27abe15d540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_63174556-8dba-496c-bb98-5a53e2e51b7d" xlink:to="loc_us-gaap_EquityComponentDomain_5faa5a9f-28d3-41ab-a956-b27abe15d540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ba752ecd-d730-49da-93bc-175dc3e8b4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5faa5a9f-28d3-41ab-a956-b27abe15d540" xlink:to="loc_us-gaap_RetainedEarningsMember_ba752ecd-d730-49da-93bc-175dc3e8b4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_91e7b10e-0b28-41af-9625-39f395e196ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5faa5a9f-28d3-41ab-a956-b27abe15d540" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_91e7b10e-0b28-41af-9625-39f395e196ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9a3b9fc9-09f1-43ce-a30d-a4e5d2402e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5faa5a9f-28d3-41ab-a956-b27abe15d540" xlink:to="loc_us-gaap_CommonStockMember_9a3b9fc9-09f1-43ce-a30d-a4e5d2402e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_92252371-ac28-4a72-b83a-b3cecb396239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5faa5a9f-28d3-41ab-a956-b27abe15d540" xlink:to="loc_us-gaap_TreasuryStockMember_92252371-ac28-4a72-b83a-b3cecb396239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ce65a349-5399-4faa-909b-2921dcf23a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2c882a81-ebf4-4b75-96a2-8394a329de09" xlink:to="loc_us-gaap_StatementLineItems_ce65a349-5399-4faa-909b-2921dcf23a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a4b33248-98e6-4bf2-a432-e5c48868e05d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ce65a349-5399-4faa-909b-2921dcf23a17" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a4b33248-98e6-4bf2-a432-e5c48868e05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b02f1b80-84d8-4572-bc68-4afdd437c5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ce65a349-5399-4faa-909b-2921dcf23a17" xlink:to="loc_us-gaap_NetIncomeLoss_b02f1b80-84d8-4572-bc68-4afdd437c5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_5f06b60d-5eb4-4b3b-a521-2b150a68749d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ce65a349-5399-4faa-909b-2921dcf23a17" xlink:to="loc_us-gaap_DividendsCommonStockCash_5f06b60d-5eb4-4b3b-a521-2b150a68749d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_befa74ff-e9e4-4499-9e1b-fd422b60e81f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ce65a349-5399-4faa-909b-2921dcf23a17" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_befa74ff-e9e4-4499-9e1b-fd422b60e81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_511de337-86e4-4718-b145-2cd24a4f7706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ce65a349-5399-4faa-909b-2921dcf23a17" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_511de337-86e4-4718-b145-2cd24a4f7706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_2be2dd46-19ce-4b52-ad2b-13486eb71325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ce65a349-5399-4faa-909b-2921dcf23a17" xlink:to="loc_us-gaap_StockholdersEquityOther_2be2dd46-19ce-4b52-ad2b-13486eb71325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_714da56d-5bda-4184-97bb-257563f2b531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ce65a349-5399-4faa-909b-2921dcf23a17" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_714da56d-5bda-4184-97bb-257563f2b531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_792c803f-ddf4-4c30-a464-2b9b7952695c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ce65a349-5399-4faa-909b-2921dcf23a17" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_792c803f-ddf4-4c30-a464-2b9b7952695c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="jnj-20220102.xsd#ConsolidatedStatementsofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_654a470f-9494-4836-b3ee-d6d3b91eed4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_c2bb9863-f17c-4399-91ea-44ec4759c12c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_654a470f-9494-4836-b3ee-d6d3b91eed4f" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_c2bb9863-f17c-4399-91ea-44ec4759c12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20220102.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_768e88db-07b9-495c-9afa-1cc32701fc52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0d4d7f38-aa94-4f3e-80f4-688bbd4f789f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_768e88db-07b9-495c-9afa-1cc32701fc52" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0d4d7f38-aa94-4f3e-80f4-688bbd4f789f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_38e08d35-0b54-468d-bac7-8dbcad2b68f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0d4d7f38-aa94-4f3e-80f4-688bbd4f789f" xlink:to="loc_us-gaap_NetIncomeLoss_38e08d35-0b54-468d-bac7-8dbcad2b68f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87d701de-2383-4a37-9f92-1e5383136d46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0d4d7f38-aa94-4f3e-80f4-688bbd4f789f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87d701de-2383-4a37-9f92-1e5383136d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fd28314f-ed8b-4243-ae20-6871803b5917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87d701de-2383-4a37-9f92-1e5383136d46" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fd28314f-ed8b-4243-ae20-6871803b5917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c1134ca3-1dcb-4839-b15f-91fc67011fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87d701de-2383-4a37-9f92-1e5383136d46" xlink:to="loc_us-gaap_ShareBasedCompensation_c1134ca3-1dcb-4839-b15f-91fc67011fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_7ddf9d8d-ab2e-42db-9b81-b7246aec5e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87d701de-2383-4a37-9f92-1e5383136d46" xlink:to="loc_us-gaap_AssetImpairmentCharges_7ddf9d8d-ab2e-42db-9b81-b7246aec5e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_fea0b485-199c-41a5-bcb6-578876f5f88c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87d701de-2383-4a37-9f92-1e5383136d46" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_fea0b485-199c-41a5-bcb6-578876f5f88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_59bcddc0-a57e-4455-a783-68d53e6b0876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87d701de-2383-4a37-9f92-1e5383136d46" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_59bcddc0-a57e-4455-a783-68d53e6b0876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ae65861d-234f-4229-88c4-fb1d43957f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87d701de-2383-4a37-9f92-1e5383136d46" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ae65861d-234f-4229-88c4-fb1d43957f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_0a10f217-4fd8-4cb2-9ea5-42face7db911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87d701de-2383-4a37-9f92-1e5383136d46" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_0a10f217-4fd8-4cb2-9ea5-42face7db911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_29fc8f9f-2a32-49f9-8749-4c23034f79f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0d4d7f38-aa94-4f3e-80f4-688bbd4f789f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_29fc8f9f-2a32-49f9-8749-4c23034f79f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_63381b71-d6dd-44cf-85b0-7ebc7de76d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_29fc8f9f-2a32-49f9-8749-4c23034f79f7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_63381b71-d6dd-44cf-85b0-7ebc7de76d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_e58fa02b-1138-4281-8da0-b14e496cbab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_29fc8f9f-2a32-49f9-8749-4c23034f79f7" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_e58fa02b-1138-4281-8da0-b14e496cbab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1db87cc1-014b-43b1-b8f0-894eb9727a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_29fc8f9f-2a32-49f9-8749-4c23034f79f7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1db87cc1-014b-43b1-b8f0-894eb9727a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0f33d094-8481-4e99-baae-231ad0e4cd88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_29fc8f9f-2a32-49f9-8749-4c23034f79f7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0f33d094-8481-4e99-baae-231ad0e4cd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1c546a9e-1e74-4de9-a3a0-ebbcca70027e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_29fc8f9f-2a32-49f9-8749-4c23034f79f7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1c546a9e-1e74-4de9-a3a0-ebbcca70027e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dac023f2-be0c-40e5-9838-95e8e851be42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_29fc8f9f-2a32-49f9-8749-4c23034f79f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dac023f2-be0c-40e5-9838-95e8e851be42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b4405c9a-cb6f-4ba7-bd45-70572222d8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_768e88db-07b9-495c-9afa-1cc32701fc52" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b4405c9a-cb6f-4ba7-bd45-70572222d8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dab031a1-b610-4a9e-84b6-084971389116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b4405c9a-cb6f-4ba7-bd45-70572222d8ed" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dab031a1-b610-4a9e-84b6-084971389116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_aea1ef46-a916-4110-b73c-0c8d3f7978c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b4405c9a-cb6f-4ba7-bd45-70572222d8ed" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_aea1ef46-a916-4110-b73c-0c8d3f7978c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0ead3c91-0ee4-47a8-a789-7aa39d4cadc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b4405c9a-cb6f-4ba7-bd45-70572222d8ed" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0ead3c91-0ee4-47a8-a789-7aa39d4cadc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_beaaf43e-f0be-45de-8c3b-eeb24ca7b7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b4405c9a-cb6f-4ba7-bd45-70572222d8ed" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_beaaf43e-f0be-45de-8c3b-eeb24ca7b7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_75bd339a-2594-4f2e-b633-eaf2571d5e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b4405c9a-cb6f-4ba7-bd45-70572222d8ed" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_75bd339a-2594-4f2e-b633-eaf2571d5e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_7dfd07ea-dcce-4b40-8fce-3793d134bba0" xlink:href="jnj-20220102.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b4405c9a-cb6f-4ba7-bd45-70572222d8ed" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_7dfd07ea-dcce-4b40-8fce-3793d134bba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6574cfcb-c26f-4cf1-9f37-557c7e0d5afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b4405c9a-cb6f-4ba7-bd45-70572222d8ed" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6574cfcb-c26f-4cf1-9f37-557c7e0d5afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f915218d-e119-47a0-b8d0-fa7e79de2cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b4405c9a-cb6f-4ba7-bd45-70572222d8ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f915218d-e119-47a0-b8d0-fa7e79de2cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4e7259d-5764-4b92-9b3b-f28241e7ce77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_768e88db-07b9-495c-9afa-1cc32701fc52" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4e7259d-5764-4b92-9b3b-f28241e7ce77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_b6b1c294-6289-46a2-87b5-77a8856ac21e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4e7259d-5764-4b92-9b3b-f28241e7ce77" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_b6b1c294-6289-46a2-87b5-77a8856ac21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c16de508-912f-4e7a-ae96-898c349173fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4e7259d-5764-4b92-9b3b-f28241e7ce77" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c16de508-912f-4e7a-ae96-898c349173fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_59e9831c-7423-4b52-93fc-83a18fe831e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4e7259d-5764-4b92-9b3b-f28241e7ce77" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_59e9831c-7423-4b52-93fc-83a18fe831e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_14bccbca-d9a1-4473-8cca-bf7115d8a0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4e7259d-5764-4b92-9b3b-f28241e7ce77" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_14bccbca-d9a1-4473-8cca-bf7115d8a0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e4a1d1e8-f917-4c3b-95e4-5cce17aeb675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4e7259d-5764-4b92-9b3b-f28241e7ce77" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e4a1d1e8-f917-4c3b-95e4-5cce17aeb675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_948cabe1-24f2-4f6d-8ee1-d0871b9c6a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4e7259d-5764-4b92-9b3b-f28241e7ce77" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_948cabe1-24f2-4f6d-8ee1-d0871b9c6a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_0b31f031-f80d-4a5a-a917-50d0ff56a7e6" xlink:href="jnj-20220102.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4e7259d-5764-4b92-9b3b-f28241e7ce77" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_0b31f031-f80d-4a5a-a917-50d0ff56a7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_4e9a61f1-9806-4b14-a7d5-3fe8edfb2fa1" xlink:href="jnj-20220102.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4e7259d-5764-4b92-9b3b-f28241e7ce77" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_4e9a61f1-9806-4b14-a7d5-3fe8edfb2fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_03558932-af25-484c-9aa6-9b961af53f66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4e7259d-5764-4b92-9b3b-f28241e7ce77" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_03558932-af25-484c-9aa6-9b961af53f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d0fadb4f-94b5-4c9f-bcd2-4021555a87dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4e7259d-5764-4b92-9b3b-f28241e7ce77" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d0fadb4f-94b5-4c9f-bcd2-4021555a87dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7c9ae80a-1a85-4b57-8a37-94ef25616829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_768e88db-07b9-495c-9afa-1cc32701fc52" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7c9ae80a-1a85-4b57-8a37-94ef25616829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_156dc9ec-e122-4053-8e65-21452b0f6d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_768e88db-07b9-495c-9afa-1cc32701fc52" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_156dc9ec-e122-4053-8e65-21452b0f6d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e2ee815d-edd9-468a-aa62-0f78b633dc67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_768e88db-07b9-495c-9afa-1cc32701fc52" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e2ee815d-edd9-468a-aa62-0f78b633dc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b94d2294-9037-4b4e-ab03-b72dd451f3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_768e88db-07b9-495c-9afa-1cc32701fc52" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b94d2294-9037-4b4e-ab03-b72dd451f3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_86a11b59-60ab-4e1c-85bd-7f793d1a5cad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_768e88db-07b9-495c-9afa-1cc32701fc52" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_86a11b59-60ab-4e1c-85bd-7f793d1a5cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashPaidDuringTheYearAbstract_a588af74-7ad7-4c3d-b8d7-f324c6fd70ba" xlink:href="jnj-20220102.xsd#jnj_CashPaidDuringTheYearAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_86a11b59-60ab-4e1c-85bd-7f793d1a5cad" xlink:to="loc_jnj_CashPaidDuringTheYearAbstract_a588af74-7ad7-4c3d-b8d7-f324c6fd70ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_499cee0b-45af-4c69-b1c3-5325a97f95df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_CashPaidDuringTheYearAbstract_a588af74-7ad7-4c3d-b8d7-f324c6fd70ba" xlink:to="loc_us-gaap_InterestPaid_499cee0b-45af-4c69-b1c3-5325a97f95df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_031d1a8a-9069-4c58-9a6f-f127752abcfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_CashPaidDuringTheYearAbstract_a588af74-7ad7-4c3d-b8d7-f324c6fd70ba" xlink:to="loc_us-gaap_InterestPaidNet_031d1a8a-9069-4c58-9a6f-f127752abcfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_f9b6a43b-84fa-4bd8-87e5-0b690a37411d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_CashPaidDuringTheYearAbstract_a588af74-7ad7-4c3d-b8d7-f324c6fd70ba" xlink:to="loc_us-gaap_IncomeTaxesPaid_f9b6a43b-84fa-4bd8-87e5-0b690a37411d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_9d73c253-fa34-47e0-8606-259852fac9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_768e88db-07b9-495c-9afa-1cc32701fc52" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_9d73c253-fa34-47e0-8606-259852fac9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_07d568dc-9b64-43a4-b4a3-3664552543ba" xlink:href="jnj-20220102.xsd#jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_9d73c253-fa34-47e0-8606-259852fac9b6" xlink:to="loc_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_07d568dc-9b64-43a4-b4a3-3664552543ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_b9e4598a-7641-4ba3-bd26-6f7be9f1637b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_9d73c253-fa34-47e0-8606-259852fac9b6" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_b9e4598a-7641-4ba3-bd26-6f7be9f1637b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_0ec3761f-b314-406f-b010-d6fcd8833dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_768e88db-07b9-495c-9afa-1cc32701fc52" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_0ec3761f-b314-406f-b010-d6fcd8833dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_3e0e4dd6-4397-42c8-9240-d238860decad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_0ec3761f-b314-406f-b010-d6fcd8833dc5" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_3e0e4dd6-4397-42c8-9240-d238860decad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_9ab19b25-7c27-4d4b-8cfc-a1159e3e1764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_0ec3761f-b314-406f-b010-d6fcd8833dc5" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_9ab19b25-7c27-4d4b-8cfc-a1159e3e1764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_3deef35d-3818-4df6-96bc-9d3d2b199515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_0ec3761f-b314-406f-b010-d6fcd8833dc5" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_3deef35d-3818-4df6-96bc-9d3d2b199515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="jnj-20220102.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9e4c7f81-f13b-4989-819f-d2039a88dede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_19349071-ca15-404b-8f01-df0afd4ea468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e4c7f81-f13b-4989-819f-d2039a88dede" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_19349071-ca15-404b-8f01-df0afd4ea468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="jnj-20220102.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_75a8e021-0c0a-4263-8bda-81bb1d6ea742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_75a8e021-0c0a-4263-8bda-81bb1d6ea742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_9273a82b-8b61-43cc-b4e3-2779c824184f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_9273a82b-8b61-43cc-b4e3-2779c824184f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_79639d0d-f57d-4395-a6a4-1f9be01a389b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_79639d0d-f57d-4395-a6a4-1f9be01a389b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_89ac2749-e3fd-4a3e-9248-0f1d4b26a199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_89ac2749-e3fd-4a3e-9248-0f1d4b26a199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_b9ba7c17-702b-4a3f-8497-b34995fefc06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_b9ba7c17-702b-4a3f-8497-b34995fefc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d555b5fb-deb4-458c-855a-e0835e6745f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d555b5fb-deb4-458c-855a-e0835e6745f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_faab65ac-bc16-4cb3-b885-11aff92d2201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_faab65ac-bc16-4cb3-b885-11aff92d2201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_1d231d00-b67c-46e5-a73b-b2cfd0d68a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_1d231d00-b67c-46e5-a73b-b2cfd0d68a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_9d008e70-bd0c-4d5e-8447-7de360a99009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_9d008e70-bd0c-4d5e-8447-7de360a99009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_bb3a4462-a4e8-4415-a623-de943125ba84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_bb3a4462-a4e8-4415-a623-de943125ba84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_7a411486-35a6-4acb-8fc4-fc94e6dc070e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_7a411486-35a6-4acb-8fc4-fc94e6dc070e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_2dc1209e-01ce-4707-a055-7b8907689b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_2dc1209e-01ce-4707-a055-7b8907689b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityPolicyTextBlock_b3522af0-5a19-4582-b2f3-7ae09602700a" xlink:href="jnj-20220102.xsd#jnj_ProductLiabilityPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_jnj_ProductLiabilityPolicyTextBlock_b3522af0-5a19-4582-b2f3-7ae09602700a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3f04eb70-929c-4d48-8f9f-42c4f9e99c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3f04eb70-929c-4d48-8f9f-42c4f9e99c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_166b46d7-381c-44d3-b23f-f34234f53368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_166b46d7-381c-44d3-b23f-f34234f53368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_5fa624f6-f815-4093-a97e-f0e0f3a9abf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_5fa624f6-f815-4093-a97e-f0e0f3a9abf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_9cc8f780-5b06-4e48-8e9b-39eb8f36aa13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_9cc8f780-5b06-4e48-8e9b-39eb8f36aa13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_5e2c9114-2350-48c9-81df-1f0c6a7640cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_us-gaap_UseOfEstimates_5e2c9114-2350-48c9-81df-1f0c6a7640cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiscalPeriodPolicyTextBlock_8f0da120-c061-424b-88a9-8f94a3a1d4fe" xlink:href="jnj-20220102.xsd#jnj_FiscalPeriodPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_jnj_FiscalPeriodPolicyTextBlock_8f0da120-c061-424b-88a9-8f94a3a1d4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_72cab605-a35a-4e9c-be4a-00fd2ac56be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6de65c2b-2b6b-442b-a8a2-f78426f605c4" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_72cab605-a35a-4e9c-be4a-00fd2ac56be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="jnj-20220102.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4dc0eb6a-cce1-4c57-8952-ab7853638ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_5a2bbe68-06c4-4b94-8ee8-6824ca1fed13" xlink:href="jnj-20220102.xsd#jnj_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4dc0eb6a-cce1-4c57-8952-ab7853638ff8" xlink:to="loc_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_5a2bbe68-06c4-4b94-8ee8-6824ca1fed13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_be571725-52ed-4f8a-aea9-b2c091771e04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskTable_5eb50d29-1bea-4074-ba5b-2acfe4fb5244" xlink:href="jnj-20220102.xsd#jnj_ConcentrationOfCreditRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_be571725-52ed-4f8a-aea9-b2c091771e04" xlink:to="loc_jnj_ConcentrationOfCreditRiskTable_5eb50d29-1bea-4074-ba5b-2acfe4fb5244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9035a417-51ce-4711-8cdd-cf927c86ad43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_5eb50d29-1bea-4074-ba5b-2acfe4fb5244" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9035a417-51ce-4711-8cdd-cf927c86ad43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_96d99343-c042-4860-ae21-35a8cc8bb0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9035a417-51ce-4711-8cdd-cf927c86ad43" xlink:to="loc_us-gaap_SegmentDomain_96d99343-c042-4860-ae21-35a8cc8bb0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_683a276d-9f8d-4be0-bedc-96daa802f84c" xlink:href="jnj-20220102.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_96d99343-c042-4860-ae21-35a8cc8bb0e2" xlink:to="loc_jnj_PharmaceuticalMember_683a276d-9f8d-4be0-bedc-96daa802f84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d0bb137c-b0d6-48d5-b173-643310e4657b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_5eb50d29-1bea-4074-ba5b-2acfe4fb5244" xlink:to="loc_srt_ProductOrServiceAxis_d0bb137c-b0d6-48d5-b173-643310e4657b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a39feb88-c62f-49f0-a467-5065b859b621" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d0bb137c-b0d6-48d5-b173-643310e4657b" xlink:to="loc_srt_ProductsAndServicesDomain_a39feb88-c62f-49f0-a467-5065b859b621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_43038d5d-1b07-4a20-b855-39f8b4c07b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a39feb88-c62f-49f0-a467-5065b859b621" xlink:to="loc_us-gaap_ShippingAndHandlingMember_43038d5d-1b07-4a20-b855-39f8b4c07b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4033b0a0-8b19-4309-a171-ce2fbfe3d660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_5eb50d29-1bea-4074-ba5b-2acfe4fb5244" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4033b0a0-8b19-4309-a171-ce2fbfe3d660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0574081d-c3da-4498-952d-fefda6e115bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4033b0a0-8b19-4309-a171-ce2fbfe3d660" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0574081d-c3da-4498-952d-fefda6e115bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e23298ac-eb26-4510-810d-50ca07e376d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0574081d-c3da-4498-952d-fefda6e115bc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e23298ac-eb26-4510-810d-50ca07e376d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e5134fa5-aab5-4972-91f7-5c95ad589d95" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_5eb50d29-1bea-4074-ba5b-2acfe4fb5244" xlink:to="loc_srt_RangeAxis_e5134fa5-aab5-4972-91f7-5c95ad589d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ed54fb0-9fd7-4f7a-ba91-00d8bcbc2c2b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e5134fa5-aab5-4972-91f7-5c95ad589d95" xlink:to="loc_srt_RangeMember_3ed54fb0-9fd7-4f7a-ba91-00d8bcbc2c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fb9b20f3-035a-4cb3-9360-6deac2069f5f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3ed54fb0-9fd7-4f7a-ba91-00d8bcbc2c2b" xlink:to="loc_srt_MinimumMember_fb9b20f3-035a-4cb3-9360-6deac2069f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8b637f4c-c057-4c5c-92aa-10dcf3b8ce7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3ed54fb0-9fd7-4f7a-ba91-00d8bcbc2c2b" xlink:to="loc_srt_MaximumMember_8b637f4c-c057-4c5c-92aa-10dcf3b8ce7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fb0ca561-133d-45f2-b037-ed33e0d0426d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_5eb50d29-1bea-4074-ba5b-2acfe4fb5244" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fb0ca561-133d-45f2-b037-ed33e0d0426d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6876a26f-ca9e-4200-bced-ba278cd7d50e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fb0ca561-133d-45f2-b037-ed33e0d0426d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6876a26f-ca9e-4200-bced-ba278cd7d50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_ae45d1c1-b210-4864-97e8-fdc790408c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6876a26f-ca9e-4200-bced-ba278cd7d50e" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_ae45d1c1-b210-4864-97e8-fdc790408c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e4057aae-9fef-4c0b-a9e5-2846dbe3008d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_5eb50d29-1bea-4074-ba5b-2acfe4fb5244" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e4057aae-9fef-4c0b-a9e5-2846dbe3008d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fe63bd84-defa-4acc-9a37-242e6d2aa6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e4057aae-9fef-4c0b-a9e5-2846dbe3008d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fe63bd84-defa-4acc-9a37-242e6d2aa6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_d988b03c-cb19-4428-ae87-1dba40d2cc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_fe63bd84-defa-4acc-9a37-242e6d2aa6ef" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_d988b03c-cb19-4428-ae87-1dba40d2cc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:href="jnj-20220102.xsd#jnj_ConcentrationOfCreditRiskLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_5eb50d29-1bea-4074-ba5b-2acfe4fb5244" xlink:to="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_086a6b69-bf64-48d0-bc64-f63f8100165c" xlink:href="jnj-20220102.xsd#jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_086a6b69-bf64-48d0-bc64-f63f8100165c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_b0bb83b1-1494-46ee-bd3b-989aacaa2e47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_NumberOfReportableSegments_b0bb83b1-1494-46ee-bd3b-989aacaa2e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_c0636a48-a6da-4016-ad43-4a1defc91a92" xlink:href="jnj-20220102.xsd#jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_c0636a48-a6da-4016-ad43-4a1defc91a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_20d0ae49-0df8-4bb5-8ce2-08968d9964f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_20d0ae49-0df8-4bb5-8ce2-08968d9964f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_5d95eb5a-d835-4d33-aae5-1c7f2a0894fb" xlink:href="jnj-20220102.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_5d95eb5a-d835-4d33-aae5-1c7f2a0894fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesReturnReserve_9cbf6593-9c6a-4cce-9606-b4478471be1a" xlink:href="jnj-20220102.xsd#jnj_SalesReturnReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_SalesReturnReserve_9cbf6593-9c6a-4cce-9606-b4478471be1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProfitLossPercentToSales_e0b097d4-9b5d-4f84-868c-535fdb81869f" xlink:href="jnj-20220102.xsd#jnj_ProfitLossPercentToSales"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_ProfitLossPercentToSales_e0b097d4-9b5d-4f84-868c-535fdb81869f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_47f599e6-c964-434e-b4a8-aed9b8202b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_47f599e6-c964-434e-b4a8-aed9b8202b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShippingandHandlingCostsasaPercentofSales_ca88b18c-11bd-4547-87f7-d5333ae90fb7" xlink:href="jnj-20220102.xsd#jnj_ShippingandHandlingCostsasaPercentofSales"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_ShippingandHandlingCostsasaPercentofSales_ca88b18c-11bd-4547-87f7-d5333ae90fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_844397e8-2a05-46e3-b26b-dfc1ba6230a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_844397e8-2a05-46e3-b26b-dfc1ba6230a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_580effa7-65d1-42ba-bd41-f602a418352b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_580effa7-65d1-42ba-bd41-f602a418352b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_d421016d-cdbb-4e69-8e45-311011d12584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_d421016d-cdbb-4e69-8e45-311011d12584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2595b624-c596-4221-968a-687816c763c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2595b624-c596-4221-968a-687816c763c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0771abb4-91b7-4f5f-ae5f-3da44247cfc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_OperatingLeaseLiability_0771abb4-91b7-4f5f-ae5f-3da44247cfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_d23029da-54d7-4de8-ba88-865043cbd70e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_OperatingLeaseCost_d23029da-54d7-4de8-ba88-865043cbd70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_03a260d8-566c-4efc-a96d-6e3389bc11dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_OperatingLeasePayments_03a260d8-566c-4efc-a96d-6e3389bc11dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationRiskThresholdPercentage_50c82758-0c2c-44b2-81a2-7a34ce065eb0" xlink:href="jnj-20220102.xsd#jnj_ConcentrationRiskThresholdPercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_ConcentrationRiskThresholdPercentage_50c82758-0c2c-44b2-81a2-7a34ce065eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_2f1c0e4e-5497-4063-bd42-d6dc8d41ef8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_AdvertisingExpense_2f1c0e4e-5497-4063-bd42-d6dc8d41ef8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_af74dba0-74e6-41fc-84ae-6a99a6a29fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_af74dba0-74e6-41fc-84ae-6a99a6a29fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_854fa16d-bac7-4423-9619-36f5778cc29d" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_854fa16d-bac7-4423-9619-36f5778cc29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_25f6963a-2615-4bcc-8c81-9fc898ff1c03" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_25f6963a-2615-4bcc-8c81-9fc898ff1c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_5b229e9f-6d9b-47cb-bac8-66c3060a8e87" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_5b229e9f-6d9b-47cb-bac8-66c3060a8e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_10278406-64f2-4a4d-8371-891b2ef885ed" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_10278406-64f2-4a4d-8371-891b2ef885ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_9690921b-680a-4e65-b59b-9aa8cb311988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_57c75b78-f183-4f6c-811d-4a3cc0bc0776" xlink:to="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_9690921b-680a-4e65-b59b-9aa8cb311988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_75723868-d469-440a-9dbe-4798090e5f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb14d088-c656-4438-9201-a58aeaf4dcaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_75723868-d469-440a-9dbe-4798090e5f9b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb14d088-c656-4438-9201-a58aeaf4dcaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_94ce0def-581e-4419-960b-618ab06352b3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb14d088-c656-4438-9201-a58aeaf4dcaa" xlink:to="loc_srt_RangeAxis_94ce0def-581e-4419-960b-618ab06352b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6d7920ab-c072-46d2-a63d-b69ad46d612b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_94ce0def-581e-4419-960b-618ab06352b3" xlink:to="loc_srt_RangeMember_6d7920ab-c072-46d2-a63d-b69ad46d612b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6a51f502-ba8f-4597-9f14-494779e2c238" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6d7920ab-c072-46d2-a63d-b69ad46d612b" xlink:to="loc_srt_MinimumMember_6a51f502-ba8f-4597-9f14-494779e2c238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c3817a52-7257-4419-a428-22d4f1fe9a40" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6d7920ab-c072-46d2-a63d-b69ad46d612b" xlink:to="loc_srt_MaximumMember_c3817a52-7257-4419-a428-22d4f1fe9a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_913b6390-04fb-45f9-95b8-fb213e532792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb14d088-c656-4438-9201-a58aeaf4dcaa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_913b6390-04fb-45f9-95b8-fb213e532792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e3b46b9b-933f-4a57-9fab-a9f7bd53ebca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_913b6390-04fb-45f9-95b8-fb213e532792" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e3b46b9b-933f-4a57-9fab-a9f7bd53ebca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_a7d20137-75e4-4d93-bb20-f7f691f54555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e3b46b9b-933f-4a57-9fab-a9f7bd53ebca" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_a7d20137-75e4-4d93-bb20-f7f691f54555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LandAndLeaseholdImprovementsMember_da4b12a2-d60b-41f2-807e-48e19fd2b527" xlink:href="jnj-20220102.xsd#jnj_LandAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e3b46b9b-933f-4a57-9fab-a9f7bd53ebca" xlink:to="loc_jnj_LandAndLeaseholdImprovementsMember_da4b12a2-d60b-41f2-807e-48e19fd2b527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_e1df7fbc-1075-4f9f-80e8-056cf88d6bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e3b46b9b-933f-4a57-9fab-a9f7bd53ebca" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_e1df7fbc-1075-4f9f-80e8-056cf88d6bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_09d3e62e-1ad1-4e25-bb34-02dc4029933e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb14d088-c656-4438-9201-a58aeaf4dcaa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_09d3e62e-1ad1-4e25-bb34-02dc4029933e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_261aae80-e241-427c-bc88-ee45924c793c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_09d3e62e-1ad1-4e25-bb34-02dc4029933e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_261aae80-e241-427c-bc88-ee45924c793c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities" xlink:type="simple" xlink:href="jnj-20220102.xsd#CashCashEquivalentsandCurrentMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_08a7a3c4-9b60-4ced-9daa-574026808f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_2b40c660-d91b-4736-9be1-7cd52885d873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_08a7a3c4-9b60-4ced-9daa-574026808f49" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_2b40c660-d91b-4736-9be1-7cd52885d873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables" xlink:type="simple" xlink:href="jnj-20220102.xsd#CashCashEquivalentsandCurrentMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_edb5854c-e78a-4914-bf8c-ab4e30f7efb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_832dd96f-c5c5-4612-a5e9-2de089d4bd38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_edb5854c-e78a-4914-bf8c-ab4e30f7efb4" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_832dd96f-c5c5-4612-a5e9-2de089d4bd38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_04f59192-9a2f-4af8-992a-f67a755b804c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_edb5854c-e78a-4914-bf8c-ab4e30f7efb4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_04f59192-9a2f-4af8-992a-f67a755b804c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_1bc96c85-91f8-4e32-a026-d696297b840d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8f1fabc3-7b18-4297-8ed5-01264b74ff18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_1bc96c85-91f8-4e32-a026-d696297b840d" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8f1fabc3-7b18-4297-8ed5-01264b74ff18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_39a88903-dc1f-4ca5-9ef6-05f652600ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8f1fabc3-7b18-4297-8ed5-01264b74ff18" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_39a88903-dc1f-4ca5-9ef6-05f652600ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_24b7ed8d-c873-490f-ada7-c34ae625f976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_39a88903-dc1f-4ca5-9ef6-05f652600ba9" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_24b7ed8d-c873-490f-ada7-c34ae625f976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_04035dda-a0fd-434c-bac4-3b442c5a3a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_24b7ed8d-c873-490f-ada7-c34ae625f976" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_04035dda-a0fd-434c-bac4-3b442c5a3a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_4580a9dd-f82e-4e31-b576-aa080febabdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_24b7ed8d-c873-490f-ada7-c34ae625f976" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_4580a9dd-f82e-4e31-b576-aa080febabdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_5f4d35f2-3605-4331-89bd-98011d9930cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8f1fabc3-7b18-4297-8ed5-01264b74ff18" xlink:to="loc_us-gaap_InvestmentTypeAxis_5f4d35f2-3605-4331-89bd-98011d9930cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_5f4d35f2-3605-4331-89bd-98011d9930cd" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_484e1b4e-0141-414c-9ada-f79d39f292d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:to="loc_us-gaap_CashMember_484e1b4e-0141-414c-9ada-f79d39f292d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_e961e9b8-1e21-419c-a484-caea14244950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_e961e9b8-1e21-419c-a484-caea14244950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_cd2f2a59-7ab4-4178-8211-47d0e76efcb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_cd2f2a59-7ab4-4178-8211-47d0e76efcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_56aca57f-ad5a-4704-8479-e5c9ed5aa53e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_56aca57f-ad5a-4704-8479-e5c9ed5aa53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_6bd6b029-600f-42c5-a2c1-3900a5166bce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_6bd6b029-600f-42c5-a2c1-3900a5166bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_2b9d2b79-71fe-406e-b17c-c4356743604b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:to="loc_us-gaap_BankTimeDepositsMember_2b9d2b79-71fe-406e-b17c-c4356743604b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_b4669046-5176-48c5-bed6-ec10dd59587e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_b4669046-5176-48c5-bed6-ec10dd59587e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherSovereignSecuritiesMember_f5763c44-0997-4900-bb2e-5b80e674b5ec" xlink:href="jnj-20220102.xsd#jnj_OtherSovereignSecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_16814350-f930-4d57-9ac2-e269e3ed3a8f" xlink:to="loc_jnj_OtherSovereignSecuritiesMember_f5763c44-0997-4900-bb2e-5b80e674b5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_7a348de8-aac4-464a-844b-100a0c42cfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8f1fabc3-7b18-4297-8ed5-01264b74ff18" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_7a348de8-aac4-464a-844b-100a0c42cfe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_7a348de8-aac4-464a-844b-100a0c42cfe1" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_93fe2d2c-7fc2-464d-a7eb-a267614184d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_HeldToMaturitySecurities_93fe2d2c-7fc2-464d-a7eb-a267614184d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a5bbd53a-b273-40c8-86b8-869d2834761c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a5bbd53a-b273-40c8-86b8-869d2834761c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_d6677ce9-0f33-4f07-9c0d-5ed4f6fc5788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_d6677ce9-0f33-4f07-9c0d-5ed4f6fc5788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_34bd4a0a-167e-4b4e-a23a-517f8037915b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_34bd4a0a-167e-4b4e-a23a-517f8037915b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f375deef-a0f8-4041-b3a2-81649ec9711f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f375deef-a0f8-4041-b3a2-81649ec9711f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_539a69fa-8437-48f0-a40f-f63ff4a4701b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_539a69fa-8437-48f0-a40f-f63ff4a4701b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_81f3cfb1-54ce-4157-9100-810c742c69fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_81f3cfb1-54ce-4157-9100-810c742c69fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5d98c66e-d843-4ce5-95ce-d92bde229303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5d98c66e-d843-4ce5-95ce-d92bde229303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_cf91211d-9ee1-49cb-b8c2-e14a238ae30a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_cf91211d-9ee1-49cb-b8c2-e14a238ae30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0c394fe0-3bfb-4094-a1bc-7f01bfb1d764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_bfb6f2a9-c7b7-4074-8fbe-a7ed1d17a9fb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0c394fe0-3bfb-4094-a1bc-7f01bfb1d764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_723dfe1b-eb55-42e6-826d-a8075cd0b786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_e48add53-e493-4067-b4f3-2c342048415e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_723dfe1b-eb55-42e6-826d-a8075cd0b786" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_e48add53-e493-4067-b4f3-2c342048415e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_c06e3412-c617-420b-aae4-52ac97720307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_e48add53-e493-4067-b4f3-2c342048415e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_c06e3412-c617-420b-aae4-52ac97720307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_9d42b42f-b18a-4f1d-869b-353ffcc7284e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_e48add53-e493-4067-b4f3-2c342048415e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_9d42b42f-b18a-4f1d-869b-353ffcc7284e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_affba2a6-ef7c-4a27-b12a-08dd824122aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_e48add53-e493-4067-b4f3-2c342048415e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_affba2a6-ef7c-4a27-b12a-08dd824122aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_9338113e-9df3-4eb5-a23c-2430b4a17ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_e48add53-e493-4067-b4f3-2c342048415e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_9338113e-9df3-4eb5-a23c-2430b4a17ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_7c1a8e06-378a-462b-bb23-ddd8df0d49ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_723dfe1b-eb55-42e6-826d-a8075cd0b786" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_7c1a8e06-378a-462b-bb23-ddd8df0d49ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ed947f61-b80c-4ce4-9219-2a720d5e2538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_7c1a8e06-378a-462b-bb23-ddd8df0d49ce" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ed947f61-b80c-4ce4-9219-2a720d5e2538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_caa733fa-354b-4286-9a09-13581eae36b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_7c1a8e06-378a-462b-bb23-ddd8df0d49ce" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_caa733fa-354b-4286-9a09-13581eae36b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_09419fde-e030-4d4d-a689-d592884e13d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_7c1a8e06-378a-462b-bb23-ddd8df0d49ce" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_09419fde-e030-4d4d-a689-d592884e13d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_5931cb46-e9bb-41bf-a1fb-3cf8368a6822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_7c1a8e06-378a-462b-bb23-ddd8df0d49ce" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_5931cb46-e9bb-41bf-a1fb-3cf8368a6822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Inventories" xlink:type="simple" xlink:href="jnj-20220102.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1dfb491b-fc84-420c-a1b8-bc51465b4812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_2f629850-8081-43fc-af18-f3b1cfad2be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1dfb491b-fc84-420c-a1b8-bc51465b4812" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_2f629850-8081-43fc-af18-f3b1cfad2be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesTables" xlink:type="simple" xlink:href="jnj-20220102.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_c739a558-7b03-4820-b139-3117e7d0430a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4f237bf3-ed9e-412b-aac7-2fd2fb2e22f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c739a558-7b03-4820-b139-3117e7d0430a" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4f237bf3-ed9e-412b-aac7-2fd2fb2e22f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_52ca12a0-0079-44b1-99e1-ab5df4a39dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_a9aa8d76-90c9-4af4-84f8-e7754e973fda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_52ca12a0-0079-44b1-99e1-ab5df4a39dcf" xlink:to="loc_us-gaap_InventoryNetAbstract_a9aa8d76-90c9-4af4-84f8-e7754e973fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_37f12706-d477-4b93-abc4-368d6cf1b573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_a9aa8d76-90c9-4af4-84f8-e7754e973fda" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_37f12706-d477-4b93-abc4-368d6cf1b573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c559cfd6-08fa-45d0-bbc3-882917f10bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_a9aa8d76-90c9-4af4-84f8-e7754e973fda" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c559cfd6-08fa-45d0-bbc3-882917f10bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_33bbf483-6250-495a-9081-08583d9e142a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_a9aa8d76-90c9-4af4-84f8-e7754e973fda" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_33bbf483-6250-495a-9081-08583d9e142a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_002888ff-e776-4707-8a4c-ca8dc779c9be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_a9aa8d76-90c9-4af4-84f8-e7754e973fda" xlink:to="loc_us-gaap_InventoryNet_002888ff-e776-4707-8a4c-ca8dc779c9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="jnj-20220102.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2715095b-379f-452f-ac43-12e9fd2fffff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ac109339-ad70-4355-9560-eeb04727a8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2715095b-379f-452f-ac43-12e9fd2fffff" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ac109339-ad70-4355-9560-eeb04727a8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="jnj-20220102.xsd#PropertyPlantandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1edac5bd-ab6e-44f0-af4f-703b0caaa6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bb4849d8-b775-4b36-9ac7-eac1c8fa3aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1edac5bd-ab6e-44f0-af4f-703b0caaa6a1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bb4849d8-b775-4b36-9ac7-eac1c8fa3aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b5cafa12-6fd1-483e-b946-bb0d0a3f9751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bdc59a4f-279b-4c1d-bf4f-c3e0b15b3768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b5cafa12-6fd1-483e-b946-bb0d0a3f9751" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bdc59a4f-279b-4c1d-bf4f-c3e0b15b3768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f594324-9949-4efb-b296-60b6a2b48393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bdc59a4f-279b-4c1d-bf4f-c3e0b15b3768" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f594324-9949-4efb-b296-60b6a2b48393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f1450dd-a83b-4432-a1d0-5066572f484f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f594324-9949-4efb-b296-60b6a2b48393" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f1450dd-a83b-4432-a1d0-5066572f484f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LandAndLeaseholdImprovementsMember_1c248d16-e26e-4f14-92a6-6ed2a797258b" xlink:href="jnj-20220102.xsd#jnj_LandAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f1450dd-a83b-4432-a1d0-5066572f484f" xlink:to="loc_jnj_LandAndLeaseholdImprovementsMember_1c248d16-e26e-4f14-92a6-6ed2a797258b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_55791192-c1dc-4dd1-a1c0-532cf7558e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f1450dd-a83b-4432-a1d0-5066572f484f" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_55791192-c1dc-4dd1-a1c0-532cf7558e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_76b9fb65-468f-45a0-8645-e10b6e21b8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f1450dd-a83b-4432-a1d0-5066572f484f" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_76b9fb65-468f-45a0-8645-e10b6e21b8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_cdc1993e-9e38-46aa-aad1-a2a065db824c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f1450dd-a83b-4432-a1d0-5066572f484f" xlink:to="loc_us-gaap_ConstructionInProgressMember_cdc1993e-9e38-46aa-aad1-a2a065db824c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8712825-1808-4c80-811f-6efbfe00f2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bdc59a4f-279b-4c1d-bf4f-c3e0b15b3768" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8712825-1808-4c80-811f-6efbfe00f2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b2a60c67-fffd-4cc1-96d5-5e5a7c13484d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8712825-1808-4c80-811f-6efbfe00f2ec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b2a60c67-fffd-4cc1-96d5-5e5a7c13484d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fbfa3b03-d89f-4751-8b11-1e851603249a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8712825-1808-4c80-811f-6efbfe00f2ec" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fbfa3b03-d89f-4751-8b11-1e851603249a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_be5ef988-f781-4a13-8976-ec8515534f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8712825-1808-4c80-811f-6efbfe00f2ec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_be5ef988-f781-4a13-8976-ec8515534f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PropertyPlantandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4b4eba7a-b640-4f10-a9fe-bcfe9265ba45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_c114effe-394c-425e-b1f0-e44943bb64b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4b4eba7a-b640-4f10-a9fe-bcfe9265ba45" xlink:to="loc_us-gaap_InterestCostsCapitalized_c114effe-394c-425e-b1f0-e44943bb64b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_4473ca8e-9773-4671-af1a-33e4c0386f3d" xlink:href="jnj-20220102.xsd#jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4b4eba7a-b640-4f10-a9fe-bcfe9265ba45" xlink:to="loc_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_4473ca8e-9773-4671-af1a-33e4c0386f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="jnj-20220102.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_60ee68a7-c2f0-4e92-85bf-ac8b4e1ffd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_a7196001-ce93-4d66-ad76-bd7ecf59b798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_60ee68a7-c2f0-4e92-85bf-ac8b4e1ffd8b" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_a7196001-ce93-4d66-ad76-bd7ecf59b798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="jnj-20220102.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_96e49502-da6e-41e1-803e-64f60449e16d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_1832de7c-785c-4ff8-af1f-b9bbccf75df4" xlink:href="jnj-20220102.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_96e49502-da6e-41e1-803e-64f60449e16d" xlink:to="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_1832de7c-785c-4ff8-af1f-b9bbccf75df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_4c55834d-0aef-4bdc-88ff-c1560a3b7db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_96e49502-da6e-41e1-803e-64f60449e16d" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_4c55834d-0aef-4bdc-88ff-c1560a3b7db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_a5aec167-9ca3-49a7-91a5-aed2b4f6426b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_96e49502-da6e-41e1-803e-64f60449e16d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_a5aec167-9ca3-49a7-91a5-aed2b4f6426b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b7d0732e-0df1-4c61-ae0a-6a2b4b3f2d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_9dec3905-2154-49a7-a567-f311ad1ab615" xlink:href="jnj-20220102.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b7d0732e-0df1-4c61-ae0a-6a2b4b3f2d4d" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_9dec3905-2154-49a7-a567-f311ad1ab615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d0dd92c7-9bd2-469c-b2d7-b2c12cc5e0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_9dec3905-2154-49a7-a567-f311ad1ab615" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d0dd92c7-9bd2-469c-b2d7-b2c12cc5e0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5d2fc7f8-c89d-4336-b45e-6aca3fc221ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d0dd92c7-9bd2-469c-b2d7-b2c12cc5e0ad" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5d2fc7f8-c89d-4336-b45e-6aca3fc221ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_1d09e84a-83e2-4c1f-a6ad-bb253d731dfd" xlink:href="jnj-20220102.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5d2fc7f8-c89d-4336-b45e-6aca3fc221ef" xlink:to="loc_jnj_AurisHealthMember_1d09e84a-83e2-4c1f-a6ad-bb253d731dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3ccce5bf-3432-43c9-9f82-1d5459db4db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_9dec3905-2154-49a7-a567-f311ad1ab615" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3ccce5bf-3432-43c9-9f82-1d5459db4db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5e7ec265-5001-4bf8-b1a8-1e25fec71de7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3ccce5bf-3432-43c9-9f82-1d5459db4db1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5e7ec265-5001-4bf8-b1a8-1e25fec71de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_19569439-23ff-4533-904a-afefb16d2684" xlink:href="jnj-20220102.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5e7ec265-5001-4bf8-b1a8-1e25fec71de7" xlink:to="loc_jnj_PatentsAndTrademarksMember_19569439-23ff-4533-904a-afefb16d2684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_551291cd-6096-4832-9c85-4530b44bd01a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5e7ec265-5001-4bf8-b1a8-1e25fec71de7" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_551291cd-6096-4832-9c85-4530b44bd01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_cd6e380d-0dbc-490e-8c51-9bb3dd90ce82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5e7ec265-5001-4bf8-b1a8-1e25fec71de7" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_cd6e380d-0dbc-490e-8c51-9bb3dd90ce82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ac0c7dbf-27f2-4769-b20e-7916142a545f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_9dec3905-2154-49a7-a567-f311ad1ab615" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ac0c7dbf-27f2-4769-b20e-7916142a545f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_48ee9bf3-7574-41c2-89ae-0cf79cfa42a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ac0c7dbf-27f2-4769-b20e-7916142a545f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_48ee9bf3-7574-41c2-89ae-0cf79cfa42a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_0c54fc7c-341f-45fe-936f-d3584692a8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_48ee9bf3-7574-41c2-89ae-0cf79cfa42a0" xlink:to="loc_us-gaap_TrademarksMember_0c54fc7c-341f-45fe-936f-d3584692a8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_73c883fa-6449-4568-8089-494c933b575a" xlink:href="jnj-20220102.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_48ee9bf3-7574-41c2-89ae-0cf79cfa42a0" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_73c883fa-6449-4568-8089-494c933b575a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_b29b7caa-dd6f-4de3-942a-e2b064af3684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_48ee9bf3-7574-41c2-89ae-0cf79cfa42a0" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_b29b7caa-dd6f-4de3-942a-e2b064af3684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1a826f07-dad1-483d-a0ec-12b0f9ca4b44" xlink:href="jnj-20220102.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_9dec3905-2154-49a7-a567-f311ad1ab615" xlink:to="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1a826f07-dad1-483d-a0ec-12b0f9ca4b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_f7a527fc-badc-4565-9d82-6b0cc0cb6da2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1a826f07-dad1-483d-a0ec-12b0f9ca4b44" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_f7a527fc-badc-4565-9d82-6b0cc0cb6da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_9826cbb1-4fee-4b05-8a7c-98a49742bc17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_f7a527fc-badc-4565-9d82-6b0cc0cb6da2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_9826cbb1-4fee-4b05-8a7c-98a49742bc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_be8d171b-dc37-4381-ab13-7fe50e70ed5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_9826cbb1-4fee-4b05-8a7c-98a49742bc17" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_be8d171b-dc37-4381-ab13-7fe50e70ed5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5286024e-5807-45c4-b5ce-8c2c4aa4298f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_9826cbb1-4fee-4b05-8a7c-98a49742bc17" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5286024e-5807-45c4-b5ce-8c2c4aa4298f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f74def34-0ea4-4aed-97ee-7e33a28a8689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_9826cbb1-4fee-4b05-8a7c-98a49742bc17" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f74def34-0ea4-4aed-97ee-7e33a28a8689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_07452004-367d-429a-9ec8-2c49e5fce907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_f7a527fc-badc-4565-9d82-6b0cc0cb6da2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_07452004-367d-429a-9ec8-2c49e5fce907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1b957188-2b66-4151-9746-069237fba76c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_07452004-367d-429a-9ec8-2c49e5fce907" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1b957188-2b66-4151-9746-069237fba76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3ced8a31-cbfe-455a-9f5b-91bd35ba321a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_07452004-367d-429a-9ec8-2c49e5fce907" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3ced8a31-cbfe-455a-9f5b-91bd35ba321a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_a6065b15-7a1a-4841-a862-4ecd27e4b8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1a826f07-dad1-483d-a0ec-12b0f9ca4b44" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_a6065b15-7a1a-4841-a862-4ecd27e4b8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#IntangibleAssetsandGoodwillGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6027d4c0-3d15-4643-bba0-dc13a02ed06d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_0346a5e4-55f8-4477-9354-33af21113529" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6027d4c0-3d15-4643-bba0-dc13a02ed06d" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_0346a5e4-55f8-4477-9354-33af21113529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f2219c9d-cbf6-403d-95b9-18a38096e7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_0346a5e4-55f8-4477-9354-33af21113529" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f2219c9d-cbf6-403d-95b9-18a38096e7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_81dee365-40df-435f-8a1a-43256010daa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f2219c9d-cbf6-403d-95b9-18a38096e7b0" xlink:to="loc_us-gaap_SegmentDomain_81dee365-40df-435f-8a1a-43256010daa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_af771109-6fec-4fb4-bbdb-8b925f80149b" xlink:href="jnj-20220102.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_81dee365-40df-435f-8a1a-43256010daa9" xlink:to="loc_jnj_ConsumerMember_af771109-6fec-4fb4-bbdb-8b925f80149b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_b83b32ce-1219-408a-a02e-2ce9fa5ef688" xlink:href="jnj-20220102.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_81dee365-40df-435f-8a1a-43256010daa9" xlink:to="loc_jnj_PharmaceuticalMember_b83b32ce-1219-408a-a02e-2ce9fa5ef688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_6b4d81a7-7287-41fd-88e7-7df77f8d0a10" xlink:href="jnj-20220102.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_81dee365-40df-435f-8a1a-43256010daa9" xlink:to="loc_jnj_MedicalDevicesMember_6b4d81a7-7287-41fd-88e7-7df77f8d0a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_c2dedc40-4d19-413f-9c45-245befc76347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_0346a5e4-55f8-4477-9354-33af21113529" xlink:to="loc_us-gaap_GoodwillLineItems_c2dedc40-4d19-413f-9c45-245befc76347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_d3a7ac06-2b62-4a4f-b45d-85ba8cfedb63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_c2dedc40-4d19-413f-9c45-245befc76347" xlink:to="loc_us-gaap_GoodwillRollForward_d3a7ac06-2b62-4a4f-b45d-85ba8cfedb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_089c87b3-3c51-41b5-b68b-ac8bea838bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d3a7ac06-2b62-4a4f-b45d-85ba8cfedb63" xlink:to="loc_us-gaap_Goodwill_089c87b3-3c51-41b5-b68b-ac8bea838bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_0cdd0414-7e7d-410b-954b-2fa640cb09a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d3a7ac06-2b62-4a4f-b45d-85ba8cfedb63" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_0cdd0414-7e7d-410b-954b-2fa640cb09a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_42213366-4efd-460f-84f3-7efaae79bad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d3a7ac06-2b62-4a4f-b45d-85ba8cfedb63" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_42213366-4efd-460f-84f3-7efaae79bad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_61114e5a-b6ab-4ef9-bf26-0bbe6aa741c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d3a7ac06-2b62-4a4f-b45d-85ba8cfedb63" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_61114e5a-b6ab-4ef9-bf26-0bbe6aa741c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7b6d88d8-f6a5-4c76-b53e-ab0c7b914000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d3a7ac06-2b62-4a4f-b45d-85ba8cfedb63" xlink:to="loc_us-gaap_Goodwill_7b6d88d8-f6a5-4c76-b53e-ab0c7b914000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e89e9e13-66a8-4b8f-9ec4-f17b20c75c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_44d460a5-559f-46ed-a038-78e895805e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e89e9e13-66a8-4b8f-9ec4-f17b20c75c12" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_44d460a5-559f-46ed-a038-78e895805e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_77a50c56-27b7-4831-ac41-dd17afc2e906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_44d460a5-559f-46ed-a038-78e895805e82" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_77a50c56-27b7-4831-ac41-dd17afc2e906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_880ebd4e-11cc-43d6-865d-db69a50e0491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_77a50c56-27b7-4831-ac41-dd17afc2e906" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_880ebd4e-11cc-43d6-865d-db69a50e0491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_14f4b21a-76b2-4e2e-b7e9-a2b7efe6966c" xlink:href="jnj-20220102.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_880ebd4e-11cc-43d6-865d-db69a50e0491" xlink:to="loc_jnj_PatentsAndTrademarksMember_14f4b21a-76b2-4e2e-b7e9-a2b7efe6966c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_0f8d6abe-134b-4205-9ca8-c86a4f06c2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_880ebd4e-11cc-43d6-865d-db69a50e0491" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_0f8d6abe-134b-4205-9ca8-c86a4f06c2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ea7122c7-4059-4860-8ba3-81f57b6207bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_44d460a5-559f-46ed-a038-78e895805e82" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ea7122c7-4059-4860-8ba3-81f57b6207bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_23162e1c-ff5b-4c51-afec-2789b6a96ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ea7122c7-4059-4860-8ba3-81f57b6207bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_23162e1c-ff5b-4c51-afec-2789b6a96ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2accd86e-7e4a-40c5-9796-b75035d4ac84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ea7122c7-4059-4860-8ba3-81f57b6207bc" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2accd86e-7e4a-40c5-9796-b75035d4ac84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8dd8181-ca7b-4d0d-b4c0-5eb9a6b81153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_03b36324-46cd-463d-9a0e-118009814c03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8dd8181-ca7b-4d0d-b4c0-5eb9a6b81153" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_03b36324-46cd-463d-9a0e-118009814c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9946a81b-71d9-4ae9-8bbd-ac49f8244ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8dd8181-ca7b-4d0d-b4c0-5eb9a6b81153" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9946a81b-71d9-4ae9-8bbd-ac49f8244ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_20191d3b-2dcc-4faa-b05a-48fca2fbd5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8dd8181-ca7b-4d0d-b4c0-5eb9a6b81153" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_20191d3b-2dcc-4faa-b05a-48fca2fbd5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_df7c1fd6-b4aa-42d5-b2ac-403822c17c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8dd8181-ca7b-4d0d-b4c0-5eb9a6b81153" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_df7c1fd6-b4aa-42d5-b2ac-403822c17c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3a60cbe0-4653-45ce-91f4-49c904aa7f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8dd8181-ca7b-4d0d-b4c0-5eb9a6b81153" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3a60cbe0-4653-45ce-91f4-49c904aa7f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="jnj-20220102.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_52ba5e3e-c047-4830-9f49-353047b7790f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_f29f7003-4feb-4cc9-84ac-f5f6119fe1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_52ba5e3e-c047-4830-9f49-353047b7790f" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_f29f7003-4feb-4cc9-84ac-f5f6119fe1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="jnj-20220102.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6dce5d9a-46cd-402f-b9e7-c47c69630d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1302af82-1f76-457d-bf65-31302ee2af05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6dce5d9a-46cd-402f-b9e7-c47c69630d34" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1302af82-1f76-457d-bf65-31302ee2af05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_dcdb0c8a-a01e-400c-8f88-09ab96e121f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6dce5d9a-46cd-402f-b9e7-c47c69630d34" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_dcdb0c8a-a01e-400c-8f88-09ab96e121f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_65cdd7b0-ee08-46c7-a2c2-6eb40fbac756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6dce5d9a-46cd-402f-b9e7-c47c69630d34" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_65cdd7b0-ee08-46c7-a2c2-6eb40fbac756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_195e217f-989f-4652-8bc2-ba6d08028854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6dce5d9a-46cd-402f-b9e7-c47c69630d34" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_195e217f-989f-4652-8bc2-ba6d08028854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_8988fac2-1a07-4995-90e4-b0e006b8f168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6dce5d9a-46cd-402f-b9e7-c47c69630d34" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_8988fac2-1a07-4995-90e4-b0e006b8f168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ec5ea7b1-a549-49f0-b5e4-35c136cc30f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_434e5a0e-7fde-4182-9a5f-b483f2aa1198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ec5ea7b1-a549-49f0-b5e4-35c136cc30f0" xlink:to="loc_us-gaap_DerivativeTable_434e5a0e-7fde-4182-9a5f-b483f2aa1198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1f01c2ef-e5d7-4fef-801e-a03722779f46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_434e5a0e-7fde-4182-9a5f-b483f2aa1198" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1f01c2ef-e5d7-4fef-801e-a03722779f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1940764b-39b6-4869-b1f3-566356b53055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1f01c2ef-e5d7-4fef-801e-a03722779f46" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1940764b-39b6-4869-b1f3-566356b53055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_eebf2d06-fc47-4d54-aa58-a487087b6d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1940764b-39b6-4869-b1f3-566356b53055" xlink:to="loc_us-gaap_EquitySecuritiesMember_eebf2d06-fc47-4d54-aa58-a487087b6d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4b201820-cfd3-4ba5-ad80-471c94afece2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_434e5a0e-7fde-4182-9a5f-b483f2aa1198" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4b201820-cfd3-4ba5-ad80-471c94afece2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f9bad65b-326b-4a81-9b36-b5fe53d0d78b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4b201820-cfd3-4ba5-ad80-471c94afece2" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f9bad65b-326b-4a81-9b36-b5fe53d0d78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_e88126da-bb83-4882-8557-3e9226e774e8" xlink:href="jnj-20220102.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f9bad65b-326b-4a81-9b36-b5fe53d0d78b" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_e88126da-bb83-4882-8557-3e9226e774e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0bcb3fde-9470-40de-b7fb-0a581b267918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_434e5a0e-7fde-4182-9a5f-b483f2aa1198" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0bcb3fde-9470-40de-b7fb-0a581b267918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b02f0d5f-e52d-43ce-b72f-29ff910484df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0bcb3fde-9470-40de-b7fb-0a581b267918" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b02f0d5f-e52d-43ce-b72f-29ff910484df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_45aa2f78-25c4-4c53-ae43-b05e81c0159e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b02f0d5f-e52d-43ce-b72f-29ff910484df" xlink:to="loc_us-gaap_ForeignExchangeContractMember_45aa2f78-25c4-4c53-ae43-b05e81c0159e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_5ecf9e28-4219-43ba-ac1f-34e23ea6913a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b02f0d5f-e52d-43ce-b72f-29ff910484df" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_5ecf9e28-4219-43ba-ac1f-34e23ea6913a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_6f2aa3b6-2059-4b7d-bc90-33569a2d81a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b02f0d5f-e52d-43ce-b72f-29ff910484df" xlink:to="loc_us-gaap_InterestRateSwapMember_6f2aa3b6-2059-4b7d-bc90-33569a2d81a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_36b7f8cc-1328-43e1-b2a2-46c40c58494e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_434e5a0e-7fde-4182-9a5f-b483f2aa1198" xlink:to="loc_us-gaap_DerivativeLineItems_36b7f8cc-1328-43e1-b2a2-46c40c58494e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_4a140f6f-7888-4016-837c-af47906dda8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_36b7f8cc-1328-43e1-b2a2-46c40c58494e" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_4a140f6f-7888-4016-837c-af47906dda8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_11bf4b80-99ad-40fa-a5f6-418a47020298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_36b7f8cc-1328-43e1-b2a2-46c40c58494e" xlink:to="loc_us-gaap_DerivativeNotionalAmount_11bf4b80-99ad-40fa-a5f6-418a47020298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_9421c292-23d7-427f-849c-6ddeb9418862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_36b7f8cc-1328-43e1-b2a2-46c40c58494e" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_9421c292-23d7-427f-849c-6ddeb9418862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_0c2f3089-63f9-4b42-8bcd-abfc8fa6137f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_36b7f8cc-1328-43e1-b2a2-46c40c58494e" xlink:to="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_0c2f3089-63f9-4b42-8bcd-abfc8fa6137f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_cc39c25a-7cd5-4bdf-a090-083a34d3e8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_36b7f8cc-1328-43e1-b2a2-46c40c58494e" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_cc39c25a-7cd5-4bdf-a090-083a34d3e8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_dcec157e-38a7-45a8-95e1-8101b2e96058" xlink:href="jnj-20220102.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_36b7f8cc-1328-43e1-b2a2-46c40c58494e" xlink:to="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_dcec157e-38a7-45a8-95e1-8101b2e96058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices_2b292945-6022-4cdd-b04f-95c4413b5075" xlink:href="jnj-20220102.xsd#jnj_EquityFairValueAdjustmentChangeinObservablePrices"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_36b7f8cc-1328-43e1-b2a2-46c40c58494e" xlink:to="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices_2b292945-6022-4cdd-b04f-95c4413b5075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_77ae61ae-1aa4-4a8e-bf71-369fa362ec97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4cfe9152-eb33-46fe-8edb-310de3745183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_77ae61ae-1aa4-4a8e-bf71-369fa362ec97" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4cfe9152-eb33-46fe-8edb-310de3745183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3b937648-e27f-4b3b-91b9-b7ec97dc30a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4cfe9152-eb33-46fe-8edb-310de3745183" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3b937648-e27f-4b3b-91b9-b7ec97dc30a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bc3e515f-e4a7-49f5-9503-967ddc8ffd00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3b937648-e27f-4b3b-91b9-b7ec97dc30a2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bc3e515f-e4a7-49f5-9503-967ddc8ffd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_a9e504ca-8410-4c1b-b6b5-cbe31bec5e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bc3e515f-e4a7-49f5-9503-967ddc8ffd00" xlink:to="loc_us-gaap_SalesMember_a9e504ca-8410-4c1b-b6b5-cbe31bec5e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6ff25c8b-d7b3-4616-b5c7-5d6cc823b6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bc3e515f-e4a7-49f5-9503-967ddc8ffd00" xlink:to="loc_us-gaap_CostOfSalesMember_6ff25c8b-d7b3-4616-b5c7-5d6cc823b6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0b063aa4-55e4-41c0-aecc-d0ac43876a31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bc3e515f-e4a7-49f5-9503-967ddc8ffd00" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0b063aa4-55e4-41c0-aecc-d0ac43876a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_03c4dd11-3291-42dc-8c3c-bc1f3ef80a07" xlink:href="jnj-20220102.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bc3e515f-e4a7-49f5-9503-967ddc8ffd00" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_03c4dd11-3291-42dc-8c3c-bc1f3ef80a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_d010c116-0220-4107-bdf5-cc19327380d4" xlink:href="jnj-20220102.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bc3e515f-e4a7-49f5-9503-967ddc8ffd00" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_d010c116-0220-4107-bdf5-cc19327380d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_bfabf382-f9de-4489-ab5c-06479311de56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4cfe9152-eb33-46fe-8edb-310de3745183" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_bfabf382-f9de-4489-ab5c-06479311de56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_240e8851-1eb0-47b7-afd2-1aa4d796cbac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bfabf382-f9de-4489-ab5c-06479311de56" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_240e8851-1eb0-47b7-afd2-1aa4d796cbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b4507ee9-4d88-466e-8712-1289826edf4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_240e8851-1eb0-47b7-afd2-1aa4d796cbac" xlink:to="loc_us-gaap_InterestRateSwapMember_b4507ee9-4d88-466e-8712-1289826edf4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_3d3f6023-404b-4f67-a466-13d23080aeda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_240e8851-1eb0-47b7-afd2-1aa4d796cbac" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_3d3f6023-404b-4f67-a466-13d23080aeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f32d687f-d78f-446f-8f1e-7f527387b4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_240e8851-1eb0-47b7-afd2-1aa4d796cbac" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f32d687f-d78f-446f-8f1e-7f527387b4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a68a463e-b4ec-4ca1-84cc-82a97a415437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4cfe9152-eb33-46fe-8edb-310de3745183" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a68a463e-b4ec-4ca1-84cc-82a97a415437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f55f01bb-51bf-453a-9705-6d846260cbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a68a463e-b4ec-4ca1-84cc-82a97a415437" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f55f01bb-51bf-453a-9705-6d846260cbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_c343f8c3-5316-4c59-a5e6-c6f8e821b0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f55f01bb-51bf-453a-9705-6d846260cbfd" xlink:to="loc_us-gaap_FairValueHedgingMember_c343f8c3-5316-4c59-a5e6-c6f8e821b0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_c0a744ae-0afc-4b0c-b6d0-c354d7f42a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f55f01bb-51bf-453a-9705-6d846260cbfd" xlink:to="loc_us-gaap_CashFlowHedgingMember_c0a744ae-0afc-4b0c-b6d0-c354d7f42a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b1ecb7ec-1681-44b4-8840-89653e6752d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4cfe9152-eb33-46fe-8edb-310de3745183" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b1ecb7ec-1681-44b4-8840-89653e6752d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_16dec9cb-ddf6-4531-92ee-c692fb8dbc42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b1ecb7ec-1681-44b4-8840-89653e6752d1" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_16dec9cb-ddf6-4531-92ee-c692fb8dbc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_a0e9e1e3-97b5-4425-bd70-2fd8711bc0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b1ecb7ec-1681-44b4-8840-89653e6752d1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_a0e9e1e3-97b5-4425-bd70-2fd8711bc0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_8e209caa-a49e-4f00-83b7-8e623ac2fe60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b1ecb7ec-1681-44b4-8840-89653e6752d1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_8e209caa-a49e-4f00-83b7-8e623ac2fe60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_a4e47b6b-f265-4165-97cc-e8b052c54cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b1ecb7ec-1681-44b4-8840-89653e6752d1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_a4e47b6b-f265-4165-97cc-e8b052c54cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a5fcd221-2e0e-4e67-b1e9-48160e541c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f2d69e6f-a6b7-4e15-8ad1-f90b7a80b4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a5fcd221-2e0e-4e67-b1e9-48160e541c6e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f2d69e6f-a6b7-4e15-8ad1-f90b7a80b4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a4a5b993-f9eb-4d37-b246-b413309956f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f2d69e6f-a6b7-4e15-8ad1-f90b7a80b4f3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a4a5b993-f9eb-4d37-b246-b413309956f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0de3ab89-69c5-41b1-b1f6-578d9db5258e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a4a5b993-f9eb-4d37-b246-b413309956f4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0de3ab89-69c5-41b1-b1f6-578d9db5258e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_9eeee69c-d8b9-4e40-aabd-f6130f23fc38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0de3ab89-69c5-41b1-b1f6-578d9db5258e" xlink:to="loc_us-gaap_LongTermDebtMember_9eeee69c-d8b9-4e40-aabd-f6130f23fc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_1406ec9b-f0fa-45e2-a29c-b2778855e901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f2d69e6f-a6b7-4e15-8ad1-f90b7a80b4f3" xlink:to="loc_us-gaap_HedgingDesignationAxis_1406ec9b-f0fa-45e2-a29c-b2778855e901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_feed4173-ef01-44b6-bcb7-2782b1cf4401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_1406ec9b-f0fa-45e2-a29c-b2778855e901" xlink:to="loc_us-gaap_HedgingDesignationDomain_feed4173-ef01-44b6-bcb7-2782b1cf4401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_20b16e9e-b075-405d-8a3f-651132e287d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_feed4173-ef01-44b6-bcb7-2782b1cf4401" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_20b16e9e-b075-405d-8a3f-651132e287d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a54adf2c-9129-49c2-8f7d-4ba86af5177e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f2d69e6f-a6b7-4e15-8ad1-f90b7a80b4f3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a54adf2c-9129-49c2-8f7d-4ba86af5177e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_74bad6c4-045c-48ab-8989-bce5e965039a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a54adf2c-9129-49c2-8f7d-4ba86af5177e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_74bad6c4-045c-48ab-8989-bce5e965039a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_10e74871-9f26-41e9-b52c-9007c14957f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a54adf2c-9129-49c2-8f7d-4ba86af5177e" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_10e74871-9f26-41e9-b52c-9007c14957f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7962bb94-5504-4705-b5b1-55996f217c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_78ca1c98-c4d2-48b2-a6af-fb81b21e3dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7962bb94-5504-4705-b5b1-55996f217c7b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_78ca1c98-c4d2-48b2-a6af-fb81b21e3dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_802bb44d-1e4c-4edc-838b-8d4920adfbef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_78ca1c98-c4d2-48b2-a6af-fb81b21e3dc8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_802bb44d-1e4c-4edc-838b-8d4920adfbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b5e3de95-2059-4370-89db-309c1e315da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_802bb44d-1e4c-4edc-838b-8d4920adfbef" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b5e3de95-2059-4370-89db-309c1e315da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_79ef6dd1-4dea-4467-a23e-92ab04166a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b5e3de95-2059-4370-89db-309c1e315da1" xlink:to="loc_us-gaap_ForeignExchangeContractMember_79ef6dd1-4dea-4467-a23e-92ab04166a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_33b7c4ae-965f-4824-aa8c-2ed9cbf5353f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_78ca1c98-c4d2-48b2-a6af-fb81b21e3dc8" xlink:to="loc_us-gaap_HedgingDesignationAxis_33b7c4ae-965f-4824-aa8c-2ed9cbf5353f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c9f7fbcb-2799-4327-a87c-7cd5483fe4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_33b7c4ae-965f-4824-aa8c-2ed9cbf5353f" xlink:to="loc_us-gaap_HedgingDesignationDomain_c9f7fbcb-2799-4327-a87c-7cd5483fe4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_bd622fbb-af16-4e72-9c6c-9d5d9885294e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_c9f7fbcb-2799-4327-a87c-7cd5483fe4a6" xlink:to="loc_us-gaap_NondesignatedMember_bd622fbb-af16-4e72-9c6c-9d5d9885294e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_09ca80e0-a73d-4a9e-8391-dca5075cbba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_78ca1c98-c4d2-48b2-a6af-fb81b21e3dc8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_09ca80e0-a73d-4a9e-8391-dca5075cbba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b41df3bc-9f13-4e7d-b6a6-caca06cd3aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_09ca80e0-a73d-4a9e-8391-dca5075cbba5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b41df3bc-9f13-4e7d-b6a6-caca06cd3aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_19cf62a7-5fc2-4c02-a62e-d12d89af0e29" xlink:href="jnj-20220102.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b41df3bc-9f13-4e7d-b6a6-caca06cd3aef" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_19cf62a7-5fc2-4c02-a62e-d12d89af0e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_510f7aa2-e555-465a-b076-94c994049a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_78ca1c98-c4d2-48b2-a6af-fb81b21e3dc8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_510f7aa2-e555-465a-b076-94c994049a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_60a5c7d8-dbb4-49ee-8738-8e778d64801d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_510f7aa2-e555-465a-b076-94c994049a0a" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_60a5c7d8-dbb4-49ee-8738-8e778d64801d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_42ed519d-b66d-44f0-9b9d-eb85205365b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e86c32b2-343b-478a-9505-97466ea60e23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_42ed519d-b66d-44f0-9b9d-eb85205365b6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e86c32b2-343b-478a-9505-97466ea60e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_32c0e54f-7980-4594-82ae-313ed5095203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e86c32b2-343b-478a-9505-97466ea60e23" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_32c0e54f-7980-4594-82ae-313ed5095203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_db74cdc5-cd0e-4a40-ad5d-5a374cf55550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_32c0e54f-7980-4594-82ae-313ed5095203" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_db74cdc5-cd0e-4a40-ad5d-5a374cf55550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_a622bec7-9c43-4994-a75a-4f1403bb5c64" xlink:href="jnj-20220102.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db74cdc5-cd0e-4a40-ad5d-5a374cf55550" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_a622bec7-9c43-4994-a75a-4f1403bb5c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d1d31e65-3b10-4bab-b065-2e9eb9a4a172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e86c32b2-343b-478a-9505-97466ea60e23" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d1d31e65-3b10-4bab-b065-2e9eb9a4a172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_83a5befb-a2e6-4b19-90ec-fea45d307d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d1d31e65-3b10-4bab-b065-2e9eb9a4a172" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_83a5befb-a2e6-4b19-90ec-fea45d307d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_f3437eed-e5a1-4d4b-b20a-7ac16a78f75c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_83a5befb-a2e6-4b19-90ec-fea45d307d2f" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_f3437eed-e5a1-4d4b-b20a-7ac16a78f75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_713f7b11-7441-45b7-822a-48b344a28d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e86c32b2-343b-478a-9505-97466ea60e23" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_713f7b11-7441-45b7-822a-48b344a28d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_aacc4aee-f50f-4f6a-928e-4676f8a10e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_713f7b11-7441-45b7-822a-48b344a28d96" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_aacc4aee-f50f-4f6a-928e-4676f8a10e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_0c798669-48f3-41ae-91f2-38926cabe8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_713f7b11-7441-45b7-822a-48b344a28d96" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_0c798669-48f3-41ae-91f2-38926cabe8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a31d23ba-e957-455e-8765-394250bc744a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_043effd3-c0c8-461c-a43c-830882969703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a31d23ba-e957-455e-8765-394250bc744a" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_043effd3-c0c8-461c-a43c-830882969703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_601a5a59-7d24-4e60-af29-0a8af9231511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_043effd3-c0c8-461c-a43c-830882969703" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_601a5a59-7d24-4e60-af29-0a8af9231511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3b30151e-0ac2-4066-9565-ab14765661e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_601a5a59-7d24-4e60-af29-0a8af9231511" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3b30151e-0ac2-4066-9565-ab14765661e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_7decf201-3605-486b-98d1-95870e4d8214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3b30151e-0ac2-4066-9565-ab14765661e7" xlink:to="loc_us-gaap_EquitySecuritiesMember_7decf201-3605-486b-98d1-95870e4d8214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a1d67706-96dd-4d13-88f4-0fe0c045d48f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_043effd3-c0c8-461c-a43c-830882969703" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a1d67706-96dd-4d13-88f4-0fe0c045d48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_0a985555-c2f9-479f-abab-49970eadc5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_a1d67706-96dd-4d13-88f4-0fe0c045d48f" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_0a985555-c2f9-479f-abab-49970eadc5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_b4f244f7-aa98-4efa-b191-ca677604cf96" xlink:href="jnj-20220102.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_0a985555-c2f9-479f-abab-49970eadc5b2" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_b4f244f7-aa98-4efa-b191-ca677604cf96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_9bd3d280-c9bd-42e2-a7ba-4bb2fb871d3e" xlink:href="jnj-20220102.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_0a985555-c2f9-479f-abab-49970eadc5b2" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_9bd3d280-c9bd-42e2-a7ba-4bb2fb871d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a0fc6dd2-4595-419c-848a-89fe81b93d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_043effd3-c0c8-461c-a43c-830882969703" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a0fc6dd2-4595-419c-848a-89fe81b93d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_75d6fc96-5b2a-4813-bc45-dcd5e783ac68" xlink:href="jnj-20220102.xsd#jnj_EquityInvestmentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a0fc6dd2-4595-419c-848a-89fe81b93d3f" xlink:to="loc_jnj_EquityInvestmentRollForward_75d6fc96-5b2a-4813-bc45-dcd5e783ac68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_712cb729-ab8e-4bf7-aa41-329cef77f0db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_75d6fc96-5b2a-4813-bc45-dcd5e783ac68" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_712cb729-ab8e-4bf7-aa41-329cef77f0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_b30c082d-0e4f-46cb-b092-d3b7ac60b642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_75d6fc96-5b2a-4813-bc45-dcd5e783ac68" xlink:to="loc_us-gaap_EquityFairValueAdjustment_b30c082d-0e4f-46cb-b092-d3b7ac60b642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_0ff52991-0964-4c50-a8f3-c11cdb582456" xlink:href="jnj-20220102.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_75d6fc96-5b2a-4813-bc45-dcd5e783ac68" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_0ff52991-0964-4c50-a8f3-c11cdb582456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_087b86b9-a1b5-44cd-9c1c-7fdd98cd5d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_75d6fc96-5b2a-4813-bc45-dcd5e783ac68" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_087b86b9-a1b5-44cd-9c1c-7fdd98cd5d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_0c6e6963-a453-4dac-b915-61d6f8e153e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_75d6fc96-5b2a-4813-bc45-dcd5e783ac68" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_0c6e6963-a453-4dac-b915-61d6f8e153e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7973c149-4815-4bad-a885-9add40ba6f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_537ab408-0e90-4ca1-885e-51e05122ea6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7973c149-4815-4bad-a885-9add40ba6f80" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_537ab408-0e90-4ca1-885e-51e05122ea6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_5645d90c-0ea0-4fc0-afa9-3aef10aefa2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_537ab408-0e90-4ca1-885e-51e05122ea6a" xlink:to="loc_us-gaap_HedgingDesignationAxis_5645d90c-0ea0-4fc0-afa9-3aef10aefa2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_55d854ad-73ab-46e9-ac11-5fdf826369f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_5645d90c-0ea0-4fc0-afa9-3aef10aefa2c" xlink:to="loc_us-gaap_HedgingDesignationDomain_55d854ad-73ab-46e9-ac11-5fdf826369f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_5ed56639-4211-49f6-aed8-6d100065ba87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_55d854ad-73ab-46e9-ac11-5fdf826369f2" xlink:to="loc_us-gaap_NondesignatedMember_5ed56639-4211-49f6-aed8-6d100065ba87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a40fff43-13b9-460f-8f9f-e1be7be735f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_537ab408-0e90-4ca1-885e-51e05122ea6a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a40fff43-13b9-460f-8f9f-e1be7be735f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_08c4d003-53f9-428e-84f0-9389fa27678e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a40fff43-13b9-460f-8f9f-e1be7be735f5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_08c4d003-53f9-428e-84f0-9389fa27678e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_daf7dfb7-c7e9-4a50-b414-56749e91e7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_08c4d003-53f9-428e-84f0-9389fa27678e" xlink:to="loc_us-gaap_InterestRateContractMember_daf7dfb7-c7e9-4a50-b414-56749e91e7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_79239312-1350-4eaf-843c-af63da7e2e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_08c4d003-53f9-428e-84f0-9389fa27678e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_79239312-1350-4eaf-843c-af63da7e2e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_28d6d0d1-ca81-40ed-84f4-b28ac0575668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_537ab408-0e90-4ca1-885e-51e05122ea6a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_28d6d0d1-ca81-40ed-84f4-b28ac0575668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1fccce53-a7f7-40eb-9ec2-f37f51b5698e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_28d6d0d1-ca81-40ed-84f4-b28ac0575668" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1fccce53-a7f7-40eb-9ec2-f37f51b5698e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6970202b-7588-4fd7-a837-ed3d14d32319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1fccce53-a7f7-40eb-9ec2-f37f51b5698e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6970202b-7588-4fd7-a837-ed3d14d32319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b52c1777-257b-42e8-a841-6f4951ee5674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1fccce53-a7f7-40eb-9ec2-f37f51b5698e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b52c1777-257b-42e8-a841-6f4951ee5674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3f88a8f3-b609-4829-a4e4-9d21563efc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1fccce53-a7f7-40eb-9ec2-f37f51b5698e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3f88a8f3-b609-4829-a4e4-9d21563efc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_3c9cb2ab-39d7-46c9-beb4-1731376aee97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_537ab408-0e90-4ca1-885e-51e05122ea6a" xlink:to="loc_us-gaap_InvestmentTypeAxis_3c9cb2ab-39d7-46c9-beb4-1731376aee97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4801c3d7-7b42-48f3-baf9-67ffcdf8cbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_3c9cb2ab-39d7-46c9-beb4-1731376aee97" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4801c3d7-7b42-48f3-baf9-67ffcdf8cbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_bffb9454-202c-4537-9a0c-a60751152326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4801c3d7-7b42-48f3-baf9-67ffcdf8cbd1" xlink:to="loc_us-gaap_EquitySecuritiesMember_bffb9454-202c-4537-9a0c-a60751152326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0c435b47-0e33-4f7a-b232-48737e6d8494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_537ab408-0e90-4ca1-885e-51e05122ea6a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0c435b47-0e33-4f7a-b232-48737e6d8494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d16a33f9-f1cb-468d-b7b7-a980a8556d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0c435b47-0e33-4f7a-b232-48737e6d8494" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d16a33f9-f1cb-468d-b7b7-a980a8556d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_eeec04e8-5659-416d-b762-1b5833ca081d" xlink:href="jnj-20220102.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d16a33f9-f1cb-468d-b7b7-a980a8556d99" xlink:to="loc_jnj_AurisHealthMember_eeec04e8-5659-416d-b762-1b5833ca081d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_299b7cbe-d073-4f79-9a42-f96197ab3d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_537ab408-0e90-4ca1-885e-51e05122ea6a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_299b7cbe-d073-4f79-9a42-f96197ab3d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_01379b83-d789-47ec-9293-adee183db6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_299b7cbe-d073-4f79-9a42-f96197ab3d14" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_01379b83-d789-47ec-9293-adee183db6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8a9bf6b5-00cc-400c-8ed0-41ce11db7b85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_01379b83-d789-47ec-9293-adee183db6a7" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8a9bf6b5-00cc-400c-8ed0-41ce11db7b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_aeb30546-0062-48ad-8da6-9f6c4a552e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_01379b83-d789-47ec-9293-adee183db6a7" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_aeb30546-0062-48ad-8da6-9f6c4a552e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_537ab408-0e90-4ca1-885e-51e05122ea6a" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_598c133f-ccc4-4d79-8516-2892ba035e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_598c133f-ccc4-4d79-8516-2892ba035e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_7b821279-f091-4727-b7df-6530f0d44188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_598c133f-ccc4-4d79-8516-2892ba035e97" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_7b821279-f091-4727-b7df-6530f0d44188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_ef789731-6ac0-4e4e-9132-33e165f8aee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_598c133f-ccc4-4d79-8516-2892ba035e97" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_ef789731-6ac0-4e4e-9132-33e165f8aee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_8a0a5b7a-77b0-4ce3-9028-5ad6461a2ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_598c133f-ccc4-4d79-8516-2892ba035e97" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_8a0a5b7a-77b0-4ce3-9028-5ad6461a2ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_6d639127-a6cc-42a4-8326-95ebb7c358ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_598c133f-ccc4-4d79-8516-2892ba035e97" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_6d639127-a6cc-42a4-8326-95ebb7c358ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_046fcc87-69f3-49dc-8b84-106a71f5e5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_598c133f-ccc4-4d79-8516-2892ba035e97" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_046fcc87-69f3-49dc-8b84-106a71f5e5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7679d04b-c7de-4612-b082-87a18d639489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_598c133f-ccc4-4d79-8516-2892ba035e97" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7679d04b-c7de-4612-b082-87a18d639489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6f1447bf-6f15-4f5e-a024-4469786c296e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_598c133f-ccc4-4d79-8516-2892ba035e97" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6f1447bf-6f15-4f5e-a024-4469786c296e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2879cce5-25d6-46e8-8c24-fcdfff6af8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2879cce5-25d6-46e8-8c24-fcdfff6af8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_843176fb-c187-4c0a-b4ee-d6a4c2542282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_843176fb-c187-4c0a-b4ee-d6a4c2542282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_4948293c-5023-4935-92c4-04bf5acb4d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_DerivativeAssets_4948293c-5023-4935-92c4-04bf5acb4d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_4271dfce-bf03-49dc-a749-b8b5d6def00f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_4271dfce-bf03-49dc-a749-b8b5d6def00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_fef645fa-3088-4f5a-968a-827db8f512b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_fef645fa-3088-4f5a-968a-827db8f512b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_0c29f7d3-359c-4297-9491-40feffc36461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_DerivativeLiabilities_0c29f7d3-359c-4297-9491-40feffc36461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a313adfa-4bb6-4999-b391-5cddd52b3d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a313adfa-4bb6-4999-b391-5cddd52b3d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_bb416a1d-0265-4259-81f7-e3ebe873d248" xlink:href="jnj-20220102.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_bb416a1d-0265-4259-81f7-e3ebe873d248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_325e050f-e0e4-407d-b82c-fc8fefba1648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_325e050f-e0e4-407d-b82c-fc8fefba1648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_f9434482-9fdf-452f-8b1d-c40edf870724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_f9434482-9fdf-452f-8b1d-c40edf870724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_23b4d9ca-dd4f-43dc-9bea-0dafee59cc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_23b4d9ca-dd4f-43dc-9bea-0dafee59cc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_32ee53b5-41d2-4e48-b69e-40a25cc8343a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3c4bbda-0167-4221-b746-7a1b55f6d374" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_32ee53b5-41d2-4e48-b69e-40a25cc8343a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Borrowings" xlink:type="simple" xlink:href="jnj-20220102.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ab6ae442-a0ea-47dd-8b45-c9f5b5d6191e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_ed9c060f-b3f1-4738-88c2-face846614df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ab6ae442-a0ea-47dd-8b45-c9f5b5d6191e" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_ed9c060f-b3f1-4738-88c2-face846614df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsTables" xlink:type="simple" xlink:href="jnj-20220102.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0f041702-295e-465c-9f5d-e838c80d9c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_a77be3a0-81dd-4d90-adae-1464deab9c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0f041702-295e-465c-9f5d-e838c80d9c3c" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_a77be3a0-81dd-4d90-adae-1464deab9c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_b0d545c2-65e9-41be-94be-d12cc2e2de1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0f041702-295e-465c-9f5d-e838c80d9c3c" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_b0d545c2-65e9-41be-94be-d12cc2e2de1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#BorrowingsScheduleofLongtermDebtInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_89f83a69-555a-4643-9651-98bae4db0379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7b55daf2-5138-4b7a-a282-0ee0ec59fb20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_89f83a69-555a-4643-9651-98bae4db0379" xlink:to="loc_us-gaap_DebtInstrumentTable_7b55daf2-5138-4b7a-a282-0ee0ec59fb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_88274a2a-7fcc-48ed-93c7-10f31a818ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7b55daf2-5138-4b7a-a282-0ee0ec59fb20" xlink:to="loc_us-gaap_DebtInstrumentAxis_88274a2a-7fcc-48ed-93c7-10f31a818ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_88274a2a-7fcc-48ed-93c7-10f31a818ce0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2021Member_632ae5ae-803d-40fd-a550-f0519fe38106" xlink:href="jnj-20220102.xsd#jnj_A3.55Notesdue2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A3.55Notesdue2021Member_632ae5ae-803d-40fd-a550-f0519fe38106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2021Member_8aa68abd-8171-42d4-a1cc-23ec5a2a3544" xlink:href="jnj-20220102.xsd#jnj_A2.45Notesdue2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A2.45Notesdue2021Member_8aa68abd-8171-42d4-a1cc-23ec5a2a3544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.65Notesdue2021Member_eb705b57-01c7-42fc-aa3f-5cdc30cd1909" xlink:href="jnj-20220102.xsd#jnj_A1.65Notesdue2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A1.65Notesdue2021Member_eb705b57-01c7-42fc-aa3f-5cdc30cd1909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.250NotesDue2022Member_59fe0348-fbb0-425c-ba5e-81d6f5a5c787" xlink:href="jnj-20220102.xsd#jnj_A0.250NotesDue2022Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A0.250NotesDue2022Member_59fe0348-fbb0-425c-ba5e-81d6f5a5c787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.25Notesdue2022Member_df78cabc-242e-4bf0-a289-d152ea571ee7" xlink:href="jnj-20220102.xsd#jnj_A2.25Notesdue2022Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A2.25Notesdue2022Member_df78cabc-242e-4bf0-a289-d152ea571ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member_cdbab93c-0dbe-441e-9e94-c2bb94a91826" xlink:href="jnj-20220102.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A6.73Debenturesdue2023Member_cdbab93c-0dbe-441e-9e94-c2bb94a91826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member_aafbeb93-1a8d-44b6-847f-29b6d2ba243c" xlink:href="jnj-20220102.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A3.375Notesdue2023Member_aafbeb93-1a8d-44b6-847f-29b6d2ba243c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.05Notesdue2023Member_d6d2308f-744b-42ce-a293-1025bfdc8c0e" xlink:href="jnj-20220102.xsd#jnj_A2.05Notesdue2023Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A2.05Notesdue2023Member_d6d2308f-744b-42ce-a293-1025bfdc8c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_2f771544-d1c3-4466-bb66-b7779934ee75" xlink:href="jnj-20220102.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A0.650NotesDue2024Member_2f771544-d1c3-4466-bb66-b7779934ee75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_1756521b-d09f-4bef-861a-671162139c1f" xlink:href="jnj-20220102.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A5.50NotesDue2024Member_1756521b-d09f-4bef-861a-671162139c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_18300166-61d6-426d-8fb3-b2b5aff9ae8b" xlink:href="jnj-20220102.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A2.625Notesdue2025Member_18300166-61d6-426d-8fb3-b2b5aff9ae8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A055NotesDue2025Member_b9e0b1ff-8c35-47d6-9350-fbef2e02e64c" xlink:href="jnj-20220102.xsd#jnj_A055NotesDue2025Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A055NotesDue2025Member_b9e0b1ff-8c35-47d6-9350-fbef2e02e64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_bac4216f-b861-499f-ba1d-32f31cfc1155" xlink:href="jnj-20220102.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A2.45Notesdue2026Member_bac4216f-b861-499f-ba1d-32f31cfc1155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_3547e848-1bd0-436e-b64b-5edcb6100019" xlink:href="jnj-20220102.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A2.95Notesdue2027Member_3547e848-1bd0-436e-b64b-5edcb6100019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_c6d94159-67ad-4a89-b477-0b9208b89625" xlink:href="jnj-20220102.xsd#jnj_A095NotesDue2027Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A095NotesDue2027Member_c6d94159-67ad-4a89-b477-0b9208b89625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_170e72aa-4313-42a3-84ae-94fadc915404" xlink:href="jnj-20220102.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A1.150NotesDue2028Member_170e72aa-4313-42a3-84ae-94fadc915404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_adaea4ec-dcd6-42dd-b760-a8370e341353" xlink:href="jnj-20220102.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A2.900Notesdue2028Member_adaea4ec-dcd6-42dd-b760-a8370e341353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_ea87dc38-1718-41bd-a8e9-2cfcd4432149" xlink:href="jnj-20220102.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A6.95Notesdue2029Member_ea87dc38-1718-41bd-a8e9-2cfcd4432149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A130NotesDue2030Member_50542be9-2e08-433c-8670-798dd9ac01a2" xlink:href="jnj-20220102.xsd#jnj_A130NotesDue2030Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A130NotesDue2030Member_50542be9-2e08-433c-8670-798dd9ac01a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_9855d2d8-8817-46ff-bfef-e286b88cd1cd" xlink:href="jnj-20220102.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_9855d2d8-8817-46ff-bfef-e286b88cd1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_10b48cf7-7fa5-4c3d-a0ff-398b7bd37ec6" xlink:href="jnj-20220102.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A4.375Notesdue2033Member_10b48cf7-7fa5-4c3d-a0ff-398b7bd37ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_07c12ea6-cacf-4777-9d5c-8a42acf19376" xlink:href="jnj-20220102.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A1.650NotesDue2035Member_07c12ea6-cacf-4777-9d5c-8a42acf19376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_337cacf7-d4f3-4814-b4b4-10c603f69862" xlink:href="jnj-20220102.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A3.55Notesdue2036Member_337cacf7-d4f3-4814-b4b4-10c603f69862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_d51d904f-0bda-445d-a482-f2b5ae4aeced" xlink:href="jnj-20220102.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A5.95Notesdue2037Member_d51d904f-0bda-445d-a482-f2b5ae4aeced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_adc6d887-d8cb-402b-87de-c69feeb3ecda" xlink:href="jnj-20220102.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A3.625Notesdue2037Member_adc6d887-d8cb-402b-87de-c69feeb3ecda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_73f970dd-741d-4576-a816-52b6cab85291" xlink:href="jnj-20220102.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_73f970dd-741d-4576-a816-52b6cab85291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_a82cf6af-c9fa-411b-a6e7-c13bfb74d6f4" xlink:href="jnj-20220102.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A3.400Notesdue2038Member_a82cf6af-c9fa-411b-a6e7-c13bfb74d6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_2c677ea2-576a-44a9-a0ac-c20d032ab388" xlink:href="jnj-20220102.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_2c677ea2-576a-44a9-a0ac-c20d032ab388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_f5328793-1d0d-45ef-839b-23df750a17a0" xlink:href="jnj-20220102.xsd#jnj_A210NotesDue2040Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A210NotesDue2040Member_f5328793-1d0d-45ef-839b-23df750a17a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_d7eb6dff-89f6-48fe-be18-8f5df098bc14" xlink:href="jnj-20220102.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A4.85Notesdue2041Member_d7eb6dff-89f6-48fe-be18-8f5df098bc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_3c206bfa-e1ae-442d-8171-c4f46cee0ed9" xlink:href="jnj-20220102.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A4.50Notesdue2043Member_3c206bfa-e1ae-442d-8171-c4f46cee0ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_1891e93c-feeb-43c8-9c84-023e3a029e03" xlink:href="jnj-20220102.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A3.70Notesdue2046Member_1891e93c-feeb-43c8-9c84-023e3a029e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_a31b3f19-8cd1-41dd-9549-74e4c0ed3a5e" xlink:href="jnj-20220102.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A3.75Notesdue2047Member_a31b3f19-8cd1-41dd-9549-74e4c0ed3a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_7350171a-9d89-4711-948c-300f7dae82c6" xlink:href="jnj-20220102.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A3.500Notesdue2048Member_7350171a-9d89-4711-948c-300f7dae82c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_1bb1abd5-b893-44e6-9182-da72e7f33ce5" xlink:href="jnj-20220102.xsd#jnj_A2250NotesDue2050Member"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A2250NotesDue2050Member_1bb1abd5-b893-44e6-9182-da72e7f33ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_9e1d62e5-a1e6-4e9c-a4d1-77b64ce135df" xlink:href="jnj-20220102.xsd#jnj_A2450NotesDue2060Member"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_jnj_A2450NotesDue2060Member_9e1d62e5-a1e6-4e9c-a4d1-77b64ce135df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_6f76c6cf-b3b0-47a5-adc9-816f3b6fd10b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_037dd7ec-1e32-49e5-a470-fe61fc618996" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_6f76c6cf-b3b0-47a5-adc9-816f3b6fd10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7b55daf2-5138-4b7a-a282-0ee0ec59fb20" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3d469cd2-f1ad-436b-90fb-fe747d42c005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3d469cd2-f1ad-436b-90fb-fe747d42c005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_fcb781bf-ed2a-45c5-86cb-55d423149675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:to="loc_us-gaap_LongTermDebt_fcb781bf-ed2a-45c5-86cb-55d423149675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b340d042-afd1-4554-837f-93b2f1665ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:to="loc_us-gaap_LongTermDebtCurrent_b340d042-afd1-4554-837f-93b2f1665ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_aa4a2a65-bea4-4148-9671-ce068456fe95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_aa4a2a65-bea4-4148-9671-ce068456fe95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_04080bdd-ee79-4972-942f-fb77d71eb333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_04080bdd-ee79-4972-942f-fb77d71eb333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_37717576-35ec-425e-a7b3-0ae4ba84e12b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_37717576-35ec-425e-a7b3-0ae4ba84e12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_aeceaf14-5c70-4899-bf7e-aec88b48f4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_aeceaf14-5c70-4899-bf7e-aec88b48f4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_ac88b29a-0d1b-4669-8559-b02bd15aae6a" xlink:href="jnj-20220102.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b287cbce-7b81-48c8-bb01-de58123603bf" xlink:to="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_ac88b29a-0d1b-4669-8559-b02bd15aae6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5fdb766a-7687-49aa-b39e-b2d93d344a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f0d98641-0ad1-4de0-9ae8-31ec4fe54f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5fdb766a-7687-49aa-b39e-b2d93d344a1b" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f0d98641-0ad1-4de0-9ae8-31ec4fe54f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_cc7180fd-7852-4f12-9854-5cc64d8d2cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5fdb766a-7687-49aa-b39e-b2d93d344a1b" xlink:to="loc_us-gaap_DebtCurrent_cc7180fd-7852-4f12-9854-5cc64d8d2cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermCommercialPaperCurrent_d8481601-e78f-40eb-9428-1f36fd8331a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermCommercialPaperCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5fdb766a-7687-49aa-b39e-b2d93d344a1b" xlink:to="loc_us-gaap_LongTermCommercialPaperCurrent_d8481601-e78f-40eb-9428-1f36fd8331a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7a42bf29-01e8-48df-9ba0-1be6a1e57c38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5fdb766a-7687-49aa-b39e-b2d93d344a1b" xlink:to="loc_us-gaap_LongTermDebtCurrent_7a42bf29-01e8-48df-9ba0-1be6a1e57c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_c80b8710-77e9-4343-ace1-f8df2e61c720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5fdb766a-7687-49aa-b39e-b2d93d344a1b" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_c80b8710-77e9-4343-ace1-f8df2e61c720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_13f44bdb-abe9-48e6-a63d-4b12ead1eb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5fdb766a-7687-49aa-b39e-b2d93d344a1b" xlink:to="loc_us-gaap_DebtInstrumentTerm_13f44bdb-abe9-48e6-a63d-4b12ead1eb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_602b2b36-c6f9-4f3f-955d-2a69ce2b00b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5fdb766a-7687-49aa-b39e-b2d93d344a1b" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_602b2b36-c6f9-4f3f-955d-2a69ce2b00b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1ef9b2ae-da5e-4cfb-aec5-78ae3a68b7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_602b2b36-c6f9-4f3f-955d-2a69ce2b00b6" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1ef9b2ae-da5e-4cfb-aec5-78ae3a68b7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_a1d0e64e-0a0a-4861-b1fc-2465505021e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1ef9b2ae-da5e-4cfb-aec5-78ae3a68b7d7" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_a1d0e64e-0a0a-4861-b1fc-2465505021e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8d632002-0eb4-4c91-927c-cbd4db668c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_a1d0e64e-0a0a-4861-b1fc-2465505021e1" xlink:to="loc_us-gaap_CommercialPaperMember_8d632002-0eb4-4c91-927c-cbd4db668c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_7635b8cb-6286-4445-99fd-0f0961e44b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_602b2b36-c6f9-4f3f-955d-2a69ce2b00b6" xlink:to="loc_us-gaap_ShortTermDebtLineItems_7635b8cb-6286-4445-99fd-0f0961e44b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_1b32f436-df61-44bb-ad16-be493a205251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7635b8cb-6286-4445-99fd-0f0961e44b56" xlink:to="loc_us-gaap_ShortTermBorrowings_1b32f436-df61-44bb-ad16-be493a205251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_91dc9046-7924-4937-982e-28d4da205a08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7635b8cb-6286-4445-99fd-0f0961e44b56" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_91dc9046-7924-4937-982e-28d4da205a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_a623a52b-ce9e-4e7d-81d2-a00a1cb07ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7635b8cb-6286-4445-99fd-0f0961e44b56" xlink:to="loc_us-gaap_DebtInstrumentTerm_a623a52b-ce9e-4e7d-81d2-a00a1cb07ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#BorrowingsAggregateMaturitiesofLongTermObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f769a2f5-02f4-4cd0-b164-fe64a30119b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_b0fa520d-6b19-4af4-8f0e-3f89d6fdbabe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f769a2f5-02f4-4cd0-b164-fe64a30119b0" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_b0fa520d-6b19-4af4-8f0e-3f89d6fdbabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_60f15246-38fc-4103-99ca-b86b1d319fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_b0fa520d-6b19-4af4-8f0e-3f89d6fdbabe" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_60f15246-38fc-4103-99ca-b86b1d319fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0ed172d3-6043-4366-a4a9-c62617e5e9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_b0fa520d-6b19-4af4-8f0e-3f89d6fdbabe" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0ed172d3-6043-4366-a4a9-c62617e5e9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_19425e2f-6235-4d65-8211-c7649883a507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_b0fa520d-6b19-4af4-8f0e-3f89d6fdbabe" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_19425e2f-6235-4d65-8211-c7649883a507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_704d4029-affe-4563-a1da-ccff0c14d653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_b0fa520d-6b19-4af4-8f0e-3f89d6fdbabe" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_704d4029-affe-4563-a1da-ccff0c14d653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_1b556e84-1af8-4cad-ba7c-c3ef42a50b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_b0fa520d-6b19-4af4-8f0e-3f89d6fdbabe" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_1b556e84-1af8-4cad-ba7c-c3ef42a50b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3a943e23-7b5a-46f8-be00-450ba1ec6075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_b0fa520d-6b19-4af4-8f0e-3f89d6fdbabe" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3a943e23-7b5a-46f8-be00-450ba1ec6075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxes" xlink:type="simple" xlink:href="jnj-20220102.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7004979a-b365-4100-9cdd-08848cd0eeef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_90ec674c-7b4c-471e-b5e4-ee69413a15fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7004979a-b365-4100-9cdd-08848cd0eeef" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_90ec674c-7b4c-471e-b5e4-ee69413a15fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="jnj-20220102.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bd691659-c697-42ea-81a6-8b5d2c1f9af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d4e70451-9b01-4cd6-ad5f-d49432476e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd691659-c697-42ea-81a6-8b5d2c1f9af8" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d4e70451-9b01-4cd6-ad5f-d49432476e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_6ea4fe6b-7515-4ced-ac96-cfe2e0d3094a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd691659-c697-42ea-81a6-8b5d2c1f9af8" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_6ea4fe6b-7515-4ced-ac96-cfe2e0d3094a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_52e6fc43-9100-4dc7-ad9f-ea4982d42191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd691659-c697-42ea-81a6-8b5d2c1f9af8" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_52e6fc43-9100-4dc7-ad9f-ea4982d42191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_bf9e5804-ea49-4d8f-aff0-781576c2431c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd691659-c697-42ea-81a6-8b5d2c1f9af8" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_bf9e5804-ea49-4d8f-aff0-781576c2431c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_45b6f2dd-61b0-44bf-9604-593d6fd98986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_fbdf4a33-6012-4a25-9eb7-3e974a931291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_45b6f2dd-61b0-44bf-9604-593d6fd98986" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_fbdf4a33-6012-4a25-9eb7-3e974a931291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_36d4b6b6-79e9-40d7-a7dd-d83d9c7f24ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_fbdf4a33-6012-4a25-9eb7-3e974a931291" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_36d4b6b6-79e9-40d7-a7dd-d83d9c7f24ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_33b921fd-94cd-4a3b-ad03-b7253cb20fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_fbdf4a33-6012-4a25-9eb7-3e974a931291" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_33b921fd-94cd-4a3b-ad03-b7253cb20fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_73027853-ef31-4e25-a939-d73c67973104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_fbdf4a33-6012-4a25-9eb7-3e974a931291" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_73027853-ef31-4e25-a939-d73c67973104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a44ef51b-eba5-46e2-865c-561e7ac7fd88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_45b6f2dd-61b0-44bf-9604-593d6fd98986" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a44ef51b-eba5-46e2-865c-561e7ac7fd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b56e7266-bb63-425b-a1d7-4c2843dbc9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a44ef51b-eba5-46e2-865c-561e7ac7fd88" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b56e7266-bb63-425b-a1d7-4c2843dbc9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_7f054f83-1799-418d-9791-d9925224b166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a44ef51b-eba5-46e2-865c-561e7ac7fd88" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_7f054f83-1799-418d-9791-d9925224b166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a8200aac-6e4c-44d3-8df9-678244855a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a44ef51b-eba5-46e2-865c-561e7ac7fd88" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a8200aac-6e4c-44d3-8df9-678244855a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_06246691-5b02-47b6-ab46-b00ba6ef1d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_45b6f2dd-61b0-44bf-9604-593d6fd98986" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_06246691-5b02-47b6-ab46-b00ba6ef1d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f1baf4dd-11a3-4e98-b98a-314961b93f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_3f57577d-346d-4afb-8bdd-f79e983d3a48" xlink:href="jnj-20220102.xsd#jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f1baf4dd-11a3-4e98-b98a-314961b93f36" xlink:to="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_3f57577d-346d-4afb-8bdd-f79e983d3a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_757dfd46-7f92-4f60-91ba-9670436b720c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_3f57577d-346d-4afb-8bdd-f79e983d3a48" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_757dfd46-7f92-4f60-91ba-9670436b720c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_fa00fb1b-cb6b-4660-813e-4608ad951cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_3f57577d-346d-4afb-8bdd-f79e983d3a48" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_fa00fb1b-cb6b-4660-813e-4608ad951cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_34030a8b-9d04-4636-9a54-e61246125089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_3f57577d-346d-4afb-8bdd-f79e983d3a48" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_34030a8b-9d04-4636-9a54-e61246125089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a2cbcce3-0fce-4076-9ccc-dd703f79b304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_3f57577d-346d-4afb-8bdd-f79e983d3a48" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a2cbcce3-0fce-4076-9ccc-dd703f79b304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2ba4d06f-af01-4905-ab4c-b945ee3b3378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a2cbcce3-0fce-4076-9ccc-dd703f79b304" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2ba4d06f-af01-4905-ab4c-b945ee3b3378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_e4be429d-3a05-4a84-a360-4da2606691fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a2cbcce3-0fce-4076-9ccc-dd703f79b304" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_e4be429d-3a05-4a84-a360-4da2606691fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_6c49d8cd-cb40-4ce4-a047-c93f7f31d669" xlink:href="jnj-20220102.xsd#jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a2cbcce3-0fce-4076-9ccc-dd703f79b304" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_6c49d8cd-cb40-4ce4-a047-c93f7f31d669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_f3d0e392-afa0-4514-8efa-b386cd51183e" xlink:href="jnj-20220102.xsd#jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a2cbcce3-0fce-4076-9ccc-dd703f79b304" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_f3d0e392-afa0-4514-8efa-b386cd51183e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_17a4e525-5b44-401d-a17b-06e1a4444fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a2cbcce3-0fce-4076-9ccc-dd703f79b304" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_17a4e525-5b44-401d-a17b-06e1a4444fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_09daa237-2e9f-45c2-90e8-cc693f4dace0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a2cbcce3-0fce-4076-9ccc-dd703f79b304" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_09daa237-2e9f-45c2-90e8-cc693f4dace0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_43200a6e-aaa6-436d-9768-1ac270506fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a2cbcce3-0fce-4076-9ccc-dd703f79b304" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_43200a6e-aaa6-436d-9768-1ac270506fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4f7fe57d-79dd-48f9-9e99-c991b8c4da38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a2cbcce3-0fce-4076-9ccc-dd703f79b304" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4f7fe57d-79dd-48f9-9e99-c991b8c4da38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1b470af6-2540-4e37-9965-0fb763aefd95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_1b99ae03-a893-40d0-8e4b-832d5f825b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1b470af6-2540-4e37-9965-0fb763aefd95" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_1b99ae03-a893-40d0-8e4b-832d5f825b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_6685cbe7-c7e6-4b2c-8797-538b6fb3ab86" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1b99ae03-a893-40d0-8e4b-832d5f825b78" xlink:to="loc_srt_LitigationCaseAxis_6685cbe7-c7e6-4b2c-8797-538b6fb3ab86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_3fcf819e-f2da-424a-810d-517d492751cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_6685cbe7-c7e6-4b2c-8797-538b6fb3ab86" xlink:to="loc_srt_LitigationCaseTypeDomain_3fcf819e-f2da-424a-810d-517d492751cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_15279079-8774-4048-a78d-e5939e19cef9" xlink:href="jnj-20220102.xsd#jnj_TalcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_3fcf819e-f2da-424a-810d-517d492751cd" xlink:to="loc_jnj_TalcMember_15279079-8774-4048-a78d-e5939e19cef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_950e1639-99ca-43df-a238-f9144cb34443" xlink:href="jnj-20220102.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_3fcf819e-f2da-424a-810d-517d492751cd" xlink:to="loc_jnj_RisperdalMember_950e1639-99ca-43df-a238-f9144cb34443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpiodsMember_e48dc568-0032-440c-b976-3383458e63fe" xlink:href="jnj-20220102.xsd#jnj_OpiodsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_3fcf819e-f2da-424a-810d-517d492751cd" xlink:to="loc_jnj_OpiodsMember_e48dc568-0032-440c-b976-3383458e63fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_38e153d0-17fd-4fd8-b786-621d9e767a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1b99ae03-a893-40d0-8e4b-832d5f825b78" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_38e153d0-17fd-4fd8-b786-621d9e767a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_560def66-ecb1-4ede-b671-b1f583f9ebcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_38e153d0-17fd-4fd8-b786-621d9e767a5f" xlink:to="loc_us-gaap_SegmentDomain_560def66-ecb1-4ede-b671-b1f583f9ebcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_27ec73f5-628d-4bff-8e8c-b669da235639" xlink:href="jnj-20220102.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_560def66-ecb1-4ede-b671-b1f583f9ebcd" xlink:to="loc_jnj_ConsumerMember_27ec73f5-628d-4bff-8e8c-b669da235639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_11a041b0-3608-4ba2-baf7-3bade6dc51bf" xlink:href="jnj-20220102.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_560def66-ecb1-4ede-b671-b1f583f9ebcd" xlink:to="loc_jnj_PharmaceuticalMember_11a041b0-3608-4ba2-baf7-3bade6dc51bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_899cc345-4ae7-4fb9-9e8a-a97ee56b04fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1b99ae03-a893-40d0-8e4b-832d5f825b78" xlink:to="loc_us-gaap_LitigationStatusAxis_899cc345-4ae7-4fb9-9e8a-a97ee56b04fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_057febda-5b22-45a5-8c29-7336d339bfbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_899cc345-4ae7-4fb9-9e8a-a97ee56b04fa" xlink:to="loc_us-gaap_LitigationStatusDomain_057febda-5b22-45a5-8c29-7336d339bfbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_9e96b377-3ab9-4fbc-8204-57f11b0b46c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_057febda-5b22-45a5-8c29-7336d339bfbf" xlink:to="loc_us-gaap_PendingLitigationMember_9e96b377-3ab9-4fbc-8204-57f11b0b46c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_93463bc3-286d-4b67-97e9-8cac45c08a40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1b99ae03-a893-40d0-8e4b-832d5f825b78" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_93463bc3-286d-4b67-97e9-8cac45c08a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_2ed07614-9f03-4138-87d7-51e77f9dc973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_93463bc3-286d-4b67-97e9-8cac45c08a40" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_2ed07614-9f03-4138-87d7-51e77f9dc973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_1e5dce04-dc9d-4c62-9a41-eed20ab6c986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_2ed07614-9f03-4138-87d7-51e77f9dc973" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_1e5dce04-dc9d-4c62-9a41-eed20ab6c986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c6e88849-6b5a-405d-9503-5f6fac4393d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1b99ae03-a893-40d0-8e4b-832d5f825b78" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c6e88849-6b5a-405d-9503-5f6fac4393d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6af69b7-5374-4643-b1b6-58a0d65774e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c6e88849-6b5a-405d-9503-5f6fac4393d9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6af69b7-5374-4643-b1b6-58a0d65774e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_d754c405-f96c-40cf-aaf4-d19b13479abf" xlink:href="jnj-20220102.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6af69b7-5374-4643-b1b6-58a0d65774e6" xlink:to="loc_jnj_AurisHealthMember_d754c405-f96c-40cf-aaf4-d19b13479abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_304a354f-6f56-439f-bb07-ee3e65e46e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1b99ae03-a893-40d0-8e4b-832d5f825b78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_304a354f-6f56-439f-bb07-ee3e65e46e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f6db525-aa97-4d9f-9d2b-c1729a4576be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_304a354f-6f56-439f-bb07-ee3e65e46e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f6db525-aa97-4d9f-9d2b-c1729a4576be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_fe76a65d-766f-4aa2-b082-26ac46384819" xlink:href="jnj-20220102.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f6db525-aa97-4d9f-9d2b-c1729a4576be" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_fe76a65d-766f-4aa2-b082-26ac46384819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_ed0734a6-26b6-43c3-83cf-d7a983b98466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1b99ae03-a893-40d0-8e4b-832d5f825b78" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_ed0734a6-26b6-43c3-83cf-d7a983b98466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_51139e74-c9a0-4bde-84d3-46d669cfa9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ed0734a6-26b6-43c3-83cf-d7a983b98466" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_51139e74-c9a0-4bde-84d3-46d669cfa9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f6f70008-3103-4429-89af-e2c3d4d306f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_51139e74-c9a0-4bde-84d3-46d669cfa9fc" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f6f70008-3103-4429-89af-e2c3d4d306f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1b99ae03-a893-40d0-8e4b-832d5f825b78" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_632fead9-63f7-4895-8f8f-09c296424f2d" xlink:href="jnj-20220102.xsd#jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_632fead9-63f7-4895-8f8f-09c296424f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_fea04f41-24c0-43dd-98fa-6a5db723613a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_fea04f41-24c0-43dd-98fa-6a5db723613a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_d3b70981-5ce5-43fa-831e-992d042629b1" xlink:href="jnj-20220102.xsd#jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_d3b70981-5ce5-43fa-831e-992d042629b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_7c091ff8-4e3c-4f32-b925-d9827c1a99c2" xlink:href="jnj-20220102.xsd#jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_7c091ff8-4e3c-4f32-b925-d9827c1a99c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_c84cee5e-b2be-41cc-b593-7d90d94316e0" xlink:href="jnj-20220102.xsd#jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_c84cee5e-b2be-41cc-b593-7d90d94316e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_1822ad17-13a9-47d6-8120-d5fbba5dc8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_LitigationSettlementExpense_1822ad17-13a9-47d6-8120-d5fbba5dc8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_693c16e5-32d4-430c-8c8a-253d25ab9714" xlink:href="jnj-20220102.xsd#jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_693c16e5-32d4-430c-8c8a-253d25ab9714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e83e26e3-9a72-450b-adcf-007e1f1f2303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e83e26e3-9a72-450b-adcf-007e1f1f2303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_d6b32ae6-385c-491d-8a44-b167adcb7cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_d6b32ae6-385c-491d-8a44-b167adcb7cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_c6906ce0-5ce9-4758-b3da-5e2e79045c19" xlink:href="jnj-20220102.xsd#jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_c6906ce0-5ce9-4758-b3da-5e2e79045c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_cd669a44-d9cb-4f71-bcb2-d70b43e95a0c" xlink:href="jnj-20220102.xsd#jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_cd669a44-d9cb-4f71-bcb2-d70b43e95a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_54c613be-ed56-4293-901a-f38285690d1e" xlink:href="jnj-20220102.xsd#jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_54c613be-ed56-4293-901a-f38285690d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_360101d5-61e4-4e5b-ba6e-685f143eb2f6" xlink:href="jnj-20220102.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_360101d5-61e4-4e5b-ba6e-685f143eb2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_5acee826-00db-405b-9193-89e9360aeed2" xlink:href="jnj-20220102.xsd#jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_5acee826-00db-405b-9193-89e9360aeed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_146685f7-c589-4888-a137-c326025c9739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_146685f7-c589-4888-a137-c326025c9739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent_ddf27dc0-00ce-4d02-a395-382b24d8a96c" xlink:href="jnj-20220102.xsd#jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent_ddf27dc0-00ce-4d02-a395-382b24d8a96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability_52cb3fa3-0f7c-4788-b19f-8bb9422fd740" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability_52cb3fa3-0f7c-4788-b19f-8bb9422fd740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset_0084e957-58c2-46c8-8988-e095e4900776" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset_0084e957-58c2-46c8-8988-e095e4900776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit_f520bee3-d754-4ef6-9e62-008101cfffb2" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit_f520bee3-d754-4ef6-9e62-008101cfffb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent_3c722055-06c9-4d71-be6f-8fd5042027e8" xlink:href="jnj-20220102.xsd#jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent_3c722055-06c9-4d71-be6f-8fd5042027e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_cbb53078-c7d0-4a38-b208-15b64f2f3f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_cbb53078-c7d0-4a38-b208-15b64f2f3f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent_3830412a-0a83-4952-9fc6-4a1df1710e2e" xlink:href="jnj-20220102.xsd#jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent_3830412a-0a83-4952-9fc6-4a1df1710e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset_eb53f995-717c-4262-b449-4a2ad7759a75" xlink:href="jnj-20220102.xsd#jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset_eb53f995-717c-4262-b449-4a2ad7759a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_fc914607-a0dc-45f6-b8fe-b66c36d31ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_fc914607-a0dc-45f6-b8fe-b66c36d31ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent_d0638ba0-f696-43bc-bfcb-1a48649f6471" xlink:href="jnj-20220102.xsd#jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent_d0638ba0-f696-43bc-bfcb-1a48649f6471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_5239159f-9d05-49aa-a01f-ceb4350442cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_5239159f-9d05-49aa-a01f-ceb4350442cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment_2c19a98a-f530-41ae-a061-8d46ada025d5" xlink:href="jnj-20220102.xsd#jnj_UnrecognizedTaxBenefitLiabilityPayment"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment_2c19a98a-f530-41ae-a061-8d46ada025d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_03bfda43-a55a-46bd-b62c-b6318b7b9a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_03bfda43-a55a-46bd-b62c-b6318b7b9a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_8a5d5f5e-9e24-40bf-bf74-37761a8329df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_eab5f742-1177-4a44-ad29-ab7f00bef782" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_8a5d5f5e-9e24-40bf-bf74-37761a8329df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0c378cd6-ebb8-4e5c-9f80-91ac7f9cb55f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_66d7f9d1-c83e-455d-9a53-b0eb96b861ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0c378cd6-ebb8-4e5c-9f80-91ac7f9cb55f" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_66d7f9d1-c83e-455d-9a53-b0eb96b861ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_10a0bd1e-e93a-4053-99a5-de0b1388f87d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_66d7f9d1-c83e-455d-9a53-b0eb96b861ee" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_10a0bd1e-e93a-4053-99a5-de0b1388f87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_d0587e6b-bf8c-41cf-b8d9-ca119d3164cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10a0bd1e-e93a-4053-99a5-de0b1388f87d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_d0587e6b-bf8c-41cf-b8d9-ca119d3164cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_fdc7cc78-401e-47c1-9354-997388aceeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10a0bd1e-e93a-4053-99a5-de0b1388f87d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_fdc7cc78-401e-47c1-9354-997388aceeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_2bb6a741-854c-458b-85d5-68f105d9022f" xlink:href="jnj-20220102.xsd#jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10a0bd1e-e93a-4053-99a5-de0b1388f87d" xlink:to="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_2bb6a741-854c-458b-85d5-68f105d9022f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_7cb7ee84-6034-4950-a1a6-94df7753f227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10a0bd1e-e93a-4053-99a5-de0b1388f87d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_7cb7ee84-6034-4950-a1a6-94df7753f227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_dd98b8fd-ee48-4c88-9d7b-6f74d1feaf61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10a0bd1e-e93a-4053-99a5-de0b1388f87d" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_dd98b8fd-ee48-4c88-9d7b-6f74d1feaf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_2358746c-8d91-488a-bbdf-00d035cacf4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10a0bd1e-e93a-4053-99a5-de0b1388f87d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_2358746c-8d91-488a-bbdf-00d035cacf4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings_8f66ce70-f473-460c-8517-724faa75b59e" xlink:href="jnj-20220102.xsd#jnj_DeferredTaxAssetsUndistributedForeignEarnings"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10a0bd1e-e93a-4053-99a5-de0b1388f87d" xlink:to="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings_8f66ce70-f473-460c-8517-724faa75b59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_2ac2a535-0ff8-4734-a810-feaa69d4f97f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10a0bd1e-e93a-4053-99a5-de0b1388f87d" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_2ac2a535-0ff8-4734-a810-feaa69d4f97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsOtherDomestic_f860a39a-b3a3-4731-8d75-c2611071e573" xlink:href="jnj-20220102.xsd#jnj_DeferredTaxAssetsOtherDomestic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10a0bd1e-e93a-4053-99a5-de0b1388f87d" xlink:to="loc_jnj_DeferredTaxAssetsOtherDomestic_f860a39a-b3a3-4731-8d75-c2611071e573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_cb1980ca-a3ed-4a6d-91f3-1f2f7623f7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_10a0bd1e-e93a-4053-99a5-de0b1388f87d" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_cb1980ca-a3ed-4a6d-91f3-1f2f7623f7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_eba868cb-79ef-4034-acef-65cdcb65b416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_66d7f9d1-c83e-455d-9a53-b0eb96b861ee" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_eba868cb-79ef-4034-acef-65cdcb65b416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_543a1e78-3382-43c1-89d9-6efe4ab890ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_eba868cb-79ef-4034-acef-65cdcb65b416" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_543a1e78-3382-43c1-89d9-6efe4ab890ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_8fc341d7-ab69-4f6d-816c-f907fa37e8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_eba868cb-79ef-4034-acef-65cdcb65b416" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_8fc341d7-ab69-4f6d-816c-f907fa37e8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_5cb7c935-0a35-4088-890e-53e84be385c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_eba868cb-79ef-4034-acef-65cdcb65b416" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_5cb7c935-0a35-4088-890e-53e84be385c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_dac10cb1-197c-4ffa-b4f2-008c9fe46ff7" xlink:href="jnj-20220102.xsd#jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_eba868cb-79ef-4034-acef-65cdcb65b416" xlink:to="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_dac10cb1-197c-4ffa-b4f2-008c9fe46ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_b49c4893-d9a5-4a3a-ab2f-7ce3c295ecb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_eba868cb-79ef-4034-acef-65cdcb65b416" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_b49c4893-d9a5-4a3a-ab2f-7ce3c295ecb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilitiesOtherDomestic_0689b357-fbdd-4750-94aa-399c267e4691" xlink:href="jnj-20220102.xsd#jnj_DeferredTaxLiabilitiesOtherDomestic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_eba868cb-79ef-4034-acef-65cdcb65b416" xlink:to="loc_jnj_DeferredTaxLiabilitiesOtherDomestic_0689b357-fbdd-4750-94aa-399c267e4691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_6a97aeb0-5660-430f-8e48-054b2f0bbe53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_eba868cb-79ef-4034-acef-65cdcb65b416" xlink:to="loc_us-gaap_DeferredTaxLiabilities_6a97aeb0-5660-430f-8e48-054b2f0bbe53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_22fd08e0-028c-4725-b320-a5874919bb2e" xlink:href="jnj-20220102.xsd#jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_66d7f9d1-c83e-455d-9a53-b0eb96b861ee" xlink:to="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_22fd08e0-028c-4725-b320-a5874919bb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_136b1732-9e81-4dc6-9079-78eb228f3a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_34f8f977-d6a4-439f-b75e-81a12352093a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_136b1732-9e81-4dc6-9079-78eb228f3a04" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_34f8f977-d6a4-439f-b75e-81a12352093a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_644d28ef-3859-408e-8842-8a27674d94dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_34f8f977-d6a4-439f-b75e-81a12352093a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_644d28ef-3859-408e-8842-8a27674d94dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c8851542-87ee-4b2e-bce6-d53561e23cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_34f8f977-d6a4-439f-b75e-81a12352093a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c8851542-87ee-4b2e-bce6-d53561e23cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_90f0be7c-f92b-4b07-8405-f1b0eab56208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_34f8f977-d6a4-439f-b75e-81a12352093a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_90f0be7c-f92b-4b07-8405-f1b0eab56208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_5ae3a7ac-0fb1-42f5-8f53-c7df11d803d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_34f8f977-d6a4-439f-b75e-81a12352093a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_5ae3a7ac-0fb1-42f5-8f53-c7df11d803d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_6b64f460-857a-4fb7-bcce-97c0d1c740c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_34f8f977-d6a4-439f-b75e-81a12352093a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_6b64f460-857a-4fb7-bcce-97c0d1c740c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_514e991c-2b20-4926-9585-0802381677cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_34f8f977-d6a4-439f-b75e-81a12352093a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_514e991c-2b20-4926-9585-0802381677cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_75c6b299-8e0c-40e6-a3ed-dfb2dad4c220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_34f8f977-d6a4-439f-b75e-81a12352093a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_75c6b299-8e0c-40e6-a3ed-dfb2dad4c220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligations" xlink:type="simple" xlink:href="jnj-20220102.xsd#EmployeeRelatedObligations"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_0ee39f7a-ba08-4707-9e95-4e5f23ddd1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsGeneralTextBlock_bb2650d7-bdc4-4eb0-9d5c-a6671468a6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_0ee39f7a-ba08-4707-9e95-4e5f23ddd1fb" xlink:to="loc_us-gaap_CompensationRelatedCostsGeneralTextBlock_bb2650d7-bdc4-4eb0-9d5c-a6671468a6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsTables" xlink:type="simple" xlink:href="jnj-20220102.xsd#EmployeeRelatedObligationsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_11256995-a63c-4cd5-b3cb-72ce0efc8430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeRelatedObligationsTableTextBlock_9cb92c7a-9dc4-4979-b08b-06e7dbf79460" xlink:href="jnj-20220102.xsd#jnj_EmployeeRelatedObligationsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_11256995-a63c-4cd5-b3cb-72ce0efc8430" xlink:to="loc_jnj_EmployeeRelatedObligationsTableTextBlock_9cb92c7a-9dc4-4979-b08b-06e7dbf79460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_0c2bd265-ed3f-404c-9c4d-d5b589ce4fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_b3d6d6c1-79c5-481b-a195-a666d39ae12f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_0c2bd265-ed3f-404c-9c4d-d5b589ce4fe2" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_b3d6d6c1-79c5-481b-a195-a666d39ae12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_d2086c77-fe4c-4837-8201-f53e512e0b64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_b3d6d6c1-79c5-481b-a195-a666d39ae12f" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_d2086c77-fe4c-4837-8201-f53e512e0b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_aa80c51f-1417-4631-b502-cece15d4a995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_b3d6d6c1-79c5-481b-a195-a666d39ae12f" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_aa80c51f-1417-4631-b502-cece15d4a995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_47a2e2b4-b491-47a5-9214-f454d66ea884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_b3d6d6c1-79c5-481b-a195-a666d39ae12f" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_47a2e2b4-b491-47a5-9214-f454d66ea884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_53393fd3-bc0a-4fdc-88ed-9de83a0cdf4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_b3d6d6c1-79c5-481b-a195-a666d39ae12f" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_53393fd3-bc0a-4fdc-88ed-9de83a0cdf4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeObligations_11a41361-973b-4ee2-b44a-140d8e05077a" xlink:href="jnj-20220102.xsd#jnj_EmployeeObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_b3d6d6c1-79c5-481b-a195-a666d39ae12f" xlink:to="loc_jnj_EmployeeObligations_11a41361-973b-4ee2-b44a-140d8e05077a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_49e8d660-7f70-4093-9161-dc87c971b521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_b3d6d6c1-79c5-481b-a195-a666d39ae12f" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_49e8d660-7f70-4093-9161-dc87c971b521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_bc2727ff-b415-4e26-a832-7cab85f0c68c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_b3d6d6c1-79c5-481b-a195-a666d39ae12f" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_bc2727ff-b415-4e26-a832-7cab85f0c68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1" xlink:type="simple" xlink:href="jnj-20220102.xsd#EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#EmployeeRelatedObligationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_e5dabde5-7e6c-46c7-bc77-4dc740104eac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_f8941ece-5522-4f86-b5c9-36483f7125d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_e5dabde5-7e6c-46c7-bc77-4dc740104eac" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_f8941ece-5522-4f86-b5c9-36483f7125d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bc90076d-a4bb-4a5e-a4e9-49813f07de6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_768f5ea8-6602-4306-bc28-514cc14bfa6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bc90076d-a4bb-4a5e-a4e9-49813f07de6e" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_768f5ea8-6602-4306-bc28-514cc14bfa6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_efb946f8-d104-4bba-a135-42b3da687c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_ffd3ffff-a3da-4ba7-8fc7-35d768371a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_efb946f8-d104-4bba-a135-42b3da687c3d" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_ffd3ffff-a3da-4ba7-8fc7-35d768371a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_9697c669-02a9-4f42-97a2-3ccd71bc1c60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_efb946f8-d104-4bba-a135-42b3da687c3d" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_9697c669-02a9-4f42-97a2-3ccd71bc1c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_379b5c45-6102-409e-9024-6ed550238796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_efb946f8-d104-4bba-a135-42b3da687c3d" xlink:to="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_379b5c45-6102-409e-9024-6ed550238796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_5f327e60-a763-4b77-8e63-1dd99ae1d941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetFundedStatusTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_efb946f8-d104-4bba-a135-42b3da687c3d" xlink:to="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_5f327e60-a763-4b77-8e63-1dd99ae1d941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_86e90b8f-14d9-408c-a958-9cf3d68d28a5" xlink:href="jnj-20220102.xsd#jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_efb946f8-d104-4bba-a135-42b3da687c3d" xlink:to="loc_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_86e90b8f-14d9-408c-a958-9cf3d68d28a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_3d870196-13f7-4185-9867-ff18c920b461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_efb946f8-d104-4bba-a135-42b3da687c3d" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_3d870196-13f7-4185-9867-ff18c920b461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_34591a32-776a-4ac3-bfeb-c3713d972f81" xlink:href="jnj-20220102.xsd#jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_efb946f8-d104-4bba-a135-42b3da687c3d" xlink:to="loc_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_34591a32-776a-4ac3-bfeb-c3713d972f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_8f96ae34-816b-4c83-a003-c78c353f3d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_efb946f8-d104-4bba-a135-42b3da687c3d" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_8f96ae34-816b-4c83-a003-c78c353f3d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_522d5590-f508-4581-b5d3-b973cf27e8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_efb946f8-d104-4bba-a135-42b3da687c3d" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_522d5590-f508-4581-b5d3-b973cf27e8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_769f0229-7a70-4d4b-a639-0a991ecb2d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0682614c-de72-49d0-88a7-c451aabf08de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_769f0229-7a70-4d4b-a639-0a991ecb2d17" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0682614c-de72-49d0-88a7-c451aabf08de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c50d4e57-b9cf-4b19-a6d8-39543ae2eada" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0682614c-de72-49d0-88a7-c451aabf08de" xlink:to="loc_srt_RangeAxis_c50d4e57-b9cf-4b19-a6d8-39543ae2eada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d5895047-3a6f-44e5-a152-32fa6be7a398" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c50d4e57-b9cf-4b19-a6d8-39543ae2eada" xlink:to="loc_srt_RangeMember_d5895047-3a6f-44e5-a152-32fa6be7a398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fb7cac5f-a806-485b-b6fa-d6f75abc8b73" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d5895047-3a6f-44e5-a152-32fa6be7a398" xlink:to="loc_srt_MaximumMember_fb7cac5f-a806-485b-b6fa-d6f75abc8b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d2b0ca93-b3c1-4cb4-b9c0-7ba81a6e20eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0682614c-de72-49d0-88a7-c451aabf08de" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d2b0ca93-b3c1-4cb4-b9c0-7ba81a6e20eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_ccdb8580-c00d-41a6-b94d-1659cef6f0db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d2b0ca93-b3c1-4cb4-b9c0-7ba81a6e20eb" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_ccdb8580-c00d-41a6-b94d-1659cef6f0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember_1f06899a-f5e1-4c62-be43-08eeaef8a23c" xlink:href="jnj-20220102.xsd#jnj_CommingledFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ccdb8580-c00d-41a6-b94d-1659cef6f0db" xlink:to="loc_jnj_CommingledFundsMember_1f06899a-f5e1-4c62-be43-08eeaef8a23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b4b74733-fdfc-495f-9cc1-a606edd55a43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0682614c-de72-49d0-88a7-c451aabf08de" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b4b74733-fdfc-495f-9cc1-a606edd55a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0b8e9003-c424-4a25-8b64-6d332c2de1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b4b74733-fdfc-495f-9cc1-a606edd55a43" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0b8e9003-c424-4a25-8b64-6d332c2de1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5d688907-d789-40fe-bcde-ca880ca147cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0b8e9003-c424-4a25-8b64-6d332c2de1c6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5d688907-d789-40fe-bcde-ca880ca147cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_f6870790-1c09-4cc6-9f01-914fd939af6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0682614c-de72-49d0-88a7-c451aabf08de" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_f6870790-1c09-4cc6-9f01-914fd939af6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_6b991303-f6dd-4a96-b8c0-3fae32ba28bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f6870790-1c09-4cc6-9f01-914fd939af6a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_6b991303-f6dd-4a96-b8c0-3fae32ba28bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_3ed6cee9-21e8-468d-9b91-5e4e2a6dab1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6b991303-f6dd-4a96-b8c0-3fae32ba28bf" xlink:to="loc_us-gaap_DomesticPlanMember_3ed6cee9-21e8-468d-9b91-5e4e2a6dab1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3a82cba7-28c3-4c76-b661-428e6998c721" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_3ed6cee9-21e8-468d-9b91-5e4e2a6dab1f" xlink:to="loc_country_US_3a82cba7-28c3-4c76-b661-428e6998c721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_9e2668a9-dedb-4dbf-bc23-27ec660000b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6b991303-f6dd-4a96-b8c0-3fae32ba28bf" xlink:to="loc_us-gaap_ForeignPlanMember_9e2668a9-dedb-4dbf-bc23-27ec660000b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_562235c8-5e4e-442f-ac32-9ae19dfcc21a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0682614c-de72-49d0-88a7-c451aabf08de" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_562235c8-5e4e-442f-ac32-9ae19dfcc21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8bdd295b-62eb-45b7-9a2f-5214bbed27ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_562235c8-5e4e-442f-ac32-9ae19dfcc21a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8bdd295b-62eb-45b7-9a2f-5214bbed27ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_3d87b228-6bca-45f6-8f10-a7c4e1a647a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8bdd295b-62eb-45b7-9a2f-5214bbed27ef" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_3d87b228-6bca-45f6-8f10-a7c4e1a647a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0533ba34-a909-47e6-82b4-fd018c0d573e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8bdd295b-62eb-45b7-9a2f-5214bbed27ef" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0533ba34-a909-47e6-82b4-fd018c0d573e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0682614c-de72-49d0-88a7-c451aabf08de" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeCompensationPeriod_b69640aa-cf98-4317-ae86-c3908f717e90" xlink:href="jnj-20220102.xsd#jnj_EmployeeCompensationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_jnj_EmployeeCompensationPeriod_b69640aa-cf98-4317-ae86-c3908f717e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_7f3ea1a2-9cdc-4ea8-a196-078975741a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_7f3ea1a2-9cdc-4ea8-a196-078975741a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_dc061b0b-8f36-4856-b0d5-e8695fdf2ede" xlink:href="jnj-20220102.xsd#jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_dc061b0b-8f36-4856-b0d5-e8695fdf2ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_64d64a95-f386-4100-b251-5d05a97977cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionContributions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_us-gaap_PensionContributions_64d64a95-f386-4100-b251-5d05a97977cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_25680176-4240-408d-a649-80593db3762a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_25680176-4240-408d-a649-80593db3762a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_e35dd13f-6485-40d0-ad90-f49fdcb3b1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_e35dd13f-6485-40d0-ad90-f49fdcb3b1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_38b0524d-7b34-41ba-bae4-55dd17165641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_38b0524d-7b34-41ba-bae4-55dd17165641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_d4ea3fb3-ce55-4a77-a773-0908494d347f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_d4ea3fb3-ce55-4a77-a773-0908494d347f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_06226fc2-4733-4b8e-bfbb-54856ffc64ee" xlink:href="jnj-20220102.xsd#jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_06226fc2-4733-4b8e-bfbb-54856ffc64ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCompanysCommonStockToPlanAsset_cb499293-674d-4396-a22b-4a482cf07bf6" xlink:href="jnj-20220102.xsd#jnj_PercentageOfCompanysCommonStockToPlanAsset"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5a6ebfb7-2a5d-48a6-b85d-074f36ca99a4" xlink:to="loc_jnj_PercentageOfCompanysCommonStockToPlanAsset_cb499293-674d-4396-a22b-4a482cf07bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5b02e380-ab11-4a5a-8e40-61dc3d5a7c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7a63bf23-85cf-4530-8de7-51c2e518ce50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5b02e380-ab11-4a5a-8e40-61dc3d5a7c5e" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7a63bf23-85cf-4530-8de7-51c2e518ce50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_61c81836-da07-425c-8b09-9ab9a493438f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7a63bf23-85cf-4530-8de7-51c2e518ce50" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_61c81836-da07-425c-8b09-9ab9a493438f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8b4a2a6b-441b-4877-b536-56e2515714c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_61c81836-da07-425c-8b09-9ab9a493438f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8b4a2a6b-441b-4877-b536-56e2515714c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_2f615b41-92f4-4290-96b7-dec1ddbe0556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8b4a2a6b-441b-4877-b536-56e2515714c0" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_2f615b41-92f4-4290-96b7-dec1ddbe0556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_84fb42a0-47c4-472b-82d3-995e0c5bbc19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8b4a2a6b-441b-4877-b536-56e2515714c0" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_84fb42a0-47c4-472b-82d3-995e0c5bbc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b71b186-f70b-42bf-9ace-0f9f09d12dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7a63bf23-85cf-4530-8de7-51c2e518ce50" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b71b186-f70b-42bf-9ace-0f9f09d12dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_493e781e-0f38-4103-b651-8e7c4985b422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b71b186-f70b-42bf-9ace-0f9f09d12dc8" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_493e781e-0f38-4103-b651-8e7c4985b422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_86bb80d3-a440-423d-8daf-d71d3b8387bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b71b186-f70b-42bf-9ace-0f9f09d12dc8" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_86bb80d3-a440-423d-8daf-d71d3b8387bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_9b6f6b5c-d6d6-497a-aff4-8463dacfd8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b71b186-f70b-42bf-9ace-0f9f09d12dc8" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_9b6f6b5c-d6d6-497a-aff4-8463dacfd8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_40104f49-a886-42bd-a2c4-9894e4d3b7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b71b186-f70b-42bf-9ace-0f9f09d12dc8" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_40104f49-a886-42bd-a2c4-9894e4d3b7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_e51fe7c6-133c-44ab-90e2-7605f68ecb77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b71b186-f70b-42bf-9ace-0f9f09d12dc8" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_e51fe7c6-133c-44ab-90e2-7605f68ecb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_b7f16320-27a4-4af3-93da-310bea563a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b71b186-f70b-42bf-9ace-0f9f09d12dc8" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_b7f16320-27a4-4af3-93da-310bea563a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_259a3f30-23d0-4dae-8b8e-736f9ffd35cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b71b186-f70b-42bf-9ace-0f9f09d12dc8" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_259a3f30-23d0-4dae-8b8e-736f9ffd35cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c89ee549-65d3-4b69-9aa7-8991afe459c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7c0e4566-1f03-4585-9c64-f7eb1c62907f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c89ee549-65d3-4b69-9aa7-8991afe459c9" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7c0e4566-1f03-4585-9c64-f7eb1c62907f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_0771ce81-1d8f-442d-ad74-52d9fa958cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7c0e4566-1f03-4585-9c64-f7eb1c62907f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_0771ce81-1d8f-442d-ad74-52d9fa958cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2966ee9f-84e8-40c0-9bb6-d8f5f7360667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_0771ce81-1d8f-442d-ad74-52d9fa958cb3" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2966ee9f-84e8-40c0-9bb6-d8f5f7360667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_7f61ce93-0f94-46fb-9393-229b7c20dde8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2966ee9f-84e8-40c0-9bb6-d8f5f7360667" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_7f61ce93-0f94-46fb-9393-229b7c20dde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_744bcc60-35a9-48c1-a319-107c248f5d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2966ee9f-84e8-40c0-9bb6-d8f5f7360667" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_744bcc60-35a9-48c1-a319-107c248f5d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ec2826aa-dbb7-4671-b248-7bf680e5a894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7c0e4566-1f03-4585-9c64-f7eb1c62907f" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ec2826aa-dbb7-4671-b248-7bf680e5a894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_ffab0d71-4277-4076-b6a1-78fa22179ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ec2826aa-dbb7-4671-b248-7bf680e5a894" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_ffab0d71-4277-4076-b6a1-78fa22179ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_1505030d-2688-4daf-89b3-656a04983c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_ffab0d71-4277-4076-b6a1-78fa22179ec2" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_1505030d-2688-4daf-89b3-656a04983c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_c195be78-bec9-4c82-9249-7ac39bd44052" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_ffab0d71-4277-4076-b6a1-78fa22179ec2" xlink:to="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_c195be78-bec9-4c82-9249-7ac39bd44052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_484a5a93-31e3-4cce-bf3c-944c67dd182b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_ffab0d71-4277-4076-b6a1-78fa22179ec2" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_484a5a93-31e3-4cce-bf3c-944c67dd182b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_362d4f86-e575-48ec-b204-89f464799df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_ffab0d71-4277-4076-b6a1-78fa22179ec2" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_362d4f86-e575-48ec-b204-89f464799df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_51d64dca-5a6b-4cfa-9f18-7f7aec79c402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ec2826aa-dbb7-4671-b248-7bf680e5a894" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_51d64dca-5a6b-4cfa-9f18-7f7aec79c402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_8f505918-add7-4e3a-89fb-3942d1e6b9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_51d64dca-5a6b-4cfa-9f18-7f7aec79c402" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_8f505918-add7-4e3a-89fb-3942d1e6b9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_ba79e350-125f-40a8-a0f6-9a897f146ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_51d64dca-5a6b-4cfa-9f18-7f7aec79c402" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_ba79e350-125f-40a8-a0f6-9a897f146ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2f140842-7e31-4570-80bb-65eb08adfd24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_5ec10dad-0f3b-48fb-bc58-9b0787ccda28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2f140842-7e31-4570-80bb-65eb08adfd24" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_5ec10dad-0f3b-48fb-bc58-9b0787ccda28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_b8e54011-ec77-4afd-919b-a69d1f60cc51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_5ec10dad-0f3b-48fb-bc58-9b0787ccda28" xlink:to="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_b8e54011-ec77-4afd-919b-a69d1f60cc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_2e2c9f4e-7eab-40b3-828a-2434f75c02bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_5ec10dad-0f3b-48fb-bc58-9b0787ccda28" xlink:to="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_2e2c9f4e-7eab-40b3-828a-2434f75c02bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_ddaf43b8-5205-4a1d-b251-9dcca162aaae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_5ec10dad-0f3b-48fb-bc58-9b0787ccda28" xlink:to="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_ddaf43b8-5205-4a1d-b251-9dcca162aaae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e166f2d4-f73a-4653-bfa7-f7869f4f50d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1658aef3-ed33-429c-8a45-d763451fb80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e166f2d4-f73a-4653-bfa7-f7869f4f50d4" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1658aef3-ed33-429c-8a45-d763451fb80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_61cf5a41-705f-4f02-b1db-5b0a5a049665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1658aef3-ed33-429c-8a45-d763451fb80f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_61cf5a41-705f-4f02-b1db-5b0a5a049665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_bb8dfce8-9b60-4466-beee-b54b0844028e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_61cf5a41-705f-4f02-b1db-5b0a5a049665" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_bb8dfce8-9b60-4466-beee-b54b0844028e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_76bca262-1656-443b-827e-e0790ffb568f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_bb8dfce8-9b60-4466-beee-b54b0844028e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_76bca262-1656-443b-827e-e0790ffb568f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4761826b-c9df-4a49-989c-3032ef93d64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_bb8dfce8-9b60-4466-beee-b54b0844028e" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4761826b-c9df-4a49-989c-3032ef93d64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f5584753-20e7-45f8-975a-7ccb83872ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1658aef3-ed33-429c-8a45-d763451fb80f" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f5584753-20e7-45f8-975a-7ccb83872ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f5584753-20e7-45f8-975a-7ccb83872ffa" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_740f2e7d-e3eb-47f0-8042-ce3bef6c121d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_740f2e7d-e3eb-47f0-8042-ce3bef6c121d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_027dddd5-5668-4367-9c77-a7a9c4f1f4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_027dddd5-5668-4367-9c77-a7a9c4f1f4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_b96ac309-dae0-42fd-8996-b4a46a08d28d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_b96ac309-dae0-42fd-8996-b4a46a08d28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_c19441fc-7a77-47b1-8f14-158f2cc6f294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_c19441fc-7a77-47b1-8f14-158f2cc6f294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_317c6873-1d0b-4fa1-934f-29e5cc0600b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_317c6873-1d0b-4fa1-934f-29e5cc0600b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_e9b9ead2-7f02-4063-a50f-4e10afafda89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_e9b9ead2-7f02-4063-a50f-4e10afafda89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_46f52ae7-4f1b-4c3e-946e-59efbd0c7ba6" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_46f52ae7-4f1b-4c3e-946e-59efbd0c7ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CurtailmentsAndSettlementsAndRestructuring_faeba6a3-dab9-4b62-8901-55c448de01b5" xlink:href="jnj-20220102.xsd#jnj_CurtailmentsAndSettlementsAndRestructuring"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_jnj_CurtailmentsAndSettlementsAndRestructuring_faeba6a3-dab9-4b62-8901-55c448de01b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_dc83c867-c115-42a2-9bd9-9734f99a9453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_dc83c867-c115-42a2-9bd9-9734f99a9453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_c4239b9f-0343-43ef-af30-f6b9ead1133d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_c4239b9f-0343-43ef-af30-f6b9ead1133d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_a14edc3f-3d77-49d2-bc6d-6424e067a6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e231be05-1257-4847-8007-5469c0477b4d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_a14edc3f-3d77-49d2-bc6d-6424e067a6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f5584753-20e7-45f8-975a-7ccb83872ffa" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_509ddaf6-d42d-442a-bf57-c53d26d72a74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_509ddaf6-d42d-442a-bf57-c53d26d72a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_9825fbea-0c77-49af-be56-4233a532e7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_9825fbea-0c77-49af-be56-4233a532e7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_939d1747-4267-4ebe-9437-ddb1758aaaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_939d1747-4267-4ebe-9437-ddb1758aaaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_dab48414-dd22-4fcc-a6c5-4ff2ef55c0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_dab48414-dd22-4fcc-a6c5-4ff2ef55c0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_20f9fcc3-4d3a-4cc9-bf09-caa986da34d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_20f9fcc3-4d3a-4cc9-bf09-caa986da34d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_b0049907-3a54-4a5b-9333-2981a2999a48" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:to="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_b0049907-3a54-4a5b-9333-2981a2999a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_0ecf9ada-d3de-4a61-902f-164bd603f9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_0ecf9ada-d3de-4a61-902f-164bd603f9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_d38c9998-eb21-47d3-9a12-432beb6a8f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_d38c9998-eb21-47d3-9a12-432beb6a8f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_a9d5381b-d09f-41d6-ad79-7bed768b735e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_a9d5381b-d09f-41d6-ad79-7bed768b735e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_63b68dd8-8b04-4cc6-a5bb-654e2e752db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ab833e00-fc56-4a82-b8a0-4c1c7a287e5c" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_63b68dd8-8b04-4cc6-a5bb-654e2e752db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_964f564d-1a0e-4f0d-bf5b-a2872e510835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f5584753-20e7-45f8-975a-7ccb83872ffa" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_964f564d-1a0e-4f0d-bf5b-a2872e510835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_3e43d347-55e4-4a82-bd6c-71b55014edb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_964f564d-1a0e-4f0d-bf5b-a2872e510835" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_3e43d347-55e4-4a82-bd6c-71b55014edb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_0f02b61d-d210-4a0a-858e-8c77ba954b93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_964f564d-1a0e-4f0d-bf5b-a2872e510835" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_0f02b61d-d210-4a0a-858e-8c77ba954b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3d333a83-d1c4-426f-83cf-10f09e3581a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_964f564d-1a0e-4f0d-bf5b-a2872e510835" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3d333a83-d1c4-426f-83cf-10f09e3581a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_4252707b-00ff-48d8-9d6b-14ab0466d47a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_964f564d-1a0e-4f0d-bf5b-a2872e510835" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_4252707b-00ff-48d8-9d6b-14ab0466d47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_e3f2e5ec-3459-42dd-8665-97cd27188bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f5584753-20e7-45f8-975a-7ccb83872ffa" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_e3f2e5ec-3459-42dd-8665-97cd27188bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_91b6e22e-1104-448d-ac8f-3052ce2e1761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_e3f2e5ec-3459-42dd-8665-97cd27188bf1" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_91b6e22e-1104-448d-ac8f-3052ce2e1761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_b216ed99-9ad7-4f70-812e-f024012a372f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_e3f2e5ec-3459-42dd-8665-97cd27188bf1" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_b216ed99-9ad7-4f70-812e-f024012a372f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_cbfb289e-4d40-4fbe-9c40-1121ea362775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_e3f2e5ec-3459-42dd-8665-97cd27188bf1" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_cbfb289e-4d40-4fbe-9c40-1121ea362775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_ab06c72a-38dc-483b-b83a-bb4a0a8df8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_e3f2e5ec-3459-42dd-8665-97cd27188bf1" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_ab06c72a-38dc-483b-b83a-bb4a0a8df8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_6160ed18-d8fe-452a-90fa-fb4fb8a7ae6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_e3f2e5ec-3459-42dd-8665-97cd27188bf1" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_6160ed18-d8fe-452a-90fa-fb4fb8a7ae6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_bc90e7c5-03d8-4264-8918-d8f676b61912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionContributions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_e3f2e5ec-3459-42dd-8665-97cd27188bf1" xlink:to="loc_us-gaap_PensionContributions_bc90e7c5-03d8-4264-8918-d8f676b61912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f5584753-20e7-45f8-975a-7ccb83872ffa" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8b226e5e-27b8-436b-bf57-698aa2ae2446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8b226e5e-27b8-436b-bf57-698aa2ae2446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_189b2554-c9cb-4ef8-b3f5-22d16ee709b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_189b2554-c9cb-4ef8-b3f5-22d16ee709b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_4a3c6834-0103-4cb8-a830-1843383e8f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_4a3c6834-0103-4cb8-a830-1843383e8f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_c75cf074-06ae-451d-a36c-6623881cd7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_c75cf074-06ae-451d-a36c-6623881cd7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_43ac39a4-d928-44c2-a82f-09ef3afc6ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_43ac39a4-d928-44c2-a82f-09ef3afc6ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectOfExchangeRates_a1fde505-e125-404e-b081-d0032f4c7dea" xlink:href="jnj-20220102.xsd#jnj_EffectOfExchangeRates"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:to="loc_jnj_EffectOfExchangeRates_a1fde505-e125-404e-b081-d0032f4c7dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_247b2e8c-84db-4cf3-bd79-20d742d682bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_247b2e8c-84db-4cf3-bd79-20d742d682bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_37cf02d1-ef18-4f0e-a4d2-f07c9f7e8aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_98f062d4-ae0d-4723-9f8d-08690fd30ff7" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_37cf02d1-ef18-4f0e-a4d2-f07c9f7e8aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4ee96edb-ccb4-48cd-9d66-8f48ba69f61e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f13bc819-98cc-4815-9506-c8afe552bf36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4ee96edb-ccb4-48cd-9d66-8f48ba69f61e" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f13bc819-98cc-4815-9506-c8afe552bf36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d36a6e81-fda2-4a98-8170-85257899efe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f13bc819-98cc-4815-9506-c8afe552bf36" xlink:to="loc_us-gaap_PlanNameAxis_d36a6e81-fda2-4a98-8170-85257899efe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1cb391ce-12ae-4137-81ec-85f2ba2d1b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d36a6e81-fda2-4a98-8170-85257899efe4" xlink:to="loc_us-gaap_PlanNameDomain_1cb391ce-12ae-4137-81ec-85f2ba2d1b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_QualifiedPlansMember_1f9c021b-13e6-4737-9b82-6b888c3cc39d" xlink:href="jnj-20220102.xsd#jnj_QualifiedPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1cb391ce-12ae-4137-81ec-85f2ba2d1b42" xlink:to="loc_jnj_QualifiedPlansMember_1f9c021b-13e6-4737-9b82-6b888c3cc39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonQualifiedPlansMember_7c797302-ea24-4465-9e12-cf0416e19750" xlink:href="jnj-20220102.xsd#jnj_NonQualifiedPlansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1cb391ce-12ae-4137-81ec-85f2ba2d1b42" xlink:to="loc_jnj_NonQualifiedPlansMember_7c797302-ea24-4465-9e12-cf0416e19750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FundedPlansMember_2e667bf7-f91e-4408-a628-27aaa0c2d22e" xlink:href="jnj-20220102.xsd#jnj_FundedPlansMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1cb391ce-12ae-4137-81ec-85f2ba2d1b42" xlink:to="loc_jnj_FundedPlansMember_2e667bf7-f91e-4408-a628-27aaa0c2d22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnfundedPlansMember_2ce4ef06-d7fa-4cfe-afcd-cef4049a83c0" xlink:href="jnj-20220102.xsd#jnj_UnfundedPlansMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1cb391ce-12ae-4137-81ec-85f2ba2d1b42" xlink:to="loc_jnj_UnfundedPlansMember_2ce4ef06-d7fa-4cfe-afcd-cef4049a83c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_4a241f8c-7971-424c-a15c-d162effd8cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f13bc819-98cc-4815-9506-c8afe552bf36" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_4a241f8c-7971-424c-a15c-d162effd8cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_d693c5dc-ec5f-44d3-be68-9087d4a89995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_4a241f8c-7971-424c-a15c-d162effd8cfb" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_d693c5dc-ec5f-44d3-be68-9087d4a89995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_c9c10b62-b34b-4155-907a-831b792962e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_d693c5dc-ec5f-44d3-be68-9087d4a89995" xlink:to="loc_us-gaap_DomesticPlanMember_c9c10b62-b34b-4155-907a-831b792962e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_abccec6b-5711-4e96-b6a9-b7f551f2c08b" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_c9c10b62-b34b-4155-907a-831b792962e9" xlink:to="loc_country_US_abccec6b-5711-4e96-b6a9-b7f551f2c08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_d12ed96a-f6ad-45b4-90c5-b7f84d056192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_d693c5dc-ec5f-44d3-be68-9087d4a89995" xlink:to="loc_us-gaap_ForeignPlanMember_d12ed96a-f6ad-45b4-90c5-b7f84d056192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_97b49c39-c366-4d02-a6db-ba37c372df18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f13bc819-98cc-4815-9506-c8afe552bf36" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_97b49c39-c366-4d02-a6db-ba37c372df18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e1ee5abd-930e-4838-a383-f295e3d61bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_97b49c39-c366-4d02-a6db-ba37c372df18" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e1ee5abd-930e-4838-a383-f295e3d61bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5f72a2db-1cae-479e-b8db-f8bf9d1bb9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_97b49c39-c366-4d02-a6db-ba37c372df18" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5f72a2db-1cae-479e-b8db-f8bf9d1bb9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_a2f4dee9-e1eb-426c-8e94-ae74f313fbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_97b49c39-c366-4d02-a6db-ba37c372df18" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_a2f4dee9-e1eb-426c-8e94-ae74f313fbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_e4c57dab-72b6-4cdf-b88c-26f7c8cc0f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_97b49c39-c366-4d02-a6db-ba37c372df18" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_e4c57dab-72b6-4cdf-b88c-26f7c8cc0f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_ea1d7ca6-26dc-4115-8daf-ab0456fc2ac0" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanOverUnderFundedStatusABO"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_97b49c39-c366-4d02-a6db-ba37c372df18" xlink:to="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_ea1d7ca6-26dc-4115-8daf-ab0456fc2ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7a7568fa-5d85-43e1-8143-6773825f4f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7151a771-2d7c-4be4-a6b4-b0ba4da4e456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7a7568fa-5d85-43e1-8143-6773825f4f01" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7151a771-2d7c-4be4-a6b4-b0ba4da4e456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_de8a9a36-d12d-4661-87f4-46beed3a517a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7151a771-2d7c-4be4-a6b4-b0ba4da4e456" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_de8a9a36-d12d-4661-87f4-46beed3a517a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7d4fe1e7-7063-4d67-ab08-8e2e02bccc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_de8a9a36-d12d-4661-87f4-46beed3a517a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7d4fe1e7-7063-4d67-ab08-8e2e02bccc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_9279acea-af10-4d51-a4c4-ab84842d991a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_7d4fe1e7-7063-4d67-ab08-8e2e02bccc1c" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_9279acea-af10-4d51-a4c4-ab84842d991a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_ebcf1212-0213-4da7-9dca-af8cf1d6b4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_7d4fe1e7-7063-4d67-ab08-8e2e02bccc1c" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_ebcf1212-0213-4da7-9dca-af8cf1d6b4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b0ca8e7d-026a-4535-a46d-48b8a1e02a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7151a771-2d7c-4be4-a6b4-b0ba4da4e456" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b0ca8e7d-026a-4535-a46d-48b8a1e02a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_38eb4cb2-48c6-4b2f-beeb-bc96c66f1686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b0ca8e7d-026a-4535-a46d-48b8a1e02a52" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_38eb4cb2-48c6-4b2f-beeb-bc96c66f1686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_00047b34-c12d-4825-a80b-e36a4152047b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b0ca8e7d-026a-4535-a46d-48b8a1e02a52" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_00047b34-c12d-4825-a80b-e36a4152047b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_bb9b5531-ac7b-4e10-b664-931d7f3fea02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b0ca8e7d-026a-4535-a46d-48b8a1e02a52" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_bb9b5531-ac7b-4e10-b664-931d7f3fea02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_f3443a4e-c540-4948-97ec-d097c3e8aac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b0ca8e7d-026a-4535-a46d-48b8a1e02a52" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_f3443a4e-c540-4948-97ec-d097c3e8aac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_ce5240a6-5431-4711-8d0c-105697c86603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b0ca8e7d-026a-4535-a46d-48b8a1e02a52" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_ce5240a6-5431-4711-8d0c-105697c86603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_249dc01c-d53a-471b-a82a-8d5244f4fee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b0ca8e7d-026a-4535-a46d-48b8a1e02a52" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_249dc01c-d53a-471b-a82a-8d5244f4fee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_eaf54585-87c4-4837-91be-d38e6db38745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_ade71adc-4ac5-44fe-a5a7-066eb325e8dc" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_eaf54585-87c4-4837-91be-d38e6db38745" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_ade71adc-4ac5-44fe-a5a7-066eb325e8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_9a45d87c-c1f6-48e6-be0d-8623089d980b" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_eaf54585-87c4-4837-91be-d38e6db38745" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_9a45d87c-c1f6-48e6-be0d-8623089d980b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_c153ddc2-7d83-4ee4-964d-b99e53bd24d6" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_eaf54585-87c4-4837-91be-d38e6db38745" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_c153ddc2-7d83-4ee4-964d-b99e53bd24d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_19dcc6b0-eafb-489e-a18d-f27c7ee6fecc" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_eaf54585-87c4-4837-91be-d38e6db38745" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_19dcc6b0-eafb-489e-a18d-f27c7ee6fecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_800f8582-49a3-40cc-ac60-693693c6afc6" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_eaf54585-87c4-4837-91be-d38e6db38745" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_800f8582-49a3-40cc-ac60-693693c6afc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_345d156d-089f-4925-b00f-bc319fd6a56e" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_eaf54585-87c4-4837-91be-d38e6db38745" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_345d156d-089f-4925-b00f-bc319fd6a56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b4fb16ce-c6eb-4ba7-bfa7-f040e852d9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0e9a9f34-8e00-4ddd-9456-73de7755674b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b4fb16ce-c6eb-4ba7-bfa7-f040e852d9c1" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0e9a9f34-8e00-4ddd-9456-73de7755674b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_89cd64e6-b723-4181-817c-26d8de07da74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0e9a9f34-8e00-4ddd-9456-73de7755674b" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_89cd64e6-b723-4181-817c-26d8de07da74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_f4f10bd6-7257-4f7e-8644-e7040e5aa821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_89cd64e6-b723-4181-817c-26d8de07da74" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_f4f10bd6-7257-4f7e-8644-e7040e5aa821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_02eb8dcd-bdcc-4770-840f-faac63c02d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f10bd6-7257-4f7e-8644-e7040e5aa821" xlink:to="loc_us-gaap_EquitySecuritiesMember_02eb8dcd-bdcc-4770-840f-faac63c02d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_c43560e4-16b8-48c2-ad46-56aa873e3a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f10bd6-7257-4f7e-8644-e7040e5aa821" xlink:to="loc_us-gaap_DebtSecuritiesMember_c43560e4-16b8-48c2-ad46-56aa873e3a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ce873a6e-8a84-48bf-8fc5-ff24b697dc70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0e9a9f34-8e00-4ddd-9456-73de7755674b" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ce873a6e-8a84-48bf-8fc5-ff24b697dc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_f5468745-7ac3-4fe6-872d-d8928c216be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ce873a6e-8a84-48bf-8fc5-ff24b697dc70" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_f5468745-7ac3-4fe6-872d-d8928c216be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_cef1e93c-b966-4731-96dd-ab0eb1b3f3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ce873a6e-8a84-48bf-8fc5-ff24b697dc70" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_cef1e93c-b966-4731-96dd-ab0eb1b3f3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_50f59ff1-2285-4bf9-be8c-367701519023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_079d9d57-1ef2-482c-a17f-07d9a0e4bc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_50f59ff1-2285-4bf9-be8c-367701519023" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_079d9d57-1ef2-482c-a17f-07d9a0e4bc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd694abb-d340-4103-902b-9560ca47e0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_079d9d57-1ef2-482c-a17f-07d9a0e4bc6e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd694abb-d340-4103-902b-9560ca47e0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ddea0521-7823-43d5-90b4-6a9915d7286d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd694abb-d340-4103-902b-9560ca47e0ed" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ddea0521-7823-43d5-90b4-6a9915d7286d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cfa482bd-055c-47ad-9485-64aa3200fd94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ddea0521-7823-43d5-90b4-6a9915d7286d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cfa482bd-055c-47ad-9485-64aa3200fd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_ebb41ada-f956-4054-ab48-a5bfe27cbfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_079d9d57-1ef2-482c-a17f-07d9a0e4bc6e" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_ebb41ada-f956-4054-ab48-a5bfe27cbfc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8ad4b0d9-e4f3-487a-b85c-3e5485e44f81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ebb41ada-f956-4054-ab48-a5bfe27cbfc5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8ad4b0d9-e4f3-487a-b85c-3e5485e44f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_bc10b2b4-f1e7-4857-be1c-1c41254ee53e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8ad4b0d9-e4f3-487a-b85c-3e5485e44f81" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_bc10b2b4-f1e7-4857-be1c-1c41254ee53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_468adf7a-9a16-43e5-9a2b-29ddc2756d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_079d9d57-1ef2-482c-a17f-07d9a0e4bc6e" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_468adf7a-9a16-43e5-9a2b-29ddc2756d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_8f13563d-2280-4855-9528-53dc3344179c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_468adf7a-9a16-43e5-9a2b-29ddc2756d3e" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_8f13563d-2280-4855-9528-53dc3344179c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShortTermInvestmentFundsMember_97bf597f-53e6-4c08-ac03-35f601356bcc" xlink:href="jnj-20220102.xsd#jnj_ShortTermInvestmentFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8f13563d-2280-4855-9528-53dc3344179c" xlink:to="loc_jnj_ShortTermInvestmentFundsMember_97bf597f-53e6-4c08-ac03-35f601356bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_ce02f9e2-29d7-4b11-86de-8a4586124b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8f13563d-2280-4855-9528-53dc3344179c" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_ce02f9e2-29d7-4b11-86de-8a4586124b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_d4fd9da5-ef50-4374-a0e4-667fb8ebca70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8f13563d-2280-4855-9528-53dc3344179c" xlink:to="loc_us-gaap_DebtSecuritiesMember_d4fd9da5-ef50-4374-a0e4-667fb8ebca70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_270ff53a-2219-42a0-bcd1-8e47d68fc104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8f13563d-2280-4855-9528-53dc3344179c" xlink:to="loc_us-gaap_EquitySecuritiesMember_270ff53a-2219-42a0-bcd1-8e47d68fc104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember_61c165c3-593a-4dac-82ce-0ca45ec1c422" xlink:href="jnj-20220102.xsd#jnj_CommingledFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8f13563d-2280-4855-9528-53dc3344179c" xlink:to="loc_jnj_CommingledFundsMember_61c165c3-593a-4dac-82ce-0ca45ec1c422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_ed78cd60-59dc-456f-882c-418e6b21ba7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8f13563d-2280-4855-9528-53dc3344179c" xlink:to="loc_us-gaap_OtherAssetsMember_ed78cd60-59dc-456f-882c-418e6b21ba7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fb46a2f0-9250-4262-8145-b36def95b76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_079d9d57-1ef2-482c-a17f-07d9a0e4bc6e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fb46a2f0-9250-4262-8145-b36def95b76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_084fa4b6-1bbe-4218-b7c2-79d2dfd062ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fb46a2f0-9250-4262-8145-b36def95b76b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_084fa4b6-1bbe-4218-b7c2-79d2dfd062ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1927d959-1497-4833-8df1-eb5fe73bdce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_084fa4b6-1bbe-4218-b7c2-79d2dfd062ee" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1927d959-1497-4833-8df1-eb5fe73bdce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_feabcf9b-2ae7-4e01-b31d-20e7013fa453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_084fa4b6-1bbe-4218-b7c2-79d2dfd062ee" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_feabcf9b-2ae7-4e01-b31d-20e7013fa453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_48f21684-6fd7-4126-8fec-190dfb019fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_084fa4b6-1bbe-4218-b7c2-79d2dfd062ee" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_48f21684-6fd7-4126-8fec-190dfb019fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_df9564d7-0398-430d-a715-f0af4a381805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_079d9d57-1ef2-482c-a17f-07d9a0e4bc6e" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_df9564d7-0398-430d-a715-f0af4a381805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e69a89ae-cb6e-4ef6-b75f-b37adb886550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_df9564d7-0398-430d-a715-f0af4a381805" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e69a89ae-cb6e-4ef6-b75f-b37adb886550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_1b81b8da-6228-4047-80b4-bdbaf169682b" xlink:href="jnj-20220102.xsd#jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_df9564d7-0398-430d-a715-f0af4a381805" xlink:to="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_1b81b8da-6228-4047-80b4-bdbaf169682b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SavingsPlan" xlink:type="simple" xlink:href="jnj-20220102.xsd#SavingsPlan"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SavingsPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanAbstract_6e609d82-43a8-4e49-9d45-4184668ca4e3" xlink:href="jnj-20220102.xsd#jnj_SavingsPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanTextBlock_6294af52-9054-47a7-a071-3aa9c931660b" xlink:href="jnj-20220102.xsd#jnj_SavingsPlanTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_SavingsPlanAbstract_6e609d82-43a8-4e49-9d45-4184668ca4e3" xlink:to="loc_jnj_SavingsPlanTextBlock_6294af52-9054-47a7-a071-3aa9c931660b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SavingsPlanNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#SavingsPlanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SavingsPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanAbstract_763ed888-5f19-473f-8cd0-196890f0de96" xlink:href="jnj-20220102.xsd#jnj_SavingsPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_fbbfb657-266c-49e0-ba41-04cba0f6cd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_SavingsPlanAbstract_763ed888-5f19-473f-8cd0-196890f0de96" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_fbbfb657-266c-49e0-ba41-04cba0f6cd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStock" xlink:type="simple" xlink:href="jnj-20220102.xsd#CapitalandTreasuryStock"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_25ace5dc-29c4-449d-81ee-8292b4b1a6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock_3765cbc8-fa04-4715-af7f-45c5bc3a51fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_25ace5dc-29c4-449d-81ee-8292b4b1a6f9" xlink:to="loc_us-gaap_TreasuryStockTextBlock_3765cbc8-fa04-4715-af7f-45c5bc3a51fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStockTables" xlink:type="simple" xlink:href="jnj-20220102.xsd#CapitalandTreasuryStockTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6790a932-1de6-4ac6-a280-64b7b7008b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockTableTextBlock_8d257d08-48ab-4c73-a16c-a3aaf0e9df7a" xlink:href="jnj-20220102.xsd#jnj_ChangesInTreasuryStockTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6790a932-1de6-4ac6-a280-64b7b7008b32" xlink:to="loc_jnj_ChangesInTreasuryStockTableTextBlock_8d257d08-48ab-4c73-a16c-a3aaf0e9df7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#CapitalandTreasuryStockChangesinTreasuryStockDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fa4f564e-2b1c-4adb-a614-ff0011735dba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_fbccf097-61d1-4181-a24f-60b99ce0ea29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fa4f564e-2b1c-4adb-a614-ff0011735dba" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_fbccf097-61d1-4181-a24f-60b99ce0ea29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d285773b-9198-4ab4-938c-1cf2bd0dd6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_fbccf097-61d1-4181-a24f-60b99ce0ea29" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d285773b-9198-4ab4-938c-1cf2bd0dd6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6b1925ae-2fa8-42d4-ac90-52f5995faa42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d285773b-9198-4ab4-938c-1cf2bd0dd6f8" xlink:to="loc_us-gaap_EquityComponentDomain_6b1925ae-2fa8-42d4-ac90-52f5995faa42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_69cc47c1-bd1d-47e5-a0ec-916af545258a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6b1925ae-2fa8-42d4-ac90-52f5995faa42" xlink:to="loc_us-gaap_TreasuryStockMember_69cc47c1-bd1d-47e5-a0ec-916af545258a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9b85989d-a52f-46b7-b664-78b0a8aaa514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_fbccf097-61d1-4181-a24f-60b99ce0ea29" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9b85989d-a52f-46b7-b664-78b0a8aaa514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e2ffb7be-3daf-46e2-abff-629c6f45856c" xlink:href="jnj-20220102.xsd#jnj_ChangesinTreasuryStockSharesOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9b85989d-a52f-46b7-b664-78b0a8aaa514" xlink:to="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e2ffb7be-3daf-46e2-abff-629c6f45856c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_11462bcf-d496-45a3-88ee-3d3078d7083c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e2ffb7be-3daf-46e2-abff-629c6f45856c" xlink:to="loc_us-gaap_TreasuryStockShares_11462bcf-d496-45a3-88ee-3d3078d7083c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_7333c102-fa42-490c-90d1-bc2d8e9cb1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e2ffb7be-3daf-46e2-abff-629c6f45856c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_7333c102-fa42-490c-90d1-bc2d8e9cb1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_3ec8b268-c665-4d0f-ba9f-273c6de74931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e2ffb7be-3daf-46e2-abff-629c6f45856c" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_3ec8b268-c665-4d0f-ba9f-273c6de74931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_f5367d98-7db1-4c32-a3f6-359795f3ea01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_e2ffb7be-3daf-46e2-abff-629c6f45856c" xlink:to="loc_us-gaap_TreasuryStockShares_f5367d98-7db1-4c32-a3f6-359795f3ea01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockRollForward_fe489b4c-ef8f-480f-9545-fe51d81614b8" xlink:href="jnj-20220102.xsd#jnj_ChangesInTreasuryStockRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9b85989d-a52f-46b7-b664-78b0a8aaa514" xlink:to="loc_jnj_ChangesInTreasuryStockRollForward_fe489b4c-ef8f-480f-9545-fe51d81614b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_89f92cdb-da26-426a-b0b0-a69f7d5c048f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_fe489b4c-ef8f-480f-9545-fe51d81614b8" xlink:to="loc_us-gaap_TreasuryStockValue_89f92cdb-da26-426a-b0b0-a69f7d5c048f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_82a8c3d9-a31a-4540-bed6-fee19ffc6528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_fe489b4c-ef8f-480f-9545-fe51d81614b8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_82a8c3d9-a31a-4540-bed6-fee19ffc6528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c4e03f1c-dd8d-4bc3-9b8c-ae1717a821fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_fe489b4c-ef8f-480f-9545-fe51d81614b8" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c4e03f1c-dd8d-4bc3-9b8c-ae1717a821fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_f5ea8278-0306-4c4a-93e0-d3b64cf35530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_fe489b4c-ef8f-480f-9545-fe51d81614b8" xlink:to="loc_us-gaap_TreasuryStockValue_f5ea8278-0306-4c4a-93e0-d3b64cf35530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#CapitalandTreasuryStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_13f0f62d-56cb-4af2-81f5-97ea9c3ba011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_360871e0-86cd-4bb6-baac-3697af48aba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_13f0f62d-56cb-4af2-81f5-97ea9c3ba011" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_360871e0-86cd-4bb6-baac-3697af48aba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_fb8ddf3b-e4ec-4223-8e27-3af8024587f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_360871e0-86cd-4bb6-baac-3697af48aba9" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_fb8ddf3b-e4ec-4223-8e27-3af8024587f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_df62eda4-75b5-4713-8046-13dd2172a10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_fb8ddf3b-e4ec-4223-8e27-3af8024587f7" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_df62eda4-75b5-4713-8046-13dd2172a10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_December172018ShareRepurchaseProgramMember_d9371433-b265-4ef0-a334-82ab4ba45bda" xlink:href="jnj-20220102.xsd#jnj_December172018ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_df62eda4-75b5-4713-8046-13dd2172a10a" xlink:to="loc_jnj_December172018ShareRepurchaseProgramMember_d9371433-b265-4ef0-a334-82ab4ba45bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a662fd8b-559f-4389-9a00-bfcfe1e6d3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_360871e0-86cd-4bb6-baac-3697af48aba9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a662fd8b-559f-4389-9a00-bfcfe1e6d3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d2af6935-743b-48b5-86a8-808b9f8c23bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a662fd8b-559f-4389-9a00-bfcfe1e6d3d8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d2af6935-743b-48b5-86a8-808b9f8c23bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_fad2cb43-4522-44c0-ad67-0a2cc9eb59a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d2af6935-743b-48b5-86a8-808b9f8c23bd" xlink:to="loc_us-gaap_SubsequentEventMember_fad2cb43-4522-44c0-ad67-0a2cc9eb59a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b12cb2b3-11bd-4299-a4ab-5f4fcc02ae14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_360871e0-86cd-4bb6-baac-3697af48aba9" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b12cb2b3-11bd-4299-a4ab-5f4fcc02ae14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d07eaed6-48fa-4d7f-8cea-d22aa9639c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b12cb2b3-11bd-4299-a4ab-5f4fcc02ae14" xlink:to="loc_us-gaap_CommonStockSharesIssued_d07eaed6-48fa-4d7f-8cea-d22aa9639c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_ca987faf-6383-4501-acb0-c47ce9a00769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b12cb2b3-11bd-4299-a4ab-5f4fcc02ae14" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_ca987faf-6383-4501-acb0-c47ce9a00769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1e171d83-1800-45a3-a78f-050d7bfecaba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b12cb2b3-11bd-4299-a4ab-5f4fcc02ae14" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1e171d83-1800-45a3-a78f-050d7bfecaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_512ca25a-58f3-4175-b745-d413269a48b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b12cb2b3-11bd-4299-a4ab-5f4fcc02ae14" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_512ca25a-58f3-4175-b745-d413269a48b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="jnj-20220102.xsd#AccumulatedOtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6f62ec59-0178-4d2f-abea-66d9fdb1b54f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_59801d87-7f03-4f73-a63d-5c089e776306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6f62ec59-0178-4d2f-abea-66d9fdb1b54f" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_59801d87-7f03-4f73-a63d-5c089e776306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="jnj-20220102.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4988abfc-b17d-4bbe-a296-5dd563a3788c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e1ff564a-eeb1-4c18-987d-c1ac978a5756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4988abfc-b17d-4bbe-a296-5dd563a3788c" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e1ff564a-eeb1-4c18-987d-c1ac978a5756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_95b353cf-14b9-4c9a-ae44-0e4a28dfcae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_631f1d92-7c18-4f38-aee2-59f26438bf64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_95b353cf-14b9-4c9a-ae44-0e4a28dfcae7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_631f1d92-7c18-4f38-aee2-59f26438bf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7e128e51-8229-440f-8544-242e56500fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_631f1d92-7c18-4f38-aee2-59f26438bf64" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7e128e51-8229-440f-8544-242e56500fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0d20e35a-3cb7-4ca1-831a-e1f931d8030b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7e128e51-8229-440f-8544-242e56500fd0" xlink:to="loc_us-gaap_EquityComponentDomain_0d20e35a-3cb7-4ca1-831a-e1f931d8030b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_e72383d0-f049-40e4-bd6d-af750478e805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0d20e35a-3cb7-4ca1-831a-e1f931d8030b" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_e72383d0-f049-40e4-bd6d-af750478e805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8f696e51-db72-49e3-803b-8e0f08e0ae75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0d20e35a-3cb7-4ca1-831a-e1f931d8030b" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8f696e51-db72-49e3-803b-8e0f08e0ae75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b2a64f6e-7a30-42fc-9a14-629be59f4426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0d20e35a-3cb7-4ca1-831a-e1f931d8030b" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b2a64f6e-7a30-42fc-9a14-629be59f4426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_91d581f7-f4f0-4179-a00b-2c6ef5a15957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0d20e35a-3cb7-4ca1-831a-e1f931d8030b" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_91d581f7-f4f0-4179-a00b-2c6ef5a15957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3aac60fd-6d06-4897-9aa0-06a5ae8388a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0d20e35a-3cb7-4ca1-831a-e1f931d8030b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3aac60fd-6d06-4897-9aa0-06a5ae8388a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e8da221-90dd-48f1-a0f2-456708cd217c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_631f1d92-7c18-4f38-aee2-59f26438bf64" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e8da221-90dd-48f1-a0f2-456708cd217c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_25d102e3-a73a-4058-b23b-cd8a6b0861bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e8da221-90dd-48f1-a0f2-456708cd217c" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_25d102e3-a73a-4058-b23b-cd8a6b0861bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1256680f-e37f-4260-8014-66846000ce5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_25d102e3-a73a-4058-b23b-cd8a6b0861bc" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1256680f-e37f-4260-8014-66846000ce5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e2b5ea38-6e0c-4a41-8867-bcb7fa245e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_25d102e3-a73a-4058-b23b-cd8a6b0861bc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e2b5ea38-6e0c-4a41-8867-bcb7fa245e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aa515e75-a4a4-4e8a-8837-691df01aa08b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_25d102e3-a73a-4058-b23b-cd8a6b0861bc" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aa515e75-a4a4-4e8a-8837-691df01aa08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InternationalCurrencyTranslation" xlink:type="simple" xlink:href="jnj-20220102.xsd#InternationalCurrencyTranslation"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InternationalCurrencyTranslation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTranslationAbstract_370751fd-ef31-4153-8bb6-5cd14f18e708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTranslationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDisclosureTextBlock_6d92b886-929f-4bb1-900a-61b86776a7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCurrencyTranslationAbstract_370751fd-ef31-4153-8bb6-5cd14f18e708" xlink:to="loc_us-gaap_ForeignCurrencyDisclosureTextBlock_6d92b886-929f-4bb1-900a-61b86776a7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#InternationalCurrencyTranslationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTranslationAbstract_61cc1f91-a910-45ae-971c-586cb66bfcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTranslationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_55908a12-4dd7-4715-a919-0c78a65b372c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCurrencyTranslationAbstract_61cc1f91-a910-45ae-971c-586cb66bfcf9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_55908a12-4dd7-4715-a919-0c78a65b372c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShare" xlink:type="simple" xlink:href="jnj-20220102.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_196fc570-4e6a-4e77-a061-8afd6dab6dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_ee2a3b53-4884-409e-8e06-f319dc9f252c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_196fc570-4e6a-4e77-a061-8afd6dab6dd2" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_ee2a3b53-4884-409e-8e06-f319dc9f252c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="jnj-20220102.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_30823166-4887-4ea0-98f2-3b64dbd0f6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5bc26b72-69fe-40e6-b976-0aff08d8a797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_30823166-4887-4ea0-98f2-3b64dbd0f6ca" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5bc26b72-69fe-40e6-b976-0aff08d8a797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3cd7b226-d312-42c4-9ac6-f0d53d682dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_c4576c62-f8c3-45cc-ac63-a8462eca472c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3cd7b226-d312-42c4-9ac6-f0d53d682dfd" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_c4576c62-f8c3-45cc-ac63-a8462eca472c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1b93292e-48cc-4ca9-b8c2-f0f51a4be1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_c4576c62-f8c3-45cc-ac63-a8462eca472c" xlink:to="loc_us-gaap_EarningsPerShareBasic_1b93292e-48cc-4ca9-b8c2-f0f51a4be1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_40bacc3f-9a42-4b98-b46f-434c6e0170bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_c4576c62-f8c3-45cc-ac63-a8462eca472c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_40bacc3f-9a42-4b98-b46f-434c6e0170bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PotentialSharesExercisableUnderStockOptionPlans_f572b327-ee19-4c6b-8968-5a28c5a10d85" xlink:href="jnj-20220102.xsd#jnj_PotentialSharesExercisableUnderStockOptionPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_c4576c62-f8c3-45cc-ac63-a8462eca472c" xlink:to="loc_jnj_PotentialSharesExercisableUnderStockOptionPlans_f572b327-ee19-4c6b-8968-5a28c5a10d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_223c1dab-9708-49aa-93ed-af6394056c94" xlink:href="jnj-20220102.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_c4576c62-f8c3-45cc-ac63-a8462eca472c" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_223c1dab-9708-49aa-93ed-af6394056c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_dc22d22b-2780-4401-94f1-ebfa1eab84ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_c4576c62-f8c3-45cc-ac63-a8462eca472c" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_dc22d22b-2780-4401-94f1-ebfa1eab84ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5a237bd9-fdc3-4fcf-baa1-c1d78263b8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_c4576c62-f8c3-45cc-ac63-a8462eca472c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5a237bd9-fdc3-4fcf-baa1-c1d78263b8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_964dfbf8-aab3-4717-b8df-28ece8c1d05b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_c4576c62-f8c3-45cc-ac63-a8462eca472c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_964dfbf8-aab3-4717-b8df-28ece8c1d05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#EarningsPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a1d14f3a-0de2-4352-93a8-8e43eb7cb5df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2220b4b1-c7fb-45e6-a25c-f2b8edf1b91f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a1d14f3a-0de2-4352-93a8-8e43eb7cb5df" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2220b4b1-c7fb-45e6-a25c-f2b8edf1b91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_a059af65-8f97-42c2-8580-c05d143fd3db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a1d14f3a-0de2-4352-93a8-8e43eb7cb5df" xlink:to="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_a059af65-8f97-42c2-8580-c05d143fd3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements" xlink:type="simple" xlink:href="jnj-20220102.xsd#CommonStockStockOptionPlansandStockCompensationAgreements"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b3760a8-2a65-42ff-b6a4-65ffdb95c60d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2140d595-7f60-4186-91b6-536870621090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b3760a8-2a65-42ff-b6a4-65ffdb95c60d" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2140d595-7f60-4186-91b6-536870621090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables" xlink:type="simple" xlink:href="jnj-20220102.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25852546-8d11-4fea-91ea-e850bbf6cb75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c44d6a9a-1845-42dc-bf2d-a0b11de0400b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25852546-8d11-4fea-91ea-e850bbf6cb75" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c44d6a9a-1845-42dc-bf2d-a0b11de0400b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6b3bdedc-8a2a-4762-a34e-3cd139b0b017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25852546-8d11-4fea-91ea-e850bbf6cb75" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6b3bdedc-8a2a-4762-a34e-3cd139b0b017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_9d25a813-9eda-41e9-b246-f3036990bd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25852546-8d11-4fea-91ea-e850bbf6cb75" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_9d25a813-9eda-41e9-b246-f3036990bd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_18108102-3943-4171-88e7-98d192e43ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25852546-8d11-4fea-91ea-e850bbf6cb75" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_18108102-3943-4171-88e7-98d192e43ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9042a16-3441-4573-9d87-f432ca714d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5a779d0-45fe-4626-8f21-88f73d0258ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9042a16-3441-4573-9d87-f432ca714d84" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5a779d0-45fe-4626-8f21-88f73d0258ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_e7927db6-7f9e-4af6-bc99-c4613656ae68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5a779d0-45fe-4626-8f21-88f73d0258ba" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_e7927db6-7f9e-4af6-bc99-c4613656ae68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_651c4d57-3868-45f7-9d2c-de4aa1218ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_e7927db6-7f9e-4af6-bc99-c4613656ae68" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_651c4d57-3868-45f7-9d2c-de4aa1218ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2012LongTermIncentivePlanMember_19feef8a-ddcf-4114-a50f-76170a33d391" xlink:href="jnj-20220102.xsd#jnj_A2012LongTermIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_651c4d57-3868-45f7-9d2c-de4aa1218ca0" xlink:to="loc_jnj_A2012LongTermIncentivePlanMember_19feef8a-ddcf-4114-a50f-76170a33d391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_598bb284-225d-42d7-8679-00b29a3bcbe7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5a779d0-45fe-4626-8f21-88f73d0258ba" xlink:to="loc_srt_RangeAxis_598bb284-225d-42d7-8679-00b29a3bcbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5fb3d636-be4f-464c-9976-32cc3bfaa7e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_598bb284-225d-42d7-8679-00b29a3bcbe7" xlink:to="loc_srt_RangeMember_5fb3d636-be4f-464c-9976-32cc3bfaa7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9ed7836d-2cd7-425a-b0ea-70352a9868db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5fb3d636-be4f-464c-9976-32cc3bfaa7e4" xlink:to="loc_srt_MinimumMember_9ed7836d-2cd7-425a-b0ea-70352a9868db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_408735e5-8136-4fba-a9f5-74024721d240" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5fb3d636-be4f-464c-9976-32cc3bfaa7e4" xlink:to="loc_srt_MaximumMember_408735e5-8136-4fba-a9f5-74024721d240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b08ed20c-6076-44a6-99a0-c3eb4391b77d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5a779d0-45fe-4626-8f21-88f73d0258ba" xlink:to="loc_us-gaap_AwardTypeAxis_b08ed20c-6076-44a6-99a0-c3eb4391b77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_821e3a21-027d-4388-8147-6ed919f9fc46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b08ed20c-6076-44a6-99a0-c3eb4391b77d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_821e3a21-027d-4388-8147-6ed919f9fc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c47bff87-0a3a-4879-9d7f-892d7bcc0329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_821e3a21-027d-4388-8147-6ed919f9fc46" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c47bff87-0a3a-4879-9d7f-892d7bcc0329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_34c59b3c-5329-467e-b5b6-0491f956c90b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_821e3a21-027d-4388-8147-6ed919f9fc46" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_34c59b3c-5329-467e-b5b6-0491f956c90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_725bf1cb-6140-4ebc-b4e7-7f53d1038320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_821e3a21-027d-4388-8147-6ed919f9fc46" xlink:to="loc_us-gaap_PerformanceSharesMember_725bf1cb-6140-4ebc-b4e7-7f53d1038320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5a779d0-45fe-4626-8f21-88f73d0258ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfStockBasedCompensationPlans_30c91225-7dcd-4f29-9422-aa2a9789b744" xlink:href="jnj-20220102.xsd#jnj_NumberOfStockBasedCompensationPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_jnj_NumberOfStockBasedCompensationPlans_30c91225-7dcd-4f29-9422-aa2a9789b744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_62fed785-614e-4760-8e1f-debd42c0498e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_62fed785-614e-4760-8e1f-debd42c0498e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_07e6eb03-280b-44bd-88f9-d228e44d09db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_07e6eb03-280b-44bd-88f9-d228e44d09db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c34327c0-fc9e-4e00-9d07-08548c0fd914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c34327c0-fc9e-4e00-9d07-08548c0fd914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_76efac1c-5bfe-4c07-9f7f-b3a25c329464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_76efac1c-5bfe-4c07-9f7f-b3a25c329464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_0b26febc-adaf-4091-9358-6d2f06511e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_0b26febc-adaf-4091-9358-6d2f06511e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a2705571-3228-4c48-ab3e-cc58449b847a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a2705571-3228-4c48-ab3e-cc58449b847a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4ae685fc-f7f5-4dba-8d57-21d75d42cde5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4ae685fc-f7f5-4dba-8d57-21d75d42cde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8634f5da-4e78-4d68-9904-a06cdfc48e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8634f5da-4e78-4d68-9904-a06cdfc48e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dcd3c7fc-0ec8-49db-bc5d-6077988714c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dcd3c7fc-0ec8-49db-bc5d-6077988714c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dfd0fec9-49a4-4913-879e-487dede7faa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dfd0fec9-49a4-4913-879e-487dede7faa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_37873ba6-1f3a-47fd-8daa-55c65146802f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_37873ba6-1f3a-47fd-8daa-55c65146802f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_359c4852-6d5e-4a83-8297-601a5b786507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_359c4852-6d5e-4a83-8297-601a5b786507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_3e2b3cf5-9267-47e5-8efb-77dbdb196b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_3e2b3cf5-9267-47e5-8efb-77dbdb196b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_888834bc-73fe-45e3-835c-1d16ecdccc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_888834bc-73fe-45e3-835c-1d16ecdccc6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1f80b5ce-70e6-4aea-aaa0-4eed6bec9e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1f80b5ce-70e6-4aea-aaa0-4eed6bec9e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e0b7dd7a-0759-4950-8c28-742b6c181d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e0b7dd7a-0759-4950-8c28-742b6c181d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9d67d782-52e3-4563-92b9-388dad3b0ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9d67d782-52e3-4563-92b9-388dad3b0ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9ffcbed2-055d-4604-b36d-575eb73ca4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78079d49-8aa4-4368-9574-a01a931e8cfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9ffcbed2-055d-4604-b36d-575eb73ca4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_881146bd-1c62-4cae-9bfb-589615137e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2d46d318-dc9d-4ef7-b76d-a925cda7ec9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_881146bd-1c62-4cae-9bfb-589615137e1d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2d46d318-dc9d-4ef7-b76d-a925cda7ec9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4c99c350-942e-4999-b956-93a4f6911337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2d46d318-dc9d-4ef7-b76d-a925cda7ec9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4c99c350-942e-4999-b956-93a4f6911337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b4c8f773-e998-44ed-82d4-4bba38e8fc47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2d46d318-dc9d-4ef7-b76d-a925cda7ec9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b4c8f773-e998-44ed-82d4-4bba38e8fc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_509bf8db-7dc8-4cd4-a9f9-6fd106d0b720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2d46d318-dc9d-4ef7-b76d-a925cda7ec9f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_509bf8db-7dc8-4cd4-a9f9-6fd106d0b720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c81de584-c6f5-4793-b60e-7cb34d3f8f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2d46d318-dc9d-4ef7-b76d-a925cda7ec9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c81de584-c6f5-4793-b60e-7cb34d3f8f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_552fc8b3-9eb6-41bc-a3b2-d0951cfc10be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_91dc72e3-47ab-4a40-b9c9-e4c544205ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_552fc8b3-9eb6-41bc-a3b2-d0951cfc10be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_91dc72e3-47ab-4a40-b9c9-e4c544205ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b8f658a-de38-4a61-aca4-ea37b9658950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_91dc72e3-47ab-4a40-b9c9-e4c544205ff6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b8f658a-de38-4a61-aca4-ea37b9658950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_be6e3f3f-ee1a-4c31-a994-1d6e1002ec1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b8f658a-de38-4a61-aca4-ea37b9658950" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_be6e3f3f-ee1a-4c31-a994-1d6e1002ec1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1fa723a4-7566-4b72-9e3e-03288028bd03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b8f658a-de38-4a61-aca4-ea37b9658950" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1fa723a4-7566-4b72-9e3e-03288028bd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_44684810-0353-4144-aa7c-1b64edaa7a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b8f658a-de38-4a61-aca4-ea37b9658950" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_44684810-0353-4144-aa7c-1b64edaa7a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_be765280-b80e-44dc-a7b9-1c0e7189b416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b8f658a-de38-4a61-aca4-ea37b9658950" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_be765280-b80e-44dc-a7b9-1c0e7189b416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d6c5019d-8edf-4e01-a0d8-e47ae2e4d596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b8f658a-de38-4a61-aca4-ea37b9658950" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d6c5019d-8edf-4e01-a0d8-e47ae2e4d596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12332c83-a4d1-4690-8cd0-7df0abdb3c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_91dc72e3-47ab-4a40-b9c9-e4c544205ff6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12332c83-a4d1-4690-8cd0-7df0abdb3c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_52f14bfc-dfdf-495e-9928-dafa2d0c16bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12332c83-a4d1-4690-8cd0-7df0abdb3c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_52f14bfc-dfdf-495e-9928-dafa2d0c16bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c8a5ad29-c963-46ce-8d82-85e3aa208e20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12332c83-a4d1-4690-8cd0-7df0abdb3c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c8a5ad29-c963-46ce-8d82-85e3aa208e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5cde6820-63aa-43ef-8760-6c446fe0d6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12332c83-a4d1-4690-8cd0-7df0abdb3c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5cde6820-63aa-43ef-8760-6c446fe0d6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_dbff7617-f9ab-4e22-b6ac-049d73ed9c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12332c83-a4d1-4690-8cd0-7df0abdb3c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_dbff7617-f9ab-4e22-b6ac-049d73ed9c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9bbe1241-b2d3-4694-97f1-9d80802ffc15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12332c83-a4d1-4690-8cd0-7df0abdb3c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9bbe1241-b2d3-4694-97f1-9d80802ffc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a111dfc3-ec5b-4a1a-8995-dbf77d6c574f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12332c83-a4d1-4690-8cd0-7df0abdb3c27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a111dfc3-ec5b-4a1a-8995-dbf77d6c574f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_59cf0c42-fc6c-46e5-bec1-430abd1e862d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_06e479c2-9a16-4b40-8cb3-437ffa9429ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_59cf0c42-fc6c-46e5-bec1-430abd1e862d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_06e479c2-9a16-4b40-8cb3-437ffa9429ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2ed6c11e-db3a-4a98-999e-445a46324b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_06e479c2-9a16-4b40-8cb3-437ffa9429ca" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2ed6c11e-db3a-4a98-999e-445a46324b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3956bd29-d8f6-4ff9-a9f2-f42c29417cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2ed6c11e-db3a-4a98-999e-445a46324b1f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3956bd29-d8f6-4ff9-a9f2-f42c29417cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeOneMember_fa43e8cc-8d84-4280-991e-0ffcbe34ae00" xlink:href="jnj-20220102.xsd#jnj_ExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3956bd29-d8f6-4ff9-a9f2-f42c29417cd3" xlink:to="loc_jnj_ExercisePriceRangeOneMember_fa43e8cc-8d84-4280-991e-0ffcbe34ae00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeTwoMember_2cabfc1d-f70e-4321-b717-731a6afcf38a" xlink:href="jnj-20220102.xsd#jnj_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3956bd29-d8f6-4ff9-a9f2-f42c29417cd3" xlink:to="loc_jnj_ExercisePriceRangeTwoMember_2cabfc1d-f70e-4321-b717-731a6afcf38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeThreeMember_4e3253a4-c464-4527-b5ed-d28a8b62e269" xlink:href="jnj-20220102.xsd#jnj_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3956bd29-d8f6-4ff9-a9f2-f42c29417cd3" xlink:to="loc_jnj_ExercisePriceRangeThreeMember_4e3253a4-c464-4527-b5ed-d28a8b62e269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFourMember_218771bc-df0f-418c-bb51-8c9b0a7eb9c4" xlink:href="jnj-20220102.xsd#jnj_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3956bd29-d8f6-4ff9-a9f2-f42c29417cd3" xlink:to="loc_jnj_ExercisePriceRangeFourMember_218771bc-df0f-418c-bb51-8c9b0a7eb9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFiveMember_76884699-1528-4ae6-af05-1a02928d98bb" xlink:href="jnj-20220102.xsd#jnj_ExercisePriceRangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3956bd29-d8f6-4ff9-a9f2-f42c29417cd3" xlink:to="loc_jnj_ExercisePriceRangeFiveMember_76884699-1528-4ae6-af05-1a02928d98bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_52e50713-9939-4d79-bb7b-6bc961dbcbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_06e479c2-9a16-4b40-8cb3-437ffa9429ca" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_52e50713-9939-4d79-bb7b-6bc961dbcbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_debf45ab-14e1-460d-ab4d-b577a2042512" xlink:href="jnj-20220102.xsd#jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_52e50713-9939-4d79-bb7b-6bc961dbcbbc" xlink:to="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_debf45ab-14e1-460d-ab4d-b577a2042512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_f60c65ba-711d-4026-9150-4c85537c57d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_debf45ab-14e1-460d-ab4d-b577a2042512" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_f60c65ba-711d-4026-9150-4c85537c57d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_0c0c52ea-3892-43d4-a05a-38dfdba940bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_debf45ab-14e1-460d-ab4d-b577a2042512" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_0c0c52ea-3892-43d4-a05a-38dfdba940bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_d0e73812-f5e0-4f5f-a17f-460c04026b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_debf45ab-14e1-460d-ab4d-b577a2042512" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_d0e73812-f5e0-4f5f-a17f-460c04026b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_c626390d-243e-4bdf-8a2b-48993c9fd049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_debf45ab-14e1-460d-ab4d-b577a2042512" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_c626390d-243e-4bdf-8a2b-48993c9fd049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_56ee6758-af09-493d-8f3a-c09a76df84d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_debf45ab-14e1-460d-ab4d-b577a2042512" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_56ee6758-af09-493d-8f3a-c09a76df84d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_382e296d-507e-49c9-a1b5-c87647dc65e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_debf45ab-14e1-460d-ab4d-b577a2042512" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_382e296d-507e-49c9-a1b5-c87647dc65e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_e2f743ae-bc16-427a-9727-20dabf5423a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_debf45ab-14e1-460d-ab4d-b577a2042512" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_e2f743ae-bc16-427a-9727-20dabf5423a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a91c35a3-0128-473f-825b-7858c54d81ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6fc2dc7-beeb-4508-88ad-1207e812d0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a91c35a3-0128-473f-825b-7858c54d81ff" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6fc2dc7-beeb-4508-88ad-1207e812d0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_31ac8ada-425b-4a9b-a0fd-c2a7632cc8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6fc2dc7-beeb-4508-88ad-1207e812d0b4" xlink:to="loc_us-gaap_AwardTypeAxis_31ac8ada-425b-4a9b-a0fd-c2a7632cc8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8571caea-11ff-4495-8b79-1f9353991158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_31ac8ada-425b-4a9b-a0fd-c2a7632cc8a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8571caea-11ff-4495-8b79-1f9353991158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_669c2fbb-551d-4fdf-94d6-2f36ee94492f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8571caea-11ff-4495-8b79-1f9353991158" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_669c2fbb-551d-4fdf-94d6-2f36ee94492f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6353170a-b2fd-4505-836d-8a02497e8190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8571caea-11ff-4495-8b79-1f9353991158" xlink:to="loc_us-gaap_PerformanceSharesMember_6353170a-b2fd-4505-836d-8a02497e8190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2042abd1-0f21-4d2a-84f6-f828f72802f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6fc2dc7-beeb-4508-88ad-1207e812d0b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2042abd1-0f21-4d2a-84f6-f828f72802f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_29cd24ef-c56b-4134-9f40-39a47128af99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2042abd1-0f21-4d2a-84f6-f828f72802f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_29cd24ef-c56b-4134-9f40-39a47128af99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9056f3bb-89e9-4791-bd9a-d47ad8ea53f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_29cd24ef-c56b-4134-9f40-39a47128af99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9056f3bb-89e9-4791-bd9a-d47ad8ea53f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7097cb22-04ae-42b4-ba86-8307d0328bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9056f3bb-89e9-4791-bd9a-d47ad8ea53f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7097cb22-04ae-42b4-ba86-8307d0328bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ccb12b44-5c7c-4bcd-aca9-2121f4bcc253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9056f3bb-89e9-4791-bd9a-d47ad8ea53f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ccb12b44-5c7c-4bcd-aca9-2121f4bcc253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_426cb757-b470-4baa-9ff7-fb537adda9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9056f3bb-89e9-4791-bd9a-d47ad8ea53f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_426cb757-b470-4baa-9ff7-fb537adda9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_51f6748d-cd1e-4757-8a9f-65ee0db55369" xlink:href="jnj-20220102.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9056f3bb-89e9-4791-bd9a-d47ad8ea53f2" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_51f6748d-cd1e-4757-8a9f-65ee0db55369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f3a0fa1b-f694-443c-a54d-3a85aca86c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9056f3bb-89e9-4791-bd9a-d47ad8ea53f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f3a0fa1b-f694-443c-a54d-3a85aca86c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="simple" xlink:href="jnj-20220102.xsd#SegmentsofBusinessandGeographicAreas"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5623411c-6c7f-478b-80d4-d22bceae5e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_8394c3d9-b543-4379-83d7-8bc02c7966a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5623411c-6c7f-478b-80d4-d22bceae5e22" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_8394c3d9-b543-4379-83d7-8bc02c7966a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="simple" xlink:href="jnj-20220102.xsd#SegmentsofBusinessandGeographicAreasTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b00afe17-1e0d-48cb-9e69-15907051ee1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_e152caa9-7141-45ef-b4ed-3f942c5d1d36" xlink:href="jnj-20220102.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b00afe17-1e0d-48cb-9e69-15907051ee1b" xlink:to="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_e152caa9-7141-45ef-b4ed-3f942c5d1d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_18ecb42f-5d26-4456-ae5d-29cd52828cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b00afe17-1e0d-48cb-9e69-15907051ee1b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_18ecb42f-5d26-4456-ae5d-29cd52828cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_c83226c0-a7ff-46e8-8705-3c5800571b24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b00afe17-1e0d-48cb-9e69-15907051ee1b" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_c83226c0-a7ff-46e8-8705-3c5800571b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_068922d0-9454-4817-bb48-c1df0362d268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_147367e5-c24f-4005-b31b-7a0b13ef4ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_068922d0-9454-4817-bb48-c1df0362d268" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_147367e5-c24f-4005-b31b-7a0b13ef4ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_bbd97f9c-73b5-4d7a-aebd-ae1b58932874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_147367e5-c24f-4005-b31b-7a0b13ef4ecc" xlink:to="loc_us-gaap_LitigationStatusAxis_bbd97f9c-73b5-4d7a-aebd-ae1b58932874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_9166e095-dbdb-474e-8f44-975c480cb568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_bbd97f9c-73b5-4d7a-aebd-ae1b58932874" xlink:to="loc_us-gaap_LitigationStatusDomain_9166e095-dbdb-474e-8f44-975c480cb568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_06ef5537-bd5d-4c80-a9eb-bc3a7a3911e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_9166e095-dbdb-474e-8f44-975c480cb568" xlink:to="loc_us-gaap_PendingLitigationMember_06ef5537-bd5d-4c80-a9eb-bc3a7a3911e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a321b9d2-8bd5-47fc-96fd-03e383a751b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_147367e5-c24f-4005-b31b-7a0b13ef4ecc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a321b9d2-8bd5-47fc-96fd-03e383a751b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_260034c1-104e-4569-837c-f3360bd423a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a321b9d2-8bd5-47fc-96fd-03e383a751b4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_260034c1-104e-4569-837c-f3360bd423a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_28e5c97d-02f8-43a5-9165-7ecb0a477dc3" xlink:href="jnj-20220102.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_260034c1-104e-4569-837c-f3360bd423a4" xlink:to="loc_jnj_AurisHealthMember_28e5c97d-02f8-43a5-9165-7ecb0a477dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e42fb96c-0a96-4339-a683-280e6662115a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_147367e5-c24f-4005-b31b-7a0b13ef4ecc" xlink:to="loc_srt_StatementGeographicalAxis_e42fb96c-0a96-4339-a683-280e6662115a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6d44f825-fea9-4d26-8767-dfd83519764e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e42fb96c-0a96-4339-a683-280e6662115a" xlink:to="loc_srt_SegmentGeographicalDomain_6d44f825-fea9-4d26-8767-dfd83519764e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_70e20403-e59a-48eb-84f6-56fa587f9c7f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6d44f825-fea9-4d26-8767-dfd83519764e" xlink:to="loc_country_US_70e20403-e59a-48eb-84f6-56fa587f9c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_4c5dbd5d-f8a8-4904-8a34-2b0990606170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6d44f825-fea9-4d26-8767-dfd83519764e" xlink:to="loc_us-gaap_NonUsMember_4c5dbd5d-f8a8-4904-8a34-2b0990606170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_41c666e0-ee62-4b7c-a5bc-9114139b6a6c" xlink:href="jnj-20220102.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6d44f825-fea9-4d26-8767-dfd83519764e" xlink:to="loc_jnj_UNITEDSTATESExportsMember_41c666e0-ee62-4b7c-a5bc-9114139b6a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0f7611aa-94cf-49af-aee5-6d44447415bd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_147367e5-c24f-4005-b31b-7a0b13ef4ecc" xlink:to="loc_srt_ProductOrServiceAxis_0f7611aa-94cf-49af-aee5-6d44447415bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0f7611aa-94cf-49af-aee5-6d44447415bd" xlink:to="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_9b2f271d-fef7-456e-a59a-ee6a1e5c195f" xlink:href="jnj-20220102.xsd#jnj_OTCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_OTCMember_9b2f271d-fef7-456e-a59a-ee6a1e5c195f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SkinHealthBeautyMember_812e41e6-0612-44d2-9a12-18600f8ee89c" xlink:href="jnj-20220102.xsd#jnj_SkinHealthBeautyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_SkinHealthBeautyMember_812e41e6-0612-44d2-9a12-18600f8ee89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_9cb6648d-a4aa-4882-b7e7-8ab6144af262" xlink:href="jnj-20220102.xsd#jnj_OralCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_OralCareMember_9cb6648d-a4aa-4882-b7e7-8ab6144af262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_ec09e638-62e0-42ba-9303-9aebe71c7907" xlink:href="jnj-20220102.xsd#jnj_BabyCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_BabyCareMember_ec09e638-62e0-42ba-9303-9aebe71c7907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember_f4197ae7-e749-4e18-bdb6-3e62a8278f89" xlink:href="jnj-20220102.xsd#jnj_WomensHealthMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_WomensHealthMember_f4197ae7-e749-4e18-bdb6-3e62a8278f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember_d9eefbe1-da2d-4cbb-b340-5c2a7bdf0317" xlink:href="jnj-20220102.xsd#jnj_WoundCareandOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_WoundCareandOtherMember_d9eefbe1-da2d-4cbb-b340-5c2a7bdf0317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_12fa329a-d249-4316-af06-d07210b2d312" xlink:href="jnj-20220102.xsd#jnj_RemicadeMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_RemicadeMember_12fa329a-d249-4316-af06-d07210b2d312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_2d1f04e0-6bb6-4091-9be2-6fa0bcf7e712" xlink:href="jnj-20220102.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_SimponiSimponiAriaMember_2d1f04e0-6bb6-4091-9be2-6fa0bcf7e712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_c6f7d91c-8ffa-48cc-b834-3d96f12777fe" xlink:href="jnj-20220102.xsd#jnj_StelaraMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_StelaraMember_c6f7d91c-8ffa-48cc-b834-3d96f12777fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_8be61d63-ecc5-4d10-b89e-eb19519e8949" xlink:href="jnj-20220102.xsd#jnj_TremfyaMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_TremfyaMember_8be61d63-ecc5-4d10-b89e-eb19519e8949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_4772d9bf-dc7b-48c0-b462-7a56018dac56" xlink:href="jnj-20220102.xsd#jnj_OtherImmunologyMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_OtherImmunologyMember_4772d9bf-dc7b-48c0-b462-7a56018dac56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member_261caf24-7d43-446d-9c53-28417050c402" xlink:href="jnj-20220102.xsd#jnj_COVID19Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_COVID19Member_261caf24-7d43-446d-9c53-28417050c402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_622d4ea8-153a-47b7-a280-6764da89dae4" xlink:href="jnj-20220102.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_EDURANTrilpivirineMember_622d4ea8-153a-47b7-a280-6764da89dae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_87815bcf-2240-4391-9b48-38bb4fd81124" xlink:href="jnj-20220102.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_87815bcf-2240-4391-9b48-38bb4fd81124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_8d650c0c-e7ee-4fa2-ae61-57bed043a943" xlink:href="jnj-20220102.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_8d650c0c-e7ee-4fa2-ae61-57bed043a943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_4ddfcb7f-60ff-4fd9-91af-7819c36f00f6" xlink:href="jnj-20220102.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_4ddfcb7f-60ff-4fd9-91af-7819c36f00f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_c2bafc5b-4582-43af-a345-afb92be26efe" xlink:href="jnj-20220102.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_c2bafc5b-4582-43af-a345-afb92be26efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember_28754b39-2426-4541-869e-addb7783fd3e" xlink:href="jnj-20220102.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_RISPERDALCONSTAMember_28754b39-2426-4541-869e-addb7783fd3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_704d7cc7-37a3-4bf6-9335-0524d7bb4ccd" xlink:href="jnj-20220102.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_704d7cc7-37a3-4bf6-9335-0524d7bb4ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_40ee56e7-65a2-485f-b947-c271d67bd601" xlink:href="jnj-20220102.xsd#jnj_DARZALEXMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_DARZALEXMember_40ee56e7-65a2-485f-b947-c271d67bd601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ErleadaMember_1d9b2ea6-0dfe-47ed-a402-34f9bbe2ec8c" xlink:href="jnj-20220102.xsd#jnj_ErleadaMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_ErleadaMember_1d9b2ea6-0dfe-47ed-a402-34f9bbe2ec8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_df081a24-0238-4a9b-901e-637f3597137e" xlink:href="jnj-20220102.xsd#jnj_IMBRUVICAMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_IMBRUVICAMember_df081a24-0238-4a9b-901e-637f3597137e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_6e777624-688f-4e76-9e9a-b34ab869dc9a" xlink:href="jnj-20220102.xsd#jnj_ZYTIGAMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_ZYTIGAMember_6e777624-688f-4e76-9e9a-b34ab869dc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_2778060c-9427-4a21-a1c2-5b6250897797" xlink:href="jnj-20220102.xsd#jnj_OtherOncologyMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_OtherOncologyMember_2778060c-9427-4a21-a1c2-5b6250897797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_6b321631-5d2a-4bdc-8d2c-acd6565653f9" xlink:href="jnj-20220102.xsd#jnj_OPSUMITMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_OPSUMITMember_6b321631-5d2a-4bdc-8d2c-acd6565653f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_5a82cd4e-6d35-4655-8285-1f3d2f3f3145" xlink:href="jnj-20220102.xsd#jnj_UPTRAVIMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_UPTRAVIMember_5a82cd4e-6d35-4655-8285-1f3d2f3f3145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_c8583e40-dac4-43dd-9fad-d45a8e95c816" xlink:href="jnj-20220102.xsd#jnj_OtherMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_OtherMember_c8583e40-dac4-43dd-9fad-d45a8e95c816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_0731547e-ac4d-42ce-8d43-87b1c4d1118e" xlink:href="jnj-20220102.xsd#jnj_XareltoMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_XareltoMember_0731547e-ac4d-42ce-8d43-87b1c4d1118e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember_527a6bc8-0b27-41fc-9b66-31afa7aa6591" xlink:href="jnj-20220102.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_INVOKANAINVOKAMETMember_527a6bc8-0b27-41fc-9b66-31afa7aa6591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PROCRITEPREXMember_cac1b266-788c-48e4-b55e-3d02c7a388b4" xlink:href="jnj-20220102.xsd#jnj_PROCRITEPREXMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_PROCRITEPREXMember_cac1b266-788c-48e4-b55e-3d02c7a388b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_11d818a7-abc7-444d-b907-2475c50b6829" xlink:href="jnj-20220102.xsd#jnj_HIPSMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_HIPSMember_11d818a7-abc7-444d-b907-2475c50b6829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_150a7a0e-04bf-43e6-9cbe-6c6b3476ebac" xlink:href="jnj-20220102.xsd#jnj_KNEESMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_KNEESMember_150a7a0e-04bf-43e6-9cbe-6c6b3476ebac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_a1e1aa32-0024-46f5-a31e-7dbea5c5138f" xlink:href="jnj-20220102.xsd#jnj_TRAUMAMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_TRAUMAMember_a1e1aa32-0024-46f5-a31e-7dbea5c5138f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINESPORTSOTHERMember_5ab45f14-306c-402b-b9dc-4d4e51838af1" xlink:href="jnj-20220102.xsd#jnj_SPINESPORTSOTHERMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_SPINESPORTSOTHERMember_5ab45f14-306c-402b-b9dc-4d4e51838af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_bdf56529-8661-4ed2-ae58-e263a08ce8e0" xlink:href="jnj-20220102.xsd#jnj_ADVANCEDMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_ADVANCEDMember_bdf56529-8661-4ed2-ae58-e263a08ce8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_44e9b292-59ce-438c-8af1-27095bd675d6" xlink:href="jnj-20220102.xsd#jnj_GENERALMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_GENERALMember_44e9b292-59ce-438c-8af1-27095bd675d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_697527f7-39bc-4ea2-bb78-3b4b8ba2c158" xlink:href="jnj-20220102.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_697527f7-39bc-4ea2-bb78-3b4b8ba2c158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_8634cfce-65f3-418e-ac50-b2899041532f" xlink:href="jnj-20220102.xsd#jnj_SURGICALMember"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0f8cc49-db7c-4e02-a260-856527cf5567" xlink:to="loc_jnj_SURGICALMember_8634cfce-65f3-418e-ac50-b2899041532f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_49e7963b-5c58-4977-acbc-929eb10a9e49" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_147367e5-c24f-4005-b31b-7a0b13ef4ecc" xlink:to="loc_srt_ConsolidationItemsAxis_49e7963b-5c58-4977-acbc-929eb10a9e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_6ac18646-3ce1-4205-9fd1-9b2904bd211d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_49e7963b-5c58-4977-acbc-929eb10a9e49" xlink:to="loc_srt_ConsolidationItemsDomain_6ac18646-3ce1-4205-9fd1-9b2904bd211d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8a8e59a3-7f4e-4809-94d6-6be735dc84ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_147367e5-c24f-4005-b31b-7a0b13ef4ecc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8a8e59a3-7f4e-4809-94d6-6be735dc84ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_105ec90a-1aa3-4f30-98a3-d94b8952156e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8a8e59a3-7f4e-4809-94d6-6be735dc84ce" xlink:to="loc_us-gaap_SegmentDomain_105ec90a-1aa3-4f30-98a3-d94b8952156e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_0aa39418-f174-43a2-b4aa-829cc6b1efd3" xlink:href="jnj-20220102.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_105ec90a-1aa3-4f30-98a3-d94b8952156e" xlink:to="loc_jnj_ConsumerMember_0aa39418-f174-43a2-b4aa-829cc6b1efd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_3f27af5c-71a6-46a9-a8b9-cd5dc470d43e" xlink:href="jnj-20220102.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_105ec90a-1aa3-4f30-98a3-d94b8952156e" xlink:to="loc_jnj_PharmaceuticalMember_3f27af5c-71a6-46a9-a8b9-cd5dc470d43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_8c3e05c4-f81f-4800-a336-ad05c2f0579f" xlink:href="jnj-20220102.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_105ec90a-1aa3-4f30-98a3-d94b8952156e" xlink:to="loc_jnj_MedicalDevicesMember_8c3e05c4-f81f-4800-a336-ad05c2f0579f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_c403bf8a-d42c-4162-a863-a197ed0fcd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_147367e5-c24f-4005-b31b-7a0b13ef4ecc" xlink:to="loc_us-gaap_SubsegmentsAxis_c403bf8a-d42c-4162-a863-a197ed0fcd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_c403bf8a-d42c-4162-a863-a197ed0fcd5f" xlink:to="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_219ae4cd-683f-419a-9296-24b8bc8fa837" xlink:href="jnj-20220102.xsd#jnj_ImmunologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_ImmunologyMember_219ae4cd-683f-419a-9296-24b8bc8fa837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_b1556862-4b42-4284-a8da-180ddd7727db" xlink:href="jnj-20220102.xsd#jnj_InfectiousDiseasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_InfectiousDiseasesMember_b1556862-4b42-4284-a8da-180ddd7727db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_0b2fa3c0-5035-4d49-82ed-0178970217a5" xlink:href="jnj-20220102.xsd#jnj_NeuroscienceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_NeuroscienceMember_0b2fa3c0-5035-4d49-82ed-0178970217a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_8ec0ea58-2d4d-4474-86e0-abfedf663637" xlink:href="jnj-20220102.xsd#jnj_OncologyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_OncologyMember_8ec0ea58-2d4d-4474-86e0-abfedf663637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_a1c56043-a0e7-472c-9fb1-6868c2040787" xlink:href="jnj-20220102.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_PulmonaryHypertensionMember_a1c56043-a0e7-472c-9fb1-6868c2040787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_0e9d6059-647c-4d0f-9128-68b8c073a873" xlink:href="jnj-20220102.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_0e9d6059-647c-4d0f-9128-68b8c073a873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_2921cfb4-4e39-4763-ace2-4361c590bb6a" xlink:href="jnj-20220102.xsd#jnj_InterventionalSolutionsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_InterventionalSolutionsMember_2921cfb4-4e39-4763-ace2-4361c590bb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_ecb2eca6-9590-4490-b992-63adaac15d51" xlink:href="jnj-20220102.xsd#jnj_OrthopaedicsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_OrthopaedicsMember_ecb2eca6-9590-4490-b992-63adaac15d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_818b3009-eaf6-4fbb-8020-80efb44209bc" xlink:href="jnj-20220102.xsd#jnj_SurgeryMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_SurgeryMember_818b3009-eaf6-4fbb-8020-80efb44209bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_d3aa1207-720e-49d7-bc13-e41ec5f9d2a2" xlink:href="jnj-20220102.xsd#jnj_VisionMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_ff9f6fc1-51a0-4261-adcc-bae542ce0c40" xlink:to="loc_jnj_VisionMember_d3aa1207-720e-49d7-bc13-e41ec5f9d2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c5dc9ab2-d99c-474f-ad57-dec021b97ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_147367e5-c24f-4005-b31b-7a0b13ef4ecc" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_c5dc9ab2-d99c-474f-ad57-dec021b97ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9b8ea337-087e-462d-9247-fc012f5a0d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c5dc9ab2-d99c-474f-ad57-dec021b97ac1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9b8ea337-087e-462d-9247-fc012f5a0d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_1e00c1b6-357d-4003-abcc-b351fe09c031" xlink:href="jnj-20220102.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c5dc9ab2-d99c-474f-ad57-dec021b97ac1" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_1e00c1b6-357d-4003-abcc-b351fe09c031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_91580321-a33e-4fbc-a7bb-6968656297b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_91580321-a33e-4fbc-a7bb-6968656297b1" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_8f30f70e-2e46-4413-aa24-b22efcb892a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_us-gaap_SubsegmentsAxis_8f30f70e-2e46-4413-aa24-b22efcb892a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_f45f9877-b3bf-46cf-a590-bcf84f326331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_8f30f70e-2e46-4413-aa24-b22efcb892a7" xlink:to="loc_us-gaap_SubsegmentsDomain_f45f9877-b3bf-46cf-a590-bcf84f326331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_33828dec-2069-454c-90e8-a8768a9b91ce" xlink:href="jnj-20220102.xsd#jnj_ImmunologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_f45f9877-b3bf-46cf-a590-bcf84f326331" xlink:to="loc_jnj_ImmunologyMember_33828dec-2069-454c-90e8-a8768a9b91ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_41f44034-8d52-4287-a872-066d6fa466ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_srt_ConsolidationItemsAxis_41f44034-8d52-4287-a872-066d6fa466ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ee9c2903-a756-43f9-92bd-27b158953d1d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_41f44034-8d52-4287-a872-066d6fa466ed" xlink:to="loc_srt_ConsolidationItemsDomain_ee9c2903-a756-43f9-92bd-27b158953d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_57412fc4-4179-40e0-a2b1-1c55057d3802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ee9c2903-a756-43f9-92bd-27b158953d1d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_57412fc4-4179-40e0-a2b1-1c55057d3802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_3a7a4a9f-ceec-4754-acc2-31bfc36429f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ee9c2903-a756-43f9-92bd-27b158953d1d" xlink:to="loc_us-gaap_OperatingSegmentsMember_3a7a4a9f-ceec-4754-acc2-31bfc36429f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_70ebb1e9-a8b8-4a49-b16a-cee962f6f612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_70ebb1e9-a8b8-4a49-b16a-cee962f6f612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_96a19212-fd62-4b60-97fe-ef2aabdea56b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_70ebb1e9-a8b8-4a49-b16a-cee962f6f612" xlink:to="loc_us-gaap_SegmentDomain_96a19212-fd62-4b60-97fe-ef2aabdea56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GeneralCorporateMember_c9247cf1-b6a9-415c-a662-f4c2a1ed9bd3" xlink:href="jnj-20220102.xsd#jnj_GeneralCorporateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_96a19212-fd62-4b60-97fe-ef2aabdea56b" xlink:to="loc_jnj_GeneralCorporateMember_c9247cf1-b6a9-415c-a662-f4c2a1ed9bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_d12f5692-fefd-461f-9484-21ecc64cd743" xlink:href="jnj-20220102.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_96a19212-fd62-4b60-97fe-ef2aabdea56b" xlink:to="loc_jnj_ConsumerMember_d12f5692-fefd-461f-9484-21ecc64cd743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_d0bd3044-6743-4cce-a612-800000b8dd97" xlink:href="jnj-20220102.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_96a19212-fd62-4b60-97fe-ef2aabdea56b" xlink:to="loc_jnj_PharmaceuticalMember_d0bd3044-6743-4cce-a612-800000b8dd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_5e322cac-8581-49d6-b5f7-c505c1af97f6" xlink:href="jnj-20220102.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_96a19212-fd62-4b60-97fe-ef2aabdea56b" xlink:to="loc_jnj_MedicalDevicesMember_5e322cac-8581-49d6-b5f7-c505c1af97f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SegmentsTotalMember_d9095ab2-f7ca-4cea-acf8-c54d14f10421" xlink:href="jnj-20220102.xsd#jnj_SegmentsTotalMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_96a19212-fd62-4b60-97fe-ef2aabdea56b" xlink:to="loc_jnj_SegmentsTotalMember_d9095ab2-f7ca-4cea-acf8-c54d14f10421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cc2b82ae-3e7a-4966-9c84-bdab6b0e7a31" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_srt_StatementGeographicalAxis_cc2b82ae-3e7a-4966-9c84-bdab6b0e7a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c7c80bd7-af03-46d8-a3b4-3bf7659baca0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_cc2b82ae-3e7a-4966-9c84-bdab6b0e7a31" xlink:to="loc_srt_SegmentGeographicalDomain_c7c80bd7-af03-46d8-a3b4-3bf7659baca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ac0d685c-dc99-44e0-9647-a1dd71197f6e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c7c80bd7-af03-46d8-a3b4-3bf7659baca0" xlink:to="loc_country_US_ac0d685c-dc99-44e0-9647-a1dd71197f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_5cf18cef-4488-424c-9ecb-bc478ff999d9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c7c80bd7-af03-46d8-a3b4-3bf7659baca0" xlink:to="loc_srt_EuropeMember_5cf18cef-4488-424c-9ecb-bc478ff999d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_29904e72-098c-40b2-a147-c1de5258d205" xlink:href="jnj-20220102.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c7c80bd7-af03-46d8-a3b4-3bf7659baca0" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_29904e72-098c-40b2-a147-c1de5258d205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_ea9c7d4a-4949-4e38-8853-ee93daee15cf" xlink:href="jnj-20220102.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c7c80bd7-af03-46d8-a3b4-3bf7659baca0" xlink:to="loc_jnj_AsiaPacificAfricaMember_ea9c7d4a-4949-4e38-8853-ee93daee15cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e507cd4b-11f8-4220-bb25-90f8cdd5594a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_srt_MajorCustomersAxis_e507cd4b-11f8-4220-bb25-90f8cdd5594a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_342c91b5-d467-4583-b4f4-0070bfe41848" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_e507cd4b-11f8-4220-bb25-90f8cdd5594a" xlink:to="loc_srt_NameOfMajorCustomerDomain_342c91b5-d467-4583-b4f4-0070bfe41848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler1Member_38274501-efab-4700-9cf4-0f919112dda0" xlink:href="jnj-20220102.xsd#jnj_Wholesaler1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_342c91b5-d467-4583-b4f4-0070bfe41848" xlink:to="loc_jnj_Wholesaler1Member_38274501-efab-4700-9cf4-0f919112dda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler2Member_eb21bb89-408c-424e-8dae-d4a53e8e1de0" xlink:href="jnj-20220102.xsd#jnj_Wholesaler2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_342c91b5-d467-4583-b4f4-0070bfe41848" xlink:to="loc_jnj_Wholesaler2Member_eb21bb89-408c-424e-8dae-d4a53e8e1de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler3Member_a30eb59c-657e-44f3-b25d-a044aa7920b0" xlink:href="jnj-20220102.xsd#jnj_Wholesaler3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_342c91b5-d467-4583-b4f4-0070bfe41848" xlink:to="loc_jnj_Wholesaler3Member_a30eb59c-657e-44f3-b25d-a044aa7920b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1e7be757-893b-4853-863f-6ad3ce262784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1e7be757-893b-4853-863f-6ad3ce262784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c6d6e9d8-dffa-4028-980a-13daf0717800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1e7be757-893b-4853-863f-6ad3ce262784" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c6d6e9d8-dffa-4028-980a-13daf0717800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_de576785-8f4b-475c-95f1-1c4294900f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c6d6e9d8-dffa-4028-980a-13daf0717800" xlink:to="loc_us-gaap_SalesRevenueNetMember_de576785-8f4b-475c-95f1-1c4294900f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dcbf6a39-70cc-49f0-a461-cbdb960b6f70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dcbf6a39-70cc-49f0-a461-cbdb960b6f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68179b48-d406-4471-ba57-5b1c1786eb04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dcbf6a39-70cc-49f0-a461-cbdb960b6f70" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68179b48-d406-4471-ba57-5b1c1786eb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_74dcb29a-e396-44a4-b95f-2b83364981a2" xlink:href="jnj-20220102.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68179b48-d406-4471-ba57-5b1c1786eb04" xlink:to="loc_jnj_AurisHealthMember_74dcb29a-e396-44a4-b95f-2b83364981a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CizHoldingsCo.Ltd.Member_670c64f5-4882-497a-85c8-29f97dd27f7b" xlink:href="jnj-20220102.xsd#jnj_CizHoldingsCo.Ltd.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68179b48-d406-4471-ba57-5b1c1786eb04" xlink:to="loc_jnj_CizHoldingsCo.Ltd.Member_670c64f5-4882-497a-85c8-29f97dd27f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ActelionMember_c3db2a14-0b8d-4b17-a0db-b4242102c788" xlink:href="jnj-20220102.xsd#jnj_ActelionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68179b48-d406-4471-ba57-5b1c1786eb04" xlink:to="loc_jnj_ActelionMember_c3db2a14-0b8d-4b17-a0db-b4242102c788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2a079afb-2669-46be-ba9f-f6522900d98a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2a079afb-2669-46be-ba9f-f6522900d98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7ad17812-59fb-43a9-b508-f20c6ab17814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2a079afb-2669-46be-ba9f-f6522900d98a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7ad17812-59fb-43a9-b508-f20c6ab17814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember_a9335944-c9a8-40ec-96ad-71332597a8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7ad17812-59fb-43a9-b508-f20c6ab17814" xlink:to="loc_us-gaap_OtherIncomeMember_a9335944-c9a8-40ec-96ad-71332597a8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_761e74aa-927a-4d08-b513-f38626619bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_us-gaap_LitigationStatusAxis_761e74aa-927a-4d08-b513-f38626619bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_bdcf9f3d-1b5e-49c4-a47d-da8949bde29e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_761e74aa-927a-4d08-b513-f38626619bea" xlink:to="loc_us-gaap_LitigationStatusDomain_bdcf9f3d-1b5e-49c4-a47d-da8949bde29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_1879cf56-ac51-47a8-b89b-cb300539963b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_bdcf9f3d-1b5e-49c4-a47d-da8949bde29e" xlink:to="loc_us-gaap_PendingLitigationMember_1879cf56-ac51-47a8-b89b-cb300539963b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_96aa312a-c745-4fa6-8edd-46cca2bd8184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_96aa312a-c745-4fa6-8edd-46cca2bd8184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bc3e24d-4c83-4268-b0fb-045f0147e980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_96aa312a-c745-4fa6-8edd-46cca2bd8184" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bc3e24d-4c83-4268-b0fb-045f0147e980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_0253a666-f19b-47c1-95b1-5610230e7843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bc3e24d-4c83-4268-b0fb-045f0147e980" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_0253a666-f19b-47c1-95b1-5610230e7843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_7eca21e0-35c0-4bca-921e-d44c6e8f67f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bc3e24d-4c83-4268-b0fb-045f0147e980" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_7eca21e0-35c0-4bca-921e-d44c6e8f67f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6ef629b0-d2c1-459d-b3ba-bcd791db3087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6ef629b0-d2c1-459d-b3ba-bcd791db3087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f12219ab-4ebb-4b96-80ef-1f2e04b93b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6ef629b0-d2c1-459d-b3ba-bcd791db3087" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f12219ab-4ebb-4b96-80ef-1f2e04b93b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AdvancedSterilizationProductsMember_60f1b1b9-1a4c-4ffc-a240-19ddb2a8a777" xlink:href="jnj-20220102.xsd#jnj_AdvancedSterilizationProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f12219ab-4ebb-4b96-80ef-1f2e04b93b28" xlink:to="loc_jnj_AdvancedSterilizationProductsMember_60f1b1b9-1a4c-4ffc-a240-19ddb2a8a777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f9dccad2-27a4-4ec0-80cc-27e538d14b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f9dccad2-27a4-4ec0-80cc-27e538d14b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e7551c60-30bc-4783-98e9-cafd949e5127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f9dccad2-27a4-4ec0-80cc-27e538d14b73" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e7551c60-30bc-4783-98e9-cafd949e5127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WholesalerConcentrationRiskMember_3ed01175-f37f-43dc-9c8c-cb240c93ff59" xlink:href="jnj-20220102.xsd#jnj_WholesalerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e7551c60-30bc-4783-98e9-cafd949e5127" xlink:to="loc_jnj_WholesalerConcentrationRiskMember_3ed01175-f37f-43dc-9c8c-cb240c93ff59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50760e08-cf39-4919-9e98-eac3ee6ab917" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1c834141-20ab-4efc-a5e8-0d5dfd425d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1c834141-20ab-4efc-a5e8-0d5dfd425d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExpenseNotAllocatedToSegments_17cc43a5-65a5-4535-8e5f-791165482b40" xlink:href="jnj-20220102.xsd#jnj_ExpenseNotAllocatedToSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_jnj_ExpenseNotAllocatedToSegments_17cc43a5-65a5-4535-8e5f-791165482b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_126cd655-eef3-4bea-8108-5d2986b464e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_Assets_126cd655-eef3-4bea-8108-5d2986b464e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_541ab24c-8edd-414f-8c86-f5a94bf58f11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_541ab24c-8edd-414f-8c86-f5a94bf58f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_01ab0d36-2c91-4313-bb28-db10f3171e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_01ab0d36-2c91-4313-bb28-db10f3171e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_722e315f-7ab6-419b-b8b5-7ab211ed14ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_722e315f-7ab6-419b-b8b5-7ab211ed14ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_f4614bc7-00d7-4c16-b9f9-79a0fe06c200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_NoncurrentAssets_f4614bc7-00d7-4c16-b9f9-79a0fe06c200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonLongLivedAssets_69d69abd-15ee-4e53-851b-040633a36760" xlink:href="jnj-20220102.xsd#jnj_OtherNonLongLivedAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_jnj_OtherNonLongLivedAssets_69d69abd-15ee-4e53-851b-040633a36760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b7fd6498-c806-4a2c-a30c-06622a76ef0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b7fd6498-c806-4a2c-a30c-06622a76ef0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_012aaf69-0cdf-4cde-8036-2c83b88ce68f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_NumberOfOperatingSegments_012aaf69-0cdf-4cde-8036-2c83b88ce68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_93013be2-f83c-460c-8fae-f3771673717e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_LitigationSettlementExpense_93013be2-f83c-460c-8fae-f3771673717e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_46579bf2-efdc-4b6d-bec4-bce86535f8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_RestructuringCharges_46579bf2-efdc-4b6d-bec4-bce86535f8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_7031a851-f238-491e-af90-00d5183f2c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_7031a851-f238-491e-af90-00d5183f2c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_788f24d8-d8fb-4bbe-8d52-8c9315a4c70e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_788f24d8-d8fb-4bbe-8d52-8c9315a4c70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_64c5bd15-baaf-4219-bcbb-23df6c7ce810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_64c5bd15-baaf-4219-bcbb-23df6c7ce810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RegulationCharge_4c39f1c7-6be9-4de7-9f2b-2138b5d32624" xlink:href="jnj-20220102.xsd#jnj_RegulationCharge"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_jnj_RegulationCharge_4c39f1c7-6be9-4de7-9f2b-2138b5d32624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_55c7f224-5b1f-4c9f-98fe-10aeca1c5f03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_55c7f224-5b1f-4c9f-98fe-10aeca1c5f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_120e2aab-b964-4c1b-abba-6f08bdb402e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_120e2aab-b964-4c1b-abba-6f08bdb402e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfEquityInvestments_785a2cc3-c99e-4359-8245-ca9bd7ec59d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_GainLossOnSaleOfEquityInvestments_785a2cc3-c99e-4359-8245-ca9bd7ec59d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_47be4a72-f4dc-41e1-adaa-ed0e9ef1624f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_47be4a72-f4dc-41e1-adaa-ed0e9ef1624f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_18b3e5cc-3376-493d-83cd-c67f5b64a4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_18b3e5cc-3376-493d-83cd-c67f5b64a4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_42684399-82b6-4896-8ee5-e916637dc833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7f9bc7e0-cb6a-4cc7-8813-726689df0505" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_42684399-82b6-4896-8ee5-e916637dc833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="simple" xlink:href="jnj-20220102.xsd#AcquisitionsandDivestitures"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_276e770c-4bdb-48d0-ab94-0d3701a4c206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_ed3887a1-71c2-4afe-bf7b-b38203b14cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_276e770c-4bdb-48d0-ab94-0d3701a4c206" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_ed3887a1-71c2-4afe-bf7b-b38203b14cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_dc8c7efe-712d-4f86-8b28-26d38c052ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3a86f2e-6a40-4be4-b02d-d0879910f1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_dc8c7efe-712d-4f86-8b28-26d38c052ac8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3a86f2e-6a40-4be4-b02d-d0879910f1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_906ad015-47e6-4cec-b5c6-66bc47c20b21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3a86f2e-6a40-4be4-b02d-d0879910f1e4" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_906ad015-47e6-4cec-b5c6-66bc47c20b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_508d59de-6bc4-441d-8968-da0c1e7dfb18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_906ad015-47e6-4cec-b5c6-66bc47c20b21" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_508d59de-6bc4-441d-8968-da0c1e7dfb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_468a5895-af9d-467f-b32d-72c7b1be03e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_508d59de-6bc4-441d-8968-da0c1e7dfb18" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_468a5895-af9d-467f-b32d-72c7b1be03e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_22b0311e-1cb7-4788-80b7-8946783a0308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3a86f2e-6a40-4be4-b02d-d0879910f1e4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_22b0311e-1cb7-4788-80b7-8946783a0308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7d54f4c0-d196-4e27-bb79-a1a42c600735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_22b0311e-1cb7-4788-80b7-8946783a0308" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7d54f4c0-d196-4e27-bb79-a1a42c600735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AdvancedSterilizationProductsMember_aed86c36-8882-49d6-bd04-3465641010e3" xlink:href="jnj-20220102.xsd#jnj_AdvancedSterilizationProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7d54f4c0-d196-4e27-bb79-a1a42c600735" xlink:to="loc_jnj_AdvancedSterilizationProductsMember_aed86c36-8882-49d6-bd04-3465641010e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember_3f5e3a46-14e9-4ab2-bc64-9bbdab58a763" xlink:href="jnj-20220102.xsd#jnj_EvraAndDoxilMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7d54f4c0-d196-4e27-bb79-a1a42c600735" xlink:to="loc_jnj_EvraAndDoxilMember_3f5e3a46-14e9-4ab2-bc64-9bbdab58a763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_65a278db-9e7a-49ae-8911-f7ddb5f41bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3a86f2e-6a40-4be4-b02d-d0879910f1e4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_65a278db-9e7a-49ae-8911-f7ddb5f41bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0cfecf51-e562-4530-bcd2-52e1c3e63583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_65a278db-9e7a-49ae-8911-f7ddb5f41bba" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0cfecf51-e562-4530-bcd2-52e1c3e63583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_f7166773-9521-49b3-a063-ade3569b0ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0cfecf51-e562-4530-bcd2-52e1c3e63583" xlink:to="loc_us-gaap_ConvertibleDebtMember_f7166773-9521-49b3-a063-ade3569b0ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f349f8d-64ba-47ec-86f6-b463efc64f7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3a86f2e-6a40-4be4-b02d-d0879910f1e4" xlink:to="loc_srt_RangeAxis_2f349f8d-64ba-47ec-86f6-b463efc64f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ab65969e-36bb-4300-abc4-c2dce46e3136" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2f349f8d-64ba-47ec-86f6-b463efc64f7d" xlink:to="loc_srt_RangeMember_ab65969e-36bb-4300-abc4-c2dce46e3136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_342845d9-79b4-4012-a920-9a514211ad9b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ab65969e-36bb-4300-abc4-c2dce46e3136" xlink:to="loc_srt_MaximumMember_342845d9-79b4-4012-a920-9a514211ad9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1f913e55-1d96-4718-8f20-6e5c6f492c1d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ab65969e-36bb-4300-abc4-c2dce46e3136" xlink:to="loc_srt_MinimumMember_1f913e55-1d96-4718-8f20-6e5c6f492c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2b24a01a-2115-4f37-accb-19b379e31091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3a86f2e-6a40-4be4-b02d-d0879910f1e4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2b24a01a-2115-4f37-accb-19b379e31091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2b24a01a-2115-4f37-accb-19b379e31091" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2019AcquisitionsMember_88e021fd-e05d-4565-9eab-0cbfc73bc058" xlink:href="jnj-20220102.xsd#jnj_A2019AcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:to="loc_jnj_A2019AcquisitionsMember_88e021fd-e05d-4565-9eab-0cbfc73bc058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_673eaf8f-45d7-4550-8955-4f2f9628b9ce" xlink:href="jnj-20220102.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:to="loc_jnj_AurisHealthMember_673eaf8f-45d7-4550-8955-4f2f9628b9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CizHoldingsCo.Ltd.Member_6fb48f99-4b2e-493a-9cc7-ac7dd5c3b0ef" xlink:href="jnj-20220102.xsd#jnj_CizHoldingsCo.Ltd.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:to="loc_jnj_CizHoldingsCo.Ltd.Member_6fb48f99-4b2e-493a-9cc7-ac7dd5c3b0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IdorsiaMember_e06d7ea2-3d8e-44fb-a135-16f6afcf8404" xlink:href="jnj-20220102.xsd#jnj_IdorsiaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:to="loc_jnj_IdorsiaMember_e06d7ea2-3d8e-44fb-a135-16f6afcf8404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MomentaMember_022c2732-c14e-478f-9e6e-a2a59ea89648" xlink:href="jnj-20220102.xsd#jnj_MomentaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:to="loc_jnj_MomentaMember_022c2732-c14e-478f-9e6e-a2a59ea89648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2020AcquisitionsMember_b65e89c6-ec0e-4dce-b915-19f91854389a" xlink:href="jnj-20220102.xsd#jnj_A2020AcquisitionsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:to="loc_jnj_A2020AcquisitionsMember_b65e89c6-ec0e-4dce-b915-19f91854389a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_70feba96-5b34-4bbb-b982-0cf93d431285" xlink:href="jnj-20220102.xsd#jnj_BermekimabMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:to="loc_jnj_BermekimabMember_70feba96-5b34-4bbb-b982-0cf93d431285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VerbSurgicalIncMember_eb4728a3-b3ad-40cf-96ff-419787773d3b" xlink:href="jnj-20220102.xsd#jnj_VerbSurgicalIncMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad5e758a-60a2-4b12-8a2a-edbf23c3be4b" xlink:to="loc_jnj_VerbSurgicalIncMember_eb4728a3-b3ad-40cf-96ff-419787773d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_267905ae-40a9-4dec-9985-7f82928a31ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3a86f2e-6a40-4be4-b02d-d0879910f1e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_267905ae-40a9-4dec-9985-7f82928a31ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0bb541ad-4851-4f8a-b105-cf77a1a8bd34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_267905ae-40a9-4dec-9985-7f82928a31ea" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0bb541ad-4851-4f8a-b105-cf77a1a8bd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2ab3139b-9c1d-45a2-8701-1ff223e58042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0bb541ad-4851-4f8a-b105-cf77a1a8bd34" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_2ab3139b-9c1d-45a2-8701-1ff223e58042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4b18603e-780b-4f75-91e6-0d9991679ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3a86f2e-6a40-4be4-b02d-d0879910f1e4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4b18603e-780b-4f75-91e6-0d9991679ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_047e726f-7ce6-40ae-a39e-f25ccd1d22e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4b18603e-780b-4f75-91e6-0d9991679ffd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_047e726f-7ce6-40ae-a39e-f25ccd1d22e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_62c8352b-dbbb-430f-9fd0-d7d83418b925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_047e726f-7ce6-40ae-a39e-f25ccd1d22e8" xlink:to="loc_us-gaap_SubsequentEventMember_62c8352b-dbbb-430f-9fd0-d7d83418b925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3a86f2e-6a40-4be4-b02d-d0879910f1e4" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_78f1c1f6-a9c2-4812-bd5b-381d86b9d5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_78f1c1f6-a9c2-4812-bd5b-381d86b9d5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_dedcdaff-af1b-42a9-bf23-269a3dde7c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_dedcdaff-af1b-42a9-bf23-269a3dde7c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_7c3cfdd8-2a52-48b6-a266-60cfeb35e21b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_7c3cfdd8-2a52-48b6-a266-60cfeb35e21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_80bb8390-8a6c-4468-8202-074fdcdd2379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_80bb8390-8a6c-4468-8202-074fdcdd2379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_3d00e4e1-d51a-46ce-a8c3-207deff4fbb7" xlink:href="jnj-20220102.xsd#jnj_BusinessCombinationProbabilityOfSuccessFactor"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_3d00e4e1-d51a-46ce-a8c3-207deff4fbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessAcquisitionDiscountRate_4732d9a4-35c2-42f0-9029-c7ab01762860" xlink:href="jnj-20220102.xsd#jnj_BusinessAcquisitionDiscountRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_jnj_BusinessAcquisitionDiscountRate_4732d9a4-35c2-42f0-9029-c7ab01762860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_89af83b0-c008-4bf2-b010-2f6dfe30a984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_89af83b0-c008-4bf2-b010-2f6dfe30a984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d9b28e8e-3f38-4295-95d9-1e158066b8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_Goodwill_d9b28e8e-3f38-4295-95d9-1e158066b8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_0502d98b-a2a2-43e6-bc83-74415c9934f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_0502d98b-a2a2-43e6-bc83-74415c9934f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_41db5c89-e517-4ac4-8412-beb93bc001a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_41db5c89-e517-4ac4-8412-beb93bc001a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c9f0c86a-3b7a-4f7b-9d76-49bbbba600cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c9f0c86a-3b7a-4f7b-9d76-49bbbba600cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_a86ae3a8-efb7-4cb8-bab3-b654823e9812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_a86ae3a8-efb7-4cb8-bab3-b654823e9812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7e66dc43-68d3-43ca-8748-2e762e23881e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7e66dc43-68d3-43ca-8748-2e762e23881e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4835e4bd-c184-4022-a94d-d340d21b3fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4835e4bd-c184-4022-a94d-d340d21b3fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f2fe4424-5f43-4d09-a702-e7468413292e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f2fe4424-5f43-4d09-a702-e7468413292e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_16c64e8d-9212-43e3-bfbe-0e321db22567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_16c64e8d-9212-43e3-bfbe-0e321db22567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_9f7b2c3e-a162-40f6-8bf5-bc96f0349996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_9f7b2c3e-a162-40f6-8bf5-bc96f0349996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a8009ed6-70ea-4ade-acb9-494fc0c8d7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a8009ed6-70ea-4ade-acb9-494fc0c8d7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_165dd177-8398-4b2b-ad5d-2e3bd9572409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_165dd177-8398-4b2b-ad5d-2e3bd9572409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_5fc8e35b-714c-4856-9d35-ffc1450f6e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfInterestInCorporateUnit"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_5fc8e35b-714c-4856-9d35-ffc1450f6e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c64aecd0-b8e6-44f2-aaea-fff94d7e20c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c64aecd0-b8e6-44f2-aaea-fff94d7e20c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConvertibleNoteEquityInterestNumberOfShares_82a40fd8-6e0a-464d-b5dd-2bfd2e97fb9e" xlink:href="jnj-20220102.xsd#jnj_ConvertibleNoteEquityInterestNumberOfShares"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_jnj_ConvertibleNoteEquityInterestNumberOfShares_82a40fd8-6e0a-464d-b5dd-2bfd2e97fb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_de3b8095-1707-41e8-a028-a639d3f37abc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_LongTermDebt_de3b8095-1707-41e8-a028-a639d3f37abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DebtInstrumentConvertibleAmountOfLoanConverted_c915adb6-4d4e-40cb-af2a-e1b629d77110" xlink:href="jnj-20220102.xsd#jnj_DebtInstrumentConvertibleAmountOfLoanConverted"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_jnj_DebtInstrumentConvertibleAmountOfLoanConverted_c915adb6-4d4e-40cb-af2a-e1b629d77110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_e2514ccf-2e2d-41f9-9225-d79d484fd222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_e2514ccf-2e2d-41f9-9225-d79d484fd222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_a16d5cc0-b378-4fea-a134-122088f261ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_a16d5cc0-b378-4fea-a134-122088f261ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_a4d40508-8e25-4573-a548-e8bc51442bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCash"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_a4d40508-8e25-4573-a548-e8bc51442bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained_e3237279-0ed1-4d08-b9c7-0787a16467d1" xlink:href="jnj-20220102.xsd#jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained_e3237279-0ed1-4d08-b9c7-0787a16467d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_8c50f642-bc16-4ccc-85dd-e466ff3d756f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fcc0e5a9-2868-4032-bcbf-c8f8808335f6" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_8c50f642-bc16-4ccc-85dd-e466ff3d756f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedings" xlink:type="simple" xlink:href="jnj-20220102.xsd#LegalProceedings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_86511d8a-eec3-4584-8c7a-9adb91c8a2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_717dcac9-7117-4128-becb-8c7799160221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_86511d8a-eec3-4584-8c7a-9adb91c8a2ef" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_717dcac9-7117-4128-becb-8c7799160221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#LegalProceedingsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e49ab615-4549-485d-a18c-3819abfce31a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_7982e945-daa5-45f1-8c41-a9e1714789b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e49ab615-4549-485d-a18c-3819abfce31a" xlink:to="loc_us-gaap_LossContingenciesTable_7982e945-daa5-45f1-8c41-a9e1714789b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d61d610a-1770-449c-a539-05a50308dadd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7982e945-daa5-45f1-8c41-a9e1714789b2" xlink:to="loc_srt_LitigationCaseAxis_d61d610a-1770-449c-a539-05a50308dadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2857825b-c8f0-41b0-92f7-8c4d06e9ad1f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_d61d610a-1770-449c-a539-05a50308dadd" xlink:to="loc_srt_LitigationCaseTypeDomain_2857825b-c8f0-41b0-92f7-8c4d06e9ad1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_9ca44d41-077e-45e8-aee1-88ba1221c92b" xlink:href="jnj-20220102.xsd#jnj_DePuyASRU.S.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2857825b-c8f0-41b0-92f7-8c4d06e9ad1f" xlink:to="loc_jnj_DePuyASRU.S.Member_9ca44d41-077e-45e8-aee1-88ba1221c92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_e7b5db57-e93e-421d-8f54-824a2e774f19" xlink:href="jnj-20220102.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2857825b-c8f0-41b0-92f7-8c4d06e9ad1f" xlink:to="loc_jnj_RisperdalMember_e7b5db57-e93e-421d-8f54-824a2e774f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_94e5c854-9bab-4fab-9291-0b87ee8863b3" xlink:href="jnj-20220102.xsd#jnj_BabyPowderMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2857825b-c8f0-41b0-92f7-8c4d06e9ad1f" xlink:to="loc_jnj_BabyPowderMember_94e5c854-9bab-4fab-9291-0b87ee8863b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_4d613aca-65d8-435e-ab02-df9c3da3dadc" xlink:href="jnj-20220102.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2857825b-c8f0-41b0-92f7-8c4d06e9ad1f" xlink:to="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_4d613aca-65d8-435e-ab02-df9c3da3dadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember_acad771d-d8d1-41bb-b57e-d0ec73db7d27" xlink:href="jnj-20220102.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2857825b-c8f0-41b0-92f7-8c4d06e9ad1f" xlink:to="loc_jnj_SurgicalMeshProductsMarketingMember_acad771d-d8d1-41bb-b57e-d0ec73db7d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_a33d6fe6-3e8f-4003-ba6f-48acaaa0a759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7982e945-daa5-45f1-8c41-a9e1714789b2" xlink:to="loc_us-gaap_LitigationStatusAxis_a33d6fe6-3e8f-4003-ba6f-48acaaa0a759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_f38dabd9-0064-4b90-91f7-ddd23a569ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_a33d6fe6-3e8f-4003-ba6f-48acaaa0a759" xlink:to="loc_us-gaap_LitigationStatusDomain_f38dabd9-0064-4b90-91f7-ddd23a569ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_8a8f7768-5c3e-47ed-940f-b8a6cd1d11e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_f38dabd9-0064-4b90-91f7-ddd23a569ceb" xlink:to="loc_us-gaap_SettledLitigationMember_8a8f7768-5c3e-47ed-940f-b8a6cd1d11e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_36989a8a-1e0a-40dd-aadb-ae22b24ac313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_JudicialRulingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_f38dabd9-0064-4b90-91f7-ddd23a569ceb" xlink:to="loc_us-gaap_JudicialRulingMember_36989a8a-1e0a-40dd-aadb-ae22b24ac313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_28b6bc9a-f22c-48d1-ac43-49504329ad08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_f38dabd9-0064-4b90-91f7-ddd23a569ceb" xlink:to="loc_us-gaap_PendingLitigationMember_28b6bc9a-f22c-48d1-ac43-49504329ad08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_df1b4662-3dba-428a-a7a9-9152e974633e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7982e945-daa5-45f1-8c41-a9e1714789b2" xlink:to="loc_srt_ProductOrServiceAxis_df1b4662-3dba-428a-a7a9-9152e974633e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_df1b4662-3dba-428a-a7a9-9152e974633e" xlink:to="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_da92a80c-1f5a-479d-8737-ed4974930845" xlink:href="jnj-20220102.xsd#jnj_AsrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_AsrMember_da92a80c-1f5a-479d-8737-ed4974930845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_37474a61-4993-4fe8-bf6c-a3655034cad4" xlink:href="jnj-20220102.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_37474a61-4993-4fe8-bf6c-a3655034cad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_d2ab89bd-55ea-41f7-8c20-2f822fe9cf6d" xlink:href="jnj-20220102.xsd#jnj_PelvicMeshesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_PelvicMeshesMember_d2ab89bd-55ea-41f7-8c20-2f822fe9cf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_b0ac8a3e-e754-4f40-8183-13def033eddd" xlink:href="jnj-20220102.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_RisperdalMember_b0ac8a3e-e754-4f40-8183-13def033eddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_7cddc59c-f627-40ad-aeb1-fd76b3b8f2d9" xlink:href="jnj-20220102.xsd#jnj_XareltoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_XareltoMember_7cddc59c-f627-40ad-aeb1-fd76b3b8f2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_7e1ef8c9-282f-4ac9-a006-97c0a466be72" xlink:href="jnj-20220102.xsd#jnj_TalcMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_TalcMember_7e1ef8c9-282f-4ac9-a006-97c0a466be72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember_0dcbf5e0-7228-473b-b52c-6e28872e5007" xlink:href="jnj-20220102.xsd#jnj_InvokanaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_InvokanaMember_0dcbf5e0-7228-473b-b52c-6e28872e5007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_f7700ec3-6608-4314-97a2-0cb8b8c1bac7" xlink:href="jnj-20220102.xsd#jnj_PhysiomeshMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_PhysiomeshMember_f7700ec3-6608-4314-97a2-0cb8b8c1bac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember_8286a093-93f3-4893-b616-bb30c9195eef" xlink:href="jnj-20220102.xsd#jnj_OpioidMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_OpioidMember_8286a093-93f3-4893-b616-bb30c9195eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ContactLensesMember_ddb2de12-7077-4a5b-a3fb-4a3ac61773b8" xlink:href="jnj-20220102.xsd#jnj_ContactLensesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2a463090-6a8c-41e4-abcf-b5b4cda051f6" xlink:to="loc_jnj_ContactLensesMember_ddb2de12-7077-4a5b-a3fb-4a3ac61773b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis_d5f4a937-deba-4437-b4b1-e655c23ecf34" xlink:href="jnj-20220102.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7982e945-daa5-45f1-8c41-a9e1714789b2" xlink:to="loc_jnj_LitigationSettlementByCompaniesAxis_d5f4a937-deba-4437-b4b1-e655c23ecf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_32b5201d-f882-43d9-bcc4-faeee29ddbe8" xlink:href="jnj-20220102.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_d5f4a937-deba-4437-b4b1-e655c23ecf34" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_32b5201d-f882-43d9-bcc4-faeee29ddbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_54441bf6-4eb4-4be1-a2a8-4acf768dc67c" xlink:href="jnj-20220102.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain_32b5201d-f882-43d9-bcc4-faeee29ddbe8" xlink:to="loc_jnj_RisperdalMember_54441bf6-4eb4-4be1-a2a8-4acf768dc67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_addde7f7-20ed-4afb-8747-1d7f94926e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7982e945-daa5-45f1-8c41-a9e1714789b2" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_addde7f7-20ed-4afb-8747-1d7f94926e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_2afe09bb-2356-4ef3-877c-ad845e7b4a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_addde7f7-20ed-4afb-8747-1d7f94926e78" xlink:to="loc_us-gaap_LossContingencyNatureDomain_2afe09bb-2356-4ef3-877c-ad845e7b4a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_1516272c-7461-44ef-aedd-72b55105a8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_2afe09bb-2356-4ef3-877c-ad845e7b4a32" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_1516272c-7461-44ef-aedd-72b55105a8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalJurisdictionAxis_c949a845-7bca-4294-a91d-db1548a8cf7c" xlink:href="jnj-20220102.xsd#jnj_LegalJurisdictionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7982e945-daa5-45f1-8c41-a9e1714789b2" xlink:to="loc_jnj_LegalJurisdictionAxis_c949a845-7bca-4294-a91d-db1548a8cf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalJurisdictionDomain_04b301f7-1884-4682-b3f9-65fa4d4481e2" xlink:href="jnj-20220102.xsd#jnj_LegalJurisdictionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalJurisdictionAxis_c949a845-7bca-4294-a91d-db1548a8cf7c" xlink:to="loc_jnj_LegalJurisdictionDomain_04b301f7-1884-4682-b3f9-65fa4d4481e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StateLevelJurisdictionMember_222c3383-c3f7-41ca-9fc8-89a62ba7c268" xlink:href="jnj-20220102.xsd#jnj_StateLevelJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalJurisdictionDomain_04b301f7-1884-4682-b3f9-65fa4d4481e2" xlink:to="loc_jnj_StateLevelJurisdictionMember_222c3383-c3f7-41ca-9fc8-89a62ba7c268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalLevelJurisdictionMember_97d42dac-ffed-478d-b5d2-abd6aa5d0f27" xlink:href="jnj-20220102.xsd#jnj_FederalLevelJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalJurisdictionDomain_04b301f7-1884-4682-b3f9-65fa4d4481e2" xlink:to="loc_jnj_FederalLevelJurisdictionMember_97d42dac-ffed-478d-b5d2-abd6aa5d0f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c3d6cb90-b874-4b51-9f7d-007c9901134f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7982e945-daa5-45f1-8c41-a9e1714789b2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c3d6cb90-b874-4b51-9f7d-007c9901134f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f9d98f43-06c2-46c8-9749-70a52fade9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c3d6cb90-b874-4b51-9f7d-007c9901134f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f9d98f43-06c2-46c8-9749-70a52fade9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_76bb509e-ecd2-49e4-b6ac-d61fdc77fb12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f9d98f43-06c2-46c8-9749-70a52fade9ef" xlink:to="loc_us-gaap_SubsequentEventMember_76bb509e-ecd2-49e4-b6ac-d61fdc77fb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_e20999f5-8c88-4374-99c2-83f4bc3da6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7982e945-daa5-45f1-8c41-a9e1714789b2" xlink:to="loc_us-gaap_LossContingenciesLineItems_e20999f5-8c88-4374-99c2-83f4bc3da6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:href="jnj-20220102.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e20999f5-8c88-4374-99c2-83f4bc3da6d6" xlink:to="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_a5e55a86-4816-4745-ae2e-915c8accf258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_a5e55a86-4816-4745-ae2e-915c8accf258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_7b942071-fcb9-4e38-91f4-e9e264284fde" xlink:href="jnj-20220102.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_7b942071-fcb9-4e38-91f4-e9e264284fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_50b494bd-b0a3-4065-9b61-dc9ba6da6caa" xlink:href="jnj-20220102.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_50b494bd-b0a3-4065-9b61-dc9ba6da6caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_fe6b63d4-dfa5-4ad7-9f45-5863e7d97619" xlink:href="jnj-20220102.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_jnj_Numberofpatientsinsettlement_fe6b63d4-dfa5-4ad7-9f45-5863e7d97619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_a46b8651-19ff-4359-8ecc-f5c55a951201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_a46b8651-19ff-4359-8ecc-f5c55a951201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue_04720082-de06-4d4e-a52f-9afeee65d57e" xlink:href="jnj-20220102.xsd#jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue_04720082-de06-4d4e-a52f-9afeee65d57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_ddc50c08-7eb2-469e-aac7-4ca5ff2ac4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_ddc50c08-7eb2-469e-aac7-4ca5ff2ac4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_d45d5afe-2867-4e0b-9197-78ed8f6c4ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_d45d5afe-2867-4e0b-9197-78ed8f6c4ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust_5aad8abb-cb3b-46a6-a435-3b7c1b81e375" xlink:href="jnj-20220102.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_jnj_LossContingencyReserveEstablishedWithinTrust_5aad8abb-cb3b-46a6-a435-3b7c1b81e375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_5fb03f22-e5e0-4e91-a0d3-ef92f6ce347f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_5fb03f22-e5e0-4e91-a0d3-ef92f6ce347f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_f2297021-c8cf-460a-ad5b-4bde2454851e" xlink:href="jnj-20220102.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_e7fc5bd5-6e68-4282-8a1d-c56cf4e3e9c1" xlink:to="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_f2297021-c8cf-460a-ad5b-4bde2454851e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Restructuring" xlink:type="simple" xlink:href="jnj-20220102.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_8ccbc750-cce0-4f13-9e37-8dadddab8481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_61b9e334-d771-47c9-b285-e02e00ce846b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_8ccbc750-cce0-4f13-9e37-8dadddab8481" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_61b9e334-d771-47c9-b285-e02e00ce846b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringTables" xlink:type="simple" xlink:href="jnj-20220102.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1b809222-ac1e-46d3-a0b7-263ac75788bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_f3576436-4c64-415b-84cb-05e0346ac852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1b809222-ac1e-46d3-a0b7-263ac75788bb" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_f3576436-4c64-415b-84cb-05e0346ac852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#RestructuringNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2a871444-bbd4-487b-9167-49fd143715b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b977c165-8ccb-4e5a-814d-c4044b5599d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2a871444-bbd4-487b-9167-49fd143715b2" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b977c165-8ccb-4e5a-814d-c4044b5599d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_b6bd741e-2730-4ada-82ff-7fcddf80819e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b977c165-8ccb-4e5a-814d-c4044b5599d6" xlink:to="loc_us-gaap_RestructuringPlanAxis_b6bd741e-2730-4ada-82ff-7fcddf80819e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_5cf49177-b1c0-46be-bdab-7ebf4829a589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_b6bd741e-2730-4ada-82ff-7fcddf80819e" xlink:to="loc_us-gaap_RestructuringPlanDomain_5cf49177-b1c0-46be-bdab-7ebf4829a589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_b12b9091-a4d0-4327-a8fd-2f45af84636d" xlink:href="jnj-20220102.xsd#jnj_SupplyChainMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_5cf49177-b1c0-46be-bdab-7ebf4829a589" xlink:to="loc_jnj_SupplyChainMember_b12b9091-a4d0-4327-a8fd-2f45af84636d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9fe0c326-7bbb-471a-b873-667932c83030" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b977c165-8ccb-4e5a-814d-c4044b5599d6" xlink:to="loc_srt_RangeAxis_9fe0c326-7bbb-471a-b873-667932c83030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52d5d599-d499-477f-9fba-8f530fcf52c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9fe0c326-7bbb-471a-b873-667932c83030" xlink:to="loc_srt_RangeMember_52d5d599-d499-477f-9fba-8f530fcf52c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fbc7f6f5-fcc2-4e78-bc1a-6c83d6098a5b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_52d5d599-d499-477f-9fba-8f530fcf52c8" xlink:to="loc_srt_MinimumMember_fbc7f6f5-fcc2-4e78-bc1a-6c83d6098a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6cca8ba4-c902-4082-9438-2a0b6308b16a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_52d5d599-d499-477f-9fba-8f530fcf52c8" xlink:to="loc_srt_MaximumMember_6cca8ba4-c902-4082-9438-2a0b6308b16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2d43c0f8-b562-459a-a5e7-4f19b9a91f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b977c165-8ccb-4e5a-814d-c4044b5599d6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2d43c0f8-b562-459a-a5e7-4f19b9a91f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ad0960ae-6b0c-4416-a3e0-92ae1b37c1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2d43c0f8-b562-459a-a5e7-4f19b9a91f10" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ad0960ae-6b0c-4416-a3e0-92ae1b37c1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_d24692ae-5834-44b2-afda-7a0a5be68021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad0960ae-6b0c-4416-a3e0-92ae1b37c1a3" xlink:to="loc_us-gaap_RestructuringChargesMember_d24692ae-5834-44b2-afda-7a0a5be68021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_23d84c12-99fb-4734-bd31-57c17e94fe58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad0960ae-6b0c-4416-a3e0-92ae1b37c1a3" xlink:to="loc_us-gaap_CostOfSalesMember_23d84c12-99fb-4734-bd31-57c17e94fe58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_c7b445cb-94b0-4aba-a09d-a16d9094bf8c" xlink:href="jnj-20220102.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad0960ae-6b0c-4416-a3e0-92ae1b37c1a3" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_c7b445cb-94b0-4aba-a09d-a16d9094bf8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_3b8ed519-61fd-4383-ade5-d0d2e9b57892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b977c165-8ccb-4e5a-814d-c4044b5599d6" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_3b8ed519-61fd-4383-ade5-d0d2e9b57892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_94c8eb8d-802d-44e1-a516-acd403f795a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b8ed519-61fd-4383-ade5-d0d2e9b57892" xlink:to="loc_us-gaap_RestructuringCharges_94c8eb8d-802d-44e1-a516-acd403f795a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_54d6199b-cf71-4e40-a047-5df486a372c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b8ed519-61fd-4383-ade5-d0d2e9b57892" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_54d6199b-cf71-4e40-a047-5df486a372c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_9c372e70-0134-4c82-ab12-2ccaf00e7ec7" xlink:href="jnj-20220102.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b8ed519-61fd-4383-ade5-d0d2e9b57892" xlink:to="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_9c372e70-0134-4c82-ab12-2ccaf00e7ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_b7d9acca-4bb2-4a90-ac0c-ee770f945160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b8ed519-61fd-4383-ade5-d0d2e9b57892" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_b7d9acca-4bb2-4a90-ac0c-ee770f945160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_191a9e83-c1db-4bcf-872d-2e5c79fac3e2" xlink:href="jnj-20220102.xsd#jnj_RestructuringandRelatedCostDurationofRestructuringPlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b8ed519-61fd-4383-ade5-d0d2e9b57892" xlink:to="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_191a9e83-c1db-4bcf-872d-2e5c79fac3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails" xlink:type="simple" xlink:href="jnj-20220102.xsd#RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_545719e4-b80f-444b-98eb-3dfda16d97a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6b288e59-64a9-4bb3-b1c1-9293b3ba0fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_545719e4-b80f-444b-98eb-3dfda16d97a7" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6b288e59-64a9-4bb3-b1c1-9293b3ba0fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_dfa324d3-d345-46d3-aada-9e9cf1a1ecc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6b288e59-64a9-4bb3-b1c1-9293b3ba0fc2" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_dfa324d3-d345-46d3-aada-9e9cf1a1ecc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_7c8461c1-0a3e-41ac-a117-ab7e2e18b8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_dfa324d3-d345-46d3-aada-9e9cf1a1ecc0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_7c8461c1-0a3e-41ac-a117-ab7e2e18b8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_e1481304-546e-417f-a196-14355266826f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7c8461c1-0a3e-41ac-a117-ab7e2e18b8a3" xlink:to="loc_us-gaap_EmployeeSeveranceMember_e1481304-546e-417f-a196-14355266826f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember_1de59062-d4ca-4a55-8db6-e9c664faa68a" xlink:href="jnj-20220102.xsd#jnj_AssetWriteoffMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7c8461c1-0a3e-41ac-a117-ab7e2e18b8a3" xlink:to="loc_jnj_AssetWriteoffMember_1de59062-d4ca-4a55-8db6-e9c664faa68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_723dbe6f-56cb-4f2f-942d-7f3244a2baab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7c8461c1-0a3e-41ac-a117-ab7e2e18b8a3" xlink:to="loc_us-gaap_OtherRestructuringMember_723dbe6f-56cb-4f2f-942d-7f3244a2baab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_37438d20-6380-451d-b996-e5c9f5bea2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6b288e59-64a9-4bb3-b1c1-9293b3ba0fc2" xlink:to="loc_us-gaap_RestructuringPlanAxis_37438d20-6380-451d-b996-e5c9f5bea2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_d2db3186-555f-456c-85ce-0e0e2cc63869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_37438d20-6380-451d-b996-e5c9f5bea2a0" xlink:to="loc_us-gaap_RestructuringPlanDomain_d2db3186-555f-456c-85ce-0e0e2cc63869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_e9ecdd9a-766c-4fc8-8135-e579185da1fb" xlink:href="jnj-20220102.xsd#jnj_SupplyChainMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_d2db3186-555f-456c-85ce-0e0e2cc63869" xlink:to="loc_jnj_SupplyChainMember_e9ecdd9a-766c-4fc8-8135-e579185da1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_697a07b5-789d-45e7-bf4f-e273a7b37f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6b288e59-64a9-4bb3-b1c1-9293b3ba0fc2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_697a07b5-789d-45e7-bf4f-e273a7b37f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ad50b66e-38d2-4e43-a311-9701d4fdffa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_697a07b5-789d-45e7-bf4f-e273a7b37f5c" xlink:to="loc_us-gaap_SegmentDomain_ad50b66e-38d2-4e43-a311-9701d4fdffa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_e39a5726-dc4b-474e-a911-cd39078ea3d9" xlink:href="jnj-20220102.xsd#jnj_SupplyChainMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ad50b66e-38d2-4e43-a311-9701d4fdffa6" xlink:to="loc_jnj_SupplyChainMember_e39a5726-dc4b-474e-a911-cd39078ea3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_aa26c795-ebe9-4d68-afb2-2d837c776f20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6b288e59-64a9-4bb3-b1c1-9293b3ba0fc2" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_aa26c795-ebe9-4d68-afb2-2d837c776f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_7210c446-6c4a-4f2f-975c-54845811673b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_aa26c795-ebe9-4d68-afb2-2d837c776f20" xlink:to="loc_us-gaap_RestructuringReserveRollForward_7210c446-6c4a-4f2f-975c-54845811673b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_727cb457-fc23-461b-9a8c-52dbbc101650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7210c446-6c4a-4f2f-975c-54845811673b" xlink:to="loc_us-gaap_RestructuringReserve_727cb457-fc23-461b-9a8c-52dbbc101650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_96a00e46-9043-4d72-aef9-438cd075e7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7210c446-6c4a-4f2f-975c-54845811673b" xlink:to="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_96a00e46-9043-4d72-aef9-438cd075e7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ee864ecd-ee3c-4bce-b394-25ae01592f93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7210c446-6c4a-4f2f-975c-54845811673b" xlink:to="loc_us-gaap_RestructuringCharges_ee864ecd-ee3c-4bce-b394-25ae01592f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_e1994b2c-3356-4e10-a116-279d5b006e28" xlink:href="jnj-20220102.xsd#jnj_GainOnSaleOfAnAssetPaymentForRestructuring"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7210c446-6c4a-4f2f-975c-54845811673b" xlink:to="loc_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_e1994b2c-3356-4e10-a116-279d5b006e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_a6b8daf0-6cb2-4a32-a6a6-db410a536e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7210c446-6c4a-4f2f-975c-54845811673b" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_a6b8daf0-6cb2-4a32-a6a6-db410a536e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_b4b32a2f-4b3d-41c2-9586-9a9810f33c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7210c446-6c4a-4f2f-975c-54845811673b" xlink:to="loc_us-gaap_RestructuringReserve_b4b32a2f-4b3d-41c2-9586-9a9810f33c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>jnj-20220102_g1.jpg
<TEXT>
begin 644 jnj-20220102_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'>@#W&BLKP)=>+;[P3H][X^L+6TUV;2[>36;6Q),,%T8U,L<98DE5<L 2<D
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M(_V9O^"?/P+T7Q7?>"I/)\8>,?%M^\.E6-SN*F +&R,[!U9,A]Q:.3:A5"]
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M$=_L;ROL'DI;IO\ M'G-YN?(SCRTQNZG'(!X7^WT /\ @JG^RLP'/VK4N?\
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MOM4\'ZEX9M]3L8KACEG@$VY8QV \LL  N\@   ?^QA^V_P#M4W'[4U_^PO\
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MRHW"I\R*6+[0  9'_!9CX3^*[W]FWPU^U#X)4#QE\&?$5IKUK<Q+D^1YD:W
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M.SYT/'&'C]JO_P#!P-<Z /V(=-TV_"/J=UX]L!HD0YE,PAN-Q0=?]67!Q_>
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M?V<O^"L:Z1=-KO\ P4>\'K8BVD-XUS\+[$1B+:=Y8F/ 7;G.>U>-V/P2\-_
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MP+MY^9DXR171_$NTMKG_ (+_ /P]FGA5F@^$,TD)(^XV-37(_!F'XUWOP/\
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M,@U]H?M026$7[-/Q$EU4@6J^!=7-R6Z",6<N[/X9KYY\&_\ !-CXT?$7XO\
MACXQ_MX?M<W?Q/?P7>B]\->&K'PY;Z9I\-TK*RS2K#A92"JG&Q22@#,RY4]#
M_P %</BKJ?@G]C[5/AAX,@>[\5_%"^@\(^&=,@.9+J2[8), /3R/,7/0,Z ]
M: ,C_@A]#J,7_!-WP2U\&\N2_P!7:TW?\\_[1N!Q[;P]?6M<)^S!\$]._9Q_
M9Z\'_ [394E7PUH,%I<3QC"SW 7=/*!VWRL[X_VJ[N@ HHHH **** "BBB@
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MBYJ^@:UX;\3WY)U+6O!VM/827C'&6D4!HRQQRP4,W5B37TA10!X[^RS^P?\
MLS_L=B^O?@OX&>+5M439J?B'5;Q[N_NDW;MAE<_*I8 E4"J2 2"0#7L5%% !
M1110 4444 %%%% ' 6O[-WPYTS]HNZ_:@T,W]AXEU+0%TC6X[.Y5;35($8-$
M]Q$5.^6/ 59 0P4;3E>*[^BB@ HHHH *\ZU']ECX/ZI^TM8?M:WFDW9\::;H
M1TBUO!?N(5M3YF5,6=I/[U_FZ\^U>BT4 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.57\51+Y7_R.*7$M%?#3;^=O\SZ%HKYTWONW[SGUS3DN;F-MT=PZGU#D5?\
MJV_^?O\ Y+_P2%Q,O^?7_DW_  #Z)HKP"#Q)XBM2#;:]>QXZ;+IQ_6N'_:W_
M &K?B?\ L]_LS^+_ (J^'?%)2_TK2Q_9TEU;QS*MS+(D,1(=3NP\B\'K3H\*
MXS%8B%&C-.4VHJ]UJW9=PJ\5X/#T)UJT&HQ3;M9Z)7?8^MZ*_'+X7_\ !QC^
MTOX>\NW^+'P9\)>)H4X:739)]-N)![MF://TC ]J^HO@I_P<"_L8_$+RK'XI
MZ1XC\!WCX$DM]8_;K-2>PEMMTA^K1*/Z>OF?AAQKEB<I85U(KK3:G_Y*O>_\
ME/.R[Q(X/S%J*Q*A)])IQ_%^[_Y,?==%<A\(OC_\$?CYHYU[X+_%;0?$ULB@
MS-H^IQS/#GM(BG=&?9@#77U\+6H5L/5=.K%QDMTTTUZIZGVU&M1Q%-5*4E*+
MV:=T_F@HHHK(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^8_V\_V,-*_:
M'L]<^)?Q8^*>OWGA3PQX+NKG2/AS9S?9].?4X8KB07URR'=<$9C"H<!?+ZD.
MRU7_ .":7B5O!G_!*OP3XP2(.=)\':A>!&Z,8I[I\?\ CM>Y_M$?\F_^.O\
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MM?JU*K2K4U4IR4HO5-.Z:\FC\RJ4ZE&HX5$U):-/1KU044459 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5IG[5I]CJL,L\.#@[XU8LN#QR*U;V]L].M)=0U"[B@@AC+S3S2!4C4#)9B>
M .YK\X/V_P#X"?L2?L\?"W0_AS^QUH^EZ;\?M'U_2XO =GX/O?.U][GS8S(U
MV(V,A1K<R.6F 4DKC@D5]6?M9?LD>*?VOD^'WA/QSX]2Q\%:3JG]H?$/PI:+
M*O\ PD+)&IA@\U'4K$L@<LI^\&!!#(IH ]B\)^// WCRVEO? WC/2=:AA?9-
M+I.HQ7*QMZ,8V(!]C6M7YZ^(_#'[-?@__@H;\&],_P""<$&BQZY%?W</Q4M/
M -P)--CT(*H;[=Y),*R []@/S[PF?F\NOT*H S/%7C7P;X%L%U7QOXMTS1K5
MY B7.JW\=O&S'^$-(P!/M5S3-4TS6M/AU;1M1@N[6XC#V]S:S+)'*IZ,K*2&
M'N*^%O@I\&_AY^W-^W[\=?&'[4FC1>*8/AGK5MX=\&>$=68O9:=;,LF^Y\@G
M:[2F+<"P(RSGG";=S]G&/PW^R=_P4_\ $_[&GPFNI+;P'XJ^'T?BJS\,+<M)
M!H>JK.8Y4@5B3$DL0:1D'&2F,    ^LS\7/A0OCO_A5K?$[P\/$Y3>/#AUJ#
M[?MV[L_9]_F8V\YV].:T/%7B[PGX$T*;Q3XW\3Z=HVF6Q07&HZK>QV\$1=PB
M[I)"%7+,JC)Y+ =37Y3ZB?A4W_!/?7[>X;1C^T__ ,+G8PK^[_X23_A(?[?7
M84S^_P!GV7.,?)C=WK[.^+Q?]K+]L[P_^SK!B?P;\)3:^*_B&5YBO-8<$Z5I
MS>H0;KMU.58",'!Q0!]-]>E%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7R'^VEXH;7/C"VBQRYBTBPB@V@\!W'F,?KAU'_ :^O*^ _B;K[>*?B)K
MGB$R;EN]4GDC.?X-YVC\%P/PK[WP_P *JN:5*[^Q'\9/_),_/_$3%NEE=.@O
MMR_"*_S:,.BBBOU\_&PHHHH **** "BBB@ IT44D\BPPQL[NP5$49+$] !3:
M]A_8W^&$?C+X@OXNU2WWV.@A94##A[EL^6/^ X+^Q"^M<.98ZEEF!J8FIM%7
M]7T7S>AW99@*N:8^GA:>\G;T75_):GN/[-WP5MOA)X,674;=3K6I(LFHRGDQ
M#JL(/HN>?5L]L8]&HHK^>\;C*^/Q4\16=Y2=W_EZ+9']&8+!X?+\)##T5:,5
M9?YOS>[\PHHHKE.H**** "BBB@ HHHH **** (KZQLM3LIM-U*SBN+:XB:*X
MMYXPZ2HPPRLIX(()!!X(-?@O_P %;?V!7_8H^/G]I^"-/E'@+Q>TEWX:?!9;
M&0',UBS?],RP*$\F-UY)5C7[VUXE_P %"OV4-+_;(_98\1_"-[2-M92 ZAX5
MN7P#!J<*L8>3]U7RT3'^Y*W?%?>^'G%E3A7/H2G+]Q4:C472W27K%Z^EUU/A
M^/>%Z?$V1RC"/[ZG>5-];]8^DEIZV?0_G0HJ6^L;S3+V;3=1M9(+BWE:*>"9
M"KQNIPRL#R""""*BK^STTU='\AM-.S"BBB@ HHHH **** "BBB@#^BO_ ()K
M_%^3XY?L+_#7Q_=WAGNSX;CT_4)6;+/<6;-:2,WNS0EO^!9[U[C7YZ_\&Z7Q
M+G\1?LN>+OAC=W&]_#7C#[1;J3S'!=P(0OT\R&9OJQK]"J_AGC/+EE/%6,PJ
M5E&I)K_#+WH_@T?VCPCF#S3AG"8EN[<$GZQ]U_BF%>:?M7_M1^"?V0/A1_PN
M3XB^'=;O]&CU:VL;R31+6.5K,3ML6>4.Z;8@V%)&YLNH"G/'I=9WB_PAX6\?
M^&+_ ,%>-_#UGJVD:G;-;ZAIU_ LL-Q$PP496X(KYD^C/DW_ (*A?!?]D6?]
MDGQC^TS/X?\ #>C^*X]/35?"OQ!T*.*VU*ZU/:IL]EW#B2?S,(H!9AL.X8VA
MAV/PX_;6MOA=X&_9]\ ?M-:9K-KXI^*WABV1_$$]O$EE#J*V<3M'=,TBM'-*
M\B ($(WR8XP<2^"_^"3W["/@7Q;8^+]+^#4EV^E7/VC2--UC7[V]L;*3.=T=
MM/,T?7D!@P'7L*]=^./P!^#W[27@.;X9_&_P%9>(=%FE67[+=[E:*500)(I$
M*O$X!(WHRMAB,X)% 'QI_P %*?A#\&?V9?$GPB^)/[)_@S1_!?Q5O?B58Z?H
M]AX/LX[)];LI2PN(IX( JSQEO*5G93_K-I.'K[JNO%_A.Q\1VW@Z]\4:=#J]
M[$TMGI4M[&MS/&H)9TB)W,H"MD@$#:?2O(O@5_P3L_9*_9V\<+\3?A]\-I9O
M$<4)AM-<U[6+K4;BTC((VPFYD<0\%AE &(8@G!(KN/$'[.OP;\4_''0?VD=>
M\'>?XT\,:=-8:'K/]H7"_9K>595D3R5D$3Y$T@RZ,1NX(P, 'S;X[^ OP8_:
M$_;9\:ZE^SE^T=XQ^%7Q?\,:=90>/?[$M5$.L6LL0,$K0S#;<;4$0\Q<JN8\
MC<0:X?\ 9/\ @=X3TK_@K9XDU#P!XTUKQ>O@/X;?9?'OC;7=1^UW.H>(;NXX
MC>10$79;*(Q$@ C%N4QD&OI_]H7]@[]F#]I[Q/9^.OBM\/Y7U^QM_L\&O:/J
MUSI]X8.?W3R6\B&1.3@/G&3C&3GK?@1^SO\ !C]F;P.OPZ^!W@&ST#2A,9I8
M;<N\EQ*0 9999"TDKD #<[$X '0 4 <S^TSKWP+_ &;/!'B']KCQ-\+=!N?$
M>BZ=ML=331H3J5]<OB&WM(YPGFDR2,D8 / ;T%?,.L_#3XN_"?1?@E^S5XB^
M(VK^'O$GQX\=ZIKWQD\6>'+TVM]+=K:?:WL(;A<F%.8[=2A!VP?+@,P/V+\6
M?@1X$^->K^%-3\?"\N(?!WB*/7-,TV.XVVTU]$K+#+,F,R>66+(,@!L$YP*K
M_M ?LX_#']I;PG:>%?B39WR-I>I1ZCHFKZ/J,EG?Z7>1Y"7%O/$0T;@$CT.>
M0>* /'_V'_$OCGPI^T9\</V3M<^(>N>*] ^'=_H=SX8U;Q+J#7E_!%J-DT\E
MG+<-\THC9/D+$L%;!/0#Z;K@?@#^S;\,OV;M"U'2?A_!J-Q=ZWJ+7_B#7M=U
M.2^U'5;H@+YMQ<2DLY"@ #A1S@ DD]]0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!F>-=6;0?!NK:XC[39:9/.&]"D;-G]*_/JON;]H6\:P^"?B6=6P6
MTMX\_P"_A/\ V:OAFOUCP[I)8*O4[R2^Y7_4_(_$BJWC:%+M%O[W;] HHHK]
M$/S<**** "BBB@ HHHH *^U/V6O!2>"_@SI8DAVW&IJ;^Y)'),F"GY1A!^=?
M&NAZ7+K>M6>BP'Y[RZC@3ZNP4?SK]"K*TM]/LXK"TC"101+'$@_A4# 'Y"OS
MKQ#QDH86CAD_B;D_^W=%^?X'Z3X<X.,\76Q37PI17_;VK_!?B24445^4'ZV%
M%%% !1110 4444 %%%% !1110 4444 ?@=_P6;_9_@^ G[>7B=M)L/(TKQC'
M'XDTY57"YN2PN .W_'S'.<=@RU\J5^K7_!R5\-89?#_PP^,-M;8D@O+_ $:\
MF ^\LB1SPJ?H8YS_ ,"-?E+7]L>'F:3S?@["5YN\E'D?K!N.OFTD_F?QUQYE
ML<JXMQ5&"M%RYEZ32EIZ-M?(****^T/D HHHH **** "BBB@#](?^#;OQQ-8
M?'7XC_#82'R]5\)6VILN>IM+H1 _^3IK]>Z_#K_@@1XD.A_\% ;;3 ^/[9\'
MZG9D>NT1W&/_ "!^E?N+7\C>,>&5#C6<U]N$)?AR_P#MI_5'A+B'6X/A#^2<
MX_CS?^W!1117Y8?I@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'GO[54C1_ +Q"RG&8[<?G<Q"OBFOM;]JJ)IO@%XA1
M.HCMV_ 7,1/\J^*:_8?#VW]CU/\ KX__ $F)^->(M_[9I_\ 7M?^E2"BBBON
MSX **** "BBB@ HHHH ZGX'VJ7GQB\,02 $?VY;,0?\ 9D#?TK[OKX0^!]TE
ME\8?#$[D ?VY;*2?]J0+_6ON^OR;Q$YOK]'MRO\ ,_7O#BW]GU^_,OR"BBBO
MSP_1@HHHH **** "BBB@ HHHH **** "BBB@#X3_ .#AC1X=1_87TO4'7Y]/
M^(=A,C>FZUO(R/I\_P"@K\3Z_;#_ (.&-8AT[]A?2]/=\/J'Q#L(47UVVMY(
M?P^3]17XGU_6O@US?ZF*_P#S\G;\/UN?RUXN<O\ K>[?\^X7_']+!1117ZN?
MF 4444 %%%% !1110!]9?\$0;S[+_P %*/ <&<?:+36(_KC2[I__ &6OWJK\
M%?\ @B%9?:O^"E/@.?;G[-::Q)],Z7=)_P"SU^]5?RKXW6_UMI6_Y\Q_]+J'
M]->#5_\ 5:K?_G]+_P!(IA1117XZ?K04444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% '&_M"V+:A\$_$L"#)72WE_!,.?_
M $&OAFOT%\:Z2VO^#M6T)%RU[ID\ 'J7C9?ZU^?73K7ZQX=U4\%7I]I)_>K?
MH?D?B12:QM"KWBU]SO\ J%%%%?HA^;A1110 4444 %%%% %K0]4ET36K/6H/
MOV=U'.F/5&##^5?H597=OJ%G%?VD@>*>)9(F'=2,@_D:_.NOM3]EKQJGC3X-
M:89)MUQIBFPN03R#& $_.,H?SK\Z\0\'*>%HXE?9;B_^WM5^7XGZ3X<XR,,7
M6PK?Q)27_;NC_!_@>B4445^4'ZV%%%% !1110 4444 %%%% !1110 4444 ?
ME[_P<E?$J&+P_P###X/6USF2>\O]9O(0?NK&D<$+'Z^9./\ @)K\I:^J_P#@
MLY\?X/CW^WEXG72;[S]*\'1Q^&].96RN;8L;@CM_Q\R3C/<*M?*E?VQX>97/
M*.#L)0FK2<>=^LVY:^:32^1_'7'N91S7BW%5H.\5+E7I!*.GJTW\PHHHK[0^
M0"BBB@ HHHH **** /M?_@@1X;?7/^"@-MJ:J2-&\'ZG>,1V#"*W_P#:]?N+
M7Y"?\&W?@>:_^.OQ'^) B_=Z5X2MM-9\=&N[H2@?^29_*OU[K^1O&/$JOQK.
M'\D(1_#F_P#;C^J/"7#NCP?"?\\YR_'E_P#;0HHHK\L/TP**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#Y-\2>$_VS_VLOVE_&WA:3XJ^+_@[\,?!<MO9:!-H&E)
M#?>*+EE)ENEN9D;]RC*5 3*D,G&<FJO[,'QP^-GP6_:T\?\ [%7[0/Q7E\?:
M;X;\#KXP\.^,;NRCBOX;$21QRVMT(QB1P9 58_,0I).'54]$_;&_;?T3]FZ;
M3?A9\//"=QXW^*OBI2GA'P)IG,DI.1]IN6'^HME(8ECC=L;& KNF9^Q;^QEX
MB^$\/BOXT?M+>)(/%'Q2^):AO&FH1C_1;.VVX33K8=H47"DC&[:HZ(M 'D'[
M,F@?MD?\%#_A[<?M:ZU^V!XD^&>D:[J%VOP_\)>#[*W,%E:P3O"LEV9%)NF,
MD;94D9"Y#!7"+[7_ ,$_/VD_B%\<_!OBWX?_ !M-B_CSX8^,+KPSXHO--B\N
M#46A/[J]1!P@D ;*C W(Q 4$*/'/V=OA-_P4+_9!\-77P$_9DLOAM\1_AJ-4
MNI?!'B;7/$4D$NC12S.[PW*0@^>$E9R1'DDEOF&0B)_P1Z\'^*/#GQ1_:0O_
M !/XQ'B.Y?XG+9ZEX@CM_*BOM2A69[QT0$A5\V?A<\+MH ^XZ_/_ /:9_;O^
M+WC7]N#X7_#KX":W=6'PTTOXMV'ACQ1K]G*%3Q#JC2(US9(?XX((R$?& 7E/
M4!37LW_!4S]HSXA_ GX#6?ASX5Z9K*:QXWU0:._B+1]*EO'T"S89N;P1Q NT
MJQDB,#'S-NR"H!^-_CI^U!^RKX,A_9I^'/P0^'_CS3M!^&GQ*L[^\35O!MS;
MSWD:E6ED0, ;BXD?<[*O)9C@#@4 ?9_[=WC?XBW_ ,5O@Q^S!X'^(6K>$;+X
MF>)M03Q#XC\/W AOX[2QM/M!MH)B#Y+2D@;U&X;.."0<S]E+XP^(_A/\4OC_
M / ?XP?%K4_$/A?X.R:5J>F^+?%%R)KV'3[W3WO)8+B8*#-Y/EMAV!<AN3T
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MJ2>XN)6EGGF<L\CL<LS$\DDDDFHJ**_L]))61_(;;;NPHHHH **** "BBB@
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M5X]^+?Q.U^SU?QE\0/$9N]0O;%7\FSTZ%?*L+"(N 2D,6<G W/(YYX->M44
M?&M__P $U?C%<^"-3_9*@^-F@I\"=6\7G6[C2SH4W]NQVS7@O6TM)Q+Y(A,R
M@^:4\P G@CY:^R5544(B@ #  ' %+10 4444 %>*?MP>#&UKX<V?BZVAW2Z-
M>XE8#I#+A2?^^Q'^9KVNLWQAX:LO&7A74/"NH#]SJ%G) [8SMW*0&'N#@CW%
M>CE&.>6YG2Q/2+5_39_@V>;G& 69Y75PW62=O7=?BD?GS15K7-&O_#NLW>@Z
MK"8[FRN7@G0]G5BI_455K^BHRC.*E%W3/YNE&4).,E9H****8@HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW#V$O*6(EZ+]7^GWGR_$6,M&.&CUU?Z+]?N"BBBOJCY,**** "BBB@ HHHH
M**** "BBB@ HHHH ****  $@Y!KR']H#]FJV\<^?XV\ 6R0:V<O>V"X6/4#U
M+KV6;U[2=>'R7]>KZ(_8C_8IU3X\:Q#\0/']G+;>#K.;.#E'U613S%&>HC!X
M=Q[JO.2OFYMG."R#!2QV)GRQC][?\J75OM\]+77KY'E689WF$<%@X<TI?<EU
MDWT2[_+6]GXS_P $7_\ @EQ<_%7Q);?M6?M#^%Y(_#.C7I_X1;0=0MRO]K7D
M3X,\J,.8(G4@*1^\D4@_*C!_V"J'3]/L-)L(=+TNSBM[:VB6*WMX$"I&BC"J
MH'   P *FK^3>+>*L?Q;FTL7B-(K2$>D8]O5[M]7Y62_KWA;AG \+97'"T-9
M/6<NLI=_1;)=%YW;****^7/I HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X'XY_
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MPMPGE?"F"]CAE>;^*;^*3_1+I'IYN[91117S)]0%%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJAJ?BGPQHNJV.AZSXCL+2]U1W33+.YO$CENV0 N(D8@R%002%!QD9KY1O/\
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M_!][\<OAQ^PS\0]?^%6GF62;QQ'<VL$LUK$2);J"QD;S98EVL=V0,*=VW#
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MV=?@Y\</$?A3Q7\4_!_]K7O@C6!JOAEI-0N(H[2\!0K,8HY%CF(*+CS%<#G
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M+W5_@AX'_8I^"M_;Q:S\9/$EIH.GFW?<EMI4+QM<394D^6O[E6]8VD]*Z/\
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MP/\ L2^ ;]HM?^-/B^VTN=XN6M]*ADCDNICCD*"8L^J>8.<$5]A44 ?*,?\
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M(0';LD1%*H\A.&B+#[WU#2],U>$6VJZ=!=1JP81W$*NH;UP0>:G "@*HP!T
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H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>jnj-20220102_g10.jpg
<TEXT>
begin 644 jnj-20220102_g10.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1"X17AI9@  34T *@    @ ! $[  (
M   7   (2H=I  0    !   (8IR=  $    N   0@NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=U>FUA;BP@
M06YD<F5A(%M*2D-54UT    !ZAP !P  " P   AT     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHT 9W]N6G_/*_P#_  77'_Q%']N6G_/*_P#_  77'_Q%:-% &=_;EI_SRO\
M_P %UQ_\11_;EI_SRO\ _P %UQ_\16C10!G?VY:?\\K_ /\ !=<?_$4?VY:?
M\\K_ /\ !=<?_$5HT4 9W]N6G_/*_P#_  77'_Q%']N6G_/*_P#_  77'_Q%
M:-% &=_;EI_SRO\ _P %UQ_\11_;EI_SRO\ _P %UQ_\16C10!G?VY:?\\K_
M /\ !=<?_$4?VY:?\\K_ /\ !=<?_$5HT4 9W]N6G_/*_P#_  77'_Q%']N6
MG_/*_P#_  77'_Q%:-% &=_;EI_SRO\ _P %UQ_\11_;EI_SRO\ _P %UQ_\
M16C10!G?VY:?\\K_ /\ !=<?_$4?VY:?\\K_ /\ !=<?_$5HT4 9W]N6G_/*
M_P#_  77'_Q%']N6G_/*_P#_  77'_Q%:-% &=_;EI_SRO\ _P %UQ_\11_;
MEI_SRO\ _P %UQ_\16C10!G?VY:?\\K_ /\ !=<?_$4?VY:?\\K_ /\ !=<?
M_$5HT4 9W]N6G_/*_P#_  77'_Q%']N6G_/*_P#_  77'_Q%:-% &=_;EI_S
MRO\ _P %UQ_\11_;EI_SRO\ _P %UQ_\16C10!G?VY:?\\K_ /\ !=<?_$4?
MVY:?\\K_ /\ !=<?_$5HT4 9W]N6G_/*_P#_  77'_Q%']N6G_/*_P#_  77
M'_Q%:-% &=_;EI_SRO\ _P %UQ_\11_;EI_SRO\ _P %UQ_\16C10!G?VY:?
M\\K_ /\ !=<?_$4?VY:?\\K_ /\ !=<?_$5HT4 9W]N6G_/*_P#_  77'_Q%
M']N6G_/*_P#_  77'_Q%:-% &=_;EI_SRO\ _P %UQ_\11_;EI_SRO\ _P %
MUQ_\16C10!G?VY:?\\K_ /\ !=<?_$4?VY:?\\K_ /\ !=<?_$5HT4 9W]N6
MG_/*_P#_  77'_Q%']N6G_/*_P#_  77'_Q%:-% &=_;EI_SRO\ _P %UQ_\
M11_;EI_SRO\ _P %UQ_\16C10!G?VY:?\\K_ /\ !=<?_$4?VY:?\\K_ /\
M!=<?_$5HT4 9W]N6G_/*_P#_  77'_Q%']N6G_/*_P#_  77'_Q%:-% &=_;
MEI_SRO\ _P %UQ_\11_;EI_SRO\ _P %UQ_\16C10!G?VY:?\\K_ /\ !=<?
M_$4?VY:?\\K_ /\ !=<?_$5HT4 9W]N6G_/*_P#_  77'_Q%']N6G_/*_P#_
M  77'_Q%:-% &=_;EI_SRO\ _P %UQ_\11_;EI_SRO\ _P %UQ_\16C10!G?
MVY:?\\K_ /\ !=<?_$4?VY:?\\K_ /\ !=<?_$5HT4 9W]N6G_/*_P#_  77
M'_Q%']N6G_/*_P#_  77'_Q%:-% &=_;EI_SRO\ _P %UQ_\11_;EI_SRO\
M_P %UQ_\16C10!G?VY:?\\K_ /\ !=<?_$4?VY:?\\K_ /\ !=<?_$5HT4 9
MW]N6G_/*_P#_  77'_Q%']N6G_/*_P#_  77'_Q%:-% &=_;EI_SRO\ _P %
MUQ_\11_;EI_SRO\ _P %UQ_\16C10!G?VY:?\\K_ /\ !=<?_$4?VY:?\\K_
M /\ !=<?_$5HT4 9W]N6G_/*_P#_  77'_Q%']N6G_/*_P#_  77'_Q%:-%
M&=_;EI_SRO\ _P %UQ_\11_;EI_SRO\ _P %UQ_\16C10!G?VY:?\\K_ /\
M!=<?_$4?VY:?\\K_ /\ !=<?_$5HT4 9W]N6G_/*_P#_  77'_Q%']N6G_/*
M_P#_  77'_Q%:-% &=_;EI_SRO\ _P %UQ_\11_;EI_SRO\ _P %UQ_\16C1
M0!G?VY:?\\K_ /\ !=<?_$4?VY:?\\K_ /\ !=<?_$5HT4 9W]N6G_/*_P#_
M  77'_Q%']N6G_/*_P#_  77'_Q%:-% &=_;EI_SRO\ _P %UQ_\11_;EI_S
MRO\ _P %UQ_\16C10!G?VY:?\\K_ /\ !=<?_$4?VY:?\\K_ /\ !=<?_$5H
MT4 9W]N6G_/*_P#_  77'_Q%']N6G_/*_P#_  77'_Q%:-,>:.)D$DBH9&VH
M&8#<?0>IH @M-0AO&984N%*C)\ZVDB'X%U&:M5A:-XLLM;\1:UHUM;7L5QHS
MHD\D\&R.0N"1Y;9^;&.>G48R.:W: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHK$\:W$UIX \07%K+)#/#IER\<L;%61A$Q# CD$'G- &W17DFB_$
MF]T?X>>"K*UTV\\4>)]:L1)%;-<A#(%&7DDF?...YSG':LCX@?$V]UGX,^))
M;.+4/#'B+1;Z"UOK9+DB2!C*N"DJ8W(PS@C&<'M@D ]RHKRJZ^,]YIFHZK9Z
MWX.NM-DM]*EU;3Q->(QO(4)X?:#Y3$#[OS$=^V7:#\8[_4]<\-VVK^#;K2=.
M\2QYT^_>]27>X0,08U&57)P&)!88..H !ZG17E.G?&JXU;QM/I&F^$KF[TVW
MU$V$][;WB27$.#M,S6B@R"(-U<\8]_EJ]XA^*FH6?B#5=,\)^#[KQ&NAQA]5
MN$NT@6#*[MJ!@3*VT'Y1SD8&: /2**\QU3XSQAO"O_"+^'KC7?\ A)[>:6UC
M6X6"1'C'^K8,"H^;(9MV% 8C=CG?^'WCJ3QK:ZHE]H\FC:EI-ZUG>6;SB8(X
M[AP &'7MVXR,&@#KZ*^>_CEXLN[#XB6NECQ/JEC:OI;K:VNAWZ6\D=\S?(UR
M21B,@KR3P 2,<D^W^%Y;^7PMIW]LW4%WJ:0+%>S6Y4HUPGRRCY>,APP(&,$$
M8'2@#5HKA/C7J-[I7P<UZ]TN\GLKN)(C'/;2M'(F9D!PRD$<$C\:JZI\1]0T
M_4M.\.>%_#=QXGUQM/CO+J/[8ELD,1& S2.""Q/;WZT >BT5X=XP^*#ZUX9\
M$Z_H7]JV)/B>&UU'387*3ED)\RW8 @/GC . <C(!R!TEG\7;Q;3Q9%KWA272
M=7\-68O'L6ODF6>,IN7$JK@'Z XSZY  /3:*\IT?XT7MWJOA]-:\&W6DZ7XA
MA9[&_:\28NRQAV'EJ,A<G )(+#!QR0'^!/C+=>-]<MX(?"5Q#I-TTBQZC;WJ
M71A*YV_:(D&8-P!QN/)QC(RP /4Z*\JU+XU7-O)JFH:3X-OM4\,:/<FVO]7B
MNHT965@',<)&9 ,CG('4G &:MZQ\6+V+QG%X=\)^%9/$<UUI4>IVLL5\ENKH
MS?Q;UPB[>=V222HQSD 'I5%<S\/O&D/C[P=;ZY#9R6+2.\4MM(VXQ.C8(S@9
M'O@?2NFH **** "BBB@ HHHH **** "BBB@#.\/?\BSI?_7G%_Z *T:SO#W_
M "+.E_\ 7G%_Z *T: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW&<<&O4Z* /+])^$UQX?\1?#^73+R"73_"]M=QW32[DEG>=&RR* 1@NQ."W
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M70!HT5G?V':?\]K_ /\ !C/_ /%T?V':?\]K_P#\&,__ ,70!HT5G?V':?\
M/:__ /!C/_\ %T?V':?\]K__ ,&,_P#\70!HT5G?V':?\]K_ /\ !C/_ /%T
M?V':?\]K_P#\&,__ ,70!HT5G?V':?\ /:__ /!C/_\ %T?V':?\]K__ ,&,
M_P#\70!HT5G?V':?\]K_ /\ !C/_ /%T?V':?\]K_P#\&,__ ,70!HT5G?V'
M:?\ /:__ /!C/_\ %T?V':?\]K__ ,&,_P#\70!HT5G?V':?\]K_ /\ !C/_
M /%T?V':?\]K_P#\&,__ ,70!HT5G?V':?\ /:__ /!C/_\ %T?V':?\]K__
M ,&,_P#\70!HT5G?V':?\]K_ /\ !C/_ /%T?V':?\]K_P#\&,__ ,70!HT5
MG?V':?\ /:__ /!C/_\ %T?V':?\]K__ ,&,_P#\70!HT5G?V':?\]K_ /\
M!C/_ /%T?V':?\]K_P#\&,__ ,70!HT5G?V':?\ /:__ /!C/_\ %T?V':?\
M]K__ ,&,_P#\70!HT5G?V':?\]K_ /\ !C/_ /%T?V':?\]K_P#\&,__ ,70
M!HT5G?V':?\ /:__ /!C/_\ %T?V':?\]K__ ,&,_P#\70!HT5G?V':?\]K_
M /\ !C/_ /%T?V':?\]K_P#\&,__ ,70!HT5G?V':?\ /:__ /!C/_\ %T?V
M':?\]K__ ,&,_P#\70!HT5G?V':?\]K_ /\ !C/_ /%T?V':?\]K_P#\&,__
M ,70!HT5G?V':?\ /:__ /!C/_\ %T?V':?\]K__ ,&,_P#\70!HT5G?V':?
M\]K_ /\ !C/_ /%T?V':?\]K_P#\&,__ ,70!HT5G?V':?\ /:__ /!C/_\
M%T?V':?\]K__ ,&,_P#\70!HT5G?V':?\]K_ /\ !C/_ /%T?V':?\]K_P#\
M&,__ ,70!HT5G?V':?\ /:__ /!C/_\ %T?V':?\]K__ ,&,_P#\70!HT5G?
MV':?\]K_ /\ !C/_ /%T?V':?\]K_P#\&,__ ,70!HT5G?V':?\ /:__ /!C
M/_\ %T?V':?\]K__ ,&,_P#\70!HT5G?V':?\]K_ /\ !C/_ /%T?V':?\]K
M_P#\&,__ ,70!HT5G?V':?\ /:__ /!C/_\ %T?V':?\]K__ ,&,_P#\70!H
MT5G?V':?\]K_ /\ !C/_ /%T?V':?\]K_P#\&,__ ,70!HT5G?V':?\ /:__
M /!C/_\ %T?V':?\]K__ ,&,_P#\70!HT5G?V':?\]K_ /\ !C/_ /%T?V':
M?\]K_P#\&,__ ,70!HT5G?V':?\ /:__ /!C/_\ %T?V':?\]K__ ,&,_P#\
M70!HT5G?V':?\]K_ /\ !C/_ /%T?V':?\]K_P#\&,__ ,70!HT5G?V':?\
M/:__ /!C/_\ %T?V':?\]K__ ,&,_P#\70!HT5G?V':?\]K_ /\ !C/_ /%T
M?V':?\]K_P#\&,__ ,70!HT5G?V':?\ /:__ /!C/_\ %T?V':?\]K__ ,&,
M_P#\70!HT5G?V':?\]K_ /\ !C/_ /%T?V':?\]K_P#\&,__ ,70!HT5G?V'
M:?\ /:__ /!C/_\ %T?V':?\]K__ ,&,_P#\70!HT5G?V':?\]K_ /\ !C/_
M /%T?V':?\]K_P#\&,__ ,70!HT5G?V':?\ /:__ /!C/_\ %T?V':?\]K__
M ,&,_P#\70!HT5G?V':?\]K_ /\ !C/_ /%T?V':?\]K_P#\&,__ ,70!HT5
MG?V':?\ /:__ /!C/_\ %T?V':?\]K__ ,&,_P#\70!HT5G?V':?\]K_ /\
M!C/_ /%T?V':?\]K_P#\&,__ ,70!HT5G?V':?\ /:__ /!C/_\ %T?V':?\
M]K__ ,&,_P#\70!HTC,%4LQ  &22>E<+J^M6(\.ZI>^#(KSQ1?Z9.+>6PM-8
MF5@^X!@3N/0$GH>A]ZMIX-O+CQ3%JT^NZG%I;V/DRZ&UU(RB4G)?S-^>G&,=
MNN#B@"?4_&R)INEZAX7T^7Q/:WU\MK)+ID@=8%)(:0D9X4CGH/4BGIX8O[S5
MO$*>(]575M!U6-(X-+D@"BW7;AQN')S^=6-)\%:%H.GK8Z+;3V%HI++#;WLR
M*">IP'J[_8=I_P ]K_\ \&,__P 70!/IFFV>C:7;:=ID"V]I:QB*&).B*!@#
MFK59W]AVG_/:_P#_  8S_P#Q=']AVG_/:_\ _!C/_P#%T :-%9W]AVG_ #VO
M_P#P8S__ !=']AVG_/:__P#!C/\ _%T :-%5;33X;-F:%[ABPP?.N9)1^ =C
MBK5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 9WA[_ )%G2_\ KSB_] %:-9WA[_D6=+_Z\XO_ $ 5HT %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6O\ H'V'_@<__P :H T:*SO/UK_H'V'_ ('/_P#&J//UK_H'V'_@<_\ \:H
MT:*SO/UK_H'V'_@<_P#\:H\_6O\ H'V'_@<__P :H T:*SO/UK_H'V'_ ('/
M_P#&J//UK_H'V'_@<_\ \:H T:*SO/UK_H'V'_@<_P#\:H\_6O\ H'V'_@<_
M_P :H T:*SO/UK_H'V'_ ('/_P#&J//UK_H'V'_@<_\ \:H T:*SO/UK_H'V
M'_@<_P#\:H\_6O\ H'V'_@<__P :H T:*SO/UK_H'V'_ ('/_P#&J//UK_H'
MV'_@<_\ \:H T:*SO/UK_H'V'_@<_P#\:H\_6O\ H'V'_@<__P :H T:*SO/
MUK_H'V'_ ('/_P#&J//UK_H'V'_@<_\ \:H T:*SO/UK_H'V'_@<_P#\:H\_
M6O\ H'V'_@<__P :H T:*SO/UK_H'V'_ ('/_P#&J//UK_H'V'_@<_\ \:H
MT:*SO/UK_H'V'_@<_P#\:H\_6O\ H'V'_@<__P :H T:*SO/UK_H'V'_ ('/
M_P#&J//UK_H'V'_@<_\ \:H T:*SO/UK_H'V'_@<_P#\:H\_6O\ H'V'_@<_
M_P :H T:*SO/UK_H'V'_ ('/_P#&J//UK_H'V'_@<_\ \:H T:*SO/UK_H'V
M'_@<_P#\:H\_6O\ H'V'_@<__P :H T:*SO/UK_H'V'_ ('/_P#&J//UK_H'
MV'_@<_\ \:H T:*SO/UK_H'V'_@<_P#\:H\_6O\ H'V'_@<__P :H T:*SO/
MUK_H'V'_ ('/_P#&J//UK_H'V'_@<_\ \:H T:*SO/UK_H'V'_@<_P#\:H\_
M6O\ H'V'_@<__P :H T:*SO/UK_H'V'_ ('/_P#&J//UK_H'V'_@<_\ \:H
MT:*SO/UK_H'V'_@<_P#\:H\_6O\ H'V'_@<__P :H T:*SO/UK_H'V'_ ('/
M_P#&J//UK_H'V'_@<_\ \:H T:*SO/UK_H'V'_@<_P#\:H\_6O\ H'V'_@<_
M_P :H T:*SO/UK_H'V'_ ('/_P#&J//UK_H'V'_@<_\ \:H T:*SO/UK_H'V
M'_@<_P#\:H\_6O\ H'V'_@<__P :H T:*SO/UK_H'V'_ ('/_P#&J//UK_H'
MV'_@<_\ \:H T:*SO/UK_H'V'_@<_P#\:H\_6O\ H'V'_@<__P :H T:*SO/
MUK_H'V'_ ('/_P#&J//UK_H'V'_@<_\ \:H T:*SO/UK_H'V'_@<_P#\:H\_
M6O\ H'V'_@<__P :H T:*SO/UK_H'V'_ ('/_P#&J//UK_H'V'_@<_\ \:H
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M_P #G_\ C5 &C156TDOW9OMUM;PKCY3#<-(2??*+BK5 !1110 4444 %%%%
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M7CJ^TRWGN?$$\\6LZ; \(;3X&93$R.6 ?!4%L')&.">1[A110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6=_PD.B_]!>P_P# E/\ &C_A(=%_Z"]A_P"!*?XT :-%9W_"0Z+_ -!>P_\
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M^!*?XT?\)#HO_07L/_ E/\: -&BL[_A(=%_Z"]A_X$I_C1_PD.B_]!>P_P#
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M#ODGN:* "BBB@#.\/?\ (LZ7_P!><7_H K1Q6=X>_P"19TO_ *\XO_0!6C0
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M0G4X;&[<"V7H=GXHT'QQ:WWPU\*>+M&\'_;+634M*O8421I"3&WEK*Q9HRK
MDYP#R2NU"OTS61XK\2V?@_PO>Z]J<<\MK9('D2W4,Y!8+P"0.I]12&>0^!/@
MUX>\1R>*+_QWX9N3>OXAN_LSW$EQ;E[<[65E"LH922V&QSZ\5[1+9PVFAR6>
MGV\<$,5N8X8($"JBA<!54< =@!4NGWL>HZ;;7T 98KF%)D#C# , 1G'?FK%
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M]*Y'[1XD\<\6@;1]';K*<[Y5]NY_# ]S6GHW@2"WN?M^OSG5-08[BTA)13[
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M1PZG!Y,LLID$C$*>=@Y&>_'N!ZQ10 56NK6:X93#?W%J ,$0K&0WUW*:LT4
M<_H6GW3^'=.9=8O8U:UB(14APOR#@9C)Q]35_P#LR[_Z#E__ -^X/_C5'A[_
M )%G2_\ KSB_] %:- &=_9EW_P!!R_\ ^_<'_P :H_LR[_Z#E_\ ]^X/_C5:
M-% &=_9EW_T'+_\ []P?_&J/[,N_^@Y?_P#?N#_XU6C10!G?V9=_]!R__P"_
M<'_QJC^S+O\ Z#E__P!^X/\ XU6C10!G?V9=_P#0<O\ _OW!_P#&J/[,N_\
MH.7_ /W[@_\ C5:-% &=_9EW_P!!R_\ ^_<'_P :H_LR[_Z#E_\ ]^X/_C5:
M-% &=_9EW_T'+_\ []P?_&J/[,N_^@Y?_P#?N#_XU6C10!G?V9=_]!R__P"_
M<'_QJC^S+O\ Z#E__P!^X/\ XU6C10!G?V9=_P#0<O\ _OW!_P#&J/[,N_\
MH.7_ /W[@_\ C5:-% &=_9EW_P!!R_\ ^_<'_P :H_LR[_Z#E_\ ]^X/_C5:
M-% &=_9EW_T'+_\ []P?_&J/[,N_^@Y?_P#?N#_XU6C10!G?V9=_]!R__P"_
M<'_QJC^S+O\ Z#E__P!^X/\ XU6C10!G?V9=_P#0<O\ _OW!_P#&J/[,N_\
MH.7_ /W[@_\ C5:-% &=_9EW_P!!R_\ ^_<'_P :H_LR[_Z#E_\ ]^X/_C5:
M-% &=_9EW_T'+_\ []P?_&J/[,N_^@Y?_P#?N#_XU6C10!G?V9=_]!R__P"_
M<'_QJC^S+O\ Z#E__P!^X/\ XU6C10!G?V9=_P#0<O\ _OW!_P#&J/[,N_\
MH.7_ /W[@_\ C5:-% &=_9EW_P!!R_\ ^_<'_P :H_LR[_Z#E_\ ]^X/_C5:
M-% &=_9EW_T'+_\ []P?_&J/[,N_^@Y?_P#?N#_XU6C10!G?V9=_]!R__P"_
M<'_QJC^S+O\ Z#E__P!^X/\ XU6C10!G?V9=_P#0<O\ _OW!_P#&J/[,N_\
MH.7_ /W[@_\ C5:-% &=_9EW_P!!R_\ ^_<'_P :H_LR[_Z#E_\ ]^X/_C5:
M-% &=_9EW_T'+_\ []P?_&J/[,N_^@Y?_P#?N#_XU6C10!G?V9=_]!R__P"_
M<'_QJC^S+O\ Z#E__P!^X/\ XU6C10!G?V9=_P#0<O\ _OW!_P#&J/[,N_\
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M[,N_^@Y?_P#?N#_XU1_9EW_T'+__ +]P?_&JT:* ,[^S+O\ Z#E__P!^X/\
MXU1_9EW_ -!R_P#^_<'_ ,:K1HH SO[,N_\ H.7_ /W[@_\ C5']F7?_ $'+
M_P#[]P?_ !JM&B@#._LR[_Z#E_\ ]^X/_C5']F7?_0<O_P#OW!_\:K1HH SO
M[,N_^@Y?_P#?N#_XU1_9EW_T'+__ +]P?_&JT:* ,[^S+O\ Z#E__P!^X/\
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M:* ,[^S+O_H.7_\ W[@_^-4?V9=_]!R__P"_<'_QJM&B@#._LR[_ .@Y?_\
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MCGM2^$_'WACQS#<2>%M6COQ;,%F41O&Z9Z$JX!P?7&.#Z4 =%1110!G>'O\
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M"4W#JK8((]R1@X( ."N+'0_B-^S['K<NDC2[;3["^G@TJSE"6HG02+OVH &
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MI38/!VI>+?"^EQ?$Y[=]4T_4!>H=)E>./*,=@.>O!_ESGFNX"@,2 ,GJ<=:
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M_P#WW!_\=H_M.Z_Z =__ -]P?_':T:* ,[^T[K_H!W__ 'W!_P#':/[3NO\
MH!W_ /WW!_\ ':T:* ,[^T[K_H!W_P#WW!_\=H_M.Z_Z =__ -]P?_':T:*
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M6C10!G?VG=?] .__ .^X/_CM']IW7_0#O_\ ON#_ ..UHT4 9W]IW7_0#O\
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M !1110 4444 %%%% !1110 4444 9WA[_D6=+_Z\XO\ T 5HUG>'O^19TO\
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M /$T?\+-\(_]!<?^ \O_ ,36GL*W\C^YF7MZ7\R^\ZNBN4_X6;X1_P"@N/\
MP'E_^)H_X6;X1_Z"X_\  >7_ .)H]A6_D?W,/;TOYE]YU=%<I_PLWPC_ -!<
M?^ \O_Q-'_"S?"/_ $%Q_P" \O\ \31["M_(_N8>WI?S+[SJZ*Y3_A9OA'_H
M+C_P'E_^)H_X6;X1_P"@N/\ P'E_^)H]A6_D?W,/;TOYE]YU=%<I_P +-\(_
M]!<?^ \O_P 31_PLWPC_ -!<?^ \O_Q-'L*W\C^YA[>E_,OO.KHKE/\ A9OA
M'_H+C_P'E_\ B:/^%F^$?^@N/_ >7_XFCV%;^1_<P]O2_F7WG5T5RG_"S?"/
M_07'_@/+_P#$T?\ "S?"/_07'_@/+_\ $T>PK?R/[F'MZ7\R^\ZNBN4_X6;X
M1_Z"X_\  >7_ .)H_P"%F^$?^@N/_ >7_P")H]A6_D?W,/;TOYE]YU=%<I_P
MLWPC_P!!<?\ @/+_ /$T?\+-\(_]!<?^ \O_ ,31["M_(_N8>WI?S+[SJZ*Y
M3_A9OA'_ *"X_P# >7_XFC_A9OA'_H+C_P !Y?\ XFCV%;^1_<P]O2_F7WG5
MT5RG_"S?"/\ T%Q_X#R__$T?\+-\(_\ 07'_ (#R_P#Q-'L*W\C^YA[>E_,O
MO.KHKE/^%F^$?^@N/_ >7_XFC_A9OA'_ *"X_P# >7_XFCV%;^1_<P]O2_F7
MWG5T5RG_  LWPC_T%Q_X#R__ !-'_"S?"/\ T%Q_X#R__$T>PK?R/[F'MZ7\
MR^\ZNBL_1M<T[Q!9M=Z1<?:(%D,;/L9<, #C# 'H16A633B[,U335T%>"?M
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M\* -&BL[_A'=%_Z!%C_X#)_A1_PCNB_] BQ_\!D_PH T:*SO^$=T7_H$6/\
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M1_PCNB_] BQ_\!D_PH T:*SO^$=T7_H$6/\ X#)_A1_PCNB_] BQ_P# 9/\
M"@#1HK._X1W1?^@18_\ @,G^%'_".Z+_ - BQ_\  9/\* -&BL[_ (1W1?\
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MOV1_Q*H,BM?92CTMZV_(S]K&76_I?\SNOL\1F69HU:55VB0J-V/K4A(526.
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M<Y:B2FU$****LS"BBB@#V[X-?\B9<_\ 7^__ * E>@5Y_P#!K_D3+G_K_?\
M] 2O0*^6Q?\ 'EZGTV%_@Q"BBBN8Z HHHH **** "BBB@#.\/?\ (LZ7_P!>
M<7_H K1K.\/?\BSI?_7G%_Z *T: "BBB@ HHHH **** "BBB@ HHHH ****
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MY:,%&57CY0>PX''M0!Q0MO%7CKPFT>I&\\#ZA!J>5-G.LS30H>,D8P&R>/\
M9!Y!Q76Q:/IL.LS:M#86R:C<1B*6[6("61!T4MU(X'Y#TJ[10 4444 %%%%
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M..-4=H?U]PI8-RWG_7WGS[J^I:CKEU'<ZA#NG2-8S(D)4R ="WJ?>J'D3?\
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MO.+_ - %:-<_H4.KGP[IQBO;)8S:Q;5:S=B!L& 3YHR?? J_Y.M?\_\ 8?\
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MV-&BL[R=:_Y_[#_P!?\ ^.T>3K7_ #_V'_@"_P#\=I#-&BL[R=:_Y_[#_P
M7_\ CM'DZU_S_P!A_P" +_\ QV@#1HK.\G6O^?\ L/\ P!?_ ..T>3K7_/\
MV'_@"_\ \=H T:*SO)UK_G_L/_ %_P#X[1Y.M?\ /_8?^ +_ /QV@#1HK.\G
M6O\ G_L/_ %__CM'DZU_S_V'_@"__P =H T:*SO)UK_G_L/_  !?_P".T>3K
M7_/_ &'_ ( O_P#': -&BL[R=:_Y_P"P_P# %_\ X[1Y.M?\_P#8?^ +_P#Q
MV@#1HK.\G6O^?^P_\ 7_ /CM'DZU_P _]A_X O\ _': -&BL[R=:_P"?^P_\
M 7_^.T>3K7_/_8?^ +__ !V@#1HK.\G6O^?^P_\  %__ ([1Y.M?\_\ 8?\
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M ,11_;MI_P \K[_P7S__ !% &C16=_;MI_SROO\ P7S_ /Q%']NVG_/*^_\
M!?/_ /$4 :-%9W]NVG_/*^_\%\__ ,11_;MI_P \K[_P7S__ !% &C16=_;M
MI_SROO\ P7S_ /Q%']NVG_/*^_\ !?/_ /$4 :-%9W]NVG_/*^_\%\__ ,11
M_;MI_P \K[_P7S__ !% &C16=_;MI_SROO\ P7S_ /Q%']NVG_/*^_\ !?/_
M /$4 :-%9W]NVG_/*^_\%\__ ,11_;MI_P \K[_P7S__ !% &C16=_;MI_SR
MOO\ P7S_ /Q%']NVG_/*^_\ !?/_ /$4 :-%9W]NVG_/*^_\%\__ ,11_;MI
M_P \K[_P7S__ !% &C16=_;MI_SROO\ P7S_ /Q%']NVG_/*^_\ !?/_ /$4
M :-%9W]NVG_/*^_\%\__ ,11_;MI_P \K[_P7S__ !% &C16=_;MI_SROO\
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M%Y2\>T; 2)"#N;IC I1N]'O_ ,-_7W ^ZV_X?^OO/2[#_CW/^]_05:JK8?\
M'N?][^@JU6,MS:.P5POC_P"%.E^.[RUU$WU[I&JVQC07UC)M=XED$FPCO@C*
MG^%L-SC![JBI*,&T\&Z1I_@-_".GQR6NEM:26F(WRX60,&;)S\Q+,<D=3TK
MUWX1:)K_ (!TKPA=:CJT.F:7M\LP31J\NT$#S"4(.,D\ <UWM% '$:=\+=.M
MM%U32=7UWQ!XBL=3A6*2'6=0\\1!22#'A1M.<'/^R/2K/@OX;Z3X)NKJ\M;W
M4]4O[I$B>]U6Y\^58E'RQJ0  HQTQ_(8ZZB@ HHHH SO#W_(LZ7_ -><7_H
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M3@LYBEKJ44(B6Z&S)^4<<'C(X-9.BW7B[5O R^(CXFMX9&BEE$$FF1B(;&8
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MVG_/6_\ _!A/_P#%UHT4 9W]AVG_ #UO_P#P83__ !=']AVG_/6__P#!A/\
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M ,71_8=I_P ];_\ \&$__P 76C10!G?V':?\];__ ,&$_P#\71_8=I_SUO\
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MVG_/6_\ _!A/_P#%UHT4 9W]AVG_ #UO_P#P83__ !=']AVG_/6__P#!A/\
M_%U4\7^+]+\$Z"=5UII3&TBPPPP1[Y;B5L[8T7NQP>XZ5B:/\6?#FJ:+K.H7
M:7^C-H8#:A9ZI;&&X@4C*DH"<[N@ YSVY&0#=N]%47%D+>74/+,Y$^+^?[GE
MO_M_WMM6?[#M/^>M_P#^#"?_ .+K \%_$O2/&UY<65K9:GI=_!$MP;/5+;R9
M7A;&V50"04.0,Y]/458T/XAZ!XD\6:IH&C7#74VE1+)<7,>TP<G&U7!Y([\8
M'KUH U_[#M/^>M__ .#"?_XNC^P[3_GK?_\ @PG_ /BZX_1_C/X:UOQ#;Z9;
MV^J0V][.]O8ZK<6FRSO)5.-D<F>2><9 Z8ZD9]!H SO[#M/^>M__ .#"?_XN
MC^P[3_GK?_\ @PG_ /BZT:* ,[^P[3_GK?\ _@PG_P#BZ/[#M/\ GK?_ /@P
MG_\ BZT:* ,[^P[3_GK?_P#@PG_^+H_L.T_YZW__ (,)_P#XNM&B@#._L.T_
MYZW_ /X,)_\ XNC^P[3_ )ZW_P#X,)__ (NM&B@#._L.T_YZW_\ X,)__BZ/
M[#M/^>M__P"#"?\ ^+K1HH SO[#M/^>M_P#^#"?_ .+H_L.T_P">M_\ ^#"?
M_P"+K1HH SO[#M/^>M__ .#"?_XNC^P[3_GK?_\ @PG_ /BZT:YSQEXYTOP1
M8VLVI17EW<7LP@M+&PA\VXN7[A%R,X!SR1Z=2 0#2_L.T_YZW_\ X,)__BZK
M7>BJ+BS%O+J&PSD3XU"?[GEO_M_WMM<_;_%_PQ-X&U'Q//\ ;;.+3)VM;NPN
M;?9=Q3@X$)CS]YB1CG R<D;6Q+H_Q6\.ZIH>L:E=B^T8Z)@ZA::I;&*XMP1E
M24!/WNV,D^E '2?V':?\];__ ,&$_P#\71_8=I_SUO\ _P &$_\ \77+^$_B
MUH?BO59---CJNB78LQ?11ZS:BW^T6^2#)&=Q!48ZY&1R,X;$?A?XP^'/%?B"
M'2K*WU2U-X)3I]U>VGE0:@(R0QA;.6Q@GD ^H!XH ZS^P[3_ )ZW_P#X,)__
M (NC^P[3_GK?_P#@PG_^+K1HH SO[#M/^>M__P"#"?\ ^+H_L.T_YZW_ /X,
M)_\ XNM&B@#._L.T_P">M_\ ^#"?_P"+H_L.T_YZW_\ X,)__BZT:* ,[^P[
M3_GK?_\ @PG_ /BZ/[#M/^>M_P#^#"?_ .+K1HH SO[#M/\ GK?_ /@PG_\
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MN9T4@>4#D$Y9<,.QW9QS6K\-K33?'=[X@U[Q/JNDW^I^(K(0/HUA?+(UE8]
MCE&W;CN&X\8..A.!Z?+X5\/3Z-#I$^A:9)ID#;XK)[.,PQMSRJ$;0?F;D#N?
M6DTGPIX=T&Y>XT/0=,TV=TV/+9V<<+,N0=I*@$C(!Q[4 >>?"VQM-,^,'Q,L
MM.MHK6UADTY(H84"(@\F3@ <"O6:JVVEV%G?75[:6-M!=7A4W,\4*J\Y487>
MP&6P"0,],U:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>jnj-20220102_g11.jpg
<TEXT>
begin 644 jnj-20220102_g11.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1$017AI9@  34T *@    @ ! $[  (
M   7   (2H=I  0    !   (8IR=  $    N   0VNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=U>FUA;BP@
M06YD<F5A(%M*2D-54UT    %D ,  @   !0  !"PD 0  @   !0  !#$DI$
M @    ,Q,P  DI(  @    ,Q,P  ZAP !P  " P   BD     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( 7D$7@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MK1_A7X:M-*\9WVO0:OJ/V9M9L(,7S6X!/DH,D_:#\J!C@YZ@')JH/&VHZ/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'_@,G^%'_"/:+_T"+#_P&3_"M&B@#._X1[1?^@18?^ R?X4?\(]HO_0(L/\
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MZ!%A_P" R?X4?\(]HO\ T"+#_P !D_PK1HH SO\ A'M%_P"@18?^ R?X4?\
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MX4?\(]HO_0(L/_ 9/\*T:* ,[_A'M%_Z!%A_X#)_A1_PCVB_] BP_P# 9/\
M"M&B@#._X1[1?^@18?\ @,G^%'_"/:+_ - BP_\  9/\*T:* ,[_ (1[1?\
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M*\&E^)_C+6/#/A#^R[JTT_5[W7I-(OG$ D@E*'&\!N<<@_*0<@\BNM^&^O\
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M.74[-'2UB5E:X0%2$&01FK_]OZ/_ -!:Q_\  E/\: -"BL_^W]'_ .@M8_\
M@2G^-']OZ/\ ]!:Q_P# E/\ &@#0HK/_ +?T?_H+6/\ X$I_C1_;^C_]!:Q_
M\"4_QH T**S_ .W]'_Z"UC_X$I_C1_;^C_\ 06L?_ E/\: -"BL_^W]'_P"@
MM8_^!*?XT?V_H_\ T%K'_P "4_QH T**S_[?T?\ Z"UC_P"!*?XT?V_H_P#T
M%K'_ ,"4_P : -"BL_\ M_1_^@M8_P#@2G^-']OZ/_T%K'_P)3_&@#0HK/\
M[?T?_H+6/_@2G^-']OZ/_P!!:Q_\"4_QH T**S_[?T?_ *"UC_X$I_C1_;^C
M_P#06L?_  )3_&@#0HK/_M_1_P#H+6/_ ($I_C1_;^C_ /06L?\ P)3_ !H
MT**S_P"W]'_Z"UC_ .!*?XT?V_H__06L?_ E/\: -"BL_P#M_1_^@M8_^!*?
MXT?V_H__ $%K'_P)3_&@#0HK/_M_1_\ H+6/_@2G^-']OZ/_ -!:Q_\  E/\
M: -"BL_^W]'_ .@M8_\ @2G^-']OZ/\ ]!:Q_P# E/\ &@#0HK/_ +?T?_H+
M6/\ X$I_C1_;^C_]!:Q_\"4_QH T**S_ .W]'_Z"UC_X$I_C1_;^C_\ 06L?
M_ E/\: -"BL_^W]'_P"@M8_^!*?XT?V_H_\ T%K'_P "4_QH T**S_[?T?\
MZ"UC_P"!*?XT?V_H_P#T%K'_ ,"4_P : -"BL_\ M_1_^@M8_P#@2G^-']OZ
M/_T%K'_P)3_&@#0HK/\ [?T?_H+6/_@2G^-']OZ/_P!!:Q_\"4_QH T**S_[
M?T?_ *"UC_X$I_C1_;^C_P#06L?_  )3_&@#0HK/_M_1_P#H+6/_ ($I_C1_
M;^C_ /06L?\ P)3_ !H T**S_P"W]'_Z"UC_ .!*?XT?V_H__06L?_ E/\:
M-"BL_P#M_1_^@M8_^!*?XT?V_H__ $%K'_P)3_&@#0HK/_M_1_\ H+6/_@2G
M^-']OZ/_ -!:Q_\  E/\: -"BL_^W]'_ .@M8_\ @2G^-']OZ/\ ]!:Q_P#
ME/\ &@#0HK/_ +?T?_H+6/\ X$I_C1_;^C_]!:Q_\"4_QH T**S_ .W]'_Z"
MUC_X$I_C1_;^C_\ 06L?_ E/\: -"BL_^W]'_P"@M8_^!*?XT?V_H_\ T%K'
M_P "4_QH T**S_[?T?\ Z"UC_P"!*?XT?V_H_P#T%K'_ ,"4_P : -"BL_\
MM_1_^@M8_P#@2G^-']OZ/_T%K'_P)3_&@#0HK/\ [?T?_H+6/_@2G^-']OZ/
M_P!!:Q_\"4_QH T**S_[?T?_ *"UC_X$I_C1_;^C_P#06L?_  )3_&@#0HK/
M_M_1_P#H+6/_ ($I_C1_;^C_ /06L?\ P)3_ !H T**S_P"W]'_Z"UC_ .!*
M?XT?V_H__06L?_ E/\: -"BL_P#M_1_^@M8_^!*?XT?V_H__ $%K'_P)3_&@
M#0HK/_M_1_\ H+6/_@2G^-']OZ/_ -!:Q_\  E/\: -"BL_^W]'_ .@M8_\
M@2G^-']OZ/\ ]!:Q_P# E/\ &@#0HK/_ +?T?_H+6/\ X$I_C1_;^C_]!:Q_
M\"4_QH T**S_ .W]'_Z"UC_X$I_C1_;^C_\ 06L?_ E/\: -"BL_^W]'_P"@
MM8_^!*?XT?V_H_\ T%K'_P "4_QH T**S_[?T?\ Z"UC_P"!*?XT?V_H_P#T
M%K'_ ,"4_P : -"BL_\ M_1_^@M8_P#@2G^-']OZ/_T%K'_P)3_&@#0HK/\
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MT>@_*L_P]_R+.E_]><7_ * *T: $VCT'Y4;1Z#\J6B@!-H]!^5&T>@_*EHH
M3:/0?E1M'H/RI:* $VCT'Y4;1Z#\J6B@!-H]!^5&T>@_*EHH 3:/0?E1M'H/
MRI:* $VCT'Y4;1Z#\J6B@!-H]!^5&T>@_*EHH 3:/0?E1M'H/RI:* $VCT'Y
M4;1Z#\J6B@!-H]!^5&T>@_*EHH 3:/0?E1M'H/RI:* $VCT'Y4;1Z#\J6B@!
M-H]!^5&T>@_*EHH 3:/0?E1M'H/RI:* $VCT'Y4;1Z#\J6B@!-H]!^5&T>@_
M*EHH 3:/0?E1M'H/RI:* $VCT'Y4;1Z#\J6B@!-H]!^5&T>@_*EHH 3:/0?E
M1M'H/RI:* $VCT'Y4;1Z#\J6B@!-H]!^5&T>@_*EHH 3:/0?E1M'H/RI:* $
MVCT'Y4;1Z#\J6B@!-H]!^5&T>@_*EHH 3:/0?E1M'H/RI:* $VCT'Y4;1Z#\
MJ6B@!-H]!^5&T>@_*EHH 3:/0?E1M'H/RI:* $VCT'Y4;1Z#\J6B@!-H]!^5
M&T>@_*EHH 3:/0?E1M'H/RI:* $VCT'Y4;1Z#\J6B@!-H]!^5&T>@_*EHH 3
M:/0?E1M'H/RI:* $VCT'Y4;1Z#\J6B@!-H]!^5&T>@_*EHH 3:/0?E1M'H/R
MI:* $VCT'Y4;1Z#\J6B@!-H]!^5&T>@_*EHH 3:/0?E1M'H/RI:* $VCT'Y4
M;1Z#\J6B@!-H]!^59MWKNF6NL0:*UY;)JUW$\MK:2/AI0H)) ].#^1]*S=1\
M46]WK^H>#M(O6M?$8TQKN"22W+1Q9^56)/#88@XJ;1/#SK9Z3>^*DL=3\1V-
MN8FU-+=5;)^]L. 0"/3'?@9Q0!E:7X:N?%-EH>K_ !'TBTM_$&D7,DUNEC._
MEQ$M@' 8@Y"J<$GIVR179[1Z#\J6B@!-H]!^5&T>@_*EHH   .@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/_@2G^- &A16?_;^C_\ 06L?_ E/\:/[?T?_ *"UC_X$I_C0!H45G_V_H_\
MT%K'_P "4_QH_M_1_P#H+6/_ ($I_C0!H45G_P!OZ/\ ]!:Q_P# E/\ &C^W
M]'_Z"UC_ .!*?XT :%%9_P#;^C_]!:Q_\"4_QH_M_1_^@M8_^!*?XT :%%9_
M]OZ/_P!!:Q_\"4_QH_M_1_\ H+6/_@2G^- &A16?_;^C_P#06L?_  )3_&C^
MW]'_ .@M8_\ @2G^- &A16?_ &_H_P#T%K'_ ,"4_P :/[?T?_H+6/\ X$I_
MC0!H45G_ -OZ/_T%K'_P)3_&C^W]'_Z"UC_X$I_C0!H45G_V_H__ $%K'_P)
M3_&C^W]'_P"@M8_^!*?XT :%%9_]OZ/_ -!:Q_\  E/\:/[?T?\ Z"UC_P"!
M*?XT :%%9_\ ;^C_ /06L?\ P)3_ !H_M_1_^@M8_P#@2G^- &A16?\ V_H_
M_06L?_ E/\:/[?T?_H+6/_@2G^- &A16?_;^C_\ 06L?_ E/\:/[?T?_ *"U
MC_X$I_C0!H45G_V_H_\ T%K'_P "4_QH_M_1_P#H+6/_ ($I_C0!H45G_P!O
MZ/\ ]!:Q_P# E/\ &C^W]'_Z"UC_ .!*?XT :%%9_P#;^C_]!:Q_\"4_QH_M
M_1_^@M8_^!*?XT :%%9_]OZ/_P!!:Q_\"4_QH_M_1_\ H+6/_@2G^- &A16?
M_;^C_P#06L?_  )3_&C^W]'_ .@M8_\ @2G^- &A16?_ &_H_P#T%K'_ ,"4
M_P :/[?T?_H+6/\ X$I_C0!H45G_ -OZ/_T%K'_P)3_&C^W]'_Z"UC_X$I_C
M0!H45G_V_H__ $%K'_P)3_&C^W]'_P"@M8_^!*?XT :%%9_]OZ/_ -!:Q_\
M E/\:/[?T?\ Z"UC_P"!*?XT :%%9_\ ;^C_ /06L?\ P)3_ !H_M_1_^@M8
M_P#@2G^- &A16?\ V_H__06L?_ E/\:/[?T?_H+6/_@2G^- &A16?_;^C_\
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M/_@2G^- &A16?_;^C_\ 06L?_ E/\:/[?T?_ *"UC_X$I_C0!H45G_V_H_\
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MM&LM/MK>6=[J6&%(GN)?ORE1@LWN3S^-6:S_ .W]'_Z"UC_X$I_C1_;^C_\
M06L?_ E/\: -"BL_^W]'_P"@M8_^!*?XT?V_H_\ T%K'_P "4_QH T**S_[?
MT?\ Z"UC_P"!*?XT?V_H_P#T%K'_ ,"4_P : -"BJEOJNG7DWE6E_:SR8SLB
MF5CCZ U;H **** "BBB@ HHHH ***Q?$7BBR\,QP/?Q7$@G+!?)0'&,=<D>M
M &U17$?\+6T/_GUU#_OVG_Q='_"UM#_Y]=0_[]I_\70!V]%<1_PM;0_^?74/
M^_:?_%T?\+6T/_GUU#_OVG_Q= ';U6U#4K'2+"2^U6\M[&TBQYEQ<RK'&F2
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MP :A=ZK<F6XG51A5+@#&WJ".<]^!C#'[/OAB:W2+5=8\2:M]FB$5BU[J98V
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M /Q%']N6G_/.]_\  "?_ .(H T:*SO[<M/\ GG>_^ $__P 11_;EI_SSO?\
MP G_ /B* -&BL[^W+3_GG>_^ $__ ,11_;EI_P \[W_P G_^(H T:*SO[<M/
M^>=[_P" $_\ \11_;EI_SSO?_ "?_P"(H T:*SO[<M/^>=[_ . $_P#\11_;
MEI_SSO?_   G_P#B* -&BL[^W+3_ )YWO_@!/_\ $4?VY:?\\[W_ , )_P#X
MB@#1HK._MRT_YYWO_@!/_P#$4?VY:?\ /.]_\ )__B* -&BL[^W+3_GG>_\
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M_P#$4?VY:?\ /.]_\ )__B* -&BL[^W+3_GG>_\ @!/_ /$4?VY:?\\[W_P
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M<M/^>=[_ . $_P#\11_;EI_SSO?_   G_P#B* -&BL[^W+3_ )YWO_@!/_\
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M/U%7_P"W+/\ YYWO_@!/_P#$4 :-%9W]N6?_ #SO?_ "?_XBC^W+/_GG>_\
M@!/_ /$4 :-%9W]N6?\ SSO?_ "?_P"(H_MRS_YYWO\ X 3_ /Q% &C16=_;
MEG_SSO?_   G_P#B*/[<L_\ GG>_^ $__P 10!HT5G?VY9_\\[W_ , )_P#X
MBC^W+/\ YYWO_@!/_P#$4 :-%9W]N6?_ #SO?_ "?_XBC^W+/_GG>_\ @!/_
M /$4 :-%9W]N6?\ SSO?_ "?_P"(H_MRS_YYWO\ X 3_ /Q% &C16=_;EG_S
MSO?_   G_P#B*/[<L_\ GG>_^ $__P 10!HT5G?VY9_\\[W_ , )_P#XBC^W
M+/\ YYWO_@!/_P#$4 :-%9W]N6?_ #SO?_ "?_XBC^W+/_GG>_\ @!/_ /$4
M :-%9W]N6?\ SSO?_ "?_P"(H_MRS_YYWO\ X 3_ /Q% &C16=_;EG_SSO?_
M   G_P#B*/[<L_\ GG>_^ $__P 10!HT5G?VY9_\\[W_ , )_P#XBC^W+/\
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M_P#$4 :-%9W]N6?_ #SO?_ "?_XBC^W+/_GG>_\ @!/_ /$4 :-%9W]N6?\
MSSO?_ "?_P"(H_MRS_YYWO\ X 3_ /Q% &C16=_;EG_SSO?_   G_P#B*/[<
ML_\ GG>_^ $__P 10!HT5G?VY9_\\[W_ , )_P#XBC^W+/\ YYWO_@!/_P#$
M4 :-%9W]N6?_ #SO?_ "?_XBC^W+/_GG>_\ @!/_ /$4 :-%9W]N6?\ SSO?
M_ "?_P"(H_MRS_YYWO\ X 3_ /Q% &C16=_;EG_SSO?_   G_P#B*/[<L_\
MGG>_^ $__P 10!HT5G?VY9_\\[W_ , )_P#XBC^W+/\ YYWO_@!/_P#$4 :-
M%9W]N6?_ #SO?_ "?_XBC^W+/_GG>_\ @!/_ /$4 :-%9W]N6?\ SSO?_ "?
M_P"(H_MRS_YYWO\ X 3_ /Q% &C16=_;EG_SSO?_   G_P#B*/[<L_\ GG>_
M^ $__P 10!HT5G?VY9_\\[W_ , )_P#XBC^W+/\ YYWO_@!/_P#$4 :-%9W]
MN6?_ #SO?_ "?_XBC^W+/_GG>_\ @!/_ /$4 :-%9W]N6?\ SSO?_ "?_P"(
MH_MRS_YYWO\ X 3_ /Q% &C16=_;EG_SSO?_   G_P#B*/[<L_\ GG>_^ $_
M_P 10!HT5G?VY9_\\[W_ , )_P#XBL+7/',"6>J67A<#4?$=G;>;'ILD$JMD
M_=WC:" ?? Z<C.: .DU"]^QV5S+#"UU<0P/,EK$1YDNT?=4>I.!]37+Z997O
MB^X\-^+KM]9\.RVL<WG:)*^U9"V5Q*N!G&-PR.F. :BTVSTR\U[3?&.M:=?6
MOB1=,6TGCBM[AHH\_,R@!<-AB1GT_"NF_MRS_P">=[_X 3__ !% %V&WAMU8
M6\4<0=B[!%"[F/4G'<^M25G?VY9_\\[W_P  )_\ XBC^W+/_ )YWO_@!/_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFW\$\OFHNQY865!@D$Y) R!@=\5Z310!XA-\//%!^#/@+0HM+QJ6D:W!=WL
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MY1_:=S_T!;__ +ZA_P#CE &C16=_:=S_ - 6_P#^^H?_ (Y1_:=S_P! 6_\
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M'_XY0!HT5G?VG<_] 6__ .^H?_CE']IW/_0%O_\ OJ'_ ..4 :-%9W]IW/\
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M!;__ +ZA_P#CE &C16=_:=S_ - 6_P#^^H?_ (Y1_:=S_P! 6_\ ^^H?_CE
M&C16=_:=S_T!;_\ [ZA_^.4?VG<_] 6__P"^H?\ XY0!HT5G?VG<_P#0%O\
M_OJ'_P".4?VG<_\ 0%O_ /OJ'_XY0!HU7FOK6&[BM'N85NYU9H;=I KRA>I4
M=2!WQTKF]1\;JNJ7'A[3+.0^)#8O<VUG.\0!ZA2V)/N[L9 YQDXJGI6EW6H2
M:)K_ (S\+&3Q5IL+QBXLY4\N/?D':#+SD>H."3B@!-/TF\\>V>A:YXOTV_\
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MF2ZQ-#$TDVD7L:*,LSR0  >Y\RN<N?B3;/(;;1]-NKV\)PJ?*5/XJ6S^'YT
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MP,\5)X/^+$WA;X&>&K_5VEUS6=5N;B& 7VHK#YFV9]S23RDA55<#)SR5''4
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M!@8=:?"7PS;^#-3\.7(O-0BU:0S7U[>W'F74\N<K(7P/F7 Q@8XY!).>WHH
MXKP[\*= T"/4_M$VH:[<:I!]ENKK6+GSY6M\8\D, ,)]!GWX&&^#OA1H7@O6
M6U2SN]4U&Y6V%I:G4KKSA909)\N(8&U>G7.,<8RV>WHH **** ,[P]_R+.E_
M]><7_H K1K.\/?\ (LZ7_P!><7_H K1H **** "BBB@ HHHH **** "BBB@
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M#1HK._M.Y_Z M_\ ]]0__'*/[3N?^@+?_P#?4/\ \<H T:*SO[3N?^@+?_\
M?4/_ ,<H_M.Y_P"@+?\ _?4/_P <H T:*SO[3N?^@+?_ /?4/_QRC^T[G_H"
MW_\ WU#_ /'* -&BL[^T[G_H"W__ 'U#_P#'*/[3N?\ H"W_ /WU#_\ '* -
M&BL[^T[G_H"W_P#WU#_\<H_M.Y_Z M__ -]0_P#QR@#1HK._M.Y_Z M__P!]
M0_\ QRC^T[G_ * M_P#]]0__ !R@#1HK._M.Y_Z M_\ ]]0__'*/[3N?^@+?
M_P#?4/\ \<H T:*SO[3N?^@+?_\ ?4/_ ,<H_M.Y_P"@+?\ _?4/_P <H T:
M*SO[3N?^@+?_ /?4/_QRC^T[G_H"W_\ WU#_ /'* -&BL[^T[G_H"W__ 'U#
M_P#'*/[3N?\ H"W_ /WU#_\ '* -&BL[^T[G_H"W_P#WU#_\<H_M.Y_Z M__
M -]0_P#QR@#1HK._M.Y_Z M__P!]0_\ QRC^T[G_ * M_P#]]0__ !R@#1HK
M._M.Y_Z M_\ ]]0__'*/[3N?^@+?_P#?4/\ \<H T:*SO[3N?^@+?_\ ?4/_
M ,<H_M.Y_P"@+?\ _?4/_P <H T:*SO[3N?^@+?_ /?4/_QRC^T[G_H"W_\
MWU#_ /'* -&BL[^T[G_H"W__ 'U#_P#'*/[3N?\ H"W_ /WU#_\ '* -&BL[
M^T[G_H"W_P#WU#_\<H_M.Y_Z M__ -]0_P#QR@#1HK._M.Y_Z M__P!]0_\
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M_M.Y_P"@+?\ _?4/_P <H T:*Y?_ (3NSDUR_P!#M+"\N-8L+<7$UBC0[PI
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M\>G *Y$)N$149R3MP!T .",-7J/PQO9KKX>Z9#>:)<:%=6,0LY[*:W:(*\8
M+)N^\AZA@3U(R2#76T4 %%%% !1110 4444 %<YXT\!Z!X_T@:?XDL_.6,EH
M)XSME@8C!*-V[9!R#@9!Q71T4 <U-\._"5QX.C\*RZ';'18B"EJ-PVL/XPX.
M[=R<MG)R<GDU)IG@+POHWA2;PUIVBV\6D7&[SK9LOYI;J69B68],$G(  &,#
M'0T4 <[X8\ >%_!NGW=CX<T>&TM[TYN59FE,W&,,SEB5P3\N<#+<<G,7A;X<
M>$O!5_=7OAG18;&YNUV2RAW=MN<[5WL=JYP2%P#A<]!CIZ* "BBB@#.\/?\
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M !-:_5ZW\C^YF7MZ7\R^\ZRBN3_X6?X0_P"@L?\ P&E_^)H_X6?X0_Z"Q_\
M :7_ .)H^KUOY']S#V]+^9?>=917)_\ "S_"'_06/_@-+_\ $T?\+/\ "'_0
M6/\ X#2__$T?5ZW\C^YA[>E_,OO.LHKD_P#A9_A#_H+'_P !I?\ XFC_ (6?
MX0_Z"Q_\!I?_ (FCZO6_D?W,/;TOYE]YUE%<G_PL_P (?]!8_P#@-+_\31_P
ML_PA_P!!8_\ @-+_ /$T?5ZW\C^YA[>E_,OO.LHKD_\ A9_A#_H+'_P&E_\
MB:/^%G^$/^@L?_ :7_XFCZO6_D?W,/;TOYE]YUE%<G_PL_PA_P!!8_\ @-+_
M /$T?\+/\(?]!8_^ TO_ ,31]7K?R/[F'MZ7\R^\ZRBN3_X6?X0_Z"Q_\!I?
M_B:/^%G^$/\ H+'_ ,!I?_B:/J];^1_<P]O2_F7WG645R?\ PL_PA_T%C_X#
M2_\ Q-'_  L_PA_T%C_X#2__ !-'U>M_(_N8>WI?S+[SK**Y/_A9_A#_ *"Q
M_P# :7_XFC_A9_A#_H+'_P !I?\ XFCZO6_D?W,/;TOYE]YUE%<G_P +/\(?
M]!8_^ TO_P 31_PL_P (?]!8_P#@-+_\31]7K?R/[F'MZ7\R^\ZRBN3_ .%G
M^$/^@L?_  &E_P#B:/\ A9_A#_H+'_P&E_\ B:/J];^1_<P]O2_F7WG645R?
M_"S_  A_T%C_ . TO_Q-:&B^,M"\0WK6FD7WVB=(S(R^2Z84$ G+*!U(I.C5
MBKN+^X:K4Y.RDOO-RBBBLC4*YSQKX]\/^ -)6_\ $EYY(E)6""-=\L[ 9(5?
MRY. ,C)&171UXG\?;2TGGLY[/6X;'Q!!IMWY%G<VS.EY;E?WP5\$(X4,1@Y/
M3@'- 'H\_P 0_"=MX-B\53:W;KHLV!'=?,=['^$(!N+<'*XR,'(X-&E_$/PK
MK/A6\\2:9J\=QI5BKM<SK&X:(*,G<A7>..<8Y[9KSRT\0^$6^'3>(/&WAZQT
M^?PSK<L2VVEY6*?4(R!OA12 Y8\C=G&"2<#-8VK>']6M/A+XSU_Q--9>&]1\
M87<#20W D:.RBW@*KF-&8.P+9..K#.#D  ]5\,?%#P=XQFNXO#NM+=-9P^?<
M%X)85C3^\3(JC%2^%OB/X2\:7]U9>&=:AOKFT7?+$$=&VYQN7>HW+G )7(&5
MSU&?(O$&L^*-'TOQEX"UC6X?$4,/ADW]O?06B6[0IE4,3*AQC:2><G'?GC3T
M7[-_PM#X4_V5Y>/^$8?SO)Q_J?)^3=[;\_CF@#W&BBH+I[M$4V4$,S9^82S&
M/ ^H5LT 5?#W_(LZ7_UYQ?\ H K1K T*;5AX=TX16-HR"UBVLUXRDC8,$CRS
MCZ9-7O/UG_H'V7_@:W_QJ@#1HK.\_6?^@?9?^!K?_&J//UG_ *!]E_X&M_\
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M*?PHB4XP^)G;45Q%SI_CG6F5KJZMM)M3R;:SN"LOXR;&Y^G%1?\ ".>-X/\
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MRE0?S(K6-:4HRDEM_E<SG24)*+>_^=C0/A#1(KDZ?=>++:/4P=AA6V=HE?\
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M16=Y^L_] ^R_\#6_^-4>?K/_ $#[+_P-;_XU0!HT5G>?K/\ T#[+_P #6_\
MC5'GZS_T#[+_ ,#6_P#C5 &C16=Y^L_] ^R_\#6_^-4>?K/_ $#[+_P-;_XU
M0!HT5G>?K/\ T#[+_P #6_\ C5'GZS_T#[+_ ,#6_P#C5 &C16=Y^L_] ^R_
M\#6_^-4>?K/_ $#[+_P-;_XU0!HT5G>?K/\ T#[+_P #6_\ C5'GZS_T#[+_
M ,#6_P#C5 &C16=Y^L_] ^R_\#6_^-4>?K/_ $#[+_P-;_XU0!HT5G>?K/\
MT#[+_P #6_\ C5'GZS_T#[+_ ,#6_P#C5 &C16=Y^L_] ^R_\#6_^-4>?K/_
M $#[+_P-;_XU0!HT5G>?K/\ T#[+_P #6_\ C5'GZS_T#[+_ ,#6_P#C5 &C
M16=Y^L_] ^R_\#6_^-4>?K/_ $#[+_P-;_XU0!HT5G>?K/\ T#[+_P #6_\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JK?_ /'NO^]_0U:JK?\
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M7<SL?X4'&3R?0'!QV=>(_M"OHH6Q2\O=1TC6&L;K[#?1!?LTR@ R6\N6!)8
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MNHW;7D\.J,C*9&(/1LMC*@].HSUKU^$ZI;QB.#2M/B0=%2[8 ?@(J?Y^L_\
M0/LO_ UO_C51*<7T^]_\,4H277[D<1#\-M7O57^V]>)4 #RX]\HQZ L1C\JV
M;+X9>'[;FX6XO#_TUEP/_'<5O>?K/_0/LO\ P-;_ .-4>?K/_0/LO_ UO_C5
M1S%\H6?A_2+#;]DTRUC9>CB(%O\ OH\UHUG>?K/_ $#[+_P-;_XU1Y^L_P#0
M/LO_  -;_P"-5)1HT5G>?K/_ $#[+_P-;_XU1Y^L_P#0/LO_  -;_P"-4 :-
M%9WGZS_T#[+_ ,#6_P#C5'GZS_T#[+_P-;_XU0!HT5G>?K/_ $#[+_P-;_XU
M1Y^L_P#0/LO_  -;_P"-4 :-%9WGZS_T#[+_ ,#6_P#C5'GZS_T#[+_P-;_X
MU0!HT5G>?K/_ $#[+_P-;_XU1Y^L_P#0/LO_  -;_P"-4 :-%9WGZS_T#[+_
M ,#6_P#C5'GZS_T#[+_P-;_XU0!HT5G>?K/_ $#[+_P-;_XU1Y^L_P#0/LO_
M  -;_P"-4 :-%9WGZS_T#[+_ ,#6_P#C5'GZS_T#[+_P-;_XU0!HT5G>?K/_
M $#[+_P-;_XU1Y^L_P#0/LO_  -;_P"-4 :-%9WGZS_T#[+_ ,#6_P#C5'GZ
MS_T#[+_P-;_XU0!HT5G>?K/_ $#[+_P-;_XU1Y^L_P#0/LO_  -;_P"-4 :-
M%9WGZS_T#[+_ ,#6_P#C5'GZS_T#[+_P-;_XU0!HT5G>?K/_ $#[+_P-;_XU
M1Y^L_P#0/LO_  -;_P"-4 :-%9WGZS_T#[+_ ,#6_P#C5'GZS_T#[+_P-;_X
MU0!HT5G>?K/_ $#[+_P-;_XU1Y^L_P#0/LO_  -;_P"-4 :-%9WGZS_T#[+_
M ,#6_P#C5'GZS_T#[+_P-;_XU0!HT5G>?K/_ $#[+_P-;_XU1Y^L_P#0/LO_
M  -;_P"-4 :-%9WGZS_T#[+_ ,#6_P#C5'GZS_T#[+_P-;_XU0!HT5G>?K/_
M $#[+_P-;_XU1Y^L_P#0/LO_  -;_P"-4 :-%9WGZS_T#[+_ ,#6_P#C5'GZ
MS_T#[+_P-;_XU0!HT5G>?K/_ $#[+_P-;_XU1Y^L_P#0/LO_  -;_P"-4 :-
M%9WGZS_T#[+_ ,#6_P#C5'GZS_T#[+_P-;_XU0!HT5G>?K/_ $#[+_P-;_XU
M1Y^L_P#0/LO_  -;_P"-4 :-%9WGZS_T#[+_ ,#6_P#C5'GZS_T#[+_P-;_X
MU0!HT5G>?K/_ $#[+_P-;_XU1Y^L_P#0/LO_  -;_P"-4 :-%9WGZS_T#[+_
M ,#6_P#C5'GZS_T#[+_P-;_XU0!HT5G>?K/_ $#[+_P-;_XU1Y^L_P#0/LO_
M  -;_P"-4 :-%9WGZS_T#[+_ ,#6_P#C5'GZS_T#[+_P-;_XU0!HT5G>?K/_
M $#[+_P-;_XU1Y^L_P#0/LO_  -;_P"-4 :-%9WGZS_T#[+_ ,#6_P#C5'GZ
MS_T#[+_P-;_XU0!HT5G>?K/_ $#[+_P-;_XU1Y^L_P#0/LO_  -;_P"-4 :-
M%9WGZS_T#[+_ ,#6_P#C5'GZS_T#[+_P-;_XU0!HT5G>?K/_ $#[+_P-;_XU
M1Y^L_P#0/LO_  -;_P"-4 :-%5+:747FQ=VEM%'C[T=RSG/T*#^=6Z "BBB@
M HHHH **** "JM__ ,>Z_P"]_0U:JK?_ /'NO^]_0U4=R9;'$SZYJ^H^*+[1
M/#PTZ&33HHY)WOU=S)YF2-B(RD*,<L<C)QVI+[Q1J&C^!;S6M9TK[->V899(
M ^Z-R#@2!AR(SG//(&<]*RO$G]CW>O7-IXW\/M);B/\ XENI6MG+,Q0@;T+1
MAF1PW(X QC'(-9-Q'KDWA=(]0;5Y/#\VKD2[][7ITXIQNQF0@R=?X]G4=JT3
M=OZ[_P!?*YG977]=/Z^=D=;X9\27.KMJ]O=M8W$FF2*OVK3RQ@FW)NP,DD$=
M^3U%9.F^(_%^H^$!XCBBT(P>7),+3RYED*HS C?OP"0O7&*Q/"%SJFB^)/[$
MTZVOCX-D$_V">33BC>:PW>4Q;#JB_-M8J,G Z8-:7@KP3;W?@6Q36)M97S1)
MYUC+?S)$1YC?*8L@;2.V.<T:M7786BT9TUWXE ^'\GB6PA!!L?MD44Q]5R%.
M/Z5CW?B/Q/H_AVW\0:I'HUS8%89)X+6.6.54DQRK,Y!(W#C'-;'C&U)^'^KV
MEE 3_H+QQ0PID],!5 _D*H:-X)T]]'TMM1FU2\\N&&0VM]?RRQ*X4$9C8XX/
M08XJMYNVVGZBVBK^?Z"6'Q TM]6U+3]6N8;26VOS:PXCD(9>-I=L%4))[D5K
M7GBS0[#4A87FH)%<%U0CRW**S=%9PNU2?0D&N,U'3+A_"7CE18S-+<:MYD:B
M$EI0'CPRC&6&,\BL/Q1_:-UI6MVCQZI'.M^LR:78Z<5BEC5T/GO*%S(2 25W
M$YQ\O%2I.ROV7Z%N*_%GIU[XMT+3]0GLKS4%2YMT\R:,12/Y2[=^YBJD ;><
MD\_6JJ?$#PM(Q6/5T<[=Z!8)291G&8_E_>?\ S7/7UI<3_\ "P)H;2<_:]+B
M6 ^2P,O^BXVKQDG/&/6IK?3I4\1^ F%E(L=IIUPKGR2! Q2( 'CY3UZ^]4KM
MV]/U_P B6E:_]=/\SM--U.SUC3X[W3+A;BVDSMD4$=#@@@X(((P01D5:KE/
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MM'DZU_S_ -A_X O_ /':Q-31HK.\G6O^?^P_\ 7_ /CM'DZU_P _]A_X O\
M_': -&BL[R=:_P"?^P_\ 7_^.T>3K7_/_8?^ +__ !V@#1HK.\G6O^?^P_\
M %__ ([5?3Y-:O\ 3+:[^V6$?VB%9=GV)SMW '&?-YZT ;-%9WDZU_S_ -A_
MX O_ /':/)UK_G_L/_ %_P#X[0!HT5G>3K7_ #_V'_@"_P#\=H\G6O\ G_L/
M_ %__CM &C16=Y.M?\_]A_X O_\ ':/)UK_G_L/_  !?_P".T :-%9WDZU_S
M_P!A_P" +_\ QVCR=:_Y_P"P_P# %_\ X[0!HT5C))K3ZG-9_;+ >5#'+O\
ML3\[F<8QYO;9^M6/)UK_ )_[#_P!?_X[0!HT5G>3K7_/_8?^ +__ !VCR=:_
MY_[#_P  7_\ CM &C16=Y.M?\_\ 8?\ @"__ ,=H\G6O^?\ L/\ P!?_ ..T
M :-%9WDZU_S_ -A_X O_ /':/)UK_G_L/_ %_P#X[0!HT5G>3K7_ #_V'_@"
M_P#\=JOJ$FM6.FW-W]LL)/L\+R[/L3C=M!.,^;QTH V:*SA#K1'_ !_V'_@"
M_P#\=H\G6O\ G_L/_ %__CM &C16=Y.M?\_]A_X O_\ ':/)UK_G_L/_  !?
M_P".T :-%9WDZU_S_P!A_P" +_\ QVCR=:_Y_P"P_P# %_\ X[0!HT5G>3K7
M_/\ V'_@"_\ \=H\G6O^?^P_\ 7_ /CM &C16=Y.M?\ /_8?^ +_ /QVJ]M)
MK5Q<7<7VRP7[-*(\_8G.[**^?];Q]['X4 ;-%9WDZU_S_P!A_P" +_\ QVCR
M=:_Y_P"P_P# %_\ X[0!HT5G>3K7_/\ V'_@"_\ \=H\G6O^?^P_\ 7_ /CM
M &C16=Y.M?\ /_8?^ +_ /QVCR=:_P"?^P_\ 7_^.T :-%9WDZU_S_V'_@"_
M_P =H\G6O^?^P_\  %__ ([0!HT5C7TFM65NLOVRP?,L<>/L3C[[JF?];VW9
M_"K'DZU_S_V'_@"__P =H T:*SO)UK_G_L/_  !?_P".T>3K7_/_ &'_ ( O
M_P#': -&BL[R=:_Y_P"P_P# %_\ X[1Y.M?\_P#8?^ +_P#QV@#1HK.\G6O^
M?^P_\ 7_ /CM'DZU_P _]A_X O\ _': -&BL[R=:_P"?^P_\ 7_^.T>3K7_/
M_8?^ +__ !V@#1HK&MI-:N+F[B^V6"_9I1'G[$YW917S_K>/O8_"K'DZU_S_
M -A_X O_ /': -&BL[R=:_Y_[#_P!?\ ^.T>3K7_ #_V'_@"_P#\=H T:*SO
M)UK_ )_[#_P!?_X[1Y.M?\_]A_X O_\ ': -&BL[R=:_Y_[#_P  7_\ CM'D
MZU_S_P!A_P" +_\ QV@#1HK.\G6O^?\ L/\ P!?_ ..U7NI-:MI[2/[98-]I
MF,6?L3C;\C-G_6\_=Q^- &S16=Y.M?\ /_8?^ +_ /QVCR=:_P"?^P_\ 7_^
M.T :-%9WDZU_S_V'_@"__P =H\G6O^?^P_\  %__ ([0!HT5G>3K7_/_ &'_
M ( O_P#':/)UK_G_ +#_ , 7_P#CM &C16=Y.M?\_P#8?^ +_P#QVCR=:_Y_
M[#_P!?\ ^.T :-%9WDZU_P _]A_X O\ _':KV,FM7D#R?;+!-LTD6/L3G.QR
MN?\ 6]]N: -FBL[R=:_Y_P"P_P# %_\ X[1Y.M?\_P#8?^ +_P#QV@#1HK.\
MG6O^?^P_\ 7_ /CM'DZU_P _]A_X O\ _': -&BL[R=:_P"?^P_\ 7_^.T>3
MK7_/_8?^ +__ !V@#1HK.\G6O^?^P_\  %__ ([1Y.M?\_\ 8?\ @"__ ,=H
M T:*RS-J5I?64=W<6D\5S,8B(K9HV7$;OG)D;^YC&.]:E !1110 4444 %%%
M% !5:^5GA 52QW=A[59HIIV=Q-75CB;WP<\VM2ZKI>I:GH]W<($N6LQ&R7 '
MW2R2HZ[@. P .#C.*A;P!9_V;%!%+?QWD5W]N74@X-P;C&#(2P*G*_+M*[<<
M8QQ7>457.3R'GUK\.X+;Q$FOOJ&KW&K%3'/=22@?:(B,")HU41A1U&U5.1G-
M;6A: GA_0[;2[,3R0VX8*THRQRQ;G  ZGTKIZ*?/;H+DN<WK.B#7-%N],NA,
MD-W$8G:,88 ^F01G\*K:KX7BU?08-)N/M*00M"RM& &/ED%<Y!';GBNMHHYP
MY#E%\+VAT.?2KJWDNK:Y=WF\T?,[,V2<C&#G&".1@5FKX$,LMH-7U?5]6M;-
MQ)!9W9C\L./NLQ2-6D*]M[-Z]>:[VBCGMT#D.3\1^&AXDTM;*>6ZM=D\=PDU
MNJ[U=#E3\ZLIY]145GX>UBVO(YI_$VKWD:'+036UHJ/[$I K?D178T4N<.0\
MI\1?#FZ.CQ6^AW.IR6T&H6]S!I.^,018F5G()4.5"[B$+E1V'  T;SX;6]Y)
M=+_:&JP65U>K?R6,3((O/#*Y;)0O@LN2I;;DD@ XQZ+10IV_KT_R0W&YY;X@
M\ 74IT>#2#?+&NO2:E<W".JR6^]96++D8(#L !ALCJ",UTNB>&1HLEW<&:[O
M[Z]=7N;RZ"^9)M&%7"*JJH'0* .2>I)KK:*%.RLOZT2_0'&^_P#6K?ZF1Y,O
M_/-_^^31Y,O_ #S?_ODUKT4_:"]FC(\F7_GF_P#WR:/)E_YYO_WR:UZ*/:![
M-&1Y,O\ SS?_ +Y-'DR_\\W_ .^36O11[0/9HY"V\*1VFE:A86\M]&M_<2W#
MS1R&.2-W.3L90",'I^N:CT_PG+:7KWUYJ6I:E?>08(;F[6+=;H>NQ4C5<DX)
M)4DX&<CBNSHHYQ\ASTFEO/ICV=T9IS)"8GF9%#MD8+<* #SV&/:JMIX;%CX5
MBT*TDNXH8K86R3KCS0N,9SMQNQWQ75T4<^^FXN3S.!UCX>V&KF$;KRRB6T%C
M-%:A0MS;;@WE/E20N<\J5.&/-=?80M%)C8RJ$P,CZ5?HH<[JPU!)A1116985
M%<VMO>VLEM>01W$$JE)(I4#*ZGJ"#P14M% !1110 444$94@''N.U &;'XDT
M.;6VT:+6=/?5$SNL5ND,ZX&3F/.[ISTZ4Z;Q!HUMK,6D7&K6,6I3 -%927*+
M-(.>50G<>AZ#L:\*E\&Z ?'6@>#_  !;S7NHZ'JRZGKGB*;:TT*@EO)>95&]
MF)QM[%>YWXP/$-C:7GP]^*'BB\AC;7[#Q7Y=K?,H\Z!4GB551NJ@*Q&!Z#TH
M ^FKR_L-)M4DO[JVLH-ZQ(T\BQKN/"J"<#)Z 4^\O;73K.6[U"YAM;:%=TDT
M\@1$'J6/ %>*_&S0;F:#0O$=_J]W,O\ :EC#;Z:,)! 6.7D('+.2, GH"1]-
M;]H/P[/J?P]U'5)M7NXK+3K8,NFPX6.:4R* \AZL #PO0$ ^U 'K,<B31+)$
MZO&ZAE=3D,#T(/<4ZL[P]_R+.E_]><7_ * *T: "BBB@ JGJFL:9H=G]KUK4
M;33K;<$\Z[G6)-QZ#<Q SP>*N5YW\4]/\'6;:?XM\=&2\BTE9(K/2W5)(KN6
M08"^4RG>YP,<@#&3P,T =NVM:6FC?VNVI6:Z9L$GVTSKY.P]&WYVX]\T_3]0
ML-7LXM0TJ[MKZVD#"*YMI%D1@#@X920>5P<=Q[5\[+X7O=*\(> ]%\1VAM;3
M6_%GVR;29"2D$3\I;L#VZDJ1U8Y&<UUG@C0YIM>^)_A7PYJ$GA^R74K=H)+&
M,9MO,7,PB'1&*KM!'W."/NB@#UZSU*QU!KA;"\M[HVLQ@G$$JOY4@ZHV#\K#
M(R#S5;2_$FAZY--#HNLZ?J,L'^N2TNDE:/G'S!2<=#UKR7X/^&K6]\$^/_#4
MEW=PV;Z_>637"2CSO+VHI.X@C) Y)'<U!X T31M3^+5CJ/P]TY;7PWX:L'L+
MC540(-5G9=N,@#S=OWB_<@'H5) /<Z*** "BBB@ K,L?$NA:GJD^FZ;K6GW=
M_;[C-:V]TDDL6U@K;D!R,$@'(X)Q5O4+,:AIEU9--+ +F%XC+ VV2/<"-RD@
MX(SD''6O"_#GA?0;GXJ>'+#X<V.-/\'F<:KKP50UU*R[1"74#S6SU/0!CCC@
M@'MB^(-&?7'T5-6L6U5!N:Q%RAG4;0V3'G<."#TZ'-37-_8::UM%>7=M:&XD
M$%NDLBIYKXX1 >IP.@YKYBL;*V7X7:#XN6"-?$D_C,/+?A?W[LTKAD+=2IQG
M;TZGN:[OXD>'9[3XM>"=<OM8N[Y[K7XXK:U?"PV<.U2511U8L,LYY.%&..0#
MUO4_$6BZ+/!#K.L6&GRW)Q!'=W21-+R!\H8C/)'3UK1KR+XP>%]'UW2/$5YH
M%MH5_P"*;6Q"WPOYS+-:VP1G!CCR1%(>"IPN<DYKO/ %Y9W_ ,.O#]QIGG_9
M#I\*Q?:2#)M5 OS$<$\<GO0!T-%%% !1110!GZMK^CZ!#'+KNK6.F1RMMC>\
MN4A#GK@%B,FGWNM:7INF#4M1U*SM+%@I%U/.J1$-]WYR<<YXYYKS?XL6'@_2
M-23Q1XFM9M=U:YM#I>DZ$Z+,EQ,S9!CCVDALD ODX!& 6*@\;8^$;C3-8^$'
M@WQBB7D'EZA<75G/B2+S/+:1$8'(;9D+W'7'!H ^@;2YM;ZVCO;&:&Y@G0-'
M/"X=9%Z@AAP1S^M,L=1LM4MOM&F7EO>0;F3S;>59%W*<$9!(R#P17C?PST"X
MU[P7XJ\-V.L7>CZ;9^*KNW1K+ D%L-I,*.?N DYR.>2.]5OAIXNM? 7[-G]K
MS*CO'=W$-K"[[1+,TI"*2>@SR3V )H ]LM]4T^ZU"ZL;6^MIKRSV_:;>.96D
M@W#*[U!RN1R,]:M5X#\!9K>Q^)7C.SNO$-GJ]_>)9S&YBN4<7<I1WF,9!^95
M9R..@QG%>_4 %%%% !1169XDT6W\1>&=0T>^N9[6VO8&AFEMW".J$?-@D$#(
MR#D=": #2O$FAZ])-'H>LZ?J3P8\U;.Z28QYSC<%)QT/7TIUMKVBZCJ5SI5I
MJMA=WUN#]HLXKA'EB .#O0'(Y('([UXAX<TW3;GQI=Z]\-].%CH'AK0Y['^T
MXHP@U2X"'!X \S:1DN>I /<5D^&=*L-(TCX/:UI5O'#JE]J,L=W=1C]Y<+(6
M#AV'+8' SG S0!]&SZE8VU_:V-S>6\-W>;_LUO)*JR3[!EMBDY; Y..@JAJG
MB[PWH=X+76O$.E:=<E0XAN[V.)RIZ':S XX//M7E.I^'9]'_ &F?!E_?ZQ=Z
MI=:D=2<F;"QV\2P/Y<4:#A0JM@G^(Y8]:R/&=IK?_"P/&?B]=!\)^(-'TF.W
MBEMM5D2YF6*-,R"-5+>4^=Y/F 'I@-SD ^@XY$FB62)U>-U#*ZG(8'H0>XIU
M9^@:A;ZOX:TS4K&+R;6\M(IX8\8V(Z!E&/8$5H4 %%%% !69JOB30]!DACUS
M6=/TUY\^4MY=)"9,8SM#$9ZCIZUIUXK\7-$\+V6HZI<36,WB'Q?XHM!8Z7IL
MBI+]F(3;YL0VYC /SEB>H."!D@ ]<U;7-)T&V2XUS4[/38'?8DMY<)"K-@G:
M"Q )P"<>U6EE@^SFY22/R67S#*&&TC'WL^F._I7AMGX3BE^+?A'PCXOBAU:W
MTOP=GRKA?,C\\R%'(#=<!0 >HV@\8%5_!>BWGBK]FBWMY=<O;2PL1>F6.W(#
M7D2%RD32=0F>"!U7Y>* /<X=6TZXTG^U(+^UET_RS+]K293#L&<MO!Q@8/.<
M<4W2M9TO7;0W6B:E::C;JY0S6DZRH& !*[E)&<$<>]?/VKS7?_#,7@"RM(EN
M%U#5;2VFMI&VI<)OD81L>RET3FNV^$6W2_&/BW0-0\/Z5I&MVQMY;I]$>46<
MZ,F4*1.<(0#S@#.>G'(!ZQ1110 4444 ,EEC@A>:>18XHU+.[MA5 Y))/052
MTG7]'U^&270M6L=3CB;;(]G<I,$/7!*DX-9WCOP]IGBCP9?:9K]_/8:8RB6Z
MG@F6(K&AWG<S @+\O/M7B5O!%<V/Q!\<>"-,.A>&AH,NF6!AB\@7SJ<M<J@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>jnj-20220102_g2.jpg
<TEXT>
begin 644 jnj-20220102_g2.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M;W<UW9116\^Y'40R.LA*, IVG ![S1110 4444 %%%% !1110 4444 %%%%
M'X@_\'O/_)K/P/\ ^R@:C_Z0BBC_ (/>?^36?@?_ -E U'_TA%% 'G__  :;
M?\I3/VN_^WC_ -/D]?O]7X _\&FW_*4S]KO_ +>/_3Y/7[_4 %%%% !1110
M4444 %%%% !1110 5_/O_P 'RY']M_LRKGD6OC#C_@6BU_017RU^UW_P1=_X
M)Q_MZ>.;?XC?M>?!/7/'&J622IIS:G\4/$D=O8I(X>1+>WAU!(;=68 E8T4'
M:HQA1@ _%[_@N/\ \$6M-^$W['?P;_X*M_L+?#ZQ\/G0? /AR;XG:#X8TN*&
M*"46MN\&O10QJ$#>:0MP0/F)CF8?ZYS^IW_!)[_@J/:_\%>O^"9^O>(_!%U9
MZ7\8= \*W.A>,-!LG$7V36&M)%MKR%<C9;W! DC/1&62/),1)^M/A1^RI\#O
M@Q\$F_9Q\'^&]2N_!#:1_9/_  CWBKQ1J.NQ#3_(^S_8PVI7$[BW\K]WY0;9
MMXQ7BW[)?_!$G_@FC^PK\4_^%T?LE? /5O!/B)H#!<76F?$SQ&\-W"6#>3/;
MS:@\%Q'N"MLE1E!4$#(!H _&?_@U)\&_##]H/P1\<_V!OBO^T=\0/ FMZE,+
MJ;P1X?URVL!KUA+;26>H(T<]M)(TD01$D"E2JS#CAB/NKX]_\$;_ /@EIXJ_
MX)NV7_!,CX2_'77-%TO7/CO=6_PX\7ZK>'4DT_QS'I=S)):"4I%'/ 8;2Z@>
M-&Q]H+Q!Q.NU?H+]H_\ X-XO^"2_[4_QZNOVDOBE^S0T7BG5+XWFNS^'O$M_
MID&JW!.7EFAMID3S'.2[QA'<L68ECFO:_C'_ ,$YOV,_CM\!_"'[,/C_ ."E
MFO@'P'JMMJ/A/PUH=]<:7#IMS;V\\$$D3V<D4B-&MQ(RLK B3:^=PS0!^-/_
M  1$^('_  4K_P""5W_!6GPU_P $4OVQ8AXD\'^(--U#4/!ZR7!OK?2(4LKR
M>+5-)G<!XK6;[+/!)"0@5F<E$=7#^<_\$.)AX7_X+A?M*_LK?M ?M&^-OAAX
MQ\8^)=96QN_#NLV]C)K>JVVKS2-:L]S!+YC213RSQXQO",06W*#^Z7P#_P""
M;_[,'[/7QMO_ -I?0M-\3>)OB+?:(FBCQQ\0O&FH>(-3M-+5BZV-O-?32&"'
M<68A,,Y8EV;->=_MN_\ !"O_ ()E?\%!_BG'\</VCOV?C/XP\J**\\1^']<N
M],N+^.,!4%Q]GD59BJA5$C*9 JJH8*H  /"-5_9B_P""1O\ P1G_ &'OVI-3
M_LO7_B)X,:VTZ;XO^#/$.I#4UNM0N&,5E8A_*2*&XFDNX69=V^)9+>9@BF-F
M_)O_ (*#?%G1?CS_ ,$ ? 7Q?\/^-?!/P_\ "E_\;6L_AO\ LT?#^Z@%OX;L
M8!JJW%Y?O,6OK^_DEQ(TKLD2QW2,(P9LC^BW3_\ @G5^Q1I7['][^P3I_P"S
MWHD7PEU*Q>UU'P@K3;+H-()6FDGW^>]QYJK)]H,AFWHK[]R@CQ_0/^#?C_@D
M%X8_9\US]F71_P!B_0T\,^([N"ZUB>35+Z35)YH6+PL-1><W<80EL(DJIAF&
MW#," ?(O[4<T<G_!FOII653M^ O@Y6PW0_;=,X^M>J?\&DOA_2-&_P""+OA#
M4M-LTBFU;QCX@N]0=%P9IA>M &/J?+AB7Z**^G+S_@D+_P $\[S]CJ']@0?
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M+;S#YSR32O)\B11DAGF4 _+[_@GE_P KCOQI_P"OWQ7_ .D\5=3^PG\9+/\
MX+7?\'$OQG\-_MA^&['QM\*OA'X6\00?#GX:^);5;S1+1K75K/38[R2RE#0R
MW$D<MQ,SNK,'D4 XBC"]A^Q=_P $[O\ @I/\+O\ @XJ\:_\ !2+XA_L-^(=+
M^%_C36]<BM[YO&WAB:[L+>\01PW,]O%JK-M&Q6=8][@-PK$8/H7P6_X)H_M#
M_P#!*#_@MM\2_P!O+X.? 37OBA\%_C+X>U:.^LO!%Q9-J_AC4KV^MM0>-[2Z
MN(/.@^T6\BHT3,%CG4, 4^8 \F_X(,_M4>,? ?\ P5K_ &G?^",GB[5+GQ+\
M&M-UWQ:G@#PWXAF:_AT2WL=5:V.G1B8M_HDMI*0\393=""%!DD+?.?\ P0E_
M9;\ ?M7_ /!8G]IO]F+XRZ]XEO/AEH5CXDCF\"V7B:\M++4[>'Q!#;V]I<&&
M59&MHPP?R5959HH]VY5*G]!/^"(O_!(GX^_!/]NCXZ?\%6_VQO"$/A+Q=\6O
M$.MR^$/A\=2@O;G0]/U+4S?RR7<MN[PB8A88E2-VVJ)-Q!?:OP!_P0G^)WQL
M^$'_  7&_:O\<?!K]GR\^)BV[^*1XA\,Z+K-K9ZK]C/B6+]]9"[>.WN)5D$>
M89)8MR,Y5RZK&X!ZI_P0]^*OC3_@GW_P<$_&'_@D9X*\8:K=_"#5M8UY/"WA
MG4;^2XCTB>UC-_:S1&0DJ_V19()&&/-.QGR47'G?A_X):7XU_P"#N[Q3^RAX
M=\:^)?!O@>]U?4FO-(\$ZW+IF;9_"S7=S:PM"0;6.=FD1VAV2*DK^6T;;67[
M!_X(]_\ !*[]KO6/^"L_Q<_X+(_MO_"$_#A_$FI:L?AWX"OM4M[K481>OY8G
MN#;NZ1B*T4P $AI'E9MJJJ[^-^&/_!.O_@I+H?\ P<U7W_!476?V'_$%O\)M
M1U^]A^WMXV\,M>0VTN@MI:7;6RZH7*>;ME*#,@C)PA<;" ?,O[*W[/\ 8_ C
M_@Z*^(7_  34_9W^)_C7P!\(O&%Q>VGB;0/"_BFYBFO=/30UU@VGVIW:>,M,
MAC^T(XN$BDD5)4+EJ[+_ ()S>'K#]@O_ (.W/&O[%?[--]J>A_#;7QJ5I?\
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M&-WX8CUCQ/?^*M8GO[Y+N_9KQK:2:=BQ\@3+;@=,0\"N;_X*NK_PNF#X/_\
M!/VR_>?\+O\ B=:)XKMQQGPIHV-7U;)[+(+:ULSV/V\#O@_7   P!0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^
M(/\ P>\_\FL_ _\ [*!J/_I"**/^#WG_ )-9^!__ &4#4?\ TA%% 'G_ /P:
M;?\ *4S]KO\ [>/_ $^3U^_U?@#_ ,&FW_*4S]KO_MX_]/D]?O\ 4 %%%% !
M1110 4444 %%%% !117G?QJ_:S_9P_9TU2RT7XW_ !>TCPW=:E;M/8P:C(RM
M-&K;2PPIX!XH ]$HKP;_ (>?_L _]'3^%_\ O_)_\11_P\__ & ?^CI_"_\
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M/7[_ % !1110 4444 %%%% !1110 5^?_P#P4UTO3-7_ &\/AA9ZMIT%U"?
M.J$Q7$*NN1.N#A@17Z 5\#_\%)/^3^?A?_V3_5?_ $>M>QP^D\[PZ?\ /'\S
MQN(FXY%B6OY)?D<3_P (#X$_Z$K2/_!;%_\ $T?\(#X$_P"A*TC_ ,%L7_Q-
M:U%?O_L*/\J^Y'\\^WK_ ,S^]F3_ ,(#X$_Z$K2/_!;%_P#$T?\ " ^!/^A*
MTC_P6Q?_ !-:U%'L*/\ *ON0>WK_ ,S^]F3_ ,(#X$_Z$K2/_!;%_P#$T?\
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M (>?_L _]'3^%_\ O_)_\11_P\__ & ?^CI_"_\ W_D_^(H ]YHKP;_AY_\
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MQJR-X^T0,K#((-QR"*\%_P"$!\"?]"5I'_@MB_\ B:]\_P""SO\ R9[:?]E
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MYG][.3\>>!?!$/@?698O!NE*RZ3<E673H@01$V"#MK[,_P""8/\ R8#\*_\
ML5H__1CU\D?$#_D0];_[!%S_ .BFKZW_ ."8/_)@/PK_ .Q6C_\ 1CU^7^(<
M(0K8?E5M)?\ MI^J^'$YSH8CF=]8_DSWBBBBOS@_2@HHHH _$'_@]Y_Y-9^!
M_P#V4#4?_2$44?\ ![S_ ,FL_ __ +*!J/\ Z0BB@#S_ /X--O\ E*9^UW_V
M\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHKA?C1KO[0NB:IX*B^
M_P /_#FNV=[XRMK?QY-K^MR6;Z9H;1RF>ZM52-Q/<*XB"Q,5#;B,C[R@'P?^
MUYX#_P""1>I_MU>._%W_  6+\7>'I-<A^PQ?"+2/BQJLUMH-OX;_ +.M/.DT
MV-V6UGF?43?>>QWSJ4C!"1^67]'_ ."2/CK]COQ7\3OBCI'_  3-T*Z@^ 6E
M6FE107MA#=Q>'I_%!DO3?C2$N>BBW^Q?:#$%A+^4R LTCM:_;*UK_@I-\3OC
M5XE^#/P__P"":GP.^*'PST;[!=:#K?Q5\6-$NH22VX:7;;/93H'BF$J$@YV[
M#_'@=]_P3\U[]OA_%7C'P'^U]^S!\._A=X6T+0-"'PZTGX::N;ZPD:274Q?*
M9###L9!'9?N@@50X()+G !]-T444 %%%% !7P/\ \%)/^3^?A?\ ]D_U7_T>
MM??%? __  4D_P"3^?A?_P!D_P!5_P#1ZU[/#W_(\PW^./YGB\1_\B'$_P""
M7Y'/T445_09_.H4444 %%%% !1110 5YM^T[_P BSX8_[*!HO_I6M>DUYM^T
M[_R+/AC_ +*!HO\ Z5K7C\0_\B/$_P""7Y'L\._\C[#?XX_F?K#1117\]G]%
MA1110 4444 ?)O\ P6=_Y,]M/^R@:'_Z45XS7LW_  6=_P"3/;3_ +*!H?\
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M_P ?#>DOSB%%%%?I)^9!1110 4444 %%%% &1\0/^1#UO_L$7/\ Z*:OK?\
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M6?#'_90-%_\ 2M:])KS;]IW_ )%GPQ_V4#1?_2M:\?B'_D1XG_!+\CV>'?\
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MY,!^%?\ V*T?_HQZ_+?$;^-AO27_ +:?J_AM_ Q/K'\F>\4445^:GZ:%%%%
M'X@_\'O/_)K/P/\ ^R@:C_Z0BBC_ (/>?^36?@?_ -E U'_TA%% 'G__  :;
M?\I3/VN_^WC_ -/D]?O]7X _\&FW_*4S]KO_ +>/_3Y/7[_4 %%%% !1110
M4444 %%%% !7P/\ \%)/^3^?A?\ ]D_U7_T>M??%? __  4D_P"3^?A?_P!D
M_P!5_P#1ZU[/#W_(\PW^./YGB\1_\B'$_P""7Y'/T445_09_.H4444 %%%%
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MI_\ ':/[;R7_ *":?_@<?\P_L/._^@6I_P" 2_R/.:*]&_X9,_:!_P"A _\
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+%$0R"",Y-% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>jnj-20220102_g3.jpg
<TEXT>
begin 644 jnj-20220102_g3.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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MR^+(-"\*^%-)FU+7M7N4=DM;:)2SMM0,[G P$4%F)"J"2!7P7J7_  < NO\
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MY:*_*']IW_@YVUS]E(?![XK_ !6_X)J>-M)^#OQ=T^*[TGQ_JGBZTAO)(Q%
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M* /Q!_X/>?\ DUGX'_\ 90-1_P#2$44?\'O/_)K/P/\ ^R@:C_Z0BB@#S_\
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MUGX'_P#90-1_](111_P>\_\ )K/P/_[*!J/_ *0BB@#S_P#X--O^4IG[7?\
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MS9Q6URFIQ2*L_A[41"J0RN#+!]GN42,N)XHI%>0F4@'VE1110 4444 %%%%
M!1110!^(/_![S_R:S\#_ /LH&H_^D(HH_P"#WG_DUGX'_P#90-1_](110!Y_
M_P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE,_:[_P"WC_T^3U^_U !1110
M4444 %%%% ''_M#?%W3_ -G[X ^.?CUJVGM=VO@CP?J>OW-HC;3-'9VLEPR
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MH#X1:?XMTN]5;'[-916[Q37QM[:[NE\J3-ON\IUEN(Q(PV2U\V_\$CO^"/\
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M2-++^(O$6CVT%M?R+=Z?:Q*SZ%IL*"V=IW%N 8GWN^3N_>2OP4_8(_X)<_\
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M\+F\'>+O#NE>)-=\0^*K*XEUG4[;3+V!&L;6U:1E@=4>5Y)VCV,5CC68%I%
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MM_RE,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%?#GQ]_P""+MU^UU\=?%7Q_P#CG_P4$_:#\-76M:GY>A^$_A)\2&T7
M1M'TR!!#;1K"8':2=T3SII"0/-F=5&U0S9W_  0.^"E[X!^#GQ4^*=G\=/B1
MX[\*^+?BWJME\-]3^)/C&;6+I_#^DS/IT-PKR;57[1<Q7LP*(@:-X<@[02 ?
M>E%<#^T=\&-?^/WP_7X7:=\6M?\ !VEZA?)_PDNH>%+MK35+JP".6M;:[4A[
M)I)/*#SQCS!$)%0QNZRI\/\ [&_[)'Q(_8N_X+*^(OA'^RW\7_'>M_ 6Z^#<
M>K?$'PSXS\77>M6OA[Q)->E+**VGNG>2.XFMXGF,;,6\HEG)5[<  _1ZBBB@
M HHHH **** "BBB@#\0?^#WG_DUGX'_]E U'_P!(111_P>\_\FL_ _\ [*!J
M/_I"** //_\ @TV_Y2F?M=_]O'_I\GK]_J_ '_@TV_Y2F?M=_P#;Q_Z?)Z_?
MZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#P+_@I]\>?%?[._P"PYXZ\8?#,EO&VLV4/ACX>
MP1OB2;Q#JT\>FZ<$ Y8K<W,<A YVQL>V:[[]F?X&>"_V2_V:/!/[/7A.:.+1
M? /A&RT>&ZDP@D2VMUC:=R> SE6D9CU+,35GXP_L^_#3X[ZKX+U7XDZ;<7G_
M  @/C&#Q1X?MH[MXX1J<$$\,$LJKQ*(Q<.ZJWRB14?&44C4^+WPI\"_';X4^
M)?@G\4-&.H^&_%^@W>C:_8+<20FYLKF%H9HQ)&RNA:-V&Y2&&<@@\T :\%SI
M/BC0UN]-U)+FQU"UW07EA=G$L3KP\<L9SR#D.IST(/>OS%\=?L':#^P=_P %
MRO@!\8?V'-9U_2+?XYMXHMOCAX,N/$5W?VFIV=EIPN%U23[3)(ZE)Y8E+%MH
ME:!4"^8X?ZR\;?\ !)C]B+QY^S!\//V1-4\ ZY9^#_A5=P7?@$Z+XTU.PU#2
M+F))$6=+RWG28N1+)DLQ&7R "%QZ3\#OV3/@O^S]J=SXG\&V&N:IXAO;".QO
MO%OC3Q9J&OZQ/:HQ=;<WNHSS3) ')?R498MY+;,DF@#TJBBB@ HHHH ****
M"BBB@#\0?^#WG_DUGX'_ /90-1_](111_P 'O/\ R:S\#_\ LH&H_P#I"**
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MQQ"II2<;.+>R3O>Z[GYGQ=XD4.%,U6"GAG4;BI74DMVU:W*^Q_13_P //_V
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M6, +N[2DO\QQLH ^QZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#\B_^#DG_ )*[\.?^Q8NO_2D5^9]?IA_P<D_\E=^'/_8L
M77_I2*_,^OZ;\(O^24E_U\E^43^7/&+_ )*V/_7J/YR"BBBOU$_*@HHHH **
M** "BBB@ K[<_P"" _\ R?S9?]BQJ7_HM:^(Z^W/^" __)_-E_V+&I?^BUK\
M]\4O^2,K?XH?^EH_1O"G_DM:'^&?_I#/W(HHHK^53^L@HHHH _$'_@]Y_P"3
M6?@?_P!E U'_ -(111_P>\_\FL_ _P#[*!J/_I"** //_P#@TV_Y2F?M=_\
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M117ZB?E04444 %%%% !1110 5]N?\$!_^3^;+_L6-2_]%K7Q'7VY_P $!_\
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MS]R****_E4_K(**** /Q!_X/>?\ DUGX'_\ 90-1_P#2$44?\'O/_)K/P/\
M^R@:C_Z0BB@#S_\ X--O^4IG[7?_ &\?^GR>OW^K\ ?^#3;_ )2F?M=_]O'_
M *?)Z_?Z@ HHHH **** "BBB@ HHHH ***_/G]I_]H#_ (+.^&/C_P"*M ^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5))X2T;]MC_@O)X3_;#^'>OV.J?"O]FCX1ZC87?CFSNDDTRZ\4:F;F&:Q@N
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M !A-\4?B1HFO>,UT:Z2=_#'A.T66:^O-15"39.K^5 L4VQWG+1*-Z,!^G8
MP!@#H!5>RTC2=-GN+K3M+M[>2[D\RZDA@5&F?IN<@?,?<U8H **** "BBB@
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M]&/?$#_PHK'_  H_XC>?V6?^C'OB!_X45C_A0!^WU%?B#_Q&\_LL_P#1CWQ
M_P#"BL?\*/\ B-Y_99_Z,>^('_A16/\ A0!^WU%?B#_Q&\_LL_\ 1CWQ _\
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M%8_X4 ?M]17X@_\ $;S^RS_T8]\0/_"BL?\ "C_B-Y_99_Z,>^('_A16/^%
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(01G)HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>jnj-20220102_g4.jpg
<TEXT>
begin 644 jnj-20220102_g4.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
MB$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-
MO^"IG_27;_RH:Y_\>K]_J* /YK?VW?\ @W=_X*6_L1_LG^.OVL/%/_!4R\US
M3_ NAMJ5WI.GZOK,<UTBNJ[$9YMH/S=3Z5^2G_#6'[4W_1ROQ _\+*^_^.U_
M7]_P7X_Y0V?M"?\ 9/YO_1T5?QA4 ?O]_P &FW_*4S]KO_MX_P#3Y/7[_5^
M/_!IM_RE,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110!SWQ0^)_A;X/^
M#;KQYXSM]:DTZS!:X_L'PS?ZM<*H!8M]GL89IBH .2$('?J*^4_AQ_P<%_\
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MBBM/ /P]T.:."6^=8$D=?,*E8+>%'C#R!&VF2-51BP% '??MD?\ !5+]A/\
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M^4IG[7?_ &\?^GR>OW^K\ ?^#3;_ )2F?M=_]O'_ *?)Z_?Z@ HHHH ****
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MB/\ A#_V:QG_ )B7BS_T7I->??\ !W%I_BCPU\6_V0OBMXBM9Y/!MMX0:)9
MA:)+J&XLYKE3C@,T+08'5A&<9VG'[.?ML?\ !)#]@'_@HOXFTCQ;^V;\%M2\
M;76@6\L.B0S^/]=LK6P679YIBMK.]BA1G\N/>X3<_EIN)VC'0?'3_@G!^QQ^
MTO\ LM6/[&OQX^$\GBOP'I21#2+/7_$-_>7UC)$&$4T6H33M=K*BLR!S*3L)
M0DH2M 'Y,_\ ![/XT\(:[^S=^SY!HOB>PNY-2\3ZIJ.GQV]VCM<V9LX,7" '
M+1_O$^<<?..>:X+_ (.N/#OCR]_X)F_L7>.=&BG?PQIVC+;:M-&"8EO9]&T]
M[/=VR8[>\VY]&K],)_\ @W*_X)(:O\/_  _\-?&O[.NI>)-.\-W(FL9=>\<Z
MM/=.JQF.&W>X%R)?LT2EA';*RPJ7=MFYV)^A?$_[!'[('C7]E3_AB'Q?\"]*
MU/X6"P2SB\(7TLTL,$2-NC\J1I#+$T9 *.CAXR!M*X% 'Q=+^Q#_ ,$X_P#@
MH/\ "7X%_P#!1'XV?MC?%+QI9Z3J&FZA\-K_ %+QK;2M8ZQ>7-H18)%:V:N]
MR;J"&)H,%P\)&!@U\2?\%CR/^(M7]F#D?\?O@+_T]W-?J;^Q-_P0F_X)D_\
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M^T1^SY^SG!H?C;4;NZN+KQ ->OY7_P!(D,DD:1/.88HMV,1I&J *O' KZBH
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MQM;>%(=&UJQL;^5H$N&CM"+=S#,DHDC\O]XL>Y&C+;!^U+ND:&21@JJ,LQ.
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M %%(SH@!=P 2 ,GN>@HDDCBC:65PJJ"69C@ #N: %HH!# ,IR#T(HH ****
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MA,:F;&/34T]I1#_:^S>=IE";^F!D&@#Z(U3_ (-^?VC/VWO^"GMA_P %(/\
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M/V0[/]D[0_C'JWCB"UUZ^U,:SJUF+;8;AP?)B@5W$4:A0<!CN=I'XWX'&?\
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M_P""_'_*&S]H3_LG\W_HZ*OXPJ /W^_X--O^4IG[7?\ V\?^GR>OW^K\ ?\
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M\+OA</BT/$WBSQ9\2_&OVK_A-=6MU6S\6744:QQW3A0%#8&!7[%5^3W[,/\
MR+'B7_L?]:_]*WKZ[@O"87&YPZ=>"E'D;LU=7NCX_C?&8K Y,JF'FX2YTKIV
M=K,/^&8?#'_12_'_ /X6MW_\51_PS#X8_P"BE^/_ /PM;O\ ^*KTFBOU;_5[
M(_\ H&A_X"C\D_UBS[_H)G_X$SS;_AF'PQ_T4OQ__P"%K=__ !5'_#,/AC_H
MI?C_ /\ "UN__BJ])HH_U>R/_H&A_P" H/\ 6+/O^@F?_@3/-O\ AF'PQ_T4
MOQ__ .%K=_\ Q5'_  S#X8_Z*7X__P#"UN__ (JO2:*/]7LC_P"@:'_@*#_6
M+/O^@F?_ ($SS;_AF'PQ_P!%+\?_ /A:W?\ \51_PS#X8_Z*7X__ /"UN_\
MXJO2:*/]7LC_ .@:'_@*#_6+/O\ H)G_ .!,\V_X9A\,?]%+\?\ _A:W?_Q5
M'_#,/AC_ **7X_\ _"UN_P#XJO2:*/\ 5[(_^@:'_@*#_6+/O^@F?_@3-/\
MX)4Z5?>#/VQ?B3X!M_%^O:CIMKX*TZXMX=:UB:[,<CSMN(,A./PK]!:^!_\
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M%^/^4-G[0G_9/YO_ $=%7\85?V>_\%^/^4-G[0G_ &3^;_T=%7\85 '[_?\
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M?^"7YQ/AO$'_ )$*_P <?RD>DT445^S'XH%%%% !1110 4444 %%%% '0?\
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M_P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE,_:[_P"WC_T^3U^_U !1110
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M^O\ [;R7_H)I_P#@<?\ ,^._L/._^@6I_P" 2_R/.:*]&_X9,_:!_P"A _\
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M;WDR( TC12*5Y8%AQQFOA7_@U@B2#_@B9\+X(QA4UKQ,JCV&O7U 'Z'4444
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MUJX\-_!/XU:'XAU"WTY-1^Q65R1+/8NVU+V%7"FXM6;Y5N(]T3'@.37YC_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>jnj-20220102_g5.jpg
<TEXT>
begin 644 jnj-20220102_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;+>7J6<J:1O<L9##<I=%=Q+*MG\S$GY@#]A_CO\ MJ?LI_LR:U;>&?CO\=M
M\.:G=Z9+J46F7ET6N5L(CB6]>*,,\5JAX:X<+$IZL*[W0?&O@WQ3X0M?B#X8
M\6Z9J.@7U@M]9:W8W\<UG<6K)O6=)D)1HROS!P2I'.<5^(G_  1Q^,>K_MC_
M /!8;_@H-\7/B/*=2$GAW4?#VE1W?SBWT:&^GM(+50?NIY%K#N48#,"Q&34G
M_!JI*G[>W_!*+XH_L$_';Q+K-SX.\,>/[>.6SL=2>"2XT.]5+J;2/-0AX[::
M:WN1($*LT=W*@9=V0 ?JG\$?^"G_ /P3Q_:2^+4_P)^ _P"V5\/O%?BZ R!=
M"T;Q'#+-<^6"7^SX.+D* 6)B+X4$]!FO;->U_0O"VBW7B3Q/K5IING6,#3WM
M_?W*PPV\2C+.[N0J*!R22 *_ 3_@K+_P2B^!7P+_ ."TO['OP[_X)A_#E? W
MC#Q7K::OXFTGPU/*(-*L].O[:1=7V%F,($*WN\C"O]E'REF;=^AO_!R?\"?A
MA\3_ /@D?\8/'/CG09[[4O"GAF*^\/NVJ7*16=REY 1,L*R"(R8)7>REMK%<
MX.* /L[X+?'+X/?M&_#ZV^+'P'^)&D>+?#%[=7-O9:_H-XMQ:7,EO/);S>7*
MF5D"RQ2+N4E3MR"1S75].M?GE_P:M_\ *#?X0?\ 7]XD_P#4@U"OIW_@I?\
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M[K[2L$-PESI]G(N][291(JD9:(E0KLR?'?[2ZJO_  >G_!8JH!/@<$D#J?\
MA']8H _<:BOB3XC_ /!77Q!XF_:7^,7[,/[%'P#TSXBZG\ ?!\FM_$[6-?\
M&+Z/9)=A6=-&LC%9W+3W;JDH+N(XHWB92S$''#_%?_@XP_9D\-?L'?!S]L[X
M:^%TOIOC9XQB\+Z'HOBO75TJT\/WRRF*^FU6\6*;R+:T(W.Z1NSHR,JA6+*
M?HG7#?'W]IC]G_\ 97\&I\1/VCOB]H7@K09+I;9=9\1WZVMJ)6^ZAD?"JQ[
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MVB);0?"/P[9ZD-.AOH9S;@7-U</'(;6-6NH$*^6\A=RNT;'* 'W+17Y]R?\
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M?_V2/$-OI%C:VUKKVH2R23W<P;:Q&%CBCC=Y&./D17D3]'_V>_\ @KQ\._\
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MRCAYK3RKR6!^JM(5SM+*?U"BEBN(EG@E5T=0R.C9# ]"#W% #J*** "BBB@
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MQ?\ %/Q%X=UGPAH$VM_$/XB^&M5BNO$&KB_U W;6=M+"#Y"-<00QPV<0MU
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MWM+2!8XHE]%50 H]@* /YO?!?Q)\,^#_ /@U'^(_[ GB"?[#\;O^%N0^&?\
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MEKM\K"TT]9/"4"+-<R %8(0S*&F<K&@.YV502.G_ ."7.BI^U]_P<Z?M&_\
M!0_X)ZA'J'P>\+Z3<Z:?'5DX;2]2O/L5C9"*&X'R3!OL]Q<;U)79&K9Q(A;V
MZV_X)J_MO0_\'(>H?\%4[KX+6,OPKNM-.CBW7Q18G5&B&@IIGVDVYD";#,F_
M9YF_RCG&_P#=U^IVB:#H?AK3DT?PYHUII]I$28[6RMUBC0DY.%4 #))/U- '
M\\W_  1>^./P9T7_ (*$_P#!2;Q;K'Q7\.VNEZUI_BS4M'U&XUF%(+ZS&K:B
MYGA<MMECVRQMN4D8D4]Q4G_!OQ\6/AAX1_X-T?VT_#_BKXB:)IM]%!XKD>RO
MM4BBE"W?A:WM[4[&8$^=.C11\?/(I1<MQ7]$%% '\S_['?P&\=?MD_\ !IS\
M3?@U^SS,OB#QIX,^,LGB74_!VDS"74+BSB%HS+Y"DN28O-F1<9D-L53<W%?H
MG_P0K_X+2?LE?M(?L>_!;]EO4[76M1^-W@C0M/\ "UUX*L/"5S<W,2V<:60U
M47'EBW@M_LRB66626,I^\CPS&-9/U-JEIGAOP[HMY=ZCH^@V5I<7\OF7T]M:
MI&]R_P#>D90"Y]SDT 2:QK&D>'M)N=>U_5+:QL;*!Y[R]O)UBB@B4%F=W8@*
MH )))  %?S;_ + OBC]DKXR_\'/'[2.C_&;QAX-UCX=?$1/&^BQ3ZMJT']FZ
MTEQ<1+Y44Q<)(71)2C(V3MRIZ&OZ4:* /YS?V;?B'\3?^#5S_@KKJG[+GQLU
MS4;_ /9F^+UTEQI>O72EX[>U9]EOJ?RC'VFT9OL]VJ@%XL2!#^X%=3_P59\2
M> ?V2?\ @X8^''_!1_\ :$BU3Q!^SA\5/"5G9IXY\&ZQ=_98H_[/>R?RKK3I
M5=S%(L-VT<;$R0R':'/ _H)JIKF@Z%XFTR31?$FBVFH6<P FM+ZV66)^_*L"
M#^(H _*OX]_"_P#X(@^-/^"6W[3WQK^&?PGU^R^#WBK2+#4/&/Q/\+17WVSQ
M5K,%Y)-;/9-J;;KJ>&\GB#7##R'DNY(VD;9.$^8?AYX;_P"">7[<7['O[,?[
M&W[:'_!7_P"!]M\/?A,+;4F\-:/<-IVKZT3%LMM/O;J\G6*R\F&5X)62,LYW
M$>4<$?K[_P %.OV:?C=^U9^P/\0?V9?V8_%WACPYXG\4:(FG:?<>*M(2YTUK
M;S8_/M9$:*41K) )(A((G,9<,J[E!'Y^?$3_ (-ZOV7_ (I? K4OA)X _P""
M-?ASX?>-[_0FLM/\>:E\=;RYT_1;QHBBWR-!++<WOE.?,$4MM&)BH5R@8LH!
MXY_P<^_%/X5VG_!5+]B$Q_$#0D@\->)+34-<\O4H=NF63ZQIDD<\V&Q%$T<3
MNK-@%4)' S7<?%+X<W?[)O\ P=F^&/VV_C5K]IIOPI^-'@YX_"'C_4+M(](C
MO8_#:V7V)[MB(DE9K0,BEAO6ZBVY+&OUL_9+^ 5E^RI^R]\//V9]/\4W6MP>
M /!>F^'X]8O5VRWHM+:.#SBN3LW;,A 2%!"@D"NXUK0]$\2:9+HOB+1[6_LY
MQB:TO;=98I!UPRL"#^(H _%S_@AM\,];\4_\%G?VT?\ @J;_ &K!8_!.XU#Q
M%H6B>-KRX6'2]9+:Q!<R7D%PY$<EO#%8%FF!V 7"_-UQ\8_\$6?BS\,/#W_!
M'C_@H[HOB#X@Z-87FI>"W?3[.]U*.*6Z6>RU&WA,:,P+[YI8HA@'+R(O5@#_
M $[V=G::?:QV-A:QP00H$AAA0*B*!@* .  .PJ2@#\P/^#1/Q5X9UG_@CMH/
MAS2?$%E<ZAH_C36TU:Q@N5>:S:2Z:2,2H#E-R$,N0,@Y%>5_\';7@/6=*\1_
ML@?M574+CPS\/_C')9^(;G'R6YO)=.N8G?\ NKMTR<9/&2!W&?V3KSC]K?\
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M-JGLX_R1LY?-ZJ/RYOD?C'$GC%@\*W1R>G[27\\KJ/RCI*7SY?FC]'_VEO\
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MMV5S[KHI(Y$E02Q.&5@"K*<@CUI:_-C]-"BBB@ HHHH **** "BBB@ HHHH
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M_BO-;?$E%%%?I)^;A1110 4444 %%%% !14EM:W-[.MK9V\DTKG"1Q(69CZ
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MZ=\)N*'FV4O+J\KU:"5N[I[+_P !?N^G*=A1117Y2?K84444 %%%% !1110
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MV@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#PI:\8+[V/XL?Z8KS<UFXX6W=K_/]#V,CIJ>-N^B;_3]39HHHKYD^P"BBB@
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M?Y;LX,TS"CE675L95^&G%R?R5[?/9'X7?M)_%)_C?^T'XV^+[,2GB7Q3?:C
MK?P12SNT:?14*K^%<3117]LT*-/#T8TH*T8I)>B5D?PW7K5,17E5F[RDVWZM
MW84445J9!1110 4444 %%%% !7]+/[&'A7_A"/V0OA=X2:/:]A\/M'BF&/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-@"MNI_Y:.#P3_=4\'J>!AM:%"KB:JITU=LQKUZ6&I.I4=DOZ^\J_%#XC_\
M"*0'1-$G']IRIEY5/-JA'!]G(Z>@YZE37D)))R3DGJ33[BXN+NX>[NYWEEE<
MO++(Q9G8G)))Y))[TROO<!@:6!H\D=6]WW_X'8^ S#'U<?6YY:);+M_P>X44
M45W' %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R_Q5^$GA3XNZ
M%_9/B",PW,*G[!J<* RVK'GID;T)ZH2 >Q4X8?(OQ%^&_BKX7>(Y/#7BJR"2
M ;K>XB):&YCS@21L0-RGZ @Y# $$#[BK%\??#_PM\3/#K^&O%ECYL)):":,@
M2VTF,;XVQP>F1T.,$&LW%Q?-'[OZZFBDI+EE]_\ 73\CX9HKK?B]\'/%'P?U
M\:;K*_:+*X+-INJ1(1'<H.H[['&1N0G(R""RE6;DJN,E)71$HN+LPHHKZ,_X
M)F_L)>(?VZ?V@[7PM<V\\'@[0GCO?&>J)D!+;=\MLC=I9BI1>ZJ'?!V8/)F&
M/PN5X*IB\3+EA!7;_KJ]DNKT.S+LOQ>:XZGA,-'FG-V2_KHMV^BU/NC_ ((
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MUOZ@\-^!EPYAOKN,7^TU%M_)'M_B?VNVW>Y1117YB?J04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 (Z)(ACD0,K##*PR"/2N
M4^'?P+^$/PE\1^)_%OPT^'VFZ)J'C+4XM0\37&GP[/MUS%:PVJ2,N=JXA@B7
M"@ [2Q!9F)ZRB@#-\0^#/!_BUK=_%?A33=3-I)YEH=0L8YO)?^\F\':?<5I
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX0M=8M]!\3Z=XAT=+D'_ $74K"X2XM;A"",,DB ^A&0<@D4 ?F9^P9H'Q%^
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M<1-YQ(A4*B+1U7]KK]L#PE^PSXKUM/VE-9O/$?PQ_;.MOAL/%%WHVF&[\0:
MWBO3[#RKU1:B(2_9;PH9;=(6)C#<$G/V7H/_  3T_91\,7_PHU+0_!>O02_!
M#3)-.^%__%P=<9=%M7MQ;-%M:\*W*F "']^)/W:A>@ K)OO^"7?[%6I> -?^
M%]]\/?$4NA^)_B&GCK7;)OB9XAS=>(5N([E;XR?;_,5A/%%+L5A'OC1MN5&
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ML<5Y-8W,D8CG6-I8C@$%TD61 \9WU\_>$/@K^WY<?M0?LL?%[XP_":VU?7?
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M0W&R,-("K;941GB,BJQ'LM?%'_!,6R_;D^$WP@^&W[%'[0O[&EOH;?!G1HM
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M=*_X*+?LF7NNZUX=USX@7OARYT/X=R^/;H>+/#M[I8E\,1,5EU6(W,2;X(V
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M 5\6?\%\_P#E'IJ7_8U:7_Z,:OM.OBS_ (+Y_P#*/34O^QJTO_T8U?2\'?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ****  @$8(R#U!JKHFAZ)X:TF#0?#FCVNGV-K&(
M[6RLK=8HH4'\*HH 4>P%6J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>jnj-20220102_g6.jpg
<TEXT>
begin 644 jnj-20220102_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /'?VHO^"@O[$O[%-WIFF_M6?M/>#_
MMYK*&32]/UW5TCN;F,$J95A&9#&&!!DV[ >,YKTGX>_$7P!\6_!.F?$KX6>-
MM*\1^'M9M5N=(US0]0CNK2\A/22*6,E'7@\@GH:^%?\ @J5_P1^_X)V_%?\
M9S^/G[4/[37@=]9\:7/A'5]=?XCZMJDPO="6SLI'LX;0*XCA@MTBC40A-LI#
M-()&D8GXB_X)?>)OVEO^"?7_  :=_&/]H;7=5U32K_79=8U3X8><[)-I5CJ(
MLM,M[J$'F/-TUQ=1X^4[UD&=^2 ?L#I'[?W[%FO_ !:7X&Z-^TSX1N?%$NM2
MZ-!IT6JJ5GU2-0TFGQS?ZJ6[0'+6R.95YR@P:ZSX]?M$_ G]EOX<W7Q=_:+^
M+>@>"O#-G(L<VM>(]3CM8/,;.R)2Y&^1L':BY9L' -?SL?&6P70O^#-;X&^.
M-'D>TU>U^-UQJUIJ=LYCGAO$US785G21<,L@10 X.1@<U^P7PA_94_9M_P""
MP'[(_P !/VJ_VXO 0\?27WP?TN\M_"VKW,BZ79ZI>VL3W]\(8F023NP6-7?=
MY21GRPAD<L ?2'[,W[8/[+O[9?@VX\?_ ++'QX\,^.])L[G[/?W/AW5$G-I,
M1D1S(#OA8CD!U4D<C(YK2^.?[2/P"_9D\+1>-/V@_C%X=\':9<W*VUG<^(-5
MCMOM<[$!885<AII"2,(@9CGI7XT_\&Y?['4OP&_X+6?M?7O[-]UJ,7P*\#3Z
MAX-LQ+=/+;SZG_:<,L%J)&SY[6D<%VA<DNJRIN/[[+<+_P '?/P*^&'P[_:L
M_97^+/A309XO$/C+Q'KB>(]3N=4N;E[M+:\T9[=/WTCB-(S=SA40*JJX4 *J
M@ '] U<Y\6?B_P#"KX#> -0^*OQJ^(NB^%/#6DQA]1USQ!J,=K:VX)"J&DD(
M&68A57JS$  D@5T=?DS_ ,'74/[5GP^^%'P#_; ^ _@]O$OA7X)_%>/Q3XVT
M":U>YLVGA-O)I]U>0IR;9&CN8G?C9]K7D;L@ ^_O!'_!1+]B3XA:O!X;\._M
M'^'8]6O+JTM['1-7F?3K^\>ZN$MK<P6MVL<TR23R1QK(B,A9P,\U[17Y.?LQ
M_P#!7O\ X)@_\%[X_AO\*/B!"GPS^-G@KXB^'_&'@S0_%<4<SC4]-U&WO)(]
M*OAM2X$\4+V[1MY4K+*S"%O+!'U7^TM_P53T#X8?M^>#?^"7_P %?!.DZ_\
M%WQGX8N-=M?^$N\0SZ/HUI;QQ3R)$UQ!9W<LMPZ6T[B)8@H2/)D!*J0#ZJ\2
M^)-#\'>'KWQ7XGU*.ST[3K5[B^NY<[88D!9G..P )-<'^SE^V/\ LJ?M?6&J
MZI^RY^T'X3\?VVAS11:Q/X5UJ*\6S>4,8UD,9.TL$8@'KM/I7SO_ ,$@?^"P
MFA?\%1?^%G_#_P 0_!B;P#\0?@_XB32?&6A1:T-2LI/,DN8HY[:Y\J)G4R6E
MPK(T8*[5Y8-D?G=_P9^_$KP)\%/@/^UW\7/B7K\&C^&_"NOZ?JNN:G.#Y=I9
MV]MJ,LLA !)"HC' !)Q@ F@#]XZ*_-M/^#@M=!_9X^''_!0#XG?LN#P]^SI\
M4/B5+X1T7Q9+XP\W7M-C\RZBBU:]TT6HBCMGDL[D,D=T\D:(KCS-X2O2/BA_
MP5ZU%_\ @I;KG_!,/]FOX5^#_$/C?PEX.AUW6SXZ^(K>'QJDTL,-PFEZ6J6-
MU]IN?LUQ'.6<QH%W \*SJ ?;E>4_$;]N;]CWX0?&C2/V=/BG^TCX0\/>._$%
MS:V^A>$]8UF.WOM1EN9!%;K!$Y!E,DC!%VYRWR]>*TOV3OC9XD_:+_9X\+_&
M?QE\,KOP7K&N63OJOA*_N/.GT>YCFDBEM9'VKN>-XV5B% R#BOQQ_P"#E75]
M1\._\%M?V$?$6C>%[O6[VQ\6:1<6NC:?)$EQJ$B>)+-DMXVF=(U=R BEW5 6
M&YE&2 #]TJ*^ /A__P %LO&G@S_@IWI?_!+_ /;M_9.MOA;XF\::5%J'PY\1
M:'X[77=/U5)1-Y4,K&TMFA=WMYX@0&!F39C!61JOPV_X+B^/=;_X*]2?\$B?
MC%^QO8>"?$0:XEL_%L_Q,:ZM=4M4LVO(9;2+^S(S,TL +!&=-I212P9-I /T
M)K,\9^-?!WPY\*:AX\^(/BO3="T/2+1[K5=9UB^CMK6S@09>6660A(T Y+,0
M!7E_P _:*^+?QB^/7Q8^&'B3X(Z1HGAKX:^(+;1;#Q?8^,I+YM<NY;&VOF1;
M9K*'R!%#=PK(?-<"4M&N_:S#XZ_X.K?A/^TO\4_^"6$MS^S?HE[JZ^%?B!I?
MB#QSH=C;F=K[1+:.Y+AX1DSQ1W+6D[I@@) 7/$9H ^L/#G_!3W]@'Q1"US8_
MM4^%;6,Z?+?VDFL7+Z>NH6L:;WGLS=+&+V,*02T'F#!'J*]XK\7?@/\ \%S?
M^":W_!=C]FR?]@3]M#1;'X2_$CQ+916_A^36X%GT===0?Z)>Z;=DKY,R3;66
M"8Q%@WD"2;>=WZ"?MY?\%+_"G['OQ;^%7[+7@KP$/&WQ<^-'B :;X*\*/J_V
M"UMX%91/J-]="*9H+:($GY(I))"C!%.UBH!]/45\5_!O_@M!\)KG5/VBOAQ^
MU;X2B^'_ (T_9BMY-0\?Z?I6JMJEGJ.D^3YL-_I\K0P22^8I0&!XU='FB7+;
M\CP#Q%_P<;?%KP[_ ,$]++_@JO)^P183?![7/&\OAW1++_A:#)KX1)IX%OYX
M?[-:W2-I[>2(Q),[(=IRX/ !^J=%?G3_ ,% O^"[GQ!_X)\?L3_";]M/X@_L
M4Z?K.G_%"]-L-$TOXL1L]AYL4US931SQZ?)%=0SVD0FW HR&14*G!:N8^.?_
M  <1_$/]EC]ISX1_#/\ :3_X)T^)/#O@7XUZ=%<>"M>LO&%O?ZZYE:.-!+I4
M4.$<R30+Y)G\P+,K'#AH5 /T]HK\]/A%_P %P/B3<_\ !6?3_P#@E;^U;^Q-
M+\,]9\5Z&^I^"]9M_'MOK#3*+6:Z1+M((5CA9X[>=3Y<L@26,(#(K"4>C_$?
M_@J9XB\3_MO^,?\ @G[^Q/\ !#2_B'XX^&W@E_$?Q!U'Q%XM?1]+TYB(C;Z7
M#+%:73SWDOG1Y^1(X@Q+.S(T8 /L2BOSP\6?\'!'P[NO^"00_P""NGP0^ DG
MBC1-)UBWTKQKX(U/Q8--OM&O)+J&T>%94M9TN"LMQ;N,B/=#*K_*W[NO(_C!
M_P '.WCWX(?!'X&_M??$?_@F]K&C_![XOW'D3>);KXA6TE_:NO,S6UDEONGB
M1=[(\I@,_E-A44QR. ?K3++%!$T\\BHB*6=W; 4#J2>PIU?CY_P=;_\ !07]
MJW]FWX7_  Z_9K^"F@6&F^$?C#J#6VM^+8]8Q>ZC%!) TVEQQA/]'@D6:(23
M$L9$=HPH7<7_ %0^ _BSXW^-/ 2ZU^T%\'-*\"^(3>2(VA:/XO\ [;A$(QLE
M^T_9K?);)RGE_+CJ<T =7JVK:5H&E7.NZ[J=O96-E;O/>7EW,L<4$2*6>1W8
M@*J@$DD@ #)KR?Q_^W_^Q9\*K#P'JOQ(_:7\):):_%"_^R?#VYU'5%CCU]]R
MKNMF/$D1,D6)O]61+$0Q$B%OAG_@J7^T?J7[3W_!8W]FW_@B_8WK#P/K$K>.
MOC%9HW[O7+:RAN[VSTFX'\5NQT]GEB.5D\^'/W.<3_@X7^/?[(WP>_:G_9@\
M+?MA?\$]K'XKQZMXHG/PW\26WQ*N=*ETBZCNM.2YCN;.*U*7$&Z:SD"-*ROY
M3 J@SO /UAHKX _X*/\ _!<77?\ @G;^W?\ "W]B_5/V-[WQU%\5Y=/3P_K7
MAKQHL=]NN+T6;1?89K0(TPD/R+]I"R KN>/)VG['?_!;+QM\:O\ @J-XV_X)
M5?M._L@M\+O'/A[1_P"T]%N++QO%K<-[%]F@NQ%*T4$:QR-;7"3 HSJ,.A(*
M@L ?>7B/Q%HOA'0+SQ1XDU!+33]/MGN+VZD!VQ1(,LQP"<  FN#_ &<OVQ/V
M5_VO=-U36/V7?V@?"?CZUT2>.'5[CPKK45XEG)(&9%D,9.TL%8@'K@UZ37\X
M_P#P;-?M%?M3?LX_LU?M3^.?V7OV1K7XGSZ'X@M-8UF/4_&\6BP16UO;WKM!
M!^XGDN+IU5RL?EI'A>90Q5& /Z'?B1\2/ /P>\ ZQ\4_BGXOT_0/#GA_3Y;[
M6M:U6Y6&WL[>-2SR2.W   _H.:\PNO\ @HY^PGI_[/\ H?[5>I?M5^"[3X<>
M))FAT7QI=ZPD6GW,JNR-%YKX"R!T="C88,K C((KX]U__@KW^S;_ ,%&?^"&
MWQ2_;(M/V8D\7^&M'TN[TKXL_"/Q!XP?39[=$2-[B.&]@MY"Y\N:*6&54BW9
MSNB="H^2_P!K+X@_L[?%7_@SMU'QO^RW^SFWPL\&3Z]9QZ9X.F\1R:Q+;21>
M+XX9II+R5$>9Y9$>0E@-N_:.%% 'Z\_$'_@HK^PK\)_AOX8^,7Q+_:P\#:%X
M3\:6_G^$_$FIZ_%#8ZM'C.8)F.R3CG .<<UH_&G]N7]C_P#9S\,^$/&?QS_:
M,\)^%])\?7<-OX-U'5]62.+5GE171H6Z&/:Z,9#A%#J68;AG\+/^"N:J?^#2
M?]D,E02/%7AK!(Z?\2;6Z][_ ."R7Q__ &2?@M^R)^Q99_MK?\$^;+XU:#J'
MA;3)/"-]%\2[K1;C2[Z/3].^T13016K+/;2H\!*F4AS$0R+M5F /VNHKY%_;
MP_X*M^'?V4_VH_A3^P9\)/AM!X[^,WQ>O%_L30;[73IFGZ1I^Z16U"^N5@GD
M6/\ <SE8XX79Q;R_=PNZ+]C'_@JYIO[2/[5_Q8_X)[?%3X66G@KXX_"6,W-[
MH-MXB:_TG7; K"8[VSO#;Q2A"+BV+QR0!XQ<(1YF'V@'U_17Y4?!W_@X[^.W
M[0^I?'[P!\&O^"8=YJGBOX!6M[<:^B?%:W&ER16<MU'<NUS+91.K9MCY,212
M/-DY$01F'K'[.?\ P7]^!_QI_P""/_B__@K)XJ^$^JZ'9^ ;FXTSQ/X,MM06
MZD_M99+:."V@N"B!TF:]L\2,B[/..5.S) /OG4M0M=)TZ?5;YF6&VA:68I$S
ML%4$G"J"S' Z $GL*S? /Q"\"?%7PA8_$#X9^,M,\0:'J<7F:?J^CWR7-M<*
M"5)22,E6P00<'@@@\@U\J?L:?\%'_CQ^TSJ7PBUOQ)^SCX.B\#?&'PW>:KH_
MCWP!\39-=M-+N8;47']D7J2:?;-%>@>:K8+)NMIAD,I4?/EY^T3?_P#!/#_@
MX]M?V4-,NS#\+_VKO!<7B.310VVVTGQC&;N%[R%.D;72V"K,% \V6Y1VY3D
M_4:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#\1?^"\W_  7K_8UT[]H^U_X)U>.-'\3>
M-?AKX9U%+KXWV?@:Z@1]>OK>17@\.-/)(H2V211)>&/+LT:VX*?OB/;?A?\
MM36O_!QG_P $K?VCOA3^SQ\!7\!>$K;PY#X5^'FGZM-"DMQKMM;_ &Y8F\EO
M)@ME;^S(T5>4!D8D@JJ_J;10!_-7X]MM9^*'_!M#\&/^"87@O2Y;SX_VG[05
MYX?O/A&F!KUI=#5-8O',]F2)8(DBN8F>9U6- X+, <U]_?\ !3?_ (*7?#;_
M ((+?\$XOA-^POX3\9-=?%>3X>Z3X;TR71(([BYT:PM[>.UN]>\J5D4ONCE^
MSI(562?KE(I0/U*C\/:!#K<GB6'0[-=1FA$,NH+;()WC'(0OC<5'H3BKE 'Y
M!?\ !!C_ (+(_LJ_M!?$7P;_ ,$U_P!@+]D?Q/X2\/Z!HFI^(/&WB3QMJ4%S
M=WD,<862\D>!RT][<7]Q:M)-)\H4NJJ,IY?SY_P>/_&WX0:S^T'^RIX9T/XE
MZ'?ZEX-USQ'<>*]/L-4BFFTF-[K1 AN$1BT))MK@ , 3Y+^AK^@"B@#)\#^/
M? OQ-\,6OC7X;^--)\0:->KNL]6T348KNVG7.,I+$S(PSZ$U\P_M[?\ !0[P
M]^Q'^UQ\#OA_\7[6Z_X5I\3/#WB^V\7:G#I+75OHL]HVC-:7]X41FBM%%Q<P
M2.<1K]K5Y"%3(^M*C:UMGN4O7MXS-'&R1S%!N56*EE!Z@$JI([[1Z"@#\ _^
M"Y?_  2W_8/^+'Q/^$?Q _X(WZKX8A^/?C?XA6JQ>%OA)K4-Q8R6&R29]?>*
MT9H]-CMI4@9KE/+B(D)(9AN'NG_!6#_@HC/X'_X+8?!_]B/XC>%]7\#^#)O#
M<<GB?XL>!O!$]YXS\00W$-RZ:5I=U9PR7UI:27*1P2FQQ/NDFPZ 9K]>/#W@
MCP7X1FN;GPIX0TO3)+V3?>2:=I\<#3MS\SE%&X\GDYZUHO;V\DR7,D"-)&"(
MY"H+*#C.#VS@?E0!^"?_  :T^/? 7P)_;Z_;6\#?$D7O@V0:U#>)8>)[6>!M
M,LK._P!7:9KV:4%+81+-"&>=URS@!F)KPW_@@E\.=3_:J_X)D?M_?LL?!_Q!
M97/COQ?H]K=>&- 2]1;K4UCCO7"QH2"5D<)"7^ZK3*&(W"OZ7H[:VBFDN(K=
M%DEQYKJ@!? P,GO@4^@#^>/_ ((K?%K_ ()+_&S]A31OV _V\?@?XF\2_&OP
M1XDO["P^$VHOK\\OB&Y:ZGEMC;6:2BUMI8_/>WD,@A$/E/+*R(S/7H?_  7J
M_8W_ &$/VH/C/\4/B+X*_:"TKX#_ +2?P#\-Z=?VO]M>(A:6GCG3(-(MKVV>
MWE<HZWL!8VJ20L\B^3!YB[98FC_<N#PQX:M==F\46OAZQCU.YB$5QJ,=H@GE
M0=%:0#<RCL"<4FJ>%?"^N*$UOPW87@%TMR!=6:28F4!5E^8'YP  &Z@ #M0!
M\T?\$4?B9^U+\8O^"7'P?^)'[9T-\/B%JGAV5]4N-5MS%=WEJMW.EC<SJ0#Y
MLMFMM*S'EB^XX+$#\XO^#D W&B?\%H?V*/BC>Z;>'P_X&U?3?$7C#5H+.22#
M1M)M?$EE)<7URR B&"-1EI'PJ\9/-?N'43V%C).]U)91-+)%Y4DAC!9H\D["
M>ZY)XZ<F@#\4_P!L7X9_\/,_^#GOX">+?V6=<L_%/@[X%^$-#UCXC>-O#]TE
MUINF3VNIW^HQ63W,1:-II0]JBQABW[]CC;&Y7=_X.JOV7?BA\.?$?P1_X*__
M ++FCS-X]^$GC'3M)U@V4#.]Q;278ETUG5>6C6\9[=EYW_VBJXQ7[#Z!X;\.
M^%;#^RO"^@66FVOF,_V:PM4ACW'JVU !D]S7Q1\%_@9_P5=^(_[2?Q$^'/[=
M_B7P5KWP07XM6OBOX?:II,\,=X=*LKAKK3]&^RQ6Z, ES%I\TLT\CL?LLL0\
MU9_,C /IG]D/X4^)?@_\ -$\/_$ POXMU,W&N>.)K=]T<FN:A.][?[&[Q+<3
MR1QC^&*.-1PH%>4?\%,/V\+K]@34/@EX\U71-6U#PIXJ^+'_  CWCB#0]'DO
MKJ#3I=&U.?[6L42/(R03P03R>6"WE128!Z'ZBIDMK;3RQSS6\;O"Q:%V0$H2
M""0>QP2..Q- 'X3_ /!PG^P'_P $I/VHO@!9_M&_L W_ (+U#]H#Q7XCT^W\
M&^&_@_J=M=2^.WN;E$N%DL;1F4-%$\MP]T$0@Q%97.X8XK_@N5\(OC?^Q7^U
M[^Q#^WE^U-H'B#Q?X,\"_#+PYX-^+.LZ!J%RLBZG9R3'49/M,#H\<MQ'>2M$
MV]/-:!EW<&OW\TSP1X+T36[KQ-HWA#2[34K[_C]U"UT^..>XYS\\BJ&?GU)J
M]J.FZ=K%C+I>K6$-U;3H4FM[F(/'(IZAE8$$>QH _-7P!X4_X(8_M#? ;X]_
MM%? ;X:ZGK/@/6O@WJUO\9/C#9?VP99M.2!)Y+*.;4R9+F\BBM1-A%<P&"%7
M*F1$/P)^S<G[!?[2O_!*?X?_ /!.'XN?\%>?A7X$^$B>/9_$PTO5[<6_C*WT
MYKVXN8])O))9UL[>?S9WD>X5)$!VJJNHWO\ O%^T[\)OB!\0/V5/''P7_9VU
M_0?"?B/6?"%[I?A>_P!4T.*ZTZQGEA9$,MJR-&\7S892CK@DE' VG\P_AY_P
M;[_LWV7P!TSX3?$G_@BUX5U/XA0>'8[+5O',/QYN[?1[_45C"R7XEB<7<"22
MYE\M+(B,-L52 !0!Y?\ \'>E_P# /PE_P2X_9V^#_P #O&&A7&A67BVQ/@NR
MTO68KH3Z':Z+<V\-Q"RLQF@56@7S02I+KSS7GG_!?OXY?!CQ!^V+_P $Z_%&
MA?%;P[>Z=I$&D:IJM]::Q#)%9V3ZCI++<2LK$1QE89B&; Q$_P#=-?L[_P $
MP/V+)_\ @G?^P;\.?V.+SQZ_B:Z\&:5/'?:VT11;BYN+N>[F$:L25B22X=(P
M>=B+G!S7O= 'X*_MC?&7X1W/_!XG\#/%5M\3M DTO3O#%CI]_J4>KPFWM[N7
M3M4$<#R!MJR,;B !2<DRI_>%<-K.M_![_@F5_P '('QNU#_@II8^)-$^%_QL
M%[J7A/QU8:IJME:H;B>&ZMY6DTZ1))88R)[.1?F\N38Q 4%J_HCJCKOACPUX
MH@BM?$WAZQU&*"99H8[^T298Y%Z.H<'##L1R* /QH_X+ ^'/V#O@U_P;E?%O
M2/V)/A5:_#OP'XZ\=Z)=^#[6Y6>S/BZ==2THRZC:6]XWGE&BM7"DJI>*T\Y0
M8G21OAO_ (*W_%#X;^)O^#=+]ACP?X=\>Z/?:M;2W'VG3+348I+B'R+::&;?
M&K%EV2,J-D<,P!ZU_4310!^%7_!W#&_CG]FC]D[]I#P.IUOP+H_B.YDU+Q3H
M_P#I5E"EU!I[V[F6/<NV06\VTYPQ3 YP*_:KX+?&KX=_M"?#ZS^*_P )M8EU
M/PWJ99M'U@V<D,6H1 X\^$2*K/"QR%DQM<#<I92K'J+BWM[N%K:Z@22-QAXY
M%#*P]"#UI] 'XV?M&> ]9^$'_!XI\#?BGXIB>/0_B3\,KZ'1-0DXB^U0:+JE
ML]N"?XPT<)('_/RGK7FG_!WM\1/ 5C^V%^QCI-WXSTN.[\.^)]6U#7[5KZ/S
M-.M)+[0C'/.N<Q1L()BK-@'RGQ]TU^L?[>O[!W@_]MGPOX4U:#Q,_A7XB?#/
MQ3;^)OA;X]MK,7$NAZK"ZMB2(LOVBTF"+'/;EE$B ?,K*C+['X N/'UUX-TZ
M?XHZ3I%CXA-N!JUMH-_+<V:S D$PR2Q1.R' 8!D!&<<XW$ _"W_@O_\ &;X1
M2_\ !P!^PUXF@^*'A^33="UOPKJ&M:C%K$+06%I)XCBGCN)I VV.-H?WH=B%
M,9#YVG-3> _BK\,I_P#@]@\5:O!\0M%>SNM"31K:[74XC%+J*^%+2!K-7W;6
MF$R/$8P=WF(4QN!%?O)10 5_/-_P;1?M%_"']CG]DW]K/6?VEO&=CX+_ +4L
M4\1>&K?Q3,+%_$.GQ0:E TNGK-M^VCSU\G]SO_>.B?>8 _T,UFWW@SP?J<5A
M!J7A33;B/2V5M,2>PC<6A4 *8@1^[(  &W&,4 ?SY_L(?LL>//V)_P#@UN_:
M;^)?[2\?_"'W?QDLKBY\)Z+X@<6D\UK]FBM[0^7+M82W#^<R1XW-&L;C(85R
MS?%OX6?\05P^'7_"Q]#_ .$@_P"$W^Q?V'_:L7VO[3_PE_VSRO)W;]_V;]_M
MQGR_GZ<U_2/10!_-M_P58^+?PL\2?\&IG[(_@OP]\1]#OM8C\7:*DNDVFJQ2
M7*-:Z5J\=R&B5BP\IY8E?(^4RQ@X+KG0_P"#D[XS?"/QC^PK^P-%X1^)N@ZJ
M\'AE+Z>/3=5BG>*V6PTN%I65&)51+%+'D_QQ2+U1@/Z.:* /Q0_X**_#Z?X-
M_P#!R5^R]_P4T\4^([*?X(>,=+MM'@^(27J/I&G7YL[^VBBEN@3%%'+]IMY8
MY&8*^^3!/EL1)_P3Z^%WB']HW_@Y\_:-_P""BOPYU"*X^#O@[2I-'F\=V\ZG
M2]2U!=+L+)[6&X!\N;RS;SRNR$J@A3<1O3/[2:GIFFZU82Z5K&G07=K.FV>V
MN85DCD7T96!!'UHTO2M+T33XM)T73;>SM8%VP6UK"L<<:^BJH  ^E '\YO\
MP1;^-OP=T3XT_P#!3K7]9^*7A^TL=;\->(-0T>[N=7A2.^M?M>LCSH69@)$S
M<0#<N0?.3^\,]E_P;Y?$+]E2P_X-W_V@/!_[5'A^'Q7X.7XQM'X_\*V5V?M]
MOI%_#H%H+](X@9@8F\V>(H SR695&##*_P! ],GMK>Z017,"2*'5PLB@@,K!
ME//<, 0>Q - 'X&?\$A/V>_B)_P3N_X+?^'OV9O^"?G[9%G\:OV<?B/X,OO$
M_BS^Q=6BO8-%L1;W"VDE^("T,%ZMU%;1),H1IDE*E$!*K[%_P5%\"ZW\=/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ KAOVA_VC_@[^RQ\-+OXL?&WQA!I&DVORQ!OFFNYB"5@@C'S2R-@X4=
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M4 %%%% !2QQR32+%$A9F("JHR23T %)7L7['?PR;Q+XV?XA:G ?L7A]E>T+
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M4\2EK'I+NX?K'=>:U._HHHK\^/T4**** "BBB@ HHHH **** "BBB@ HHHH
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M HHHH **** "BBB@ J*^OK+3+*;4M2O(K>VMXFEN+B>0(D2*,LS,>   22>
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MOVNH+3Q_XYW^ _ \X62'5]3M"UYJ,9YS:VY*DJ1TE<JF""OF8(KZZ_X)>_\
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M);B1V!"QNYZXK\'O^"N/[)W[/O[5G[9_B[XV_P#!,_X@Z1JWQXU;]H_P[9^
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M_>$LS1G_ *XCTK]T]8U:PT'2;K7-5N%AM;*V>>YE;HD:*69C] ":_F#^+/Q
MU/XL?%/Q)\4=:=FN_$>O7>IW)<Y.^>9Y2/S:OV+P<RU5\WQ&-DOX<5%>LWO]
MT6OF?C'C1F3H9/A\%%_Q9N3](+;[Y)_(Y^BBBOZ*/YN"BBB@ HHHH **** "
MBBB@ K]@?^")W_!+VR^&GAW3OVQ?CYX>63Q+JEN)_!>BWD.?[)MG'RWCJ?\
MEO(IR@_Y9HV?O-A/D7_@C%^PG!^UU^T5_P )SX_TD3^!_ ;PWNK0S1YCU&\)
M)M[,YX925,D@Y&Q-IQY@-?NZ % 51@#H!7XCXJ<8U,,GDV#E:35ZC71/:'S6
MLO*RZL_=/"?@RGB6L[QL;Q3M23ZM;S^3TCYW?1!1117X"?T(%%%% !1110 4
M444 %%%% !1110!\E_\ !0W]C:W\8:5=?'GX8Z2%UBSB,GB#3[>/_C^A4<SJ
M!_RU0<M_>4?WE^;X/K]I" 1@BOS7_P""@/[-D7P,^*H\2>%[ 1>'/$K/<6,<
M:_+:W (,L'L,D,H_NM@?=-?OWA7QC4Q*638R5Y)7IM]4MX?):Q\KKHC^>_%C
M@RGAG_;>"C:+=JJ6R;VG\WI+SL^K/ Z***_;C\+"BBB@ HHHH **** "BBB@
M#W[_ ()M?$9_ _[3%CH<]QLM/$EE-I\P8_+YF/-B/UWQA1_OFOTFK\;_  /X
MJOO WC32/&FFD_:-(U*"\AP<9:.17 _2OV*TZ_M=5T^#5+&4207,*RPN.C(P
M!!_(U_.OC'EJH9O0QL5I4BXOU@]_NDE\C^D?!?,W7R?$8&3UI34EZ36WWQ;^
M9-1117XZ?LX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% ".B2(8Y$#*PPRL,@CTKE/AW\"_A#\)?$?B?
MQ;\-/A]INB:AXRU.+4/$UQI\.S[=<Q6L-JDC+G:N(8(EPH .TL069B>LHH S
M?$/@SP?XM:W?Q7X4TW4S:2>9:'4+&.;R7_O)O!VGW%:0  P!110 5!?:9INJ
M)''J>GP7*Q3+-$L\0<)(IRKC(X8'D'J*GHH **** "BBB@#PK_@IM\2I?A+^
MP-\5/&-O,8Y6\*3:=!(#@I)>LMFK#W#3@CW%?SH5^X__  <!>-/^$7_8 DT$
M3;3XC\9:;IY7/W@@EN_RS;#]*_#BOZ4\'\*J7#E6LUK.H_NC&*7XW/YD\9<6
MZW$M*@GI"FOOE*3?X6"BBBOU@_(@HHHH **** "BBB@ I41Y'$<:EF8X50,D
MFDKZ&_X)5_ F']H3]N_P#X-U.Q%QIFG:F=9U=&7*&"S4SA7'=7D2.,C_ *:5
MQYAC:678"KBJGPTXN3]$KG9EV"JYEF%+"4OBJ2C%>LG8_:;_ ()L?LK6W[('
M[(?A?X7W6GI#KMU;?VIXJ<+AGU&X56D5CW\M0D(/I"*]XHHK^*L=C:^8XVIB
MJ[O.;<GZMW^[L?W#@,%A\MP5/"T%:%.*BO1*WW]PHHHKD.L**** "BBB@ HH
MHH **** "BBB@ KS7]K;X+0?'?X%ZSX-BM@^I0P_;=%;;DK=Q E /3>-T9]I
M#7I5%=6!QE?+L;3Q5%VG!J2]4[_\.<F/P6'S+!5,+75X3BXOT:M_PQ^+C*R,
M4=2"#@@CD&DKU3]M7X;1_"W]I;Q/H-I!Y=G=WG]H6( POEW $I"^RNSI_P
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M3<^-\.UT4W_Y))?J?6U%%%?RF?UJ%%%% !1110 4444 %%%% !1110 4444
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M8V5HMWI-[)O>'S>L?.ZZH_2*BBBOP$_H0**** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4+GQMX?CN/%?P[>;_1_$EK!^^T]2?ECO8U_U9Z 2C]VQQRC-L'R77]-99FF
MSC!QQ6#J*<'U7Y-;IKJGJ?RYFF59ADN,EA<;3<)KH^OFGLT^C6@4445Z!YX4
M444 %%%% !6[\+?"A\>?$WPYX&"D_P!M:]9V.!U/G3)'_P"S5A5[3_P3L\)K
MXS_;8^'>D/'N$&N_;\8Z&UBDN0?P,(-<N.K?5L%5K?RQD_N39UX"A]9QU*C_
M #2BOO:1^UX 4!54 #H , 4445_-I_3(4444 %%%% !1110 4444 %%%% !1
M173>"/AGJ_BUUO)PUM8YYG9>7]D'?Z]/KTK*M7I8>FYU'9&U"A6Q-10IJ[,O
MPQX5U?Q9J L-+@R!@RS,/DC'J3_3J:]E\)>$-*\'Z<++3X]SM@SW##YI&]_0
M>@[?K5K1-"TOP[IZ:;I-JL42]<=6/J3W-6Z^*S+-:F.ERQTAV[^O^1]OEF4T
M\#'GEK-]>WI_F%%%%>2>N%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!%>V5GJ5G-IVHVD5Q;W$3
M1SP3QATD1AAE93P002"#P<U^<G[>_P#P01\"_$N2^^*'[&UQ:>&-<D+37/@V
MZ;9IEXW4_9WY-HYYPAS%D@#R@":_2"BO:R3B#-N'L5[? U'%]5O&2[26S_-=
M&CQ,\X=RCB/">PQU-271[2B^\7NOR?5,_F#^+WP6^*_P#\:W/PZ^,O@'4O#N
MLVI_>6.I6Y0LN<!T;[LB''#H2I[$UR]?TV?'G]FWX&_M.>#F\"?'7X:Z;XBT
M_P"8P"\BQ-:L1@O#,I$D+_[2,I[=*_,;]KO_ (-X?''AUKKQ=^QSXX77K/+.
M/"7B2=(+Q!_=AN?EBE]A((L ?>8U^_<.>*N39FHTLP_<5.[^!^C^S_V]HOYF
M?SWQ+X39UE;E6R[]_2[+^(O^W?M?]NZO^5'YF45TOQ4^#GQ6^!WBJ7P3\8/A
MYJ_AO58LDV6L6+P,ZYQO3<,.A[,I*GL37-5^HTZE.M34Z<DXO9IW3]&?E-6E
M4HU'3J1<9+=-6:]4%%%%60%?6O\ P1@\*+K_ .V&^M219&A^$[V[1B/NL[PV
M_P">)V_6ODJOT _X(2>%1-K_ ,1O&\L.#;V>G6,$A'7S'GD<#Z>5'GZBOG^*
MJWL.'\1+NK?^!-+]3Z+A.A]8XBP\>SO_ . IO]#]&****_ S^@@HHHH ****
M "BBB@ HHJQINE:EK%P+32[&6XD/\$2$X^OH*4I1BKMV0XQE)V2NRO5C2])U
M+6KM;'2K*2>5NB1KG'N?0>YKN/#/P.NYBMSXIO1"O7[-;D%C[%N@_#/UKT'1
M]"TC0+066CV$<$8ZA!RWN3U)^M>'C,]P]'W:/O/\/^#\OO/=P>0XFN^:M[L?
MQ_X'S^XX_P &_!BQT_9J'BEEN9ARMJO^K3_>_O']/K7=(B1J$10JJ,  8 %+
M17RN)Q=?%SYJKO\ DO0^MPV$P^#I\E*-OS?J%%%%<QTA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 <]\3?A)\+OC/X9D\&_%KX?:/XDTN7.ZQUK3X[B,'&-
MRAP=K#LPP1V(KX?_ &B/^#>C]ESXBM/K'P%\9ZSX OW)9+)R=2T_/7 CE83)
MD]_-('9>,5^@-%>SE/$.=Y'/FP->4/).\7ZQ=XOYH\3-^',CSV'+CL/&?FU:
M2])*TE\F?A'\<?\ @A7^WK\(WFO/"OA#2_'6G1Y877A;4E,P7MFWG\N0M_LQ
MA_J>M?*WQ ^%'Q1^$^J'1/BC\.->\.7@8C[+KND36DA(ZX655)K^H6JFMZ#H
M7B;39-&\2:+::A9S#$MI?6RRQ./=6!!_$5^E9;XQYM02CC:$:B[Q;@__ &Y?
M<D?F69^"^3UVY8'$3IOM)*:^7PO[VS^6:OU,_P""(GA4Z5^S'KWBF:';)JWC
M&98VQ]Z**W@53_WVTH_"OM_XC_\ !,']@'XJ223>*_V5O"L4DN?,ET2T;2W8
MGN39M$2??K6_\'OV*/@1\!/ ,'PS^%.D7^EZ/;3S306YU!IF5I'+M\\NYCR>
M,D\8%=^?>)^49UE/U>%*<)-INZ35EYIWWMT.#A_PLSG(\V^LSJPG!1:5G).[
MMT:MM?JSC:*]/F^ NCL?]'UZY0>CQJW\L5 _P!B)_=^*F'^]99_]GKX=9WEK
M^W^#_P C[IY'F:^Q?YK_ #/-Z*]('P!B[^*6]\67_P!G4\/P%T9?^/C7KEO7
M9&J_SS0\[RU?;_!_Y LCS)_8_%?YGF%%>O6GP4\%V_\ KQ=S^OFSX_\ 00*U
MK#X?>"]-(-KX<MB1T,R^81^+YKGJ<0X./PQ;^Y?J=%/AW&R^*27WO]/U/$K'
M3-2U.3R=-L)KA_[L,18_I71Z1\'?&>ID-=6T=G&?XKB09Q_NKD_GBO8(H8H$
M$4$2HHZ*BX IU>=6XBQ$M*44O77_ "/2H\.8>.M6;EZ:?YG%:'\$?#E@5EUB
MZFO7'5/]6GY#G]:Z^PTW3]+MQ:Z;9101CHD2!1^E345X]?%XG$N]63?Y?=L>
MUA\'AL*K4H)?G]^X4445S'2?!O\ P<:_MU_M"_\ !/G_ ()PW/QC_9K$]IKF
ML>,]-\/WWB.UM$FFT"QN$G>6\C$JM&)"84MT9U*J]RIQD+7SM^Q1X?C_ &W=
M,^-/[5?_  2I_;?^*D>K:%\4/#-WX;_X2/XA:AJ4'B"Q7PUH37^G:M8ZM++"
M9GD%_$L^Q#%+&J1R>1$J#],OVGM4_9ZU#P=I7P4_::\/:9J_AKXIZZOA(:3K
M=HDUE>W,]M<3QP3!^!O^S,B$9/FM$!@D$?SG?MM_L@?&_P#X(4_MK^./VW_^
M"87Q U'1_!/@KXTZ-X(G\"W.HRW,MW_:'A[3]:6SF!_X_K.1KFX@"/F6+RX6
M#.Y\Q #]8O\ @YC^+'[9'[./_!.+Q/\ M"_LP?M4WWP^CT6]TNTOK'0-#B%_
M?I=WBVTF-0=VDML>;&RF!8W&QP78.-GM7_!#7Q-XD\9_\$D/@-XL\8>(+[5M
M5U'P'#/J&IZG=O/<7,K2R%I))')9V)Y+$DFO#/\ @ZON)+G_ ((=_$6XN+9H
M))=9\-LT+D$HQU>T)4XZD=/PK:_X)M:U^T3H/_!N'\/-8_9%\-P:Q\3H/@A)
M_P ()IURT(2;5")A!GSG2/AR&P[!25P>,T ?,W_!UW_P4C^.'@']EB^^ W[*
MVJ7.F^'G\;V7ACXI>.].NVAD6_FLY[^/0[21.2XAMUENV4C8L]O#EO-F5/US
M^ ,TUQ\"?!5Q<2M)))X2TUG=VR6)M8R22>IK^:'_ (+C^-/^"G^A_P#!.+X;
M_L[_ +87_!-[2_@[X#T'XCQWFG>+HO'MKK-_KFMR66H/,]V8KB1Y)[@S7=U+
M.RC=)N)(+ 5^WOP,_P""E'P[_94_X)[_  6^*7_!5/7/#GP-\3^+K)=*M?#U
MUJ+7J$Q2/';.KVWF_(]HMM/)(2$B,X#LAXH \Y_X+L_\%??&O["M_P##S]CG
M]EG4= M_C7\9=0BMM(U[Q/)&--\(:;)<"W.K70D^0CS"^PR?NE$$TDF5CV/[
M[_P3Q^%/[+EEX)3XA_"W]K./]H/Q;"/L_B?XKWOC]/$,TMXRYE2$1326^F1'
MHMK;+&JH%!#G+'\L?^"G/@V"+_@[1_9K\5_&71+/5O!'B_1=%M_#3:E;I<6-
MU_Q_0+"-X*.PO)$?;S@S1M_$"=[]@KX::Q^S=_P=Y_'OX(_LW:0-'^'MYX-.
MK>+]"TF(16,"7.EZ9?*YB3"(5U"[ 3 &U9G5<!F% '[CT444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[]G?Q'JVD_$WX%>'O"?PUU:3Q#HN[7[ZQTC5;*4,)+]7@S)?0G?.L8(60]0
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M_!OPYTG0]>T>ZOK2Y,-S:VL<+[9;2:6)T)0E2KG@C(!XKWFB@ HHHH ****
M"BBB@ HHHH _"S_@OA_RD-U7_L5]+_\ 11KXNK^J2BOV3)O%K^R<JH8+ZES>
MSBHW]I:]E:]O9NWWL_%LZ\(/[8S:OC?KO+[23E;V=[7=[7]HK^MD?D+_ ,&V
M'_):?B9_V*]G_P"E+5^O5%%?GG%.??ZRYS/'^S]GS**Y;\UK)+>RWMV/T;A3
MA_\ U8R2GE_M/:<KD^:W+?F;>UY;7[A1117SQ]&%>?\ [5VE>+_$'[,WC_PQ
MX \$WOB/6]6\':E8:5HVGW5K#+=7$]K)%&H>ZFBB0;F&2[J ,UZ!10!\O?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\D/VDO^3B?'W_ &.NJ_\
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M"&:*6\^'R^!]3T_0_$VHZ9I^HZ BR+#8W5G9W$5O<I")I/*,L;-%N!0J57:
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MZ5-;B]BU6W72+B8BZMC/.LZ7*&,30%-@1S)]5>$?V,/V<_!_Q2L?C;'X,O\
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8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>jnj-20220102_g7.jpg
<TEXT>
begin 644 jnj-20220102_g7.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
M6 *\ P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD:;=WEOXH.BHFAZJMLZK,MK/YIE?&[<'>%(W524=LKNUOB?_ ,%HOV:/"/Q
M^)GP^^$7PM^(_P 7I/@KIQO?B_JOPOTBPN;'PFB^87CGEO+VV^TS((9BT%H+
MB5?)E!7=&ZJ ?7M<O\7_ (U?"CX ^#)?B)\9_'FG>&]"@?9<:MJLWEP0G8SY
M=^B#:C$DX  ZUD_LP?M/? []LGX&Z!^T;^SEX\MO$?A'Q);&;3=2MU9#E6*2
M121N \4J.K(\; ,K*017;ZG:VU]IUQ97L"2PS0.DL4BY5U((((/4$<4 ?-5M
M_P %I?\ @DG=SK;Q?\%'/@X&8\&7Q[9(OXLT@ _$U[9\&?VA?@'^T;X<?Q?^
MSY\;O"/CK2HG"2ZEX/\ $EKJ4$;D9"L]N[JK<'@G/%?S<_\ !EQHVD>(?^"A
M_P 4M$U_2K:^LKKX&7D=S:7D"RQ2H=8TK*LC A@?0BJG[)M]KW[,O_!V5JGP
MD_8&+V/A._\ C+?Z)KGAWP^2+ Z,P:34[9HD^3R;9EG=%QB)K9-N-@H _J!H
MKXN^+O\ P7=_8L^ G[<VE_\ !//XQ^'O'WA_XA:UXAT_2M,-[H$!TZ?[=,L5
MK=BY2Y91;ON#;R R#(=5964)^QS_ ,%[O^"?O[>'[9^N?L1?LVZ]XFUG7=&T
MRZOK?Q0^BI'HFJI;.B3"UG\TROC?N#/"D;JI*.V5R ?:5%?'GBG_ (+5_LW2
M_'3QY^SW^SK\&_BC\;]=^%ED]S\29OA-H5C=6?AXH65H9)[Z]M5N)P8Y!Y-M
MYTA:.10I9'5?0_V<O^"EO[+_ .V'^R=J/[8/[*&K:M\0M!TF&4ZEH'AW30=:
MM[B)5>6T:SF>-A<*C!A'G]XN#&9-R;@#Z HKXJ_X)[_\%YOV*/\ @IS\:KOX
M%?LJ^'?'][JVF:1+JFLW>L^'H+*UT^T1EC\R1GN2S;I7CC"QJ[;I 2 H9E]7
MT#_@H'X6\5_M*^/_ -E#PQ^SM\3[[Q9\-]*BU+Q"8=)L%LFMYU=K,PW+WHC=
M[E8W,49*O\K;UCV/M .E^ _[=O['?[3_ ,2_%GP=_9]_:,\+>+O$_@><Q>*=
M&T74EEFL2)#&Q(Z2(L@*%T+*K84D$@5ZS7X\_P#!O?:?\$3[G]O3XQ>*O^"<
MT/Q?7XA:EX=NI]>T[XC6L45EH>F/J4#3V=F$ ?FY\C/G-(X6%0'&&W_7I_X+
M;_LVZ[XS^(VD?"#X'?%WXB^%_A'JKZ;\1OB/X"\)VU]HNCW4:L9D -VEY>>4
M$8NUK;3*H&[)4AB ?3?QV^/?P:_9C^%>K?&[]H#XD:5X2\)Z'$CZIKNLW(B@
M@#NL:+GJS,[*BHH+,S  $D"G_!#XY?"#]I/X6:/\;O@-\1-+\5^$]?MVFTC7
M='N1+!<JKLC 'J&5U9&4@,K*RL 017PG_P %:_VH?^">'[47_!'[1?C#^UOX
M-^*C? [XJV>EZG:^)?!=A:#4_#\TCQS6,DT;S,(W=B4^Y-%D,KE2R;O3_P#@
MC%KW[ WPN_X)/>#_ !M^QQXCUW3/@MH]GK-Z/$/Q(GB@O@+>^NA?WEZXVQQC
MS8IF)4*BH!@*!@ 'V117P6G_  <.?L=W?PCU/]J71?@A\:-0^!^C>)5T34OC
MC:>#+;^P(9S*D/F^2]XNI-!YDB(95LRH=PGWCMKZ/^+_ .W7\#/A3^Q]/^W9
MH\VI>-_AO;:"-<FUGP+%#>G^R]A=[U4>6/?&BC+A277G*_*VT ]EHK\Y=*_X
M.B/^":?BOX Z_P#'_P"''A_XL>*[?PS=NFM>&_#7@!KG4[.U2.-WU"=?.$%I
M9CS%43W$T2LX=4W%&Q]2_P#!/'_@HM^S1_P4\_9\B_:/_9?UO49M)74I=-U7
M2];LUM[_ $J]C5':WN(U=T#;)(W!1W1E<$,>0 #W6O)?VA_V[/V1/V4M9M/#
M'Q^^/6A^']8OM.GU"TT%Y'N=1ELH4=YKL6ENLDWD1JCL\VSRU",2PP:]#^('
MB^/X?> ];\>S>'=7UA-$TBYU!M)\/Z>UW?WHAB:0P6T"_--.^W:D8Y=F51UK
M^:+]D+]JFW^-W_!RK\9_B-\=/@C\5?%^C>-8?%GA6Z\$6GA"ZFUVRTB9!81V
MMS9QL);1(;91'+@@Q8)SGF@#^C[]GS]I'X#?M7?#&S^,W[-_Q8T3QGX7OI'C
MM]9T&]6:+S$.'B;',<BY&48!AD9 S7;5\*GXA?\ !+S_ (-Y/A+X5_9.^%'@
M_P 01:G\2?%[S>$/AGX3,VM^(?$^JW)@MC*BW$P"@[+>$/+)%'\BJ"6!KTS]
MGO\ X*Q?LW_'']J+5/V(/&/A;QC\*_C'IMDM['\.?B;I]I;7NHVIB\[SK.>R
MNKJTN@(\N5CG9P%<[<1OM /IZBOC+]O'_@NE^QM_P3?^.NE_L_?M1^%/B%IN
MK:]:17?A^_TWP[#=V6I0._E^9'*EQD;9 R,KJK@KG;M96:MX9_X+]?\ !//Q
MU_P47LO^"9?P^\3^(M?\;WFHW6FGQ#I.D1R:##J-O%))+9M<F82-(/*=-T<3
MQ!Q@R#!P ?:U?,!_X+6?\$D%)5O^"C/P@!!Y'_"<6G_Q=?3]? _Q/_8)^#__
M  3J_P"" 7QG_9R^&'AG2HKS2/V:/%2>)]?L;%8YM=U,Z%=&ZO)7QO?S)2Q4
M,3L38@PJ   ]9_X?6_\ !(__ *2-?!__ ,+BT_\ BZ]B_9Y_:D_9S_:T\'7?
MQ"_9D^-GAKQWH=CJ;Z=>:MX7U6.\@ANUCCE:!GC) <)+$Q7KAU/>OPR_X,=+
M&RU.?]J'3]2LXKBWFM?!R303QATD4G7,AE/!'L:_7G]GO]FK]FK_ ()3^!/C
ME\2++6]"\$?#/Q%X^NOB!=V_EBUL?#D;Z5I]O=1J!PJ-/9S3*B# $ZQHO %
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M"WL&T#'0#MZ5]0_\'KW_ "C9^&O_ &7&S_\ 3/JM>H?\%?\ _@WK^+G_  6
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MEL_^$JT[0WMWL?[0B98FN;=92C2+NAN(GA=%EC.1C:';V3]J_P#X(N_M3?\
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M;H_ABW:W2U\JSADFFEDD%M&D'G2/GRRR[<LS-Y/^VA_P;U_&+]KS_@J#X?\
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M'+^G_'VQA?3/@]\6+I]1U(01$01Z+JTVS4HL*.EG?(;E8EY"0VXQAAG]Q_\
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MQ+\5/%>B1:/I6E>!_"TNEZ/HELD$-N\P$]Q/-<W,D4"*9790H>10I#+L^W*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MJCXG\4>&O!/AV^\8>,_$5CI&DZ9:O=:EJFIW:6]M:0(I9Y999"%C15!)9B
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M[3__  3QU_P3^RMI<&L^+-&\1:/XCC\(W<@6'Q-;Z?>QW4FFN"0KA_+#"-B
M[1*F1NR/L&O)?VP/VN_A_P#L7>#_  S\4/BXPM/"6I^-+30_$?B"7<(=!@N8
M9_+OIR%(2!9T@221RJ1I*SLP"X(!\8?\$R?VM/V4/^"M%O\ $;PUXST>3P=\
M2M$^/&B^/;GX6^*(UBU_PY>:5;:(OF*DBJS1_:;"XMVE0!A%,5D6(R[*^U]0
M_8S_ &=/$_QA\2?';XD?"W1/%WB7Q'96^G?;_%.D07S:=I<,(0:=;>:A\FW:
M5IYW4??DN'+%@$"_E%^W1\.?@%^T-^U/!\>?V%/&FCZG^U(G[5NBGP%KWP]U
M>.YN;OPR-$T;^T)M0-LS*VDQ1^<6FE^0$M$&(F=&^K/^"D__  6U_8:^ 'QG
M;]A+QC^V%9?#W6KBS\SXA^+["PO;VY\.63@?Z':?8X)MFJ3HWR,X"VT9,[;G
M$,4H!S7_  18_90L? 'B3]M/0O@9JFH>%?@OXN^,U_I'PMCT.;RX]-N+>VDM
M=5O--R"BQI=N((G4% =/"C(CJW_P6\_X)]?L.>%O^"0'C3X;^!_V8/"NEZEH
MME8V7PHA\.Z!#'J8\0SW<%M816TB+YTL\\\B1R?,S2B1RY;)->J?L/?\%5_^
M"6OQ3^'GB#P3^Q5\0K1/A9\$?!45UXI\3G0[S2=%\-VHW+;V[27\43RR/'#<
M2EE#C$+%G+N ?F70_P#@X0_X(U?''XR6G[0O[1W[85IIFD>!]1G;X6^ 9O!F
MMW+VMQM>!]>O!#9.CWDD;2);1*6%M!*[$^=.ZP 'Z8?LX^%/'_@/]GGP'X'^
M*^O-JOBG1O!FEV/B75'F\PWFH0VD4=Q,7_B+RJ[9[YS7PE_P6$^)GQ@_X)]_
MMJ?"#_@K=/\ #J\\=?![P5X3U/P5\3=&TUD:^\,PZG=V[)K-I&Y"L[/'#"Y!
M&5C6,LHEWI](^-/^"IW[*GPL_9C^&?[6OQ=U+7O#?A+XN^(M/TCP*UUX?N)K
MF[?4/->PEDAA5V@2:WB^T?. 55@K /\ +7DG[8WBJ?PM_P %AO@;?_M2:A;Z
M?\"(OAMK7_"':AK,BIHR?$-[E(T6]=_W*3'3&G6U\XC+R3"+YR: +?\ P34O
M=)_;#_:M^*'_  5H^&'B>QC^''Q'\+:/X1\#:58WT<EQJL&E37+2ZMJ,49(M
MIVDN&AB@D/GQPI^]6)G\M?M^OSA_X)R_LO> _P!F[_@K]\;9?V#]7A/[/'B;
MX;66I^+]%T&Z$VA:/X^?4"HM;%D)B1A8I)++#&3Y/VB%6VJ847]'J "BBB@
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MYDG_ $%4_P#P./\ F>C45YS_ ,-9_L_?]#__ .4J[_\ C5'_  UG^S]_T/\
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MDG_053_\#C_F>C45YS_PUG^S]_T/_P#Y2KO_ .-4?\-9_L_?]#__ .4J[_\
MC5']B9U_T#5/_ )?Y!_;F2?]!5/_ ,#C_F>C44R">*Y@2Y@;<DB!D;&,@C(I
M]>6TTSU4TT%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!\1_M-_\EV\1?]?:?^BDK@Z[S]IO_DNW
MB+_K[3_T4E<'7]&91_R*</\ X(?^DH_FS./^1OB/^OD__2F%%%%>@><%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?H=H7_(#L_P#KTC_]!%6JJZ%_R [/_KTC_P#015JOYFJ?
MQ'ZG]0T_X:] HHHJ"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@BK5?S-4_B/U/ZAI_P ->@4445!84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?$?[3?_ "7;Q%_U]I_Z
M*2N#KO/VF_\ DNWB+_K[3_T4E<'7]&91_P BG#_X(?\ I*/YLSC_ )&^(_Z^
M3_\ 2F%%%%>@><%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?H=H7_ " [/_KTC_\ 015JJNA?
M\@.S_P"O2/\ ]!%6J_F:I_$?J?U#3_AKT"BBBH+"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XC_ &F_
M^2[>(O\ K[3_ -%)7!UWG[3?_)=O$7_7VG_HI*X.OZ,RC_D4X?\ P0_])1_-
MF<?\C?$?]?)_^E,****] \X**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _0[0O^0'9_P#7I'_Z
M"*M55T+_ ) =G_UZ1_\ H(JU7\S5/XC]3^H:?\->@4445!84444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M?$?[3?\ R7;Q%_U]I_Z*2N#KO/VF_P#DNWB+_K[3_P!%)7!U_1F4?\BG#_X(
M?^DH_FS./^1OB/\ KY/_ -*84445Z!YP4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^AVA?\@.
MS_Z](_\ T$5:JKH7_(#L_P#KTC_]!%6J_F:I_$?J?U#3_AKT"BBBH+"BBB@
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M2:XOY[6[ACF@46T*O(9"LJ94 A>2Q 4D>=?\$Z_^"@?PY_X*1_!;6OCO\*_
M?B+P[I&E>-M1\.)9>*K>.&^>6S\H22211NXARTA&PL6&WG!.!ZS\(]4^&6M?
M"KPUJWP5O]+NO!UQH-H_A6XT217LY-.,*_9S R?*8O*V;<<;<5\*_P#!MF /
MV//BJ , ?M-^-\?^!<5 'US^U-^V)\%OV0] T:^^)U_J%[K7BG55TOP5X,\.
M6)O=:\2WY&1;65JI!D8#!>1BD42_-(Z+\U=1\)?%OQ2\::&^N?$[X1IX,>4J
MUCI,_B&*_O40YR+D6Z&"*0<?+%-.IR?GXY_+?]F+4_VN/VX?^"U7[5'[4'PI
M;P$)O@3(GPN^&4WQ%6^N[30F4R_;G@L[4QEI+B:!B]QY\;I'*4"RJV$^O?\
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M>D?_ *"*M5_,U3^(_4_J&G_#7H%%%%06%%%% !7FGQ\_:(_X4??:;9?\(?\
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MW_5)O_*]_P#:*^<Z*/\ 4WAO_GQ_Y-/_ .2#_77B;_G_ /\ DL/_ )$^C/\
MAO[_ *I-_P"5[_[11_PW]_U2;_RO?_:*^<Z*/]3>&_\ GQ_Y-/\ ^2#_ %UX
MF_Y__P#DL/\ Y$^C/^&_O^J3?^5[_P"T4?\ #?W_ %2;_P KW_VBOG.BC_4W
MAO\ Y\?^33_^2#_77B;_ )__ /DL/_D3Z,_X;^_ZI-_Y7O\ [17LGP=^)/\
MPMGP);>-O[%_L_[1+*GV;[3YNW8Y7.[:N<XSTKX/K[(_8[_Y(3IW_7W<_P#H
MUJ^5XOX?RC*\KC6PM+EDY)7YI/2S[MKH?6<&\19QFN:RHXJKS14&[<L5K>/9
M)]3U"BBBOS0_3PHHHH **** "BBB@ HHHH **** /B/]IO\ Y+MXB_Z^T_\
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M1\^T445^Y'X.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHK]R/P<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *^R/V._\ DA.G?]?=S_Z-:OC>OLC]CO\
MY(3IW_7W<_\ HUJ^(X__ .1)'_&ORD?=>'O_ "/)?]>Y?G$]0HHHK\:/VH**
M** "BBB@ HHHH **** "BBB@#XC_ &F_^2[>(O\ K[3_ -%)7!UWG[3?_)=O
M$7_7VG_HI*X.OZ,RC_D4X?\ P0_])1_-F<?\C?$?]?)_^E,****] \X****
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M:[H'A70?$.G1)XOT?P^8(;BXM2MQ]BCM[R-"\<?^C,P:/8=RJ-P#5\Q_M_\
M[(O[0_@;XD_L^:?XI_X* ^//$\VN_&G3]/TJ[U+2+"-]$N61RM["(XP&D7!
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M;_Z]+G_T*.OI:OFG]OC_ )#GAO\ Z]+G_P!"CKZK@O\ Y**EZ2_])9\GQO\
M\DW6]8_^E(^?:***_<C\'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OLC]CO_DA.G?\ 7W<_
M^C6KXWK[(_8[_P"2$Z=_U]W/_HUJ^(X__P"1)'_&ORD?=>'O_(\E_P!>Y?G$
M]0HHHK\:/VH**** "BBB@ HHHH **** "BBB@#XC_:;_ .2[>(O^OM/_ $4E
M<'7>?M-_\EV\1?\ 7VG_ **2N#K^C,H_Y%.'_P $/_24?S9G'_(WQ'_7R?\
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M1N%@LK*UC+232,> !_7H!DG@5^L'[?/[ WAO]JOPVWB_PA%;Z=XZTZWQ97K
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MBBO0/."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M _X*;_$;P3\++?P[XM^('B"'3-.57@:ZG5B/,EEB1%PH)R68#I^E?6-?,?\
MP4%L+'4M4\.6FHV45Q$;:X)BFC#J2'C(.#QUKZC@N47G]%6U]_7_ +=>GRU^
M\^6XVC)</5W?3W-/^WUK\_T/ 9)8X@#+(JY8*-QQDGH*=6#\1OACX&^+7A]/
M"OQ"T%=2T]+V&[6V>>2,>=$X>-B8V4G# '!.#W!IOQ'\&ZUXWT>UTS0O'NI>
M'I;?4X+J2[TO;OFCC;+0-N!^1QP>]?MY^%'045S_ ,1!\4C8:?\ \*I.@BZ_
MMBW_ +4_M_SO+^P;CY_E"+DS8QL#$+GJ:/B!XQUSP;#I,FA^ M1U\ZCKMM87
M*::R V,,I(:[DW$?NDP-V.<-GM0!T%%8'CKXG^!OAI)HL7C;719-XAUR#1]'
M7[/)(;B]F#&.+Y%;;G8WS-A1W(R*V;O4+"P:%+Z^AA-Q,(K<2RA3+(02$7/W
MFP"<#G@T 34444 %%%% !1110!RGQ;^+.D_"G0[>=M-GU76M5N/L?AOPY8LO
MVK5KPJ6$,>>%4 %Y)6PD4:L[D*I-<I\"?A;HOP4O-0UCXC^*M/O/B-\3]7:_
M\17T;[/MEQ%;D1V=HK?/]EM+:/RXP>=JM(V'D;.5^TC_ ,$[_P!D3]KGQA9^
M._VAOAI?^(=2TZR^R6$G_"8ZM:16T1;<P2&VNHXD+'!9@NYMJY)VC$'[./\
MP3;_ &+/V2OB#<?%3X _!<:)X@NM,?3IM3G\0ZC?/]F=T=D47=Q*J9:-/F4!
ML#&<$@^;*&/EC5)P@X)Z/F=TNKY>2U]TO>T7J[^G&>7PP3BIS4VM5RJS?1<W
M/?EV;]W5^BMXY_P0RT.?X3_LB^*?@3XM*VFL?#CXH:YH^O13D(8W1HY1*<_P
M,CAE;H0,@TS_ ((?Z--X7_8_\7?&;Q1,NGZ7\0/BOKOBC3+B^<1(+&1H;=)"
M6QM#-;.03U!!Z$5]%_$']D/X&_$KQ3J_C#7=$U2TO/$EE%9^*AH7B.]TZ+7K
M>)2L<=[';2HMQA"8]S@L8R8R2AVU?^,?[,7P2^.WP&N_V9OB!X)B;P5=V=M:
MG1-,E>S2&*WDCD@2(P%3&J-%'@+@87&,9%<>&RS$894K6?L8RC'5^\W:U]-+
M)6>^K\M>S$YIA\5*JW=>VE&4]%[J5W*VNMV[J]M%YZ?-/[:GAN\\&?\ !5K]
ME3]H+4HS_8-Q+KWA6XN_X(+ZZL)Q:(3TW2M,X4=_*:E_;A\-:C\6O^"IW[*?
M@/PY&TDGA%?$?BK7WCY^R602U2*1\=%>:'R@>[.!7U)XT^ WPF^(7PNM_@SX
MO\'Q7?AVSAM4L+,W$J26AMMIMY89T82Q2QE%*2HXD4J"&SS4/PR_9^^&?PH\
M0:GXS\.V%]>:_K,,4&J>(M>U:XU"_N((L^5!Y]P[LD*%F(B0J@9F;;N9B;JY
M95J2J1NN2I.$WW3CRW2TUNX+6ZW?97FEFE*G"G.SYZ<)TUV:ES6;UTLIO2SV
M7=VY+XT_#O\ 9K^$1N_VC/$?PIM[[6[?6(K_ $VPLPS/JFO2*MK:O#:EA ^H
M2%HX$N"GF $9=54D>/?M)>(/B_\ LM?"#P?=0^(8K;XD_'?XU>'?#?C/Q981
MK+_8R7TC*T5IYJE1%;6\1MH2R]6:8KYDCD_3_B3X6^&?%WC[P]\0O$+W5S<>
M%Q<R:-8O*/LL-S,@C-V4QEIUB,D2,3A4GE &7S5?XT_!3X>_'[P)+\/?B3I,
MES9&[@O+6:VN&AN+*[@D66"Y@E0AHI8Y%5E8>F#D$@]&)P52I"I[*T7]FVFK
MW;:ZO:^Z5WUL<^&QM.G.G[6\E]J^NBVBD^B^)K9NRZ7/'_V5OC%X[?\ :\^.
M'[)GB?Q'>:YI'@ Z#J/AC5-3<27<-OJ-FTLEI-* #*$EC9HW?+[9"&9MH-?1
ME<+\&_V>_ 7P4U/Q)XHT&;4-2\0^,=1COO%?B;6KA9;W5)8XA#"'9%1$CCC4
M(D<:(B#.%!9B>ZKIP5*M2H<M5W=Y/O9.3<5\E9?(Y<;5HUJ_-25E:*[7:BE)
M_-IOYA11174<@4444 %%%% !1110 4444 %?9'['?_)"=._Z^[G_ -&M7QO7
MV1^QW_R0G3O^ONY_]&M7Q''_ /R)(_XU^4C[KP]_Y'DO^O<OSB>H4445^-'[
M4%%%% !1110 4444 %%%% !1110!\1_M-_\ )=O$7_7VG_HI*X.N\_:;_P"2
M[>(O^OM/_125P=?T9E'_ "*</_@A_P"DH_FS./\ D;XC_KY/_P!*84445Z!Y
MP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!^AVA?\ (#L_^O2/_P!!%6JJZ%_R [/_ *](_P#T
M$5:K^9JG\1^I_4-/^&O0****@L**** "OFG]OC_D.>&_^O2Y_P#0HZ^EJ^:?
MV^/^0YX;_P"O2Y_]"CKZK@O_ )**EZ2_])9\GQO_ ,DW6]8_^E(^?:***_<C
M\'"BBB@!'C20 2(& ((##/(.0:QO%_P[\%>/;G2+SQAX>@OY-"U6/4M(>8M_
MHMW'G9*N"/F&3USUK:HH Y_QKX%NO&&JZ#J=OXXUO2!HFJK>R6NDW8BBU%0I
M7R+D;29(N<[01R!UH\8VOQ-GUW0)? FJ:1;Z=%J);Q+'J4$CRS6NPX6 KPLF
M[!RW&*Z"B@#G_%GBGQ9H?B;P_HV@_#VXU:RU6[EBU;5(KV.--)C5-RR.C?-(
M&/R@+T/6CQ1\3O!_@[QAX=\"Z]>S1ZEXIGN(=%BCLY)%E>&/S) S(I$>$YRQ
M .#S7044 5;S7-$T_4;71[_6+6"[OM_V&UFN%62XV %]BDY?:""<9QD9JU63
MK'@7P?X@\3:1XSUKPY:7.JZ 9SHNH31 RV9F3RY?+;^'>G!]0!Z55U_X?PZ_
MX]T#Q\_BW7;1_#Z72QZ58ZB8K*^$\80_:8@/WVS 9,D;6&: .@HKG]:TSXC7
M'Q!T75-#\3V%OX;M[>Y77=+FL=\]W(RCR6CES^[","2,<@T:IXA\=6GQ%TKP
MWIGP]^U:!=V4\FI^)#JL<?V&9<>5%]G(+R[^?F& N.<YH Z"L_Q7XK\-^!O#
M=[XO\7ZU;Z=IFG6[3WM[=2!8X8U'))_IU)P!R:Y_QU\=/AW\-?$J>&_&^HSZ
M>#HL^JS:G/:L+."WA(#F2;&U6R1A>K9&,DBOR_\ V^?V^?$G[5?B1O"'A"6X
MT[P+IUQFRLF)6349%/%Q./\ T"/HHY/S'@ _0#]ES]OGX*?M5^)-8\(>$);C
M3M3TZXD-E9:F5634;13Q<1#_ -"C^\HP3P>/<*_ _P *>*_$G@;Q)9>+_"&M
M7&G:GIUPL]E>VLA62&13P0?Z=",@\&OU@_8&_;Y\-_M5^&U\(>+Y;?3O'6G6
M^;VR4A8]1C4<W$ _]#CZJ>1\IX /I"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K[(_8[_Y(3IW_ %]W/_HUJ^-Z^R/V._\ DA.G?]?=S_Z-:OB./_\
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M@ HHHH **** "BBB@ HHHH _0[0O^0'9_P#7I'_Z"*M55T+_ ) =G_UZ1_\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?H=H7_ " [/_KTC_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M10!^AVA?\@.S_P"O2/\ ]!%6JJZ%_P @.S_Z](__ $$5:K^9JG\1^I_4-/\
MAKT"BBBH+"BBB@ KYI_;X_Y#GAO_ *]+G_T*.OI:OFG]OC_D.>&_^O2Y_P#0
MHZ^JX+_Y**EZ2_\ 26?)\;_\DW6]8_\ I2/GVBBBOW(_!PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K[(_8[_P"2$Z=_U]W/_HUJ^-Z^R/V._P#DA.G?]?=S_P"C6KXCC_\
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M  >P?_%4?\-*_L]?]%M\*_\ @]@_^*K])?\ A1GP2_Z([X5_\)ZV_P#B*/\
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M[X5_\)ZV_P#B*/\ B(.=?\^Z?W2_^3#_ (AUDG_/RI]\?_D#\VO^&E?V>O\
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M3#_B'62?\_*GWQ_^0/S:_P"&E?V>O^BV^%?_  >P?_%4?\-*_L]?]%M\*_\
M@]@_^*K])?\ A1GP2_Z([X5_\)ZV_P#B*/\ A1GP2_Z([X5_\)ZV_P#B*/\
MB(.=?\^Z?W2_^3#_ (AUDG_/RI]\?_D#R32?^"H/_!/ZVTJVMI_VJO"JO';H
MKK]H<X(4 _P58_X>D?\ !/G_ *.L\*_^!$G_ ,17J?\ PHSX)?\ 1'?"O_A/
M6W_Q%'_"C/@E_P!$=\*_^$];?_$5\+)N3;/O8I121Y9_P](_X)\_]'6>%?\
MP(D_^(H_X>D?\$^?^CK/"O\ X$2?_$5ZG_PHSX)?]$=\*_\ A/6W_P 11_PH
MSX)?]$=\*_\ A/6W_P 12&>6?\/2/^"?/_1UGA7_ ,")/_B*/^'I'_!/G_HZ
MSPK_ .!$G_Q%>I_\*,^"7_1'?"O_ (3UM_\ $4?\*,^"7_1'?"O_ (3UM_\
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M/^%&?!+_ *([X5_\)ZV_^(H_XB#G7_/NG]TO_DP_XAUDG_/RI]\?_D#\VO\
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MMOA7_P 'L'_Q5'_#2O[/7_1;?"O_ (/8/_BJ_27_ (49\$O^B.^%?_">MO\
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M_P#B*Z:"""U@2UM84CBC0+''&H"JH&  !T ':@!]%%% !1110 4444 %%%%
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M#<PR,]7X*\;>#OB1X2T[Q]\/?%>G:[H>L6:7>DZQI%ZES:WD#C*2Q2QDK(C
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MA?\ &R/7?!MAG]WIEMKWVNZFLH%Z1P)-;NZQC 4SN1U-5OV*['P=_P $Q/\
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MG('S'W-6*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO)I&D
MS:G'K4NEV[7D,9CBNV@4RHAZJ&QD ^F:L44 %%%% %?4](TG6H%M=8TNWNXT
MD61([F!9%5UY# ,#@CL>U6*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
-BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>jnj-20220102_g8.jpg
<TEXT>
begin 644 jnj-20220102_g8.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXANM#L/!+7GVZ\UJ^C<K#%8R216_G>9A\ED01^1.6.V(L<+Q?_P7O\8_LT^
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M)9;0\*MJ-[J\4+16EJGGQ[V\MV3>N5QN90#[KHKYO_9\_;+_ &A/&O[6-_\
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M:7ILDAEO/M,1BFEFN)&:::9DPOFR.SX51G"@#RG1_P#@B+_P3TT:U\+^%?\
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MZRDET*S3M&J$G[BHJ@@$#(!KZ>H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **222.*-I97"JH)9F.  .YJ'3-3TW6M-M]8T?4(+NTNX$FM;JVE$D<T;
M ,KHRDAE((((X(.: )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /S=_X+%_M::?\$OVYO@%\&?VI
MO&VL>$?V=O&NA>(!KVMV&J7&GV.H^)4B5;"SU.[MW1TM$#;_ "BZQ2/*&E#1
MQ-L]=_X)H_LG7GP?\+?!_P",_P +/B!XCMO!/B+]GJPA\5>!K_Q5=WFF#7&B
MTJ:UU&TMKB1TM',(OXY1#L1LQ'9G+'V/]J;P#^RY^UAX/\7_ +''[0/@S1O%
ML4GA&/6]0\,:S:EA]FDDN88+J)N&21);>3$D;!XCL.5WJ3^<G_!'"U_:3_X)
MX_M9?![]@:'XU:G\1O@K\;/@ GQ \,:7X@(EU#P!?1P027,"2+_RX222[44A
M5WRJ%"LDC3 'K_[8G_!'3QC\9?@QXS_:E^)7[>/QBT+XZVNC7OB#1=>\,?$*
MYL=!\*W,,;SPZ;9V46Q%L8MJQ-(<3R[6F9P[D#SSXA?\%0?VKM._X('?L[?'
MKQOXEG\._$SX\>*O#O@;4_&UK;I%/IT%]=7*2:S&I79'-+86C2HP4*DERKJ
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MV;=,_9,_9FT75?A]X(T>::2QL?#6NW(N4\Z:2>8&[G>6X)>25R7,F\<!64*
M/7:* .(^!O[.7P6_9OT._P!"^#G@:'2AJ^H-?Z[J,UU-=W^KWC##75[>7+R7
M%Y,0 /-FD=\ #.  .?UK]B;]G#Q!^V/H_P"WOJO@>63XH:%X-E\+:9KPU6X6
M./37EDE,9MP_DLVZ:7#E"V)",\+M]7HH \NU7]C[X*^+?BGIWQD^)UAJOC'6
MM#U)K_PTGBO69[RPT2Y);;-:6!86L,Z!BJ7 B,ZJ<"3DY]1HHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7T&77+??J^J'2;RUO/$;1%\MN#2V=B,?ZEKB==PO(MGUSXB^+/[4D/[;>C_
MK3?V6H;[X-ZCX!GU'6OBRWB:%&LM7$[HNF_8C^\<&,1MO'!\[((\I@?FG]J'
M_@WY_P""8NJ_LT?$32_@+_P3Z\"KXZN? NKQ>"VMD,,@U9K*46922698XV\\
MQX9R%!Y) !- 'H__  0Q\3>&]>_X)*_L_P"GZ'X@L;V?3OA7H\.H06EVDCVL
MGV=?DD"DE&X/!P>*^LJ^3/\ @B_^P)X7_8!_84\#^ KSX&Z;X)^(>J>%M-D^
M*D5C<Q3R7FL10;)'EEADDBE<%F&Z-BISP37UG0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\Y_M_?\ ,I?]O_\
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MCE_UUX9_Y_\ _DL__D3Z,HKYS_X;^_ZI-_Y7O_M%'_#?W_5)O_*]_P#:*/\
M4WB3_GQ_Y-#_ .2#_77AG_G_ /\ DL__ )$^C**^<_\ AO[_ *I-_P"5[_[1
M1_PW]_U2;_RO?_:*/]3>)/\ GQ_Y-#_Y(/\ 77AG_G__ .2S_P#D3Z,HKYS_
M .&_O^J3?^5[_P"T4?\ #?W_ %2;_P KW_VBC_4WB3_GQ_Y-#_Y(/]=>&?\
MG_\ ^2S_ /D3Z,HKYS_X;^_ZI-_Y7O\ [11_PW]_U2;_ ,KW_P!HH_U-XD_Y
M\?\ DT/_ )(/]=>&?^?_ /Y+/_Y$^C**^<_^&_O^J3?^5[_[11_PW]_U2;_R
MO?\ VBC_ %-XD_Y\?^30_P#D@_UUX9_Y_P#_ )+/_P"1/HRBOG/_ (;^_P"J
M3?\ E>_^T4?\-_?]4F_\KW_VBC_4WB3_ )\?^30_^2#_ %UX9_Y__P#DL_\
MY$^C**^<_P#AO[_JDW_E>_\ M%'_  W]_P!4F_\ *]_]HH_U-XD_Y\?^30_^
M2#_77AG_ )__ /DL_P#Y$^C**^<_^&_O^J3?^5[_ .T4?\-_?]4F_P#*]_\
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M!]&?L _\S;_VX?\ MQ7T97SG^P#_ ,S;_P!N'_MQ7T97X5QE_P E)7_[=_\
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M4 %%%% !1110 4444 %%%% !1110 4444 ?1G[ /_,V_]N'_ +<5]&5\Y_L
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M\?\ A6]E_P -#CP__P )/S]J_P"$;\SR-F!MW>9_RUZ[]OR9^[Q0!V%%<_\
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MIX*_Y*:A_P!O?^D2/HRBBBOPH_>PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OG/\ ;^_YE+_M_P#_ &WKZ,KYS_;^_P"92_[?_P#VWKZ?@W_D
MI*'_ &]_Z1(^6XU_Y)FO_P!N_P#I<3YSHHHK]U/P0**** "BBB@ HHHH *^;
M_P!OG]@;PW^U7X;;Q?X0BM].\=:=;XLKU@%CU&-1Q;SG_P! DZJ>#\IX^D**
M /F_]@;]@;PW^RIX;7Q?XOBM]1\=:C;XO;U0&CTZ-AS;P'_T.3JQX'RCGZ0H
MHH **** "BBB@ HHHH **** /HS]@'_F;?\ MP_]N*^C*^<_V ?^9M_[</\
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M92NMK--6OIK=.^CZV>B:+U%?(O\ P1BU_P :>(?V:_&,WC[QWK/B74;3XO\
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M ^<_V_O^92_[?_\ VWKYSKZ,_;^_YE+_ +?_ /VWKYSK]UX-_P"2;H?]O?\
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M )E+_M__ /;>OI^#?^2DH?\ ;W_I$CY;C7_DF:__ &[_ .EQ/G.BBBOW4_!
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Z,_8!_YFW_MP
M_P#;BOHROG/]@'_F;?\ MP_]N*^C*_"N,O\ DI*__;O_ *1$_>^"O^29H?\
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MZ1(^6XU_Y)FO_P!N_P#I<3YSHHHK]U/P0**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ^C/V ?^9M_[</\ VXKZ,KYS_8!_YFW_ +</_;BO
MHROPKC+_ )*2O_V[_P"D1/WO@K_DF:'_ &]_Z7(****^8/J0HHHH **** "B
MBB@ HHHH **** /G/]O[_F4O^W__ -MZ^<Z^C/V_O^92_P"W_P#]MZ^<Z_=>
M#?\ DFZ'_;W_ *7(_!.-?^2FK_\ ;O\ Z1$****^G/E@HHHH **** "BBB@
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M &[_ .D1"BBBOISY8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKZ,_8!_YFW_MP_\ ;BOG.OHS]@'_ )FW_MP_]N*^8XR_Y)NO_P!N_P#I<3ZG
M@K_DIJ'_ &]_Z1(^C****_"C]["BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *^<_P!O[_F4O^W_ /\ ;>OHROG/]O[_ )E+_M__ /;>OI^#?^2D
MH?\ ;W_I$CY;C7_DF:__ &[_ .EQ/G.BBBOW4_! HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#Z,_8!_YFW_MP_P#;BOHROG/]@'_F;?\
MMP_]N*^C*_"N,O\ DI*__;O_ *1$_>^"O^29H?\ ;W_I<@HHHKY@^I"BBB@
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M .EQ/J>"O^2FH?\ ;W_I$CZ,HHHK\*/WL**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KYS_ &_O^92_[?\ _P!MZ^C*^<_V_O\ F4O^W_\ ]MZ^
MGX-_Y*2A_P!O?^D2/EN-?^29K_\ ;O\ Z7$^<Z***_=3\$"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /HS]@'_F;?^W#_ -N*^C*^<_V
M?^9M_P"W#_VXKZ,K\*XR_P"2DK_]N_\ I$3][X*_Y)FA_P!O?^ER"BBBOF#Z
MD**** "BBB@ HHHH **** "BBB@#YS_;^_YE+_M__P#;>OG.OHS]O[_F4O\
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M_&O=** /"_\ AWO\$_\ H;?'?_A97/\ C1_P[W^"?_0V^.__  LKG_&O=**
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M/_H;?'?_ (65S_C1_P .]_@G_P!#;X[_ /"RN?\ &O=** /"_P#AWO\ !/\
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M;X[_ /"RN?\ &O=** /"_P#AWO\ !/\ Z&WQW_X65S_C1_P[W^"?_0V^._\
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M)%KJJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_9HUG7/%'B?4GO\ 7=9O/BSXI\V[G?JQVZF%4  *J* J*JJH"J  #S[_ (+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>jnj-20220102_g9.jpg
<TEXT>
begin 644 jnj-20220102_g9.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRDFB*ZA':L?)E1\!S;AE='4I@!V^5?\ @VJ_:F_8+_:!\5?']OV!/^"<-O\
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MBRFN99[F8D1PQ0PJTDCMAC@#A59CA5)'3? 3X[_"?]I[X-^'?C_\#/&$&O\
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M%=J11HH544=@   /:OF?]K__ ((T?\$X/V]?%VD>-OVL/V?[OQ5>^'],73]
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M):]H_P 2;N_N;S4?%A^*GB6YN-0FN)/-N#="?472Z663YG2975SRP-4O$/\
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MS?+^]DW 'Y<?\&/?A_2(/@?\?_%45F@O[KQ7H=I/<;?F:&*VNG1<^@::0_\
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MM;_\&[OPQ_9G^)]MYN@^./@]/I&H,J!GA$SSJLR9Z21OMD0]G13VKVGXP_\
M!('_ ()Y_'K]GSP[^RI\4O@3=WWP]\+WK7NE^%[3QSK=E!)=L6+75R;6]C>]
MG)=SYURTLF7<[LLQ/I_[*W[)WP*_8J^#]C\ OV;_  SJ6B>$=+D=M+T:_P#%
M&HZJMD';<T<+W]Q.\4>XEO+5@@+,0H+$D _!C_@W=TK]J/3/CI\4_P#@A5\7
M?"T[^%/"/Q1@\5_$"\9CY-E:Z5<;;FQ3=_K(M0O;?1U"C"O;?;&^;S#7H/\
MP>HQ?$#PG\0/V7?C'##?-X9T/4=;7S[-MHM]0$NFS@;B"JR/'"2A(.?(?@@&
MOVK^'G[+/P*^%?QW\?\ [2O@3P';6'C/XGIIB^-=9C8E]0%A T%KD$X3;&Q!
MV@;L G) IG[5'[)7[.G[;/P;O_@#^U'\*].\7^%-1D26;3;\NC13)G9-#+$R
MRP2KE@)(V5@&89PQ! /C2[_8!_X)Q?M/>,/@'_P4C\??MB?$OQ_>Z=X@T6Z^
M#6N:IXQMYQ<WDEY'<6]HL%K:*TG[U,S1D9C2.8R%$CD9?T0KY/\ V%?^")/_
M  3@_P""<_CFX^*/[,GP*:S\330R00:_KNMW6I7%E#(,.EM]HD9;?</E9HU5
MV4E68KQ7UA0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX8^(5S8Z#X5N88WGATVSLHMB+8Q;5B:0XGEVM,SAW('T!_P21_:;^*G[0O\
MP2O^$O[4/[5>HV]CXBU;P.=0\3:O>!+:*:&&25%U"3[J1B6WB2X8C:@\PD +
MC%[]IXWW[;%[KO[#?PRUJXMO"T@%C\</&.GRE?L5A(@:7P_:2#K?W<+!)2O_
M !ZVLS.VV6:W#<%_P41\&_M&_$KX*>$O@'_P3N^$?P^\<>$_#/BN+2_B;X%U
M#Q:ND6ATZQM8I+?1"\:.%@+M;>? %^>&/R&^25P0#YSO_C[^T)\;?^"\O[*7
MQ*U_Q+JFB_#/QKX/\=7/P[\"2"2#?I<&F$1:O>QD@FXO"WGI&XS#;K;*0LIF
M%?JS7XA_M._&G_@L'>_\%H/V7O$GC3]A_P"%FG_$73_!GC*/P1X6L_BD\MAJ
MEL]D!=R3W7V<&W:-.44*=YXXK]KX=>TL:E!X>O=4M(]5ELS<_P!FBY4RF,$*
MSJF=Q0,P7=C&2/6@#X5^+?\ P1$B_:(^)WBO]H?]HC_@H_\ M&Z'K/B/6)[Z
M30_AG\4SHN@:'8K\EM:6\#6[G$5ND:R3$KYL@>38F_:-?_@@#\+M<\'?L+W'
MQ/U3XL^/O%^F_$CQYK/B'P7>_$CQ//JNI0>&_M!M=*1Y9<#,EK;QW1V*JEKL
M\#@#T3_@KQ\0O%GAK]BC6?A%\,M2:U\:?&76-/\ AKX-F3[T5YK4PM);@'M]
MGLVN[K=V%L3QC-?0'PQ^'7A/X0?#;P]\)O 6FK9:'X7T.TTC1K->D%I;0I#"
M@^B(H_"@#<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \=_:$_89^ W[1WCS3?C#XJMO$&C>.=$T2?2=&\9>$O%NH:3?6
M]E,V^2V<VD\:W,!?#F&970L <9 -97[(/_!/;X&?LB>$K6/08]1UWQE+X+T[
MPWK_ ,0=:U:\GU.^L[2%8T@@DFGD?3[4,#(EK;ND4;'< 6&\^[T4 ?"NJ_\
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M@3X*V/@CP/X:TK1?*TOP=";>$7;2$74K:A>2/$D<EPLD41C0I&B@ESYUH_\
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M.O\ GY3^^7_R!Y__ !$7)/\ GW4^Z/\ \F?:5%?%O_#6?[0/_0__ /E*M/\
MXU1_PUG^T#_T/_\ Y2K3_P"-4?\ $/LZ_P"?E/[Y?_(!_P 1%R3_ )]U/NC_
M /)GVE17Q;_PUG^T#_T/_P#Y2K3_ .-4?\-9_M _]#__ .4JT_\ C5'_ !#[
M.O\ GY3^^7_R ?\ $1<D_P"?=3[H_P#R9]I45\6_\-9_M _]#_\ ^4JT_P#C
M5'_#6?[0/_0__P#E*M/_ (U1_P 0^SK_ )^4_OE_\@'_ !$7)/\ GW4^Z/\
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MVE17Q;_PUG^T#_T/_P#Y2K3_ .-4?\-9_M _]#__ .4JT_\ C5'_ !#[.O\
MGY3^^7_R ?\ $1<D_P"?=3[H_P#R9]I45\6_\-9_M _]#_\ ^4JT_P#C5>T_
ML@_%KX@_%'_A(?\ A._$'V[[#]D^R_Z)%%LW^=N_U:+G.Q>N>E<&9\'9GE6!
MGBJLX.,;7LY7U:76*[]ST,KXTRO-L=#"4834I7M=1MHF^DF]EV/::***^3/K
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OG/]O[_F4O\ M_\
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MH **** /HS]@'_F;?^W#_P!N*^C*^<_V ?\ F;?^W#_VXKZ,K\*XR_Y*2O\
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M "S'DGJ3UH\/^&/#7A.R?3?"OAZQTRVDG>9[?3[1(4:5SEW*H "S'DGJ3UH
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M?^2DH?\ ;W_I$CY;C7_DF:__ &[_ .EQ/G.BBBOW4_! HHHH **** "BBB@
MKS_]I+]FWX<?M0_#BX^'GQ#L/633-3A4>?I\^,"6,G\F4\,.#V(] HH \_\
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M,T/^WO\ TN04445\P?4A1110 4444 %%%% !1110 4444 ?.?[?W_,I?]O\
M_P"V]?.=?1G[?W_,I?\ ;_\ ^V]?.=?NO!O_ "3=#_M[_P!+D?@G&O\ R4U?
M_MW_ -(B%%%%?3GRP4444 0ZCJ-AI&GSZMJMY%;6MK"TUS<3N%2*-069F)X
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M HHHH **** "BBB@ HHHH *^<_V_O^92_P"W_P#]MZ^C*^<_V_O^92_[?_\
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MM51%NC GVE8S\HDVC<![9S4]%%>PM$>*]6%%%% !1110!]&?L _\S;_VX?\
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M3-?_ +=_]+B?.=%%%?NI^"!1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %%%% !1110 4444 %%%% 'T9^P#_P S;_VX?^W%?1E?.?[
M/_,V_P#;A_[<5]&5^%<9?\E)7_[=_P#2(G[WP5_R3-#_ +>_]+D%%%%?,'U(
M4444 %%%% !1110 4444 %%%% 'SG^W]_P RE_V__P#MO7SG7T9^W]_S*7_;
M_P#^V]?.=?NO!O\ R3=#_M[_ -+D?@G&O_)35_\ MW_TB(4445].?+!1110
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MO_)35_\ MW_TB(4445].?+!1110 4444 %%%% !1110 4444 %%%% !1110
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M_1UGA7_P(D_^(H ]\KYS_;^_YE+_ +?_ /VWK0_X>D?\$^?^CK/"O_@1)_\
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M_BJ/[;R7_H)I_P#@<?\ ,/[#SO\ Z!:G_@$O\CMJ*XG_ (:5_9Z_Z+;X5_\
M![!_\51_PTK^SU_T6WPK_P"#V#_XJC^V\E_Z":?_ (''_,/[#SO_ *!:G_@$
MO\CMJ*XG_AI7]GK_ *+;X5_\'L'_ ,51_P -*_L]?]%M\*_^#V#_ .*H_MO)
M?^@FG_X''_,/[#SO_H%J?^ 2_P CMJ*XG_AI7]GK_HMOA7_P>P?_ !5'_#2O
M[/7_ $6WPK_X/8/_ (JC^V\E_P"@FG_X''_,/[#SO_H%J?\ @$O\CMJ*XG_A
MI7]GK_HMOA7_ ,'L'_Q5'_#2O[/7_1;?"O\ X/8/_BJ/[;R7_H)I_P#@<?\
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M]AYW_P! M3_P"7^1VU?1G[ /_,V_]N'_ +<5\>_\-*_L]?\ 1;?"O_@]@_\
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M;_XBC_A1GP2_Z([X5_\ ">MO_B*ZFB@#EO\ A1GP2_Z([X5_\)ZV_P#B*/\
MA1GP2_Z([X5_\)ZV_P#B*ZFB@#EO^%&?!+_HCOA7_P )ZV_^(H_X49\$O^B.
M^%?_  GK;_XBNIHH Y;_ (49\$O^B.^%?_">MO\ XBC_ (49\$O^B.^%?_">
MMO\ XBNIHH Y;_A1GP2_Z([X5_\ ">MO_B*/^%&?!+_HCOA7_P )ZV_^(KJ:
M* .6_P"%&?!+_HCOA7_PGK;_ .(H_P"%&?!+_HCOA7_PGK;_ .(KJ:* .6_X
M49\$O^B.^%?_  GK;_XBC_A1GP2_Z([X5_\ ">MO_B*ZFB@#EO\ A1GP2_Z(
M[X5_\)ZV_P#B*/\ A1GP2_Z([X5_\)ZV_P#B*ZFB@#EO^%&?!+_HCOA7_P )
MZV_^(H_X49\$O^B.^%?_  GK;_XBNIHH Y;_ (49\$O^B.^%?_">MO\ XBC_
M (49\$O^B.^%?_">MO\ XBNIHH Y;_A1GP2_Z([X5_\ ">MO_B*/^%&?!+_H
MCOA7_P )ZV_^(KJ:* .6_P"%&?!+_HCOA7_PGK;_ .(H_P"%&?!+_HCOA7_P
MGK;_ .(KJ:* .6_X49\$O^B.^%?_  GK;_XBC_A1GP2_Z([X5_\ ">MO_B*Z
MFB@#EO\ A1GP2_Z([X5_\)ZV_P#B*/\ A1GP2_Z([X5_\)ZV_P#B*ZFB@#EO
M^%&?!+_HCOA7_P )ZV_^(H_X49\$O^B.^%?_  GK;_XBNIHH Y;_ (49\$O^
MB.^%?_">MO\ XBC_ (49\$O^B.^%?_">MO\ XBNIHH Y;_A1GP2_Z([X5_\
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M[:ULX$!9Y999"$C10"2S$  <UR/P4_:J_9X_:+N[_3?@O\6-*UV\TN"&XO\
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M^.O$'C/1K:[N+VW8$1V\LTJ96VMK=8X(D!"QI"&^^6=OG#_@VU^#WBCX.?\
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MN;F=&80[MXA4R[=F"?T>JOIFD:3HMN;/1M+M[2$R,YBM8%C4L3DMA0!DGJ:
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MG5+A8K>SMHU+/+([<*H -;5% 'Y.:'_P<(?\$:OCC\9+3]H7]H[]L*TTS2/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
>HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740168193016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  02,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">JOHNSON & JOHNSON<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-1024240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Johnson & Johnson Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Brunswick<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">524-0400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,629,268,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000200406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--01-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, Par Value $1.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes Due May 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.650% Notes Due May 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24C<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes Due November 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">5.50% Notes Due November 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24BP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes Due November 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.150% Notes Due November 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes Due May 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.650% Notes Due May 2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740169802552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Florham Park, New Jersey<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740165907080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents (Notes&#160;1 and 2)</a></td>
<td class="nump">$ 14,487<span></span>
</td>
<td class="nump">$ 13,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities (Notes&#160;1 and 2)</a></td>
<td class="nump">17,121<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable trade, less allowances for doubtful accounts $230 (2020, $293)</a></td>
<td class="nump">15,283<span></span>
</td>
<td class="nump">13,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (Notes&#160;1 and 3)</a></td>
<td class="nump">10,387<span></span>
</td>
<td class="nump">9,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other receivables</a></td>
<td class="nump">3,701<span></span>
</td>
<td class="nump">3,132<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">60,979<span></span>
</td>
<td class="nump">51,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net (Notes&#160;1 and 4)</a></td>
<td class="nump">18,962<span></span>
</td>
<td class="nump">18,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net (Notes&#160;1 and 5)</a></td>
<td class="nump">46,392<span></span>
</td>
<td class="nump">53,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Notes&#160;1 and 5)</a></td>
<td class="nump">35,246<span></span>
</td>
<td class="nump">36,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred taxes on income (Note&#160;8)</a></td>
<td class="nump">10,223<span></span>
</td>
<td class="nump">8,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">10,216<span></span>
</td>
<td class="nump">6,562<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">182,018<span></span>
</td>
<td class="nump">174,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loans and notes payable (Note&#160;7)</a></td>
<td class="nump">3,766<span></span>
</td>
<td class="nump">2,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,055<span></span>
</td>
<td class="nump">9,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">13,612<span></span>
</td>
<td class="nump">13,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_AccruedRebatesReturnsAndPromotions', window );">Accrued rebates, returns and promotions</a></td>
<td class="nump">12,095<span></span>
</td>
<td class="nump">11,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee related obligations</a></td>
<td class="nump">3,586<span></span>
</td>
<td class="nump">3,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued taxes on income (Note 8)</a></td>
<td class="nump">1,112<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">45,226<span></span>
</td>
<td class="nump">42,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt (Note&#160;7)</a></td>
<td class="nump">29,985<span></span>
</td>
<td class="nump">32,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred taxes on income (Note 8)</a></td>
<td class="nump">7,487<span></span>
</td>
<td class="nump">7,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Employee related obligations (Notes&#160;9 and 10)</a></td>
<td class="nump">8,898<span></span>
</td>
<td class="nump">10,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term taxes payable (Note 1)</a></td>
<td class="nump">5,713<span></span>
</td>
<td class="nump">6,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">10,686<span></span>
</td>
<td class="nump">11,944<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">107,995<span></span>
</td>
<td class="nump">111,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 19)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock&#160;&#8212; without par value (authorized and unissued 2,000,000&#160;shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#160;&#8212; par value $1.00 per share (Note&#160;12) (authorized 4,320,000,000&#160;shares; issued 3,119,843,000&#160;shares)</a></td>
<td class="nump">3,120<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss) (Note&#160;13)</a></td>
<td class="num">(13,058)<span></span>
</td>
<td class="num">(15,242)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">123,060<span></span>
</td>
<td class="nump">113,890<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityBeforeTreasuryStock', window );">Stockholders' Equity before Treasury Stock</a></td>
<td class="nump">113,122<span></span>
</td>
<td class="nump">101,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less: common stock held in treasury, at cost (Note&#160;12) (490,878,000&#160;shares and 487,331,000&#160;shares)</a></td>
<td class="nump">39,099<span></span>
</td>
<td class="nump">38,490<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">74,023<span></span>
</td>
<td class="nump">63,278<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 182,018<span></span>
</td>
<td class="nump">$ 174,894<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AccruedRebatesReturnsAndPromotions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AccruedRebatesReturnsAndPromotions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityBeforeTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityBeforeTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167324728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowances for doubtful accounts</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">4,320,000,000<span></span>
</td>
<td class="nump">4,320,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">3,119,843,000<span></span>
</td>
<td class="nump">3,119,843,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">490,878,000<span></span>
</td>
<td class="nump">487,331,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740168044600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 93,775<span></span>
</td>
<td class="nump">$ 82,584<span></span>
</td>
<td class="nump">$ 82,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">29,855<span></span>
</td>
<td class="nump">28,427<span></span>
</td>
<td class="nump">27,556<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">63,920<span></span>
</td>
<td class="nump">54,157<span></span>
</td>
<td class="nump">54,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, marketing and administrative expenses</a></td>
<td class="nump">24,659<span></span>
</td>
<td class="nump">22,084<span></span>
</td>
<td class="nump">22,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">14,714<span></span>
</td>
<td class="nump">12,159<span></span>
</td>
<td class="nump">11,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development (Note 5)</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net of portion capitalized (Note&#160;4)</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="nump">489<span></span>
</td>
<td class="nump">2,899<span></span>
</td>
<td class="nump">2,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring (Note 20)</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">22,776<span></span>
</td>
<td class="nump">16,497<span></span>
</td>
<td class="nump">17,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for taxes on income (Note&#160;8)</a></td>
<td class="nump">1,898<span></span>
</td>
<td class="nump">1,783<span></span>
</td>
<td class="nump">2,209<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 20,878<span></span>
</td>
<td class="nump">$ 14,714<span></span>
</td>
<td class="nump">$ 15,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net earnings per share (Notes 1 and 15)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 7.93<span></span>
</td>
<td class="nump">$ 5.59<span></span>
</td>
<td class="nump">$ 5.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 7.81<span></span>
</td>
<td class="nump">$ 5.51<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Average shares outstanding (Notes 1 and 15)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">2,632.1<span></span>
</td>
<td class="nump">2,632.8<span></span>
</td>
<td class="nump">2,645.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">2,674.0<span></span>
</td>
<td class="nump">2,670.7<span></span>
</td>
<td class="nump">2,684.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740165591368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 20,878<span></span>
</td>
<td class="nump">$ 14,714<span></span>
</td>
<td class="nump">$ 15,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign currency translation</a></td>
<td class="num">(1,079)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) arising during period</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassifications to earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Employee benefit plans:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax', window );">Prior service credit (cost), net of amortization</a></td>
<td class="num">(169)<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax', window );">Gain (loss), net of amortization</a></td>
<td class="nump">4,318<span></span>
</td>
<td class="num">(1,135)<span></span>
</td>
<td class="num">(714)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax', window );">Effect of exchange rates</a></td>
<td class="nump">106<span></span>
</td>
<td class="num">(229)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net change</a></td>
<td class="nump">4,255<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="num">(733)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Derivatives &amp; hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gain (loss) arising during period</a></td>
<td class="num">(199)<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="num">(107)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassifications to earnings</a></td>
<td class="num">(789)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change</a></td>
<td class="num">(988)<span></span>
</td>
<td class="nump">947<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">649<span></span>
</td>
<td class="num">(669)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 23,062<span></span>
</td>
<td class="nump">$ 15,363<span></span>
</td>
<td class="nump">$ 14,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>other comprehensive income loss, pension and other , effects of exchange rate net of tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740165558776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation</a></td>
<td class="num">$ (346)<span></span>
</td>
<td class="num">$ (536)<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Securities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax', window );">Employee benefits</a></td>
<td class="nump">1,198<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Derivatives &amp; hedges</a></td>
<td class="num">$ (263)<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740166053992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Common Stock Issued Amount</div></th>
<th class="th"><div>Treasury Stock Amount</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 30, 2018</a></td>
<td class="nump">$ 59,752<span></span>
</td>
<td class="nump">$ 106,216<span></span>
</td>
<td class="num">$ (15,222)<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (34,362)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">15,119<span></span>
</td>
<td class="nump">15,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(9,917)<span></span>
</td>
<td class="num">(9,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee compensation and stock option plans</a></td>
<td class="nump">1,933<span></span>
</td>
<td class="num">(758)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(6,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,746)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(669)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(669)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 29, 2019</a></td>
<td class="nump">59,471<span></span>
</td>
<td class="nump">110,659<span></span>
</td>
<td class="num">(15,891)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(38,417)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">14,714<span></span>
</td>
<td class="nump">14,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(10,481)<span></span>
</td>
<td class="num">(10,481)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee compensation and stock option plans</a></td>
<td class="nump">2,217<span></span>
</td>
<td class="num">(931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(3,221)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,221)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jan. 03, 2021</a></td>
<td class="nump">63,278<span></span>
</td>
<td class="nump">113,890<span></span>
</td>
<td class="num">(15,242)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(38,490)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">20,878<span></span>
</td>
<td class="nump">20,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(11,032)<span></span>
</td>
<td class="num">(11,032)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee compensation and stock option plans</a></td>
<td class="nump">2,171<span></span>
</td>
<td class="num">(676)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(3,456)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,456)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">2,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jan. 02, 2022</a></td>
<td class="nump">$ 74,023<span></span>
</td>
<td class="nump">$ 123,060<span></span>
</td>
<td class="num">$ (13,058)<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (39,099)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740170065144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividends paid (in dollars per share)</a></td>
<td class="nump">$ 4.19<span></span>
</td>
<td class="nump">$ 3.98<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740162439544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 20,878<span></span>
</td>
<td class="nump">$ 14,714<span></span>
</td>
<td class="nump">$ 15,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings to cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization of property and intangibles</a></td>
<td class="nump">7,390<span></span>
</td>
<td class="nump">7,231<span></span>
</td>
<td class="nump">7,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset write-downs</a></td>
<td class="nump">989<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,148)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Net gain on sale of assets/businesses</a></td>
<td class="num">(617)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
<td class="num">(2,154)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax provision</a></td>
<td class="num">(2,079)<span></span>
</td>
<td class="num">(1,141)<span></span>
</td>
<td class="num">(2,476)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit losses and accounts receivable allowances</a></td>
<td class="num">(48)<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase)/Decrease in accounts receivable</a></td>
<td class="num">(2,402)<span></span>
</td>
<td class="nump">774<span></span>
</td>
<td class="num">(289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(1,248)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
<td class="num">(277)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable and accrued liabilities</a></td>
<td class="nump">2,437<span></span>
</td>
<td class="nump">5,141<span></span>
</td>
<td class="nump">4,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Increase in other current and non-current assets</a></td>
<td class="num">(1,964)<span></span>
</td>
<td class="num">(3,704)<span></span>
</td>
<td class="num">(1,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">(Decrease)/Increase in other current and non-current liabilities</a></td>
<td class="num">(1,061)<span></span>
</td>
<td class="nump">744<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows from operating activities</a></td>
<td class="nump">23,410<span></span>
</td>
<td class="nump">23,536<span></span>
</td>
<td class="nump">23,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="num">(3,652)<span></span>
</td>
<td class="num">(3,347)<span></span>
</td>
<td class="num">(3,498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from the disposal of assets/businesses, net</a></td>
<td class="nump">711<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="nump">3,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired (Note&#160;18)</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(7,323)<span></span>
</td>
<td class="num">(5,810)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(30,394)<span></span>
</td>
<td class="num">(21,089)<span></span>
</td>
<td class="num">(3,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Sales of investments</a></td>
<td class="nump">25,006<span></span>
</td>
<td class="nump">12,137<span></span>
</td>
<td class="nump">3,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities', window );">Credit support agreements activity, net</a></td>
<td class="nump">214<span></span>
</td>
<td class="num">(987)<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other (primarily licenses and milestones)</a></td>
<td class="num">(508)<span></span>
</td>
<td class="num">(521)<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used by investing activities</a></td>
<td class="num">(8,683)<span></span>
</td>
<td class="num">(20,825)<span></span>
</td>
<td class="num">(6,194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfOrdinaryDividends', window );">Dividends to shareholders</a></td>
<td class="num">(11,032)<span></span>
</td>
<td class="num">(10,481)<span></span>
</td>
<td class="num">(9,917)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(3,456)<span></span>
</td>
<td class="num">(3,221)<span></span>
</td>
<td class="num">(6,746)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term debt</a></td>
<td class="nump">1,997<span></span>
</td>
<td class="nump">3,391<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short-term debt</a></td>
<td class="num">(1,190)<span></span>
</td>
<td class="num">(2,663)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt, net of issuance costs</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">7,431<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(1,802)<span></span>
</td>
<td class="num">(1,064)<span></span>
</td>
<td class="num">(2,823)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits', window );">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</a></td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities', window );">Credit support agreements activity, net</a></td>
<td class="nump">281<span></span>
</td>
<td class="num">(333)<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">114<span></span>
</td>
<td class="num">(294)<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used by financing activities</a></td>
<td class="num">(14,047)<span></span>
</td>
<td class="num">(6,120)<span></span>
</td>
<td class="num">(18,015)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(178)<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase/(Decrease) in cash and cash equivalents</a></td>
<td class="nump">502<span></span>
</td>
<td class="num">(3,320)<span></span>
</td>
<td class="num">(802)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year (Note&#160;1)</a></td>
<td class="nump">13,985<span></span>
</td>
<td class="nump">17,305<span></span>
</td>
<td class="nump">18,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year (Note&#160;1)</a></td>
<td class="nump">14,487<span></span>
</td>
<td class="nump">13,985<span></span>
</td>
<td class="nump">17,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CashPaidDuringTheYearAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
<td class="nump">990<span></span>
</td>
<td class="nump">904<span></span>
</td>
<td class="nump">995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest, net of amount capitalized</a></td>
<td class="nump">941<span></span>
</td>
<td class="nump">841<span></span>
</td>
<td class="nump">925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">4,768<span></span>
</td>
<td class="nump">4,619<span></span>
</td>
<td class="nump">4,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds', window );">Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards</a></td>
<td class="nump">1,811<span></span>
</td>
<td class="nump">1,937<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1', window );">Fair value of assets acquired</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">7,755<span></span>
</td>
<td class="nump">7,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Fair value of liabilities assumed and noncontrolling interests</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(432)<span></span>
</td>
<td class="num">(1,418)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Net cash paid for acquisitions (Note 18)</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 7,323<span></span>
</td>
<td class="nump">$ 5,810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CashPaidDuringTheYearAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Paid During The Year [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CashPaidDuringTheYearAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Treasury stock issued for employee compensation and stock option plans, net of cash proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfOrdinaryDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfOrdinaryDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740166974792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Johnson&#160;&amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of the Company and Business Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has approximately 141,700&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is organized into three business segments: Consumer Health, Pharmaceutical and Medical Devices. The Consumer Health segment includes a broad range of products used in the Baby Care, Oral Care, Skin Health/Beauty, Over-the-Counter pharmaceutical, Women&#8217;s Health and Wound Care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on six therapeutic areas, including Immunology, Infectious diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The Medical Devices segment includes a broad range of products used in the Orthopaedic, Surgery, Interventional Solutions (cardiovascular and neurovascular) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company announced its intention to separate the Company&#8217;s Consumer Health business, with the intention to create a new, publicly traded company. The Company is targeting completion of the planned separation in 18 to 24 months after initial announcement.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in fiscal 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Adopted as of January 2, 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. There were no new material accounting standards issued in fiscal 2021 that impacted the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASU 2021-01: Reference Rate Reform </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In mid- 2017, the Financial Conduct Authority (FCA) announced that it will no longer require banks to submit rates for the London Interbank Offered Rate (LIBOR) after 2021 hence market participants should work to transition to alternative reference rates (Reference Rate Reform) and should not rely on LIBOR being available after the end of 2021. Reference rate reform is the term used to refer to the efforts that have been undertaken by regulators and other market participants to introduce new reference rates that are based on a larger and more liquid population of observable transactions. The Company evaluated the implications of reference rate reform and applicable financial reporting guidance in ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting on its key financial and commercial contracts that referenced LIBOR including any hedging relationships. Most contracts reviewed will mature prior to the termination of LIBOR or will be modified to apply a new reference rate (primarily the Secured Overnight Financing Rate &#8220;SOFR&#8221; where applicable). The company also applied available practical expedients under ASC 848 to in scope financial and commercial contracts that previously referenced LIBOR when applicable. As a result, the Company's implementation of any reference rate reform provisions to commercial and financial contracts did not result in any material change for the Company.  </span><span style="color:#1f3864;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at least an investment grade credit rating.  The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value.  The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.&#160;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment and Depreciation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:86.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;- 30&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;- 20&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;- 13&#160;years</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8&#160;years.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#8217;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Managed Care, Medicare and Medicaid programs, which amounted to $7.7 billion and $7.2 billion as of January&#160;2, 2022 and January&#160;3, 2021, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#8217;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#8217;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years&#160;2021,&#160;2020&#160;and&#160;2019.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. For all years presented, profit-share payments were less than 3.0% of the total revenues and are included in sales to customers.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs incurred were $1.1 billion, $1.0 billion and $1.0 billion in fiscal years 2021, 2020 and 2019, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2021 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions.  See Note&#160;5 for further details on Intangible Assets and Goodwill.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value.  Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#8217;s impact on the Company&#8217;s financial performance; (2)&#160;protect the Company&#8217;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTI0_2cce01d2-b420-436a-93e5-bea5f12e0c78"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTI0_dee6b310-adcd-43bf-a063-cd1559b71416">Other assets</span></span>, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODU5_5e9c1949-8e21-4631-bf9f-ba8181485230"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTM2_2dbaf7d6-873f-4b21-881f-1b610527d361">Accrued liabilities</span></span>, and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODgz_5fa03461-5e24-4b61-b8c9-f2468f3220fb"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODgz_8dab58da-7c04-4417-a1bc-72271f9a3a36">Other liabilities</span></span> on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $0.9&#160;billion and $1.0&#160;billion in 2021 and 2020, respectively. The lease liability was $1.0&#160;billion and $1.1&#160;billion in 2021and 2020, respectively. The operating lease costs were $0.3&#160;billion, $0.3&#160;billion and $0.3&#160;billion in 2021, 2020 and 2019, respectively. Cash paid for amounts included in the measurement of lease liabilities were $0.3&#160;billion, $0.3&#160;billion and $0.3&#160;billion in 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Product Liability</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development.  Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product.  Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#8217;s operations. In general, the income statement presentation for these collaborations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:48.533%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nature/Type of Collaboration</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Earnings Presentation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third-party sale of product &amp; profit share payments received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to customers</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties/milestones paid to collaborative partner (post-regulatory approval)*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties received from collaborative partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payments&#160;&amp; milestones paid to collaborative partner (pre-regulatory approval)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development payments to collaborative partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development payments received from collaborative partner or government entity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:0.1%"/><td style="width:1.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, co-developed with Bayer HealthCare AG and IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, licensed from Genmab A/S.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $2.7 billion, $2.1 billion and $2.2 billion in fiscal years 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2021 was approximately $6.9&#160;billion, of which $6.1&#160;billion is classified as noncurrent and reflected as &#8220;Long-term taxes payable&#8221; on the Company&#8217;s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI).  GILTI is described as the excess of a U.S. shareholder&#8217;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#8220;period cost&#8221;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., &#8220;deferred method&#8221;). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $0.7 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">See Note 8 to the Consolidated Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">for further information regarding income taxes.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Earnings Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of January 2, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#8217;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the fiscal year ended January 2, 2022, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Closing Date</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167153160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Current Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash, Cash Equivalents and Current Marketable Securities</a></td>
<td class="text">Cash, Cash Equivalents and Current Marketable Securities<div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the fiscal year 2021 and 2020, cash, cash equivalents and current marketable securities were comprised of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.615%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.690%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Loss</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Subtotal </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Sovereign Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Subtotal available for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,487</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Gain</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Subtotal </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gov't Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Sovereign Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Subtotal available for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,985</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale debt securities at January&#160;2, 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"/><td style="width:43.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,731&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,727&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167110360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2021 and 2020, inventories were comprised of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"/><td style="width:66.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740166983784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property, Plant and Equipment<div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2021 and 2020, property, plant and equipment at cost and accumulated depreciation were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:67.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.307%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,962</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,766</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in fiscal years 2021, 2020 and 2019 was $49 million, $63 million and $70 million, respectively.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense, including the amortization of capitalized interest in fiscal years 2021, 2020 and 2019 was $2.7 billion, $2.6 billion and $2.5 billion, respectively. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167028920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text">Intangible Assets and Goodwill<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2021 and 2020, the gross and net amounts of intangible assets were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks&#160;&#8212; gross</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,618)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks&#160;&#8212; net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,372</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,011&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,898&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,925)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,912)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,086</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,822</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,044</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets&#160;&#8212; net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,392</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53,402</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In fiscal 2021, the Company recorded a partial IPR&amp;D impairment charge of $0.9&#160;billion primarily related to expected development delays in the general surgery digital robotics platform (Ottava) acquired with the Auris Health acquisition in 2019. The impairment charge was calculated based on revisions to the discounted cash flow valuation model reflecting a delay of first in human procedures of approximately two years from the initial acquisition model assumption of the second half of 2022. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of January&#160;2, 2022 and January&#160;3, 2021, as allocated by segment of business, was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:33.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical Devices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,734&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,336&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,009&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,048&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,393&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to divestitures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,810</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,580</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,856</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable assets included in Cost of products sold was $4.7 billion, $4.7 billion and $4.5 billion before tax, for the fiscal years ended January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019, respectively. Intangible asset write-downs are included in Other (income) expense, net.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"/><td style="width:18.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.910%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167039544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements.  As of January&#160;2, 2022, the total amount of cash collateral paid by the Company under the CSA amounted to $570 million net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of January&#160;2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.8 billion, $37.4 billion and $10.0 billion, respectively. As of January&#160;3, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $37.8 billion and  $30.6 billion, respectively.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings.&#160;Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedge are accounted through the currency translation account within accumulated other comprehensive income.&#160;The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of January&#160;2, 2022, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $336 million&#160;after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note&#160;13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedges. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021, net of tax:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income) Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 2, 2022 and January 3, 2021, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:30.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:37.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.532%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following table is the effect of net investment hedges for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:20.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.621%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.032%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)           Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense<br/></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company measures equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:25.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales/ Purchases/Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:25.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.505%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales/ Purchases/Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021 for equity investments without readily determinable market values, $28 million and $76 million, respectively, of the changes in fair value reflected in net income were the result of impairments. There were offsetting impacts of  $422 million and $21 million, respectively, of changes in fair value reflected in net income due to changes in observable prices and gains on the disposal of investments. The impact in fiscal 2021 was driven by the gain on disposal of the Grail investment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability.  In accordance with ASC 820, a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S.&#160;Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level&#160;1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following three levels of inputs are used to measure fair value:</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#160;&#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#160;&#8212; Significant other observable inputs.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#160;&#8212; Significant unobservable inputs.</span></div><div style="margin-top:7pt"><span><br/></span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of the fiscal year ended January&#160;2, 2022 and January&#160;3, 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.218%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,089</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,860</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,860</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Available For Sale Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.409%"><tr><td style="width:1.0%"/><td style="width:53.627%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.695%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2020 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $1,481 million, which are classified as Level&#160;1 and contingent consideration of $633 million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes cross currency interest rate swaps and interest rate swaps.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Classified as non-current other assets.  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Classified as cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes $520 million, $594 million and $1,631 million, classified as non-current other liabilities as of January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019, respectively. Includes $13 million, $39&#160;million and $84&#160;million classified as current liabilities as of January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019, respectively.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt">Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense.  The Company recorded a contingent consideration reversal of $1,148&#160;million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes&#160;2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167502232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term debt are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.289%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Rate %</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Rate %</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65% Notes due 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.250% Notes due 2022                                                        (1B Euro 1.1311)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(1B Euro 1.2281)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% Notes due 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73%&#160;Debentures due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Notes due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.650% Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(750MM Euro 1.1311)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(750MM Euro 1.2281)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50%&#160;Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(500MM 1.3485 GBP )</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(500MM GBP 1.3654)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.150% Notes due 2028                                                (750MM Euro 1.1311)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(750MM Euro 1.2281)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95%&#160;Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95%&#160;Debentures due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% Notes due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.650% Notes due 2035                                                     (1.5B Euro 1.1311)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(1.5B Euro 1.2281)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2036</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95%&#160;Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85%&#160;Debentures due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.400%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%&#160;Debentures due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% Notes due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85% Notes due 2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Notes due 2043</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% Notes due 2046</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Notes due 2047</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.500% Notes due 2048</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.250% Notes due 2050</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.450% Notes due 2060</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,116</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,985</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,635</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Weighted average effective rate.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Translation rate at January&#160;2, 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Translation rate at January&#160;3, 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The excess of the fair value over the carrying value of debt was $3.2 billion at the end of fiscal year 2021 and $5.4 billion at the end of fiscal year 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has access to substantial sources of funds at numerous banks worldwide. In September 2021, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10 billion, which expires on September&#160;8, 2022. Interest charged on borrowings under the credit line agreement is based on either the Term SOFR Reference Rate or other applicable market rates as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreements are not material.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Throughout fiscal years 2021 and 2020, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $3.8 billion and $2.6 billion at the end of fiscal years 2021 and 2020, respectively. The current portion of the long term debt was $2.1 billion and $1.8 billion in 2021 and 2020, respectively, and the remainder is commercial paper and local borrowing by international subsidiaries. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The current debt balance as of January&#160;2, 2022 includes $1.6&#160;billion of commercial paper which has a weighted average interest rate of 0.11% and a weighted average maturity of approximately three months.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate maturities of long-term debt obligations commencing in 2022 are:</span></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"/><td style="width:15.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.879%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.882%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">After 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,189</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740166992136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for taxes on income consists of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"/><td style="width:50.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.003%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currently payable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total currently payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,065)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,079)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,476)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Provision for taxes on income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,783</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A comparison of income tax expense at the U.S.&#160;statutory rate of 21% in fiscal years 2021, 2020 and 2019, to the Company&#8217;s effective tax rate is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:48.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,312&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,543&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes on income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,776&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rates:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes on international income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefits from loss on capital assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefits on share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TCJA and related impacts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflects the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2021 amounts include the reorganization of international subsidiaries; the 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. The 2021 amounts include the reorganization of international subsidiaries; the 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, both of which is further described below. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Represents impact of adjustments to balances originally recorded as part of the 2017 TCJA provisional tax charge. Further information provided below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fiscal year 2021 tax rate decreased by 2.5% compared to the fiscal year 2020 tax rate, which was primarily driven by the following items. In fiscal year 2021, the Company reorganized the ownership structure of certain wholly-owned international subsidiaries. As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with applicable local regulations. The net impact of this restructuring was approximately $0.6&#160;billion net benefit or 2.7% benefit to the Company&#8217;s annual effective tax rate, comprised of the following items: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $2.3&#160;billion of local deferred tax assets to record the remeasurement of the tax basis of these assets to fair value, this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $1.7&#160;billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of these deferred tax assets. This expense has been reflected as &#8220;U.S. tax on international income&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Also, in the fiscal fourth quarter of 2021, the Company recognized a loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2021 tax rate by approximately 1.3% which is reflected as a &#8220;Tax benefits from loss on capital assets&#8221; on the effective tax rate reconciliation. Additionally other fiscal 2021 impacts to the rate were primarily driven by litigation and acquisition related items as follows:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company accrued additional legal expenses, of approximately $1.6&#160;billion for talc at an effective tax rate of 23.5% and $0.8&#160;billion for Risperdal settlements at an effective tax rate of 16.4% (See Note 19 to the Consolidated Financial Statements for more details).</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company recorded a partial IPR&amp;D charge of $0.9&#160;billion for the Ottava intangible asset (acquired with the Auris Health acquisition in 2019) at an effective rate of 22.4% (See Notes 5 and 18 to the Consolidated Financial Statements for more details).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The fiscal year 2020 tax rate decreased by 1.9% compared to the fiscal year 2019 tax rate. which was primarily driven by the following items. In fiscal year 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF) which became effective on January 1, 2020. The Federal transitional provisions of TRAF allow companies, under certain conditions, to adjust the tax basis in certain assets to fair value (i.e., &#8220;step-up&#8221;) to be depreciated and amortized resulting in an incremental Swiss tax deduction over the transitional period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">TRAF also provides for parameters which enable the Swiss cantons to establish localized tax rates and regulations for companies. The new cantonal tax parameters include favorable tax benefits for patents and additional research and development </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">tax deductions. The cantonal transitional provisions of TRAF allowed companies to elect either 1) tax basis step-up similar to the Federal transition benefit or 2) alternative statutory tax rate for a period not to exceed 5 years. The Company currently has operations located in various Swiss cantons. During the fiscal year 2019, as described in further detail below, the Company recorded the impacts of the TRAF that were enacted in that period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">During the fiscal year 2020, the final canton where the Company maintains significant operations enacted TRAF legislation. Additionally, the Company received rulings from the Swiss Federal and cantonal tax authorities in the remaining jurisdictions where it has significant operations. These rulings resulted in the Company revising its estimate on the tax basis adjustment (i.e., &#8220;step-up&#8221;) for its assets and as a result, the Company recorded additional deferred tax benefits in 2020. The Company recognized a net benefit in the fiscal year 2020 for Swiss Tax Reform of approximately $0.4&#160;billion or 2.6% benefit to the Company&#8217;s annual effective tax rate, comprised of the following items: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $0.3 billion tax benefit relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred in the fiscal year 2020; this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $450 million deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company&#8217;s Swiss subsidiaries&#8217; assets as described above; this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $0.3 billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities in the fiscal year 2020. This benefit has been reflected as &#8220;U.S. tax on international income&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company does not expect to receive future rulings regarding the transitional provisions of TRAF. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Also, in the fiscal year 2020, the Company recognized a capital loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2020 tax rate by approximately 1.2% which is reflected as a &#8220;Tax benefits from loss on capital assets&#8221; on the effective tax rate reconciliation. In addition, in the fiscal year 2020, the Company had lower income in higher tax jurisdictions, primarily driven by:       </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the accrual of litigation costs related to talc for $4.0&#160;billion which reduced the U.S. earnings before taxes at an effective tax rate of 23.5%;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accrual of additional legal costs, including an additional $1.0&#160;billion associated with a revised agreement in principle to settle opioid litigation at an effective tax rate of 21.4% </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also reduced the contingent consideration liability related to the Auris Health acquisition (see Note 18) and reversed of some of its unrecognized tax benefits due to the completion of several years of tax examinations in certain jurisdictions during the fiscal year 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In fiscal year 2019, the Company reorganized the ownership structure of certain wholly-owned international subsidiaries in the fiscal fourth quarter of 2019, which resulted in a reduction of certain withholding and local taxes that it had previously recognized as part of the provisional Tax Cuts and Jobs Act (TCJA) tax charge in the fiscal year 2017 and finalized in the fiscal year 2018. Following the completion of this restructuring and approval by the applicable local authorities, the Company reversed a deferred tax liability of  $0.6 billion and a related deferred tax asset of $0.2 billion for U.S. foreign tax credits, for a net deferred tax benefit of $0.4 billion decreasing the annual effective tax rate by 2.2%. This benefit has been reflected as &#8220;TCJA and related impacts&#8221; on the Company&#8217;s effective tax rate reconciliation. The following items also impacted the fiscal year 2019 effective tax rate: </span></div><div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of the agreement in principle to settle opioid litigation for $4 billion (see Note 19 to the Consolidated Financial Statements) which reduced the U.S. earnings before taxes at an effective tax rate of 23.5% and decreased the Company&#8217;s annual effective tax rate by approximately 2.1%. </span></div><div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December of fiscal year 2019, the U.S. Treasury issued final foreign tax credit regulations, which resulted in the Company revising the amount of foreign tax credits that were initially recorded in the fiscal year 2017 as part of the provisional TCJA tax charge. As a result, the Company recorded an increased deferred tax asset related to these foreign tax credits of approximately $0.3 billion or 1.7% to the annual effective tax rate.  This benefit has been reflected as &#8220;TCJA and related impacts&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company reassessed its uncertain tax positions related to the current IRS audit and increased its unrecognized tax benefit by $0.3 billion liability which increased the annual effective tax rate by approximately 1.5% (see section on Unrecognized Tax Benefits for additional information). As these positions were related to uncertain tax regarding international transfer pricing, this expense has been classified as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described above for the Swiss tax legislation, in the fiscal year 2019, the Company recorded a net tax expense of $0.1&#160;billion which increased the effective tax rate for the fiscal year 2019 by approximately 0.6%. This net tax expense related to federal and certain cantonal enactments in the fiscal year 2019 consisting of the following provisions:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $0.6&#160;billion tax expense relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred by December 29, 2019; this expense has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $0.9&#160;billion deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company&#8217;s Swiss subsidiaries&#8217; assets; this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $450&#160;million of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities and the new deferred tax asset for the Federal step-up. This benefit has been reflected as &#8220;U.S. tax on international income&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-right:4.5pt"><span><br/></span></div><div style="margin-bottom:9.9pt;margin-top:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Temporary differences and carryforwards at the end of fiscal years 2021 and 2020 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 Deferred Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Deferred Tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation of property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(823)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,659)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,023)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D capitalized for tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves&#160;&amp; liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income reported for tax purposes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realizable operating loss carryforward</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undistributed foreign earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global intangible low-taxed income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,853)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous international</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,624</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,888)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,477</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,157)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount is inclusive of the $2.3&#160;billion deferred tax asset established as part of the reorganized ownership structure of certain wholly-owned international subsidiaries, as previously described. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has wholly-owned international subsidiaries that have cumulative net losses. The Company believes that it is more likely than not that these subsidiaries will generate future taxable income sufficient to utilize these deferred tax assets. However, in certain jurisdictions, valuation allowances have been recorded against deferred tax assets for loss carryforwards that are not more likely than not to be realized. Such valuation allowances are not material.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to unrecognized tax benefits:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"/><td style="width:50.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.495%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to prior period tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to prior period tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(839)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,323</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,373</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,853</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The unrecognized tax benefits of $3.3 billion at January&#160;2, 2022, if recognized, would affect the Company&#8217;s annual effective tax rate. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. In the fiscal year 2020, the Company made its final payments for approximately$0.7 billion to the U.S. Treasury related to the final settlement of 2010-2012 tax audit liability.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities, except as previously noted on amounts related to the current United States IRS audit. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $44 million, $32 million and $50 million in fiscal years 2021, 2020 and 2019, respectively. The total amount of accrued interest was $512&#160;million and $468 million in fiscal years 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167111480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Related Obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsGeneralTextBlock', window );">Employee Related Obligations</a></td>
<td class="text">Employee Related Obligations<div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal 2021 and fiscal 2020, employee related obligations recorded on the Consolidated Balance Sheets were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postretirement benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postemployment benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total employee obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current benefits payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations&#160;&#8212; non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,771</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid employee related obligations of $4,436 million and $656 million for 2021 and 2020, respectively, are included in Other assets on the Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsGeneralTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items.  Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6409950&amp;loc=d3e20396-108366<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsGeneralTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740166985064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pensions and Other Benefit Plans</a></td>
<td class="text">Pensions and Other Benefit Plans<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily healthcare, to all eligible U.S.&#160;retired employees and their dependents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many international employees are covered by government-sponsored programs and the cost to the Company is not significant.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S, non-union pension benefits for employees hired before January 1, 2015 are primarily based on the employee&#8217;s compensation during the last five years before retirement and the number of years of service (the Final Average Pay formula). U.S. pension benefits for employees hired after 2014, are calculated using a different formula based on employee compensation over total years of service (the Retirement Value formula).</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees,</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accrued under the Final Average Pay formula for service before January 1, 2026. The impact of this change decreases the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projected Benefit Obligation as of January 3, 2021 by approximately $1.8&#160;billion and is included in the &#8220;Amendments&#8221; line in the Change in Benefit Obligation.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not fund retiree healthcare benefits in advance and has the right to modify these plans in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 and 2020 the Company used December 31, 2021 and December 31, 2020, respectively, as the measurement date for all U.S.&#160;and international retirement and other benefit plans.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans for 2021, 2020 and 2019 include the following components:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">623</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">593</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">503</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">524</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized gains and losses for the U.S.&#160;pension plans are amortized over the average remaining future service for each plan.  For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S.&#160;benefit plans is determined by using a 10% corridor of the greater of the market value of assets or the accumulated postretirement benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior service costs/benefits for the U.S.&#160;pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S.&#160;benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average actuarial assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:39.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Worldwide Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Periodic Benefit Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.63&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.45&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of increase in compensation levels</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.39&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of increase in compensation levels</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. The Company's methodology in determining service and interest cost uses duration specific spot rates along that yield curve to the plans' liability cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the assumed healthcare cost trend rates, for all individuals:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"/><td style="width:71.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.946%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Healthcare Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare cost trend rate assumed for next year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline (ultimate trend)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year the rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2046&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2021 and 2020 for the Company&#8217;s defined benefit retirement plans and other post-retirement plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation&#160;&#8212; beginning of year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,300&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,188&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,076&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains) losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures&#160;&amp; acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments, settlements&#160;&amp; restructuring</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid from plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,582</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,878</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value&#160;&#8212; beginning of year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,195&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,201&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures&#160;&amp; acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid from plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(574)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,930</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status &#8212; end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,105)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,776)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,938)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(438)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,105)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,776)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,938)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,860&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,797)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net transition obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax effects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,929</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,419</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligations&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,356</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The actuarial gain for retirement plans in 2021 was primarily related to increases in discount rates; the actuarial losses for retirement plans in 2020 were primarily related to decreases in discount rates.</span></div></td></tr></table><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">623</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">503</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">524</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial (gain) loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,927)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,616&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (cost) credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total loss/(income) recognized in other comprehensive income, before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,134)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(319)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(191)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in net periodic benefit cost and other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,511)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company contributed $102 million and $867 million to its U.S.&#160;and international pension plans, respectively.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the funded status of the Company's U.S. Qualified &amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2021 and December&#160;31, 2020, respectively:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:25.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plans</span></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Qualified Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Qualified Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unfunded Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Benefit Obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Benefit Obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over (Under) Funded Status</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Benefit Obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,703)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,748)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,900)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Benefit Obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,479)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(569)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(493)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $3.9 billion, $4.2 billion and $0.3 billion, respectively, at the end of 2021, and $8.8 billion, $9.8 billion and $4.4 billion, respectively, at the end of 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the projected future benefit payments from the Company&#8217;s retirement and other benefit plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:35.089%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027-2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected future benefit payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other benefit plans&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the projected future minimum contributions to the unfunded retirement plans.  These amounts do not include any discretionary contributions that the Company may elect to make in the future.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:35.089%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027-2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected future contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company&#8217;s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s retirement plan asset allocation at the end of 2021 and 2020 and target allocations for 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:58.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.755%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent of<br/>Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Target<br/>Allocation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Worldwide Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Determination of Fair Value of Plan Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan has an established and well-documented process for determining fair values.  Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation Hierarchy</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       The Net Asset Value (NAV) is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial instrument&#8217;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a description of the valuation methodologies used for the investments measured at fair value.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Short-term investment funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the NAV provided by the administrator of the fund. The NAV is a quoted price in a market that is not active and classified as Level&#160;2.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Government and agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level&#160;1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level&#160;2.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Debt instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level&#160;1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level&#160;2. Level&#160;3 debt instruments are priced based on unobservable inputs.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level&#160;1 of the valuation hierarchy.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commingled funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; These investment vehicles are valued using the NAV provided by the fund administrator. Assets in the Level&#160;2 category have a quoted market price.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Other assets are represented primarily by limited partnerships. These investment vehicles are valued using the NAV provided by the fund administrator. Other assets that are exchange listed and actively traded are classified as Level&#160;1, while inactively traded assets are classified as Level&#160;2. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2021 and December&#160;31, 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:18.235%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.161%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government and agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investments at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,086</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">181</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,515</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,092</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,930</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The activity for the Level 3 assets is not significant for all years presented.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Other Benefit Plans are unfunded except for U.S.&#160;commingled funds (Level 2) of $102 million and $90 million at December&#160;31, 2021 and December&#160;31, 2020, respectively. </span></div>The fair value of Johnson&#160;&amp; Johnson Common Stock directly held in plan assets was $385 million (0.9% of total plan assets) at December&#160;31, 2021 and $946 million (2.5% of total plan assets) at December&#160;31, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167105512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Savings Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SavingsPlanAbstract', window );"><strong>Savings Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SavingsPlanTextBlock', window );">Savings Plan</a></td>
<td class="text">Savings PlanThe Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee&#8217;s contributions consistent with the provisions of the plan for which he/she is eligible. Total Company matching contributions to the plans were $256 million, $243 million and $235 million in fiscal years 2021, 2020 and 2019, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SavingsPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Savings Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SavingsPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SavingsPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Savings Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SavingsPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167134984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital and Treasury Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">Capital and Treasury Stock</a></td>
<td class="text">Capital and Treasury Stock<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in treasury stock were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in Millions Except Treasury Stock Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,362&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,053)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,691)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,336&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,417&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,847)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,099&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate shares of common stock issued were approximately 3,119,843,000&#160;shares at the end of fiscal years 2021, 2020 and 2019.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash dividends paid were $4.19 per share in fiscal year 2021, compared with dividends of $3.98 per share in fiscal year 2020, and $3.75 per share in fiscal year 2019. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2022, the Board of Directors declared a regular cash dividend of $1.06 per share, payable on March 8, 2022 to shareholders of record as of February 22, 2022.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2018, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's shares of common stock. This share repurchase program was completed as of September 29, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208821<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167490232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">Accumulated Other Comprehensive Income (Loss)<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign<br/>Currency Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss) On Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/<br/>(Loss) On<br/>Derivatives &amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,869)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,158)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,222)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2019 changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(733)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(669)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,705)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,891)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,891)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2020 changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,938)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,957)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,242)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2021 changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,079)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,017)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,702)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,058)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details.</span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction.  See Note 6 for additional details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167475368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>International Currency Translation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTranslationAbstract', window );"><strong>Foreign Currency Translation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDisclosureTextBlock', window );">International Currency Transalation</a></td>
<td class="text">International Currency Translation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For translation of its subsidiaries operating in non-U.S.&#160;Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency. For the majority of the Company's subsidiaries the local currency is the functional currency. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. The other current and non-current assets line within the Statement of Cash flows includes the impact of foreign currency translation. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies, (Argentina and Venezuela). The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the changes during fiscal years 2021, 2020 and 2019 for foreign currency translation adjustments is included in Note&#160;13. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net currency transaction gains and losses included in Other (income) expense were losses of $236 million, $209 million and $267 million in fiscal years 2021, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30885-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTranslationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTranslationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167215976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions Except Per Share Amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding&#160;&#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,645.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted average shares outstanding&#160;&#8212; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.81&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.63&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The diluted net earnings per share calculation for fiscal year 2021 included all shares related to stock options, as the exercise price of these options was less than the average market value of the Company's stock. As of January 2, 2022, the Company did not have convertible debt. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The diluted net earnings per share calculation for fiscal year 2020 excluded 18 million shares related to stock options, as the exercise price of these options was greater than the average market value of the Company's stock. As of January 3, 2021, the Company did not have convertible debt. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The diluted net earnings per share calculation for fiscal year 2019 excluded an insignificant number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company&#8217;s stock. The diluted net earnings per share calculation for fiscal year 2019 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense of $1 million after-tax.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167471512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Common Stock, Stock Option Plans and Stock Compensation Agreements</a></td>
<td class="text">Common Stock, Stock Option Plans and Stock Compensation Agreements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January&#160;2, 2022, the Company had 2 stock-based compensation plans. The shares outstanding are for contracts under the Company's 2005 Long-Term Incentive Plan and the 2012 Long-Term Incentive Plan. The 2005 Long-Term Incentive Plan expired April 26, 2012. All options and restricted shares granted subsequent to that date were under the 2012 Long-Term Incentive Plan. Under the 2012 Long-Term Incentive Plan, the Company may issue up to 650 million shares of common stock, plus any shares canceled, expired, forfeited, or not issued from the 2005 Long-Term Incentive Plan subsequent to April 26, 2012. Shares available for future grants under the 2012 Long-Term Incentive Plan were 240 million at the end of fiscal year 2021.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation cost that has been charged against income for these plans was $1,135 million, $1,005 million and $977 million for fiscal years 2021, 2020 and 2019, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $218 million, $210 million and $227 million for fiscal years 2021, 2020 and 2019, respectively. The Company also recognized additional income tax benefits of $223&#160;million, $248&#160;million and $209&#160;million for fiscal years 2021, 2020 and 2019, respectively, for which options were exercised or restricted shares were vested. The total unrecognized compensation cost was $862 million, $804 million and $823 million for fiscal years 2021, 2020 and 2019, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively.  The weighted average period for this cost to be recognized was 1.78&#160;years, 1.76&#160;years and 1.71&#160;years for fiscal years 2021, 2020, and 2019, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished through market purchases throughout the year for the number of shares used to settle employee benefit equity issuances. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options expire 10&#160;years from the date of grant and vest over service periods that range from 6 months to 4 years.  All options are granted at the average of the high and low prices of the Company&#8217;s Common Stock on the New York Stock Exchange on the date of grant. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. For 2021, 2020 and 2019 grants, expected volatility represents a blended rate of 10-year weekly historical overall volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson&#160;&amp; Johnson options with a life of 2&#160;years. For all grants, historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S.&#160;Treasury yield curve in effect at the time of grant.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average fair value of options granted was $20.86, $16.42 and $17.80, in fiscal years 2021, 2020 and 2019, respectively.  The fair value was estimated based on the weighted average assumptions of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:56.819%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the Plan as of January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019, and changes during the years ending on those dates is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"/><td style="width:47.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(Dollars in Millions) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,975)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">117,361</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,364</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was $919 million, $1,021 million and $807 million in fiscal years 2021, 2020 and 2019, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock options outstanding and exercisable at January&#160;2, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:29.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.168%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price Range</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$65.08-$90.44</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$81.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$81.92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.06-$101.87</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$101.07</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$101.07</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$115.67-$129.51</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$122.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$122.43</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$131.94-$151.41</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$142.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$140.72</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$151.42-$164.62</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$164.62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$164.62</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">117,361</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$125.36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62,742</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$104.42</span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Average contractual life remaining in years.</span></div><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding at January&#160;3, 2021 and December&#160;29, 2019 were 114,250 and an average life of 6.0 years and 111,637 and an average life of 6.0&#160;years, respectively. Stock options exercisable at January&#160;3, 2021 and December&#160;29, 2019 were 61,289 at an average price of $96.97 and 60,761 at an average price of $88.88, respectively. </span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Share Units and Performance Share Units</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company grants restricted share units which vest over service periods that range from 6 months to 3 years. The Company also grants performance share units, which are paid in shares of Johnson &amp; Johnson Common Stock after the end of a three-year performance period. Whether any performance share units vest, and the amount that does vest, is tied to the completion of service periods that range from 6 months to 3 years and the achievement, over a three-year period, of three equally-weighted goals that directly align with or help drive long-term total shareholder return: operational sales, adjusted operational earnings per share, and relative total shareholder return. Beginning in fiscal 2020, performance shares were granted with two equally-weighted goals that directly align with or help drive long-term total shareholder return: adjusted operational earnings per share and relative total shareholder return. The number of shares actually earned at the end of the three-year period will vary, based only on actual performance, from 0% to 200% of the target number of performance share units granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the restricted share units and performance share units activity under the Plans as of January&#160;2, 2022 is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"/><td style="width:55.231%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.611%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.032%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Performance Share Units</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited/adjusted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,122&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average fair value of the restricted share units granted was $152.62, $139.58 and $121.31 in fiscal years 2021, 2020 and 2019, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $611 million, $650 million and $586 million in 2021, 2020 and 2019, respectively.</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value of the performance share units granted was $179.35, $160.54 and $124.67 in fiscal years 2021, 2020 and 2019, calculated using the weighted average fair market value for each of the component goals at the date of grant.&#160; </span></div>The fair values for the sales and earnings per share goals of each performance share unit were estimated on the date of grant using the fair market value of the shares at the time of the award discounted for dividends, which are not paid on the performance share units during the vesting period.&#160;The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model.&#160;The fair value of performance share units issued was $83 million, $91 million and $119 million in fiscal years 2021, 2020 and 2019, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167102920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments of Business and Geographic Areas</a></td>
<td class="text">Segments of Business* and Geographic Areas<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217;21 vs. &#8217;20</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217;20 vs. &#8217;19</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:189pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / rilpivirine</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> /                                              </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / methylphenidate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* *</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* *</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:57pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**Percentage greater than 100% or not meaningful</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (Loss) Before Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,064)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,848&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,163&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,829&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,091&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,776</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,497</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">182,018</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174,894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions to Property,<br/>Plant &amp; Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation and<br/>Amortization</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segments total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,074&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,689&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,652</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,347</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,498</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,390</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,231</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-Lived Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere excluding U.S.&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segments total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non long-lived assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93,775</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,584</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">182,018</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174,894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;1 for a description of the segments in which the Company operates. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Export sales are not significant. In fiscal year 2021, the Company utilized three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0% and 11.0% of the total consolidated revenues. In fiscal year 2020, the Company had three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0% and 12.0% of the total consolidated revenues. In fiscal year 2019, the Company had three wholesalers distributing products for all three segments that represented approximately 15.0%, 12.0%, and 11.0% of the total consolidated revenues. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">General corporate includes cash, cash equivalents and marketable securities.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $1.6&#160;billion, primarily talc related reserves</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.1&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.6&#160;billion, primarily related to Risperdal </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Divestiture gains of $0.6&#160;billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Gains on securities of $0.5&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.1&#160;billion </span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.3&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $0.9&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A Medical Device Regulation charge of $0.2&#160;billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.1&#160;billion </span></div><div style="margin-top:3pt;padding-left:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $3.9&#160;billion, primarily talc related reserves and certain settlements.</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.8&#160;billion, primarily related to the agreement in principle to settle opioid litigation </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An unrealized gain on securities of $0.5&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.1&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A contingent consideration reversal of $1.1&#160;billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.3&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.3&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $0.2&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A Medical Device Regulation charge of $0.1&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.4 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.1 billion </span></div><div style="margin-top:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $4.3 billion of which $4.0 billion is related to the agreement in principle to settle opioid litigation</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $0.9 billion related to the Alios asset</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A research and development expense of $0.3 billion for an upfront payment related to argenx </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An unrealized gain on securities of $0.6 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Actelion acquisition and integration related costs of $0.2 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring charge of $0.1 billion</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Medical Devices includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $2.0 billion from the divestiture of the ASP business</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.4 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.4 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Auris Health acquisition and integration related costs of $0.1 billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Long-lived assets include property, plant and equipment, net for fiscal years 2021, and 2020 of $18,962 and $18,766, respectively, and intangible assets and goodwill, net for fiscal years 2021 and 2020 of $81,638 and $89,795, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167109800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions and Divestitures</a></td>
<td class="text">Acquisitions and Divestitures<div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During fiscal year 2021, the Company did not make any material acquisitions. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During fiscal year 2020, certain businesses were acquired for $7.3&#160;billion in cash and $0.4&#160;billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $7.5&#160;billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fiscal year 2020 acquisitions primarily included: all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc. (XBiotech), Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases and the outstanding shares in Verb Surgical Inc., a company with significant  robotics and data science capabilities.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $0.8&#160;billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $0.8&#160;billion applying a probability of success factor that ranged from 20% to  60% to reflect inherent development, regulatory and commercial risk for the different indications. The discount rate applied was approximately 16%.  XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. On January 28, 2022, subsequent to the fiscal year 2021, additional information regarding efficacy became available which led the Company to the decision to terminate the development of bermekimab for Atopic Dermatitis (AD). The Company recorded an intangible asset impairment charge of approximately $0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of AD and Hidradenitis Suppurativa (HS). The impairment charge is related to the AD indication and is a nonrecognized subsequent event and will be reflected in the first quarter 2022 financial statements. The Company acquired all rights to bermekimab from XBiotech, Inc. in fiscal year 2020.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in the fiscal first quarter of 2020, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with significant robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the Medical Devices segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $0.4&#160;billion, goodwill for $0.2&#160;billion, other assets of $0.2&#160;billion and liabilities assumed of $0.3&#160;billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $0.4&#160;billion. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 1, 2020, the Company completed the acquisition of Momenta for a purchase price of approximately $6.1&#160;billion, net of cash acquired. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets (IPR&amp;D) of $6.0&#160;billion, goodwill of $1.2&#160;billion, other assets of $0.5&#160;billion and liabilities of $1.6&#160;billion. The assets acquired are intended to address substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Depending on the asset, probability of success factors ranging from 20% to 77% were used in the fair value calculation to reflect inherent development and regulatory risk of the IPR&amp;D. The discount rate applied was approximately 13%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. The transaction was accounted for as a business combination and included in the Pharmaceutical segment.                   </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2019 certain businesses were acquired for $5.8 billion in cash and $1.4 billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $6.8&#160;billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fiscal year 2019 acquisitions primarily included DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products and Auris Health, Inc. a </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">privately held developer of robotic technologies, initially focused in lung cancer, with an U.S. FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 17, 2019, the Company acquired DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products for a total purchase price of approximately &#165;230 billion, which equates to approximately $2.1 billion, using the exchange rate of 109.06 Japanese Yen to each U.S. Dollar on January 16, 2019. Additionally, in the fiscal first quarter of 2019, the Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company treated this transaction as a business combination and included it in the Consumer Health segment.  During the fiscal first quarter of 2020, the Company finalized the purchase price allocation. The final fair value of the acquisition was allocated primarily to amortizable intangible assets for $1.5 billion, goodwill for $1.2 billion and liabilities of $0.4 billion. The amortizable intangible assets were comprised of brand/trademarks and customer relationships with a weighted average life of 15.3 years. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 1, 2019 the Company&#160;completed the acquisition of Auris Health, Inc. for approximately $3.4 billion, net of cash acquired. Additional contingent payments of up to $2.35 billion, in the aggregate, may be payable upon reaching certain predetermined milestones. Auris Health was a privately held developer of robotic technologies, initially focused in lung cancer, with a U.S. FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. The Company treated this transaction as a business combination and included it in the Medical Devices segment. The fair value of the acquisition was allocated primarily to amortizable and non-amortizable intangible assets, primarily IPR&amp;D for $3.0 billion, goodwill for $2.0 billion, marketable securities of $0.2 billion and liabilities assumed of $1.8 billion, which includes the fair value of the contingent payments mentioned above. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. During the fiscal second quarter of 2020, the Company finalized the purchase price allocation. During fiscal 2020, the Company recorded Other income of approximately $1.1&#160;billion for the reversal of all of the contingent consideration related to the timing of certain developmental and commercial milestones, which are not expected to be met based on the Company&#8217;s current timelines. During the fiscal third quarter of 2020, the Company recorded a partial IPR&amp;D impairment charge of $0.1&#160;billion related to timing and progression of the digital surgery platforms. In the fiscal third quarter of 2021, the Company recorded a partial IPR&amp;D charge of $0.9&#160;billion primarily related to expected development delays in the general surgery digital robotics platform (Ottava). A probability of success factor ranging from 18% to 66% across Ottava sub-platforms, was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&amp;D. The discount rate applied was approximately 9.5%.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with U.S.&#160;GAAP standards related to business combinations, and goodwill and other intangible assets, supplemental pro forma information for fiscal years 2021, 2020 and 2019 is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company&#8217;s results of operations, cash flows or financial position.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestitures</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During fiscal year 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately  $0.6&#160;billion. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2020, the Company sold 11.8&#160;million shares of Idorsia LTD (Idorsia), or its 8.3% ownership in the company at that time. The transaction resulted in gross proceeds of approximately CHF 337&#160;million ($357&#160;million) based on a sales price of CHF 28.55/share and resulted in an immaterial net loss. At the end of fiscal 2020, the Company had rights to approximately 38.7&#160;million shares through a convertible loan with a principal amount of CHF 445&#160;million (due June 2027). During fiscal year 2021, the Company converted CHF 110&#160;million ($120&#160;million) of this loan into approximately 9.6&#160;million shares of Idorsia which were reflected at fair value as of January 2, 2022. During the fiscal third quarter of 2021, the Company's undrawn credit facility with Idorsia was terminated. </span></div>During fiscal year 2019, the Company divested its ASP business to Fortive Corporation for an aggregate value of approximately $2.8 billion, consisting of $2.7 billion of cash proceeds and $0.1 billion of retained net receivables. The Company recognized a pre-tax gain recorded in Other ( income) expense, net, of approximately $2.0 billion.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740166996472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Proceedings</a></td>
<td class="text">Legal ProceedingsJohnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. Due to the ongoing impacts of the COVID-19 pandemic, certain trials have been rescheduled or delayed. The Company continues to monitor its legal proceedings as the situation evolves and in person trials resume.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of January&#160;2, 2022, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company&#8217;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#8217;s balance sheet, is not expected to have a material adverse effect on the Company&#8217;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#8217;s results of operations and cash flows for that period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PRODUCT LIABILITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The most significant of these cases include: the DePuy ASR&#8482; XL Acetabular System and DePuy ASR&#8482; Hip Resurfacing System; the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Acetabular Cup System; pelvic meshes; RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">; XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">; body powders containing talc, primarily JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Baby Powder; INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">; and ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Flexible Composite Mesh. As of January&#160;2, 2022, in the United States there were approximately 250 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR&#8482; XL Acetabular System and DePuy ASR&#8482; Hip Resurfacing System; 5,300 with respect to the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Acetabular Cup System; 10,100 with respect to pelvic meshes; 8,800 with respect to RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">; 5,500 with respect to XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">; 40,400 with respect to body powders containing talc; 100 with respect to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and 4,700 with respect to ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Flexible Composite Mesh. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> XL Acetabular System and DePuy ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp; Johnson. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000  claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle </span><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the class actions filed in that country</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company continues to receive information with respect to potential additional </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp; Johnson (collectively, DePuy) relating to the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation also has been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System and the related settlement program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson arising out of Ethicon&#8217;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#8217;s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#8217;s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands and class actions in Israel, Australia and Canada. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021, and the High Court heard oral argument on the application in November 2021. Special leave was refused. While this brings an end to the appellate process, there will now be an individual case assessment process for the remaining group member claims. The parties currently are in discussions with the Court to determine the form and mechanism of that individual case assessment process. The next hearing is scheduled for late February 2022. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently negotiating the wording and some of the terms thereof and once finalized, the settlement will be subject to court approval. The parties are due to update the court on the status of the finalization of the settlement negotiations by the end of February 2022. The Company has established accruals with respect to product liability litigation associated with Ethicon&#8217;s pelvic mesh products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. The deadline for issuance of Individual Allocation amounts by the Special Master is March 2022. The costs associated with this proposed settlement are reflected in the Company&#8217;s accruals. Post-Settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of February 2022, there are approximately 90 active cases subject to these orders which are being reviewed and evaluated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">Claims have also been filed against Ethicon and Johnson &amp; Johnson alleging personal injuries arising from the PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"> Mesh and PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"> Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. Discovery is underway in the MCL proceedings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ethicon and Johnson &amp; Johnson also have been subject to claims for personal injuries arising from the PROLENE&#8482; Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Flexible Composite Mesh, PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Mesh and PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Ventral Patch, and PROLENE&#8482; Polypropylene Hernia System products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson arising out of the use of RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury arising out of the use of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp; Johnson; and JPI&#8217;s collaboration partner for XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Bayer Healthcare AG, and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson &amp; Johnson announced an agreement in principle to settle the XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp; Johnson Consumer Inc. and Johnson &amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase through fiscal year 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of  $4.7&#160;billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham v. Johnson &amp; Johnson, et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No. ED 207476 (Mo. App.), reducing the overall award to $2.1&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5&#160;billion. The facts and circumstances, including the terms of the award, were unique to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, Johnson &amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#8217;s direct parent, Johnson &amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#8217;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#8217; compensation statute or act (the Talc-Related Liabilities). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, notwithstanding the Company&#8217;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). As a result of the LTL Bankruptcy Case, the Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, Johnson &amp; Johnson, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court subsequently extended the PI through the end of February 2022. Claimants have filed a motion to dismiss the LTL Bankruptcy Case. The court commenced a hearing on February 14, 2022 regarding the motion to dismiss and on whether the PI should be extended. While the PI effectively stays all of the Company&#8217;s talc-related personal injury litigation, LTL has agreed to lift the automatic stay on a small number of appeals where appeal bonds have been filed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has agreed to provide funding to LTL for the payment of amounts the Bankruptcy Court determines are owed by LTL through the establishment of a $2&#160;billion trust in furtherance of this purpose. The Company has established a reserve for approximately $2&#160;billion in connection with the aforementioned trust. Subsequent to the fiscal third quarter of 2021, the Company de-consolidated LTL, which is a related party, as a result of the bankruptcy filing. The impact of the de-consolidation is not material to the Company. The parties have not yet been able to reach a resolution of all matters related to talc, and while certain amounts under various scenarios have recently been referred to in testimony as part of the LTL bankruptcy proceedings, the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217;s potential liability for personal injury from exposure to talcum powder sold by Imerys (Talc Claims). In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants&#8217; Committee (TCC), and the Future Claimants&#8217; Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent&#8217;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan. The Company challenged certain improprieties with respect to portions of the vote and sought to disqualify those votes. In October 2021, the Bankruptcy Court issued a ruling deeming thousands of votes as withdrawn as improperly voted. In October 2021, Imerys cancelled the confirmation hearing on the Plan. Imerys, the TCC, the FCR, and certain of Imerys&#8217;s insurers (the Mediation Parties) have since agreed to engage in mediation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys adversary proceeding). The Imerys adversary proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company&#8217;s talc liabilities from its other assets. The Bankruptcy Court denied the motion. The Company thereafter filed a motion to dismiss the adversary proceeding. The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Imerys adversary proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2020, Cyprus Mines Corporation and its parent (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus adversary proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan. The Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against Talc Claims asserted against it. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the TCC and FCR appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus adversary proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2021, several of the Company&#8217;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Coverage Action.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2018, a securities class action lawsuit was filed against Johnson &amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Baby Powder, and that purchasers of Johnson &amp; Johnson&#8217;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, the Company answered the complaint. In April 2021, briefing on Plaintiffs&#8217; motion for class certification was completed. In July 2021, the Company filed a notice of supplemental authority in opposition to Plaintiff&#8217;s motion for class certification, and Plaintiff filed a response. In December 2021, the Company filed a motion to supplement the class certification record, and in January 2022, Plaintiff responded. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson &amp; Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. In February 2022, the Court granted Johnson &amp; Johnson's cross motion to dismiss. In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Baby Powder, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2020, a report was delivered to the Company&#8217;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues and demanding that suit be brought against certain Directors. Four of the shareholders who sent demands are plaintiffs in th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp; Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson &amp; Johnson&#8217;s motion to dismiss pending a decision on Plaintiff&#8217;s motion for discovery. In November 2021, at the Court&#8217;s request, the parties submitted supplemental briefing on Plaintiff&#8217;s motion for discovery. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp; Johnson Savings Plan against Johnson &amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp; Johnson stock as a Johnson &amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#8217; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#8217; motion was complete. In February 2021, the Court granted Defendants&#8217; motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice. In May 2021, Plaintiffs filed a notice of appeal with the Third Circuit. In July 2021, Plaintiffs filed their opening brief in the Third Circuit and in September 2021, Defendants filed their response brief, and in October 2021, Plaintiffs filed their reply brief. In January 2022, the Third Circuit heard oral argument.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#8217;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Baby Powder. In that lawsuit, the plaintiffs allege that Johnson &amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#8217;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. In October 2021, Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit. A bankruptcy stay was imposed in December 2021, and the Court held the reply deadline in abeyance.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters, including from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice, the Subcommittee on Economic and Consumer Policy of the House Committee on Oversight and Reform, the Senate </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Committee on the Judiciary, the House Committee on Oversight and Reform, and individual Members of Congress. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases also have been filed in various state courts. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> related product liability litigation.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">INTELLECTUAL PROPERTY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain subsidiaries of Johnson &amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#8217;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medical Devices</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that Acclarent&#8217;s RELIEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Spin and RELIEVEA SpinPlus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> products infringe U.S. Patent No. 9,011,412. Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of Acclarent&#8217;s U.S. Patent No. 8,414,473. Trial began in October 2021, and shortly thereafter, the parties reached an agreement to settle the case. Plaintiff&#8217;s motion to dismiss with prejudice was filed in October 2021. The case was dismissed with prejudice in November 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (&#8217;200); 6,491,701 (&#8217;701); 6,522,906 (&#8217;906); 6,800,056 (&#8217;056); 8,142,447 (&#8217;447); 8,620,473 (&#8217;473); 8,801,601 (&#8217;601); and 9,452,276 (&#8217;276) based on Auris&#8217; Monarch&#8482; Platform. Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the &#8217;200, &#8217;056, &#8217;601 &#8217;701, &#8217;447, &#8217;276 and &#8217;906 patents. Intuitive subsequently dropped the &#8217;200, &#8217;473 and &#8217;701 patents from the suit. In December 2019, the USPTO instituted review of the &#8217;601 patent and denied review of the &#8217;056 patent. In February and March 2020, the USPTO instituted review of the &#8217;200, &#8217;447, &#8217;701 and &#8217;906 patents and denied review of the &#8217;276 patent. In December 2020, the USPTO declared all of the challenged claims in the &#8217;601 patent to be invalid. Intuitive has appealed that decision. In March 2021, the USPTO ruled that the challenged claims of the &#8217;447 and &#8217;906 patents are not invalid. Auris has appealed that decision. Auris filed a request for reexamination of the &#8217;276 patent in November 2021, and in January 2022, the USPTO granted the reexamination request. Trial is scheduled to begin in January 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in the United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 and 9,713,537 by one or more of the following products:  ZERO-P-VA&#8482; Spacer, ZERO-P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Spacer, ZERO-P NATURAL&#8482; Plate, SYNFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> LR Spacer and SYNFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Evolution System. RSB Spine seeks </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. A stay that had been entered pending Inter Partes Review at the U.S. Patent &amp; Trademark Office has been lifted, and trial is scheduled to begin in December 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2020, Osteoplastics, LLC filed a patent infringement suit against DePuy Synthes, Inc., DePuy Synthes Products, Inc., Medical Device Business Services, Inc., and Synthes, Inc. (collectively, DePuy Synthes) in the United States District Court for the District of Delaware. In the suit, Osteoplastics alleges willful infringement of U.S. Patent Nos. 8,781,557; 9,929,920; 9,330,206; 9,626,756; 9,672,617; 9,672,302; and 9,275,191 based on the PROPLAN CMF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Virtual Surgical Planning Services and the TruMatch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> CMF Personalize Solutions. In April 2020, Osteoplastics filed an amended complaint to substitute U.S. Patent No. 9,292,920 for U.S. Patent No. 9,929,920. Osteoplastics seeks monetary damages and injunctive relief. In June 2020, DePuy Synthes filed a motion to dismiss the complaint. In October 2020, the Court dismissed Medical Device Business Services, Inc. from the case but otherwise denied the motion. In June 2021, Osteoplastics admitted that the PROPLAN CMF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Virtual Surgical Planning Services do not infringe any asserted patents. Trial was scheduled for October 2022. In October 2021, the case was settled and dismissed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Rasmussen Instruments, LLC (Rasmussen) filed a patent infringement suit against DePuy Synthes Products, Inc., DePuy Synthes Sales, Inc. and Medical Device Business Services, Inc. (collectively, DePuy) in the United States District Court for the District of Massachusetts. Rasmussen alleges that DePuy willfully infringes U.S. Patent Nos. 9,492,180 and 10,517,583 (&#8217;583) by making and selling the Attune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Balanced Sizer. In April 2021, Rasmussen sought permission to amend its infringement contentions to allege that DePuy also willfully infringes the &#8217;583 patent by making and selling the Attune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Balancing Blocks. Rasmussen seeks treble damages for willful infringement. Trial is scheduled for February 2022.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmaceutical</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes lawsuits the Company&#8217;s subsidiaries have brought against generic companies that have filed ANDAs with the U.S. FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. In the event the Company&#8217;s subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the generic companies involved would have the ability, upon approval of the U.S. FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#8217;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in January 2019, Janssen Inc. and Janssen Oncology, Inc. (collectively, Janssen) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex Inc. (Apotex), Pharmascience Inc. (Pharmascience) and Dr. Reddy&#8217;s Laboratories Ltd. and Dr. Reddy&#8217;s Laboratories, Inc. (collectively, DRL) in response to those parties&#8217; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before the expiration of the Canadian Patent No. 2,661,422 (&#8217;422). The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#8217;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of U.S. Patent No. 10,828,310 (&#8217;310). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories, Ltd. which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;310 patent.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc. (collectively, Taro) which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;310 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;310 patent. In August 2021, the court entered a joint stipulation dismissing Teva Pharmaceutical Industries Ltd.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the court consolidated the Delaware lawsuits for all purposes, including trial. Trial for the consolidated Delaware lawsuits is scheduled to begin in May 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan Pharmaceuticals Inc. and Mylan Inc. which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;310 patent. In August 2021, JPI and Bayer filed a motion before the United States Judicial Panel on Multidistrict Litigation (the MDL panel) to transfer this lawsuit to the United States District Court for the District of Delaware for coordinated and consolidated pretrial proceedings. In December 2021, the MDL panel granted the motion. No trial date has been set in this lawsuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In each of these lawsuits, JPI and Bayer are seeking an order enjoining defendants from marketing their generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before the expiration of the &#8217;310 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, Janssen Pharmaceuticals, Inc., Janssen Research &amp; Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories Ltd (DRL), who filed an ANDA seeking approval to market a generic version of INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before expiration of MTPC&#8217;s United States Patent No. 7,943,788 (&#8217;788) relating to INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In January 2021, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before expiration of MTPC&#8217;s United States Patent Nos. 7,943,582 (&#8217;582) and/or 8,513,202 (&#8217;202) relating to INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">In each of these U.S. lawsuits, Janssen and MTPC are seeking an order enjoining the defendant from marketing their generic versions of INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"> and/or, INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, Janssen Inc., Janssen Pharmaceutica NV and MTPC initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the Canadian Patent Nos. 2,799,204, 2,534,024 and 2,671,357. Janssen Inc., Janssen Pharmaceutica NV and MTPC are seeking an order enjoining Sandoz from marketing its generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents. The trial is scheduled to begin in August 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2020, Janssen Inc. (Janssen) and Actelion Pharmaceuticals Ltd (Actelion) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of Canadian Patent No. 2,659,770 (&#8217;770). Trial is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the &#8217;770 patent. Trial is scheduled to begin in February 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (JAMP) in Canada in response to JAMP&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg before the expiration of the &#8217;770 patent and Canadian Patent No. 2,621,273 (&#8217;273). Trial is scheduled to begin in April 2022. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before the expiration of United States Patent No. 9,439,906 (&#8217;906). Trial concluded in October 2020. In October 2021, the court issued a decision in Janssen&#8217;s favor. Teva has appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;906 patent. Pursuant to an agreement by the parties, judgment in favor of Janssen was entered in December 2021. Mylan has filed an appeal. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Tolmar, Inc., Tolmar Therapeutics, Inc., Tolmar Pharmaceuticals, Inc. and Tolmar Holding, Inc. (collectively, Tolmar), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of Canadian Patent Nos. 2,309,629 (&#8217;629) and 2,655,335 (&#8217;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#8217;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#8217;s generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if approved, would infringe certain claims of the &#8217;335 patent and that the claims of the &#8217;335 patent are not invalid for obviousness. Teva Canada appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in November 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. A trial on the issue of validity is scheduled to begin in July 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in December 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Apotex has not contested validity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LLC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (546 mg) before expiration of United States Patent No. 10,143,693 (&#8217;693) relating to INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(546 mg). Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> before the expiration of the &#8217;693 patent. Trial is scheduled to begin in October 2022. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(819 mg) before expiration of the &#8217;693 patent. Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (819 mg) before the expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (273 mg and 410 mg) before expiration of the &#8217;693 patent. Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (273 mg and 410 mg) before the expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the court consolidated the three cases into the case filed in September 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, asserting infringement of United States Patent Nos. 7,514,444; 8,003,309; 8,476,284; 8,497,277; 8,697,711; 8,753,403; 8,754,090; 8,754,091; 8,952,015; 8,957,079; 9,181,257; 9,296,753; 9,655,857; 9,725,455; 10,010,507; 10,106,548; and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386. Pharmacyclics and JBI are seeking an order enjoining the defendants from marketing generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trial against Alvogen took place in October 2020. In August 2021, the District Court issued a decision in favor of Pharmacyclics and Janssen finding the asserted claims against Alvogen to be infringed and not invalid. Alvogen has appealed that decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2021, Pharmacyclics and Janssen Inc. (Janssen Canada) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco Pharma (Canada) Inc. (Natco) in response to Natco&#8217;s filing of two ANDSs seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">capsules before the expiration of Canadian Patent Nos. 2,663,116; 2,928,721; 2,800,913; 3,007,787; 3,007,788; 2,875,986; and 3,022,256. The trial is scheduled to begin in July 2023. Pharmacyclics and Janssen are seeking an order enjoining Natco from marketing its generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2020, Actelion Pharmaceuticals Ltd (Actelion) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Zydus Pharmaceuticals (USA), Inc. and Zydus Worldwide DMCC (collectively, Zydus), who filed an ANDA seeking approval to market a generic version of UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">before expiration of Nippon Shinyaku&#8217;s United States Patent Nos. 7,205,302 (&#8217;302); relating to UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Actelion is the exclusive licensee of the &#8217;302 patent. In January 2022, Actelion, Nippon Shinyaku and Zydus entered into a confidential settlement agreement and the lawsuit was dismissed.</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GOVERNMENT PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Average Wholesale Price (AWP) Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;J AWP Defendants were ultimately dismissed. The J&amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp; Johnson and ALZA Corporation. All other cases have been resolved.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Opioid Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in 2014 and continuing to the present, Johnson &amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in approximately 3,400 lawsuits related to the marketing of opioids, including DURAGESIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, NUCYNTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and NUCYNTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including Johnson &amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The Government of Puerto Rico filed suit in Superior Court of San Juan. There are over 380 cases pending in various state courts. There are close to 3,000 federal cases coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio. In addition, the Province of British Columbia filed suit against Johnson &amp; Johnson and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against Johnson &amp; Johnson and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. In October 2019, an antitrust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2019, the trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp; Johnson and JPI in the amount of $465&#160;million. Johnson &amp; Johnson and JPI appealed the judgment, and in November 2021, the Oklahoma Supreme Court reversed the trial court&#8217;s judgment. In October 2019 Johnson &amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against Johnson &amp; Johnson and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial concluded in October 2021, and in December 2021, the Court entered a final trial judgment in favor of Defendants on all claims. In February 2022, Plaintiffs' motion to set aside and vacate the judgment was denied.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Johnson &amp; Johnson received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. In September 2019, Johnson &amp; Johnson received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums. In September 2020, the Company learned that NYDFS filed a statement of charges related to this investigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2021, the Company and JPI announced a settlement agreement with the State of New York and its participating subdivisions, including Nassau County and Suffolk County, resolving their opioid-related claims against the Company on terms consistent with the Company&#8217;s previously announced agreement in principle to contribute up to $5&#160;billion to all-in settlement of opioid-related claims by states, cities, counties, and tribal governments. The settlement provides New York and its participating subdivisions with up to $263&#160;million to address opioid-related issues, reimburses attorney fees and costs, and removes the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Company and Janssen from a multi-defendant trial of opioid-related claims that commenced in Suffolk County in June 2021. In exchange, the Company and JPI receive releases from the claims asserted by New York and the participating parties, including NYDFS.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the Company and JPI announced a settlement agreement with the State of Texas and its participating subdivisions, including Dallas County, Bexar County, and Tarrant County, resolving their opioid-related claims against the Company on terms consistent with the Company&#8217;s previously announced agreement to contribute up to $5&#160;billion to all-in settlement of opioid-related claims by states, cities, counties, and tribal governments. The settlement provides Texas and its participating subdivisions with up to $297&#160;million to address opioid-related issues and reimburse attorney fees and costs, and removes the Company and Janssen from multi-defendant bellwether trials of opioid-related claims scheduled to commence in Texas state courts in early 2022. In exchange, the Company and JPI will receive releases from the claims asserted by Texas and the participating subdivisions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Johnson &amp; Johnson, JPI and other pharmaceutical companies have also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#8217;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $4&#160;billion as settlement of these matters. In October 2020, the Company agreed to contribute up to an additional $1&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of $5&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement in principle is not an admission of liability or wrong-doing. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims have been finalized and up to one-third of the all-in settlement is expected to be paid within the next 12 months, depending upon the level of participation by the states and their subdivisions. The terms provide a period of time for states to elect to participate in the agreement and, thereafter, a period for the subdivisions of the participating states to opt-in. As of January 2022, 45 states, five territories, and the District of Columbia had elected to participate in the settlement. The subdivision opt-in period expired in January 2022. The Company retains the right to opt-out of the agreement until late February 2022 if, in its sole discretion, there is insufficient participation. Based on expected participation, the Company has committed in advance to proceed with the settlement in five of the participating states (New York, Texas, Florida, Nevada, and New Mexico) and with tribal governments, whose cases were scheduled for trial in 2021, 2022, or 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From June 2017 through December 2019, the Company&#8217;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In May 2020, the shareholder filed an amended complaint challenging the Board&#8217;s rejection of his demand. In August 2020, Johnson &amp; Johnson moved to dismiss the amended complaint. In February 2021, the Court held oral argument on Johnson &amp; Johnson&#8217;s motion. In February 2022, the Court granted Johnson &amp; Johnson&#8217;s motion to dismiss the amended complaint. In August 2020, another shareholder who sent a demand filed a separate derivative complaint in the same court making similar allegations. In October 2020, the Court granted defendants&#8217; request to reassign the second-filed case to the division where the first-filed case is pending. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2019, two additional shareholders who sent demands filed two separate derivative complaints making similar allegations against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the United States District for the District of New Jersey. In April 2020, the two federal cases were consolidated into a single action captioned</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> In re Johnson &amp; Johnson Opioid Stockholder Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In July 2020, the shareholders filed a consolidated complaint. In September 2020, Johnson &amp; Johnson moved to dismiss the consolidated complaint, and in December 2020, the shareholders opposed Johnson &amp; Johnson&#8217;s motion. Johnson &amp; Johnson filed its reply in February 2021. In July 2020, an additional shareholder who sent a demand filed a derivative complaint in the same federal court making similar allegations against the same defendants named in the consolidated action. In January 2021, pursuant to an order in the consolidated action, the third case was consolidated into the consolidated action. In February 2021, the Court granted the shareholders motion to voluntarily dismiss the consolidated action without prejudice, and the shareholders&#8217; counsel then filed a notice of association in the first-filed derivative action pending in the Superior Court of New Jersey. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney&#8217;s Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR&#8482; XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#8217; motion to dismiss with prejudice, unsealed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint, and denied the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators&#8217; request for leave to file a further amended complaint. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#8217;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#8217; request to file a third amended complaint. In March 2021, DePuy filed its motion to strike and dismiss the relators&#8217; second amended complaint; the District Court denied DePuy&#8217;s motion to strike and dismiss in July 2021. DePuy filed a motion for reconsideration of the District Court&#8217;s July 2021 ruling. In November 2021, the District Court granted DePuy&#8217;s motion for reconsideration and dismissed the case with prejudice. The District Court&#8217;s order was unsealed in December 2021. The Relators filed several post-dismissal motions, including a January 2022 omnibus motion for reconsideration. Following the District Court&#8217;s order dismissing the case with prejudice, DePuy filed a December 2021 motion seeking the recovery of attorneys&#8217; fees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2012, Johnson &amp; Johnson was contacted by the California Attorney General&#8217;s office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp; Johnson&#8217;s subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp; Johnson and Ethicon settled the Washington case. The California case started trial in July 2019 and concluded in September 2019. In October 2019, Johnson &amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $344&#160;million. In April 2020, the Court in California denied the Company&#8217;s motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of  $344&#160;million, but denied the Attorney General&#8217;s request for injunctive relief. The Company is appealing the penalty judgment. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon. Trial in the Kentucky matter is scheduled for May 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp; Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers&#8217; use of talc contained in JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Baby Powder and JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. Johnson &amp; Johnson and JJCI moved for summary judgment on the grounds that the State&#8217;s claim was barred by preemption, which the trial court denied. The Mississippi Supreme Court granted Johnson &amp; Johnson and JJCI&#8217;s request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Briefing and oral argument were completed. Thereafter, the Court rejected the interlocutory appeal in April 2021 and remanded the matter to the trial court. Thereafter, the State moved for a trial setting. JJCI objected to any trial setting due to the LTL Bankruptcy and that any decision on whether the stay applied should be deferred to the LTL Bankruptcy court. The State opposed any stay and argued that the trial court should decide issues concerning the stay. The motion for trial setting and JJCI&#8217;s objections were heard in November 2021 and in January 2022, the Court granted plaintiff&#8217;s motion for trial setting and directed the parties to consult with the Court administrator to secure a trial date. That process is underway. In August 2021, JJCI filed a Petition for Writ of Certiorari in the United States Supreme Court as to the Mississippi Supreme Court&#8217;s ruling of April 2021, the State responded to the Petition for Writ of Certiorari in November 2021, the JJCI filed a reply in November 2021, and the United States Supreme Court denied the Petition for Writ of Certiorari in December 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. The Company made its first document production in February 2021 and discovery is currently scheduled to close on April 25, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forty-two states and the District of Columbia have commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, Janssen Pharmaceuticals, Inc. (JPI) received a Civil Investigative Demand from the United States Attorney&#8217;s Office for the Southern District of New York related to JPI&#8217;s contractual relationships with pharmacy benefit managers over the period from January 1, 2006 to the present with regard to certain of JPI&#8217;s pharmaceutical products. The demand was issued in connection with an investigation under the False Claims Act. The Company has provided documents in response to the demand. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2016, Johnson &amp; Johnson and Janssen Products LP were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and INTELENCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Daubert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April and September 2017, Johnson &amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, OLYSIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, SIMPONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The subpoenas also seek documents relating to Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, Johnson &amp; Johnson received a subpoena from the United States Attorney&#8217;s Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc.(DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these hospitals. Johnson &amp; Johnson and DePuy have produced documents in response to the subpoena and are fully cooperating with the government&#8217;s investigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp; Johnson to cooperate with these inquiries by producing the requested information.</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL LITIGATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April 2015, over 30 putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. Discovery and pre-trial motion practice are complete. Trial is scheduled to begin in March 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The cases were consolidated for pre-trial purposes as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Antitrust Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in United States District Court for the Eastern District of Pennsylvania. The consolidated complaint seeks damages and injunctive relief. Discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, Walgreen Co. and Kroger Co., filed an antitrust complaint against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The complaint seeks damages and injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#8217;s decision. This matter was settled in January 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp; Johnson in connection with its investigation of whether Janssen&#8217;s REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#8217;s decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. TRACLEER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In October 2019, the Court granted Actelion&#8217;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. Discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint filed on behalf of the United States, 28 states, and the District of Columbia. The complaint, which was filed in December 2017 in United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to the government in connection with direct government sales and government-funded drug reimbursement programs. At this time, the federal and state governments have declined to intervene. The case has been transferred to United States District Court for the District of New Jersey. Janssen&#8217;s motion to dismiss was denied in December 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2019, a class action antitrust complaint was filed against Janssen R&amp;D Ireland (Janssen) and Johnson &amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#8217; motions to dismiss. Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint. In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. In December 2021, several insurance companies and other payers filed individual &#8220;Opt-Out&#8221; complaints containing allegations similar to the original complaint. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#8217;s business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. In August 2020, the Court granted in part and denied in part BWI&#8217;s motion to dismiss. In December 2021, BWI filed a motion for summary judgment. The trial is set for April 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, Johnson &amp; Johnson received a demand for indemnification from Pfizer Inc., pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp; Johnson Inc. received a demand for indemnification from Sanofi Consumer Health, Inc., pursuant to the 2016 Asset Purchase Agreement between Johnson &amp; Johnson Inc. and Sanofi. In January 2020, Johnson &amp; Johnson received a demand for indemnification from </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boehringer Ingelheim Pharmaceuticals, Inc., pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim. The notices seek indemnification for legal claims related to over-the-counter ZANTAC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#8217; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in May 2021, multiple </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">putative </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">class actions were filed in state and federal courts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(California, Florida, New York, and New Jersey)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> against various Johnson &amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and the affirmative promotion of those products as &#8220;safe&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; and, in at least one case, alleging a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strict liability manufacturing defect and failure to warn </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">claims, asserting that the named plaintiffs</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> suffered unspecified injuries as a result of alleged exposure to benzene.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability case and one case pending in New Jersey state court, in the United States District Court for the Southern District of Florida, Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court. In December 2021, plaintiffs in the consolidated actions filed a motion for preliminary approval of a nationwide class settlement.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson (subsequently substituted by Johnson &amp; Johnson Consumer Inc. (JJCI)) along with more than 120 other companies, is a defendant in a cost recovery and contribution action brought by Occidental Chemical Corporation in June 2018 in the United States District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson or its subsidiaries are also parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740166986184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">Restructuring<div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal second quarter of 2018, the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In fiscal year 2021, the Company recorded a pre-tax charge of $0.5 billion, which is included on the following lines of the Consolidated Statement of Earnings, $0.3 billion in restructuring, $0.1 billion in other (income) expense and $0.1 billion in cost of products sold. Total project costs of approximately $1.8 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by the end of 2022. The program is set to be completed at the end of 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company expects to record pre-tax restructuring charges of approximately $2.1 billion to $2.3 billion, over the 4 to 5 year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2021: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs/Sales </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, December&#160;29, 2019</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January&#160;3, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(427)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January&#160;2, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Cash outlays for severance are expected to be substantially paid out over the next year in accordance with the Company's plans and local laws. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div>The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740165681368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Johnson&#160;&amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Description of the Company And Business Segments</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of the Company and Business Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has approximately 141,700&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is organized into three business segments: Consumer Health, Pharmaceutical and Medical Devices. The Consumer Health segment includes a broad range of products used in the Baby Care, Oral Care, Skin Health/Beauty, Over-the-Counter pharmaceutical, Women&#8217;s Health and Wound Care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on six therapeutic areas, including Immunology, Infectious diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The Medical Devices segment includes a broad range of products used in the Orthopaedic, Surgery, Interventional Solutions (cardiovascular and neurovascular) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company announced its intention to separate the Company&#8217;s Consumer Health business, with the intention to create a new, publicly traded company. The Company is targeting completion of the planned separation in 18 to 24 months after initial announcement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Standards</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in fiscal 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Adopted as of January 2, 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. There were no new material accounting standards issued in fiscal 2021 that impacted the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASU 2021-01: Reference Rate Reform </span></div>In mid- 2017, the Financial Conduct Authority (FCA) announced that it will no longer require banks to submit rates for the London Interbank Offered Rate (LIBOR) after 2021 hence market participants should work to transition to alternative reference rates (Reference Rate Reform) and should not rely on LIBOR being available after the end of 2021. Reference rate reform is the term used to refer to the efforts that have been undertaken by regulators and other market participants to introduce new reference rates that are based on a larger and more liquid population of observable transactions. The Company evaluated the implications of reference rate reform and applicable financial reporting guidance in ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting on its key financial and commercial contracts that referenced LIBOR including any hedging relationships. Most contracts reviewed will mature prior to the termination of LIBOR or will be modified to apply a new reference rate (primarily the Secured Overnight Financing Rate &#8220;SOFR&#8221; where applicable). The company also applied available practical expedients under ASC 848 to in scope financial and commercial contracts that previously referenced LIBOR when applicable. As a result, the Company's implementation of any reference rate reform provisions to commercial and financial contracts did not result in any material change for the Company.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at least an investment grade credit rating.  The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value.  The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text">InvestmentsInvestments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment and Depreciation</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment and Depreciation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:86.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;- 30&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;- 20&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;- 13&#160;years</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8&#160;years.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#8217;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Managed Care, Medicare and Medicaid programs, which amounted to $7.7 billion and $7.2 billion as of January&#160;2, 2022 and January&#160;3, 2021, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#8217;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#8217;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years&#160;2021,&#160;2020&#160;and&#160;2019.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. For all years presented, profit-share payments were less than 3.0% of the total revenues and are included in sales to customers.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and Handling</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs incurred were $1.1 billion, $1.0 billion and $1.0 billion in fiscal years 2021, 2020 and 2019, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2021 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions.  See Note&#160;5 for further details on Intangible Assets and Goodwill.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value.  Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#8217;s impact on the Company&#8217;s financial performance; (2)&#160;protect the Company&#8217;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTI0_2cce01d2-b420-436a-93e5-bea5f12e0c78"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTI0_dee6b310-adcd-43bf-a063-cd1559b71416">Other assets</span></span>, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODU5_5e9c1949-8e21-4631-bf9f-ba8181485230"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTM2_2dbaf7d6-873f-4b21-881f-1b610527d361">Accrued liabilities</span></span>, and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODgz_5fa03461-5e24-4b61-b8c9-f2468f3220fb"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODgz_8dab58da-7c04-4417-a1bc-72271f9a3a36">Other liabilities</span></span> on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $0.9&#160;billion and $1.0&#160;billion in 2021 and 2020, respectively. The lease liability was $1.0&#160;billion and $1.1&#160;billion in 2021and 2020, respectively. The operating lease costs were $0.3&#160;billion, $0.3&#160;billion and $0.3&#160;billion in 2021, 2020 and 2019, respectively. Cash paid for amounts included in the measurement of lease liabilities were $0.3&#160;billion, $0.3&#160;billion and $0.3&#160;billion in 2021, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityPolicyTextBlock', window );">Product Liability</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Product Liability</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div> The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development.  Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product.  Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#8217;s operations. In general, the income statement presentation for these collaborations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:48.533%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nature/Type of Collaboration</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Earnings Presentation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third-party sale of product &amp; profit share payments received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to customers</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties/milestones paid to collaborative partner (post-regulatory approval)*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties received from collaborative partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payments&#160;&amp; milestones paid to collaborative partner (pre-regulatory approval)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development payments to collaborative partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development payments received from collaborative partner or government entity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:0.1%"/><td style="width:1.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, co-developed with Bayer HealthCare AG and IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, licensed from Genmab A/S.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $2.7 billion, $2.1 billion and $2.2 billion in fiscal years 2021, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2021 was approximately $6.9&#160;billion, of which $6.1&#160;billion is classified as noncurrent and reflected as &#8220;Long-term taxes payable&#8221; on the Company&#8217;s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI).  GILTI is described as the excess of a U.S. shareholder&#8217;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#8220;period cost&#8221;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., &#8220;deferred method&#8221;). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $0.7 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">See Note 8 to the Consolidated Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">for further information regarding income taxes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Earnings Per Share</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Earnings Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of January 2, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#8217;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the fiscal year ended January 2, 2022, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FiscalPeriodPolicyTextBlock', window );">Annual Closing Date</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Closing Date</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FiscalPeriodPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FiscalPeriodPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProductLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProductLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167095944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock', window );">Estimated Useful Lives of Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:86.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;- 30&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;- 20&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;- 13&#160;years</span></div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated useful lives of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EstimatedUsefulLivesOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740171487480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Current Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash and Cash Equivalent Composition</a></td>
<td class="text"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the fiscal year 2021 and 2020, cash, cash equivalents and current marketable securities were comprised of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.615%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.690%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Loss</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Subtotal </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Sovereign Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Subtotal available for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,487</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Gain</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Subtotal </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gov't Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Sovereign Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Subtotal available for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,985</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Contractual Maturities of Available for Sale Securities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale debt securities at January&#160;2, 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"/><td style="width:43.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,731&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,727&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167471512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2021 and 2020, inventories were comprised of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"/><td style="width:66.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,344</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740166985624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment at Cost and Accumulated Depreciation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2021 and 2020, property, plant and equipment at cost and accumulated depreciation were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:67.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.307%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,962</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,766</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740171583304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock', window );">Schedule of Intangible Assets and Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2021 and 2020, the gross and net amounts of intangible assets were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks&#160;&#8212; gross</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,618)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks&#160;&#8212; net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,372</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,011&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,898&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,925)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,912)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,086</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,822</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,044</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets&#160;&#8212; net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,392</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53,402</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In fiscal 2021, the Company recorded a partial IPR&amp;D impairment charge of $0.9&#160;billion primarily related to expected development delays in the general surgery digital robotics platform (Ottava) acquired with the Auris Health acquisition in 2019. The impairment charge was calculated based on revisions to the discounted cash flow valuation model reflecting a delay of first in human procedures of approximately two years from the initial acquisition model assumption of the second half of 2022. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Goodwill</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of January&#160;2, 2022 and January&#160;3, 2021, as allocated by segment of business, was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:33.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical Devices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,734&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,336&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,009&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,048&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,393&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to divestitures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,810</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,580</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,856</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Intangible Asset Amortization Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"/><td style="width:18.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.910%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740168099800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Derivative Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021, net of tax:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income) Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 2, 2022 and January 3, 2021, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:30.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Effect of Derivatives not Designated as Hedging Instruments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:37.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.532%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Effect of Net Investment Hedges</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following table is the effect of net investment hedges for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:20.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.621%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.032%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)           Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense<br/></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Activity Related to Equity Investments</a></td>
<td class="text"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:25.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales/ Purchases/Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:25.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.505%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales/ Purchases/Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Financial Assets and Liabilities at Fair Value</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of the fiscal year ended January&#160;2, 2022 and January&#160;3, 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.218%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,089</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,860</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,860</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Available For Sale Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.409%"><tr><td style="width:1.0%"/><td style="width:53.627%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.695%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2020 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $1,481 million, which are classified as Level&#160;1 and contingent consideration of $633 million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes cross currency interest rate swaps and interest rate swaps.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Classified as non-current other assets.  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Classified as cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes $520 million, $594 million and $1,631 million, classified as non-current other liabilities as of January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019, respectively. Includes $13 million, $39&#160;million and $84&#160;million classified as current liabilities as of January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019, respectively.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt">Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense.  The Company recorded a contingent consideration reversal of $1,148&#160;million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740165950472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instruments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term debt are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.289%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Rate %</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Rate %</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65% Notes due 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.250% Notes due 2022                                                        (1B Euro 1.1311)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(1B Euro 1.2281)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% Notes due 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73%&#160;Debentures due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Notes due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.650% Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(750MM Euro 1.1311)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(750MM Euro 1.2281)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50%&#160;Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(500MM 1.3485 GBP )</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(500MM GBP 1.3654)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.150% Notes due 2028                                                (750MM Euro 1.1311)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(750MM Euro 1.2281)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95%&#160;Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95%&#160;Debentures due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% Notes due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.650% Notes due 2035                                                     (1.5B Euro 1.1311)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(1.5B Euro 1.2281)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2036</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95%&#160;Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85%&#160;Debentures due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.400%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%&#160;Debentures due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% Notes due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85% Notes due 2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Notes due 2043</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% Notes due 2046</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Notes due 2047</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.500% Notes due 2048</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.250% Notes due 2050</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.450% Notes due 2060</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,116</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,985</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,635</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Weighted average effective rate.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Translation rate at January&#160;2, 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Translation rate at January&#160;3, 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The excess of the fair value over the carrying value of debt was $3.2 billion at the end of fiscal year 2021 and $5.4 billion at the end of fiscal year 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Aggregate Maturities of Long Term Obligations</a></td>
<td class="text"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate maturities of long-term debt obligations commencing in 2022 are:</span></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"/><td style="width:15.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.879%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.882%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">After 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,189</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740170078376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Provision for Income Taxes</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for taxes on income consists of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"/><td style="width:50.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.003%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currently payable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total currently payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,065)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,079)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,476)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Provision for taxes on income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,783</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate</a></td>
<td class="text"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A comparison of income tax expense at the U.S.&#160;statutory rate of 21% in fiscal years 2021, 2020 and 2019, to the Company&#8217;s effective tax rate is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:48.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,312&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,543&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes on income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,776&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rates:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes on international income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefits from loss on capital assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefits on share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TCJA and related impacts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflects the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2021 amounts include the reorganization of international subsidiaries; the 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. The 2021 amounts include the reorganization of international subsidiaries; the 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, both of which is further described below. </span></div>(3) Represents impact of adjustments to balances originally recorded as part of the 2017 TCJA provisional tax charge. Further information provided below.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Temporary Differences and Carryforwards</a></td>
<td class="text"><div style="margin-bottom:9.9pt;margin-top:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Temporary differences and carryforwards at the end of fiscal years 2021 and 2020 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 Deferred Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Deferred Tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation of property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(823)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,659)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,023)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D capitalized for tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves&#160;&amp; liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income reported for tax purposes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realizable operating loss carryforward</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undistributed foreign earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global intangible low-taxed income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,853)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous international</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,624</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,888)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,477</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,157)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to current year presentation</span></div>(2)Amount is inclusive of the $2.3&#160;billion deferred tax asset established as part of the reorganized ownership structure of certain wholly-owned international subsidiaries, as previously described.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Activity Related to Unrecognized Tax Benefits</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to unrecognized tax benefits:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"/><td style="width:50.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.495%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to prior period tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to prior period tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(839)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,323</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,373</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,853</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167089096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Related Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EmployeeRelatedObligationsTableTextBlock', window );">Employee Related Obligations</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal 2021 and fiscal 2020, employee related obligations recorded on the Consolidated Balance Sheets were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postretirement benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postemployment benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total employee obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current benefits payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations&#160;&#8212; non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,771</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EmployeeRelatedObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee related obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EmployeeRelatedObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740168373240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of Net Periodic Benefit Cost</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans for 2021, 2020 and 2019 include the following components:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">623</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">593</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">503</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">524</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average actuarial assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:39.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Worldwide Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Periodic Benefit Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.63&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.45&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of increase in compensation levels</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.39&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of increase in compensation levels</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock', window );">Assumed Health Care Cost Trend Rates</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the assumed healthcare cost trend rates, for all individuals:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"/><td style="width:71.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.946%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Healthcare Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare cost trend rate assumed for next year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline (ultimate trend)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year the rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2046&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetFundedStatusTableTextBlock', window );">Schedule of Net Funded Status</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2021 and 2020 for the Company&#8217;s defined benefit retirement plans and other post-retirement plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation&#160;&#8212; beginning of year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,300&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,188&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,076&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains) losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures&#160;&amp; acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments, settlements&#160;&amp; restructuring</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid from plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,582</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,878</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value&#160;&#8212; beginning of year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,195&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,201&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures&#160;&amp; acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid from plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(574)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,930</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status &#8212; end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,105)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,776)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,938)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(438)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,105)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,776)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,938)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,860&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,797)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net transition obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax effects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,929</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,419</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligations&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,356</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The actuarial gain for retirement plans in 2021 was primarily related to increases in discount rates; the actuarial losses for retirement plans in 2020 were primarily related to decreases in discount rates.</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">623</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">503</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">524</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial (gain) loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,927)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,616&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (cost) credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total loss/(income) recognized in other comprehensive income, before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,134)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(319)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(191)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in net periodic benefit cost and other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,511)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock', window );">Information Related to the Benefit Obligation and the Fair Value of Plan Assets</a></td>
<td class="text"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the funded status of the Company's U.S. Qualified &amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2021 and December&#160;31, 2020, respectively:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:25.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plans</span></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Qualified Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Qualified Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unfunded Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Benefit Obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Benefit Obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over (Under) Funded Status</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Benefit Obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,703)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,748)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,900)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Benefit Obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,479)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(569)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(493)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the projected future benefit payments from the Company&#8217;s retirement and other benefit plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:35.089%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027-2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected future benefit payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other benefit plans&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock', window );">Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the projected future minimum contributions to the unfunded retirement plans.  These amounts do not include any discretionary contributions that the Company may elect to make in the future.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:35.089%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027-2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected future contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Company' Retirement Plan Asset Allocation and Target Allocations</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s retirement plan asset allocation at the end of 2021 and 2020 and target allocations for 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:58.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.755%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent of<br/>Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Target<br/>Allocation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Worldwide Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock', window );">Schedule of Defined Benefit Plans Disclosures</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2021 and December&#160;31, 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:18.235%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.161%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government and agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investments at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,086</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">181</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,515</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,092</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,930</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The activity for the Level 3 assets is not significant for all years presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to the benefit obligation and the fair value of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated future employer contributions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2439-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2410-114920<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetFundedStatusTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of net funded status of pension plans and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetFundedStatusTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167097384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital and Treasury Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ChangesInTreasuryStockTableTextBlock', window );">Changes in Treasury Stock</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in treasury stock were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in Millions Except Treasury Stock Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,362&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,053)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,691)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,336&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,417&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,847)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,099&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ChangesInTreasuryStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ChangesInTreasuryStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167100232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of Accumulated Other Comprehensive Income</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign<br/>Currency Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss) On Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/<br/>(Loss) On<br/>Derivatives &amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,869)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,158)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,222)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2019 changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(733)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(669)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,705)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,891)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,891)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2020 changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,938)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,957)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,242)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2021 changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,079)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,017)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,702)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,058)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167014680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions Except Per Share Amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding&#160;&#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,645.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted average shares outstanding&#160;&#8212; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.81&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.63&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740172810360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule Valuation Assumptions</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average fair value of options granted was $20.86, $16.42 and $17.80, in fiscal years 2021, 2020 and 2019, respectively.  The fair value was estimated based on the weighted average assumptions of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:56.819%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the Plan as of January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019, and changes during the years ending on those dates is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"/><td style="width:47.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(Dollars in Millions) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,975)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">117,361</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,364</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Options Outstanding</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock options outstanding and exercisable at January&#160;2, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:29.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.168%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price Range</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$65.08-$90.44</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$81.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$81.92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.06-$101.87</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$101.07</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$101.07</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$115.67-$129.51</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$122.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$122.43</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$131.94-$151.41</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$142.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$140.72</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$151.42-$164.62</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$164.62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$164.62</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">117,361</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$125.36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62,742</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$104.42</span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Average contractual life remaining in years.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Restricted Share Units</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the restricted share units and performance share units activity under the Plans as of January&#160;2, 2022 is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"/><td style="width:55.231%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.611%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.032%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Performance Share Units</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited/adjusted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,122&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740168147928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas (Tables)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SalesBySegmentOfBusinessTableTextBlock', window );">Schedule of Sales by Segment of Business</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217;21 vs. &#8217;20</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217;20 vs. &#8217;19</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:189pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / rilpivirine</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> /                                              </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / methylphenidate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* *</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* *</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:57pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**Percentage greater than 100% or not meaningful</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (Loss) Before Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,064)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,848&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,163&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,829&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,091&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,776</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,497</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">182,018</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174,894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions to Property,<br/>Plant &amp; Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation and<br/>Amortization</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segments total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,074&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,689&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,652</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,347</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,498</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,390</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,231</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-Lived Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere excluding U.S.&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segments total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non long-lived assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93,775</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,584</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">182,018</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174,894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;1 for a description of the segments in which the Company operates. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Export sales are not significant. In fiscal year 2021, the Company utilized three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0% and 11.0% of the total consolidated revenues. In fiscal year 2020, the Company had three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0% and 12.0% of the total consolidated revenues. In fiscal year 2019, the Company had three wholesalers distributing products for all three segments that represented approximately 15.0%, 12.0%, and 11.0% of the total consolidated revenues. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">General corporate includes cash, cash equivalents and marketable securities.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $1.6&#160;billion, primarily talc related reserves</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.1&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.6&#160;billion, primarily related to Risperdal </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Divestiture gains of $0.6&#160;billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Gains on securities of $0.5&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.1&#160;billion </span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.3&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $0.9&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A Medical Device Regulation charge of $0.2&#160;billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.1&#160;billion </span></div><div style="margin-top:3pt;padding-left:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $3.9&#160;billion, primarily talc related reserves and certain settlements.</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.8&#160;billion, primarily related to the agreement in principle to settle opioid litigation </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An unrealized gain on securities of $0.5&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.1&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A contingent consideration reversal of $1.1&#160;billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.3&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.3&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $0.2&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A Medical Device Regulation charge of $0.1&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.4 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.1 billion </span></div><div style="margin-top:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $4.3 billion of which $4.0 billion is related to the agreement in principle to settle opioid litigation</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $0.9 billion related to the Alios asset</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A research and development expense of $0.3 billion for an upfront payment related to argenx </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An unrealized gain on securities of $0.6 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Actelion acquisition and integration related costs of $0.2 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring charge of $0.1 billion</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Medical Devices includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $2.0 billion from the divestiture of the ASP business</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.4 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.4 billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Auris Health acquisition and integration related costs of $0.1 billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Long-lived assets include property, plant and equipment, net for fiscal years 2021, and 2020 of $18,962 and $18,766, respectively, and intangible assets and goodwill, net for fiscal years 2021 and 2020 of $81,638 and $89,795, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesBySegmentOfBusinessTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesBySegmentOfBusinessTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740166970504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Summary of Severance Charges and Associated Spending</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2021: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs/Sales </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, December&#160;29, 2019</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January&#160;3, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(427)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January&#160;2, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Cash outlays for severance are expected to be substantially paid out over the next year in accordance with the Company's plans and local laws. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740165328968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>Employee</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 29, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide', window );">Number of employees | Employee</a></td>
<td class="nump">141,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of business segments | Segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement', window );">Minimum reverse repurchase agreement collateral (as a percent)</a></td>
<td class="nump">102.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_AccruedRebatesReturnsAndPromotions', window );">Accrued Rebates Returns And Promotions</a></td>
<td class="nump">$ 12,095<span></span>
</td>
<td class="nump">$ 11,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SalesReturnReserve', window );">Sales return reserve (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProfitLossPercentToSales', window );">Percentage of profit share payments (less than)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">$ 29,855<span></span>
</td>
<td class="nump">$ 28,427<span></span>
</td>
<td class="nump">$ 27,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ShippingandHandlingCostsasaPercentofSales', window );">Shipping and handling costs as a percent of sales</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other assets, noncurrent<span></span>
</td>
<td class="text">Other assets, noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued Liabilities, Current<span></span>
</td>
<td class="text">Accrued Liabilities, Current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating leases</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent', window );">TCJA, undistributed foreign earnings percent related to cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent', window );">TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability', window );">TCJA, provisional liability</a></td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent', window );">TJCA , provisional liability, non-current</a></td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings', window );">Repatriation of foreign earnings amount</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Software Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Software Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expense | Project Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ConcentrationRiskThresholdPercentage', window );">Concentration risk, threshold percentage (as a percent)</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_AccruedRebatesReturnsAndPromotions', window );">Accrued Rebates Returns And Promotions</a></td>
<td class="nump">$ 7,700<span></span>
</td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AccruedRebatesReturnsAndPromotions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AccruedRebatesReturnsAndPromotions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ConcentrationOfCreditRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration of credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ConcentrationOfCreditRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ConcentrationRiskThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Threshold Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ConcentrationRiskThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum Collateral Value as a Percent, Reverse Repurchase Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of employees engaged in company activities worldwide.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProfitLossPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit loss percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProfitLossPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesReturnReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales return reserve</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesReturnReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShippingandHandlingCostsasaPercentofSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shipping and Handling Costs as a Percent of Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShippingandHandlingCostsasaPercentofSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740162288296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Building and building equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Land and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Building and building equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Land and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">13 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=jnj_LandAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=jnj_LandAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740161475608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale</a></td>
<td class="nump">$ 19,727<span></span>
</td>
<td class="nump">$ 14,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">14,487<span></span>
</td>
<td class="nump">13,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">17,121<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">11,881<span></span>
</td>
<td class="nump">11,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="nump">11,880<span></span>
</td>
<td class="nump">11,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">7,686<span></span>
</td>
<td class="nump">9,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">4,195<span></span>
</td>
<td class="nump">1,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity, unrecognized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">2,936<span></span>
</td>
<td class="nump">2,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="nump">2,936<span></span>
</td>
<td class="nump">2,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">2,936<span></span>
</td>
<td class="nump">2,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity, unrecognized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Non-U.S. Sovereign Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">1,006<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="nump">1,006<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">916<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity, unrecognized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | U.S. Reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">1,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">1,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">1,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity, unrecognized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">3,479<span></span>
</td>
<td class="nump">2,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="nump">3,478<span></span>
</td>
<td class="nump">2,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">1,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">3,279<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity, unrecognized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">1,901<span></span>
</td>
<td class="nump">2,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="nump">1,901<span></span>
</td>
<td class="nump">2,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">1,901<span></span>
</td>
<td class="nump">2,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity, unrecognized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Time deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity, unrecognized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount, available-for-sale</a></td>
<td class="nump">19,731<span></span>
</td>
<td class="nump">14,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale</a></td>
<td class="nump">19,727<span></span>
</td>
<td class="nump">14,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">6,801<span></span>
</td>
<td class="nump">4,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">12,926<span></span>
</td>
<td class="nump">9,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, unrecognized loss</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, unrecognized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount, available-for-sale</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, unrecognized loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, unrecognized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | U.S. Gov't Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount, available-for-sale</a></td>
<td class="nump">19,485<span></span>
</td>
<td class="nump">13,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale</a></td>
<td class="nump">19,481<span></span>
</td>
<td class="nump">13,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">6,785<span></span>
</td>
<td class="nump">4,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">12,696<span></span>
</td>
<td class="nump">9,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, unrecognized loss</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, unrecognized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Other Sovereign Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount, available-for-sale</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, unrecognized loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, unrecognized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_SovereignDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_SovereignDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=jnj_OtherSovereignSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=jnj_OtherSovereignSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740165936776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Cost Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due within one year</a></td>
<td class="nump">$ 19,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total debt securities</a></td>
<td class="nump">19,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">19,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total debt securities</a></td>
<td class="nump">$ 19,727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740170120712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Summary of Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">$ 1,592<span></span>
</td>
<td class="nump">$ 1,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Goods in process</a></td>
<td class="nump">2,287<span></span>
</td>
<td class="nump">2,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">6,508<span></span>
</td>
<td class="nump">5,894<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 10,387<span></span>
</td>
<td class="nump">$ 9,344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740165931112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment, gross</a></td>
<td class="nump">$ 47,679<span></span>
</td>
<td class="nump">$ 46,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="nump">28,717<span></span>
</td>
<td class="nump">28,038<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">18,962<span></span>
</td>
<td class="nump">18,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=jnj_LandAndLeaseholdImprovementsMember', window );">Land and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment, gross</a></td>
<td class="nump">884<span></span>
</td>
<td class="nump">882<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and building equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment, gross</a></td>
<td class="nump">12,882<span></span>
</td>
<td class="nump">12,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment, gross</a></td>
<td class="nump">29,774<span></span>
</td>
<td class="nump">29,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment, gross</a></td>
<td class="nump">$ 4,139<span></span>
</td>
<td class="nump">$ 4,316<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=jnj_LandAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=jnj_LandAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167324744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest expense capitalized</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest', window );">Depreciation expense, including the amortization of capitalized interest</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation expense including the amortization of capitalized interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740165220392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,822<span></span>
</td>
<td class="nump">$ 19,044<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets - net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,392<span></span>
</td>
<td class="nump">53,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,985<span></span>
</td>
<td class="nump">7,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember', window );">Purchased in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,837<span></span>
</td>
<td class="nump">11,849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite lived intangible assets gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,572<span></span>
</td>
<td class="nump">39,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,088)<span></span>
</td>
<td class="num">(17,618)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite lived intangible assets net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,484<span></span>
</td>
<td class="nump">22,372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite lived intangible assets gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,011<span></span>
</td>
<td class="nump">22,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,925)<span></span>
</td>
<td class="num">(10,912)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite lived intangible assets net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,086<span></span>
</td>
<td class="nump">$ 11,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets, excluding goodwill</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets, excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740165344920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill beginning of period</a></td>
<td class="nump">$ 36,393<span></span>
</td>
<td class="nump">$ 33,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, related to divestitures</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/other</a></td>
<td class="num">(1,138)<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill end of period</a></td>
<td class="nump">35,246<span></span>
</td>
<td class="nump">36,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill beginning of period</a></td>
<td class="nump">10,336<span></span>
</td>
<td class="nump">9,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, related to divestitures</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/other</a></td>
<td class="num">(517)<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill end of period</a></td>
<td class="nump">9,810<span></span>
</td>
<td class="nump">10,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill beginning of period</a></td>
<td class="nump">11,009<span></span>
</td>
<td class="nump">9,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, related to divestitures</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/other</a></td>
<td class="num">(429)<span></span>
</td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill end of period</a></td>
<td class="nump">10,580<span></span>
</td>
<td class="nump">11,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill beginning of period</a></td>
<td class="nump">15,048<span></span>
</td>
<td class="nump">14,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, related to divestitures</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/other</a></td>
<td class="num">(192)<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill end of period</a></td>
<td class="nump">$ 14,856<span></span>
</td>
<td class="nump">$ 15,048<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740166037752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Narrative (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of amortizable intangible assets</a></td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167266312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Estimated Amortization of Intangible Assets (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 4,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">4,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">4,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">3,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740165352088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax', window );">Deferred net losses (gains) on derivatives included in accumulated other comprehensive income</a></td>
<td class="nump">$ 336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss', window );">Description of reclassification of cash flow hedge gain (loss)</a></td>
<td class="text">next 12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge', window );">Maximum length of time for hedging transaction exposure</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral paid</a></td>
<td class="nump">$ 570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">45,800<span></span>
</td>
<td class="nump">$ 37,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">37,400<span></span>
</td>
<td class="nump">30,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities | Equity Investments without readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityFairValueAdjustmentImpairmentLoss', window );">Equity, fair value adjustment, impairment loss</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityFairValueAdjustmentChangeinObservablePrices', window );">Equity, fair value adjustment, change in observable prices</a></td>
<td class="nump">$ 422<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityFairValueAdjustmentChangeinObservablePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity, Fair Value Adjustment, Change in Observable Prices</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityFairValueAdjustmentChangeinObservablePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityFairValueAdjustmentImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity, Fair Value Adjustment, Impairment Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityFairValueAdjustmentImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the transactions or other events that will result in the reclassification into earnings of gains or losses reported in accumulated other comprehensive income. May include the time period over which gains or losses will be reclassified to earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740160504824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 789<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(199)<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="num">$ (107)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Sales | Interest Rate Swap | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Sales | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Sales | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Sales | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(94)<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Products Sold | Interest Rate Swap | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Products Sold | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Products Sold | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Products Sold | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">119<span></span>
</td>
<td class="num">(329)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(557)<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expense | Interest Rate Swap | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expense | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expense | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expense | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">30<span></span>
</td>
<td class="num">(137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">123<span></span>
</td>
<td class="num">(91)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember', window );">Interest (Income) Expense | Interest Rate Swap | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="num">(109)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember', window );">Interest (Income) Expense | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember', window );">Interest (Income) Expense | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember', window );">Interest (Income) Expense | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense | Interest Rate Swap | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">47<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="num">$ (52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061172-113977<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740162278488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Carrying Amount of the Hedged Liability</a></td>
<td class="nump">$ 1,888<span></span>
</td>
<td class="nump">$ 2,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember', window );">Long-term Debt | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Carrying Amount of the Hedged Liability</a></td>
<td class="nump">9,793<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</a></td>
<td class="num">$ (142)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740171036488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts: | Not Designated as Hedging Instrument | Other (Income) Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain/(Loss) Recognized In Income on Derivative</a></td>
<td class="num">$ (70)<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167286408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 387<span></span>
</td>
<td class="num">$ (473)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps contracts:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 548<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Gain/(Loss) Reclassified From Accumulated OCI Into Income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense | Cross currency interest rate swaps contracts:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Gain/(Loss) Reclassified From Accumulated OCI Into Income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740161955096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="nump">$ 10,216<span></span>
</td>
<td class="nump">$ 6,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities | Equity Investments with readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, noncurrent</a></td>
<td class="nump">1,884<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">$ 1,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Equity, fair value adjustment</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Equity investments, increase (decrease) from acquisition (sale) during period</a></td>
<td class="nump">205<span></span>
</td>
<td class="num">(194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="nump">1,884<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities | Equity Investments without readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Equity, fair value adjustment</a></td>
<td class="nump">394<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Equity investments, increase (decrease) from acquisition (sale) during period</a></td>
<td class="num">(632)<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities without readily determinable fair value, amount</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 738<span></span>
</td>
<td class="nump">$ 712<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Investment [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740160883944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Apr. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">$ 1,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Investments</a></td>
<td class="nump">1,884<span></span>
</td>
<td class="nump">$ 1,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">19,727<span></span>
</td>
<td class="nump">14,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total Gross Assets</a></td>
<td class="nump">1,360<span></span>
</td>
<td class="nump">1,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Credit Support Agreement (CSA)</a></td>
<td class="num">(1,285)<span></span>
</td>
<td class="num">(1,107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Total Net Asset</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total Gross Liabilities</a></td>
<td class="nump">1,888<span></span>
</td>
<td class="nump">2,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossAsset', window );">Credit Support Agreement (CSA)</a></td>
<td class="num">(1,855)<span></span>
</td>
<td class="num">(2,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total Net Liabilities</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">633<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
<td class="nump">$ 397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue', window );">Changes in estimated fair value</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,148)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">594<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="num">(1,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Investments</a></td>
<td class="nump">1,884<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">1,336<span></span>
</td>
<td class="nump">1,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="nump">2,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">19,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swaps contracts:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swaps contracts: | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swaps contracts: | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">796<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">979<span></span>
</td>
<td class="nump">1,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swaps contracts: | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">881<span></span>
</td>
<td class="nump">702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740156282120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Schedule of Long-term Debt Instruments (Details)<br> &#8364; in Millions, &#163; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.89%<span></span>
</td>
<td class="nump">2.85%<span></span>
</td>
<td class="nump">2.89%<span></span>
</td>
<td class="nump">2.89%<span></span>
</td>
<td class="nump">2.85%<span></span>
</td>
<td class="nump">2.85%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 32,116<span></span>
</td>
<td class="nump">$ 34,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion</a></td>
<td class="nump">2,131<span></span>
</td>
<td class="nump">1,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">29,985<span></span>
</td>
<td class="nump">32,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ExcessOfFairValueOverCarryingValueOfDebt', window );">Excess of fair value over carrying value of debt</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2021Member', window );">3.55% Notes due 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.67%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.67%<span></span>
</td>
<td class="nump">3.67%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2021Member', window );">2.45% Notes due 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.48%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.48%<span></span>
</td>
<td class="nump">2.48%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.65Notesdue2021Member', window );">1.65% Notes due 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.250NotesDue2022Member', window );">0.250% Notes due 2022 (1B Euro 1.1311)(2)/(1B Euro 1.2281)(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.26%<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,131<span></span>
</td>
<td class="nump">$ 1,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.1311<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
<td class="nump">1.1311<span></span>
</td>
<td class="nump">1.1311<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.25Notesdue2022Member', window );">2.25% Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.31%<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member', window );">6.73%&#160;Debentures due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">6.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member', window );">3.375% Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.18%<span></span>
</td>
<td class="nump">3.17%<span></span>
</td>
<td class="nump">3.18%<span></span>
</td>
<td class="nump">3.18%<span></span>
</td>
<td class="nump">3.17%<span></span>
</td>
<td class="nump">3.17%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 802<span></span>
</td>
<td class="nump">$ 803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.05Notesdue2023Member', window );">2.05% Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="nump">$ 499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.05%<span></span>
</td>
<td class="nump">2.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 1.1311)(2)/(750MM Euro 1.2281)(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 847<span></span>
</td>
<td class="nump">$ 919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.1311<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
<td class="nump">1.1311<span></span>
</td>
<td class="nump">1.1311<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50%&#160;Notes due 2024 (500MM 1.3485 GBP )(2)/(500MM GBP 1.3654)(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 672<span></span>
</td>
<td class="nump">$ 679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.3485<span></span>
</td>
<td class="nump">1.3654<span></span>
</td>
<td class="nump">1.3485<span></span>
</td>
<td class="nump">1.3485<span></span>
</td>
<td class="nump">1.3654<span></span>
</td>
<td class="nump">1.3654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 749<span></span>
</td>
<td class="nump">$ 748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.625%<span></span>
</td>
<td class="nump">2.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A055NotesDue2025Member', window );">0.55% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.57%<span></span>
</td>
<td class="nump">0.57%<span></span>
</td>
<td class="nump">0.57%<span></span>
</td>
<td class="nump">0.57%<span></span>
</td>
<td class="nump">0.57%<span></span>
</td>
<td class="nump">0.57%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 983<span></span>
</td>
<td class="nump">$ 996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,995<span></span>
</td>
<td class="nump">$ 1,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 978<span></span>
</td>
<td class="nump">$ 997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.96%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,478<span></span>
</td>
<td class="nump">$ 1,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 1.1311)(2)/(750MM Euro 1.2281)(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 843<span></span>
</td>
<td class="nump">$ 915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.1311<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
<td class="nump">1.1311<span></span>
</td>
<td class="nump">1.1311<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,495<span></span>
</td>
<td class="nump">$ 1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95%&#160;Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">7.14%<span></span>
</td>
<td class="nump">7.14%<span></span>
</td>
<td class="nump">7.14%<span></span>
</td>
<td class="nump">7.14%<span></span>
</td>
<td class="nump">7.14%<span></span>
</td>
<td class="nump">7.14%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">6.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.95%<span></span>
</td>
<td class="nump">6.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A130NotesDue2030Member', window );">1.30% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,723<span></span>
</td>
<td class="nump">$ 1,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95%&#160;Debentures due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 498<span></span>
</td>
<td class="nump">$ 498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 854<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes due 2035 (1.5B Euro 1.1311)(2)/(1.5B Euro 1.2281)(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,683<span></span>
</td>
<td class="nump">$ 1,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.1311<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
<td class="nump">1.1311<span></span>
</td>
<td class="nump">1.1311<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
<td class="nump">1.2281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 974<span></span>
</td>
<td class="nump">$ 989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95%&#160;Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">5.99%<span></span>
</td>
<td class="nump">5.99%<span></span>
</td>
<td class="nump">5.99%<span></span>
</td>
<td class="nump">5.99%<span></span>
</td>
<td class="nump">5.99%<span></span>
</td>
<td class="nump">5.99%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">$ 992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.95%<span></span>
</td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.64%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,475<span></span>
</td>
<td class="nump">$ 1,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85%&#160;Debentures due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 696<span></span>
</td>
<td class="nump">$ 696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.400%&#160;Notes due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 992<span></span>
</td>
<td class="nump">$ 991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50%&#160;Debentures due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.63%<span></span>
</td>
<td class="nump">4.63%<span></span>
</td>
<td class="nump">4.63%<span></span>
</td>
<td class="nump">4.63%<span></span>
</td>
<td class="nump">4.63%<span></span>
</td>
<td class="nump">4.63%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 540<span></span>
</td>
<td class="nump">$ 539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 974<span></span>
</td>
<td class="nump">$ 986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 297<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.85%<span></span>
</td>
<td class="nump">4.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.52%<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 496<span></span>
</td>
<td class="nump">$ 496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="nump">$ 1,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 971<span></span>
</td>
<td class="nump">$ 991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.500% Notes due 2048</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.52%<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 743<span></span>
</td>
<td class="nump">$ 742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.250% Notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.29%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 983<span></span>
</td>
<td class="nump">$ 984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.450% Notes due 2060</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,222<span></span>
</td>
<td class="nump">$ 1,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ExcessOfFairValueOverCarryingValueOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of fair value over carrying value of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ExcessOfFairValueOverCarryingValueOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32618-110901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.65Notesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.65Notesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A0.250NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A0.250NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.25Notesdue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.25Notesdue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.05Notesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.05Notesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A055NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A055NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A130NotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A130NotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740162292520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity under credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings and the current portion of long-term debt</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermCommercialPaperCurrent', window );">Borrowed under the commercial paper program</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long term debt</a></td>
<td class="nump">2,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loans and notes payable</a></td>
<td class="nump">$ 3,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Debt, weighted average interest rate</a></td>
<td class="nump">0.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loans and notes payable</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Debt, weighted average interest rate</a></td>
<td class="nump">0.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermCommercialPaperCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the current portion of long-term unsecured obligations issued by corporations and other borrowers to investors (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermCommercialPaperCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740169568792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Aggregate Maturities of Long Term Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Aggregate maturities of long-term obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 2,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">1,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">1,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">1,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2026</a></td>
<td class="nump">1,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">After 2026</a></td>
<td class="nump">$ 23,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740161960376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Currently payable:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">U.S. taxes</a></td>
<td class="nump">$ 1,525<span></span>
</td>
<td class="nump">$ 1,026<span></span>
</td>
<td class="nump">$ 1,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">International taxes</a></td>
<td class="nump">2,452<span></span>
</td>
<td class="nump">1,898<span></span>
</td>
<td class="nump">2,744<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total currently payable</a></td>
<td class="nump">3,977<span></span>
</td>
<td class="nump">2,924<span></span>
</td>
<td class="nump">4,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S. taxes</a></td>
<td class="nump">583<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="num">(814)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">International taxes</a></td>
<td class="num">(2,662)<span></span>
</td>
<td class="num">(1,065)<span></span>
</td>
<td class="num">(1,662)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="num">(2,079)<span></span>
</td>
<td class="num">(1,141)<span></span>
</td>
<td class="num">(2,476)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for taxes on income</a></td>
<td class="nump">$ 1,898<span></span>
</td>
<td class="nump">$ 1,783<span></span>
</td>
<td class="nump">$ 2,209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740172565960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract', window );"><strong>Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,110<span></span>
</td>
<td class="nump">$ 4,312<span></span>
</td>
<td class="nump">$ 3,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,666<span></span>
</td>
<td class="nump">12,185<span></span>
</td>
<td class="nump">13,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,776<span></span>
</td>
<td class="nump">$ 16,497<span></span>
</td>
<td class="nump">$ 17,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Tax rates:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">International operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.40%)<span></span>
</td>
<td class="num">(9.90%)<span></span>
</td>
<td class="num">(5.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome', window );">U.S. taxes on international income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss', window );">Tax benefits from loss on capital assets</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther', window );">Tax benefits on share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent', window );">TCJA and related impacts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="num">(3.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">All other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="nump">10.80%<span></span>
</td>
<td class="nump">12.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comparison of income tax expense at the Statutory rate and Company's tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Capital Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation related to domestic tax on international income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740161164008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent', window );">Effective tax rate reconciliation, net increase (decrease) in tax rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization', window );">Deferred tax assets, tax basis increase of certain assets due to reorganization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI', window );">Increase (decrease) in deferred tax liabilities, global intangible low-taxed income (GILTI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss', window );">Tax benefits from loss on capital assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit', window );">Income tax expense recorded related to TRAF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent', window );">TRAF effect on tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit', window );">Income tax expense related to change in tax rate from TRAF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset', window );">Deferred tax asset recorded related to TRAF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit', window );">Deferred tax expense related to TRAF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Effective income tax rate reconciliation, deduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent', window );">Effective tax rate reconciliation, litigation settlement, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability', window );">Reversal of deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset', window );">Reversal of deferred tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit', window );">Tax Cuts And Jobs Act Of 2017, foreign tax credits, net deferred tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent', window );">TJCA, foreign tax credit percent</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent', window );">Increase (decrease) in earnings before taxes, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset', window );">TCJA, increase (decrease) in deferred tax asset</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Increase (decrease) in unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent', window );">Effective tax rate reconciliation, unrecognized tax benefits, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 3,853<span></span>
</td>
<td class="nump">$ 3,323<span></span>
</td>
<td class="nump">$ 3,853<span></span>
</td>
<td class="nump">$ 3,323<span></span>
</td>
<td class="nump">$ 3,373<span></span>
</td>
<td class="nump">$ 3,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense', window );">Unrecognized tax benefits, interest on income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Unrecognized tax benefits, interest on income taxes accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 512<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent', window );">Effective tax rate reconciliation, net increase (decrease) in tax rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health | Purchased in-process research and development(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets, excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Effective income tax rate reconciliation, nondeductible expense, impairment losses, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_UnrecognizedTaxBenefitLiabilityPayment', window );">Payment on unrecognized tax benefit liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_TalcMember', window );">Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent', window );">Effective income tax rate reconciliation, litigation settlement, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_TalcMember', window );">Talc | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent', window );">Effective income tax rate reconciliation, litigation settlement, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_RisperdalMember', window );">Risperdal | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent', window );">Effective income tax rate reconciliation, litigation settlement, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_OpiodsMember', window );">Opiods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent', window );">Effective income tax rate reconciliation, litigation settlement, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_OpiodsMember', window );">Opiods | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Capital Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Litigation Settlement, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Federal Act On Tax Reform And AHV Financing, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Litigation Settlement, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Unrecognized Tax Benefits, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal Act On Tax Reform And AHV Financing, Change In Tax Rate, Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal Act On Tax Reform And AHV Financing, Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Earnings Before Taxes, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Increase (Decrease) In Deferred Tax Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Net Deferred Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_UnrecognizedTaxBenefitLiabilityPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefit Liability, Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_UnrecognizedTaxBenefitLiabilityPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_RisperdalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_RisperdalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_OpiodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_OpiodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740162406616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Temporary Differences and Carryforwards (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits', window );">Employee related obligations</a></td>
<td class="nump">$ 1,244<span></span>
</td>
<td class="nump">$ 2,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized', window );">R&amp;D capitalized for tax</a></td>
<td class="nump">1,664<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Reserves&#160;&amp; liabilities</a></td>
<td class="nump">2,882<span></span>
</td>
<td class="nump">3,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Income reported for tax purposes</a></td>
<td class="nump">2,566<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Net realizable operating loss carryforward</a></td>
<td class="nump">1,073<span></span>
</td>
<td class="nump">990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DeferredTaxAssetsUndistributedForeignEarnings', window );">Undistributed foreign earnings</a></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Miscellaneous international</a></td>
<td class="nump">1,006<span></span>
</td>
<td class="nump">854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DeferredTaxAssetsOtherDomestic', window );">Miscellaneous U.S.&#160;</a></td>
<td class="nump">495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred income taxes</a></td>
<td class="nump">12,624<span></span>
</td>
<td class="nump">12,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation of property, plant and equipment</a></td>
<td class="num">(876)<span></span>
</td>
<td class="num">(823)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Goodwill and intangibles</a></td>
<td class="num">(2,659)<span></span>
</td>
<td class="num">(5,023)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Undistributed foreign earnings</a></td>
<td class="num">(1,461)<span></span>
</td>
<td class="num">(1,435)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome', window );">Global intangible low-taxed income</a></td>
<td class="num">(4,853)<span></span>
</td>
<td class="num">(3,606)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Miscellaneous international</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DeferredTaxLiabilitiesOtherDomestic', window );">Miscellaneous U.S.&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred income taxes</a></td>
<td class="num">(9,888)<span></span>
</td>
<td class="num">$ (11,157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization', window );">Deferred tax assets, tax basis increase of certain assets due to reorganization</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets international research and development capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxAssetsOtherDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets other domestic.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxAssetsOtherDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxAssetsUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Undistributed Foreign Earnings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxAssetsUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxLiabilitiesOtherDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Other Domestic</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxLiabilitiesOtherDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liability, Global Intangible Low-Taxed Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740170056984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Summary of unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning of year</a></td>
<td class="nump">$ 3,373<span></span>
</td>
<td class="nump">$ 3,853<span></span>
</td>
<td class="nump">$ 3,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases related to prior period tax positions</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">668<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases related to prior period tax positions</a></td>
<td class="num">(128)<span></span>
</td>
<td class="num">(551)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(187)<span></span>
</td>
<td class="num">(839)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">End of year</a></td>
<td class="nump">$ 3,323<span></span>
</td>
<td class="nump">$ 3,373<span></span>
</td>
<td class="nump">$ 3,853<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740172697576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee Related Obligations - Employee Related Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Employee-related Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities', window );">Pension benefits</a></td>
<td class="nump">$ 4,088<span></span>
</td>
<td class="nump">$ 5,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent', window );">Postretirement benefits</a></td>
<td class="nump">2,069<span></span>
</td>
<td class="nump">2,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent', window );">Postemployment benefits</a></td>
<td class="nump">3,117<span></span>
</td>
<td class="nump">3,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent', window );">Deferred compensation</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EmployeeObligations', window );">Total employee obligations</a></td>
<td class="nump">9,455<span></span>
</td>
<td class="nump">11,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Less current benefits payable</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Employee related obligations&#160;&#8212; non-current</a></td>
<td class="nump">$ 8,898<span></span>
</td>
<td class="nump">$ 10,771<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EmployeeObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total employee obligations current and non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EmployeeObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension plan. Excludes other postretirement benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan. Excludes pension plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the balance sheet date of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79691-111665<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79708-111665<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740166992136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee Related Obligations - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Prepaid employee related obligations</a></td>
<td class="nump">$ 4,436<span></span>
</td>
<td class="nump">$ 656<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740161383752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Amendments</a></td>
<td class="num">$ (1,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets', window );">Percentage of corridor of greater of market value of assets</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Accumulated benefit obligation unfunded plans</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">$ 8,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Projected benefit obligation, unfunded plans</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Plan with accumulated benefit obligation in excess of plan assets, plan assets</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets', window );">Fair value of company's common stock directly held in plan assets</a></td>
<td class="nump">$ 385<span></span>
</td>
<td class="nump">$ 946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageOfCompanysCommonStockToPlanAsset', window );">Percentage of company's common stock to plan asset</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Amendments</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">$ (1,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">41,930<span></span>
</td>
<td class="nump">38,195<span></span>
</td>
<td class="nump">$ 32,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Amendments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="nump">867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember', window );">Commingled funds | Level 2 | Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EmployeeCompensationPeriod', window );">Retirement plan benefits Employee compensation Period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EmployeeCompensationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Compensation Period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EmployeeCompensationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of company's common stock directly held in plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageOfCompanysCommonStockToPlanAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the company's common stock to the total plan asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageOfCompanysCommonStockToPlanAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of corridor of greater of market value of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAmendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAmendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740165205976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 1,421<span></span>
</td>
<td class="nump">$ 1,380<span></span>
</td>
<td class="nump">$ 1,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">770<span></span>
</td>
<td class="nump">955<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(2,645)<span></span>
</td>
<td class="num">(2,461)<span></span>
</td>
<td class="num">(2,322)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="num">(181)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial losses (gains)</a></td>
<td class="nump">1,257<span></span>
</td>
<td class="nump">891<span></span>
</td>
<td class="nump">579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">623<span></span>
</td>
<td class="nump">790<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">287<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial losses (gains)</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">$ 503<span></span>
</td>
<td class="nump">$ 524<span></span>
</td>
<td class="nump">$ 551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167287656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Net Periodic Benefit Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Service cost discount rate</a></td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.82%<span></span>
</td>
<td class="nump">3.63%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate', window );">Interest cost discount rate</a></td>
<td class="nump">2.34%<span></span>
</td>
<td class="nump">3.13%<span></span>
</td>
<td class="nump">4.13%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of increase in compensation levels</a></td>
<td class="nump">4.01%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.99%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected long-term rate of return on plan assets</a></td>
<td class="nump">7.71%<span></span>
</td>
<td class="nump">8.12%<span></span>
</td>
<td class="nump">8.31%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of increase in compensation levels</a></td>
<td class="nump">4.01%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.01%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Net Periodic Benefit Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Service cost discount rate</a></td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">3.04%<span></span>
</td>
<td class="nump">4.45%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate', window );">Interest cost discount rate</a></td>
<td class="nump">2.33%<span></span>
</td>
<td class="nump">3.08%<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of increase in compensation levels</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="nump">4.29%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.68%<span></span>
</td>
<td class="nump">2.23%<span></span>
</td>
<td class="nump">3.39%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of increase in compensation levels</a></td>
<td class="nump">4.21%<span></span>
</td>
<td class="nump">4.27%<span></span>
</td>
<td class="nump">4.29%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740252794728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract', window );"><strong>Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear', window );">Healthcare cost trend rate assumed for next year</a></td>
<td class="nump">5.33%<span></span>
</td>
<td class="nump">5.68%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1', window );">Rate to which the cost trend rate is assumed to decline (ultimate trend)</a></td>
<td class="nump">3.73%<span></span>
</td>
<td class="nump">4.49%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate', window );">Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate</a></td>
<td class="text">2046<span></span>
</td>
<td class="text">2040<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ultimate trend rate for health care cost for defined benefit postretirement plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Year ultimate health care cost trend rate is expected to be reached, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740161560424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Amendments</a></td>
<td class="num">$ (1,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">4,436<span></span>
</td>
<td class="nump">$ 656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(557)<span></span>
</td>
<td class="num">(547)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="num">(8,898)<span></span>
</td>
<td class="num">(10,771)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation - beginning of year</a></td>
<td class="nump">43,300<span></span>
</td>
<td class="nump">37,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">1,421<span></span>
</td>
<td class="nump">1,380<span></span>
</td>
<td class="nump">$ 1,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">770<span></span>
</td>
<td class="nump">955<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Amendments</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(1,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gains) losses(2)</a></td>
<td class="num">(2,132)<span></span>
</td>
<td class="nump">5,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease', window );">Divestitures&#160;&amp; acquisitions</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CurtailmentsAndSettlementsAndRestructuring', window );">Curtailments, settlements&#160;&amp; restructuring</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid from plan</a></td>
<td class="num">(1,157)<span></span>
</td>
<td class="num">(1,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Effect of exchange rates</a></td>
<td class="num">(683)<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation - end of year</a></td>
<td class="nump">41,582<span></span>
</td>
<td class="nump">43,300<span></span>
</td>
<td class="nump">37,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value&#160;&#8212; beginning of year</a></td>
<td class="nump">38,195<span></span>
</td>
<td class="nump">32,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">4,439<span></span>
</td>
<td class="nump">5,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">969<span></span>
</td>
<td class="nump">870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease', window );">Divestitures&#160;&amp; acquisitions</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid from plan assets</a></td>
<td class="num">(1,157)<span></span>
</td>
<td class="num">(1,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Effect of exchange rates</a></td>
<td class="num">(574)<span></span>
</td>
<td class="nump">747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value&#160;- End of year</a></td>
<td class="nump">41,930<span></span>
</td>
<td class="nump">38,195<span></span>
</td>
<td class="nump">32,201<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status - end of year</a></td>
<td class="nump">348<span></span>
</td>
<td class="num">(5,105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">4,436<span></span>
</td>
<td class="nump">656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(115)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="num">(3,973)<span></span>
</td>
<td class="num">(5,636)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</a></td>
<td class="nump">348<span></span>
</td>
<td class="num">(5,105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract', window );"><strong>Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Net actuarial loss</a></td>
<td class="nump">5,539<span></span>
</td>
<td class="nump">10,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service cost (credit)(1)</a></td>
<td class="num">(1,610)<span></span>
</td>
<td class="num">(1,797)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax', window );">Unrecognized net transition obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Total before tax effects</a></td>
<td class="nump">3,929<span></span>
</td>
<td class="nump">9,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">39,049<span></span>
</td>
<td class="nump">40,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract', window );"><strong>Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">623<span></span>
</td>
<td class="nump">790<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net actuarial (gain) loss</a></td>
<td class="num">(3,927)<span></span>
</td>
<td class="nump">2,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Amortization of net actuarial loss</a></td>
<td class="num">(1,257)<span></span>
</td>
<td class="num">(891)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service cost (credit)</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(1,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Amortization of prior service (cost) credit</a></td>
<td class="nump">181<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectOfExchangeRates', window );">Effect of exchange rates</a></td>
<td class="num">(136)<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total loss/(income) recognized in other comprehensive income, before tax</a></td>
<td class="num">(5,134)<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax', window );">Total recognized in net periodic benefit cost and other comprehensive income</a></td>
<td class="num">(4,511)<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation - beginning of year</a></td>
<td class="nump">5,028<span></span>
</td>
<td class="nump">5,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">287<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Amendments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gains) losses(2)</a></td>
<td class="num">(188)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease', window );">Divestitures&#160;&amp; acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CurtailmentsAndSettlementsAndRestructuring', window );">Curtailments, settlements&#160;&amp; restructuring</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid from plan</a></td>
<td class="num">(348)<span></span>
</td>
<td class="num">(396)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Effect of exchange rates</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation - end of year</a></td>
<td class="nump">4,878<span></span>
</td>
<td class="nump">5,028<span></span>
</td>
<td class="nump">5,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value&#160;&#8212; beginning of year</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">343<span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease', window );">Divestitures&#160;&amp; acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid from plan assets</a></td>
<td class="num">(348)<span></span>
</td>
<td class="num">(396)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Effect of exchange rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value&#160;- End of year</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status - end of year</a></td>
<td class="num">(4,776)<span></span>
</td>
<td class="num">(4,938)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(438)<span></span>
</td>
<td class="num">(418)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="num">(4,338)<span></span>
</td>
<td class="num">(4,520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</a></td>
<td class="num">(4,776)<span></span>
</td>
<td class="num">(4,938)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract', window );"><strong>Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Net actuarial loss</a></td>
<td class="nump">1,113<span></span>
</td>
<td class="nump">1,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service cost (credit)(1)</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax', window );">Unrecognized net transition obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Total before tax effects</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract', window );"><strong>Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">524<span></span>
</td>
<td class="nump">$ 551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net actuarial (gain) loss</a></td>
<td class="num">(199)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Amortization of net actuarial loss</a></td>
<td class="num">(151)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service cost (credit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Amortization of prior service (cost) credit</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectOfExchangeRates', window );">Effect of exchange rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total loss/(income) recognized in other comprehensive income, before tax</a></td>
<td class="num">(319)<span></span>
</td>
<td class="num">(191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax', window );">Total recognized in net periodic benefit cost and other comprehensive income</a></td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">$ 333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CurtailmentsAndSettlementsAndRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase or decrease related to curtailments, settlements and restructuring.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CurtailmentsAndSettlementsAndRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectOfExchangeRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effect Of Exchange Rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectOfExchangeRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized in net periodic benefit cost (credit) and other comprehensive (income) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) for transition asset (obligation) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increase benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAmendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAmendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167451048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jnj_QualifiedPlansMember', window );">Qualified Plans | U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">$ 27,944<span></span>
</td>
<td class="nump">$ 25,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected Benefit Obligation</a></td>
<td class="nump">25,041<span></span>
</td>
<td class="nump">25,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">23,985<span></span>
</td>
<td class="nump">24,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Projected Benefit Obligation</a></td>
<td class="nump">2,903<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">3,959<span></span>
</td>
<td class="nump">1,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jnj_NonQualifiedPlansMember', window );">Non-Qualified Plans | U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected Benefit Obligation</a></td>
<td class="nump">2,703<span></span>
</td>
<td class="nump">2,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">2,479<span></span>
</td>
<td class="nump">2,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Projected Benefit Obligation</a></td>
<td class="num">(2,703)<span></span>
</td>
<td class="num">(2,748)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO', window );">Accumulated Benefit Obligation</a></td>
<td class="num">(2,479)<span></span>
</td>
<td class="num">(2,495)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jnj_FundedPlansMember', window );">Funded Plans | International Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">13,986<span></span>
</td>
<td class="nump">12,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected Benefit Obligation</a></td>
<td class="nump">13,428<span></span>
</td>
<td class="nump">14,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">12,212<span></span>
</td>
<td class="nump">13,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Projected Benefit Obligation</a></td>
<td class="nump">558<span></span>
</td>
<td class="num">(1,900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">1,774<span></span>
</td>
<td class="num">(569)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jnj_UnfundedPlansMember', window );">Unfunded Plans | International Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected Benefit Obligation</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Projected Benefit Obligation</a></td>
<td class="num">(410)<span></span>
</td>
<td class="num">(545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO', window );">Accumulated Benefit Obligation</a></td>
<td class="num">$ (373)<span></span>
</td>
<td class="num">$ (493)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan over (under) funded status ABO</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanOverUnderFundedStatusABO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jnj_QualifiedPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jnj_QualifiedPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jnj_NonQualifiedPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jnj_NonQualifiedPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jnj_FundedPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jnj_FundedPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jnj_UnfundedPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jnj_UnfundedPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740161921416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2023</a></td>
<td class="nump">1,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2024</a></td>
<td class="nump">1,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2025</a></td>
<td class="nump">1,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2026</a></td>
<td class="nump">1,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2027-2031</a></td>
<td class="nump">9,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other benefit plans&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2022</a></td>
<td class="nump">447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2023</a></td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2024</a></td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2025</a></td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2026</a></td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2027-2031</a></td>
<td class="nump">$ 2,379<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740171738120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne', window );">2022</a></td>
<td class="nump">$ 114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo', window );">2023</a></td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree', window );">2024</a></td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour', window );">2025</a></td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive', window );">2026</a></td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter', window );">2027-2031</a></td>
<td class="nump">$ 794<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year five.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740172424360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)<br></strong></div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Percent of Plan Assets</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Percent of Plan Assets</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">61.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Percent of Plan Assets</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740161773816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details) - Retirement plans - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">$ 41,930<span></span>
</td>
<td class="nump">$ 38,195<span></span>
</td>
<td class="nump">$ 32,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">41,930<span></span>
</td>
<td class="nump">38,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets', window );">Investments Measured at Net Asset Value</a></td>
<td class="nump">10,515<span></span>
</td>
<td class="nump">9,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">14,209<span></span>
</td>
<td class="nump">14,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">17,086<span></span>
</td>
<td class="nump">14,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Short-term investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Short-term investment funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Short-term investment funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">1,033<span></span>
</td>
<td class="nump">763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Short-term investment funds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">7,016<span></span>
</td>
<td class="nump">5,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government and agency securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government and agency securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">7,016<span></span>
</td>
<td class="nump">5,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government and agency securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">3,505<span></span>
</td>
<td class="nump">3,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Debt instruments | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Debt instruments | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">3,505<span></span>
</td>
<td class="nump">3,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Debt instruments | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">14,109<span></span>
</td>
<td class="nump">14,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Equity securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">14,107<span></span>
</td>
<td class="nump">14,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Equity securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Equity securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commingled funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">14,309<span></span>
</td>
<td class="nump">13,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets', window );">Investments Measured at Net Asset Value</a></td>
<td class="nump">8,708<span></span>
</td>
<td class="nump">8,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commingled funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commingled funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">5,496<span></span>
</td>
<td class="nump">4,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commingled funds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">1,856<span></span>
</td>
<td class="nump">888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets', window );">Investments Measured at Net Asset Value</a></td>
<td class="nump">1,807<span></span>
</td>
<td class="nump">856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Other assets | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Other assets | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Other assets | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_ShortTermInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_ShortTermInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167165560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Savings Plan - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SavingsPlanAbstract', window );"><strong>Savings Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Matching contributions</a></td>
<td class="nump">$ 256<span></span>
</td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">$ 235<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SavingsPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Savings Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SavingsPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740165208264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital and Treasury Stock - Changes in Treasury Stock (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ChangesinTreasuryStockSharesOutstandingRollForward', window );"><strong>Changes in Treasury Stock Shares Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, beginning balance (shares)</a></td>
<td class="nump">487,331<span></span>
</td>
<td class="nump">487,336<span></span>
</td>
<td class="nump">457,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Employee compensation and stock option plans (shares)</a></td>
<td class="num">(17,399)<span></span>
</td>
<td class="num">(21,765)<span></span>
</td>
<td class="num">(20,053)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, ending balance (shares)</a></td>
<td class="nump">490,878<span></span>
</td>
<td class="nump">487,331<span></span>
</td>
<td class="nump">487,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ChangesInTreasuryStockRollForward', window );"><strong>Changes in treasury stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Balance</a></td>
<td class="nump">$ 38,490<span></span>
</td>
<td class="nump">$ 38,417<span></span>
</td>
<td class="nump">$ 34,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Employee compensation and stock option plans</a></td>
<td class="num">(2,847)<span></span>
</td>
<td class="num">(3,148)<span></span>
</td>
<td class="num">(2,691)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="nump">3,456<span></span>
</td>
<td class="nump">3,221<span></span>
</td>
<td class="nump">6,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Ending Balance</a></td>
<td class="nump">$ 39,099<span></span>
</td>
<td class="nump">$ 38,490<span></span>
</td>
<td class="nump">$ 38,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ChangesinTreasuryStockSharesOutstandingRollForward', window );"><strong>Changes in Treasury Stock Shares Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (shares)</a></td>
<td class="nump">20,946<span></span>
</td>
<td class="nump">21,760<span></span>
</td>
<td class="nump">49,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ChangesInTreasuryStockRollForward', window );"><strong>Changes in treasury stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="nump">$ 3,456<span></span>
</td>
<td class="nump">$ 3,221<span></span>
</td>
<td class="nump">$ 6,746<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ChangesInTreasuryStockRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ChangesInTreasuryStockRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ChangesinTreasuryStockSharesOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in Treasury Stock Shares Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ChangesinTreasuryStockSharesOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167873336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital and Treasury Stock - Narrative (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Billions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 04, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 17, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,119,843<span></span>
</td>
<td class="nump">3,119,843<span></span>
</td>
<td class="nump">3,119,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividends paid (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.19<span></span>
</td>
<td class="nump">$ 3.98<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common Stock, Dividends, Per Share, Declared</a></td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=jnj_December172018ShareRepurchaseProgramMember', window );">December 17, 2018 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=jnj_December172018ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=jnj_December172018ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740171653912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="nump">$ 63,278<span></span>
</td>
<td class="nump">$ 59,471<span></span>
</td>
<td class="nump">$ 59,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">649<span></span>
</td>
<td class="num">(669)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="nump">74,023<span></span>
</td>
<td class="nump">63,278<span></span>
</td>
<td class="nump">59,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(8,938)<span></span>
</td>
<td class="num">(8,705)<span></span>
</td>
<td class="num">(8,869)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(1,079)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(10,017)<span></span>
</td>
<td class="num">(8,938)<span></span>
</td>
<td class="num">(8,705)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Gain/(Loss) On Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Employee Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(6,957)<span></span>
</td>
<td class="num">(6,891)<span></span>
</td>
<td class="num">(6,158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">4,255<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="num">(733)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(2,702)<span></span>
</td>
<td class="num">(6,957)<span></span>
</td>
<td class="num">(6,891)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Gain/ (Loss) On Derivatives &amp; Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="nump">652<span></span>
</td>
<td class="num">(295)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(988)<span></span>
</td>
<td class="nump">947<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(336)<span></span>
</td>
<td class="nump">652<span></span>
</td>
<td class="num">(295)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(15,242)<span></span>
</td>
<td class="num">(15,891)<span></span>
</td>
<td class="num">(15,222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">649<span></span>
</td>
<td class="num">(669)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">$ (13,058)<span></span>
</td>
<td class="num">$ (15,242)<span></span>
</td>
<td class="num">$ (15,891)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740172651208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>International Currency Translation - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTranslationAbstract', window );"><strong>Foreign Currency Translation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction gain (loss), before tax</a></td>
<td class="num">$ (236)<span></span>
</td>
<td class="num">$ (209)<span></span>
</td>
<td class="num">$ (267)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTranslationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTranslationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740172797048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Reconciliation of basic net earnings per share to diluted net earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net earnings per share (in dollars per share)</a></td>
<td class="nump">$ 7.93<span></span>
</td>
<td class="nump">$ 5.59<span></span>
</td>
<td class="nump">$ 5.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Average shares outstanding&#160;&#8212; basic (in shares)</a></td>
<td class="nump">2,632.1<span></span>
</td>
<td class="nump">2,632.8<span></span>
</td>
<td class="nump">2,645.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PotentialSharesExercisableUnderStockOptionPlans', window );">Potential shares exercisable under stock option plans (in shares)</a></td>
<td class="nump">138.0<span></span>
</td>
<td class="nump">118.3<span></span>
</td>
<td class="nump">136.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod', window );">Less: shares repurchased under treasury stock method (in shares)</a></td>
<td class="num">(96.1)<span></span>
</td>
<td class="num">(80.4)<span></span>
</td>
<td class="num">(97.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Convertible debt shares (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Average shares outstanding - diluted (in shares)</a></td>
<td class="nump">2,674.0<span></span>
</td>
<td class="nump">2,670.7<span></span>
</td>
<td class="nump">2,684.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net earnings per share (in dollars per share)</a></td>
<td class="nump">$ 7.81<span></span>
</td>
<td class="nump">$ 5.51<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PotentialSharesExercisableUnderStockOptionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Shares Exercisable Under Stock Option Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PotentialSharesExercisableUnderStockOptionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2029-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167370984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Narrative (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Interest expense convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestOnConvertibleDebtNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestOnConvertibleDebtNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740161302776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>USD ($) </div>
<div>StockBasedCompensationPlans </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 29, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_NumberOfStockBasedCompensationPlans', window );">Number of stock-based compensation plans | StockBasedCompensationPlans</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost charged for Long term incentive plan</a></td>
<td class="nump">$ 1,135<span></span>
</td>
<td class="nump">$ 1,005<span></span>
</td>
<td class="nump">$ 977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Total income tax benefit recognized</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Exercise of options, tax benefit</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost not yet recognized for option</a></td>
<td class="nump">$ 862<span></span>
</td>
<td class="nump">$ 804<span></span>
</td>
<td class="nump">$ 823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for total compensation cost not yet recognized</a></td>
<td class="text">1 year 9 months 10 days<span></span>
</td>
<td class="text">1 year 9 months 3 days<span></span>
</td>
<td class="text">1 year 8 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Average fair value of option granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 20.86<span></span>
</td>
<td class="nump">$ 16.42<span></span>
</td>
<td class="nump">$ 17.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="nump">$ 919<span></span>
</td>
<td class="nump">$ 1,021<span></span>
</td>
<td class="nump">$ 807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Stock options outstanding (in shares) | shares</a></td>
<td class="nump">117,361<span></span>
</td>
<td class="nump">114,250<span></span>
</td>
<td class="nump">111,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Stock option average life</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,289<span></span>
</td>
<td class="nump">60,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options average price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96.97<span></span>
</td>
<td class="nump">$ 88.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Average fair value of RSU's and PSU's granted | $ / shares</a></td>
<td class="nump">$ 152.62<span></span>
</td>
<td class="nump">$ 139.58<span></span>
</td>
<td class="nump">$ 121.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair Value of RSU or PSU units settled</a></td>
<td class="nump">$ 611<span></span>
</td>
<td class="nump">$ 650<span></span>
</td>
<td class="nump">$ 586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Average fair value of RSU's and PSU's granted | $ / shares</a></td>
<td class="nump">$ 179.35<span></span>
</td>
<td class="nump">$ 160.54<span></span>
</td>
<td class="nump">$ 124.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair Value of RSU or PSU units settled</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=jnj_A2012LongTermIncentivePlanMember', window );">2012 Long-Term Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance under long-term incentive plan | shares</a></td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants under long-term incentive plan | shares</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_NumberOfStockBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock-based compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_NumberOfStockBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=jnj_A2012LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=jnj_A2012LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740167266472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions of fair value of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">0.83%<span></span>
</td>
<td class="nump">1.47%<span></span>
</td>
<td class="nump">2.56%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">18.59%<span></span>
</td>
<td class="nump">15.33%<span></span>
</td>
<td class="nump">16.27%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740161520824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Outstanding Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding beginning of period</a></td>
<td class="nump">114,250<span></span>
</td>
<td class="nump">111,637<span></span>
</td>
<td class="nump">109,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted</a></td>
<td class="nump">18,525<span></span>
</td>
<td class="nump">20,723<span></span>
</td>
<td class="nump">19,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="num">(13,248)<span></span>
</td>
<td class="num">(16,275)<span></span>
</td>
<td class="num">(14,785)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options canceled/forfeited</a></td>
<td class="num">(2,166)<span></span>
</td>
<td class="num">(1,835)<span></span>
</td>
<td class="num">(2,975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding end of period</a></td>
<td class="nump">117,361<span></span>
</td>
<td class="nump">114,250<span></span>
</td>
<td class="nump">111,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options exercise price beginning of period (in dollars per share)</a></td>
<td class="nump">$ 116.22<span></span>
</td>
<td class="nump">$ 105.63<span></span>
</td>
<td class="nump">$ 98.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, average exercise price (in dollars per share)</a></td>
<td class="nump">164.62<span></span>
</td>
<td class="nump">151.41<span></span>
</td>
<td class="nump">131.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, average exercise price (in dollars per share)</a></td>
<td class="nump">97.48<span></span>
</td>
<td class="nump">86.05<span></span>
</td>
<td class="nump">82.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options canceled/forfeited, average exercise price (in dollars per share)</a></td>
<td class="nump">149.75<span></span>
</td>
<td class="nump">137.62<span></span>
</td>
<td class="nump">125.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options exercise price end of period (in dollars per share)</a></td>
<td class="nump">$ 125.36<span></span>
</td>
<td class="nump">$ 116.22<span></span>
</td>
<td class="nump">$ 105.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 5,364<span></span>
</td>
<td class="nump">$ 4,703<span></span>
</td>
<td class="nump">$ 4,478<span></span>
</td>
<td class="nump">$ 3,214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740161328936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">117,361<span></span>
</td>
<td class="nump">114,250<span></span>
</td>
<td class="nump">111,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 125.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">62,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 104.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeOneMember', window );">$65.08-$90.44</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">65.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 90.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">16,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 81.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">16,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 81.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeTwoMember', window );">$100.06-$101.87</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">100.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 101.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">22,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 101.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">22,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 101.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeThreeMember', window );">$115.67-$129.51</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">115.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 129.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">24,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 122.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">23,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 122.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFourMember', window );">$131.94-$151.41</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">131.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 151.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">36,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 142.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 140.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFiveMember', window );">$151.42-$164.62</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">151.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 164.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">17,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 164.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 164.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation shares authorized under stock option plans by exercise price range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740170095496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 02, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">14,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">4,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Issued (in shares)</a></td>
<td class="num">(5,101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod', window );">Canceled/forfeited/adjusted (in shares)</a></td>
<td class="nump">756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">14,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Issued (in shares)</a></td>
<td class="num">(610)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod', window );">Canceled/forfeited/adjusted (in shares)</a></td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">2,312<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740145018520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Sales by Segment of Business (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 93,775<span></span>
</td>
<td class="nump">$ 82,584<span></span>
</td>
<td class="nump">$ 82,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">13.60%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 14,635<span></span>
</td>
<td class="nump">$ 14,053<span></span>
</td>
<td class="nump">13,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 52,080<span></span>
</td>
<td class="nump">$ 45,572<span></span>
</td>
<td class="nump">42,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">14.30%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 16,750<span></span>
</td>
<td class="nump">$ 15,055<span></span>
</td>
<td class="nump">13,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">11.30%<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,861<span></span>
</td>
<td class="nump">$ 3,574<span></span>
</td>
<td class="nump">3,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 7,011<span></span>
</td>
<td class="nump">$ 6,548<span></span>
</td>
<td class="nump">6,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">7.10%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 14,548<span></span>
</td>
<td class="nump">$ 12,367<span></span>
</td>
<td class="nump">10,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">17.60%<span></span>
</td>
<td class="nump">15.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,450<span></span>
</td>
<td class="nump">$ 3,148<span></span>
</td>
<td class="nump">2,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">9.60%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,460<span></span>
</td>
<td class="nump">$ 4,878<span></span>
</td>
<td class="nump">5,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(8.60%)<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 27,060<span></span>
</td>
<td class="nump">$ 22,959<span></span>
</td>
<td class="nump">25,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">17.90%<span></span>
</td>
<td class="num">(11.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Interventional Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,971<span></span>
</td>
<td class="nump">$ 3,046<span></span>
</td>
<td class="nump">2,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">30.40%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 8,588<span></span>
</td>
<td class="nump">$ 7,763<span></span>
</td>
<td class="nump">8,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">10.60%<span></span>
</td>
<td class="num">(12.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 9,812<span></span>
</td>
<td class="nump">$ 8,232<span></span>
</td>
<td class="nump">9,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">19.20%<span></span>
</td>
<td class="num">(13.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,688<span></span>
</td>
<td class="nump">$ 3,919<span></span>
</td>
<td class="nump">4,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">19.60%<span></span>
</td>
<td class="num">(15.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OTCMember', window );">OTC | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,227<span></span>
</td>
<td class="nump">$ 4,824<span></span>
</td>
<td class="nump">4,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">8.40%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_SkinHealthBeautyMember', window );">Skin health/Beauty | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,541<span></span>
</td>
<td class="nump">$ 4,450<span></span>
</td>
<td class="nump">4,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="num">(3.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OralCareMember', window );">Oral Care | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,645<span></span>
</td>
<td class="nump">$ 1,641<span></span>
</td>
<td class="nump">1,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">7.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_BabyCareMember', window );">Baby Care | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,566<span></span>
</td>
<td class="nump">$ 1,517<span></span>
</td>
<td class="nump">1,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="num">(9.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_WomensHealthMember', window );">Women's Health | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 917<span></span>
</td>
<td class="nump">$ 901<span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="num">(8.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember', window );">Wound Care and Other | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 739<span></span>
</td>
<td class="nump">$ 720<span></span>
</td>
<td class="nump">671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">7.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_RemicadeMember', window );">Remicade | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,190<span></span>
</td>
<td class="nump">$ 3,747<span></span>
</td>
<td class="nump">4,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(14.90%)<span></span>
</td>
<td class="num">(14.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember', window );">Simponi/Simponi Aria | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,276<span></span>
</td>
<td class="nump">$ 2,243<span></span>
</td>
<td class="nump">2,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_StelaraMember', window );">Stelara | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 9,134<span></span>
</td>
<td class="nump">$ 7,707<span></span>
</td>
<td class="nump">6,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">18.50%<span></span>
</td>
<td class="nump">21.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TremfyaMember', window );">Tremfya | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,127<span></span>
</td>
<td class="nump">$ 1,347<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">57.90%<span></span>
</td>
<td class="nump">33.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherImmunologyMember', window );">Other Immunology | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_COVID19Member', window );">COVID-19 | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">2,385<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember', window );">EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 994<span></span>
</td>
<td class="nump">$ 964<span></span>
</td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">11.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember', window );">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,083<span></span>
</td>
<td class="nump">$ 2,184<span></span>
</td>
<td class="nump">2,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(4.60%)<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember', window );">Other Infectious Diseases | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 399<span></span>
</td>
<td class="nump">$ 427<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(6.50%)<span></span>
</td>
<td class="num">(3.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember', window );">CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 667<span></span>
</td>
<td class="nump">$ 622<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">7.30%<span></span>
</td>
<td class="num">(10.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember', window );">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,022<span></span>
</td>
<td class="nump">$ 3,653<span></span>
</td>
<td class="nump">3,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">10.10%<span></span>
</td>
<td class="nump">9.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember', window );">RISPERDAL CONSTA | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 592<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(7.70%)<span></span>
</td>
<td class="num">(6.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember', window );">OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,729<span></span>
</td>
<td class="nump">$ 1,632<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_DARZALEXMember', window );">DARZALEX | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 6,023<span></span>
</td>
<td class="nump">$ 4,190<span></span>
</td>
<td class="nump">2,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">43.80%<span></span>
</td>
<td class="nump">39.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ErleadaMember', window );">ERLEADA | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,291<span></span>
</td>
<td class="nump">$ 760<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_IMBRUVICAMember', window );">IMBRUVICA | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,369<span></span>
</td>
<td class="nump">$ 4,128<span></span>
</td>
<td class="nump">3,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">5.80%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ZYTIGAMember', window );">ZYTIGA/abiraterone acetate | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,297<span></span>
</td>
<td class="nump">$ 2,470<span></span>
</td>
<td class="nump">2,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(7.00%)<span></span>
</td>
<td class="num">(11.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherOncologyMember', window );">Other Oncology | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 568<span></span>
</td>
<td class="nump">$ 821<span></span>
</td>
<td class="nump">1,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(30.80%)<span></span>
</td>
<td class="num">(29.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OPSUMITMember', window );">OPSUMIT | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,819<span></span>
</td>
<td class="nump">$ 1,639<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">23.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_UPTRAVIMember', window );">UPTRAVI | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,237<span></span>
</td>
<td class="nump">$ 1,093<span></span>
</td>
<td class="nump">819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">13.10%<span></span>
</td>
<td class="nump">33.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherMember', window );">Other | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 395<span></span>
</td>
<td class="nump">$ 416<span></span>
</td>
<td class="nump">476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(5.00%)<span></span>
</td>
<td class="num">(12.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherMember', window );">Other | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 981<span></span>
</td>
<td class="nump">$ 1,186<span></span>
</td>
<td class="nump">1,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(17.30%)<span></span>
</td>
<td class="num">(12.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_XareltoMember', window );">XARELTO | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,438<span></span>
</td>
<td class="nump">$ 2,345<span></span>
</td>
<td class="nump">2,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember', window );">INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 563<span></span>
</td>
<td class="nump">$ 795<span></span>
</td>
<td class="nump">735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(29.30%)<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PROCRITEPREXMember', window );">PROCRIT/EPREX | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 479<span></span>
</td>
<td class="nump">$ 552<span></span>
</td>
<td class="nump">790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(13.30%)<span></span>
</td>
<td class="num">(30.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_HIPSMember', window );">HIPS | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,485<span></span>
</td>
<td class="nump">$ 1,280<span></span>
</td>
<td class="nump">1,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_KNEESMember', window );">KNEES | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,325<span></span>
</td>
<td class="nump">$ 1,170<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">13.30%<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TRAUMAMember', window );">TRAUMA | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,885<span></span>
</td>
<td class="nump">$ 2,614<span></span>
</td>
<td class="nump">2,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">10.40%<span></span>
</td>
<td class="num">(3.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_SPINESPORTSOTHERMember', window );">SPINE,SPORTS &amp; OTHER | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,893<span></span>
</td>
<td class="nump">$ 2,699<span></span>
</td>
<td class="nump">3,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">7.20%<span></span>
</td>
<td class="num">(15.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ADVANCEDMember', window );">ADVANCED | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,622<span></span>
</td>
<td class="nump">$ 3,839<span></span>
</td>
<td class="nump">4,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">20.40%<span></span>
</td>
<td class="num">(6.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_GENERALMember', window );">GENERAL | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,190<span></span>
</td>
<td class="nump">$ 4,392<span></span>
</td>
<td class="nump">5,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">18.10%<span></span>
</td>
<td class="num">(18.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember', window );">CONTACT LENSES/OTHER | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,440<span></span>
</td>
<td class="nump">$ 2,994<span></span>
</td>
<td class="nump">3,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">14.90%<span></span>
</td>
<td class="num">(11.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_SURGICALMember', window );">SURGICAL | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,248<span></span>
</td>
<td class="nump">$ 925<span></span>
</td>
<td class="nump">1,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">34.90%<span></span>
</td>
<td class="num">(24.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 47,156<span></span>
</td>
<td class="nump">$ 43,133<span></span>
</td>
<td class="nump">42,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">9.30%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 6,516<span></span>
</td>
<td class="nump">$ 6,362<span></span>
</td>
<td class="nump">5,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 27,954<span></span>
</td>
<td class="nump">$ 25,735<span></span>
</td>
<td class="nump">23,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">8.60%<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 10,843<span></span>
</td>
<td class="nump">$ 10,175<span></span>
</td>
<td class="nump">9,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,249<span></span>
</td>
<td class="nump">$ 1,735<span></span>
</td>
<td class="nump">1,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">29.70%<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,347<span></span>
</td>
<td class="nump">$ 3,091<span></span>
</td>
<td class="nump">2,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">8.30%<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,958<span></span>
</td>
<td class="nump">$ 5,092<span></span>
</td>
<td class="nump">4,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">18.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,365<span></span>
</td>
<td class="nump">$ 2,133<span></span>
</td>
<td class="nump">1,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">10.90%<span></span>
</td>
<td class="nump">26.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,192<span></span>
</td>
<td class="nump">$ 3,509<span></span>
</td>
<td class="nump">3,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 12,686<span></span>
</td>
<td class="nump">$ 11,036<span></span>
</td>
<td class="nump">12,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">14.90%<span></span>
</td>
<td class="num">(10.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Medical Devices | Interventional Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,836<span></span>
</td>
<td class="nump">$ 1,452<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">26.40%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,126<span></span>
</td>
<td class="nump">$ 4,779<span></span>
</td>
<td class="nump">5,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">7.30%<span></span>
</td>
<td class="num">(10.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,867<span></span>
</td>
<td class="nump">$ 3,249<span></span>
</td>
<td class="nump">3,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="num">(15.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,857<span></span>
</td>
<td class="nump">$ 1,557<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">19.30%<span></span>
</td>
<td class="num">(13.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | OTC | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,594<span></span>
</td>
<td class="nump">$ 2,460<span></span>
</td>
<td class="nump">2,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">22.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Skin health/Beauty | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 2,350<span></span>
</td>
<td class="nump">2,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Oral Care | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 637<span></span>
</td>
<td class="nump">$ 683<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(6.70%)<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Baby Care | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 378<span></span>
</td>
<td class="nump">$ 376<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Women's Health | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Wound Care and Other | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 495<span></span>
</td>
<td class="nump">$ 480<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">8.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Remicade | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,019<span></span>
</td>
<td class="nump">$ 2,508<span></span>
</td>
<td class="nump">3,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(19.50%)<span></span>
</td>
<td class="num">(18.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Simponi/Simponi Aria | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,127<span></span>
</td>
<td class="nump">$ 1,155<span></span>
</td>
<td class="nump">1,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(2.40%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Stelara | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,938<span></span>
</td>
<td class="nump">$ 5,240<span></span>
</td>
<td class="nump">4,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">13.30%<span></span>
</td>
<td class="nump">20.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Tremfya | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,503<span></span>
</td>
<td class="nump">$ 926<span></span>
</td>
<td class="nump">764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">62.30%<span></span>
</td>
<td class="nump">21.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other Immunology | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | COVID-19 | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">634<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(7.60%)<span></span>
</td>
<td class="num">(11.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,508<span></span>
</td>
<td class="nump">$ 1,587<span></span>
</td>
<td class="nump">1,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(4.90%)<span></span>
</td>
<td class="nump">11.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other Infectious Diseases | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(36.00%)<span></span>
</td>
<td class="num">(17.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(5.80%)<span></span>
</td>
<td class="num">(21.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,550<span></span>
</td>
<td class="nump">$ 2,314<span></span>
</td>
<td class="nump">2,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">10.20%<span></span>
</td>
<td class="nump">9.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | RISPERDAL CONSTA | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 287<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(2.90%)<span></span>
</td>
<td class="num">(5.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 338<span></span>
</td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">13.30%<span></span>
</td>
<td class="nump">12.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | DARZALEX | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,169<span></span>
</td>
<td class="nump">$ 2,232<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">42.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | ERLEADA | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 813<span></span>
</td>
<td class="nump">$ 583<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">39.30%<span></span>
</td>
<td class="nump">96.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | IMBRUVICA | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,747<span></span>
</td>
<td class="nump">$ 1,821<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">17.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | ZYTIGA/abiraterone acetate | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 119<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(68.10%)<span></span>
</td>
<td class="num">(54.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other Oncology | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">31.70%<span></span>
</td>
<td class="nump">18.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | OPSUMIT | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,147<span></span>
</td>
<td class="nump">$ 1,008<span></span>
</td>
<td class="nump">766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">13.70%<span></span>
</td>
<td class="nump">31.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | UPTRAVI | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,056<span></span>
</td>
<td class="nump">$ 955<span></span>
</td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">10.50%<span></span>
</td>
<td class="nump">33.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(3.70%)<span></span>
</td>
<td class="num">(17.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 223<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(31.00%)<span></span>
</td>
<td class="num">(15.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | XARELTO | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,438<span></span>
</td>
<td class="nump">$ 2,345<span></span>
</td>
<td class="nump">2,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 308<span></span>
</td>
<td class="nump">$ 564<span></span>
</td>
<td class="nump">536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(45.40%)<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | PROCRIT/EPREX | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 223<span></span>
</td>
<td class="nump">$ 277<span></span>
</td>
<td class="nump">505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(19.70%)<span></span>
</td>
<td class="num">(45.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | HIPS | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 883<span></span>
</td>
<td class="nump">$ 793<span></span>
</td>
<td class="nump">863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">11.40%<span></span>
</td>
<td class="num">(8.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | KNEES | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 787<span></span>
</td>
<td class="nump">$ 743<span></span>
</td>
<td class="nump">889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">5.90%<span></span>
</td>
<td class="num">(16.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | TRAUMA | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,819<span></span>
</td>
<td class="nump">$ 1,648<span></span>
</td>
<td class="nump">1,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">10.40%<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | SPINE,SPORTS &amp; OTHER | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,637<span></span>
</td>
<td class="nump">$ 1,595<span></span>
</td>
<td class="nump">1,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="num">(16.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | ADVANCED | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,761<span></span>
</td>
<td class="nump">$ 1,535<span></span>
</td>
<td class="nump">1,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">14.90%<span></span>
</td>
<td class="num">(6.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | GENERAL | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,105<span></span>
</td>
<td class="nump">$ 1,714<span></span>
</td>
<td class="nump">2,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">22.70%<span></span>
</td>
<td class="num">(21.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | CONTACT LENSES/OTHER | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,398<span></span>
</td>
<td class="nump">$ 1,213<span></span>
</td>
<td class="nump">1,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">15.20%<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | SURGICAL | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 459<span></span>
</td>
<td class="nump">$ 344<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">33.50%<span></span>
</td>
<td class="num">(29.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 46,619<span></span>
</td>
<td class="nump">$ 39,451<span></span>
</td>
<td class="nump">39,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">18.20%<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 8,119<span></span>
</td>
<td class="nump">$ 7,691<span></span>
</td>
<td class="nump">8,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="num">(4.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 24,126<span></span>
</td>
<td class="nump">$ 19,837<span></span>
</td>
<td class="nump">18,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">21.60%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,907<span></span>
</td>
<td class="nump">$ 4,880<span></span>
</td>
<td class="nump">4,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">13.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,612<span></span>
</td>
<td class="nump">$ 1,839<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">96.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,664<span></span>
</td>
<td class="nump">$ 3,457<span></span>
</td>
<td class="nump">3,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 8,590<span></span>
</td>
<td class="nump">$ 7,275<span></span>
</td>
<td class="nump">6,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">18.10%<span></span>
</td>
<td class="nump">13.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,085<span></span>
</td>
<td class="nump">$ 1,015<span></span>
</td>
<td class="nump">939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,268<span></span>
</td>
<td class="nump">$ 1,369<span></span>
</td>
<td class="nump">1,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(7.40%)<span></span>
</td>
<td class="num">(6.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 14,374<span></span>
</td>
<td class="nump">$ 11,923<span></span>
</td>
<td class="nump">13,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">20.60%<span></span>
</td>
<td class="num">(12.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Medical Devices | Interventional Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,135<span></span>
</td>
<td class="nump">$ 1,594<span></span>
</td>
<td class="nump">1,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,462<span></span>
</td>
<td class="nump">$ 2,984<span></span>
</td>
<td class="nump">3,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="num">(15.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,945<span></span>
</td>
<td class="nump">$ 4,983<span></span>
</td>
<td class="nump">5,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">19.30%<span></span>
</td>
<td class="num">(12.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,831<span></span>
</td>
<td class="nump">$ 2,362<span></span>
</td>
<td class="nump">2,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">19.80%<span></span>
</td>
<td class="num">(16.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | OTC | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,634<span></span>
</td>
<td class="nump">$ 2,364<span></span>
</td>
<td class="nump">2,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">11.40%<span></span>
</td>
<td class="num">(2.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Skin health/Beauty | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,141<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">2,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="num">(4.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Oral Care | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,008<span></span>
</td>
<td class="nump">$ 958<span></span>
</td>
<td class="nump">906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Baby Care | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,188<span></span>
</td>
<td class="nump">$ 1,141<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="num">(13.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Women's Health | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 905<span></span>
</td>
<td class="nump">$ 888<span></span>
</td>
<td class="nump">974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="num">(8.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Wound Care and Other | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Remicade | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 935<span></span>
</td>
<td class="nump">$ 893<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="num">(11.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Simponi/Simponi Aria | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,148<span></span>
</td>
<td class="nump">$ 1,088<span></span>
</td>
<td class="nump">1,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Stelara | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,196<span></span>
</td>
<td class="nump">$ 2,467<span></span>
</td>
<td class="nump">2,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">29.60%<span></span>
</td>
<td class="nump">22.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Tremfya | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 624<span></span>
</td>
<td class="nump">$ 421<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">48.20%<span></span>
</td>
<td class="nump">69.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other Immunology | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(73.30%)<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | COVID-19 | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,751<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 953<span></span>
</td>
<td class="nump">$ 920<span></span>
</td>
<td class="nump">812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">13.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 575<span></span>
</td>
<td class="nump">$ 597<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(3.60%)<span></span>
</td>
<td class="num">(13.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other Infectious Diseases | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 333<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 495<span></span>
</td>
<td class="nump">$ 439<span></span>
</td>
<td class="nump">463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">12.80%<span></span>
</td>
<td class="num">(5.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,472<span></span>
</td>
<td class="nump">$ 1,339<span></span>
</td>
<td class="nump">1,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">9.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | RISPERDAL CONSTA | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 305<span></span>
</td>
<td class="nump">$ 346<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(11.80%)<span></span>
</td>
<td class="num">(7.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,391<span></span>
</td>
<td class="nump">$ 1,334<span></span>
</td>
<td class="nump">1,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | DARZALEX | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,854<span></span>
</td>
<td class="nump">$ 1,958<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">45.80%<span></span>
</td>
<td class="nump">36.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | ERLEADA | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 478<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | IMBRUVICA | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,622<span></span>
</td>
<td class="nump">$ 2,307<span></span>
</td>
<td class="nump">1,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">13.60%<span></span>
</td>
<td class="nump">24.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | ZYTIGA/abiraterone acetate | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,178<span></span>
</td>
<td class="nump">$ 2,097<span></span>
</td>
<td class="nump">1,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other Oncology | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 458<span></span>
</td>
<td class="nump">$ 738<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(37.90%)<span></span>
</td>
<td class="num">(32.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | OPSUMIT | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 672<span></span>
</td>
<td class="nump">$ 631<span></span>
</td>
<td class="nump">562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">12.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | UPTRAVI | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">31.10%<span></span>
</td>
<td class="nump">30.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(5.90%)<span></span>
</td>
<td class="num">(9.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 758<span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
<td class="nump">974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(12.20%)<span></span>
</td>
<td class="num">(11.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | XARELTO | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 254<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="nump">16.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | PROCRIT/EPREX | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 256<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(6.80%)<span></span>
</td>
<td class="num">(3.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | HIPS | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 602<span></span>
</td>
<td class="nump">$ 487<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">23.60%<span></span>
</td>
<td class="num">(15.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | KNEES | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 538<span></span>
</td>
<td class="nump">$ 427<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">26.10%<span></span>
</td>
<td class="num">(27.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | TRAUMA | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,066<span></span>
</td>
<td class="nump">$ 966<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">10.40%<span></span>
</td>
<td class="num">(9.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | SPINE,SPORTS &amp; OTHER | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,256<span></span>
</td>
<td class="nump">$ 1,104<span></span>
</td>
<td class="nump">1,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">13.80%<span></span>
</td>
<td class="num">(14.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | ADVANCED | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,861<span></span>
</td>
<td class="nump">$ 2,304<span></span>
</td>
<td class="nump">2,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">24.10%<span></span>
</td>
<td class="num">(6.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | GENERAL | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,085<span></span>
</td>
<td class="nump">$ 2,679<span></span>
</td>
<td class="nump">3,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">15.20%<span></span>
</td>
<td class="num">(16.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | CONTACT LENSES/OTHER | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,043<span></span>
</td>
<td class="nump">$ 1,781<span></span>
</td>
<td class="nump">2,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">14.70%<span></span>
</td>
<td class="num">(14.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | SURGICAL | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 788<span></span>
</td>
<td class="nump">$ 581<span></span>
</td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">35.70%<span></span>
</td>
<td class="num">(21.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember', window );">UNITED STATES Exports | Remicade | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 236<span></span>
</td>
<td class="nump">$ 346<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(31.90%)<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInSalesBySegmentOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage change in sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInSalesBySegmentOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_SurgeryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_SurgeryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_VisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_VisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SkinHealthBeautyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SkinHealthBeautyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OralCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OralCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_BabyCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_BabyCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_WomensHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_WomensHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RemicadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RemicadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_StelaraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_StelaraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TremfyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TremfyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_DARZALEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_DARZALEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ErleadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ErleadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_IMBRUVICAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_IMBRUVICAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ZYTIGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ZYTIGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OPSUMITMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OPSUMITMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_UPTRAVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_UPTRAVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_XareltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_XareltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PROCRITEPREXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PROCRITEPREXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_HIPSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_HIPSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_KNEESMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_KNEESMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TRAUMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TRAUMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SPINESPORTSOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SPINESPORTSOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ADVANCEDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ADVANCEDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_GENERALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_GENERALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SURGICALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SURGICALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740080887688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 29, 2019 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">$ 22,776<span></span>
</td>
<td class="nump">$ 16,497<span></span>
</td>
<td class="nump">$ 17,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">182,018<span></span>
</td>
<td class="nump">174,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">3,652<span></span>
</td>
<td class="nump">3,347<span></span>
</td>
<td class="nump">3,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">7,390<span></span>
</td>
<td class="nump">7,231<span></span>
</td>
<td class="nump">7,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 93,775<span></span>
</td>
<td class="nump">82,584<span></span>
</td>
<td class="nump">$ 82,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments | Segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,148)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_AdvancedSterilizationProductsMember', window );">AdvancedSterilizationProducts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">18,962<span></span>
</td>
<td class="nump">18,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">81,638<span></span>
</td>
<td class="nump">$ 89,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="num">$ (1,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=jnj_Wholesaler1Member', window );">Wholesaler 1 | Sales Revenue, Net | Wholesaler Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=jnj_Wholesaler2Member', window );">Wholesaler 2 | Sales Revenue, Net | Wholesaler Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=jnj_Wholesaler3Member', window );">Wholesaler 3 | Sales Revenue, Net | Wholesaler Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 47,156<span></span>
</td>
<td class="nump">$ 43,133<span></span>
</td>
<td class="nump">$ 42,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">14,635<span></span>
</td>
<td class="nump">14,053<span></span>
</td>
<td class="nump">13,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Ci:z Holdings Co. Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfEquityInvestments', window );">Gain (loss) on sale of equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">6,516<span></span>
</td>
<td class="nump">6,362<span></span>
</td>
<td class="nump">5,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">52,080<span></span>
</td>
<td class="nump">45,572<span></span>
</td>
<td class="nump">42,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on divestiture</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Marketable securities, realized gain (loss)</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Actelion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">27,954<span></span>
</td>
<td class="nump">25,735<span></span>
</td>
<td class="nump">23,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">27,060<span></span>
</td>
<td class="nump">22,959<span></span>
</td>
<td class="nump">25,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RegulationCharge', window );">Regulation charge</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Auris Health | Other Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">12,686<span></span>
</td>
<td class="nump">11,036<span></span>
</td>
<td class="nump">12,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_SegmentsTotalMember', window );">Segments Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">142,829<span></span>
</td>
<td class="nump">143,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">3,462<span></span>
</td>
<td class="nump">3,091<span></span>
</td>
<td class="nump">3,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">7,074<span></span>
</td>
<td class="nump">6,931<span></span>
</td>
<td class="nump">6,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ExpenseNotAllocatedToSegments', window );">Less: Expense not allocated to segments</a></td>
<td class="nump">1,072<span></span>
</td>
<td class="nump">945<span></span>
</td>
<td class="nump">835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherNonLongLivedAssets', window );">Other Non Long Lived Assets</a></td>
<td class="nump">81,418<span></span>
</td>
<td class="nump">66,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment | General Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">39,189<span></span>
</td>
<td class="nump">31,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">1,014<span></span>
</td>
<td class="nump">1,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">23,848<span></span>
</td>
<td class="nump">17,442<span></span>
</td>
<td class="nump">18,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">93,775<span></span>
</td>
<td class="nump">82,584<span></span>
</td>
<td class="nump">82,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">99,586<span></span>
</td>
<td class="nump">107,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">47,156<span></span>
</td>
<td class="nump">43,133<span></span>
</td>
<td class="nump">42,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">48,586<span></span>
</td>
<td class="nump">49,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">23,594<span></span>
</td>
<td class="nump">18,980<span></span>
</td>
<td class="nump">18,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">43,257<span></span>
</td>
<td class="nump">49,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Western Hemisphere excluding U.S.&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">5,750<span></span>
</td>
<td class="nump">5,335<span></span>
</td>
<td class="nump">5,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">2,708<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Asia-Pacific, Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">17,275<span></span>
</td>
<td class="nump">15,136<span></span>
</td>
<td class="nump">15,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">5,035<span></span>
</td>
<td class="nump">5,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">1,294<span></span>
</td>
<td class="num">(1,064)<span></span>
</td>
<td class="nump">2,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">25,081<span></span>
</td>
<td class="nump">27,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">759<span></span>
</td>
<td class="nump">785<span></span>
</td>
<td class="nump">765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">18,181<span></span>
</td>
<td class="nump">15,462<span></span>
</td>
<td class="nump">8,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">64,376<span></span>
</td>
<td class="nump">66,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">1,198<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="nump">950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">4,029<span></span>
</td>
<td class="nump">4,006<span></span>
</td>
<td class="nump">3,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss) on securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">4,373<span></span>
</td>
<td class="nump">3,044<span></span>
</td>
<td class="nump">7,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">53,372<span></span>
</td>
<td class="nump">49,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">1,933<span></span>
</td>
<td class="nump">1,980<span></span>
</td>
<td class="nump">1,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">2,286<span></span>
</td>
<td class="nump">2,140<span></span>
</td>
<td class="nump">2,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical Devices | AdvancedSterilizationProducts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember', window );">Immunology | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">16,750<span></span>
</td>
<td class="nump">15,055<span></span>
</td>
<td class="nump">13,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember', window );">Immunology | Pharmaceutical | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 10,843<span></span>
</td>
<td class="nump">$ 10,175<span></span>
</td>
<td class="nump">$ 9,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ExpenseNotAllocatedToSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense not allocated to segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ExpenseNotAllocatedToSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherNonLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other non long lived assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherNonLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RegulationCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulation charge</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RegulationCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_AdvancedSterilizationProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_AdvancedSterilizationProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=jnj_Wholesaler1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=jnj_Wholesaler1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=jnj_WholesalerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=jnj_WholesalerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=jnj_Wholesaler2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=jnj_Wholesaler2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=jnj_Wholesaler3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=jnj_Wholesaler3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_CizHoldingsCo.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_CizHoldingsCo.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_ActelionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_ActelionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_SegmentsTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_SegmentsTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_GeneralCorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_GeneralCorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740158020888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Narrative (Details)<br> $ / shares in Units, shares in Millions, SFr in Millions, $ in Millions, &#165; in Billions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 17, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 17, 2019 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Oct. 03, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>CHF (SFr) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>CHF (SFr) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 29, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th"><div>Jan. 16, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Notes&#160;1 and 5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(489)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,899)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,525)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets, excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_A2019AcquisitionsMember', window );">2019 Acquisitions | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Purchase price over fair value of assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_BusinessAcquisitionDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Notes&#160;1 and 5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Marketable securities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets, excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_CizHoldingsCo.Ltd.Member', window );">Ci:z Holdings Co. Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">&#165; 230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Notes&#160;1 and 5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life of acquired intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_IdorsiaMember', window );">Idorsia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction', window );">Sale of stock, percentage of ownership before transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit', window );">Proceeds from sale of equity interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">SFr 337.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ConvertibleNoteEquityInterestNumberOfShares', window );">Convertible note, equity Interest (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.7<span></span>
</td>
<td class="nump">38.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_MomentaMember', window );">Momenta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_BusinessAcquisitionDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Notes&#160;1 and 5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Other assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_MomentaMember', window );">Momenta | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_A2020AcquisitionsMember', window );">2020 Acquisitions | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Purchase price over fair value of assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember', window );">bermekimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_BusinessAcquisitionDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember', window );">bermekimab | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets, excluding goodwill</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_VerbSurgicalIncMember', window );">Verb Surgical Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Notes&#160;1 and 5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Other assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Equity method investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Momenta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | bermekimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Momenta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | bermekimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Idorsia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 445.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DebtInstrumentConvertibleAmountOfLoanConverted', window );">Convertible debt, amount of loan converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">SFr 110.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Convertible Debt, number of equity instruments (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_AdvancedSterilizationProductsMember', window );">AdvancedSterilizationProducts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_EvraAndDoxilMember', window );">Evra and Doxil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestiture of brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember', window );">Discontinued Operations, Held-for-sale or Disposed of by Sale | AdvancedSterilizationProducts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Disposal group, including discontinued operation, consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash', window );">Disposal group, including discontinued operation, cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained', window );">Disposal group, including discontinued operation, receivables retained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_BusinessAcquisitionDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_BusinessAcquisitionDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_BusinessCombinationProbabilityOfSuccessFactor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Probability Of Success Factor</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_BusinessCombinationProbabilityOfSuccessFactor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ConvertibleNoteEquityInterestNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Note, Equity Interest, number of shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ConvertibleNoteEquityInterestNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DebtInstrumentConvertibleAmountOfLoanConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Amount of Loan Converted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DebtInstrumentConvertibleAmountOfLoanConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Receivables Retained</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand, demand deposits with banks or financial institutions, and  other kinds of accounts that have the general characteristics of demand deposits, held by a disposal group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125513658&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32618-110901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow resulting from the sale of an interest in a corporate unit during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfInterestInCorporateUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_A2019AcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_A2019AcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_CizHoldingsCo.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_CizHoldingsCo.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_IdorsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_IdorsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_MomentaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_MomentaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_A2020AcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_A2020AcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_VerbSurgicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_VerbSurgicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_AdvancedSterilizationProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_AdvancedSterilizationProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_EvraAndDoxilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_EvraAndDoxilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740159308888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 20, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 28, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 29, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>cases</div>
</th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>claimant</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>cases</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>claimant </div>
<div>cases</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2015 </div>
<div>claim</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_AsrMember', window );">ASR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember', window );">Pinnacle Acetabular Cup System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember', window );">Pelvic Meshes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_RisperdalMember', window );">Risperdal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_XareltoMember', window );">XARELTO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TalcMember', window );">Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_InvokanaMember', window );">Invokana</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember', window );">Physiomesh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OpioidMember', window );">Opioid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ContactLensesMember', window );">Contact Lenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation | Opioid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue', window );">Damages awarded, including settlement for related issues, reimbursement for legal fees, and removal from related claims | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297.0<span></span>
</td>
<td class="nump">263.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember', window );">Judicial Ruling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 8,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LossContingencyEstimateOfAdditionalPossibleLoss', window );">Loss contingency, estimate of additional possible loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation | Physiomesh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement', window );">Number of claims within settlement agreement | cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation | Physiomesh | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation | Opioid | State Level Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation | Opioid | Federal Level Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member', window );">DePuy ASR U.S. | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_Numberofpatientsinsettlement', window );">Number of patients in settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_BabyPowderMember', window );">Baby Powder | Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LossContingencyReserveEstablishedWithinTrust', window );">Reserve established | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_BabyPowderMember', window );">Baby Powder | Judicial Ruling | Damages from Product Defects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Litigation contingency | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember', window );">Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember', window );">Surgical Mesh Products Marketing | Judicial Ruling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="nump">$ 344.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LegalProceedingTextualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal Proceeding Textuals Abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LegalProceedingTextualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Damages Awarded, Additional Reimbursement, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyEstimateOfAdditionalPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Additional Possible Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyEstimateOfAdditionalPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Claims within Settlement Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyReserveEstablishedWithinTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Reserve Established within Trust</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyReserveEstablishedWithinTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_Numberofpatientsinsettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patients in settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_Numberofpatientsinsettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProductLiabilityContingencyNumberOfClaimant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product liability contingency number of claimant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProductLiabilityContingencyNumberOfClaimant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_AsrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_AsrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PelvicMeshesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RisperdalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RisperdalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_XareltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_XareltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_InvokanaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_InvokanaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PhysiomeshMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OpioidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OpioidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ContactLensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ContactLensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LegalJurisdictionAxis=jnj_StateLevelJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LegalJurisdictionAxis=jnj_StateLevelJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LegalJurisdictionAxis=jnj_FederalLevelJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LegalJurisdictionAxis=jnj_FederalLevelJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_BabyPowderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_BabyPowderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740165599320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring costs incurred since announced</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Other Income Expense Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostExpectedFutureSavings', window );">Restructuring and related cost, expected future savings</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Pre-tax restructuring charges</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostDurationofRestructuringPlan', window );">Restructuring and related cost, duration of restructuring plan</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostExpectedFutureSavings', window );">Restructuring and related cost, expected future savings</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Pre-tax restructuring charges</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostDurationofRestructuringPlan', window );">Restructuring and related cost, duration of restructuring plan</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RestructuringandRelatedCostDurationofRestructuringPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Duration of Restructuring Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RestructuringandRelatedCostDurationofRestructuringPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RestructuringandRelatedCostExpectedFutureSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Expected Future Savings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RestructuringandRelatedCostExpectedFutureSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740160733528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Summary of Severance Charges and Associated Spending (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Activity during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_GainOnSaleOfAnAssetPaymentForRestructuring', window );">Cash settlements</a></td>
<td class="num">(427)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance | Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Activity during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_GainOnSaleOfAnAssetPaymentForRestructuring', window );">Cash settlements</a></td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance | Supply Chain | Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember', window );">Asset Write-offs/Sales | Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Activity during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_GainOnSaleOfAnAssetPaymentForRestructuring', window );">Cash settlements</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember', window );">Asset Write-offs/Sales | Supply Chain | Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other | Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Activity during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_GainOnSaleOfAnAssetPaymentForRestructuring', window );">Cash settlements</a></td>
<td class="num">(404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other | Supply Chain | Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_GainOnSaleOfAnAssetPaymentForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on Sale of an Asset (Payment) for Restructuring</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_GainOnSaleOfAnAssetPaymentForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReservePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the accrual for restructuring costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReservePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveSettledWithoutCash2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the reserve for full or partial settlement through consideration other than cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveSettledWithoutCash2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_SupplyChainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_SupplyChainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>jnj-20220102_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:jnj="http://www.jnj.com/20220102"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="jnj-20220102.xsd" xlink:type="simple"/>
    <context id="i20918a3d76934ae3867fbaabde676443_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i358cc237f97d4810a1abd5b9de60ad85_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="idab25bcb2e7e45a48ac378b27f9146f5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i392be2e4ae3149e8afab760b8a03cf5a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i72f05d226e504140b886d1d1d2e1240e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i4245bb20b07345a4913a280495de0ce9_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ic57d5f238fed45668d8b43777b0d8cec_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="i90afe5d53fd9474bad9a6c64ad556568_I20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-02-10</instant>
        </period>
    </context>
    <context id="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i2291de62b68a41a0b629948bd1c56c1c_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ia2087646dc6744a28755f382fc0a83c8_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="i37828c53082f418d82b181eca97c9828_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="i8503a818334a40a588f1d51c6b02cbdd_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="ib9eaed1449a745b293b614e71ca57f4e_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="i6ad9ecbc1c9a4fc99c00bdc33b0042a9_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="id7363031583c4556a56c66f8230d2edb_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i506f1bb3ec9a4c2fa89004c3dc9d077b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i0f88c24f46d04306b18b2052c29a8b77_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i70ed7bf48d664a018365719e86ad0f9b_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i2c3c777d14a94558a9524c8d48022809_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i00d93b4bd07f45c5b3b285162b1f7ac1_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i32714d4caccf4a978d06df9c559c7342_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i3dbfa2026c924048a41d1a2e7ab20fe2_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if090847b243c45b38f83514b26483411_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iaa5fa270dceb439ab74cfc1fa351ade8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5986c2c6f01d4f0ba394a6d7cad02794_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i2264aac360274fdbb45a327357031ad9_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ice303ba3fb57401c902937dcecc85b8a_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ice5631336113469c8d53050918b83329_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i3a3fc6829cad467cbb53b7a1fe81a50a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ide5f195a7f1f400580767c19f5aada99_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i91696814d2cc4ce18c1ad6fe530463f4_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i456831c91d5b4616a6190fa546fd617b_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i857ac21d217c4940938fa16c01722dcd_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i864da61d817849afadab2a86db4b41cb_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i32f1b367b80b48e593609d66c7aa128c_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i43031434703546208388df65cfb38be8_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i014ba6f3e80849a28122f5bc50cd0d40_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id99da0671adc429480c2f2f9dfd88fcc_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i698e54dd726c4d32801340b6a2864ac6_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia09026d98ab54d0ab3a6818b803f2d60_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7bd54d7094d64fd0b19d0a1281d9b700_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia0ad24090c2d488cb2a8dadbaca511fa_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i28f696c1c6874735a62135bedd0cf600_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i19a5a3c7ee35405ba80137bf84570da6_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ib90b59b163b542a1adf97f356be068eb_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i460777456be14637947184c662627b8b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9624c6a1bedd497c80dbb2352574e47f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i093d06247d2c44aa8f18996fcd289352_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ic2ccb55418494f0c9e1a4c75f0b03e66_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="if755ebb14d5b4945b2b45f2055df1f4d_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i2214ef047a294d0ca9d41d06ad0fb607_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i13202586bd644a6e92b8bfdf9c3a4ede_D20170102-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2017-01-02</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i90352e12079c4d1fb386797dfa54f1b7_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ibe0d9084821448c9b54197410a611a82_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ied5749f9adf2410da151a894ff6b6ef6_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i252e4b54420c4dde85f5fd67aa0422b4_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i452410a40d07461f83a08316f634a401_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i70e8bf5abffa4483b11b26ea2161affe_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="if52d136488484e92a32ea314340d972c_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i9fb97dbd3891498f92976302fc99a0ec_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="id14a4eca31dd4e00a85267ec8f40ec78_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="idf6e725073c14b38991908baa96e1d7d_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">jnj:OtherSovereignSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="if7ea071f45f34fd7ba90322c1178679b_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ica9cfb292ef54c7a93d6ee930b4c18b6_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i22c801516ef3458cb70b9d6768e94cc8_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i71f498cef62e47498c8115a8257a7f5c_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i8d7e47ac51a74794aa5dd2b7dddcbc9a_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i2dda7dc33acb494ab90787cb95a42bd6_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i3ec8bdf1492e47008be52fa4584b89b6_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i8f3e3e39127c4af6809fdfd339d25195_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i2d963d3b70ad451fab86f669cf84769c_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i9ee19fc5a38645fd8e5d2c3bde0c13ae_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i2732aa7ddf3c4fc584a545a80ed55496_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">jnj:OtherSovereignSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i2b07805351ce42b98b594c790d5114ee_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i8c6300a66b9a4b979eb41526a4c94fb3_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i4a7352ca619841d79bdbb2c6ab3f2250_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ib364b47fe9454f339d85cae2d78e751e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="id0f4b2d54b954ffba9bb73844eeb14ce_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i88b324b449f448d9b34e40182d15e032_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i9f40ebb739fb428985cccbc8ef38df17_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ia56c56468be347ee80d5f33b118fa31d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i5ed4936b7ad042b8b7e83fda8d3b4873_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ia1204533ce0a4d7aaffb4e685bdbfa57_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i7ae060052d4740af8581a0a0eb3df2c9_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i48cb4cc5378a4a059f9b5fdc68b7045f_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ifc2ea168b3aa471788ebf1eb8f662c13_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i663b04fe910b4db3913be35f413b1086_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="iee8c7d3f6c6c4979b1116a020a60940f_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ic27bd4dd176844408f1e04f435bb2a53_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i07a8e81747cd49fdb8dd11022b941933_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="iabc2d103024d42f6b18c1c1e3fead71d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i6c822c4eb5ed4bbcb5d13167c9341beb_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7efc7098a12d46b8a4268c1f5f6471f0_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i0b8d65d037cb434ebb1aab6adcf3472e_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="if7e98efb6dee498ba2fde96801469678_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="if43f753e349c40788db498a0b8a5fe34_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia9f7770a07704889bef20acb8a0c5220_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i86ddb5ada6e24683aa7c697889661250_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i87ca486a39254f2e9a23c4f2f015bf3a_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i9bd00e52fe1e423e8c220d276d67dac9_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i1198f98bdb8f4597b4a10112426c5f06_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i98801c17d85a449bba4c52f12426dc9a_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i795ce14783b64a95bab66ad564c35fe9_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i44e7c974360849d3ba8c0295bf5a75f9_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i003dc23bbef8425a95b799e88c2ea3cc_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i481d55d4f8994158a9674ef0152c9f10_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ide40f8c8eeea4d2e8f7770aabdc662ff_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ife54767ac5ea4ca28081964675153a39_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ifd2d53c5c93540bc8d713ea6f655ed74_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i84703fb2bb5c49cabc6f3a6a621d65b8_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i808995d91a27460c9150c476dd1da392_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia0192bf715a243bf91d01442328393a5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id60bdb5b63a8467fa3b6eeb112fbe483_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9b7e0a2b5849409ca6652a1b1d9009f8_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i0c3d3ec9cd0343bea423885018d25702_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i3c38412ef9e6497482c4931bff7adc40_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i19a92a1966c547b5b282d744cb467936_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6100225b54fc4ad197e03ca829ba928d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib720add8d11a4684b8b6655ee5659b4c_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i106b831f4ff540dab0212fc0f723cb2f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i52a259e92c5049eda0dbf8c42cea6804_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id786d862a5f04ff48bcbb29805518774_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i985b96ccd9484a66b346bc504f80d0a1_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7dbc1cc0cc71418babaecbd428b53b3b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i2ec2a313be1445888459a2cb95ec031b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9d672893c8cc417db3f3cd8f14697306_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5dd978faac464658a1798c339c543b0a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if14f023407364aa181f33d20d53b160b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if3c166abab67452688a30d1ef04d16f1_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id5665ea9b95743bf9c890aefaf80d04a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1b31f531f8d1475f88bdb4724aace2fd_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i92c7f67b422f4287a1a96e34cff07706_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i0446032e1785439f985c59f1a7df1bcc_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i63c2845f743f49b9b13f7ad7d5f81f15_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia828ba075e524e7090012a4cdc4a5662_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i05d7cbac295a4d9d8247f5d8e6c2cdaa_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i78f4b6c63cab436a8845f1c2ac4c66f9_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i848c6b8efe174f4e9f95b5f1dd159ef4_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i07bde8491d87476ca7b9ebedfa820539_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i634edb5f28be4c3db07ca7a3116c19fb_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib0123bf3fb024b76ae1885d1761a5b82_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="idfd790bc28d74dff8d098e4985e0db53_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i1ae16c703b374886a06975f54aceaedc_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i0d4ccba4445542b791db72cb4a2b0c5e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i8eb2552df8fe44b0a4e1444a56e55504_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i032a01d82e6b46aca1a6b8385c458f94_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9affd553b7d74c819ed99f3018b801a6_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ief391a34b2eb4d2d8fe2aaaff100ce78_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if28f0b8b33504b4f9f89e9d449f06cb6_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ifa5a045453b74d8195dd434da3e842f7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if076b21d69e44a83b09033d94b086ac3_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i52546e6d078c45f7ac9bd5ced9ab7cf3_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i92e2a8e7af49412bbc0f28e465623b6f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i174a527600c44ee8992a7b48db2a0f80_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie117c70d8dab414e86a30cd9df792971_D20211004-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia2a9a8b7f5c64483bd4a1030ddd50c04_D20200928-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-28</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ibd102efd0d744d738ffe8f80c0ea4d4f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia8082b83eab643a19df9232e909a1570_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i223217fcf82c4c9fbd27757bd7ab98f3_D20211004-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="idf5fca83f72e4903ab75e0c5be5d0b90_D20200928-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-28</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iaba88d1e19f44fdeb865036ee60e1e26_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i039392ea3c3b403db051bc1af156bce0_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i0ded06cef625444b86727e06867cbda7_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ic0a4bb0a45cf4321a078221f082dc745_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i5bb81f8d839b475bac63d7d23d05d99b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id87a7804b1f44de484b175a96356f43f_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i1bbf538e3b42487aabaada415c912f2b_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="iaec68da81f3f4ed78748a512faa1b83a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8e2c57afbb094c14a7064ef903706da7_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i904861e4f8ed471381dbacfc8e3ab52e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8c8d98bc79544f2796d5f14b04f588e5_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ifc765a63065f4fc7a9606b02f261afad_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i071cfab120ae4af6b209509a7218091d_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ie4babc1d42ff4632a1e3e6b5c723c86f_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i7b06190f006c4dce9af3c9f28a239d36_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ibcee04e7edb6498692d55fa0db8bfab5_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i1b3713ead11f41faa96420921c930eba_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ieab28e9d35ce41f88040fcdf057e21e4_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="if6fce32d455546de8f77cd04c86b5dd7_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i769b6005fa4c4532801176ab7112c4aa_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i7ed3758031c041a586a6a2d9b7ea4c75_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="iac6290a59e7c45c899a410f1f0e2c835_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i4e2707e7b5d243d78d1b3c5313fcea06_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ic7b9bae4686a473695740b6d4c2202f6_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i81f3450daac144e3af1b7a08f181808b_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i5254374306bb4a078614cffdec9aabe0_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i093bf273c79847d989c1c903a61b7968_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ia24860d7401b457eba3d9b0be9935de4_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i1d16f4e3e01647648ac49ed4c2dda9b8_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i3965bff979ef4a58b0bbda03ce593630_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ieb6f78322e8048bd9abad306b8359695_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="if923e101b65a4eb9b85820250bc20ec0_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id163764cde774d6e9f3063f4dd81d013_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i5edd790b7e564a90a840e7e6dc7e272b_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i9a7fe279402746beaab8e640a5291e42_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i1abb55e4e6ba4d30a5bddbb2e70b1191_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i5a0bea261b2440189c3155cacb540621_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.65Notesdue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i904410fb32534db6ae296a0c7b27b0ca_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.65Notesdue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i69182c330b4b414e89f02252079a1706_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="if497493118ae4cde8380f3ccac17ff11_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i550e73b82fa342f982d286fe29ff7070_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.25Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i90668084b50c4dd2ba37011a73641c3e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.25Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i813c37b3fb784cd4be0ce6ef143587ab_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i1d636f7f126a4235961db45e96929aee_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i6c3b7af038464a8783ea5368d254f51b_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i6319e5cd14e849fb9bc1d26f55976e25_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i46c00efd504548b0a772f17dfaaf31a4_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="iaaad724dc80d4d528b251ff223f924c3_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ie52eb5fe20d44487a51c329a11aaefdb_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i35d501ad10624baf887280017b6b88cf_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ic325e42974444401b43cd0f7a06ca840_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i23ebbe6c25ea4f94a4f7a79af3ae380c_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="id03e49fef75f4ad086ee0152d3b7896f_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i7856d21e578e46b9b1070fee609a0e37_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ice544b21d87b4663b518b0e214c4294b_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A055NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ib04d55053c914695966b620bbf97d8eb_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A055NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="iff56df08a53e4e72b5ba1d8f127ae174_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i739863a8ea5642299f1ea5847ac97114_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ie1a46192ec1b4ed09aaafc90b80400a3_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i1831bd89995549639d1c19d6d216a958_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i972bf884bfea41ffb590c5a7eac07cd4_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i205cddf8beb44dffb12b506c83e24428_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i7fa3f9944b0c403d9f46170a329df816_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i1c5bee0e48bf4e4099a183bdeee52392_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i5cf895e15ef54040bfac0247f96946b9_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i37d3ee2aa4344396b0069afab5218f8a_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i6bbfeb41492140249fab5192b682546a_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i658f3103f74c4c7fbb7b36c491a45202_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i57a48838d3bc409fbed2cc1936c123cd_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A130NotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i0408738fa2104741b459f57515ad3ab1_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A130NotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i17953ea1893e452cb3c1c9dd6916994c_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i2c0880f1340c45b89ff33b5be547b0ce_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i2976154beffb47c4be5a474bc8db9894_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ic5d27e50b0964bbcb629a108b11c7420_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="iae7e9316990b44f98989c64c67ff0c10_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i2685a9e688f94a75a231df74311feb24_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ie17e8d053df0468983d5b9c5221888e5_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="if74440cec8d14911a94f8cbf380782ef_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i0adb5ffb62d14519a2797379c107d86e_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i47b9c1e7af3946a08254176836ec29a7_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i3ed9c4f37ce1466fa53ccf042656f5d6_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ia83c020a1a4849fb88e0231815c8866d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i0118c5eed732427f9cf06f31486fc01c_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ife7c692d97564c858b7b4ed1c803b286_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ic38bc0786162462d9877b064a6a205e6_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i726718a28d4d4e549a41a17182d08fe6_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i53a8fedc553f4f0f9de5d0a709173803_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i62b1dedd1b83419bb98c00b29d60b882_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i8bd1c41b5d0d42c69a6f96b89a46e668_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ib5eb48543498494ca45ded9c606d3d15_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib69f13bfa815433e85d3e00eef71fedf_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ie8d56c9e88f342bea407c38d6cd7e55f_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="icfa4a27c5acc457f8dfe7f024890432d_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="if36ddad29b164d53899d8ee23f080abd_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i11c0c665fc394565a535f0b2c5c1317b_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i54250135a56c4cd5be1d66d5f63431cf_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i50afe1be5edb4180890a7b5b27e4d27a_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i3faf3f90111144d7a940a9a2c71d768d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i6e28fa051d454297b4accf2668e5f29a_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="icbd71c42f6294b2fbf205f288d70c25a_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i168b47008a8445648dc5777fadae1587_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="id7aefbac28e2470ea9d6063671ef8da1_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i03664ec5ebbe4d8da845ff31701a77f2_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="idd4a9a1de87b4f128a0bb747c7a11f74_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i6aa10255024e47998e73466dc7e568bc_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="iec495cbb0c2c4cedbd4600d7d89a94d8_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ied2f6ed477eb4ce6ad7d7bfaa6f716d3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i64bd5e8b71f34e13ac4ffb87991525cb_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ie196b853653742808afbef735bb258c5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i8cd6b32233734c51bca233601a3752ae_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="icf0d50ada4f346ffb63114cb3d32ba28_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i2f79758b58cf409fb7e5e1f32144e7f6_D20211004-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7b0c1ad768954c3cb5d973a4cb0b4f0d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i161f67e1e8fc4b20952f5d16b610a1cc_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:RisperdalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i8aa69bd5ba1f43b3b6d5887ae14e8e86_D20211004-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i5b5fd248c6fa4b22b336af4f57cb8a47_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if70cf172b8f449b8bb218775e0fcb014_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i063d308c5d8f4797bb4e17583565d9b7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OpiodsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4882989be8b64ae0bf4ca80baf92c148_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OpiodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i7f6076db24f64e8b8d695cf2700ed061_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="ia9954ad68ee94f408f19784fd44dc96b_D20191001-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i7a80321fb97a41e480b2b933fde2af82_D20191201-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ieb7ecccc89964876b8660c4b222156cc_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie6a7535dcc684ff5971979c84c966ae9_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i152260c6c54041ec8a625469070aec87_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="if217fbfb3878426eba07b1762dc50833_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="idb9083ce9021495581a16b2fab55b31b_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i20e1360ceda342bdac619fa006a12c36_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i08e791c0544949eea59d9bb4511c337e_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i00ddcc25df744b98bd6075a18db56c7a_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i4cf76105357f41648e3142ea1703f16a_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i58b503af83254025807546f7f976450b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i5a1c5e25bdb6461788f20271b3996e97_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i58f88b3066f8425fb8a00e6f0f402f0c_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:QualifiedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i7e8d176ee39d4902bc1ae66d486ece07_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:QualifiedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ia15acadd24374bdd89b9144660681aac_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:NonQualifiedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i70e0e58ded464efe87df57667936575e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:NonQualifiedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib54b3dfabff34851a1673d1bd91d3667_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:FundedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ie541284941f54eb39c0cdd62a5aff1ac_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:FundedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ia1605c791bdd4560a2228fadfa81e2c5_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:UnfundedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="if7fcbc33c13a41e8885b35d3df83c640_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:UnfundedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i52c49a8c4db34117958d49e77780d7e7_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i1b45609e47e840bd9bc2b4829a2dfa26_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ic5c7a5058f0d4ea482b056a1543610b3_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ie47761f8002e45c199053ae0a267c678_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="iaafdd23d13d0493891e7d7ac9afa2c86_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i3c80cbf0e584468d8ffebcfcd75988d6_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i2fe30c736fe24e1ca4d36fc6c3007110_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="id4dd9dc19e6149b88426c05b99e85df6_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="id064b00e4ce442d3ab5bb43fe94a8111_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i6c1a29cf707e4f78a4258d452faef951_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i6980acd8ab1348a7a9d21340b15bbad1_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i547106227f34401da5bb7b68702b3644_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i1f22835beae34a80914d14a3e622b9b6_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ibc5fd4a09af04cc889161a3e85ab6ebb_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="iedb15225c1b941948e9771dbfe0bec89_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i93af333b5f5246b98690e521de9166f3_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ia3af6ce2fee94f8b8ad34e9cbe4c2959_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="id97dc2bfbc6b4c75a3fda94dda89b30d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i6398c3336be94b3782104a66be75812c_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i1fa9057e6eac45ea8abc150ad50bb903_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i4bae6b71cd68453fb9432e997b2ec281_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i99cb936201fa4622b0837f8dfecd6b89_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ic774cb65db23481fa83313228c547f8e_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ibc8a4ada79bb4caea9c29a70213afbb9_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i1f76e7653f5d4d2aa16e4e2b1264054d_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ibee6b63499d74ba8843e5919b699a3d5_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i2811f795aee94f61a4b7ca5101e1bb88_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="icb935c546f034a40abf2db76a024a9ce_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i8d95f694324341bc841a0a7101ef54b5_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ie917ced662c542a288e1c9403b69f779_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i5498d11f3d2542428717838316f8244c_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i8b5e7375ea064e46babac18112aa607e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i7140a79533384965ad078f1d35179c5d_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i4b431efe4f564593ae595088e0d47426_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ic7c92fe0ae4748908db33019e0c4de42_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ic5a1066842f549089f6164c20f388be6_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i783e5becfec34efabd5b62b1ed29b447_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i64a34f28344246b3b17696830a6b62bb_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ica3bf1a545d84c639cb2f963349213d2_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ibc20ad9303354673b2fc373f330c597f_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i5d0542bd36b04ade9a1445e4d2bd9293_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i5dab0c78d2044636b1b0795ffb41ceba_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i05353447c3f44422a85c9a643c4158e7_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ib9481f72b68741a38d64130564e80f8b_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ie9ef3d78b9964c72bc181499fe2a8a48_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ib8663f2154b743c0a9082ef7ef48c04c_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib44c796f51604beeb234f0a74a350c2f_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ic90e615b8bd94bd0bd916ce166a2e1a5_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ia206a3f6344d4adb8fd0339224dd9315_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ice03248f0c7342dd9422615211a7ce92_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ic68aa1aedc3b40c5b7b80e1388117a04_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i6f74ff9d83eb4bff80eca87771ac8af3_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ic288cd72530f4cd2842d023a50460e18_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ia30f04104b444cd3b652b8554c878f2c_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ic047ffb5ebe44765a2e2ca57b1137125_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i52201b2d7c81445d9be675a280747548_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i65a16fd18d26435eb42b51c0b3b1b851_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i20eeda577995420193ec4dd9d63bba01_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i65cf763a87bd4988a9339426e416baea_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i011f2815be9247198ea2477163de1299_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ia84d82cf676c42178e9d4fe5cfa9c970_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i7161773f423d4d04b3b04039512ea242_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="id8c97df697f946a4a28e06f21b923b40_D20220104-20220104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-04</startDate>
            <endDate>2022-01-04</endDate>
        </period>
    </context>
    <context id="i7122062f1c554f58bcf1918e884a09af_I20181217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">jnj:December172018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-17</instant>
        </period>
    </context>
    <context id="ia54143af8e294de8a878b870cb6ea183_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="ib4f8e689cd0845169580efef9b726eb8_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="icfa5021c9521460ea844d42abe8a5aeb_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="i484c2311f67440a3876482adeb22ccb3_I20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-30</instant>
        </period>
    </context>
    <context id="i2b3e5218e47b4138b803ab86e37ed163_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i2dadf43537624342b93174d221447d45_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i7d10b1357d4345dabd40e640f459d595_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ieb2239aebff9499e9a34c274aaeb6c7f_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i09358b98b87140529a0feb97fb9db596_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i51768edbfc634fdda12f4209d23a3fe8_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i40dc9b8885b14646ad4ca14020da2020_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ia91a8b98474c492b93ac66dd2c441f86_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i491bbfb299144dc0a55fa842720b7ce9_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ieb17cd90126f48b89e2321d3bacf6a95_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8c595eaa21f3452191aa3045d9aaf15e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8d84caefa07e483fb905ffb4ad67b125_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i803bbc6136dd4d39b64cf980705d6a38_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ibc1c4f9ce70e4d3ebe6058b0e4183d02_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i21cfba8b0adc47c8a606f3009b7f1da4_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i3b43e493bfda4958aafcf54a1f7de911_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="icf4efa66d2f54bfe8f36fb497d4ba3c0_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9de3dfaa4b2047e3b29dfc3f5c5f3140_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i0fddeabd9fa049fe9b79fddca48ac307_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i8bb21536fb564a0d91048d2a7f920ea4_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia2e15d2205eb426fb0faa00095711ac7_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i5aa9d5da1c0d4119a4ea3ab746d49fa9_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="id50338dbd5c54672ae5cc0b8d7addd69_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ief6a4d3a16fb4a8695e2f75ad4fe9856_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ibac73284db3c4555ab751fa7712d96fa_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">jnj:A2012LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i878c87afdf46469b95b60a72ffa60b1f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i67642e6fd25c46c7b9f6124eab76fddc_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ife1e770bea9143ada35c3572dfd2a7ec_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="idd89ef5ec708419d83c0f50bd2e3f33a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i1cd5b16b5eb54677834e76fbba9c913b_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="idec9b1a5f62642c0b966a067f115c2f0_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie82cdef29cc04363906a567a9d6829fd_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i8082802da5c34e03b65215fbc1747020_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i53a0b42ef8b740cb82bebc7e9ad442e7_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i42e155106ee54d669ceeb882529be05f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id67bcb0b84aa42ffbafbcc561a13093e_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ic399470ff9944abebce0ebbbfc9f95be_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i239ccf8862324768acca0b6dd0899121_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ib2ff139955b84bebb659527301f2d7f3_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i6608a73388e94a39a929181aeaf3e2ea_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7982e382a8c642f3ab7e8d233cd63f23_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9cf80e986c6a49168d7e1239ef86064b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ic8597ec09b7848ea847316c99dd326ef_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7038702487ec4c45a376b222a0a20d05_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i31cd18cf81d841f5a062c0c4dff7e8d9_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i164575311ea140df89ecfa92b9b8b764_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia84f3c7aa69a4e3ca4e10cee006b35d6_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i9a880d0282e64618a404c4e5c8cda751_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="iaa26f4b3444e4c15a4078dc66b339b0d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i7364abb0a14f4216bcad7a962281ebf6_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i7ed28ab7d2664b82bbdff0bc1302e139_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if7b0fdaa9d9e46c9afcb09b831c329a4_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i192bc4de755f43dea6fc766f7aea65d0_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="iffb82aff41a04d54b8471dfaef55cbfb_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9131515b36de452dba77389706d7cf68_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ibcd0fc1997c54c228fd7a7bd70bf4aac_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="icebbd7181a854a83b106002262a3f05a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8d99e38809f24798a6aa6262467560c6_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i6c63ea6850a74252ba3d49fa9fe7b74a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i2ba444b93d124ce393b5b3f193a70f2f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i94f3652f4af1446da52491a28d5ec451_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i5d10f0f5f973460c82f6e46d69e2962a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ief6f2ac5fd8f4812a89cc848a4c1df06_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i32966c9a84284da0b58c8d0ae0faa3c8_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="if3128d308ffe4613906d97816a65e9bd_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i2a561bfd58ec4ccabd2025a6e7cf9bd5_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i400f84b397df414cbbedb7f3a7926c43_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ic3d80b5dc4e343d19875dae1cb177ef0_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i0ac3647e660b4922bcde7ec55782e160_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i7fdb4bd463a34c9fa3b35815b52e6ef3_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="iadd4ee8352f9426fae8e6bdc7fe52372_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id1577281a68942e6b6973a3973d33136_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if8cfdad6d51e400e8669811b1b2b4267_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i35d06bb332e74e4982e637a9ca92913d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i0dc75eb155004e52844ffebf7174bbd0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i375d3135400b433096c8e5dab3fa38a1_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ic6952a648640445fbdd6cdd36431a750_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i07542366df9243c6abac2d16b1dfb58b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i064e7c0f8fa548429b040cde3913d49f_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i77b6cd743a414007b81cd6a3d310ef78_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ib2fafb4659f34a019ee6e466fc04640f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ifdbca246df0847e9a8c4c4c568f2f273_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i022c563362694b598da5b24ae2277042_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9241b397d581403bba8152c090405eca_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6771db02e5f8466e9669560f1ce16529_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i84e86bd12edd4e36b8b1f925a62c221d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i4f3c558885324ba1953b737d2adc0dd0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if2db5485b4bd4b42a522def325281378_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i6f56f359990241d3a0b4c60663ba73e8_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i050c5285c0d645479744c7f00e88de1a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0cb9f8fb040f4aa586cf78caa70caec0_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i23807e0c5b084f52943e64733569f8b6_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i2eefeafc846f4408a7e000284e1799b2_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3dbbbd6fc37c4d11acae7021cffb7cfd_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="iad865eab405c42688b73a15ad42a8b8d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ifef895456d614fdabb4ee70a7406be36_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ieda9b733b51a4ce4b729836ac29a9802_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i6576ad6b7f6341ec9b085c6461df5f80_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i65ba73df1e8b4801b72d2316d8a633c3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i615e942c7fdf4b2f990bb45b5b38934e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i4735078cb2534ea1aac702a26e874601_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i08b088a9453b40469d5f8fbb460e6662_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iffdc846cb23b49548ae67d105477e7ca_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i75581ba7e91e4e2680d33c3738c407a9_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id405ef4ec29047a392666ca100c5896f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i44c0cd51f839449b841b58440ac22a33_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i5cd93ab841884a5493587a7b877c5d6b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9be280a895e24bc2b461be2b202dc790_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9a50b9c81baf410eace82766e4ac78e0_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i1ea74d1c2c27413fad7f2b508f4aa451_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ib5d8bff62eea4ed39c39a6731f599a92_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4495a7b68b684dcc8ad8b2dd0d0cb678_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ib63ccacb9faa4b73878a9057b0fd6b30_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i00834d1d0411420090b5c1edf63e1dfa_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie6071637def043888bf3deb3a4c15799_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i22f5ca4ce57845c5b53fc4f1d13397db_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="icba87799cace4d7ea02ee1f5e0a4d031_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ib5c52e9cc9c14137918169f0b8a1bdb5_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iedf0e8d371a6458193259414109945a4_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i23071b0ab3d54897a0d5dd7749feafe6_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i931a1c9f97ec484da90098853ca3c244_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie9c2e9c0297b447e93e02db4e79afb3c_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i07618356beec49e9917628c554e15b4b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i6280e9e226a04001a209231428e7818e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ibaf44ff1272d49ce93687c31a2fcd512_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i00f4796c099b4277b9207e1042e91c37_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i8ab4cfd32f2b4e75a6eb344b3faa7585_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i128aea28460a455aaf7714a32b5ec211_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ied68b4d63a6e47f99762e52306477051_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i78385204266240099fc582cb7e7fbd51_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iced1449a3371463397b9b7085addc2d0_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i650a133233af49bfaee6ed4af066a9d6_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie3e283c3e9214f85ae2918d74ac3d82d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i94ce48e00f8545ec8e7a84f01797b22c_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i2d4bf4b9e3694ef285c9c31b956b677e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="idd06b502c49a4f488fc11fb2c3838ef3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i233cf7fe392245428889ea57e0fc2d22_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="id4c61950fc8949c5b32766ec79d02eaf_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="iebf3d76775d644ba97bdf492a1dd1267_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i05a8ae6b440b4b81b32f6a052e5a8558_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i875c8735b8514e90bad447aeb6eadbc2_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i1f3798ee8de34093a99e42ecc9db1ecd_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5a3f22a534874f458fb9c7bdc05cb65c_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i387f05cfe3524712bad1d9f54eb5cccd_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia62cfbf9f33d4aa284727311f21d634e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i15b688eb12f54afc92d5afd59ea3c706_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i2ff56877211249dd8ac926ef0d64f13b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i522f8a96ab7444c9b0a072059a13e972_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i27123f6e396341619661b5c3adc7e7d7_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ic7809d87d5c845608f30c8285db41530_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i2f1a5560e5b14f0893f3ee125948348a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ifcd59309ca0944688a41953f08782f58_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i25b9271bf3d148c1862fbcdce1ca1e53_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="icc8570ebb01c438ea0f57235642eacc7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1e5920e5bf6749e2a8feab5aaad9c855_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ia490b063eb8a46d3bdd2ff016e7d7783_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i4565c280598049f3aa2278617178658f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia8317c263da5445e96ef10c57d87335e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i08a754bdc99b4589aafca7079db10c80_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i82dfe65f5fd84478bfecb83176d8cf1a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i61a8303dc0bc4b82b4eb802262faa800_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i5106140dfc9c442095b0f77e74bd6ab5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i92703c0c3b7349978b612c21f233b393_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i590ff19ce91142bcb3863bd2c6e2f069_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ic9f224616f5a463b8f804675e284a7d3_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ife046f7abde54338b2b69413c736da26_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i83e3aa3c5f51435b93d1dbe65ac91d90_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i5465f74052f34acfb49d0e1a25300dc8_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie74fbb87373b4b59ab055d2fff965e07_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3530f8c2ec644b0780f82d2251ffd602_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="icf363f3dae664585a3f17f32b6970829_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i40eda5c751a24278a262d5a7707bbf96_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i69b0b0d154c1422f9d32b3d2082d49eb_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ia2db3c45977049f1acbf33a46b8f1197_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7b2cef1544584a32a4606c9be98a902b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib308904527464b1f9f083c28369a2106_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="id02c8176e6b54fbd95f6a63b9d32b50f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="iee1ededb6af34beeb2892f0c47c60708_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6c7e3cb454244e8fbcbbac2736af573a_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i6ddc954bdfca40e5b84a70e77aa5b0ff_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="if5d8535a6c304a3ca7e7a68a08f5c836_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib18a2c82e5bd42faa30e52df5f67d0f1_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="id1bea3a5e88f4153ac03408e384f810b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i3fa30ec743194334be89aabe3830b90b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i08d85765adf1424dbaac0219f0177c84_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i0cb2fe12284743f396b4f94eba5b3803_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="idff0f007396e4810b440aabe3054aef9_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i789f89f97ffa47c7b42b23eb088f0422_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="id21042f6fd3244f6887b53a8d4813430_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ibf047bcbe355467c8f65460dba57e264_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id8bc791af8b648d782365c72c1a39a7c_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i4861e2b2aeb543fbb746c4b4f1195f46_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i6b56e952fcde4c7e91401eb5a85ca321_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id1625d21dd2242ec893225588e77f1b9_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i805f444f9b4f4b78a5e115f7da23f40b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i67a0e2e227a4493a886e7e12cc63281f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ifb4f242ab4b94ba3bb07fea9dbb6f194_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i9d93d7178a424340b255ab8cc1671993_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i50a2f88597bb4e56babe220ec155c933_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="icba7b86a3b9b4ffc8203367aff4b1f12_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i00ca4566672f4e21b57db409f2ca399b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i72fd0da598264bf58922963c2e268f9f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i68dfc09b6cc74b269337c9823085c75d_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ie0dbfabf4ce84c5dadfb5096deb252aa_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i71a5ddf6505c49959a39142a4734937d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib7eef150a18e4e7c9fb366789c95e51b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i844da3be083d4b0991bcf4a93b302f05_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i93f0f46a5f794204849d8974443208af_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9c3bc420ba184db5b0c0a09e582ba601_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i90a6c337bc74400ead0814dfe3ded9ac_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i8d256c783ba14651b3deabb6dbca6ac3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i23065d742db5456abc56ab20b4266dea_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="if55330cd78f747a88fbccd460f0ec00f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i2d1488ec3e3c4b168ab09734e1cb2ef9_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if1b7f8f06d9d4045bbceff6b94ee3210_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ieb742dc6f1a14657ade44dbb3734869a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia7b5d7e03ed1438bb2eb5544aa5e51a0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic3ecc659932b4e20a391e656b1cf4600_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i6e82f975ef30440e880e83c96d9d5a6d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7172a6f847d4499da4684dd32ff6587d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id47c5bf1c0fe4beb961f5f32232ec895_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ie8d54437eaba48faad57862e220ec9ba_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ic172a5b3e234408b904ca83aea199d14_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i716ef7913074441580f76f25ff473db3_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i045f6bb81e3d4317b32f42c7864f0ce5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ieeea74059fd94beeac322670b9baabca_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3f7304198142471ca4e3ba8d2b8b2dbb_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i62a4d2b818ce406f90793b13460001fb_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i1f347c3391bc41aa85bcd9845a2709af_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iec40c04f9d454e2f8463d169e94a0db7_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ib20ac18affec473182fcb58284b62b0e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9073991f08b1465283d39628e414f9d0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="icffef1f5716b4b64b0f0bdfba755b0e7_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i4e1c17df3e194f1e91c5e45244f1f77c_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7eaeef50117a46faa8df83f358a7edea_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i70636291997f49208bb484bc59053d07_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ibd513a7d62984d5f9d3b9a8b8e403e60_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia04a63eca2254a59a36cde0f40f8f746_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="idf8ef533f70c490d94f9db77743e9b87_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i7cc68bd95fc3478a9e77570132e953cf_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie2255cd9d9c44cf8a9e8c1c315f656b6_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i01e4b54306a4415da8f707b8ded967a0_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i814ea4ac6baf497f8b3622d1588dd4fe_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ib635c2bb6a9c4682b88d93ff9e2e12c6_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i370e769b4db246bf866de99ce8aec22c_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i7dc879599c5a46cdbbdff6a01666beef_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7d5dec1e00694287b6044e170dc592de_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id8d79f0300124a3fb9fc87ac1735b564_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ic94160fb0a474a0687f27b40423f5cb5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i4222851f7d5c417c83afe973ae5d0159_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8de04364812e434785d220fe797cd119_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i9c934290591045e6af2df7d8b360299f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i2dc793642dc34fb8bc13264db3c2b910_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i08089cf711014f1e98f6d9a9cdf4e5a6_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ib48aeb94da2f440daa0044b9d1b46d05_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i0dabbfb12da541ddb881aa0135400f3b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iabe57c96bf62464fa90fd751cdaa6812_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="if16b1050a2ea4ac38b8dbfa679f48f95_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i56944bb518044ff2b8fd31922efe406c_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia2d0a9ad27884389aa902fa95d666252_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i5923e8e2b04e40f0b40227e5c5493fbc_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7e85127952964447a44873c81135f105_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0167f5d01f2e48d5bf9bf67a240ff929_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i8677e4e7312c443d8f02f7836a90e787_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i12482888cede42db9e124e85eb782d12_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic22cf04ce4d04163abd28d1680da2cc6_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ia95a87c453d545bd97f71c7a6e370768_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="idf575c6968d644f098e6c4cd687f9282_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4feb8a8b5d184238a0d534cd46a60f1b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i4b56ab9b20b540b0827829a4d1b8215c_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="icf7815787e2f468c9ad07ae016d7952f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9f9d60e84a26463286cb9128b46e9bf0_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i7e6ad08ba3564fa58b0dd76578714f7c_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ieb9d9b491866496f84b91c1509866032_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i30dae1e51bed48feafdb469324840549_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i08ea090a5dab4707b69bb4be8924ab82_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i40e6f8b6cb1d43a5be16680ce48b6661_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9ecec90ffdef42469fcadfbe71238277_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i3085b2c60dfb4078a65276bee9eeeb4f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i1f25409391b04e50bb4df4caaef16032_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0083624867b449aeaf811f3a98d73be4_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i84eb225252644245a3b20653e29a4713_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i855fb40e563f4b2f99bad8082fb5326e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie2f5f8e7f36e4be19b1b70e62c43a23a_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i9fb5c6e054854c3fb2c00e7bcc0e2daa_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i416100c083414a9baae7c6d73ede58a3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4f73cee4bf7345c49d627dffc1663c72_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i26ad055634a14d8ab152b50284444586_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="iaaf78fa003384e408fb12bf4bd5f741e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i7bc205f26e72447cb7d40dbcea60293e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i69934e81fab444219448ad5bb5307afa_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ife0fe4d393c848648fc39692c666de5d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6b8d232b64864d51b020808f0bad00c3_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ib916361cb7fa43a59ebd580516312c23_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7977fec0d5a6435aa250b1252dbcb344_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i508045fb141245bebe09d1c312027357_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i2492cd00dc6a41f19230bb05436b06c3_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="idb3e5d251b9a41f0974af3234b4d0c1e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1d5d82a3078b4b23af81af36ccc607cc_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i3c61c8c074234f0789152b71643a576c_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i64bb03a2c1e24381b5b0b4ede7a5b34b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5ba710a9effd497494383ecca075e6ba_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="iacd5e055a14f4fb6a23943dca90aaf64_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id445257ea7744bfd9a8983407adc2143_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia936a49b95f0497a8473b15cdbbce2ae_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="iec35270655784d61a34b51b61a34c955_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i97e5cdc0c9e3484eb182d85a7402eb77_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6bd1c0392a134aa99e761b2f95847293_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i9318604febe14a94af81eecc0a785bb1_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="if25ceca79c15413b8f30df32f846e465_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if9ac0f5fe82940299f1a331d5d44bd02_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i4829eb8419034125807a23e98d8ee355_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i43084feb39e24663ad525e292889d8d8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i09244b74cab94aa2a7ad31bd955792cc_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i1b994b9bb38d4894bcf7722b7dd244de_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i07925528b3644a4e9e4ed3e3b71c3c9d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie5efd22e32d44db38c958a3060f57dba_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i87d7442d0ab6421c845a0cfc7bee4bef_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie18c8a66affb47e294a84056ff86c0fb_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i271b0b2860ef4bc48fe0bb5645096466_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i16bab441088648eeac5e89da18478b3d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i281b34eb0d124b8090359d19f5649c26_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i21c2f4162852419f9469e508c07e9f59_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i7bdc57ec26d64526a8a02e0b5eefbdce_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i75393431ba4b43ec999c0c626b97a85a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i24ed0f45654143e7bd119e8dba14a248_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i00781dd599394b27a4548a96fdf47dcd_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i5285c14317334dcdb114e8f542b05e55_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0142ba4580f9403e859c146d50423865_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i3c0c0ffc4f67453684f177809b84b6d1_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i603a5b11ffb34e64b886e811464da6d1_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i33e35fd935b449cd87da860775063b45_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="icff8555c708a43078ad2afecb67d66e6_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i766c492cc7c9493e81c043bab5ce0792_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i63014d356cf948fb90cbd74710d1a00f_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i2c41d11433d64accb3db5ddb31b09a77_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i6d1ffed8e4c846e99dc9439de4ed307b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i7944381e57ad429a8fcb8c4561513ca1_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i44edb1d49d2f465e924c4e1e880b74a1_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i57c87e25c87c4e1a9a1aaed707a48369_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9b3120cc75a64c70b1146e4c34e24ae6_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="if3dd0bb1f6a24599b7fae40ad2e6e3a1_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i5969e842241246218b535a59d92380f8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if4064a0928a04ccbbdd9885f05ec28ca_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="idd90a7b4fb61410a89aeeeaaa41f4305_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i3ff91543c3e8429f958c8e05d94d0522_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i93d13747093f4c91ad73a481a62db2a5_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ic61250cfcef0490b8e1042b72907be02_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="if19796a0c1cd4f1b8e7233548fdde432_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ice1a20fa60764b468728eb227dfcf93f_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="iaab1d242f57c4857bc07508d3fef7f57_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i675381e27e8e4f8c92cf3dee1a9f85e1_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9c624bba8b9c43b0aff6e81143910b91_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i4abe8cd280bc4dc38415f6a54595a59e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i5c16bc456bd940bb901d164807f45809_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5243c3d264ac40d09b1366108f2813a5_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i297695ea47c64a8ab41165f4e8cd24ca_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i09d261dd66bc4a6fa3474295db120684_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6585c5f17b5243029be20ef4718f4ea1_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i84ccf738ed9a45f9bbe93e37729899b0_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i211d1d903be349e7b8c4d90c4d8e7ea8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic41939995d744557b2fadc86190eb309_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i59cfc473af604a8da15221699e4b413a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i67b7e2f978c5475796d2aeac43f69af0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i258c4fd8ba0447d5964abdb213044818_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i3e04698c0f76437fa764204c1042ea2a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i15858ed4ab2a40ba98560ad9c345f601_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib8d2d7a4b4074a02adf791b11dbeea4b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i9cb15999bd6c4c56a5291296be65bdc9_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ic841ebde283e4fe69105c52901291b20_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3ed18e2587674e6bb9e55bb50d6174e6_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i7ebc2042874040a2b7bab4e67bea27e1_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i1242f0ab963e4cdebfae1b38000d1c0e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i88046ddeac01478aae7aa3b6fd4cd0f2_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ib6fd4aec56fe4857881bc9ca6e2ebc28_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i0f3a036d977f4825a3d6b45499f1bf73_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i545bab733e4f449cafdf90c3798807d7_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i9a2648c41e074ca5a9b6e8509a34ba69_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ida37c995a07f44bdb1293caa0b49b88f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i830c2e05cc524c80a9769de9a4ecc07f_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i65a015a3eee243aaba77cfdb4761746f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ib761e394f720484e86bb1215c1c4a5d7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i128f3aaa257a46b78b36a2dfb202715e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i876ae032ad75425dbf80231e9170bcbc_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ic7ab917ab8b04eda955e8203c8814bad_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4de6312edbab4fc1b98af49b4891a217_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i8ad086a689a4494b8f7603e98b20bf80_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="iaf56df821a7c433d8bce9033b393786f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia277734b806943c9a73e6ecb6dbe0eef_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="id1daa11474a049bdaebda77832fe66e0_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i4e24ec61f60841539515b9dad3105f4d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia2b6cac63b0c4cb4af1c8513a38855bd_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i9df7f3da552d44fe9c15d7efd001a255_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7e6d423063d240c680e574f22c368d85_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i39fe54bd882c4e64976ec42f3c86ea0d_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i67be3029faf745a8adc9589c55128db4_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ib9efd22575fd4bcfbf17627fcfa7cbd2_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i443b2dc23fbc4bb9b95e55dbe54d0032_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i65dfeabf7bf04ff3b9e4a50912b6534e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="if74ce695258e4192a81f8bd943d68de8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iaed80240aaab4a27988be21654755b5a_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ib2cf37c66bfb4ef5bce478f5333fb5df_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i60ed8921747044c5a0cacb0bdbb61ee5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i14e5877a920f4ed5b8884f48704c60dd_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5d312ed9a008438aafe8e2616054ee50_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ib8a398a171a24a8498a76f0430bf01d8_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ice5069a97d424275971a265d90db25f2_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie6664751dc074f608b93f8348f757b2b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i47511162d73d4b6d9f5256e85c7e0459_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i643aacdc85d74fc88245ec3722a90e65_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia0d5c2adced94c5db905a0ccc543024b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i636b39044d77475baa810025fccb74fc_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i106843425fe24320805510bfc4532f23_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib806ab041535413685cecd33d2128890_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i64dc60886f8947f0b033db2e2d716436_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie402bd95c7f249bcb616b6d175dbf07b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i7fa0825611594020b2fe056c0e4efae8_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i0f0fac6b04c84b689a79771f385713c2_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i816f338852d14f0fb2d6dfbdc728effd_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib46440e9fa084f209298e0c8b233ad13_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i51e39d41add6463b9092b617f971b75f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ice66c64ac61048f19a21734cafb5097d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib72662fc19e040589f8f2ec556ad1d4c_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i75c9d64349fb47d0be110ff26bce965f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i3d4d5a35e0264fa3a59ab55f6e08dc1b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if8dfb56f1cc3472b91d0ad823df8d237_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="id20b1d22e77a4da4a5261a8d5004c3d7_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i4a6ff7e9dc76409ab4354387f1f95d6e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="icf0f0d1cba3e4983876bb49c63f4d22f_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i1865f77461f6431495acc8c63093e96f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie347616036fd4a74b6a373520ba980d7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6b643a5b78824e2497a25c62b3737d1e_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ia7196fd596c74749bad40acfaea1b70a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i64ccbb362945429fac924633eba5f320_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i12ce06e19cb740a191f99093f0e41f93_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i0420b48e154a40cd94667e4f7c079b72_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id844326b0acb41a7b4c00cb04e75dcc9_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic34d26533be64f5db220b79da72535d4_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i5e00c0c4a5a54349a215833e43d01f5c_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9eac76a3b41a46829772c0e6030b7607_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ied4367d37c7141298cb4fdc3adef842d_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i07c3c76ed88d4612a15d8daf5874486b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="iab9c0e490e5b409f818ad1fd0ba564a7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i7d8921ae00644e968ea3b39b44e5e6be_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i9bfdee030cbc49baadf91413f3bd72b9_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie1342fc470d44486822d04a68d8d00ec_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib3b235e18a384746bae631a4c9642be1_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="id08aa391f2684371a6971aa72bb4521a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9a86230afa1e4a6cad4c6e87b5261ff7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="idbe1f9d829d845418d0507a31d92c4d0_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ib0e3cb79b02940e3afc4af2a5a631cd9_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i00778b10e5af4bc791d1e8bbdd2bc204_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iacbdfe154b164f529f2e69136f05274f_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ie3304f9e4e7c4ee8b06281744d7d29d5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i661a37b39e8c487aa2f3ff704761f5d2_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id1a4981a319243a488072bbdd896bf56_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ia27aa4eb532a45a799170754ae5ed161_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i8e557585fa834313b8b97ce7709070a9_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i949f6e0a191b4f4eb7c2781bbac7d13f_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="idca63bfd34644ba5bc55002b5b4d5a8e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia2be122533f1424399fcc358654c4c3c_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i92e59ba1db31451aa3a8f14eb7816088_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i234ad40879c94cc2969e46faf33c17cc_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie3d9dccc5c584c4980e7a904d8a983bf_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3253049e290946cd8a51612d31bcd76b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i273e42d494bc4b7eb94a87f9d5987d1f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i6368f09f9b35486ea7cba69aacb7e3b0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i275015b2876d4c6d8fcb7fcdbd81df65_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i6f3e3713f381473f97efa9d195f99ffc_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i98f25d91afdc48968db8d33b505ba457_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5d48dd9d0d814bbca1d1b0419263f649_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="iefd23a50dc7c42fcb55115309d6d6cb5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i54751f70883943a59eb320c03774cc90_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if904c809a5cc47d7b5470bf8066c13bc_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i11256befd90346248d26afa528551f9f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie7ccd3dcadf64c67aceef9eec40f6b84_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0409bf3aaf47499c862aca1869e89dc5_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i3e8300916c9f4f18862cbda08e5f8057_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i092132d8bdf1497aa5fa557713c95b5f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4425ca9af5e64e22ac69aa3be800b66a_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i21660177d3cf4725a1adfee86587c410_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="iaa74aa704e1a4c00aa265ccc209e1380_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i066cce25039f4a8caa66512b868996f8_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i0af309f3267d40c3b42203456d5ad2d9_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i84982e9d6460466bb3d6705abbfb2f69_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iea0e3ef3419b4d75adf175b93648c1b6_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i08a1d8e556c2462dbffb82954114233c_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i449dac796d2545b3b9f5d700d9bc735e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5a9c0705fde748bebf4dc83c4526eedc_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i67279a229f6346a78562ee616f898161_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ifd6421c05ae448adb09f10e096aa875a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i222491a1b870418a91eeb762d8d1eee8_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i0d7dc7d7e32844b18dadac4c73fcc43d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="icff33641613a4644b8764afca4e5e006_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i40f24e02fa214e8ca63a5dc798f5aa78_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="icb35b47d312946dabc1007fce8107f34_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ib15659c9d6514a6f8707334b438bf18b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5e80c257552240eeb8c38ce4765cb32d_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="id65abc97d55744b0b397e09a73a60cb2_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i8149a55d6d9e44f08db766c017d527a4_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4d3a78039e7f4b40946cc088fba95f07_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i870d2071335a4c349e9bdf6c5dd8d221_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="icfabb85d57ed4e6e887596a521298fb6_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ifd907d3be6c6488b96c02cf61fe58ae2_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ic800efd413714d9d8a60516ca5f7d6ee_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7cc24ee69c5e41af8566a1fcd0f833bc_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie2509eddc1f545e09f38e5e2b4414e6b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i028b50c377714c899ae9c599c83171a0_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i66dd731836ac479eae5b91d919a1282b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4ef2752fd1b046dbba1e17488a65f77c_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i926ba91f36ef48a68fe6266e71d6869a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id4e5ad3b9bd24320b4d78a6d53743649_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iff991be03a2b4d159d3a77225971b22b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ib476ce85857e4f488b4ac69194703bb8_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="iaf5c33d3be83417685f6d8ce5f603a71_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic6386cedfeef4e04b42dfa0d05731d11_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i41f47282388e46edaf2c190bca1a05f3_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i4fff9f5f7b7143e383cbb939bdf7ad11_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i708657b70522407092d787ab45a8beb0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if5b9bb0bcfc4462ba8d103cb379d694b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ic23bf00a30e04ba28d25d34bb814c35e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i65b6178ffad3411eb9697a130c03e546_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9b4a5583c6aa48ceacfd7cb8304fe30c_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i07875b0557b747c1817c640f15714392_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia502d9d60b7a47f6a866b6d2e0e7126f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i58017869d1b24f54bed182c8572366f0_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="idd9ab20dc83c431fbee3c5fe6720e9f8_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i8aebbc77b14247239abf6a5e633c97fd_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ie1c87e0aa1f746979a526054fc431766_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ida08580984a943569bd4235ee5579e20_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i542883a564ac49d99d576a6b19e782b4_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ib6ffed65f4a64a30906e469a8d768eb0_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i1d5630eefc3e4b02942a364b65337f88_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="id2ee8524f73941a28f36ded1f0ae9694_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7b9faf917d1049188734075ab026d41d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i08a55e3eca274722b79aa4b030bf30ff_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i9d8c1b87d69949739491c09dd1df4a3e_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i41d128ea214b4e15bed9dcde7d5f5996_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i84f072c0693846e9987d24a6f8158c06_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ic11d6e0c7a594cc58857314068a88853_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8fc205a8aa4348dabb8157a34a1f17e6_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i9c942d86e2b2405fba98d51d0541433d_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ibff7c2542e2e46b386cc5c9b9e43ed68_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ie56b8a3a16e2475b9f30017cd504ca86_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i5f314714a5bd4eb3b5976682016d9f0d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9ffa3bbb13054be0b90f9be2fe0a69de_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i9a4ad3308fb2433ab4bb66f0ed570ddf_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i161c8b4e12a84317ab8397b42ebcbd69_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="icf6748ed9caa4723bfd8c2a5895eb586_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ib5d16014da004533a78f87eb30d1bbdb_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ifd6a6522853c4fd39a5c2f6393777cda_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="icfec35f176a949e19fc22a208824eaf9_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i43234b4b84a444a9add41d11cc2a72e9_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i89612e90f2314e95be21fae3c19c58e6_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i5dde3b1fc1c140b7b975e1257746af2a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie55616146f624252916d67d0fb6270a3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1329742ce6594bfc9eddf10d9e6e6d1b_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ic66ee5c432fb43989fab14ab0949bd32_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ie0eaa56b37ca45d6be7c0ae8cc029a05_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i12c344a819924cb3abc49e0e78326cb5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i86027318c21946418cf4bac6b9766a4a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if180dfc034c94229b3b69b27873c5523_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="id6d295d1a9e8463fae253f66cb1dd8c9_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ib2d14c5a6d394ef9a183cc124fa5a80a_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i9002b75b28cf45caa22c4976168c7b62_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i192b54c044b440f48ee211083347803e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic4eab92d733042da922500164d7a49b1_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ia624c75d38284ec6a2ec845b2560bce2_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i2be65f500ff545279a1db64b6247c724_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="if8f488e3ce82400e9d20999f51bfd957_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i684ab47875044db597f5dfe5c54f245d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ibffd9ab5bd7e43d2bdabc0050f445bbc_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i53bf7c2112b84b558b199f49dd38db16_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ie0df24236c7145dea99c2071261ac7b9_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i5cdc558e3419463e9447cf921a59d40e_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ie7b52918f61f47df92b761c6d628e9dd_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i4b4e08a0ee17422a8c214d277d942d69_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i91c7274c6de64cad9ae9f5f8d47e3a03_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i8caaafd1850845b59365f8e185f8173c_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id3b5a13cbe6b4786982dea5ebe78b704_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="if99789229d014c78a17d5f4a81bbfa36_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i30ec518ef4e84aff82c8baa7363b31de_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ibe41c007f8e74211896f3015a2132bd1_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i25b4bc0c83d64827aac46f72ea370c2b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i59011837e8e74865818d7c6e22573da3_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i84ff03e41df948aea3483799d1cbea10_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i9dd8d7d4f2d84befa81f6c55d1286f96_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i2b01d17f27cf45d1be57134c670e1e36_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ibc662de37ec34428972835cc3abf9da7_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i96b4301ec6a748738bcd3da3c58a855d_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ActelionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i74b5f6e37afe4a4db8b8e7f9fdd0b2ef_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:AdvancedSterilizationProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i5dcfe72e83d94e7f84475a87d6457756_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i6ff6ac9a46e741ebb0af1c793cb24164_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="iad866650cbf4417d988e0b72205283fc_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="iab994f6e28264437bf740f3cb576b596_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i7c5552cc49964c378bbb9b282742a62d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i6c4338357956452382a3b4130bcd7e7e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:A2020AcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="id0305d06bfd34bdfb74072845ac023d4_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ic56891ab2cd6480ba37ea1ceb033b908_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="if085f95b01a24cb5b37a6f4a5c06c613_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="i652360a76ef04b59bdc669400214e356_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="iab3ebcc4c2ae4fe293b17a266c45d8fb_D20220128-20220128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-28</startDate>
            <endDate>2022-01-28</endDate>
        </period>
    </context>
    <context id="ie4dfe20935d14ee3bdc74b4b396d04be_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:VerbSurgicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="i38342c75b72a472b9fd00cc1e1df9f64_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="ic5ee7cee5c044dc895e1060a81eb1b2b_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i3dc89baa93fd48229b56fd011dd9c983_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="iafbc6103989b414a84c18b6479a23d0b_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i657d184bcd08449dbbd5a6d436f9a8f6_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i1c34dca13b3246238c5245124b592b5c_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:A2019AcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="if156d32e424b440faf1f0d3e777e112b_D20190117-20190117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-17</startDate>
            <endDate>2019-01-17</endDate>
        </period>
    </context>
    <context id="i31c41bc161bd4282b210e004dbeb91e5_I20190116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-16</instant>
        </period>
    </context>
    <context id="ief3cab3c65b84702aa8c68b0beb5654a_D20181231-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ia63d28caef88416ba2d4d20a17561867_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="i7bb9d754278d494ea4868d3a7a6440d8_D20200928-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:CizHoldingsCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-28</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i27523630f0dc4c789b10d08289448d52_D20190401-20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="idf01140629ce4b44992bec25a4d0157b_I20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-01</instant>
        </period>
    </context>
    <context id="i4958dd807d8c42a3b81c7c535df76aae_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i91459e999e794e2a864d95b8eb009680_D20200629-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i2b6fbd9b80d84153817595caadafdadd_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if9f9f41fdfe94421ada2b29f1eda2e7d_I20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-01</instant>
        </period>
    </context>
    <context id="ic68faf24908f44f48cafea31ccd53622_I20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-01</instant>
        </period>
    </context>
    <context id="ie12611a8a0b5457b8429c851c4a1acb1_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i12d629a6349442e1bcd3b89fd1744c17_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0028bc7fe5bc4af89fae762f116f5492_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i96cb437b61cd4edc8359b3f5f09fa26c_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i9fed2deb8c9147eb8ff44239290a9c54_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i1c2687a93cd147aa9d8a4fba7100335e_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:AdvancedSterilizationProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i5fb558e71971413fb73765983f5dcf7c_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:AdvancedSterilizationProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="i1293b88bd90d458eac2d0d6a7b850b0d_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i16e6e6646c3b4d109123795d9c7df84e_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="idb4e5502065243778f8d181c244dd324_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ic9d5ee581ec640ec80ed1f8d2ef956fe_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ia4378318856543098e6cf32dbe8237ca_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i7ac530b2a8144cd796fa1d12ee757dfa_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ie7be14aefb4947a6870ffa19e0bf31ca_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:InvokanaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ieb92b728ef4e453193b6bc673799a78b_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i55464ad945a643baa712e791b033c1ed_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i8a3b65d9882f4457b2a58709975f0f58_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i09cbeb4b729f4746a9c451af63dd91c7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib1cc0378da84475bbc08a06b2a879405_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="i5cd3b425c568464d84bffc5929d955ac_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i6133d5a7101f441a9444db674a47b348_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i8473134a97db464ab939bcb0bb98f418_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i659974d043fe4a37b83a80d13bc59d65_D20200601-20200628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="if17dccaaceb943739755c40b7c59083d_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifba96edcac3c4389a3b0bb8b2c90cd45_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="ieb58c35946ea47c2a018ec31bb2540d3_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i9c3dc4fb3ece45fdbc810c1cbca8eab7_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jnj:LegalJurisdictionAxis">jnj:StateLevelJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i60459746fbf841b59219889ad727de9f_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jnj:LegalJurisdictionAxis">jnj:FederalLevelJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ia204f8664a9d4e17b4e9da7fc3db9fc3_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ie9e9d5c5c1ab4177a2b9d89bb136c5e3_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0d6e9afb25e04fc1adbd653da6d9243e_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i07cc6e7b5efd42c9b9d122106a692420_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i3ec18e9e128b4bcb867c217e36034665_D20200120-20200120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-20</startDate>
            <endDate>2020-01-20</endDate>
        </period>
    </context>
    <context id="i15323762d4454d4fa681a2ea0ef1eab5_I20150430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ContactLensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-04-30</instant>
        </period>
    </context>
    <context id="i9040c31d4c1748199785beebbd0586ea_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7f2a0b2a8ead42e18de0ad368f5442fb_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ifd48c767309c46d8a8d98cc62c7d4f0e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9f942e7d06b448759571f02f4385e4ca_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i6a7d77bec63f4ec9ba629e605fa7f760_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i4742330f4c264777a98ea1c8e9843989_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i070444329d4348a7b9c8aebe5a9aa3c9_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="iaf61a7957d2e4fbf85c40c9d23a9297e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i49ac509f65b740f7bf421ae80e274e2a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie7cc0a51e3df46baa43c1b66bf2a029e_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ia5c2f9e6ae2646e49bca2879436ed3ed_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i54a04675fe8142f985b33a5c678e172f_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i125634f59e794aada3577c9ee8b1c64b_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="id60a51c9ec914539bb291a40e2bd0afd_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i46179c58ccf9458a966c4f2d2c9cb18a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ibcec504d9dde41a1b752577a2c9939c5_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ifdd89adfa0f0484b84b07f77e48731a8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i2327edec83cc47c299891dc7c339c323_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i872fb39f2b694b7b97a09c5a2b7bfa67_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i531752ccd3b04bb4bd2ee5442e9d418a_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i01b7633b6f6a47ac92f6869a755469fb_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ie8f0b1a408074a8f9ca58bbfea6c3348_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia09f9acab5bd428d86b7dafd5dd2f6bc_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie50addf0e3d44897a0a2e867211ed920_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i918a4b3733da4e56bf9e7e5969d09d95_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i91a2f9eb45f44e87b7a3dd02889d98b3_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i5b09fb038985486b93ffe0bcfbe958f1_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="if116a595b26043caaadde3e9d3b3c0a2_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="employee">
        <measure>jnj:Employee</measure>
    </unit>
    <unit id="segment">
        <measure>jnj:Segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <unit id="stockbasedcompensationplans">
        <measure>jnj:StockBasedCompensationPlans</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="chf">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="claimant">
        <measure>jnj:claimant</measure>
    </unit>
    <unit id="cases">
        <measure>jnj:cases</measure>
    </unit>
    <unit id="claim">
        <measure>jnj:claim</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN180L2ZyYWc6YWFmNWJjYjVlM2EwNDY5ODkxNTliNTk5NzRmOWYwZGEvdGFibGU6ZTg4OTBhNWJhZjc3NDQyOGI2Mzg3ZDFmOWFjNmUwMjMvdGFibGVyYW5nZTplODg5MGE1YmFmNzc0NDI4YjYzODdkMWY5YWM2ZTAyM18yLTEtMS0xLTI5NzI2_7ce5f9cd-4e40-4c94-a616-e68ee571d44a">0000200406</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN180L2ZyYWc6YWFmNWJjYjVlM2EwNDY5ODkxNTliNTk5NzRmOWYwZGEvdGFibGU6ZTg4OTBhNWJhZjc3NDQyOGI2Mzg3ZDFmOWFjNmUwMjMvdGFibGVyYW5nZTplODg5MGE1YmFmNzc0NDI4YjYzODdkMWY5YWM2ZTAyM18zLTEtMS0xLTI5NzI2_f5ccba38-3823-4b92-89f7-af9b27f505bc">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN180L2ZyYWc6YWFmNWJjYjVlM2EwNDY5ODkxNTliNTk5NzRmOWYwZGEvdGFibGU6ZTg4OTBhNWJhZjc3NDQyOGI2Mzg3ZDFmOWFjNmUwMjMvdGFibGVyYW5nZTplODg5MGE1YmFmNzc0NDI4YjYzODdkMWY5YWM2ZTAyM180LTEtMS0xLTI5NzI2_f69fbbc2-2786-417b-9dfc-f6719b860cfd">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN180L2ZyYWc6YWFmNWJjYjVlM2EwNDY5ODkxNTliNTk5NzRmOWYwZGEvdGFibGU6ZTg4OTBhNWJhZjc3NDQyOGI2Mzg3ZDFmOWFjNmUwMjMvdGFibGVyYW5nZTplODg5MGE1YmFmNzc0NDI4YjYzODdkMWY5YWM2ZTAyM181LTEtMS0xLTI5NzI2_34bb7b98-5f39-47ae-81cc-ea4842d35e66">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTI0_2cce01d2-b420-436a-93e5-bea5f12e0c78">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTI0_dee6b310-adcd-43bf-a063-cd1559b71416">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODU5_5e9c1949-8e21-4631-bf9f-ba8181485230">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTM2_2dbaf7d6-873f-4b21-881f-1b610527d361">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODgz_5fa03461-5e24-4b61-b8c9-f2468f3220fb">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODgz_8dab58da-7c04-4417-a1bc-72271f9a3a36">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODQx_27b1bd73-0611-415b-b65f-810c46c70a5c">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6YmFiMTIzYzM3Nzg0NGEwN2EzMDJjMDk0NmM3NGE5MmEvdGFibGVyYW5nZTpiYWIxMjNjMzc3ODQ0YTA3YTMwMmMwOTQ2Yzc0YTkyYV8wLTAtMS0xLTI5NzI2_de183da4-8c09-46ed-ad79-02643363a1fb">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18xMTY_9fcb31af-3c34-470e-b0e8-446c26bac89b">2022-01-02</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18xMTY_b6260daf-ab1c-4c31-8767-ba20b89e8769">--01-02</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6ZGNjMDgwMjc4OTAwNGIxMWIyMTZhZjMyNjQyZTYxZDYvdGFibGVyYW5nZTpkY2MwODAyNzg5MDA0YjExYjIxNmFmMzI2NDJlNjFkNl8wLTAtMS0xLTI5NzI2_583b511a-f608-45fa-928e-91298757719f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODUx_a66e230e-b1ae-4a46-a865-773e4ec2eb1e">1-3215</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODUy_8082e1e7-779d-4196-aac6-6295cedc80d1">JOHNSON &amp; JOHNSON</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6ZjM4YzVlZmQzMWViNDY2NGFkYTlkZDc1ZWYwMmIyYzEvdGFibGVyYW5nZTpmMzhjNWVmZDMxZWI0NjY0YWRhOWRkNzVlZjAyYjJjMV8wLTAtMS0xLTI5NzI2_6042dabb-0bbc-400d-b14e-aa5b8a5580ef">NJ</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6ZjM4YzVlZmQzMWViNDY2NGFkYTlkZDc1ZWYwMmIyYzEvdGFibGVyYW5nZTpmMzhjNWVmZDMxZWI0NjY0YWRhOWRkNzVlZjAyYjJjMV8wLTItMS0xLTI5NzI2_b8c9d46e-cdd0-44ab-9323-eed568fbdc04">22-1024240</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODQ3_5a7a0c66-423e-40e0-bbdf-952fe1846aaa">One Johnson &amp; Johnson Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODQ4_df38dbca-4e73-415f-b5b7-353760df4724">New Brunswick</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODQ5_a9b92aaa-8fbb-41ff-932b-dd82794356e0">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODQz_72bd6cd9-56f3-460f-8544-0ff31ec91880">08933</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODUz_977c298c-f44c-49dd-8218-fea36773b7fb">732</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODQy_500b02c0-7380-4f2b-805d-b6c5d4931240">524-0400</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i358cc237f97d4810a1abd5b9de60ad85_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV8xLTAtMS0xLTI5NzI2_37e7dd42-9c86-4b75-adea-524866205a4c">Common Stock, Par Value $1.00</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i358cc237f97d4810a1abd5b9de60ad85_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV8xLTEtMS0xLTI5NzI2_ff5ce16d-5e85-4e21-918b-07e05b3f832a">JNJ</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i358cc237f97d4810a1abd5b9de60ad85_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV8xLTItMS0xLTI5NzI2_6c388257-ecda-4350-8936-05f0c5daec80">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="idab25bcb2e7e45a48ac378b27f9146f5_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV8zLTAtMS0xLTI5NzI2_efbe23be-6620-49e5-97a5-6fab6f75d3e1">0.650% Notes Due May 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="idab25bcb2e7e45a48ac378b27f9146f5_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV8zLTEtMS0xLTI5NzI2_c45a87a0-2354-41c5-aed6-8cd79ab393ec">JNJ24C</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="idab25bcb2e7e45a48ac378b27f9146f5_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV8zLTItMS0xLTI5NzI2_24feae56-83a4-4bbc-91a1-0b30855807e4">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i392be2e4ae3149e8afab760b8a03cf5a_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV80LTAtMS0xLTI5NzI2_f3ccd581-45da-4286-9934-4941a5a385d2">5.50% Notes Due November 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i392be2e4ae3149e8afab760b8a03cf5a_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV80LTEtMS0xLTI5NzI2_bc38934a-24b2-473a-8a05-d13b59e6f0bd">JNJ24BP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i392be2e4ae3149e8afab760b8a03cf5a_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV80LTItMS0xLTI5NzI2_5700f1c5-d64f-4c2e-9783-d6d03962fc8c">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i72f05d226e504140b886d1d1d2e1240e_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV81LTAtMS0xLTI5NzI2_e59d3345-c11b-4a92-9f7c-ebfaaf1934a0">1.150% Notes Due November 2028</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i72f05d226e504140b886d1d1d2e1240e_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV81LTEtMS0xLTI5NzI2_4d12fbe9-f966-46de-9b2a-1741c03da5d3">JNJ28</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i72f05d226e504140b886d1d1d2e1240e_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV81LTItMS0xLTI5NzI2_2807bfce-2511-45de-a2ed-c3540e2ae1d6">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i4245bb20b07345a4913a280495de0ce9_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV82LTAtMS0xLTI5NzI2_340e468d-965b-4ae0-94dc-afb58948a5e2">1.650% Notes Due May 2035</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4245bb20b07345a4913a280495de0ce9_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV82LTEtMS0xLTI5NzI2_0ecd040a-1626-44d6-b71f-1a0d2763f0fd">JNJ35</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4245bb20b07345a4913a280495de0ce9_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6Nzg4YjEwZmNlZWExNDkzODk5MDczY2VjYTI4YzIwMzUvdGFibGVyYW5nZTo3ODhiMTBmY2VlYTE0OTM4OTkwNzNjZWNhMjhjMjAzNV82LTItMS0xLTI5NzI2_500f9d56-0c5d-4541-9e3c-7b7b959dfbc3">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODU0_250055b7-e056-4201-876b-65ff47a729e7">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODQ0_9d0cb4e7-e28e-4c4d-a24e-444da91e2f39">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODU1_39980524-dfb4-4591-bdd7-f8950dcec4eb">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODUw_f68deef9-1aea-451c-96ce-b1d8115e5cfb">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6MTdlYTYxZmRkNjQxNDcxOTkzN2M4OGVkZDMwNWQ4YTMvdGFibGVyYW5nZToxN2VhNjFmZGQ2NDE0NzE5OTM3Yzg4ZWRkMzA1ZDhhM18wLTEtMS0xLTI5NzI2_c4ff9a9d-3736-4a67-866c-0f00b188d99f">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6MTdlYTYxZmRkNjQxNDcxOTkzN2M4OGVkZDMwNWQ4YTMvdGFibGVyYW5nZToxN2VhNjFmZGQ2NDE0NzE5OTM3Yzg4ZWRkMzA1ZDhhM18xLTQtMS0xLTI5NzI2_47bc666f-f840-4850-85b3-16551642c2bb">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGFibGU6MTdlYTYxZmRkNjQxNDcxOTkzN2M4OGVkZDMwNWQ4YTMvdGFibGVyYW5nZToxN2VhNjFmZGQ2NDE0NzE5OTM3Yzg4ZWRkMzA1ZDhhM18yLTItMS0xLTI5NzI2_e3e60bd5-e61b-40da-bee6-62b76ab9e1ff">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODQ1_847e993e-c14b-4597-ae5c-26154298a655">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yODQ2_94f153de-968c-41c3-9aab-67450eb840f7">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ic57d5f238fed45668d8b43777b0d8cec_I20210704"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yNzI4_a253a88a-bcc6-4c3d-bb1d-f4e3acd20ed2"
      unitRef="usd">445000000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i90afe5d53fd9474bad9a6c64ad556568_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xL2ZyYWc6OWQxYzI2YmI3NmIzNGY4ZTgwY2NjMGQzZDZkZDU2YjcvdGV4dHJlZ2lvbjo5ZDFjMjZiYjc2YjM0ZjhlODBjY2MwZDNkNmRkNTZiN18yNzY1_8a91337f-9222-4b1a-83db-3b45b66a0ddb"
      unitRef="shares">2629268158</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMDkvZnJhZzozNDdjNGY0MWUwZGY0ZDYzYTBhYmFhOGMxNmNiYzQxZi90YWJsZTo4MmJjYmI0OWU5ZWQ0NDNmYjEwZmFhY2IwOThiMjM0MS90YWJsZXJhbmdlOjgyYmNiYjQ5ZTllZDQ0M2ZiMTBmYWFjYjA5OGIyMzQxXzctMS0xLTEtNTEyMjUvdGV4dHJlZ2lvbjo5YWUzZTE2OWM3YmI0NGE0YTY4MWY2NGJlNzAzMjdjM182NTk3MDY5NzY2NzM1_d503d707-1061-468d-b9ae-b18d6b33a357">238</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzMtMS0xLTEtMjk3MjY_48b17659-0204-44b5-9656-f9a6f5f682c6"
      unitRef="usd">14487000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzMtMy0xLTEtMjk3MjY_2840c495-590d-41f8-9f55-0fc1cec41dc9"
      unitRef="usd">13985000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzQtMS0xLTEtMjk3MjY_2a1bc963-ff02-4a3b-9b78-18bc1bcbaf47"
      unitRef="usd">17121000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzQtMy0xLTEtMjk3MjY_9971dd86-f3fe-4ef9-a9e2-b7668adb2f30"
      unitRef="usd">11200000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzUtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjoxMTMxNWVhM2NkYzc0MGM0YjQ4OGU5ZDQyZWQ2ZGI3Y183MA_35d0e655-5881-4a5d-8b6a-1e0b7511f862"
      unitRef="usd">230000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzUtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjoxMTMxNWVhM2NkYzc0MGM0YjQ4OGU5ZDQyZWQ2ZGI3Y184MQ_5537a794-8008-4b54-b994-3124daa0d3f1"
      unitRef="usd">293000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzUtMS0xLTEtMjk3MjY_8cd1432a-3706-4653-b4e2-3e6dfee173cd"
      unitRef="usd">15283000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzUtMy0xLTEtMjk3MjY_1f4f21ec-9f95-4db9-9ffe-b40a43b2aec9"
      unitRef="usd">13576000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzYtMS0xLTEtMjk3MjY_112564ed-a1fa-4daf-bd37-56d8010cc222"
      unitRef="usd">10387000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzYtMy0xLTEtMjk3MjY_6e87cd29-fd8d-487a-b96c-3603e0b91a7e"
      unitRef="usd">9344000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzgtMS0xLTEtMjk3MjY_e7a5bd29-402f-4d49-b562-ff5ba8fbb880"
      unitRef="usd">3701000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzgtMy0xLTEtMjk3MjY_302e954d-4738-47df-962b-5edbee963e62"
      unitRef="usd">3132000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzEwLTEtMS0xLTI5NzI2_f10eedb4-826f-43b2-9cd7-90d5cb820c34"
      unitRef="usd">60979000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzEwLTMtMS0xLTI5NzI2_9cfcf9be-8009-47a2-b750-a1dab0160ed5"
      unitRef="usd">51237000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzExLTEtMS0xLTI5NzI2_448b1b42-cefc-4c9b-98b7-c7a4f7556116"
      unitRef="usd">18962000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzExLTMtMS0xLTI5NzI2_ad6e31ab-c241-495a-8daf-433607cf9137"
      unitRef="usd">18766000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzEyLTEtMS0xLTI5NzI2_4b5af859-dd55-48ec-944a-ce565540d5de"
      unitRef="usd">46392000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzEyLTMtMS0xLTI5NzI2_1ddb0e57-d58a-4af5-a230-cfbafa97fc04"
      unitRef="usd">53402000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzEzLTEtMS0xLTI5NzI2_3680d9a7-b8af-4207-b518-e193c6124f0c"
      unitRef="usd">35246000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzEzLTMtMS0xLTI5NzI2_858f258d-da9a-4078-ab3f-d0a6b0142141"
      unitRef="usd">36393000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzE0LTEtMS0xLTI5NzI2_6997292b-db55-4e3c-9e3a-83213b1fad4b"
      unitRef="usd">10223000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzE0LTMtMS0xLTI5NzI2_a4a69b04-e2ea-4d49-b4a0-732b00c8e6f7"
      unitRef="usd">8534000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzE1LTEtMS0xLTI5NzI2_665ce8e5-b724-4110-9d71-a9210718c986"
      unitRef="usd">10216000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzE1LTMtMS0xLTI5NzI2_78093e63-f0b9-49f1-8ab4-970a836a967e"
      unitRef="usd">6562000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzE2LTEtMS0xLTI5NzI2_7f2a612c-529a-4dfe-801c-900ed2605357"
      unitRef="usd">182018000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzE2LTMtMS0xLTI5NzI2_a5be1890-1a0c-412c-a986-53c0e9389577"
      unitRef="usd">174894000000</us-gaap:Assets>
    <us-gaap:ShortTermBorrowings
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzE5LTEtMS0xLTI5NzI2_63b7e40d-c6ef-4dbf-8998-1a69546a2fa9"
      unitRef="usd">3766000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzE5LTMtMS0xLTI5NzI2_b724e1f2-b917-48bb-99de-a354e33f65ca"
      unitRef="usd">2631000000</us-gaap:ShortTermBorrowings>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzIwLTEtMS0xLTI5NzI2_84cbee1f-7c69-49a2-9944-67ca75ca28eb"
      unitRef="usd">11055000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzIwLTMtMS0xLTI5NzI2_a7ba9b58-7d18-49f3-a9c7-ddac0c2e86d8"
      unitRef="usd">9505000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzIxLTEtMS0xLTI5NzI2_cc7eb195-f1be-4d2b-bdf3-e7df5bc8b69b"
      unitRef="usd">13612000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzIxLTMtMS0xLTI5NzI2_eb7f1194-3487-49d8-9128-2573cfc16486"
      unitRef="usd">13968000000</us-gaap:AccruedLiabilitiesCurrent>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzIyLTEtMS0xLTI5NzI2_0160afec-7644-49fb-9157-ee293b189371"
      unitRef="usd">12095000000</jnj:AccruedRebatesReturnsAndPromotions>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzIyLTMtMS0xLTI5NzI2_6fd10492-180e-4e5e-b205-a5cd22e14571"
      unitRef="usd">11513000000</jnj:AccruedRebatesReturnsAndPromotions>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzIzLTEtMS0xLTI5NzI2_bd8b422d-1ce8-4a9e-8948-243d2b90957c"
      unitRef="usd">3586000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzIzLTMtMS0xLTI5NzI2_8344321d-119e-48e0-ac9b-395860b8f660"
      unitRef="usd">3484000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI0LTEtMS0xLTI5NzI2_d36080ac-e808-4dbd-8937-8e9f4ad3c167"
      unitRef="usd">1112000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI0LTMtMS0xLTI5NzI2_0cfba561-3b04-440c-be96-18a4be129eda"
      unitRef="usd">1392000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI1LTEtMS0xLTI5NzI2_c7069afd-7c07-4acb-a94f-8c614a2679ac"
      unitRef="usd">45226000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI1LTMtMS0xLTI5NzI2_afb56fc7-ed7f-4408-b289-2b28e8877669"
      unitRef="usd">42493000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI2LTEtMS0xLTI5NzI2_012cfa33-30b8-4de0-a268-1ebbe41fbc8b"
      unitRef="usd">29985000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI2LTMtMS0xLTI5NzI2_7050595c-1b25-44a4-82e9-05059b38c42c"
      unitRef="usd">32635000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI3LTEtMS0xLTI5NzI2_135e08aa-aa75-42e0-a786-9b79b53cf2a9"
      unitRef="usd">7487000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI3LTMtMS0xLTI5NzI2_504cd34b-2674-4deb-8406-c18c3ef05618"
      unitRef="usd">7214000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI4LTEtMS0xLTI5NzI2_684011a5-bcfd-4bd3-afa3-12da94219d4f"
      unitRef="usd">8898000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI4LTMtMS0xLTI5NzI2_ac7a5ac6-92e8-4c56-ab26-105a13582d3b"
      unitRef="usd">10771000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI5LTEtMS0xLTI5NzI2_e128b2bc-87fa-436c-93b2-4b806256c8d7"
      unitRef="usd">5713000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzI5LTMtMS0xLTI5NzI2_dbfa5906-321c-46f1-8182-e9590fc5c2fa"
      unitRef="usd">6559000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzMwLTEtMS0xLTI5NzI2_b3e0ce70-e5f9-4bf4-9755-e54cce3f817e"
      unitRef="usd">10686000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzMwLTMtMS0xLTI5NzI2_3f0d2001-2c73-43f7-afd4-51d682b4314f"
      unitRef="usd">11944000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzMxLTEtMS0xLTI5NzI2_b94f3340-4fce-481c-9c78-1b05bd2fe358"
      unitRef="usd">107995000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzMxLTMtMS0xLTI5NzI2_8e10aaaa-3197-4bee-92c5-e674e1624b00"
      unitRef="usd">111616000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzMxLTEtMS0xLTUyOTY3_f32dac7c-fd4a-4cfc-bcd4-05437b73be37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzMxLTMtMS0xLTUyOTY5_f673bca5-2f0a-442c-b4c3-49de86a2def2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM0LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MTUzYjcyYWEzNzIyNDMxMDhkYzljMWM5YTk1YzM1ZGFfNjU_74b0b8af-1e5d-42f0-88a9-792e473deb61"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM0LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MTUzYjcyYWEzNzIyNDMxMDhkYzljMWM5YTk1YzM1ZGFfNjU_b8f564e0-17ee-4c10-801a-e2f2e004edec"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM0LTEtMS0xLTI5NzI2_440a16e9-c345-4bbc-8090-f93524b6247d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM0LTMtMS0xLTI5NzI2_505fc1b0-6e57-49e6-8310-950616f81766"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDc2OWMzZjM2ZjAxNGJmMzkwNzA4MGJkNzIxNjdiODRfMzA_0c80bc19-5858-4247-90da-e92642f7f012"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDc2OWMzZjM2ZjAxNGJmMzkwNzA4MGJkNzIxNjdiODRfMzA_378b6c3a-54b2-43b0-a4fd-ec6ad172a820"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDc2OWMzZjM2ZjAxNGJmMzkwNzA4MGJkNzIxNjdiODRfNjU_6180cff2-3af0-43b6-bde8-521a1eba84c8"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDc2OWMzZjM2ZjAxNGJmMzkwNzA4MGJkNzIxNjdiODRfNjU_ce7fe11a-9c00-49b4-b20f-16ba585bc8ef"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDc2OWMzZjM2ZjAxNGJmMzkwNzA4MGJkNzIxNjdiODRfODM_795c70b2-779b-4c4d-819d-e2425afcdba0"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDc2OWMzZjM2ZjAxNGJmMzkwNzA4MGJkNzIxNjdiODRfODM_c63e2f3e-58ef-467b-be83-b78d62d48841"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM1LTEtMS0xLTI5NzI2_bf8b82cd-ec60-4da7-88fb-3b5f03b30b1a"
      unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM1LTMtMS0xLTI5NzI2_6cb4dc1d-adde-4463-bfab-f13da48b5557"
      unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM2LTEtMS0xLTI5NzI2_eef6fbe1-f220-420f-90ca-29a3071e1e44"
      unitRef="usd">-13058000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM2LTMtMS0xLTI5NzI2_a7515e19-b18f-4289-966b-573fcc1bd7eb"
      unitRef="usd">-15242000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM3LTEtMS0xLTI5NzI2_19c14cb6-cd88-4f7f-bb81-1aed45e270ec"
      unitRef="usd">123060000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM3LTMtMS0xLTI5NzI2_d4b5e5b1-28c6-41c8-a5ee-e1fe480dc6a9"
      unitRef="usd">113890000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityBeforeTreasuryStock
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM4LTEtMS0xLTI5NzI2_63091a4a-64e0-4407-8b42-07cd1de4d57a"
      unitRef="usd">113122000000</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:StockholdersEquityBeforeTreasuryStock
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM4LTMtMS0xLTI5NzI2_89a5c10a-cb24-4aad-8081-151a2ca3a304"
      unitRef="usd">101768000000</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:TreasuryStockShares
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM5LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MjdhMjJlN2FhMWUxNDY5MDk4ZmNjZGE3YmZjODRiYjZfNjA_1bf057a2-f978-44df-984f-6cfd1d79f0d2"
      unitRef="shares">490878000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM5LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MjdhMjJlN2FhMWUxNDY5MDk4ZmNjZGE3YmZjODRiYjZfNzQ_fa75b33d-5ec5-41a7-a55c-df5a0d4a1086"
      unitRef="shares">487331000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM5LTEtMS0xLTI5NzI2_17684634-be01-42c5-abfc-a38852906f00"
      unitRef="usd">39099000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzM5LTMtMS0xLTI5NzI2_62ad8d6e-f573-4312-84df-09aa8d7ff61b"
      unitRef="usd">38490000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzQwLTEtMS0xLTI5NzI2_e376468f-a6c5-4d50-88b8-34d94a2dc4b8"
      unitRef="usd">74023000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzQwLTMtMS0xLTI5NzI2_fea5bff2-5f69-465c-b928-735f9423037e"
      unitRef="usd">63278000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzQxLTEtMS0xLTI5NzI2_727730eb-74ef-4498-a816-800bf47361c8"
      unitRef="usd">182018000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTIvZnJhZzpjNzY4YWNjZDUwYzQ0NzJiYjhhMmUzN2YxZGUyNmE2Zi90YWJsZTo4NTgyMWMwOTgyZDc0ZjlhYTdiYzA4YThiNTlhMDk1Ni90YWJsZXJhbmdlOjg1ODIxYzA5ODJkNzRmOWFhN2JjMDhhOGI1OWEwOTU2XzQxLTMtMS0xLTI5NzI2_fd144760-3ce7-437f-92a7-54db804db18b"
      unitRef="usd">174894000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEtMS0xLTEtMjk3MjY_ab529d60-1618-45d0-99c3-aa6ca01ac9b1"
      unitRef="usd">93775000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEtMy0xLTEtMjk3MjY_01a348f2-1f14-4fe7-8663-51d363aa2c46"
      unitRef="usd">82584000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEtNS0xLTEtMjk3MjY_d74441ff-5fbd-44a3-b004-03531e7f0315"
      unitRef="usd">82059000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzItMS0xLTEtMjk3MjY_ea8a0e92-9b12-4ecb-8863-403543a85330"
      unitRef="usd">29855000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzItMy0xLTEtMjk3MjY_34f921c0-f66c-413f-b287-f69d519f7919"
      unitRef="usd">28427000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzItNS0xLTEtMjk3MjY_4f8a5330-d21e-4ec6-8642-0a2b759d7120"
      unitRef="usd">27556000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzMtMS0xLTEtMjk3MjY_909accf0-7bee-4c88-ad75-44758eec9afe"
      unitRef="usd">63920000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzMtMy0xLTEtMjk3MjY_6618fb6c-acf6-4371-bd68-193660e8e7f8"
      unitRef="usd">54157000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzMtNS0xLTEtMjk3MjY_15f681bf-1b3f-4abd-9d40-bf6f3ecdef19"
      unitRef="usd">54503000000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzQtMS0xLTEtMjk3MjY_e435ac47-400d-44a1-8607-a35df3fd9c24"
      unitRef="usd">24659000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzQtMy0xLTEtMjk3MjY_ced10d8d-8091-42a1-9cf5-c229decd89f7"
      unitRef="usd">22084000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzQtNS0xLTEtMjk3MjY_9eeb0426-522b-400f-ac8c-65128881475f"
      unitRef="usd">22178000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzUtMS0xLTEtMjk3MjY_bd0ca7ad-5636-40a3-a00d-e1b521c2e3f3"
      unitRef="usd">14714000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzUtMy0xLTEtMjk3MjY_3eb07dec-82f8-4529-9409-0188d27d08fc"
      unitRef="usd">12159000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzUtNS0xLTEtMjk3MjY_19c7e53c-12c6-4c87-ad2e-67a359c12ab6"
      unitRef="usd">11355000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzYtMS0xLTEtMjk3MjY_09335fb8-03bc-44c7-ac0f-28263ac00a4e"
      unitRef="usd">900000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzYtMy0xLTEtMjk3MjY_888cfdfe-6e99-40c5-87a1-276e7e9e0cf7"
      unitRef="usd">181000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzYtNS0xLTEtMjk3MjY_66a95e91-9562-4652-bea0-aab44950eb7d"
      unitRef="usd">890000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzctMS0xLTEtMjk3MjY_cd524c75-b434-4fb2-a4ee-5663ad1f8979"
      unitRef="usd">53000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzctMy0xLTEtMjk3MjY_cdfee8ad-2c06-444f-af07-a93fb969c27b"
      unitRef="usd">111000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzctNS0xLTEtMjk3MjY_6905e13d-3e79-4c73-89c9-cf69696c9ffc"
      unitRef="usd">357000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzgtMS0xLTEtMjk3MjY_23365afe-5435-4fe2-b7af-8e229e3b77ec"
      unitRef="usd">183000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzgtMy0xLTEtMjk3MjY_c7de60d7-977f-4cd6-98bf-87c5f60a3047"
      unitRef="usd">201000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzgtNS0xLTEtMjk3MjY_2617971e-61c7-4bcd-96bc-632820954c9e"
      unitRef="usd">318000000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzktMS0xLTEtMjk3MjY_68d7c683-20dd-4304-bf52-6221215d84fd"
      unitRef="usd">-489000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzktMy0xLTEtMjk3MjY_5c227758-63c8-49c1-b80e-89ca5c066da8"
      unitRef="usd">-2899000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzktNS0xLTEtMjk3MjY_1e6b20fd-a4e9-4452-9c73-33939457ecf6"
      unitRef="usd">-2525000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:RestructuringCharges
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEwLTEtMS0xLTI5NzI2_49899cfa-2612-47c2-a581-88f14996ab4b"
      unitRef="usd">252000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEwLTMtMS0xLTI5NzI2_67f3e0b3-ba94-4288-b707-d1c7a6bc1cf5"
      unitRef="usd">247000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEwLTUtMS0xLTI5NzI2_100cd858-a63a-49b9-b97e-6e2d6ae868af"
      unitRef="usd">266000000</us-gaap:RestructuringCharges>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzExLTEtMS0xLTI5NzI2_7995301b-e17a-4e00-a068-5d6c03774854"
      unitRef="usd">22776000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzExLTMtMS0xLTI5NzI2_50cce635-0fdb-4c3e-b9cc-0dbd1fde0831"
      unitRef="usd">16497000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzExLTUtMS0xLTI5NzI2_24dbbd56-6ea6-4e13-8102-9e9f00bbee34"
      unitRef="usd">17328000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEyLTEtMS0xLTI5NzI2_27b49939-33f6-4cf5-ac47-39f950e0c060"
      unitRef="usd">1898000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEyLTMtMS0xLTI5NzI2_39541dea-3c6c-44f2-b138-75d1fb720173"
      unitRef="usd">1783000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEyLTUtMS0xLTI5NzI2_9d02ef4e-ad2a-4c7a-b0d1-4a552d64d7d2"
      unitRef="usd">2209000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEzLTEtMS0xLTI5NzI2_d95ec3c5-a122-4dcf-81ed-8c0910132632"
      unitRef="usd">20878000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEzLTMtMS0xLTI5NzI2_477ed28b-fb6d-4c49-b37a-367c0e8b13bc"
      unitRef="usd">14714000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzEzLTUtMS0xLTI5NzI2_0b8e2506-4ea7-4349-9fd2-89e85ae8b979"
      unitRef="usd">15119000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzE2LTEtMS0xLTI5NzI2_e40f2da3-2912-43b7-811d-71f31be44954"
      unitRef="usdPerShare">7.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzE2LTMtMS0xLTI5NzI2_73832526-fa47-4360-836a-f422f7664bb2"
      unitRef="usdPerShare">5.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzE2LTUtMS0xLTI5NzI2_233b4834-76ef-4a76-989b-168b555d75b7"
      unitRef="usdPerShare">5.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzE3LTEtMS0xLTI5NzI2_cb2d9fa0-dc00-404e-ac76-b9ba30500c54"
      unitRef="usdPerShare">7.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzE3LTMtMS0xLTI5NzI2_743d9624-63f2-4eaf-a54d-13a0038aade8"
      unitRef="usdPerShare">5.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzE3LTUtMS0xLTI5NzI2_d5ebdca1-71f1-491e-9c13-cced8a36bca3"
      unitRef="usdPerShare">5.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzE5LTEtMS0xLTI5NzI2_e25dbae9-b3b8-4414-b278-7ef3f8f70378"
      unitRef="shares">2632100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzE5LTMtMS0xLTI5NzI2_e5f61934-6861-46bc-b1de-8e398cc087e3"
      unitRef="shares">2632800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzE5LTUtMS0xLTI5NzI2_617786f8-c390-46b5-b8c1-a767b562d360"
      unitRef="shares">2645100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzIwLTEtMS0xLTI5NzI2_47156813-c0f0-4338-924c-4fabbc4e193e"
      unitRef="shares">2674000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzIwLTMtMS0xLTI5NzI2_8d8a9ce9-00d2-47f4-b2ec-352f549e1a47"
      unitRef="shares">2670700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMTgvZnJhZzphYmFhMjZjZDIzNjI0MzVjYTVhZDcwMjAyNTQ2MGQ2Mi90YWJsZTo5MjJjMjAwMjRmOTc0MDhiOTg1Y2EzOGRhOGQ0ZTkzMi90YWJsZXJhbmdlOjkyMmMyMDAyNGY5NzQwOGI5ODVjYTM4ZGE4ZDRlOTMyXzIwLTUtMS0xLTI5NzI2_a6801d3a-fc8d-4512-aca8-d0de97131881"
      unitRef="shares">2684300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzEtMS0xLTEtMjk3MjY_5b0f3c9b-91b6-46f7-ba82-52cdda712969"
      unitRef="usd">20878000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzEtMy0xLTEtMjk3MjY_3270e9d3-51ef-4f60-b7b8-16e1f98dc1c2"
      unitRef="usd">14714000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzEtNS0xLTEtMjk3MjY_7fbf5bd0-2e4f-4da5-8756-51a847ce5dcf"
      unitRef="usd">15119000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzQtMS0xLTEtMjk3MjY_1eeb1ba2-300c-4123-b059-97f1882ca100"
      unitRef="usd">-1079000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzQtMy0xLTEtMjk3MjY_c90f98bd-1ebe-47bd-b84e-9d55d4f98a6b"
      unitRef="usd">-233000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzQtNS0xLTEtMjk3MjY_e2a99b8c-df74-4548-9198-337cd6140e88"
      unitRef="usd">164000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzctMS0xLTEtMjk3MjY_625037ea-f29a-4737-a4f1-ab433f4553b3"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzctMy0xLTEtMjk3MjY_11b06376-5ca5-4005-b7b7-e8af9c92a62e"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzctNS0xLTEtMjk3MjY_4a5b1192-8ca0-4680-a4a8-ce6da677c6f6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzgtMS0xLTEtMjk3MjY_ce478faa-fb13-48b9-96a9-afe98cd542bd"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzgtMy0xLTEtMjk3MjY_72a01396-f83d-4dd7-913b-2aa99cbd9270"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzgtNS0xLTEtMjk3MjY_27caad73-ac55-4d43-a8cd-a42bce612bf9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzktMS0xLTEtMjk3MjY_c9cc99aa-5ebc-492f-93fb-33b136513625"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzktMy0xLTEtMjk3MjY_0b13daf7-09d9-47c3-9f6f-2e3b1ba94c3c"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzktNS0xLTEtMjk3MjY_351df772-a399-49da-aa96-336707bf7db9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzEyLTEtMS0xLTI5NzI2_2ee72bc3-9b41-462e-9030-cadf8b1d281c"
      unitRef="usd">169000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzEyLTMtMS0xLTI5NzI2_c8f22681-a99c-47e7-bc25-3739f19898cf"
      unitRef="usd">-1298000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzEyLTUtMS0xLTI5NzI2_ba94e443-fe89-4d85-aaf7-151d44b1eb61"
      unitRef="usd">18000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzEzLTEtMS0xLTI5NzI2_b7644c57-764f-4c20-a46d-926aa15e88f5"
      unitRef="usd">-4318000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzEzLTMtMS0xLTI5NzI2_082a1c63-ed75-4218-a374-6b98a0a901d5"
      unitRef="usd">1135000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzEzLTUtMS0xLTI5NzI2_d94f4372-f3b7-4611-90df-6bdf03e3faf1"
      unitRef="usd">714000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE0LTEtMS0xLTI5NzI2_88c72a35-3d65-409a-a6dd-de90e8f0cca5"
      unitRef="usd">-106000000</jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax>
    <jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE0LTMtMS0xLTI5NzI2_74410623-2cae-4fb6-928b-23a3b6bd32f3"
      unitRef="usd">229000000</jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax>
    <jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE0LTUtMS0xLTI5NzI2_33008e8b-0740-46f1-8e67-bf7708c5f92a"
      unitRef="usd">1000000</jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE1LTEtMS0xLTI5NzI2_e530865f-3e58-480c-b2f2-2704d43da505"
      unitRef="usd">-4255000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE1LTMtMS0xLTI5NzI2_0aebe1d3-7610-4b0e-97eb-5acf33ebc7d9"
      unitRef="usd">66000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE1LTUtMS0xLTI5NzI2_ef5eb551-84b2-4ce5-ad2d-34550851e46c"
      unitRef="usd">733000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE4LTEtMS0xLTI5NzI2_2c576823-4ad1-4772-a121-f20eaf56d037"
      unitRef="usd">-199000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE4LTMtMS0xLTI5NzI2_6a2fedd2-2c1d-43a3-a7b1-190732d1ec25"
      unitRef="usd">1000000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE4LTUtMS0xLTI5NzI2_7d0080c8-a8d8-47bf-b848-6e9d0fcd5758"
      unitRef="usd">-107000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE5LTEtMS0xLTI5NzI2_c619de52-95bc-483c-8828-22ae34ba3d6a"
      unitRef="usd">789000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE5LTMtMS0xLTI5NzI2_83a43e8b-090e-4b6b-a909-66bd8e971445"
      unitRef="usd">53000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzE5LTUtMS0xLTI5NzI2_cbeb6233-e3fa-4a71-9002-591b284acab4"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzIwLTEtMS0xLTI5NzI2_c7820b16-82b0-4dec-9f7d-00368483a14d"
      unitRef="usd">-988000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzIwLTMtMS0xLTI5NzI2_e7b37d3a-f6aa-487f-9bce-690c6b5b5704"
      unitRef="usd">947000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzIwLTUtMS0xLTI5NzI2_333108ef-1730-4d5f-8d7d-ec1fca118f9e"
      unitRef="usd">-100000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzIyLTEtMS0xLTI5NzI2_35a12603-2a82-4fe9-852e-f9404ce1e538"
      unitRef="usd">2184000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzIyLTMtMS0xLTI5NzI2_ad46ea46-2de1-4f3f-9b0b-d8c61f5745b2"
      unitRef="usd">649000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzIyLTUtMS0xLTI5NzI2_5673d3c2-f614-45a7-b6af-87339e13602a"
      unitRef="usd">-669000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzI0LTEtMS0xLTI5NzI2_2590b93e-feb7-4d0c-a394-6c6717122ebe"
      unitRef="usd">23062000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzI0LTMtMS0xLTI5NzI2_6dea4173-cd89-4305-8cdc-fa9b89625066"
      unitRef="usd">15363000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo4MzE4MjdkOThiMmI0YTc4YjkyZDI2YTZiMzdkYzhhYi90YWJsZXJhbmdlOjgzMTgyN2Q5OGIyYjRhNzhiOTJkMjZhNmIzN2RjOGFiXzI0LTUtMS0xLTI5NzI2_80af5aeb-37dd-403f-aebb-ab83b76ebec2"
      unitRef="usd">14450000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY18xMzY_bc74488a-7797-4aeb-8ca5-e7fd19b5713f"
      unitRef="usd">-346000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY18xNDk_4238add3-f9af-4489-9abb-bdeaca3b4bf9"
      unitRef="usd">-536000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY18xNjU_decb6a37-ac72-442b-abcd-82112e9bc7db"
      unitRef="usd">19000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY182NTk3MDY5NzY3MDYy_d3ffab35-04a6-45ce-befc-9bb04f0dfe11"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY18yMDI_1608d158-6146-4cb6-8965-fbf761ea0d07"
      unitRef="usd">-1198000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY18yMTU_54b8fa40-b80e-4fe6-8000-49f66f7eabcf"
      unitRef="usd">21000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY18yMzE_8ecff339-ae63-41a5-a326-5b4fcdf0f2a1"
      unitRef="usd">222000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY18yNjY_32855123-cb8a-44e0-a715-df4d61eee7ba"
      unitRef="usd">-263000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY18yNzk_08b3fd26-f072-4a6e-bb7a-6abc01735c52"
      unitRef="usd">252000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjEvZnJhZzpmMjMxZGIwNmVmZDg0YTM4OTExOGM1MTJhNTlhZjdjZS90YWJsZTo0MTlmZjI0MTg1ODE0MGZkYjUyOTA1NmI4NWYzMTI4My90YWJsZXJhbmdlOjQxOWZmMjQxODU4MTQwZmRiNTI5MDU2Yjg1ZjMxMjgzXzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozOWE3Nzg3MjQyNjE0MzgwYTA4OGJjNjg1ZTJlYzlkY18yOTU_13c1dcd4-5063-429c-af29-58f6a469a98d"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2087646dc6744a28755f382fc0a83c8_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEtMS0xLTEtMjk3MjY_2c4f9f16-7510-4799-8485-61e20175a6af"
      unitRef="usd">59752000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i37828c53082f418d82b181eca97c9828_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEtMy0xLTEtMjk3MjY_e6469dc5-a31e-461f-a785-57272b0549e7"
      unitRef="usd">106216000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8503a818334a40a588f1d51c6b02cbdd_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEtNS0xLTEtMjk3MjY_32c1d5d6-9f7f-4c22-8cdf-69b6052c04f1"
      unitRef="usd">-15222000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9eaed1449a745b293b614e71ca57f4e_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEtNy0xLTEtMjk3MjY_871b37dc-e145-44da-a20f-e958d790c698"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6ad9ecbc1c9a4fc99c00bdc33b0042a9_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEtOS0xLTEtMjk3MjY_6737533d-99e6-4cc9-8b7e-d8fba483b443"
      unitRef="usd">-34362000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzMtMS0xLTEtMjk3MjY_d0ac73e9-b155-4fd3-9b3d-d90f3eb981f3"
      unitRef="usd">15119000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id7363031583c4556a56c66f8230d2edb_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzMtMy0xLTEtMjk3MjY_21ec4559-74d1-4113-a1e7-8389024672c8"
      unitRef="usd">15119000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzQtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozZDBhMzNmZTRlZDk0Y2JmOTJjY2MyN2M3NGI0ZmYxNV8yNg_f35a61d6-89ee-48d8-9930-936954187940"
      unitRef="usdPerShare">3.75</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzQtMS0xLTEtMjk3MjY_ca01924e-92b8-4a92-a14a-5c58ee7d62bc"
      unitRef="usd">9917000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="id7363031583c4556a56c66f8230d2edb_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzQtMy0xLTEtMjk3MjY_dee20016-8b32-4c35-b40f-72aeedfa282b"
      unitRef="usd">9917000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzUtMS0xLTEtMjk3MjY_769ffffd-ee65-4d04-9c48-119ba3842e12"
      unitRef="usd">1933000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id7363031583c4556a56c66f8230d2edb_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzUtMy0xLTEtMjk3MjY_182a70d0-5b10-452c-b577-bae04c21e14d"
      unitRef="usd">-758000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i506f1bb3ec9a4c2fa89004c3dc9d077b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzUtOS0xLTEtMjk3MjY_f1dacd24-7895-4362-9513-5eb81f449c3c"
      unitRef="usd">2691000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzYtMS0xLTEtMjk3MjY_3e40588b-8f68-47fe-8856-d281da1525f2"
      unitRef="usd">6746000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i506f1bb3ec9a4c2fa89004c3dc9d077b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzYtOS0xLTEtMjk3MjY_633f60b8-2d10-498e-8ff9-b04ef1d617d1"
      unitRef="usd">6746000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOther
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzctMS0xLTEtMjk3MjY_2a315f15-9f56-49b8-bca0-50f8b89bf024"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="id7363031583c4556a56c66f8230d2edb_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzctMy0xLTEtMjk3MjY_241a4687-d50e-4199-9810-420f28d0ac2e"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzgtMS0xLTEtMjk3MjY_c8e521de-d2eb-4770-bf35-380b5f4870d8"
      unitRef="usd">-669000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0f88c24f46d04306b18b2052c29a8b77_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzgtNS0xLTEtMjk3MjY_5445adec-a135-4e83-b2d0-1fa5c81788e1"
      unitRef="usd">-669000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzktMS0xLTEtMjk3MjY_1385c261-3961-43d5-9220-5c1084230931"
      unitRef="usd">59471000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70ed7bf48d664a018365719e86ad0f9b_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzktMy0xLTEtMjk3MjY_c1117a6a-7f82-44ef-8855-8048214024ca"
      unitRef="usd">110659000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2c3c777d14a94558a9524c8d48022809_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzktNS0xLTEtMjk3MjY_5fa2ab01-a36c-4acf-87e8-f7bc40574b42"
      unitRef="usd">-15891000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00d93b4bd07f45c5b3b285162b1f7ac1_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzktNy0xLTEtMjk3MjY_707d6e1d-b163-4716-8f9a-a909115472ef"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32714d4caccf4a978d06df9c559c7342_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzktOS0xLTEtMjk3MjY_96eaa855-e6cb-4cd6-9b2b-715af5b8c5fd"
      unitRef="usd">-38417000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzExLTEtMS0xLTI5NzI2_29cc54dd-511d-4842-841a-0c1e18a40438"
      unitRef="usd">14714000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3dbfa2026c924048a41d1a2e7ab20fe2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzExLTMtMS0xLTI5NzI2_f31fbccf-445c-4707-9088-6eb2383f4b51"
      unitRef="usd">14714000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEyLTAtMS0xLTI5NzI2L3RleHRyZWdpb246ZWQ1ZjRlY2JmMjNmNGRkODkzZTlkZjIxMThjYWZkMGFfMjY_9bfb4154-5cc3-4da5-ae75-d5e8e5001b6d"
      unitRef="usdPerShare">3.98</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEyLTEtMS0xLTI5NzI2_8cf3d9e8-e6a1-4f76-9616-328f1b6e9101"
      unitRef="usd">10481000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i3dbfa2026c924048a41d1a2e7ab20fe2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEyLTMtMS0xLTI5NzI2_72512645-33bc-4fbc-a780-37052b90eb98"
      unitRef="usd">10481000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEzLTEtMS0xLTI5NzI2_3be31bcd-3626-4c95-b1bb-62c30124a20e"
      unitRef="usd">2217000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3dbfa2026c924048a41d1a2e7ab20fe2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEzLTMtMS0xLTI5NzI2_ec1cfb09-1ecc-4b30-98b4-b8ea5a894105"
      unitRef="usd">-931000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if090847b243c45b38f83514b26483411_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzEzLTktMS0xLTI5NzI2_1b37190b-e344-4d20-bf61-ac25389a679b"
      unitRef="usd">3148000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE0LTEtMS0xLTI5NzI2_38135f5d-6b60-4131-a4c9-26b282baea16"
      unitRef="usd">3221000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if090847b243c45b38f83514b26483411_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE0LTktMS0xLTI5NzI2_b974e49d-e42a-4637-8773-46c5d4e2cb57"
      unitRef="usd">3221000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOther
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE1LTEtMS0xLTI5NzI2_224f0835-6de2-495f-ad29-f0402d2877b9"
      unitRef="usd">71000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i3dbfa2026c924048a41d1a2e7ab20fe2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE1LTMtMS0xLTI5NzI2_e14fadd8-05f4-4270-bb6f-99bdf20cb28e"
      unitRef="usd">71000000</us-gaap:StockholdersEquityOther>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE2LTEtMS0xLTI5NzI2_a40f446a-ae6b-40f2-9678-22de15f33edd"
      unitRef="usd">649000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iaa5fa270dceb439ab74cfc1fa351ade8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE2LTUtMS0xLTI5NzI2_3d4845c4-6600-4b1d-9775-8eb4168bd2a0"
      unitRef="usd">649000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE3LTEtMS0xLTI5NzI2_22c378f7-7b3d-4f2e-898a-1eac34421c49"
      unitRef="usd">63278000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5986c2c6f01d4f0ba394a6d7cad02794_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE3LTMtMS0xLTI5NzI2_48705a74-eeb2-4c3b-aea7-86aff001bc3c"
      unitRef="usd">113890000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2264aac360274fdbb45a327357031ad9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE3LTUtMS0xLTI5NzI2_a9a1371a-49cb-4b72-80bb-958c135575c1"
      unitRef="usd">-15242000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice303ba3fb57401c902937dcecc85b8a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE3LTctMS0xLTI5NzI2_afdbd07c-73b2-4b97-ba66-f64d1f143c9b"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice5631336113469c8d53050918b83329_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE3LTktMS0xLTI5NzI2_7b64130e-5c37-4a08-94b2-6344b4ec4ab4"
      unitRef="usd">-38490000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE5LTEtMS0xLTI5NzI2_e42a6e7b-8da6-4b95-82a7-2e8ed972e796"
      unitRef="usd">20878000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3a3fc6829cad467cbb53b7a1fe81a50a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzE5LTMtMS0xLTI5NzI2_f1d73549-02a7-4506-8c2a-e3169a581b6a"
      unitRef="usd">20878000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzIwLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MTg2MzQ0MDFlYjJmNGZkZGI1MTgyNzM1NzBiZDEzYmRfMjY_4f1f47bd-02ba-4440-ab7a-f1a0184e6b3b"
      unitRef="usdPerShare">4.19</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzIwLTEtMS0xLTI5NzI2_b6de4016-a0c4-42c1-b8b2-fc3195fb179c"
      unitRef="usd">11032000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i3a3fc6829cad467cbb53b7a1fe81a50a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzIwLTMtMS0xLTI5NzI2_2c8118ab-5e1a-4057-942f-42f982d28a2e"
      unitRef="usd">11032000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzIxLTEtMS0xLTI5NzI2_81ca41d7-1778-4248-8985-98f3258c7819"
      unitRef="usd">2171000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3a3fc6829cad467cbb53b7a1fe81a50a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzIxLTMtMS0xLTI5NzI2_8b4addd1-b249-4189-8632-e1f61296d5ef"
      unitRef="usd">-676000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ide5f195a7f1f400580767c19f5aada99_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzIxLTktMS0xLTI5NzI2_983e9e27-251e-40a6-855b-2cceb8fb66a3"
      unitRef="usd">2847000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzIyLTEtMS0xLTI5NzI2_90f3abb7-57ef-4b59-a3b9-bf33cde8c26a"
      unitRef="usd">3456000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ide5f195a7f1f400580767c19f5aada99_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzIyLTktMS0xLTI5NzI2_d485660d-eac8-4438-8699-c6083b6b341b"
      unitRef="usd">3456000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzI0LTEtMS0xLTI5NzI2_fb6792d6-d1e9-49ab-9802-fbb367998ceb"
      unitRef="usd">2184000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i91696814d2cc4ce18c1ad6fe530463f4_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzI0LTUtMS0xLTI5NzI2_d981db58-9e96-433f-86bb-5412be4ea018"
      unitRef="usd">2184000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzI1LTEtMS0xLTI5NzI2_6b33b669-a890-4830-8c35-79869dee8294"
      unitRef="usd">74023000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i456831c91d5b4616a6190fa546fd617b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzI1LTMtMS0xLTI5NzI2_6ee36eda-cf67-4e03-88ff-378bd5ef5c32"
      unitRef="usd">123060000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i857ac21d217c4940938fa16c01722dcd_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzI1LTUtMS0xLTI5NzI2_2b33a45c-1e71-4eb3-9a0d-a98dcba03395"
      unitRef="usd">-13058000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i864da61d817849afadab2a86db4b41cb_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzI1LTctMS0xLTI5NzI2_0f0821fb-a933-4184-a8b1-cff31ead388a"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32f1b367b80b48e593609d66c7aa128c_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMjcvZnJhZzoyZDZiNmE1N2QwYzQ0Yjc4OWM1OTc1YzQ3YzM1NDQ0MC90YWJsZTo0MGE1ZjhjYjEzMjA0MDNhYmM5OWZmYzU3YzQxZTQxMy90YWJsZXJhbmdlOjQwYTVmOGNiMTMyMDQwM2FiYzk5ZmZjNTdjNDFlNDEzXzI1LTktMS0xLTI5NzI2_df126bef-75bf-4f3a-90b5-22069fa3fcb0"
      unitRef="usd">-39099000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzItMS0xLTEtMjk3MjY_1a4e3228-7ebd-4469-be59-c9b0b4671439"
      unitRef="usd">20878000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzItMy0xLTEtMjk3MjY_7473f685-e52c-4c89-b9aa-dffd38623f1a"
      unitRef="usd">14714000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzItNS0xLTEtMjk3MjY_41e3a64b-c57f-477b-81e6-5abeb7563757"
      unitRef="usd">15119000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQtMS0xLTEtMjk3MjY_4df7a077-0abc-4096-b799-44981ba738d9"
      unitRef="usd">7390000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQtMy0xLTEtMjk3MjY_e492809c-abf1-43f4-a9d1-3ee1e1986419"
      unitRef="usd">7231000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQtNS0xLTEtMjk3MjY_2448a6ee-5489-4809-9680-683d748f90d1"
      unitRef="usd">7009000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzUtMS0xLTEtMjk3MjY_5f546c3c-de02-427f-8439-d5d4b9e93d5f"
      unitRef="usd">1135000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzUtMy0xLTEtMjk3MjY_ebb019c6-0f98-4252-b27b-00ca93c834fd"
      unitRef="usd">1005000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzUtNS0xLTEtMjk3MjY_b6ecd27a-c844-4224-8104-7c9595941818"
      unitRef="usd">977000000</us-gaap:ShareBasedCompensation>
    <us-gaap:AssetImpairmentCharges
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzctMS0xLTEtMjk3MjY_6d2fc922-f1aa-4788-b9b8-4de2e98cef0a"
      unitRef="usd">989000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzctMy0xLTEtMjk3MjY_9dce6cc8-d871-416f-b270-5f84ec548ad2"
      unitRef="usd">233000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzctNS0xLTEtMjk3MjY_346b3755-1013-4a36-846e-24d0dbfc9695"
      unitRef="usd">1096000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzgtMS0xLTEtMjk3MjY_f64af6e0-f2d9-4025-95a4-f7af37ed0e48"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzgtMy0xLTEtMjk3MjY_09458da0-7e70-45f9-a5a0-ee623d869dae"
      unitRef="usd">-1148000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzgtNS0xLTEtMjk3MjY_7b1c82f4-63f6-4bfd-878c-a9f84547f960"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzktMS0xLTEtMjk3MjY_ee4c4cda-11c0-4c4f-b491-4526b088ac1a"
      unitRef="usd">617000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzktMy0xLTEtMjk3MjY_f455b289-dbb5-4d47-84e8-3c9a0482a409"
      unitRef="usd">111000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzktNS0xLTEtMjk3MjY_8b2944d8-e96b-4d85-9008-9bef1637a92a"
      unitRef="usd">2154000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzExLTEtMS0xLTI5NzI2_ac04cb96-0895-4c1e-be23-661377c0a6d4"
      unitRef="usd">-2079000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzExLTMtMS0xLTI5NzI2_b3f3eedb-e3da-447f-935d-f2d55bf6bed7"
      unitRef="usd">-1141000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzExLTUtMS0xLTI5NzI2_08dde179-e31c-4c6d-bea9-2be6fb590db4"
      unitRef="usd">-2476000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzEyLTEtMS0xLTI5NzI2_8dfc5c82-6ce6-4346-a11a-ad9364aed634"
      unitRef="usd">-48000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzEyLTMtMS0xLTI5NzI2_37246538-843a-419f-b6a2-87681047566e"
      unitRef="usd">63000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzEyLTUtMS0xLTI5NzI2_fa512007-e4e7-467c-a062-5a40ef39d502"
      unitRef="usd">-20000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE0LTEtMS0xLTI5NzI2_64799808-812d-4299-a2b8-629d8d43a74c"
      unitRef="usd">2402000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE0LTMtMS0xLTI5NzI2_d47f5244-239a-4c5e-8f72-b765ec1ae573"
      unitRef="usd">-774000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE0LTUtMS0xLTI5NzI2_7c5265b1-d88c-4123-a74d-b71f02c6e714"
      unitRef="usd">289000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE1LTEtMS0xLTI5NzI2_a94249f9-d08c-4d40-afe7-c1aa37636ace"
      unitRef="usd">1248000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE1LTMtMS0xLTI5NzI2_7026920f-3bb7-41ab-894d-b8d40eca3baa"
      unitRef="usd">265000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE1LTUtMS0xLTI5NzI2_1bc0967b-4427-4b3e-818e-82052eaa77af"
      unitRef="usd">277000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE2LTEtMS0xLTI5NzI2_c522e0c1-64ac-43f0-984a-4e8f7652a7db"
      unitRef="usd">2437000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE2LTMtMS0xLTI5NzI2_f64f1e4d-56ad-4385-8aec-9f198505a720"
      unitRef="usd">5141000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE2LTUtMS0xLTI5NzI2_91dcde38-0845-41cb-9e48-bce5da71139a"
      unitRef="usd">4060000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE3LTEtMS0xLTI5NzI2_acba46b5-06ce-4dc0-ba21-bd2da2556de7"
      unitRef="usd">1964000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE3LTMtMS0xLTI5NzI2_50ac6a1c-a8a2-46d6-b4ca-fb89997a850c"
      unitRef="usd">3704000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE3LTUtMS0xLTI5NzI2_44cf8264-7c53-4be1-9a11-c7d31dffa597"
      unitRef="usd">1054000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE4LTEtMS0xLTI5NzI2_110483de-05a9-4d0d-849e-48909f4d3819"
      unitRef="usd">-1061000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE4LTMtMS0xLTI5NzI2_491d8f05-1b8b-405f-a82b-75ca52870256"
      unitRef="usd">744000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE4LTUtMS0xLTI5NzI2_220c0de2-d9ee-4bf2-8498-bfb8e17b54ba"
      unitRef="usd">1425000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE5LTEtMS0xLTI5NzI2_3d67475e-a346-4df4-9a40-884c45a52323"
      unitRef="usd">23410000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE5LTMtMS0xLTI5NzI2_92380605-a725-4a84-8e36-3eda026024e4"
      unitRef="usd">23536000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzE5LTUtMS0xLTI5NzI2_12854f16-9fc4-4bfe-8252-290ebe0fee97"
      unitRef="usd">23416000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzIxLTEtMS0xLTI5NzI2_4f20cff2-b7e8-480a-b45d-2ab14a0cc34b"
      unitRef="usd">3652000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzIxLTMtMS0xLTI5NzI2_26281358-d883-48c5-9763-f848e27f9816"
      unitRef="usd">3347000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzIxLTUtMS0xLTI5NzI2_e195c6e4-b8b2-4b5c-8446-731f380d8a6e"
      unitRef="usd">3498000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzIyLTEtMS0xLTI5NzI2_28b77ac2-1a5a-42b6-b0ff-ef6e608ea207"
      unitRef="usd">711000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzIyLTMtMS0xLTI5NzI2_a5cc252a-5c7d-4836-bf1e-5c05b5cf1899"
      unitRef="usd">305000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzIyLTUtMS0xLTI5NzI2_34410055-510d-4bd2-9e64-8108e69da70f"
      unitRef="usd">3265000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzIzLTEtMS0xLTI5NzI2_2d3e0922-c957-4dbc-b35b-2acea2bc6f64"
      unitRef="usd">60000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzIzLTMtMS0xLTI5NzI2_be663a32-ae67-491f-8c54-e2786ea644e3"
      unitRef="usd">7323000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzIzLTUtMS0xLTI5NzI2_9bc6a1e0-ee53-4685-9bee-558ac0897b9b"
      unitRef="usd">5810000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI0LTEtMS0xLTI5NzI2_db7421b6-8a65-4afc-9907-4bfd60f40448"
      unitRef="usd">30394000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI0LTMtMS0xLTI5NzI2_c7875c45-49e2-4d16-b5af-dc558ae1fa8f"
      unitRef="usd">21089000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI0LTUtMS0xLTI5NzI2_4eeaa0dc-57f3-4a6f-97da-c4044c51f4d3"
      unitRef="usd">3920000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI1LTEtMS0xLTI5NzI2_4cb14f77-2054-4f51-8d99-98c25e3f0fb3"
      unitRef="usd">25006000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI1LTMtMS0xLTI5NzI2_b4b8d88f-92c9-4411-a302-0185bfb9d97e"
      unitRef="usd">12137000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI1LTUtMS0xLTI5NzI2_955cdabe-c047-41fc-a96c-cef8fc8a9a37"
      unitRef="usd">3387000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI2LTEtMS0xLTI5NzI2_c70ad05c-f8b2-45fb-9c6c-c4859c489780"
      unitRef="usd">214000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI2LTMtMS0xLTI5NzI2_efdd781e-e77c-423d-9d3c-72394c2481a4"
      unitRef="usd">-987000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI2LTUtMS0xLTI5NzI2_f908ca00-d11a-4768-8f74-83b3ee9da35f"
      unitRef="usd">338000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI3LTEtMS0xLTI5NzI2_48352e94-fe50-46ff-8e74-90320f3688d2"
      unitRef="usd">508000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI3LTMtMS0xLTI5NzI2_334ab26e-ebe7-4d50-a10f-eabcd6a049e9"
      unitRef="usd">521000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI3LTUtMS0xLTI5NzI2_cd2d2c51-00e5-4132-9d66-2ae4b2b6b9fe"
      unitRef="usd">-44000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI4LTEtMS0xLTI5NzI2_49746f9d-db41-4c16-90b8-286e9d48f6f2"
      unitRef="usd">-8683000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI4LTMtMS0xLTI5NzI2_61c22f24-929b-4017-917f-cbd46357638f"
      unitRef="usd">-20825000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzI4LTUtMS0xLTI5NzI2_356d6c7e-de7b-4aa0-9ec0-b0f2409c1fea"
      unitRef="usd">-6194000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMwLTEtMS0xLTI5NzI2_282e325d-2f12-4004-bff7-c2dfb83eebc8"
      unitRef="usd">11032000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMwLTMtMS0xLTI5NzI2_2abb9144-4668-423f-9c55-c4395d7c5cbd"
      unitRef="usd">10481000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMwLTUtMS0xLTI5NzI2_93af165c-223a-4e23-b187-3b62ebe3c9fa"
      unitRef="usd">9917000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMxLTEtMS0xLTI5NzI2_5343d432-ee25-45bc-8672-e74e12db7fd2"
      unitRef="usd">3456000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMxLTMtMS0xLTI5NzI2_75ce441f-1aea-47b2-9285-9f24cdf96289"
      unitRef="usd">3221000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMxLTUtMS0xLTI5NzI2_2a372809-9b71-47b8-9442-555a943c7e16"
      unitRef="usd">6746000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMyLTEtMS0xLTI5NzI2_68e71ee4-2050-4699-8714-3517ae5e1ff6"
      unitRef="usd">1997000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMyLTMtMS0xLTI5NzI2_b58978e5-5b05-4514-9739-1afdb0264703"
      unitRef="usd">3391000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMyLTUtMS0xLTI5NzI2_625687e7-a5c7-4744-90fa-3e712c8182ea"
      unitRef="usd">39000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMzLTEtMS0xLTI5NzI2_84320525-d4fc-4e70-9730-ff0d443fc20a"
      unitRef="usd">1190000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMzLTMtMS0xLTI5NzI2_c6f07919-c678-4a86-a08c-6074b9799788"
      unitRef="usd">2663000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzMzLTUtMS0xLTI5NzI2_843a5e86-9a51-4ab4-a2da-c1c01664c325"
      unitRef="usd">100000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM0LTEtMS0xLTI5NzI2_9e2ae773-781c-4402-8833-ad99dfdc14ac"
      unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM0LTMtMS0xLTI5NzI2_0115afd1-6973-4c0e-a6ee-2853f4917162"
      unitRef="usd">7431000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM0LTUtMS0xLTI5NzI2_7dc16b49-009a-4361-abc4-482abddf49ae"
      unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM1LTEtMS0xLTI5NzI2_7efb490c-bfa6-464c-ab24-86b4248856cc"
      unitRef="usd">1802000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM1LTMtMS0xLTI5NzI2_4bd04ec3-b90c-4a66-a4dc-04a05409dc19"
      unitRef="usd">1064000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM1LTUtMS0xLTI5NzI2_0b7e4871-cafc-49a5-9bfc-054bf806f1de"
      unitRef="usd">2823000000</us-gaap:RepaymentsOfLongTermDebt>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM2LTEtMS0xLTI5NzI2_625682d5-922a-499f-9894-9e9a598d91a4"
      unitRef="usd">1036000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM2LTMtMS0xLTI5NzI2_e4c7db6e-8515-4043-a9ce-5671c7f5f635"
      unitRef="usd">1114000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM2LTUtMS0xLTI5NzI2_3d1ed05f-b6e6-4994-b9be-ccaf522f03da"
      unitRef="usd">954000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM3LTEtMS0xLTI5NzI2_300a0739-8047-4e22-aa49-403391b10782"
      unitRef="usd">281000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM3LTMtMS0xLTI5NzI2_85e95f79-1d0f-40a2-8467-159af4e8421f"
      unitRef="usd">-333000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM3LTUtMS0xLTI5NzI2_690ce44c-c8c6-4905-be03-d27bb58b8ee8"
      unitRef="usd">100000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM4LTEtMS0xLTI5NzI2_c9dd73d8-10ed-4b90-9af6-daf2deaa2e76"
      unitRef="usd">114000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM4LTMtMS0xLTI5NzI2_df5cfefb-0895-4ac1-8a85-6c8b0c1e51f4"
      unitRef="usd">-294000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM4LTUtMS0xLTI5NzI2_cdab6f93-7ebd-4b33-a478-d3ecc63a7842"
      unitRef="usd">475000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM5LTEtMS0xLTI5NzI2_b411f18b-e083-4336-aa47-a89b6f243111"
      unitRef="usd">-14047000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM5LTMtMS0xLTI5NzI2_e4bc9e0a-06c5-4633-8344-79dcd0f76ce7"
      unitRef="usd">-6120000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzM5LTUtMS0xLTI5NzI2_871965bb-bdd5-47af-8ee0-060fc64a7b46"
      unitRef="usd">-18015000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQwLTEtMS0xLTI5NzI2_9969119a-5ad2-45b2-9919-dfe345f1fba6"
      unitRef="usd">-178000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQwLTMtMS0xLTI5NzI2_c3fad9f4-b311-4120-ac7a-b7d5b871dcc3"
      unitRef="usd">89000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQwLTUtMS0xLTI5NzI2_0412adb1-bff9-426d-b26d-56f0be609d04"
      unitRef="usd">-9000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQxLTEtMS0xLTI5NzI2_28bc0dcf-0268-4441-b8b1-2514e9e3d744"
      unitRef="usd">502000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQxLTMtMS0xLTI5NzI2_d5801e2e-c5c7-48f4-81c9-87f2877fcaed"
      unitRef="usd">-3320000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQxLTUtMS0xLTI5NzI2_8f335752-adf8-4b32-bfab-0d7b9af94090"
      unitRef="usd">-802000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQyLTEtMS0xLTI5NzI2_38c98703-1d00-426b-b091-52dce989eb98"
      unitRef="usd">13985000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQyLTMtMS0xLTI5NzI2_ef3148cc-1cd4-4ec5-8c62-533cb9b697fd"
      unitRef="usd">17305000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia2087646dc6744a28755f382fc0a83c8_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQyLTUtMS0xLTI5NzI2_c9433189-6de2-427a-89c5-673bafd581a2"
      unitRef="usd">18107000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQzLTEtMS0xLTI5NzI2_631e1e7f-cc73-4420-87ea-c1842595eb45"
      unitRef="usd">14487000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQzLTMtMS0xLTI5NzI2_8d8589ce-00e3-4546-a20d-edbbadd21354"
      unitRef="usd">13985000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQzLTUtMS0xLTI5NzI2_616121e7-2b3a-4cf1-9634-5f00605456b0"
      unitRef="usd">17305000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaid
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQ3LTEtMS0xLTI5NzI2_b0151cf0-d41e-43c5-aca9-6a54d244c733"
      unitRef="usd">990000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQ3LTMtMS0xLTI5NzI2_e3b8f076-b14a-429b-9447-09bfa72129ee"
      unitRef="usd">904000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQ3LTUtMS0xLTI5NzI2_84b28a47-21cd-425c-90a1-2115709b9ef8"
      unitRef="usd">995000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaidNet
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQ4LTEtMS0xLTI5NzI2_7413bdab-6920-4a29-95c8-b99edb4ea2cd"
      unitRef="usd">941000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQ4LTMtMS0xLTI5NzI2_83628638-22c3-475b-bc9d-6901522da4b9"
      unitRef="usd">841000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQ4LTUtMS0xLTI5NzI2_99d5bf83-25a8-4a54-a7bd-c57151175dff"
      unitRef="usd">925000000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQ5LTEtMS0xLTI5NzI2_9a043dba-b00f-40a6-9fce-4616e0d70305"
      unitRef="usd">4768000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQ5LTMtMS0xLTI5NzI2_f2147b6b-f5ff-44b4-b91d-95caf099d9d2"
      unitRef="usd">4619000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzQ5LTUtMS0xLTI5NzI2_5e2c4522-b563-43ea-81fd-c362a477bfcc"
      unitRef="usd">4191000000</us-gaap:IncomeTaxesPaid>
    <jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzUyLTEtMS0xLTI5NzI2_88b13ed7-4551-487b-8dff-379a4d32f816"
      unitRef="usd">1811000000</jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds>
    <jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzUyLTMtMS0xLTI5NzI2_8147b34e-f343-4af3-bd41-ad4b5bf963d3"
      unitRef="usd">1937000000</jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds>
    <jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzUyLTUtMS0xLTI5NzI2_be170f46-74a0-439c-bcbe-f9e626b29d4f"
      unitRef="usd">1736000000</jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzUzLTEtMS0xLTI5NzI2_625a6984-3fd0-4f02-95a8-440f20651e85"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzUzLTMtMS0xLTI5NzI2_79c88237-4810-485c-b478-b58b1beec489"
      unitRef="usd">27000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzUzLTUtMS0xLTI5NzI2_a65e4831-f4aa-4910-824d-529d85411b2c"
      unitRef="usd">1000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzU2LTEtMS0xLTI5NzI2_653f9fe7-4c3b-4027-8d97-832748a3119a"
      unitRef="usd">61000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzU2LTMtMS0xLTI5NzI2_3328ce27-7762-4200-a6c6-385e83ac188e"
      unitRef="usd">7755000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzU2LTUtMS0xLTI5NzI2_1de24905-b20d-4c93-979a-3b87f49abc04"
      unitRef="usd">7228000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzU3LTEtMS0xLTI5NzI2_26be08bd-97c5-4d4f-be69-783fbaab8a91"
      unitRef="usd">1000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzU3LTMtMS0xLTI5NzI2_b2525b28-ef53-4e32-ab40-e7a58478c00f"
      unitRef="usd">432000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzU3LTUtMS0xLTI5NzI2_065f2428-62c9-4693-bae6-d4961c060bc6"
      unitRef="usd">1418000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzU4LTEtMS0xLTI5NzI2_06b225da-11c7-431d-bf29-8c877472d654"
      unitRef="usd">60000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzU4LTMtMS0xLTI5NzI2_71282c1a-442f-4458-bb59-0fa16c2889f2"
      unitRef="usd">7323000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzMvZnJhZzozN2RjYjAxMTc3ZDI0MzY0YTY4ZWY0MzViNzQyN2Q1MC90YWJsZTo2ZTgyYzBmMGE1YzE0NzJiYmM3NzMyOGI5OTU5NDljNS90YWJsZXJhbmdlOjZlODJjMGYwYTVjMTQ3MmJiYzc3MzI4Yjk5NTk0OWM1XzU4LTUtMS0xLTI5NzI2_d73d3013-20a1-4d4a-9da7-db529f2f9e55"
      unitRef="usd">5810000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzY1OTcwNjk4MjE0MzU_93ff29ca-8893-4b8d-831f-1bad62915176">Summary of Significant Accounting Policies&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Johnson&#160;&amp;amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description of the Company and Business Segments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has approximately 141,700&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is organized into three business segments: Consumer Health, Pharmaceutical and Medical Devices. The Consumer Health segment includes a broad range of products used in the Baby Care, Oral Care, Skin Health/Beauty, Over-the-Counter pharmaceutical, Women&#x2019;s Health and Wound Care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on six therapeutic areas, including Immunology, Infectious diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The Medical Devices segment includes a broad range of products used in the Orthopaedic, Surgery, Interventional Solutions (cardiovascular and neurovascular) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Company announced its intention to separate the Company&#x2019;s Consumer Health business, with the intention to create a new, publicly traded company. The Company is targeting completion of the planned separation in 18 to 24 months after initial announcement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in fiscal 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Not Adopted as of January 2, 2022&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. There were no new material accounting standards issued in fiscal 2021 that impacted the Company.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ASU 2021-01: Reference Rate Reform &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In mid- 2017, the Financial Conduct Authority (FCA) announced that it will no longer require banks to submit rates for the London Interbank Offered Rate (LIBOR) after 2021 hence market participants should work to transition to alternative reference rates (Reference Rate Reform) and should not rely on LIBOR being available after the end of 2021. Reference rate reform is the term used to refer to the efforts that have been undertaken by regulators and other market participants to introduce new reference rates that are based on a larger and more liquid population of observable transactions. The Company evaluated the implications of reference rate reform and applicable financial reporting guidance in ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting on its key financial and commercial contracts that referenced LIBOR including any hedging relationships. Most contracts reviewed will mature prior to the termination of LIBOR or will be modified to apply a new reference rate (primarily the Secured Overnight Financing Rate &#x201c;SOFR&#x201d; where applicable). The company also applied available practical expedients under ASC 848 to in scope financial and commercial contracts that previously referenced LIBOR when applicable. As a result, the Company's implementation of any reference rate reform provisions to commercial and financial contracts did not result in any material change for the Company.  &lt;/span&gt;&lt;span style="color:#1f3864;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;        &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;at least an investment grade credit rating.  The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value.  The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment and Depreciation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;- 30&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;- 20&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;- 13&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#x2019;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Managed Care, Medicare and Medicaid programs, which amounted to $7.7 billion and $7.2 billion as of January&#160;2, 2022 and January&#160;3, 2021, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#x2019;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#x2019;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years&#160;2021,&#160;2020&#160;and&#160;2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. For all years presented, profit-share payments were less than 3.0% of the total revenues and are included in sales to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shipping and Handling&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shipping and handling costs incurred were $1.1 billion, $1.0 billion and $1.0 billion in fiscal years 2021, 2020 and 2019, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2021 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions.  See Note&#160;5 for further details on Intangible Assets and Goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value.  Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#x2019;s impact on the Company&#x2019;s financial performance; (2)&#160;protect the Company&#x2019;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTI0_2cce01d2-b420-436a-93e5-bea5f12e0c78"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTI0_dee6b310-adcd-43bf-a063-cd1559b71416"&gt;Other assets&lt;/span&gt;&lt;/span&gt;, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODU5_5e9c1949-8e21-4631-bf9f-ba8181485230"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTM2_2dbaf7d6-873f-4b21-881f-1b610527d361"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;, and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODgz_5fa03461-5e24-4b61-b8c9-f2468f3220fb"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODgz_8dab58da-7c04-4417-a1bc-72271f9a3a36"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt; on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $0.9&#160;billion and $1.0&#160;billion in 2021 and 2020, respectively. The lease liability was $1.0&#160;billion and $1.1&#160;billion in 2021and 2020, respectively. The operating lease costs were $0.3&#160;billion, $0.3&#160;billion and $0.3&#160;billion in 2021, 2020 and 2019, respectively. Cash paid for amounts included in the measurement of lease liabilities were $0.3&#160;billion, $0.3&#160;billion and $0.3&#160;billion in 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development.  Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product.  Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#x2019;s operations. In general, the income statement presentation for these collaborations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nature/Type of Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Earnings Presentation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third-party sale of product &amp;amp; profit share payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales to customers&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties/milestones paid to collaborative partner (post-regulatory approval)*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties received from collaborative partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Upfront payments&#160;&amp;amp; milestones paid to collaborative partner (pre-regulatory approval)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development payments to collaborative partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development payments received from collaborative partner or government entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:96.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, co-developed with Bayer HealthCare AG and IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, licensed from Genmab A/S.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $2.7 billion, $2.1 billion and $2.2 billion in fiscal years 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2021 was approximately $6.9&#160;billion, of which $6.1&#160;billion is classified as noncurrent and reflected as &#x201c;Long-term taxes payable&#x201d; on the Company&#x2019;s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI).  GILTI is described as the excess of a U.S. shareholder&#x2019;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#x201c;period cost&#x201d;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., &#x201c;deferred method&#x201d;). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $0.7 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;See Note 8 to the Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;for further information regarding income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which COVID-19 impacts the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of January 2, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#x2019;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#x2019;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#x2019;s consolidated financial statements as of and for the fiscal year ended January 2, 2022, the Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Annual Closing Date&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODY0_7cf5e221-c61e-4819-a85b-df1580f0e995">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Johnson&#160;&amp;amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTIy_cd361460-6d5d-44f1-a46e-87767bec70ff">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description of the Company and Business Segments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has approximately 141,700&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is organized into three business segments: Consumer Health, Pharmaceutical and Medical Devices. The Consumer Health segment includes a broad range of products used in the Baby Care, Oral Care, Skin Health/Beauty, Over-the-Counter pharmaceutical, Women&#x2019;s Health and Wound Care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on six therapeutic areas, including Immunology, Infectious diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The Medical Devices segment includes a broad range of products used in the Orthopaedic, Surgery, Interventional Solutions (cardiovascular and neurovascular) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Company announced its intention to separate the Company&#x2019;s Consumer Health business, with the intention to create a new, publicly traded company. The Company is targeting completion of the planned separation in 18 to 24 months after initial announcement.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzQ1NA_0c59a766-461c-4cba-8c54-8f069418173c"
      unitRef="employee">141700</jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide>
    <us-gaap:NumberOfReportableSegments
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzc3MQ_881238ae-32f2-42c1-a1f0-dc5208b77d46"
      unitRef="segment">3</us-gaap:NumberOfReportableSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTQ2_6416aba8-dd2c-4e74-8c54-f8c175ab033d">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in fiscal 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Not Adopted as of January 2, 2022&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. There were no new material accounting standards issued in fiscal 2021 that impacted the Company.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ASU 2021-01: Reference Rate Reform &lt;/span&gt;&lt;/div&gt;In mid- 2017, the Financial Conduct Authority (FCA) announced that it will no longer require banks to submit rates for the London Interbank Offered Rate (LIBOR) after 2021 hence market participants should work to transition to alternative reference rates (Reference Rate Reform) and should not rely on LIBOR being available after the end of 2021. Reference rate reform is the term used to refer to the efforts that have been undertaken by regulators and other market participants to introduce new reference rates that are based on a larger and more liquid population of observable transactions. The Company evaluated the implications of reference rate reform and applicable financial reporting guidance in ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting on its key financial and commercial contracts that referenced LIBOR including any hedging relationships. Most contracts reviewed will mature prior to the termination of LIBOR or will be modified to apply a new reference rate (primarily the Secured Overnight Financing Rate &#x201c;SOFR&#x201d; where applicable). The company also applied available practical expedients under ASC 848 to in scope financial and commercial contracts that previously referenced LIBOR when applicable. As a result, the Company's implementation of any reference rate reform provisions to commercial and financial contracts did not result in any material change for the Company.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTA5_04a09443-87cc-40bb-9323-75ab12987dfc">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;at least an investment grade credit rating.  The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value.  The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzUzNTQ_0941b941-2234-4acb-a64a-4a13cf4a7862"
      unitRef="number">1.02</jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement>
    <jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzU3Mjc_9aeb75c3-7754-4695-bcfe-9651e5a10506"
      unitRef="number">1.02</jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODY1_6f107230-336b-4d28-ba28-f93906011398">InvestmentsInvestments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODc0_138cd3f7-0299-40e2-8c65-b44f0cd47bda">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment and Depreciation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;- 30&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;- 20&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;- 13&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#x2019;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <jnj:EstimatedUsefulLivesOfAssetsTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODM1_02968779-91a6-434d-9739-9895e2e4379d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;- 30&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;- 20&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;- 13&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</jnj:EstimatedUsefulLivesOfAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i43031434703546208388df65cfb38be8_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90YWJsZToyY2E3YTE0MGJmYWI0NDE0YWM4Yzc3ODJmZmFmMzFkOS90YWJsZXJhbmdlOjJjYTdhMTQwYmZhYjQ0MTRhYzhjNzc4MmZmYWYzMWQ5XzAtMS0xLTEtMjk3MjYvdGV4dHJlZ2lvbjpjZWVmZjgyNGJmYzA0OTM4YWIyMzA0YjY5YjNkMzc5ZF80_488d08d1-8c14-4ec2-9116-39f6b0706862">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i014ba6f3e80849a28122f5bc50cd0d40_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90YWJsZToyY2E3YTE0MGJmYWI0NDE0YWM4Yzc3ODJmZmFmMzFkOS90YWJsZXJhbmdlOjJjYTdhMTQwYmZhYjQ0MTRhYzhjNzc4MmZmYWYzMWQ5XzAtMS0xLTEtMjk3MjYvdGV4dHJlZ2lvbjpjZWVmZjgyNGJmYzA0OTM4YWIyMzA0YjY5YjNkMzc5ZF85_cf817473-25b8-49c9-bed2-9844fe81e51d">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id99da0671adc429480c2f2f9dfd88fcc_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90YWJsZToyY2E3YTE0MGJmYWI0NDE0YWM4Yzc3ODJmZmFmMzFkOS90YWJsZXJhbmdlOjJjYTdhMTQwYmZhYjQ0MTRhYzhjNzc4MmZmYWYzMWQ5XzEtMS0xLTEtMjk3MjYvdGV4dHJlZ2lvbjowOTk0NTk1MWI5Y2Y0OGU5OTkwNjY1MDk3NmIzZWQyNV80_23aff49a-e7b6-43b7-ba11-1f1e073a2e87">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i698e54dd726c4d32801340b6a2864ac6_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90YWJsZToyY2E3YTE0MGJmYWI0NDE0YWM4Yzc3ODJmZmFmMzFkOS90YWJsZXJhbmdlOjJjYTdhMTQwYmZhYjQ0MTRhYzhjNzc4MmZmYWYzMWQ5XzEtMS0xLTEtMjk3MjYvdGV4dHJlZ2lvbjowOTk0NTk1MWI5Y2Y0OGU5OTkwNjY1MDk3NmIzZWQyNV85_afde01e5-4181-48cd-8aeb-1a3ad5035ac2">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia09026d98ab54d0ab3a6818b803f2d60_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90YWJsZToyY2E3YTE0MGJmYWI0NDE0YWM4Yzc3ODJmZmFmMzFkOS90YWJsZXJhbmdlOjJjYTdhMTQwYmZhYjQ0MTRhYzhjNzc4MmZmYWYzMWQ5XzItMS0xLTEtMjk3MjYvdGV4dHJlZ2lvbjo3MGJlOGM1ZWY3NjI0ZjY2OWY0MDQ0OTRkNTkxNTI1Yl80_0c897137-7de6-44ab-b695-57f9e8ac5b8b">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7bd54d7094d64fd0b19d0a1281d9b700_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90YWJsZToyY2E3YTE0MGJmYWI0NDE0YWM4Yzc3ODJmZmFmMzFkOS90YWJsZXJhbmdlOjJjYTdhMTQwYmZhYjQ0MTRhYzhjNzc4MmZmYWYzMWQ5XzItMS0xLTEtMjk3MjYvdGV4dHJlZ2lvbjo3MGJlOGM1ZWY3NjI0ZjY2OWY0MDQ0OTRkNTkxNTI1Yl85_50b45c53-0e0f-499d-b8b4-f9eed479a02c">P13Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia0ad24090c2d488cb2a8dadbaca511fa_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzcyMzM_c53845f4-499e-434f-aecf-402f1e2ab972">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i28f696c1c6874735a62135bedd0cf600_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzcyMzk_7dd027c5-6c30-4c75-88ab-da131e537b90">P8Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODE4_3ff70e78-fa33-4f92-943c-cd9f5b88bab0">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Managed Care, Medicare and Medicaid programs, which amounted to $7.7 billion and $7.2 billion as of January&#160;2, 2022 and January&#160;3, 2021, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#x2019;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#x2019;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years&#160;2021,&#160;2020&#160;and&#160;2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. For all years presented, profit-share payments were less than 3.0% of the total revenues and are included in sales to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="i19a5a3c7ee35405ba80137bf84570da6_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzg5OTE_723c208c-7d0d-4180-8319-b393eebbc4c9"
      unitRef="usd">7700000000</jnj:AccruedRebatesReturnsAndPromotions>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="ib90b59b163b542a1adf97f356be068eb_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzg5OTg_9cb06134-769f-4660-8ab1-13726b17ad2e"
      unitRef="usd">7200000000</jnj:AccruedRebatesReturnsAndPromotions>
    <jnj:SalesReturnReserve
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzEwNTM0_0402de88-4b59-42d4-ac26-6d92d78a1d10"
      unitRef="number">0.010</jnj:SalesReturnReserve>
    <jnj:SalesReturnReserve
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzEwNTM0_7df76798-3905-4814-942c-a09d04c15da1"
      unitRef="number">0.010</jnj:SalesReturnReserve>
    <jnj:SalesReturnReserve
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzEwNTM0_c22fd06c-16e8-46d0-81d9-7315c0908a5a"
      unitRef="number">0.010</jnj:SalesReturnReserve>
    <jnj:ProfitLossPercentToSales
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzExNDI0_0106fb8d-d7a7-4e81-990d-8f9a6a4deca1"
      unitRef="number">0.030</jnj:ProfitLossPercentToSales>
    <jnj:ProfitLossPercentToSales
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzExNDI0_646ac5b4-6d9f-41af-8bb4-6bcc8f64154b"
      unitRef="number">0.030</jnj:ProfitLossPercentToSales>
    <jnj:ProfitLossPercentToSales
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzExNDI0_afbb7540-da97-4d5e-891f-b1d811b36e39"
      unitRef="number">0.030</jnj:ProfitLossPercentToSales>
    <us-gaap:ShippingAndHandlingCostPolicyTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTMz_1dffb8b5-1363-43c5-a6f0-72bb7d7ef43f">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shipping and Handling&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shipping and handling costs incurred were $1.1 billion, $1.0 billion and $1.0 billion in fiscal years 2021, 2020 and 2019, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i460777456be14637947184c662627b8b_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzExNjQ1_18881b25-c447-4126-895b-2d6ff986718a"
      unitRef="usd">1100000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9624c6a1bedd497c80dbb2352574e47f_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzExNjQ5_118e6e83-fbc8-474c-b671-c83c03d06af0"
      unitRef="usd">1000000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i093d06247d2c44aa8f18996fcd289352_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzExNjU2_99f3b1c2-bbba-4899-8607-faae83ff2983"
      unitRef="usd">1000000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:ShippingandHandlingCostsasaPercentofSales
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzExODQx_2e8d4def-cfb6-4e4d-84c6-2dcd4f7189fe"
      unitRef="number">0.005</jnj:ShippingandHandlingCostsasaPercentofSales>
    <jnj:ShippingandHandlingCostsasaPercentofSales
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzExODQx_c0281ca5-b274-4f13-929c-681ca21db445"
      unitRef="number">0.005</jnj:ShippingandHandlingCostsasaPercentofSales>
    <jnj:ShippingandHandlingCostsasaPercentofSales
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzExODQx_e65d58ae-4b54-4dc6-825f-c4275cf06c97"
      unitRef="number">0.005</jnj:ShippingandHandlingCostsasaPercentofSales>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTM0_8236dbb4-664d-4abd-bacb-000ca93a9128">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODc2_c36eca7a-9b02-46c8-a807-d52be9122e01">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2021 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions.  See Note&#160;5 for further details on Intangible Assets and Goodwill.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODU1_c6e45f46-e0d6-490a-9e01-8ad810a3e18c">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value.  Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#x2019;s impact on the Company&#x2019;s financial performance; (2)&#160;protect the Company&#x2019;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODI4_45526e87-8e3c-48f3-95a6-594111826ee8">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTI0_2cce01d2-b420-436a-93e5-bea5f12e0c78"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTI0_dee6b310-adcd-43bf-a063-cd1559b71416"&gt;Other assets&lt;/span&gt;&lt;/span&gt;, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODU5_5e9c1949-8e21-4631-bf9f-ba8181485230"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTM2_2dbaf7d6-873f-4b21-881f-1b610527d361"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;, and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODgz_5fa03461-5e24-4b61-b8c9-f2468f3220fb"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODgz_8dab58da-7c04-4417-a1bc-72271f9a3a36"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt; on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $0.9&#160;billion and $1.0&#160;billion in 2021 and 2020, respectively. The lease liability was $1.0&#160;billion and $1.1&#160;billion in 2021and 2020, respectively. The operating lease costs were $0.3&#160;billion, $0.3&#160;billion and $0.3&#160;billion in 2021, 2020 and 2019, respectively. Cash paid for amounts included in the measurement of lease liabilities were $0.3&#160;billion, $0.3&#160;billion and $0.3&#160;billion in 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE2MjA5_a7887645-2b20-4619-bdba-7d308219b21a"
      unitRef="usd">900000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE2MjE2_3956ad1f-bf74-4431-aeef-9eeeceb092fb"
      unitRef="usd">1000000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE2Mjc1_ff535cbc-d8ca-4ca7-8e7b-3fbc9afc8160"
      unitRef="usd">1000000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE2Mjgy_81235d1b-c13e-46c7-934f-309596d68b12"
      unitRef="usd">1100000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE2MzQ4_614f8af6-2b14-4be1-86bb-322a9585b96c"
      unitRef="usd">300000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE2MzUy_fa99ae69-6e5c-48e5-8deb-fb68938d01c0"
      unitRef="usd">300000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE2MzU5_8dcae0da-438b-4241-8ed7-f8502c39afe2"
      unitRef="usd">300000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE2NDc2_6d4fe5e0-2e44-4442-a1f7-238493b46ef6"
      unitRef="usd">300000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE2NDgz_a49a461e-8ff1-4c7a-a997-5be5bb2f10c8"
      unitRef="usd">300000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzU0OTc1NTgxOTMzMDE_873ef49f-2539-4d89-ab4e-b1f4f56d5da9"
      unitRef="usd">300000000</us-gaap:OperatingLeasePayments>
    <jnj:ProductLiabilityPolicyTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODMy_d9041113-5333-4a62-a6b6-2a71f28e5601">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt; The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.</jnj:ProductLiabilityPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODg0_8ac9023a-bb37-45ea-943c-c368d6c056ff">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development.  Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product.  Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#x2019;s operations. In general, the income statement presentation for these collaborations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nature/Type of Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Earnings Presentation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third-party sale of product &amp;amp; profit share payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales to customers&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties/milestones paid to collaborative partner (post-regulatory approval)*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties received from collaborative partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Upfront payments&#160;&amp;amp; milestones paid to collaborative partner (pre-regulatory approval)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development payments to collaborative partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development payments received from collaborative partner or government entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:96.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, co-developed with Bayer HealthCare AG and IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, licensed from Genmab A/S.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <jnj:ConcentrationRiskThresholdPercentage
      contextRef="ic2ccb55418494f0c9e1a4c75f0b03e66_D20210104-20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE5MjQ5_1006ff07-af51-4c87-937c-7a0ca0ab1409"
      unitRef="number">0.05</jnj:ConcentrationRiskThresholdPercentage>
    <jnj:ConcentrationRiskThresholdPercentage
      contextRef="if755ebb14d5b4945b2b45f2055df1f4d_D20181231-20191229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE5MjQ5_46050c12-4323-4140-a7b8-276814f18219"
      unitRef="number">0.05</jnj:ConcentrationRiskThresholdPercentage>
    <jnj:ConcentrationRiskThresholdPercentage
      contextRef="i2214ef047a294d0ca9d41d06ad0fb607_D20191230-20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE5MjQ5_ceaa9e52-5205-4c82-b852-22c1bd2ab8c7"
      unitRef="number">0.05</jnj:ConcentrationRiskThresholdPercentage>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODM4_4e6986aa-b09c-4fb0-a1f8-b4c0d8156d27">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $2.7 billion, $2.1 billion and $2.2 billion in fiscal years 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE5OTc4_489bd204-26b5-41ee-a36d-f85b048f6086"
      unitRef="usd">2700000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE5OTgy_f379ade7-0d76-4ff3-8c1c-a24203c11ce3"
      unitRef="usd">2100000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzE5OTg5_f6fb8db9-ec6a-477b-8dd8-77922dfed803"
      unitRef="usd">2200000000</us-gaap:AdvertisingExpense>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODQ5_056ca1ba-a3a6-40ac-ac81-eda584d0b1f9">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2021 was approximately $6.9&#160;billion, of which $6.1&#160;billion is classified as noncurrent and reflected as &#x201c;Long-term taxes payable&#x201d; on the Company&#x2019;s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI).  GILTI is described as the excess of a U.S. shareholder&#x2019;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#x201c;period cost&#x201d;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., &#x201c;deferred method&#x201d;). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $0.7 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;See Note 8 to the Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;for further information regarding income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i13202586bd644a6e92b8bfdf9c3a4ede_D20170102-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzIxMTk3_f3bba072-b7eb-43a3-b1c2-e8d6eec54e8f"
      unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i90352e12079c4d1fb386797dfa54f1b7_D20180101-20181230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzIxMjAz_c6aba3b9-b1bf-4e8c-bba5-b4ea980dc4b6"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent
      contextRef="i90352e12079c4d1fb386797dfa54f1b7_D20180101-20181230"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzIxNDU4_d54b827a-0ced-468d-a45c-50d68875048d"
      unitRef="number">0.155</jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent>
    <jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent
      contextRef="i90352e12079c4d1fb386797dfa54f1b7_D20180101-20181230"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzIxNTA4_c5d680e6-e3fe-4b40-96c1-e72f0a5e8cb8"
      unitRef="number">0.080</jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent>
    <jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzIxNjk5_af3d661a-0ecb-4cbc-9a88-b771099a34bf"
      unitRef="usd">6900000000</jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability>
    <jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzIxNzEy_903dd59e-480e-44ba-b50c-936b907a4df3"
      unitRef="usd">6100000000</jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent>
    <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzIzNTM0_859d778e-3883-4576-9f6f-602a2e6c1335"
      unitRef="usd">700000000</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2OTQx_e60adc56-e726-4047-8476-1158c4190f0e">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODY3_e7eb8c6e-99b9-4b42-aa01-252ada84ee6a">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which COVID-19 impacts the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of January 2, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#x2019;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#x2019;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#x2019;s consolidated financial statements as of and for the fiscal year ended January 2, 2022, the Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <jnj:FiscalPeriodPolicyTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODQy_516ef94d-e2b4-433e-9dea-61c247d90750">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Annual Closing Date&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.&lt;/span&gt;&lt;/div&gt;</jnj:FiscalPeriodPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xMzkvZnJhZzowYzhkNDk0MzA3YTQ0ZGJjYThiNzYwZDcwODY5NWZiMC90ZXh0cmVnaW9uOjBjOGQ0OTQzMDdhNDRkYmNhOGI3NjBkNzA4Njk1ZmIwXzI2ODU2_56e0ef4b-c701-4d93-9d8b-c877af9e3877">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90ZXh0cmVnaW9uOjZiN2ZjYzZmYjA4NjQ5OGFiMGE4MjMwOGZkZDgwZjNjXzEwOTU_9746d2fa-7d8f-4b90-a2ee-226d064f9aa2">Cash, Cash Equivalents and Current Marketable Securities&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of the fiscal year 2021 and 2020, cash, cash equivalents and current marketable securities were comprised of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. Sovereign Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Sovereign Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.287%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. Sovereign Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gov't Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Sovereign Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of the available for sale debt securities at January&#160;2, 2022 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90ZXh0cmVnaW9uOjZiN2ZjYzZmYjA4NjQ5OGFiMGE4MjMwOGZkZDgwZjNjXzEwODg_1256febe-dc89-41a0-87ca-ebfda85ddedc">&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of the fiscal year 2021 and 2020, cash, cash equivalents and current marketable securities were comprised of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. Sovereign Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Sovereign Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.287%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. Sovereign Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gov't Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Sovereign Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ibe0d9084821448c9b54197410a611a82_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzItMi0xLTEtMjk3MjY_5ae299a3-8d6f-4c0d-9df1-5817b448d221"
      unitRef="usd">2936000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="ibe0d9084821448c9b54197410a611a82_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzItNi0xLTEtMjk3MjY_ae5ada8f-c25f-483d-84ec-b509f55c6903"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ibe0d9084821448c9b54197410a611a82_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzItOC0xLTEtMjk3MjY_81a985eb-1de5-4e5d-8fde-5a1564159bd6"
      unitRef="usd">2936000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibe0d9084821448c9b54197410a611a82_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzItMTAtMS0xLTI5NzI2_45072976-054d-49c7-9dfe-9f483ada15c9"
      unitRef="usd">2936000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ibe0d9084821448c9b54197410a611a82_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzItMTItMS0xLTI5NzI2_7058adf5-c07f-4428-9b94-169dede6ab54"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ied5749f9adf2410da151a894ff6b6ef6_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzQtMi0xLTEtMjk3MjY_229aea46-432e-42ee-b414-ffdea38dc08b"
      unitRef="usd">1006000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="ied5749f9adf2410da151a894ff6b6ef6_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzQtNi0xLTEtMjk3MjY_d9464523-c276-45ac-883b-bd4d58c1df0c"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ied5749f9adf2410da151a894ff6b6ef6_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzQtOC0xLTEtMjk3MjY_4b0be5ca-2df4-49ae-8dd9-e5729eee6a14"
      unitRef="usd">1006000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ied5749f9adf2410da151a894ff6b6ef6_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzQtMTAtMS0xLTI5NzI2_b20226ab-6249-440e-bc4c-8f3b9a8d1a12"
      unitRef="usd">90000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ied5749f9adf2410da151a894ff6b6ef6_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzQtMTItMS0xLTI5NzI2_248c590b-fee0-4471-a38d-4a51c212e3b1"
      unitRef="usd">916000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i252e4b54420c4dde85f5fd67aa0422b4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzUtMi0xLTEtMjk3MjY_25038257-7d0a-4433-85c7-94a265900ebc"
      unitRef="usd">1659000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i252e4b54420c4dde85f5fd67aa0422b4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzUtNi0xLTEtMjk3MjY_2b1b8b56-c1da-4e09-bce7-456618ae9c92"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i252e4b54420c4dde85f5fd67aa0422b4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzUtOC0xLTEtMjk3MjY_3d312071-1920-45b3-8d35-02b574e3b03b"
      unitRef="usd">1659000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i252e4b54420c4dde85f5fd67aa0422b4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzUtMTAtMS0xLTI5NzI2_0bee8270-b6a7-4271-9d5d-82f64d6b5d91"
      unitRef="usd">1659000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i252e4b54420c4dde85f5fd67aa0422b4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzUtMTItMS0xLTI5NzI2_160aa922-bd15-4f6b-b574-d9fc6b1ed223"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i452410a40d07461f83a08316f634a401_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzctMi0xLTEtMjk3MjY_5edc3b46-bd32-45f4-a5a3-ae196322817e"
      unitRef="usd">3479000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i452410a40d07461f83a08316f634a401_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzctNi0xLTEtMjk3MjY_f79cf6f1-a32a-4eef-845a-e6800eaee35b"
      unitRef="usd">1000000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i452410a40d07461f83a08316f634a401_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzctOC0xLTEtMjk3MjY_85989d8a-2ea1-4fb2-bedd-ff6f19c11af8"
      unitRef="usd">3478000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i452410a40d07461f83a08316f634a401_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzctMTAtMS0xLTI5NzI2_92dc30bf-0d8b-4345-9bd0-3243063b8ba2"
      unitRef="usd">200000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i452410a40d07461f83a08316f634a401_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzctMTItMS0xLTI5NzI2_b7db61d4-8a61-4a7c-99cb-2ead233ef61b"
      unitRef="usd">3279000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i70e8bf5abffa4483b11b26ea2161affe_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzgtMi0xLTEtMjk3MjY_b82e10e6-9238-461f-afd4-590fd221bf96"
      unitRef="usd">1901000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i70e8bf5abffa4483b11b26ea2161affe_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzgtNi0xLTEtMjk3MjY_40bb6935-5aac-442a-8a0d-d2248086f537"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i70e8bf5abffa4483b11b26ea2161affe_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzgtOC0xLTEtMjk3MjY_38c98ca5-f37e-4dba-923f-5ef93bb097dc"
      unitRef="usd">1901000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i70e8bf5abffa4483b11b26ea2161affe_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzgtMTAtMS0xLTI5NzI2_06a90dc2-65b6-4127-ab5b-14d072ff9fde"
      unitRef="usd">1901000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i70e8bf5abffa4483b11b26ea2161affe_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzgtMTItMS0xLTI5NzI2_deb9fb21-6193-4634-882a-b6a6119e9e38"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="if52d136488484e92a32ea314340d972c_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzktMi0xLTEtMjk3MjY_e4764190-49f1-4b26-9940-e7a6b7cf799b"
      unitRef="usd">900000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="if52d136488484e92a32ea314340d972c_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzktNi0xLTEtMjk3MjY_19759346-1315-48fc-9768-fd99b8ec6145"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="if52d136488484e92a32ea314340d972c_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzktOC0xLTEtMjk3MjY_6878e92d-a64e-4932-bb06-296478763f44"
      unitRef="usd">900000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if52d136488484e92a32ea314340d972c_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzktMTAtMS0xLTI5NzI2_812a5fae-d3b9-4df4-a2be-897236d2b4ff"
      unitRef="usd">900000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="if52d136488484e92a32ea314340d972c_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzktMTItMS0xLTI5NzI2_59698640-2a11-482a-b352-7595348ad47d"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i9fb97dbd3891498f92976302fc99a0ec_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEwLTItMS0xLTI5NzI2_b7c7ad37-ceac-4a34-b265-1320f95c128b"
      unitRef="usd">11881000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i9fb97dbd3891498f92976302fc99a0ec_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEwLTYtMS0xLTI5NzI2_e263bc16-9c13-45ee-9a6b-5a5a50088d89"
      unitRef="usd">1000000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i9fb97dbd3891498f92976302fc99a0ec_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEwLTgtMS0xLTI5NzI2_6bf23c99-4d49-4f6a-9876-8c3c529c200e"
      unitRef="usd">11880000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9fb97dbd3891498f92976302fc99a0ec_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEwLTEwLTEtMS0yOTcyNg_e9843c08-ef7b-4f8c-a29e-bedec61a7353"
      unitRef="usd">7686000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i9fb97dbd3891498f92976302fc99a0ec_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEwLTEyLTEtMS0yOTcyNg_55f57d8a-d32e-46dd-b75d-8064587ee232"
      unitRef="usd">4195000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id14a4eca31dd4e00a85267ec8f40ec78_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEyLTItMS0xLTI5NzI2_5b53e09c-dc60-44ff-b4b3-e61ead57f962"
      unitRef="usd">19485000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id14a4eca31dd4e00a85267ec8f40ec78_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEyLTYtMS0xLTI5NzI2_8bdfae22-65ac-4e12-8ec0-79626b765c12"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id14a4eca31dd4e00a85267ec8f40ec78_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEyLTgtMS0xLTI5NzI2_aa5c6f99-385d-4aec-9358-03b741bbe355"
      unitRef="usd">19481000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id14a4eca31dd4e00a85267ec8f40ec78_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEyLTEwLTEtMS0yOTcyNg_6de8381b-f9c2-49e9-bd01-cbd3ace66ce3"
      unitRef="usd">6785000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="id14a4eca31dd4e00a85267ec8f40ec78_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEyLTEyLTEtMS0yOTcyNg_60338d2f-b2a4-43a3-86e9-aba0c6243db3"
      unitRef="usd">12696000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idf6e725073c14b38991908baa96e1d7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEzLTItMS0xLTI5NzI2_55b8bb6a-f0dc-4b53-883a-a45938f441de"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idf6e725073c14b38991908baa96e1d7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEzLTYtMS0xLTI5NzI2_ef5bab9e-3471-48eb-b940-c977349fed79"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idf6e725073c14b38991908baa96e1d7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEzLTgtMS0xLTI5NzI2_018ec2dc-f174-47dc-aa0e-9a449c6b82ac"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idf6e725073c14b38991908baa96e1d7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEzLTEwLTEtMS0yOTcyNg_4089a6f5-7c14-400f-ac23-eccc8d5e5d4c"
      unitRef="usd">1000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="idf6e725073c14b38991908baa96e1d7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzEzLTEyLTEtMS0yOTcyNg_298f2ea6-e20c-428e-86ca-8e25d127f4da"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if7ea071f45f34fd7ba90322c1178679b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE0LTItMS0xLTI5NzI2_c85b1d09-cce3-4bae-b5a9-bdbcc8359ea5"
      unitRef="usd">245000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if7ea071f45f34fd7ba90322c1178679b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE0LTYtMS0xLTI5NzI2_9c4782cf-e5cc-4507-bc70-b8a5d159e399"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if7ea071f45f34fd7ba90322c1178679b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE0LTgtMS0xLTI5NzI2_1f9c7bbf-dda8-4181-904b-8f8694643489"
      unitRef="usd">245000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if7ea071f45f34fd7ba90322c1178679b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE0LTEwLTEtMS0yOTcyNg_5b15c3e4-9df5-4509-975a-d0b4eaff58c6"
      unitRef="usd">15000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="if7ea071f45f34fd7ba90322c1178679b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE0LTEyLTEtMS0yOTcyNg_ba986952-162b-40d3-9dfd-d1eaeb76012e"
      unitRef="usd">230000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ica9cfb292ef54c7a93d6ee930b4c18b6_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE2LTItMS0xLTI5NzI2_63a6c2bd-f9a4-4dfd-ac55-2c1aa57c552f"
      unitRef="usd">19731000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ica9cfb292ef54c7a93d6ee930b4c18b6_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE2LTYtMS0xLTI5NzI2_73ec889d-d139-4920-a7e5-d98fb2659ddb"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ica9cfb292ef54c7a93d6ee930b4c18b6_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE2LTgtMS0xLTI5NzI2_49aca93a-0720-43f4-9631-78ab60b14ccd"
      unitRef="usd">19727000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ica9cfb292ef54c7a93d6ee930b4c18b6_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE2LTEwLTEtMS0yOTcyNg_269c83b2-c866-4493-89f5-4dd625e49cb6"
      unitRef="usd">6801000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ica9cfb292ef54c7a93d6ee930b4c18b6_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE2LTEyLTEtMS0yOTcyNg_800fd79d-5f17-43b1-b7c3-a82d280bf720"
      unitRef="usd">12926000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE4LTEwLTEtMS0yOTcyNg_6ddcc9fa-beca-4848-8467-8bb220ab9737"
      unitRef="usd">14487000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpkMTA3OGMyYmYyNTA0Y2FmOGFhNmNjNTQzNThmZjBhNC90YWJsZXJhbmdlOmQxMDc4YzJiZjI1MDRjYWY4YWE2Y2M1NDM1OGZmMGE0XzE4LTEyLTEtMS0yOTcyNg_34e0c792-e2c7-4e67-85af-c670951fc605"
      unitRef="usd">17121000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i22c801516ef3458cb70b9d6768e94cc8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzItMi0xLTEtMjk3MjY_176e139a-2adf-4f7f-9656-afefc13c6d93"
      unitRef="usd">2863000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i22c801516ef3458cb70b9d6768e94cc8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzItNC0xLTEtMjk3MjY_40f2651e-8787-459c-8393-809a043d8206"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i22c801516ef3458cb70b9d6768e94cc8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzItOC0xLTEtMjk3MjY_d30bcec1-f51c-47a3-9b53-4239c412af59"
      unitRef="usd">2863000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i22c801516ef3458cb70b9d6768e94cc8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzItMTAtMS0xLTI5NzI2_5ae8d6e4-23d6-4206-bcac-358b0a3e34d9"
      unitRef="usd">2863000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i22c801516ef3458cb70b9d6768e94cc8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzItMTItMS0xLTI5NzI2_8c875d50-eb8e-4181-928d-c5869866df5e"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i71f498cef62e47498c8115a8257a7f5c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzQtMi0xLTEtMjk3MjY_719f5994-80c4-4027-9eeb-257b22faf3de"
      unitRef="usd">690000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i71f498cef62e47498c8115a8257a7f5c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzQtNC0xLTEtMjk3MjY_ccd180d2-53db-4418-b25a-1dc0695cbd4e"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i71f498cef62e47498c8115a8257a7f5c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzQtOC0xLTEtMjk3MjY_25a410b2-d067-4589-a38e-ff8448b580cd"
      unitRef="usd">690000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i71f498cef62e47498c8115a8257a7f5c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzQtMTAtMS0xLTI5NzI2_1ce5f145-63b1-4803-91a1-2ea0ad2df127"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i71f498cef62e47498c8115a8257a7f5c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzQtMTItMS0xLTI5NzI2_3342f958-946c-4507-b516-016f99a37a01"
      unitRef="usd">690000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i8d7e47ac51a74794aa5dd2b7dddcbc9a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzUtMi0xLTEtMjk3MjY_0d73699f-8f9a-494d-ae4b-35cde0b2ddfe"
      unitRef="usd">1937000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i8d7e47ac51a74794aa5dd2b7dddcbc9a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzUtNC0xLTEtMjk3MjY_14548fa5-4fc9-4b61-b371-b364d8a4f04b"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i8d7e47ac51a74794aa5dd2b7dddcbc9a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzUtOC0xLTEtMjk3MjY_2e3b123f-61cf-4eaa-8d28-f89df668765f"
      unitRef="usd">1937000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8d7e47ac51a74794aa5dd2b7dddcbc9a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzUtMTAtMS0xLTI5NzI2_af2148f8-3d18-45b9-8e2f-9bb6e63dec43"
      unitRef="usd">1937000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i8d7e47ac51a74794aa5dd2b7dddcbc9a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzUtMTItMS0xLTI5NzI2_09eafca4-5d58-4b45-bede-173c5daaae0a"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i2dda7dc33acb494ab90787cb95a42bd6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzctMi0xLTEtMjk3MjY_74d6d83d-71f0-4e62-a399-e920b9d4a95b"
      unitRef="usd">2674000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i2dda7dc33acb494ab90787cb95a42bd6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzctNC0xLTEtMjk3MjY_22191a82-d65c-4434-ae39-3b16c5c2ac04"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i2dda7dc33acb494ab90787cb95a42bd6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzctOC0xLTEtMjk3MjY_4900fc58-9d52-4ccf-baa2-4d6510d4def0"
      unitRef="usd">2674000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2dda7dc33acb494ab90787cb95a42bd6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzctMTAtMS0xLTI5NzI2_954166b2-492f-4835-9fd1-123f3b35fdff"
      unitRef="usd">1451000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i2dda7dc33acb494ab90787cb95a42bd6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzctMTItMS0xLTI5NzI2_e656c38c-1ef5-4862-86fb-36c2262c5092"
      unitRef="usd">1223000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i3ec8bdf1492e47008be52fa4584b89b6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzgtMi0xLTEtMjk3MjY_f4ea7e7d-766f-4715-b8a7-38e82982b8d6"
      unitRef="usd">2102000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i3ec8bdf1492e47008be52fa4584b89b6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzgtNC0xLTEtMjk3MjY_11469a1b-d204-40db-b1d8-6af596f7767a"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i3ec8bdf1492e47008be52fa4584b89b6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzgtOC0xLTEtMjk3MjY_c5a36e5e-6cac-4bed-92ff-e743a24d95d6"
      unitRef="usd">2102000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3ec8bdf1492e47008be52fa4584b89b6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzgtMTAtMS0xLTI5NzI2_ec4020fb-b763-410b-b159-97d39c33324d"
      unitRef="usd">2102000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i3ec8bdf1492e47008be52fa4584b89b6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzgtMTItMS0xLTI5NzI2_667dcc53-915e-4b30-8386-6524e2edd539"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i8f3e3e39127c4af6809fdfd339d25195_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzktMi0xLTEtMjk3MjY_b0d45f9a-1a1c-48eb-985d-45ed5174553a"
      unitRef="usd">877000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i8f3e3e39127c4af6809fdfd339d25195_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzktNC0xLTEtMjk3MjY_51725f49-0c62-4135-8d00-71c20d70a62c"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i8f3e3e39127c4af6809fdfd339d25195_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzktOC0xLTEtMjk3MjY_25a7918e-6a02-4589-83ed-e187a851d40a"
      unitRef="usd">877000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8f3e3e39127c4af6809fdfd339d25195_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzktMTAtMS0xLTI5NzI2_64a5217a-7efe-4473-8c85-5530f5d417b7"
      unitRef="usd">877000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i8f3e3e39127c4af6809fdfd339d25195_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzktMTItMS0xLTI5NzI2_7037bf52-2807-42e5-8a7b-0a5aacd73bee"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i2d963d3b70ad451fab86f669cf84769c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEwLTItMS0xLTI5NzI2_a485954c-145c-4a45-a3c4-30be7d592c18"
      unitRef="usd">11143000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i2d963d3b70ad451fab86f669cf84769c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEwLTQtMS0xLTI5NzI2_2ec62409-e86b-4a12-b2a7-500dd68fbd7b"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i2d963d3b70ad451fab86f669cf84769c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEwLTgtMS0xLTI5NzI2_be93c2f8-8332-4960-8bde-ac32f3a9d270"
      unitRef="usd">11143000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2d963d3b70ad451fab86f669cf84769c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEwLTEwLTEtMS0yOTcyNg_b66ebfa4-2073-444a-926c-562a0c4702ba"
      unitRef="usd">9230000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i2d963d3b70ad451fab86f669cf84769c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEwLTEyLTEtMS0yOTcyNg_0998d82e-b78e-43c1-ba9f-457cdb6061ae"
      unitRef="usd">1913000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9ee19fc5a38645fd8e5d2c3bde0c13ae_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEyLTItMS0xLTI5NzI2_aec311b9-7f6b-452b-b4c3-1da68ffac798"
      unitRef="usd">13777000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9ee19fc5a38645fd8e5d2c3bde0c13ae_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEyLTQtMS0xLTI5NzI2_636d9ead-0004-4c01-8803-6477776109f0"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9ee19fc5a38645fd8e5d2c3bde0c13ae_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEyLTgtMS0xLTI5NzI2_2df29372-60ea-451a-ac25-ef5eea069bbc"
      unitRef="usd">13778000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9ee19fc5a38645fd8e5d2c3bde0c13ae_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEyLTEwLTEtMS0yOTcyNg_806a3fc5-1757-4d6e-bc3f-ff1354e3f465"
      unitRef="usd">4731000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i9ee19fc5a38645fd8e5d2c3bde0c13ae_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEyLTEyLTEtMS0yOTcyNg_f659fd69-4d89-4652-aced-e9f694712d1d"
      unitRef="usd">9047000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2732aa7ddf3c4fc584a545a80ed55496_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEzLTItMS0xLTI5NzI2_1143f34f-b64e-46b2-9ab2-53686e37a4c1"
      unitRef="usd">14000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2732aa7ddf3c4fc584a545a80ed55496_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEzLTQtMS0xLTI5NzI2_796fe1d5-bae6-4666-919b-65ca0a68f05a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2732aa7ddf3c4fc584a545a80ed55496_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEzLTgtMS0xLTI5NzI2_98a612f1-8064-4694-b473-8efb012c6d17"
      unitRef="usd">14000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2732aa7ddf3c4fc584a545a80ed55496_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEzLTEwLTEtMS0yOTcyNg_b4c20af4-deb5-4d54-9dee-6c0169e79bd5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i2732aa7ddf3c4fc584a545a80ed55496_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzEzLTEyLTEtMS0yOTcyNg_d0bc8dd6-432d-4ecc-928f-a4443d9c7508"
      unitRef="usd">14000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2b07805351ce42b98b594c790d5114ee_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE0LTItMS0xLTI5NzI2_dd0a080e-b987-43a1-b882-157dbadd4d50"
      unitRef="usd">250000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2b07805351ce42b98b594c790d5114ee_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE0LTQtMS0xLTI5NzI2_08df7b2f-5c2a-4097-9d9d-b30e0c00bd0b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2b07805351ce42b98b594c790d5114ee_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE0LTgtMS0xLTI5NzI2_f26f31f7-81cf-407a-8232-76e34b8a2c09"
      unitRef="usd">250000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2b07805351ce42b98b594c790d5114ee_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE0LTEwLTEtMS0yOTcyNg_1c7559cb-0411-4893-807c-e64d6bf0ca77"
      unitRef="usd">24000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i2b07805351ce42b98b594c790d5114ee_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE0LTEyLTEtMS0yOTcyNg_ecf5829a-0505-455a-bbb2-7c313a8cf6a7"
      unitRef="usd">226000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8c6300a66b9a4b979eb41526a4c94fb3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE2LTItMS0xLTI5NzI2_15963110-8e84-428e-846f-0aa10faab043"
      unitRef="usd">14041000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8c6300a66b9a4b979eb41526a4c94fb3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE2LTQtMS0xLTI5NzI2_789b8eeb-4ec9-4678-8962-0037d3e47681"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c6300a66b9a4b979eb41526a4c94fb3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE2LTgtMS0xLTI5NzI2_abde620c-285d-49b6-873b-8c8fae49136e"
      unitRef="usd">14042000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8c6300a66b9a4b979eb41526a4c94fb3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE2LTEwLTEtMS0yOTcyNg_5b004d4d-d755-4f0f-bdee-9a3b53925498"
      unitRef="usd">4755000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i8c6300a66b9a4b979eb41526a4c94fb3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE2LTEyLTEtMS0yOTcyNg_a980458d-f455-4adc-9f5c-71544c967001"
      unitRef="usd">9287000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE4LTEwLTEtMS0yOTcyNg_b48d6ba5-ceb1-4ac4-a7b0-f11fbbb1bdc0"
      unitRef="usd">13985000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTpiNmNlZDFkNDE1MWE0ZWMxYWY4MzgxYmY2MTdkYzk5MC90YWJsZXJhbmdlOmI2Y2VkMWQ0MTUxYTRlYzFhZjgzODFiZjYxN2RjOTkwXzE4LTEyLTEtMS0yOTcyNg_1e43086a-b043-48cc-9b45-b514a3356d0e"
      unitRef="usd">11200000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90ZXh0cmVnaW9uOjZiN2ZjYzZmYjA4NjQ5OGFiMGE4MjMwOGZkZDgwZjNjXzEwOTM_6e2c5590-cff3-4963-8a42-562e8365d32a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of the available for sale debt securities at January&#160;2, 2022 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTozZmY4ODdjZmI3N2Q0MDZiYTlkYWQ3ZDgxMzNmN2IyZi90YWJsZXJhbmdlOjNmZjg4N2NmYjc3ZDQwNmJhOWRhZDdkODEzM2Y3YjJmXzEtMi0xLTEtMjk3MjY_1662b487-4bfb-4c64-adee-d16fe355001d"
      unitRef="usd">19709000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTozZmY4ODdjZmI3N2Q0MDZiYTlkYWQ3ZDgxMzNmN2IyZi90YWJsZXJhbmdlOjNmZjg4N2NmYjc3ZDQwNmJhOWRhZDdkODEzM2Y3YjJmXzEtNC0xLTEtMjk3MjY_5e96bda5-1288-4286-b054-edc1d2899c96"
      unitRef="usd">19705000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTozZmY4ODdjZmI3N2Q0MDZiYTlkYWQ3ZDgxMzNmN2IyZi90YWJsZXJhbmdlOjNmZjg4N2NmYjc3ZDQwNmJhOWRhZDdkODEzM2Y3YjJmXzItMi0xLTEtMjk3MjY_93d886c5-1d13-4201-8157-c000275abce9"
      unitRef="usd">22000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTozZmY4ODdjZmI3N2Q0MDZiYTlkYWQ3ZDgxMzNmN2IyZi90YWJsZXJhbmdlOjNmZjg4N2NmYjc3ZDQwNmJhOWRhZDdkODEzM2Y3YjJmXzItNC0xLTEtMjk3MjY_ca33fb0b-4587-4106-8f66-15d4eee60bbe"
      unitRef="usd">22000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTozZmY4ODdjZmI3N2Q0MDZiYTlkYWQ3ZDgxMzNmN2IyZi90YWJsZXJhbmdlOjNmZjg4N2NmYjc3ZDQwNmJhOWRhZDdkODEzM2Y3YjJmXzMtMi0xLTEtMjk3MjY_1465e11f-2d51-475e-aeb0-6b0968365956"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTozZmY4ODdjZmI3N2Q0MDZiYTlkYWQ3ZDgxMzNmN2IyZi90YWJsZXJhbmdlOjNmZjg4N2NmYjc3ZDQwNmJhOWRhZDdkODEzM2Y3YjJmXzMtNC0xLTEtMjk3MjY_0247f7db-9626-4201-8774-c9d92772ec85"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTozZmY4ODdjZmI3N2Q0MDZiYTlkYWQ3ZDgxMzNmN2IyZi90YWJsZXJhbmdlOjNmZjg4N2NmYjc3ZDQwNmJhOWRhZDdkODEzM2Y3YjJmXzQtMi0xLTEtMjk3MjY_7be0cd0f-aeb1-4c39-8ab5-fad73cbb5c14"
      unitRef="usd">19731000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDUvZnJhZzo2YjdmY2M2ZmIwODY0OThhYjBhODIzMDhmZGQ4MGYzYy90YWJsZTozZmY4ODdjZmI3N2Q0MDZiYTlkYWQ3ZDgxMzNmN2IyZi90YWJsZXJhbmdlOjNmZjg4N2NmYjc3ZDQwNmJhOWRhZDdkODEzM2Y3YjJmXzQtNC0xLTEtMjk3MjY_dffce029-a890-4216-9526-7e40cff55b43"
      unitRef="usd">19727000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90ZXh0cmVnaW9uOmJjMzI5OWJhNDZiYjQwZjg4ZjcxNGMwMDdmYTU4OGQxXzMxNA_cf90943e-0a91-45ed-821b-6f346146c935">Inventories&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal years 2021 and 2020, inventories were comprised of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90ZXh0cmVnaW9uOmJjMzI5OWJhNDZiYjQwZjg4ZjcxNGMwMDdmYTU4OGQxXzMxOQ_34ef9f1e-c2a9-40ee-a73f-d78f637ec029">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal years 2021 and 2020, inventories were comprised of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90YWJsZTplNTNmMzVmMGE4MmY0NGE1OTU3NDc5ZjkyZjNlYWE4Ni90YWJsZXJhbmdlOmU1M2YzNWYwYTgyZjQ0YTU5NTc0NzlmOTJmM2VhYTg2XzEtMi0xLTEtMjk3MjY_00ac7173-e820-40b2-b44b-a9f7d85f9caf"
      unitRef="usd">1592000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90YWJsZTplNTNmMzVmMGE4MmY0NGE1OTU3NDc5ZjkyZjNlYWE4Ni90YWJsZXJhbmdlOmU1M2YzNWYwYTgyZjQ0YTU5NTc0NzlmOTJmM2VhYTg2XzEtNC0xLTEtMjk3MjY_2a07b88d-7ec7-4f8f-a40f-db275bf84f40"
      unitRef="usd">1410000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90YWJsZTplNTNmMzVmMGE4MmY0NGE1OTU3NDc5ZjkyZjNlYWE4Ni90YWJsZXJhbmdlOmU1M2YzNWYwYTgyZjQ0YTU5NTc0NzlmOTJmM2VhYTg2XzItMi0xLTEtMjk3MjY_f8ae7c90-d052-4d7a-b660-47500a60abe2"
      unitRef="usd">2287000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90YWJsZTplNTNmMzVmMGE4MmY0NGE1OTU3NDc5ZjkyZjNlYWE4Ni90YWJsZXJhbmdlOmU1M2YzNWYwYTgyZjQ0YTU5NTc0NzlmOTJmM2VhYTg2XzItNC0xLTEtMjk3MjY_8f2b89a3-c72b-4f50-accf-f39966892312"
      unitRef="usd">2040000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90YWJsZTplNTNmMzVmMGE4MmY0NGE1OTU3NDc5ZjkyZjNlYWE4Ni90YWJsZXJhbmdlOmU1M2YzNWYwYTgyZjQ0YTU5NTc0NzlmOTJmM2VhYTg2XzMtMi0xLTEtMjk3MjY_c696857e-95d7-49ea-93d5-ff6f914d46f3"
      unitRef="usd">6508000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90YWJsZTplNTNmMzVmMGE4MmY0NGE1OTU3NDc5ZjkyZjNlYWE4Ni90YWJsZXJhbmdlOmU1M2YzNWYwYTgyZjQ0YTU5NTc0NzlmOTJmM2VhYTg2XzMtNC0xLTEtMjk3MjY_ec4b6fd4-1728-469a-8c07-590966c0be0a"
      unitRef="usd">5894000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90YWJsZTplNTNmMzVmMGE4MmY0NGE1OTU3NDc5ZjkyZjNlYWE4Ni90YWJsZXJhbmdlOmU1M2YzNWYwYTgyZjQ0YTU5NTc0NzlmOTJmM2VhYTg2XzQtMi0xLTEtMjk3MjY_d6539fca-4d6f-4f51-a9c4-bacaf1aeae78"
      unitRef="usd">10387000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNDgvZnJhZzpiYzMyOTliYTQ2YmI0MGY4OGY3MTRjMDA3ZmE1ODhkMS90YWJsZTplNTNmMzVmMGE4MmY0NGE1OTU3NDc5ZjkyZjNlYWE4Ni90YWJsZXJhbmdlOmU1M2YzNWYwYTgyZjQ0YTU5NTc0NzlmOTJmM2VhYTg2XzQtNC0xLTEtMjk3MjY_7cc46025-e9b8-46e5-87ee-e9ad3324c7ef"
      unitRef="usd">9344000000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90ZXh0cmVnaW9uOmFjMzZlZDZhNDM3ZjQ2ZTA5ODIyYjcyODU0YWU3YmQ2XzEwMDY_d0d62adb-91a2-4c80-a589-37d766090368">Property, Plant and Equipment&lt;div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal years 2021 and 2020, property, plant and equipment at cost and accumulated depreciation were:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and building equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,962&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,766&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in fiscal years 2021, 2020 and 2019 was $49 million, $63 million and $70 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense, including the amortization of capitalized interest in fiscal years 2021, 2020 and 2019 was $2.7 billion, $2.6 billion and $2.5 billion, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90ZXh0cmVnaW9uOmFjMzZlZDZhNDM3ZjQ2ZTA5ODIyYjcyODU0YWU3YmQ2XzEwMDI_06ea828e-bf0f-451b-8415-f827edcb3a65">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal years 2021 and 2020, property, plant and equipment at cost and accumulated depreciation were:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and building equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,962&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,766&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4a7352ca619841d79bdbb2c6ab3f2250_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzEtMi0xLTEtMjk3MjY_1c5420aa-02da-477f-985e-2c6970215685"
      unitRef="usd">884000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib364b47fe9454f339d85cae2d78e751e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzEtNC0xLTEtMjk3MjY_ab9991fd-b8f2-4c87-8c1b-39b99c7fc0bd"
      unitRef="usd">882000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id0f4b2d54b954ffba9bb73844eeb14ce_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzItMi0xLTEtMjk3MjY_b09117d8-f4e7-41cb-964c-3c788616673e"
      unitRef="usd">12882000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i88b324b449f448d9b34e40182d15e032_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzItNC0xLTEtMjk3MjY_f14b9761-8e2f-490c-9cef-f621d607a9c3"
      unitRef="usd">12502000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9f40ebb739fb428985cccbc8ef38df17_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzMtMi0xLTEtMjk3MjY_b10703ca-d846-4dd5-a52c-f37536b9607d"
      unitRef="usd">29774000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia56c56468be347ee80d5f33b118fa31d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzMtNC0xLTEtMjk3MjY_a4f747a2-6352-447f-9011-5490b936d455"
      unitRef="usd">29104000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5ed4936b7ad042b8b7e83fda8d3b4873_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzQtMi0xLTEtMjk3MjY_f19223ac-b133-4b25-b018-d1e5eef0db7d"
      unitRef="usd">4139000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia1204533ce0a4d7aaffb4e685bdbfa57_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzQtNC0xLTEtMjk3MjY_4039f700-df31-41d8-94f2-8a499d560b5a"
      unitRef="usd">4316000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzUtMi0xLTEtMjk3MjY_a651af25-633a-47cf-9134-73fd81307def"
      unitRef="usd">47679000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzUtNC0xLTEtMjk3MjY_34d84fc1-8ab4-414e-be09-93d39129f00f"
      unitRef="usd">46804000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzYtMi0xLTEtMjk3MjY_c38fde3a-57e9-4669-9a28-22bf0f528829"
      unitRef="usd">28717000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzYtNC0xLTEtMjk3MjY_63ffcb2d-618e-46ab-8bb9-e652bc25e7b4"
      unitRef="usd">28038000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzctMi0xLTEtMjk3MjY_c36cdfd1-522c-4abc-8bda-f986d2914a23"
      unitRef="usd">18962000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90YWJsZTphZTA0MTA1ODAwYmI0YWUyYWQ2OTYzOTE4NDM2ZDJkMy90YWJsZXJhbmdlOmFlMDQxMDU4MDBiYjRhZTJhZDY5NjM5MTg0MzZkMmQzXzctNC0xLTEtMjk3MjY_b007caee-5a5f-4931-a922-d2d0f8a2aaee"
      unitRef="usd">18766000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:InterestCostsCapitalized
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90ZXh0cmVnaW9uOmFjMzZlZDZhNDM3ZjQ2ZTA5ODIyYjcyODU0YWU3YmQ2XzUxNA_d90a0f68-7aa8-407f-91ae-d808f598a1e6"
      unitRef="usd">49000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90ZXh0cmVnaW9uOmFjMzZlZDZhNDM3ZjQ2ZTA5ODIyYjcyODU0YWU3YmQ2XzUxOA_dffd9323-0499-4b6d-8095-7806cc6f6ca4"
      unitRef="usd">63000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90ZXh0cmVnaW9uOmFjMzZlZDZhNDM3ZjQ2ZTA5ODIyYjcyODU0YWU3YmQ2XzUyNQ_3ec3246f-6731-4477-87bd-3b0d5db49f2b"
      unitRef="usd">70000000</us-gaap:InterestCostsCapitalized>
    <jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90ZXh0cmVnaW9uOmFjMzZlZDZhNDM3ZjQ2ZTA5ODIyYjcyODU0YWU3YmQ2XzY1MA_4b1908db-4715-401a-97ea-3a1cbe9f818c"
      unitRef="usd">2700000000</jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest>
    <jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90ZXh0cmVnaW9uOmFjMzZlZDZhNDM3ZjQ2ZTA5ODIyYjcyODU0YWU3YmQ2XzY1NA_021341ac-408e-4bea-8c24-6e19ec6c07e1"
      unitRef="usd">2600000000</jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest>
    <jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTEvZnJhZzphYzM2ZWQ2YTQzN2Y0NmUwOTgyMmI3Mjg1NGFlN2JkNi90ZXh0cmVnaW9uOmFjMzZlZDZhNDM3ZjQ2ZTA5ODIyYjcyODU0YWU3YmQ2XzY2MQ_84d5b08f-cf37-4cc5-8333-c0bcf69c199c"
      unitRef="usd">2500000000</jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzEyNTg_61fd065d-6fb3-4a89-a542-5f0bba5cd510">Intangible Assets and Goodwill&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal years 2021 and 2020, the gross and net amounts of intangible assets were:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks&#160;&#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks&#160;&#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,484&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,372&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,086&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased in-process research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,044&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&#160;&#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46,392&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;53,402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In fiscal 2021, the Company recorded a partial IPR&amp;amp;D impairment charge of $0.9&#160;billion primarily related to expected development delays in the general surgery digital robotics platform (Ottava) acquired with the Auris Health acquisition in 2019. The impairment charge was calculated based on revisions to the discounted cash flow valuation model reflecting a delay of first in human procedures of approximately two years from the initial acquisition model assumption of the second half of 2022. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill as of January&#160;2, 2022 and January&#160;3, 2021, as allocated by segment of business, was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,810&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,580&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,856&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35,246&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable assets included in Cost of products sold was $4.7 billion, $4.7 billion and $4.5 billion before tax, for the fiscal years ended January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019, respectively. Intangible asset write-downs are included in Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzEyNjA_b26a0411-f6aa-4b36-ba5b-1e523357cbc8">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal years 2021 and 2020, the gross and net amounts of intangible assets were:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks&#160;&#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks&#160;&#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,484&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,372&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,086&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased in-process research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,044&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&#160;&#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46,392&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;53,402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In fiscal 2021, the Company recorded a partial IPR&amp;amp;D impairment charge of $0.9&#160;billion primarily related to expected development delays in the general surgery digital robotics platform (Ottava) acquired with the Auris Health acquisition in 2019. The impairment charge was calculated based on revisions to the discounted cash flow valuation model reflecting a delay of first in human procedures of approximately two years from the initial acquisition model assumption of the second half of 2022. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.&lt;/span&gt;&lt;/div&gt;</jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7ae060052d4740af8581a0a0eb3df2c9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzItMi0xLTEtMjk3MjY_0d6b3e7a-6c4e-4c2a-b6ad-b4dc67beca37"
      unitRef="usd">38572000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i48cb4cc5378a4a059f9b5fdc68b7045f_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzItNC0xLTEtMjk3MjY_b1a1969c-6916-4ef3-b8fb-a61b6efea4bf"
      unitRef="usd">39990000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7ae060052d4740af8581a0a0eb3df2c9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzMtMi0xLTEtMjk3MjY_1cb7cc51-42b1-4596-8655-b0cda24fe0ba"
      unitRef="usd">20088000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i48cb4cc5378a4a059f9b5fdc68b7045f_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzMtNC0xLTEtMjk3MjY_7c3b00ad-2d3d-4816-9ac5-447bb662cabe"
      unitRef="usd">17618000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7ae060052d4740af8581a0a0eb3df2c9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzQtMi0xLTEtMjk3MjY_fd50bd16-00fb-4f53-9eac-d4e72e25ead5"
      unitRef="usd">18484000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i48cb4cc5378a4a059f9b5fdc68b7045f_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzQtNC0xLTEtMjk3MjY_87906089-0544-43c7-85fd-b6fc92380249"
      unitRef="usd">22372000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ifc2ea168b3aa471788ebf1eb8f662c13_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzUtMi0xLTEtMjk3MjY_45143b89-d0db-4bbb-8b68-58391c6cfc8a"
      unitRef="usd">23011000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i663b04fe910b4db3913be35f413b1086_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzUtNC0xLTEtMjk3MjY_e53ecccd-3d91-4a73-96ea-55efabc51c91"
      unitRef="usd">22898000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ifc2ea168b3aa471788ebf1eb8f662c13_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzYtMi0xLTEtMjk3MjY_9bab8703-7c3c-4b8a-8687-9db62c74b61c"
      unitRef="usd">11925000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i663b04fe910b4db3913be35f413b1086_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzYtNC0xLTEtMjk3MjY_27dc09ff-acb1-4f93-99d8-c75da1add30c"
      unitRef="usd">10912000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ifc2ea168b3aa471788ebf1eb8f662c13_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzctMi0xLTEtMjk3MjY_68c36051-43b5-4ae5-8c6d-6e77f9fd2c77"
      unitRef="usd">11086000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i663b04fe910b4db3913be35f413b1086_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzctNC0xLTEtMjk3MjY_dc7b107f-5882-46e6-9ec5-0a6ce751080d"
      unitRef="usd">11986000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iee8c7d3f6c6c4979b1116a020a60940f_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzktMi0xLTEtMjk3MjY_94ee59ed-c5f1-45d6-bbfb-d48a7ad1f805"
      unitRef="usd">6985000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic27bd4dd176844408f1e04f435bb2a53_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzktNC0xLTEtMjk3MjY_95a14c09-8f27-443b-ab73-a92d4f74a8cf"
      unitRef="usd">7195000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i07a8e81747cd49fdb8dd11022b941933_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzEwLTItMS0xLTI5NzI2_495b406a-ab9e-44ed-9cce-04bb1d09f2a1"
      unitRef="usd">9837000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iabc2d103024d42f6b18c1c1e3fead71d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzEwLTQtMS0xLTI5NzI2_7b86fe19-bdb1-4aeb-b9cf-71bb6a9d47c5"
      unitRef="usd">11849000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzExLTItMS0xLTI5NzI2_91360bd7-ac71-4b05-b3f3-adef5c5755a9"
      unitRef="usd">16822000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzExLTQtMS0xLTI5NzI2_5c11b1f7-f3ed-42c8-bc36-22bfe13f696a"
      unitRef="usd">19044000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzEyLTItMS0xLTI5NzI2_d9617bcd-fb38-42ae-bf0a-14711a125c79"
      unitRef="usd">46392000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToxYzMwYWE4MDljZjU0N2Q3YWM4NDg3ODllOTc5OWJkZC90YWJsZXJhbmdlOjFjMzBhYTgwOWNmNTQ3ZDdhYzg0ODc4OWU5Nzk5YmRkXzEyLTQtMS0xLTI5NzI2_b888d556-6df6-4d82-8c02-1c6bb6882f43"
      unitRef="usd">53402000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i6c822c4eb5ed4bbcb5d13167c9341beb_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzU0OTc1NTgxNDE0MzQ_f775f42c-6bbe-4269-9129-d9a0342dbfe0"
      unitRef="usd">900000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzEyNTA_d9b874f8-b1e2-42c7-8b7a-3fa38f187ab9">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill as of January&#160;2, 2022 and January&#160;3, 2021, as allocated by segment of business, was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,810&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,580&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,856&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35,246&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i7efc7098a12d46b8a4268c1f5f6471f0_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzEtMi0xLTEtMjk3MjY_bc5db28b-3fe4-4b23-bf26-24047cb5002b"
      unitRef="usd">9736000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0b8d65d037cb434ebb1aab6adcf3472e_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzEtNC0xLTEtMjk3MjY_f998f646-11c9-49a9-bfdc-f04b66f7baf6"
      unitRef="usd">9169000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if7e98efb6dee498ba2fde96801469678_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzEtNi0xLTEtMjk3MjY_76674877-c0a2-4cf8-836f-75b04a165d00"
      unitRef="usd">14734000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzEtOC0xLTEtMjk3MjY_4a233338-25bd-43bc-adec-58078907cf8d"
      unitRef="usd">33639000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="if43f753e349c40788db498a0b8a5fe34_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzItMi0xLTEtMjk3MjY_8d69d99f-5a6f-4f0a-abf8-ef087467f5d3"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ia9f7770a07704889bef20acb8a0c5220_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzItNC0xLTEtMjk3MjY_aa0f51c5-66f9-4f9d-a1bc-01e9042171d4"
      unitRef="usd">1222000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i86ddb5ada6e24683aa7c697889661250_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzItNi0xLTEtMjk3MjY_1670a120-373e-488f-b79f-83437aab0b49"
      unitRef="usd">238000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzItOC0xLTEtMjk3MjY_c64d16d9-76d1-4221-a110-22e29e5df720"
      unitRef="usd">1460000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="if43f753e349c40788db498a0b8a5fe34_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzQtMi0xLTEtMjk3MjY_23b5de9e-adc5-43a2-aa02-9b66c23423c3"
      unitRef="usd">600000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ia9f7770a07704889bef20acb8a0c5220_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzQtNC0xLTEtMjk3MjY_a9250d42-33c9-44b5-89b9-b86192bca356"
      unitRef="usd">618000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i86ddb5ada6e24683aa7c697889661250_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzQtNi0xLTEtMjk3MjY_077e244c-29a6-4eef-9545-450fa781d821"
      unitRef="usd">76000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzQtOC0xLTEtMjk3MjY_841acfc4-b9c9-4572-9380-3c332efdddbd"
      unitRef="usd">1294000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i87ca486a39254f2e9a23c4f2f015bf3a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzUtMi0xLTEtMjk3MjY_f932c66f-c816-4346-bf3e-eec486b0eab1"
      unitRef="usd">10336000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib90b59b163b542a1adf97f356be068eb_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzUtNC0xLTEtMjk3MjY_71de13eb-4fd0-46ce-8f7f-8b73009f3b93"
      unitRef="usd">11009000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9bd00e52fe1e423e8c220d276d67dac9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzUtNi0xLTEtMjk3MjY_8fddca1c-815f-492c-b469-2dcfa180c6ba"
      unitRef="usd">15048000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzUtOC0xLTEtMjk3MjY_f5d082c6-d9b4-4058-8e7a-e64197cf7e55"
      unitRef="usd">36393000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i1198f98bdb8f4597b4a10112426c5f06_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzYtMi0xLTEtMjk3MjY_0f5d9910-997f-4c7c-a351-2029ebc059fe"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzYtNC0xLTEtMjk3MjY_13ff1907-03d8-4559-bfba-f09a057c1d3a"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzYtNi0xLTEtMjk3MjY_03298460-29eb-438f-87fe-44b13554fe75"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzYtOC0xLTEtMjk3MjY_43261806-7c68-4aa0-b8bf-a4a7e73f5cea"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i1198f98bdb8f4597b4a10112426c5f06_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzctMi0xLTEtMjk3MjY_499c0d05-3eaf-40a9-aa31-b4d815962725"
      unitRef="usd">9000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzctNC0xLTEtMjk3MjY_be4660eb-2646-4f6c-9783-d5f2516a10f5"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzctNi0xLTEtMjk3MjY_ba1b105b-a266-4d72-a163-e32625a4b1c3"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzctOC0xLTEtNDE2Njc_c3cf57e3-b06f-4cc1-b3f3-bc727493577b"
      unitRef="usd">9000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i1198f98bdb8f4597b4a10112426c5f06_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzgtMi0xLTEtMjk3MjY_e704438d-1659-49cb-8185-c4b6b8636933"
      unitRef="usd">-517000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzgtNC0xLTEtMjk3MjY_d5f3c80d-1231-438a-aeb0-99cfbf5f2d3f"
      unitRef="usd">-429000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzgtNi0xLTEtMjk3MjY_b1b6d1e1-94ee-4a3b-80de-6e9183b50fa2"
      unitRef="usd">-192000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzgtOC0xLTEtMjk3MjY_483cea30-2b6f-4ee1-bccd-79fb776c140a"
      unitRef="usd">-1138000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i98801c17d85a449bba4c52f12426dc9a_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzktMi0xLTEtMjk3MjY_abf340c4-deb9-4a91-9923-eb123ea9fb15"
      unitRef="usd">9810000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i19a5a3c7ee35405ba80137bf84570da6_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzktNC0xLTEtMjk3MjY_af0ab462-55e5-486e-b3ac-99d5807832c1"
      unitRef="usd">10580000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i795ce14783b64a95bab66ad564c35fe9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzktNi0xLTEtMjk3MjY_823c1405-f2bf-43c5-8451-c0143b5f2631"
      unitRef="usd">14856000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZTo2Nzg0Njc5MTZmOTQ0MjhiYjIyM2RmODYxN2I2ZTFiYy90YWJsZXJhbmdlOjY3ODQ2NzkxNmY5NDQyOGJiMjIzZGY4NjE3YjZlMWJjXzktOC0xLTEtMjk3MjY_fb6a9f22-d2d0-40bd-acaa-f368f098a3d6"
      unitRef="usd">35246000000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i44e7c974360849d3ba8c0295bf5a75f9_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzY2MA_859cf60a-c506-4c17-bbe4-1169117f22ae">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i003dc23bbef8425a95b799e88c2ea3cc_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzc2Mw_dc9612c3-7275-4933-9009-bc4286ca71cb">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzg1Mg_6be6463e-a86c-490d-8050-8a50582b6055"
      unitRef="usd">4700000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzg1Ng_f1aa89d0-7978-44b4-9652-4656a5876b69"
      unitRef="usd">4700000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzg2Mw_17fe9414-462d-4e58-ad4d-430f32a730ab"
      unitRef="usd">4500000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90ZXh0cmVnaW9uOjM4NDYxNzJmYjdiZjQwZGRhODdmMTQ1NTM1NzhmZDBjXzEyNTI_4d8883b3-46c3-48c3-abb3-7cc60256f864">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToyZWE5YjJhOTgzMDg0Y2IwOThlMGU3Y2U2MzZjYjU4Ny90YWJsZXJhbmdlOjJlYTliMmE5ODMwODRjYjA5OGUwZTdjZTYzNmNiNTg3XzItMC0xLTEtMjk3MjY_69be8c7b-4896-4c64-9716-1455f21c7bc9"
      unitRef="usd">4600000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToyZWE5YjJhOTgzMDg0Y2IwOThlMGU3Y2U2MzZjYjU4Ny90YWJsZXJhbmdlOjJlYTliMmE5ODMwODRjYjA5OGUwZTdjZTYzNmNiNTg3XzItMi0xLTEtMjk3MjY_446f95cd-a08f-42a2-96ac-fcdba596ce4e"
      unitRef="usd">4600000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToyZWE5YjJhOTgzMDg0Y2IwOThlMGU3Y2U2MzZjYjU4Ny90YWJsZXJhbmdlOjJlYTliMmE5ODMwODRjYjA5OGUwZTdjZTYzNmNiNTg3XzItNC0xLTEtMjk3MjY_889c7b87-cae2-4846-b44e-e4718937b2b6"
      unitRef="usd">4400000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToyZWE5YjJhOTgzMDg0Y2IwOThlMGU3Y2U2MzZjYjU4Ny90YWJsZXJhbmdlOjJlYTliMmE5ODMwODRjYjA5OGUwZTdjZTYzNmNiNTg3XzItNi0xLTEtMjk3MjY_c718f7c9-18b2-4f7e-b133-ecdb8ad862a0"
      unitRef="usd">3600000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTQvZnJhZzozODQ2MTcyZmI3YmY0MGRkYTg3ZjE0NTUzNTc4ZmQwYy90YWJsZToyZWE5YjJhOTgzMDg0Y2IwOThlMGU3Y2U2MzZjYjU4Ny90YWJsZXJhbmdlOjJlYTliMmE5ODMwODRjYjA5OGUwZTdjZTYzNmNiNTg3XzItOC0xLTEtMjk3MjY_5ec367ea-76ee-4141-995e-854a276f9bc2"
      unitRef="usd">3000000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5Xzk4NTY_e41282ba-8c70-4d08-83eb-a126b049473c">Fair Value Measurements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;       The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements.  As of January&#160;2, 2022, the total amount of cash collateral paid by the Company under the CSA amounted to $570 million net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of January&#160;2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.8 billion, $37.4 billion and $10.0 billion, respectively. As of January&#160;3, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $37.8 billion and  $30.6 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings.&#160;Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedge are accounted through the currency translation account within accumulated other comprehensive income.&#160;The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of January&#160;2, 2022, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $336 million&#160;after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note&#160;13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedges. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021, net of tax:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of January 2, 2022 and January 3, 2021, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Line item in the Consolidated Balance Sheet in which the hedged item is included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location of Gain /(Loss) Recognized in Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;The following table is the effect of net investment hedges for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)           Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company measures equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.505%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021 for equity investments without readily determinable market values, $28 million and $76 million, respectively, of the changes in fair value reflected in net income were the result of impairments. There were offsetting impacts of  $422 million and $21 million, respectively, of changes in fair value reflected in net income due to changes in observable prices and gains on the disposal of investments. The impact in fiscal 2021 was driven by the gain on disposal of the Grail investment. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability.  In accordance with ASC 820, a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S.&#160;Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#x2019;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level&#160;1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following three levels of inputs are used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#160;&#x2014; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#160;&#x2014; Significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#160;&#x2014; Significant unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of the fiscal year ended January&#160;2, 2022 and January&#160;3, 2021 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,089&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,860&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,860&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Available For Sale Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.409%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about changes in liabilities for contingent consideration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;2020 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $1,481 million, which are classified as Level&#160;1 and contingent consideration of $633 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Includes cross currency interest rate swaps and interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Classified as non-current other assets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Classified as cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Includes $520 million, $594 million and $1,631 million, classified as non-current other liabilities as of January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019, respectively. Includes $13 million, $39&#160;million and $84&#160;million classified as current liabilities as of January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt"&gt;Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense.  The Company recorded a contingent consideration reversal of $1,148&#160;million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Notes&#160;2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CollateralAlreadyPostedAggregateFairValue
      contextRef="i481d55d4f8994158a9674ef0152c9f10_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzE2NDc_575a5b8b-5adf-42a3-a09f-3bd94b97f39a"
      unitRef="usd">570000000</us-gaap:CollateralAlreadyPostedAggregateFairValue>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i481d55d4f8994158a9674ef0152c9f10_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzIyOTc_84858a05-dce5-4792-a5e2-a46234c98972"
      unitRef="usd">45800000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ide40f8c8eeea4d2e8f7770aabdc662ff_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzIzMDQ_d2df5401-bee6-4c9a-bf12-20704afc0869"
      unitRef="usd">37400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ife54767ac5ea4ca28081964675153a39_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzMyOTg1MzQ4OTMyOTA_8a033c0f-6f6b-4c4a-96c4-5a2127a8f500"
      unitRef="usd">10000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ifd2d53c5c93540bc8d713ea6f655ed74_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzI0NTg_d0b61395-f3b0-4448-9e6b-7407de77a360"
      unitRef="usd">37800000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i84703fb2bb5c49cabc6f3a6a621d65b8_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzI0NjY_511ad652-aa12-40c3-9d5a-35539eae602b"
      unitRef="usd">30600000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzQ2NjE_44222f3c-7366-4f87-8920-b9bbe6dd0668"
      unitRef="usd">336000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzQ5MjA_a5265257-daf9-4e18-8106-d7a238f72311">next 12 months</us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss>
    <us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzUwODE_6636dd39-3d55-40b9-aa5c-08be6537bbe5">P18M</us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5Xzk4MzY_e8786929-0c49-4840-8b33-8888b8419650">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021, net of tax:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of January 2, 2022 and January 3, 2021, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Line item in the Consolidated Balance Sheet in which the hedged item is included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i808995d91a27460c9150c476dd1da392_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtMS0xLTEtNTMyMjk_bb95b50b-a4d7-4cbf-9e61-fa1f4f1713c7"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ia0192bf715a243bf91d01442328393a5_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtMi0xLTEtNTMyMjk_1afb9afe-3b53-4cde-9434-a1ed0b8ce378"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="id60bdb5b63a8467fa3b6eeb112fbe483_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtMy0xLTEtNTMyMjk_2f654d23-36ee-45b4-bcc3-8ec466bbffdc"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i9b7e0a2b5849409ca6652a1b1d9009f8_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtNC0xLTEtMjk3MjY_c84d5242-ac0f-4f85-8517-87b608f42066"
      unitRef="usd">-109000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i0c3d3ec9cd0343bea423885018d25702_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtNS0xLTEtNTMyMjk_b1744438-ad4f-4fad-b5c3-e2553950e678"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i3c38412ef9e6497482c4931bff7adc40_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtNi0xLTEtNTMyMjk_daf00d71-dfb0-42b2-86bc-5323eabbefbb"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i19a92a1966c547b5b282d744cb467936_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtNy0xLTEtNTMyMjk_82e37962-a6cb-41de-a541-cbcd40aad83c"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i6100225b54fc4ad197e03ca829ba928d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtOC0xLTEtNTMyMjk_a4d9f260-ad1d-4ea1-ba83-ef8e1cd3724a"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ib720add8d11a4684b8b6655ee5659b4c_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtOS0xLTEtMjk3MjY_76fb37f9-e4b3-4335-9004-6d6e9cbc402f"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i106b831f4ff540dab0212fc0f723cb2f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzgtMTAtMS0xLTUzMjI5_987c752d-08df-403e-9816-ce1f6e8a16c0"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i808995d91a27460c9150c476dd1da392_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktMS0xLTEtNTMyMjk_52dfd201-6247-44a5-bdba-4e69a87547b4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ia0192bf715a243bf91d01442328393a5_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktMi0xLTEtNTMyMjk_19424602-ec60-4c1c-b285-22df09cc6cea"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="id60bdb5b63a8467fa3b6eeb112fbe483_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktMy0xLTEtNTMyMjk_1678e2d7-53a6-4769-ad3d-99f3c14a7142"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i9b7e0a2b5849409ca6652a1b1d9009f8_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktNC0xLTEtMjk3MjY_cfef8833-551a-436b-b7c2-39b74fcc5d78"
      unitRef="usd">109000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i0c3d3ec9cd0343bea423885018d25702_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktNS0xLTEtNTMyMjk_bc28bbf9-2f13-46a6-ae44-ccb6dc0f178f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i3c38412ef9e6497482c4931bff7adc40_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktNi0xLTEtNTMyMjk_9b08b181-c7c1-4f84-9096-7e5e85539983"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i19a92a1966c547b5b282d744cb467936_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktNy0xLTEtNTMyMjk_a512e5e8-1306-4f42-809f-37fd9652130f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i6100225b54fc4ad197e03ca829ba928d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktOC0xLTEtNTMyMjk_03e20faf-a031-4a29-bb20-3135ddfe79e5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ib720add8d11a4684b8b6655ee5659b4c_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktOS0xLTEtMjk3MjY_d5f26286-b44c-471c-827f-c205ee978730"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i106b831f4ff540dab0212fc0f723cb2f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzktMTAtMS0xLTUzMjI5_5e33c297-eb01-408c-8ef3-cc47f8208fa0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i52a259e92c5049eda0dbf8c42cea6804_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTEtMS0xLTI5NzI2_032ed5a8-cd01-425c-bcf2-495839c4481f"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="id786d862a5f04ff48bcbb29805518774_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTItMS0xLTI5NzI2_ae1b725e-1021-4aa2-8018-dfcab9364f01"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i985b96ccd9484a66b346bc504f80d0a1_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTMtMS0xLTI5NzI2_d1fd6bd3-c275-4921-8478-6184ace08cc7"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i7dbc1cc0cc71418babaecbd428b53b3b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTQtMS0xLTI5NzI2_24fbf105-eb03-4a85-9ed2-14b340367b4b"
      unitRef="usd">174000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i2ec2a313be1445888459a2cb95ec031b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTUtMS0xLTI5NzI2_cdaa8c92-f10c-4f1b-abfd-943bd4025a08"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i9d672893c8cc417db3f3cd8f14697306_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTYtMS0xLTI5NzI2_dc3c5309-9dec-4cf6-a90c-91435e839b87"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i5dd978faac464658a1798c339c543b0a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTctMS0xLTI5NzI2_0f864b82-09db-457f-95d0-cb501d2a855c"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="if14f023407364aa181f33d20d53b160b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTgtMS0xLTI5NzI2_8cf4da97-6928-4288-be7e-6301bb0a4e2a"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="if3c166abab67452688a30d1ef04d16f1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTktMS0xLTI5NzI2_e02440ef-b420-45e1-a9ee-16e874bfaa1e"
      unitRef="usd">153000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="id5665ea9b95743bf9c890aefaf80d04a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzEzLTEwLTEtMS0yOTcyNg_89a73c37-c4e3-471e-9210-e5b9175b8a01"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i52a259e92c5049eda0dbf8c42cea6804_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTEtMS0xLTI5NzI2_0fcaf1bb-edb3-4e19-bb9c-63feaaee6945"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="id786d862a5f04ff48bcbb29805518774_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTItMS0xLTI5NzI2_fdd48d4d-5c95-4652-a6bf-823754bd97b7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i985b96ccd9484a66b346bc504f80d0a1_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTMtMS0xLTI5NzI2_56b52f88-698b-4c07-8b54-103ca8b2318e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i7dbc1cc0cc71418babaecbd428b53b3b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTQtMS0xLTI5NzI2_46cb1279-19ef-4b80-8ab8-ee3e1c1db049"
      unitRef="usd">174000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i2ec2a313be1445888459a2cb95ec031b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTUtMS0xLTI5NzI2_c06cf6a4-560f-4e2c-8839-70549bfa37c1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i9d672893c8cc417db3f3cd8f14697306_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTYtMS0xLTI5NzI2_485fba9a-6091-4796-8b01-9be6ad5f2764"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5dd978faac464658a1798c339c543b0a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTctMS0xLTI5NzI2_7b2052da-6a3c-4ede-b6d8-5c01626a8ee0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="if14f023407364aa181f33d20d53b160b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTgtMS0xLTI5NzI2_1480d0f7-7404-46c0-82d1-99040ae06456"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="if3c166abab67452688a30d1ef04d16f1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTktMS0xLTI5NzI2_2f26c7ce-1dbb-4312-86b6-393c1613825d"
      unitRef="usd">153000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="id5665ea9b95743bf9c890aefaf80d04a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE0LTEwLTEtMS0yOTcyNg_65dadc45-2c9c-4091-96e7-54848a23565c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i1b31f531f8d1475f88bdb4724aace2fd_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTEtMS0xLTI5NzI2_efe1a884-007e-45f7-ab7d-0d0f295c9d4c"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i92c7f67b422f4287a1a96e34cff07706_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTItMS0xLTI5NzI2_7d1832a7-e79b-4a21-9a8e-b40cca95a4c1"
      unitRef="usd">119000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i0446032e1785439f985c59f1a7df1bcc_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTMtMS0xLTI5NzI2_496a2196-cd4b-4a53-9a4c-e7a9a57e55d3"
      unitRef="usd">30000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i63c2845f743f49b9b13f7ad7d5f81f15_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTQtMS0xLTI5NzI2_56c27bc7-80af-4793-830b-051d63e26edd"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ia828ba075e524e7090012a4cdc4a5662_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTUtMS0xLTI5NzI2_04baaaa2-cc7e-4238-8c79-024022925fa9"
      unitRef="usd">47000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i05d7cbac295a4d9d8247f5d8e6c2cdaa_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTYtMS0xLTI5NzI2_980eeabb-a3cb-4094-8194-f3181a986d63"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i78f4b6c63cab436a8845f1c2ac4c66f9_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTctMS0xLTI5NzI2_1939296d-d29b-40c4-b3d5-1c0d7edc0f0d"
      unitRef="usd">-329000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i848c6b8efe174f4e9f95b5f1dd159ef4_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTgtMS0xLTI5NzI2_1c3d142d-bfe6-423d-96a3-39ad001d7412"
      unitRef="usd">-137000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i07bde8491d87476ca7b9ebedfa820539_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTktMS0xLTI5NzI2_9b02220e-c2a2-4005-9aa4-4506df09da30"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i634edb5f28be4c3db07ca7a3116c19fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzE4LTEwLTEtMS0yOTcyNg_2c1b3069-af57-403e-a4e6-d681e7264b1f"
      unitRef="usd">-16000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i1b31f531f8d1475f88bdb4724aace2fd_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTEtMS0xLTI5NzI2_dbfa8944-0e47-44f7-b5ee-44b6f27b6dcb"
      unitRef="usd">-94000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i92c7f67b422f4287a1a96e34cff07706_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTItMS0xLTI5NzI2_8be74a3e-388a-44b0-abe9-3546a665b131"
      unitRef="usd">-557000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i0446032e1785439f985c59f1a7df1bcc_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTMtMS0xLTI5NzI2_0a86b4d3-55db-4489-9fcb-a499e091e218"
      unitRef="usd">123000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i63c2845f743f49b9b13f7ad7d5f81f15_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTQtMS0xLTI5NzI2_adab5875-6843-48d3-be6c-e396b2f34b76"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ia828ba075e524e7090012a4cdc4a5662_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTUtMS0xLTI5NzI2_98487c2d-d3af-48b9-867a-fbba27a2fc6e"
      unitRef="usd">146000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i05d7cbac295a4d9d8247f5d8e6c2cdaa_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTYtMS0xLTI5NzI2_b5a51cbf-118b-4b71-a64f-294b7dbc8fd0"
      unitRef="usd">44000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i78f4b6c63cab436a8845f1c2ac4c66f9_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTctMS0xLTI5NzI2_2f2612b9-dc42-4058-a438-2948e2626ec2"
      unitRef="usd">298000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i848c6b8efe174f4e9f95b5f1dd159ef4_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTgtMS0xLTI5NzI2_d71829bb-69e5-4c26-9f32-e0982bc051f9"
      unitRef="usd">-91000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i07bde8491d87476ca7b9ebedfa820539_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTktMS0xLTI5NzI2_e23433f8-ee04-4d6a-8830-88fc902764dc"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i634edb5f28be4c3db07ca7a3116c19fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzIyLTEwLTEtMS0yOTcyNg_30e6bacc-f6c4-4b8c-894e-7fa1f3f8e545"
      unitRef="usd">-52000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ib0123bf3fb024b76ae1885d1761a5b82_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTEtMS0xLTI5NzI2_e91fc067-2d73-4ce3-87fc-e43b689f9264"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="idfd790bc28d74dff8d098e4985e0db53_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTItMS0xLTI5NzI2_3672dd62-b5c5-4b0f-9441-40e3c5f4c9aa"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i1ae16c703b374886a06975f54aceaedc_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTMtMS0xLTI5NzI2_d894ca95-0a74-44a6-88e3-848468066b6a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i0d4ccba4445542b791db72cb4a2b0c5e_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTQtMS0xLTI5NzI2_b423a639-9dc8-46b4-b4e9-cd80d8ce71b2"
      unitRef="usd">402000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i8eb2552df8fe44b0a4e1444a56e55504_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTUtMS0xLTI5NzI2_f4e0d9e4-de99-4f91-b6b2-ec15ef027ab8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i032a01d82e6b46aca1a6b8385c458f94_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTYtMS0xLTI5NzI2_3a388636-7418-41c6-a1d4-b739b9a8b121"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i9affd553b7d74c819ed99f3018b801a6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTctMS0xLTI5NzI2_07caab3e-8179-4b2a-af2c-97eee447e653"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ief391a34b2eb4d2d8fe2aaaff100ce78_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTgtMS0xLTI5NzI2_2b035be8-3240-4237-8131-8ecb9f298310"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="if28f0b8b33504b4f9f89e9d449f06cb6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTktMS0xLTI5NzI2_05be0a18-8c48-4698-bde9-dfa0e3ca6d53"
      unitRef="usd">370000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ifa5a045453b74d8195dd434da3e842f7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI1LTEwLTEtMS0yOTcyNg_bfb6fbc3-2654-4be7-a95d-8df93164920e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ib0123bf3fb024b76ae1885d1761a5b82_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTEtMS0xLTI5NzI2_bdaa458e-3d64-47c3-a5a6-41881503364b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="idfd790bc28d74dff8d098e4985e0db53_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTItMS0xLTI5NzI2_c0b11fe2-2ed1-4ad5-8f0b-f3e83417073d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i1ae16c703b374886a06975f54aceaedc_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTMtMS0xLTI5NzI2_b5727fc7-e0f1-4109-a1f6-d902de233469"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i0d4ccba4445542b791db72cb4a2b0c5e_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTQtMS0xLTI5NzI2_a3de5386-b9f2-476b-b642-90717d6e3dda"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i8eb2552df8fe44b0a4e1444a56e55504_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTUtMS0xLTI5NzI2_d7ac445e-724a-4c6e-9fea-101ed238a68e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i032a01d82e6b46aca1a6b8385c458f94_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTYtMS0xLTI5NzI2_efd22941-3ed3-4fc4-b394-5c090454dcb7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i9affd553b7d74c819ed99f3018b801a6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTctMS0xLTI5NzI2_c2a725f9-85d4-4894-ab8f-d856026db5d5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ief391a34b2eb4d2d8fe2aaaff100ce78_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTgtMS0xLTI5NzI2_4b99a4cc-a345-4c92-9f95-bb77c8fc52df"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="if28f0b8b33504b4f9f89e9d449f06cb6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTktMS0xLTI5NzI2_fb6d0793-8dd7-42b3-b9ad-fe9777b4abba"
      unitRef="usd">748000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ifa5a045453b74d8195dd434da3e842f7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTphMzNkNjQ0YmQyNDQ0YjE4YTRkM2YzZGJjNTc1YTdlMy90YWJsZXJhbmdlOmEzM2Q2NDRiZDI0NDRiMThhNGQzZjNkYmM1NzVhN2UzXzI3LTEwLTEtMS0yOTcyNg_470d3798-efde-4710-bc2f-efdcf790aa36"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="if076b21d69e44a83b09033d94b086ac3_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmNGQ0Mjg4MDliZWY0YTRkYTYwOWIzM2M1OTc2Njc3Zi90YWJsZXJhbmdlOmY0ZDQyODgwOWJlZjRhNGRhNjA5YjMzYzU5NzY2NzdmXzQtMi0xLTEtMzUzMDg_9a205fc1-785a-43e5-8da4-39b34ff1d887"
      unitRef="usd">9793000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i52546e6d078c45f7ac9bd5ced9ab7cf3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmNGQ0Mjg4MDliZWY0YTRkYTYwOWIzM2M1OTc2Njc3Zi90YWJsZXJhbmdlOmY0ZDQyODgwOWJlZjRhNGRhNjA5YjMzYzU5NzY2NzdmXzQtNC0xLTEtMzUzMzE_5efdbe2a-bb89-4b01-9b68-9d6d145a178b"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="if076b21d69e44a83b09033d94b086ac3_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmNGQ0Mjg4MDliZWY0YTRkYTYwOWIzM2M1OTc2Njc3Zi90YWJsZXJhbmdlOmY0ZDQyODgwOWJlZjRhNGRhNjA5YjMzYzU5NzY2NzdmXzQtNi0xLTEtMzUzNDk_083bd0cf-8b4e-448d-9553-d9c4f9d89ed4"
      unitRef="usd">-142000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i52546e6d078c45f7ac9bd5ced9ab7cf3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmNGQ0Mjg4MDliZWY0YTRkYTYwOWIzM2M1OTc2Njc3Zi90YWJsZXJhbmdlOmY0ZDQyODgwOWJlZjRhNGRhNjA5YjMzYzU5NzY2NzdmXzQtOC0xLTEtMzUzNjQ_3d70991a-4096-4250-883a-02f6325c7993"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5Xzk4Njk_6a5eb062-d7aa-4587-90a6-c5e960c73918">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location of Gain /(Loss) Recognized in Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i92e2a8e7af49412bbc0f28e465623b6f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo4ZWI0MGU0N2RmZGY0NDEyYmMwYmY4ZjY2NmJkNDc4My90YWJsZXJhbmdlOjhlYjQwZTQ3ZGZkZjQ0MTJiYzBiZjhmNjY2YmQ0NzgzXzItNC0xLTEtMjk3MjY_c6e47788-a523-46ec-aacd-d36a4c5df4fa"
      unitRef="usd">-70000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i174a527600c44ee8992a7b48db2a0f80_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo4ZWI0MGU0N2RmZGY0NDEyYmMwYmY4ZjY2NmJkNDc4My90YWJsZXJhbmdlOjhlYjQwZTQ3ZGZkZjQ0MTJiYzBiZjhmNjY2YmQ0NzgzXzItNi0xLTEtMjk3MjY_ea7792ce-f3d0-4e21-b440-ae9494beccb5"
      unitRef="usd">24000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5Xzk4NTE_d930707a-da81-4739-ae9d-f1a795c28cd7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;The following table is the effect of net investment hedges for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)           Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmMTdkYTZhM2EyZTM0ZDEzOWMxMjdkNzE0NjRjOTk5Ny90YWJsZXJhbmdlOmYxN2RhNmEzYTJlMzRkMTM5YzEyN2Q3MTQ2NGM5OTk3XzItMi0xLTEtMjk3MjY_c07a82cd-0479-4f36-bd63-98595b6d0a3b"
      unitRef="usd">387000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmMTdkYTZhM2EyZTM0ZDEzOWMxMjdkNzE0NjRjOTk5Ny90YWJsZXJhbmdlOmYxN2RhNmEzYTJlMzRkMTM5YzEyN2Q3MTQ2NGM5OTk3XzItNC0xLTEtMjk3MjY_abac0c5b-e7f5-47ef-b196-2c080686a657"
      unitRef="usd">-473000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ie117c70d8dab414e86a30cd9df792971_D20211004-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmMTdkYTZhM2EyZTM0ZDEzOWMxMjdkNzE0NjRjOTk5Ny90YWJsZXJhbmdlOmYxN2RhNmEzYTJlMzRkMTM5YzEyN2Q3MTQ2NGM5OTk3XzItOC0xLTEtMjk3MjY_0936d8ac-cae6-4734-8fb7-bd6da456c561"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ia2a9a8b7f5c64483bd4a1030ddd50c04_D20200928-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmMTdkYTZhM2EyZTM0ZDEzOWMxMjdkNzE0NjRjOTk5Ny90YWJsZXJhbmdlOmYxN2RhNmEzYTJlMzRkMTM5YzEyN2Q3MTQ2NGM5OTk3XzItMTAtMS0xLTI5NzI2_95d94286-97c2-468e-849e-387eddc948e1"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="ibd102efd0d744d738ffe8f80c0ea4d4f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmMTdkYTZhM2EyZTM0ZDEzOWMxMjdkNzE0NjRjOTk5Ny90YWJsZXJhbmdlOmYxN2RhNmEzYTJlMzRkMTM5YzEyN2Q3MTQ2NGM5OTk3XzMtMi0xLTEtMjk3MjY_3cd0caef-54bf-4a12-8b76-0ef0d62160a6"
      unitRef="usd">548000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="ia8082b83eab643a19df9232e909a1570_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmMTdkYTZhM2EyZTM0ZDEzOWMxMjdkNzE0NjRjOTk5Ny90YWJsZXJhbmdlOmYxN2RhNmEzYTJlMzRkMTM5YzEyN2Q3MTQ2NGM5OTk3XzMtNC0xLTEtMjk3MjY_c03e9f4f-aa16-4b54-8dec-fb994381a1cf"
      unitRef="usd">65000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i223217fcf82c4c9fbd27757bd7ab98f3_D20211004-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmMTdkYTZhM2EyZTM0ZDEzOWMxMjdkNzE0NjRjOTk5Ny90YWJsZXJhbmdlOmYxN2RhNmEzYTJlMzRkMTM5YzEyN2Q3MTQ2NGM5OTk3XzMtOC0xLTEtMjk3MjY_0cc2430e-6c7b-4ae9-b0be-fda5e961449a"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="idf5fca83f72e4903ab75e0c5be5d0b90_D20200928-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmMTdkYTZhM2EyZTM0ZDEzOWMxMjdkNzE0NjRjOTk5Ny90YWJsZXJhbmdlOmYxN2RhNmEzYTJlMzRkMTM5YzEyN2Q3MTQ2NGM5OTk3XzMtMTAtMS0xLTI5NzI2_ecaeddd3-596b-43e1-b76b-00c3dfaaaa3a"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5Xzk4NzA_5263f7ed-fcca-406c-99f5-97def9994969">&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments for the fiscal years ended January&#160;2, 2022 and January&#160;3, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.505%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="iaba88d1e19f44fdeb865036ee60e1e26_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzItMi0xLTEtMjk3MjY_c2ba3f03-1047-4fbd-ba8a-378d8d6aace6"
      unitRef="usd">1481000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:EquityFairValueAdjustment
      contextRef="i039392ea3c3b403db051bc1af156bce0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzItNC0xLTEtMjk3MjY_888522e7-d446-4ce6-a769-12bf00c2537e"
      unitRef="usd">198000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="i039392ea3c3b403db051bc1af156bce0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzItNi0xLTEtMjk3MjY_b7e2d299-4e9d-4627-9b14-3d6951ac4143"
      unitRef="usd">205000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i0ded06cef625444b86727e06867cbda7_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzItOC0xLTEtMjk3MjY_9e2101b1-2e89-49d8-94a2-c3d9e72e99d4"
      unitRef="usd">1884000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0ded06cef625444b86727e06867cbda7_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzItMTAtMS0xLTI5NzI2_b2e89544-e83f-4bbc-9be6-983f4f0d324e"
      unitRef="usd">1884000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ic0a4bb0a45cf4321a078221f082dc745_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzQtMi0xLTEtMjk3MjY_b5b9c35e-df66-43a4-bc52-215231319ec8"
      unitRef="usd">738000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityFairValueAdjustment
      contextRef="i5bb81f8d839b475bac63d7d23d05d99b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzQtNC0xLTEtMjk3MjY_cb00fc3e-1344-45bf-a726-11fe59851f5a"
      unitRef="usd">394000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="i5bb81f8d839b475bac63d7d23d05d99b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzQtNi0xLTEtMjk3MjY_a6e6dce2-c862-49e6-be3c-5c5c9305cf78"
      unitRef="usd">-632000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="id87a7804b1f44de484b175a96356f43f_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzQtOC0xLTEtMjk3MjY_ef57f0ff-61a3-4a1f-8eaf-8ba119f5ee3b"
      unitRef="usd">500000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id87a7804b1f44de484b175a96356f43f_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkYTIyYjBlMTFmMGY0N2MxYTY1OTk1M2RhZWNmOTgzYi90YWJsZXJhbmdlOmRhMjJiMGUxMWYwZjQ3YzFhNjU5OTUzZGFlY2Y5ODNiXzQtMTAtMS0xLTI5NzI2_d18d34f8-fcc9-4a7b-a08c-6381bf086a2c"
      unitRef="usd">500000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i1bbf538e3b42487aabaada415c912f2b_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzItMi0xLTEtMjk3MjY_1a1c23de-663c-4acf-8846-e779c73c3a83"
      unitRef="usd">1148000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:EquityFairValueAdjustment
      contextRef="iaec68da81f3f4ed78748a512faa1b83a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzItNC0xLTEtMjk3MjY_6ae6385f-e675-49f9-9b7e-b4dfdbdc933d"
      unitRef="usd">527000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="iaec68da81f3f4ed78748a512faa1b83a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzItNi0xLTEtMjk3MjY_6ba217de-983f-46f2-850c-18883dcf4535"
      unitRef="usd">-194000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="iaba88d1e19f44fdeb865036ee60e1e26_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzItOC0xLTEtMjk3MjY_d9e5d71e-2c74-4b0f-980e-8a6ec73dd1e1"
      unitRef="usd">1481000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iaba88d1e19f44fdeb865036ee60e1e26_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzItMTAtMS0xLTI5NzI2_c0b1c0b4-2466-4cbd-a8a5-f305562a1bfa"
      unitRef="usd">1481000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i8e2c57afbb094c14a7064ef903706da7_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzQtMi0xLTEtMjk3MjY_2c47ddc5-b631-42de-9bdf-3a83abd90e54"
      unitRef="usd">712000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityFairValueAdjustment
      contextRef="i904861e4f8ed471381dbacfc8e3ab52e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzQtNC0xLTEtMjk3MjY_77da4878-6e1d-4003-a855-a6b74bb3ef5f"
      unitRef="usd">-55000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="i904861e4f8ed471381dbacfc8e3ab52e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzQtNi0xLTEtMjk3MjY_f26679ab-f390-45bc-bc19-98b4cbd65d3e"
      unitRef="usd">81000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ic0a4bb0a45cf4321a078221f082dc745_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzQtOC0xLTEtMjk3MjY_cd4fafaa-6751-4978-99a4-43701ec0260b"
      unitRef="usd">738000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic0a4bb0a45cf4321a078221f082dc745_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpkZTNjMjMyY2JhYWE0OTM5OTQzMGY1NzBkN2Q2MTc1Ny90YWJsZXJhbmdlOmRlM2MyMzJjYmFhYTQ5Mzk5NDMwZjU3MGQ3ZDYxNzU3XzQtMTAtMS0xLTI5NzI2_e7c651f9-8951-41e8-8b31-7e1e862854c8"
      unitRef="usd">738000000</us-gaap:OtherAssetsNoncurrent>
    <jnj:EquityFairValueAdjustmentImpairmentLoss
      contextRef="i5bb81f8d839b475bac63d7d23d05d99b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzY0MzE_6e536945-c81c-4f3f-85df-e3ae6b981f5a"
      unitRef="usd">-28000000</jnj:EquityFairValueAdjustmentImpairmentLoss>
    <jnj:EquityFairValueAdjustmentImpairmentLoss
      contextRef="i904861e4f8ed471381dbacfc8e3ab52e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzY0Mzg_1e694f91-1e9f-4353-8b84-5f18f8c14d10"
      unitRef="usd">-76000000</jnj:EquityFairValueAdjustmentImpairmentLoss>
    <jnj:EquityFairValueAdjustmentChangeinObservablePrices
      contextRef="i5bb81f8d839b475bac63d7d23d05d99b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzY1NTI_2023e1e7-145d-47f2-a567-23d809f25648"
      unitRef="usd">422000000</jnj:EquityFairValueAdjustmentChangeinObservablePrices>
    <jnj:EquityFairValueAdjustmentChangeinObservablePrices
      contextRef="i904861e4f8ed471381dbacfc8e3ab52e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzY1NTk_c561c9aa-d877-4189-979b-40de605bb227"
      unitRef="usd">21000000</jnj:EquityFairValueAdjustmentChangeinObservablePrices>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5Xzk4MzE_26d99c5a-54e6-45f9-b9f5-fb1ae0465d8e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of the fiscal year ended January&#160;2, 2022 and January&#160;3, 2021 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,089&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,860&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,860&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Available For Sale Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.409%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about changes in liabilities for contingent consideration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;2020 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $1,481 million, which are classified as Level&#160;1 and contingent consideration of $633 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Includes cross currency interest rate swaps and interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Classified as non-current other assets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Classified as cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Includes $520 million, $594 million and $1,631 million, classified as non-current other liabilities as of January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019, respectively. Includes $13 million, $39&#160;million and $84&#160;million classified as current liabilities as of January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt"&gt;Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense.  The Company recorded a contingent consideration reversal of $1,148&#160;million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i8c8d98bc79544f2796d5f14b04f588e5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzQtMi0xLTEtMjk3MjY_e4061ed9-78c8-4374-8dd1-31919bec6f1d"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ifc765a63065f4fc7a9606b02f261afad_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzQtNC0xLTEtMjk3MjY_3ff4ea1a-e8f6-4302-9fc8-b7769913a86e"
      unitRef="usd">540000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i071cfab120ae4af6b209509a7218091d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzQtNi0xLTEtMjk3MjY_3db67b6c-260b-410a-9b2c-337e0daa7014"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i481d55d4f8994158a9674ef0152c9f10_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzQtOC0xLTEtMjk3MjY_2ab27984-05a6-47cb-8673-935a5d3d453b"
      unitRef="usd">540000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ie4babc1d42ff4632a1e3e6b5c723c86f_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzQtMTAtMS0xLTI5NzI2_25752e89-30d4-4fdc-b401-ae8ad922ac99"
      unitRef="usd">849000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i7b06190f006c4dce9af3c9f28a239d36_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzUtMi0xLTEtMjk3MjY_03fe783a-88e0-4506-a58e-f8bce83303b2"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ibcee04e7edb6498692d55fa0db8bfab5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzUtNC0xLTEtMjk3MjY_4cb175aa-ff39-44c3-a004-dbb1b4df546a"
      unitRef="usd">796000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i1b3713ead11f41faa96420921c930eba_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzUtNi0xLTEtMjk3MjY_5264aec2-e745-42f6-b9dc-745bb5692aef"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ieab28e9d35ce41f88040fcdf057e21e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzUtOC0xLTEtMjk3MjY_02b3cf3a-c987-4c93-a8e0-570e114d64db"
      unitRef="usd">796000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="if6fce32d455546de8f77cd04c86b5dd7_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzUtMTAtMS0xLTI5NzI2_5fd0a4d7-bafe-4bc8-bfec-9e8e8e800c1c"
      unitRef="usd">240000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i769b6005fa4c4532801176ab7112c4aa_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzctMi0xLTEtMjk3MjY_b2a23edb-e838-462f-8fcb-c8377510e1fe"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i7ed3758031c041a586a6a2d9b7ea4c75_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzctNC0xLTEtMjk3MjY_d68f8088-7718-4104-8451-a68608ca2277"
      unitRef="usd">1336000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="iac6290a59e7c45c899a410f1f0e2c835_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzctNi0xLTEtMjk3MjY_76163be4-e28c-4c06-a4db-d642a7259a80"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzctOC0xLTEtMjk3MjY_a263da74-7811-4ad7-bbb8-2372223cb6d8"
      unitRef="usd">1336000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i4e2707e7b5d243d78d1b3c5313fcea06_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzctMTAtMS0xLTI5NzI2_4c504b64-15d8-46b1-897a-238a2126aaa2"
      unitRef="usd">1089000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i8c8d98bc79544f2796d5f14b04f588e5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzktMi0xLTEtMjk3MjY_119461e9-ce2b-4593-bcb3-24dc31ea748c"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ifc765a63065f4fc7a9606b02f261afad_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzktNC0xLTEtMjk3MjY_5cbc5df1-24fb-4a3c-9107-21f373309277"
      unitRef="usd">881000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i071cfab120ae4af6b209509a7218091d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzktNi0xLTEtMjk3MjY_3bacd2b3-0f51-4e0d-a30c-4c2a6ff6ff8d"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i481d55d4f8994158a9674ef0152c9f10_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzktOC0xLTEtMjk3MjY_bf675cf1-0753-4fc7-b28c-14e1d93f6c52"
      unitRef="usd">881000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ie4babc1d42ff4632a1e3e6b5c723c86f_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzktMTAtMS0xLTI5NzI2_16550927-2b77-4c43-981e-14e51507880c"
      unitRef="usd">702000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i7b06190f006c4dce9af3c9f28a239d36_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEwLTItMS0xLTI5NzI2_9466fd99-ad4a-4490-8c80-75d1c581c9b7"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ibcee04e7edb6498692d55fa0db8bfab5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEwLTQtMS0xLTI5NzI2_707f10ac-924b-4aaa-9aa7-fda5c4cc7aac"
      unitRef="usd">979000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i1b3713ead11f41faa96420921c930eba_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEwLTYtMS0xLTI5NzI2_10fc3d0b-d0a1-4f00-b3e4-54bb89629de4"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ieab28e9d35ce41f88040fcdf057e21e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEwLTgtMS0xLTI5NzI2_76360966-12d1-4172-89e5-13d125524ba5"
      unitRef="usd">979000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="if6fce32d455546de8f77cd04c86b5dd7_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEwLTEwLTEtMS0yOTcyNg_f608be36-f73a-47fb-ba90-148623c030d2"
      unitRef="usd">1569000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i769b6005fa4c4532801176ab7112c4aa_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEzLTItMS0xLTI5NzI2_f9f66964-9f1b-4d72-a7bb-af43e66387ff"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i7ed3758031c041a586a6a2d9b7ea4c75_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEzLTQtMS0xLTI5NzI2_cba1b85b-39a5-4d81-b9b3-0faf6ce234a6"
      unitRef="usd">1860000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="iac6290a59e7c45c899a410f1f0e2c835_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEzLTYtMS0xLTI5NzI2_0896d774-29ef-4f2e-8ae4-eca79d541683"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEzLTgtMS0xLTI5NzI2_f498388c-a30a-4136-b788-f520921a8ee7"
      unitRef="usd">1860000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i4e2707e7b5d243d78d1b3c5313fcea06_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzEzLTEwLTEtMS0yOTcyNg_004379ae-5d78-4fc6-9949-6f107c266032"
      unitRef="usd">2271000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i8c8d98bc79544f2796d5f14b04f588e5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE2LTItMS0xLTI5NzI2_792a42f1-c4b3-4493-bed0-dd8cf6646411"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="ifc765a63065f4fc7a9606b02f261afad_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE2LTQtMS0xLTI5NzI2_1bf51ba1-e0bd-4643-a304-1802b29e5741"
      unitRef="usd">24000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i071cfab120ae4af6b209509a7218091d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE2LTYtMS0xLTI5NzI2_1589de23-52c8-4737-b7ac-2d6fa66c380d"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i481d55d4f8994158a9674ef0152c9f10_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE2LTgtMS0xLTI5NzI2_7a6d3635-42bd-4446-a299-7bde5be4ba23"
      unitRef="usd">24000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="ie4babc1d42ff4632a1e3e6b5c723c86f_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE2LTEwLTEtMS0yOTcyNg_f0950be4-afc7-42a6-b74a-ccc5d87dbc7e"
      unitRef="usd">49000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i8c8d98bc79544f2796d5f14b04f588e5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE4LTItMS0xLTI5NzI2_93faa8f1-02c0-4b4e-843a-6782440c8eef"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="ifc765a63065f4fc7a9606b02f261afad_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE4LTQtMS0xLTI5NzI2_b9935422-9e6e-4b15-b6f8-1c1db92dedc2"
      unitRef="usd">28000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i071cfab120ae4af6b209509a7218091d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE4LTYtMS0xLTI5NzI2_9b3b435c-8515-4463-92a1-16a7986431ad"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i481d55d4f8994158a9674ef0152c9f10_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE4LTgtMS0xLTI5NzI2_f37a369f-05c9-49bd-bb01-bd23130a530f"
      unitRef="usd">28000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="ie4babc1d42ff4632a1e3e6b5c723c86f_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzE4LTEwLTEtMS0yOTcyNg_e89c88bb-010e-4a5d-bbdf-7d698a7afacd"
      unitRef="usd">38000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i769b6005fa4c4532801176ab7112c4aa_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIwLTItMS0xLTI5NzI2_d3ee73e5-1781-4bec-8a0f-06cc1bbf1f0d"
      unitRef="usd">1884000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7ed3758031c041a586a6a2d9b7ea4c75_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIwLTQtMS0xLTI5NzI2_2f932078-d9fd-48d4-a3ec-7b73b2ec4b68"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iac6290a59e7c45c899a410f1f0e2c835_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIwLTYtMS0xLTI5NzI2_4bdece4c-9f67-4e88-98dc-5761cb382a9d"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIwLTgtMS0xLTI5NzI2_421da651-0fb0-42d9-b101-49246659411d"
      unitRef="usd">1884000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIwLTEwLTEtMS0yOTcyNg_69517408-9b90-488e-94e4-2486b4708599"
      unitRef="usd">1481000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i769b6005fa4c4532801176ab7112c4aa_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIxLTItMS0xLTI5NzI2_bf29f004-2139-4171-bac9-26825ac4f507"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7ed3758031c041a586a6a2d9b7ea4c75_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIxLTQtMS0xLTI5NzI2_717b778d-2f47-450f-b53d-69cc02275f4a"
      unitRef="usd">19727000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iac6290a59e7c45c899a410f1f0e2c835_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIxLTYtMS0xLTI5NzI2_ff92bd90-f04e-4963-9806-46b19cec167b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIxLTgtMS0xLTI5NzI2_ea398c6d-179a-4aef-81e8-c6c03b254c3b"
      unitRef="usd">19727000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIxLTEwLTEtMS0yOTcyNg_798de2e5-4035-4bc2-9f65-e41b950bc0e8"
      unitRef="usd">14042000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iac6290a59e7c45c899a410f1f0e2c835_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIzLTYtMS0xLTI5NzI2_52026e2f-7a8d-4ce5-8228-56f2f320379e"
      unitRef="usd">533000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIzLTgtMS0xLTI5NzI2_75e4e3aa-686a-404b-9645-17a98dc17ee7"
      unitRef="usd">533000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo5OTNiNDVjZDlmZTY0YjZjYWFkYTEyZTBjMmRjYjI5MC90YWJsZXJhbmdlOjk5M2I0NWNkOWZlNjRiNmNhYWRhMTJlMGMyZGNiMjkwXzIzLTEwLTEtMS0yOTcyNg_6983f031-0df0-4441-b4f3-000caf1e428c"
      unitRef="usd">633000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzItMi0xLTEtMjk3MjY_7270d315-79bc-4096-a65b-9975e33bff9b"
      unitRef="usd">1360000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzItNC0xLTEtMjk3MjY_3cb9801b-a576-43f5-a32b-980ac36725f7"
      unitRef="usd">1138000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzMtMi0xLTEtMjk3MjY_0468558a-c1da-4cac-ade3-4f7bcb022ec6"
      unitRef="usd">1285000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzMtNC0xLTEtMjk3MjY_f0698fd9-6128-468d-b1df-2bd6a8bfa0b9"
      unitRef="usd">1107000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssets
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzQtMi0xLTEtMjk3MjY_3b93f5d5-8c93-46c3-9f16-7ed4d9cace78"
      unitRef="usd">75000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzQtNC0xLTEtMjk3MjY_3a3fbe03-5319-4a01-8100-d3a4126cd1eb"
      unitRef="usd">31000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzYtMi0xLTEtMjk3MjY_b5df05c5-47e4-4239-9ef0-58113ba3a144"
      unitRef="usd">1888000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzYtNC0xLTEtMjk3MjY_9b0de8a4-c248-4b47-9878-7208d6fbfcf7"
      unitRef="usd">2309000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzctMi0xLTEtMjk3MjY_a14d69ec-293d-43e8-b532-51ac9cf8ac2f"
      unitRef="usd">1855000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzctNC0xLTEtMjk3MjY_649c93e8-38f7-4d87-8cfe-c05962ff19e6"
      unitRef="usd">2172000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzgtMi0xLTEtMjk3MjY_35a72178-342c-4ce5-8e75-efe943bb46fa"
      unitRef="usd">33000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTpmYTk5ZDE0NTAyMmQ0YmUzOGZkMjY3NzE0NjBmODIzNy90YWJsZXJhbmdlOmZhOTlkMTQ1MDIyZDRiZTM4ZmQyNjc3MTQ2MGY4MjM3XzgtNC0xLTEtMjk3MjY_6462e505-d27e-43d7-b679-7bf43e8b470d"
      unitRef="usd">137000000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzItMy0xLTEtMjk3MjY_0a45a993-afb2-47fd-b668-994a0ba01ae4"
      unitRef="usd">633000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzItNC0xLTEtMjk3MjY_7bf046a1-5593-4f95-903a-2767eff7e96b"
      unitRef="usd">1715000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia2087646dc6744a28755f382fc0a83c8_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzItNS0xLTEtMjk3MjY_00b8fc58-f6ce-4798-b517-bfbe3df57d57"
      unitRef="usd">397000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzMtMy0xLTEtMjk3MjY_3b47caf8-ec46-4029-b5b3-306b109a2323"
      unitRef="usd">-52000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzMtNC0xLTEtMjk3MjY_24eb4a44-90c1-4b5a-9cc3-51398d0f35c3"
      unitRef="usd">-1089000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzMtNS0xLTEtMjk3MjY_6da90b55-0c08-4c76-ac29-df775a8c1eb0"
      unitRef="usd">151000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzQtMy0xLTEtMjk3MjY_04b335f6-677d-4117-97c8-473b66efe4ab"
      unitRef="usd">0</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzQtNC0xLTEtMjk3MjY_d1a26198-dc97-4088-95a3-8148ebe984b3"
      unitRef="usd">106000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzQtNS0xLTEtMjk3MjY_9af8d0f3-7d7e-4929-9db0-8fd9faef4d11"
      unitRef="usd">1246000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzUtMy0xLTEtMjk3MjY_976e7453-1674-45fe-8ce0-88ecd06e4555"
      unitRef="usd">48000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzUtNC0xLTEtMjk3MjY_00d39006-c330-423c-a47c-019df3918ff7"
      unitRef="usd">99000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzUtNS0xLTEtMjk3MjY_e2164dd0-d197-4830-9a9e-21359f0bc7d8"
      unitRef="usd">79000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzYtMy0xLTEtMjk3MjY_ef5ebc8f-eea6-43fd-a859-6ab65e4a04de"
      unitRef="usd">533000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzYtNC0xLTEtMjk3MjY_479ad611-3baa-430f-a9f7-c21d05df3068"
      unitRef="usd">633000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90YWJsZTo2ZjQyYzAwY2NlNDE0ODcxYWZlY2Q1ZTNhOTVmMDRjZS90YWJsZXJhbmdlOjZmNDJjMDBjY2U0MTQ4NzFhZmVjZDVlM2E5NWYwNGNlXzYtNS0xLTEtMjk3MjY_aa5b1bb8-c2aa-49c5-9a7b-b9ce1a5a600a"
      unitRef="usd">1715000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic7b9bae4686a473695740b6d4c2202f6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5Xzg4MTg_3706e12d-27e4-4fc7-a750-5f9e74d38a63"
      unitRef="usd">1481000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i81f3450daac144e3af1b7a08f181808b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5Xzg4ODY_1537b5fe-1924-479c-9214-7f640bec275a"
      unitRef="usd">633000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5254374306bb4a078614cffdec9aabe0_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzkxNDM_49238704-0945-43cd-94a7-b8a587a49e5f"
      unitRef="usd">520000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i093bf273c79847d989c1c903a61b7968_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzkxNDc_85289b90-eb9a-4441-8f9a-f42582d86a1f"
      unitRef="usd">594000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia24860d7401b457eba3d9b0be9935de4_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzkxOTA_de0344bd-ffd2-4e86-bf51-b2f5e9330df7"
      unitRef="usd">1631000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1d16f4e3e01647648ac49ed4c2dda9b8_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzkyODI_6a9b7df5-56d8-4f43-becc-e7719823f17e"
      unitRef="usd">13000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3965bff979ef4a58b0bbda03ce593630_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzkyODk_5cda9459-4be6-4275-95fd-84a3504cad01"
      unitRef="usd">39000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ieb6f78322e8048bd9abad306b8359695_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5XzMyOTg1MzQ4OTM2MjM_09441f96-a0e9-4dc4-8f00-315f415c73ae"
      unitRef="usd">84000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="if923e101b65a4eb9b85820250bc20ec0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNTcvZnJhZzplNzgxMTRhNWVkZDY0NTA0OTNkMjFmODU4ZDE3NDhkOS90ZXh0cmVnaW9uOmU3ODExNGE1ZWRkNjQ1MDQ5M2QyMWY4NThkMTc0OGQ5Xzk1MTY_18b1580c-fd32-4bfe-a76c-6dd80e95e5b7"
      unitRef="usd">-1148000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzE5NjY_790ae9a1-b0fc-403c-b29f-2ada5ce97525">Borrowings&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of long-term debt are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective Rate %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective Rate %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65% Notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.250% Notes due 2022                                                        (1B Euro 1.1311)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(1B Euro 1.2281)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% Notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73%&#160;Debentures due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.05% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.650% Notes due 2024 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(750MM Euro 1.1311)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(750MM Euro 1.2281)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50%&#160;Notes due 2024 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(500MM 1.3485 GBP )&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(500MM GBP 1.3654)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.150% Notes due 2028                                                (750MM Euro 1.1311)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(750MM Euro 1.2281)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95%&#160;Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95%&#160;Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.650% Notes due 2035                                                     (1.5B Euro 1.1311)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(1.5B Euro 1.2281)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95%&#160;Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85%&#160;Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.400%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&#160;Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.500% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.250% Notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.450% Notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,116&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34,434&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,635&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Weighted average effective rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Translation rate at January&#160;2, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Translation rate at January&#160;3, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The excess of the fair value over the carrying value of debt was $3.2 billion at the end of fiscal year 2021 and $5.4 billion at the end of fiscal year 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has access to substantial sources of funds at numerous banks worldwide. In September 2021, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10 billion, which expires on September&#160;8, 2022. Interest charged on borrowings under the credit line agreement is based on either the Term SOFR Reference Rate or other applicable market rates as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreements are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Throughout fiscal years 2021 and 2020, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $3.8 billion and $2.6 billion at the end of fiscal years 2021 and 2020, respectively. The current portion of the long term debt was $2.1 billion and $1.8 billion in 2021 and 2020, respectively, and the remainder is commercial paper and local borrowing by international subsidiaries. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The current debt balance as of January&#160;2, 2022 includes $1.6&#160;billion of commercial paper which has a weighted average interest rate of 0.11% and a weighted average maturity of approximately three months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate maturities of long-term debt obligations commencing in 2022 are:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;After 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2,131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,551&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,732&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,189&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzE5Nzc_8123259e-ef27-467e-a54b-aa114bbf207a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of long-term debt are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective Rate %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective Rate %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65% Notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.250% Notes due 2022                                                        (1B Euro 1.1311)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(1B Euro 1.2281)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% Notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73%&#160;Debentures due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.05% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.650% Notes due 2024 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(750MM Euro 1.1311)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(750MM Euro 1.2281)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50%&#160;Notes due 2024 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(500MM 1.3485 GBP )&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(500MM GBP 1.3654)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.150% Notes due 2028                                                (750MM Euro 1.1311)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(750MM Euro 1.2281)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95%&#160;Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95%&#160;Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.650% Notes due 2035                                                     (1.5B Euro 1.1311)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(1.5B Euro 1.2281)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95%&#160;Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85%&#160;Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.400%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&#160;Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.500% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.250% Notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.450% Notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,116&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34,434&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,635&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Weighted average effective rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Translation rate at January&#160;2, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Translation rate at January&#160;3, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The excess of the fair value over the carrying value of debt was $3.2 billion at the end of fiscal year 2021 and $5.4 billion at the end of fiscal year 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id163764cde774d6e9f3063f4dd81d013_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjpiOWRlNjZiYjk5OWE0OWZlODhjYTRlYzY1ZGZkMDg4NF80_0537ac07-f829-4b42-b61a-52f397cd10a9"
      unitRef="number">0.0355</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="id163764cde774d6e9f3063f4dd81d013_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQtMi0xLTEtMjk3MjY_26469b2b-2e5c-4861-913e-431e643e550f"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id163764cde774d6e9f3063f4dd81d013_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQtNC0xLTEtMjk3MjY_9c2e3dc2-de77-456d-ae79-5cafc974a738"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i5edd790b7e564a90a840e7e6dc7e272b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQtNi0xLTEtMjk3MjY_6d246e5b-189e-47e5-99c3-d1ac743da91b"
      unitRef="usd">450000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i5edd790b7e564a90a840e7e6dc7e272b_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQtOC0xLTEtMjk3MjY_6ca9534e-cbe4-4e5f-9905-6db6710319dd"
      unitRef="number">0.0367</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9a7fe279402746beaab8e640a5291e42_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzUtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjoyZGI1MzRjMjk4ZjQ0Zjg4YmRkNGVhY2E5ZDgxYjkzY180_1e545c2e-fe86-4ca4-9a69-7731a6aac4e3"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i9a7fe279402746beaab8e640a5291e42_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzUtMi0xLTEtMjk3MjY_006e0ea8-a8f9-4fa7-9d63-82ae481d6bc7"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i9a7fe279402746beaab8e640a5291e42_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzUtNC0xLTEtMjk3MjY_6a1c8bbd-6fc6-4bbe-be52-969b7dd1f1e9"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i1abb55e4e6ba4d30a5bddbb2e70b1191_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzUtNi0xLTEtMjk3MjY_dd1f503b-4647-4ceb-8eb9-bfe133e8006f"
      unitRef="usd">350000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i1abb55e4e6ba4d30a5bddbb2e70b1191_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzUtOC0xLTEtMjk3MjY_a4410427-75e0-4e46-ad80-beca549ab80d"
      unitRef="number">0.0248</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5a0bea261b2440189c3155cacb540621_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzYtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjoxMmM3NDY3NDYxYWQ0NWJjOWY5YjJhNDZmZjI4NmNhNl80_8d211c39-9328-4882-92eb-4d3ae1730742"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i5a0bea261b2440189c3155cacb540621_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzYtMi0xLTEtMjk3MjY_e4e3d791-b501-47ae-ab95-ccd4fa17631c"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i5a0bea261b2440189c3155cacb540621_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzYtNC0xLTEtMjk3MjY_f0407678-1038-4130-8d5e-30bda8ea7e1f"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i904410fb32534db6ae296a0c7b27b0ca_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzYtNi0xLTEtMjk3MjY_d400f234-b64c-4553-b9d3-551c7a6e91ab"
      unitRef="usd">999000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i904410fb32534db6ae296a0c7b27b0ca_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzYtOC0xLTEtMjk3MjY_71f54c02-47b9-422c-ae60-919bfc6dbc7e"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i69182c330b4b414e89f02252079a1706_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzctMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozODFlMWYyMmQ2NTA0MTQyYjA2M2Y5YmJlYmUzZTM5N180_a5a3527e-dd89-4cef-b53b-74256bbfa899"
      unitRef="number">0.00250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i69182c330b4b414e89f02252079a1706_I20220102"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzctMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozODFlMWYyMmQ2NTA0MTQyYjA2M2Y5YmJlYmUzZTM5N183OA_bb346d20-123a-4eb7-a917-3bab6a7f316a"
      unitRef="eur">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i69182c330b4b414e89f02252079a1706_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzctMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozODFlMWYyMmQ2NTA0MTQyYjA2M2Y5YmJlYmUzZTM5N184Nw_42579e0a-26f0-43d6-9630-0e516c7031ae"
      unitRef="number">1.1311</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if497493118ae4cde8380f3ccac17ff11_I20210103"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzctMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozODFlMWYyMmQ2NTA0MTQyYjA2M2Y5YmJlYmUzZTM5N185NQ_8df48b27-303d-4444-b89a-1cfc92b64159"
      unitRef="eur">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="if497493118ae4cde8380f3ccac17ff11_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzctMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjozODFlMWYyMmQ2NTA0MTQyYjA2M2Y5YmJlYmUzZTM5N18xMDQ_7057e40d-d0a9-411e-ac20-6c16a2cd1999"
      unitRef="number">1.2281</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt
      contextRef="i69182c330b4b414e89f02252079a1706_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzctMi0xLTEtMjk3MjY_0e361adf-2dc4-4f7c-8573-3ab7026ce2c9"
      unitRef="usd">1131000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i69182c330b4b414e89f02252079a1706_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzctNC0xLTEtMjk3MjY_f672af8c-cd18-4bc9-b6a7-334b3b5c7b94"
      unitRef="number">0.0026</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="if497493118ae4cde8380f3ccac17ff11_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzctNi0xLTEtMjk3MjY_bc1ab45e-320e-4e52-a83b-cb6f7454a176"
      unitRef="usd">1227000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="if497493118ae4cde8380f3ccac17ff11_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzctOC0xLTEtMjk3MjY_e52ca744-46a5-467b-8d7d-ab28af78b0b2"
      unitRef="number">0.0026</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i550e73b82fa342f982d286fe29ff7070_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzgtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjplZjFiNzFmMWM5ODE0MjdmODI5YjQ4NmYxM2QwYjkzOF80_ee593cad-1e15-4fcc-86b9-880073de0314"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i550e73b82fa342f982d286fe29ff7070_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzgtMi0xLTEtMjk3MjY_206538aa-2844-430f-a233-123354253a1b"
      unitRef="usd">1000000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i550e73b82fa342f982d286fe29ff7070_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzgtNC0xLTEtMjk3MjY_d81c3e7a-cbe8-4520-9fdf-1e9a5409ab48"
      unitRef="number">0.0231</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i90668084b50c4dd2ba37011a73641c3e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzgtNi0xLTEtMjk3MjY_0d30587a-2b91-4565-a443-dd6a1acb2363"
      unitRef="usd">999000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i90668084b50c4dd2ba37011a73641c3e_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzgtOC0xLTEtMjk3MjY_887bad84-512c-4702-b0a1-d4442d094f32"
      unitRef="number">0.0231</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i813c37b3fb784cd4be0ce6ef143587ab_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzktMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjplMzBkMWM2YzI3NjY0ZGM5YjQ0MzBkNDc1MmViNTJlZF80_c0588070-a92c-4fb3-9acd-5677bb1a07f2"
      unitRef="number">0.0673</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i813c37b3fb784cd4be0ce6ef143587ab_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzktMi0xLTEtMjk3MjY_1f99d57f-9f34-41db-8fdd-c99b8d3e79c9"
      unitRef="usd">250000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i813c37b3fb784cd4be0ce6ef143587ab_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzktNC0xLTEtMjk3MjY_8ef4e7e1-c7d6-4559-86fc-8fc1d1b1062b"
      unitRef="number">0.0673</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i1d636f7f126a4235961db45e96929aee_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzktNi0xLTEtMjk3MjY_26825f63-0194-4048-acd9-f8fc881261fe"
      unitRef="usd">250000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i1d636f7f126a4235961db45e96929aee_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzktOC0xLTEtMjk3MjY_b7807d09-4918-4c01-afce-f7b2ca8de177"
      unitRef="number">0.0673</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6c3b7af038464a8783ea5368d254f51b_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEwLTAtMS0xLTI5NzI2L3RleHRyZWdpb246NDgxNmE1ZjU3YjM3NGUwNGIxYTk4NjQ2NTg4NmZiODlfNA_cb946713-895e-48a4-af6b-7f1457a2d21f"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i6c3b7af038464a8783ea5368d254f51b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEwLTItMS0xLTI5NzI2_053b7757-366a-4865-b76f-39ab7931c137"
      unitRef="usd">802000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i6c3b7af038464a8783ea5368d254f51b_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEwLTQtMS0xLTI5NzI2_ccc838db-0f04-4011-a559-5f7f8a220fa8"
      unitRef="number">0.0318</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i6319e5cd14e849fb9bc1d26f55976e25_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEwLTYtMS0xLTI5NzI2_7f141bbb-759a-46a2-8c57-62edb74f612d"
      unitRef="usd">803000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i6319e5cd14e849fb9bc1d26f55976e25_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEwLTgtMS0xLTI5NzI2_09032ea9-998d-44c8-b672-184b595a0be7"
      unitRef="number">0.0317</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i46c00efd504548b0a772f17dfaaf31a4_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzExLTAtMS0xLTI5NzI2L3RleHRyZWdpb246YjJmOTU4NDMyNDllNDY2ZGI4ODk4ZjQyOTkyNDZhZGRfNA_8c713664-d274-47f4-a012-099e85757ad4"
      unitRef="number">0.0205</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i46c00efd504548b0a772f17dfaaf31a4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzExLTItMS0xLTI5NzI2_1bb57273-97ec-4905-baa7-5634ec331d1f"
      unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i46c00efd504548b0a772f17dfaaf31a4_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzExLTQtMS0xLTI5NzI2_972d5c39-7522-4834-86ae-22a924469edc"
      unitRef="number">0.0209</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="iaaad724dc80d4d528b251ff223f924c3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzExLTYtMS0xLTI5NzI2_1e50c8b5-31a4-4cbf-b49f-9c43b1fb14e8"
      unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="iaaad724dc80d4d528b251ff223f924c3_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzExLTgtMS0xLTI5NzI2_582bfe44-c6a5-4466-adb3-abcea4abd01e"
      unitRef="number">0.0209</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie52eb5fe20d44487a51c329a11aaefdb_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEyLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MmE0NTUzNDdmNTg5NDZkZDgwZmI3OTRiNmQwMzI2YzZfNA_4ee9e1ad-fa1e-418a-a461-36d5fb0c0e45"
      unitRef="number">0.00650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie52eb5fe20d44487a51c329a11aaefdb_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEyLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MmE0NTUzNDdmNTg5NDZkZDgwZmI3OTRiNmQwMzI2YzZfMjQ_878fa749-66b7-4ab2-9941-e9143b4d24a3"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="ie52eb5fe20d44487a51c329a11aaefdb_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEyLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MmE0NTUzNDdmNTg5NDZkZDgwZmI3OTRiNmQwMzI2YzZfMzQ_b2c68464-243b-4630-bccd-06f1f4c3b55a"
      unitRef="number">1.1311</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i35d501ad10624baf887280017b6b88cf_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEyLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MmE0NTUzNDdmNTg5NDZkZDgwZmI3OTRiNmQwMzI2YzZfNDI_e42e832f-9b83-4229-a2a9-10ce45e80bc7"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i35d501ad10624baf887280017b6b88cf_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEyLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MmE0NTUzNDdmNTg5NDZkZDgwZmI3OTRiNmQwMzI2YzZfNTI_62f5bf45-f4bb-4f89-a0f2-b2f1a72438c0"
      unitRef="number">1.2281</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt
      contextRef="ie52eb5fe20d44487a51c329a11aaefdb_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEyLTItMS0xLTI5NzI2_30d8e518-669c-4754-bf03-cfe97da4e810"
      unitRef="usd">847000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie52eb5fe20d44487a51c329a11aaefdb_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEyLTQtMS0xLTI5NzI2_37ed8daf-d046-4b73-b4f0-887b64569c14"
      unitRef="number">0.0068</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i35d501ad10624baf887280017b6b88cf_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEyLTYtMS0xLTI5NzI2_b96fb1f8-ab08-44dd-8348-5fdd6bd99b8a"
      unitRef="usd">919000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i35d501ad10624baf887280017b6b88cf_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEyLTgtMS0xLTI5NzI2_f5a9d1d4-b431-4a1a-a3c8-600f15512b93"
      unitRef="number">0.0068</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic325e42974444401b43cd0f7a06ca840_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEzLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MjFkNGMzNGJiM2ZkNDU2ZTg5M2I3Zjc5MDQ1ZTljNzJfNA_6878ad46-68cb-4406-8ae4-6345d7ca9fc0"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic325e42974444401b43cd0f7a06ca840_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEzLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MjFkNGMzNGJiM2ZkNDU2ZTg5M2I3Zjc5MDQ1ZTljNzJfMjQ_902a5dfe-465a-4563-a65c-5f5366c466fe"
      unitRef="gbp">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="ic325e42974444401b43cd0f7a06ca840_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEzLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MjFkNGMzNGJiM2ZkNDU2ZTg5M2I3Zjc5MDQ1ZTljNzJfMjk_77f0ad1c-944b-4bff-a79f-59dbd59191ef"
      unitRef="number">1.3485</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i23ebbe6c25ea4f94a4f7a79af3ae380c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEzLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MjFkNGMzNGJiM2ZkNDU2ZTg5M2I3Zjc5MDQ1ZTljNzJfNDI_77d9630c-bc9a-4060-8de2-e927c087fea0"
      unitRef="gbp">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i23ebbe6c25ea4f94a4f7a79af3ae380c_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEzLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MjFkNGMzNGJiM2ZkNDU2ZTg5M2I3Zjc5MDQ1ZTljNzJfNTE_fe9b2f9a-c9e2-4f8e-911c-c59ce927abf1"
      unitRef="number">1.3654</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt
      contextRef="ic325e42974444401b43cd0f7a06ca840_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEzLTItMS0xLTI5NzI2_5f497021-cf5f-47db-a4e9-810832191b09"
      unitRef="usd">672000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ic325e42974444401b43cd0f7a06ca840_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEzLTQtMS0xLTI5NzI2_a58a421e-9e26-4451-926c-2bbbe5435862"
      unitRef="number">0.0675</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i23ebbe6c25ea4f94a4f7a79af3ae380c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEzLTYtMS0xLTI5NzI2_3443b9a9-5ac0-4933-82dc-d712e2063bf6"
      unitRef="usd">679000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i23ebbe6c25ea4f94a4f7a79af3ae380c_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzEzLTgtMS0xLTI5NzI2_daa91d9c-e32b-4e6c-9534-90226fdd1eb4"
      unitRef="number">0.0675</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id03e49fef75f4ad086ee0152d3b7896f_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE0LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MWVmYTU3NGVlMmQ5NGQ5MjgwOTFlNTVkNTA5ZjAwOWVfNA_f6461db1-f07c-4a1a-996e-ed569e9e1c49"
      unitRef="number">0.02625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="id03e49fef75f4ad086ee0152d3b7896f_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE0LTItMS0xLTI5NzI2_affd0393-a064-4d43-a85d-8eb430975b01"
      unitRef="usd">749000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id03e49fef75f4ad086ee0152d3b7896f_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE0LTQtMS0xLTI5NzI2_50c76873-e50f-43d0-9be2-ae6b7bccba48"
      unitRef="number">0.0263</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i7856d21e578e46b9b1070fee609a0e37_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE0LTYtMS0xLTI5NzI2_cc963076-8840-4fa2-b278-da9bf1cb2853"
      unitRef="usd">748000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i7856d21e578e46b9b1070fee609a0e37_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE0LTgtMS0xLTI5NzI2_69940cf0-dca2-40be-8613-1f33d4d93be9"
      unitRef="number">0.0263</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ice544b21d87b4663b518b0e214c4294b_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246NjE3OTMyYWQ5ZjJmNDJiMGFjZDQ0ZGVjYTIwZTY5ODJfNA_27115619-2d8f-44f8-90b2-1bd326c33bf8"
      unitRef="number">0.0055</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ice544b21d87b4663b518b0e214c4294b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE1LTItMS0xLTI5NzI2_e88885f2-7dc9-4210-9d72-3670952611d0"
      unitRef="usd">983000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ice544b21d87b4663b518b0e214c4294b_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE1LTQtMS0xLTI5NzI2_626fd4b6-55b9-4a76-90d6-ad59211e1655"
      unitRef="number">0.0057</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ib04d55053c914695966b620bbf97d8eb_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE1LTYtMS0xLTI5NzI2_6bec302c-cbf6-40f1-8b91-674ea1ea5cfc"
      unitRef="usd">996000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib04d55053c914695966b620bbf97d8eb_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE1LTgtMS0xLTI5NzI2_0530b67e-884c-4852-9e7b-fc7369ecbea6"
      unitRef="number">0.0057</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iff56df08a53e4e72b5ba1d8f127ae174_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE2LTAtMS0xLTI5NzI2L3RleHRyZWdpb246NGVkOTQxMDlhNzZkNDRmMmI2YTFlYzE5ODA1OWM0NTFfNA_ef908604-6cab-42d2-ab0b-a76fcc20f0a6"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="iff56df08a53e4e72b5ba1d8f127ae174_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE2LTItMS0xLTI5NzI2_22098f12-b431-41e1-b7b9-d9cf731b7d88"
      unitRef="usd">1995000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="iff56df08a53e4e72b5ba1d8f127ae174_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE2LTQtMS0xLTI5NzI2_ad57faf6-378f-4444-bc96-9fdea3089a84"
      unitRef="number">0.0247</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i739863a8ea5642299f1ea5847ac97114_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE2LTYtMS0xLTI5NzI2_fc4e7fc2-2725-4b7e-8de0-e94007089e65"
      unitRef="usd">1994000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i739863a8ea5642299f1ea5847ac97114_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE2LTgtMS0xLTI5NzI2_22574c69-911a-4365-938d-09f06885fc98"
      unitRef="number">0.0247</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie1a46192ec1b4ed09aaafc90b80400a3_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE3LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDg4ZGZiOWQzMTM2NGQxM2JmMzNhY2FjMmM4YmY4YWJfNA_2e4e56c2-7c15-4dca-9091-05154e15c270"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ie1a46192ec1b4ed09aaafc90b80400a3_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE3LTItMS0xLTI5NzI2_5b5d2a3c-0f02-4aa6-ae3c-5fb2770742ee"
      unitRef="usd">978000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie1a46192ec1b4ed09aaafc90b80400a3_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE3LTQtMS0xLTI5NzI2_93feae64-1758-4b4d-b6d1-69fbe51e964c"
      unitRef="number">0.0296</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i1831bd89995549639d1c19d6d216a958_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE3LTYtMS0xLTI5NzI2_2795afc7-b667-4188-9c5f-45aadf61add8"
      unitRef="usd">997000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i1831bd89995549639d1c19d6d216a958_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE3LTgtMS0xLTI5NzI2_2f1249f0-bd9c-4455-99f8-1271bd7de04f"
      unitRef="number">0.0296</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i972bf884bfea41ffb590c5a7eac07cd4_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE4LTAtMS0xLTI5NzI2L3RleHRyZWdpb246YzdlNmU0NWM4YWYwNDQ0ZWFkZDkwN2Q4ZDllODhlMDVfNA_9d192c1f-df4f-4f83-9657-ebefe9bd8c14"
      unitRef="number">0.0095</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i972bf884bfea41ffb590c5a7eac07cd4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE4LTItMS0xLTI5NzI2_95411435-7741-4f5f-9e61-7e8143b6eceb"
      unitRef="usd">1478000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i972bf884bfea41ffb590c5a7eac07cd4_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE4LTQtMS0xLTI5NzI2_d0ca83c3-b4f0-4085-88ad-6941a39de162"
      unitRef="number">0.0096</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i205cddf8beb44dffb12b506c83e24428_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE4LTYtMS0xLTI5NzI2_ea174b37-be21-4697-92cb-6fc40d4d31ee"
      unitRef="usd">1494000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i205cddf8beb44dffb12b506c83e24428_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE4LTgtMS0xLTI5NzI2_744f8dc0-5a4a-4f38-801d-b7d77d4e604f"
      unitRef="number">0.0096</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7fa3f9944b0c403d9f46170a329df816_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE5LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MzNmMTBhMjkzMjc1NGZkZTllZTQzN2VjMGNjMGZhNDNfNA_f4aafe94-3c12-4010-890d-e6595592cea1"
      unitRef="number">0.01150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7fa3f9944b0c403d9f46170a329df816_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE5LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MzNmMTBhMjkzMjc1NGZkZTllZTQzN2VjMGNjMGZhNDNfNzA_7b6e264a-06a4-49b6-86f8-c3c170f81302"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i7fa3f9944b0c403d9f46170a329df816_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE5LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MzNmMTBhMjkzMjc1NGZkZTllZTQzN2VjMGNjMGZhNDNfODA_45093f8d-a096-4d54-a6e6-1419860b92b5"
      unitRef="number">1.1311</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1c5bee0e48bf4e4099a183bdeee52392_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE5LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MzNmMTBhMjkzMjc1NGZkZTllZTQzN2VjMGNjMGZhNDNfODg_93f65a6f-9449-4bbf-bdfd-ead12c788d4b"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i1c5bee0e48bf4e4099a183bdeee52392_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE5LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MzNmMTBhMjkzMjc1NGZkZTllZTQzN2VjMGNjMGZhNDNfOTg_d39cb758-b931-4112-a36d-3b311ee36823"
      unitRef="number">1.2281</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt
      contextRef="i7fa3f9944b0c403d9f46170a329df816_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE5LTItMS0xLTI5NzI2_30b1ab15-5b62-4db6-bd93-814e6b7d6c9f"
      unitRef="usd">843000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i7fa3f9944b0c403d9f46170a329df816_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE5LTQtMS0xLTI5NzI2_a44b486f-8a11-4319-bf10-b87af154a03e"
      unitRef="number">0.0121</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i1c5bee0e48bf4e4099a183bdeee52392_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE5LTYtMS0xLTI5NzI2_c1c045b4-1a6b-4548-8fbd-cf6b0190c6d6"
      unitRef="usd">915000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i1c5bee0e48bf4e4099a183bdeee52392_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzE5LTgtMS0xLTI5NzI2_673083e3-8b32-480a-8cb8-8f3df6e25544"
      unitRef="number">0.0121</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5cf895e15ef54040bfac0247f96946b9_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIwLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MzI2YjcyMmZiODVmNDNiNmFiNGQ3ZjZkMTg0NmY2NDlfNA_08b704dc-c8c8-48d6-ba86-3f07603b4013"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i5cf895e15ef54040bfac0247f96946b9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIwLTItMS0xLTI5NzI2_c6c7f9d4-0646-4eb5-a8e6-acae8a47f895"
      unitRef="usd">1495000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i5cf895e15ef54040bfac0247f96946b9_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIwLTQtMS0xLTI5NzI2_bb04999f-2aec-46f0-bf9e-d70ebc521532"
      unitRef="number">0.0291</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i37d3ee2aa4344396b0069afab5218f8a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIwLTYtMS0xLTI5NzI2_e01f39e2-54ba-41e1-9838-99b9c70fc7e4"
      unitRef="usd">1495000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i37d3ee2aa4344396b0069afab5218f8a_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIwLTgtMS0xLTI5NzI2_0be7f4eb-7d7d-49ba-873e-d9c0a60df4f6"
      unitRef="number">0.0291</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6bbfeb41492140249fab5192b682546a_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIxLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDE4MDY0ZjU4OGEyNGMwNjk3MTEzM2IwMDllODJjMmNfNA_101cc1fd-3488-4605-bbff-048bc0c23362"
      unitRef="number">0.0695</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i6bbfeb41492140249fab5192b682546a_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIxLTItMS0xLTI5NzI2_8f7fa660-1134-4038-a77a-4d78b4a2a703"
      unitRef="usd">298000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i6bbfeb41492140249fab5192b682546a_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIxLTQtMS0xLTI5NzI2_05cdd92d-2399-48b4-b60c-5a770f0cdcf9"
      unitRef="number">0.0714</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i658f3103f74c4c7fbb7b36c491a45202_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIxLTYtMS0xLTI5NzI2_7888b1f1-51aa-4852-9c18-6cc0fd60181a"
      unitRef="usd">297000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i658f3103f74c4c7fbb7b36c491a45202_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIxLTgtMS0xLTI5NzI2_4f169ac6-bb40-4902-95ba-66a30baec286"
      unitRef="number">0.0714</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i57a48838d3bc409fbed2cc1936c123cd_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIyLTAtMS0xLTI5NzI2L3RleHRyZWdpb246OWZhM2FhODdiNjRjNGYzNWI5Njk4MzlmZDhlMzdjNjRfNA_9d984f40-323f-49c0-ba1b-6e9c0d30ef22"
      unitRef="number">0.0130</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i57a48838d3bc409fbed2cc1936c123cd_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIyLTItMS0xLTI5NzI2_814c60be-101a-454e-b5b3-70a6e077b6bd"
      unitRef="usd">1723000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i57a48838d3bc409fbed2cc1936c123cd_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIyLTQtMS0xLTI5NzI2_15f11666-f772-490f-87f6-016b84ef1697"
      unitRef="number">0.0130</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i0408738fa2104741b459f57515ad3ab1_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIyLTYtMS0xLTI5NzI2_20dbf01c-3f3c-4f9c-b58f-318404ccaed9"
      unitRef="usd">1743000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i0408738fa2104741b459f57515ad3ab1_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIyLTgtMS0xLTI5NzI2_ddacce34-593f-46a5-931a-3b6fa7a74a95"
      unitRef="number">0.0130</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i17953ea1893e452cb3c1c9dd6916994c_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIzLTAtMS0xLTI5NzI2L3RleHRyZWdpb246YWNkMDlmY2Q1MzFiNDY4MzkyMmM1NTgwMGY1Yzk3YTZfNA_609450f0-6f5a-4d0f-9dff-ad5aad0beb1a"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i17953ea1893e452cb3c1c9dd6916994c_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIzLTItMS0xLTI5NzI2_88634876-3c7a-43a3-8bda-6583d4685145"
      unitRef="usd">498000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i17953ea1893e452cb3c1c9dd6916994c_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIzLTQtMS0xLTI5NzI2_a12933f4-e6a3-4ed0-8e55-d815003303e6"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i2c0880f1340c45b89ff33b5be547b0ce_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIzLTYtMS0xLTI5NzI2_2b368ffe-eee4-429c-9f44-1743bfa360e9"
      unitRef="usd">498000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i2c0880f1340c45b89ff33b5be547b0ce_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzIzLTgtMS0xLTI5NzI2_74d6f659-db3f-4be1-a995-337c9b73281a"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2976154beffb47c4be5a474bc8db9894_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI0LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MzU2MWQ0ZTMxODJiNDcwZTgxOWI4NDAwYzk4ZTliY2JfNA_d264bbf9-cb95-4f88-b470-3798bfd1ba32"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i2976154beffb47c4be5a474bc8db9894_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI0LTItMS0xLTI5NzI2_274401ab-373f-4a8b-bcaf-69b851c930fd"
      unitRef="usd">854000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i2976154beffb47c4be5a474bc8db9894_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI0LTQtMS0xLTI5NzI2_04735a42-de0f-46ad-b3ca-a9e2e8fcd8e8"
      unitRef="number">0.0424</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ic5d27e50b0964bbcb629a108b11c7420_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI0LTYtMS0xLTI5NzI2_afc1d9f2-bc77-46e5-bd51-2b81ff763b90"
      unitRef="usd">855000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ic5d27e50b0964bbcb629a108b11c7420_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI0LTgtMS0xLTI5NzI2_4460382b-bf17-49ef-9d29-9f792582a700"
      unitRef="number">0.0424</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iae7e9316990b44f98989c64c67ff0c10_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246NjFjYzg0NTEyMDU3NGEyMGE2NDc3OTE0MjdlZDIzMGJfNA_b1cd2f48-2a2c-49c9-8fa5-bf37a49f3227"
      unitRef="number">0.01650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iae7e9316990b44f98989c64c67ff0c10_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246NjFjYzg0NTEyMDU3NGEyMGE2NDc3OTE0MjdlZDIzMGJfNzU_26ba0104-8cf4-4fd8-8e42-5c4bb948f191"
      unitRef="eur">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="iae7e9316990b44f98989c64c67ff0c10_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246NjFjYzg0NTEyMDU3NGEyMGE2NDc3OTE0MjdlZDIzMGJfODQ_a61bd701-592c-46e6-ba8f-a4d002e212ec"
      unitRef="number">1.1311</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2685a9e688f94a75a231df74311feb24_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246NjFjYzg0NTEyMDU3NGEyMGE2NDc3OTE0MjdlZDIzMGJfOTI_cf4cca1f-3e14-47bc-be8a-70a1e4e66005"
      unitRef="eur">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i2685a9e688f94a75a231df74311feb24_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246NjFjYzg0NTEyMDU3NGEyMGE2NDc3OTE0MjdlZDIzMGJfMTAx_99a38f65-5aaf-4381-8597-cc47fda0afa9"
      unitRef="number">1.2281</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt
      contextRef="iae7e9316990b44f98989c64c67ff0c10_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI1LTItMS0xLTI5NzI2_a1b1d334-37b2-41a3-9bbd-8b9396066402"
      unitRef="usd">1683000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="iae7e9316990b44f98989c64c67ff0c10_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI1LTQtMS0xLTI5NzI2_04dc27ae-5b98-42c2-a943-805ed0d26fbe"
      unitRef="number">0.0168</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i2685a9e688f94a75a231df74311feb24_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI1LTYtMS0xLTI5NzI2_762f7a96-9625-4c18-becc-d9416f848a5a"
      unitRef="usd">1827000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i2685a9e688f94a75a231df74311feb24_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI1LTgtMS0xLTI5NzI2_3114717a-0b7b-4168-92e3-7da7fd801315"
      unitRef="number">0.0168</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie17e8d053df0468983d5b9c5221888e5_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI2LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDI2ZTlkOTAzMzAxNDI1Yjk3MDNhMWVjYmNmYjAzNTVfNA_5d324507-ede2-4b59-b500-aa9ee3577692"
      unitRef="number">0.0355</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ie17e8d053df0468983d5b9c5221888e5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI2LTItMS0xLTI5NzI2_fd5ace8a-f9ea-4c7f-88f3-5d07960df109"
      unitRef="usd">974000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie17e8d053df0468983d5b9c5221888e5_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI2LTQtMS0xLTI5NzI2_cb0f7178-2ff6-4d98-8562-49b2f1233011"
      unitRef="number">0.0359</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="if74440cec8d14911a94f8cbf380782ef_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI2LTYtMS0xLTI5NzI2_ec1c53df-8929-4b67-8ea3-232a30b1c836"
      unitRef="usd">989000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="if74440cec8d14911a94f8cbf380782ef_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI2LTgtMS0xLTI5NzI2_0b211b24-f333-44ec-ae98-44e8075c1066"
      unitRef="number">0.0359</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0adb5ffb62d14519a2797379c107d86e_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI3LTAtMS0xLTI5NzI2L3RleHRyZWdpb246OGI4MDM0ZjY2ZmRhNDIwNzk0ZWY2ZmFkMGU1OGJkY2JfNA_d96b26cc-abce-46c5-b18a-57eea0a27f6b"
      unitRef="number">0.0595</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i0adb5ffb62d14519a2797379c107d86e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI3LTItMS0xLTI5NzI2_a28daccf-8e8a-4311-94a6-ba8d465fa393"
      unitRef="usd">993000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i0adb5ffb62d14519a2797379c107d86e_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI3LTQtMS0xLTI5NzI2_5e876ea4-987f-4e28-a829-30a15864be3c"
      unitRef="number">0.0599</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i47b9c1e7af3946a08254176836ec29a7_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI3LTYtMS0xLTI5NzI2_2da710a2-c94a-47d6-ba63-7175a4d23070"
      unitRef="usd">992000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i47b9c1e7af3946a08254176836ec29a7_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI3LTgtMS0xLTI5NzI2_8f17b495-639b-4dcb-b6fa-a68b03e8f7aa"
      unitRef="number">0.0599</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3ed9c4f37ce1466fa53ccf042656f5d6_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI4LTAtMS0xLTI5NzI2L3RleHRyZWdpb246ZWI1M2VhMDdiNjFjNDBkNGIyZGEyZGE3MWE4OTIxZTlfNA_ed3eb9ea-2b08-420c-9aea-4c108548a4e0"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i3ed9c4f37ce1466fa53ccf042656f5d6_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI4LTItMS0xLTI5NzI2_c41b7f6e-f741-4af7-b2ab-3be45f8f9278"
      unitRef="usd">1475000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i3ed9c4f37ce1466fa53ccf042656f5d6_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI4LTQtMS0xLTI5NzI2_3ca8666e-56de-49b2-83e9-5b7402863d76"
      unitRef="number">0.0364</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ia83c020a1a4849fb88e0231815c8866d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI4LTYtMS0xLTI5NzI2_817ee777-d9ee-41df-8df5-e94951d96f51"
      unitRef="usd">1488000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ia83c020a1a4849fb88e0231815c8866d_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI4LTgtMS0xLTI5NzI2_7b98b900-5121-405d-9fea-4b446602c157"
      unitRef="number">0.0364</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0118c5eed732427f9cf06f31486fc01c_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI5LTAtMS0xLTI5NzI2L3RleHRyZWdpb246NjliYzgzYmU4MDRlNGE5NGIzM2JjMmQ4ZTJkZGI2YWVfNA_a97e2e97-37fb-455b-ab7e-e43adde303a1"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i0118c5eed732427f9cf06f31486fc01c_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI5LTItMS0xLTI5NzI2_213b4408-41ae-488b-8539-57d27f6c1312"
      unitRef="usd">696000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i0118c5eed732427f9cf06f31486fc01c_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI5LTQtMS0xLTI5NzI2_34e1e457-0aa2-4e39-974c-c8c33aafb6f6"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ife7c692d97564c858b7b4ed1c803b286_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI5LTYtMS0xLTI5NzI2_17cb4c3a-0deb-430f-81c8-6830d39ea673"
      unitRef="usd">696000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ife7c692d97564c858b7b4ed1c803b286_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzI5LTgtMS0xLTI5NzI2_5b2f0722-0229-4625-a32a-417baea73074"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic38bc0786162462d9877b064a6a205e6_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMwLTAtMS0xLTI5NzI2L3RleHRyZWdpb246NDM1YTVmYTIxYjY0NDY1MWJjYmZiOWM5ZjIwM2M4Y2NfNA_bf9b5672-738c-4d8a-b058-8339378d6e84"
      unitRef="number">0.03400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ic38bc0786162462d9877b064a6a205e6_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMwLTItMS0xLTI5NzI2_dd1dc6cc-0287-469e-9ea9-0f61dbe00c1f"
      unitRef="usd">992000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ic38bc0786162462d9877b064a6a205e6_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMwLTQtMS0xLTI5NzI2_67326c83-6ef2-4f2b-9aa9-95eec8ca74a5"
      unitRef="number">0.0342</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i726718a28d4d4e549a41a17182d08fe6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMwLTYtMS0xLTI5NzI2_f63163b5-0108-4c1e-94a2-6e0b953c88d3"
      unitRef="usd">991000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i726718a28d4d4e549a41a17182d08fe6_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMwLTgtMS0xLTI5NzI2_ceb7d8e9-04ea-458a-86c4-124ecc84e916"
      unitRef="number">0.0342</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i53a8fedc553f4f0f9de5d0a709173803_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMxLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MzQ4MGQzMzRjNzFkNDJlNThmM2E5ZTFhNTVlYzljZmFfNA_737e7da7-eb3b-47a9-839b-afbad5ba4f1d"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i53a8fedc553f4f0f9de5d0a709173803_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMxLTItMS0xLTI5NzI2_9ddb1caf-df8f-4d07-b910-150d34da82c0"
      unitRef="usd">540000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i53a8fedc553f4f0f9de5d0a709173803_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMxLTQtMS0xLTI5NzI2_848a6c05-3dc1-444d-af48-94970836f167"
      unitRef="number">0.0463</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i62b1dedd1b83419bb98c00b29d60b882_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMxLTYtMS0xLTI5NzI2_00427609-5f3e-4ebb-9e6c-b661305b5c07"
      unitRef="usd">539000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i62b1dedd1b83419bb98c00b29d60b882_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMxLTgtMS0xLTI5NzI2_7c02dc41-21ac-4c03-a15f-a4b4a105c51e"
      unitRef="number">0.0463</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8bd1c41b5d0d42c69a6f96b89a46e668_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMyLTAtMS0xLTI5NzI2L3RleHRyZWdpb246YWExNzhjYzU2NWJkNDY5MTkyZjEyNDZjMGRkMGZhNWZfNA_0ee6c613-51d0-4f81-abc4-721cfbe8e1d3"
      unitRef="number">0.0210</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i8bd1c41b5d0d42c69a6f96b89a46e668_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMyLTItMS0xLTI5NzI2_981979ee-7bbf-4c7b-9a43-d82d3d02db87"
      unitRef="usd">974000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i8bd1c41b5d0d42c69a6f96b89a46e668_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMyLTQtMS0xLTI5NzI2_da22082c-9cc0-4f0b-a9bf-92ffbaad34fe"
      unitRef="number">0.0214</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ib5eb48543498494ca45ded9c606d3d15_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMyLTYtMS0xLTI5NzI2_1426d40e-1321-449c-a88e-5ec17b0481c1"
      unitRef="usd">986000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib5eb48543498494ca45ded9c606d3d15_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMyLTgtMS0xLTI5NzI2_edbd0288-23c2-4c09-bd66-56337228fc23"
      unitRef="number">0.0214</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib69f13bfa815433e85d3e00eef71fedf_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMzLTAtMS0xLTI5NzI2L3RleHRyZWdpb246MjczNzg5MTZlMGMwNGZiZThmZDExY2NiYTAzZjg1MWNfNA_57bc6cb3-3097-4c76-b981-3f4bba0a3e26"
      unitRef="number">0.0485</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ib69f13bfa815433e85d3e00eef71fedf_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMzLTItMS0xLTI5NzI2_ef266dc5-6c48-451b-8c46-54d093b48330"
      unitRef="usd">297000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib69f13bfa815433e85d3e00eef71fedf_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMzLTQtMS0xLTI5NzI2_e2eb425b-60de-44a3-bb3b-c1b58e100b4e"
      unitRef="number">0.0489</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ie8d56c9e88f342bea407c38d6cd7e55f_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMzLTYtMS0xLTI5NzI2_696e8612-7418-4b14-855f-469068a3c523"
      unitRef="usd">297000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie8d56c9e88f342bea407c38d6cd7e55f_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzMzLTgtMS0xLTI5NzI2_b6f4df65-a741-4e2a-863a-91a995fec589"
      unitRef="number">0.0489</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icfa4a27c5acc457f8dfe7f024890432d_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM0LTAtMS0xLTI5NzI2L3RleHRyZWdpb246NDgyZTVjNGI0ZmQ4NDUxM2I4OWQ3NWMwODZlOTIyZmRfNA_44f92617-dd22-44ee-b973-e645a29ad68d"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="icfa4a27c5acc457f8dfe7f024890432d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM0LTItMS0xLTI5NzI2_e02d0f48-9bde-4150-a46e-64990631a51e"
      unitRef="usd">496000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="icfa4a27c5acc457f8dfe7f024890432d_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM0LTQtMS0xLTI5NzI2_2e0eb975-5427-49ba-8df7-1f49fa6ac989"
      unitRef="number">0.0452</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="if36ddad29b164d53899d8ee23f080abd_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM0LTYtMS0xLTI5NzI2_349a4f0e-ad7d-4fce-b4b8-81d7999defa5"
      unitRef="usd">496000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="if36ddad29b164d53899d8ee23f080abd_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM0LTgtMS0xLTI5NzI2_4b80858e-1260-435f-93d1-87efd2a382bb"
      unitRef="number">0.0452</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i11c0c665fc394565a535f0b2c5c1317b_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM1LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MzVkODZhNmIxNmYwNGI1NTkyOGQwZjE0ZjgxYzlmMDBfNA_64d789b9-c3c3-4dbf-8cac-dab462afdcd3"
      unitRef="number">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i11c0c665fc394565a535f0b2c5c1317b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM1LTItMS0xLTI5NzI2_f745af9a-ca7f-4521-a87b-db6ecc4dbfe6"
      unitRef="usd">1975000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i11c0c665fc394565a535f0b2c5c1317b_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM1LTQtMS0xLTI5NzI2_7fe4ef59-d79c-4368-9707-edf59c5d9b48"
      unitRef="number">0.0374</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i54250135a56c4cd5be1d66d5f63431cf_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM1LTYtMS0xLTI5NzI2_bc43e013-37a4-4497-8313-e17930537050"
      unitRef="usd">1974000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i54250135a56c4cd5be1d66d5f63431cf_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM1LTgtMS0xLTI5NzI2_36bd475c-bcd6-4f6e-8026-5313abbf2c7e"
      unitRef="number">0.0374</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i50afe1be5edb4180890a7b5b27e4d27a_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM2LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MTgzOTgwZjQ0MTc1NGUyNmFkODg4YjkzNzFlNjkxYTRfNA_930a78f0-794a-4208-b51f-cc9d0ca25855"
      unitRef="number">0.0375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i50afe1be5edb4180890a7b5b27e4d27a_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM2LTItMS0xLTI5NzI2_4e7041df-0077-48ed-867f-b19d8d6ea3be"
      unitRef="usd">971000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i50afe1be5edb4180890a7b5b27e4d27a_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM2LTQtMS0xLTI5NzI2_e24dc118-e450-4c2b-bd8d-a2b881c02733"
      unitRef="number">0.0376</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i3faf3f90111144d7a940a9a2c71d768d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM2LTYtMS0xLTI5NzI2_64eeca44-31bf-4a32-bde9-4ed5e19be5c5"
      unitRef="usd">991000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i3faf3f90111144d7a940a9a2c71d768d_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM2LTgtMS0xLTI5NzI2_9d66ef39-cff2-4b5c-8620-46c1d2534e25"
      unitRef="number">0.0376</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6e28fa051d454297b4accf2668e5f29a_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM3LTAtMS0xLTI5NzI2L3RleHRyZWdpb246MDUyMGQ0ZDJiZTE3NDBmMjhlMzA5OWRmZjk4ZWVjMTdfNA_f8abb625-a4dc-4ab3-a394-8bd4a721d6e9"
      unitRef="number">0.03500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i6e28fa051d454297b4accf2668e5f29a_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM3LTItMS0xLTI5NzI2_3662dd74-6776-426f-ac1b-ef7589e11871"
      unitRef="usd">743000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i6e28fa051d454297b4accf2668e5f29a_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM3LTQtMS0xLTI5NzI2_bae24664-9711-4548-9dd1-39c912bf1480"
      unitRef="number">0.0352</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="icbd71c42f6294b2fbf205f288d70c25a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM3LTYtMS0xLTI5NzI2_836f039c-3b86-49d5-98cd-a605431bbd59"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="icbd71c42f6294b2fbf205f288d70c25a_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM3LTgtMS0xLTI5NzI2_2020780f-6987-439d-9149-c59e37cbf92a"
      unitRef="number">0.0352</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i168b47008a8445648dc5777fadae1587_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM4LTAtMS0xLTI5NzI2L3RleHRyZWdpb246ODA2MmE0ZGI5NzNhNDdlNWJmNTAyZDFmN2ZmOWMzMzVfNA_9061a763-3a5c-4492-83d3-83d4032d67ec"
      unitRef="number">0.02250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i168b47008a8445648dc5777fadae1587_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM4LTItMS0xLTI5NzI2_c125b8b1-adaa-4768-88ad-f9bc60964518"
      unitRef="usd">983000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i168b47008a8445648dc5777fadae1587_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM4LTQtMS0xLTI5NzI2_fc6fc105-ec57-4e01-966c-7765c5c77d57"
      unitRef="number">0.0229</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="id7aefbac28e2470ea9d6063671ef8da1_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM4LTYtMS0xLTI5NzI2_ad75a7bc-f27d-4108-81b7-7ce377af477f"
      unitRef="usd">984000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id7aefbac28e2470ea9d6063671ef8da1_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM4LTgtMS0xLTI5NzI2_9ff19ec8-d22e-47cf-b269-89393a48082f"
      unitRef="number">0.0229</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i03664ec5ebbe4d8da845ff31701a77f2_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM5LTAtMS0xLTI5NzI2L3RleHRyZWdpb246OTUxN2JhNjcwMTczNGZjMmJmODRmNDdmZDllYjg3YzZfNA_066a7fce-5f34-450d-8733-a9d33f74dcd0"
      unitRef="number">0.02450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i03664ec5ebbe4d8da845ff31701a77f2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM5LTItMS0xLTI5NzI2_ae11c634-ce1b-4622-8319-6d460c6617a5"
      unitRef="usd">1222000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i03664ec5ebbe4d8da845ff31701a77f2_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM5LTQtMS0xLTI5NzI2_28b96e9f-aa88-41c2-9bf3-69fc9aea39fe"
      unitRef="number">0.0249</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="idd4a9a1de87b4f128a0bb747c7a11f74_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM5LTYtMS0xLTI5NzI2_39baf271-d61b-4d71-bdf8-cc95d39ca102"
      unitRef="usd">1228000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="idd4a9a1de87b4f128a0bb747c7a11f74_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzM5LTgtMS0xLTI5NzI2_f20c00df-5025-4332-bc56-eab55304a6fd"
      unitRef="number">0.0249</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i6aa10255024e47998e73466dc7e568bc_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQwLTItMS0xLTI5NzI2_c464fc4c-0351-45b6-a72f-ba21be2ec415"
      unitRef="usd">7000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i6aa10255024e47998e73466dc7e568bc_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQwLTQtMS0xLTI5NzI2_16329aa6-0b8c-4ff3-9696-7c0626e062be"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="iec495cbb0c2c4cedbd4600d7d89a94d8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQwLTYtMS0xLTI5NzI2_b2555111-085e-4a25-be20-f8a7776b89a3"
      unitRef="usd">7000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="iec495cbb0c2c4cedbd4600d7d89a94d8_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQwLTgtMS0xLTI5NzI2_37e5525d-d1f9-4ae2-8327-a367f8877db0"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQxLTItMS0xLTI5NzI2_6b34250e-ee3b-4b63-898b-378507507eab"
      unitRef="usd">32116000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQxLTQtMS0xLTI5NzI2_6d5029c7-c6a1-48cb-8173-f3b76333de6e"
      unitRef="number">0.0289</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQxLTYtMS0xLTI5NzI2_ad0ba312-c7c6-4950-846a-e098b0b210e4"
      unitRef="usd">34434000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQxLTgtMS0xLTI5NzI2_f5039092-52cc-4075-8249-5dd70d3fef3a"
      unitRef="number">0.0285</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtCurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQyLTItMS0xLTI5NzI2_e90d86ec-d20b-4d96-ba31-fabf3f345bda"
      unitRef="usd">2131000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQyLTYtMS0xLTI5NzI2_19f25162-05e6-4f6d-9894-c88fc4d489fa"
      unitRef="usd">1799000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQzLTItMS0xLTI5NzI2_7a4699a8-0981-40e3-9972-ba00a7d5a0c4"
      unitRef="usd">29985000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTphZjgzODk0NzYwZWM0OTYzYWUwYjlkNTYwZGExNGI2ZC90YWJsZXJhbmdlOmFmODM4OTQ3NjBlYzQ5NjNhZTBiOWQ1NjBkYTE0YjZkXzQzLTYtMS0xLTI5NzI2_84905b47-8dd0-4d00-a358-5771af89fd78"
      unitRef="usd">32635000000</us-gaap:LongTermDebtNoncurrent>
    <jnj:ExcessOfFairValueOverCarryingValueOfDebt
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzIxNg_de18f223-4462-4abe-9543-42241fce1d66"
      unitRef="usd">3200000000</jnj:ExcessOfFairValueOverCarryingValueOfDebt>
    <jnj:ExcessOfFairValueOverCarryingValueOfDebt
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzI1Mg_b5f95211-b068-418a-a049-44f9ff39f55f"
      unitRef="usd">5400000000</jnj:ExcessOfFairValueOverCarryingValueOfDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ied2f6ed477eb4ce6ad7d7bfaa6f716d3_I20210930"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzczNA_d57be58f-d52d-4649-aa53-02cc87edc006"
      unitRef="usd">10000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtCurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzEzMDE_1337476f-6544-463b-84a4-0aa16a83a7dc"
      unitRef="usd">3800000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzEwOTk1MTE2MzExOTE_30730433-bd12-46a4-81d4-bae87093cb2c"
      unitRef="usd">2600000000</us-gaap:DebtCurrent>
    <us-gaap:LongTermCommercialPaperCurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzEzNDM_f66fda4e-db8e-4431-8c5c-d7fdb380718d"
      unitRef="usd">2100000000</us-gaap:LongTermCommercialPaperCurrent>
    <us-gaap:LongTermCommercialPaperCurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzE3MzQ_09e10629-77f5-4df8-ae39-0af1e97b0f5d"
      unitRef="usd">1800000000</us-gaap:LongTermCommercialPaperCurrent>
    <us-gaap:ShortTermBorrowings
      contextRef="i64bd5e8b71f34e13ac4ffb87991525cb_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzU0OTc1NTgxNDMzMzY_126f4962-d2c9-4f4f-ac7e-52e615dc961d"
      unitRef="usd">1600000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i64bd5e8b71f34e13ac4ffb87991525cb_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzU0OTc1NTgxNDMzNTQ_03378004-e32c-495c-98b9-9486a1b1ca0d"
      unitRef="number">0.0011</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentTerm
      contextRef="ie196b853653742808afbef735bb258c5_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzU0OTc1NTgxNDMzODU_fdfcf27d-d47f-47a6-a1ad-427c0e8f2af1">P3M</us-gaap:DebtInstrumentTerm>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90ZXh0cmVnaW9uOjRlMGM1NDA2OTQ2NTRmYzU4NzliNzM0NjE1MDhhZmMzXzE5NzQ_0d9db74e-88ad-41f1-8537-92592e5f76c7">&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate maturities of long-term debt obligations commencing in 2022 are:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;After 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2,131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,551&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,732&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,189&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTpjMDkxMGQ0MjA0N2I0OTdmOTgyZjgzNjZlNzJjYWRkZC90YWJsZXJhbmdlOmMwOTEwZDQyMDQ3YjQ5N2Y5ODJmODM2NmU3MmNhZGRkXzItMC0xLTEtMjk3MjY_9a32ed94-136e-473b-98e7-12bcc3da1602"
      unitRef="usd">2131000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTpjMDkxMGQ0MjA0N2I0OTdmOTgyZjgzNjZlNzJjYWRkZC90YWJsZXJhbmdlOmMwOTEwZDQyMDQ3YjQ5N2Y5ODJmODM2NmU3MmNhZGRkXzItMi0xLTEtMjk3MjY_0e989ae5-b921-4548-b6fe-8631fe82012c"
      unitRef="usd">1551000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTpjMDkxMGQ0MjA0N2I0OTdmOTgyZjgzNjZlNzJjYWRkZC90YWJsZXJhbmdlOmMwOTEwZDQyMDQ3YjQ5N2Y5ODJmODM2NmU3MmNhZGRkXzItNC0xLTEtMjk3MjY_a7dd77cc-3728-4a11-a2a7-97c78f2d5b7f"
      unitRef="usd">1518000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTpjMDkxMGQ0MjA0N2I0OTdmOTgyZjgzNjZlNzJjYWRkZC90YWJsZXJhbmdlOmMwOTEwZDQyMDQ3YjQ5N2Y5ODJmODM2NmU3MmNhZGRkXzItNi0xLTEtMjk3MjY_72b0b7d7-dfb3-4da1-a447-b79bfe2c4363"
      unitRef="usd">1732000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTpjMDkxMGQ0MjA0N2I0OTdmOTgyZjgzNjZlNzJjYWRkZC90YWJsZXJhbmdlOmMwOTEwZDQyMDQ3YjQ5N2Y5ODJmODM2NmU3MmNhZGRkXzItOC0xLTEtMjk3MjY_d4295256-5255-4c66-92c3-f203095f0f56"
      unitRef="usd">1995000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjMvZnJhZzo0ZTBjNTQwNjk0NjU0ZmM1ODc5YjczNDYxNTA4YWZjMy90YWJsZTpjMDkxMGQ0MjA0N2I0OTdmOTgyZjgzNjZlNzJjYWRkZC90YWJsZXJhbmdlOmMwOTEwZDQyMDQ3YjQ5N2Y5ODJmODM2NmU3MmNhZGRkXzItMTAtMS0xLTI5NzI2_b1bded58-c4fd-48d5-865c-01a2927405a8"
      unitRef="usd">23189000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNTc1_8cfd6906-41f5-43a9-a636-df54f29ac251">Income Taxes&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for taxes on income consists of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.003%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Currently payable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total currently payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Provision for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,783&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A comparison of income tax expense at the U.S.&#160;statutory rate of 21% in fiscal years 2021, 2020 and 2019, to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings before taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax rates:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxes on international income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefits from loss on capital assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefits on share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TCJA and related impacts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflects the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2021 amounts include the reorganization of international subsidiaries; the 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. The 2021 amounts include the reorganization of international subsidiaries; the 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, both of which is further described below. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3) Represents impact of adjustments to balances originally recorded as part of the 2017 TCJA provisional tax charge. Further information provided below. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fiscal year 2021 tax rate decreased by 2.5% compared to the fiscal year 2020 tax rate, which was primarily driven by the following items. In fiscal year 2021, the Company reorganized the ownership structure of certain wholly-owned international subsidiaries. As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with applicable local regulations. The net impact of this restructuring was approximately $0.6&#160;billion net benefit or 2.7% benefit to the Company&#x2019;s annual effective tax rate, comprised of the following items: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;approximately $2.3&#160;billion of local deferred tax assets to record the remeasurement of the tax basis of these assets to fair value, this benefit has been reflected as &#x201c;International Operations&#x201d; on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;approximately $1.7&#160;billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of these deferred tax assets. This expense has been reflected as &#x201c;U.S. tax on international income&#x201d; on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Also, in the fiscal fourth quarter of 2021, the Company recognized a loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2021 tax rate by approximately 1.3% which is reflected as a &#x201c;Tax benefits from loss on capital assets&#x201d; on the effective tax rate reconciliation. Additionally other fiscal 2021 impacts to the rate were primarily driven by litigation and acquisition related items as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the Company accrued additional legal expenses, of approximately $1.6&#160;billion for talc at an effective tax rate of 23.5% and $0.8&#160;billion for Risperdal settlements at an effective tax rate of 16.4% (See Note 19 to the Consolidated Financial Statements for more details).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the Company recorded a partial IPR&amp;amp;D charge of $0.9&#160;billion for the Ottava intangible asset (acquired with the Auris Health acquisition in 2019) at an effective rate of 22.4% (See Notes 5 and 18 to the Consolidated Financial Statements for more details).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The fiscal year 2020 tax rate decreased by 1.9% compared to the fiscal year 2019 tax rate. which was primarily driven by the following items. In fiscal year 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF) which became effective on January 1, 2020. The Federal transitional provisions of TRAF allow companies, under certain conditions, to adjust the tax basis in certain assets to fair value (i.e., &#x201c;step-up&#x201d;) to be depreciated and amortized resulting in an incremental Swiss tax deduction over the transitional period. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;TRAF also provides for parameters which enable the Swiss cantons to establish localized tax rates and regulations for companies. The new cantonal tax parameters include favorable tax benefits for patents and additional research and development &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;tax deductions. The cantonal transitional provisions of TRAF allowed companies to elect either 1) tax basis step-up similar to the Federal transition benefit or 2) alternative statutory tax rate for a period not to exceed 5 years. The Company currently has operations located in various Swiss cantons. During the fiscal year 2019, as described in further detail below, the Company recorded the impacts of the TRAF that were enacted in that period. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;During the fiscal year 2020, the final canton where the Company maintains significant operations enacted TRAF legislation. Additionally, the Company received rulings from the Swiss Federal and cantonal tax authorities in the remaining jurisdictions where it has significant operations. These rulings resulted in the Company revising its estimate on the tax basis adjustment (i.e., &#x201c;step-up&#x201d;) for its assets and as a result, the Company recorded additional deferred tax benefits in 2020. The Company recognized a net benefit in the fiscal year 2020 for Swiss Tax Reform of approximately $0.4&#160;billion or 2.6% benefit to the Company&#x2019;s annual effective tax rate, comprised of the following items: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;approximately $0.3 billion tax benefit relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred in the fiscal year 2020; this benefit has been reflected as &#x201c;International Operations&#x201d; on the Company&#x2019;s effective tax rate reconciliation. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;a $450 million deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company&#x2019;s Swiss subsidiaries&#x2019; assets as described above; this benefit has been reflected as &#x201c;International Operations&#x201d; on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;approximately $0.3 billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities in the fiscal year 2020. This benefit has been reflected as &#x201c;U.S. tax on international income&#x201d; on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company does not expect to receive future rulings regarding the transitional provisions of TRAF. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Also, in the fiscal year 2020, the Company recognized a capital loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2020 tax rate by approximately 1.2% which is reflected as a &#x201c;Tax benefits from loss on capital assets&#x201d; on the effective tax rate reconciliation. In addition, in the fiscal year 2020, the Company had lower income in higher tax jurisdictions, primarily driven by:       &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the impact of the accrual of litigation costs related to talc for $4.0&#160;billion which reduced the U.S. earnings before taxes at an effective tax rate of 23.5%;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the accrual of additional legal costs, including an additional $1.0&#160;billion associated with a revised agreement in principle to settle opioid litigation at an effective tax rate of 21.4% &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company also reduced the contingent consideration liability related to the Auris Health acquisition (see Note 18) and reversed of some of its unrecognized tax benefits due to the completion of several years of tax examinations in certain jurisdictions during the fiscal year 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In fiscal year 2019, the Company reorganized the ownership structure of certain wholly-owned international subsidiaries in the fiscal fourth quarter of 2019, which resulted in a reduction of certain withholding and local taxes that it had previously recognized as part of the provisional Tax Cuts and Jobs Act (TCJA) tax charge in the fiscal year 2017 and finalized in the fiscal year 2018. Following the completion of this restructuring and approval by the applicable local authorities, the Company reversed a deferred tax liability of  $0.6 billion and a related deferred tax asset of $0.2 billion for U.S. foreign tax credits, for a net deferred tax benefit of $0.4 billion decreasing the annual effective tax rate by 2.2%. This benefit has been reflected as &#x201c;TCJA and related impacts&#x201d; on the Company&#x2019;s effective tax rate reconciliation. The following items also impacted the fiscal year 2019 effective tax rate: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The impact of the agreement in principle to settle opioid litigation for $4 billion (see Note 19 to the Consolidated Financial Statements) which reduced the U.S. earnings before taxes at an effective tax rate of 23.5% and decreased the Company&#x2019;s annual effective tax rate by approximately 2.1%. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In December of fiscal year 2019, the U.S. Treasury issued final foreign tax credit regulations, which resulted in the Company revising the amount of foreign tax credits that were initially recorded in the fiscal year 2017 as part of the provisional TCJA tax charge. As a result, the Company recorded an increased deferred tax asset related to these foreign tax credits of approximately $0.3 billion or 1.7% to the annual effective tax rate.  This benefit has been reflected as &#x201c;TCJA and related impacts&#x201d; on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The Company reassessed its uncertain tax positions related to the current IRS audit and increased its unrecognized tax benefit by $0.3 billion liability which increased the annual effective tax rate by approximately 1.5% (see section on Unrecognized Tax Benefits for additional information). As these positions were related to uncertain tax regarding international transfer pricing, this expense has been classified as &#x201c;International Operations&#x201d; on the Company&#x2019;s effective tax rate reconciliation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As described above for the Swiss tax legislation, in the fiscal year 2019, the Company recorded a net tax expense of $0.1&#160;billion which increased the effective tax rate for the fiscal year 2019 by approximately 0.6%. This net tax expense related to federal and certain cantonal enactments in the fiscal year 2019 consisting of the following provisions:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;approximately $0.6&#160;billion tax expense relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred by December 29, 2019; this expense has been reflected as &#x201c;International Operations&#x201d; on the Company&#x2019;s effective tax rate reconciliation. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;a $0.9&#160;billion deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company&#x2019;s Swiss subsidiaries&#x2019; assets; this benefit has been reflected as &#x201c;International Operations&#x201d; on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;approximately $450&#160;million of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities and the new deferred tax asset for the Federal step-up. This benefit has been reflected as &#x201c;U.S. tax on international income&#x201d; on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.9pt;margin-top:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Temporary differences and carryforwards at the end of fiscal years 2021 and 2020 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021 Deferred Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 Deferred Tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee related obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,659)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D capitalized for tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves&#160;&amp;amp; liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income reported for tax purposes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realizable operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undistributed foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global intangible low-taxed income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Miscellaneous international&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Miscellaneous U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,624&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,477&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Certain prior year amounts have been reclassified to conform to current year presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amount is inclusive of the $2.3&#160;billion deferred tax asset established as part of the reorganized ownership structure of certain wholly-owned international subsidiaries, as previously described. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has wholly-owned international subsidiaries that have cumulative net losses. The Company believes that it is more likely than not that these subsidiaries will generate future taxable income sufficient to utilize these deferred tax assets. However, in certain jurisdictions, valuation allowances have been recorded against deferred tax assets for loss carryforwards that are not more likely than not to be realized. Such valuation allowances are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to unrecognized tax benefits:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,323&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,853&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The unrecognized tax benefits of $3.3 billion at January&#160;2, 2022, if recognized, would affect the Company&#x2019;s annual effective tax rate. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. In the fiscal year 2020, the Company made its final payments for approximately$0.7 billion to the U.S. Treasury related to the final settlement of 2010-2012 tax audit liability.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities, except as previously noted on amounts related to the current United States IRS audit. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $44 million, $32 million and $50 million in fiscal years 2021, 2020 and 2019, respectively. The total amount of accrued interest was $512&#160;million and $468 million in fiscal years 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNTc4_42368869-2325-4fda-a1f7-a2eaa9891b68">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for taxes on income consists of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.003%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Currently payable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total currently payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Provision for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,783&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzItMi0xLTEtMjk3MjY_6de60cdb-2c2b-460f-9536-1dd366455dc2"
      unitRef="usd">1525000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzItNC0xLTEtMjk3MjY_ec0768f5-a8a5-487c-88a8-8e71b8b20701"
      unitRef="usd">1026000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzItNi0xLTEtMjk3MjY_42f0b057-da7e-4fc3-8080-e4178ca65524"
      unitRef="usd">1941000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzQtMi0xLTEtMjk3MjY_537c697b-4f21-4769-b986-7be1293ce065"
      unitRef="usd">2452000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzQtNC0xLTEtMjk3MjY_2ad49bd3-3b02-46a3-9de8-39029668413c"
      unitRef="usd">1898000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzQtNi0xLTEtMjk3MjY_7ea7622f-0533-4dc6-b34e-1ca34fdd8afa"
      unitRef="usd">2744000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzUtMi0xLTEtMjk3MjY_06defaed-4a09-4c87-9835-ef48c0025ec5"
      unitRef="usd">3977000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzUtNC0xLTEtMjk3MjY_57225879-39fd-48f2-8df9-28daae6204bf"
      unitRef="usd">2924000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzUtNi0xLTEtMjk3MjY_31ee1dfb-7f66-4ada-95d1-17b7a68b7106"
      unitRef="usd">4685000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzctMi0xLTEtMjk3MjY_4eb7e788-d8c2-4d06-a325-7059b73d66df"
      unitRef="usd">583000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzctNC0xLTEtMjk3MjY_d8ee6b91-7f42-41c6-8347-59f0343f655a"
      unitRef="usd">-76000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzctNi0xLTEtMjk3MjY_6e5b28d5-f163-467e-8077-7ad3bb3f0701"
      unitRef="usd">-814000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzktMi0xLTEtMjk3MjY_df3a8c3e-04aa-420f-9507-730c9f46cab0"
      unitRef="usd">-2662000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzktNC0xLTEtMjk3MjY_8fa81b15-5007-4897-b581-6f0fb24f757c"
      unitRef="usd">-1065000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzktNi0xLTEtMjk3MjY_90c12e9b-7f10-40a5-967a-d080a7afd634"
      unitRef="usd">-1662000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzEwLTItMS0xLTI5NzI2_255c498f-857e-47cb-86b4-684a39680d86"
      unitRef="usd">-2079000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzEwLTQtMS0xLTI5NzI2_4a6c3a1d-93a0-4eb0-be93-83d37af1aad8"
      unitRef="usd">-1141000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzEwLTYtMS0xLTI5NzI2_b390f25a-d076-4a08-8de7-f6299d987acd"
      unitRef="usd">-2476000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzExLTItMS0xLTI5NzI2_a21be182-6b9c-4703-b1f1-976d37dc40f0"
      unitRef="usd">1898000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzExLTQtMS0xLTI5NzI2_5b884d95-67e3-45eb-8c90-0cc10baad710"
      unitRef="usd">1783000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo2OGNkYjY3MDNmYWU0ZTY1ODc4NzU0YmViMGNhOTRhZi90YWJsZXJhbmdlOjY4Y2RiNjcwM2ZhZTRlNjU4Nzg3NTRiZWIwY2E5NGFmXzExLTYtMS0xLTI5NzI2_c641abf2-e9d8-43e9-ad98-5697550ce1db"
      unitRef="usd">2209000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNTY2_d258b8b6-414d-4344-ad8d-d69e1cdad254">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A comparison of income tax expense at the U.S.&#160;statutory rate of 21% in fiscal years 2021, 2020 and 2019, to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings before taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax rates:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxes on international income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefits from loss on capital assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefits on share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TCJA and related impacts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflects the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2021 amounts include the reorganization of international subsidiaries; the 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. The 2021 amounts include the reorganization of international subsidiaries; the 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, both of which is further described below. &lt;/span&gt;&lt;/div&gt;(3) Represents impact of adjustments to balances originally recorded as part of the 2017 TCJA provisional tax charge. Further information provided below.</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzIzNw_35001ae2-f803-4591-81af-8ddd55998e4c"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzIzNw_ae84e403-869d-4593-8326-5da351efb219"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzEtMi0xLTEtMjk3MjY_1431248e-25a2-42ce-8dea-83ddc13bcd7e"
      unitRef="usd">6110000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzEtNC0xLTEtMjk3MjY_794460e6-fb17-460a-8d50-a480290602ba"
      unitRef="usd">4312000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzEtNi0xLTEtMjk3MjY_68313247-8fb6-411f-b81f-3c84c58d55ef"
      unitRef="usd">3543000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzItMi0xLTEtMjk3MjY_bee04e5a-a6b5-4b12-916f-b2bb778438d8"
      unitRef="usd">16666000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzItNC0xLTEtMjk3MjY_885c88cf-3d03-49ab-b5a8-1a854582941b"
      unitRef="usd">12185000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzItNi0xLTEtMjk3MjY_c54964f6-3021-4bd5-a6f1-c870c9dbc232"
      unitRef="usd">13785000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzMtMi0xLTEtMjk3MjY_e21a1e51-8c94-4289-8f8b-6aed7e85cc8f"
      unitRef="usd">22776000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzMtNC0xLTEtMjk3MjY_fbbf1807-c7dc-41f8-9d8e-3444c28389a3"
      unitRef="usd">16497000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzMtNi0xLTEtMjk3MjY_ebef13bd-91df-420f-bc67-2b9675b0f636"
      unitRef="usd">17328000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzUtMi0xLTEtMjk3MjY_939a0feb-b902-40a8-9847-d86b24d83942"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzUtNC0xLTEtMjk3MjY_441e85c9-7989-4753-85e9-a00bd77f6d3f"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzUtNi0xLTEtMjk3MjY_0844b689-637c-4c24-9d49-75bbd97b4df5"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzYtMi0xLTEtMjk3MjY_f54e2733-fdf2-492b-b22b-1e514751e3c2"
      unitRef="number">-0.164</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzYtNC0xLTEtMjk3MjY_921111e2-e992-4890-a775-c42ced42186d"
      unitRef="number">-0.099</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzYtNi0xLTEtMjk3MjY_fe043229-71bf-4ac4-a806-d55d51c9d2ab"
      unitRef="number">-0.059</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzEwLTItMS0xLTI5NzI2_53af6c32-255e-49f1-a169-e7827c1d683c"
      unitRef="number">0.067</jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome>
    <jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzEwLTQtMS0xLTI5NzI2_ef76c985-56dd-4d7a-864a-a8f5874b3a0c"
      unitRef="number">0.027</jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome>
    <jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzEwLTYtMS0xLTI5NzI2_68f1965a-6c19-4916-8adf-4d6bca201c2e"
      unitRef="number">0.018</jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome>
    <jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzExLTItMS0xLTI5NzI2_accc8478-eb33-461f-9203-e7bfed5ae470"
      unitRef="number">-0.013</jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss>
    <jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzExLTQtMS0xLTI5NzI2_0d9bff24-3b5c-43c9-873d-d18af50958b1"
      unitRef="number">-0.012</jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss>
    <jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzExLTYtMS0xLTI5NzI2_f8d9466b-23de-41c0-bb6f-bbe57b9d7cdf"
      unitRef="number">-0.003</jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzEyLTItMS0xLTI5NzI2_0fc3b033-dc53-41a3-b743-08611fa8c5ee"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzEyLTQtMS0xLTI5NzI2_946d8890-bf79-4cf2-b336-237af7c43535"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzEyLTYtMS0xLTI5NzI2_2afe26a6-0f95-4585-91db-55a708fc021b"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzE0LTItMS0xLTI5NzI2_41069f60-18cb-47ef-82cc-6a11f9c907a6"
      unitRef="rate">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzE0LTQtMS0xLTI5NzI2_26146a66-fe58-4240-a16a-53ccdd717760"
      unitRef="rate">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzE0LTYtMS0xLTI5NzI2_9e235eec-fba8-4aaa-80a3-03e25b76bb2e"
      unitRef="rate">-0.039</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzE1LTItMS0xLTI5NzI2_bcf04aef-a571-4f62-a214-d077a2d87a13"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzE1LTQtMS0xLTI5NzI2_4f3f7b37-842f-4d1d-8f8e-30b4f0a7d40e"
      unitRef="number">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzE1LTYtMS0xLTI5NzI2_7a0c299d-0b40-4d8e-a0dd-000b90a07cab"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzE2LTItMS0xLTI5NzI2_77d73955-f779-4d9f-8b29-e47b9cc94900"
      unitRef="number">0.083</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzE2LTQtMS0xLTI5NzI2_17007844-533a-4179-96cd-9fba0a21a5b8"
      unitRef="number">0.108</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpjN2Q4MDdlZDJjMWQ0MmNhYTkxZTBhY2U0ZWI4ZmY3Ni90YWJsZXJhbmdlOmM3ZDgwN2VkMmMxZDQyY2FhOTFlMGFjZTRlYjhmZjc2XzE2LTYtMS0xLTI5NzI2_721d41a8-b9b4-42e9-8a24-c30b1cf47ae7"
      unitRef="number">0.127</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEyOTY_8eb4d543-9522-4d93-aecf-fb5ca6ffce0a"
      unitRef="number">-0.025</jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i8cd6b32233734c51bca233601a3752ae_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNTc1MTY_b03e911a-a8c7-44cc-b932-e6efeb229570"
      unitRef="usd">600000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent
      contextRef="icf0d50ada4f346ffb63114cb3d32ba28_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNTc1MDk_af9dee68-b3d2-4636-93c5-4411e5ab292a"
      unitRef="number">0.027</jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent>
    <jnj:DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNTg1Njc_b5cf4389-6c62-42d9-892e-47812073715b"
      unitRef="usd">2300000000</jnj:DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization>
    <jnj:IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNTg1ODE_eb959b63-417b-4500-8506-9b26d67e4958"
      unitRef="usd">1700000000</jnj:IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI>
    <jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss
      contextRef="i2f79758b58cf409fb7e5e1f32144e7f6_D20211004-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNjAzMzQ_dd74ad76-695c-4434-a93b-0e180f83f728"
      unitRef="number">-0.013</jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss>
    <us-gaap:LitigationSettlementExpense
      contextRef="i7b0c1ad768954c3cb5d973a4cb0b4f0d_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNjAyNzE_4ed79bf6-69a3-470b-831d-6ccebf718d38"
      unitRef="usd">1600000000</us-gaap:LitigationSettlementExpense>
    <jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent
      contextRef="i7b0c1ad768954c3cb5d973a4cb0b4f0d_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNjAyODU_00fff484-f3af-4d6d-9a39-a10233a42d18"
      unitRef="number">0.235</jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent>
    <us-gaap:LitigationSettlementExpense
      contextRef="i161f67e1e8fc4b20952f5d16b610a1cc_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNjAyOTI_a95e3f4d-c27f-4799-af00-13b0c9e2495c"
      unitRef="usd">800000000</us-gaap:LitigationSettlementExpense>
    <jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent
      contextRef="i161f67e1e8fc4b20952f5d16b610a1cc_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNjAzMDY_15f0e7fd-9a77-4d3d-ab97-f2fbe27155bc"
      unitRef="number">0.164</jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i8aa69bd5ba1f43b3b6d5887ae14e8e86_D20211004-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNjAzMTM_df5742d9-b286-4be4-bad4-9e49499d708e"
      unitRef="usd">900000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i8aa69bd5ba1f43b3b6d5887ae14e8e86_D20211004-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNjAzMjc_de900e08-c7a8-4486-8c59-325b5f163090"
      unitRef="number">0.224</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzU0OTc1NTgxNjIwMTQ_04872d55-f745-45f6-a610-47e9c87d4fc6"
      unitRef="number">0.019</jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent>
    <jnj:FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzMwODY_059c84c8-267d-44ab-a4ca-d0e35c42654c"
      unitRef="usd">400000000</jnj:FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit>
    <jnj:EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzMwOTI_56a4fe24-bf16-4c38-aeca-4a04d3c1a875"
      unitRef="number">0.026</jnj:EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent>
    <jnj:FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzMxOTg_d28eb514-d72e-4c9f-a1f3-31c4b113f679"
      unitRef="usd">300000000</jnj:FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit>
    <jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzM1MDk_bb478821-a369-481d-98b0-2540218121c9"
      unitRef="usd">450000000</jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset>
    <jnj:FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzM3ODY_24e27d8f-4687-4ce2-8360-f8294edf7254"
      unitRef="usd">300000000</jnj:FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzQ0MjQ_44ddff9a-6c87-489c-921a-195e93f377ad"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:LitigationSettlementExpense
      contextRef="i5b5fd248c6fa4b22b336af4f57cb8a47_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzQ3MTQ_253eb461-11f4-4943-8ead-b8c46d3ba47d"
      unitRef="usd">4000000000</us-gaap:LitigationSettlementExpense>
    <jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent
      contextRef="if70cf172b8f449b8bb218775e0fcb014_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzQ3OTA_87c5deb6-95b3-4b2f-be6a-5d1eb467ec4f"
      unitRef="number">0.235</jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent>
    <us-gaap:LitigationSettlementExpense
      contextRef="i063d308c5d8f4797bb4e17583565d9b7_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzQ4NTc_389063b3-02bd-4d86-9f82-8a33d8e39ca1"
      unitRef="usd">1000000000</us-gaap:LitigationSettlementExpense>
    <jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent
      contextRef="i4882989be8b64ae0bf4ca80baf92c148_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzQ5NjU_e3caf9c8-ea1a-47a1-aab2-b8234ccbb7db"
      unitRef="number">0.214</jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent>
    <jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzYwOTA_d394d274-2bc2-4227-99b6-2727c07c82d0"
      unitRef="usd">600000000</jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability>
    <jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzYxMjk_cfd0705e-0902-4845-8a9d-f5c544e7abab"
      unitRef="usd">200000000</jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset>
    <jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzYxOTY_7f8d56b6-e566-46e3-99cb-fa484fb2503a"
      unitRef="usd">-400000000</jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit>
    <jnj:EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzYyNDM_0361ccb7-ea30-4090-be0e-586d1d72d1f1"
      unitRef="number">-0.022</jnj:EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i7f6076db24f64e8b8d695cf2700ed061_I20191031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzY0MzQ_2e2b10c8-29b6-4829-aabb-25b5f4eb7998"
      unitRef="usd">4000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <jnj:IncreaseDecreaseInEarningsBeforeTaxesPercent
      contextRef="ia9954ad68ee94f408f19784fd44dc96b_D20191001-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzY1NjU_9c71545a-58b6-4ca2-bf90-6b71716511b0"
      unitRef="number">-0.235</jnj:IncreaseDecreaseInEarningsBeforeTaxesPercent>
    <jnj:EffectiveTaxRateReconciliationLitigationSettlementPercent
      contextRef="ia9954ad68ee94f408f19784fd44dc96b_D20191001-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzY2Mzk_4bd17616-ad54-4bab-ae3e-dfd7809f76a2"
      unitRef="number">-0.021</jnj:EffectiveTaxRateReconciliationLitigationSettlementPercent>
    <jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset
      contextRef="i7a80321fb97a41e480b2b933fde2af82_D20191201-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzcwMzA_1728aaa8-0f7c-4862-9ba4-a8ded2bec729"
      unitRef="usd">300000000</jnj:TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset>
    <jnj:EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent
      contextRef="i7a80321fb97a41e480b2b933fde2af82_D20191201-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzcwMzY_9bfe9ac5-d98f-4153-88da-d10282ef37a3"
      unitRef="number">0.017</jnj:EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzczMTg_48d7abfb-fa01-4f92-b240-25caabc154d3"
      unitRef="usd">300000000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <jnj:EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzczOTQ_98909458-9141-487d-b6e5-9291c2f13b81"
      unitRef="number">0.015</jnj:EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent>
    <jnj:FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzgzOTg_2a44c42b-4083-4928-bff6-4f187b5a10c3"
      unitRef="usd">100000000</jnj:FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit>
    <jnj:EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzg0ODI_c637ebfc-bfbf-48fc-88a0-5a3c3972cda4"
      unitRef="number">0.006</jnj:EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent>
    <jnj:FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzg2Mzg_bc36d224-ae17-4694-8402-76a2e90b1acd"
      unitRef="usd">600000000</jnj:FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit>
    <jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzg5NDY_42b54399-6859-4994-a383-b26e94b8de0d"
      unitRef="usd">900000000</jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset>
    <jnj:FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzkyMDQ_9a8c71c8-16d7-483d-b406-744cbf898d7a"
      unitRef="usd">450000000</jnj:FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNTkx_0b1437bf-b74b-4e4b-af9c-7f97b16550bc">&lt;div style="margin-bottom:9.9pt;margin-top:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Temporary differences and carryforwards at the end of fiscal years 2021 and 2020 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021 Deferred Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 Deferred Tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee related obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,659)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D capitalized for tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves&#160;&amp;amp; liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income reported for tax purposes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realizable operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undistributed foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global intangible low-taxed income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Miscellaneous international&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Miscellaneous U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,624&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,477&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Certain prior year amounts have been reclassified to conform to current year presentation&lt;/span&gt;&lt;/div&gt;(2)Amount is inclusive of the $2.3&#160;billion deferred tax asset established as part of the reorganized ownership structure of certain wholly-owned international subsidiaries, as previously described.</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzItMi0xLTEtMjk3MjY_4565d83a-3422-402c-9601-ca4dafc19c91"
      unitRef="usd">1244000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzItNi0xLTEtMjk3MjY_1896fea4-8ba0-4f0b-b8ec-f21d40ca825a"
      unitRef="usd">2434000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzMtMi0xLTEtMjk3MjY_07aa146e-8b44-47da-b868-4cb1bf380daf"
      unitRef="usd">679000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzMtNi0xLTEtMjk3MjY_00f6980e-7c82-4f4a-ae9b-605a3b7900f5"
      unitRef="usd">627000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzQtNC0xLTEtMjk3MjY_d12a9429-cd12-4bf5-8afc-d119c235ad18"
      unitRef="usd">876000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzQtOC0xLTEtMjk3MjY_f6779aca-a061-427a-856d-a7057138f6d0"
      unitRef="usd">823000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzUtNC0xLTEtMjk3MjY_24cf43e6-0795-43b7-832a-4bad8a18e749"
      unitRef="usd">2659000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzUtOC0xLTEtMjk3MjY_365fabd4-3cb8-4da3-a4b7-7858072ae637"
      unitRef="usd">5023000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzYtMi0xLTEtMjk3MjY_453b7b6c-2eef-4c9d-95af-dc061fbe5f7a"
      unitRef="usd">1664000000</jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized>
    <jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzYtNi0xLTEtMjk3MjY_5a9e7698-0dab-41c4-8326-97f94b62c301"
      unitRef="usd">1517000000</jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzctMi0xLTEtMjk3MjY_1d459f8d-a4d8-46ea-9dde-2ede43079566"
      unitRef="usd">2882000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzctNi0xLTEtMjk3MjY_a9b9f8bc-d4c4-4b7d-85be-2ed016a6d807"
      unitRef="usd">3466000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzgtMi0xLTEtMjk3MjY_705bab5c-4464-4dd4-b91e-e964083c7f60"
      unitRef="usd">2566000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzgtNi0xLTEtMjk3MjY_7db1fa76-0ab5-4315-989b-28ea27bcf0d7"
      unitRef="usd">1777000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzktMi0xLTEtMjk3MjY_7087bb87-0102-4813-b9f8-cf45add039a6"
      unitRef="usd">1073000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzktNi0xLTEtMjk3MjY_40ec774c-3929-49ff-861c-c88d85d0cb77"
      unitRef="usd">990000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <jnj:DeferredTaxAssetsUndistributedForeignEarnings
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEwLTItMS0xLTI5NzI2_842fa246-3c9a-4ecf-8d4d-053c7d1a9762"
      unitRef="usd">1015000000</jnj:DeferredTaxAssetsUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEwLTQtMS0xLTI5NzI2_dece6f2c-4e27-4b67-8c54-39443a5aa963"
      unitRef="usd">1461000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <jnj:DeferredTaxAssetsUndistributedForeignEarnings
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEwLTYtMS0xLTI5NzI2_6407b035-45e9-40d1-bdd9-116fe4c202f7"
      unitRef="usd">812000000</jnj:DeferredTaxAssetsUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEwLTgtMS0xLTI5NzI2_a2768e2b-af0f-4cd8-bc21-30cc0f429b5d"
      unitRef="usd">1435000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzExLTQtMS0xLTI5NzI2_517d8154-c688-4819-a893-155d27faca2d"
      unitRef="usd">4853000000</jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome>
    <jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzExLTgtMS0xLTI5NzI2_49590af2-a7e4-43fc-9470-594842a57325"
      unitRef="usd">3606000000</jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEyLTItMS0xLTI5NzI2_693ae5d8-b265-4d53-942d-d6b0ee14a9df"
      unitRef="usd">1006000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEyLTQtMS0xLTI5NzI2_4d5e3145-7606-468a-8981-aa5f53225db1"
      unitRef="usd">39000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEyLTYtMS0xLTI5NzI2_02051953-bf9a-4034-b43c-31c0cf3f8ae0"
      unitRef="usd">854000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEyLTgtMS0xLTI5NzI2_f5330d6f-772f-4e23-8fa5-64550604faff"
      unitRef="usd">211000000</us-gaap:DeferredTaxLiabilitiesOther>
    <jnj:DeferredTaxAssetsOtherDomestic
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEzLTItMS0xLTI5NzI2_c105388d-2b85-4f8a-a355-b5f2cfffb305"
      unitRef="usd">495000000</jnj:DeferredTaxAssetsOtherDomestic>
    <jnj:DeferredTaxLiabilitiesOtherDomestic
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzEzLTgtMS0xLTI5NzI2_81066d19-0ee4-4f68-ad6e-335bc1d2d24c"
      unitRef="usd">59000000</jnj:DeferredTaxLiabilitiesOtherDomestic>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzE0LTItMS0xLTI5NzI2_0cccc343-5579-4869-8aa5-f24f9febc078"
      unitRef="usd">12624000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzE0LTQtMS0xLTI5NzI2_0fcb849a-dd00-4334-9e9a-bb040f0f6bd7"
      unitRef="usd">9888000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzE0LTYtMS0xLTI5NzI2_a4234aa4-4434-4982-96e2-4760525b99ee"
      unitRef="usd">12477000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTo3OTUzOTA2MGM3NzA0YjViOWQ0Y2Y5M2IzMGIxZjQxNi90YWJsZXJhbmdlOjc5NTM5MDYwYzc3MDRiNWI5ZDRjZjkzYjMwYjFmNDE2XzE0LTgtMS0xLTI5NzI2_6ff235fa-71f3-4832-b656-968753e6ab8a"
      unitRef="usd">11157000000</us-gaap:DeferredTaxLiabilities>
    <jnj:DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEwOTk1MTE2MzA3OTky_055dbf51-8422-41cc-accb-418f001ea71d"
      unitRef="usd">2300000000</jnj:DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNTky_feca309a-799f-4049-8bbb-0a740c0dffc1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to unrecognized tax benefits:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,323&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,853&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzEtMi0xLTEtMjk3MjY_a0435dbf-d884-4577-a570-7b10f0da0723"
      unitRef="usd">3373000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzEtNC0xLTEtMjk3MjY_dfeab324-adce-4ec6-9611-2ec13f327839"
      unitRef="usd">3853000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia2087646dc6744a28755f382fc0a83c8_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzEtNi0xLTEtMjk3MjY_47abe825-02e4-4de0-8968-8f1313f0112d"
      unitRef="usd">3326000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzItMi0xLTEtMjk3MjY_fd4dac62-8892-4193-9f46-04fdb81a01a7"
      unitRef="usd">242000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzItNC0xLTEtMjk3MjY_c836c440-4a35-4ab9-9f98-3e6f5c03bc69"
      unitRef="usd">265000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzItNi0xLTEtMjk3MjY_7a1e698f-3667-4622-ae6d-99ec5a9effb6"
      unitRef="usd">249000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzMtMi0xLTEtMjk3MjY_b2ba78b2-fb44-428b-b41d-8dbc5791b0e7"
      unitRef="usd">23000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzMtNC0xLTEtMjk3MjY_94b7ddc8-8c9a-4b86-a396-3eecbcc76281"
      unitRef="usd">668000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzMtNi0xLTEtMjk3MjY_5fef84ee-6c79-4196-90f0-9a80c935af70"
      unitRef="usd">408000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzQtMi0xLTEtMjk3MjY_81b8210b-00ca-48dd-b6c0-fb29d240438d"
      unitRef="usd">128000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzQtNC0xLTEtMjk3MjY_ad092b1c-9b2d-4a0e-bf9c-870ef800179a"
      unitRef="usd">551000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzQtNi0xLTEtMjk3MjY_23bb5ba2-5545-4765-91b2-2925c6da140a"
      unitRef="usd">105000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzUtMi0xLTEtMjk3MjY_3ea02fef-a82c-4b7f-9a90-1b7468c2fade"
      unitRef="usd">187000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzUtNC0xLTEtMjk3MjY_1dbb9bb9-d6ae-439c-b735-230e23c1b025"
      unitRef="usd">839000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzUtNi0xLTEtMjk3MjY_b7d092c8-cafe-49d1-812a-f50e5480c5e9"
      unitRef="usd">9000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzYtMi0xLTEtMjk3MjY_c8376ae9-6a5d-47d9-8b46-7ebbb369ad89"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzYtNC0xLTEtMjk3MjY_35b32306-ecd7-4599-b297-1cc698ad5800"
      unitRef="usd">23000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzYtNi0xLTEtMjk3MjY_1afa3f40-36cf-4d42-8c7b-de1eaa637d36"
      unitRef="usd">16000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzctMi0xLTEtMjk3MjY_f9bcc8f4-7e9f-47d2-8dec-365b6dd3a953"
      unitRef="usd">3323000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzctNC0xLTEtMjk3MjY_3f87113c-81e2-468d-a2b4-f7098b04bd40"
      unitRef="usd">3373000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90YWJsZTpkYTc2NGI5YTlkYjQ0OTU0YWExMjE4MzE3ZDZlMDcyNC90YWJsZXJhbmdlOmRhNzY0YjlhOWRiNDQ5NTRhYTEyMTgzMTdkNmUwNzI0XzctNi0xLTEtMjk3MjY_54cb5690-e860-401a-bf81-451962ca2c3e"
      unitRef="usd">3853000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzExODQy_953b7ffa-ee34-47ea-816f-67c81cf4522b"
      unitRef="usd">3300000000</us-gaap:UnrecognizedTaxBenefits>
    <jnj:UnrecognizedTaxBenefitLiabilityPayment
      contextRef="ieb7ecccc89964876b8660c4b222156cc_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEyNDg3_9b4901b4-7d3a-4471-a89c-4eec11cbeef1"
      unitRef="usd">700000000</jnj:UnrecognizedTaxBenefitLiabilityPayment>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNDE0_dfa822c8-7885-42c5-9adf-bba9b3ea87ae"
      unitRef="usd">44000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNDE4_b57e1176-cc12-4b25-b1e2-fb5e9a10ea05"
      unitRef="usd">32000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNDI1_46acecae-a585-4468-bc75-cbcf12a345f2"
      unitRef="usd">50000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNTE0_7b5188e4-f8f1-4031-820b-7bd3b9b61ef9"
      unitRef="usd">512000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNjkvZnJhZzplMTQ4ZGQwNDc1MDQ0NDE0OWZlOWVjYjdlMTk4N2U4My90ZXh0cmVnaW9uOmUxNDhkZDA0NzUwNDQ0MTQ5ZmU5ZWNiN2UxOTg3ZTgzXzEzNTIx_3abb4f8e-57ac-46ff-bd20-e6ba32920d1c"
      unitRef="usd">468000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:CompensationRelatedCostsGeneralTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90ZXh0cmVnaW9uOjQ2ODU5MjYzMTNmMjQ3ZjBiMjMwYjliMjQzZjkxODIzXzMwNA_85104835-8c20-4c2b-a5b7-49e30ecd93d4">Employee Related Obligations&lt;div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal 2021 and fiscal 2020, employee related obligations recorded on the Consolidated Balance Sheets were:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Postretirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Postemployment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total employee obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current benefits payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee related obligations&#160;&#x2014; non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,771&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid employee related obligations of $4,436 million and $656 million for 2021 and 2020, respectively, are included in Other assets on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsGeneralTextBlock>
    <jnj:EmployeeRelatedObligationsTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90ZXh0cmVnaW9uOjQ2ODU5MjYzMTNmMjQ3ZjBiMjMwYjliMjQzZjkxODIzXzMxMA_a500fd58-a56d-47fa-89e1-4d43c2cd6329">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal 2021 and fiscal 2020, employee related obligations recorded on the Consolidated Balance Sheets were:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Postretirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Postemployment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total employee obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current benefits payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee related obligations&#160;&#x2014; non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,771&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</jnj:EmployeeRelatedObligationsTableTextBlock>
    <us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzEtMi0xLTEtMjk3MjY_70c5c1ae-b3d9-4e9c-838a-2c03a3ec9d88"
      unitRef="usd">4088000000</us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities>
    <us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzEtNC0xLTEtMjk3MjY_4a1878bb-556c-4865-9dcb-2d957cfde665"
      unitRef="usd">5761000000</us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzItMi0xLTEtMjk3MjY_a4a897a1-602e-459c-856c-3604694246dc"
      unitRef="usd">2069000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzItNC0xLTEtMjk3MjY_b583da27-7302-44ab-856f-416022f6ea1b"
      unitRef="usd">2229000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzMtMi0xLTEtMjk3MjY_d8d413ef-f7a3-4521-9671-3afcf6cb4ed3"
      unitRef="usd">3117000000</us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzMtNC0xLTEtMjk3MjY_ad35841f-b6f1-4fc7-bd61-169c7a588341"
      unitRef="usd">3078000000</us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzQtMi0xLTEtMjk3MjY_a7ddb0df-c2c1-478f-815b-1cda237c097b"
      unitRef="usd">181000000</us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzQtNC0xLTEtMjk3MjY_c4e9c0b0-5f78-4b33-a423-bd200b20ebdf"
      unitRef="usd">250000000</us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent>
    <jnj:EmployeeObligations
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzUtMi0xLTEtMjk3MjY_7af71a24-08fd-44e7-b8a2-9d26bbebf2d9"
      unitRef="usd">9455000000</jnj:EmployeeObligations>
    <jnj:EmployeeObligations
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzUtNC0xLTEtMjk3MjY_02d8baa7-d04b-4724-92d1-64393e29ecf4"
      unitRef="usd">11318000000</jnj:EmployeeObligations>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzYtMi0xLTEtMjk3MjY_05786698-18b7-474a-8c18-63a7a70dcf91"
      unitRef="usd">557000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzYtNC0xLTEtMjk3MjY_37d1ef1f-6433-45d0-b2d6-30d05d30b119"
      unitRef="usd">547000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzctMi0xLTEtMjk3MjY_4ab91fe4-07d5-4ed3-96c3-bd26ad5d053c"
      unitRef="usd">8898000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90YWJsZTowMjNlOTgwYjExZGQ0NmEzODEzZmUxZWI2NjIwYjE4MS90YWJsZXJhbmdlOjAyM2U5ODBiMTFkZDQ2YTM4MTNmZTFlYjY2MjBiMTgxXzctNC0xLTEtMjk3MjY_67bdc3ea-2189-4f1e-b7bd-95daf77ae384"
      unitRef="usd">10771000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90ZXh0cmVnaW9uOjQ2ODU5MjYzMTNmMjQ3ZjBiMjMwYjliMjQzZjkxODIzXzE5Ng_2c32a027-4cbf-434c-b543-aa3f72ab5225"
      unitRef="usd">4436000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzUvZnJhZzo0Njg1OTI2MzEzZjI0N2YwYjIzMGI5YjI0M2Y5MTgyMy90ZXh0cmVnaW9uOjQ2ODU5MjYzMTNmMjQ3ZjBiMjMwYjliMjQzZjkxODIzXzIwMw_839c6a2b-4d6c-4c0f-8827-b95be9a3a552"
      unitRef="usd">656000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODY1_3632f357-fa70-4cc3-a10c-546fc1fe3d78">Pensions and Other Benefit Plans&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily healthcare, to all eligible U.S.&#160;retired employees and their dependents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many international employees are covered by government-sponsored programs and the cost to the Company is not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.S, non-union pension benefits for employees hired before January 1, 2015 are primarily based on the employee&#x2019;s compensation during the last five years before retirement and the number of years of service (the Final Average Pay formula). U.S. pension benefits for employees hired after 2014, are calculated using a different formula based on employee compensation over total years of service (the Retirement Value formula).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees,&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accrued under the Final Average Pay formula for service before January 1, 2026. The impact of this change decreases the&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Projected Benefit Obligation as of January 3, 2021 by approximately $1.8&#160;billion and is included in the &#x201c;Amendments&#x201d; line in the Change in Benefit Obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not fund retiree healthcare benefits in advance and has the right to modify these plans in the future.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021 and 2020 the Company used December 31, 2021 and December 31, 2020, respectively, as the measurement date for all U.S.&#160;and international retirement and other benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans for 2021, 2020 and 2019 include the following components:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial losses (gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;623&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;790&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;593&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;524&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;551&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized gains and losses for the U.S.&#160;pension plans are amortized over the average remaining future service for each plan.  For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S.&#160;benefit plans is determined by using a 10% corridor of the greater of the market value of assets or the accumulated postretirement benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior service costs/benefits for the U.S.&#160;pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S.&#160;benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the weighted-average actuarial assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Worldwide Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Periodic Benefit Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of increase in compensation levels&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected long-term rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of increase in compensation levels&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. The Company's methodology in determining service and interest cost uses duration specific spot rates along that yield curve to the plans' liability cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the assumed healthcare cost trend rates, for all individuals:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Healthcare Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare cost trend rate assumed for next year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate to which the cost trend rate is assumed to decline (ultimate trend)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year the rate reaches the ultimate trend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2021 and 2020 for the Company&#x2019;s defined benefit retirement plans and other post-retirement plans:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&#160;&#x2014; beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amendments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gains) losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&#160;&amp;amp; acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments, settlements&#160;&amp;amp; restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid from plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41,582&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;43,300&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,878&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&#160;&#x2014; beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&#160;&amp;amp; acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid from plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41,930&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funded status &#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized in the Company&#x2019;s Balance Sheet consist of the following:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in the consolidated balance sheet&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized net transition obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,929&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,063&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,419&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Benefit Obligations&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40,356&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The actuarial gain for retirement plans in 2021 was primarily related to increases in discount rates; the actuarial losses for retirement plans in 2020 were primarily related to decreases in discount rates.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;623&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;790&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;524&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,927)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service (cost) credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total loss/(income) recognized in other comprehensive income, before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in net periodic benefit cost and other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, the Company contributed $102 million and $867 million to its U.S.&#160;and international pension plans, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the funded status of the Company's U.S. Qualified &amp;amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2021 and December&#160;31, 2020, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Qualified Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-Qualified Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Funded Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unfunded Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over (Under) Funded Status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(493)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $3.9 billion, $4.2 billion and $0.3 billion, respectively, at the end of 2021, and $8.8 billion, $9.8 billion and $4.4 billion, respectively, at the end of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the projected future benefit payments from the Company&#x2019;s retirement and other benefit plans:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2027-2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Projected future benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other benefit plans&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the projected future minimum contributions to the unfunded retirement plans.  These amounts do not include any discretionary contributions that the Company may elect to make in the future.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2027-2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Projected future contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company&#x2019;s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s retirement plan asset allocation at the end of 2021 and 2020 and target allocations for 2022 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.131%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Percent of&lt;br/&gt;Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Target&lt;br/&gt;Allocation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Worldwide Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Determination of Fair Value of Plan Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Plan has an established and well-documented process for determining fair values.  Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;       The Net Asset Value (NAV) is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial instrument&#x2019;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a description of the valuation methodologies used for the investments measured at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Short-term investment funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the NAV provided by the administrator of the fund. The NAV is a quoted price in a market that is not active and classified as Level&#160;2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Government and agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level&#160;1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level&#160;2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Debt instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level&#160;1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level&#160;2. Level&#160;3 debt instruments are priced based on unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level&#160;1 of the valuation hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Commingled funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; These investment vehicles are valued using the NAV provided by the fund administrator. Assets in the Level&#160;2 category have a quoted market price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Other assets are represented primarily by limited partnerships. These investment vehicles are valued using the NAV provided by the fund administrator. Other assets that are exchange listed and actively traded are classified as Level&#160;1, while inactively traded assets are classified as Level&#160;2. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2021 and December&#160;31, 2020:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.235%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;br/&gt;Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Investments at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,086&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,420&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,515&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,092&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41,930&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The activity for the Level 3 assets is not significant for all years presented.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Other Benefit Plans are unfunded except for U.S.&#160;commingled funds (Level 2) of $102 million and $90 million at December&#160;31, 2021 and December&#160;31, 2020, respectively. &lt;/span&gt;&lt;/div&gt;The fair value of Johnson&#160;&amp;amp; Johnson Common Stock directly held in plan assets was $385 million (0.9% of total plan assets) at December&#160;31, 2021 and $946 million (2.5% of total plan assets) at December&#160;31, 2020.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <jnj:EmployeeCompensationPeriod
      contextRef="ie6a7535dcc684ff5971979c84c966ae9_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzYyNw_7675f936-414a-43db-a30f-3d38c5fc9e81">P5Y</jnj:EmployeeCompensationPeriod>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEzMDQ_3d7be2fb-dc49-4113-aa8c-d70e905b3d6b"
      unitRef="usd">-1800000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODY2_52a0e139-174f-44a8-91b5-7a57d8b535d5">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans for 2021, 2020 and 2019 include the following components:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial losses (gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;623&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;790&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;593&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;524&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;551&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzItMi0xLTEtMjk3MjY_b2768c63-99f1-4645-b249-dbeed6dd2702"
      unitRef="usd">1421000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzItNC0xLTEtMjk3MjY_35f89fe7-bcdd-471e-aa18-4d07d024d323"
      unitRef="usd">1380000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzItNi0xLTEtMjk3MjY_0b3eec7a-2f8d-4a25-b586-0cf42576c3da"
      unitRef="usd">1163000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzItOC0xLTEtMjk3MjY_4e6c6415-09a0-4710-9855-fe3634759798"
      unitRef="usd">309000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzItMTAtMS0xLTI5NzI2_8ea70533-e021-4fe3-900a-fbe097acbadf"
      unitRef="usd">287000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzItMTItMS0xLTI5NzI2_32e67553-eb83-4623-b552-8ea14a503d46"
      unitRef="usd">274000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzMtMi0xLTEtMjk3MjY_aaf48701-5132-4483-9913-e318800ad038"
      unitRef="usd">770000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzMtNC0xLTEtMjk3MjY_44a2496b-013d-4177-b9c8-b947f672f831"
      unitRef="usd">955000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzMtNi0xLTEtMjk3MjY_e22554cc-a4cf-4333-a891-73fbf85aabef"
      unitRef="usd">1096000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzMtOC0xLTEtMjk3MjY_77a6588f-2fdf-4dd3-bad7-8686855bbe32"
      unitRef="usd">81000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzMtMTAtMS0xLTI5NzI2_105db3ca-f790-446d-8113-74b6b4de51e3"
      unitRef="usd">133000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzMtMTItMS0xLTI5NzI2_61cd2b01-f0db-4d50-b3fa-62210137d439"
      unitRef="usd">185000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzQtMi0xLTEtMjk3MjY_992d57e5-660f-428f-acd3-9735ea323a9a"
      unitRef="usd">2645000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzQtNC0xLTEtMjk3MjY_b8c2b984-6618-4943-b8ef-5fcb84355bb3"
      unitRef="usd">2461000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzQtNi0xLTEtMjk3MjY_8067acda-6311-4127-af7d-db2d6454797d"
      unitRef="usd">2322000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzQtOC0xLTEtMjk3MjY_c12776d3-277e-4562-b0cf-c7a3a41e8c87"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzQtMTAtMS0xLTI5NzI2_dfb836ba-b7b4-4973-81d9-807ef79d5d14"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzQtMTItMS0xLTI5NzI2_6f9a92bb-85b8-40bb-808b-6157b306f9d6"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzUtMi0xLTEtMjk3MjY_dd1a778f-3ecc-42f7-a7ec-639bedf9ccc7"
      unitRef="usd">-181000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzUtNC0xLTEtMjk3MjY_2d48ee77-b5c2-4715-8a7a-7b5f7df7ebff"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzUtNi0xLTEtMjk3MjY_e309a9bf-09ba-47e3-83aa-90ee9789459e"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzUtOC0xLTEtMjk3MjY_1cda5009-cf2f-4baf-b556-b1f99237f967"
      unitRef="usd">-31000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzUtMTAtMS0xLTI5NzI2_96da5722-1b49-41e5-9594-f44b67c22bbf"
      unitRef="usd">-31000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzUtMTItMS0xLTI5NzI2_ce60a89e-1558-4213-8940-602fa9292920"
      unitRef="usd">-31000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzctMi0xLTEtMjk3MjY_f278fb44-f659-47e5-95f3-f0a776a8e728"
      unitRef="usd">-1257000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzctNC0xLTEtMjk3MjY_d814ddb4-6c50-4358-aa9d-a5c7d1ffc61f"
      unitRef="usd">-891000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzctNi0xLTEtMjk3MjY_44877d63-1080-4479-968a-b747566504ff"
      unitRef="usd">-579000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzctOC0xLTEtMjk3MjY_74ed2c08-3df6-45b5-819c-b61960dafbae"
      unitRef="usd">-151000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzctMTAtMS0xLTI5NzI2_ea340f96-e5aa-4797-b67a-548a5eee6d9f"
      unitRef="usd">-142000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzctMTItMS0xLTI5NzI2_bce1f87e-3d30-45ea-8d59-eb3cadff836d"
      unitRef="usd">-129000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzgtMi0xLTEtMjk3MjY_f401a6cf-6038-43f7-8ce4-65143d34c7db"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzgtNC0xLTEtMjk3MjY_a04ee517-b742-45ed-a629-19bdde0947ab"
      unitRef="usd">-23000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzgtNi0xLTEtMjk3MjY_7c14ea05-3106-4239-99c6-ccca6571ea3b"
      unitRef="usd">-73000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzgtOC0xLTEtMjk3MjY_afefd409-52bb-485a-a2e0-5cd2c6ffa99a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzgtMTAtMS0xLTI5NzI2_674b0167-6cd9-497a-adab-896523d108a0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzgtMTItMS0xLTI5NzI2_c61d4905-2ec7-4426-b433-303f6c12f793"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzktMi0xLTEtMjk3MjY_40abb03c-dd43-40a9-b20b-8c0109544570"
      unitRef="usd">623000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzktNC0xLTEtMjk3MjY_ef2fcbdf-81da-4db6-bc5b-5dbd38c884d2"
      unitRef="usd">790000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzktNi0xLTEtMjk3MjY_dceb1f4d-862b-4088-b05f-1210d9af6179"
      unitRef="usd">593000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzktOC0xLTEtMjk3MjY_af7c5e04-8e72-44cb-bb87-98807c239206"
      unitRef="usd">503000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzktMTAtMS0xLTI5NzI2_c0f3d9dc-7376-4672-9d0d-3da72e41e32f"
      unitRef="usd">524000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozZGNiOTA2ZGQ1YTc0NjlkYjg3YzJlNjNiYTRjZGI3Yy90YWJsZXJhbmdlOjNkY2I5MDZkZDVhNzQ2OWRiODdjMmU2M2JhNGNkYjdjXzktMTItMS0xLTI5NzI2_f10c66c6-be43-4d6b-b772-61ba3d28c9d5"
      unitRef="usd">551000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzIyOTA_bc29512a-cf1b-4345-89b9-1fed612972c9"
      unitRef="number">0.10</jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODIw_bc5f9966-a027-4a52-90f2-882ba6752e31">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the weighted-average actuarial assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Worldwide Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Periodic Benefit Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of increase in compensation levels&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected long-term rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of increase in compensation levels&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzMtMi0xLTEtMjk3MjY_4fa4a877-c33c-4e51-b703-dbba1a60e9e5"
      unitRef="number">0.0214</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzMtNC0xLTEtMjk3MjY_a7e315dd-1808-4ace-9848-d463f06f114c"
      unitRef="number">0.0282</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzMtNi0xLTEtMjk3MjY_2d49436c-71f1-4720-bbf8-b0da9f5db42f"
      unitRef="number">0.0363</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzMtOC0xLTEtMjk3MjY_ea9ba5fa-5f68-490e-b5dc-1ff2503b52b4"
      unitRef="number">0.0209</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzMtMTAtMS0xLTI5NzI2_9aa4e89b-9e6d-4f10-99a7-90ec7aef1496"
      unitRef="number">0.0304</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzMtMTItMS0xLTI5NzI2_60ff8447-1fbe-47e1-9750-e97b59c3b778"
      unitRef="number">0.0445</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzQtMi0xLTEtMjk3MjY_ed1bfb2d-6411-4578-a5f4-940f048efb13"
      unitRef="number">0.0234</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzQtNC0xLTEtMjk3MjY_b8a26bc1-2af2-4cd3-963f-e8ee42ff4ced"
      unitRef="number">0.0313</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzQtNi0xLTEtMjk3MjY_4354cc62-2d69-433a-8aa9-1032c155c2fd"
      unitRef="number">0.0413</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzQtOC0xLTEtMjk3MjY_1d51b9cc-dc53-4e48-89ef-5cea5aa36590"
      unitRef="number">0.0233</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzQtMTAtMS0xLTI5NzI2_82207509-8a14-4a35-b6d4-1f05b9370b61"
      unitRef="number">0.0308</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzQtMTItMS0xLTI5NzI2_3fee2d46-8526-4938-8622-f5bacd2ee7d5"
      unitRef="number">0.0425</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzUtMi0xLTEtMjk3MjY_5b03c718-fca9-40c0-8610-cd9c6ed05b43"
      unitRef="number">0.0401</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzUtNC0xLTEtMjk3MjY_1a0ad94a-f662-442a-a238-fa1eb8f25c16"
      unitRef="number">0.0400</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzUtNi0xLTEtMjk3MjY_cdf9ba35-e5a7-4bf8-8f82-024eb62d229a"
      unitRef="number">0.0399</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzUtOC0xLTEtMjk3MjY_fe1d7918-4f2b-4101-beef-2cf2b626d6a1"
      unitRef="number">0.0425</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzUtMTAtMS0xLTI5NzI2_f6d38675-a38a-41cb-8677-612fb3f4e256"
      unitRef="number">0.0425</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i1ef53c06a5d541acaa9f1e6036518b49_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzUtMTItMS0xLTI5NzI2_5ad76eb4-e607-480c-b790-1ba1b8e966c0"
      unitRef="number">0.0429</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzYtMi0xLTEtMjk3MjY_a46b9c05-fc77-4d23-bd47-f581ab237532"
      unitRef="number">0.0771</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzYtNC0xLTEtMjk3MjY_f96b77f8-e96c-44a5-aed4-e605b36ea674"
      unitRef="number">0.0812</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i152260c6c54041ec8a625469070aec87_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzYtNi0xLTEtMjk3MjY_e0ca3fbb-0cda-49c3-a1ba-84a077fe8d30"
      unitRef="number">0.0831</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzktMi0xLTEtMjk3MjY_771b47c4-11c2-4ce9-8072-d79e52c2ed83"
      unitRef="number">0.0249</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzktNC0xLTEtMjk3MjY_f0dea56c-ff09-415a-a493-ee11fb3946c1"
      unitRef="number">0.0214</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i20e1360ceda342bdac619fa006a12c36_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzktNi0xLTEtMjk3MjY_b3eb33ed-0118-49f3-85f6-9ace553be359"
      unitRef="number">0.0291</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzktOC0xLTEtMjk3MjY_253ea0c0-ef75-41a2-86c3-37d3180b7b7f"
      unitRef="number">0.0268</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzktMTAtMS0xLTI5NzI2_9896f25c-4cfb-4cb3-bdff-eba53ec47cac"
      unitRef="number">0.0223</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i4cf76105357f41648e3142ea1703f16a_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzktMTItMS0xLTI5NzI2_a87750c5-e796-4549-b800-2581c136332a"
      unitRef="number">0.0339</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzEwLTItMS0xLTI5NzI2_5dd8a96f-d802-4b4a-8194-9225b3eebfb6"
      unitRef="number">0.0401</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzEwLTQtMS0xLTI5NzI2_5db86987-44c1-4a7b-a235-4490bf251953"
      unitRef="number">0.0400</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i20e1360ceda342bdac619fa006a12c36_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzEwLTYtMS0xLTI5NzI2_c09d1f00-e2a7-4aed-90ae-449f1e0ad5f3"
      unitRef="number">0.0401</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzEwLTgtMS0xLTI5NzI2_4b14bd8c-29e6-48b4-936d-85b3bb2b28b0"
      unitRef="number">0.0421</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzEwLTEwLTEtMS0yOTcyNg_3db821cf-02c3-44f6-8d22-849a3b5aa203"
      unitRef="number">0.0427</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i4cf76105357f41648e3142ea1703f16a_I20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo0NWY5MGVkOGM1Njk0MmYxOTBhMjQ2ODc0MzJjNTlmNi90YWJsZXJhbmdlOjQ1ZjkwZWQ4YzU2OTQyZjE5MGEyNDY4NzQzMmM1OWY2XzEwLTEyLTEtMS0yOTcyNg_0c4bea58-5d7b-4fff-bbe2-f5a616d724c7"
      unitRef="number">0.0429</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODEz_5eecebd2-ec2d-4853-b520-b8c415850c5a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the assumed healthcare cost trend rates, for all individuals:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Healthcare Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare cost trend rate assumed for next year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate to which the cost trend rate is assumed to decline (ultimate trend)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year the rate reaches the ultimate trend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock>
    <us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo4MjgwZTFmY2I4Njc0NzFhODE2OTI3ODZhZWNjNTZhMC90YWJsZXJhbmdlOjgyODBlMWZjYjg2NzQ3MWE4MTY5Mjc4NmFlY2M1NmEwXzEtMi0xLTEtMjk3MjY_1c331f8c-3ee0-4618-99b5-79eff8b1f16c"
      unitRef="number">0.0533</us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo4MjgwZTFmY2I4Njc0NzFhODE2OTI3ODZhZWNjNTZhMC90YWJsZXJhbmdlOjgyODBlMWZjYjg2NzQ3MWE4MTY5Mjc4NmFlY2M1NmEwXzEtNC0xLTEtMjk3MjY_bc486edd-5a2b-4fe7-be73-67bb082a6da7"
      unitRef="number">0.0568</us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo4MjgwZTFmY2I4Njc0NzFhODE2OTI3ODZhZWNjNTZhMC90YWJsZXJhbmdlOjgyODBlMWZjYjg2NzQ3MWE4MTY5Mjc4NmFlY2M1NmEwXzItMi0xLTEtMjk3MjY_6b511762-895c-4a03-821f-e228c5c5df31"
      unitRef="number">0.0373</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo4MjgwZTFmY2I4Njc0NzFhODE2OTI3ODZhZWNjNTZhMC90YWJsZXJhbmdlOjgyODBlMWZjYjg2NzQ3MWE4MTY5Mjc4NmFlY2M1NmEwXzItNC0xLTEtMjk3MjY_49b32010-b7dc-49ac-b861-98b785fd6952"
      unitRef="number">0.0449</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo4MjgwZTFmY2I4Njc0NzFhODE2OTI3ODZhZWNjNTZhMC90YWJsZXJhbmdlOjgyODBlMWZjYjg2NzQ3MWE4MTY5Mjc4NmFlY2M1NmEwXzMtMi0xLTEtMjk3MjY_5ced3980-1bc2-4f51-8e7b-bff7d1a336c8">2046</us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
    <us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo4MjgwZTFmY2I4Njc0NzFhODE2OTI3ODZhZWNjNTZhMC90YWJsZXJhbmdlOjgyODBlMWZjYjg2NzQ3MWE4MTY5Mjc4NmFlY2M1NmEwXzMtNC0xLTEtMjk3MjY_7e5f68a3-6520-4536-920f-166ac27fd84a">2040</us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
    <us-gaap:ScheduleOfNetFundedStatusTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODcx_f9ed0e51-202d-46e7-b855-ac188cde2348">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2021 and 2020 for the Company&#x2019;s defined benefit retirement plans and other post-retirement plans:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&#160;&#x2014; beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amendments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gains) losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&#160;&amp;amp; acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments, settlements&#160;&amp;amp; restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid from plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41,582&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;43,300&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,878&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&#160;&#x2014; beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&#160;&amp;amp; acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid from plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41,930&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funded status &#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized in the Company&#x2019;s Balance Sheet consist of the following:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in the consolidated balance sheet&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized net transition obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,929&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,063&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,419&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Benefit Obligations&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40,356&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The actuarial gain for retirement plans in 2021 was primarily related to increases in discount rates; the actuarial losses for retirement plans in 2020 were primarily related to decreases in discount rates.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;623&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;790&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;524&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,927)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service (cost) credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total loss/(income) recognized in other comprehensive income, before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in net periodic benefit cost and other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetFundedStatusTableTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMtMi0xLTEtMjk3MjY_59874dc4-a0c7-4d5e-ad4a-0c6fe28311a9"
      unitRef="usd">43300000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i20e1360ceda342bdac619fa006a12c36_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMtNC0xLTEtMjk3MjY_8c266286-eecf-476b-875e-49838d60a210"
      unitRef="usd">37188000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMtNi0xLTEtMjk3MjY_63e8dc2e-ddbf-40ac-965f-5b9c53177266"
      unitRef="usd">5028000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i4cf76105357f41648e3142ea1703f16a_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMtOC0xLTEtMjk3MjY_e4f62e37-cedd-4d61-8078-89af0036fc4f"
      unitRef="usd">5076000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQtMi0xLTEtMjk3MjY_62a29a41-653c-48b9-a0c4-1527916bf0b8"
      unitRef="usd">1421000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQtNC0xLTEtMjk3MjY_fcbcb471-56b5-47f3-8be6-8703fac4f8c8"
      unitRef="usd">1380000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQtNi0xLTEtMjk3MjY_c4ddb0c2-793e-48c0-a203-ba6f4fefa930"
      unitRef="usd">309000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQtOC0xLTEtMjk3MjY_65192530-2fe6-4d3b-8aca-43b533241032"
      unitRef="usd">287000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzUtMi0xLTEtMjk3MjY_d59fbc13-32aa-4f87-ab5a-efb9e6f69bcd"
      unitRef="usd">770000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzUtNC0xLTEtMjk3MjY_ce817f2e-ff92-4ba2-8b10-06d9cc5ca883"
      unitRef="usd">955000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzUtNi0xLTEtMjk3MjY_53188fd1-d74e-4b4c-92ef-ccd8fa47377d"
      unitRef="usd">81000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzUtOC0xLTEtMjk3MjY_4d572846-8237-42bc-a513-62d70aaec2f9"
      unitRef="usd">133000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzYtMi0xLTEtMjk3MjY_0a7b3be5-0278-431c-a223-36633f530900"
      unitRef="usd">67000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzYtNC0xLTEtMjk3MjY_5111ed23-dcdb-4b64-8940-c252065477bd"
      unitRef="usd">61000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzYtNi0xLTEtMjk3MjY_602886b0-ba30-43ec-9f57-bcc75ac42aac"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzYtOC0xLTEtMjk3MjY_e813eec9-2cba-4be6-b05b-7bb4df5baadc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzctMi0xLTEtMjk3MjY_ec9bda1b-3765-4e0b-a156-76bdf0e9a47b"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzctNC0xLTEtMjk3MjY_30efdc62-aa54-43b7-b080-624b5b9ed022"
      unitRef="usd">-1780000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzctNi0xLTEtMjk3MjY_f8f62458-0a53-4279-afaa-cf89a70bf6b5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzctOC0xLTEtMjk3MjY_4bd58e59-77a6-4ad9-98ab-14112eae8c40"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzgtMi0xLTEtMjk3MjY_c5750910-bbcb-4f4f-a192-0f7097076946"
      unitRef="usd">2132000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzgtNC0xLTEtMjk3MjY_e14506ca-4b14-4733-8878-e8663edb1ec0"
      unitRef="usd">-5716000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzgtNi0xLTEtMjk3MjY_6fc8fa09-bc3d-4374-9142-d6595e14c33a"
      unitRef="usd">188000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzgtOC0xLTEtMjk3MjY_db0d10d7-394e-4b1b-a0e8-6aeae7cff341"
      unitRef="usd">75000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzktMi0xLTEtMjk3MjY_f945a179-c654-4b6e-8407-76c90c3685eb"
      unitRef="usd">-2000000</jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzktNC0xLTEtMjk3MjY_92880c9f-4bb8-4dad-b010-d5a801b3fa82"
      unitRef="usd">-88000000</jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzktNi0xLTEtMjk3MjY_a7cb09cc-db4e-48ee-ac60-70f07656dd29"
      unitRef="usd">0</jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzktOC0xLTEtMjk3MjY_4f9858f9-3173-46ec-96ce-b58430f321b0"
      unitRef="usd">0</jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:CurtailmentsAndSettlementsAndRestructuring
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEwLTItMS0xLTI5NzI2_42606f29-e2fb-4d05-b2ed-46731f5b4ec0"
      unitRef="usd">7000000</jnj:CurtailmentsAndSettlementsAndRestructuring>
    <jnj:CurtailmentsAndSettlementsAndRestructuring
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEwLTQtMS0xLTI5NzI2_60993dc7-6d48-4269-871c-ebd4de0e4d8d"
      unitRef="usd">24000000</jnj:CurtailmentsAndSettlementsAndRestructuring>
    <jnj:CurtailmentsAndSettlementsAndRestructuring
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEwLTYtMS0xLTI5NzI2_11acae10-a4d8-482d-a594-75fd43bdcc7d"
      unitRef="usd">0</jnj:CurtailmentsAndSettlementsAndRestructuring>
    <jnj:CurtailmentsAndSettlementsAndRestructuring
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEwLTgtMS0xLTI5NzI2_2b353d6a-b658-42dd-9251-5aae585edc08"
      unitRef="usd">0</jnj:CurtailmentsAndSettlementsAndRestructuring>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzExLTItMS0xLTI5NzI2_7763c6fe-81f7-4e24-a0e1-236841cce119"
      unitRef="usd">1157000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzExLTQtMS0xLTI5NzI2_28d289c0-e634-42f6-8331-d94e85b10dd2"
      unitRef="usd">1111000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzExLTYtMS0xLTI5NzI2_b73ba4f6-36ad-4408-ac36-84c7bbf114d6"
      unitRef="usd">348000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzExLTgtMS0xLTI5NzI2_d79f18eb-9757-4a44-924f-ae1396b32639"
      unitRef="usd">396000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEyLTItMS0xLTI5NzI2_020ede9e-ce22-4c04-b43f-4cfde23a9776"
      unitRef="usd">683000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEyLTQtMS0xLTI5NzI2_c0c742a3-bc8a-4f7f-a03d-70ab9e795261"
      unitRef="usd">-1003000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEyLTYtMS0xLTI5NzI2_95de8753-4015-442e-93a5-59ddced41a8b"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEyLTgtMS0xLTI5NzI2_9c3d9164-6078-45dc-b337-8cc8508e2291"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEzLTItMS0xLTI5NzI2_64baea35-7b6f-41b2-a2a5-14fe90f7fc94"
      unitRef="usd">41582000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEzLTQtMS0xLTI5NzI2_291b268f-b622-4544-bf99-91d58382251c"
      unitRef="usd">43300000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEzLTYtMS0xLTI5NzI2_899b043f-cd46-4b12-9349-364c8ef7b026"
      unitRef="usd">4878000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzEzLTgtMS0xLTI5NzI2_311e1445-5f29-43f7-83d7-98073aaf5257"
      unitRef="usd">5028000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE1LTItMS0xLTI5NzI2_c924e0bd-db42-4e80-b268-d5fd44a4bd2b"
      unitRef="usd">38195000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i20e1360ceda342bdac619fa006a12c36_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE1LTQtMS0xLTI5NzI2_0d8bf734-e4b3-4988-a9a5-101e184d0277"
      unitRef="usd">32201000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE1LTYtMS0xLTI5NzI2_d80f41bc-f58b-4b77-91bd-93cc768acf1d"
      unitRef="usd">90000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4cf76105357f41648e3142ea1703f16a_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE1LTgtMS0xLTI5NzI2_455cb84f-3edf-45bb-83c3-e678ff58b2b6"
      unitRef="usd">115000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE2LTItMS0xLTI5NzI2_a1e2f8f1-2d18-46ee-b637-9dbe1f7d27b3"
      unitRef="usd">4439000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE2LTQtMS0xLTI5NzI2_1cb66b3e-0360-4f9b-92ae-55b5d92ddb94"
      unitRef="usd">5524000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE2LTYtMS0xLTI5NzI2_62e13806-8463-4255-bccf-5796769e6343"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE2LTgtMS0xLTI5NzI2_1a1a430c-b8b6-4215-8a07-43f7ab44ce31"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE3LTItMS0xLTI5NzI2_680b7ac0-8c14-4682-bf83-01a306cc030c"
      unitRef="usd">969000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE3LTQtMS0xLTI5NzI2_53c3631e-f27a-46ab-9caa-62cd2e3c3e45"
      unitRef="usd">870000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE3LTYtMS0xLTI5NzI2_1ff68ace-6303-42cb-a580-77e638330c56"
      unitRef="usd">343000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE3LTgtMS0xLTI5NzI2_43028c87-6ba4-43be-9b10-50e0e8d2054d"
      unitRef="usd">357000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE4LTItMS0xLTI5NzI2_1ff74c02-ea0a-4c63-9bc4-03a70331e799"
      unitRef="usd">67000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE4LTQtMS0xLTI5NzI2_77968673-eec8-4204-a740-ea357ba5686f"
      unitRef="usd">61000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE4LTYtMS0xLTI5NzI2_af2f69ba-bfc5-4023-945c-5e90caff1713"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE4LTgtMS0xLTI5NzI2_a80b106f-a73b-4982-973c-fa396ae7b636"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE5LTItMS0xLTI5NzI2_7368820c-2c20-4d87-8c55-ad752149b735"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE5LTQtMS0xLTI5NzI2_3dbf7fa7-3545-45c9-a174-a06248839b81"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE5LTYtMS0xLTI5NzI2_74a81dce-4929-44d5-938f-14f4f3bb853d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzE5LTgtMS0xLTI5NzI2_b339d921-2623-4ae0-a45d-85820e4decd0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIwLTItMS0xLTI5NzI2_f4fd2a6b-d59a-4870-b3ff-c1acb13c1378"
      unitRef="usd">-2000000</jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIwLTQtMS0xLTI5NzI2_76af1318-9054-4b48-bfb6-b5be06b07a7b"
      unitRef="usd">-84000000</jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIwLTYtMS0xLTI5NzI2_c53f55c9-c126-49ed-a0af-ac448f19c448"
      unitRef="usd">0</jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIwLTgtMS0xLTI5NzI2_1396a694-d75f-489a-94d3-2cb933ddb8f4"
      unitRef="usd">0</jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIxLTItMS0xLTI5NzI2_9d61fe28-6e77-4863-9922-9a157ffeecb0"
      unitRef="usd">1157000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIxLTQtMS0xLTI5NzI2_3e55ee20-7a19-49ee-98af-2272a135ffec"
      unitRef="usd">1111000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIxLTYtMS0xLTI5NzI2_da85c531-165b-4a73-9a82-47d8b257b249"
      unitRef="usd">348000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIxLTgtMS0xLTI5NzI2_174cf22a-7345-4067-8182-101a6da2f343"
      unitRef="usd">396000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIyLTItMS0xLTI5NzI2_85c1baae-bc03-482e-b0c4-2d459b5335f1"
      unitRef="usd">-574000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIyLTQtMS0xLTI5NzI2_3f680de0-9563-4350-8b0f-451ea9e3eb4a"
      unitRef="usd">747000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIyLTYtMS0xLTI5NzI2_52415688-1c7a-49e7-b8e5-aa675b70b3fd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIyLTgtMS0xLTI5NzI2_2b41d29f-0472-4002-93be-470660e58781"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIzLTItMS0xLTI5NzI2_ea7977c8-f1cb-4aa3-a43e-3675656aa998"
      unitRef="usd">41930000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIzLTQtMS0xLTI5NzI2_c8177486-40d0-4cdb-ae2f-edc662295aa6"
      unitRef="usd">38195000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIzLTYtMS0xLTI5NzI2_bbf89f77-e62a-40b1-8033-4130c3e7c5ae"
      unitRef="usd">102000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzIzLTgtMS0xLTI5NzI2_8850789c-adb1-48fa-b984-1ad68bd01d3d"
      unitRef="usd">90000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI0LTItMS0xLTI5NzI2_6d73b970-4cb8-428b-91bc-59243e863c12"
      unitRef="usd">348000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI0LTQtMS0xLTI5NzI2_cf2331ae-d405-4772-835c-879a5dced81c"
      unitRef="usd">-5105000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI0LTYtMS0xLTI5NzI2_9f45ac7b-13f4-45e4-9b3a-1c88196de836"
      unitRef="usd">-4776000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI0LTgtMS0xLTI5NzI2_d51f35e0-e89e-48e9-9115-f7ea031c502a"
      unitRef="usd">-4938000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI2LTItMS0xLTI5NzI2_4ad9ffb9-7df4-4acc-a73f-4e2321efb62e"
      unitRef="usd">4436000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI2LTQtMS0xLTI5NzI2_4bc814a1-591b-4422-a42e-ce280f751747"
      unitRef="usd">656000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI2LTYtMS0xLTI5NzI2_63b61eb5-9cd1-4337-a0d8-9f52816f7f63"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI2LTgtMS0xLTI5NzI2_ecb8e794-7a42-4c69-8ce1-bf32f474ba05"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI3LTItMS0xLTI5NzI2_1b854ec8-ce3c-4ebc-852d-245149d0eebd"
      unitRef="usd">115000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI3LTQtMS0xLTI5NzI2_ac61bf39-4da9-4b44-ae64-49fbdb6110a1"
      unitRef="usd">125000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI3LTYtMS0xLTI5NzI2_7fbac882-ca40-49db-8257-8926f5a02d75"
      unitRef="usd">438000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI3LTgtMS0xLTI5NzI2_385ed932-4a94-4672-bef5-6b290b9babbf"
      unitRef="usd">418000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI4LTItMS0xLTI5NzI2_74587f31-4eee-4e61-9c9f-59a8e2f65e09"
      unitRef="usd">3973000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI4LTQtMS0xLTI5NzI2_fc68f3f8-e747-4858-8394-d57c234a3617"
      unitRef="usd">5636000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI4LTYtMS0xLTI5NzI2_f11403d5-9fde-4e13-8a76-1e455c96329b"
      unitRef="usd">4338000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI4LTgtMS0xLTI5NzI2_65728470-31a8-4a67-a224-acaa3b98f65c"
      unitRef="usd">4520000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI5LTItMS0xLTI5NzI2_bdd034d2-381e-4cfb-9585-df314e87ba71"
      unitRef="usd">348000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI5LTQtMS0xLTI5NzI2_e8bb03fa-d15d-474f-a0d5-7f5c66b78fb5"
      unitRef="usd">-5105000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI5LTYtMS0xLTI5NzI2_6ea9fb6f-ab2c-4887-b7ff-3a7d37f07711"
      unitRef="usd">-4776000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzI5LTgtMS0xLTI5NzI2_a035a809-bb9a-48e0-b440-1d1b526a6f2f"
      unitRef="usd">-4938000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMxLTItMS0xLTI5NzI2_f197d502-c483-419e-9e68-ea6f1a9b2d40"
      unitRef="usd">-5539000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMxLTQtMS0xLTI5NzI2_b7e42af5-a9d5-46e1-8fcd-0b546c2aef2c"
      unitRef="usd">-10860000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMxLTYtMS0xLTI5NzI2_bc3192af-ef04-446d-9e5f-f979ce4489fe"
      unitRef="usd">-1113000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMxLTgtMS0xLTI5NzI2_43fd7f6e-bed3-48a5-97dc-ce2ab0204f00"
      unitRef="usd">-1463000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMyLTItMS0xLTI5NzI2_63f03570-e8ca-4b91-a915-27d0c2b66716"
      unitRef="usd">-1610000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMyLTQtMS0xLTI5NzI2_8231edf3-356c-497f-bfde-e78b1690e8a2"
      unitRef="usd">-1797000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMyLTYtMS0xLTI5NzI2_9358f4d3-7b0f-44e1-9a82-05b87b84740e"
      unitRef="usd">-13000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMyLTgtMS0xLTI5NzI2_8c718539-3128-4f68-8a47-f571dfbe28c0"
      unitRef="usd">-44000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMzLTItMS0xLTI5NzI2_2d8bef37-c2e2-413f-aa92-3fb502ca740d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax
      contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMzLTQtMS0xLTI5NzI2_4e04d799-cd17-44fb-b41d-05439084973f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax
      contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMzLTYtMS0xLTI5NzI2_fe637d67-3a83-4d5c-b38c-a3252f4a2c3b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax
      contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzMzLTgtMS0xLTI5NzI2_90f5852c-f91a-49a0-82f9-3cce3088e50e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzM0LTItMS0xLTI5NzI2_30fcd810-f5f8-4d32-83f2-2da89978b369"
      unitRef="usd">3929000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzM0LTQtMS0xLTI5NzI2_cc3cee0a-2d5f-4e86-9137-aa317b85c3c3"
      unitRef="usd">9063000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzM0LTYtMS0xLTI5NzI2_2c84d070-c0ac-469d-a10b-deaf1e413012"
      unitRef="usd">1100000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i00ddcc25df744b98bd6075a18db56c7a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzM0LTgtMS0xLTI5NzI2_9e59b225-dd9b-401f-b1f2-be45a5275742"
      unitRef="usd">1419000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzM2LTItMS0xLTI5NzI2_9c322b50-e99b-47f4-b590-e33c128cbec5"
      unitRef="usd">39049000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="idb9083ce9021495581a16b2fab55b31b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzM2LTQtMS0xLTI5NzI2_7ad86b55-47f0-4396-8544-be206db99bd9"
      unitRef="usd">40356000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQyLTItMS0xLTI5NzI2_a01847da-fc34-4f38-8198-d1312a134748"
      unitRef="usd">623000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQyLTQtMS0xLTI5NzI2_7149b967-c275-48e0-a4cb-b4df5df1f125"
      unitRef="usd">790000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQyLTYtMS0xLTI5NzI2_a4c3d09e-f2ba-4fda-a83f-1c90585eee16"
      unitRef="usd">503000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQyLTgtMS0xLTI5NzI2_3c3bf348-4808-4ba8-a348-9e07260e479b"
      unitRef="usd">524000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQzLTItMS0xLTI5NzI2_63a39209-04a7-44f6-b986-3be9dd576d7b"
      unitRef="usd">3927000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQzLTQtMS0xLTI5NzI2_4d0f7d76-dab2-4f4d-83c3-c6c6f2b1b4bc"
      unitRef="usd">-2616000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQzLTYtMS0xLTI5NzI2_d68cf0f2-18f0-433f-9d58-6550bce6e70f"
      unitRef="usd">199000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQzLTgtMS0xLTI5NzI2_91f511ce-145d-4020-91a3-141c4c1e7b0a"
      unitRef="usd">81000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ0LTItMS0xLTI5NzI2_c9ab92fc-b6c6-4ffd-8b1b-d233391f7664"
      unitRef="usd">-1257000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ0LTQtMS0xLTI5NzI2_57a344a2-2d69-4d40-aa1e-f5025b152d05"
      unitRef="usd">-891000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ0LTYtMS0xLTI5NzI2_99d9a5fc-6d29-4e47-ae43-2ce36e04286d"
      unitRef="usd">-151000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ0LTgtMS0xLTI5NzI2_fe69caca-54c0-467c-816e-23f54119b3f2"
      unitRef="usd">-142000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ1LTItMS0xLTI5NzI2_720cecbc-a785-402b-ad70-28b12eabfebc"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ1LTQtMS0xLTI5NzI2_f8865e47-9aeb-48b6-87d5-807d0707c1da"
      unitRef="usd">-1780000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ1LTYtMS0xLTI5NzI2_f0f584a6-3d63-43a1-bc05-affcd2ad166a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ1LTgtMS0xLTI5NzI2_0f8332ec-edee-4e63-b473-25a3f80be608"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ2LTItMS0xLTI5NzI2_48763032-acd3-4ef2-9808-7281ebd9223d"
      unitRef="usd">-181000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ2LTQtMS0xLTI5NzI2_2dcddbb5-5ed5-4db8-a13a-8c80e95e9c69"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ2LTYtMS0xLTI5NzI2_e91e2a2b-f9f4-4e61-883e-2463dbce2dff"
      unitRef="usd">-31000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ2LTgtMS0xLTI5NzI2_0d695808-458d-4d5d-98bb-fc057a3dd5eb"
      unitRef="usd">-31000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <jnj:EffectOfExchangeRates
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ3LTItMS0xLTI5NzI2_6ae10998-2fe5-4fe4-b6ea-ecd9b964f5a6"
      unitRef="usd">-136000000</jnj:EffectOfExchangeRates>
    <jnj:EffectOfExchangeRates
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ3LTQtMS0xLTI5NzI2_c03764b5-4880-4244-b8d3-8f58749069a5"
      unitRef="usd">293000000</jnj:EffectOfExchangeRates>
    <jnj:EffectOfExchangeRates
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ3LTYtMS0xLTI5NzI2_1b270da7-fd72-4baf-b51a-d576a3edca13"
      unitRef="usd">0</jnj:EffectOfExchangeRates>
    <jnj:EffectOfExchangeRates
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ3LTgtMS0xLTI5NzI2_30a9024e-88ff-4af9-a4b3-da3826e56242"
      unitRef="usd">1000000</jnj:EffectOfExchangeRates>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ4LTItMS0xLTI5NzI2_3bbca482-6f51-43d2-aabf-862f9f889f19"
      unitRef="usd">-5134000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ4LTQtMS0xLTI5NzI2_f684e52d-a3cd-4cf3-a5d9-e31f9e918a1c"
      unitRef="usd">236000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ4LTYtMS0xLTI5NzI2_1541bb96-0258-440d-a703-c4ececf531f5"
      unitRef="usd">-319000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ4LTgtMS0xLTI5NzI2_ce4f0085-0f40-4ad7-b6d6-bc2c48c1d90d"
      unitRef="usd">-191000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ5LTItMS0xLTI5NzI2_8aee5b1a-e0c6-48d4-9189-4efe453cb92a"
      unitRef="usd">-4511000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="ica69d97c2d274775b691ce7c2ed4bf66_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ5LTQtMS0xLTI5NzI2_02489647-3dac-46f6-b2dc-9dbca9cd7c9b"
      unitRef="usd">1026000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="i962cd043e9b4492faaf0588d48ce19c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ5LTYtMS0xLTI5NzI2_ec656c0a-547e-4a64-a5ed-41304435e3ca"
      unitRef="usd">184000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="idb1336b6527049b3a0800de5e99daf77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTplYzY0Y2NlYjhmZWU0NDY1YjVkOTdiYjgzMGUyZmZhNC90YWJsZXJhbmdlOmVjNjRjY2ViOGZlZTQ0NjViNWQ5N2JiODMwZTJmZmE0XzQ5LTgtMS0xLTI5NzI2_b76515a1-260b-462d-a042-635899c5a6e7"
      unitRef="usd">333000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:PensionContributions
      contextRef="i58b503af83254025807546f7f976450b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzQ1MjI_3f4ddf1c-710a-4087-8ed1-386bd5413aff"
      unitRef="usd">102000000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="i5a1c5e25bdb6461788f20271b3996e97_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzQ1Mjk_c837f27d-6cd4-4813-9e28-c80066285a7b"
      unitRef="usd">867000000</us-gaap:PensionContributions>
    <jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODI4_5321e1bb-113e-4668-9c53-2909f0407d8a">&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the funded status of the Company's U.S. Qualified &amp;amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2021 and December&#160;31, 2020, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Qualified Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-Qualified Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Funded Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unfunded Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over (Under) Funded Status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(493)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i58f88b3066f8425fb8a00e6f0f402f0c_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzMtMS0xLTEtMjk3MjY_66c798c0-cc56-4df1-971b-66b6061d99d9"
      unitRef="usd">27944000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7e8d176ee39d4902bc1ae66d486ece07_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzMtMi0xLTEtMjk3MjY_d36ece34-7f44-40a6-a3cb-c67cadd2dd2b"
      unitRef="usd">25554000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia15acadd24374bdd89b9144660681aac_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzMtMy0xLTEtMjk3MjY_79b39619-29fd-4221-a92a-4f2acb5f48a6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i70e0e58ded464efe87df57667936575e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzMtNC0xLTEtMjk3MjY_95c49945-d83f-457e-a8d8-7f2ba6a69ff5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib54b3dfabff34851a1673d1bd91d3667_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzMtNS0xLTEtMjk3MjY_73c7979e-a373-441a-bfbf-4ee30df44c4e"
      unitRef="usd">13986000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie541284941f54eb39c0cdd62a5aff1ac_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzMtNi0xLTEtMjk3MjY_70159aba-c6b4-4ddc-81a1-2a3432e27f3f"
      unitRef="usd">12641000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia1605c791bdd4560a2228fadfa81e2c5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzMtNy0xLTEtMjk3MjY_d29bbf5f-45f7-4572-a477-e821b09466b8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if7fcbc33c13a41e8885b35d3df83c640_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzMtOC0xLTEtMjk3MjY_08249f96-0360-4e8d-a661-5d5bfae7277b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i58f88b3066f8425fb8a00e6f0f402f0c_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzQtMS0xLTEtMjk3MjY_42793617-c9dc-4e9c-8fa4-6268970d364e"
      unitRef="usd">25041000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i7e8d176ee39d4902bc1ae66d486ece07_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzQtMi0xLTEtMjk3MjY_d07d1a5c-d941-479c-9776-a213acd2571f"
      unitRef="usd">25466000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ia15acadd24374bdd89b9144660681aac_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzQtMy0xLTEtMjk3MjY_78b5cf20-8d4b-4b0a-a2a0-4caedaba2b79"
      unitRef="usd">2703000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i70e0e58ded464efe87df57667936575e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzQtNC0xLTEtMjk3MjY_19cfa5e0-7c64-44ce-9196-d22f878adc82"
      unitRef="usd">2748000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ib54b3dfabff34851a1673d1bd91d3667_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzQtNS0xLTEtMjk3MjY_19a6d3da-c09b-4fc6-ac61-6d435d2c36f7"
      unitRef="usd">13428000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ie541284941f54eb39c0cdd62a5aff1ac_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzQtNi0xLTEtMjk3MjY_b3ea6cc0-806e-4bb2-9c99-9ba7a070e94b"
      unitRef="usd">14541000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ia1605c791bdd4560a2228fadfa81e2c5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzQtNy0xLTEtMjk3MjY_00088ed5-7676-40ab-bcae-0250031ce6b5"
      unitRef="usd">410000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="if7fcbc33c13a41e8885b35d3df83c640_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzQtOC0xLTEtMjk3MjY_7c610ff2-c9c9-438c-a834-68dcdd82af49"
      unitRef="usd">545000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i58f88b3066f8425fb8a00e6f0f402f0c_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzUtMS0xLTEtMjk3MjY_1d8cd45b-1d2f-49e4-a536-3c91cefbf3ce"
      unitRef="usd">23985000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i7e8d176ee39d4902bc1ae66d486ece07_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzUtMi0xLTEtMjk3MjY_3a42fa64-287d-4c49-ba51-3c509837145c"
      unitRef="usd">24158000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="ia15acadd24374bdd89b9144660681aac_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzUtMy0xLTEtMjk3MjY_b687af34-55c2-4b86-ad7f-1c07d7ebb8d0"
      unitRef="usd">2479000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i70e0e58ded464efe87df57667936575e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzUtNC0xLTEtMjk3MjY_a6cdea8c-8471-4fcb-9703-f0bec0cfd10b"
      unitRef="usd">2495000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="ib54b3dfabff34851a1673d1bd91d3667_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzUtNS0xLTEtMjk3MjY_651f80b1-39ce-4d0a-a157-52a095130968"
      unitRef="usd">12212000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="ie541284941f54eb39c0cdd62a5aff1ac_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzUtNi0xLTEtMjk3MjY_2e37bbbe-70bf-4ccd-963a-0f1b60342670"
      unitRef="usd">13210000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="ia1605c791bdd4560a2228fadfa81e2c5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzUtNy0xLTEtMjk3MjY_5471ad68-394e-450e-af78-486f9494962d"
      unitRef="usd">373000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="if7fcbc33c13a41e8885b35d3df83c640_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzUtOC0xLTEtMjk3MjY_7c3ad552-c26d-451b-8dfd-d3a764babb97"
      unitRef="usd">493000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i58f88b3066f8425fb8a00e6f0f402f0c_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzctMS0xLTEtMjk3MjY_f624e12f-de54-4b24-a5cd-0acc67fd8f1d"
      unitRef="usd">2903000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i7e8d176ee39d4902bc1ae66d486ece07_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzctMi0xLTEtMjk3MjY_9e3e790c-e83f-4305-824d-83e3bdb14d55"
      unitRef="usd">88000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="ia15acadd24374bdd89b9144660681aac_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzctMy0xLTEtMjk3MjY_9ef5f338-41b0-4dff-9c98-7be21f7ad858"
      unitRef="usd">-2703000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i70e0e58ded464efe87df57667936575e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzctNC0xLTEtMjk3MjY_0fc72ac3-e2c7-4292-8ac6-95d133030cef"
      unitRef="usd">-2748000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="ib54b3dfabff34851a1673d1bd91d3667_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzctNS0xLTEtMjk3MjY_d46b6fd6-1189-4d8f-8319-dae3fc1d8534"
      unitRef="usd">558000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="ie541284941f54eb39c0cdd62a5aff1ac_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzctNi0xLTEtMjk3MjY_d0f5679c-ba26-44ea-ab7d-2234bc7552a5"
      unitRef="usd">-1900000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="ia1605c791bdd4560a2228fadfa81e2c5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzctNy0xLTEtMjk3MjY_dd7ca895-c107-47e4-b9aa-d903a56cc282"
      unitRef="usd">-410000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="if7fcbc33c13a41e8885b35d3df83c640_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzctOC0xLTEtMjk3MjY_62dad0af-72eb-4c38-b917-195e5ed42905"
      unitRef="usd">-545000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="i58f88b3066f8425fb8a00e6f0f402f0c_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzgtMS0xLTEtMjk3MjY_ad83bfee-30b2-4e5f-afaf-2dd2544b89fb"
      unitRef="usd">3959000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="i7e8d176ee39d4902bc1ae66d486ece07_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzgtMi0xLTEtMjk3MjY_211e07ce-4609-4656-a857-a2b2bc090376"
      unitRef="usd">1396000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="ia15acadd24374bdd89b9144660681aac_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzgtMy0xLTEtMjk3MjY_185781ce-eeb3-4b02-80cc-3add5082e96d"
      unitRef="usd">-2479000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="i70e0e58ded464efe87df57667936575e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzgtNC0xLTEtMjk3MjY_7f258594-49c8-445d-8d56-af64dc03138a"
      unitRef="usd">-2495000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="ib54b3dfabff34851a1673d1bd91d3667_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzgtNS0xLTEtMjk3MjY_e962bc4c-cab7-4135-ae83-a51465aaa1dc"
      unitRef="usd">1774000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="ie541284941f54eb39c0cdd62a5aff1ac_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzgtNi0xLTEtMjk3MjY_3e29ec32-ef06-4560-9258-1e5aedb95979"
      unitRef="usd">-569000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="ia1605c791bdd4560a2228fadfa81e2c5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzgtNy0xLTEtMjk3MjY_598a3289-35a7-4937-a531-25a0d8cf60e5"
      unitRef="usd">-373000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="if7fcbc33c13a41e8885b35d3df83c640_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozYTY3YzMxYWIxNmU0ZWFlYTNkYWZkNWUxMzA2YjcwYy90YWJsZXJhbmdlOjNhNjdjMzFhYjE2ZTRlYWVhM2RhZmQ1ZTEzMDZiNzBjXzgtOC0xLTEtMjk3MjY_b34c0f63-d2b4-4111-ae22-45a1258b5208"
      unitRef="usd">-493000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzQ5Njk_2d604456-2f36-462b-8c2c-1247c54f17bd"
      unitRef="usd">3900000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzQ5NzM_f16d36a7-fa32-40d5-8af2-717a3d378e9c"
      unitRef="usd">4200000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzQ5ODA_2fd033c8-14be-4982-bb5e-6b66d2fa486d"
      unitRef="usd">300000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzUwMjA_77ff044b-e1ea-4b53-997d-422d6cc08f92"
      unitRef="usd">8800000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzUwMjQ_315e8724-ebc1-4f09-8313-72062214314d"
      unitRef="usd">9800000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzUwMzE_d30a972f-76f1-4a97-a352-d88ab934b2c0"
      unitRef="usd">4400000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODYy_d6a9d481-275a-48f1-aa04-8c1342c6d0a9">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the projected future benefit payments from the Company&#x2019;s retirement and other benefit plans:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2027-2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Projected future benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other benefit plans&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzItMi0xLTEtMjk3MjY_bd06eb27-4a53-4997-a39e-a0e857bc975a"
      unitRef="usd">1317000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzItNC0xLTEtMjk3MjY_05fa750c-0722-4373-9490-3b9621bd6e35"
      unitRef="usd">1386000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzItNi0xLTEtMjk3MjY_8abc65db-f7ff-4230-834d-5f5cf8dca98d"
      unitRef="usd">1421000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzItOC0xLTEtMjk3MjY_873e63c6-f171-445a-ae6c-6aae40a1f699"
      unitRef="usd">1496000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzItMTAtMS0xLTI5NzI2_1c33a008-859d-484a-bafd-33b47d4ca296"
      unitRef="usd">1572000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="if217fbfb3878426eba07b1762dc50833_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzItMTItMS0xLTI5NzI2_41a3fa08-5199-4a7a-9b55-a38ea9be74f4"
      unitRef="usd">9279000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzUtMi0xLTEtMjk3MjY_3fb4f0e9-05fd-47c9-ba9a-d925d754c087"
      unitRef="usd">447000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzUtNC0xLTEtMjk3MjY_2f4081bb-da6f-4e49-8040-88cbf31d6843"
      unitRef="usd">459000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzUtNi0xLTEtMjk3MjY_3727f4b5-fd87-42ad-8979-f1e02b5f9f86"
      unitRef="usd">472000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzUtOC0xLTEtMjk3MjY_407e62fc-1209-437d-a587-6eb14382ed9e"
      unitRef="usd">485000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzUtMTAtMS0xLTI5NzI2_8e46d634-2406-4e27-a0b8-15141d0b9346"
      unitRef="usd">434000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i08e791c0544949eea59d9bb4511c337e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxY2VmM2Q3YmU1ODA0NTdjYjViOTYzN2FjNjY0NDM3ZS90YWJsZXJhbmdlOjFjZWYzZDdiZTU4MDQ1N2NiNWI5NjM3YWM2NjQ0MzdlXzUtMTItMS0xLTI5NzI2_cc755141-4c90-4e95-993f-2504b61c4e7a"
      unitRef="usd">2379000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODM2_d70ecc80-1f77-470e-a536-133680fbdc3d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the projected future minimum contributions to the unfunded retirement plans.  These amounts do not include any discretionary contributions that the Company may elect to make in the future.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2027-2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Projected future contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo3MjNiMWQ1MThlZWQ0ZmU3YjQwNjk1MDgxOGI4MDhmZS90YWJsZXJhbmdlOjcyM2IxZDUxOGVlZDRmZTdiNDA2OTUwODE4YjgwOGZlXzEtMi0xLTEtMjk3MjY_62623718-1930-48b9-9263-f4c24192380a"
      unitRef="usd">114000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo3MjNiMWQ1MThlZWQ0ZmU3YjQwNjk1MDgxOGI4MDhmZS90YWJsZXJhbmdlOjcyM2IxZDUxOGVlZDRmZTdiNDA2OTUwODE4YjgwOGZlXzEtNC0xLTEtMjk3MjY_d2cb328d-ddda-45dd-8619-362fd21043ff"
      unitRef="usd">119000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo3MjNiMWQ1MThlZWQ0ZmU3YjQwNjk1MDgxOGI4MDhmZS90YWJsZXJhbmdlOjcyM2IxZDUxOGVlZDRmZTdiNDA2OTUwODE4YjgwOGZlXzEtNi0xLTEtMjk3MjY_1338c66f-11bf-436e-9ee2-a4f67f5c4359"
      unitRef="usd">126000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo3MjNiMWQ1MThlZWQ0ZmU3YjQwNjk1MDgxOGI4MDhmZS90YWJsZXJhbmdlOjcyM2IxZDUxOGVlZDRmZTdiNDA2OTUwODE4YjgwOGZlXzEtOC0xLTEtMjk3MjY_4e3be636-a005-4ea8-8712-b5513b725991"
      unitRef="usd">133000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo3MjNiMWQ1MThlZWQ0ZmU3YjQwNjk1MDgxOGI4MDhmZS90YWJsZXJhbmdlOjcyM2IxZDUxOGVlZDRmZTdiNDA2OTUwODE4YjgwOGZlXzEtMTAtMS0xLTI5NzI2_a7419415-e47c-4d08-8a3d-a3d441d06f99"
      unitRef="usd">139000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTo3MjNiMWQ1MThlZWQ0ZmU3YjQwNjk1MDgxOGI4MDhmZS90YWJsZXJhbmdlOjcyM2IxZDUxOGVlZDRmZTdiNDA2OTUwODE4YjgwOGZlXzEtMTItMS0xLTI5NzI2_2e723e40-7704-4d51-b9ed-542eef675cca"
      unitRef="usd">794000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODY5_f5dba70e-e42d-441a-b392-75bc4eb8af54">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s retirement plan asset allocation at the end of 2021 and 2020 and target allocations for 2022 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.131%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Percent of&lt;br/&gt;Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Target&lt;br/&gt;Allocation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Worldwide Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="i52c49a8c4db34117958d49e77780d7e7_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxYjkxYzgzMmNjMWE0ODc5OTdhNjliYWY4ZjE1NDBhNi90YWJsZXJhbmdlOjFiOTFjODMyY2MxYTQ4Nzk5N2E2OWJhZjhmMTU0MGE2XzMtMi0xLTEtMjk3MjY_5761b211-d592-40ea-bc13-4cf9fa8f37aa"
      unitRef="number">0.65</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="i1b45609e47e840bd9bc2b4829a2dfa26_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxYjkxYzgzMmNjMWE0ODc5OTdhNjliYWY4ZjE1NDBhNi90YWJsZXJhbmdlOjFiOTFjODMyY2MxYTQ4Nzk5N2E2OWJhZjhmMTU0MGE2XzMtNC0xLTEtMjk3MjY_ece145c7-e62c-4fb8-960c-5be0d515dcf3"
      unitRef="number">0.66</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i52c49a8c4db34117958d49e77780d7e7_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxYjkxYzgzMmNjMWE0ODc5OTdhNjliYWY4ZjE1NDBhNi90YWJsZXJhbmdlOjFiOTFjODMyY2MxYTQ4Nzk5N2E2OWJhZjhmMTU0MGE2XzMtNi0xLTEtMjk3MjY_cc4e2f08-1de3-43df-aa8b-40cd446166a1"
      unitRef="number">0.61</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="ic5c7a5058f0d4ea482b056a1543610b3_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxYjkxYzgzMmNjMWE0ODc5OTdhNjliYWY4ZjE1NDBhNi90YWJsZXJhbmdlOjFiOTFjODMyY2MxYTQ4Nzk5N2E2OWJhZjhmMTU0MGE2XzQtMi0xLTEtMjk3MjY_0bbc3de5-32da-4579-aaf4-6c8aa9e66509"
      unitRef="number">0.35</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="ie47761f8002e45c199053ae0a267c678_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxYjkxYzgzMmNjMWE0ODc5OTdhNjliYWY4ZjE1NDBhNi90YWJsZXJhbmdlOjFiOTFjODMyY2MxYTQ4Nzk5N2E2OWJhZjhmMTU0MGE2XzQtNC0xLTEtMjk3MjY_716e8d8e-0447-4e17-8bf4-3a7d2ae14d07"
      unitRef="number">0.34</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ic5c7a5058f0d4ea482b056a1543610b3_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxYjkxYzgzMmNjMWE0ODc5OTdhNjliYWY4ZjE1NDBhNi90YWJsZXJhbmdlOjFiOTFjODMyY2MxYTQ4Nzk5N2E2OWJhZjhmMTU0MGE2XzQtNi0xLTEtMjk3MjY_814bd2be-d5dd-4e04-b9cd-e3f557886662"
      unitRef="number">0.39</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxYjkxYzgzMmNjMWE0ODc5OTdhNjliYWY4ZjE1NDBhNi90YWJsZXJhbmdlOjFiOTFjODMyY2MxYTQ4Nzk5N2E2OWJhZjhmMTU0MGE2XzUtMi0xLTEtMjk3MjY_4f1b61c3-c032-41fc-98b2-85d51296b3ae"
      unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxYjkxYzgzMmNjMWE0ODc5OTdhNjliYWY4ZjE1NDBhNi90YWJsZXJhbmdlOjFiOTFjODMyY2MxYTQ4Nzk5N2E2OWJhZjhmMTU0MGE2XzUtNC0xLTEtMjk3MjY_ab23779a-5766-4f89-abce-e748db85357d"
      unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZToxYjkxYzgzMmNjMWE0ODc5OTdhNjliYWY4ZjE1NDBhNi90YWJsZXJhbmdlOjFiOTFjODMyY2MxYTQ4Nzk5N2E2OWJhZjhmMTU0MGE2XzUtNi0xLTEtMjk3MjY_8579182a-925d-47d8-8b56-937d07d271a8"
      unitRef="number">1</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwODQ1_e9d96d63-9585-4349-aac2-566ab58b0b87">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2021 and December&#160;31, 2020:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.235%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;br/&gt;Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Investments at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,086&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,420&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,515&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,092&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41,930&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The activity for the Level 3 assets is not significant for all years presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaafdd23d13d0493891e7d7ac9afa2c86_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzMtMi0xLTEtMjk3MjY_8115dead-d2aa-4bf5-af71-a94080218355"
      unitRef="usd">102000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3c80cbf0e584468d8ffebcfcd75988d6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzMtNC0xLTEtMjk3MjY_773ce8c5-1760-4a01-8eae-67edf0470b09"
      unitRef="usd">127000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2fe30c736fe24e1ca4d36fc6c3007110_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzMtNi0xLTEtMjk3MjY_e332e838-baa4-4f09-9cc4-bb803d7632b8"
      unitRef="usd">1033000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id4dd9dc19e6149b88426c05b99e85df6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzMtOC0xLTEtMjk3MjY_dfdab624-e16a-4274-b9b5-f92c70e98c5b"
      unitRef="usd">763000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id064b00e4ce442d3ab5bb43fe94a8111_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzMtMTAtMS0xLTI5NzI2_bc16b609-6945-4715-9c5c-f60431e93807"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6c1a29cf707e4f78a4258d452faef951_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzMtMTItMS0xLTI5NzI2_83601093-f8d0-4b6b-b925-72e838a9dda5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6980acd8ab1348a7a9d21340b15bbad1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzMtMTgtMS0xLTI5NzI2_de76ca35-f373-433c-bcd9-1484274f7e9d"
      unitRef="usd">1135000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i547106227f34401da5bb7b68702b3644_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzMtMjAtMS0xLTI5NzI2_658ec67b-a616-40b9-a356-53de62c86eab"
      unitRef="usd">890000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1f22835beae34a80914d14a3e622b9b6_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzQtMi0xLTEtMjk3MjY_fbc87741-93a8-405d-aa84-5955b97c5ba8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibc5fd4a09af04cc889161a3e85ab6ebb_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzQtNC0xLTEtMjk3MjY_3fde126b-5609-43f9-9007-4eecf94e7afc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iedb15225c1b941948e9771dbfe0bec89_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzQtNi0xLTEtMjk3MjY_5f382625-84ca-4ef1-a5f5-4763dfa365a8"
      unitRef="usd">7016000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i93af333b5f5246b98690e521de9166f3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzQtOC0xLTEtMjk3MjY_54dad198-69ca-4d7b-b707-6f079ee70b5a"
      unitRef="usd">5023000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia3af6ce2fee94f8b8ad34e9cbe4c2959_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzQtMTAtMS0xLTI5NzI2_da4bd7bf-8239-4381-8fa2-3c3f4dd39053"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id97dc2bfbc6b4c75a3fda94dda89b30d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzQtMTItMS0xLTI5NzI2_ebd5dc39-baa4-44e8-8b9d-e5df677a5e0f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6398c3336be94b3782104a66be75812c_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzQtMTgtMS0xLTI5NzI2_ad59fd0b-4e8a-4824-96ac-5c76df7e587a"
      unitRef="usd">7016000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1fa9057e6eac45ea8abc150ad50bb903_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzQtMjAtMS0xLTI5NzI2_f5d14b3d-6d45-4b76-8655-9468d59b2d9d"
      unitRef="usd">5023000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4bae6b71cd68453fb9432e997b2ec281_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzUtMi0xLTEtMjk3MjY_98650f50-b1d5-4a33-bb66-84a33dd6cb38"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i99cb936201fa4622b0837f8dfecd6b89_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzUtNC0xLTEtMjk3MjY_8b90b99a-a601-43c4-968a-7952b836a21a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic774cb65db23481fa83313228c547f8e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzUtNi0xLTEtMjk3MjY_a992c7be-c0c9-4fbc-aaad-984f0c1151c8"
      unitRef="usd">3505000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibc8a4ada79bb4caea9c29a70213afbb9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzUtOC0xLTEtMjk3MjY_66637edf-20aa-4a31-a292-acb999a4743d"
      unitRef="usd">3931000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1f76e7653f5d4d2aa16e4e2b1264054d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzUtMTAtMS0xLTI5NzI2_dda7fb8d-aaca-460e-b393-6ffcefb85d0b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibee6b63499d74ba8843e5919b699a3d5_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzUtMTItMS0xLTI5NzI2_d6424451-f227-489a-96c1-f2c4fec65691"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2811f795aee94f61a4b7ca5101e1bb88_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzUtMTgtMS0xLTI5NzI2_9b52bec0-1047-4726-9fb7-51d1f91b51d0"
      unitRef="usd">3505000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icb935c546f034a40abf2db76a024a9ce_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzUtMjAtMS0xLTI5NzI2_a85d3a87-6490-4387-96d9-7c621c2a07ab"
      unitRef="usd">3931000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8d95f694324341bc841a0a7101ef54b5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzYtMi0xLTEtMjk3MjY_b3c39fff-c294-4f17-a9ca-aef4a8b40595"
      unitRef="usd">14107000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie917ced662c542a288e1c9403b69f779_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzYtNC0xLTEtMjk3MjY_48d620b2-741d-412a-a94d-94f4c67cab4f"
      unitRef="usd">14375000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5498d11f3d2542428717838316f8244c_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzYtNi0xLTEtMjk3MjY_92c25f9f-b316-4512-8a3a-22ef694d5a02"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8b5e7375ea064e46babac18112aa607e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzYtOC0xLTEtMjk3MjY_d34879fa-bbf7-411d-bc45-25179985f87f"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7140a79533384965ad078f1d35179c5d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzYtMTAtMS0xLTI5NzI2_808612ec-d127-4319-9532-98194d2a7060"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4b431efe4f564593ae595088e0d47426_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzYtMTItMS0xLTI5NzI2_658157fb-b33a-45f7-82c8-d00f2040fd71"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic7c92fe0ae4748908db33019e0c4de42_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzYtMTgtMS0xLTI5NzI2_2a80b707-5112-4779-bd2f-8dc470438cd3"
      unitRef="usd">14109000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic5a1066842f549089f6164c20f388be6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzYtMjAtMS0xLTI5NzI2_9b1c22c4-094c-4328-b6ce-59bc0da7a238"
      unitRef="usd">14377000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i783e5becfec34efabd5b62b1ed29b447_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctMi0xLTEtMjk3MjY_71a3245b-6aca-469e-b34a-d464a6e06e91"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i64a34f28344246b3b17696830a6b62bb_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctNC0xLTEtMjk3MjY_9a04bb82-d65f-475d-ae77-ea359c966065"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ica3bf1a545d84c639cb2f963349213d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctNi0xLTEtMjk3MjY_cc88aece-287c-4371-b2d4-652021218fc3"
      unitRef="usd">5496000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibc20ad9303354673b2fc373f330c597f_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctOC0xLTEtMjk3MjY_76cc14ba-11ee-4eb1-8532-a98519ee2d94"
      unitRef="usd">4690000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5d0542bd36b04ade9a1445e4d2bd9293_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctMTAtMS0xLTI5NzI2_e1ed0b58-c9a4-4ee5-99fc-61a8c72d777e"
      unitRef="usd">105000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5dab0c78d2044636b1b0795ffb41ceba_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctMTItMS0xLTI5NzI2_fc55f464-f100-4057-8af7-826373b51cfd"
      unitRef="usd">160000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets
      contextRef="i05353447c3f44422a85c9a643c4158e7_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctMTQtMS0xLTI5NzI2_e5e72ef8-5761-4d22-9aad-a781ed443a28"
      unitRef="usd">8708000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets
      contextRef="ib9481f72b68741a38d64130564e80f8b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctMTYtMS0xLTI5NzI2_1d9e7c01-726f-4e53-9a29-b7ea2b5b664c"
      unitRef="usd">8236000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i05353447c3f44422a85c9a643c4158e7_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctMTgtMS0xLTI5NzI2_49e982ce-1026-43b8-bd26-da67547413e2"
      unitRef="usd">14309000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib9481f72b68741a38d64130564e80f8b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzctMjAtMS0xLTI5NzI2_24da01b4-5749-461d-a383-f3d7227a1b1e"
      unitRef="usd">13086000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie9ef3d78b9964c72bc181499fe2a8a48_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktMi0xLTEtMjk3MjY_106bc5b8-648d-4b41-a2b8-b901bc170a16"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib8663f2154b743c0a9082ef7ef48c04c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktNC0xLTEtMjk3MjY_f2b59ab4-10c9-44d6-b293-9601fb5503b9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib44c796f51604beeb234f0a74a350c2f_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktNi0xLTEtMjk3MjY_fc5575d8-2b6f-4596-9443-df6d394ad846"
      unitRef="usd">34000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic90e615b8bd94bd0bd916ce166a2e1a5_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktOC0xLTEtMjk3MjY_a2ecca88-ae09-4283-beae-b62ab6aef184"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia206a3f6344d4adb8fd0339224dd9315_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktMTAtMS0xLTI5NzI2_e5497dfb-63a3-4ccd-8021-52731035ed2a"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ice03248f0c7342dd9422615211a7ce92_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktMTItMS0xLTI5NzI2_bd708cf6-d39e-4810-86e7-686a9248fd5c"
      unitRef="usd">21000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets
      contextRef="ic68aa1aedc3b40c5b7b80e1388117a04_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktMTQtMS0xLTI5NzI2_c2662588-85ad-45a5-b0e4-02dfb74232e9"
      unitRef="usd">1807000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets
      contextRef="i6f74ff9d83eb4bff80eca87771ac8af3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktMTYtMS0xLTI5NzI2_f359440e-1f69-4804-9aac-474f4c367e2a"
      unitRef="usd">856000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic68aa1aedc3b40c5b7b80e1388117a04_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktMTgtMS0xLTI5NzI2_1fff820f-8f3a-42f2-af91-35fc67b45cc5"
      unitRef="usd">1856000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6f74ff9d83eb4bff80eca87771ac8af3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzktMjAtMS0xLTI5NzI2_32aa8392-5ccd-49ce-bdd7-2d264c1c654d"
      unitRef="usd">888000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic288cd72530f4cd2842d023a50460e18_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTItMS0xLTI5NzI2_de38bd53-1cc2-4c1c-9bb9-c0da1d834e59"
      unitRef="usd">14209000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia30f04104b444cd3b652b8554c878f2c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTQtMS0xLTI5NzI2_62b9ee1a-7367-426e-b67c-11b1c89e0f03"
      unitRef="usd">14502000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic047ffb5ebe44765a2e2ca57b1137125_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTYtMS0xLTI5NzI2_75711a62-1058-4eb6-8735-e919ac28f922"
      unitRef="usd">17086000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i52201b2d7c81445d9be675a280747548_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTgtMS0xLTI5NzI2_758b2bba-a4f1-4afc-805e-550a90249883"
      unitRef="usd">14420000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i65a16fd18d26435eb42b51c0b3b1b851_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTEwLTEtMS0yOTcyNg_0831b39a-27c4-413d-8cae-611c25cf7d2a"
      unitRef="usd">120000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i20eeda577995420193ec4dd9d63bba01_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTEyLTEtMS0yOTcyNg_f7de2029-7397-49e1-a3ae-4763e1fdbf5a"
      unitRef="usd">181000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets
      contextRef="i65cf763a87bd4988a9339426e416baea_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTE0LTEtMS0yOTcyNg_56ef2ce2-0758-4f22-b9ad-f80763425eaa"
      unitRef="usd">10515000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets
      contextRef="i011f2815be9247198ea2477163de1299_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTE2LTEtMS0yOTcyNg_2a7243cc-0c2e-4505-85d4-2c442a5b118e"
      unitRef="usd">9092000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i65cf763a87bd4988a9339426e416baea_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTE4LTEtMS0yOTcyNg_3e316c92-c42d-4071-a3d8-2320b9d60d53"
      unitRef="usd">41930000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i011f2815be9247198ea2477163de1299_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90YWJsZTozM2RkZmIxMTdkZWQ0YTYxYjk5ZTY4ZTkzNWQ5YzdkNC90YWJsZXJhbmdlOjMzZGRmYjExN2RlZDRhNjFiOTllNjhlOTM1ZDljN2Q0XzEwLTIwLTEtMS0yOTcyNg_66691b0f-953d-46ee-b190-888a7606a43c"
      unitRef="usd">38195000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia84d82cf676c42178e9d4fe5cfa9c970_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwNDgx_02edb717-6857-4120-b1b9-6aa3e759d1b1"
      unitRef="usd">102000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7161773f423d4d04b3b04039512ea242_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwNDg4_c320e1d6-0225-4a93-8714-6c3e297f27de"
      unitRef="usd">90000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwNzA2_c9b2f96e-6d22-4825-a4ed-aef8835b5a76"
      unitRef="usd">385000000</jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets>
    <jnj:PercentageOfCompanysCommonStockToPlanAsset
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwNzEw_a26d755b-868b-48d4-bf57-7b7343a10c46"
      unitRef="number">0.009</jnj:PercentageOfCompanysCommonStockToPlanAsset>
    <jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwNzYw_f1b8edd8-6967-4dd5-8ea0-6f62dfd011cb"
      unitRef="usd">946000000</jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets>
    <jnj:PercentageOfCompanysCommonStockToPlanAsset
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xNzgvZnJhZzphMGZkMzliZWFjYTI0NDhkYWUwYzI2ODc0NWM0ZTNlOS90ZXh0cmVnaW9uOmEwZmQzOWJlYWNhMjQ0OGRhZTBjMjY4NzQ1YzRlM2U5XzEwNzY0_d1ebfe02-ade8-40da-b850-b91333d6fbae"
      unitRef="number">0.025</jnj:PercentageOfCompanysCommonStockToPlanAsset>
    <jnj:SavingsPlanTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODQvZnJhZzpiZGYxZjYwZTgxMTE0M2U3OTk3ZDM2MDVkNGM2YWVlNi90ZXh0cmVnaW9uOmJkZjFmNjBlODExMTQzZTc5OTdkMzYwNWQ0YzZhZWU2XzQwNQ_67fdaa53-f9c1-43c7-bd68-ce4ba13c6f97">Savings PlanThe Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee&#x2019;s contributions consistent with the provisions of the plan for which he/she is eligible. Total Company matching contributions to the plans were $256 million, $243 million and $235 million in fiscal years 2021, 2020 and 2019, respectively.</jnj:SavingsPlanTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODQvZnJhZzpiZGYxZjYwZTgxMTE0M2U3OTk3ZDM2MDVkNGM2YWVlNi90ZXh0cmVnaW9uOmJkZjFmNjBlODExMTQzZTc5OTdkMzYwNWQ0YzZhZWU2XzM0Mg_4edf0df4-23fa-4dd8-8ea1-7919da72a643"
      unitRef="usd">256000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODQvZnJhZzpiZGYxZjYwZTgxMTE0M2U3OTk3ZDM2MDVkNGM2YWVlNi90ZXh0cmVnaW9uOmJkZjFmNjBlODExMTQzZTc5OTdkMzYwNWQ0YzZhZWU2XzM0Ng_566d96d0-b691-4315-a30a-af91a8a017b8"
      unitRef="usd">243000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODQvZnJhZzpiZGYxZjYwZTgxMTE0M2U3OTk3ZDM2MDVkNGM2YWVlNi90ZXh0cmVnaW9uOmJkZjFmNjBlODExMTQzZTc5OTdkMzYwNWQ0YzZhZWU2XzM1Mw_a1d4013b-640a-47db-ba5f-1972632687cf"
      unitRef="usd">235000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:TreasuryStockTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzc3Ng_453a30b4-4c22-4b99-8d54-c78bb5b8974e">Capital and Treasury Stock&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in treasury stock were:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts in Millions Except Treasury Stock Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate shares of common stock issued were approximately 3,119,843,000&#160;shares at the end of fiscal years 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash dividends paid were $4.19 per share in fiscal year 2021, compared with dividends of $3.98 per share in fiscal year 2020, and $3.75 per share in fiscal year 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 4, 2022, the Board of Directors declared a regular cash dividend of $1.06 per share, payable on March 8, 2022 to shareholders of record as of February 22, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 17, 2018, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's shares of common stock. This share repurchase program was completed as of September 29, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:TreasuryStockTextBlock>
    <jnj:ChangesInTreasuryStockTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzc2Nw_fa884284-c984-4de2-87e6-e9040f5a71ca">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in treasury stock were:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts in Millions Except Treasury Stock Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</jnj:ChangesInTreasuryStockTableTextBlock>
    <us-gaap:TreasuryStockShares
      contextRef="ia2087646dc6744a28755f382fc0a83c8_I20181230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzItMi0xLTEtMjk3MjY_c7cfe4f9-521d-4738-ad16-7c44d1da7c79"
      unitRef="shares">457519000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ia2087646dc6744a28755f382fc0a83c8_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzItNC0xLTEtMjk3MjY_33f375f6-be9a-4dd0-bb76-efc7aa5972c8"
      unitRef="usd">34362000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzMtMi0xLTEtMjk3MjY_c861fae1-8e12-4f93-ae54-34f4d5e3a075"
      unitRef="shares">20053000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzMtNC0xLTEtMjk3MjY_23dabf9d-2745-4dc8-bdff-1b2d0cd30bb9"
      unitRef="usd">2691000000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i506f1bb3ec9a4c2fa89004c3dc9d077b_D20181231-20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzQtMi0xLTEtMjk3MjY_46d5e4f1-55c5-48b4-8601-63c4f468211f"
      unitRef="shares">49870000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i506f1bb3ec9a4c2fa89004c3dc9d077b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzQtNC0xLTEtMjk3MjY_dd71afdf-68e7-4223-848d-6786f80e388a"
      unitRef="usd">6746000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockShares
      contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzUtMi0xLTEtMjk3MjY_5301c6ad-f0d9-4e5f-befd-a05a1bf8e179"
      unitRef="shares">487336000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzUtNC0xLTEtMjk3MjY_75ed6cda-eecb-40cc-bc4a-e60d66b5b23f"
      unitRef="usd">38417000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzYtMi0xLTEtMjk3MjY_913ee169-57dd-447a-b532-8d13610403cf"
      unitRef="shares">21765000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzYtNC0xLTEtMjk3MjY_32212f39-afc8-44d2-b80b-e2fd004a19d7"
      unitRef="usd">3148000000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="if090847b243c45b38f83514b26483411_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzctMi0xLTEtMjk3MjY_e0ff4df1-fd31-4887-ad80-13e0adfb1c44"
      unitRef="shares">21760000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if090847b243c45b38f83514b26483411_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzctNC0xLTEtMjk3MjY_c35ecf57-be13-4ca8-adf1-276e2024ca44"
      unitRef="usd">3221000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockShares
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzgtMi0xLTEtMjk3MjY_5e2b8042-0fcb-4fb9-a5cd-d393d62231cf"
      unitRef="shares">487331000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzgtNC0xLTEtMjk3MjY_a2cfa328-f5f7-44ad-821b-56c13a772040"
      unitRef="usd">38490000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzktMi0xLTEtMjk3MjY_e9d0649c-69f4-49e8-93b4-8e3fee5c8248"
      unitRef="shares">17399000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzktNC0xLTEtMjk3MjY_81ee0d70-7eb4-4c4d-a6c4-2985780853d3"
      unitRef="usd">2847000000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ide5f195a7f1f400580767c19f5aada99_D20210104-20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzEwLTItMS0xLTI5NzI2_8bd727b0-d9ca-443c-bbd9-966c49a91d27"
      unitRef="shares">20946000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ide5f195a7f1f400580767c19f5aada99_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzEwLTQtMS0xLTI5NzI2_5b1b8a94-fe2a-4d71-8ab3-2566125f4c1a"
      unitRef="usd">3456000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockShares
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzExLTItMS0xLTI5NzI2_75c2f725-3f6c-4157-962c-2ab6ce2a797a"
      unitRef="shares">490878000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90YWJsZTo0MjM2ZWVhOGY5MTk0MWYwOGE0N2ViZTJmNDMyOTRjMC90YWJsZXJhbmdlOjQyMzZlZWE4ZjkxOTQxZjA4YTQ3ZWJlMmY0MzI5NGMwXzExLTQtMS0xLTI5NzI2_0b7b939f-ad52-4dea-a39a-8af9c637be1c"
      unitRef="usd">39099000000</us-gaap:TreasuryStockValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzEyNw_4beb959b-e4d9-4047-90db-cc54ca805112"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzEyNw_5135bc06-7550-4e0c-8d5f-10314f249e72"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzEyNw_61732a38-15b4-4150-806b-9bed290e6e30"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzIwNQ_ede7e57d-ee7e-4e31-b314-1d2c4767a0e3"
      unitRef="usdPerShare">4.19</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzI2NA_445ef538-2590-4341-83b7-d412f7802c71"
      unitRef="usdPerShare">3.98</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzMwMA_96ec704d-2813-4a5d-80f2-d9a083a65e96"
      unitRef="usdPerShare">3.75</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="id8c97df697f946a4a28e06f21b923b40_D20220104-20220104"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzQxMg_193ac7c9-f7b9-46fa-bf64-fc95744bc97c"
      unitRef="usdPerShare">1.06</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i7122062f1c554f58bcf1918e884a09af_I20181217"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xODcvZnJhZzplMzA4NGZhNjM4OGI0OTRmYTliYjM1MmQ1MWFhN2JhYS90ZXh0cmVnaW9uOmUzMDg0ZmE2Mzg4YjQ5NGZhOWJiMzUyZDUxYWE3YmFhXzY1Mw_0d7a914e-4b43-4244-84e9-55ca562af097"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90ZXh0cmVnaW9uOjA0YTA0NDQ0YTYyZTQzMzRhMzlhZjVhZTgzMjRiYzJmXzk4NA_37b4749d-90bc-4880-9d34-d58cfb2681dc">Accumulated Other Comprehensive Income (Loss)&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss) On Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Employee Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/&lt;br/&gt;(Loss) On&lt;br/&gt;Derivatives &amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net 2019 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net 2020 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net 2021 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details on reclassifications out of Accumulated Other Comprehensive Income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain/(Loss) On Derivatives &amp;amp; Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction.  See Note 6 for additional details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90ZXh0cmVnaW9uOjA0YTA0NDQ0YTYyZTQzMzRhMzlhZjVhZTgzMjRiYzJmXzk3Mw_9ec1bcf5-0013-4a7f-b577-5532069e8458">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss) On Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Employee Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/&lt;br/&gt;(Loss) On&lt;br/&gt;Derivatives &amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net 2019 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net 2020 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net 2021 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia54143af8e294de8a878b870cb6ea183_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEtMi0xLTEtMjk3MjY_cd18818f-bec5-4b68-91a3-3c3023bc6030"
      unitRef="usd">-8869000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib4f8e689cd0845169580efef9b726eb8_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEtNC0xLTEtMjk3MjY_b3365ba9-89af-4883-920e-461117e69e67"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icfa5021c9521460ea844d42abe8a5aeb_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEtNi0xLTEtMjk3MjY_79be6963-f3f4-45e6-a199-145f4ae99735"
      unitRef="usd">-6158000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i484c2311f67440a3876482adeb22ccb3_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEtOC0xLTEtMjk3MjY_e278c725-dcb7-4f6c-9bb8-3892b9578b76"
      unitRef="usd">-195000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8503a818334a40a588f1d51c6b02cbdd_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEtMTAtMS0xLTI5NzI2_bb5dbffa-9d94-4932-bafc-fbe5ffbdb8c7"
      unitRef="usd">-15222000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2b3e5218e47b4138b803ab86e37ed163_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzMtMi0xLTEtMjk3MjY_c449eaaa-19f2-4577-8ce5-b49cf8baafbb"
      unitRef="usd">164000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2dadf43537624342b93174d221447d45_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzMtNC0xLTEtMjk3MjY_2e674a4a-41b1-4155-8da7-df092a36d717"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7d10b1357d4345dabd40e640f459d595_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzMtNi0xLTEtMjk3MjY_2c17c276-beab-4fc9-92e4-f44f369e4cec"
      unitRef="usd">-733000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ieb2239aebff9499e9a34c274aaeb6c7f_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzMtOC0xLTEtMjk3MjY_79ce8f1e-24bd-4f5c-9750-751cf871c44d"
      unitRef="usd">-100000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0f88c24f46d04306b18b2052c29a8b77_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzMtMTAtMS0xLTI5NzI2_fa47b6b3-9e2e-43d4-b39b-ffff5812177b"
      unitRef="usd">-669000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i09358b98b87140529a0feb97fb9db596_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzQtMi0xLTEtMjk3MjY_086c4426-e24e-470a-8e7d-861cb0970959"
      unitRef="usd">-8705000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i51768edbfc634fdda12f4209d23a3fe8_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzQtNC0xLTEtMjk3MjY_ac670724-93c0-4b5f-a53f-e170dc2b6fcf"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i40dc9b8885b14646ad4ca14020da2020_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzQtNi0xLTEtMjk3MjY_1b44e32a-6dc2-47ad-bf04-1c654d3aa48a"
      unitRef="usd">-6891000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia91a8b98474c492b93ac66dd2c441f86_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzQtOC0xLTEtMjk3MjY_a03dc9bd-8438-4dfd-908b-8919cb871f0f"
      unitRef="usd">-295000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2c3c777d14a94558a9524c8d48022809_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzQtMTAtMS0xLTI5NzI2_d7928896-eac1-422a-9028-5ca0cda0f959"
      unitRef="usd">-15891000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i491bbfb299144dc0a55fa842720b7ce9_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzYtMi0xLTEtMjk3MjY_9a4fbf83-4821-4f55-9d3a-a10d4ec73d94"
      unitRef="usd">-233000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ieb17cd90126f48b89e2321d3bacf6a95_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzYtNC0xLTEtMjk3MjY_53d67138-1b69-4043-a8db-bdbbae7e9c38"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8c595eaa21f3452191aa3045d9aaf15e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzYtNi0xLTEtMjk3MjY_cefcd61f-6a50-49d3-9947-06b3eddceb2b"
      unitRef="usd">-66000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8d84caefa07e483fb905ffb4ad67b125_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzYtOC0xLTEtMjk3MjY_3099e46a-f30a-47f4-8296-5c9398bd0fa7"
      unitRef="usd">947000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iaa5fa270dceb439ab74cfc1fa351ade8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzYtMTAtMS0xLTI5NzI2_0124a7a7-9494-409c-bd30-2c3cc42bebc7"
      unitRef="usd">649000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i803bbc6136dd4d39b64cf980705d6a38_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzctMi0xLTEtMjk3MjY_03ef234d-75cd-4db2-a40b-680926fdaa97"
      unitRef="usd">-8938000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc1c4f9ce70e4d3ebe6058b0e4183d02_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzctNC0xLTEtMjk3MjY_688cd65c-a286-49de-847d-73f54b8fc795"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21cfba8b0adc47c8a606f3009b7f1da4_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzctNi0xLTEtMjk3MjY_95e0812c-1b5a-44c3-b0eb-352785ec8fe5"
      unitRef="usd">-6957000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b43e493bfda4958aafcf54a1f7de911_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzctOC0xLTEtMjk3MjY_2c30c943-3be9-424c-8497-bafc86292081"
      unitRef="usd">652000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2264aac360274fdbb45a327357031ad9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzctMTAtMS0xLTI5NzI2_b9701583-8e29-4a98-b0d9-a32cd2b3dd6b"
      unitRef="usd">-15242000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icf4efa66d2f54bfe8f36fb497d4ba3c0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzktMi0xLTEtMjk3MjY_2a3fcaca-d86e-4996-b998-289c4e578c38"
      unitRef="usd">-1079000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9de3dfaa4b2047e3b29dfc3f5c5f3140_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzktNC0xLTEtMjk3MjY_3f5fd8f5-3ad1-47fb-bc09-95f7b34e8dc0"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0fddeabd9fa049fe9b79fddca48ac307_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzktNi0xLTEtMjk3MjY_9326e91a-85f8-4b21-83c2-3390a846d083"
      unitRef="usd">4255000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8bb21536fb564a0d91048d2a7f920ea4_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzktOC0xLTEtMjk3MjY_c36f9eeb-8e2a-4505-a1fb-e4ae6be11978"
      unitRef="usd">-988000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i91696814d2cc4ce18c1ad6fe530463f4_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzktMTAtMS0xLTI5NzI2_76012344-2a28-4a29-a1a9-3e3e5b9227cb"
      unitRef="usd">2184000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2e15d2205eb426fb0faa00095711ac7_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEwLTItMS0xLTI5NzI2_13dd10a9-aa77-4dbb-be7b-c170d704fb1f"
      unitRef="usd">-10017000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5aa9d5da1c0d4119a4ea3ab746d49fa9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEwLTQtMS0xLTI5NzI2_c846888e-890e-4101-9571-9e3644dfcc11"
      unitRef="usd">-3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id50338dbd5c54672ae5cc0b8d7addd69_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEwLTYtMS0xLTI5NzI2_0cbced30-2d0b-4f2a-8462-902a324f5a41"
      unitRef="usd">-2702000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief6a4d3a16fb4a8695e2f75ad4fe9856_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEwLTgtMS0xLTI5NzI2_df0dac80-08a4-421d-add5-89814cb948a7"
      unitRef="usd">-336000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i857ac21d217c4940938fa16c01722dcd_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTMvZnJhZzowNGEwNDQ0NGE2MmU0MzM0YTM5YWY1YWU4MzI0YmMyZi90YWJsZToxNTBkMGUxZTBlODg0NGZkOTJkZjZhMTdjYjgzNTk2MS90YWJsZXJhbmdlOjE1MGQwZTFlMGU4ODQ0ZmQ5MmRmNmExN2NiODM1OTYxXzEwLTEwLTEtMS0yOTcyNg_b3efbbbf-71b9-4880-8f81-e9ac6353b41d"
      unitRef="usd">-13058000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ForeignCurrencyDisclosureTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTYvZnJhZzo2MDI4YTM2M2NmNGM0YWM5YTZiYjI4YjlkNDJhYWFjYS90ZXh0cmVnaW9uOjYwMjhhMzYzY2Y0YzRhYzlhNmJiMjhiOWQ0MmFhYWNhXzE1MjA_339ccb55-944f-404f-8704-aa4006a71177">International Currency Translation&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For translation of its subsidiaries operating in non-U.S.&#160;Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency. For the majority of the Company's subsidiaries the local currency is the functional currency. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. The other current and non-current assets line within the Statement of Cash flows includes the impact of foreign currency translation. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies, (Argentina and Venezuela). The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A rollforward of the changes during fiscal years 2021, 2020 and 2019 for foreign currency translation adjustments is included in Note&#160;13. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net currency transaction gains and losses included in Other (income) expense were losses of $236 million, $209 million and $267 million in fiscal years 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyDisclosureTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTYvZnJhZzo2MDI4YTM2M2NmNGM0YWM5YTZiYjI4YjlkNDJhYWFjYS90ZXh0cmVnaW9uOjYwMjhhMzYzY2Y0YzRhYzlhNmJiMjhiOWQ0MmFhYWNhXzE0NTc_eb1bff38-f897-4916-bf17-b48f2b6ddb44"
      unitRef="usd">-236000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTYvZnJhZzo2MDI4YTM2M2NmNGM0YWM5YTZiYjI4YjlkNDJhYWFjYS90ZXh0cmVnaW9uOjYwMjhhMzYzY2Y0YzRhYzlhNmJiMjhiOWQ0MmFhYWNhXzE0NjE_678de814-37fa-4a42-b533-a9b0ad8a5074"
      unitRef="usd">-209000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTYvZnJhZzo2MDI4YTM2M2NmNGM0YWM5YTZiYjI4YjlkNDJhYWFjYS90ZXh0cmVnaW9uOjYwMjhhMzYzY2Y0YzRhYzlhNmJiMjhiOWQ0MmFhYWNhXzE0Njg_ec4ab126-b2c8-494a-9174-378182aca733"
      unitRef="usd">-267000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90ZXh0cmVnaW9uOjk2YTg0NTQwMTQxYzQ2YTk5Mjc0ZDY2YWYyMzRiNmFlXzEyOTI_6f51c52c-3424-42e8-995a-4a1f00c8bbf3">Earnings Per Share&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In Millions Except Per Share Amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding&#160;&#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,645.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: shares repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted average shares outstanding&#160;&#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,670.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The diluted net earnings per share calculation for fiscal year 2021 included all shares related to stock options, as the exercise price of these options was less than the average market value of the Company's stock. As of January 2, 2022, the Company did not have convertible debt. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The diluted net earnings per share calculation for fiscal year 2020 excluded 18 million shares related to stock options, as the exercise price of these options was greater than the average market value of the Company's stock. As of January 3, 2021, the Company did not have convertible debt. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The diluted net earnings per share calculation for fiscal year 2019 excluded an insignificant number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company&#x2019;s stock. The diluted net earnings per share calculation for fiscal year 2019 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense of $1 million after-tax.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90ZXh0cmVnaW9uOjk2YTg0NTQwMTQxYzQ2YTk5Mjc0ZDY2YWYyMzRiNmFlXzEyODg_df89801f-1e2b-4251-ade3-c4d78d2d04d4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In Millions Except Per Share Amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding&#160;&#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,645.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: shares repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted average shares outstanding&#160;&#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,670.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:EarningsPerShareBasic
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzEtMi0xLTEtMjk3MjY_13391024-52c3-4200-8932-88b401c53d8a"
      unitRef="usdPerShare">7.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzEtNC0xLTEtMjk3MjY_11240899-b900-4174-aa95-56c76f905d5f"
      unitRef="usdPerShare">5.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzEtNi0xLTEtMjk3MjY_8c813b3d-83a2-4bcd-81a3-25cb8b43a489"
      unitRef="usdPerShare">5.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzItMi0xLTEtMjk3MjY_27d9d0ce-e0f5-4a8f-bf56-20b54d17fb24"
      unitRef="shares">2632100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzItNC0xLTEtMjk3MjY_9bf55f61-083d-4190-9365-e25f3cb4037a"
      unitRef="shares">2632800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzItNi0xLTEtMjk3MjY_770113e4-e9e9-4c67-9259-3e7236d55c7c"
      unitRef="shares">2645100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <jnj:PotentialSharesExercisableUnderStockOptionPlans
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzMtMi0xLTEtMjk3MjY_f5dfa00f-1355-490c-b386-95626bb99800"
      unitRef="shares">138000000.0</jnj:PotentialSharesExercisableUnderStockOptionPlans>
    <jnj:PotentialSharesExercisableUnderStockOptionPlans
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzMtNC0xLTEtMjk3MjY_91398e3e-edcb-4039-91e3-f85ee2ccd6a9"
      unitRef="shares">118300000</jnj:PotentialSharesExercisableUnderStockOptionPlans>
    <jnj:PotentialSharesExercisableUnderStockOptionPlans
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzMtNi0xLTEtMjk3MjY_13155acd-30b6-44e2-815e-9c22676bebec"
      unitRef="shares">136300000</jnj:PotentialSharesExercisableUnderStockOptionPlans>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzQtMi0xLTEtMjk3MjY_2d798aff-3eb8-4baa-95ee-8ee78ea9f51a"
      unitRef="shares">96100000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzQtNC0xLTEtMjk3MjY_a6425e0f-76bb-41b1-b93f-98f81177b931"
      unitRef="shares">80400000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzQtNi0xLTEtMjk3MjY_ff42050e-a369-4c9d-8ac0-6fba3443ee8e"
      unitRef="shares">97800000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzUtMi0xLTEtMjk3MjY_dde521ef-6075-4af8-b23b-c4f8e8a20f96"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzUtNC0xLTEtMjk3MjY_122207e3-af69-47f6-920f-b758ee0b3392"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzUtNi0xLTEtMjk3MjY_a14d20d0-fdcd-4827-ac63-c63cd2c38a6b"
      unitRef="shares">700000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzYtMi0xLTEtMjk3MjY_fcd6e890-2765-4166-a97a-643c89f74828"
      unitRef="shares">2674000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzYtNC0xLTEtMjk3MjY_11899dc4-6d46-4e62-8a3b-c3a1f366e2de"
      unitRef="shares">2670700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzYtNi0xLTEtMjk3MjY_8892c556-d9de-4acc-894a-419cc302c4f6"
      unitRef="shares">2684300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzctMi0xLTEtMjk3MjY_43af21fb-d815-4ca8-99bb-8447853dc5ff"
      unitRef="usdPerShare">7.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzctNC0xLTEtMjk3MjY_f5e0a04a-d7d2-47d2-8d8a-ae1bdeb5f6d9"
      unitRef="usdPerShare">5.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90YWJsZTo1MDk5NmVhYTQ5Y2Y0M2QzYjFkYTFkZGZmOGI1YzIzYS90YWJsZXJhbmdlOjUwOTk2ZWFhNDljZjQzZDNiMWRhMWRkZmY4YjVjMjNhXzctNi0xLTEtMjk3MjY_c536bd61-bb91-4700-8202-3472c8a42297"
      unitRef="usdPerShare">5.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90ZXh0cmVnaW9uOjk2YTg0NTQwMTQxYzQ2YTk5Mjc0ZDY2YWYyMzRiNmFlXzI0Nw_72040611-5bc0-4b77-bc10-5a91751ab905"
      unitRef="shares">18000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18xOTkvZnJhZzo5NmE4NDU0MDE0MWM0NmE5OTI3NGQ2NmFmMjM0YjZhZS90ZXh0cmVnaW9uOjk2YTg0NTQwMTQxYzQ2YTk5Mjc0ZDY2YWYyMzRiNmFlXzg1OA_3979de3d-9aa0-4639-9f66-7ab07caf2d51"
      unitRef="usd">1000000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzYwNDc_aee6bcfe-aca7-4ac1-bbf5-e113975938d1">Common Stock, Stock Option Plans and Stock Compensation Agreements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At January&#160;2, 2022, the Company had 2 stock-based compensation plans. The shares outstanding are for contracts under the Company's 2005 Long-Term Incentive Plan and the 2012 Long-Term Incentive Plan. The 2005 Long-Term Incentive Plan expired April 26, 2012. All options and restricted shares granted subsequent to that date were under the 2012 Long-Term Incentive Plan. Under the 2012 Long-Term Incentive Plan, the Company may issue up to 650 million shares of common stock, plus any shares canceled, expired, forfeited, or not issued from the 2005 Long-Term Incentive Plan subsequent to April 26, 2012. Shares available for future grants under the 2012 Long-Term Incentive Plan were 240 million at the end of fiscal year 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The compensation cost that has been charged against income for these plans was $1,135 million, $1,005 million and $977 million for fiscal years 2021, 2020 and 2019, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $218 million, $210 million and $227 million for fiscal years 2021, 2020 and 2019, respectively. The Company also recognized additional income tax benefits of $223&#160;million, $248&#160;million and $209&#160;million for fiscal years 2021, 2020 and 2019, respectively, for which options were exercised or restricted shares were vested. The total unrecognized compensation cost was $862 million, $804 million and $823 million for fiscal years 2021, 2020 and 2019, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively.  The weighted average period for this cost to be recognized was 1.78&#160;years, 1.76&#160;years and 1.71&#160;years for fiscal years 2021, 2020, and 2019, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished through market purchases throughout the year for the number of shares used to settle employee benefit equity issuances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options expire 10&#160;years from the date of grant and vest over service periods that range from 6 months to 4 years.  All options are granted at the average of the high and low prices of the Company&#x2019;s Common Stock on the New York Stock Exchange on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. For 2021, 2020 and 2019 grants, expected volatility represents a blended rate of 10-year weekly historical overall volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson&#160;&amp;amp; Johnson options with a life of 2&#160;years. For all grants, historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S.&#160;Treasury yield curve in effect at the time of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The average fair value of options granted was $20.86, $16.42 and $17.80, in fiscal years 2021, 2020 and 2019, respectively.  The fair value was estimated based on the weighted average assumptions of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of option activity under the Plan as of January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019, and changes during the years ending on those dates is presented below:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Outstanding Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(Dollars in Millions) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at December 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;117,361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,364&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of options exercised was $919 million, $1,021 million and $807 million in fiscal years 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock options outstanding and exercisable at January&#160;2, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$65.08-$90.44&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$81.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$81.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$100.06-$101.87&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$101.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$101.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$115.67-$129.51&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$122.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$122.43&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$131.94-$151.41&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$142.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$140.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$151.42-$164.62&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$164.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$164.62&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;117,361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$125.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62,742&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$104.42&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Average contractual life remaining in years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options outstanding at January&#160;3, 2021 and December&#160;29, 2019 were 114,250 and an average life of 6.0 years and 111,637 and an average life of 6.0&#160;years, respectively. Stock options exercisable at January&#160;3, 2021 and December&#160;29, 2019 were 61,289 at an average price of $96.97 and 60,761 at an average price of $88.88, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Share Units and Performance Share Units&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company grants restricted share units which vest over service periods that range from 6 months to 3 years. The Company also grants performance share units, which are paid in shares of Johnson &amp;amp; Johnson Common Stock after the end of a three-year performance period. Whether any performance share units vest, and the amount that does vest, is tied to the completion of service periods that range from 6 months to 3 years and the achievement, over a three-year period, of three equally-weighted goals that directly align with or help drive long-term total shareholder return: operational sales, adjusted operational earnings per share, and relative total shareholder return. Beginning in fiscal 2020, performance shares were granted with two equally-weighted goals that directly align with or help drive long-term total shareholder return: adjusted operational earnings per share and relative total shareholder return. The number of shares actually earned at the end of the three-year period will vary, based only on actual performance, from 0% to 200% of the target number of performance share units granted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the restricted share units and performance share units activity under the Plans as of January&#160;2, 2022 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Performance Share Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited/adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The average fair value of the restricted share units granted was $152.62, $139.58 and $121.31 in fiscal years 2021, 2020 and 2019, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $611 million, $650 million and $586 million in 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average fair value of the performance share units granted was $179.35, $160.54 and $124.67 in fiscal years 2021, 2020 and 2019, calculated using the weighted average fair market value for each of the component goals at the date of grant.&#160; &lt;/span&gt;&lt;/div&gt;The fair values for the sales and earnings per share goals of each performance share unit were estimated on the date of grant using the fair market value of the shares at the time of the award discounted for dividends, which are not paid on the performance share units during the vesting period.&#160;The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model.&#160;The fair value of performance share units issued was $83 million, $91 million and $119 million in fiscal years 2021, 2020 and 2019, respectively.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <jnj:NumberOfStockBasedCompensationPlans
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4Xzk2_8bfc9953-7cad-4c63-8729-ef942bc33f80"
      unitRef="stockbasedcompensationplans">2</jnj:NumberOfStockBasedCompensationPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ibac73284db3c4555ab751fa7712d96fa_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzUwMQ_559916bd-eec6-46e9-bc4e-4983e5263505"
      unitRef="shares">650000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ibac73284db3c4555ab751fa7712d96fa_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzczOA_e0514005-0af5-4c70-a264-d2f565389f89"
      unitRef="shares">240000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4Xzg1MA_b33a9c07-0cdd-4e69-a70a-95ff0376f901"
      unitRef="usd">1135000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4Xzg1NA_18846259-8d51-49a1-811f-ab265e82e1d1"
      unitRef="usd">1005000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4Xzg2MQ_8e4186db-fed2-42ec-b49a-37a69921f2f5"
      unitRef="usd">977000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzEwMTM_fcacdba8-6171-464b-ac54-374e67f931f0"
      unitRef="usd">218000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzEwMTc_25780636-38b8-40ab-849a-323e67437d6a"
      unitRef="usd">210000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzEwMjQ_750a38d1-994d-437d-8884-c18017d1c946"
      unitRef="usd">227000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzExMzU_03a94771-9a2e-4961-8b77-575cb5f07bc1"
      unitRef="usd">223000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzExMzk_3ab91dc0-0a05-4473-bfe1-96167c46d048"
      unitRef="usd">248000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzExNDY_89c03a86-f02c-4054-92d6-d41c86f4bb97"
      unitRef="usd">209000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzEzMTM_b7001e97-bbf2-47aa-8576-8a304bb6e749"
      unitRef="usd">862000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzEzMTc_1b5ca670-1b74-4e14-8e6f-e529d54116f8"
      unitRef="usd">804000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzEzMjQ_f4d28c86-0673-42e7-9ea5-a0a97b9da370"
      unitRef="usd">823000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzE0Mzc_4e90e6a3-0705-4e14-b8ad-20ae8f0eba2a">P1Y9M10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzE0NDc_0562826e-5481-418c-86a9-b54d8747c70f">P1Y9M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzE0NjA_0e56c1fe-7813-4925-b889-4967ca34c8d4">P1Y8M15D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i878c87afdf46469b95b60a72ffa60b1f_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzE4Nzk_d800c3a2-03d8-4f7d-9122-8070ac259dd3">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i67642e6fd25c46c7b9f6124eab76fddc_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzE5NTc_1e05ae93-2e23-494f-888f-2d1261c3bb3c">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ife1e770bea9143ada35c3572dfd2a7ec_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzE5NjM_41529066-4734-4844-8951-8f6e73196242">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzYwNTQ_efeeea0b-b466-4b47-8f86-6b3839976ce6">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The average fair value of options granted was $20.86, $16.42 and $17.80, in fiscal years 2021, 2020 and 2019, respectively.  The fair value was estimated based on the weighted average assumptions of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzI3NzU_861081d7-2826-4cb8-9ec4-c6e800d79bac"
      unitRef="usdPerShare">20.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzI3Nzk_ed3419f0-2362-49b9-acf9-f60a0d6f244b"
      unitRef="usdPerShare">16.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzI3ODY_4c1b8949-ffe0-45d1-a7aa-50d2c565f5a1"
      unitRef="usdPerShare">17.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzEtMS0xLTEtMjk3MjY_cd130965-2ef3-4c95-9ac9-99793e77ca18"
      unitRef="number">0.0083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzEtMy0xLTEtMjk3MjY_a8169d4c-5e48-40be-85ac-f48a8be4e7ae"
      unitRef="number">0.0147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzEtNS0xLTEtMjk3MjY_17b80761-bd5c-4872-8557-9570e8e610a0"
      unitRef="number">0.0256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzItMS0xLTEtMjk3MjY_cf9890be-b880-45ff-af66-c104aa76dc30"
      unitRef="number">0.1859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzItMy0xLTEtMjk3MjY_73f39df8-d734-45af-adfb-cd4e047815ab"
      unitRef="number">0.1533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzItNS0xLTEtMjk3MjY_c00ac0cc-f24c-4b75-953c-bd2b99a3d6df"
      unitRef="number">0.1627</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzMtMS0xLTEtMjk3MjY_846586a2-8ba8-4901-b674-bd999fd30b6e">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzMtMy0xLTEtMjk3MjY_5079beff-4f37-4937-9786-ba6f4e0bacf2">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzMtNS0xLTEtMjk3MjY_15813da4-6c25-4d28-bef4-5110d2b92855">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzQtMS0xLTEtMjk3MjY_72143cb6-6096-4484-8664-8f25cadf2bdd"
      unitRef="number">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzQtMy0xLTEtMjk3MjY_90137b80-07aa-4ef4-bbbf-0a1fdb202a79"
      unitRef="number">0.0260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTowM2VmMDFmM2I5YWM0ZDcwYjViODY1YTkzOGViMzg5ZC90YWJsZXJhbmdlOjAzZWYwMWYzYjlhYzRkNzBiNWI4NjVhOTM4ZWIzODlkXzQtNS0xLTEtMjk3MjY_1c671f2f-ca3e-4650-a509-5db679e5cbcd"
      unitRef="number">0.0280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzYwNDQ_03a6388e-8abf-4da1-9778-7009a5cac737">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of option activity under the Plan as of January&#160;2, 2022, January&#160;3, 2021 and December&#160;29, 2019, and changes during the years ending on those dates is presented below:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Outstanding Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(Dollars in Millions) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at December 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;117,361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,364&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia2087646dc6744a28755f382fc0a83c8_I20181230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEtMi0xLTEtMjk3MjY_fb6d9a10-d94d-4e46-bd18-b3cf7373bcb9"
      unitRef="shares">109652000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia2087646dc6744a28755f382fc0a83c8_I20181230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEtNC0xLTEtMjk3MjY_2b6fdabb-6295-417e-92c3-83aef6dfc514"
      unitRef="usdPerShare">98.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ia2087646dc6744a28755f382fc0a83c8_I20181230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEtNi0xLTEtMjk3MjY_ce2e1048-c114-4327-8280-a9e519f83228"
      unitRef="usd">3214000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzItMi0xLTEtMjk3MjY_e2e49246-d6a1-4531-88bb-4918023b3756"
      unitRef="shares">19745000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzItNC0xLTEtMjk3MjY_71a355d8-9516-4dc8-b709-f7cfe1f0e567"
      unitRef="usdPerShare">131.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzMtMi0xLTEtMjk3MjY_258b58fd-cef0-4978-8de4-094e0082c152"
      unitRef="shares">14785000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzMtNC0xLTEtMjk3MjY_f4a83bdc-1266-47e4-8f25-86d75c32f49b"
      unitRef="usdPerShare">82.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzQtMi0xLTEtMjk3MjY_b53afc52-0756-4302-890e-b54ecbe4c890"
      unitRef="shares">2975000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzQtNC0xLTEtMjk3MjY_0cd3e14c-9dde-4877-a1d3-bad795ec35cd"
      unitRef="usdPerShare">125.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzUtMi0xLTEtMjk3MjY_aa50f412-f87b-4705-9e6c-18245fe533ca"
      unitRef="shares">111637000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzUtNC0xLTEtMjk3MjY_bb85c629-c903-477c-9e03-af7b58744077"
      unitRef="usdPerShare">105.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzUtNi0xLTEtMjk3MjY_b65a9804-5b78-487e-b9f5-b073bb5abc4c"
      unitRef="usd">4478000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzYtMi0xLTEtMjk3MjY_0b78f974-e90a-479a-95aa-11857653e196"
      unitRef="shares">20723000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzYtNC0xLTEtMjk3MjY_eb0db9eb-a5b5-4169-9eaa-cf62699c551a"
      unitRef="usdPerShare">151.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzctMi0xLTEtMjk3MjY_4f1248d7-34e3-42e5-9343-55c8e1e5b847"
      unitRef="shares">16275000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzctNC0xLTEtMjk3MjY_69fa6021-35c4-4c72-b0b9-0f8ccacc81a1"
      unitRef="usdPerShare">86.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzgtMi0xLTEtMjk3MjY_8d8f4f7d-d9f9-47b1-9de8-f9a2f7d2f6db"
      unitRef="shares">1835000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzgtNC0xLTEtMjk3MjY_1ffb24c4-7f51-497d-9710-a6163571e6f2"
      unitRef="usdPerShare">137.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzktMi0xLTEtMjk3MjY_3af3159a-c58b-4a50-abab-922675c7dec2"
      unitRef="shares">114250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzktNC0xLTEtMjk3MjY_21cc75bf-7e76-4b14-a8cd-eac0307536af"
      unitRef="usdPerShare">116.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzktNi0xLTEtMjk3MjY_56b2124a-e51c-47ed-b227-1506faba08ed"
      unitRef="usd">4703000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEwLTItMS0xLTI5NzI2_6357f7af-3799-4a58-87ec-875dd427b5f6"
      unitRef="shares">18525000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEwLTQtMS0xLTI5NzI2_4df83da1-2653-4ec7-9d7b-509869dbd362"
      unitRef="usdPerShare">164.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzExLTItMS0xLTI5NzI2_427b2f9d-c601-44d9-a86d-c89acc54e8fb"
      unitRef="shares">13248000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzExLTQtMS0xLTI5NzI2_9676c017-917b-456a-aa4c-575c2c08d3ab"
      unitRef="usdPerShare">97.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEyLTItMS0xLTI5NzI2_525dc7e1-657a-4011-bb54-cf155aa39404"
      unitRef="shares">2166000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEyLTQtMS0xLTI5NzI2_d51376cd-48cb-4ef6-bf2b-9c4d81a7699c"
      unitRef="usdPerShare">149.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEzLTItMS0xLTI5NzI2_784cc260-ac3d-4d66-94fa-8bf81bf7a337"
      unitRef="shares">117361000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEzLTQtMS0xLTI5NzI2_fdd5d6f5-f1bc-42f6-b994-52d36410459d"
      unitRef="usdPerShare">125.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTozZjA1MWJhNTA3NDc0N2NmOTQ1NmRiMzVjYWQxMzEyZC90YWJsZXJhbmdlOjNmMDUxYmE1MDc0NzQ3Y2Y5NDU2ZGIzNWNhZDEzMTJkXzEzLTYtMS0xLTI5NzI2_3d624c8b-f84b-44cd-a46a-3d54abf7cc3d"
      unitRef="usd">5364000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzMxMDQ_dc828100-0096-48d9-9b0b-99ec6b6bdc1c"
      unitRef="usd">919000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzMxMDg_f0634d56-4ecb-48ad-90c6-e525cdbeb578"
      unitRef="usd">1021000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzMxMTU_298d9709-6162-4c9b-8fce-ffcb7b70075a"
      unitRef="usd">807000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzYwMzY_ec86824b-e43c-43db-9404-13f4092d70d8">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock options outstanding and exercisable at January&#160;2, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$65.08-$90.44&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$81.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$81.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$100.06-$101.87&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$101.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$101.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$115.67-$129.51&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$122.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$122.43&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$131.94-$151.41&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$142.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$140.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$151.42-$164.62&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$164.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$164.62&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;117,361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$125.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62,742&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$104.42&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Average contractual life remaining in years.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="idd89ef5ec708419d83c0f50bd2e3f33a_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjo4ZmI4ZDMxOGFhMDE0NDdmOGU1MjcwYzdkMzkwNmIyZF81_87c7624c-9629-4850-8f12-d849eb5ce820"
      unitRef="usdPerShare">65.08</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="idd89ef5ec708419d83c0f50bd2e3f33a_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzItMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjo4ZmI4ZDMxOGFhMDE0NDdmOGU1MjcwYzdkMzkwNmIyZF85_c53d0cee-aa15-4557-b8f0-1822d4b2fa64"
      unitRef="usdPerShare">90.44</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i1cd5b16b5eb54677834e76fbba9c913b_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzItMi0xLTEtMjk3MjY_689d2e20-ec7a-4c0f-a38d-c8a1d3043c6f"
      unitRef="shares">16007000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="idd89ef5ec708419d83c0f50bd2e3f33a_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzItNC0xLTEtMjk3MjY_af700b6f-e452-4148-8aea-2142b3039b4a">P1Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i1cd5b16b5eb54677834e76fbba9c913b_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzItNi0xLTEtMjk3MjY_2b258751-03fa-4650-9b06-934b9eb02651"
      unitRef="usdPerShare">81.92</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i1cd5b16b5eb54677834e76fbba9c913b_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzItOC0xLTEtMjk3MjY_c4686dd0-3ab2-4380-84df-2dc0bacbc944"
      unitRef="shares">16007000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i1cd5b16b5eb54677834e76fbba9c913b_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzItMTAtMS0xLTI5NzI2_a41fa241-8d3d-4ebd-9be6-3ced15ce1d27"
      unitRef="usdPerShare">81.92</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="idec9b1a5f62642c0b966a067f115c2f0_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzMtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjpiMTk0ODc1YTViYjI0Yjg2OTg5MzIzYjhlYThiNWY2Nl81_a98bba42-1293-4051-bbd5-1a4c2e330e7c"
      unitRef="usdPerShare">100.06</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="idec9b1a5f62642c0b966a067f115c2f0_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzMtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjpiMTk0ODc1YTViYjI0Yjg2OTg5MzIzYjhlYThiNWY2Nl85_73cdbf39-07fd-4482-a0fa-cf08513d0b2d"
      unitRef="usdPerShare">101.87</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ie82cdef29cc04363906a567a9d6829fd_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzMtMi0xLTEtMjk3MjY_16ae7f3e-b297-4520-8205-b43f39414b1b"
      unitRef="shares">22647000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="idec9b1a5f62642c0b966a067f115c2f0_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzMtNC0xLTEtMjk3MjY_92a3a841-6a38-4dd7-bf0d-f4eb8f306a7c">P3Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ie82cdef29cc04363906a567a9d6829fd_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzMtNi0xLTEtMjk3MjY_2db892fc-3d94-4640-945f-6eba46f265f4"
      unitRef="usdPerShare">101.07</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ie82cdef29cc04363906a567a9d6829fd_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzMtOC0xLTEtMjk3MjY_3d22e7ba-c926-41db-99bc-c93feedd2b86"
      unitRef="shares">22647000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ie82cdef29cc04363906a567a9d6829fd_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzMtMTAtMS0xLTI5NzI2_79947038-646e-4bb4-aef5-a419fdc01374"
      unitRef="usdPerShare">101.07</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i8082802da5c34e03b65215fbc1747020_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzQtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjplYzg3ZDI5NTEzZDY0OWU2OTAwOTE0NzRkYzNkYTVkZF81_6b009c49-2351-4884-a6b6-7415be6fa9aa"
      unitRef="usdPerShare">115.67</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i8082802da5c34e03b65215fbc1747020_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzQtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjplYzg3ZDI5NTEzZDY0OWU2OTAwOTE0NzRkYzNkYTVkZF85_de407e8a-5880-4748-8ccd-a5b2aff75eb0"
      unitRef="usdPerShare">129.51</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i53a0b42ef8b740cb82bebc7e9ad442e7_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzQtMi0xLTEtMjk3MjY_e4b2f29f-69ee-4b38-8e9d-2e68666c1aad"
      unitRef="shares">24543000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i8082802da5c34e03b65215fbc1747020_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzQtNC0xLTEtMjk3MjY_9a54834c-1667-4405-a714-e077dcac91df">P5Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i53a0b42ef8b740cb82bebc7e9ad442e7_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzQtNi0xLTEtMjk3MjY_f23a95dc-bf4a-48fb-93cf-c9cddbec94de"
      unitRef="usdPerShare">122.59</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i53a0b42ef8b740cb82bebc7e9ad442e7_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzQtOC0xLTEtMjk3MjY_33deb237-eb2f-498e-b2bc-2e8b7f45eb3d"
      unitRef="shares">23972000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i53a0b42ef8b740cb82bebc7e9ad442e7_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzQtMTAtMS0xLTI5NzI2_472f131a-dffe-4b22-af02-f3b7b13c1e32"
      unitRef="usdPerShare">122.43</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i42e155106ee54d669ceeb882529be05f_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzUtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjo4YThhZGM5YjMzZTM0NzllOWMyZmJiYWJlMDVmZTAwN181_f5f43bbf-8a9d-4581-91b4-8cea8707a74b"
      unitRef="usdPerShare">131.94</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i42e155106ee54d669ceeb882529be05f_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzUtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjo4YThhZGM5YjMzZTM0NzllOWMyZmJiYWJlMDVmZTAwN185_6caa095e-5a12-4b0c-beb8-022518f925fb"
      unitRef="usdPerShare">151.41</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="id67bcb0b84aa42ffbafbcc561a13093e_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzUtMi0xLTEtMjk3MjY_d83def95-2a7b-4909-acbe-290f551aefef"
      unitRef="shares">36304000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i42e155106ee54d669ceeb882529be05f_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzUtNC0xLTEtMjk3MjY_f7aacfcf-1627-447a-a562-48ed6ed8eeb7">P7Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="id67bcb0b84aa42ffbafbcc561a13093e_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzUtNi0xLTEtMjk3MjY_063caa18-0a3f-41b2-a1d7-7be22db55374"
      unitRef="usdPerShare">142.23</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="id67bcb0b84aa42ffbafbcc561a13093e_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzUtOC0xLTEtMjk3MjY_35525814-847e-4924-a584-911263201335"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="id67bcb0b84aa42ffbafbcc561a13093e_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzUtMTAtMS0xLTI5NzI2_c0812314-16cf-4337-8762-9b34fdf0b79e"
      unitRef="usdPerShare">140.72</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ic399470ff9944abebce0ebbbfc9f95be_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzYtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjplOTQwYTE3YmJjYjQ0YmQ3OTExYTFjMGIyM2U4NmRlY181_4ce6feed-61da-49c0-ad63-e6cb5fb4822d"
      unitRef="usdPerShare">151.42</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ic399470ff9944abebce0ebbbfc9f95be_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzYtMC0xLTEtMjk3MjYvdGV4dHJlZ2lvbjplOTQwYTE3YmJjYjQ0YmQ3OTExYTFjMGIyM2U4NmRlY185_deb825ff-d4da-4bab-bfb8-4f1c2a57cb57"
      unitRef="usdPerShare">164.62</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i239ccf8862324768acca0b6dd0899121_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzYtMi0xLTEtMjk3MjY_20936a40-08ad-4b97-8a8d-0b26581db90e"
      unitRef="shares">17860000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ic399470ff9944abebce0ebbbfc9f95be_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzYtNC0xLTEtMjk3MjY_c2cf94e6-f78c-46cd-82b0-84b1dfd25725">P9Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i239ccf8862324768acca0b6dd0899121_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzYtNi0xLTEtMjk3MjY_812e539c-3293-4623-89d6-1129e1f60b8c"
      unitRef="usdPerShare">164.62</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i239ccf8862324768acca0b6dd0899121_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzYtOC0xLTEtMjk3MjY_22ded970-ce47-4403-81db-dc6e2c171249"
      unitRef="shares">16000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i239ccf8862324768acca0b6dd0899121_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzYtMTAtMS0xLTI5NzI2_d9da795d-a4c7-439c-b26b-bd51deb29117"
      unitRef="usdPerShare">164.62</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzctMi0xLTEtMjk3MjY_985f427a-6e8f-4138-a8f1-31732efa7a4d"
      unitRef="shares">117361000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzctNC0xLTEtMjk3MjY_6c75e472-d649-49ef-b83c-5f006b731293">P5Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzctNi0xLTEtMjk3MjY_4ad80d75-e390-4c79-8218-61d8e474c4db"
      unitRef="usdPerShare">125.36</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzctOC0xLTEtMjk3MjY_3c98956d-2adb-4876-8ed0-37d999de29c9"
      unitRef="shares">62742000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5NTc5YzdhOTYyMzA0OTJiOTNmYWJlMGJhZGI1MDYzOS90YWJsZXJhbmdlOjk1NzljN2E5NjIzMDQ5MmI5M2ZhYmUwYmFkYjUwNjM5XzctMTAtMS0xLTI5NzI2_0df9e58f-df4f-4fbf-819a-7506d20a40bd"
      unitRef="usdPerShare">104.42</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzMzNDE_963d148a-4e3d-4d2a-a993-1c4a7745e2a3"
      unitRef="shares">114250000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzMzNjc_504d49be-7bf9-42e1-ae60-56c56bd000f1">P6Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzMzODA_0a69f83d-235c-4311-9c74-3d4b17d885b6"
      unitRef="shares">111637000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzM0MDY_c0de2f5a-e6e6-4190-b70e-906c84536a6e">P6Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzM0NzQ_cd2bf4b0-a813-4126-b09a-9efb58ba03fb"
      unitRef="shares">61289000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzM1MDA_85e3cf1c-f762-4f7f-bf2e-fa9da15958ce"
      unitRef="usdPerShare">96.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzM1MDc_07b9771d-7d37-44d3-b08e-6a39868e74e3"
      unitRef="shares">60761000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzM1MzM_fc0e99ab-4838-4baa-b89e-e0cfcd82bcba"
      unitRef="usdPerShare">88.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib2ff139955b84bebb659527301f2d7f3_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzM2OTM_dd562ba6-acde-443a-83ab-346c8f661322">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6608a73388e94a39a929181aeaf3e2ea_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzM2OTk_304c95ba-1a47-4653-9d89-c29cef69ae15">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7982e382a8c642f3ab7e8d233cd63f23_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzYwNTA_ca0a1beb-83f2-4bce-8002-d5baa855a6d7">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9cf80e986c6a49168d7e1239ef86064b_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzM5OTI_6eb840d9-c7b0-4013-a86d-310583b36d52">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic8597ec09b7848ea847316c99dd326ef_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzM5OTg_602b66bb-9a2b-45f1-883e-9fdc7b61d2f7">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7982e382a8c642f3ab7e8d233cd63f23_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzYwNjE_10035172-61bc-4e0f-ab7d-c1b6a6146109">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7982e382a8c642f3ab7e8d233cd63f23_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzYwMzc_8e9ca1a1-ba6e-446f-b0bc-dcab0f7ff14e">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i9cf80e986c6a49168d7e1239ef86064b_D20210104-20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzQ2MTU_262e0efd-4407-473b-807c-5bfaa47849a9"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ic8597ec09b7848ea847316c99dd326ef_D20210104-20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzQ2MjE_8e35eec8-993d-4bcf-83c2-7c899815b9dc"
      unitRef="number">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzYwMzM_278123ff-ba25-48c5-a3f6-ae00bcef6b86">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the restricted share units and performance share units activity under the Plans as of January&#160;2, 2022 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Performance Share Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited/adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i7038702487ec4c45a376b222a0a20d05_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzktMi0xLTEtMjk3MjY_5648acb1-484b-44de-a13a-184765057f35"
      unitRef="shares">14998000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i31cd18cf81d841f5a062c0c4dff7e8d9_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzktNC0xLTEtMjk3MjY_beaa3c08-2f9b-4876-92ad-7e06ea311a00"
      unitRef="shares">2236000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i164575311ea140df89ecfa92b9b8b764_D20210104-20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzEwLTItMS0xLTI5NzI2_f1cf4b3f-b491-43ce-a68a-7acadbcb5e36"
      unitRef="shares">4981000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7982e382a8c642f3ab7e8d233cd63f23_D20210104-20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzEwLTQtMS0xLTI5NzI2_f0ddcf0c-db60-4de7-a7d6-cb560c3e28d7"
      unitRef="shares">741000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i164575311ea140df89ecfa92b9b8b764_D20210104-20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzExLTItMS0xLTI5NzI2_7b259cfb-52c6-406f-8e1d-8804359b9759"
      unitRef="shares">5101000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i7982e382a8c642f3ab7e8d233cd63f23_D20210104-20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzExLTQtMS0xLTI5NzI2_eed18761-b9e8-48c0-828b-a8ae078d4264"
      unitRef="shares">610000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod
      contextRef="i164575311ea140df89ecfa92b9b8b764_D20210104-20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzEyLTItMS0xLTI5NzI2_15bb5ff0-77b3-41b7-a110-5a8268c5e343"
      unitRef="shares">756000</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod
      contextRef="i7982e382a8c642f3ab7e8d233cd63f23_D20210104-20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzEyLTQtMS0xLTI5NzI2_43b0bd6a-97d0-4c98-a828-8ace2d6611d3"
      unitRef="shares">-55000</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia84f3c7aa69a4e3ca4e10cee006b35d6_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzEzLTItMS0xLTI5NzI2_d9782a0a-7d34-4620-8ca8-69c7fd534d10"
      unitRef="shares">14122000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9a880d0282e64618a404c4e5c8cda751_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90YWJsZTo5MWM0M2Y2ZTIzN2Q0NDRkOGJmODU5MDc5MDM4YjcyZC90YWJsZXJhbmdlOjkxYzQzZjZlMjM3ZDQ0NGQ4YmY4NTkwNzkwMzhiNzJkXzEzLTQtMS0xLTI5NzI2_d70ea796-6308-4f53-8305-98f019d1780c"
      unitRef="shares">2312000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i164575311ea140df89ecfa92b9b8b764_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzQ4NzI_8ac69559-e405-44dc-b6ec-c94d5c74433f"
      unitRef="usdPerShare">152.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iaa26f4b3444e4c15a4078dc66b339b0d_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzQ4NzY_b6775266-8490-493b-bff9-8e09ab7daf67"
      unitRef="usdPerShare">139.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7364abb0a14f4216bcad7a962281ebf6_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzQ4ODM_125c87f8-4186-4ab2-a9ba-610083b6918f"
      unitRef="usdPerShare">121.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i164575311ea140df89ecfa92b9b8b764_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzUxODA_4e927c75-7260-4586-bbbe-89f475f31bcf"
      unitRef="usd">611000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="iaa26f4b3444e4c15a4078dc66b339b0d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzUxODQ_3f33d1d1-eeca-45dd-b459-a89c5b7dab52"
      unitRef="usd">650000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i7364abb0a14f4216bcad7a962281ebf6_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzUxOTE_b05a7dcb-e364-473e-99d6-213aae1c8fc0"
      unitRef="usd">586000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7982e382a8c642f3ab7e8d233cd63f23_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzUzMDE_68db7fa2-67ff-4fd6-84bb-79644176b533"
      unitRef="usdPerShare">179.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7ed28ab7d2664b82bbdff0bc1302e139_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzUzMDU_600057b0-acc4-48e9-b7b1-da41c0e52605"
      unitRef="usdPerShare">160.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if7b0fdaa9d9e46c9afcb09b831c329a4_D20181231-20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzUzMTI_7f6172ea-cde3-47b0-9547-1afe424eabb5"
      unitRef="usdPerShare">124.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i7982e382a8c642f3ab7e8d233cd63f23_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzU5NzQ_a62b9d72-8b9a-4f27-8eb8-3429267e813f"
      unitRef="usd">83000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i7ed28ab7d2664b82bbdff0bc1302e139_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzU5Nzg_c4b6a808-bdec-4c85-a834-26163c422fc2"
      unitRef="usd">91000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="if7b0fdaa9d9e46c9afcb09b831c329a4_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMDUvZnJhZzoxZTNjZjFkZWEzNjk0OTc1YWFjN2E5NzM2ODU5Y2JkOC90ZXh0cmVnaW9uOjFlM2NmMWRlYTM2OTQ5NzVhYWM3YTk3MzY4NTljYmQ4XzU5ODU_4a1d3470-4b96-46e6-b1c5-5f83e1a4a7e1"
      unitRef="usd">119000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzM0NDQ_37d27699-8500-4b17-9428-74d7ad6554ff">Segments of Business* and Geographic Areas&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2019;21 vs. &#x2019;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2019;20 vs. &#x2019;19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skin Health/Beauty&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oral Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Baby Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Women's Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Wound Care/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL CONSUMER HEALTH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:189pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;COVID-19 VACCINE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EDURANT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / rilpivirine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;PREZISTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / PREZCOBIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; /                                              &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; REZOLSTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / SYMTUZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONCERTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / methylphenidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / XEPLION&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / TREVICTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;RISPERDAL CONSTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;* *&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;* *&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;/&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;abiraterone acetate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;PROCRIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / EPREX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:57pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;MEDICAL DEVICES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interventional Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL MEDICAL DEVICES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Certain prior year amounts have been reclassified to conform to current year presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;**Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income (Loss) Before Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,776&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,497&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,328&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;182,018&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;174,894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions to Property,&lt;br/&gt;Plant &amp;amp; Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Depreciation and&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segments total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,652&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,347&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,390&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,231&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,009&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-Lived Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Western Hemisphere excluding U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segments total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;93,775&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;82,584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;82,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;182,018&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;174,894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note&#160;1 for a description of the segments in which the Company operates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Export sales are not significant. In fiscal year 2021, the Company utilized three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0% and 11.0% of the total consolidated revenues. In fiscal year 2020, the Company had three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0% and 12.0% of the total consolidated revenues. In fiscal year 2019, the Company had three wholesalers distributing products for all three segments that represented approximately 15.0%, 12.0%, and 11.0% of the total consolidated revenues. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;General corporate includes cash, cash equivalents and marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $1.6&#160;billion, primarily talc related reserves&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.6&#160;billion, primarily related to Risperdal &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Divestiture gains of $0.6&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Gains on securities of $0.5&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.1&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Devices includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An in-process research and development expense of $0.9&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A Medical Device Regulation charge of $0.2&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.1&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;        &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $3.9&#160;billion, primarily talc related reserves and certain settlements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.8&#160;billion, primarily related to the agreement in principle to settle opioid litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An unrealized gain on securities of $0.5&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Devices includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A contingent consideration reversal of $1.1&#160;billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An in-process research and development expense of $0.2&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A Medical Device Regulation charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.4 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.1 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;    Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $4.3 billion of which $4.0 billion is related to the agreement in principle to settle opioid litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An in-process research and development expense of $0.9 billion related to the Alios asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A research and development expense of $0.3 billion for an upfront payment related to argenx &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An unrealized gain on securities of $0.6 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Actelion acquisition and integration related costs of $0.2 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring charge of $0.1 billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;    Medical Devices includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A gain of $2.0 billion from the divestiture of the ASP business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.4 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.4 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Auris Health acquisition and integration related costs of $0.1 billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Long-lived assets include property, plant and equipment, net for fiscal years 2021, and 2020 of $18,962 and $18,766, respectively, and intangible assets and goodwill, net for fiscal years 2021 and 2020 of $81,638 and $89,795, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <jnj:SalesBySegmentOfBusinessTableTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzM0MzI_57b56d7f-8c46-4943-a602-88d675b724bf">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2019;21 vs. &#x2019;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2019;20 vs. &#x2019;19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skin Health/Beauty&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oral Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Baby Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Women's Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Wound Care/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL CONSUMER HEALTH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:189pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;COVID-19 VACCINE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EDURANT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / rilpivirine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;PREZISTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / PREZCOBIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; /                                              &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; REZOLSTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / SYMTUZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONCERTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / methylphenidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / XEPLION&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / TREVICTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;RISPERDAL CONSTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;* *&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;* *&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;/&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;abiraterone acetate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;PROCRIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / EPREX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:57pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;MEDICAL DEVICES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interventional Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL MEDICAL DEVICES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Certain prior year amounts have been reclassified to conform to current year presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;**Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;</jnj:SalesBySegmentOfBusinessTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i192bc4de755f43dea6fc766f7aea65d0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUtMi0xLTEtMjk3MjY_b50d1f20-b43d-494c-9d74-aab34bf6b122"
      unitRef="usd">2594000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffb82aff41a04d54b8471dfaef55cbfb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUtNC0xLTEtMjk3MjY_34ae80e7-191d-4987-80dc-a3f01ccb537e"
      unitRef="usd">2460000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9131515b36de452dba77389706d7cf68_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUtNi0xLTEtMjk3MjY_9fed1999-3d5e-4ddf-a87e-33b0444af98c"
      unitRef="usd">2010000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i192bc4de755f43dea6fc766f7aea65d0_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUtOC0xLTEtMjk3MjY_51b2ed51-90ba-4e37-8d17-c11e983fd645"
      unitRef="number">0.054</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iffb82aff41a04d54b8471dfaef55cbfb_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUtMTAtMS0xLTI5NzI2_0ba7ca04-4efe-4d22-ad9b-3c47a4839863"
      unitRef="number">0.224</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcd0fc1997c54c228fd7a7bd70bf4aac_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYtMi0xLTEtMjk3MjY_fc6a0712-4964-4155-9e1f-45caefffd484"
      unitRef="usd">2634000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icebbd7181a854a83b106002262a3f05a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYtNC0xLTEtMjk3MjY_d27f5cc1-38d5-42bc-8022-b83d771e8367"
      unitRef="usd">2364000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d99e38809f24798a6aa6262467560c6_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYtNi0xLTEtMjk3MjY_7e97e3d4-5e23-46c3-888b-4b5f367e1b48"
      unitRef="usd">2434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibcd0fc1997c54c228fd7a7bd70bf4aac_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYtOC0xLTEtMjk3MjY_851a5a62-1bfb-4ad2-97f8-49b4d25312c0"
      unitRef="number">0.114</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icebbd7181a854a83b106002262a3f05a_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYtMTAtMS0xLTI5NzI2_6788aaf8-41f1-43af-ba8f-f39c16ff6210"
      unitRef="number">-0.029</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c63ea6850a74252ba3d49fa9fe7b74a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzctMi0xLTEtMjk3MjY_39a3ea7b-3c76-46c1-bfc8-8585674122c4"
      unitRef="usd">5227000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ba444b93d124ce393b5b3f193a70f2f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzctNC0xLTEtMjk3MjY_9ae85f77-5fdb-4867-808c-702e73a66342"
      unitRef="usd">4824000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94f3652f4af1446da52491a28d5ec451_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzctNi0xLTEtMjk3MjY_9ce52388-d9da-4768-84ac-a26142cfd6bb"
      unitRef="usd">4444000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6c63ea6850a74252ba3d49fa9fe7b74a_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzctOC0xLTEtMjk3MjY_263d6e97-515c-4143-b2f2-5bb40c52ddc0"
      unitRef="number">0.084</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2ba444b93d124ce393b5b3f193a70f2f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzctMTAtMS0xLTI5NzI2_3e3da999-8ab5-4170-93c9-f284eb41be8e"
      unitRef="number">0.085</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d10f0f5f973460c82f6e46d69e2962a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzktMi0xLTEtMjk3MjY_2cee6a52-ab95-4384-8a4b-4329b22a8b57"
      unitRef="usd">2400000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief6f2ac5fd8f4812a89cc848a4c1df06_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzktNC0xLTEtMjk3MjY_49b426c9-ad82-4df0-a39d-cb19b62c73e7"
      unitRef="usd">2350000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32966c9a84284da0b58c8d0ae0faa3c8_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzktNi0xLTEtMjk3MjY_853a7628-dbec-441b-924e-3063d9c0868a"
      unitRef="usd">2392000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5d10f0f5f973460c82f6e46d69e2962a_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzktOC0xLTEtMjk3MjY_9aa19d3e-f34f-4cb4-8c6c-556abddbe46b"
      unitRef="number">0.021</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ief6f2ac5fd8f4812a89cc848a4c1df06_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzktMTAtMS0xLTI5NzI2_ce421e5d-0e62-4c80-9c91-c234a864f610"
      unitRef="number">-0.017</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3128d308ffe4613906d97816a65e9bd_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwLTItMS0xLTI5NzI2_cd1adb89-db0a-4422-86f5-1b816a467d4e"
      unitRef="usd">2141000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a561bfd58ec4ccabd2025a6e7cf9bd5_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwLTQtMS0xLTI5NzI2_fd24e785-5c22-4f45-8f40-3ecc161d9e80"
      unitRef="usd">2100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i400f84b397df414cbbedb7f3a7926c43_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwLTYtMS0xLTI5NzI2_171a963b-5ef4-45ee-a266-7a7fefe360c3"
      unitRef="usd">2201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if3128d308ffe4613906d97816a65e9bd_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwLTgtMS0xLTI5NzI2_a860a3e8-ad88-46ec-bdd6-4de8b9babfe5"
      unitRef="number">0.019</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2a561bfd58ec4ccabd2025a6e7cf9bd5_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwLTEwLTEtMS0yOTcyNg_c3b1a034-1346-4d88-b39b-1adb56c2f4d3"
      unitRef="number">-0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3d80b5dc4e343d19875dae1cb177ef0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExLTItMS0xLTI5NzI2_ae57d04c-ad51-4cd2-b94d-0c7b78a14486"
      unitRef="usd">4541000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ac3647e660b4922bcde7ec55782e160_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExLTQtMS0xLTI5NzI2_f096b994-1276-4487-93c9-c6d0f99299d6"
      unitRef="usd">4450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7fdb4bd463a34c9fa3b35815b52e6ef3_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExLTYtMS0xLTI5NzI2_181f158f-d1b3-4e0e-ad06-2a89b14e5251"
      unitRef="usd">4593000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic3d80b5dc4e343d19875dae1cb177ef0_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExLTgtMS0xLTI5NzI2_61a6d9b5-bba5-47b2-ba70-dddb00fa2f52"
      unitRef="number">0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0ac3647e660b4922bcde7ec55782e160_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExLTEwLTEtMS0yOTcyNg_290ef07c-2a6a-473c-ad01-cc76e53cecb0"
      unitRef="number">-0.031</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iadd4ee8352f9426fae8e6bdc7fe52372_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzLTItMS0xLTI5NzI2_1b10898b-a2d9-4cca-8768-f89db6cbea44"
      unitRef="usd">637000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1577281a68942e6b6973a3973d33136_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzLTQtMS0xLTI5NzI2_dabecca3-8f9e-4c32-82fe-1e24060a1391"
      unitRef="usd">683000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8cfdad6d51e400e8669811b1b2b4267_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzLTYtMS0xLTI5NzI2_af1b84b2-0d48-45db-b693-1fd8996ca811"
      unitRef="usd">621000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iadd4ee8352f9426fae8e6bdc7fe52372_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzLTgtMS0xLTI5NzI2_cb54534b-e3e7-4ebf-9448-96549f7ffffd"
      unitRef="number">-0.067</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id1577281a68942e6b6973a3973d33136_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzLTEwLTEtMS0yOTcyNg_7f72a1c9-032f-40db-ae36-e303f9f877e3"
      unitRef="number">0.099</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35d06bb332e74e4982e637a9ca92913d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0LTItMS0xLTI5NzI2_47735993-177b-419e-b7cc-db851cec6fb4"
      unitRef="usd">1008000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dc75eb155004e52844ffebf7174bbd0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0LTQtMS0xLTI5NzI2_bfabc1fc-d4c9-4121-8790-369a49b078af"
      unitRef="usd">958000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i375d3135400b433096c8e5dab3fa38a1_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0LTYtMS0xLTI5NzI2_d07ce67f-3a9f-4595-aa79-07c3f909a9d0"
      unitRef="usd">906000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i35d06bb332e74e4982e637a9ca92913d_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0LTgtMS0xLTI5NzI2_6e06bfc2-eb6e-4202-9078-e8f3fe8d61a1"
      unitRef="number">0.051</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0dc75eb155004e52844ffebf7174bbd0_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0LTEwLTEtMS0yOTcyNg_a8c3287b-3b0e-4503-8726-302c4b601358"
      unitRef="number">0.057</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6952a648640445fbdd6cdd36431a750_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1LTItMS0xLTI5NzI2_2d6c7b0f-e33b-48be-bd13-e6785647f2cb"
      unitRef="usd">1645000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07542366df9243c6abac2d16b1dfb58b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1LTQtMS0xLTI5NzI2_38e1a832-cb75-4bcb-9812-3454e784309c"
      unitRef="usd">1641000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i064e7c0f8fa548429b040cde3913d49f_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1LTYtMS0xLTI5NzI2_acd6dd62-1e94-4f33-96f0-1f875318802c"
      unitRef="usd">1528000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic6952a648640445fbdd6cdd36431a750_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1LTgtMS0xLTI5NzI2_f2f41c17-e832-4fd0-b5e5-76911cb9bcc3"
      unitRef="number">0.002</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i07542366df9243c6abac2d16b1dfb58b_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1LTEwLTEtMS0yOTcyNg_5af4746b-3c5a-4169-8789-9e5df5fee6f5"
      unitRef="number">0.074</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77b6cd743a414007b81cd6a3d310ef78_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE3LTItMS0xLTI5NzI2_bd008ff4-33fa-4137-95f0-deebbff98b7a"
      unitRef="usd">378000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2fafb4659f34a019ee6e466fc04640f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE3LTQtMS0xLTI5NzI2_b940cc66-b976-43af-8334-9d2b56c4b4f3"
      unitRef="usd">376000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifdbca246df0847e9a8c4c4c568f2f273_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE3LTYtMS0xLTI5NzI2_0a498fab-3002-45f2-afbd-7c425f7d514e"
      unitRef="usd">362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i77b6cd743a414007b81cd6a3d310ef78_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE3LTgtMS0xLTI5NzI2_7c06ca87-a4e5-48a0-b716-5cdec52c173c"
      unitRef="number">0.005</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib2fafb4659f34a019ee6e466fc04640f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE3LTEwLTEtMS0yOTcyNg_5d1fbe50-33d8-42c4-a1da-dfb53abbd3af"
      unitRef="number">0.037</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i022c563362694b598da5b24ae2277042_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4LTItMS0xLTI5NzI2_ccb3c334-af08-44bf-9f4a-c4389702b3e3"
      unitRef="usd">1188000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9241b397d581403bba8152c090405eca_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4LTQtMS0xLTI5NzI2_d54e7a51-023c-45aa-8330-d22e15648abd"
      unitRef="usd">1141000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6771db02e5f8466e9669560f1ce16529_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4LTYtMS0xLTI5NzI2_d9ce14b1-69a6-4227-b9df-a89419c8d1f6"
      unitRef="usd">1313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i022c563362694b598da5b24ae2277042_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4LTgtMS0xLTI5NzI2_2c5d8cfa-cf25-46ca-8ccd-616901b03e5b"
      unitRef="number">0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9241b397d581403bba8152c090405eca_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4LTEwLTEtMS0yOTcyNg_a3234bd5-a472-45a5-b921-6f3a1047c24e"
      unitRef="number">-0.131</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84e86bd12edd4e36b8b1f925a62c221d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5LTItMS0xLTI5NzI2_8e65f7cb-42b8-4b2b-a199-a72277f6f625"
      unitRef="usd">1566000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f3c558885324ba1953b737d2adc0dd0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5LTQtMS0xLTI5NzI2_75aff1fe-992b-4301-b166-53d5d276c16d"
      unitRef="usd">1517000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2db5485b4bd4b42a522def325281378_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5LTYtMS0xLTI5NzI2_01c8bf68-0f1b-4de8-ac07-9bd09f89864e"
      unitRef="usd">1675000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i84e86bd12edd4e36b8b1f925a62c221d_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5LTgtMS0xLTI5NzI2_dc5aaed9-e496-414a-bd76-35db4a4134fd"
      unitRef="number">0.032</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4f3c558885324ba1953b737d2adc0dd0_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5LTEwLTEtMS0yOTcyNg_3049ea97-1ec6-4bdf-b862-9f7de9ab4b4b"
      unitRef="number">-0.094</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f56f359990241d3a0b4c60663ba73e8_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxLTItMS0xLTI5NzI2_221506c1-3a2b-49a8-881d-3aa9208b7737"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i050c5285c0d645479744c7f00e88de1a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxLTQtMS0xLTI5NzI2_a99459f6-8e04-416e-a422-c637c508fb18"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cb9f8fb040f4aa586cf78caa70caec0_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxLTYtMS0xLTI5NzI2_6f81bd41-0bd2-496c-a6c3-184a7d840495"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6f56f359990241d3a0b4c60663ba73e8_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxLTgtMS0xLTI5NzI2_3a7ae271-6623-4d27-8d09-4fe4938fbe52"
      unitRef="number">-0.016</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i050c5285c0d645479744c7f00e88de1a_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxLTEwLTEtMS0yOTcyNg_0b0a59cf-1bf7-4873-87f8-a4fdc139c0e6"
      unitRef="number">0.082</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23807e0c5b084f52943e64733569f8b6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyLTItMS0xLTI5NzI2_55919f8f-9251-423b-97d4-5376b8158c2f"
      unitRef="usd">905000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2eefeafc846f4408a7e000284e1799b2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyLTQtMS0xLTI5NzI2_67f58cae-b1bf-43d3-af68-174c2f7b9787"
      unitRef="usd">888000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dbbbd6fc37c4d11acae7021cffb7cfd_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyLTYtMS0xLTI5NzI2_58d7a746-c5f1-4440-9eda-d3f0e15d8795"
      unitRef="usd">974000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i23807e0c5b084f52943e64733569f8b6_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyLTgtMS0xLTI5NzI2_3ea0acb2-a6da-46b2-998b-d07be46148c9"
      unitRef="number">0.018</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2eefeafc846f4408a7e000284e1799b2_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyLTEwLTEtMS0yOTcyNg_6fc06837-9cd5-477d-b7e2-aab05aa04ea1"
      unitRef="number">-0.088</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad865eab405c42688b73a15ad42a8b8d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzLTItMS0xLTI5NzI2_b81727e4-1bb4-4540-a07b-8922eccba276"
      unitRef="usd">917000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifef895456d614fdabb4ee70a7406be36_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzLTQtMS0xLTI5NzI2_6c336e29-ad66-4f17-849a-7fc6a154d91d"
      unitRef="usd">901000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieda9b733b51a4ce4b729836ac29a9802_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzLTYtMS0xLTI5NzI2_92cfb9ae-8009-452f-9ddc-43237d63ecf4"
      unitRef="usd">986000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iad865eab405c42688b73a15ad42a8b8d_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzLTgtMS0xLTI5NzI2_1a6d0d43-366a-45e0-be9d-6be3ce239f08"
      unitRef="number">0.018</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifef895456d614fdabb4ee70a7406be36_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzLTEwLTEtMS0yOTcyNg_8f09b9ae-169c-4053-a3bf-a1f2a6450487"
      unitRef="number">-0.086</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6576ad6b7f6341ec9b085c6461df5f80_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI1LTItMS0xLTI5NzI2_49c74143-9c29-4e86-8fd5-86d5b822448c"
      unitRef="usd">495000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65ba73df1e8b4801b72d2316d8a633c3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI1LTQtMS0xLTI5NzI2_aaf42550-9b1b-4456-9e35-c756bd3c1b55"
      unitRef="usd">480000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i615e942c7fdf4b2f990bb45b5b38934e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI1LTYtMS0xLTI5NzI2_d9fd4269-b40c-4ba1-8f1e-408a5363452c"
      unitRef="usd">441000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6576ad6b7f6341ec9b085c6461df5f80_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI1LTgtMS0xLTI5NzI2_02837cb0-3810-4e2e-917d-4a954fb673e8"
      unitRef="number">0.031</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i65ba73df1e8b4801b72d2316d8a633c3_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI1LTEwLTEtMS0yOTcyNg_e325a1d6-8823-44a6-b38d-522f6ec311ad"
      unitRef="number">0.089</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4735078cb2534ea1aac702a26e874601_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI2LTItMS0xLTI5NzI2_402974e2-e7d9-4717-a867-f5fb3b4ce60d"
      unitRef="usd">243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08b088a9453b40469d5f8fbb460e6662_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI2LTQtMS0xLTI5NzI2_a91d7efb-78a1-42da-9465-a73f00bb2f78"
      unitRef="usd">240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffdc846cb23b49548ae67d105477e7ca_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI2LTYtMS0xLTI5NzI2_87ed8b9e-9963-44b1-bc75-f826320ff92a"
      unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4735078cb2534ea1aac702a26e874601_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI2LTgtMS0xLTI5NzI2_cf670c4f-febd-4246-9e78-57f9b045bf42"
      unitRef="number">0.017</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i08b088a9453b40469d5f8fbb460e6662_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI2LTEwLTEtMS0yOTcyNg_138c9ae5-9ce8-46de-a274-b9fd63b31ec9"
      unitRef="number">0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75581ba7e91e4e2680d33c3738c407a9_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI3LTItMS0xLTI5NzI2_8f873564-7a78-4fc1-8198-968d030fe50f"
      unitRef="usd">739000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id405ef4ec29047a392666ca100c5896f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI3LTQtMS0xLTI5NzI2_f66f759a-d04d-41d1-b3ef-4965449323ab"
      unitRef="usd">720000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44c0cd51f839449b841b58440ac22a33_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI3LTYtMS0xLTI5NzI2_95ea5d8c-5893-426b-aa91-50d61a202f25"
      unitRef="usd">671000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i75581ba7e91e4e2680d33c3738c407a9_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI3LTgtMS0xLTI5NzI2_8a61680b-6447-40b2-a4f3-fe44ac456a8b"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id405ef4ec29047a392666ca100c5896f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI3LTEwLTEtMS0yOTcyNg_6364031b-ff10-44bd-91e7-62ad1457f53c"
      unitRef="number">0.072</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cd93ab841884a5493587a7b877c5d6b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI5LTItMS0xLTI5NzI2_14170a05-5f0a-4f17-873a-cc6985b1aeb0"
      unitRef="usd">6516000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9be280a895e24bc2b461be2b202dc790_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI5LTQtMS0xLTI5NzI2_b1b3be0f-5803-4cbe-bc0d-1ae2076c6030"
      unitRef="usd">6362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a50b9c81baf410eace82766e4ac78e0_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI5LTYtMS0xLTI5NzI2_2419e7f7-0d61-4816-bec9-b2dcff3657ec"
      unitRef="usd">5839000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5cd93ab841884a5493587a7b877c5d6b_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI5LTgtMS0xLTI5NzI2_964ead42-5965-4942-93f7-fb051814e217"
      unitRef="number">0.024</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9be280a895e24bc2b461be2b202dc790_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzI5LTEwLTEtMS0yOTcyNg_125457a6-02c8-4c3c-8a8d-b5e32d5d6036"
      unitRef="number">0.090</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ea74d1c2c27413fad7f2b508f4aa451_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMwLTItMS0xLTI5NzI2_a0e2d36e-3bc1-43b9-b83e-937650cfd13a"
      unitRef="usd">8119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5d8bff62eea4ed39c39a6731f599a92_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMwLTQtMS0xLTI5NzI2_6dee1eb9-192c-42db-af93-988fd7d1f86c"
      unitRef="usd">7691000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4495a7b68b684dcc8ad8b2dd0d0cb678_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMwLTYtMS0xLTI5NzI2_53c5e65b-e14d-467b-b1a9-e807d9ebeec6"
      unitRef="usd">8059000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1ea74d1c2c27413fad7f2b508f4aa451_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMwLTgtMS0xLTI5NzI2_34332763-92d8-4c25-a803-8ff491c76a0f"
      unitRef="number">0.056</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib5d8bff62eea4ed39c39a6731f599a92_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMwLTEwLTEtMS0yOTcyNg_b84e5972-5401-45bb-816b-c3ace9c2ed11"
      unitRef="number">-0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1198f98bdb8f4597b4a10112426c5f06_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMxLTItMS0xLTI5NzI2_82280380-dfbd-44e3-a279-661f479e4e23"
      unitRef="usd">14635000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if43f753e349c40788db498a0b8a5fe34_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMxLTQtMS0xLTI5NzI2_781cc6fb-5015-487a-b5e6-821077a75429"
      unitRef="usd">14053000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib63ccacb9faa4b73878a9057b0fd6b30_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMxLTYtMS0xLTI5NzI2_22eaa077-f922-4d5e-8d66-efbd7eba120f"
      unitRef="usd">13898000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1198f98bdb8f4597b4a10112426c5f06_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMxLTgtMS0xLTI5NzI2_a3bb8bc7-1b0d-48c1-808e-8ae3383a078d"
      unitRef="number">0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if43f753e349c40788db498a0b8a5fe34_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzMxLTEwLTEtMS0yOTcyNg_c3483510-ebc0-44e2-ac97-e418959ffe36"
      unitRef="number">0.011</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00834d1d0411420090b5c1edf63e1dfa_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM1LTItMS0xLTI5NzI2_c43e3fb4-4003-4316-b9a5-6df24530e21e"
      unitRef="usd">10843000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6071637def043888bf3deb3a4c15799_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM1LTQtMS0xLTI5NzI2_657d0a21-f812-41f0-8968-286a240a6632"
      unitRef="usd">10175000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22f5ca4ce57845c5b53fc4f1d13397db_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM1LTYtMS0xLTI5NzI2_e9933207-42c0-4c56-9092-b303ebd92974"
      unitRef="usd">9641000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i00834d1d0411420090b5c1edf63e1dfa_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM1LTgtMS0xLTI5NzI2_8150f62b-f63a-49e4-ba63-be19fe8db3ef"
      unitRef="number">0.066</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie6071637def043888bf3deb3a4c15799_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM1LTEwLTEtMS0yOTcyNg_488e866b-bd9c-4d22-abcb-f00bef4d1483"
      unitRef="number">0.055</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icba87799cace4d7ea02ee1f5e0a4d031_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM2LTItMS0xLTI5NzI2_79aa8199-b57f-40a1-8a32-5482907bf991"
      unitRef="usd">5907000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5c52e9cc9c14137918169f0b8a1bdb5_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM2LTQtMS0xLTI5NzI2_ba7da21b-a490-4ed1-90b1-e4cd376a1ef4"
      unitRef="usd">4880000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedf0e8d371a6458193259414109945a4_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM2LTYtMS0xLTI5NzI2_f3171dc6-21d3-437b-ba32-df7ed480a10e"
      unitRef="usd">4309000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icba87799cace4d7ea02ee1f5e0a4d031_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM2LTgtMS0xLTI5NzI2_9ecd5a74-317a-48b5-a383-3438c744c2ca"
      unitRef="number">0.210</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib5c52e9cc9c14137918169f0b8a1bdb5_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM2LTEwLTEtMS0yOTcyNg_b9a159bf-aa90-4e42-b294-9fb04aca57e1"
      unitRef="number">0.132</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23071b0ab3d54897a0d5dd7749feafe6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM3LTItMS0xLTI5NzI2_f43c3262-0b13-492c-b2f8-b536c70a3f2c"
      unitRef="usd">16750000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i931a1c9f97ec484da90098853ca3c244_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM3LTQtMS0xLTI5NzI2_0c27426b-3c30-4ba8-8abc-f6c4b3888de9"
      unitRef="usd">15055000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9c2e9c0297b447e93e02db4e79afb3c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM3LTYtMS0xLTI5NzI2_62d3ae92-34b2-441a-9338-29a873cdd607"
      unitRef="usd">13950000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i23071b0ab3d54897a0d5dd7749feafe6_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM3LTgtMS0xLTI5NzI2_a0d0f379-113f-456a-a2bb-52d0db895f5d"
      unitRef="number">0.113</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i931a1c9f97ec484da90098853ca3c244_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM3LTEwLTEtMS0yOTcyNg_f919920a-adc5-4157-a677-680ee649983c"
      unitRef="number">0.079</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07618356beec49e9917628c554e15b4b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM5LTItMS0xLTI5NzI2_98970269-7377-4824-bd43-dd958eade71e"
      unitRef="usd">2019000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6280e9e226a04001a209231428e7818e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM5LTQtMS0xLTI5NzI2_c2f7bbd6-344f-42cd-a2b1-d303644667bf"
      unitRef="usd">2508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibaf44ff1272d49ce93687c31a2fcd512_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM5LTYtMS0xLTI5NzI2_85c73cd4-f720-42e7-9405-2deaaf8e1a0d"
      unitRef="usd">3079000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i07618356beec49e9917628c554e15b4b_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM5LTgtMS0xLTI5NzI2_ced60dc3-da23-4492-9561-f0cb681b43e2"
      unitRef="number">-0.195</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6280e9e226a04001a209231428e7818e_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzM5LTEwLTEtMS0yOTcyNg_5d473514-58a8-4371-831d-50fff5c1b77a"
      unitRef="number">-0.185</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00f4796c099b4277b9207e1042e91c37_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQwLTItMS0xLTI5NzI2_bfbad8f1-210f-4286-81eb-6882606d85e4"
      unitRef="usd">236000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ab4cfd32f2b4e75a6eb344b3faa7585_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQwLTQtMS0xLTI5NzI2_14bd58f8-09d5-44e6-812f-67cabe5d241b"
      unitRef="usd">346000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i128aea28460a455aaf7714a32b5ec211_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQwLTYtMS0xLTI5NzI2_8128c3ac-cd23-43fd-a7c7-0c7c74c5c216"
      unitRef="usd">294000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i00f4796c099b4277b9207e1042e91c37_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQwLTgtMS0xLTI5NzI2_db93da8e-cfe2-42db-8814-4e32df145d78"
      unitRef="number">-0.319</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8ab4cfd32f2b4e75a6eb344b3faa7585_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQwLTEwLTEtMS0yOTcyNg_08348f39-6897-47e2-9b65-aa5f152f2c16"
      unitRef="number">0.180</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied68b4d63a6e47f99762e52306477051_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQxLTItMS0xLTI5NzI2_a9995093-93ec-4171-bd42-fc9f34c85bb6"
      unitRef="usd">935000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78385204266240099fc582cb7e7fbd51_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQxLTQtMS0xLTI5NzI2_32d057d0-5aa8-4e38-93ac-a1f571327235"
      unitRef="usd">893000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iced1449a3371463397b9b7085addc2d0_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQxLTYtMS0xLTI5NzI2_a2bc2ae2-3c54-41f6-98e3-905b7ec242ce"
      unitRef="usd">1007000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ied68b4d63a6e47f99762e52306477051_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQxLTgtMS0xLTI5NzI2_d29e70cb-6679-4df9-ac5a-5ae216fe6a3e"
      unitRef="number">0.048</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i78385204266240099fc582cb7e7fbd51_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQxLTEwLTEtMS0yOTcyNg_6a10a304-a1a0-4b63-a28f-2c3ae905d370"
      unitRef="number">-0.114</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i650a133233af49bfaee6ed4af066a9d6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQyLTItMS0xLTI5NzI2_ee154a01-8044-4ccf-92b2-2d0d01eea839"
      unitRef="usd">3190000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3e283c3e9214f85ae2918d74ac3d82d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQyLTQtMS0xLTI5NzI2_8c4cb02f-3a0d-46fa-8426-b432f3ac2472"
      unitRef="usd">3747000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94ce48e00f8545ec8e7a84f01797b22c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQyLTYtMS0xLTI5NzI2_81bd23e8-dc24-492c-91f8-b778f3688de7"
      unitRef="usd">4380000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i650a133233af49bfaee6ed4af066a9d6_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQyLTgtMS0xLTI5NzI2_f5609cbc-6739-4c05-bfe3-1282a4f2f759"
      unitRef="number">-0.149</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie3e283c3e9214f85ae2918d74ac3d82d_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQyLTEwLTEtMS0yOTcyNg_675d2f0e-5340-4a1d-b65e-675e78b8bd3f"
      unitRef="number">-0.144</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d4bf4b9e3694ef285c9c31b956b677e_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ0LTItMS0xLTI5NzI2_46cdcae8-f92e-457f-be8c-35f18f4464e6"
      unitRef="usd">1127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd06b502c49a4f488fc11fb2c3838ef3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ0LTQtMS0xLTI5NzI2_4b594d1e-1124-479b-b50f-26506188eacc"
      unitRef="usd">1155000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i233cf7fe392245428889ea57e0fc2d22_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ0LTYtMS0xLTI5NzI2_52881d0f-1183-47e6-af6f-e09ef1ea313c"
      unitRef="usd">1159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2d4bf4b9e3694ef285c9c31b956b677e_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ0LTgtMS0xLTI5NzI2_398146f2-fc8d-4c9d-bad8-87b2cacc7bdc"
      unitRef="number">-0.024</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idd06b502c49a4f488fc11fb2c3838ef3_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ0LTEwLTEtMS0yOTcyNg_811ccda3-44ec-40b6-a59c-0830a1c54ba5"
      unitRef="number">-0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4c61950fc8949c5b32766ec79d02eaf_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ1LTItMS0xLTI5NzI2_876f8134-533b-42c2-a9e6-afda83987b37"
      unitRef="usd">1148000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iebf3d76775d644ba97bdf492a1dd1267_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ1LTQtMS0xLTI5NzI2_9e83a937-ad72-4ec8-b77a-37ba72d5f215"
      unitRef="usd">1088000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05a8ae6b440b4b81b32f6a052e5a8558_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ1LTYtMS0xLTI5NzI2_bdad626c-38ab-479a-9f44-7c7e0f40974a"
      unitRef="usd">1029000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id4c61950fc8949c5b32766ec79d02eaf_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ1LTgtMS0xLTI5NzI2_7037d691-3232-4725-91bb-758115c0291c"
      unitRef="number">0.055</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iebf3d76775d644ba97bdf492a1dd1267_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ1LTEwLTEtMS0yOTcyNg_84c5cf64-3ae0-4854-9a95-0843f92b8f20"
      unitRef="number">0.058</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i875c8735b8514e90bad447aeb6eadbc2_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ2LTItMS0xLTI5NzI2_35e67a4b-a4a5-4e9a-b13f-5524a95b54f3"
      unitRef="usd">2276000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f3798ee8de34093a99e42ecc9db1ecd_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ2LTQtMS0xLTI5NzI2_86045eb8-1fcb-4f5c-b39e-716625d38e5b"
      unitRef="usd">2243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a3f22a534874f458fb9c7bdc05cb65c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ2LTYtMS0xLTI5NzI2_66683293-4d2c-4366-aaff-a525211263ac"
      unitRef="usd">2188000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i875c8735b8514e90bad447aeb6eadbc2_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ2LTgtMS0xLTI5NzI2_9387a535-f8d2-488d-b886-3a85d5782676"
      unitRef="number">0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1f3798ee8de34093a99e42ecc9db1ecd_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ2LTEwLTEtMS0yOTcyNg_35034253-4305-4528-8499-094bb2e327c9"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i387f05cfe3524712bad1d9f54eb5cccd_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ4LTItMS0xLTI5NzI2_66919be4-dcf9-4d94-a340-011df4a51f00"
      unitRef="usd">5938000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia62cfbf9f33d4aa284727311f21d634e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ4LTQtMS0xLTI5NzI2_6352767e-8c98-4d89-8590-9fcc8cb6c3be"
      unitRef="usd">5240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15b688eb12f54afc92d5afd59ea3c706_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ4LTYtMS0xLTI5NzI2_b85dc8f4-a8c2-4207-b588-c48e7d9b51cf"
      unitRef="usd">4346000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i387f05cfe3524712bad1d9f54eb5cccd_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ4LTgtMS0xLTI5NzI2_91b8f184-6075-4fd6-bbb9-7b1e1bcf4120"
      unitRef="number">0.133</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia62cfbf9f33d4aa284727311f21d634e_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ4LTEwLTEtMS0yOTcyNg_f81ed3d8-1c7b-44de-897c-1a9c7367426c"
      unitRef="number">0.206</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ff56877211249dd8ac926ef0d64f13b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ5LTItMS0xLTI5NzI2_9705b34e-c47b-42c2-ace9-8897048029d1"
      unitRef="usd">3196000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i522f8a96ab7444c9b0a072059a13e972_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ5LTQtMS0xLTI5NzI2_824d6251-c5da-47c7-b754-021b4690356f"
      unitRef="usd">2467000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27123f6e396341619661b5c3adc7e7d7_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ5LTYtMS0xLTI5NzI2_f9af9d0d-bc81-46e2-b77a-cf3c66c7f67f"
      unitRef="usd">2015000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2ff56877211249dd8ac926ef0d64f13b_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ5LTgtMS0xLTI5NzI2_9b2593b1-6fe8-473a-8cc7-6175056c5c75"
      unitRef="number">0.296</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i522f8a96ab7444c9b0a072059a13e972_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzQ5LTEwLTEtMS0yOTcyNg_f888fc44-6fb0-4211-9d95-9e3389e862a7"
      unitRef="number">0.224</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7809d87d5c845608f30c8285db41530_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUwLTItMS0xLTI5NzI2_5ebb4210-dcd5-4f7d-a173-ec8a156e8677"
      unitRef="usd">9134000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f1a5560e5b14f0893f3ee125948348a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUwLTQtMS0xLTI5NzI2_192a5f87-4879-4e77-8ba4-03dfc72b4834"
      unitRef="usd">7707000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcd59309ca0944688a41953f08782f58_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUwLTYtMS0xLTI5NzI2_14a1b5ba-c816-43fa-81f9-5a353cc1d6c1"
      unitRef="usd">6361000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic7809d87d5c845608f30c8285db41530_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUwLTgtMS0xLTI5NzI2_f64e1e9f-025b-4221-9a83-2c2583ac45f9"
      unitRef="number">0.185</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2f1a5560e5b14f0893f3ee125948348a_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUwLTEwLTEtMS0yOTcyNg_ecba3bc1-d1d0-4ad3-9583-dca9c2fde42c"
      unitRef="number">0.211</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25b9271bf3d148c1862fbcdce1ca1e53_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUyLTItMS0xLTI5NzI2_fc7e0d33-c737-479e-916a-e6590fb1cc2e"
      unitRef="usd">1503000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc8570ebb01c438ea0f57235642eacc7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUyLTQtMS0xLTI5NzI2_a7d0b3f2-cb22-4851-8dac-5484937152c7"
      unitRef="usd">926000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e5920e5bf6749e2a8feab5aaad9c855_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUyLTYtMS0xLTI5NzI2_25b77eb5-e5a2-4625-9c3a-d7f278551326"
      unitRef="usd">764000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i25b9271bf3d148c1862fbcdce1ca1e53_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUyLTgtMS0xLTI5NzI2_5793b05c-76b0-4362-920a-411fe743ee16"
      unitRef="number">0.623</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icc8570ebb01c438ea0f57235642eacc7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUyLTEwLTEtMS0yOTcyNg_4ff06f2e-fa82-4160-bbaa-06c9fafc2b8e"
      unitRef="number">0.213</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia490b063eb8a46d3bdd2ff016e7d7783_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUzLTItMS0xLTI5NzI2_2def00aa-e591-47a4-8be6-e76e77be36b4"
      unitRef="usd">624000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4565c280598049f3aa2278617178658f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUzLTQtMS0xLTI5NzI2_24118bbf-90fb-42a7-bb41-c4990c071e9c"
      unitRef="usd">421000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8317c263da5445e96ef10c57d87335e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUzLTYtMS0xLTI5NzI2_b2d0ff54-ee13-4761-b8ac-d1cb4c62a615"
      unitRef="usd">248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia490b063eb8a46d3bdd2ff016e7d7783_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUzLTgtMS0xLTI5NzI2_60bb8705-4672-4ef5-b0d7-58eff11d3501"
      unitRef="number">0.482</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4565c280598049f3aa2278617178658f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzUzLTEwLTEtMS0yOTcyNg_762215cd-105b-4d12-829c-ee360be3c9c0"
      unitRef="number">0.699</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08a754bdc99b4589aafca7079db10c80_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU0LTItMS0xLTI5NzI2_d7d5dfab-6736-469b-b1b2-0e086d71aa04"
      unitRef="usd">2127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82dfe65f5fd84478bfecb83176d8cf1a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU0LTQtMS0xLTI5NzI2_05e7f87e-e6bc-4c69-9176-0a8a802d0f52"
      unitRef="usd">1347000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61a8303dc0bc4b82b4eb802262faa800_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU0LTYtMS0xLTI5NzI2_bc813a37-954a-4a98-8cdb-b61ba7daa32d"
      unitRef="usd">1012000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i08a754bdc99b4589aafca7079db10c80_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU0LTgtMS0xLTI5NzI2_477bcf77-ff6d-4f81-be9c-e4dab369dcf2"
      unitRef="number">0.579</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i82dfe65f5fd84478bfecb83176d8cf1a_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU0LTEwLTEtMS0yOTcyNg_89cf8c16-3f20-4879-b1a3-268835d65ee4"
      unitRef="number">0.332</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5106140dfc9c442095b0f77e74bd6ab5_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU2LTItMS0xLTI5NzI2_031451da-440a-43cf-9a49-80340121cd3d"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92703c0c3b7349978b612c21f233b393_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU2LTQtMS0xLTI5NzI2_51a94357-e6c1-4dc3-8d66-e390717d62e0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i590ff19ce91142bcb3863bd2c6e2f069_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU2LTYtMS0xLTI5NzI2_d82b7532-c4ce-4745-bb03-5f89915c9bfc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i92703c0c3b7349978b612c21f233b393_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU2LTEwLTEtMS0yOTcyNg_907079c8-539d-45d0-97e1-4d59562102ff"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9f224616f5a463b8f804675e284a7d3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU3LTItMS0xLTI5NzI2_2913489e-4a15-4e0d-8d6c-e1911066ecf8"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife046f7abde54338b2b69413c736da26_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU3LTQtMS0xLTI5NzI2_8172e38e-8c13-4ec8-9a73-dcd819e439af"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83e3aa3c5f51435b93d1dbe65ac91d90_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU3LTYtMS0xLTI5NzI2_c0294fc7-3b02-45a5-9d10-8eec965a37d5"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic9f224616f5a463b8f804675e284a7d3_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU3LTgtMS0xLTI5NzI2_2170b076-c612-4d25-b04c-8db208010297"
      unitRef="number">-0.733</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ife046f7abde54338b2b69413c736da26_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU3LTEwLTEtMS0yOTcyNg_2fda7b1b-c167-4795-a7fc-16d829d36e85"
      unitRef="number">0.064</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5465f74052f34acfb49d0e1a25300dc8_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU4LTItMS0xLTI5NzI2_d94714e3-f644-4ec5-981b-aad213fe03f1"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie74fbb87373b4b59ab055d2fff965e07_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU4LTQtMS0xLTI5NzI2_d1f2477f-b00e-46aa-9986-318fe2ed4611"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3530f8c2ec644b0780f82d2251ffd602_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU4LTYtMS0xLTI5NzI2_429840eb-c762-4d4f-bad1-6994a2e047e8"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie74fbb87373b4b59ab055d2fff965e07_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzU4LTEwLTEtMS0yOTcyNg_74de71d8-9ef3-48c0-8547-130eb35fa3cf"
      unitRef="number">0.064</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf363f3dae664585a3f17f32b6970829_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYxLTItMS0xLTI5NzI2_89abced4-7572-4834-b007-12543f81da6e"
      unitRef="usd">2249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40eda5c751a24278a262d5a7707bbf96_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYxLTQtMS0xLTI5NzI2_ec3baff3-67c7-46b2-85ca-c1e9077d883b"
      unitRef="usd">1735000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69b0b0d154c1422f9d32b3d2082d49eb_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYxLTYtMS0xLTI5NzI2_bd007b75-df15-4d99-aacb-32f7b14046f6"
      unitRef="usd">1597000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icf363f3dae664585a3f17f32b6970829_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYxLTgtMS0xLTI5NzI2_93a06b87-63a4-4e2c-99a3-215609010513"
      unitRef="number">0.297</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i40eda5c751a24278a262d5a7707bbf96_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYxLTEwLTEtMS0yOTcyNg_f932c62a-37ec-48ec-b038-f1722e4e91ff"
      unitRef="number">0.086</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2db3c45977049f1acbf33a46b8f1197_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYyLTItMS0xLTI5NzI2_10e88b36-07b6-4196-a57c-a223e2834531"
      unitRef="usd">3612000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b2cef1544584a32a4606c9be98a902b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYyLTQtMS0xLTI5NzI2_6e514d03-cbf9-43d0-8f0a-a2263db61539"
      unitRef="usd">1839000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib308904527464b1f9f083c28369a2106_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYyLTYtMS0xLTI5NzI2_4e2419f9-a91c-4053-85b0-b8282592b34a"
      unitRef="usd">1815000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia2db3c45977049f1acbf33a46b8f1197_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYyLTgtMS0xLTI5NzI2_e102f698-ff86-4397-b066-49952ba239d7"
      unitRef="number">0.963</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7b2cef1544584a32a4606c9be98a902b_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYyLTEwLTEtMS0yOTcyNg_b7e073eb-c918-409f-bae9-33796e6f0ae9"
      unitRef="number">0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id02c8176e6b54fbd95f6a63b9d32b50f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYzLTItMS0xLTI5NzI2_03884669-c6fa-4eed-afeb-c2c00692edd2"
      unitRef="usd">5861000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee1ededb6af34beeb2892f0c47c60708_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYzLTQtMS0xLTI5NzI2_75a84e7d-ed83-4aa5-9072-0e7f35f2be47"
      unitRef="usd">3574000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c7e3cb454244e8fbcbbac2736af573a_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYzLTYtMS0xLTI5NzI2_332566b4-7c1f-47f9-9dab-fa1920e42494"
      unitRef="usd">3413000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id02c8176e6b54fbd95f6a63b9d32b50f_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYzLTgtMS0xLTI5NzI2_03a97e6b-75fa-452a-aa22-6083b363c079"
      unitRef="number">0.640</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iee1ededb6af34beeb2892f0c47c60708_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzYzLTEwLTEtMS0yOTcyNg_ea5bc54a-2b04-4304-8948-27c6e2080514"
      unitRef="number">0.047</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ddc954bdfca40e5b84a70e77aa5b0ff_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY1LTItMS0xLTM2OTg1_9db979d2-5266-4b2f-8e54-0650c6ec20e3"
      unitRef="usd">634000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5d8535a6c304a3ca7e7a68a08f5c836_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY1LTQtMS0xLTM2OTg1_ff2a7465-aa9c-492d-aeca-b985b1202216"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib18a2c82e5bd42faa30e52df5f67d0f1_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY1LTYtMS0xLTM2OTg1_3386cc98-7f40-4f2c-a681-5c7fe612eda0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1bea3a5e88f4153ac03408e384f810b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY2LTItMS0xLTM2OTg1_f4cd2be2-f8f8-4e16-a0e3-47db352a2570"
      unitRef="usd">1751000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fa30ec743194334be89aabe3830b90b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY2LTQtMS0xLTM2OTg1_65576f6e-dcdc-493f-8c9d-f9caa9af606a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08d85765adf1424dbaac0219f0177c84_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY2LTYtMS0xLTM2OTg1_26ea622a-3d07-48f5-8a4d-ecc245101564"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cb2fe12284743f396b4f94eba5b3803_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY3LTItMS0xLTM2OTg1_0d1e4186-20aa-4453-9c30-2d73fa242c7d"
      unitRef="usd">2385000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idff0f007396e4810b440aabe3054aef9_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY3LTQtMS0xLTM2OTg1_19f229b3-5480-4da5-aba1-368af2ffd5fe"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i789f89f97ffa47c7b42b23eb088f0422_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY3LTYtMS0xLTM2OTg1_0be9e461-a7ba-4de4-9b18-5ef070f103ea"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id21042f6fd3244f6887b53a8d4813430_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY1LTItMS0xLTI5NzI2_25b0d866-8616-4d5e-a9f1-d5d74c795613"
      unitRef="usd">41000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf047bcbe355467c8f65460dba57e264_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY1LTQtMS0xLTI5NzI2_2aa94921-f94c-4684-b4fb-270127e87610"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8bc791af8b648d782365c72c1a39a7c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY1LTYtMS0xLTI5NzI2_ea36709a-b5fb-4ea3-a196-bd956060f40c"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id21042f6fd3244f6887b53a8d4813430_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY1LTgtMS0xLTI5NzI2_0086b092-c71a-46f9-97fb-022b80d57102"
      unitRef="number">-0.076</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibf047bcbe355467c8f65460dba57e264_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY1LTEwLTEtMS0yOTcyNg_cbe82e8b-bc7b-431c-8b70-5afd7111ad59"
      unitRef="number">-0.112</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4861e2b2aeb543fbb746c4b4f1195f46_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY2LTItMS0xLTI5NzI2_db37870e-9c6d-458b-8535-e92e05c13f3b"
      unitRef="usd">953000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b56e952fcde4c7e91401eb5a85ca321_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY2LTQtMS0xLTI5NzI2_89bd6f63-1312-469c-a6ae-b2dbb4d10351"
      unitRef="usd">920000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1625d21dd2242ec893225588e77f1b9_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY2LTYtMS0xLTI5NzI2_0fb19327-a649-4935-ac0a-5036649f0dbb"
      unitRef="usd">812000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4861e2b2aeb543fbb746c4b4f1195f46_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY2LTgtMS0xLTI5NzI2_f3bfdcbe-e02c-47e3-a476-5f35bb7a4b59"
      unitRef="number">0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6b56e952fcde4c7e91401eb5a85ca321_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY2LTEwLTEtMS0yOTcyNg_aedce388-a063-4bd1-9679-0e03be461fb9"
      unitRef="number">0.133</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i805f444f9b4f4b78a5e115f7da23f40b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY3LTItMS0xLTI5NzI2_255fb96a-49cf-46c3-8b17-aceca53072c8"
      unitRef="usd">994000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67a0e2e227a4493a886e7e12cc63281f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY3LTQtMS0xLTI5NzI2_07508a32-034f-4d74-9f31-77ae76932130"
      unitRef="usd">964000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb4f242ab4b94ba3bb07fea9dbb6f194_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY3LTYtMS0xLTI5NzI2_ebdf2453-176b-49d9-81ac-37823f3397d2"
      unitRef="usd">861000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i805f444f9b4f4b78a5e115f7da23f40b_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY3LTgtMS0xLTI5NzI2_0184a408-b6f5-4169-a3a1-a59847471d8e"
      unitRef="number">0.031</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i67a0e2e227a4493a886e7e12cc63281f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY3LTEwLTEtMS0yOTcyNg_7b81fcfc-faa8-4ce1-b1fb-c32a4e660baa"
      unitRef="number">0.119</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d93d7178a424340b255ab8cc1671993_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY5LTItMS0xLTI5NzI2_7b1c90de-e3f8-40ba-a23d-acb261d0c9e8"
      unitRef="usd">1508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50a2f88597bb4e56babe220ec155c933_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY5LTQtMS0xLTI5NzI2_167ca83b-6b8a-406b-9f3e-72ffb5db192b"
      unitRef="usd">1587000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icba7b86a3b9b4ffc8203367aff4b1f12_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY5LTYtMS0xLTI5NzI2_6fa89f91-0571-4c7a-ac70-99687d021de8"
      unitRef="usd">1422000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9d93d7178a424340b255ab8cc1671993_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY5LTgtMS0xLTI5NzI2_ca2f7db8-d966-4cc9-8a8f-ee98cd3bfd61"
      unitRef="number">-0.049</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i50a2f88597bb4e56babe220ec155c933_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzY5LTEwLTEtMS0yOTcyNg_2dccaa78-8541-4371-a4b6-6e66c067d7fd"
      unitRef="number">0.116</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00ca4566672f4e21b57db409f2ca399b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcwLTItMS0xLTI5NzI2_743cee9f-1541-456c-b607-1045e9eb0ee2"
      unitRef="usd">575000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72fd0da598264bf58922963c2e268f9f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcwLTQtMS0xLTI5NzI2_ee81fe0c-0267-4f95-a4a5-38697379401e"
      unitRef="usd">597000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68dfc09b6cc74b269337c9823085c75d_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcwLTYtMS0xLTI5NzI2_c5ca654c-66fd-4d07-b2b1-5cc9dd088801"
      unitRef="usd">689000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i00ca4566672f4e21b57db409f2ca399b_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcwLTgtMS0xLTI5NzI2_31fa7e65-96c9-4a7f-8fa6-be235f573a31"
      unitRef="number">-0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i72fd0da598264bf58922963c2e268f9f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcwLTEwLTEtMS0yOTcyNg_52baf13a-f11d-466c-9634-4f44efd81e51"
      unitRef="number">-0.134</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0dbfabf4ce84c5dadfb5096deb252aa_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcxLTItMS0xLTI5NzI2_98ed78bc-cfed-4916-9fc4-dae11c9f9134"
      unitRef="usd">2083000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71a5ddf6505c49959a39142a4734937d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcxLTQtMS0xLTI5NzI2_d5224eac-0f9f-48b5-a3e5-55a07fbceaa8"
      unitRef="usd">2184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7eef150a18e4e7c9fb366789c95e51b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcxLTYtMS0xLTI5NzI2_0f7eccfd-73cd-4089-bcae-7f32d4a25938"
      unitRef="usd">2110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie0dbfabf4ce84c5dadfb5096deb252aa_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcxLTgtMS0xLTI5NzI2_f2d2248c-9e2a-40d0-a065-37c856e52e45"
      unitRef="number">-0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i71a5ddf6505c49959a39142a4734937d_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzcxLTEwLTEtMS0yOTcyNg_90ec5e73-54dd-41e1-9d35-e6bec767f8a2"
      unitRef="number">0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i844da3be083d4b0991bcf4a93b302f05_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzczLTItMS0xLTI5NzI2_373a00e9-9ce6-464a-ab27-291f58cfc82d"
      unitRef="usd">66000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93f0f46a5f794204849d8974443208af_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzczLTQtMS0xLTI5NzI2_18e46fc1-cf5d-4af8-9511-8beb1d64da61"
      unitRef="usd">104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c3bc420ba184db5b0c0a09e582ba601_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzczLTYtMS0xLTI5NzI2_508d83ad-98ef-4b8f-9433-3567a941565f"
      unitRef="usd">126000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i844da3be083d4b0991bcf4a93b302f05_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzczLTgtMS0xLTI5NzI2_584a4ad0-7001-47d2-9956-c52c2b8bcd5d"
      unitRef="number">-0.360</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i93f0f46a5f794204849d8974443208af_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzczLTEwLTEtMS0yOTcyNg_0809aabb-3266-4b15-81d9-7faebb9912fa"
      unitRef="number">-0.176</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90a6c337bc74400ead0814dfe3ded9ac_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc0LTItMS0xLTI5NzI2_73d30a8d-cccb-4e3a-8e96-1a2162548a4e"
      unitRef="usd">333000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d256c783ba14651b3deabb6dbca6ac3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc0LTQtMS0xLTI5NzI2_30a37d90-637e-4e74-98c3-678d9711d9f1"
      unitRef="usd">323000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23065d742db5456abc56ab20b4266dea_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc0LTYtMS0xLTI5NzI2_61ccefe2-c336-4e9f-869e-bcb7cb4af695"
      unitRef="usd">315000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i90a6c337bc74400ead0814dfe3ded9ac_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc0LTgtMS0xLTI5NzI2_f39395e3-4843-4702-841c-7b6d2d4a94a9"
      unitRef="number">0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8d256c783ba14651b3deabb6dbca6ac3_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc0LTEwLTEtMS0yOTcyNg_96556f4b-6c41-470f-af13-5bdbf29c98cb"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if55330cd78f747a88fbccd460f0ec00f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc1LTItMS0xLTI5NzI2_141286de-6b08-4420-b4bc-1c3dfa693098"
      unitRef="usd">399000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d1488ec3e3c4b168ab09734e1cb2ef9_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc1LTQtMS0xLTI5NzI2_60b21115-e4f4-4460-b63b-22c8cef23727"
      unitRef="usd">427000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1b7f8f06d9d4045bbceff6b94ee3210_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc1LTYtMS0xLTI5NzI2_18b13db4-6089-440f-be05-c361f6c43500"
      unitRef="usd">441000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if55330cd78f747a88fbccd460f0ec00f_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc1LTgtMS0xLTI5NzI2_61155370-e1fb-4691-bcc7-1f1541dce412"
      unitRef="number">-0.065</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2d1488ec3e3c4b168ab09734e1cb2ef9_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc1LTEwLTEtMS0yOTcyNg_7e37da9a-002b-4f59-ac2f-577ff9fa82a2"
      unitRef="number">-0.032</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb742dc6f1a14657ade44dbb3734869a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc4LTItMS0xLTI5NzI2_2b20d9af-3087-446f-b0f4-1ee4e7678660"
      unitRef="usd">3347000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7b5d7e03ed1438bb2eb5544aa5e51a0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc4LTQtMS0xLTI5NzI2_5629d986-66f5-4fde-a3e9-99ab3a12d198"
      unitRef="usd">3091000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3ecc659932b4e20a391e656b1cf4600_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc4LTYtMS0xLTI5NzI2_12345e8b-5e0e-46e1-a383-cba5a41df8cf"
      unitRef="usd">2919000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ieb742dc6f1a14657ade44dbb3734869a_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc4LTgtMS0xLTI5NzI2_f7bf3457-5bb0-4ced-94ab-827503ff2261"
      unitRef="number">0.083</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia7b5d7e03ed1438bb2eb5544aa5e51a0_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc4LTEwLTEtMS0yOTcyNg_9627bc06-7169-4cee-811f-080ea48b72b5"
      unitRef="number">0.059</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e82f975ef30440e880e83c96d9d5a6d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc5LTItMS0xLTI5NzI2_0f6fe67e-ba39-46ce-8ba0-59d590a05870"
      unitRef="usd">3664000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7172a6f847d4499da4684dd32ff6587d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc5LTQtMS0xLTI5NzI2_76a2220d-ee6f-4582-892a-1923805d68a5"
      unitRef="usd">3457000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id47c5bf1c0fe4beb961f5f32232ec895_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc5LTYtMS0xLTI5NzI2_e69424b0-c5f7-41a3-b9f1-36130ebf188e"
      unitRef="usd">3409000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6e82f975ef30440e880e83c96d9d5a6d_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc5LTgtMS0xLTI5NzI2_6332c6e9-36b7-4f61-a76a-807198748519"
      unitRef="number">0.060</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7172a6f847d4499da4684dd32ff6587d_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzc5LTEwLTEtMS0yOTcyNg_c813b266-de51-459d-b265-f0c8fc6955a8"
      unitRef="number">0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8d54437eaba48faad57862e220ec9ba_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgwLTItMS0xLTI5NzI2_16d94a62-a317-44b7-aa46-0c315a59e22a"
      unitRef="usd">7011000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic172a5b3e234408b904ca83aea199d14_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgwLTQtMS0xLTI5NzI2_2853b567-67f0-40f5-96a9-63098ffd309f"
      unitRef="usd">6548000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i716ef7913074441580f76f25ff473db3_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgwLTYtMS0xLTI5NzI2_c6d459d9-e9b5-438a-b0e6-8990640ce4d5"
      unitRef="usd">6328000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie8d54437eaba48faad57862e220ec9ba_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgwLTgtMS0xLTI5NzI2_1cb87612-1a58-4b74-bfcd-bdcb1d69a824"
      unitRef="number">0.071</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic172a5b3e234408b904ca83aea199d14_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgwLTEwLTEtMS0yOTcyNg_a4247c93-4a32-4fba-bbc3-564eaf71f0a1"
      unitRef="number">0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i045f6bb81e3d4317b32f42c7864f0ce5_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgyLTItMS0xLTI5NzI2_57938330-f118-431c-931f-be2b41af433a"
      unitRef="usd">172000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieeea74059fd94beeac322670b9baabca_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgyLTQtMS0xLTI5NzI2_18b6e885-12d4-428c-9a13-003e7726aa45"
      unitRef="usd">183000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f7304198142471ca4e3ba8d2b8b2dbb_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgyLTYtMS0xLTI5NzI2_033ea001-4807-4f39-b9c0-196026abbbec"
      unitRef="usd">233000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i045f6bb81e3d4317b32f42c7864f0ce5_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgyLTgtMS0xLTI5NzI2_447b1a84-f31e-4768-9681-9a7aeaa1f8cc"
      unitRef="number">-0.058</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ieeea74059fd94beeac322670b9baabca_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgyLTEwLTEtMS0yOTcyNg_073cb283-064e-4942-a391-93c650a52434"
      unitRef="number">-0.214</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62a4d2b818ce406f90793b13460001fb_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgzLTItMS0xLTI5NzI2_cf55acad-d523-4871-8539-c1fbb43477b3"
      unitRef="usd">495000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f347c3391bc41aa85bcd9845a2709af_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgzLTQtMS0xLTI5NzI2_5075c0a8-8139-47cc-9f8f-5dedfc6c8a3e"
      unitRef="usd">439000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec40c04f9d454e2f8463d169e94a0db7_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgzLTYtMS0xLTI5NzI2_73f2d2e9-864e-44c0-8f90-bb4c54f96c9e"
      unitRef="usd">463000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i62a4d2b818ce406f90793b13460001fb_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgzLTgtMS0xLTI5NzI2_487c363d-a19c-4ea2-abf8-ebd7012d4bde"
      unitRef="number">0.128</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1f347c3391bc41aa85bcd9845a2709af_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzgzLTEwLTEtMS0yOTcyNg_9d90b767-7e54-42b3-9146-95413906c6ee"
      unitRef="number">-0.051</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib20ac18affec473182fcb58284b62b0e_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg0LTItMS0xLTI5NzI2_1ed156ff-17f1-4ad7-8034-b1f035daf6d7"
      unitRef="usd">667000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9073991f08b1465283d39628e414f9d0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg0LTQtMS0xLTI5NzI2_8314d803-1b12-418a-88de-e3cfdcef323b"
      unitRef="usd">622000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icffef1f5716b4b64b0f0bdfba755b0e7_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg0LTYtMS0xLTI5NzI2_6570014a-43cc-4dc5-8352-758397102f71"
      unitRef="usd">696000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib20ac18affec473182fcb58284b62b0e_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg0LTgtMS0xLTI5NzI2_13cf9d13-1eba-421d-9938-dba530084954"
      unitRef="number">0.073</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9073991f08b1465283d39628e414f9d0_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg0LTEwLTEtMS0yOTcyNg_ed877325-4fd1-4f56-93e1-fcdf7e858294"
      unitRef="number">-0.106</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e1c17df3e194f1e91c5e45244f1f77c_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg2LTItMS0xLTI5NzI2_5f76b94c-53e6-4ae8-b3a4-f568c441598f"
      unitRef="usd">2550000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7eaeef50117a46faa8df83f358a7edea_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg2LTQtMS0xLTI5NzI2_31807650-f919-45c7-a358-1c8be92de6d6"
      unitRef="usd">2314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70636291997f49208bb484bc59053d07_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg2LTYtMS0xLTI5NzI2_837181b6-66a7-409a-beb1-532387b3a275"
      unitRef="usd">2107000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4e1c17df3e194f1e91c5e45244f1f77c_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg2LTgtMS0xLTI5NzI2_12d478df-04d0-4444-ba5d-96c23e4d75e7"
      unitRef="number">0.102</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7eaeef50117a46faa8df83f358a7edea_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg2LTEwLTEtMS0yOTcyNg_b48de9ad-2fef-4f40-9ff5-51dbeb45bdfd"
      unitRef="number">0.098</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd513a7d62984d5f9d3b9a8b8e403e60_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg3LTItMS0xLTI5NzI2_df0a2472-399d-43fc-8cab-68a704119ae8"
      unitRef="usd">1472000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia04a63eca2254a59a36cde0f40f8f746_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg3LTQtMS0xLTI5NzI2_2ada2779-46ab-4a78-8ec2-94dcade2abd2"
      unitRef="usd">1339000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf8ef533f70c490d94f9db77743e9b87_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg3LTYtMS0xLTI5NzI2_50495490-dd46-4324-8c21-b6959fb2e2a4"
      unitRef="usd">1224000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibd513a7d62984d5f9d3b9a8b8e403e60_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg3LTgtMS0xLTI5NzI2_85706ace-f1a0-418a-b175-d774fe48e31f"
      unitRef="number">0.100</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia04a63eca2254a59a36cde0f40f8f746_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg3LTEwLTEtMS0yOTcyNg_af452516-b404-488c-b29c-63f9c2614539"
      unitRef="number">0.094</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cc68bd95fc3478a9e77570132e953cf_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg4LTItMS0xLTI5NzI2_81df342d-2212-4bdc-acc9-071b30c45714"
      unitRef="usd">4022000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2255cd9d9c44cf8a9e8c1c315f656b6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg4LTQtMS0xLTI5NzI2_0a436aed-3f00-4038-b285-7f320b74fc08"
      unitRef="usd">3653000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01e4b54306a4415da8f707b8ded967a0_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg4LTYtMS0xLTI5NzI2_3d5a38e4-df45-40a5-a321-300df577647b"
      unitRef="usd">3330000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7cc68bd95fc3478a9e77570132e953cf_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg4LTgtMS0xLTI5NzI2_66f11ef4-855f-4957-80e7-42159bc9f932"
      unitRef="number">0.101</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie2255cd9d9c44cf8a9e8c1c315f656b6_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzg4LTEwLTEtMS0yOTcyNg_e84e65f5-1d25-456b-853e-e19406cad737"
      unitRef="number">0.097</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i814ea4ac6baf497f8b3622d1588dd4fe_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkwLTItMS0xLTI5NzI2_b3a53e57-f1a7-4e94-9a02-65ee682b2bb4"
      unitRef="usd">287000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib635c2bb6a9c4682b88d93ff9e2e12c6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkwLTQtMS0xLTI5NzI2_a09f253d-edf6-4eeb-95b9-b7712ca9efa0"
      unitRef="usd">296000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i370e769b4db246bf866de99ce8aec22c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkwLTYtMS0xLTI5NzI2_742b05c0-32d7-4b01-802b-05312a69923c"
      unitRef="usd">314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i814ea4ac6baf497f8b3622d1588dd4fe_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkwLTgtMS0xLTI5NzI2_840a2f93-298c-4592-a23f-9ffaca6701f9"
      unitRef="number">-0.029</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib635c2bb6a9c4682b88d93ff9e2e12c6_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkwLTEwLTEtMS0yOTcyNg_26225049-b64d-4a41-bf7b-238d4d3b7fa7"
      unitRef="number">-0.059</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7dc879599c5a46cdbbdff6a01666beef_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkxLTItMS0xLTI5NzI2_1fc84e04-5aa4-4ca5-acf2-620e1f0f4cfe"
      unitRef="usd">305000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d5dec1e00694287b6044e170dc592de_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkxLTQtMS0xLTI5NzI2_a4ee5d35-c03e-4891-904f-688e5c6633e8"
      unitRef="usd">346000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8d79f0300124a3fb9fc87ac1735b564_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkxLTYtMS0xLTI5NzI2_2f077f0a-1272-4fcd-b33e-eefe9a096269"
      unitRef="usd">374000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7dc879599c5a46cdbbdff6a01666beef_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkxLTgtMS0xLTI5NzI2_4a735cb4-727c-484d-a4eb-4118197ab1b4"
      unitRef="number">-0.118</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7d5dec1e00694287b6044e170dc592de_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkxLTEwLTEtMS0yOTcyNg_ffc47a3a-66cb-467c-b850-a48375a81bac"
      unitRef="number">-0.075</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic94160fb0a474a0687f27b40423f5cb5_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkyLTItMS0xLTI5NzI2_0e2a11ca-c49a-4b20-a2e7-935ef0d91ee5"
      unitRef="usd">592000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4222851f7d5c417c83afe973ae5d0159_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkyLTQtMS0xLTI5NzI2_d3d75d48-d76b-4823-b6e7-186b1dcd16a7"
      unitRef="usd">642000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8de04364812e434785d220fe797cd119_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkyLTYtMS0xLTI5NzI2_e69dc72a-79d7-47da-b285-4fd591ef7e0b"
      unitRef="usd">688000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic94160fb0a474a0687f27b40423f5cb5_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkyLTgtMS0xLTI5NzI2_e59d07a4-ee77-490b-8dab-f53faa023eb8"
      unitRef="number">-0.077</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4222851f7d5c417c83afe973ae5d0159_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzkyLTEwLTEtMS0yOTcyNg_d500b82f-2a58-4ca0-811a-b87fddd4613b"
      unitRef="number">-0.068</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c934290591045e6af2df7d8b360299f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk0LTItMS0xLTI5NzI2_1f09c85e-3a37-4936-888a-46b40ca9705a"
      unitRef="usd">338000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2dc793642dc34fb8bc13264db3c2b910_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk0LTQtMS0xLTI5NzI2_b5098821-8f85-4c46-8337-b39046f4c550"
      unitRef="usd">298000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08089cf711014f1e98f6d9a9cdf4e5a6_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk0LTYtMS0xLTI5NzI2_684a5870-b117-4299-bb32-93b76f5aac46"
      unitRef="usd">266000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9c934290591045e6af2df7d8b360299f_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk0LTgtMS0xLTI5NzI2_052aebf8-8637-455d-a9e8-92ca270dfcb7"
      unitRef="number">0.133</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2dc793642dc34fb8bc13264db3c2b910_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk0LTEwLTEtMS0yOTcyNg_d491091f-4d37-4c69-a466-821e2ed300ba"
      unitRef="number">0.124</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib48aeb94da2f440daa0044b9d1b46d05_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk1LTItMS0xLTI5NzI2_fd24f640-6ed9-4092-ab82-6cc04dc67362"
      unitRef="usd">1391000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dabbfb12da541ddb881aa0135400f3b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk1LTQtMS0xLTI5NzI2_61f797c6-d77e-425c-97ec-112335508574"
      unitRef="usd">1334000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iabe57c96bf62464fa90fd751cdaa6812_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk1LTYtMS0xLTI5NzI2_423701ba-794d-48a8-85fb-257a5eafa29b"
      unitRef="usd">1349000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib48aeb94da2f440daa0044b9d1b46d05_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk1LTgtMS0xLTI5NzI2_74afe2bf-a47a-4a61-95e0-d2eb6d9bc49c"
      unitRef="number">0.043</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0dabbfb12da541ddb881aa0135400f3b_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk1LTEwLTEtMS0yOTcyNg_fbbb750f-1d06-4f7c-9bfc-cfc605e875ae"
      unitRef="number">-0.011</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if16b1050a2ea4ac38b8dbfa679f48f95_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk2LTItMS0xLTI5NzI2_4fad34ce-490a-4e8b-8b71-143f0764aedc"
      unitRef="usd">1729000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56944bb518044ff2b8fd31922efe406c_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk2LTQtMS0xLTI5NzI2_0797ccad-986d-492c-8eeb-30da1e166b92"
      unitRef="usd">1632000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2d0a9ad27884389aa902fa95d666252_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk2LTYtMS0xLTI5NzI2_99012220-498a-43a9-a44d-95978d25dea1"
      unitRef="usd">1614000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if16b1050a2ea4ac38b8dbfa679f48f95_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk2LTgtMS0xLTI5NzI2_9f2bbbe4-59d5-4dfb-86b3-9a298f007ff8"
      unitRef="number">0.060</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i56944bb518044ff2b8fd31922efe406c_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk2LTEwLTEtMS0yOTcyNg_d366899b-90d8-4195-bbb9-2f2edd960ea2"
      unitRef="number">0.011</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5923e8e2b04e40f0b40227e5c5493fbc_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk5LTItMS0xLTI5NzI2_013524fe-8fe8-48cd-8d5f-cf7bce1f806d"
      unitRef="usd">5958000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e85127952964447a44873c81135f105_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk5LTQtMS0xLTI5NzI2_08a4a009-df23-4a1e-bf29-1d72d808d6ce"
      unitRef="usd">5092000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0167f5d01f2e48d5bf9bf67a240ff929_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk5LTYtMS0xLTI5NzI2_ce213365-1088-4669-9476-1aa9124197bd"
      unitRef="usd">4299000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5923e8e2b04e40f0b40227e5c5493fbc_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk5LTgtMS0xLTI5NzI2_f9bbe109-79dd-4375-b078-1ca12c22dcd0"
      unitRef="number">0.170</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7e85127952964447a44873c81135f105_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzk5LTEwLTEtMS0yOTcyNg_03c3d8b3-e194-4696-8d4a-11a087a82794"
      unitRef="number">0.185</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8677e4e7312c443d8f02f7836a90e787_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMC0yLTEtMS0yOTcyNg_fa08d4cd-45fc-4e42-9b5f-f23fcfbc2091"
      unitRef="usd">8590000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12482888cede42db9e124e85eb782d12_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMC00LTEtMS0yOTcyNg_b0f706bd-4d4e-4d35-82e1-52875b60a3b0"
      unitRef="usd">7275000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic22cf04ce4d04163abd28d1680da2cc6_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMC02LTEtMS0yOTcyNg_0f18e9bb-c312-433d-926b-8aa64e79ba75"
      unitRef="usd">6393000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8677e4e7312c443d8f02f7836a90e787_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMC04LTEtMS0yOTcyNg_902296ac-36b2-4254-b589-709d858e853f"
      unitRef="number">0.181</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i12482888cede42db9e124e85eb782d12_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMC0xMC0xLTEtMjk3MjY_b5355113-81b7-4294-a12d-bd0246929f71"
      unitRef="number">0.138</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia95a87c453d545bd97f71c7a6e370768_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMS0yLTEtMS0yOTcyNg_9adc1fcf-8b10-4dbc-af58-9658347975fe"
      unitRef="usd">14548000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf575c6968d644f098e6c4cd687f9282_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMS00LTEtMS0yOTcyNg_ee6aae14-86a6-4bc3-9a91-ee18e8bc5cfb"
      unitRef="usd">12367000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4feb8a8b5d184238a0d534cd46a60f1b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMS02LTEtMS0yOTcyNg_0d40d75c-f5fb-4e1a-b1ef-06fd35959826"
      unitRef="usd">10692000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia95a87c453d545bd97f71c7a6e370768_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMS04LTEtMS0yOTcyNg_a95e436e-6a49-4ebd-8332-d767903524cb"
      unitRef="number">0.176</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idf575c6968d644f098e6c4cd687f9282_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMS0xMC0xLTEtMjk3MjY_f51806a6-fdd1-4122-869a-714f2364f6ca"
      unitRef="number">0.157</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b56ab9b20b540b0827829a4d1b8215c_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMy0yLTEtMS0yOTcyNg_b9fa0591-857e-4b53-860f-7260abfdab82"
      unitRef="usd">3169000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf7815787e2f468c9ad07ae016d7952f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMy00LTEtMS0yOTcyNg_b4ade27f-18cb-4f05-902e-933d4b503a8a"
      unitRef="usd">2232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f9d60e84a26463286cb9128b46e9bf0_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMy02LTEtMS0yOTcyNg_ee298e86-8164-4c82-ab05-385cef7abeeb"
      unitRef="usd">1567000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4b56ab9b20b540b0827829a4d1b8215c_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMy04LTEtMS0yOTcyNg_98e595ac-4cb9-424b-a692-2f91d3a16efd"
      unitRef="number">0.420</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icf7815787e2f468c9ad07ae016d7952f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwMy0xMC0xLTEtMjk3MjY_7887487f-0341-4c17-ad9a-81052bfbe63d"
      unitRef="number">0.424</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e6ad08ba3564fa58b0dd76578714f7c_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNC0yLTEtMS0yOTcyNg_29a79e00-b5fb-4386-9f61-dbce539b1118"
      unitRef="usd">2854000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb9d9b491866496f84b91c1509866032_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNC00LTEtMS0yOTcyNg_8eb01cc4-3199-48b1-ba81-29081518aaed"
      unitRef="usd">1958000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30dae1e51bed48feafdb469324840549_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNC02LTEtMS0yOTcyNg_94ec6bf3-8988-43c0-a215-f5a995ddf708"
      unitRef="usd">1430000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7e6ad08ba3564fa58b0dd76578714f7c_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNC04LTEtMS0yOTcyNg_271c648c-1a92-4721-9aaf-2ff96db8b4ee"
      unitRef="number">0.458</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ieb9d9b491866496f84b91c1509866032_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNC0xMC0xLTEtMjk3MjY_39fd9069-46fc-4303-b843-8ed1137846d2"
      unitRef="number">0.369</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08ea090a5dab4707b69bb4be8924ab82_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNS0yLTEtMS0yOTcyNg_0e472c88-9dc0-47f0-95d3-3c5b17bef2b6"
      unitRef="usd">6023000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40e6f8b6cb1d43a5be16680ce48b6661_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNS00LTEtMS0yOTcyNg_3289f7aa-33ce-4140-a3e7-377b3a0dc892"
      unitRef="usd">4190000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ecec90ffdef42469fcadfbe71238277_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNS02LTEtMS0yOTcyNg_ad5cc596-eebf-445b-93fa-1ae3bb6ec70f"
      unitRef="usd">2998000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i08ea090a5dab4707b69bb4be8924ab82_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNS04LTEtMS0yOTcyNg_64a2e269-e20b-4d06-a18d-86df305a2d52"
      unitRef="number">0.438</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i40e6f8b6cb1d43a5be16680ce48b6661_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNS0xMC0xLTEtMjk3MjY_b5b80726-17a5-4f94-87e7-f26a9ba58723"
      unitRef="number">0.398</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3085b2c60dfb4078a65276bee9eeeb4f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNy0yLTEtMS0yOTcyNg_8ed508a6-42a9-497c-95fb-173cee7304e5"
      unitRef="usd">813000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f25409391b04e50bb4df4caaef16032_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNy00LTEtMS0yOTcyNg_28c5dc34-424e-45b4-bd21-c33512ccd2a0"
      unitRef="usd">583000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0083624867b449aeaf811f3a98d73be4_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNy02LTEtMS0yOTcyNg_3a5c12a8-a122-40e8-8e8d-7f4e36d67ab5"
      unitRef="usd">297000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3085b2c60dfb4078a65276bee9eeeb4f_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNy04LTEtMS0yOTcyNg_ba181cdb-b71c-4cc8-97bc-14f3a4967160"
      unitRef="number">0.393</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1f25409391b04e50bb4df4caaef16032_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwNy0xMC0xLTEtMjk3MjY_ec71af30-d8b0-4412-a24b-39c18d7ccb87"
      unitRef="number">0.961</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84eb225252644245a3b20653e29a4713_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwOC0yLTEtMS0yOTcyNg_309f13e9-08b4-4d00-abff-a4edde592fcb"
      unitRef="usd">478000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i855fb40e563f4b2f99bad8082fb5326e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwOC00LTEtMS0yOTcyNg_9fe058b8-84d0-4abc-944b-56a695f0b085"
      unitRef="usd">176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2f5f8e7f36e4be19b1b70e62c43a23a_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwOC02LTEtMS0yOTcyNg_dddcd9c6-f806-4212-835d-067ac4be4882"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fb5c6e054854c3fb2c00e7bcc0e2daa_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwOS0yLTEtMS0yOTcyNg_f8e8c00d-8827-4ed5-94c8-c9c88ab065fe"
      unitRef="usd">1291000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i416100c083414a9baae7c6d73ede58a3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwOS00LTEtMS0yOTcyNg_bea6771e-a851-4d20-9a23-b9344284692c"
      unitRef="usd">760000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f73cee4bf7345c49d627dffc1663c72_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwOS02LTEtMS0yOTcyNg_c77b0cb6-0174-4dca-8f07-efa8fdd6627c"
      unitRef="usd">332000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9fb5c6e054854c3fb2c00e7bcc0e2daa_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEwOS04LTEtMS0yOTcyNg_e5c60c9b-93ab-4e2a-b62b-e6cf13cbb7d1"
      unitRef="number">0.700</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26ad055634a14d8ab152b50284444586_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMS0yLTEtMS0yOTcyNg_f947c3e5-4b41-4c85-9ac5-25c950eb7c29"
      unitRef="usd">1747000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaaf78fa003384e408fb12bf4bd5f741e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMS00LTEtMS0yOTcyNg_b1a233e9-1cd6-4e84-adee-1b1da3f37fb5"
      unitRef="usd">1821000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7bc205f26e72447cb7d40dbcea60293e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMS02LTEtMS0yOTcyNg_ad5fbc1d-c0ec-4e46-8e16-9a45ac2fbc6f"
      unitRef="usd">1555000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i26ad055634a14d8ab152b50284444586_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMS04LTEtMS0yOTcyNg_5ce260d4-0dc7-422c-9bdc-578601701731"
      unitRef="number">-0.040</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iaaf78fa003384e408fb12bf4bd5f741e_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMS0xMC0xLTEtMjk3MjY_348e43f6-c858-4ae1-998c-b0a57dc2842f"
      unitRef="number">0.171</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69934e81fab444219448ad5bb5307afa_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMi0yLTEtMS0yOTcyNg_5cffec84-18a8-4bc5-ba71-d103a1ae6b90"
      unitRef="usd">2622000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife0fe4d393c848648fc39692c666de5d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMi00LTEtMS0yOTcyNg_8850c4a7-fbd6-4dd0-aaea-71506536fe99"
      unitRef="usd">2307000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b8d232b64864d51b020808f0bad00c3_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMi02LTEtMS0yOTcyNg_42a85892-d7e7-45d2-b7f9-b35bdd0865db"
      unitRef="usd">1856000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i69934e81fab444219448ad5bb5307afa_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMi04LTEtMS0yOTcyNg_ccbf2ce0-df07-4bf6-8f8c-ced399eca26d"
      unitRef="number">0.136</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ife0fe4d393c848648fc39692c666de5d_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMi0xMC0xLTEtMjk3MjY_bd71d8bb-8f29-4902-b740-8ea780f5cb43"
      unitRef="number">0.243</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib916361cb7fa43a59ebd580516312c23_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMy0yLTEtMS0yOTcyNg_9bbfc46f-9eaa-4835-85d4-afd73e0b3565"
      unitRef="usd">4369000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7977fec0d5a6435aa250b1252dbcb344_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMy00LTEtMS0yOTcyNg_e0d3d006-8d5f-45b3-853e-97b62fc197ea"
      unitRef="usd">4128000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i508045fb141245bebe09d1c312027357_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMy02LTEtMS0yOTcyNg_a0399181-3c3f-42d1-96ed-6afeed111c96"
      unitRef="usd">3411000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib916361cb7fa43a59ebd580516312c23_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMy04LTEtMS0yOTcyNg_1ccfbf43-a510-4d1f-b7c7-5ff247fb1054"
      unitRef="number">0.058</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7977fec0d5a6435aa250b1252dbcb344_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExMy0xMC0xLTEtMjk3MjY_86a7b048-e91f-4c57-9c77-a2042c815093"
      unitRef="number">0.210</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2492cd00dc6a41f19230bb05436b06c3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExOS0yLTEtMS0yOTcyNg_bd6f2957-2d47-4f9a-892b-c04f48d97b5f"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb3e5d251b9a41f0974af3234b4d0c1e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExOS00LTEtMS0yOTcyNg_c79d81b9-d03c-4725-888a-abce155eb2c7"
      unitRef="usd">373000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d5d82a3078b4b23af81af36ccc607cc_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExOS02LTEtMS0yOTcyNg_d78e8f67-53af-41e9-af1b-2311301aaf56"
      unitRef="usd">810000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2492cd00dc6a41f19230bb05436b06c3_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExOS04LTEtMS0yOTcyNg_372f1432-7d46-4b5b-8b9d-fe94aa1154e5"
      unitRef="number">-0.681</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idb3e5d251b9a41f0974af3234b4d0c1e_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzExOS0xMC0xLTEtMjk3MjY_fd7bb53d-0503-4221-8d1f-404b2bfe45f1"
      unitRef="number">-0.540</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c61c8c074234f0789152b71643a576c_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMC0yLTEtMS0yOTcyNg_a3a26551-599a-402d-b642-fabb43704941"
      unitRef="usd">2178000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64bb03a2c1e24381b5b0b4ede7a5b34b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMC00LTEtMS0yOTcyNg_b7e3de17-4691-4b5f-b66e-921dcecc075f"
      unitRef="usd">2097000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ba710a9effd497494383ecca075e6ba_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMC02LTEtMS0yOTcyNg_0d3efaab-33a3-434f-ac3a-9d557bdaa8e8"
      unitRef="usd">1985000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3c61c8c074234f0789152b71643a576c_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMC04LTEtMS0yOTcyNg_58d2c0e9-ae65-4f50-b81d-227411bb331a"
      unitRef="number">0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i64bb03a2c1e24381b5b0b4ede7a5b34b_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMC0xMC0xLTEtMjk3MjY_362ea968-0abf-4913-913a-5413807f98b6"
      unitRef="number">0.056</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacd5e055a14f4fb6a23943dca90aaf64_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMS0yLTEtMS0yOTcyNg_e420336a-6470-48cf-952a-b37fde2ef414"
      unitRef="usd">2297000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id445257ea7744bfd9a8983407adc2143_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMS00LTEtMS0yOTcyNg_1c6ab187-4c00-45df-b99b-2ca258680806"
      unitRef="usd">2470000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia936a49b95f0497a8473b15cdbbce2ae_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMS02LTEtMS0yOTcyNg_07b8e4fc-4b55-45fc-80f3-8e23e561bd61"
      unitRef="usd">2795000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iacd5e055a14f4fb6a23943dca90aaf64_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMS04LTEtMS0yOTcyNg_2bb91847-b923-4052-9a43-81555ee9a477"
      unitRef="number">-0.070</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id445257ea7744bfd9a8983407adc2143_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyMS0xMC0xLTEtMjk3MjY_9ecfebba-b832-41d4-9046-26ad579d700b"
      unitRef="number">-0.116</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec35270655784d61a34b51b61a34c955_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNC0yLTEtMS0yOTcyNg_85995fb3-e265-4f46-a32b-da6e242fa9ba"
      unitRef="usd">110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97e5cdc0c9e3484eb182d85a7402eb77_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNC00LTEtMS0yOTcyNg_88c3ab5e-c579-4b42-a505-1c2cadcbfcfc"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bd1c0392a134aa99e761b2f95847293_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNC02LTEtMS0yOTcyNg_deea1f0c-c0ca-4a35-bfe9-a58c31c84134"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iec35270655784d61a34b51b61a34c955_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNC04LTEtMS0yOTcyNg_beffdc99-0df6-4065-8fae-49c416675847"
      unitRef="number">0.317</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i97e5cdc0c9e3484eb182d85a7402eb77_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNC0xMC0xLTEtMjk3MjY_c2487e6e-bed1-4126-b94b-27a0f18fb9ee"
      unitRef="number">0.186</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9318604febe14a94af81eecc0a785bb1_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNS0yLTEtMS0yOTcyNg_65c19d7c-dd70-42d8-b919-554b444a80ad"
      unitRef="usd">458000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if25ceca79c15413b8f30df32f846e465_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNS00LTEtMS0yOTcyNg_209bbd6c-a5ae-479f-8271-6b5b7dfa1b38"
      unitRef="usd">738000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9ac0f5fe82940299f1a331d5d44bd02_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNS02LTEtMS0yOTcyNg_eb55912e-6bd1-43a9-b5da-d48c719965ab"
      unitRef="usd">1087000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9318604febe14a94af81eecc0a785bb1_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNS04LTEtMS0yOTcyNg_90f2ea15-f61b-4791-a5e8-ed41705d93d4"
      unitRef="number">-0.379</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if25ceca79c15413b8f30df32f846e465_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNS0xMC0xLTEtMjk3MjY_1e7e2357-d9d6-423e-a62b-25c1ab876012"
      unitRef="number">-0.321</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4829eb8419034125807a23e98d8ee355_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNi0yLTEtMS0yOTcyNg_1ac4b0ce-797c-4780-9a04-87728672197c"
      unitRef="usd">568000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43084feb39e24663ad525e292889d8d8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNi00LTEtMS0yOTcyNg_7314646f-bed8-467f-924f-d3395df8d4ad"
      unitRef="usd">821000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09244b74cab94aa2a7ad31bd955792cc_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNi02LTEtMS0yOTcyNg_72e0ad17-92df-43b1-988a-889295ec11b4"
      unitRef="usd">1158000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4829eb8419034125807a23e98d8ee355_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNi04LTEtMS0yOTcyNg_7946db24-42ed-4cbf-b72e-9f1211b018ab"
      unitRef="number">-0.308</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i43084feb39e24663ad525e292889d8d8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyNi0xMC0xLTEtMjk3MjY_dea27c80-0047-4457-930f-62dfdd188318"
      unitRef="number">-0.291</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b994b9bb38d4894bcf7722b7dd244de_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyOS0yLTEtMS0yOTcyNg_b81ad496-40ae-4f85-805b-a7d53c91f1ba"
      unitRef="usd">2365000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07925528b3644a4e9e4ed3e3b71c3c9d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyOS00LTEtMS0yOTcyNg_e9b476bd-0124-4ddf-9ab1-13f29ad2f5fb"
      unitRef="usd">2133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5efd22e32d44db38c958a3060f57dba_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyOS02LTEtMS0yOTcyNg_7866a412-590f-4e35-b6ad-e6cbaed4ba0d"
      unitRef="usd">1684000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1b994b9bb38d4894bcf7722b7dd244de_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyOS04LTEtMS0yOTcyNg_08ca7de5-5072-4ba2-9069-235ae425e9af"
      unitRef="number">0.109</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i07925528b3644a4e9e4ed3e3b71c3c9d_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEyOS0xMC0xLTEtMjk3MjY_7eccf52f-1ee1-40b4-8bc1-02adfbc56172"
      unitRef="number">0.266</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87d7442d0ab6421c845a0cfc7bee4bef_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMC0yLTEtMS0yOTcyNg_1b5d6ea5-b558-476d-aec1-0cb68c9539ac"
      unitRef="usd">1085000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie18c8a66affb47e294a84056ff86c0fb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMC00LTEtMS0yOTcyNg_98e309a3-71ad-4463-ae51-ab81d2ae2711"
      unitRef="usd">1015000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i271b0b2860ef4bc48fe0bb5645096466_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMC02LTEtMS0yOTcyNg_d53aa066-6ac2-4bba-b900-cb12f342dfea"
      unitRef="usd">939000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i87d7442d0ab6421c845a0cfc7bee4bef_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMC04LTEtMS0yOTcyNg_24b78292-29d0-4562-8017-e28b77ec09fe"
      unitRef="number">0.069</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie18c8a66affb47e294a84056ff86c0fb_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMC0xMC0xLTEtMjk3MjY_f104f663-8579-447f-9c7b-f2c96fcfdd37"
      unitRef="number">0.082</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16bab441088648eeac5e89da18478b3d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMS0yLTEtMS0yOTcyNg_d52cf378-cc57-48b9-bfbe-5a58b45e5a69"
      unitRef="usd">3450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i281b34eb0d124b8090359d19f5649c26_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMS00LTEtMS0yOTcyNg_1130b53f-c63f-47ea-bf14-9b5b8444b310"
      unitRef="usd">3148000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21c2f4162852419f9469e508c07e9f59_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMS02LTEtMS0yOTcyNg_0de5b095-5793-4dff-b174-9e95dc860e47"
      unitRef="usd">2623000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i16bab441088648eeac5e89da18478b3d_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMS04LTEtMS0yOTcyNg_57a68f4b-baa3-4098-b0a8-89e967e9237c"
      unitRef="number">0.096</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i281b34eb0d124b8090359d19f5649c26_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMS0xMC0xLTEtMjk3MjY_704ee6a6-1be4-4165-936c-41fe68c4998f"
      unitRef="number">0.200</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7bdc57ec26d64526a8a02e0b5eefbdce_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMy0yLTEtMS0yOTcyNg_693707a2-a1ae-483c-962e-52f1e90f0dec"
      unitRef="usd">1147000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75393431ba4b43ec999c0c626b97a85a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMy00LTEtMS0yOTcyNg_27969005-22bc-43a5-a4fe-347041f9cee9"
      unitRef="usd">1008000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24ed0f45654143e7bd119e8dba14a248_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMy02LTEtMS0yOTcyNg_e912b466-5540-44aa-a68e-39c6378a0b06"
      unitRef="usd">766000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7bdc57ec26d64526a8a02e0b5eefbdce_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMy04LTEtMS0yOTcyNg_f7389ab8-5259-446a-b874-bff6838cd379"
      unitRef="number">0.137</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i75393431ba4b43ec999c0c626b97a85a_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzMy0xMC0xLTEtMjk3MjY_623370a4-8eae-43a5-aac1-8459b47d38a5"
      unitRef="number">0.317</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00781dd599394b27a4548a96fdf47dcd_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNC0yLTEtMS0yOTcyNg_d7592a23-36fb-4d36-a1db-5f4ff3328247"
      unitRef="usd">672000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5285c14317334dcdb114e8f542b05e55_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNC00LTEtMS0yOTcyNg_99934777-4de8-4ada-acbb-459daddc3e24"
      unitRef="usd">631000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0142ba4580f9403e859c146d50423865_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNC02LTEtMS0yOTcyNg_7822a9f9-10e5-43bb-90c3-29549c5ad0ba"
      unitRef="usd">562000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i00781dd599394b27a4548a96fdf47dcd_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNC04LTEtMS0yOTcyNg_d8301771-a704-4a93-aec3-0e11610536b4"
      unitRef="number">0.066</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5285c14317334dcdb114e8f542b05e55_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNC0xMC0xLTEtMjk3MjY_6140a102-a872-45f4-9003-2a3ab5317520"
      unitRef="number">0.123</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c0c0ffc4f67453684f177809b84b6d1_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNS0yLTEtMS0yOTcyNg_674cec9c-d215-4791-beaf-e872c25cb628"
      unitRef="usd">1819000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i603a5b11ffb34e64b886e811464da6d1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNS00LTEtMS0yOTcyNg_4791ccb8-0035-45da-bd93-2a499c457e98"
      unitRef="usd">1639000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33e35fd935b449cd87da860775063b45_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNS02LTEtMS0yOTcyNg_1a303e10-da5f-4057-81ba-e82ce0b31085"
      unitRef="usd">1327000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3c0c0ffc4f67453684f177809b84b6d1_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNS04LTEtMS0yOTcyNg_3a5e9b4c-882b-4956-aecf-63739f3ac755"
      unitRef="number">0.110</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i603a5b11ffb34e64b886e811464da6d1_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNS0xMC0xLTEtMjk3MjY_1ade08a9-971d-4caa-b726-dea90bbe4999"
      unitRef="number">0.235</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icff8555c708a43078ad2afecb67d66e6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNy0yLTEtMS0yOTcyNg_551ef3c4-36df-4934-995d-10117132ba6b"
      unitRef="usd">1056000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i766c492cc7c9493e81c043bab5ce0792_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNy00LTEtMS0yOTcyNg_5c767f94-21c1-45f5-b135-e63231dd3624"
      unitRef="usd">955000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63014d356cf948fb90cbd74710d1a00f_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNy02LTEtMS0yOTcyNg_e30da035-4708-434f-8fd2-4b586548df41"
      unitRef="usd">714000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icff8555c708a43078ad2afecb67d66e6_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNy04LTEtMS0yOTcyNg_bca1acce-d543-45f4-8717-183a84237198"
      unitRef="number">0.105</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i766c492cc7c9493e81c043bab5ce0792_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzNy0xMC0xLTEtMjk3MjY_e0890856-7e5f-4daf-aabc-95ee2a09b61b"
      unitRef="number">0.338</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c41d11433d64accb3db5ddb31b09a77_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOC0yLTEtMS0yOTcyNg_d7198975-0ff5-46e0-8245-2666ac25f8d1"
      unitRef="usd">181000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d1ffed8e4c846e99dc9439de4ed307b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOC00LTEtMS0yOTcyNg_4cc4b7eb-422b-4d0e-87d1-f0da8c929f7e"
      unitRef="usd">138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7944381e57ad429a8fcb8c4561513ca1_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOC02LTEtMS0yOTcyNg_26882cf1-a323-4f17-9479-c7132d7fcf2c"
      unitRef="usd">105000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2c41d11433d64accb3db5ddb31b09a77_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOC04LTEtMS0yOTcyNg_895c8e24-fa3b-45b4-b84b-7424874a74df"
      unitRef="number">0.311</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6d1ffed8e4c846e99dc9439de4ed307b_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOC0xMC0xLTEtMjk3MjY_aceffb59-026a-4a73-a9fb-50ba4a314fcd"
      unitRef="number">0.309</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44edb1d49d2f465e924c4e1e880b74a1_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOS0yLTEtMS0yOTcyNg_a7b7609c-dcd2-4fa8-971c-717e545a5039"
      unitRef="usd">1237000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57c87e25c87c4e1a9a1aaed707a48369_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOS00LTEtMS0yOTcyNg_f678beca-7862-4b87-be38-22f135328b2a"
      unitRef="usd">1093000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b3120cc75a64c70b1146e4c34e24ae6_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOS02LTEtMS0yOTcyNg_586fbe34-d030-48b6-a449-a1a714eab65c"
      unitRef="usd">819000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i44edb1d49d2f465e924c4e1e880b74a1_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOS04LTEtMS0yOTcyNg_a6d80ee6-7b4c-44c5-9e81-92a866534a35"
      unitRef="number">0.131</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i57c87e25c87c4e1a9a1aaed707a48369_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzEzOS0xMC0xLTEtMjk3MjY_87ff2297-2815-4ff0-94ba-fe33c6431d39"
      unitRef="number">0.335</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3dd0bb1f6a24599b7fae40ad2e6e3a1_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0MS0yLTEtMS0yOTcyNg_c4317430-5a60-4f2d-b7f9-6548979d83ed"
      unitRef="usd">163000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5969e842241246218b535a59d92380f8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0MS00LTEtMS0yOTcyNg_4cc6e5f5-8094-41bc-8ae3-f2facda71edd"
      unitRef="usd">169000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4064a0928a04ccbbdd9885f05ec28ca_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0MS02LTEtMS0yOTcyNg_68db0da7-ced0-4f56-b48a-f8ca6ca80867"
      unitRef="usd">205000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if3dd0bb1f6a24599b7fae40ad2e6e3a1_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0MS04LTEtMS0yOTcyNg_ba48f0db-391e-4cd2-9517-36910cfcc87e"
      unitRef="number">-0.037</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5969e842241246218b535a59d92380f8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0MS0xMC0xLTEtMjk3MjY_8189d2eb-112f-45b7-8243-d3d3a1c71e31"
      unitRef="number">-0.176</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd90a7b4fb61410a89aeeeaaa41f4305_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Mi0yLTEtMS0yOTcyNg_5ca4d565-3c0f-4d5c-ac3c-0bf3dbc0bc0c"
      unitRef="usd">232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ff91543c3e8429f958c8e05d94d0522_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Mi00LTEtMS0yOTcyNg_74d01f68-ed60-4148-b0b5-fd8a9915932d"
      unitRef="usd">247000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93d13747093f4c91ad73a481a62db2a5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Mi02LTEtMS0yOTcyNg_3fc643ca-3a94-4f7a-85cc-2c944a8d28e7"
      unitRef="usd">272000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idd90a7b4fb61410a89aeeeaaa41f4305_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Mi04LTEtMS0yOTcyNg_7ce5206f-bbed-41de-9aa4-c2d532b16091"
      unitRef="number">-0.059</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3ff91543c3e8429f958c8e05d94d0522_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Mi0xMC0xLTEtMjk3MjY_3e317f15-a471-4c20-9aed-1c4ee63d6b09"
      unitRef="number">-0.092</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic61250cfcef0490b8e1042b72907be02_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0My0yLTEtMS0yOTcyNg_e1fd5ff6-f7ca-4afc-8fc4-b10511231ca7"
      unitRef="usd">395000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if19796a0c1cd4f1b8e7233548fdde432_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0My00LTEtMS0yOTcyNg_42635171-71fc-4b96-a1cc-71fbf4b5ecdf"
      unitRef="usd">416000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice1a20fa60764b468728eb227dfcf93f_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0My02LTEtMS0yOTcyNg_44e7a7ed-dc0e-42bf-9836-39143f63280f"
      unitRef="usd">476000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic61250cfcef0490b8e1042b72907be02_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0My04LTEtMS0yOTcyNg_6c10bb3f-a329-49aa-abdc-442d20a33fcd"
      unitRef="number">-0.050</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if19796a0c1cd4f1b8e7233548fdde432_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0My0xMC0xLTEtMjk3MjY_ab642f52-6578-4a7a-ae97-093c5344746e"
      unitRef="number">-0.128</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaab1d242f57c4857bc07508d3fef7f57_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0NS0yLTEtMS0yOTcyNg_df2f0804-f229-4bac-8091-d5a971698d23"
      unitRef="usd">3192000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i675381e27e8e4f8c92cf3dee1a9f85e1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0NS00LTEtMS0yOTcyNg_a49d1867-59f4-4a14-bc9e-c9111154eb95"
      unitRef="usd">3509000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c624bba8b9c43b0aff6e81143910b91_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0NS02LTEtMS0yOTcyNg_40626360-7d17-449f-a2f2-e3812bc79c46"
      unitRef="usd">3734000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iaab1d242f57c4857bc07508d3fef7f57_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0NS04LTEtMS0yOTcyNg_2b006191-ae79-40da-ab7f-07543be91cf4"
      unitRef="number">-0.090</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i675381e27e8e4f8c92cf3dee1a9f85e1_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0NS0xMC0xLTEtMjk3MjY_863da83a-8f87-4db0-8571-570e20321bf2"
      unitRef="number">-0.060</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4abe8cd280bc4dc38415f6a54595a59e_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ni0yLTEtMS0yOTcyNg_093fdcdc-a6b6-4334-94c2-4d4962118cfa"
      unitRef="usd">1268000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c16bc456bd940bb901d164807f45809_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ni00LTEtMS0yOTcyNg_2d0cbc26-0c85-4698-9d7c-2be61a150fe2"
      unitRef="usd">1369000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5243c3d264ac40d09b1366108f2813a5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ni02LTEtMS0yOTcyNg_d6ed486d-7cd2-4087-a093-63b4b44767a5"
      unitRef="usd">1458000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4abe8cd280bc4dc38415f6a54595a59e_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ni04LTEtMS0yOTcyNg_e971c30a-dee8-463a-b24d-b1626840fd3f"
      unitRef="number">-0.074</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5c16bc456bd940bb901d164807f45809_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ni0xMC0xLTEtMjk3MjY_e90c0398-2530-4689-bb13-57b996c29ce1"
      unitRef="number">-0.061</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i297695ea47c64a8ab41165f4e8cd24ca_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ny0yLTEtMS0yOTcyNg_a7d95de3-b17e-43b3-9195-b6a6d213e00e"
      unitRef="usd">4460000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09d261dd66bc4a6fa3474295db120684_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ny00LTEtMS0yOTcyNg_7301a3c9-943d-40c5-bb3d-bbed5e69ed02"
      unitRef="usd">4878000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6585c5f17b5243029be20ef4718f4ea1_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ny02LTEtMS0yOTcyNg_178478cc-36fb-4cea-a425-0cf2989f0802"
      unitRef="usd">5192000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i297695ea47c64a8ab41165f4e8cd24ca_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ny04LTEtMS0yOTcyNg_b8128353-fcf6-4eee-9d94-dedfb1df8aad"
      unitRef="number">-0.086</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i09d261dd66bc4a6fa3474295db120684_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0Ny0xMC0xLTEtMjk3MjY_1e959de1-c464-4498-b837-48e09d4abd4a"
      unitRef="number">-0.060</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84ccf738ed9a45f9bbe93e37729899b0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0OS0yLTEtMS0yOTcyNg_295718b7-812f-4b02-b628-2ef725df8c50"
      unitRef="usd">2438000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i211d1d903be349e7b8c4d90c4d8e7ea8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0OS00LTEtMS0yOTcyNg_613ee501-a58b-4837-ad52-54f175224563"
      unitRef="usd">2345000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic41939995d744557b2fadc86190eb309_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0OS02LTEtMS0yOTcyNg_5b0bb66b-8966-443c-b6ab-dee945a6f75e"
      unitRef="usd">2313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i84ccf738ed9a45f9bbe93e37729899b0_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0OS04LTEtMS0yOTcyNg_1025763c-bc8b-4402-909b-142faad4ece5"
      unitRef="number">0.040</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i211d1d903be349e7b8c4d90c4d8e7ea8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE0OS0xMC0xLTEtMjk3MjY_e4eaf273-ed6d-40cb-89ae-77c5481e2f50"
      unitRef="number">0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59cfc473af604a8da15221699e4b413a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MC0yLTEtMS0yOTcyNg_ebfaece3-dfbe-4929-903e-db5966da7f62"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67b7e2f978c5475796d2aeac43f69af0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MC00LTEtMS0yOTcyNg_1c4ba13a-d3f5-4b5e-b834-5d90279bb5a1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i258c4fd8ba0447d5964abdb213044818_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MC02LTEtMS0yOTcyNg_564810bc-3692-4d3b-81b4-ad4eb951df9f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i59cfc473af604a8da15221699e4b413a_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MC04LTEtMS0yOTcyNg_142b0381-6770-441f-b7d2-04b66b014faa"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i67b7e2f978c5475796d2aeac43f69af0_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MC0xMC0xLTEtMjk3MjY_e39249c4-fbf2-4730-9bdd-1cfa3ce59841"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e04698c0f76437fa764204c1042ea2a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MS0yLTEtMS0yOTcyNg_994d3298-fea8-433a-979a-23fa862f57fc"
      unitRef="usd">2438000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15858ed4ab2a40ba98560ad9c345f601_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MS00LTEtMS0yOTcyNg_78c15a31-0065-46b2-885f-81bdc6f6346e"
      unitRef="usd">2345000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8d2d7a4b4074a02adf791b11dbeea4b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MS02LTEtMS0yOTcyNg_6896af98-4be0-4908-adc9-d410a4183c0d"
      unitRef="usd">2313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3e04698c0f76437fa764204c1042ea2a_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MS04LTEtMS0yOTcyNg_ed6cabc8-c4da-4aef-b8df-e0a44ed81833"
      unitRef="number">0.040</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i15858ed4ab2a40ba98560ad9c345f601_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1MS0xMC0xLTEtMjk3MjY_e703709c-37c7-400b-a3c9-33a761caffe2"
      unitRef="number">0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cb15999bd6c4c56a5291296be65bdc9_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1My0yLTEtMS0yOTcyNg_7fbd1991-ddad-4297-a2c4-385682dad36b"
      unitRef="usd">308000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic841ebde283e4fe69105c52901291b20_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1My00LTEtMS0yOTcyNg_92cf4868-ea04-40a2-ada3-5cfe9ab81f6e"
      unitRef="usd">564000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ed18e2587674e6bb9e55bb50d6174e6_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1My02LTEtMS0yOTcyNg_372d8da0-8319-45c1-ab2d-c4fb80833eb6"
      unitRef="usd">536000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9cb15999bd6c4c56a5291296be65bdc9_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1My04LTEtMS0yOTcyNg_e32976c9-ebec-4618-9a51-63de559982fa"
      unitRef="number">-0.454</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic841ebde283e4fe69105c52901291b20_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1My0xMC0xLTEtMjk3MjY_3c86680d-67e9-4c2c-bfa8-1df98bbaa145"
      unitRef="number">0.052</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ebc2042874040a2b7bab4e67bea27e1_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NC0yLTEtMS0yOTcyNg_12155ad6-2632-49a6-b40c-89c49e65e2f8"
      unitRef="usd">254000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1242f0ab963e4cdebfae1b38000d1c0e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NC00LTEtMS0yOTcyNg_8cce744b-817d-459e-9024-895aa7ddfe6b"
      unitRef="usd">231000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88046ddeac01478aae7aa3b6fd4cd0f2_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NC02LTEtMS0yOTcyNg_aee5f8be-617d-4504-aece-adad6a5c9e72"
      unitRef="usd">199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7ebc2042874040a2b7bab4e67bea27e1_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NC04LTEtMS0yOTcyNg_2748b65e-74ad-4a0d-b6f6-bc44128da82e"
      unitRef="number">0.099</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1242f0ab963e4cdebfae1b38000d1c0e_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NC0xMC0xLTEtMjk3MjY_dde90bbf-de5b-4759-bc10-d704d5754b8f"
      unitRef="number">0.163</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6fd4aec56fe4857881bc9ca6e2ebc28_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NS0yLTEtMS0yOTcyNg_e5a7dae9-6027-4f46-ac99-e5341792cea6"
      unitRef="usd">563000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f3a036d977f4825a3d6b45499f1bf73_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NS00LTEtMS0yOTcyNg_beb57644-95ec-4591-b98c-b2415e8236d7"
      unitRef="usd">795000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i545bab733e4f449cafdf90c3798807d7_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NS02LTEtMS0yOTcyNg_50482c29-2a32-4237-be9a-d0dd3217f66d"
      unitRef="usd">735000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib6fd4aec56fe4857881bc9ca6e2ebc28_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NS04LTEtMS0yOTcyNg_f4d789a9-72d5-4f51-b1f1-ccc34af7a343"
      unitRef="number">-0.293</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0f3a036d977f4825a3d6b45499f1bf73_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1NS0xMC0xLTEtMjk3MjY_5d489ef6-a787-4311-b2fb-3c0acb3647bc"
      unitRef="number">0.082</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a2648c41e074ca5a9b6e8509a34ba69_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1Ny0yLTEtMS0yOTcyNg_86300d24-eaa8-4f7d-9b6f-67092b8e26b1"
      unitRef="usd">223000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida37c995a07f44bdb1293caa0b49b88f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1Ny00LTEtMS0yOTcyNg_072af17b-379d-4081-94c0-d90d9d0a88ab"
      unitRef="usd">277000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i830c2e05cc524c80a9769de9a4ecc07f_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1Ny02LTEtMS0yOTcyNg_cbbfbe88-bd2d-45fe-ab69-58d74a69a78b"
      unitRef="usd">505000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9a2648c41e074ca5a9b6e8509a34ba69_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1Ny04LTEtMS0yOTcyNg_20f58b29-ed40-448d-b507-e7d4b4827154"
      unitRef="number">-0.197</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ida37c995a07f44bdb1293caa0b49b88f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1Ny0xMC0xLTEtMjk3MjY_58355704-d6ec-4a80-9fb6-240343b2f543"
      unitRef="number">-0.451</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65a015a3eee243aaba77cfdb4761746f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OC0yLTEtMS0yOTcyNg_cee67b53-4701-4c24-bc1c-a030db8f003e"
      unitRef="usd">256000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib761e394f720484e86bb1215c1c4a5d7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OC00LTEtMS0yOTcyNg_43b18815-8c8a-4f44-8263-dbb28875200f"
      unitRef="usd">274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i128f3aaa257a46b78b36a2dfb202715e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OC02LTEtMS0yOTcyNg_ef972f83-fc8f-4271-87bf-6878b4713183"
      unitRef="usd">285000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i65a015a3eee243aaba77cfdb4761746f_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OC04LTEtMS0yOTcyNg_e13f2d96-7068-4c3f-9ddc-36a1966ebb55"
      unitRef="number">-0.068</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib761e394f720484e86bb1215c1c4a5d7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OC0xMC0xLTEtMjk3MjY_7fc15e77-021e-4268-b485-f38d9a19c8eb"
      unitRef="number">-0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i876ae032ad75425dbf80231e9170bcbc_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OS0yLTEtMS0yOTcyNg_bfe2359e-9c16-44d3-ac9b-88dafcae635b"
      unitRef="usd">479000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7ab917ab8b04eda955e8203c8814bad_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OS00LTEtMS0yOTcyNg_2909cf13-6a24-42ed-9773-2256ca6ad16e"
      unitRef="usd">552000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4de6312edbab4fc1b98af49b4891a217_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OS02LTEtMS0yOTcyNg_efa18d65-f535-4ffe-807d-19ee64ec62fe"
      unitRef="usd">790000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i876ae032ad75425dbf80231e9170bcbc_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OS04LTEtMS0yOTcyNg_486c92a7-a3c2-4383-a4d3-e422de9a53c3"
      unitRef="number">-0.133</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic7ab917ab8b04eda955e8203c8814bad_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE1OS0xMC0xLTEtMjk3MjY_6c7ab4e9-1bc7-41ce-b100-1d0eb99641a1"
      unitRef="number">-0.302</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ad086a689a4494b8f7603e98b20bf80_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2MS0yLTEtMS0yOTcyNg_1f6c3c91-255f-4b87-a293-6c3e3af0a009"
      unitRef="usd">223000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf56df821a7c433d8bce9033b393786f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2MS00LTEtMS0yOTcyNg_9cf6c5c0-a928-41a8-ba82-1edc0b0b05b9"
      unitRef="usd">323000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia277734b806943c9a73e6ecb6dbe0eef_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2MS02LTEtMS0yOTcyNg_b529aad4-bcd5-48c4-967b-c26ba6254fe2"
      unitRef="usd">380000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8ad086a689a4494b8f7603e98b20bf80_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2MS04LTEtMS0yOTcyNg_ac310779-0739-49cf-acde-4cebb48eed5c"
      unitRef="number">-0.310</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iaf56df821a7c433d8bce9033b393786f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2MS0xMC0xLTEtMjk3MjY_cb7f0a56-1253-464f-abaf-f788cc7d7c70"
      unitRef="number">-0.151</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1daa11474a049bdaebda77832fe66e0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Mi0yLTEtMS0yOTcyNg_ee55cb24-f7e4-4a35-9c37-cc0e9f0f0d4b"
      unitRef="usd">758000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e24ec61f60841539515b9dad3105f4d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Mi00LTEtMS0yOTcyNg_c9eb20fc-fc53-4c61-98af-1790bd0ff0a6"
      unitRef="usd">864000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2b6cac63b0c4cb4af1c8513a38855bd_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Mi02LTEtMS0yOTcyNg_b14974ba-474a-4702-ba77-57c39e6e02a2"
      unitRef="usd">974000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id1daa11474a049bdaebda77832fe66e0_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Mi04LTEtMS0yOTcyNg_7d67e279-dcb3-480b-bffe-05fb8ec595ec"
      unitRef="number">-0.122</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4e24ec61f60841539515b9dad3105f4d_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Mi0xMC0xLTEtMjk3MjY_1ae546ec-4695-4a3c-a6f9-55dce7e61b27"
      unitRef="number">-0.113</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9df7f3da552d44fe9c15d7efd001a255_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2My0yLTEtMS0yOTcyNg_94e1cb4e-c9de-48a5-8006-b777e2662801"
      unitRef="usd">981000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e6d423063d240c680e574f22c368d85_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2My00LTEtMS0yOTcyNg_bd5919c9-1fc1-4255-abee-396f705470a2"
      unitRef="usd">1186000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39fe54bd882c4e64976ec42f3c86ea0d_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2My02LTEtMS0yOTcyNg_f0578e2d-db10-4b56-a0d0-7088237a1d9b"
      unitRef="usd">1353000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9df7f3da552d44fe9c15d7efd001a255_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2My04LTEtMS0yOTcyNg_8d8fb542-70db-4dd9-9e62-58e2870bfe59"
      unitRef="number">-0.173</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7e6d423063d240c680e574f22c368d85_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2My0xMC0xLTEtMjk3MjY_361dbaa0-6df4-48a1-bb25-34c01d8c378a"
      unitRef="number">-0.124</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67be3029faf745a8adc9589c55128db4_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ni0yLTEtMS0yOTcyNg_c8201f05-c50e-476b-b4f6-b8b3d4a3ae0f"
      unitRef="usd">27954000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9efd22575fd4bcfbf17627fcfa7cbd2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ni00LTEtMS0yOTcyNg_2bacdcee-bcc1-49d9-87c4-6c70e8e481af"
      unitRef="usd">25735000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i443b2dc23fbc4bb9b95e55dbe54d0032_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ni02LTEtMS0yOTcyNg_19e35242-1dd2-4e96-a40a-1aef9fe342e2"
      unitRef="usd">23874000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i67be3029faf745a8adc9589c55128db4_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ni04LTEtMS0yOTcyNg_c3bd277d-3a17-4e1f-bc74-f6676940d52e"
      unitRef="number">0.086</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib9efd22575fd4bcfbf17627fcfa7cbd2_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ni0xMC0xLTEtMjk3MjY_8c29b385-dfa8-44cc-9409-91873f26f525"
      unitRef="number">0.078</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65dfeabf7bf04ff3b9e4a50912b6534e_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ny0yLTEtMS0yOTcyNg_a59ea948-309c-43ae-adfc-7e3cab0b8cc5"
      unitRef="usd">24126000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if74ce695258e4192a81f8bd943d68de8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ny00LTEtMS0yOTcyNg_f96b2083-8c59-4d77-acd0-5f1e1585cba7"
      unitRef="usd">19837000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaed80240aaab4a27988be21654755b5a_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ny02LTEtMS0yOTcyNg_1e5af828-9315-4a05-99c2-c05783d845fc"
      unitRef="usd">18324000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i65dfeabf7bf04ff3b9e4a50912b6534e_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ny04LTEtMS0yOTcyNg_dc3735bb-bc8c-4616-8be6-c8b07bd60942"
      unitRef="number">0.216</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if74ce695258e4192a81f8bd943d68de8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2Ny0xMC0xLTEtMjk3MjY_ab65f66b-42fe-46f2-bf8d-6c3b7746f42f"
      unitRef="number">0.083</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2OC0yLTEtMS0yOTcyNg_139633be-49db-4dd4-b9dc-6cb2b66fb433"
      unitRef="usd">52080000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9f7770a07704889bef20acb8a0c5220_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2OC00LTEtMS0yOTcyNg_52d2d0ea-81b0-46de-aff3-a19be88ad744"
      unitRef="usd">45572000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2cf37c66bfb4ef5bce478f5333fb5df_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2OC02LTEtMS0yOTcyNg_f7d5ac07-52d3-4832-969f-b95be4a22567"
      unitRef="usd">42198000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2OC04LTEtMS0yOTcyNg_24e21388-87d4-40bb-8afe-591db42ab87c"
      unitRef="number">0.143</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia9f7770a07704889bef20acb8a0c5220_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE2OC0xMC0xLTEtMjk3MjY_47a590ac-81f2-4b80-95bb-a87de2213eb4"
      unitRef="number">0.080</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60ed8921747044c5a0cacb0bdbb61ee5_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4MS0yLTEtMS0yOTcyNg_30dcfa67-2107-4a99-a5bc-0b749011f6d1"
      unitRef="usd">1836000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14e5877a920f4ed5b8884f48704c60dd_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4MS00LTEtMS0yOTcyNg_54a589dd-6d44-4085-a2b5-12e2c1d40d4c"
      unitRef="usd">1452000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d312ed9a008438aafe8e2616054ee50_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4MS02LTEtMS0yOTcyNg_abff8c5c-5422-4d62-88d5-f88ab828e9ba"
      unitRef="usd">1443000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i60ed8921747044c5a0cacb0bdbb61ee5_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4MS04LTEtMS0yOTcyNg_18d46887-af79-43b8-b84e-7d6845659b73"
      unitRef="number">0.264</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i14e5877a920f4ed5b8884f48704c60dd_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4MS0xMC0xLTEtMjk3MjY_483f51ee-eaaa-4033-8a03-773038c2ec23"
      unitRef="number">0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8a398a171a24a8498a76f0430bf01d8_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Mi0yLTEtMS0yOTcyNg_cd5a7e95-05b9-4659-9b68-08603130642e"
      unitRef="usd">2135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice5069a97d424275971a265d90db25f2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Mi00LTEtMS0yOTcyNg_71eca803-140b-4002-93af-1a333141baf7"
      unitRef="usd">1594000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6664751dc074f608b93f8348f757b2b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Mi02LTEtMS0yOTcyNg_b6bdd993-79ec-477e-b85e-72b71bfeeed9"
      unitRef="usd">1554000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib8a398a171a24a8498a76f0430bf01d8_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Mi04LTEtMS0yOTcyNg_5786a93c-b261-48f8-91f2-ed43f5a90ee1"
      unitRef="number">0.340</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ice5069a97d424275971a265d90db25f2_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Mi0xMC0xLTEtMjk3MjY_bf264f10-2c88-4681-8b04-7c0bffd562fb"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47511162d73d4b6d9f5256e85c7e0459_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4My0yLTEtMS0yOTcyNg_fdc415ae-9d9a-4bda-80da-ad33b70ffc50"
      unitRef="usd">3971000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i643aacdc85d74fc88245ec3722a90e65_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4My00LTEtMS0yOTcyNg_460f9214-4f65-4011-8e5f-896a874ebb86"
      unitRef="usd">3046000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0d5c2adced94c5db905a0ccc543024b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4My02LTEtMS0yOTcyNg_a29490c1-a7e1-4b8c-9434-b7a0b8ceb07f"
      unitRef="usd">2997000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i47511162d73d4b6d9f5256e85c7e0459_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4My04LTEtMS0yOTcyNg_7ac9564e-89c8-44fc-a848-a40a0912963a"
      unitRef="number">0.304</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i643aacdc85d74fc88245ec3722a90e65_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4My0xMC0xLTEtMjk3MjY_bc9cfc8a-f9de-42ac-bec6-14201250ea21"
      unitRef="number">0.016</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i636b39044d77475baa810025fccb74fc_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4NS0yLTEtMS0yOTcyNg_5189000e-63c1-42e9-84e1-f5b237eb89d2"
      unitRef="usd">5126000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i106843425fe24320805510bfc4532f23_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4NS00LTEtMS0yOTcyNg_884bce91-6fad-4fdd-9d5e-48440d726d3a"
      unitRef="usd">4779000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib806ab041535413685cecd33d2128890_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4NS02LTEtMS0yOTcyNg_633c53a9-d7bc-4c1b-9857-fd4b86320a1f"
      unitRef="usd">5319000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i636b39044d77475baa810025fccb74fc_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4NS04LTEtMS0yOTcyNg_1fc166ba-48d4-4b20-8d0b-91d4ceeaa90d"
      unitRef="number">0.073</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i106843425fe24320805510bfc4532f23_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4NS0xMC0xLTEtMjk3MjY_67c7675f-1d81-428b-84cd-02dca80f2537"
      unitRef="number">-0.102</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64dc60886f8947f0b033db2e2d716436_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ni0yLTEtMS0yOTcyNg_ba2e2494-a5bd-4785-9aaf-6963f99d5585"
      unitRef="usd">3462000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie402bd95c7f249bcb616b6d175dbf07b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ni00LTEtMS0yOTcyNg_ab2abffa-89fd-4366-8934-2c545cee00db"
      unitRef="usd">2984000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7fa0825611594020b2fe056c0e4efae8_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ni02LTEtMS0yOTcyNg_68bd6f9e-d7f9-4fd1-9ac8-a351d574e237"
      unitRef="usd">3520000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i64dc60886f8947f0b033db2e2d716436_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ni04LTEtMS0yOTcyNg_df6a5c53-ed61-42ee-9121-8b8a9a713f11"
      unitRef="number">0.160</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie402bd95c7f249bcb616b6d175dbf07b_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ni0xMC0xLTEtMjk3MjY_18aa607a-10fe-44b9-a7f8-6026e3639f7f"
      unitRef="number">-0.152</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f0fac6b04c84b689a79771f385713c2_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ny0yLTEtMS0yOTcyNg_c54af3b3-f26b-4af7-a9e5-2dc2dcef2536"
      unitRef="usd">8588000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i816f338852d14f0fb2d6dfbdc728effd_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ny00LTEtMS0yOTcyNg_d22b034a-6132-49d9-bbdc-b41c82e18668"
      unitRef="usd">7763000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib46440e9fa084f209298e0c8b233ad13_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ny02LTEtMS0yOTcyNg_2a8946be-75fc-4249-a419-5274ee23083c"
      unitRef="usd">8839000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0f0fac6b04c84b689a79771f385713c2_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ny04LTEtMS0yOTcyNg_ceba8200-fa95-4ded-9717-c807ddfbcf1a"
      unitRef="number">0.106</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i816f338852d14f0fb2d6dfbdc728effd_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4Ny0xMC0xLTEtMjk3MjY_1cd9e76e-bc93-47d0-bfc1-4aca8581e666"
      unitRef="number">-0.122</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51e39d41add6463b9092b617f971b75f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4OS0yLTEtMS0yOTcyNg_835718e0-e8eb-47fa-90da-c999a1374374"
      unitRef="usd">883000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice66c64ac61048f19a21734cafb5097d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4OS00LTEtMS0yOTcyNg_7e60c73c-f211-45a4-8dce-b356723c8828"
      unitRef="usd">793000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib72662fc19e040589f8f2ec556ad1d4c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4OS02LTEtMS0yOTcyNg_e4c2e36b-c108-418d-b521-183058106cf0"
      unitRef="usd">863000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i51e39d41add6463b9092b617f971b75f_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4OS04LTEtMS0yOTcyNg_7969e9db-e2fd-471b-8df8-42ffb0e144d5"
      unitRef="number">0.114</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ice66c64ac61048f19a21734cafb5097d_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE4OS0xMC0xLTEtMjk3MjY_2f0a51d5-2d05-4bf3-ac90-c5c0c8f8bc1e"
      unitRef="number">-0.082</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75c9d64349fb47d0be110ff26bce965f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MC0yLTEtMS0yOTcyNg_e1712eff-e963-4057-ac69-bc519cc25c97"
      unitRef="usd">602000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d4d5a35e0264fa3a59ab55f6e08dc1b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MC00LTEtMS0yOTcyNg_8da6e4d1-814c-441e-83c6-531521ee5714"
      unitRef="usd">487000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8dfb56f1cc3472b91d0ad823df8d237_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MC02LTEtMS0yOTcyNg_5982c2fa-03a8-431e-b2f3-1533a326134d"
      unitRef="usd">575000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i75c9d64349fb47d0be110ff26bce965f_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MC04LTEtMS0yOTcyNg_0eccc706-8eaf-4461-8a77-08e24007f7d4"
      unitRef="number">0.236</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3d4d5a35e0264fa3a59ab55f6e08dc1b_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MC0xMC0xLTEtMjk3MjY_0bfe9ee5-98fb-4274-9fa8-a93fa6153d01"
      unitRef="number">-0.153</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id20b1d22e77a4da4a5261a8d5004c3d7_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MS0yLTEtMS0yOTcyNg_a8d98535-832d-4f72-bd8f-9d7a7e4c8a05"
      unitRef="usd">1485000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a6ff7e9dc76409ab4354387f1f95d6e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MS00LTEtMS0yOTcyNg_8f641bba-3a9b-4ff8-9449-d2a416c1c955"
      unitRef="usd">1280000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf0f0d1cba3e4983876bb49c63f4d22f_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MS02LTEtMS0yOTcyNg_ab77930d-84ea-489d-833c-b1aee38e97ca"
      unitRef="usd">1438000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id20b1d22e77a4da4a5261a8d5004c3d7_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MS04LTEtMS0yOTcyNg_9d0e9c15-dd96-4778-b385-20ac6221010a"
      unitRef="number">0.160</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4a6ff7e9dc76409ab4354387f1f95d6e_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5MS0xMC0xLTEtMjk3MjY_3d655d0b-ee99-4be1-9497-952d33842fea"
      unitRef="number">-0.110</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1865f77461f6431495acc8c63093e96f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5My0yLTEtMS0yOTcyNg_844442ce-9152-4524-b1ee-5428a917cd85"
      unitRef="usd">787000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie347616036fd4a74b6a373520ba980d7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5My00LTEtMS0yOTcyNg_2c0445b3-0d7d-4898-bdb6-038e3a5053fa"
      unitRef="usd">743000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b643a5b78824e2497a25c62b3737d1e_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5My02LTEtMS0yOTcyNg_e3c4e1be-7c7d-425b-af7b-91b1690c3482"
      unitRef="usd">889000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1865f77461f6431495acc8c63093e96f_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5My04LTEtMS0yOTcyNg_e8889806-102d-45b3-99c1-04c5ca06d4f2"
      unitRef="number">0.059</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie347616036fd4a74b6a373520ba980d7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5My0xMC0xLTEtMjk3MjY_54bb1241-386e-4266-be4f-c3110184fd5f"
      unitRef="number">-0.164</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7196fd596c74749bad40acfaea1b70a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NC0yLTEtMS0yOTcyNg_571a59cf-40ad-4695-9620-91f91664cebc"
      unitRef="usd">538000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64ccbb362945429fac924633eba5f320_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NC00LTEtMS0yOTcyNg_9f6c8de8-35ad-4af6-bc2a-70ed3f96f117"
      unitRef="usd">427000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12ce06e19cb740a191f99093f0e41f93_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NC02LTEtMS0yOTcyNg_274b5f65-065e-48b7-8ff3-80b576ddc110"
      unitRef="usd">591000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia7196fd596c74749bad40acfaea1b70a_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NC04LTEtMS0yOTcyNg_f37c3dea-176f-4a52-a4dd-235d625c321d"
      unitRef="number">0.261</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i64ccbb362945429fac924633eba5f320_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NC0xMC0xLTEtMjk3MjY_106181c4-1895-466b-a8b2-aab1be9f23a7"
      unitRef="number">-0.278</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0420b48e154a40cd94667e4f7c079b72_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NS0yLTEtMS0yOTcyNg_55343f83-02ae-481b-a736-d1f770042790"
      unitRef="usd">1325000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id844326b0acb41a7b4c00cb04e75dcc9_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NS00LTEtMS0yOTcyNg_8608464a-d7c8-47b3-ab33-571743c02874"
      unitRef="usd">1170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic34d26533be64f5db220b79da72535d4_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NS02LTEtMS0yOTcyNg_4c43dc87-d1a5-4a06-b7b4-39cf7127e234"
      unitRef="usd">1480000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0420b48e154a40cd94667e4f7c079b72_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NS04LTEtMS0yOTcyNg_e0728ea8-14c9-4c73-af4e-ad8e2c4f215f"
      unitRef="number">0.133</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id844326b0acb41a7b4c00cb04e75dcc9_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5NS0xMC0xLTEtMjk3MjY_3e31e5ef-cb8e-490f-a3f3-c51f966fea79"
      unitRef="number">-0.210</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e00c0c4a5a54349a215833e43d01f5c_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5Ny0yLTEtMS0yOTcyNg_66d3732e-e31f-451c-acd3-4a2cf922eaaf"
      unitRef="usd">1819000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9eac76a3b41a46829772c0e6030b7607_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5Ny00LTEtMS0yOTcyNg_eae2234a-25f0-4ae7-9aa5-eb17f6384172"
      unitRef="usd">1648000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied4367d37c7141298cb4fdc3adef842d_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5Ny02LTEtMS0yOTcyNg_bb999bc2-350c-4558-b9ae-8ebc80d8a5a9"
      unitRef="usd">1652000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5e00c0c4a5a54349a215833e43d01f5c_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5Ny04LTEtMS0yOTcyNg_688e4c37-ac24-45fe-a37f-9b6a3800df14"
      unitRef="number">0.104</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9eac76a3b41a46829772c0e6030b7607_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5Ny0xMC0xLTEtMjk3MjY_80f0e51d-3662-4045-a55d-989c043c5c75"
      unitRef="number">-0.002</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07c3c76ed88d4612a15d8daf5874486b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OC0yLTEtMS0yOTcyNg_852cd255-2a9a-4a78-89f8-c8d04f26ca32"
      unitRef="usd">1066000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab9c0e490e5b409f818ad1fd0ba564a7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OC00LTEtMS0yOTcyNg_a20cce70-c16a-4bde-bbcb-025340ce50a5"
      unitRef="usd">966000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d8921ae00644e968ea3b39b44e5e6be_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OC02LTEtMS0yOTcyNg_8601a907-c23e-46f1-b040-e22024d484fd"
      unitRef="usd">1068000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i07c3c76ed88d4612a15d8daf5874486b_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OC04LTEtMS0yOTcyNg_f15f34b1-22e3-4ae6-a9a2-f3453bc54e40"
      unitRef="number">0.104</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iab9c0e490e5b409f818ad1fd0ba564a7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OC0xMC0xLTEtMjk3MjY_eea999b4-4d87-43ee-863e-0006cbe6ab62"
      unitRef="number">-0.096</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bfdee030cbc49baadf91413f3bd72b9_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OS0yLTEtMS0yOTcyNg_f0d5c8f5-f7a3-4f7c-814d-99ce9c4acfc3"
      unitRef="usd">2885000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1342fc470d44486822d04a68d8d00ec_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OS00LTEtMS0yOTcyNg_8508f165-971e-442d-bebe-59d55e25bfab"
      unitRef="usd">2614000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3b235e18a384746bae631a4c9642be1_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OS02LTEtMS0yOTcyNg_4a363290-6e3c-45a0-ae14-71643051798e"
      unitRef="usd">2720000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9bfdee030cbc49baadf91413f3bd72b9_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OS04LTEtMS0yOTcyNg_26c434dd-55c0-404d-84af-fe268f485488"
      unitRef="number">0.104</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie1342fc470d44486822d04a68d8d00ec_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzE5OS0xMC0xLTEtMjk3MjY_b6ac5cf2-5a88-4e38-a57e-249b445537a7"
      unitRef="number">-0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id08aa391f2684371a6971aa72bb4521a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMS0yLTEtMS0yOTcyNg_e5613b60-3134-441e-952e-b177d783f49a"
      unitRef="usd">1637000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a86230afa1e4a6cad4c6e87b5261ff7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMS00LTEtMS0yOTcyNg_599d56b7-94f2-43af-bf43-cf58db5aef26"
      unitRef="usd">1595000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbe1f9d829d845418d0507a31d92c4d0_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMS02LTEtMS0yOTcyNg_6f48b106-7b53-4d21-a976-d0a62d6327ec"
      unitRef="usd">1915000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id08aa391f2684371a6971aa72bb4521a_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMS04LTEtMS0yOTcyNg_e751a691-ba57-4fb4-94cb-8297daec9fa1"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9a86230afa1e4a6cad4c6e87b5261ff7_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMS0xMC0xLTEtMjk3MjY_3010fe84-29f3-4715-9cac-2c69a3286e08"
      unitRef="number">-0.167</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0e3cb79b02940e3afc4af2a5a631cd9_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMi0yLTEtMS0yOTcyNg_a292322a-1d54-4a4b-ba8b-df33ff7f1914"
      unitRef="usd">1256000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00778b10e5af4bc791d1e8bbdd2bc204_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMi00LTEtMS0yOTcyNg_4af3897d-0f09-4a19-bbb7-aa29663903fd"
      unitRef="usd">1104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacbdfe154b164f529f2e69136f05274f_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMi02LTEtMS0yOTcyNg_14fbdbf8-0f31-42dd-a379-bdfb00829b37"
      unitRef="usd">1286000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib0e3cb79b02940e3afc4af2a5a631cd9_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMi04LTEtMS0yOTcyNg_dcdb3290-9c7f-4d65-b6d8-57295bc12bd9"
      unitRef="number">0.138</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i00778b10e5af4bc791d1e8bbdd2bc204_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMi0xMC0xLTEtMjk3MjY_215b44f6-4662-4f22-8095-a25179767fea"
      unitRef="number">-0.141</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3304f9e4e7c4ee8b06281744d7d29d5_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMy0yLTEtMS0yOTcyNg_9ce4dca2-8b38-47c2-8236-cc26502050a5"
      unitRef="usd">2893000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i661a37b39e8c487aa2f3ff704761f5d2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMy00LTEtMS0yOTcyNg_0ba3e6ba-ea7c-4222-a80c-56ca2ff73f0e"
      unitRef="usd">2699000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1a4981a319243a488072bbdd896bf56_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMy02LTEtMS0yOTcyNg_6e8388b7-f78a-46e9-af1a-f2a1641c30fb"
      unitRef="usd">3201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie3304f9e4e7c4ee8b06281744d7d29d5_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMy04LTEtMS0yOTcyNg_aca02d06-ce0a-4ad6-8172-5903b0dac902"
      unitRef="number">0.072</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i661a37b39e8c487aa2f3ff704761f5d2_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwMy0xMC0xLTEtMjk3MjY_2213698b-d0c0-40f8-ad5b-67b1933c2948"
      unitRef="number">-0.157</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia27aa4eb532a45a799170754ae5ed161_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNS0yLTEtMS0yOTcyNg_1ddb62be-007d-4f2c-8c89-894712a53f6f"
      unitRef="usd">3867000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e557585fa834313b8b97ce7709070a9_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNS00LTEtMS0yOTcyNg_dab2fda8-2359-4dfe-a54c-288d9decf03a"
      unitRef="usd">3249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i949f6e0a191b4f4eb7c2781bbac7d13f_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNS02LTEtMS0yOTcyNg_a6099767-e437-47bc-a02b-62f9d0c9ef84"
      unitRef="usd">3828000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia27aa4eb532a45a799170754ae5ed161_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNS04LTEtMS0yOTcyNg_55706c4d-fdd8-4d17-8714-c038672cff5d"
      unitRef="number">0.190</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8e557585fa834313b8b97ce7709070a9_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNS0xMC0xLTEtMjk3MjY_48d17627-96d0-4533-ad2e-470f6a630ee1"
      unitRef="number">-0.151</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idca63bfd34644ba5bc55002b5b4d5a8e_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNi0yLTEtMS0yOTcyNg_8026057b-0fd6-4e5b-b3f8-62c22c28c24b"
      unitRef="usd">5945000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2be122533f1424399fcc358654c4c3c_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNi00LTEtMS0yOTcyNg_54ace91d-fb5b-4fc3-8fbf-668e2ec7b1c7"
      unitRef="usd">4983000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92e59ba1db31451aa3a8f14eb7816088_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNi02LTEtMS0yOTcyNg_35955df6-7c00-478c-b784-aabc9a3f9f87"
      unitRef="usd">5673000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idca63bfd34644ba5bc55002b5b4d5a8e_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNi04LTEtMS0yOTcyNg_9c0b21be-77e1-43ad-9f31-bb615b52bf26"
      unitRef="number">0.193</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia2be122533f1424399fcc358654c4c3c_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNi0xMC0xLTEtMjk3MjY_5b8ee6a2-02c5-43b0-9d21-5298630c8a11"
      unitRef="number">-0.122</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i234ad40879c94cc2969e46faf33c17cc_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNy0yLTEtMS0yOTcyNg_516c332b-1f90-4a08-9acd-e7aac8b51425"
      unitRef="usd">9812000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3d9dccc5c584c4980e7a904d8a983bf_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNy00LTEtMS0yOTcyNg_56327337-ab04-4f61-a390-3e8d6f328fc0"
      unitRef="usd">8232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3253049e290946cd8a51612d31bcd76b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNy02LTEtMS0yOTcyNg_14e3d2c7-ddb3-4937-8775-8bcd363fede0"
      unitRef="usd">9501000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i234ad40879c94cc2969e46faf33c17cc_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNy04LTEtMS0yOTcyNg_71622b98-8b6e-45b7-9243-ff07abdff9f6"
      unitRef="number">0.192</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie3d9dccc5c584c4980e7a904d8a983bf_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwNy0xMC0xLTEtMjk3MjY_f74ad438-6ea9-44b1-b959-45c691362c4f"
      unitRef="number">-0.134</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i273e42d494bc4b7eb94a87f9d5987d1f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwOS0yLTEtMS0yOTcyNg_2c6cee31-733d-427f-9001-48838cf714c8"
      unitRef="usd">1761000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6368f09f9b35486ea7cba69aacb7e3b0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwOS00LTEtMS0yOTcyNg_deb274f3-cee6-4eb0-94e5-f3b89815fea8"
      unitRef="usd">1535000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i275015b2876d4c6d8fcb7fcdbd81df65_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwOS02LTEtMS0yOTcyNg_7f89b7e0-50fa-4948-b897-aec2bc859c1f"
      unitRef="usd">1637000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i273e42d494bc4b7eb94a87f9d5987d1f_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwOS04LTEtMS0yOTcyNg_a5ffd6f4-24e1-4440-954e-ab8d2858fb94"
      unitRef="number">0.149</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6368f09f9b35486ea7cba69aacb7e3b0_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIwOS0xMC0xLTEtMjk3MjY_8409dd9a-8363-4292-815b-8de138f6b817"
      unitRef="number">-0.062</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f3e3713f381473f97efa9d195f99ffc_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMC0yLTEtMS0yOTcyNg_244e5f64-9242-4327-819d-5c39bcb1ed08"
      unitRef="usd">2861000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98f25d91afdc48968db8d33b505ba457_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMC00LTEtMS0yOTcyNg_b950b2d3-a5ef-4af5-b85a-2157f1b91542"
      unitRef="usd">2304000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d48dd9d0d814bbca1d1b0419263f649_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMC02LTEtMS0yOTcyNg_931fe3a3-a39a-4e2f-aaf7-39e5ba566c8f"
      unitRef="usd">2458000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6f3e3713f381473f97efa9d195f99ffc_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMC04LTEtMS0yOTcyNg_71f63355-bbaf-4d54-954e-850539af146c"
      unitRef="number">0.241</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i98f25d91afdc48968db8d33b505ba457_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMC0xMC0xLTEtMjk3MjY_82c143d3-3820-43a1-92b2-f68198e9071d"
      unitRef="number">-0.062</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefd23a50dc7c42fcb55115309d6d6cb5_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMS0yLTEtMS0yOTcyNg_ef2f7850-403c-4a68-98e4-837adc80f11d"
      unitRef="usd">4622000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54751f70883943a59eb320c03774cc90_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMS00LTEtMS0yOTcyNg_08088740-429a-4abc-a8c3-ac0f14739311"
      unitRef="usd">3839000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if904c809a5cc47d7b5470bf8066c13bc_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMS02LTEtMS0yOTcyNg_dabfc1fb-2151-44cb-848f-b31333248432"
      unitRef="usd">4095000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iefd23a50dc7c42fcb55115309d6d6cb5_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMS04LTEtMS0yOTcyNg_3125261b-937e-420f-8f72-2331ade05028"
      unitRef="number">0.204</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i54751f70883943a59eb320c03774cc90_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMS0xMC0xLTEtMjk3MjY_48a3b8f8-bd23-4785-952b-a2cf4b02ed48"
      unitRef="number">-0.062</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11256befd90346248d26afa528551f9f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMy0yLTEtMS0yOTcyNg_e4a8627d-2ed0-4347-a3b5-64b3607d4aea"
      unitRef="usd">2105000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7ccd3dcadf64c67aceef9eec40f6b84_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMy00LTEtMS0yOTcyNg_5d0020fd-37eb-41a8-af47-e21090c7b424"
      unitRef="usd">1714000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0409bf3aaf47499c862aca1869e89dc5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMy02LTEtMS0yOTcyNg_12b6d16d-096a-4bae-a88a-41df96a5a7b7"
      unitRef="usd">2192000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i11256befd90346248d26afa528551f9f_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMy04LTEtMS0yOTcyNg_fee1989e-f9f3-4b96-a3ad-37d9b6950425"
      unitRef="number">0.227</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie7ccd3dcadf64c67aceef9eec40f6b84_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxMy0xMC0xLTEtMjk3MjY_c7d08ea0-d094-446a-ab89-19a5f815e3bb"
      unitRef="number">-0.218</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e8300916c9f4f18862cbda08e5f8057_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNC0yLTEtMS0yOTcyNg_00240299-8c73-4820-9396-66ac58d86689"
      unitRef="usd">3085000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i092132d8bdf1497aa5fa557713c95b5f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNC00LTEtMS0yOTcyNg_5d4cdc33-a78f-43b9-899a-7826939e578c"
      unitRef="usd">2679000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4425ca9af5e64e22ac69aa3be800b66a_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNC02LTEtMS0yOTcyNg_c6c0df68-3157-4aa2-95ee-5deb32818aa8"
      unitRef="usd">3215000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3e8300916c9f4f18862cbda08e5f8057_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNC04LTEtMS0yOTcyNg_9b39a9ca-62d8-4c83-8e04-13f2adfa8213"
      unitRef="number">0.152</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i092132d8bdf1497aa5fa557713c95b5f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNC0xMC0xLTEtMjk3MjY_37c09da9-4323-48e8-854c-9936627129af"
      unitRef="number">-0.167</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21660177d3cf4725a1adfee86587c410_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNS0yLTEtMS0yOTcyNg_ed624b42-feb7-464e-91b0-342e20d063ce"
      unitRef="usd">5190000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa74aa704e1a4c00aa265ccc209e1380_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNS00LTEtMS0yOTcyNg_03ef82bc-254c-44f6-b773-8883c70969ad"
      unitRef="usd">4392000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i066cce25039f4a8caa66512b868996f8_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNS02LTEtMS0yOTcyNg_46601363-c0a4-42a7-bf97-6d5e48a84beb"
      unitRef="usd">5406000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i21660177d3cf4725a1adfee86587c410_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNS04LTEtMS0yOTcyNg_69ca57b7-96b4-4e3a-89f1-a7564408a007"
      unitRef="number">0.181</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iaa74aa704e1a4c00aa265ccc209e1380_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNS0xMC0xLTEtMjk3MjY_14c669ac-bbd3-42a7-956b-3528a11097de"
      unitRef="number">-0.188</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0af309f3267d40c3b42203456d5ad2d9_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNy0yLTEtMS0yOTcyNg_e32f2ef7-5d9b-4ba6-9e41-73f3208fedf7"
      unitRef="usd">1857000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84982e9d6460466bb3d6705abbfb2f69_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNy00LTEtMS0yOTcyNg_f8ed24dd-6621-421f-9cd7-3c2edfe9a150"
      unitRef="usd">1557000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea0e3ef3419b4d75adf175b93648c1b6_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNy02LTEtMS0yOTcyNg_b85adcf7-c1d6-41b6-bc66-1162c0da7f49"
      unitRef="usd">1794000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0af309f3267d40c3b42203456d5ad2d9_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNy04LTEtMS0yOTcyNg_54b2600b-9e92-4cc7-8ba6-6bf659695d41"
      unitRef="number">0.193</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i84982e9d6460466bb3d6705abbfb2f69_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxNy0xMC0xLTEtMjk3MjY_146b0a9e-5559-4b7f-899d-bea7bb17621d"
      unitRef="number">-0.132</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08a1d8e556c2462dbffb82954114233c_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOC0yLTEtMS0yOTcyNg_434d9011-2057-4781-ade0-1f40b0b470c5"
      unitRef="usd">2831000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i449dac796d2545b3b9f5d700d9bc735e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOC00LTEtMS0yOTcyNg_f0befe95-48e7-4ebd-a542-5a604d080158"
      unitRef="usd">2362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a9c0705fde748bebf4dc83c4526eedc_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOC02LTEtMS0yOTcyNg_4ea715c0-d498-4a84-b003-304fc6de9c93"
      unitRef="usd">2830000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i08a1d8e556c2462dbffb82954114233c_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOC04LTEtMS0yOTcyNg_5b84aa11-9394-48d7-a73d-a4d7b57b1e01"
      unitRef="number">0.198</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i449dac796d2545b3b9f5d700d9bc735e_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOC0xMC0xLTEtMjk3MjY_2126f8f4-3d17-49b9-a069-a652da6c4458"
      unitRef="number">-0.165</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67279a229f6346a78562ee616f898161_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOS0yLTEtMS0yOTcyNg_a889ec72-0a43-4c8b-9756-a3d04b9945b2"
      unitRef="usd">4688000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd6421c05ae448adb09f10e096aa875a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOS00LTEtMS0yOTcyNg_fa62ef71-d644-4cc3-be71-c8516f07d98e"
      unitRef="usd">3919000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i222491a1b870418a91eeb762d8d1eee8_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOS02LTEtMS0yOTcyNg_bc5a56d9-5371-411a-8352-e25d3a439a11"
      unitRef="usd">4624000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i67279a229f6346a78562ee616f898161_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOS04LTEtMS0yOTcyNg_3eedf428-2f3a-4f36-ab6c-db488e6382cc"
      unitRef="number">0.196</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifd6421c05ae448adb09f10e096aa875a_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIxOS0xMC0xLTEtMjk3MjY_c7121bfa-ccaa-445c-8432-f2545181a246"
      unitRef="number">-0.152</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d7dc7d7e32844b18dadac4c73fcc43d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMi0yLTEtMS0yOTcyNg_b1d913c6-12ff-482d-b8ed-3992fdab4022"
      unitRef="usd">1398000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icff33641613a4644b8764afca4e5e006_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMi00LTEtMS0yOTcyNg_ca4ebc1e-86b0-4f06-b9e5-8680dbedee5c"
      unitRef="usd">1213000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40f24e02fa214e8ca63a5dc798f5aa78_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMi02LTEtMS0yOTcyNg_d59f7e45-e4f3-4388-b6aa-cb9918831a27"
      unitRef="usd">1304000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0d7dc7d7e32844b18dadac4c73fcc43d_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMi04LTEtMS0yOTcyNg_803274f4-e068-4fe0-bd5e-2970461e7f76"
      unitRef="number">0.152</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icff33641613a4644b8764afca4e5e006_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMi0xMC0xLTEtMjk3MjY_dd214a35-3477-4fe6-a970-d4936118c62d"
      unitRef="number">-0.070</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb35b47d312946dabc1007fce8107f34_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMy0yLTEtMS0yOTcyNg_3c07d868-5ea7-4765-95b7-de2dc6b5503c"
      unitRef="usd">2043000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib15659c9d6514a6f8707334b438bf18b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMy00LTEtMS0yOTcyNg_f313060a-22d5-4c25-b196-9016ff4f191d"
      unitRef="usd">1781000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e80c257552240eeb8c38ce4765cb32d_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMy02LTEtMS0yOTcyNg_b2b34876-6adb-4eee-b63f-d9fb1d971639"
      unitRef="usd">2088000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icb35b47d312946dabc1007fce8107f34_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMy04LTEtMS0yOTcyNg_b780ea81-8add-48b1-83b9-cee8e24f2177"
      unitRef="number">0.147</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib15659c9d6514a6f8707334b438bf18b_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyMy0xMC0xLTEtMjk3MjY_8e2d4aa9-78b6-45ba-828f-f670c72111d2"
      unitRef="number">-0.147</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id65abc97d55744b0b397e09a73a60cb2_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNC0yLTEtMS0yOTcyNg_9235aea8-5816-4aba-ba70-69930c19190e"
      unitRef="usd">3440000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8149a55d6d9e44f08db766c017d527a4_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNC00LTEtMS0yOTcyNg_48ffa8d3-9b4b-4a37-81f9-7ef8c2aabee2"
      unitRef="usd">2994000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d3a78039e7f4b40946cc088fba95f07_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNC02LTEtMS0yOTcyNg_cff4ce10-34f1-4bec-999b-a150c89df1bf"
      unitRef="usd">3392000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id65abc97d55744b0b397e09a73a60cb2_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNC04LTEtMS0yOTcyNg_f4acc83c-127b-44b5-8c53-cf5de053b47f"
      unitRef="number">0.149</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8149a55d6d9e44f08db766c017d527a4_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNC0xMC0xLTEtMjk3MjY_d7f85a5a-88df-4114-a2ca-fbcb5b73fbcc"
      unitRef="number">-0.117</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i870d2071335a4c349e9bdf6c5dd8d221_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNi0yLTEtMS0yOTcyNg_03b0cf9e-9226-4b06-929e-26e594103303"
      unitRef="usd">459000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icfabb85d57ed4e6e887596a521298fb6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNi00LTEtMS0yOTcyNg_00de787d-b756-477d-b2ad-e83b1c54e6bb"
      unitRef="usd">344000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd907d3be6c6488b96c02cf61fe58ae2_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNi02LTEtMS0yOTcyNg_ffdd02cf-90fb-479a-ac21-d49961d47acc"
      unitRef="usd">490000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i870d2071335a4c349e9bdf6c5dd8d221_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNi04LTEtMS0yOTcyNg_6a2cdd18-4c81-42aa-ae5d-769f6eeac1ff"
      unitRef="number">0.335</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icfabb85d57ed4e6e887596a521298fb6_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNi0xMC0xLTEtMjk3MjY_08e15a84-9753-4ef4-b48e-2991180e74a5"
      unitRef="number">-0.297</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic800efd413714d9d8a60516ca5f7d6ee_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNy0yLTEtMS0yOTcyNg_0292d574-a14b-4cb3-858f-e43186e471c3"
      unitRef="usd">788000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cc24ee69c5e41af8566a1fcd0f833bc_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNy00LTEtMS0yOTcyNg_fd5afa88-6f5b-4af5-9d70-bcda5c0bf739"
      unitRef="usd">581000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2509eddc1f545e09f38e5e2b4414e6b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNy02LTEtMS0yOTcyNg_dca7653b-ef74-494b-9ee0-7907503475ed"
      unitRef="usd">742000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic800efd413714d9d8a60516ca5f7d6ee_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNy04LTEtMS0yOTcyNg_82700450-db58-44bd-9d89-859809daf7c8"
      unitRef="number">0.357</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7cc24ee69c5e41af8566a1fcd0f833bc_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyNy0xMC0xLTEtMjk3MjY_9dbe600f-4395-49c1-9a53-6cfac170d66f"
      unitRef="number">-0.217</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i028b50c377714c899ae9c599c83171a0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyOC0yLTEtMS0yOTcyNg_0d836a59-5124-4613-9e4f-94db880e6e77"
      unitRef="usd">1248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66dd731836ac479eae5b91d919a1282b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyOC00LTEtMS0yOTcyNg_a30e18c5-d624-4311-a7c4-458332cd8c94"
      unitRef="usd">925000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ef2752fd1b046dbba1e17488a65f77c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyOC02LTEtMS0yOTcyNg_a2a1c916-86dd-45a1-9809-ce8f87e7f182"
      unitRef="usd">1232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i028b50c377714c899ae9c599c83171a0_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyOC04LTEtMS0yOTcyNg_eba30d0a-f6df-467e-9ccc-9a0f9dc042c0"
      unitRef="number">0.349</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i66dd731836ac479eae5b91d919a1282b_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIyOC0xMC0xLTEtMjk3MjY_0c0c937d-ea5e-4ba3-a374-62d7b462b71a"
      unitRef="number">-0.249</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i926ba91f36ef48a68fe6266e71d6869a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMS0yLTEtMS0yOTcyNg_e80f7771-0902-42d9-8736-be2443b8fcc7"
      unitRef="usd">12686000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4e5ad3b9bd24320b4d78a6d53743649_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMS00LTEtMS0yOTcyNg_830f831e-0a36-4f53-a7dc-a160f23931a4"
      unitRef="usd">11036000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff991be03a2b4d159d3a77225971b22b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMS02LTEtMS0yOTcyNg_5c12dd2b-1f1e-482e-a5f5-9769a79306cc"
      unitRef="usd">12384000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i926ba91f36ef48a68fe6266e71d6869a_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMS04LTEtMS0yOTcyNg_f3ed1c09-1538-4be7-ade1-6c180c902a27"
      unitRef="number">0.149</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id4e5ad3b9bd24320b4d78a6d53743649_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMS0xMC0xLTEtMjk3MjY_ac2e1370-b774-4b4f-b297-8dc79e1d22ae"
      unitRef="number">-0.109</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib476ce85857e4f488b4ac69194703bb8_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMi0yLTEtMS0yOTcyNg_06d7613c-bd02-44e3-b59b-3f162f900ac3"
      unitRef="usd">14374000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf5c33d3be83417685f6d8ce5f603a71_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMi00LTEtMS0yOTcyNg_7e528cb9-4476-4b4c-98c8-7bb2cede0b57"
      unitRef="usd">11923000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6386cedfeef4e04b42dfa0d05731d11_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMi02LTEtMS0yOTcyNg_0f252c1f-ddd7-4d3d-a712-9fcb1f9752d7"
      unitRef="usd">13579000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib476ce85857e4f488b4ac69194703bb8_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMi04LTEtMS0yOTcyNg_d7b11306-ea86-4308-8946-7db4c4f3cd37"
      unitRef="number">0.206</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iaf5c33d3be83417685f6d8ce5f603a71_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMi0xMC0xLTEtMjk3MjY_56bb3a3c-b5d0-420a-967e-8e5f59f22ca6"
      unitRef="number">-0.122</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMy0yLTEtMS0yOTcyNg_c195e9a2-f51f-4a40-ad6b-a4c95640a2e1"
      unitRef="usd">27060000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86ddb5ada6e24683aa7c697889661250_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMy00LTEtMS0yOTcyNg_4deed2aa-21d8-46a5-9ad0-eb9f3b56dd06"
      unitRef="usd">22959000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41f47282388e46edaf2c190bca1a05f3_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMy02LTEtMS0yOTcyNg_56a7f796-d885-49d2-bfa9-1f1e146a346c"
      unitRef="usd">25963000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMy04LTEtMS0yOTcyNg_ccf40389-59c4-4563-a59d-05638ef816a2"
      unitRef="number">0.179</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i86ddb5ada6e24683aa7c697889661250_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzMy0xMC0xLTEtMjk3MjY_da2e99c8-2db3-487f-86e0-4215756073d8"
      unitRef="number">-0.116</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4fff9f5f7b7143e383cbb939bdf7ad11_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNi0yLTEtMS0yOTcyNg_029c5688-2b42-4ab0-bf67-be5b7da79068"
      unitRef="usd">47156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i708657b70522407092d787ab45a8beb0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNi00LTEtMS0yOTcyNg_c16671d3-d355-477e-b03c-86b34e3cf533"
      unitRef="usd">43133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5b9bb0bcfc4462ba8d103cb379d694b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNi02LTEtMS0yOTcyNg_b694490c-5e8e-4921-9233-76f354724afb"
      unitRef="usd">42097000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4fff9f5f7b7143e383cbb939bdf7ad11_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNi04LTEtMS0yOTcyNg_05f9310d-f831-4e37-b0c0-c8274e5769c6"
      unitRef="number">0.093</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i708657b70522407092d787ab45a8beb0_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNi0xMC0xLTEtMjk3MjY_39ec1aa0-054f-4566-9a09-574b544e598e"
      unitRef="number">0.025</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic23bf00a30e04ba28d25d34bb814c35e_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNy0yLTEtMS0yOTcyNg_efe9bdc9-ade3-49db-b196-2fdea39cb96b"
      unitRef="usd">46619000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65b6178ffad3411eb9697a130c03e546_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNy00LTEtMS0yOTcyNg_f987add6-fde5-4dce-8a22-0880ce4541ca"
      unitRef="usd">39451000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b4a5583c6aa48ceacfd7cb8304fe30c_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNy02LTEtMS0yOTcyNg_b3986bee-dfad-4fa0-b1f8-f47724fcef21"
      unitRef="usd">39962000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic23bf00a30e04ba28d25d34bb814c35e_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNy04LTEtMS0yOTcyNg_fdd54b8e-fcd4-45b9-802d-3ae839e6ea8d"
      unitRef="number">0.182</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i65b6178ffad3411eb9697a130c03e546_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzNy0xMC0xLTEtMjk3MjY_28648985-e7e9-4711-8546-3b20facf1110"
      unitRef="number">-0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzOC0yLTEtMS0yOTcyNg_a0f72eeb-1ded-4d3f-a5b3-9923511a8c0e"
      unitRef="usd">93775000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzOC00LTEtMS0yOTcyNg_3388bee2-c04d-4e26-9f11-68a698c4b718"
      unitRef="usd">82584000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzOC02LTEtMS0yOTcyNg_1c94192f-2fed-45e6-8469-23a02c21610f"
      unitRef="usd">82059000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzOC04LTEtMS0yOTcyNg_f044720e-3f88-4016-b12e-f927fcf5e14c"
      unitRef="number">0.136</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTpjMmFjZjZjMDNkMGU0NzA3OTY1NTA4YzY4MTcwNTlmZC90YWJsZXJhbmdlOmMyYWNmNmMwM2QwZTQ3MDc5NjU1MDhjNjgxNzA1OWZkXzIzOC0xMC0xLTEtMjk3MjY_e8287230-e17e-49e3-b070-13efb505e2d7"
      unitRef="number">0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzM0MjU_a1a92abf-e868-4c9a-986f-b3631f9cf3a5">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income (Loss) Before Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,776&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,497&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,328&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;182,018&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;174,894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions to Property,&lt;br/&gt;Plant &amp;amp; Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Depreciation and&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segments total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,652&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,347&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,390&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,231&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,009&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i07875b0557b747c1817c640f15714392_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzItMi0xLTEtMjk3MjY_200df569-31af-4b3e-aaff-f8ab775cd478"
      unitRef="usd">1294000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia502d9d60b7a47f6a866b6d2e0e7126f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzItNC0xLTEtMjk3MjY_65421e09-e151-4747-98e2-95b3dcd13532"
      unitRef="usd">-1064000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i58017869d1b24f54bed182c8572366f0_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzItNi0xLTEtMjk3MjY_d7a9b4bb-38a7-458c-a688-9d47d6abebf1"
      unitRef="usd">2061000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:Assets
      contextRef="idd9ab20dc83c431fbee3c5fe6720e9f8_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzItOC0xLTEtMjk3MjY_24783a4e-683a-4ae7-bd2b-7b94495b4f60"
      unitRef="usd">25081000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8aebbc77b14247239abf6a5e633c97fd_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzItMTAtMS0xLTI5NzI2_ce740799-905d-4a42-b127-a8e8ea291de5"
      unitRef="usd">27355000000</us-gaap:Assets>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie1c87e0aa1f746979a526054fc431766_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzMtMi0xLTEtMjk3MjY_8c1598c7-16a5-4d7c-a1f5-9bf67890cf91"
      unitRef="usd">18181000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ida08580984a943569bd4235ee5579e20_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzMtNC0xLTEtMjk3MjY_4f22944f-cccb-4694-8a60-a05813ee295b"
      unitRef="usd">15462000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i542883a564ac49d99d576a6b19e782b4_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzMtNi0xLTEtMjk3MjY_ea1fe425-e83b-473b-9095-6c1e30c2a3a6"
      unitRef="usd">8816000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:Assets
      contextRef="ib6ffed65f4a64a30906e469a8d768eb0_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzMtOC0xLTEtMjk3MjY_6ec383b0-b7c1-4869-9431-681b58e723e6"
      unitRef="usd">64376000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i1d5630eefc3e4b02942a364b65337f88_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzMtMTAtMS0xLTI5NzI2_6ded1ef9-db62-4626-af94-810502119547"
      unitRef="usd">66158000000</us-gaap:Assets>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id2ee8524f73941a28f36ded1f0ae9694_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzQtMi0xLTEtMjk3MjY_14b4fec6-3648-432a-8b86-7ca1660139cb"
      unitRef="usd">4373000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7b9faf917d1049188734075ab026d41d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzQtNC0xLTEtMjk3MjY_eca71265-4fa0-4e06-a1bb-3b0d298568f7"
      unitRef="usd">3044000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i08a55e3eca274722b79aa4b030bf30ff_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzQtNi0xLTEtMjk3MjY_731c38fc-7bee-4034-8e81-5240f9ef2997"
      unitRef="usd">7286000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:Assets
      contextRef="i9d8c1b87d69949739491c09dd1df4a3e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzQtOC0xLTEtMjk3MjY_1d7eba55-d70d-4be9-9acc-8660526870d1"
      unitRef="usd">53372000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i41d128ea214b4e15bed9dcde7d5f5996_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzQtMTAtMS0xLTI5NzI2_a1ed7b87-4843-41d7-835f-11ffec73f430"
      unitRef="usd">49578000000</us-gaap:Assets>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i84f072c0693846e9987d24a6f8158c06_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzUtMi0xLTEtMjk3MjY_4c42b44d-f8de-46ba-9f61-2f108a44c86f"
      unitRef="usd">23848000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic11d6e0c7a594cc58857314068a88853_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzUtNC0xLTEtMjk3MjY_821fdbda-f447-4474-8e90-196c7acdb0c1"
      unitRef="usd">17442000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8fc205a8aa4348dabb8157a34a1f17e6_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzUtNi0xLTEtMjk3MjY_799f9121-4109-429b-86a9-6b95f7fdb2c0"
      unitRef="usd">18163000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:Assets
      contextRef="i9c942d86e2b2405fba98d51d0541433d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzUtOC0xLTEtMjk3MjY_2774bcf0-571e-48d2-b26b-b095347e4b78"
      unitRef="usd">142829000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ibff7c2542e2e46b386cc5c9b9e43ed68_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzUtMTAtMS0xLTI5NzI2_6669c6c0-e121-4b76-8845-f14227f8e0c6"
      unitRef="usd">143091000000</us-gaap:Assets>
    <jnj:ExpenseNotAllocatedToSegments
      contextRef="ie56b8a3a16e2475b9f30017cd504ca86_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzYtMi0xLTEtMjk3MjY_f7fd4fc1-9e8d-41eb-bfec-e74aace4e08c"
      unitRef="usd">1072000000</jnj:ExpenseNotAllocatedToSegments>
    <jnj:ExpenseNotAllocatedToSegments
      contextRef="i5f314714a5bd4eb3b5976682016d9f0d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzYtNC0xLTEtMjk3MjY_7bf44c52-341e-4b56-90a4-4dd5896a5638"
      unitRef="usd">945000000</jnj:ExpenseNotAllocatedToSegments>
    <jnj:ExpenseNotAllocatedToSegments
      contextRef="i9ffa3bbb13054be0b90f9be2fe0a69de_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzYtNi0xLTEtMjk3MjY_91ac8e8c-d164-4aa4-a156-1381396685a3"
      unitRef="usd">835000000</jnj:ExpenseNotAllocatedToSegments>
    <us-gaap:Assets
      contextRef="i9a4ad3308fb2433ab4bb66f0ed570ddf_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzctOC0xLTEtMjk3MjY_1fce997d-a00f-407a-87d1-b3e5239bf974"
      unitRef="usd">39189000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i161c8b4e12a84317ab8397b42ebcbd69_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzctMTAtMS0xLTI5NzI2_8b9bb670-6f48-4d34-a10f-459cea60787b"
      unitRef="usd">31803000000</us-gaap:Assets>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzgtMi0xLTEtMjk3MjY_50de66ba-e124-49bd-ab79-3941c7e3fe83"
      unitRef="usd">22776000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzgtNC0xLTEtMjk3MjY_6fc38b08-0573-4b52-93d6-4cbccbb713b4"
      unitRef="usd">16497000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzgtNi0xLTEtMjk3MjY_e22bcd9f-e9c5-487a-9192-c0fd96eb25e5"
      unitRef="usd">17328000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:Assets
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzgtOC0xLTEtMjk3MjY_be61c009-74a1-4799-918c-e475ea8aef68"
      unitRef="usd">182018000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplMzI5OWIyOGJjNGI0MWE2OWFiYzBlMjRkMTFiNzA2NC90YWJsZXJhbmdlOmUzMjk5YjI4YmM0YjQxYTY5YWJjMGUyNGQxMWI3MDY0XzgtMTAtMS0xLTI5NzI2_badcf5ce-b4ad-47a0-b89a-a00fd05c90fd"
      unitRef="usd">174894000000</us-gaap:Assets>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i07875b0557b747c1817c640f15714392_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzItMi0xLTEtMjk3MjY_5dd53a7a-7747-477f-a966-0f068761ab6c"
      unitRef="usd">331000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="ia502d9d60b7a47f6a866b6d2e0e7126f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzItNC0xLTEtMjk3MjY_a7e283ae-c30d-4f3b-b54a-cb27d707f1c1"
      unitRef="usd">248000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i58017869d1b24f54bed182c8572366f0_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzItNi0xLTEtMjk3MjY_540b36fc-b8aa-4df3-b144-c5277cfabc43"
      unitRef="usd">328000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i07875b0557b747c1817c640f15714392_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzItOC0xLTEtMjk3MjY_cc18b51f-f3d3-40c4-9b06-35d224739f19"
      unitRef="usd">759000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia502d9d60b7a47f6a866b6d2e0e7126f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzItMTAtMS0xLTI5NzI2_57f29536-b662-4267-bbf1-6e5917d021b0"
      unitRef="usd">785000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i58017869d1b24f54bed182c8572366f0_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzItMTItMS0xLTI5NzI2_70798105-cd0f-486f-9063-55e974051248"
      unitRef="usd">765000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="ie1c87e0aa1f746979a526054fc431766_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzMtMi0xLTEtMjk3MjY_f06bef64-cb93-4f3a-9f05-49b68acc618b"
      unitRef="usd">1198000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="ida08580984a943569bd4235ee5579e20_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzMtNC0xLTEtMjk3MjY_660bdd19-ca7f-4589-bcc7-00c079bd624e"
      unitRef="usd">863000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i542883a564ac49d99d576a6b19e782b4_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzMtNi0xLTEtMjk3MjY_b343d347-24ce-4d9a-aa6d-21a44e3ed864"
      unitRef="usd">950000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie1c87e0aa1f746979a526054fc431766_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzMtOC0xLTEtMjk3MjY_81db2060-e1cc-407d-86eb-4776fb5b7259"
      unitRef="usd">4029000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ida08580984a943569bd4235ee5579e20_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzMtMTAtMS0xLTI5NzI2_0d5dd57a-c6b6-4861-b063-9457d1c92616"
      unitRef="usd">4006000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i542883a564ac49d99d576a6b19e782b4_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzMtMTItMS0xLTI5NzI2_15d6118e-536e-49d2-a871-5e318fdd3c34"
      unitRef="usd">3910000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="id2ee8524f73941a28f36ded1f0ae9694_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzQtMi0xLTEtMjk3MjY_6fdef2be-7da5-47ad-b19e-b768c3d04b5d"
      unitRef="usd">1933000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i7b9faf917d1049188734075ab026d41d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzQtNC0xLTEtMjk3MjY_41682cb7-7614-4069-accf-aceb2cc8e85b"
      unitRef="usd">1980000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i08a55e3eca274722b79aa4b030bf30ff_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzQtNi0xLTEtMjk3MjY_c4b13fc4-ce3d-4338-8fdb-434b14ed794a"
      unitRef="usd">1912000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id2ee8524f73941a28f36ded1f0ae9694_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzQtOC0xLTEtMjk3MjY_eaf2f7cc-21b3-449a-8155-e050ab120cda"
      unitRef="usd">2286000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7b9faf917d1049188734075ab026d41d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzQtMTAtMS0xLTI5NzI2_022dd515-9df6-4ec4-9721-f83209e0d1a2"
      unitRef="usd">2140000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i08a55e3eca274722b79aa4b030bf30ff_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzQtMTItMS0xLTI5NzI2_ff23bf2a-c76a-439a-9930-a059483141cc"
      unitRef="usd">2014000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="icf6748ed9caa4723bfd8c2a5895eb586_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzUtMi0xLTEtMjk3MjY_9b749ae5-3fe0-40de-a916-ad28b8642462"
      unitRef="usd">3462000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="ib5d16014da004533a78f87eb30d1bbdb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzUtNC0xLTEtMjk3MjY_2b8805d0-ee0a-467f-9ef7-6ad92d228419"
      unitRef="usd">3091000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="ifd6a6522853c4fd39a5c2f6393777cda_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzUtNi0xLTEtMjk3MjY_00f5b399-4931-40a5-882b-53fcf6d863b9"
      unitRef="usd">3190000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="icf6748ed9caa4723bfd8c2a5895eb586_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzUtOC0xLTEtMjk3MjY_75bffa85-34e3-47cf-94d7-58e4108006ba"
      unitRef="usd">7074000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib5d16014da004533a78f87eb30d1bbdb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzUtMTAtMS0xLTI5NzI2_431b4ecc-3e78-4900-bcd2-3162f9b223d6"
      unitRef="usd">6931000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifd6a6522853c4fd39a5c2f6393777cda_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzUtMTItMS0xLTI5NzI2_99057a43-9850-459f-bee0-2b66bf103cc4"
      unitRef="usd">6689000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="icfec35f176a949e19fc22a208824eaf9_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzYtMi0xLTEtMjk3MjY_718c967c-5c63-4d1d-8857-45f64d87106e"
      unitRef="usd">190000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i43234b4b84a444a9add41d11cc2a72e9_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzYtNC0xLTEtMjk3MjY_3edbf2ca-2137-4182-abeb-23929a5f128b"
      unitRef="usd">256000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i89612e90f2314e95be21fae3c19c58e6_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzYtNi0xLTEtMjk3MjY_c810716e-e546-44c6-872c-beef9fbb3667"
      unitRef="usd">308000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="icfec35f176a949e19fc22a208824eaf9_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzYtOC0xLTEtMjk3MjY_a96f38f9-e72a-4aee-a851-c56cbad04092"
      unitRef="usd">316000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i43234b4b84a444a9add41d11cc2a72e9_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzYtMTAtMS0xLTI5NzI2_180e5976-613d-4d4f-adce-2fc0ee1e6e75"
      unitRef="usd">300000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i89612e90f2314e95be21fae3c19c58e6_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzYtMTItMS0xLTI5NzI2_cf656c5d-4342-4b1f-b8b9-6c15c65b27ca"
      unitRef="usd">320000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzctMi0xLTEtMjk3MjY_a94037ee-d108-47cf-8a5f-caea67dcc72e"
      unitRef="usd">3652000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzctNC0xLTEtMjk3MjY_fde45f1b-9766-4753-bd3f-4e5b7182e08b"
      unitRef="usd">3347000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzctNi0xLTEtMjk3MjY_f39bba5b-f6a5-449a-9bfd-ade6bcbb6d36"
      unitRef="usd">3498000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzctOC0xLTEtMjk3MjY_ad192cde-259c-4405-b4af-a96f51cb5d0b"
      unitRef="usd">7390000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzctMTAtMS0xLTI5NzI2_fe3ac21e-a6de-4132-857e-584bb61e3fb6"
      unitRef="usd">7231000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTo0ZDI4NmFkMDZhZjg0ZWJiODhiZDczZTAxZWQyNDM4YS90YWJsZXJhbmdlOjRkMjg2YWQwNmFmODRlYmI4OGJkNzNlMDFlZDI0MzhhXzctMTItMS0xLTI5NzI2_76d8b7e3-4494-484a-800e-4d1b07bb0b31"
      unitRef="usd">7009000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzM0Mjc_e2705d41-9d9e-46cb-85e2-c10bef5edd4f">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-Lived Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Western Hemisphere excluding U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segments total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;93,775&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;82,584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;82,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;182,018&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;174,894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note&#160;1 for a description of the segments in which the Company operates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Export sales are not significant. In fiscal year 2021, the Company utilized three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0% and 11.0% of the total consolidated revenues. In fiscal year 2020, the Company had three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0% and 12.0% of the total consolidated revenues. In fiscal year 2019, the Company had three wholesalers distributing products for all three segments that represented approximately 15.0%, 12.0%, and 11.0% of the total consolidated revenues. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;General corporate includes cash, cash equivalents and marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $1.6&#160;billion, primarily talc related reserves&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.6&#160;billion, primarily related to Risperdal &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Divestiture gains of $0.6&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Gains on securities of $0.5&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.1&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Devices includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An in-process research and development expense of $0.9&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A Medical Device Regulation charge of $0.2&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.1&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;        &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $3.9&#160;billion, primarily talc related reserves and certain settlements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.8&#160;billion, primarily related to the agreement in principle to settle opioid litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An unrealized gain on securities of $0.5&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Devices includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A contingent consideration reversal of $1.1&#160;billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An in-process research and development expense of $0.2&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A Medical Device Regulation charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.4 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.1 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;    Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $4.3 billion of which $4.0 billion is related to the agreement in principle to settle opioid litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An in-process research and development expense of $0.9 billion related to the Alios asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A research and development expense of $0.3 billion for an upfront payment related to argenx &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An unrealized gain on securities of $0.6 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Actelion acquisition and integration related costs of $0.2 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring charge of $0.1 billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;    Medical Devices includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A gain of $2.0 billion from the divestiture of the ASP business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.4 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.4 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Auris Health acquisition and integration related costs of $0.1 billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Long-lived assets include property, plant and equipment, net for fiscal years 2021, and 2020 of $18,962 and $18,766, respectively, and intangible assets and goodwill, net for fiscal years 2021 and 2020 of $81,638 and $89,795, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5dde3b1fc1c140b7b975e1257746af2a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzItMi0xLTEtMjk3MjY_f5ce6d9e-a939-4cd7-b95a-77cfda1784fb"
      unitRef="usd">47156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie55616146f624252916d67d0fb6270a3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzItNC0xLTEtMjk3MjY_6708344d-c631-4e5a-b11d-a8b77da3077f"
      unitRef="usd">43133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1329742ce6594bfc9eddf10d9e6e6d1b_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzItNi0xLTEtMjk3MjY_619b8fdf-fffc-4390-afbe-9acd2e37cf57"
      unitRef="usd">42097000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets
      contextRef="ic66ee5c432fb43989fab14ab0949bd32_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzItOC0xLTEtMjk3MjY_291ed013-282a-4c79-bde3-02b0a3310470"
      unitRef="usd">48586000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ie0eaa56b37ca45d6be7c0ae8cc029a05_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzItMTAtMS0xLTI5NzI2_ee73fb59-1c84-42e1-88bf-5b9c42985077"
      unitRef="usd">49951000000</us-gaap:NoncurrentAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12c344a819924cb3abc49e0e78326cb5_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzMtMi0xLTEtMjk3MjY_5ba47c64-ae2f-4e7b-9ca8-1993000f40aa"
      unitRef="usd">23594000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86027318c21946418cf4bac6b9766a4a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzMtNC0xLTEtMjk3MjY_217a24ff-1087-4ebd-a78e-e7913bb0d527"
      unitRef="usd">18980000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if180dfc034c94229b3b69b27873c5523_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzMtNi0xLTEtMjk3MjY_00503af0-b517-480d-a053-0d58f985f3d0"
      unitRef="usd">18466000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets
      contextRef="id6d295d1a9e8463fae253f66cb1dd8c9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzMtOC0xLTEtMjk3MjY_ce0cfa68-631d-48db-b4b8-20a74f8dfd80"
      unitRef="usd">43257000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ib2d14c5a6d394ef9a183cc124fa5a80a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzMtMTAtMS0xLTI5NzI2_e038b2a4-3b8f-481e-84d3-df1277663c04"
      unitRef="usd">49363000000</us-gaap:NoncurrentAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9002b75b28cf45caa22c4976168c7b62_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzQtMi0xLTEtMjk3MjY_d4eff0cc-865a-4cc5-9647-8388fbf2e767"
      unitRef="usd">5750000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i192b54c044b440f48ee211083347803e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzQtNC0xLTEtMjk3MjY_c1f0b6d5-207b-4865-ba30-ec9af6f09371"
      unitRef="usd">5335000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4eab92d733042da922500164d7a49b1_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzQtNi0xLTEtMjk3MjY_5e3712b0-3d26-492b-b0fa-dd7b1b5b2dd9"
      unitRef="usd">5941000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets
      contextRef="ia624c75d38284ec6a2ec845b2560bce2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzQtOC0xLTEtMjk3MjY_4be6bfb3-cc7c-4298-b021-32a6fad04605"
      unitRef="usd">2708000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i2be65f500ff545279a1db64b6247c724_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzQtMTAtMS0xLTI5NzI2_a62bd078-9c1c-46e1-a0e7-f290113aece3"
      unitRef="usd">2734000000</us-gaap:NoncurrentAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8f488e3ce82400e9d20999f51bfd957_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzUtMi0xLTEtMjk3MjY_5ae7dd7f-4b4a-4894-8fe2-634c10d32ce5"
      unitRef="usd">17275000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i684ab47875044db597f5dfe5c54f245d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzUtNC0xLTEtMjk3MjY_e96fd8e3-3d26-4818-a256-66fe6e6111ff"
      unitRef="usd">15136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibffd9ab5bd7e43d2bdabc0050f445bbc_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzUtNi0xLTEtMjk3MjY_980d021b-5612-466e-a326-17f19492fe45"
      unitRef="usd">15555000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets
      contextRef="i53bf7c2112b84b558b199f49dd38db16_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzUtOC0xLTEtMjk3MjY_09827880-42f9-406f-9ece-f25924d2f588"
      unitRef="usd">5035000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ie0df24236c7145dea99c2071261ac7b9_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzUtMTAtMS0xLTI5NzI2_4fe4f584-41ca-4f4f-b895-a9e33d661762"
      unitRef="usd">5484000000</us-gaap:NoncurrentAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84f072c0693846e9987d24a6f8158c06_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzYtMi0xLTEtMjk3MjY_e7ad530b-f528-4352-9211-7f2f6fde94c2"
      unitRef="usd">93775000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic11d6e0c7a594cc58857314068a88853_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzYtNC0xLTEtMjk3MjY_f4afd3e3-a71b-423b-97f4-faeb79754db2"
      unitRef="usd">82584000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fc205a8aa4348dabb8157a34a1f17e6_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzYtNi0xLTEtMjk3MjY_608e6b07-b1ba-49e5-9b0d-c1d99d7e3cd7"
      unitRef="usd">82059000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets
      contextRef="i5cdc558e3419463e9447cf921a59d40e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzYtOC0xLTEtMjk3MjY_bc3d248e-dd81-4f88-ab36-a896d97e7dee"
      unitRef="usd">99586000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ie7b52918f61f47df92b761c6d628e9dd_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzYtMTAtMS0xLTI5NzI2_c2b848d4-1a4c-4c49-80d4-0bccdc565891"
      unitRef="usd">107532000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i9a4ad3308fb2433ab4bb66f0ed570ddf_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzctOC0xLTEtMjk3MjY_603f99aa-24e1-485e-a0a8-8be2ea89a6d1"
      unitRef="usd">1014000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i161c8b4e12a84317ab8397b42ebcbd69_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzctMTAtMS0xLTI5NzI2_6921ffb8-d61e-4c47-ae82-4bb01762ed20"
      unitRef="usd">1029000000</us-gaap:NoncurrentAssets>
    <jnj:OtherNonLongLivedAssets
      contextRef="i4b4e08a0ee17422a8c214d277d942d69_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzgtOC0xLTEtMjk3MjY_c9b0d8c9-c1b6-42b1-bb87-20d1e6911a7b"
      unitRef="usd">81418000000</jnj:OtherNonLongLivedAssets>
    <jnj:OtherNonLongLivedAssets
      contextRef="i91c7274c6de64cad9ae9f5f8d47e3a03_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzgtMTAtMS0xLTI5NzI2_1a6cfb78-605a-4d2c-9634-cb4c66c116da"
      unitRef="usd">66333000000</jnj:OtherNonLongLivedAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzktMi0xLTEtMjk3MjY_bb538a78-085f-4e29-b956-e293771a178f"
      unitRef="usd">93775000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzktNC0xLTEtMjk3MjY_588bbb49-4342-4a26-affb-7a7955067f49"
      unitRef="usd">82584000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzktNi0xLTEtMjk3MjY_fea7a282-7878-40dc-a939-cb08c7b0b748"
      unitRef="usd">82059000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Assets
      contextRef="ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzktOC0xLTEtMjk3MjY_0efe0fe7-af82-46ac-9083-a88cd109f8ea"
      unitRef="usd">182018000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90YWJsZTplYzJhOTk0Nzg4M2Q0OGUxOTc4MmFiOTU0ZjQ3ZDEyNy90YWJsZXJhbmdlOmVjMmE5OTQ3ODgzZDQ4ZTE5NzgyYWI5NTRmNDdkMTI3XzktMTAtMS0xLTI5NzI2_a8342e1d-1de1-4781-b468-9c799a2b2f02"
      unitRef="usd">174894000000</us-gaap:Assets>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzQ0NQ_e93ab160-cc72-46c2-9c82-c81858431e26"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8caaafd1850845b59365f8e185f8173c_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzQ4OA_078f88b2-2061-45fa-a1e4-312b71a5dfa1"
      unitRef="number">0.140</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id3b5a13cbe6b4786982dea5ebe78b704_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzQ5Mg_16fb4dde-c678-4482-b121-88d030fd0329"
      unitRef="number">0.110</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if99789229d014c78a17d5f4a81bbfa36_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzQ5OQ_23ac3ec2-af68-4918-b818-174a8c568998"
      unitRef="number">0.110</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzYyMQ_e93ab160-cc72-46c2-9c82-c81858431e26"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i30ec518ef4e84aff82c8baa7363b31de_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzY2NA_bac8c584-ba78-4276-9d1d-ae0c2a700c01"
      unitRef="number">0.160</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibe41c007f8e74211896f3015a2132bd1_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzY2OA_11eebcf6-8d5c-4ffc-b497-7478b51a3176"
      unitRef="number">0.120</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i25b4bc0c83d64827aac46f72ea370c2b_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzY3NQ_828fde59-832d-4d7b-9a21-9d69d92d6c5c"
      unitRef="number">0.120</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0Xzc5Nw_e46ca588-3660-42f6-a9fb-fbef5ff4f7ce"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i59011837e8e74865818d7c6e22573da3_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0Xzg0MA_2b4d4d59-cea6-4812-867f-efc7e9ef9a5a"
      unitRef="number">0.150</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i84ff03e41df948aea3483799d1cbea10_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0Xzg0NA_692ea272-1d8f-45b3-8e2a-8d480fbea8ab"
      unitRef="number">0.120</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9dd8d7d4f2d84befa81f6c55d1286f96_D20181231-20191229"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0Xzg1Mg_bc10cec6-bcf4-4177-baa7-78db7899fd84"
      unitRef="number">0.110</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LitigationSettlementExpense
      contextRef="i1198f98bdb8f4597b4a10112426c5f06_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDQ5NTE_09a19424-67da-4501-8474-13fb40583edd"
      unitRef="usd">1600000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:RestructuringCharges
      contextRef="i1198f98bdb8f4597b4a10112426c5f06_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDQ5NjU_71c272f2-be24-4756-8ee3-8c86ab79cf33"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:LitigationSettlementExpense
      contextRef="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDQ5Nzk_97a25dc7-720f-440a-b2bb-3077b5896303"
      unitRef="usd">600000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDQ5OTM_00da5b21-15e7-48d1-96c7-24ddf7f1a1b5"
      unitRef="usd">600000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDUwMDc_eb35aedc-20bb-464a-b90a-f894f3b33381"
      unitRef="usd">500000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:RestructuringCharges
      contextRef="i154d9581472b4a4fa920ac4d0c95c724_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDUwMjE_91f23763-2def-4df6-b632-c43401d2b880"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDUwMzU_55919dba-3039-40f5-b1d5-089c041abda0"
      unitRef="usd">300000000</us-gaap:RestructuringCharges>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDUwNDk_809b5757-3114-4da3-abec-86c98727c287"
      unitRef="usd">900000000</us-gaap:ResearchAndDevelopmentInProcess>
    <jnj:RegulationCharge
      contextRef="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDUwNjM_48e9576d-fdf9-42b2-8f3b-49663a66c7e3"
      unitRef="usd">200000000</jnj:RegulationCharge>
    <us-gaap:LitigationSettlementExpense
      contextRef="ie16a1f6c7fb64998905543a1d7f7106a_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzU0OTc1NTgxNDUwNzc_83080604-af47-4252-b1f6-f32cf66dec7c"
      unitRef="usd">100000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="if43f753e349c40788db498a0b8a5fe34_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzExMjc_2a246e41-1d28-460e-9079-ddb2defd5016"
      unitRef="usd">3900000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="ia9f7770a07704889bef20acb8a0c5220_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzEyMzU_e6a7331f-b33c-4c95-89df-60068887964d"
      unitRef="usd">800000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ida08580984a943569bd4235ee5579e20_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzEzNTI_0534ddf9-c9d3-4bff-9965-d00a5f19f3ed"
      unitRef="usd">500000000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:RestructuringCharges
      contextRef="ia9f7770a07704889bef20acb8a0c5220_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzEzOTA_e0b99685-c66a-4e32-a46e-5239a1cd4352"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i2b01d17f27cf45d1be57134c670e1e36_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE0NTg_46b9c8f5-0a90-4a8b-9717-6ae6242f1e07"
      unitRef="usd">-1100000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:LitigationSettlementExpense
      contextRef="i86ddb5ada6e24683aa7c697889661250_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE1ODg_c51b088c-2108-462c-bcbf-20739046c185"
      unitRef="usd">300000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:RestructuringCharges
      contextRef="i86ddb5ada6e24683aa7c697889661250_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE2MjY_6526b578-0a82-4bd9-81b6-cf102c9819a1"
      unitRef="usd">300000000</us-gaap:RestructuringCharges>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i86ddb5ada6e24683aa7c697889661250_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE2ODA_7c209f6a-fec1-4d62-8430-b83d7c580c20"
      unitRef="usd">200000000</us-gaap:ResearchAndDevelopmentInProcess>
    <jnj:RegulationCharge
      contextRef="i86ddb5ada6e24683aa7c697889661250_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE3MjI_eed0b33f-dd1b-416b-bc8e-2d5e936d379c"
      unitRef="usd">100000000</jnj:RegulationCharge>
    <us-gaap:GainLossOnSaleOfEquityInvestments
      contextRef="ibc662de37ec34428972835cc3abf9da7_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE3NjU_e081bf23-36bf-4d3e-adfa-c7dcc0aae434"
      unitRef="usd">300000000</us-gaap:GainLossOnSaleOfEquityInvestments>
    <us-gaap:LitigationSettlementExpense
      contextRef="ib63ccacb9faa4b73878a9057b0fd6b30_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE4NjQ_0a63694c-f4c8-422a-a1ed-0d2e66641127"
      unitRef="usd">400000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:RestructuringCharges
      contextRef="ib63ccacb9faa4b73878a9057b0fd6b30_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE5MDI_3ce290bc-d780-4a8a-932c-02e9329f473d"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:LitigationSettlementExpense
      contextRef="ib2cf37c66bfb4ef5bce478f5333fb5df_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE5NTM_58cf8318-b429-416e-9202-8ee71184fd99"
      unitRef="usd">4300000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i7f6076db24f64e8b8d695cf2700ed061_I20191031"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzE5NjU_122c3a6f-56c9-47d9-ab11-13a2aa8d55a9"
      unitRef="usd">4000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ib2cf37c66bfb4ef5bce478f5333fb5df_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzIwODc_56690ea6-fbe9-4e7d-a232-17a1104ac06d"
      unitRef="usd">900000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib2cf37c66bfb4ef5bce478f5333fb5df_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzIxNTU_230424f3-c67c-48e0-b274-c6c34d64c67f"
      unitRef="usd">300000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i542883a564ac49d99d576a6b19e782b4_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzIyMzY_0d1d66d2-ca43-48b6-9b49-408d07bc0749"
      unitRef="usd">600000000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i96b4301ec6a748738bcd3da3c58a855d_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzIyOTQ_63b3986a-7c29-4543-88ad-049c851665e5"
      unitRef="usd">200000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:RestructuringCharges
      contextRef="ib2cf37c66bfb4ef5bce478f5333fb5df_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzIzMjQ_d13a03ea-16f7-433a-9b51-f5d2bdb0c87c"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i74b5f6e37afe4a4db8b8e7f9fdd0b2ef_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzIzNjM_bdcce145-9d78-4b3f-b166-4fa3e9cc30c9"
      unitRef="usd">2000000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:RestructuringCharges
      contextRef="i41f47282388e46edaf2c190bca1a05f3_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzI0NDE_34975f1b-c4fd-4404-a4be-0e7fa204fbfe"
      unitRef="usd">400000000</us-gaap:RestructuringCharges>
    <us-gaap:LitigationSettlementExpense
      contextRef="i41f47282388e46edaf2c190bca1a05f3_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzI0Njc_3914d19c-a943-42f8-9138-d7d679fb35f3"
      unitRef="usd">400000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i5dcfe72e83d94e7f84475a87d6457756_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzI1Mjk_862d8308-4684-4342-a9cd-2a847776fa1a"
      unitRef="usd">100000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:NoncurrentAssets
      contextRef="i6ff6ac9a46e741ebb0af1c793cb24164_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzMyODg_50e0a8e0-5af8-4f86-8c3f-539e0cfce28d"
      unitRef="usd">18962000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="iad866650cbf4417d988e0b72205283fc_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzMyOTU_a921da6c-5812-4451-9381-f16f6541e3d0"
      unitRef="usd">18766000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="iab994f6e28264437bf740f3cb576b596_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzMzODM_4ec916e2-23ab-4eff-ac7a-fa476a9ca203"
      unitRef="usd">81638000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i7c5552cc49964c378bbb9b282742a62d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTEvZnJhZzo2YzhlMmQ1ZWI0ZWM0MjlhOGFlMGZjM2VjOWFmOGE0NC90ZXh0cmVnaW9uOjZjOGUyZDVlYjRlYzQyOWE4YWUwZmMzZWM5YWY4YTQ0XzMzOTA_6958e8fd-7793-4134-9425-532f8a7ebc22"
      unitRef="usd">89795000000</us-gaap:NoncurrentAssets>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEwNjAx_9acc3303-b5f9-4b6b-8b2f-37909a830e7b">Acquisitions and Divestitures&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During fiscal year 2021, the Company did not make any material acquisitions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During fiscal year 2020, certain businesses were acquired for $7.3&#160;billion in cash and $0.4&#160;billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $7.5&#160;billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fiscal year 2020 acquisitions primarily included: all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc. (XBiotech), Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases and the outstanding shares in Verb Surgical Inc., a company with significant  robotics and data science capabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $0.8&#160;billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;amp;D, for $0.8&#160;billion applying a probability of success factor that ranged from 20% to  60% to reflect inherent development, regulatory and commercial risk for the different indications. The discount rate applied was approximately 16%.  XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. On January 28, 2022, subsequent to the fiscal year 2021, additional information regarding efficacy became available which led the Company to the decision to terminate the development of bermekimab for Atopic Dermatitis (AD). The Company recorded an intangible asset impairment charge of approximately $0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of AD and Hidradenitis Suppurativa (HS). The impairment charge is related to the AD indication and is a nonrecognized subsequent event and will be reflected in the first quarter 2022 financial statements. The Company acquired all rights to bermekimab from XBiotech, Inc. in fiscal year 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, in the fiscal first quarter of 2020, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with significant robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the Medical Devices segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;amp;D, for $0.4&#160;billion, goodwill for $0.2&#160;billion, other assets of $0.2&#160;billion and liabilities assumed of $0.3&#160;billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $0.4&#160;billion. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On October 1, 2020, the Company completed the acquisition of Momenta for a purchase price of approximately $6.1&#160;billion, net of cash acquired. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets (IPR&amp;amp;D) of $6.0&#160;billion, goodwill of $1.2&#160;billion, other assets of $0.5&#160;billion and liabilities of $1.6&#160;billion. The assets acquired are intended to address substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Depending on the asset, probability of success factors ranging from 20% to 77% were used in the fair value calculation to reflect inherent development and regulatory risk of the IPR&amp;amp;D. The discount rate applied was approximately 13%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. The transaction was accounted for as a business combination and included in the Pharmaceutical segment.                   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal year 2019 certain businesses were acquired for $5.8 billion in cash and $1.4 billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $6.8&#160;billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fiscal year 2019 acquisitions primarily included DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products and Auris Health, Inc. a &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;privately held developer of robotic technologies, initially focused in lung cancer, with an U.S. FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 17, 2019, the Company acquired DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products for a total purchase price of approximately &#xa5;230 billion, which equates to approximately $2.1 billion, using the exchange rate of 109.06 Japanese Yen to each U.S. Dollar on January 16, 2019. Additionally, in the fiscal first quarter of 2019, the Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company treated this transaction as a business combination and included it in the Consumer Health segment.  During the fiscal first quarter of 2020, the Company finalized the purchase price allocation. The final fair value of the acquisition was allocated primarily to amortizable intangible assets for $1.5 billion, goodwill for $1.2 billion and liabilities of $0.4 billion. The amortizable intangible assets were comprised of brand/trademarks and customer relationships with a weighted average life of 15.3 years. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On April 1, 2019 the Company&#160;completed the acquisition of Auris Health, Inc. for approximately $3.4 billion, net of cash acquired. Additional contingent payments of up to $2.35 billion, in the aggregate, may be payable upon reaching certain predetermined milestones. Auris Health was a privately held developer of robotic technologies, initially focused in lung cancer, with a U.S. FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. The Company treated this transaction as a business combination and included it in the Medical Devices segment. The fair value of the acquisition was allocated primarily to amortizable and non-amortizable intangible assets, primarily IPR&amp;amp;D for $3.0 billion, goodwill for $2.0 billion, marketable securities of $0.2 billion and liabilities assumed of $1.8 billion, which includes the fair value of the contingent payments mentioned above. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. During the fiscal second quarter of 2020, the Company finalized the purchase price allocation. During fiscal 2020, the Company recorded Other income of approximately $1.1&#160;billion for the reversal of all of the contingent consideration related to the timing of certain developmental and commercial milestones, which are not expected to be met based on the Company&#x2019;s current timelines. During the fiscal third quarter of 2020, the Company recorded a partial IPR&amp;amp;D impairment charge of $0.1&#160;billion related to timing and progression of the digital surgery platforms. In the fiscal third quarter of 2021, the Company recorded a partial IPR&amp;amp;D charge of $0.9&#160;billion primarily related to expected development delays in the general surgery digital robotics platform (Ottava). A probability of success factor ranging from 18% to 66% across Ottava sub-platforms, was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&amp;amp;D. The discount rate applied was approximately 9.5%.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In accordance with U.S.&#160;GAAP standards related to business combinations, and goodwill and other intangible assets, supplemental pro forma information for fiscal years 2021, 2020 and 2019 is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company&#x2019;s results of operations, cash flows or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Divestitures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During fiscal year 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately  $0.6&#160;billion. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal year 2020, the Company sold 11.8&#160;million shares of Idorsia LTD (Idorsia), or its 8.3% ownership in the company at that time. The transaction resulted in gross proceeds of approximately CHF 337&#160;million ($357&#160;million) based on a sales price of CHF 28.55/share and resulted in an immaterial net loss. At the end of fiscal 2020, the Company had rights to approximately 38.7&#160;million shares through a convertible loan with a principal amount of CHF 445&#160;million (due June 2027). During fiscal year 2021, the Company converted CHF 110&#160;million ($120&#160;million) of this loan into approximately 9.6&#160;million shares of Idorsia which were reflected at fair value as of January 2, 2022. During the fiscal third quarter of 2021, the Company's undrawn credit facility with Idorsia was terminated. &lt;/span&gt;&lt;/div&gt;During fiscal year 2019, the Company divested its ASP business to Fortive Corporation for an aggregate value of approximately $2.8 billion, consisting of $2.7 billion of cash proceeds and $0.1 billion of retained net receivables. The Company recognized a pre-tax gain recorded in Other ( income) expense, net, of approximately $2.0 billion.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzc1_d7e20394-a1e4-4e4f-b774-555446e070cc"
      unitRef="usd">7300000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i2291de62b68a41a0b629948bd1c56c1c_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzkw_ac874c07-2e1b-485a-ae34-796cfcf74640"
      unitRef="usd">400000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i6c4338357956452382a3b4130bcd7e7e_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzQzOA_714825ad-0369-4cc9-9ea1-798430b853fa"
      unitRef="usd">7500000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="id0305d06bfd34bdfb74072845ac023d4_D20191230-20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEyNTQ_d763ccc3-f389-4451-9d34-cc98e1a79ff3"
      unitRef="usd">800000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ic56891ab2cd6480ba37ea1ceb033b908_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEzNzU_9e2796d2-5bb3-41a9-bb06-d8d7b3881a08"
      unitRef="usd">800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="if085f95b01a24cb5b37a6f4a5c06c613_I20200329"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzE0MzY_ea54440e-cb85-4d1b-bb9f-bd7a8bd12995"
      unitRef="number">0.20</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="i652360a76ef04b59bdc669400214e356_I20200329"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzE0NDM_39444ff5-1266-4032-be48-139493888e06"
      unitRef="number">0.60</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessAcquisitionDiscountRate
      contextRef="ic56891ab2cd6480ba37ea1ceb033b908_I20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzE1ODU_f6b91629-f85e-4cb9-9268-ef65910b7df0"
      unitRef="number">0.16</jnj:BusinessAcquisitionDiscountRate>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="iab3ebcc4c2ae4fe293b17a266c45d8fb_D20220128-20220128"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEwOTk1MTE2NDc0Mzc_c2c0dcaf-ff98-43c8-99f5-e9cfb98fa434"
      unitRef="usd">600000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ie4dfe20935d14ee3bdc74b4b396d04be_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzIyOTA_c767ea10-183e-466d-90ea-75193c0e0f61"
      unitRef="usd">400000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="ie4dfe20935d14ee3bdc74b4b396d04be_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzIzMDc_30b46716-4338-4576-8454-ec5e33525235"
      unitRef="usd">200000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="ie4dfe20935d14ee3bdc74b4b396d04be_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzIzMjc_b599792d-dfc1-4dcb-a51e-78501dbc47db"
      unitRef="usd">200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="ie4dfe20935d14ee3bdc74b4b396d04be_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzIzNTc_3f1672ba-0970-48e5-9b3d-c73fb01657b0"
      unitRef="usd">300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="ie4dfe20935d14ee3bdc74b4b396d04be_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzI0NTM_bf6a3662-dc43-4f81-8f98-ae19b2d50f70"
      unitRef="usd">400000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i38342c75b72a472b9fd00cc1e1df9f64_D20201001-20201001"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzI1NjU_d0549a27-1ad7-4e0d-a17c-7c421190351d"
      unitRef="usd">6100000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ic5ee7cee5c044dc895e1060a81eb1b2b_I20201001"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzI2OTc_6ca07869-17ba-4426-b826-967b70a8bc6c"
      unitRef="usd">6000000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="i3dc89baa93fd48229b56fd011dd9c983_I20201001"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzI3MTM_06745105-58a2-4e9a-a2c5-bb0cce09f98d"
      unitRef="usd">1200000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i3dc89baa93fd48229b56fd011dd9c983_I20201001"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzI3MzM_b3a957ba-f006-4217-aac7-5378e504e1fc"
      unitRef="usd">500000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i3dc89baa93fd48229b56fd011dd9c983_I20201001"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzI3NTU_0640b44c-c973-49f1-bdcf-a58d55b959ca"
      unitRef="usd">1600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="iafbc6103989b414a84c18b6479a23d0b_I20201001"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzMwMTQ_f3c849c3-0024-4b74-9e7e-adbd6efda56c"
      unitRef="number">0.20</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="i657d184bcd08449dbbd5a6d436f9a8f6_I20201001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzMwMjA_970ebab6-0944-43a8-b9cd-2ebae7bad1e5"
      unitRef="number">0.77</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessAcquisitionDiscountRate
      contextRef="i3dc89baa93fd48229b56fd011dd9c983_I20201001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzMxNzM_000e9577-9a9e-4c16-910f-f658986b50c2"
      unitRef="number">0.13</jnj:BusinessAcquisitionDiscountRate>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i1d4e143273414cecb4ad1e77ad5b2ca5_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzM1MTY_0eee7be8-7470-412b-94a9-70607078ca07"
      unitRef="usd">5800000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i62d3f67a745e40cfb7f34338a5e1abf4_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzM1MzE_ea2284b9-130c-42be-9977-5b0ad4fa72d9"
      unitRef="usd">1400000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i1c34dca13b3246238c5245124b592b5c_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzM4NTY_30c550da-1fb1-436f-9394-b83aa856002b"
      unitRef="usd">6800000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="if156d32e424b440faf1f0d3e777e112b_D20190117-20190117"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzQ2MTI_237b648a-d236-40cd-8cf1-8e76ddcb38a6"
      unitRef="jpy">230000000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="if156d32e424b440faf1f0d3e777e112b_D20190117-20190117"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzQ2NDc_4a63ce1e-4ee2-4900-b642-38582f9088d9"
      unitRef="usd">2100000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i31c41bc161bd4282b210e004dbeb91e5_I20190116"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzQ2Nzg_8cf41967-abe9-49cc-ba0c-b42d41a43d1d"
      unitRef="number">109.06</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ief3cab3c65b84702aa8c68b0beb5654a_D20181231-20190331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzQ4ODI_5a4681bc-14ee-4dfc-b596-be2b635c4d19"
      unitRef="usd">300000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ia63d28caef88416ba2d4d20a17561867_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzUyNjg_e73d7bf4-06a1-4c50-9a4f-1f36a2ebcf79"
      unitRef="usd">1500000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="ia63d28caef88416ba2d4d20a17561867_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzUyODU_49259ada-e086-4cb8-99a3-2044b3219cb4"
      unitRef="usd">1200000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="ia63d28caef88416ba2d4d20a17561867_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzUzMDc_b09c29a5-b181-445e-bf95-3c437af8995b"
      unitRef="usd">400000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i7bb9d754278d494ea4868d3a7a6440d8_D20200928-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzU0Mzk_1f7820d8-5090-46a7-a15f-66d85a5cb045">P15Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i27523630f0dc4c789b10d08289448d52_D20190401-20190401"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzU2OTI_f9841983-9abd-4f7d-96fe-1c76266d931a"
      unitRef="usd">3400000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="idf01140629ce4b44992bec25a4d0157b_I20190401"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzU3NTg_e6b62e6c-6d3b-4296-99a2-907495ef294c"
      unitRef="usd">2350000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="idf01140629ce4b44992bec25a4d0157b_I20190401"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzYyODk_4801f926-99a1-4798-b782-1a86479d0d98"
      unitRef="usd">3000000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="idf01140629ce4b44992bec25a4d0157b_I20190401"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzYzMDY_abbe65ba-6cb3-4815-8a11-e4549c610829"
      unitRef="usd">2000000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="idf01140629ce4b44992bec25a4d0157b_I20190401"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzYzMzU_b1561cd2-c9a6-47cd-b516-963f12430b21"
      unitRef="usd">200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="idf01140629ce4b44992bec25a4d0157b_I20190401"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzYzNjU_f7f3e028-4237-41a5-82df-eca8b4e96651"
      unitRef="usd">1800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4958dd807d8c42a3b81c7c535df76aae_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzY2MDk_f4515db9-60f3-4586-bdf1-85300dc3f5ff"
      unitRef="usd">1100000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i91459e999e794e2a864d95b8eb009680_D20200629-20200927"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzY5MTY_820c01c9-5c6b-4333-96e5-a0e3f96f7dcc"
      unitRef="usd">100000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i2b6fbd9b80d84153817595caadafdadd_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEwOTk1MTE2Mjk4NDE3_e7e07178-28de-4e7e-98e2-e9d1706c1c0b"
      unitRef="usd">900000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="if9f9f41fdfe94421ada2b29f1eda2e7d_I20190401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzcwMzI_b98015c1-bc7f-42d1-b513-9f9216a596b3"
      unitRef="number">0.18</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="ic68faf24908f44f48cafea31ccd53622_I20190401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzcwMzg_f4294bb8-ee94-49a0-a849-220f38a7d037"
      unitRef="number">0.66</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessAcquisitionDiscountRate
      contextRef="idf01140629ce4b44992bec25a4d0157b_I20190401"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzcyMTM_dcbb2424-7c35-4026-a32b-4a492b3e5863"
      unitRef="number">0.095</jnj:BusinessAcquisitionDiscountRate>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="ie12611a8a0b5457b8429c851c4a1acb1_D20210104-20220102"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzg0Mjg_b6e9c6de-0f34-45f7-9889-0249595da999"
      unitRef="usd">600000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i12d629a6349442e1bcd3b89fd1744c17_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzg1NTc_35b26396-a576-4917-b21e-1de0b7c9a1a3"
      unitRef="shares">11800000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction
      contextRef="i12d629a6349442e1bcd3b89fd1744c17_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzg2MDA_34bec073-2a6d-4d0b-bfe4-3daea2b867fa"
      unitRef="number">0.083</us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction>
    <us-gaap:ProceedsFromSaleOfInterestInCorporateUnit
      contextRef="i12d629a6349442e1bcd3b89fd1744c17_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzg2OTM_91711bd2-7343-4ba3-a54f-9844d7864e97"
      unitRef="chf">337000000</us-gaap:ProceedsFromSaleOfInterestInCorporateUnit>
    <us-gaap:ProceedsFromSaleOfInterestInCorporateUnit
      contextRef="i12d629a6349442e1bcd3b89fd1744c17_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzg2OTc_756e5d54-1b1f-4977-86a1-91883502a6f0"
      unitRef="usd">357000000</us-gaap:ProceedsFromSaleOfInterestInCorporateUnit>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i0028bc7fe5bc4af89fae762f116f5492_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzg3MzE_45326c88-1a80-4926-a40f-d97da8adc493"
      unitRef="usdPerShare">28.55</us-gaap:SaleOfStockPricePerShare>
    <jnj:ConvertibleNoteEquityInterestNumberOfShares
      contextRef="i12d629a6349442e1bcd3b89fd1744c17_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEwOTk1MTE2Mjk4NDMx_8e7ab85f-3c2d-4da6-99e5-7c7a36a9482d"
      unitRef="shares">38700000</jnj:ConvertibleNoteEquityInterestNumberOfShares>
    <us-gaap:LongTermDebt
      contextRef="i96cb437b61cd4edc8359b3f5f09fa26c_I20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEwOTk1MTE2Mjk4NDQ1_70af0d0d-96a6-46a8-a4b3-601e3cd68da4"
      unitRef="chf">445000000</us-gaap:LongTermDebt>
    <jnj:DebtInstrumentConvertibleAmountOfLoanConverted
      contextRef="i9fed2deb8c9147eb8ff44239290a9c54_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEwOTk1MTE2Mjk4NDcx_73b6728f-3b97-43df-acad-70ea660fb7be"
      unitRef="chf">110000000</jnj:DebtInstrumentConvertibleAmountOfLoanConverted>
    <jnj:DebtInstrumentConvertibleAmountOfLoanConverted
      contextRef="i9fed2deb8c9147eb8ff44239290a9c54_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEwOTk1MTE2Mjk4NDg0_9b40f039-5867-47cb-93cf-cc0f93f6cda2"
      unitRef="usd">120000000</jnj:DebtInstrumentConvertibleAmountOfLoanConverted>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="i9fed2deb8c9147eb8ff44239290a9c54_D20210104-20220102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzEwOTk1MTE2Mjk4NDU4_0e373eaa-5122-4e2e-bd3b-3e6a03e8bfff"
      unitRef="shares">9600000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="i1c2687a93cd147aa9d8a4fba7100335e_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzkyNTE_a3ac1e7c-d488-4fbf-a6ac-ca6f14fa6bfd"
      unitRef="usd">2800000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCash
      contextRef="i1c2687a93cd147aa9d8a4fba7100335e_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzkyNjk_33bbc1ce-83b9-4c9b-813e-f3c691b3d663"
      unitRef="usd">2700000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCash>
    <jnj:DisposalGroupIncludingDiscontinuedOperationReceivablesRetained
      contextRef="i1c2687a93cd147aa9d8a4fba7100335e_I20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzkyOTM_6486eff0-4d9a-46b1-8f41-b63be9e07231"
      unitRef="usd">100000000</jnj:DisposalGroupIncludingDiscontinuedOperationReceivablesRetained>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i5fb558e71971413fb73765983f5dcf7c_D20181231-20191229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTQvZnJhZzpmZmVjY2U2NzgxNzM0MDU3OGI2YmE0ODE0ZDI3Y2JjMy90ZXh0cmVnaW9uOmZmZWNjZTY3ODE3MzQwNTc4YjZiYTQ4MTRkMjdjYmMzXzk0MjI_8478910b-68a1-452e-b16b-6e125e59cf7a"
      unitRef="usd">2000000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2Xzg4NDI3_9151385d-7683-44f4-9516-9c0f94f4bf76">Legal ProceedingsJohnson &amp;amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. Due to the ongoing impacts of the COVID-19 pandemic, certain trials have been rescheduled or delayed. The Company continues to monitor its legal proceedings as the situation evolves and in person trials resume.&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of January&#160;2, 2022, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the Company&#x2019;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#x2019;s balance sheet, is not expected to have a material adverse effect on the Company&#x2019;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#x2019;s results of operations and cash flows for that period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;PRODUCT LIABILITY&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The most significant of these cases include: the DePuy ASR&#x2122; XL Acetabular System and DePuy ASR&#x2122; Hip Resurfacing System; the PINNACLE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Acetabular Cup System; pelvic meshes; RISPERDAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;; XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;; body powders containing talc, primarily JOHNSON'S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Baby Powder; INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;; and ETHICON PHYSIOMESH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Flexible Composite Mesh. As of January&#160;2, 2022, in the United States there were approximately 250 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR&#x2122; XL Acetabular System and DePuy ASR&#x2122; Hip Resurfacing System; 5,300 with respect to the PINNACLE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Acetabular Cup System; 10,100 with respect to pelvic meshes; 8,800 with respect to RISPERDAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;; 5,500 with respect to XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;; 40,400 with respect to body powders containing talc; 100 with respect to INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and 4,700 with respect to ETHICON PHYSIOMESH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Flexible Composite Mesh. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; XL Acetabular System and DePuy ASR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp;amp; Johnson. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000  claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle &lt;/span&gt;&lt;span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the class actions filed in that country&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company continues to receive information with respect to potential additional &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp;amp; Johnson (collectively, DePuy) relating to the PINNACLE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation also has been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Acetabular Cup System and the related settlement program.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp;amp; Johnson arising out of Ethicon&#x2019;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#x2019;s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#x2019;s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands and class actions in Israel, Australia and Canada. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021, and the High Court heard oral argument on the application in November 2021. Special leave was refused. While this brings an end to the appellate process, there will now be an individual case assessment process for the remaining group member claims. The parties currently are in discussions with the Court to determine the form and mechanism of that individual case assessment process. The next hearing is scheduled for late February 2022. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently negotiating the wording and some of the terms thereof and once finalized, the settlement will be subject to court approval. The parties are due to update the court on the status of the finalization of the settlement negotiations by the end of February 2022. The Company has established accruals with respect to product liability litigation associated with Ethicon&#x2019;s pelvic mesh products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp;amp; Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. The deadline for issuance of Individual Allocation amounts by the Special Master is March 2022. The costs associated with this proposed settlement are reflected in the Company&#x2019;s accruals. Post-Settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of February 2022, there are approximately 90 active cases subject to these orders which are being reviewed and evaluated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt;Claims have also been filed against Ethicon and Johnson &amp;amp; Johnson alleging personal injuries arising from the PROCEED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt; Mesh and PROCEED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt; Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. Discovery is underway in the MCL proceedings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Ethicon and Johnson &amp;amp; Johnson also have been subject to claims for personal injuries arising from the PROLENE&#x2122; Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Flexible Composite Mesh, PROCEED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Mesh and PROCEED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Ventral Patch, and PROLENE&#x2122; Polypropylene Hernia System products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson arising out of the use of RISPERDAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company&#x2019;s accruals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Claims for personal injury arising out of the use of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp;amp; Johnson; and JPI&#x2019;s collaboration partner for XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, Bayer Healthcare AG, and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson &amp;amp; Johnson announced an agreement in principle to settle the XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp;amp; Johnson Consumer Inc. and Johnson &amp;amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase through fiscal year 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of  $4.7&#160;billion in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Ingham v. Johnson &amp;amp; Johnson, et al., &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;No. ED 207476 (Mo. App.), reducing the overall award to $2.1&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Ingham &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5&#160;billion. The facts and circumstances, including the terms of the award, were unique to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Ingham&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#x2019;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2021, Johnson &amp;amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#x2019;s direct parent, Johnson &amp;amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#x2019;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#x2019; compensation statute or act (the Talc-Related Liabilities). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2021, notwithstanding the Company&#x2019;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). As a result of the LTL Bankruptcy Case, the Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, Johnson &amp;amp; Johnson, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court subsequently extended the PI through the end of February 2022. Claimants have filed a motion to dismiss the LTL Bankruptcy Case. The court commenced a hearing on February 14, 2022 regarding the motion to dismiss and on whether the PI should be extended. While the PI effectively stays all of the Company&#x2019;s talc-related personal injury litigation, LTL has agreed to lift the automatic stay on a small number of appeals where appeal bonds have been filed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has agreed to provide funding to LTL for the payment of amounts the Bankruptcy Court determines are owed by LTL through the establishment of a $2&#160;billion trust in furtherance of this purpose. The Company has established a reserve for approximately $2&#160;billion in connection with the aforementioned trust. Subsequent to the fiscal third quarter of 2021, the Company de-consolidated LTL, which is a related party, as a result of the bankruptcy filing. The impact of the de-consolidation is not material to the Company. The parties have not yet been able to reach a resolution of all matters related to talc, and while certain amounts under various scenarios have recently been referred to in testimony as part of the LTL bankruptcy proceedings, the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2019, the Company&#x2019;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#x2019;s potential liability for personal injury from exposure to talcum powder sold by Imerys (Talc Claims). In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants&#x2019; Committee (TCC), and the Future Claimants&#x2019; Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent&#x2019;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan. The Company challenged certain improprieties with respect to portions of the vote and sought to disqualify those votes. In October 2021, the Bankruptcy Court issued a ruling deeming thousands of votes as withdrawn as improperly voted. In October 2021, Imerys cancelled the confirmation hearing on the Plan. Imerys, the TCC, the FCR, and certain of Imerys&#x2019;s insurers (the Mediation Parties) have since agreed to engage in mediation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys adversary proceeding). The Imerys adversary proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company&#x2019;s talc liabilities from its other assets. The Bankruptcy Court denied the motion. The Company thereafter filed a motion to dismiss the adversary proceeding. The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Imerys adversary proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2020, Cyprus Mines Corporation and its parent (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus adversary proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan. The Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against Talc Claims asserted against it. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the TCC and FCR appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus adversary proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2021, several of the Company&#x2019;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Coverage Action.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2018, a securities class action lawsuit was filed against Johnson &amp;amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp;amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Baby Powder, and that purchasers of Johnson &amp;amp; Johnson&#x2019;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, the Company answered the complaint. In April 2021, briefing on Plaintiffs&#x2019; motion for class certification was completed. In July 2021, the Company filed a notice of supplemental authority in opposition to Plaintiff&#x2019;s motion for class certification, and Plaintiff filed a response. In December 2021, the Company filed a motion to supplement the class certification record, and in January 2022, Plaintiff responded. Discovery is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson &amp;amp; Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. In February 2022, the Court granted Johnson &amp;amp; Johnson's cross motion to dismiss. In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp;amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Baby Powder, and that Johnson &amp;amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;In re Johnson &amp;amp; Johnson Talc Stockholder Derivative Litigation&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2020, a report was delivered to the Company&#x2019;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues and demanding that suit be brought against certain Directors. Four of the shareholders who sent demands are plaintiffs in th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;e &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;In re Johnson &amp;amp; Johnson Talc Stockholder Derivative Litigation&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#x2019;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp;amp; Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson &amp;amp; Johnson&#x2019;s motion to dismiss pending a decision on Plaintiff&#x2019;s motion for discovery. In November 2021, at the Court&#x2019;s request, the parties submitted supplemental briefing on Plaintiff&#x2019;s motion for discovery. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp;amp; Johnson Savings Plan against Johnson &amp;amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp;amp; Johnson stock as a Johnson &amp;amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#x2019; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#x2019; motion was complete. In February 2021, the Court granted Defendants&#x2019; motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice. In May 2021, Plaintiffs filed a notice of appeal with the Third Circuit. In July 2021, Plaintiffs filed their opening brief in the Third Circuit and in September 2021, Defendants filed their response brief, and in October 2021, Plaintiffs filed their reply brief. In January 2022, the Third Circuit heard oral argument.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#x2019;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Baby Powder. In that lawsuit, the plaintiffs allege that Johnson &amp;amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#x2019;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. In October 2021, Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit. A bankruptcy stay was imposed in December 2021, and the Court held the reply deadline in abeyance.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters, including from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice, the Subcommittee on Economic and Consumer Policy of the House Committee on Oversight and Reform, the Senate &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Committee on the Judiciary, the House Committee on Oversight and Reform, and individual Members of Congress. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have been made against a number of Johnson &amp;amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson, arising out of the use of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company&#x2019;s accruals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Claims for personal injury have been made against a number of Johnson &amp;amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson, arising out of the use of ELMIRON&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases also have been filed in various state courts. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;INTELLECTUAL PROPERTY&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain subsidiaries of Johnson &amp;amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#x2019;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medical Devices&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that Acclarent&#x2019;s RELIEVA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Spin and RELIEVEA SpinPlus&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; products infringe U.S. Patent No. 9,011,412. Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of Acclarent&#x2019;s U.S. Patent No. 8,414,473. Trial began in October 2021, and shortly thereafter, the parties reached an agreement to settle the case. Plaintiff&#x2019;s motion to dismiss with prejudice was filed in October 2021. The case was dismissed with prejudice in November 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (&#x2019;200); 6,491,701 (&#x2019;701); 6,522,906 (&#x2019;906); 6,800,056 (&#x2019;056); 8,142,447 (&#x2019;447); 8,620,473 (&#x2019;473); 8,801,601 (&#x2019;601); and 9,452,276 (&#x2019;276) based on Auris&#x2019; Monarch&#x2122; Platform. Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the &#x2019;200, &#x2019;056, &#x2019;601 &#x2019;701, &#x2019;447, &#x2019;276 and &#x2019;906 patents. Intuitive subsequently dropped the &#x2019;200, &#x2019;473 and &#x2019;701 patents from the suit. In December 2019, the USPTO instituted review of the &#x2019;601 patent and denied review of the &#x2019;056 patent. In February and March 2020, the USPTO instituted review of the &#x2019;200, &#x2019;447, &#x2019;701 and &#x2019;906 patents and denied review of the &#x2019;276 patent. In December 2020, the USPTO declared all of the challenged claims in the &#x2019;601 patent to be invalid. Intuitive has appealed that decision. In March 2021, the USPTO ruled that the challenged claims of the &#x2019;447 and &#x2019;906 patents are not invalid. Auris has appealed that decision. Auris filed a request for reexamination of the &#x2019;276 patent in November 2021, and in January 2022, the USPTO granted the reexamination request. Trial is scheduled to begin in January 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in the United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 and 9,713,537 by one or more of the following products:  ZERO-P-VA&#x2122; Spacer, ZERO-P&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Spacer, ZERO-P NATURAL&#x2122; Plate, SYNFIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; LR Spacer and SYNFIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Evolution System. RSB Spine seeks &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. A stay that had been entered pending Inter Partes Review at the U.S. Patent &amp;amp; Trademark Office has been lifted, and trial is scheduled to begin in December 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In March 2020, Osteoplastics, LLC filed a patent infringement suit against DePuy Synthes, Inc., DePuy Synthes Products, Inc., Medical Device Business Services, Inc., and Synthes, Inc. (collectively, DePuy Synthes) in the United States District Court for the District of Delaware. In the suit, Osteoplastics alleges willful infringement of U.S. Patent Nos. 8,781,557; 9,929,920; 9,330,206; 9,626,756; 9,672,617; 9,672,302; and 9,275,191 based on the PROPLAN CMF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Virtual Surgical Planning Services and the TruMatch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; CMF Personalize Solutions. In April 2020, Osteoplastics filed an amended complaint to substitute U.S. Patent No. 9,292,920 for U.S. Patent No. 9,929,920. Osteoplastics seeks monetary damages and injunctive relief. In June 2020, DePuy Synthes filed a motion to dismiss the complaint. In October 2020, the Court dismissed Medical Device Business Services, Inc. from the case but otherwise denied the motion. In June 2021, Osteoplastics admitted that the PROPLAN CMF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Virtual Surgical Planning Services do not infringe any asserted patents. Trial was scheduled for October 2022. In October 2021, the case was settled and dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2020, Rasmussen Instruments, LLC (Rasmussen) filed a patent infringement suit against DePuy Synthes Products, Inc., DePuy Synthes Sales, Inc. and Medical Device Business Services, Inc. (collectively, DePuy) in the United States District Court for the District of Massachusetts. Rasmussen alleges that DePuy willfully infringes U.S. Patent Nos. 9,492,180 and 10,517,583 (&#x2019;583) by making and selling the Attune&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Balanced Sizer. In April 2021, Rasmussen sought permission to amend its infringement contentions to allege that DePuy also willfully infringes the &#x2019;583 patent by making and selling the Attune&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Balancing Blocks. Rasmussen seeks treble damages for willful infringement. Trial is scheduled for February 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pharmaceutical&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes lawsuits the Company&#x2019;s subsidiaries have brought against generic companies that have filed ANDAs with the U.S. FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp;amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. In the event the Company&#x2019;s subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the generic companies involved would have the ability, upon approval of the U.S. FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#x2019;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in January 2019, Janssen Inc. and Janssen Oncology, Inc. (collectively, Janssen) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex Inc. (Apotex), Pharmascience Inc. (Pharmascience) and Dr. Reddy&#x2019;s Laboratories Ltd. and Dr. Reddy&#x2019;s Laboratories, Inc. (collectively, DRL) in response to those parties&#x2019; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; before the expiration of the Canadian Patent No. 2,661,422 (&#x2019;422). The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#x2019;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. which filed an ANDA seeking approval to market a generic version of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of U.S. Patent No. 10,828,310 (&#x2019;310). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Dr. Reddy&#x2019;s Laboratories, Inc. and Dr. Reddy&#x2019;s Laboratories, Ltd. which filed an ANDA seeking approval to market a generic version of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of the &#x2019;310 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc. (collectively, Taro) which filed an ANDA seeking approval to market a generic version of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of the &#x2019;310 patent. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. which filed an ANDA seeking approval to market a generic version of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of the &#x2019;310 patent. In August 2021, the court entered a joint stipulation dismissing Teva Pharmaceutical Industries Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2021, the court consolidated the Delaware lawsuits for all purposes, including trial. Trial for the consolidated Delaware lawsuits is scheduled to begin in May 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan Pharmaceuticals Inc. and Mylan Inc. which filed an ANDA seeking approval to market a generic version of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of the &#x2019;310 patent. In August 2021, JPI and Bayer filed a motion before the United States Judicial Panel on Multidistrict Litigation (the MDL panel) to transfer this lawsuit to the United States District Court for the District of Delaware for coordinated and consolidated pretrial proceedings. In December 2021, the MDL panel granted the motion. No trial date has been set in this lawsuit.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In each of these lawsuits, JPI and Bayer are seeking an order enjoining defendants from marketing their generic version of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; before the expiration of the &#x2019;310 patent. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;/INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;/INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2019, Janssen Pharmaceuticals, Inc., Janssen Research &amp;amp; Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#x2019;s Laboratories, Inc. and Dr. Reddy&#x2019;s Laboratories Ltd (DRL), who filed an ANDA seeking approval to market a generic version of INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; before expiration of MTPC&#x2019;s United States Patent No. 7,943,788 (&#x2019;788) relating to INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. In January 2021, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; before expiration of MTPC&#x2019;s United States Patent Nos. 7,943,582 (&#x2019;582) and/or 8,513,202 (&#x2019;202) relating to INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt;In each of these U.S. lawsuits, Janssen and MTPC are seeking an order enjoining the defendant from marketing their generic versions of INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt; and/or, INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:102%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt;before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2020, Janssen Inc., Janssen Pharmaceutica NV and MTPC initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#x2019;s filing of an ANDS seeking approval to market a generic version of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the Canadian Patent Nos. 2,799,204, 2,534,024 and 2,671,357. Janssen Inc., Janssen Pharmaceutica NV and MTPC are seeking an order enjoining Sandoz from marketing its generic version of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the relevant patents. The trial is scheduled to begin in August 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2020, Janssen Inc. (Janssen) and Actelion Pharmaceuticals Ltd (Actelion) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10 mg,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;before the expiration of Canadian Patent No. 2,659,770 (&#x2019;770). Trial is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10 mg,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before the expiration of the &#x2019;770 patent. Trial is scheduled to begin in February 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (JAMP) in Canada in response to JAMP&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10 mg before the expiration of the &#x2019;770 patent and Canadian Patent No. 2,621,273 (&#x2019;273). Trial is scheduled to begin in April 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; before the expiration of United States Patent No. 9,439,906 (&#x2019;906). Trial concluded in October 2020. In October 2021, the court issued a decision in Janssen&#x2019;s favor. Teva has appealed the decision.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the &#x2019;906 patent. Pursuant to an agreement by the parties, judgment in favor of Janssen was entered in December 2021. Mylan has filed an appeal. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of the &#x2019;906 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Tolmar, Inc., Tolmar Therapeutics, Inc., Tolmar Pharmaceuticals, Inc. and Tolmar Holding, Inc. (collectively, Tolmar), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of the &#x2019;906 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva&#x2019;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of Canadian Patent Nos. 2,309,629 (&#x2019;629) and 2,655,335 (&#x2019;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#x2019;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#x2019;s generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if approved, would infringe certain claims of the &#x2019;335 patent and that the claims of the &#x2019;335 patent are not invalid for obviousness. Teva Canada appealed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.&#x2019;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the &#x2019;335 patent. A summary trial on the issue of infringement took place in November 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. A trial on the issue of validity is scheduled to begin in July 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in response to Apotex&#x2019;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the &#x2019;335 patent. A summary trial on the issue of infringement took place in December 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Apotex has not contested validity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp;amp; Development, LLC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (546 mg) before expiration of United States Patent No. 10,143,693 (&#x2019;693) relating to INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(546 mg). Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; before the expiration of the &#x2019;693 patent. Trial is scheduled to begin in October 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(819 mg) before expiration of the &#x2019;693 patent. Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (819 mg) before the expiration of the &#x2019;693 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (273 mg and 410 mg) before expiration of the &#x2019;693 patent. Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (273 mg and 410 mg) before the expiration of the &#x2019;693 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the court consolidated the three cases into the case filed in September 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, asserting infringement of United States Patent Nos. 7,514,444; 8,003,309; 8,476,284; 8,497,277; 8,697,711; 8,753,403; 8,754,090; 8,754,091; 8,952,015; 8,957,079; 9,181,257; 9,296,753; 9,655,857; 9,725,455; 10,010,507; 10,106,548; and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386. Pharmacyclics and JBI are seeking an order enjoining the defendants from marketing generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Trial against Alvogen took place in October 2020. In August 2021, the District Court issued a decision in favor of Pharmacyclics and Janssen finding the asserted claims against Alvogen to be infringed and not invalid. Alvogen has appealed that decision.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2021, Pharmacyclics and Janssen Inc. (Janssen Canada) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco Pharma (Canada) Inc. (Natco) in response to Natco&#x2019;s filing of two ANDSs seeking approval to market generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;capsules before the expiration of Canadian Patent Nos. 2,663,116; 2,928,721; 2,800,913; 3,007,787; 3,007,788; 2,875,986; and 3,022,256. The trial is scheduled to begin in July 2023. Pharmacyclics and Janssen are seeking an order enjoining Natco from marketing its generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2020, Actelion Pharmaceuticals Ltd (Actelion) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Zydus Pharmaceuticals (USA), Inc. and Zydus Worldwide DMCC (collectively, Zydus), who filed an ANDA seeking approval to market a generic version of UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;before expiration of Nippon Shinyaku&#x2019;s United States Patent Nos. 7,205,302 (&#x2019;302); relating to UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. Actelion is the exclusive licensee of the &#x2019;302 patent. In January 2022, Actelion, Nippon Shinyaku and Zydus entered into a confidential settlement agreement and the lawsuit was dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;GOVERNMENT PROCEEDINGS&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp;amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Average Wholesale Price (AWP) Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;amp;J AWP Defendants were ultimately dismissed. The J&amp;amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp;amp; Johnson and ALZA Corporation. All other cases have been resolved.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Opioid Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in 2014 and continuing to the present, Johnson &amp;amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in approximately 3,400 lawsuits related to the marketing of opioids, including DURAGESIC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, NUCYNTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; and NUCYNTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including Johnson &amp;amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The Government of Puerto Rico filed suit in Superior Court of San Juan. There are over 380 cases pending in various state courts. There are close to 3,000 federal cases coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio. In addition, the Province of British Columbia filed suit against Johnson &amp;amp; Johnson and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against Johnson &amp;amp; Johnson and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. In October 2019, an antitrust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In 2019, the trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp;amp; Johnson and JPI in the amount of $465&#160;million. Johnson &amp;amp; Johnson and JPI appealed the judgment, and in November 2021, the Oklahoma Supreme Court reversed the trial court&#x2019;s judgment. In October 2019 Johnson &amp;amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against Johnson &amp;amp; Johnson and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial concluded in October 2021, and in December 2021, the Court entered a final trial judgment in favor of Defendants on all claims. In February 2022, Plaintiffs' motion to set aside and vacate the judgment was denied.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2019, Johnson &amp;amp; Johnson received a grand jury subpoena from the United States Attorney&#x2019;s Office for the Eastern District of New York for documents related to the Company&#x2019;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#x2019; and distributors&#x2019; monitoring programs and reporting under the Controlled Substances Act. In September 2019, Johnson &amp;amp; Johnson received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums. In September 2020, the Company learned that NYDFS filed a statement of charges related to this investigation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2021, the Company and JPI announced a settlement agreement with the State of New York and its participating subdivisions, including Nassau County and Suffolk County, resolving their opioid-related claims against the Company on terms consistent with the Company&#x2019;s previously announced agreement in principle to contribute up to $5&#160;billion to all-in settlement of opioid-related claims by states, cities, counties, and tribal governments. The settlement provides New York and its participating subdivisions with up to $263&#160;million to address opioid-related issues, reimburses attorney fees and costs, and removes the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Company and Janssen from a multi-defendant trial of opioid-related claims that commenced in Suffolk County in June 2021. In exchange, the Company and JPI receive releases from the claims asserted by New York and the participating parties, including NYDFS.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2021, the Company and JPI announced a settlement agreement with the State of Texas and its participating subdivisions, including Dallas County, Bexar County, and Tarrant County, resolving their opioid-related claims against the Company on terms consistent with the Company&#x2019;s previously announced agreement to contribute up to $5&#160;billion to all-in settlement of opioid-related claims by states, cities, counties, and tribal governments. The settlement provides Texas and its participating subdivisions with up to $297&#160;million to address opioid-related issues and reimburse attorney fees and costs, and removes the Company and Janssen from multi-defendant bellwether trials of opioid-related claims scheduled to commence in Texas state courts in early 2022. In exchange, the Company and JPI will receive releases from the claims asserted by Texas and the participating subdivisions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Johnson &amp;amp; Johnson, JPI and other pharmaceutical companies have also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp;amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#x2019;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $4&#160;billion as settlement of these matters. In October 2020, the Company agreed to contribute up to an additional $1&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of $5&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement in principle is not an admission of liability or wrong-doing. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims have been finalized and up to one-third of the all-in settlement is expected to be paid within the next 12 months, depending upon the level of participation by the states and their subdivisions. The terms provide a period of time for states to elect to participate in the agreement and, thereafter, a period for the subdivisions of the participating states to opt-in. As of January 2022, 45 states, five territories, and the District of Columbia had elected to participate in the settlement. The subdivision opt-in period expired in January 2022. The Company retains the right to opt-out of the agreement until late February 2022 if, in its sole discretion, there is insufficient participation. Based on expected participation, the Company has committed in advance to proceed with the settlement in five of the participating states (New York, Texas, Florida, Nevada, and New Mexico) and with tribal governments, whose cases were scheduled for trial in 2021, 2022, or 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From June 2017 through December 2019, the Company&#x2019;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsel&#x2019;s report.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp;amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp;amp; Johnson has suffered damages as a result of those alleged breaches. In May 2020, the shareholder filed an amended complaint challenging the Board&#x2019;s rejection of his demand. In August 2020, Johnson &amp;amp; Johnson moved to dismiss the amended complaint. In February 2021, the Court held oral argument on Johnson &amp;amp; Johnson&#x2019;s motion. In February 2022, the Court granted Johnson &amp;amp; Johnson&#x2019;s motion to dismiss the amended complaint. In August 2020, another shareholder who sent a demand filed a separate derivative complaint in the same court making similar allegations. In October 2020, the Court granted defendants&#x2019; request to reassign the second-filed case to the division where the first-filed case is pending. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2019, two additional shareholders who sent demands filed two separate derivative complaints making similar allegations against Johnson &amp;amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the United States District for the District of New Jersey. In April 2020, the two federal cases were consolidated into a single action captioned&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; In re Johnson &amp;amp; Johnson Opioid Stockholder Derivative Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. In July 2020, the shareholders filed a consolidated complaint. In September 2020, Johnson &amp;amp; Johnson moved to dismiss the consolidated complaint, and in December 2020, the shareholders opposed Johnson &amp;amp; Johnson&#x2019;s motion. Johnson &amp;amp; Johnson filed its reply in February 2021. In July 2020, an additional shareholder who sent a demand filed a derivative complaint in the same federal court making similar allegations against the same defendants named in the consolidated action. In January 2021, pursuant to an order in the consolidated action, the third case was consolidated into the consolidated action. In February 2021, the Court granted the shareholders motion to voluntarily dismiss the consolidated action without prejudice, and the shareholders&#x2019; counsel then filed a notice of association in the first-filed derivative action pending in the Superior Court of New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp;amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney&#x2019;s Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR&#x2122; XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#x2019; motion to dismiss with prejudice, unsealed the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; complaint, and denied the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; relators&#x2019; request for leave to file a further amended complaint. The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#x2019;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#x2019; request to file a third amended complaint. In March 2021, DePuy filed its motion to strike and dismiss the relators&#x2019; second amended complaint; the District Court denied DePuy&#x2019;s motion to strike and dismiss in July 2021. DePuy filed a motion for reconsideration of the District Court&#x2019;s July 2021 ruling. In November 2021, the District Court granted DePuy&#x2019;s motion for reconsideration and dismissed the case with prejudice. The District Court&#x2019;s order was unsealed in December 2021. The Relators filed several post-dismissal motions, including a January 2022 omnibus motion for reconsideration. Following the District Court&#x2019;s order dismissing the case with prejudice, DePuy filed a December 2021 motion seeking the recovery of attorneys&#x2019; fees.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2012, Johnson &amp;amp; Johnson was contacted by the California Attorney General&#x2019;s office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp;amp; Johnson&#x2019;s subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp;amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp;amp; Johnson and Ethicon settled the Washington case. The California case started trial in July 2019 and concluded in September 2019. In October 2019, Johnson &amp;amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $344&#160;million. In April 2020, the Court in California denied the Company&#x2019;s motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of  $344&#160;million, but denied the Attorney General&#x2019;s request for injunctive relief. The Company is appealing the penalty judgment. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon. Trial in the Kentucky matter is scheduled for May 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp;amp; Johnson and Johnson &amp;amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp;amp; Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers&#x2019; use of talc contained in JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Baby Powder and JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. Johnson &amp;amp; Johnson and JJCI moved for summary judgment on the grounds that the State&#x2019;s claim was barred by preemption, which the trial court denied. The Mississippi Supreme Court granted Johnson &amp;amp; Johnson and JJCI&#x2019;s request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Briefing and oral argument were completed. Thereafter, the Court rejected the interlocutory appeal in April 2021 and remanded the matter to the trial court. Thereafter, the State moved for a trial setting. JJCI objected to any trial setting due to the LTL Bankruptcy and that any decision on whether the stay applied should be deferred to the LTL Bankruptcy court. The State opposed any stay and argued that the trial court should decide issues concerning the stay. The motion for trial setting and JJCI&#x2019;s objections were heard in November 2021 and in January 2022, the Court granted plaintiff&#x2019;s motion for trial setting and directed the parties to consult with the Court administrator to secure a trial date. That process is underway. In August 2021, JJCI filed a Petition for Writ of Certiorari in the United States Supreme Court as to the Mississippi Supreme Court&#x2019;s ruling of April 2021, the State responded to the Petition for Writ of Certiorari in November 2021, the JJCI filed a reply in November 2021, and the United States Supreme Court denied the Petition for Writ of Certiorari in December 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. The Company made its first document production in February 2021 and discovery is currently scheduled to close on April 25, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forty-two states and the District of Columbia have commenced a joint investigation into the Company&#x2019;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, Janssen Pharmaceuticals, Inc. (JPI) received a Civil Investigative Demand from the United States Attorney&#x2019;s Office for the Southern District of New York related to JPI&#x2019;s contractual relationships with pharmacy benefit managers over the period from January 1, 2006 to the present with regard to certain of JPI&#x2019;s pharmaceutical products. The demand was issued in connection with an investigation under the False Claims Act. The Company has provided documents in response to the demand. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2016, Johnson &amp;amp; Johnson and Janssen Products LP were served with a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; and INTELENCE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Daubert&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or SIMPONI ARIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April and September 2017, Johnson &amp;amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, OLYSIO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, STELARA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The subpoenas also seek documents relating to Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2017, Johnson &amp;amp; Johnson received a subpoena from the United States Attorney&#x2019;s Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc.(DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these hospitals. Johnson &amp;amp; Johnson and DePuy have produced documents in response to the subpoena and are fully cooperating with the government&#x2019;s investigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp;amp; Johnson do Brasil Ind&#xfa;stria e Com&#xe9;rcio de Produtos para Sa&#xfa;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp;amp; Johnson to cooperate with these inquiries by producing the requested information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;GENERAL LITIGATION&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March and April 2015, over 30 putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp;amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. Discovery and pre-trial motion practice are complete. Trial is scheduled to begin in March 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; against Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The cases were consolidated for pre-trial purposes as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; In re &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Antitrust Litigation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in United States District Court for the Eastern District of Pennsylvania. The consolidated complaint seeks damages and injunctive relief. Discovery is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, Walgreen Co. and Kroger Co., filed an antitrust complaint against Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The complaint seeks damages and injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#x2019;s decision. This matter was settled in January 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp;amp; Johnson in connection with its investigation of whether Janssen&#x2019;s REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp;amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#x2019;s decision.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. TRACLEER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In October 2019, the Court granted Actelion&#x2019;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. Discovery is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp;amp; Development, LLC, and Johnson &amp;amp; Johnson (collectively, Janssen) were served with a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; complaint filed on behalf of the United States, 28 states, and the District of Columbia. The complaint, which was filed in December 2017 in United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; to the government in connection with direct government sales and government-funded drug reimbursement programs. At this time, the federal and state governments have declined to intervene. The case has been transferred to United States District Court for the District of New Jersey. Janssen&#x2019;s motion to dismiss was denied in December 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2019, a class action antitrust complaint was filed against Janssen R&amp;amp;D Ireland (Janssen) and Johnson &amp;amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#x2019; motions to dismiss. Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint. In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. In December 2021, several insurance companies and other payers filed individual &#x201c;Opt-Out&#x201d; complaints containing allegations similar to the original complaint. Discovery is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#x2019;s business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. In August 2020, the Court granted in part and denied in part BWI&#x2019;s motion to dismiss. In December 2021, BWI filed a motion for summary judgment. The trial is set for April 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, Johnson &amp;amp; Johnson received a demand for indemnification from Pfizer Inc., pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp;amp; Johnson Inc. received a demand for indemnification from Sanofi Consumer Health, Inc., pursuant to the 2016 Asset Purchase Agreement between Johnson &amp;amp; Johnson Inc. and Sanofi. In January 2020, Johnson &amp;amp; Johnson received a demand for indemnification from &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Boehringer Ingelheim Pharmaceuticals, Inc., pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim. The notices seek indemnification for legal claims related to over-the-counter ZANTAC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp;amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#x2019;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#x2019; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Beginning in May 2021, multiple &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;putative &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;class actions were filed in state and federal courts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(California, Florida, New York, and New Jersey)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; against various Johnson &amp;amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and the affirmative promotion of those products as &#x201c;safe&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;; and, in at least one case, alleging a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;strict liability manufacturing defect and failure to warn &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;claims, asserting that the named plaintiffs&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; suffered unspecified injuries as a result of alleged exposure to benzene.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability case and one case pending in New Jersey state court, in the United States District Court for the Southern District of Florida, Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court. In December 2021, plaintiffs in the consolidated actions filed a motion for preliminary approval of a nationwide class settlement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Johnson &amp;amp; Johnson (subsequently substituted by Johnson &amp;amp; Johnson Consumer Inc. (JJCI)) along with more than 120 other companies, is a defendant in a cost recovery and contribution action brought by Occidental Chemical Corporation in June 2018 in the United States District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Johnson &amp;amp; Johnson or its subsidiaries are also parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i1293b88bd90d458eac2d0d6a7b850b0d_I20220102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzQ1NTM_fac0ebb1-4f81-43ab-a5b1-e8666cd68d92"
      unitRef="claimant">250</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i16e6e6646c3b4d109123795d9c7df84e_I20220102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzQ3MTc_cf17c795-13c0-4ac4-9da6-f0ecb82b18ce"
      unitRef="claimant">5300</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="idb4e5502065243778f8d181c244dd324_I20220102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzQ3NzM_904557c1-0b01-4f88-95fd-213b7fd3ef09"
      unitRef="claimant">10100</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ic9d5ee581ec640ec80ed1f8d2ef956fe_I20220102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzQ4MDc_274ac128-a67f-4f5a-b056-cd846afd2e12"
      unitRef="claimant">8800</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ia4378318856543098e6cf32dbe8237ca_I20220102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzQ4Mzg_61a8a3d6-b5f9-466c-8b54-512df166c083"
      unitRef="claimant">5500</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i7ac530b2a8144cd796fa1d12ee757dfa_I20220102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzQ4Njc_f298d91d-baa9-497a-9876-4bea9cf3d3a5"
      unitRef="claimant">40400</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ie7be14aefb4947a6870ffa19e0bf31ca_I20220102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzQ5MTY_09b98891-435f-4cda-8090-932062719aef"
      unitRef="claimant">100</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ieb92b728ef4e453193b6bc673799a78b_I20220102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzQ5NTA_8ece3776-2499-4409-b3de-1d0822905411"
      unitRef="claimant">4700</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:Numberofpatientsinsettlement
      contextRef="i55464ad945a643baa712e791b033c1ed_I20220102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYzNDA_2b7f69f9-2133-4bba-aaa9-6abad309af7f"
      unitRef="claimant">10000</jnj:Numberofpatientsinsettlement>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i8a3b65d9882f4457b2a58709975f0f58_I20210531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzY1OTcwNzAxNzE0MDY_d61a19f6-61e5-4538-b0e4-bf3fddbb5ac7"
      unitRef="cases">3600</us-gaap:LossContingencyPendingClaimsNumber>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i8a3b65d9882f4457b2a58709975f0f58_I20210531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYwNDczMTQwNzE2NzE_12b6d541-6555-4beb-a84a-8b7f6d4854de"
      unitRef="claimant">4300</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement
      contextRef="i09cbeb4b729f4746a9c451af63dd91c7_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYwNDczMTQwNzU5Mzg_98cdad4b-2bb4-4e4b-868d-3059e7338b6c"
      unitRef="cases">3729</jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ib1cc0378da84475bbc08a06b2a879405_I20220228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYwNDczMTQwNzU5NDU_b587507f-76b8-4559-8a36-16ae6085c91e"
      unitRef="cases">90</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i5cd3b425c568464d84bffc5929d955ac_D20191001-20191031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzEzMzEx_79be0016-f7b7-4b31-bcaa-a52ae6882ce7"
      unitRef="usd">8000000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i6133d5a7101f441a9444db674a47b348_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzEzNDE2_cf08dc22-db56-4a83-8d5b-f47e579c60c3"
      unitRef="usd">6800000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i8473134a97db464ab939bcb0bb98f418_D20180701-20180731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzE2MzQ4_91743db1-4b4b-4a1a-a335-df3214d7e037"
      unitRef="usd">4700000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i659974d043fe4a37b83a80d13bc59d65_D20200601-20200628"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzE2NDQ3_b6281cfb-1077-4029-8a5b-a88506f1daf0"
      unitRef="usd">2100000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="if17dccaaceb943739755c40b7c59083d_D20210601-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzE2NTU1_5f86d0a9-0f3a-4eb5-8a6c-cfbb059d8368"
      unitRef="usd">2500000000</us-gaap:PaymentsForLegalSettlements>
    <jnj:LossContingencyReserveEstablishedWithinTrust
      contextRef="ifba96edcac3c4389a3b0bb8b2c90cd45_D20211001-20211031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYwNDczMTQwOTE1ODc_e145726d-c113-423d-8013-a673da075dca"
      unitRef="usd">2000000000</jnj:LossContingencyReserveEstablishedWithinTrust>
    <jnj:LossContingencyReserveEstablishedWithinTrust
      contextRef="ifba96edcac3c4389a3b0bb8b2c90cd45_D20211001-20211031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYwNDczMTQwOTE1NzU_12875cb5-a5ac-432a-ae4c-7efd013a3eab"
      unitRef="usd">2000000000</jnj:LossContingencyReserveEstablishedWithinTrust>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ieb58c35946ea47c2a018ec31bb2540d3_I20220102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzU3Mjg1_7cfd2fd1-0b06-40c9-a5d4-b915a378ccb8"
      unitRef="claimant">3400</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i9c3dc4fb3ece45fdbc810c1cbca8eab7_I20220102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzY1OTcwNzAxNzE0MjA_2bf08ee4-c00d-4fe7-97ad-0bbbcfd4360b"
      unitRef="claimant">380</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i60459746fbf841b59219889ad727de9f_I20220102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzY1OTcwNzAxNzE0MTM_16f45659-12b6-4338-ba6d-63d063b68a92"
      unitRef="claimant">3000</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ia204f8664a9d4e17b4e9da7fc3db9fc3_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYwMjE2_2d1a75d7-f44a-456c-bf4a-4096f6cc33b1"
      unitRef="usd">465000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ie9e9d5c5c1ab4177a2b9d89bb136c5e3_D20210601-20210630"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYxMDkx_f0ed82a3-aaa6-4a92-9352-483cbfbeefeb"
      unitRef="usd">5000000000</us-gaap:LossContingencyDamagesAwardedValue>
    <jnj:LossContingencyDamagesAwardedAdditionalReimbursementValue
      contextRef="ie9e9d5c5c1ab4177a2b9d89bb136c5e3_D20210601-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYxMTk2_dfe192e6-30c9-48fc-a5a0-72c3694ea7e1"
      unitRef="usd">263000000</jnj:LossContingencyDamagesAwardedAdditionalReimbursementValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i0d6e9afb25e04fc1adbd653da6d9243e_D20211001-20211031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzY1OTcwNzAxNzE0MjU_b4eddceb-f767-41a0-9eff-f419b6aaa242"
      unitRef="usd">5000000000</us-gaap:LossContingencyDamagesAwardedValue>
    <jnj:LossContingencyDamagesAwardedAdditionalReimbursementValue
      contextRef="i0d6e9afb25e04fc1adbd653da6d9243e_D20211001-20211031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzY1OTcwNzAxNzE0Mzc_bb691326-b7f0-4459-8625-ab22ad1ba35b"
      unitRef="usd">297000000</jnj:LossContingencyDamagesAwardedAdditionalReimbursementValue>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i7f6076db24f64e8b8d695cf2700ed061_I20191031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYwNDczMTQxODcwNjk_385722e1-2a3d-42a3-8ea4-aae8984a6c7e"
      unitRef="usd">4000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <jnj:LossContingencyEstimateOfAdditionalPossibleLoss
      contextRef="i07cc6e7b5efd42c9b9d122106a692420_I20201031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzY1OTcwNzAxNzE0NTE_43677cfa-cfd5-42e7-8857-27d10f793f20"
      unitRef="usd">1000000000</jnj:LossContingencyEstimateOfAdditionalPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i07cc6e7b5efd42c9b9d122106a692420_I20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzYwNDczMTQxODcwODE_f890b44d-3a89-4a1b-9c6f-76280be2e892"
      unitRef="usd">5000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i3ec18e9e128b4bcb867c217e36034665_D20200120-20200120"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzY4MDEx_f7f09c61-481c-4716-9f45-ef7b23bbbf25"
      unitRef="usd">344000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i3ec18e9e128b4bcb867c217e36034665_D20200120-20200120"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzY4MTc1_0c3fc25a-5197-491a-8290-111fe9b24684"
      unitRef="usd">344000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i15323762d4454d4fa681a2ea0ef1eab5_I20150430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMTcvZnJhZzo0NjRmZWMwYjkwOTM0ODY2YmNiODY2ZmY5OGVmYWRhNi90ZXh0cmVnaW9uOjQ2NGZlYzBiOTA5MzQ4NjZiY2I4NjZmZjk4ZWZhZGE2XzY1OTcwNzAxNzE0NjM_89efcbb4-1a4b-48ca-968f-84ff4ce1145e"
      unitRef="claim">30</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzI2NTU_9e14ed9c-ea95-418f-8c64-7c05831b8dcb">Restructuring&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fiscal second quarter of 2018, the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In fiscal year 2021, the Company recorded a pre-tax charge of $0.5 billion, which is included on the following lines of the Consolidated Statement of Earnings, $0.3 billion in restructuring, $0.1 billion in other (income) expense and $0.1 billion in cost of products sold. Total project costs of approximately $1.8 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by the end of 2022. The program is set to be completed at the end of 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company expects to record pre-tax restructuring charges of approximately $2.1 billion to $2.3 billion, over the 4 to 5 year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2021: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Write-offs/Sales &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, December&#160;29, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January&#160;3, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Charges  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cash settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Settled non cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January&#160;2, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Cash outlays for severance are expected to be substantially paid out over the next year in accordance with the Company's plans and local laws. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.&lt;/span&gt;&lt;/div&gt;The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="i9040c31d4c1748199785beebbd0586ea_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzc5NQ_67827444-9e45-43f9-acec-c9f0269829de"
      unitRef="usd">500000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i7f2a0b2a8ead42e18de0ad368f5442fb_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzg4Mw_ae6ae96c-6dda-49bc-9cd1-8975b6b729f7"
      unitRef="usd">300000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ifd48c767309c46d8a8d98cc62c7d4f0e_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzkwNA_4e67fef6-6100-4f4d-ac7e-1b746a3ca9a1"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i9f942e7d06b448759571f02f4385e4ca_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzkzNw_cccde1e8-5f2e-4462-8450-a7dccdd771b7"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i6a7d77bec63f4ec9ba629e605fa7f760_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzEwMDM_a01e5908-d7fa-44af-86d8-47cf68f80d06"
      unitRef="usd">1800000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <jnj:RestructuringandRelatedCostExpectedFutureSavings
      contextRef="i4742330f4c264777a98ea1c8e9843989_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzEyMzA_76b1f572-e626-442a-8b3a-48f74b29a6a5"
      unitRef="usd">600000000</jnj:RestructuringandRelatedCostExpectedFutureSavings>
    <jnj:RestructuringandRelatedCostExpectedFutureSavings
      contextRef="i070444329d4348a7b9c8aebe5a9aa3c9_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzEyMzY_ac528153-fcce-42c8-a71b-ba1b679cd992"
      unitRef="usd">800000000</jnj:RestructuringandRelatedCostExpectedFutureSavings>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i4742330f4c264777a98ea1c8e9843989_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzEzOTM_0e713ef1-ab92-4b9f-86ff-c21b2160d6bc"
      unitRef="usd">2100000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i070444329d4348a7b9c8aebe5a9aa3c9_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzEzOTk_76f5ed60-57dc-4d9f-b6d3-534af764f27f"
      unitRef="usd">2300000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <jnj:RestructuringandRelatedCostDurationofRestructuringPlan
      contextRef="iaf61a7957d2e4fbf85c40c9d23a9297e_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzE0MTI_e7807ae8-6827-459f-8d71-33eb5225d8a4">P4Y</jnj:RestructuringandRelatedCostDurationofRestructuringPlan>
    <jnj:RestructuringandRelatedCostDurationofRestructuringPlan
      contextRef="i49ac509f65b740f7bf421ae80e274e2a_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzE0MTg_f93c0039-198b-4256-ba8c-aacc8c67fc69">P5Y</jnj:RestructuringandRelatedCostDurationofRestructuringPlan>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90ZXh0cmVnaW9uOmZhYzhiYTIzMDgwMzRkMjA4ZmMwN2MxMzY0ZjFkMzcyXzI2NTE_408525e8-2a90-4568-a61c-d1195b757be4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2021: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Write-offs/Sales &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, December&#160;29, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January&#160;3, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Charges  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cash settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Settled non cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January&#160;2, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Cash outlays for severance are expected to be substantially paid out over the next year in accordance with the Company's plans and local laws. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="ie7cc0a51e3df46baa43c1b66bf2a029e_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzE4LTEtMS0xLTI5NzI2_c31be8a0-5505-458d-9e19-afa51b762450"
      unitRef="usd">164000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ia5c2f9e6ae2646e49bca2879436ed3ed_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzE4LTItMS0xLTI5NzI2_50fc2276-47c2-4ea5-9891-a4718eb7138f"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i54a04675fe8142f985b33a5c678e172f_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzE4LTQtMS0xLTI5NzI2_1a7eb55e-c35b-43df-8123-9cec96d6d560"
      unitRef="usd">16000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i125634f59e794aada3577c9ee8b1c64b_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzE4LTYtMS0xLTI5NzI2_e760e9a0-1f56-480f-a364-adaadd4dec77"
      unitRef="usd">180000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease
      contextRef="id60a51c9ec914539bb291a40e2bd0afd_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzIwLTEtMS0xLTI5NzI2_57dd34c5-792d-4066-a69d-c01978e224ea"
      unitRef="usd">-29000000</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease
      contextRef="i46179c58ccf9458a966c4f2d2c9cb18a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzIwLTItMS0xLTI5NzI2_0073eece-1423-421c-b277-ca4d23d9632f"
      unitRef="usd">0</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease
      contextRef="ibcec504d9dde41a1b752577a2c9939c5_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzIwLTQtMS0xLTI5NzI2_5e03dc2b-e0f5-4dac-80f7-bddefee88ff6"
      unitRef="usd">-7000000</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease
      contextRef="ifdd89adfa0f0484b84b07f77e48731a8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzIwLTYtMS0xLTI5NzI2_27e8aad3-016d-4f56-80f4-abc1920a40f1"
      unitRef="usd">-36000000</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReserve
      contextRef="i2327edec83cc47c299891dc7c339c323_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzIyLTEtMS0xLTI5NzI2_23fae20c-f7c5-45c7-b95d-b6f087e42123"
      unitRef="usd">135000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i872fb39f2b694b7b97a09c5a2b7bfa67_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzIyLTItMS0xLTI5NzI2_7409a2af-ca23-4336-bd8f-592e3cd7d917"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i531752ccd3b04bb4bd2ee5442e9d418a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzIyLTQtMS0xLTI5NzI2_4eed61e2-ab69-4ae1-93db-522b4def8fb8"
      unitRef="usd">9000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i01b7633b6f6a47ac92f6869a755469fb_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzIyLTYtMS0xLTI5NzI2_32fcc143-c674-448c-80e9-5d3f9d30697c"
      unitRef="usd">144000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="ie8f0b1a408074a8f9ca58bbfea6c3348_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI1LTEtMS0xLTI5NzI2_3448f968-327f-43c7-8778-7aae4e62bdcd"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ia09f9acab5bd428d86b7dafd5dd2f6bc_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI1LTItMS0xLTI5NzI2_8fb560ae-9028-4e31-9adb-1b4786de57ec"
      unitRef="usd">53000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ie50addf0e3d44897a0a2e867211ed920_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI1LTQtMS0xLTI5NzI2_2c25694b-fe18-4ea1-a873-9a225aa9379b"
      unitRef="usd">420000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i9040c31d4c1748199785beebbd0586ea_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI1LTYtMS0xLTI5NzI2_cd2393d9-16e4-418e-a0d3-e1f2116273e7"
      unitRef="usd">473000000</us-gaap:RestructuringCharges>
    <jnj:GainOnSaleOfAnAssetPaymentForRestructuring
      contextRef="ie8f0b1a408074a8f9ca58bbfea6c3348_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI2LTEtMS0xLTI5NzI2_e1c17459-dd74-4d6a-93e3-a95476fbf84f"
      unitRef="usd">23000000</jnj:GainOnSaleOfAnAssetPaymentForRestructuring>
    <jnj:GainOnSaleOfAnAssetPaymentForRestructuring
      contextRef="ia09f9acab5bd428d86b7dafd5dd2f6bc_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI2LTItMS0xLTI5NzI2_9cde4f38-25dc-4819-b5d1-5016be6c31ac"
      unitRef="usd"
      xsi:nil="true"/>
    <jnj:GainOnSaleOfAnAssetPaymentForRestructuring
      contextRef="ie50addf0e3d44897a0a2e867211ed920_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI2LTQtMS0xLTI5NzI2_05e3286e-9881-495a-a874-2d5fc23bc206"
      unitRef="usd">404000000</jnj:GainOnSaleOfAnAssetPaymentForRestructuring>
    <jnj:GainOnSaleOfAnAssetPaymentForRestructuring
      contextRef="i9040c31d4c1748199785beebbd0586ea_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI2LTYtMS0xLTI5NzI2_9bf116c2-5e5e-4d83-9696-777094d17a2e"
      unitRef="usd">427000000</jnj:GainOnSaleOfAnAssetPaymentForRestructuring>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="ie8f0b1a408074a8f9ca58bbfea6c3348_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI3LTEtMS0xLTI5NzI2_40cf01df-b328-4dd7-8091-1c5f808ab0de"
      unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="ia09f9acab5bd428d86b7dafd5dd2f6bc_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI3LTItMS0xLTI5NzI2_a1052955-ae38-48af-90e7-ce694684ebac"
      unitRef="usd">53000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="ie50addf0e3d44897a0a2e867211ed920_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI3LTQtMS0xLTI5NzI2_c13c3fb0-82e5-4b7d-b526-80008d3c4492"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i9040c31d4c1748199785beebbd0586ea_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI3LTYtMS0xLTI5NzI2_1cca0990-e0c3-4bb0-9df7-900183959def"
      unitRef="usd">53000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserve
      contextRef="i918a4b3733da4e56bf9e7e5969d09d95_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI4LTEtMS0xLTI5NzI2_a5f26fe0-2a5f-4708-8f18-5507eaa5bafc"
      unitRef="usd">112000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i91a2f9eb45f44e87b7a3dd02889d98b3_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI4LTItMS0xLTI5NzI2_431a3378-905d-4b5b-af7a-99415fd5a56a"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i5b09fb038985486b93ffe0bcfbe958f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI4LTQtMS0xLTI5NzI2_5af558fe-04d0-451a-adf0-2554e76a663c"
      unitRef="usd">25000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="if116a595b26043caaadde3e9d3b3c0a2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjAvZnJhZzpmYWM4YmEyMzA4MDM0ZDIwOGZjMDdjMTM2NGYxZDM3Mi90YWJsZTplYzEzZGEzMDUyZDQ0MmYzOGZhYzE5OTQwYTFiYjZlYS90YWJsZXJhbmdlOmVjMTNkYTMwNTJkNDQyZjM4ZmFjMTk5NDBhMWJiNmVhXzI4LTYtMS0xLTI5NzI2_b0ffaec0-48d4-4ffe-9102-99cf02c81602"
      unitRef="usd">137000000</us-gaap:RestructuringReserve>
    <dei:AuditorName
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjkvZnJhZzpiOTQxMmIwMzlhNzg0OWQzYTQxZmRmYTM0N2U4OThmZi90ZXh0cmVnaW9uOmI5NDEyYjAzOWE3ODQ5ZDNhNDFmZGZhMzQ3ZTg5OGZmXzEwOTk1MTE2Mjk1NTI5_29fde36f-c12a-4b23-814d-42267a86759d">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i20918a3d76934ae3867fbaabde676443_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYmU4ZjhmMjE2YTRjMzlhZGI1MTNhNjA2YmZlOTM3L3NlYzowMWJlOGY4ZjIxNmE0YzM5YWRiNTEzYTYwNmJmZTkzN18yMjkvZnJhZzpiOTQxMmIwMzlhNzg0OWQzYTQxZmRmYTM0N2U4OThmZi90ZXh0cmVnaW9uOmI5NDEyYjAzOWE3ODQ5ZDNhNDFmZGZhMzQ3ZTg5OGZmXzEwOTk1MTE2Mjk1NTMx_872654e9-e865-4e12-a0f9-d9d04df5ccaf">Florham Park, New Jersey</dei:AuditorLocation>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>128
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M":C9Y!2B_H7=Y_=#7>Q>I<:G:[W>'5%-0A>'UT^DHD'I2='0;'1QF)G3T"
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MP2S-*$G?M[M/\QQR/Y*-A<EVJU[:F39R\[7K ^U]Z'OT5)B=; Q,-H4>>=G
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MN&4T94(+X/]K#C%6-W0'S3W>XC]02P,$%     @ U(!15'6(=U6H!   OQ$
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M!E]G-\VPX8*R!OA_):79+ZR#NH6/_P)02P,$%     @ U(!15$A!:+'Q!
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MZOS>[GS!:5F_9WJDG-.\_GD@."&5!(C_=Y3RMPOYZJI]>[K\%U!+ P04
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M,LB=N<)[+X=!MN;C5A254!H ?]](&+#IBW[ X=KX[?\ 4$L#!!0    ( -2
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MN2_NF?O\HOBQ:X>M*[YK*UOE$SPA0 .T%Q[:UQ</SO@7TRZ+LXM%<7%V<?'
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M;"]W;W)K<VAE971S+W-H965T,34N>&ULK5=M;]LV$/XKA!<4":#:>K,MM4F
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MR9+<Z50Y3M+MK:0[&_?,/&SM TQ"$J8I4DV0L;U?O^<"@"!%14K2_3 /MF[
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MK:K9X4-,-_4#I)8:$D-EDSR7-Q(-;,%@9JLZ3^R6(((+U!I*\"!#JQ/>^+E
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MITBK)B_XNLVVN2@9]AEYB@,'U-M=T,^U&D:7>A(-41=5DE"L>12&J-/. +L
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MFS]4Q8X>GWXHJJK8TMN-DL Y7 "_X[,X[@,>X)^G?_7_4$L#!!0    ( -2
M452%;KP]P0<  &(3   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;)U8
M66_C.!+^*P5OLN@ 'EFB[MXD0-+'; \F.XVD=^=AL0^T3-M"9-%-24G\[_<K
M4CYBN3.#>;%+K(-U?$45=?FLS6.S5*JEEU55-U>C9=NNWT\F3;%4*]EX>JUJ
M<.;:K&2+1[.8-&NCY,PJK:J)\/UDLI)E/;J^M&M?S?6E[MJJK-570TVW6DFS
MN565?KX:!:/MPGVY6+:\,+F^7,N%>E#MO]=?#9XF.RNS<J7JIM0U&36_&MT$
M[V\CEK<"_RG5<W- $T<RU?J1'[[,KD8^.Z0J5;1L0>+O27U05<6&X,;WWN9H
MMR4K'M);ZY]M[(AE*AOU05>_E[-V>37*1C13<]E5[;U^_J?JXXG97J&KQO[2
MLY,5Z8B*KFGUJE>&!ZNR=O_RI<_#@4+F_T!!] K"^NTVLEY^E*V\OC3ZF0Q+
MPQH3-E2K#>?*FHORT!IP2^BUU[?:0*.L%\WEI(4]7IT4O>ZMTQ4_T T$W>FZ
M73;TJ9ZIV6L#$YC=>2.VWMR*-RW^(FN/?#$FX0OQAKUP%UUH[84_L/=135OZ
M6#9%I9O.*/KOS;1I#9#POS>,1SOCD34>_:74_5E=^K945.C56M>J;AO2<ZIT
MO?BI568%>,%_"<=E0W-=H8.:]_3N(RAI&BIKNBNK"N!N+CAC 7V:SY6%.=W+
M5M$YK_K#U="+XW/ZEVY50[-..=TS^OO?,A&(?^S^S[$6Q3[$DY1M>=%0ZU@G
MA#P$,PJ\Y(^E\SRW@N1[(O:/Q 6]"V[I4V<T9((P""[HG;B@R<&J$!FOAA<4
MC"%A^3"5X%&(U#+LHX#Y@?5@[/OL+/38#TLD7AJ>$V"#6@ P.^F0X)_E[HG0
M"]-CJR%EO@ GR$"P2)#"L#\4B^R.?KXG?.3A. 41O4MC_^[N5!9>,?:)R**T
M3T.241[D?1+P$'NG[,<^FPF\,,IB^OGV*VWM.P:O@)G$D3.?I,+RD8$8#\Z\
M?1!>,DAR3&G$X24AB,P1_A!\,>699:2H1.*($VCCLN8Y[X08F8P<*;S\6!2&
M4MX/UO(\=81_2BP81Q#TF0\2%AWI!8-<97^E%J$5P!HP%L0.J?P AX;VV0&.
M+@\.R63H-E*:9Y1Z 1* Z"R!(AU9#'V828$U9C$9]61D+0Y 'C(J,\L]((8@
MAUP61^  /ED<.R(8HC=$O($7GV[A@_7#)DZR;<82SD?6-[%]')Y:(:J;1LS(
M@:#<$?$@7R'#*F0&Q'+AB' (U]#!(69>Q&26.3+VLI,)RR@!6)B[)T(O\H\3
MD=EMP1$@ D=$MAL'-B.?XHA+A$Z)P]P1P@N.3$*$(Q=<^3Q+'!%9-U^)!18@
M8.1[(AJ< Q%7/F&&V!.AEQZ+V0:T^4DC2T:.Q,_QQMR '&F:]"&#0'F.4X-#
M@6$9\H9I)!PAAB\#G+E\1(##E8X<P4?$D5SBVZ.?;>#@83)SY&_M4AE*=V^>
M/?7035O=RHI",0Z"A-[AI!.<IW/ ]X+":!R%T78U[E=_54V#\<P85(_6VM@)
M4]AW$!H-\/IF31Z]R<]0A'$.(V>\66(;Y()^MY.CFI%\4@:#,*G=^]K@?>W9
MAOAF9-U4TN[#JR1;PK3489"F?E[R;*N\)1A:P<"ST?#<H5X*#@0S!])#<UD:
M>I(5,JGABETKI#$;S"G;];F+Y!D#R5GH"9JZ 81W87%5SUAFCI$+X6^4-.[%
M+[%^%GO1GY/W/?I\X(OS[BB7[(%JVA*#.5+7->PCKA6/N,>L38FPQO2\+(LE
M/2O# Q;FK:DV5GBZH>^=MI31CPC4*5@GFW)1E_.RD*BKMIC1TT:9)SFM% :N
M=8<KD$W=!XQLLM[0$G[(PJ:QU;C;8,"$;HEH&MT9-LOQ=?6LX9CK;J6,[AK<
M).K'AF\LU0P#/XK\I:8'M6[5:JI<SL8VZNTVC0+:&"-4XZ83)M%/,[FA#U@J
M6R2K**NRW7@][ JW+)]D65G'X=FA,;E>&_UB4X<R!OZV*MN4J9=UR4>2/O0I
MVZ+L2XTJ(/54+*59P">(3??S+$+=8L>YP;,OR851:L7=4C;V&F755&E3S,+?
MN+(/OWV^IWLUA_VZZ,=5;?I"P.L*A>%X^D(;&P 7@$=CAL%N;P;*#MB[S<>T
MKI#\UY8698V:(C>KLK4>SI4Z#&.GW=A1O-8M<>8,:LQ00#D72UQW#T'<[%'/
M<'Y=R@)WIK+NX"[*LD33'^"G*K]W)9*V@88U[!()WY0I&%1KN89;+GZ/'I8X
M>EQ3'%2 M[5J1^?3B:O%2G=UZSPY $6UX>;.]LW*W8OA[8^[=Q X@+)VAUFU
M<8USPJMM>]/K]L:6P6L?@@.G</MY8Z_Q+@M&\;<)+B:0-\@D2U6:W=\ED,^'
MDC%>VU.4.QE=C:I(4ZKF=1#6UZFL),-56L =G<HP553=S#;:008A./#%-9\]
M4'!J';T4RFW7V4,=ZKX7!.?6_Q/2J&)G&$80?%U8X$J!;^_M'MTL .X%6^PU
M2G7J"JJG5;FPV>A36!><*%<"P6WQQK54]!<HOF[88=^.\C?SUAUT">K<OSCC
MV/X&//JEH=B.^^$XR/)3%_;)P7</I')AO^ZPAP"U^P2R6]U]0+IQWTWVXN[K
MTYT[!ZA2<ZCZ&&A&9-P7'??0ZK7]BC+5;:M7EEPJ"5BQ /ASC3=*_\ ;[#ZK
M7?\?4$L#!!0    ( -2 453$,98R7Q,  +Y"   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;-5<:7/;R!']*U.*G)*J8 H 3_FJDJ^LMG83E^Q-/J3R
M80@,R=D% 2X&D*S\^KSN&0 #$I3E9)-UJFR)QQP]?;[N:>C%75'^8C9*5>+S
M-LO-RY--5>V>75R89*.VTHR*G<KQS:HHM[+"VW)]87:EDBE/VF87<1C.+K92
MYR>O7O!G'\I7+XJZRG2N/I3"U-NM+.]?JZRX>WD2G30?W.CUIJ(/+EZ]V,FU
M^JBJGW8?2KR[:%=)]5;E1A>Y*-7JY<E5].SUA,;S@+]J=6>\UX).LBR*7^C-
M=?KR)"2"5*:2BE:0^'6KWJ@LHX5 QJ]NS9-V2YKHOVY6?\]GQUF6TJ@W1?8W
MG5:;ER>+$Y&JE:RSZJ:X^TZY\TQIO:3(#/\4=W;L>'PBDMI4Q=9-!@5;G=O?
M\K/C@S=A$1Z9$+L),=-M-V(JW\I*OGI1%G>BI-%8C5[P47DVB-,Y">5C5>);
MC7G5J^L\*;9*?)*?E7EQ46%%^OPB<;-?V]GQD=E1+'XL\FICQ+L\56E_@0N0
MTM(3-_2\CA]<\7N9CT0X#D0<QM$#ZXW;\XUYO?$7SR?>:I-DA:E+)?Y^M315
M"8WXQP-;3-HM)KS%Y-]DX>-GBT\;)79E<:M9YV%RHN+/\4;;<4D!>S 5/EH]
M$V=OBRR3I<&7XD>=99ADSIES]"/$C^A2O*G+4N55=B]V\EXN,_5,_#3Z.'(K
MGXHHF,93_ SC&7Y>3B)QG5>JS"59C<S<N#B83&-\O[A<X/5\,A&?B@K?)ONK
MBW%P.9]CS&4\$9-@MIB*MVJE,"KM;3Q=C,79?'8NSA;1Y'QPS[,XF,UBC !Q
MLRG_YO=VY]2M2L/"^25_'4VB<WH_H84_/,C(4W>8*)B#DCB(PTMQ!?9N=[+4
M!N.*53,44X7Z##=HE)"5J" D/HBI9%5717DO2EDIFA!'3T@6*V@:*+Q7)!L2
M1V#E(?.491*(JN!EWM!V^?T?_["(H_ES(]1JI=A-\9Z\JC9"&IP@@_LTCQ0Y
M4W<J9D$4A9#!&&8Z#J:3\1Z7HQGX":''000I16-P8BK>R3+7^=J(I0+;U#[?
MGF'=& HPG]'TR>5<1/-@'"_8PHA@\VR0.7$T"L43^XM_]$E!D"GY-:1.(HQF
M(RC%V>6(Y#JEGY[J,#'^;">G,^C&; 3=P_]H9$E:JERM-.QE519; ?/GZ8G<
M:=(A:8RJ:,O1F#8=D;*%]+HW%1/,1I;J*;G_E'4$NL";TZ20ITYY*GY^>O/]
M%4NZ5!E.G@H-&2>T"W\=@KBS,9\+^UQE.#LTH:1O6=5I.0P4[UI5N"'^+49C
ML"\*<:R(SD=<0E@2$@N =[I(#3R',K!%;.GIEMA ?4R]-#K5T&QBG^5UOB8=
M^E"K$LIXHY-"U/#AI;C%J*(VK(%@+!8$$69T7& (HQ1C#>_:'!;&X W!1C_7
M,*M4)_:#.UUM/!5IM-V(5./<Y%&PFLQ;6PO@7LI*)S5T'[[FFGB;IX'XB(7^
MJ4IZPSSWCA.(NXU.-FQ 8B5OBY+=DR609$IK#Q@<V&6] /C(9!ZQ]Q%[:[8\
MN2WJO*)C)EF=*IY1*B EF>M_6CUA;^(ST!?)<Y[1<Q&#:S:TK_A=#LA#5&=J
MK4UFMU$Y!FR)?6"YQYQ +*%F--,R!:<3J[IDS4N524J]Q'&7A-%&;$?7=ELS
ML.^?KG_X=$T[!_P66@CHDS]]"RV\Q2+0$YFO-?':Q38@@]IA,)S.JOO*SFI=
M[ :.5;/2L92L*K:<IV,F1?K_S7,<[SC+X0MNE#-@XVTJTY\! K?\*11[*;%R
M0D9<ZK7&F6 ,I4J*$CPFS24K:6C%D>;6&[60PH96D<";K<',]XX<G5MT3Z?A
ML6E'&3'<BV>6^:VQI"I!*D!><7D/OSM]TMF."W%[<\-V;F.?=T1VJ9$2:!PF
M)27*:36>S&&/756EMNR$#H@)>MZN50'G!8N[7)5FHW>PWA):2.@/_$G@)I"Q
M@ 3L</^41J4/*,M(7/F\U69/U?HT0'T<4^A3.B\"AS;^OB[P@$<KJ<GG9K4B
M]9$)R9)$;'V/W.TRG;!)9 4=NU3KVNJ=L;+)D;CY.LJT-6<ESA%_L4Q9? :/
M*P4>GX:CF5A:\,#S7:2#4E'L?-*^/X)29)[7(.70=P8L??AY'-TIX9X$GPE:
M)9X]WR<I1GQK2,)4>]@6XM$&'<NLPCN+WX+3-?W*6\7O<1P?$&P;X'=@N=4<
MEN+D4JF\B6?6H)C<\'D_^/VEC6S\=?2\"2>/P'-$?)[H3/,"HV/\B!#C/7ZP
M%^RQHP&DC#*(OTY8UCOWAF(O+*4KL@Z#;)5&,QPZQD&CAEA/^@9^-1L_R*_6
M:Q_!:O\YWZXR@Q"O<]_)K IR:.+7&I8*MT: ?,!!),7:^@?9X4%GEDRV7*UX
M&V5:".=X"_]\2]@( B*3T\0?*C@X^_7L6[=!T#1^KJ0HZ'Q"WXG"V?6E#SCZ
MI L:/?[*AL./!;=[G'X,9]-46V&!%!>M+7^9[ ;A.9[P$G> ;(-.'%JGU[*-
M_3+YM48@JFQ%Q\%C\@N]'*<Q"5]L<(QE32QHB:,83%[(JB/83-%RWX@Z/V=S
MP"RA# [ <H /I"YC"F%$Z2DA;7_NC3:P^I0"@ZJJ3-F0_-!BE,,\$6<?E1)_
M+O 1 $;K4'-39#KE\[]'& ?[L?!'X$NW+NVXI?0K5="GS)R/!KG2A7Z+C['(
M]8>;/\KM[OE;%^6)$ASFLL\(K/&7JI*WTM-4JS#BC(740[]7A-W%=TIF%)(\
M&4+3"3B='_"A96C<XP'2?N9NM/B/6#& 2<(CF"0:77X)DY!<W-S1;X))*,'W
M$Q,&B,[RWRL 6PR]LCD(6?$-)=I;YLO5=W]MF(#USS[=7+T_=R0M52*WOOUB
M]O<2@1CIB*LO6,8T.U2ES$UC*RT"Y)A(ZU+F6-Q9UN2:[,=B[L:#P2=82S-<
MK; X="^\ZOQA0'.F1PJIF_-8IE*[I_7..:1SAK,D+7C51+/\V45 UA6[YRY8
MT?JYA56D$Z0?=]K8%+5++HI;ES+T3\[)\:@YLRD:A&LU"WH!MB):&,=G"(ML
M@=:QFR0RKXAO(!>X"E]JL['XQ(+,-G6U.7\+SWCYEKT-6+MSZSDD[FW?)!U=
MJEKU7#P36UFOD_<<(64-LJ2L#I^GZA; ?<?1O,<?1T*W_6/TPY4[^ C, 8I$
M0FF."M&YIPM.NL+HK4:2WIC:H3;VT"8\1^;0 53ZL"# QY9.B"(O&).JSXD"
M85-;8+/':CQB5X\D?.*5($AB'&[RML+1D^](O+5X><A!!!2?NJ2-2GQM)D=.
MR29+AT"#??->683>,H,YY^7(V3@(1C/XL-'9HQ3%8> ^)>'9$T!_:2V?!+J4
M(>N$=)!KZY6FD3Y3FHV9'B^G[8. @W,I3O3+.N-"80LE+3\;B9,R]G1=UM4&
M:6M%JN1P&^P9Y-$9]\I#?!0'RH=I9[$3_G546&_1,-$GEQ2;O;4A V9PT*"A
M3GV[//L+7HL4DI9R#H]-D6"9W?^("GC&V@/6K75S(&T\^"!4]?.T/NKM0B#1
M9H7@Q95#6!2.)EUN02G?['=)^4(OY?.8<9#1'&0H]HA#R2%)H\EVM//PM 2@
M4+Y6#=^.:BC[\<!I7U?6*1+V*NDQOC__MA))<3J9AF+K.'O(IOVLIC&*M$MC
M9.>W#QR\D_(^A58H?M'$?=7*QO>@<HEH_8WQ[;AV_L\3\*]0\2,ZZ9+U1_'V
MOY^L^UXM+4 U17)B8%*Y@@Z%% 15KL]U+GTMR[2)@%_ *\,5@;UX.>A9FWSY
M=RP&A \6 ^+?L1B Y*8)7H_D[49"08$<RZ:VCUD;O2:P1+OT GTPE&7U"P#]
M^CN7 >CZ:>67%I*";L1]^5"B3\[_=#(*6S,^9#V+6 W>>'ZQ3/"\1Z9'V$&)
M@LD+', G=9:Y/^@T\FB$G J7#=D"L 4P).]UJ51SS0"V04H[2A(*5Y  -M*%
M3GLEEX?.$%%F[ALF)T<^=Z )Y*IH2VX[2)W3[?FSGDT<+12<F;8*LCAWF1+2
M-8<:#*D)W=9 BG7N&6</(Z6U:O8AS)&IYI+'T%+M?3MI"KMGN=5Y=__8&&,?
M:*;'$?:1Q/Z_?]GPB*(F$=)H<P=[I95>PY9V6^@1=G::E[K:NM5R>^]6L=%Z
M#LWWC_U+)?\JB;S.F]K%I.^+I>&JQAE=.9U[]TS#;B.:\S3.8'BCX5&+D7C?
MXLE#T0_<=S B)P\*/]S4; ZN4;Q<9%^D3BWEL1!NZVE=89'W:PUA &[9"7&O
M ,>.I[D#959ACB8O81->0OM#F8);K,/OKMC5<.<H3K?W<_&3K\$%QSH9?AL\
ML)<F6/=C=W#F=%"F.URYBQ6?#F/%USM,&S):YGI>Z_&UV_/?.,ZXJHY_I?CH
M[.P03<2CZ$F'>>'AW@)[;9?6L0Q[.R;^4\D@%5C'&*K#V\K#H0;[%; A'S68
MFK.T^.Z=J3@T"Z]6HG--=6[_WONH?WG =9%J^U?A5U_.X7/O8O>+6951@^<8
M2L;'?C(>T?VK4[6C8OTVC-BWO(Y;Q QC^%Z'@GD3A+C865@T< "E7=%.7-]\
MA&<F+2*".VX_A M(Q7M,[#RU \V]V_BO,)6(C(]=@'$MQ/CWDT\&!<#7?H'6
M0W5>3\4YJY=5BHX'K,T>(_J\ZG*?/E#@+ BZ1PZ-+@G<)?;!I6R201!ZI?]'
M2?3507+?UEZZ4KU78#R22QP"K/9^BR*BGW;;0!CM@?N^L <(;Z@ZB"T'XD>,
M;Z+E_MZ>U%9^+:FY.FEJ2FT)Z4B:CFU=/R\)^J!\UB6Y#]309KT:VK&BQ+=3
M0P.?VY 37P;,A>='E/AW*Z#Y]Z7?2@'MFZZ6^17';[E:1N\K=Q$W(-A&UQOA
M.9%]8\4TM=T5)=W[-LVRB3M9(LOR'F>X0^@P3:NZRM,];&=<!R6W/<:AC41^
M P9_W73M<Y3C<;U/N$U[L!G]BEGY0RO%_??OD, 5]ZISH\4R<P#</H\03R;T
MO,%X E1=)+^(@;;KV?Q2S.(Y2'*WQT[QH)10]NH^$+N,[HOX^OW76MO[T+.%
M?> @'I^+/Q5%>@>:'=1H*W3\U,&4VK.I'7L:A#2X;:FPU30._NZA D$/)4SH
M*0H@SAN$^/(6B_#XGN;%P6)!;?B3V:SIBRT5Y%AY2^WJ$OB !T^I,3^8S^?B
MS^QP:%/.7[ON;2[Q^2*GASCF8W%Y&0*FI(@J",>U6Y^1:)N!8& TI0<F)C.(
M<1'%_'H\!5NR8LFZVG:%0"6>4JJ2MFWVDV QI7[Y<3 +P<\?H5D*>I KNE3M
MZSPV"F<8"7XNIA/P-(KV)[#!3"Y!#G%][]F.[@D,^ZP*9!-CF4LP<W%.;R=S
MZH6/@F@Z!T5T)?W&16$ )+"5(VW3U[N1L"MGN1Y @BN"A?%E&;UT8)1GNHY<
MU^L/C;BR:8IV]_6&.S&L%^KU, XXE[9[X+"JXA>2?ILB$M]8>Q6=%IWUB_'D
MRAY;EN(<C%F8U%O.\6YM^RDIHMJ[AU^J3*M;K\($CG$73Z9_H8C!W?U\G[^Q
M?@JQH;<;V^8:'M?"-GLST+2'.[4P]6H%%,RM#@#0E2;+=(L--C!^5]Q1?2<X
M6A ,.(2[ZBEY0]MMW5,<ATC7=+%>#48=LN<#ZW2LH,Y[.O<P,[@EQEH[B>IC
M#4P[2%&[#+A3(A_>KZE4S"?[J"76,JY(#9GME6V/UEL?^:S1:X#Z/'?XE6WF
M%%YN##\T)C=!KV/V>(S+>ZE?S]+Z"6(\B44\F^+WY?!<:]VN+V1O[EC,9@LQ
M"1>$-+]JZED4+\CK3_D9I!#^\*/7['<6+<C)+,B;G>'_#W)G$Q';MZ+LK<16
M5RZ6A? 8_%P1G.0[&X4[!L7C'IM(>L=+WY3LC#WO CUJ>K]B[OW"3[WRRK8
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MN.SSVF/=/N3.!ZKKD9ZKFDY9ET=0?B&,TUD4$.T"HL4A@_%(\KV/+@XM2<O
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MUXI8]P#:2B>.%+5:\;*:B72#M2I-E_18'K2F,@TP1&_CH@Q@=4L+W!ZU' H
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M&Q5V&<?M'=I5:=>&JS&%C\#L6&^ -8C1:_9TV7CH\@KK0FK4T8D8V 0M.^%
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MTRHG.[MZP[3D<F?@%C7<54SC(K*$ZU:CO,?8=!CI$QA)"C=*VLK &UE@\2E
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M4#,D06?#KM?\%I<'4CCN1./M*G6>5:AYJ'<-0%TOAG4ADPS4'-)_(3BB[^@
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M/J/6;,P0?5L4Z CS_#.K=1>+>&@>F<6BF-\VZ"XV?.K;_Z>MO[( .][+WY)
M&5.CFS^X.'QZ^'.5D?DKC<?AYF]=+A%ARKP\O<.E]C#TGZG2_/V(>5,76_F;
MC7=%71=K>;E*$Y1"#L#O[PHTLLT;+G#X(YX?_Q=02P,$%     @ U(!15+1A
M7'4<#0  4BP  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL[5I;;QLW
M%OXKA%NW-B#+NEBRDR8!Y'B[2= B0=)V=['8!VJ&D@C/#"<DQX[ZZ_<[AYR+
M+K:3(.GF85]L24,>GNMW+IPGM\9>NY527GS(L\(]/5AY7SX^/77)2N72]4VI
M"CQ9&)M+CZ]V>>I*JV3*F_+L=#083$]SJ8N#9T_XMS?VV1-3^4P7ZHT5KLIS
M:=>7*C.W3P^&!_4/;_5RY>F'TV=/2KE4[Y3_O7QC\>VTH9+J7!5.FT)8M7AZ
M,!L^OCRC];S@#ZUN7>>S($GFQES3EY?ITX,!,:0RE7BB(/'O1CU764:$P,;[
M2/.@.9(V=C_7U']FV2'+7#KUW&3_T*E?/3VX.!"I6L@J\V_-[0L5Y9D0O<1D
MCO^*V[!V<G8@DLIYD\?-X"#71?@O/T0]=#9<#.[8,(H;1LQW.(BYO))>/GMB
MS:VPM!K4Z .+RKO!G"[(*.^\Q5.-??[9+'E?::=)0T[((A574)+SVE=6N2>G
M'D?0PM,DDKL,Y$9WD!N.Q*^F\"LG_E:D*MTD< K>&@9'-8.7HWLIOI)%7PS&
M/3$:C(;WT!LW H^9WO@.>I>5PR_.B><FG^M"!M^ X#/G$ ,=?8A_S^;.6_C-
M?^XY]ZPY]XS//?M2BKZ7',7J8U?*1#T]0# Z96_4P?UGB*O*ZF(I%MHE,A-K
M)2WKM"?\2I$V2EFL1:I341@/%[M6@GZ XRNKL4%VB/?O(#;HB419#RP0\ZAG
M''RKK K;K4H%@$1\?]X?B[G.,E(S%B?2K9CA[P?]L^:!68A,2WS#H2 C'9!#
MI7WQVPH";_!3'Y&8JO#Q##I_R;)U5HI<^95)Z:P>K[<I5F7K'@#&(9 ='0K$
MLS+07<D;)>9*$9=)5L&EB5TBNH#O% DIQGFH"#B%S0MK<GJJ+=$K%4..2/&<
M"7<882F$^I"0*^)16=ED!701I=6)$N9&63Z&S$<F@$P25&]D5BE:[V6QU/-,
MD5843F[4*_.H V](S9-&FZ1>G!"DP2Z]+,(JG8)WO8"F04X76Y1[ "2_8E>
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M*X5NVM("/%\8X^LO=$#S&O&S_P)02P,$%     @ U(!15.MBEZ-7)P  H88
M !D   !X;"]W;W)K<VAE971S+W-H965T,CDN>&ULW5UY<QO'E?\J4THJ(:M&
M$$E+EFS)JH) R:)#22Q2<3:UM7\T9AK 6(-I> Y"R*??=_4U,X!(6TDV6[4;
MB\!,]^O7[_B]HQLOMJ;^U*RT;I//Z[)J?GBP:MO-]X\>-=E*KU4S,1M=P3<+
M4Z]5"W_6RT?-IM8JIY?6Y:.SDY-O'ZU543UX^8(^NZI?OC!=6Q:5OJJ3IENO
M5;U[I4NS_>'!Z0/[P76Q7+7XP:.7+S9JJ6]T^]?-50U_/7*CY,5:5TUAJJ36
MBQ\>3$^_?_48GZ<'?B[TM@G^G>!*YL9\PC\N\A\>G"!!NM19BR,H^,^MGNFR
MQ(& C%]ES =N2GPQ_+<=_0VM'=8R5XV>F?)O1=ZN?GCP[$&2ZX7JRO;:;-]J
M6<\3'"\S94/_FVSYV2=G#Y*L:UJSEI>!@G51\7_59^%#\,*SDSTOG,D+9T0W
M3T14GJM6O7Q1FVU2X],P&OZ#EDIO W%%A9MRT];P;0'OM2\O]5*5R55M,JWS
MHEHV+QZU,"Q^^2B3(5[Q$&=[AC@]2]Z9JETUR>LJUWD\P".@QQ%U9HEZ=79P
MQ)]4-4E.SM+D[.3L[,!XW[A%?D/C?;-GO)E9KXL61*EM$E7ER0S(A;7J*BMT
MDYP735::IJMU\M_3>=/6("G_<V#6QV[6QS3KX]_#VGL.\9-950T(\Y_4>O,\
ML7_AFC)=MZ"#B5DD!2RSZ>9-D1>JQA4J6%I1W9KR5N?PC^06/C9=DY1JVW2%
M,"4K5;%N0-&6JL:YDDUM\BYKD[)0\Z(LVMUS>+<%_0&%ZH L^'X#D\+'&?!7
MUUFA2GPDU^NJ6!298K6#H4V[TC5(;=OJNGF>+,VMKBO<#A@%Z-)-6RSI:?C2
M/U_2XC=^\4F[4BTLIFATLJC-.FG!/"2MX?_"NN"UQ"#Q8%Z J*Z&!X$?\'$!
MNMLUP-VFF23G';^%3U=+@VLMUAO8]4:>3F8??KXX?WCZ7;)1N)PB2QU_VQJ6
MV20K=:N3N=9HF=!2YET)O#4U6(12[70^23[B. ;&K9 6%+@.M@+F79NJ:.%)
M9/QPC:HA"IH">$P,U+1OO$<P/[ <MUS(@,F[M8XGJW4&3( 7LJSN\"$PW0D(
M>"-D6+E736-@SUJ@>UNT*YP6^,44R5XEVQ6LL&B3HD$BYVI>:MD%+Q;P=ED"
M+X"ZK*MKG:=$*ZY"K4U7M9:K3(.J\%EP(+ ,&&^7X/:OD8Q),J4= /7O< ?%
M *2\);*Z%3 HUT <&$.=,S$TN) SMC*[=_@U"YI;(*J&6QFIP2'Z/O8((1;#
M+,AA9I\;M\J9+W;KPYW7*EO!#"51R POFJ9C E3^"YA]OWLPS1I="U*U576M
M*GP+/1'(6Y54X/B*BKVSU;=%5Y,&Y?H6O.Z&#5^!+A E0U699KY,;V;)XR<G
M#\_@_YY,DC=N%8$2>I;AAV =.B#;P.[8E>9@/KL&J9FCBR=>;%<%K%#QCH>R
M ]\%G-W UP5\'.\P/-]5+&G&,9^>L,_SN#B6 FE&D:$/YGIG(L%S&P22%7_
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MS%0H\O$6*IZ=LI^'>60@C=4J%E13PYH2[-RQ2@B/,7/]\XP,1'DY(T6T4*%
MW$=8PVLD TX^%<L4:!0 H !MX*EWPM$>ST-!<2[#2VG@+2P\ZQDT1WBHET$<
M34G)+;:]1$@JQ$[#+>#56EW[4D*4+4V8"O=:NI84A8Q8XV>+DE,">RI.%J#0
M=EI6I3T,QG8^!]B;4S]13\]Y.LP,LRW \@628=.UN)&2@[*O<%$''Z+2_5TT
MVN^3KS('+5)WC4U]R3ZLKDH*=#18)<])Y?22$L/2@Q7P!UZ\:&J%Y4&'N[E_
MC3#P('+]C@=](\K.&D#QFWV9ZM/HA&QY-LSKM530XSIZW^IX#U!4@K^PKL8*
MU*X <B>7&@S(=+,I*<3A]2QUA:24HZ_E&D.B%,2XZC!YW=58;ZK%=(*4/H1H
M_Y-N45;!S 92B<),+0H5!K@PY4Y".[,V05'6[7$1!"Y?QX2'1NK$!B/(;L?A
M7&<<D.(HUFRY2@-5R0_RKU>K(2PB>N^&EO<Q!5&O 5%36@Z>+$N'ID0DNE+D
M0=I&&-J@<5MI(*47L9^=<C6P&)IB/Y*WQ5Z:).%G#3)/ \B%P%1I6P)1<5&R
MT :7&O5/%O*V6*[&Q!;I=+YL"A%\*119&Q6\R.LQ! CK94=D20DXI*&(5.?L
M%&!D1!&#P04*BR]Y0LA&P3W7S*K<%5<<SZE0W]AD '> 569+;3=5:.S(N7C!
MMB\Z3^FM[K(V )W63"H;%]Y$VY(1% :Y^V709>#%DZIWTB3!P!6 !K%QK;,5
MN/UFS<JCVCM0*\EC_9G93E8$[+1KAZ0F*V1+*%MG_-; U+%1XXH%M0 Q,*(]
M1RUC-"*=64"C"G$C_<V<LI$2>^DP=Q<#:[&M19S&"',7)/X[$8^0XV+11P?
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M06M_?52G_@H>0V+TW72 >:"P4>U\="9TG)ZZ+8B;[^XAPR#YWCLXO;HV:+(
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MP9R<(C$E$R,2@,:;!<+@_><<#.(!#)1@Q('B,I<!_#(^1M#1.4=I_8EGY.=
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M\TGX+8H08TGRF(4-( RZCU+S;J>"Z8*A34YQ^U@"2C[,Z,JOB; UXZ]R:=*
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MA95'C;7/GN6@AH9-HX'%VB\Y1^__D \LSOL-9MS &C":A+&@,8FO4M00W_B
MPA3\(I!%*.2H<#<E%))VCB7,HSD<IGGOF/M1PP*4%(%OZ4>'.# T)+5LAG,_
M@[!EBS_A$'*]6;ERN 0";VAD2I+(8Z&Y935=A8O\0PAZ8>*35 \\\OS71ZDA
MWH<P/WY]P;7)+YT>)87/FT)=AJM:,/;CKZT12S@M>4ZBW1P"H:P"%3@EN=6T
M6&MTTZ?)#RV"U;&BGY-T_(-D_)N+X5/E?[+R@G^H,3[.OW?Y2K<KO(J\,DL8
M>C9]_.@>=\?Y-UVSI9]M7#1=UVSH)1@%H%#Q ?A^V8 W)V]P@?!#GM__'U!+
M P04    " #4@%%4#OCJ])H"  "2!0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S,BYX;6Q]5%%OVC 0_BNG/&U22T*@6U4!$G2=MFF54&FWAVD/)KDD5AT[
MM2^E[-?O[$!*I<(#Q&=_]WW?V3Y/-L8^N@J1X*56VDVCBJBYBF.755@+-S -
M:EXIC*T%<6C+V#4611Z2:A6G2?(IKH74T6P2YI9V-C$M*:EQ:<&U=2WL=H'*
M;*;1,-I/W,FR(C\1SR:-*'&%]- L+4=QSY++&K631H/%8AK-AU>+L<<'P"^)
M&W<P!E_)VIA''WS/IU'B#:'"C#R#X,\S7J-2GHAM/.TXHU[2)QZ.]^Q?0^U<
MRUHXO#;JM\RIFD:7$>18B%;1G=E\PUT]%YXO,\J%?]ATV(LT@JQU9.I=,CNH
MI>Z^XF6W#P<)E\F1A'27D ;?G5!P^460F$VLV8#U:&;S@U!JR&9S4OM#69'E
M5<EY-%MUAP&F@)4LM2QD)C3!/,M,JTGJ$I9&R4RB@P_W8JW0?9S$Q,(^/<YV
M(HM.)#TB,DSAUFBJ'-SH'/.W!#$[[FVG>]N+]"3C#Z$'D*1GD"9I>H)OU&_#
M*/"-CO"]5^^?^=J1Y6OS]X3 N!<8!X'Q$8$;1Y+O$.;PX+!H%?SDR^C\ML^=
M0W+O;>IIQJ7ESK2T/8-&^2,3.@=\:F7#+<.117 4! 5!9AP-X+Y"N#9U(_06
M6I)*_F,'5'F@%?[VGGL-J)$JDWMK.7*C9U*$_C'/: ,:^U+:KA2U+\6OBE#.
M%2Q:J7*_G][7>A^\&DP3.(=1 EL4UL%/C_(_A=QBE5$YR+JQK.G!#H8>G>[1
MMR*KV"E?V[=%IPP:CCK0>V<6'_1)C;8,KX&#</1=R_2S_8,S[_KL%=Z]5K?"
MEE([]EMP:C+X?!&![5Z +B#3A*Y;&^(>#L.*'TVT'L#KA3&T#[Q _PS/_@-0
M2P,$%     @ U(!15%=T>VE,!0  7PX  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S,N>&ULM5=M;]LV$/XK!Z_H$D"S)5J6K#0QD+AO&Y:MJ)/NP[ /M$Q;
M0B31)2D[V:_?'27+LN-HW88!@7-WXKWR'O)XN97J02="&'C,LT)?]1)CUA>#
M@8X3D7/=EVM1X)>E5#DWR*K50*^5X NKE&<#YKK!(.=IT9M<6MDG-;F4I<G2
M0GQ2H,L\Y^KI1F1R>]7S>CO!YW25&!(,)I=KOA(S8>[7GQ1R@\;*(LU%H5-9
M@!++J]ZU=W$SHO5VP9=4;'6+!LID+N4#,3\NKGHN!20R$1NRP/'?1DQ%EI$A
M#.-K;;/7N"3%-KVS_M[FCKG,N193F?V6+DQRU1OW8"&6O,S,9[G]*.I\;("Q
MS+3]A6VU-@AZ$)?:R+Q6Q@CRM*C^\\>Z#BV%L?N" JL5F(V[<F2C?,L-GUPJ
MN05%J]$:$395JXW!I05MRLPH_)JBGIE,N4X<H%]X][5,-SP3A=' BP5,2Z60
M@5NN'H3A\TS 3,2E2DTJ-)S=D42?7PX,AD'&!G'M\J9RR5YPZ3&XE85)-+PK
M%F)Q:&" \3=)L%T2-ZS3XD^\Z(/+'& N8QWVADU1AM;>L*,H50F.Z_+[]5P;
MA:WT1X<;OW'C6S?^/W0#4YFOI4ZI;4^5M]OJM0&3"!!H5RXMN4QUS#-X$EQ1
MA3SK$PG7@=AN/_V".-K^N-[^?+_]>K_]6Z$$Q!BG2K4@3Q=P]E9F&5<:T@)N
MTRS#Z/5YY7#*E7I*BQ5<Y[)$F_>%$K%<%>F?J/NSU-@*VJ2(,63?\U3!%YZ5
MHJK+:YZOWSS?B>[NM,M? 7.B80"OOQLSC[VIN4/9+[+XX;X_Z\-,;C"E=%4<
M-+EW#IZ#YUNSON(B%R(O *OX6:"B%GA"K4L5)WA" %\I(7(;IN<$HZBE3=RA
M;"K56BI,'0^3N6G7F+P/'3^,&FJ,Y7218BA##(FG>G=@618+<A:Y7LL9<8>R
M.SQ0T8_MKLI!A 9W7XEN\[-R;J3!UGD%GN>,QUY5$")=")U@'(#O>-&H*L0'
MN?G>M*N'6I'CCT=PYI]7I >!$Z+ 8TX0!? K=J<Z7?E6&BWZY5HQ?[3?9Z2]
M$;"AN\^ ;WB:V2[!BPPT-A&<L?,JQ'#H[4(,68@ACJENV"<L@#NK_:]A@O9]
MS#L$+W0\!,*+&'&[,?(!K]?_#2/C8-C""'&'LK_'2!#MF^:8_B:01,.PW;?(
M'<JZ08+=%/JM%(CS'']$W<_8\!14F..YK*5"W*'L.53&X3X@HMO\(50\?U^]
MFHT<ZD?,RAN>1,K0"=&<5Q%CQ!5U9>2X?M@)DWW:AV0'4D;[_2&:^<"PT;\!
M*3Y&0VBT!*,01R/*"]O[O\-DZ$1T,."&X0%$U?XHL@48B1J&ECTA9#9"FZIC
MN+*])!6A@1O@.9(6*;'4QGK$$36SDA5B1P/FDN%%(XYT$59X+1:(.]VW>5X_
M3_^X@L?.EX3&C47C-C4)E,61;PJG=M[H%=B*=#_S1V%/ VDWV=ZH(J&A=R-0
MC+SH=XP:HV;4&'6/&CAPT=A2XB[=5@6E3#" PWQG_.",.#5]=#JB-\2%7O-8
M7/4P$2W41O0F=PG-"OL(\H,(:$0YT73/JFX Y[P27PY03WIV([A&E0S?%OJE
M"61*'7'#=:K;Y^;;>K>H](6HAJ/J-G"CZM_(KN%+@_O2+#&)DN4JP9EJ4TD0
M4(S^]FM;GW:KC2AJR0YYS2EC@7.<:W,MU5?2J0X8M(;^7*B5?=IHK#->'M7\
MWTB;U]-U]6C8+Z^>7G@_K*A/,[%$5;<?XAZKZCE3,4:N[1-B+@T^2"R9X M0
M*%J WY=2FAU##IHWY>0O4$L#!!0    ( -2 4520!9+<AP(  $L%   9
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M''8=K,(!\/F4<UG?H(+F-QW7_P-02P,$%     @ U(!15+;O#"JZ!0  M@X
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MB15J322+_4M-<F*1Q7"G+.7?9;Z?\7G8SS)(DK"7Y/ -C:&6(Z#]. U[<DT
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M6L))[*7I,&?IN",W&<^U::Z]Y#8&<YH+K\'< !\MEY$J24,("< +I2!?ID"
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M*W$MLXS$#B$I@W[$'-NP*1KZ!@\"YAJFI:Z^MQ_+AQ"G!3?3P*:!-+0[MHN
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M-A3]*Q=:,<B $$F49$N9;2!.NJW%L@9-MST,>Z#E:TLH1;HD53?_OI>4K"9
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M59;FE5\V](- [0SH^UXI>]XX@>F7L_X*4$L#!!0    ( -2 451!%]"^/P,
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MA+T25($$#]P HX+Z+].=9RJ)!Y[S,">F9<_T@@8U"+#.#S<%$_"95 R@>P=
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MKK^GV %4)P.JD[>B^@9O:4P,9<RA![[6I=W[[7%0Y!ON&^K_>JO-.&UKTN;
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MAY='.P?T@&W5\S5#XK4V;#OU7W&Y)X7C5F3DKE#G20%U@WI7 ]1V0ECG,\E
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M)U-U]5MN%D)9)F%.DE%K0"F9JE-6$]2E[QTSC=2)_#"GGPL8!Z#]N=:XGK@
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M<<H;Q??%.<B&*\6SXC(A."8B#]#OMYRKUYM\@/HH;?4;4$L#!!0    ( -2
M452\ZKN%Y@(  ,4(   9    >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;+U6
MVT[;0!#]E97% T@EON1&4!(IE]*F@BJ"TCY4?=C$XWC%>C?=71/HUW=V[9A
M$\-#Q4OB'<\Y9R[VC/L;J>YT"F#(0\:%'GBI,>MSW]?+%#*J&W(- N\D4F74
MX%&M?+U60&,'RK@?!4''SR@3WK#O;',U[,O<<"9@KHC.LXRJQS%PN1EXH;<U
M7+-5:JS!'_;7= 4W8&[7<X4GOV*)609",RF(@F3@C<+S:1A8@//XSF"C=ZZ)
M364AY9T]S.*!%]B(@,/26 J*?_<P <XM$\;QNR3U*DT+W+W>LE^XY#&9!=4P
MD?P'BTTZ\,X\$D-"<VZNY>8SE FU+=]2<NU^R:;P[78]LLRUD5D)Q@@R)HI_
M^E 68@<0=@X HA(0O02T#@":):#Y5D"K!+1<98I47!VFU-!A7\D-4=8;V>R%
M*Z9#8_I,V+[?&(5W&>+,<"8,%2NVX$!&6H/1A(J8?)(RWC#.R2GY2I6BMC?D
M> J&,JY/T'I[,R7'1R?DB#!!QNB)/=1]WV!$EM=?ENKC0CTZH!Y&Y$H*DVKR
M4<00/R?P,94JGVB;SSBJ9?Q"18,$T0<2!5&T)Z#)6^!-!P_WP*?U\"DL&R3J
M67C8J\FF676GZ?B:!_@NF& &3B^Q_#'YMU4_+]&?S QD^E>-6JM2:SFUU@&U
M42:587^H>R'A 4>+!B(30DN[569/05 7Q+ZF%S(X#*R.G3SWPU:CV_?O=QOQ
M%J?I7J=VY?0LS7:59KLVS3DU(+!Z(WS0ORD:XR#%(5M3OTY%W'F';G4KM6YM
M&K.7G2"YAB3GA+,$]G6EG@Y?Q4>@JJX.9U5D9[54$S>V0.%>X.YATBE;%X-%
MFA3MKSQ$ST1[E6CO'8H?!D]S,_B_Y7^%+PH/U]_?F>]8UY7;DYHL92Y,,1HK
M:[6+1VX#O;"/[8YV>^.)IECP5U2MF-"$0X*40:.+[Y J=F9Q,'+MMLA"&FRN
MNTSQ.P.4=<#[B91F>[ "U9?+\"]02P,$%     @ U(!15$&]00H\ @  NP4
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M%80IT.\+SM7;Q)SX_KY._P!02P,$%     @ U(!15,?657,X!   H0T  !D
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M?'.><O-&LF5VPO [DY+%V<L%#13[4@/U^8PQ^?0F'2 _U7KQ/U!+ P04
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MJ)T#G2^4LEO#7=#\-0S_ E!+ P04    " #4@%%41!1>E%4#  "$"P  &0
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ME88F)/>XI#$9E36@]YF4YGYA'32#]_@?4$L#!!0    ( -2 450;"OT;S0,
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M@"BM@/F^%$*_3*R#ZK4V^P]02P,$%     @ U(!15+/[D"A<"   F3<  !D
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M26J(O 81',1#TPU")+34,AC(#KO9[G/ZU5H@8)VPWH4:A!B$5MJ^&X02&\P
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M5F>.+(H ^2(\3^)& 'G1&.1-E;B1CHS)RO:D#W QFK9R'7O6IY>O*UL;+ +
MC=P%K#LTT%]H_/@0]1Y^SG2HCP _HVGQTQ$DWM 9 71&8P\SIPT1;XR- &,C
M-\9Z!HBKBHX 6:/5/ $2 S;&TY:?]@")]9JRCR+=(W%#X1G:GM@#^L;NNG/B
M.(KU K4/-=U*="$<Q19 B@'58S>J>\:;J]R, :+CF6ZGQ "X\5SW4V+O9D$,
M"!W/>C\E]JZ(X][U%#>B?R@%5W8A_F7=/ ^$Z'#Y!R Y3F8*"8#8>*R,G2PD
M##=)K.@"J!Q/VV@8"PJ]QF766T& XXD_CA>E_(<;F9A@VF(BH'3BC]*^)H[L
M9:*#,+%TC!. X,0-P?8,\ZH'$X#?9";X30!^D[G@-_&&WP3@-YD5?A-O^$T
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M\[SJ1;$$980GZ*1DX0[5MH8M66!@CH("!0L4+ %0ZS-%R01'O_0E&)JP9]E
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M&!.FZKFW?C&R<I/@6AJ<*]WC#G\K@+(&^/U&8B4T+W:#]M?'XB=02P,$%
M  @ U(!15-/R-&)- @  %08  !D   !X;"]W;W)K<VAE971S+W-H965T-C@N
M>&ULA951;YLP%(7_BH7ZT$IK !,(J0A2TFC:ID6+FG5[=I(+6#68V4[2_?O9
MAM!T(<U+L,T]Y[N'8),<N'B1!8!"KR6KY,0IE*H?7%=N"BB)'/ :*GTGXZ(D
M2D]%[LI: -E:4<E<['F16Q):.6EBUY8B3?A.,5K!4B"Y*TLB_LZ \</$\9WC
MPA/-"V46W#2I20XK4,_U4NB9V[EL:0F5I+Q" K*),_4?9K&IMP6_*!SDR1B9
M)&O.7\SDZW;B>*8A8+!1QH'HRQX>@3%CI-OXTWHZ'=((3\=']\\VN\ZR)A(>
M.?M-MZJ8.+&#MI"1'5-/_/ %VCRA\=MP)NTO.K2UGH,V.ZEXV8IU!R6MFBMY
M;9_#B0#[%P2X%6#;=P.R7<Z)(FDB^ $)4ZW=S,!&M6K='*W,G[)20M^E6J?2
M&1=:0:M<HGLTS7,!.5& %D3M!%44).(9^LZK'/T$4:(?:T9U@7Z>$MW.01'*
MY!VZ0;1""\J864]<I?LR[NZF[6'6]( O]/"-5 /DX4\(>Q@_K^;H]N;NO8NK
M>^RBX2X:MK;!!=NW-.6[-$RGN5<F#7]+\P$OZ'B!Y0TO\$SW?>$;56A59H_L
M4^P'?N+N>UC#CC6\Q@KZ6(TJ.F'Y87B!%7:L\!IKV,<*>UA^W,^*.E9TC17V
ML:)SUBC _:Q1QQI=8T5]K-$Y:SP.^UEQQXH_9$TS_<*A2\3X_ T)_'C\'](]
MV>7FP%P0D5.]#QED6N<-1MI -(=0,U&\MAM_S94^1NRPT.<V"%.@[V><J^/$
MG"7=ER#]!U!+ P04    " #4@%%4ZM+6<#$#  "7"@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970V.2YX;6RM5EUOVR 4_2O(VD,G;;$A_JR22&N\:9U4J5K;
M[9G:)+&&(0/2M/]^@%W/L8E5:7M)##[G< _W&N[BR,4ON2-$@>>:,KGT=DKM
M+WU?%CM28SGC>\+TFPT7-59Z*+:^W N"2TNJJ8^"(/9K7#%OM;!SMV*UX =%
M*T9N!9"'NL;BY8I0?EQZT'N=^%YM=\I,^*O%'F_)'5$/^UNA1WZG4E8U8;+B
M# BR67J?X&4.+<$B?E3D*'O/P%AYY/R7&5R72R\P$1%*"F4DL/Y[(FM"J5'2
M<?QN1;UN34/L/[^J?['FM9E'+,F:TY]5J79++_5 23;X0-5W?OQ*6D.1T2LX
ME?87'!ML$GN@.$C%ZY:L(Z@KUOSCYW8C>@1XCH!: AH2PC.$>4N8OY40MH30
M[DQCQ>Y#CA5>+00_ F'06LT\V,VT;&V_8B;O=TKHMY7FJ=4U*WA-P#U^)A)\
M!+>"/U4VI[JDP,G+BYPH7%'Y7L,>[G)P\>X]> <J!FXJ2C5#+GRE S*R?M$N
M?M4LCLXL#A&XX4SM)/C,2E*>"OC:26<'O=JY0I.*WS";@0!] "A R!'0^BWT
MN:5#!SV?IN>DF &4&3K,)MS,N^3,K=[\C-[Z( 1ABKZ /7[!CY1<3HB&G6AH
M1<,SH@^SNQE0)J6NA#7<R'+-F?&T@A&*%OY3?Q,=H #%IZ#< <I"V(%.8H^Z
MV*/)V*^9(H)A<V)@>MY$(Q+WED9AA 8FQB"89NG A$,I"4.WB;@S$4^:N.=*
M!U\,<^LR$H^6GV=),C R!J$,A0,C8U 8IY';2-(922;+,R<;HDV44U69=EKI
M/U1E.HH^2N>#;1AC/B;#FG1@4G@FG5D7>?8_:C(;+XWB>%B4#A0,XL'WE[M0
M?:T3'S#X>Q4$;RC,LLVJ\S@/'"Z")!NX<,$@['W\C0VG6MA+VJF/WI4&)WV<
M7F(V(T /*GN;.6W!\5DU.@O6+E0R+,/<@4(HR :>_-Z-71.QM9V/! 4_,-7<
M=MULUUU]LCW%8/[*=%VV$_@KT[1L-UAL*R8!)1LM&<P2'9)HNJ!FH/C>]@6/
M7.DNPS[N=.=(A 'H]QO.U>O +-#UHJL_4$L#!!0    ( -2 452\ LU(C00
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M,0'-?-A.?4^WHTM3G):>NSHP)>[VS71RP YZE1SH54V-V,Y-#=J.!7G*T[D
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MB%BN!L#?9UDFUQ^4@\U+QA?_ U!+ P04    " #4@%%4")P$=*T$   S$
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M%S#K #.S,JT5LPXYEGB]Y.R(N(Y6;/K%+*9!*_N$ZKK?2J[^)0HGUU]HP6I
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MO>HN@>L ]?^6,?D\T GZ?G7]"U!+ P04    " #4@%%4C7V-5N@"  ","
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M@UYIT+.);LEL6A.BR&@@^ 8)H];>S,#6QEKK;&AN=O%>";U*M9T:?<H*QE\
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M,3Y#-9^AD_ 9JOD,'6F"W=112@^=U-&R*.K@-%1S&G)SVBU^IFF>ZEA_H+]
M->F@Z!2!#FI:"MS]UAX*V^^5[;K^NY]N&7\AQ#:(.M6+UEWWCI0G;5MRQ,X0
MO! L6H/D[=V.I$2L[2V3:4?S3!77"M5L=9-U9>]O#N:OX<6LN(^JU1378[=8
MK&DF 2,KK=+OCW52B.+&J7A0?&OO8)9<*9[:X8;@A BS0+]?<:Y>'XR!ZMYO
M^A]02P,$%     @ U(!15.,E>_Y<!   51$  !D   !X;"]W;W)K<VAE971S
M+W-H965T-S<N>&ULO5A1;ZLV&/TK5G0?6FDMV$ (51JI#7=:IW6+6MWM8=J#
M"TYB7<#,=IKN_OK90" QAK1WTEX2,.?[? [?9Y\X\SWC7\66$ G>\JP0MY.M
ME.6-XXAD2W(LKEE)"O5DS7B.I;KE&T>4G."T"LHS![GNU,DQ+2:+>36VXHLY
MV\F,%F3%@=CE.>;_W).,[6\G<'(8>**;K=0#SF)>X@UY)O)+N>+JSFFSI#0G
MA:"L )RL;R=W\"9&K@ZH$+]3LA='UT!+>6'LJ[YY2&\GKF9$,I)(G0*KKU>R
M)%FF,RD>?S=))^V<.O#X^I#]QTJ\$O."!5FR[ ^:RNWM9#8!*5GC72:?V/XG
MT@@*=+Z$9:+Z!/L&ZTY LA.2Y4VP8I#3HO[&;\V+. J TX$ U 0@,\ ?"/":
M .^] 7X3X%=OII92O8<82[R8<[8'7*-5-GU1O<PJ6LFGA:[[L^3J*55Q<K&J
M2R@ +E+PF]P2#NY)0=94@E6&U?@56+*\9 4II !L#7Y5O;@BG+*4)BUTR80$
M%S&1F&;B4L5\>8[!Q:=+\ G0 CS2+--SS!VI&.MYG:1A=U^S0P/L( */K)!;
M 3X7*4E/$SA*:JL7'?3>H]&,/^/B&KCH!X!<A"R$EN\)]ZIP: F/Q\-CDEP#
M%.EP&(VH\=KJ>54^?R#?$Y&4$[4,FVJ-I/3;E'Z5TANDN%8CZ4D7@)B*)&-B
MQPGX\Q?U&#Q(DHN_1J8+VNF"407/A+_2A(!$=9"M/^KHH(K6>]CK OKZS;\>
MU\P"\F;N*2BV@.#4:T$G[*<M^^DH^X="$DY4[P_1K\.G1Y.&H4%LV<=$06"0
M[V.@&TWMY,.6?#A*_O-;J39?56I.Y(X70.W"I2XV%H)(ZV(->RRNT-0WN"YM
M*']JU"RVH3R])&V29JVDV:BDNYQQ2;_ARE+49E6J?4J9W)D>F_6IP)G98WT0
M,A3U$;Y=3=2JB<ZL[H1M"OI-E4C9XPYSBC.@EJ$@ EQLE*>+2YN<J-\K* @-
M.7W0+#)+U,<$8627!-W.;]Q14<L=URZ15WZB34<UF\RJ/<QN$&Y?CJ'% D&>
MH<6""0<6/SSR3CBJ17MA>?#"EV;#'.JR)M<Q@ZE)<VD!A9&YDUE 030D!G5B
MT*@8B_F/[.^PLRCH_1^& CL#@_Y_LI0F_/CU>6YD%J(/0K/0+(0%% XL>M@Y
M(ARWQ+.FTL2?+-[>FNACH-=;%!;0+!C@WWDB'#?%C_L*[-O;E;EAO0,3VS #
M)@D[EX3C-OE]G@(M_N;UBO0.4'P&=*JJ,THX[I3?Z2VP;W(PZ,FR@'S3+6T@
M-.0NG6/"<<O\L+OT/<[\>78>$H]"3H\IG4^B<9_\D+<TN8Y_W :NZ2TV$/(-
M*3908':;<W3>S G?5.=VH=CM"ED?Q=K1]K^!N^I$;(S?PYNX/N%W:>H_'!XQ
MWZ@F!!E9JY3N=:@8\?H,7]](5E:GVA<FU1FYNMP2G!*N >KYFC%YN-$3M/^D
M+/X%4$L#!!0    ( -2 4523!K@O_P,  #D2   9    >&PO=V]R:W-H965T
M<R]S:&5E=#<X+GAM;+5876_;-A3]*X2  ANP2B*E^*.P#<16AW5 5R-!NV=&
MNK:Y2J)'TG'V[T=2LI0X-)6VZ8LM43I']YY+\I"<';GX*G< "CU492WGP4ZI
M_;LHDOD.*BI#OH=:/]EP45&E;\4VDGL!M+"@JHQ('(^BBK(Z6,QLVUHL9OR@
M2E;#6B!YJ"HJ_EM"R8_S  >GAANVW2G3$"UF>[J%6U"?]VNA[Z*.I6 5U)+Q
M&@G8S(-K_"[#4P.P;WQA<)2/KI%)Y8[SK^;F0S$/8A,1E) K0T'UWSVLH"P-
MDX[CWY8TZ+YI@(^O3^R_V^1U,G=4PHJ7?[-"[>;!)$ %;.BA5#?\^ >T"5T9
MOIR7TOZB8_MN'*#\(!6O6K".H&)U\T\?6B$> ?#H H"T '(.2"\ DA:0O!20
MMH#4*M.D8G7(J**+F>!'),S;FLU<6#$M6J?/:E/W6R7T4Z9Q:K%N2B@1K0OT
M2>U H"74L&$*K4NJV]^B&ZI HL\2"J0XRN!>=Y8]NL[5@0I&2[06(*%6Z LM
M#X#X1C?P?W19]?LGJD]W)=M26^A?,E"4E?+76:1T_":**&]C73:QD@NQ8H(^
M\EKM)'I?%U \)8ATXEWVY)3]DG@9_Z1UB&+R&R(Q(8Z 5B^!)Q:.'?#,#\\@
M#Q&9&CB>>K))NEHFEB^]P'<#B@FH3"UL[3R4:4>96LKD N5?>N99@V"\8'E7
MS167RL-]U7%?><.]!7'/<D"YID,%DSD_Z,B%[FVNKN'G(B%.W[@*. 2;$!<L
M\\.2<)2\\2@PZA08>7D^U KTX%$OE,!/1L+$+8$?EH3X/)=& C\L?0Y[(L&X
MDV#L[[,Z5S-GL#K7MB5!7V@U*FUKLIDO2C/?2)<<?N(TC+%3CD%8[)3##TO"
MZ=0GQZ238^+E>?^P;V;.DM?;M[IW5+8W&(4$J(.HD99DKP<WHE*"<NKB_\(X
M'+MU\<,F(7:/E"%8<OZU)[I,.UVFWGGHN9%X2''<FU_L#2\;&G(#>!*FYV5O
MQ!S$N:>K;! W]<J)']D^_EGC;H#YXL ;QKE'WK=_[ZDFI->$>)D<RQ\?;V_+
M.'EU$\6]0^/T%6UT@(R$\84.[<<E87RA0_MQ:9A>>8O7+R:PWY._T4L'V+29
M.EUQ-8#3.DS<.OAQ:4C\.O1+"NPWYA\9V$.6_RS&5I/OPV7#.*^GXGZ-@<>O
MZ!Z]5V._N0V[AQ]/PI&SLZP&<<2]9!O )6'B%[1W8SS]:9W,SZR+?L$]!G%C
MMR:#.+<FT:,]=05B:\\F)+(%;S:876MW_G%M=_UG[4MS+F+WZCU-<ZCRD8HM
MTUOL$C::,@['>HX0S3E%<Z/XWN[<[[A2O+*7.Z %"/."?K[A7)UNS >ZTZ+%
M_U!+ P04    " #4@%%4_&^Q5JX"  "&!P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970W.2YX;6R-5>]OVC 0_5=.D29U4D="0FE7 5*AF[I)U1!=-TW3/KC)
M0:PF-K./T?[W.SLA95U(^X7XUWOWWMG<C;;:W-L<D>"A+)0=!SG1^CP,;9IC
M*6Q/KU'QSE*;4A!/S2JT:X,B\Z"R".,H&H:ED"J8C/S:W$Q&>D.%5#@W8#=E
M*<SC% N]'0?]8+>PD*N<W$(X&:W%"F^0;M=SP[.P8<EDB<I*K<#@<AQ<],]G
M0W?>'_@F<6OWQN"<W&E][R:?LG$0.4%88$J.0?#G#\ZP*!P1R_A=<P9-2 ?<
M'^_8/WKO[.5.6)SIXKO,*!\'9P%DN!2;@A9Z>X6UGQ/'E^K"^E_8UF>C -*-
M)5W68%902E5]Q4.=ASU ?W@ $-> ^#E@< "0U(#$&ZV4>5N7@L1D9/06C#O-
M;&[@<^/1[$8J=XLW9'A7,HXF\^I"+ B5P1?*T< 4%2XEP;P0O/X.+BQ?,69P
MA:*@'&;"(,RT)?AJD$$+06CAZ!))R,*^'87$LAQYF-82II6$^("$?@S76E%N
MX8/*,/N7(&0_C:EX9VH:=S)^%JH'47P,<13'+8)FKX$G'M[OD),T.4X\7W*
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M+YIRU7W1P4W9-.6R^_5.I7-5M0+]]T59-H\OV@MLOUSC_-]02P,$%     @
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MX/ZD!7[? >Z/+'S\%NYBJ9MZ!TV] \L7GN&[>RZ9?NG!@A.E0&S?%_WKWPB
M3YIFZML%=V'C+K3NHG/M);(,]P]EN%^;0ZF2)G"-35%9;MJ*6A$/+;'9'_?S
MT/<GXRB<NOO3ZG5<=_?K=6\41HW"Z+)"HE)(V)XE%'L="L(J98G@G$@T4%FI
M;!59<8].@HKZIDW>*/QY4=B?C-_):ULT&K1K&S3:!A>UK<N-HL\ES37<[?%Y
MH2&&#>7P=_3?J'$WZM)_ZZK_EL<R]6"%95F;LJ"5QE@IFK1M3*.?LNKWO6%[
M5L=-3..+,:$_FFW0__&WK@*!!UJ4,D[QF(25%#M)L@L)F#3.)K\CW[[W>IYX
MEWO&TLI7+46EI0>DU*F0['_\]4DFRO?M5.^&%?O@)./OF]@].>W,[><?(G<L
M5\#I%C$>=KT#LKI05!,M"GL ;H3&X]0.4[R$46D6X/>M$/HX,6=J<ZV;_P!0
M2P,$%     @ U(!15&5,T]GX!   ^1<  !D   !X;"]W;W)K<VAE971S+W-H
M965T.#DN>&ULS9A=<Z,V%(;_BL:ST\G.; (27R9U/!.;;3>=9I-)=MN+3B\4
MD&UF07*%'"?_O@(3,)*@Z9"+W"1\O.?P'AV)!VNV9_Q'L2%$@*<\H\7%9"/$
M]MRRBGA#<ER<L2VA\LZ*\1P+><K75K'E!"=54)Y9R+9]*\<IG<QGU;5;/I^Q
MG<A22FXY*'9YCOGS@F1L?S&!DY<+=^EZ(\H+UGRVQ6MR3\3W[2V79U:3)4ES
M0HN44<#)ZF)R"<\CIPJH%'^D9%\<'8.RE ?&?I0G5\G%Q"X=D8S$HDR!Y;]'
MLB195F:2/OZIDTZ:9Y:!Q\<OV7^IBI?%/.""+%GV9YJ(S<5D.@$)6>%=)N[8
M_@NI"_+*?#'+BNHOV-=:>P+B72%87@=+!WE*#__Q4ST01P'0[PE =0!2 ]R>
M *<.<%X;X-8!;C4RAU*J<8BPP/,99WO 2[7,5AY4@UE%R_)36O;]7G!Y-Y5Q
M8GX9Q[M\EV%!$G C-H2#)<OE#-J4K7TDX(K&+"?@Y'=6%!_!240$3C-Y= J^
MWT?@Y,-'\ &D%%RG62;;6,PL(4V5J:VX-K X&$ ]!B "UXR*30$^TX0DW026
MK*8I";V4M$"#&7_#] S8Z!- -D(&0\O7A#M5.#2$1\/A$8G/  K+<!@.5.,T
M#7*J?$Y?@VZ65V47LEV2TC6X9;Q:+Y="\/1A)_!#1H!@X"N3C:*",]D'*;NB
M@G!2B$_@JWQWL!7XAI_ 7W?R+I#+98]Y\O> -[?QYE;>W!YO"[).*2V?M\ 9
MIC$QM?^0PJM2E&^AQ[GOH& ZLQZ/>Z*KO- -8%<5F52!AQI5IPJOJ<(;K*(<
MH7B#Z=IH_Q#K'ST2P:FKN-=%OALJWG7-J>^'9NM^8]T?M"Z7S'^,OJ\]-7!M
MY"C^=96A1Y&NZO:H4T+0E! ,EB"GHWPW4[#<<4YH_ R^<4P+^4*2LWQ@BDZ;
M]--WMWS"QELX?OF$^K29AHZZ?$RJP/:4!II4T[XY".T6(?:(!50'=YX*[4!9
M'DN3##G*1(T,*NB[/04<,1".7$9U J4(&P9J%0:=WJ[(*#ON5[<0U!:"!@OY
M57[H636K;RBX)_&.IR(EQ<!LA2V)X/M#$6Q9!-\ 1G6.SOQ16ZA+;+5]0Y*N
M_19"< R%H($>*H0,&I6?!DF?\19!<"R#H Z.4Y5 !HUF7I?TF6_A X?I\SG?
M9NR9$+ @E*Q2 6YE%8.KI04/?'_D@2UZX!NP!QJ X8>>]M(SR::AUC^3#'I3
M<P]1BQ\T!C]()X:+/(6,2X-*?ITI!9A$P1&BNOY;^J"Q]$$&7*# 1FH1!IG>
MKL@H.VY7MXX6/N@5\ $M?2+"TT=<_JPOP$\XW_X,OI!D/<@BU+((O3\6H99%
MZ U8A'2*^)[64UUTBD+UP\ZD@F'/YP1JF83&, D9F!1.U2]3@TK^:%#]&U+)
MSZL>_RV:T%@T(1.:'%^MP?#[2.U49$J%>GO0$@H-$^I_;= ,3=X67.C]@0NU
MX$)O "YD0 WTD*NM+J-.1U=//M2S\^"T['+&L,O1@6/8?#"H]-T'@ZA_^\%I
MV>6,95>=P.L,G6-[ZGO"J--;%IEU.KZLHSW1G/!UM;=<@)CMJ#CL)397F_WK
MRVK75KF^@.?181>Z37/8%+_&7,[% F1D)5/:9X$TQ0_[S(<3P;;5SNL#$X+E
MU>&&X(3P4B#OKQ@3+R?E YK=_OF_4$L#!!0    ( -2 451RQWL_;@(  .(%
M   9    >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;(U444_;,!#^*Z>(!Y"@
M3IU2!DHCT6;30&)",+:':0]N<FTL'+NSW1;^_6PGS0IJ.UX2^WS?=W<^WY>N
ME7XV%:*%EUI(,XHJ:Q=7A)BBPIJ9GEJ@="<SI6MFW5;/B5EH9&4 U8+0.!Z2
MFG$996FPW>LL54LKN,1[#699UTR_CE&H]2CJ1QO# Y]7UAM(EB[8'!_1/BWN
MM=N1CJ7D-4K#E02-LU%TW;_*!]X_./S@N#9;:_"53)5Z]IN;<A3%/B$46%C/
MP-QOA1,4PA.Y-/ZTG%$7T@.WUQOV+Z%V5\N4&9PH\9.7MAI%GR(H<<:6PCZH
M]5=LZSGW?(42)GQAW?K&$11+8U7=@ET&-9?-G[VT][ %Z _W &@+H.\!@SV
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M5=9-;%A63H11>P=W/E/*;C8^0"?KV5]02P,$%     @ U(!15(;;Q3"S P
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M!<E ALE1HN*:Q(<,28B)^*B,_P0<(/2NZ"Z8@D=,B#I*+!VIH+1K3MX";!H
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MO!DFFX5DM1FO=DRJ8<W<EFH 1UP+J.=[IAICN] ']"/]^E]02P,$%     @
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MQC-;C(+; #+,627LB]I^QB8?+S!5PO@O;)O8;@!I9:PJ&S I*+FL_VS7U.$
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M'> U6JG5#SKZFJWB1:LZ41:2JZ]4\>3TD96EFJ^%9-G;;?,#OFWT',X+7 F
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MFYH11-W]9C-3,^AAOVZV-T!:#Y!V'> YN'YEF20C^"-:,M. [%(4?+ PRT$
MDJI\X00LP@_3#+BU*WF5DJG4_H?A7ER\.BY>Y\3OPG)7E18##UDT9V7V%SR.
MBS%O9&&4E6 LA*HKOYDZ1!WLF5/GUR[Z5A?O=*7WKTW_H)H\Y!-D]FA2>S3I
MZM'Y\*A-#J/F$J?-QZ#V,;#Z>.91QYW\. M<AQ!+H4!7/V[<D_,(-AYNT.I_
M%<7',%W)&-]':91LDQY!5>I!,_%%0,Q!A4B[A7JX%;[W=0L=)%LER.B6?E1
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M8!R  #1(I5R)$J?Q'-S#  B0@Y3>2S81R0%BD!RX3AXX@;1$^<-X3$('!',
M!N8P.Y^^'Q6>J9.7):(T0 Q* PA\770(2P0$?D& >_<K$9;;GGX !*1!@.^<
M/"!( \2 -'"=2+\J.;P#4.!+:[0HZ3&8AO/U:K>\Z,SVYY?;; X@Y@+$8"X
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MH) ,Y9N03Y6(R0 QF Q<)RU;E!R1X6$*;E4E(C( 0V1@5'EOZ'?+[;=RS*6
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M:R@HY<1 *7"=)+[KR;F&DKF5"!!& 1B,@JW+W\H/;OWWVX,4GRA.E)1B !4
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MD- ^J1\IY,-3K+<UQU2089E]&*@*:Y[Q!<\"N$0L!\FP',+(F>FD2S&&JE]
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M,N=Z!T7@*,I)TSM!HOP2@T?!=0+"=P2*:_EP'V/;)X=H%(JA4;2H\DE\-87
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M@] ,#.)1I^=G\VG_PRB03E'F2F,<$4<(!<T@%([4:4:<_<Z<51DJRIU5,^J
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MPDG-9Y38.JI5P'CN38?YH!RQ+92;(^U&$VQ%L*>5J7AN51EK4\ A)) N!>*
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M& G8I0W$_7D4\?U%^L96\>;GY7]02P,$%     @ U(!15!4.@P_A P  Z!
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ME +Z^Q7GZOVB=-">L,W_!U!+ P04    " #4@%%4A$E=1X,#  #%%P  #0
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M;T];]75]Y(Z=Z5,CEO?_BN+^WVA\^ ]02P,$%     @ U(!15 I(4F[K @
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MKWI[@-Y>]?8 O8/J'0!Z!]4[ /0.JG< Z!U4[P#0.ZC> :!WJ/ZL!.@=5.\
MT#NHW@&@=U"] T#OH'H'@-Y1]8X O:/J'0%Z1]4[ O2.JG<$Z!U5[PC0.ZK>
M$:!WK#:; /2.JG<$Z!U5[PC0.ZK>$:!W4KT30.^D>B> WDGU3@"]D^J= 'HG
MU3L!]$ZJ=P+HG53O!- [59L% 7HGU3L!]$ZJ=P+HG57O#- [J]X9H'=6O3-
M[ZQZ9X#>6?7. +VSZIT!>F?5.P/TSJIW!NB=J\W> +VSZIT!>A?5NP#T+JIW
M >A=5.\"T+NHW@6@=U&]"T#OHGH7@-Y%]2X O8OJ70!Z%]6[ /0NU6$=@-ZF
MJX_K /PV775@IP,(;KKJR$X',-QTU:&=[CL5'Z?/?3_>BK[65<!WFCU=/MO?
MOO^Z_+I8WS!7IMO[C/'I+U!+ P04    " #4@%%4A'6;AV,"  !A.@  $P
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M 5!+ 0(4 Q0    ( -2 450'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ U(!15%RFG)+N    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ U(!15)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " #4@%%4H?Z$W=8&   X(P  &
M        @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ U(!15(O$KYPE @  >P4  !@              ("!&0\  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( -2 450;28,51P<  * =   8
M              " @701  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    " #4@%%4-7&_^N$"  !["   &               @('Q&   >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ U(!15#Q^9$$\!0
MTQ,  !@              ("!"!P  'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( -2 451UB'=5J 0  +\1   8              " @7HA
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #4@%%4ZZCM
MU=@"  #.!P  &               @(%8)@  >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ U(!15$A!:+'Q!   214  !@
M ("!9BD  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( -2
M450">,&X; (  ,L%   8              " @8TN  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    " #4@%%4K#45CU(*  !"+@  &0
M        @($O,0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( -2 452S'!2-OB4  &QP   9              " @;@[  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ U(!15!YE_T/<!0  F@\
M !D              ("!K6$  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    " #4@%%4-%EIK7@"  !#!0  &0              @(' 9P
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( -2 453S#BNL
MS ,  "H)   9              " @6]J  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ U(!15)'^.9&H!@  W0\  !D
M ("!<FX  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #4
M@%%4D7%Q;Z<2  !;/P  &0              @(%1=0  >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( -2 452%;KP]P0<  &(3   9
M          " @2^(  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#
M%     @ U(!15,0QEC)?$P  OD(  !D              ("!)Y   'AL+W=O
M<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #4@%%4 HS.R0$#  #2
M!@  &0              @(&]HP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM
M;%!+ 0(4 Q0    ( -2 451!J!?F?Q<  .](   9              " @?6F
M  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ U(!15%82
M$7&U @  Y 4  !D              ("!J[X  'AL+W=O<FMS:&5E=',O<VAE
M970R,2YX;6Q02P$"% ,4    " #4@%%4L9G:<A$$  "F"0  &0
M    @(&7P0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M -2 4502UGHL. 0  *X)   9              " @=_%  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ U(!15$% BK-7!   >PH  !D
M             ("!3LH  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    " #4@%%4RX%&^ 8$  #L"@  &0              @('<S@  >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( -2 452/U\2@A@L
M *<A   9              " @1G3  !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ U(!15()@,;-8%   T#,  !D              ("!
MUMX  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #4@%%4
MM&%<=1P-  !2+   &0              @(%E\P  >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( -2 453K8I>C5R<  *&&   9
M      " @;@  0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ U(!15#N5+V,#!@  A@T  !D              ("!1B@! 'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #4@%%4YX2R$.,D  #4<P
M&0              @(& +@$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( -2 450.^.KTF@(  )(%   9              " @9I3 0!X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ U(!15%=T>VE,
M!0  7PX  !D              ("!:U8! 'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    " #4@%%4D 62W(<"  !+!0  &0
M@('N6P$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( -2
M450I(SIKWP(  'T&   9              " @:Q> 0!X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ U(!15(B,<4DG!@  D@X  !D
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M=#0P+GAM;%!+ 0(4 Q0    ( -2 450OFW)IB0T  . H   9
M  " @7Z# 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
MU(!15$Z;XECU @  PP8  !D              ("!/I$! 'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    " #4@%%4XD+PJAH#  !^!@  &0
M            @(%JE $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( -2 451!%]"^/P,  #4'   9              " @;N7 0!X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ U(!15"(<-I;A!0
MI@X  !D              ("!,9L! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6Q02P$"% ,4    " #4@%%4"]10]MT4  #A-0  &0              @(%)
MH0$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( -2 451B
M_4XTH@,  )D'   9              " @5VV 0!X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L! A0#%     @ U(!15-IIV$(F!P  I"   !D
M     ("!-KH! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -2 451%$,^6/ ,  %P,   9              "
M@<'2 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ U(!1
M5 *6J,6A @  N@8  !D              ("!--8! 'AL+W=O<FMS:&5E=',O
M<VAE970U-"YX;6Q02P$"% ,4    " #4@%%4\U_<IX,$   <$P  &0
M        @($,V0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0
M   ( -2 452-'@S33P0  %83   9              " @<;= 0!X;"]W;W)K
M<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ U(!15+SJNX7F @  Q0@
M !D              ("!3.(! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q0
M2P$"% ,4    " #4@%%40;U!"CP"  "[!0  &0              @(%IY0$
M>&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( -2 453'UE5S
M. 0  *$-   9              " @=SG 0!X;"]W;W)K<VAE971S+W-H965T
M-3DN>&UL4$L! A0#%     @ U(!15)O65 QB!P  X3H  !D
M ("!2^P! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #4
M@%%45D!QU,4"  !;!P  &0              @('D\P$ >&PO=V]R:W-H965T
M<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( -2 452X=$3HL@(  "8&   9
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M970V-BYX;6Q02P$"% ,4    " #4@%%4#Z2S-: #  ")#   &0
M    @($M' ( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    (
M -2 4533\C1B30(  !4&   9              " @00@ @!X;"]W;W)K<VAE
M971S+W-H965T-C@N>&UL4$L! A0#%     @ U(!15.K2UG Q P  EPH  !D
M             ("!B"(" 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"
M% ,4    " #4@%%4O +-2(T$  "<$@  &0              @('P)0( >&PO
M=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( -2 452_)^REB0@
M ' L   9              " @;0J @!X;"]W;W)K<VAE971S+W-H965T-S$N
M>&UL4$L! A0#%     @ U(!15 B<!'2M!   ,Q   !D              ("!
M=#," 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " #4@%%4
M'%"R-E4#  "["@  &0              @(%8. ( >&PO=V]R:W-H965T<R]S
M:&5E=#<S+GAM;%!+ 0(4 Q0    ( -2 452-?8U6Z (  (P(   9
M      " @>0[ @!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%
M  @ U(!15 J-AXH7 @  CP0  !D              ("! S\" 'AL+W=O<FMS
M:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    " #4@%%4$KD'%-<$   #%
M&0              @(%100( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+
M 0(4 Q0    ( -2 453C)7O^7 0  %41   9              " @5]& @!X
M;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ U(!15),&N"__
M P  .1(  !D              ("!\DH" 'AL+W=O<FMS:&5E=',O<VAE970W
M."YX;6Q02P$"% ,4    " #4@%%4_&^Q5JX"  "&!P  &0
M@($H3P( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( -2
M450,H!@*G0L  &A#   9              " @0U2 @!X;"]W;W)K<VAE971S
M+W-H965T.# N>&UL4$L! A0#%     @ U(!15![1@PA$!   4!0  !D
M         ("!X5T" 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4
M    " #4@%%4B"Y#6A #   @"@  &0              @(%<8@( >&PO=V]R
M:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( -2 450M?CU8> (  $\&
M   9              " @:-E @!X;"]W;W)K<VAE971S+W-H965T.#,N>&UL
M4$L! A0#%     @ U(!15&OEX7Z= @  F0D  !D              ("!4F@"
M 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"% ,4    " #4@%%4^M_Y
MW?(&  #U,@  &0              @($F:P( >&PO=V]R:W-H965T<R]S:&5E
M=#@U+GAM;%!+ 0(4 Q0    ( -2 451JL':N3 (  )L%   9
M  " @4]R @!X;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @
MU(!15$:G_2W= P  ;0X  !D              ("!TG0" 'AL+W=O<FMS:&5E
M=',O<VAE970X-RYX;6Q02P$"% ,4    " #4@%%458>HQC8#  #B"0  &0
M            @('F> ( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4
M Q0    ( -2 451E3-/9^ 0  /D7   9              " @5-\ @!X;"]W
M;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @ U(!15'+'>S]N @
MX@4  !D              ("!@H$" 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX
M;6Q02P$"% ,4    " #4@%%4AMO%,+,#  #>"P  &0              @($G
MA ( >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    ( -2 452V
M6$S,?0(  ,$%   9              " @1&( @!X;"]W;W)K<VAE971S+W-H
M965T.3(N>&UL4$L! A0#%     @ U(!15%ZJT;Y-!P  !B4  !D
M     ("!Q8H" 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q02P$"% ,4
M" #4@%%4C.-$-.<"   @"0  &0              @(%)D@( >&PO=V]R:W-H
M965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    ( -2 451XL?3 8 0  "T0   9
M              " @6>5 @!X;"]W;W)K<VAE971S+W-H965T.34N>&UL4$L!
M A0#%     @ U(!15!12G*3N!0  52(  !D              ("!_ID" 'AL
M+W=O<FMS:&5E=',O<VAE970Y-BYX;6Q02P$"% ,4    " #4@%%4/Y6TR6,#
M   Q"P  &0              @($CH ( >&PO=V]R:W-H965T<R]S:&5E=#DW
M+GAM;%!+ 0(4 Q0    ( -2 451@11]2 S   "*D 0 9              "
M@;VC @!X;"]W;W)K<VAE971S+W-H965T.3@N>&UL4$L! A0#%     @ U(!1
M5"1EFGZ@#@  _5H  !D              ("!]]," 'AL+W=O<FMS:&5E=',O
M<VAE970Y.2YX;6Q02P$"% ,4    " #4@%%4A4%HUI,+  ![00  &@
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( -2 453W,N8+"@<  ,I#   /
M      "  7<$ P!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #4@%%4"DA2
M;NL"  "&/   &@              @ &N"P, >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " #4@%%4A'6;AV,"  !A.@  $P
M    @ '1#@, 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     ;P!O (0>  !E
%$0,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1063</ContextCount>
  <ElementCount>680</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>237</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>15</UnitCount>
  <MyReports>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEarnings</Role>
      <ShortName>Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1007009 - Statement - Consolidated Statements of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1008010 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106102 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities</Role>
      <ShortName>Cash, Cash Equivalents and Current Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2123106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2132107 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2137108 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2144109 - Disclosure - Employee Related Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EmployeeRelatedObligations</Role>
      <ShortName>Employee Related Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2148110 - Disclosure - Pensions and Other Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlans</Role>
      <ShortName>Pensions and Other Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2160111 - Disclosure - Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SavingsPlan</Role>
      <ShortName>Savings Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2162112 - Disclosure - Capital and Treasury Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CapitalandTreasuryStock</Role>
      <ShortName>Capital and Treasury Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2166113 - Disclosure - Accumulated Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2169114 - Disclosure - International Currency Translation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InternationalCurrencyTranslation</Role>
      <ShortName>International Currency Translation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2171115 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2175116 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2182117 - Disclosure - Segments of Business and Geographic Areas</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas</Role>
      <ShortName>Segments of Business and Geographic Areas</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2186118 - Disclosure - Acquisitions and Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsandDivestitures</Role>
      <ShortName>Acquisitions and Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2188119 - Disclosure - Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalProceedings</Role>
      <ShortName>Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2190120 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2307302 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables</Role>
      <ShortName>Cash, Cash Equivalents and Current Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2311303 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Inventories</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2314304 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2318305 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2324306 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/FairValueMeasurements</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2333307 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Borrowings</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2338308 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2345309 - Disclosure - Employee Related Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EmployeeRelatedObligationsTables</Role>
      <ShortName>Employee Related Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/EmployeeRelatedObligations</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2349310 - Disclosure - Pensions and Other Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansTables</Role>
      <ShortName>Pensions and Other Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/PensionsandOtherBenefitPlans</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2363311 - Disclosure - Capital and Treasury Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CapitalandTreasuryStockTables</Role>
      <ShortName>Capital and Treasury Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/CapitalandTreasuryStock</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2367312 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2372313 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/EarningsPerShare</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2376314 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2383315 - Disclosure - Segments of Business and Geographic Areas (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables</Role>
      <ShortName>Segments of Business and Geographic Areas (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2391316 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Restructuring</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails</Role>
      <ShortName>Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/InventoriesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails</Role>
      <ShortName>Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Property, Plant and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails</Role>
      <ShortName>Property, Plant and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - Intangible Assets and Goodwill - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Intangible Assets and Goodwill - Estimated Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Estimated Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Derivative Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Borrowings - Schedule of Long-term Debt Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails</Role>
      <ShortName>Borrowings - Schedule of Long-term Debt Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Borrowings - Aggregate Maturities of Long Term Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails</Role>
      <ShortName>Borrowings - Aggregate Maturities of Long Term Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2441424 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2442425 - Disclosure - Income Taxes - Temporary Differences and Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Temporary Differences and Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2443426 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Employee Related Obligations - Employee Related Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails</Role>
      <ShortName>Employee Related Obligations - Employee Related Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2447428 - Disclosure - Employee Related Obligations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails</Role>
      <ShortName>Employee Related Obligations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Pensions and Other Benefit Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2451430 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2452431 - Disclosure - Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2453432 - Disclosure - Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2454433 - Disclosure - Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2455434 - Disclosure - Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2456435 - Disclosure - Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2457436 - Disclosure - Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2458437 - Disclosure - Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2459438 - Disclosure - Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2461439 - Disclosure - Savings Plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SavingsPlanNarrativeDetails</Role>
      <ShortName>Savings Plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2464440 - Disclosure - Capital and Treasury Stock - Changes in Treasury Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails</Role>
      <ShortName>Capital and Treasury Stock - Changes in Treasury Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2465441 - Disclosure - Capital and Treasury Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails</Role>
      <ShortName>Capital and Treasury Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2468442 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2470443 - Disclosure - International Currency Translation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails</Role>
      <ShortName>International Currency Translation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2473444 - Disclosure - Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails</Role>
      <ShortName>Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2474445 - Disclosure - Earnings Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareNarrativeDetails</Role>
      <ShortName>Earnings Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2477446 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2478447 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2479448 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2480449 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>2481450 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>2484451 - Disclosure - Segments of Business and Geographic Areas - Sales by Segment of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Sales by Segment of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>2485452 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>2487453 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails</Role>
      <ShortName>Acquisitions and Divestitures - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>2489454 - Disclosure - Legal Proceedings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalProceedingsDetails</Role>
      <ShortName>Legal Proceedings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/LegalProceedings</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>2492455 - Disclosure - Restructuring - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringNarrativeDetails</Role>
      <ShortName>Restructuring - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="jnj-20220102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>2493456 - Disclosure - Restructuring - Summary of Severance Charges and Associated Spending (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails</Role>
      <ShortName>Restructuring - Summary of Severance Charges and Associated Spending (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="jnj-20220102.htm">jnj-20220102.htm</File>
    <File>ex21-subsidiariesxform10xk.htm</File>
    <File>ex23-pwcconsentxform10xkx2.htm</File>
    <File>ex311-302certofceoxform10x.htm</File>
    <File>ex312-302certofcfoxform10x.htm</File>
    <File>ex321-906certofceoxform10x.htm</File>
    <File>ex322-906certofcfoxform10x.htm</File>
    <File>jnj-20220102.xsd</File>
    <File>jnj-20220102_cal.xml</File>
    <File>jnj-20220102_def.xml</File>
    <File>jnj-20220102_lab.xml</File>
    <File>jnj-20220102_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>jnj-20220102_g1.jpg</File>
    <File>jnj-20220102_g10.jpg</File>
    <File>jnj-20220102_g11.jpg</File>
    <File>jnj-20220102_g2.jpg</File>
    <File>jnj-20220102_g3.jpg</File>
    <File>jnj-20220102_g4.jpg</File>
    <File>jnj-20220102_g5.jpg</File>
    <File>jnj-20220102_g6.jpg</File>
    <File>jnj-20220102_g7.jpg</File>
    <File>jnj-20220102_g8.jpg</File>
    <File>jnj-20220102_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2497">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="48">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>133
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "jnj-20220102.htm": {
   "axisCustom": 1,
   "axisStandard": 46,
   "contextCount": 1063,
   "dts": {
    "calculationLink": {
     "local": [
      "jnj-20220102_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "jnj-20220102_def.xml"
     ]
    },
    "inline": {
     "local": [
      "jnj-20220102.htm"
     ]
    },
    "labelLink": {
     "local": [
      "jnj-20220102_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "jnj-20220102_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "jnj-20220102.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 1049,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 6,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 10
   },
   "keyCustom": 99,
   "keyStandard": 581,
   "memberCustom": 146,
   "memberStandard": 78,
   "nsprefix": "jnj",
   "nsuri": "http://www.jnj.com/20220102",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.jnj.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1008010 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2487453 - Disclosure - Acquisitions and Divestitures - Narrative (Details)",
     "role": "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
     "shortName": "Acquisitions and Divestitures - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i1293b88bd90d458eac2d0d6a7b850b0d_I20220102",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "jnj:ProductLiabilityContingencyNumberOfClaimant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claimant",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2489454 - Disclosure - Legal Proceedings (Details)",
     "role": "http://www.jnj.com/role/LegalProceedingsDetails",
     "shortName": "Legal Proceedings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i1293b88bd90d458eac2d0d6a7b850b0d_I20220102",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "jnj:ProductLiabilityContingencyNumberOfClaimant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claimant",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2492455 - Disclosure - Restructuring - Narrative (Details)",
     "role": "http://www.jnj.com/role/RestructuringNarrativeDetails",
     "shortName": "Restructuring - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i6a7d77bec63f4ec9ba629e605fa7f760_I20220102",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2493456 - Disclosure - Restructuring - Summary of Severance Charges and Associated Spending (Details)",
     "role": "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails",
     "shortName": "Restructuring - Summary of Severance Charges and Associated Spending (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ifdd89adfa0f0484b84b07f77e48731a8_D20191230-20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReservePeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106102 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities",
     "role": "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities",
     "shortName": "Cash, Cash Equivalents and Current Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Inventories",
     "role": "http://www.jnj.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - Property, Plant and Equipment",
     "role": "http://www.jnj.com/role/PropertyPlantandEquipment",
     "shortName": "Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123106 - Disclosure - Fair Value Measurements",
     "role": "http://www.jnj.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132107 - Disclosure - Borrowings",
     "role": "http://www.jnj.com/role/Borrowings",
     "shortName": "Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137108 - Disclosure - Income Taxes",
     "role": "http://www.jnj.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144109 - Disclosure - Employee Related Obligations",
     "role": "http://www.jnj.com/role/EmployeeRelatedObligations",
     "shortName": "Employee Related Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.jnj.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148110 - Disclosure - Pensions and Other Benefit Plans",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlans",
     "shortName": "Pensions and Other Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SavingsPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160111 - Disclosure - Savings Plan",
     "role": "http://www.jnj.com/role/SavingsPlan",
     "shortName": "Savings Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SavingsPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162112 - Disclosure - Capital and Treasury Stock",
     "role": "http://www.jnj.com/role/CapitalandTreasuryStock",
     "shortName": "Capital and Treasury Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2166113 - Disclosure - Accumulated Other Comprehensive Income (Loss)",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss",
     "shortName": "Accumulated Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2169114 - Disclosure - International Currency Translation",
     "role": "http://www.jnj.com/role/InternationalCurrencyTranslation",
     "shortName": "International Currency Translation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2171115 - Disclosure - Earnings Per Share",
     "role": "http://www.jnj.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2175116 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2182117 - Disclosure - Segments of Business and Geographic Areas",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas",
     "shortName": "Segments of Business and Geographic Areas",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2186118 - Disclosure - Acquisitions and Divestitures",
     "role": "http://www.jnj.com/role/AcquisitionsandDivestitures",
     "shortName": "Acquisitions and Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2188119 - Disclosure - Legal Proceedings",
     "role": "http://www.jnj.com/role/LegalProceedings",
     "shortName": "Legal Proceedings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2190120 - Disclosure - Restructuring",
     "role": "http://www.jnj.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:EstimatedUsefulLivesOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:EstimatedUsefulLivesOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307302 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities (Tables)",
     "role": "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables",
     "shortName": "Cash, Cash Equivalents and Current Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311303 - Disclosure - Inventories (Tables)",
     "role": "http://www.jnj.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314304 - Disclosure - Property, Plant and Equipment (Tables)",
     "role": "http://www.jnj.com/role/PropertyPlantandEquipmentTables",
     "shortName": "Property, Plant and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318305 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324306 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333307 - Disclosure - Borrowings (Tables)",
     "role": "http://www.jnj.com/role/BorrowingsTables",
     "shortName": "Borrowings (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338308 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.jnj.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:EmployeeRelatedObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345309 - Disclosure - Employee Related Obligations (Tables)",
     "role": "http://www.jnj.com/role/EmployeeRelatedObligationsTables",
     "shortName": "Employee Related Obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:EmployeeRelatedObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2349310 - Disclosure - Pensions and Other Benefit Plans (Tables)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables",
     "shortName": "Pensions and Other Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ChangesInTreasuryStockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2363311 - Disclosure - Capital and Treasury Stock (Tables)",
     "role": "http://www.jnj.com/role/CapitalandTreasuryStockTables",
     "shortName": "Capital and Treasury Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ChangesInTreasuryStockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2367312 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2372313 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.jnj.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2376314 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2383315 - Disclosure - Segments of Business and Geographic Areas (Tables)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables",
     "shortName": "Segments of Business and Geographic Areas (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2391316 - Disclosure - Restructuring (Tables)",
     "role": "http://www.jnj.com/role/RestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "jnj:EstimatedUsefulLivesOfAssetsTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i43031434703546208388df65cfb38be8_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
     "shortName": "Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "jnj:EstimatedUsefulLivesOfAssetsTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i43031434703546208388df65cfb38be8_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Earnings",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
     "shortName": "Consolidated Statements of Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details)",
     "role": "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails",
     "shortName": "Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i9fb97dbd3891498f92976302fc99a0ec_I20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details)",
     "role": "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails",
     "shortName": "Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Inventories (Details)",
     "role": "http://www.jnj.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)",
     "role": "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
     "shortName": "Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestCostsCapitalized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Property, Plant and Equipment - Narrative (Details)",
     "role": "http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails",
     "shortName": "Property, Plant and Equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestCostsCapitalized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i2291de62b68a41a0b629948bd1c56c1c_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - Intangible Assets and Goodwill - Goodwill (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
     "shortName": "Intangible Assets and Goodwill - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Intangible Assets and Goodwill - Estimated Amortization of Intangible Assets (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails",
     "shortName": "Intangible Assets and Goodwill - Estimated Amortization of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements of Comprehensive Income",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
     "shortName": "Fair Value Measurements - Summary of Derivative Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i808995d91a27460c9150c476dd1da392_D20210104-20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails",
     "shortName": "Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "if076b21d69e44a83b09033d94b086ac3_I20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i92e2a8e7af49412bbc0f28e465623b6f_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i92e2a8e7af49412bbc0f28e465623b6f_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
     "shortName": "Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
     "shortName": "Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i0ded06cef625444b86727e06867cbda7_I20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Borrowings - Schedule of Long-term Debt Instruments (Details)",
     "role": "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
     "shortName": "Borrowings - Schedule of Long-term Debt Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-8",
      "lang": "en-US",
      "name": "jnj:ExcessOfFairValueOverCarryingValueOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ied2f6ed477eb4ce6ad7d7bfaa6f716d3_I20210930",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Borrowings - Narrative (Details)",
     "role": "http://www.jnj.com/role/BorrowingsNarrativeDetails",
     "shortName": "Borrowings - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ied2f6ed477eb4ce6ad7d7bfaa6f716d3_I20210930",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Borrowings - Aggregate Maturities of Long Term Obligations (Details)",
     "role": "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails",
     "shortName": "Borrowings - Aggregate Maturities of Long Term Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Income Taxes - Provision for Income Taxes (Details)",
     "role": "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)",
     "role": "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails",
     "shortName": "Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441424 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442425 - Disclosure - Income Taxes - Temporary Differences and Carryforwards (Details)",
     "role": "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails",
     "shortName": "Income Taxes - Temporary Differences and Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i2291de62b68a41a0b629948bd1c56c1c_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443426 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)",
     "role": "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "jnj:EmployeeRelatedObligationsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Employee Related Obligations - Employee Related Obligations (Details)",
     "role": "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails",
     "shortName": "Employee Related Obligations - Employee Related Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "jnj:EmployeeRelatedObligationsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447428 - Disclosure - Employee Related Obligations - Narrative (Details)",
     "role": "http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails",
     "shortName": "Employee Related Obligations - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPlanAmendments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Pensions and Other Benefit Plans - Narrative (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
     "shortName": "Pensions and Other Benefit Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "2",
      "lang": "en-US",
      "name": "jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetFundedStatusTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451430 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452431 - Disclosure - Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
     "shortName": "Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453432 - Disclosure - Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails",
     "shortName": "Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ia2087646dc6744a28755f382fc0a83c8_I20181230",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statements of Equity",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i37828c53082f418d82b181eca97c9828_I20181230",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPlanAmendments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454433 - Disclosure - Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails",
     "shortName": "Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetFundedStatusTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i16cd3f48718d47db9c0db556be902ba3_D20210104-20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i58f88b3066f8425fb8a00e6f0f402f0c_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455434 - Disclosure - Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
     "shortName": "Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i58f88b3066f8425fb8a00e6f0f402f0c_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "if217fbfb3878426eba07b1762dc50833_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456435 - Disclosure - Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
     "shortName": "Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "if217fbfb3878426eba07b1762dc50833_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457436 - Disclosure - Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails",
     "shortName": "Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458437 - Disclosure - Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
     "shortName": "Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetFundedStatusTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "if217fbfb3878426eba07b1762dc50833_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459438 - Disclosure - Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
     "shortName": "Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i65cf763a87bd4988a9339426e416baea_I20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461439 - Disclosure - Savings Plan - Narrative (Details)",
     "role": "http://www.jnj.com/role/SavingsPlanNarrativeDetails",
     "shortName": "Savings Plan - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "jnj:ChangesInTreasuryStockTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i2291de62b68a41a0b629948bd1c56c1c_I20210103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464440 - Disclosure - Capital and Treasury Stock - Changes in Treasury Stock (Details)",
     "role": "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
     "shortName": "Capital and Treasury Stock - Changes in Treasury Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "jnj:ChangesInTreasuryStockTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ia2087646dc6744a28755f382fc0a83c8_I20181230",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465441 - Disclosure - Capital and Treasury Stock - Narrative (Details)",
     "role": "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails",
     "shortName": "Capital and Treasury Stock - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i62d3f67a745e40cfb7f34338a5e1abf4_I20191229",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i2291de62b68a41a0b629948bd1c56c1c_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468442 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ia54143af8e294de8a878b870cb6ea183_I20181230",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007009 - Statement - Consolidated Statements of Equity (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical",
     "shortName": "Consolidated Statements of Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470443 - Disclosure - International Currency Translation - Narrative (Details)",
     "role": "http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails",
     "shortName": "International Currency Translation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2473444 - Disclosure - Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)",
     "role": "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails",
     "shortName": "Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-5",
      "lang": "en-US",
      "name": "jnj:PotentialSharesExercisableUnderStockOptionPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474445 - Disclosure - Earnings Per Share - Narrative (Details)",
     "role": "http://www.jnj.com/role/EarningsPerShareNarrativeDetails",
     "shortName": "Earnings Per Share - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i0eed0d6c651346189cd3f0d707c3b43f_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "jnj:NumberOfStockBasedCompensationPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "stockbasedcompensationplans",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2477446 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details)",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "jnj:NumberOfStockBasedCompensationPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "stockbasedcompensationplans",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2478447 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i2291de62b68a41a0b629948bd1c56c1c_I20210103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2479448 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details)",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ia2087646dc6744a28755f382fc0a83c8_I20181230",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2480449 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details)",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "ie66d6dccc9d94eca902fa0a8c7d7d9e4_I20220102",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i7038702487ec4c45a376b222a0a20d05_I20210103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2481450 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details)",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i7038702487ec4c45a376b222a0a20d05_I20210103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2484451 - Disclosure - Segments of Business and Geographic Areas - Sales by Segment of Business (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
     "shortName": "Segments of Business and Geographic Areas - Sales by Segment of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:PercentageChangeInSalesBySegmentOfBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2485452 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
     "shortName": "Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220102.htm",
      "contextRef": "i20918a3d76934ae3867fbaabde676443_D20210104-20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 237,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States",
        "verboseLabel": "U.S. Plans"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r864",
      "r865",
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r864",
      "r865",
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r864",
      "r865",
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r864",
      "r865",
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r870"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r864",
      "r865",
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r861"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "jnj_A0.250NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.250% Notes Due 2022 [Member]",
        "label": "0.250% Notes Due 2022 [Member]",
        "terseLabel": "0.250% Notes due 2022 (1B Euro 1.1311)(2)/(1B Euro 1.2281)(3)"
       }
      }
     },
     "localname": "A0.250NotesDue2022Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A0.650NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.650% Notes Due 2024 [Member]",
        "label": "0.650% Notes Due 2024 [Member]",
        "terseLabel": "0.650% Notes due 2024 (750MM Euro 1.1311)(2)/(750MM Euro 1.2281)(3)",
        "verboseLabel": "0.650% Notes Due May 2024"
       }
      }
     },
     "localname": "A0.650NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A055NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.55% Notes due 2025",
        "label": "0.55% Notes due 2025 [Member]",
        "terseLabel": "0.55% Notes due 2025"
       }
      }
     },
     "localname": "A055NotesDue2025Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A095NotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.95% Notes due 2027",
        "label": "0.95% Notes due 2027 [Member]",
        "terseLabel": "0.95% Notes due 2027"
       }
      }
     },
     "localname": "A095NotesDue2027Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.150NotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.150% Notes Due 2028 [Member]",
        "label": "1.150% Notes Due 2028 [Member]",
        "terseLabel": "1.150% Notes due 2028 (750MM Euro 1.1311)(2)/(750MM Euro 1.2281)(3)",
        "verboseLabel": "1.150% Notes Due November 2028"
       }
      }
     },
     "localname": "A1.150NotesDue2028Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.650NotesDue2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.650% Notes Due 2035 [Member]",
        "label": "1.650% Notes Due 2035 [Member]",
        "terseLabel": "1.650% Notes due 2035 (1.5B Euro 1.1311)(2)/(1.5B Euro 1.2281)(3)",
        "verboseLabel": "1.650% Notes Due May 2035"
       }
      }
     },
     "localname": "A1.650NotesDue2035Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.65Notesdue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.65% Notes due 2021 [Member]",
        "label": "1.65% Notes due 2021 [Member]",
        "terseLabel": "1.65% Notes due 2021"
       }
      }
     },
     "localname": "A1.65Notesdue2021Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A130NotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.30% Notes due 2030",
        "label": "1.30% Notes due 2030 [Member]",
        "terseLabel": "1.30% Notes due 2030"
       }
      }
     },
     "localname": "A130NotesDue2030Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.05Notesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.05% Notes due 2023 [Member]",
        "label": "2.05% Notes due 2023 [Member]",
        "terseLabel": "2.05% Notes due 2023"
       }
      }
     },
     "localname": "A2.05Notesdue2023Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.25Notesdue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.25% Notes due 2022 [Member]",
        "label": "2.25% Notes due 2022 [Member]",
        "terseLabel": "2.25% Notes due 2022"
       }
      }
     },
     "localname": "A2.25Notesdue2022Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.45Notesdue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.45% Notes due 2021 [Member]",
        "label": "2.45% Notes due 2021 [Member]",
        "terseLabel": "2.45% Notes due 2021"
       }
      }
     },
     "localname": "A2.45Notesdue2021Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.45Notesdue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.45% Notes due 2026 [Member]",
        "label": "2.45% Notes due 2026 [Member]",
        "terseLabel": "2.45% Notes due 2026"
       }
      }
     },
     "localname": "A2.45Notesdue2026Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.625Notesdue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.625 Notes due 2025 [Member]",
        "label": "2.625 Notes due 2025 [Member]",
        "terseLabel": "2.625% Notes due 2025"
       }
      }
     },
     "localname": "A2.625Notesdue2025Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.900Notesdue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.900% Notes due 2028 [Member]",
        "label": "2.900% Notes due 2028 [Member]",
        "terseLabel": "2.90%\u00a0Notes due 2028"
       }
      }
     },
     "localname": "A2.900Notesdue2028Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.95Notesdue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.95% Notes due 2027 [Member]",
        "label": "2.95% Notes due 2027 [Member]",
        "terseLabel": "2.95% Notes due 2027"
       }
      }
     },
     "localname": "A2.95Notesdue2027Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2012LongTermIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2012 Long-Term Incentive Plan [Member]",
        "label": "2012 Long-Term Incentive Plan [Member]",
        "terseLabel": "2012 Long-Term Incentive Plan"
       }
      }
     },
     "localname": "A2012LongTermIncentivePlanMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2019AcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Acquisitions [Member]",
        "label": "2019 Acquisitions [Member]",
        "terseLabel": "2019 Acquisitions"
       }
      }
     },
     "localname": "A2019AcquisitionsMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2020AcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Acquisitions",
        "label": "2020 Acquisitions [Member]",
        "terseLabel": "2020 Acquisitions"
       }
      }
     },
     "localname": "A2020AcquisitionsMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A210NotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.10% Notes due 2040",
        "label": "2.10% Notes due 2040 [Member]",
        "terseLabel": "2.10% Notes due 2040"
       }
      }
     },
     "localname": "A210NotesDue2040Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2250NotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.250% Notes due 2050",
        "label": "2.250% Notes due 2050 [Member]",
        "terseLabel": "2.250% Notes due 2050"
       }
      }
     },
     "localname": "A2250NotesDue2050Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2450NotesDue2060Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.450% Notes due 2060",
        "label": "2.450% Notes due 2060 [Member]",
        "terseLabel": "2.450% Notes due 2060"
       }
      }
     },
     "localname": "A2450NotesDue2060Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.375Notesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.375% Notes due 2023 [Member]",
        "label": "3.375% Notes due 2023 [Member]",
        "terseLabel": "3.375% Notes due 2023"
       }
      }
     },
     "localname": "A3.375Notesdue2023Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.400Notesdue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.400% Notes due 2038 [Member]",
        "label": "3.400% Notes due 2038 [Member]",
        "terseLabel": "3.400%\u00a0Notes due 2038"
       }
      }
     },
     "localname": "A3.400Notesdue2038Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.500Notesdue2048Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.500% Notes due 2048 [Member]",
        "label": "3.500% Notes due 2048 [Member]",
        "terseLabel": "3.500% Notes due 2048"
       }
      }
     },
     "localname": "A3.500Notesdue2048Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.55Notesdue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.55% Notes due 2021 [Member]",
        "label": "3.55% Notes due 2021 [Member]",
        "terseLabel": "3.55% Notes due 2021"
       }
      }
     },
     "localname": "A3.55Notesdue2021Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.55Notesdue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.55% Notes due 2036 [Member]",
        "label": "3.55% Notes due 2036 [Member]",
        "terseLabel": "3.55% Notes due 2036"
       }
      }
     },
     "localname": "A3.55Notesdue2036Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.625Notesdue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.625% Notes due 2037 [Member]",
        "label": "3.625% Notes due 2037 [Member]",
        "terseLabel": "3.625% Notes due 2037"
       }
      }
     },
     "localname": "A3.625Notesdue2037Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.70Notesdue2046Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.70% Notes due 2046 [Member]",
        "label": "3.70% Notes due 2046 [Member]",
        "terseLabel": "3.70% Notes due 2046"
       }
      }
     },
     "localname": "A3.70Notesdue2046Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.75Notesdue2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.75% Notes due 2047 [Member]",
        "label": "3.75% Notes due 2047 [Member]",
        "terseLabel": "3.75% Notes due 2047"
       }
      }
     },
     "localname": "A3.75Notesdue2047Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.375Notesdue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.375% Notes due 2033 [Member]",
        "label": "4.375% Notes due 2033 [Member]",
        "terseLabel": "4.375% Notes due 2033"
       }
      }
     },
     "localname": "A4.375Notesdue2033Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.50Debenturesdue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Debentures due 2040 [Member]",
        "label": "4.50% Debentures due 2040 [Member]",
        "terseLabel": "4.50%\u00a0Debentures due 2040"
       }
      }
     },
     "localname": "A4.50Debenturesdue2040Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.50Notesdue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Notes due 2043 [Member]",
        "label": "4.50% Notes due 2043 [Member]",
        "terseLabel": "4.50% Notes due 2043"
       }
      }
     },
     "localname": "A4.50Notesdue2043Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.85Notesdue2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.85% Notes due 2041 [Member]",
        "label": "4.85% Notes due 2041 [Member]",
        "terseLabel": "4.85% Notes due 2041"
       }
      }
     },
     "localname": "A4.85Notesdue2041Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.95Debenturesdue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.95% Debentures due 2033 [Member]",
        "label": "4.95% Debentures due 2033 [Member]",
        "terseLabel": "4.95%\u00a0Debentures due 2033"
       }
      }
     },
     "localname": "A4.95Debenturesdue2033Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.50NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.50% Notes Due 2024 [Member]",
        "label": "5.50% Notes Due 2024 [Member]",
        "terseLabel": "5.50%\u00a0Notes due 2024 (500MM 1.3485 GBP )(2)/(500MM GBP 1.3654)(3)",
        "verboseLabel": "5.50% Notes Due November 2024"
       }
      }
     },
     "localname": "A5.50NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.85Debenturesdue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.85% Debentures due 2038 [Member]",
        "label": "5.85% Debentures due 2038 [Member]",
        "terseLabel": "5.85%\u00a0Debentures due 2038"
       }
      }
     },
     "localname": "A5.85Debenturesdue2038Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.95Notesdue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.95% Notes due 2037 [Member]",
        "label": "5.95% Notes due 2037 [Member]",
        "terseLabel": "5.95%\u00a0Notes due 2037"
       }
      }
     },
     "localname": "A5.95Notesdue2037Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A6.73Debenturesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.73% Debentures due 2023 [Member]",
        "label": "6.73% Debentures due 2023 [Member]",
        "terseLabel": "6.73%\u00a0Debentures due 2023"
       }
      }
     },
     "localname": "A6.73Debenturesdue2023Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A6.95Notesdue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.95% Notes due 2029 [Member]",
        "label": "6.95% Notes due 2029 [Member]",
        "terseLabel": "6.95%\u00a0Notes due 2029"
       }
      }
     },
     "localname": "A6.95Notesdue2029Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ADVANCEDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ADVANCED [Member]",
        "label": "ADVANCED [Member]",
        "terseLabel": "ADVANCED"
       }
      }
     },
     "localname": "ADVANCEDMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AccruedRebatesReturnsAndPromotions": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.",
        "label": "Accrued Rebates Returns And Promotions",
        "terseLabel": "Accrued Rebates Returns And Promotions",
        "verboseLabel": "Accrued rebates, returns and promotions"
       }
      }
     },
     "localname": "AccruedRebatesReturnsAndPromotions",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ActelionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actelion",
        "label": "Actelion [Member]",
        "terseLabel": "Actelion"
       }
      }
     },
     "localname": "ActelionMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AdvancedSterilizationProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AdvancedSterilizationProducts [Member]",
        "label": "AdvancedSterilizationProducts [Member]",
        "terseLabel": "AdvancedSterilizationProducts"
       }
      }
     },
     "localname": "AdvancedSterilizationProductsMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AsiaPacificAfricaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asia-Pacific, Africa [Member]",
        "label": "Asia-Pacific, Africa [Member]",
        "terseLabel": "Asia-Pacific, Africa"
       }
      }
     },
     "localname": "AsiaPacificAfricaMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AsrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASR.",
        "label": "ASR [Member]",
        "terseLabel": "ASR"
       }
      }
     },
     "localname": "AsrMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AssetWriteoffMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Write-off [Member]",
        "label": "Asset Write-off [Member]",
        "terseLabel": "Asset Write-offs/Sales"
       }
      }
     },
     "localname": "AssetWriteoffMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://www.jnj.com/20220102",
     "xbrltype": "stringItemType"
    },
    "jnj_AurisHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auris Health",
        "label": "Auris Health [Member]",
        "terseLabel": "Auris Health"
       }
      }
     },
     "localname": "AurisHealthMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BabyCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baby Care [Member]",
        "label": "Baby Care [Member]",
        "terseLabel": "Baby Care"
       }
      }
     },
     "localname": "BabyCareMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BabyPowderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baby Powder [Member]",
        "label": "Baby Powder [Member]",
        "terseLabel": "Baby Powder"
       }
      }
     },
     "localname": "BabyPowderMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BermekimabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "bermekimab",
        "label": "bermekimab [Member]",
        "terseLabel": "bermekimab"
       }
      }
     },
     "localname": "BermekimabMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BusinessAcquisitionDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Discount Rate",
        "label": "Business Acquisition, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "BusinessAcquisitionDiscountRate",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_BusinessCombinationProbabilityOfSuccessFactor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Probability Of Success Factor",
        "label": "Business Combination, Probability Of Success Factor",
        "terseLabel": "Probability of success factor"
       }
      }
     },
     "localname": "BusinessCombinationProbabilityOfSuccessFactor",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_CONCERTAMethylphenidateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONCERTA/Methylphenidate [Member]",
        "label": "CONCERTA/Methylphenidate [Member]",
        "terseLabel": "CONCERTA/Methylphenidate"
       }
      }
     },
     "localname": "CONCERTAMethylphenidateMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CONTACTLENSESOTHERMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONTACT LENSES/OTHER [Member]",
        "label": "CONTACT LENSES/OTHER [Member]",
        "terseLabel": "CONTACT LENSES/OTHER"
       }
      }
     },
     "localname": "CONTACTLENSESOTHERMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19",
        "label": "COVID-19 [Member]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CardiovascularMetabolismOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardiovascular/Metabolism/Other [Member]",
        "label": "Cardiovascular/Metabolism/Other [Member]",
        "terseLabel": "Cardiovascular/Metabolism/Other"
       }
      }
     },
     "localname": "CardiovascularMetabolismOtherMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CashPaidDuringTheYearAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid During The Year [Abstract]",
        "label": "Cash Paid During The Year [Abstract]",
        "terseLabel": "Cash paid during the year for:"
       }
      }
     },
     "localname": "CashPaidDuringTheYearAbstract",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_ChangesInTreasuryStockRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in treasury stock.",
        "label": "Changes In Treasury Stock [Roll Forward]",
        "terseLabel": "Changes in treasury stock"
       }
      }
     },
     "localname": "ChangesInTreasuryStockRollForward",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_ChangesInTreasuryStockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in treasury stock.",
        "label": "Changes In Treasury Stock [Table Text Block]",
        "terseLabel": "Changes in Treasury Stock"
       }
      }
     },
     "localname": "ChangesInTreasuryStockTableTextBlock",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ChangesinTreasuryStockSharesOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in Treasury Stock Shares Outstanding [Roll Forward]",
        "label": "Changes in Treasury Stock Shares Outstanding [Roll Forward]",
        "terseLabel": "Changes in Treasury Stock Shares Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ChangesinTreasuryStockSharesOutstandingRollForward",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_CizHoldingsCo.Ltd.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ci:z Holdings Co. Ltd. [Member]",
        "label": "Ci:z Holdings Co. Ltd. [Member]",
        "terseLabel": "Ci:z Holdings Co. Ltd."
       }
      }
     },
     "localname": "CizHoldingsCo.Ltd.Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CommingledFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commingled funds.",
        "label": "Commingled Funds [Member]",
        "terseLabel": "Commingled funds"
       }
      }
     },
     "localname": "CommingledFundsMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comparison of income tax expense at the Statutory rate and Company's tax rate.",
        "label": "Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract",
        "terseLabel": "Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract"
       }
      }
     },
     "localname": "ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_ConcentrationOfCreditRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration of credit risk.",
        "label": "Concentration of Credit Risk [Line Items]",
        "terseLabel": "Concentration of Credit Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationOfCreditRiskLineItems",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_ConcentrationOfCreditRiskTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration of Credit Risk [Table]",
        "label": "Concentration of Credit Risk [Table]",
        "terseLabel": "Concentration of Credit Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationOfCreditRiskTable",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_ConcentrationRiskThresholdPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Threshold Percentage",
        "label": "Concentration Risk, Threshold Percentage",
        "terseLabel": "Concentration risk, threshold percentage (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskThresholdPercentage",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "jnj_ConsumerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer.",
        "label": "Consumer [Member]",
        "terseLabel": "Consumer Health"
       }
      }
     },
     "localname": "ConsumerMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ContactLensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contact Lenses",
        "label": "Contact Lenses [Member]",
        "terseLabel": "Contact Lenses"
       }
      }
     },
     "localname": "ContactLensesMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ConvertibleNoteEquityInterestNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Note, Equity Interest, number of shares",
        "label": "Convertible Note, Equity Interest, number of shares",
        "terseLabel": "Convertible note, equity Interest (in shares)"
       }
      }
     },
     "localname": "ConvertibleNoteEquityInterestNumberOfShares",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_CurtailmentsAndSettlementsAndRestructuring": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase or decrease related to curtailments, settlements and restructuring.",
        "label": "Curtailments And Settlements And Restructuring",
        "negatedTerseLabel": "Curtailments, settlements\u00a0&amp; restructuring"
       }
      }
     },
     "localname": "CurtailmentsAndSettlementsAndRestructuring",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DARZALEXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DARZALEX [Member]",
        "label": "DARZALEX [Member]",
        "terseLabel": "DARZALEX"
       }
      }
     },
     "localname": "DARZALEXMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_DePuyASRU.S.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DePuy ASR U.S. [Member]",
        "label": "DePuy ASR U.S. [Member]",
        "terseLabel": "DePuy ASR U.S."
       }
      }
     },
     "localname": "DePuyASRU.S.Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_DebtInstrumentConvertibleAmountOfLoanConverted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Amount of Loan Converted",
        "label": "Debt Instrument, Convertible, Amount of Loan Converted",
        "terseLabel": "Convertible debt, amount of loan converted"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleAmountOfLoanConverted",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_December172018ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 17, 2018 Share Repurchase Program [Member]",
        "label": "December 17, 2018 Share Repurchase Program [Member]",
        "terseLabel": "December 17, 2018 Share Repurchase Program"
       }
      }
     },
     "localname": "December172018ShareRepurchaseProgramMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets international research and development capitalized.",
        "label": "Deferred Tax Assets International Research And Development Capitalized",
        "terseLabel": "R&amp;D capitalized for tax"
       }
      }
     },
     "localname": "DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DeferredTaxAssetsOtherDomestic": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets other domestic.",
        "label": "Deferred Tax Assets Other Domestic",
        "terseLabel": "Miscellaneous U.S."
       }
      }
     },
     "localname": "DeferredTaxAssetsOtherDomestic",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization",
        "label": "Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization",
        "terseLabel": "Deferred tax assets, tax basis increase of certain assets due to reorganization"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DeferredTaxAssetsUndistributedForeignEarnings": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Undistributed Foreign Earnings",
        "label": "Deferred Tax Assets, Undistributed Foreign Earnings",
        "terseLabel": "Undistributed foreign earnings"
       }
      }
     },
     "localname": "DeferredTaxAssetsUndistributedForeignEarnings",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DeferredTaxLiabilitiesOtherDomestic": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Other Domestic",
        "label": "Deferred Tax Liabilities, Other Domestic",
        "negatedTerseLabel": "Miscellaneous U.S."
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOtherDomestic",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liability, Global Intangible Low-Taxed Income",
        "label": "Deferred Tax Liability, Global Intangible Low-Taxed Income",
        "negatedTerseLabel": "Global intangible low-taxed income"
       }
      }
     },
     "localname": "DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets",
        "label": "Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets",
        "terseLabel": "Investments Measured at Net Asset Value"
       }
      }
     },
     "localname": "DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate",
        "terseLabel": "Interest cost discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)",
        "label": "Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)",
        "terseLabel": "Divestitures\u00a0&amp; acquisitions"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan expected future benefit contribution in five fiscal years thereafter.",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Five Fiscal Years Thereafter",
        "terseLabel": "2027-2031"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan expected future benefit contribution in year five.",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan expected future benefit contribution in year four.",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan expected future benefit contribution in year one.",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan expected future benefit contribution in year three.",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan expected future benefit contribution in year two.",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanOverUnderFundedStatusABO": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan over (under) funded status ABO",
        "label": "Defined Benefit Plan Over (Under) Funded Status ABO",
        "terseLabel": "Accumulated Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanOverUnderFundedStatusABO",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)",
        "label": "Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)",
        "terseLabel": "Divestitures\u00a0&amp; acquisitions"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation expense including the amortization of capitalized interest.",
        "label": "Depreciation Expense Including Amortization Of Capitalized Interest",
        "terseLabel": "Depreciation expense, including the amortization of capitalized interest"
       }
      }
     },
     "localname": "DepreciationExpenseIncludingAmortizationOfCapitalizedInterest",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DisposalGroupIncludingDiscontinuedOperationReceivablesRetained": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Receivables Retained",
        "label": "Disposal Group, Including Discontinued Operation, Receivables Retained",
        "terseLabel": "Disposal group, including discontinued operation, receivables retained"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationReceivablesRetained",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EDURANTrilpivirineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EDURANT/rilpivirine [Member]",
        "label": "EDURANT/rilpivirine [Member]",
        "terseLabel": "EDURANT/rilpivirine"
       }
      }
     },
     "localname": "EDURANTrilpivirineMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EffectOfExchangeRates": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect Of Exchange Rates.",
        "label": "Effect Of Exchange Rates",
        "terseLabel": "Effect of exchange rates"
       }
      }
     },
     "localname": "EffectOfExchangeRates",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Capital Loss",
        "label": "Effective Income Tax Rate Reconciliation, Capital Loss",
        "negatedTerseLabel": "Tax benefits from loss on capital assets",
        "terseLabel": "Tax benefits from loss on capital assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationCapitalLoss",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails",
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Litigation Settlement, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Litigation Settlement, Percent",
        "terseLabel": "Effective income tax rate reconciliation, litigation settlement, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation related to domestic tax on international income.",
        "label": "Effective Income Tax Rate Reconciliation Related To Domestic Tax On International Income",
        "terseLabel": "U.S. taxes on international income"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, Federal Act On Tax Reform And AHV Financing, Percent",
        "label": "Effective Tax Rate Reconciliation, Federal Act On Tax Reform And AHV Financing, Percent",
        "terseLabel": "TRAF effect on tax rate"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EffectiveTaxRateReconciliationLitigationSettlementPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, Litigation Settlement, Percent",
        "label": "Effective Tax Rate Reconciliation, Litigation Settlement, Percent",
        "terseLabel": "Effective tax rate reconciliation, litigation settlement, percent"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationLitigationSettlementPercent",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent",
        "label": "Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent",
        "terseLabel": "Effective tax rate reconciliation, net increase (decrease) in tax rate, percent"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Percent",
        "label": "Effective Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Percent",
        "terseLabel": "TJCA, foreign tax credit percent"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationTaxCutsAndJobsActOf2017ForeignTaxCreditsPercent",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, Unrecognized Tax Benefits, Percent",
        "label": "Effective Tax Rate Reconciliation, Unrecognized Tax Benefits, Percent",
        "terseLabel": "Effective tax rate reconciliation, unrecognized tax benefits, percent"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationUnrecognizedTaxBenefitsPercent",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EmployeeCompensationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Compensation Period.",
        "label": "Employee Compensation Period",
        "terseLabel": "Retirement plan benefits Employee compensation Period"
       }
      }
     },
     "localname": "EmployeeCompensationPeriod",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "jnj_EmployeeObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total employee obligations current and non current.",
        "label": "Employee Obligations",
        "totalLabel": "Total employee obligations"
       }
      }
     },
     "localname": "EmployeeObligations",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EmployeeRelatedObligationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee related obligations.",
        "label": "Employee Related Obligations [Table Text Block]",
        "terseLabel": "Employee Related Obligations"
       }
      }
     },
     "localname": "EmployeeRelatedObligationsTableTextBlock",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_EquityFairValueAdjustmentChangeinObservablePrices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity, Fair Value Adjustment, Change in Observable Prices",
        "label": "Equity, Fair Value Adjustment, Change in Observable Prices",
        "terseLabel": "Equity, fair value adjustment, change in observable prices"
       }
      }
     },
     "localname": "EquityFairValueAdjustmentChangeinObservablePrices",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityFairValueAdjustmentImpairmentLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity, Fair Value Adjustment, Impairment Loss",
        "label": "Equity, Fair Value Adjustment, Impairment Loss",
        "terseLabel": "Equity, fair value adjustment, impairment loss"
       }
      }
     },
     "localname": "EquityFairValueAdjustmentImpairmentLoss",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityInvestmentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investment [Roll Forward]",
        "label": "Equity Investment [Roll Forward]",
        "terseLabel": "Equity Investment [Roll Forward]"
       }
      }
     },
     "localname": "EquityInvestmentRollForward",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period",
        "label": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period",
        "terseLabel": "Equity investments, increase (decrease) from acquisition (sale) during period"
       }
      }
     },
     "localname": "EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityInvestmentswithReadilyDeterminableValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments with Readily Determinable Value [Member]",
        "label": "Equity Investments with Readily Determinable Value [Member]",
        "terseLabel": "Equity Investments with readily determinable value"
       }
      }
     },
     "localname": "EquityInvestmentswithReadilyDeterminableValueMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EquityInvestmentswithoutReadilyDeterminableValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments without Readily Determinable Value [Member]",
        "label": "Equity Investments without Readily Determinable Value [Member]",
        "terseLabel": "Equity Investments without readily determinable value"
       }
      }
     },
     "localname": "EquityInvestmentswithoutReadilyDeterminableValueMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ErleadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Erleada",
        "label": "Erleada [Member]",
        "terseLabel": "ERLEADA"
       }
      }
     },
     "localname": "ErleadaMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EstimatedUsefulLivesOfAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated useful lives of the assets.",
        "label": "Estimated Useful Lives Of Assets [Table Text Block]",
        "terseLabel": "Estimated Useful Lives of Assets"
       }
      }
     },
     "localname": "EstimatedUsefulLivesOfAssetsTableTextBlock",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_EvraAndDoxilMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evra and Doxil",
        "label": "Evra and Doxil [Member]",
        "terseLabel": "Evra and Doxil"
       }
      }
     },
     "localname": "EvraAndDoxilMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExcessOfFairValueOverCarryingValueOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of fair value over carrying value of debt.",
        "label": "Excess Of Fair Value Over Carrying Value Of Debt",
        "terseLabel": "Excess of fair value over carrying value of debt"
       }
      }
     },
     "localname": "ExcessOfFairValueOverCarryingValueOfDebt",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ExercisePriceRangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range.",
        "label": "Exercise Price Range Five [Member]",
        "terseLabel": "$151.42-$164.62"
       }
      }
     },
     "localname": "ExercisePriceRangeFiveMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExercisePriceRangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range.",
        "label": "Exercise Price Range Four [Member]",
        "terseLabel": "$131.94-$151.41"
       }
      }
     },
     "localname": "ExercisePriceRangeFourMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price range.",
        "label": "Exercise Price Range One Member",
        "terseLabel": "$65.08-$90.44"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range.",
        "label": "Exercise Price Range Three [Member]",
        "terseLabel": "$115.67-$129.51"
       }
      }
     },
     "localname": "ExercisePriceRangeThreeMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range.",
        "label": "Exercise Price Range Two [Member]",
        "terseLabel": "$100.06-$101.87"
       }
      }
     },
     "localname": "ExercisePriceRangeTwoMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExpenseNotAllocatedToSegments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense not allocated to segments.",
        "label": "Expense Not Allocated To Segments",
        "terseLabel": "Less: Expense not allocated to segments"
       }
      }
     },
     "localname": "ExpenseNotAllocatedToSegments",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value",
        "terseLabel": "Changes in estimated fair value"
       }
      }
     },
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of company's common stock directly held in plan assets.",
        "label": "Fair Value Of Company's Common Stock Directly Held In Plan Assets",
        "terseLabel": "Fair value of company's common stock directly held in plan assets"
       }
      }
     },
     "localname": "FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Act On Tax Reform And AHV Financing, Change In Tax Rate, Income Tax Expense (Benefit)",
        "label": "Federal Act On Tax Reform And AHV Financing, Change In Tax Rate, Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense related to change in tax rate from TRAF"
       }
      }
     },
     "localname": "FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset",
        "label": "Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset",
        "terseLabel": "Deferred tax asset recorded related to TRAF"
       }
      }
     },
     "localname": "FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)",
        "label": "Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax expense related to TRAF"
       }
      }
     },
     "localname": "FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Act On Tax Reform And AHV Financing, Income Tax Expense (Benefit)",
        "label": "Federal Act On Tax Reform And AHV Financing, Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense recorded related to TRAF"
       }
      }
     },
     "localname": "FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FederalLevelJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Level Jurisdiction",
        "label": "Federal Level Jurisdiction [Member]",
        "terseLabel": "Federal Level Jurisdiction"
       }
      }
     },
     "localname": "FederalLevelJurisdictionMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_FiscalPeriodPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period policy.",
        "label": "Fiscal Period [Policy Text Block]",
        "terseLabel": "Annual Closing Date"
       }
      }
     },
     "localname": "FiscalPeriodPolicyTextBlock",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_FundedPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funded plans.",
        "label": "Funded Plans [Member]",
        "terseLabel": "Funded Plans"
       }
      }
     },
     "localname": "FundedPlansMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_GENERALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GENERAL [Member]",
        "label": "GENERAL [Member]",
        "terseLabel": "GENERAL"
       }
      }
     },
     "localname": "GENERALMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_GainOnSaleOfAnAssetPaymentForRestructuring": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on Sale of an Asset (Payment) for Restructuring",
        "label": "Gain on Sale of an Asset (Payment) for Restructuring",
        "negatedTerseLabel": "Cash settlements"
       }
      }
     },
     "localname": "GainOnSaleOfAnAssetPaymentForRestructuring",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_GeneralCorporateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General corporate member.",
        "label": "General Corporate [Member]",
        "terseLabel": "General Corporate"
       }
      }
     },
     "localname": "GeneralCorporateMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_HIPSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIPS [Member]",
        "label": "HIPS [Member]",
        "terseLabel": "HIPS"
       }
      }
     },
     "localname": "HIPSMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IMBRUVICAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMBRUVICA [Member]",
        "label": "IMBRUVICA [Member]",
        "terseLabel": "IMBRUVICA"
       }
      }
     },
     "localname": "IMBRUVICAMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]",
        "label": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]",
        "terseLabel": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA"
       }
      }
     },
     "localname": "INVEGASUSTENNAXEPLIONTRINZATREVICTAMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_INVOKANAINVOKAMETMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INVOKANA/INVOKAMET [Member]",
        "label": "INVOKANA/INVOKAMET [Member]",
        "terseLabel": "INVOKANA/INVOKAMET"
       }
      }
     },
     "localname": "INVOKANAINVOKAMETMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IdorsiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Idorsia [Member]",
        "label": "Idorsia [Member]",
        "terseLabel": "Idorsia"
       }
      }
     },
     "localname": "IdorsiaMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunology [Member]",
        "label": "Immunology [Member]",
        "terseLabel": "Immunology"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)",
        "label": "Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)",
        "terseLabel": "Increase (decrease) in deferred tax liabilities, global intangible low-taxed income (GILTI)"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_IncreaseDecreaseInEarningsBeforeTaxesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Earnings Before Taxes, Percent",
        "label": "Increase (Decrease) In Earnings Before Taxes, Percent",
        "terseLabel": "Increase (decrease) in earnings before taxes, percent"
       }
      }
     },
     "localname": "IncreaseDecreaseInEarningsBeforeTaxesPercent",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_InfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infectious Diseases [Member]",
        "label": "Infectious Diseases [Member]",
        "terseLabel": "Infectious Diseases"
       }
      }
     },
     "localname": "InfectiousDiseasesMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the benefit obligation and the fair value of plan assets.",
        "label": "Information Related To Benefit Obligation And Fair Value Of Plan Assets [Table Text Block]",
        "terseLabel": "Information Related to the Benefit Obligation and the Fair Value of Plan Assets"
       }
      }
     },
     "localname": "InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_InterestIncomeExpenseNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Income Expense Net Member.",
        "label": "Interest Income Expense Net Member",
        "terseLabel": "Interest (Income) Expense"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InterventionalSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interventional Solutions [Member]",
        "label": "Interventional Solutions [Member]",
        "terseLabel": "Interventional Solutions"
       }
      }
     },
     "localname": "InterventionalSolutionsMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InvokanaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Invokana [Member]",
        "label": "Invokana [Member]",
        "terseLabel": "Invokana"
       }
      }
     },
     "localname": "InvokanaMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_KNEESMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KNEES [Member]",
        "label": "KNEES [Member]",
        "terseLabel": "KNEES"
       }
      }
     },
     "localname": "KNEESMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LandAndLeaseholdImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Land and leasehold improvements.",
        "label": "Land And Leasehold Improvements [Member]",
        "terseLabel": "Land and leasehold improvements"
       }
      }
     },
     "localname": "LandAndLeaseholdImprovementsMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LegalJurisdictionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Jurisdiction",
        "label": "Legal Jurisdiction [Axis]",
        "terseLabel": "Legal Jurisdiction [Axis]"
       }
      }
     },
     "localname": "LegalJurisdictionAxis",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_LegalJurisdictionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Jurisdiction [Domain]",
        "label": "Legal Jurisdiction [Domain]",
        "terseLabel": "Legal Jurisdiction [Domain]"
       }
      }
     },
     "localname": "LegalJurisdictionDomain",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LegalProceedingTextualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Proceeding Textuals Abstract.",
        "label": "Legal Proceeding (Textuals) [Abstract]",
        "terseLabel": "Legal Proceeding (Textuals)"
       }
      }
     },
     "localname": "LegalProceedingTextualsAbstract",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_LitigationSettlementByCompaniesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement by companies.",
        "label": "Litigation Settlement By Companies [Axis]",
        "terseLabel": "Litigation Settlement By Companies"
       }
      }
     },
     "localname": "LitigationSettlementByCompaniesAxis",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_LitigationSettlementByCompaniesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement by companies.",
        "label": "Litigation Settlement By Companies [Domain]",
        "terseLabel": "Litigation Settlement By Companies"
       }
      }
     },
     "localname": "LitigationSettlementByCompaniesDomain",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LossContingencyDamagesAwardedAdditionalReimbursementValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Damages Awarded, Additional Reimbursement, Value",
        "label": "Loss Contingency, Damages Awarded, Additional Reimbursement, Value",
        "terseLabel": "Damages awarded, including settlement for related issues, reimbursement for legal fees, and removal from related claims"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedAdditionalReimbursementValue",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_LossContingencyEstimateOfAdditionalPossibleLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Estimate of Additional Possible Loss",
        "label": "Loss Contingency, Estimate of Additional Possible Loss",
        "terseLabel": "Loss contingency, estimate of additional possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfAdditionalPossibleLoss",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of Claims within Settlement Agreement",
        "label": "Loss Contingency, Number of Claims within Settlement Agreement",
        "terseLabel": "Number of claims within settlement agreement"
       }
      }
     },
     "localname": "LossContingencyNumberOfClaimsWithinSettlementAgreement",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_LossContingencyReserveEstablishedWithinTrust": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Reserve Established within Trust",
        "label": "Loss Contingency, Reserve Established within Trust",
        "terseLabel": "Reserve established"
       }
      }
     },
     "localname": "LossContingencyReserveEstablishedWithinTrust",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_MedicalDevicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Devices [Member]",
        "label": "Medical Devices [Member]",
        "terseLabel": "Medical Devices",
        "verboseLabel": "Medical Devices"
       }
      }
     },
     "localname": "MedicalDevicesMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Collateral Value as a Percent, Reverse Repurchase Agreement",
        "label": "Minimum Collateral Value as a Percent, Reverse Repurchase Agreement",
        "terseLabel": "Minimum reverse repurchase agreement collateral (as a percent)"
       }
      }
     },
     "localname": "MinimumCollateralValueasaPercentReverseRepurchaseAgreement",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_MomentaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Momenta",
        "label": "Momenta [Member]",
        "terseLabel": "Momenta"
       }
      }
     },
     "localname": "MomentaMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neuroscience [Member]",
        "label": "Neuroscience [Member]",
        "terseLabel": "Neuroscience"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NonQualifiedPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non qualified plans.",
        "label": "Non Qualified Plans [Member]",
        "terseLabel": "Non-Qualified Plans"
       }
      }
     },
     "localname": "NonQualifiedPlansMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of employees engaged in company activities worldwide.",
        "label": "Number Of Employees Engaged In Company Activities Worldwide",
        "terseLabel": "Number of employees"
       }
      }
     },
     "localname": "NumberOfEmployeesEngagedInCompanyActivitiesWorldwide",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_NumberOfStockBasedCompensationPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock-based compensation plans.",
        "label": "Number Of Stock Based Compensation Plans",
        "terseLabel": "Number of stock-based compensation plans"
       }
      }
     },
     "localname": "NumberOfStockBasedCompensationPlans",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_Numberofpatientsinsettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patients in settlement",
        "label": "Number of patients in settlement",
        "terseLabel": "Number of patients in settlement"
       }
      }
     },
     "localname": "Numberofpatientsinsettlement",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_OPSUMITMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OPSUMIT [Member]",
        "label": "OPSUMIT [Member]",
        "terseLabel": "OPSUMIT"
       }
      }
     },
     "localname": "OPSUMITMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OTCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OTC [Member]",
        "label": "OTC [Member]",
        "terseLabel": "OTC"
       }
      }
     },
     "localname": "OTCMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OTHERNEUROSCIENCEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OTHER NEUROSCIENCE [Member]",
        "label": "OTHER NEUROSCIENCE [Member]",
        "terseLabel": "OTHER NEUROSCIENCE"
       }
      }
     },
     "localname": "OTHERNEUROSCIENCEMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]",
        "label": "Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]",
        "terseLabel": "Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI"
       }
      }
     },
     "localname": "OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oncology [Member]",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OpiodsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opiods [Member]",
        "label": "Opiods [Member]",
        "terseLabel": "Opiods"
       }
      }
     },
     "localname": "OpiodsMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OpioidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid",
        "label": "opioid [Member]",
        "terseLabel": "Opioid"
       }
      }
     },
     "localname": "OpioidMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OralCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oral Care [Member]",
        "label": "Oral Care [Member]",
        "terseLabel": "Oral Care"
       }
      }
     },
     "localname": "OralCareMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OrthopaedicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orthopaedics [Member]",
        "label": "Orthopaedics [Member]",
        "terseLabel": "Orthopaedics"
       }
      }
     },
     "localname": "OrthopaedicsMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "other comprehensive income loss, pension and other , effects of exchange rate net of tax",
        "label": "Other comprehensive income (loss), pension and other, effects of exchange rate net of tax",
        "negatedTerseLabel": "Effect of exchange rates"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax",
        "negatedTerseLabel": "Prior service credit (cost), net of amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax",
        "label": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax",
        "negatedTerseLabel": "Gain (loss), net of amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Immunology [Member]",
        "label": "Other Immunology [Member]",
        "terseLabel": "Other Immunology"
       }
      }
     },
     "localname": "OtherImmunologyMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherIncomeExpenseNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income Expense Net [Member]",
        "label": "Other Income Expense Net [Member]",
        "terseLabel": "Other (Income) Expense",
        "verboseLabel": "Other Income Expense Net"
       }
      }
     },
     "localname": "OtherIncomeExpenseNetMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Infectious Diseases [Member]",
        "label": "Other Infectious Diseases [Member]",
        "terseLabel": "Other Infectious Diseases"
       }
      }
     },
     "localname": "OtherInfectiousDiseasesMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other [Member]",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherNonLongLivedAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other non long lived assets.",
        "label": "Other Non Long Lived Assets",
        "terseLabel": "Other Non Long Lived Assets"
       }
      }
     },
     "localname": "OtherNonLongLivedAssets",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Oncology [Member]",
        "label": "Other Oncology [Member]",
        "terseLabel": "Other Oncology"
       }
      }
     },
     "localname": "OtherOncologyMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherSovereignSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Sovereign Securities",
        "label": "Other Sovereign Securities [Member]",
        "terseLabel": "Other Sovereign Securities"
       }
      }
     },
     "localname": "OtherSovereignSecuritiesMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]",
        "label": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]",
        "terseLabel": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA"
       }
      }
     },
     "localname": "PREZISTAPREZCOBIXREZOLSTASYMTUZAMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PROCRITEPREXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PROCRIT/EPREX [Member]",
        "label": "PROCRIT/EPREX [Member]",
        "terseLabel": "PROCRIT/EPREX"
       }
      }
     },
     "localname": "PROCRITEPREXMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PatentsAndTrademarksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents And Trademarks [Member]",
        "label": "Patents And Trademarks [Member]",
        "terseLabel": "Patents And Trademarks"
       }
      }
     },
     "localname": "PatentsAndTrademarksMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PelvicMeshesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pelvic meshes.",
        "label": "Pelvic Meshes [Member]",
        "terseLabel": "Pelvic Meshes"
       }
      }
     },
     "localname": "PelvicMeshesMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PercentageChangeInSalesBySegmentOfBusiness": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in sales by segment of business.",
        "label": "Percentage Change In Sales By Segment Of Business",
        "terseLabel": "Percentage Change In Sales By Segment Of Business"
       }
      }
     },
     "localname": "PercentageChangeInSalesBySegmentOfBusiness",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PercentageOfCompanysCommonStockToPlanAsset": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the company's common stock to the total plan asset.",
        "label": "Percentage Of Company's Common Stock To Plan Asset",
        "terseLabel": "Percentage of company's common stock to plan asset"
       }
      }
     },
     "localname": "PercentageOfCompanysCommonStockToPlanAsset",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of corridor of greater of market value of assets.",
        "label": "Percentage Of Corridor Of Greater Of Market Value Of Assets",
        "terseLabel": "Percentage of corridor of greater of market value of assets"
       }
      }
     },
     "localname": "PercentageOfCorridorOfGreaterOfMarketValueOfAssets",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical.",
        "label": "Pharmaceutical [Member]",
        "terseLabel": "Pharmaceutical",
        "verboseLabel": "Pharmaceutical"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PhysiomeshMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physiomesh [Member]",
        "label": "Physiomesh [Member]",
        "terseLabel": "Physiomesh"
       }
      }
     },
     "localname": "PhysiomeshMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PinnacleAcetabularCupSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pinnacle Acetabular cup system.",
        "label": "Pinnacle Acetabular Cup System [Member]",
        "terseLabel": "Pinnacle Acetabular Cup System"
       }
      }
     },
     "localname": "PinnacleAcetabularCupSystemMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PotentialSharesExercisableUnderStockOptionPlans": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Shares Exercisable Under Stock Option Plans",
        "label": "Potential Shares Exercisable Under Stock Option Plans",
        "terseLabel": "Potential shares exercisable under stock option plans (in shares)"
       }
      }
     },
     "localname": "PotentialSharesExercisableUnderStockOptionPlans",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits",
        "label": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits",
        "verboseLabel": "Proceeds from the exercise of stock options/employee withholding tax on stock awards, net"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities",
        "terseLabel": "Credit support agreements activity, net"
       }
      }
     },
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities",
        "terseLabel": "Credit support agreements activity, net"
       }
      }
     },
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProductLiabilityContingencyNumberOfClaimant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product liability contingency number of claimant.",
        "label": "Product Liability Contingency Number Of Claimant",
        "terseLabel": "Product liability contingency, number of claimants"
       }
      }
     },
     "localname": "ProductLiabilityContingencyNumberOfClaimant",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_ProductLiabilityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product liability.",
        "label": "Product Liability [Policy Text Block]",
        "terseLabel": "Product Liability"
       }
      }
     },
     "localname": "ProductLiabilityPolicyTextBlock",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ProfitLossPercentToSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit loss percent to sales.",
        "label": "Profit Loss Percent To Sales",
        "terseLabel": "Percentage of profit share payments (less than)"
       }
      }
     },
     "localname": "ProfitLossPercentToSales",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PulmonaryHypertensionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pulmonary Hypertension [Member]",
        "label": "Pulmonary Hypertension [Member]",
        "terseLabel": "Pulmonary Hypertension"
       }
      }
     },
     "localname": "PulmonaryHypertensionMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PurchasedInProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased In-Process Research And Development [Member]",
        "label": "Purchased In-Process Research And Development [Member]",
        "terseLabel": "Purchased in-process research and development(1)",
        "verboseLabel": "Purchased in-process research and development"
       }
      }
     },
     "localname": "PurchasedInProcessResearchAndDevelopmentMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_QualifiedPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qualified plans.",
        "label": "Qualified Plans [Member]",
        "terseLabel": "Qualified Plans"
       }
      }
     },
     "localname": "QualifiedPlansMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RISPERDALCONSTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RISPERDAL CONSTA [Member]",
        "label": "RISPERDAL CONSTA [Member]",
        "terseLabel": "RISPERDAL CONSTA"
       }
      }
     },
     "localname": "RISPERDALCONSTAMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RegulationCharge": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulation charge",
        "label": "Regulation charge",
        "terseLabel": "Regulation charge"
       }
      }
     },
     "localname": "RegulationCharge",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_RemicadeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remicade [Member]",
        "label": "Remicade [Member]",
        "terseLabel": "Remicade"
       }
      }
     },
     "localname": "RemicadeMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RestructuringandRelatedCostDurationofRestructuringPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and Related Cost, Duration of Restructuring Plan",
        "label": "Restructuring and Related Cost, Duration of Restructuring Plan",
        "terseLabel": "Restructuring and related cost, duration of restructuring plan"
       }
      }
     },
     "localname": "RestructuringandRelatedCostDurationofRestructuringPlan",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "jnj_RestructuringandRelatedCostExpectedFutureSavings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and Related Cost, Expected Future Savings",
        "label": "Restructuring and Related Cost, Expected Future Savings",
        "terseLabel": "Restructuring and related cost, expected future savings"
       }
      }
     },
     "localname": "RestructuringandRelatedCostExpectedFutureSavings",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_RisperdalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risperdal.",
        "label": "Risperdal [Member]",
        "terseLabel": "Risperdal"
       }
      }
     },
     "localname": "RisperdalMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SPINESPORTSOTHERMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPINE &amp; OTHER [Member]",
        "label": "SPINE, SPORTS &amp; OTHER [Member]",
        "terseLabel": "SPINE,SPORTS &amp; OTHER"
       }
      }
     },
     "localname": "SPINESPORTSOTHERMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SURGICALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SURGICAL [Member]",
        "label": "SURGICAL [Member]",
        "terseLabel": "SURGICAL"
       }
      }
     },
     "localname": "SURGICALMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SalesBySegmentOfBusinessTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales by segment of business.",
        "label": "Sales By Segment Of Business [Table Text Block]",
        "terseLabel": "Schedule of Sales by Segment of Business"
       }
      }
     },
     "localname": "SalesBySegmentOfBusinessTableTextBlock",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_SalesReturnReserve": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales return reserve",
        "label": "Sales Return Reserve",
        "terseLabel": "Sales return reserve (as a percent)"
       }
      }
     },
     "localname": "SalesReturnReserve",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_SavingsPlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Savings Plan.",
        "label": "Savings Plan [Abstract]",
        "terseLabel": "Savings Plan [Abstract]"
       }
      }
     },
     "localname": "SavingsPlanAbstract",
     "nsuri": "http://www.jnj.com/20220102",
     "xbrltype": "stringItemType"
    },
    "jnj_SavingsPlanTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Savings Plan.",
        "label": "Savings Plan [Text Block]",
        "terseLabel": "Savings Plan"
       }
      }
     },
     "localname": "SavingsPlanTextBlock",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SavingsPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of estimated future employer contributions.",
        "label": "Schedule Of Estimated Future Employer Contributions [Table Text Block]",
        "terseLabel": "Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans"
       }
      }
     },
     "localname": "ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]",
        "label": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]",
        "verboseLabel": "Schedule of Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "label": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "terseLabel": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_SegmentsTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segments Total",
        "label": "Segments Total [Member]",
        "terseLabel": "Segments Total"
       }
      }
     },
     "localname": "SegmentsTotalMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period",
        "terseLabel": "Canceled/forfeited/adjusted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation shares authorized under stock option plans by exercise price range.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Abstract]",
        "terseLabel": "Stock options outstanding and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.",
        "label": "Shares Which Could Be Repurchased Under Treasury Stock Method",
        "negatedTerseLabel": "Less: shares repurchased under treasury stock method (in shares)"
       }
      }
     },
     "localname": "SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_ShippingandHandlingCostsasaPercentofSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shipping and Handling Costs as a Percent of Sales",
        "label": "Shipping and Handling Costs as a Percent of Sales",
        "terseLabel": "Shipping and handling costs as a percent of sales"
       }
      }
     },
     "localname": "ShippingandHandlingCostsasaPercentofSales",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_ShortTermInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term investment funds.",
        "label": "Short Term Investment Funds [Member]",
        "terseLabel": "Short-term investment funds"
       }
      }
     },
     "localname": "ShortTermInvestmentFundsMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SimponiSimponiAriaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simponi/Simponi Aria [Member]",
        "label": "Simponi/Simponi Aria [Member]",
        "terseLabel": "Simponi/Simponi Aria"
       }
      }
     },
     "localname": "SimponiSimponiAriaMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SkinHealthBeautyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Skin health/Beauty",
        "label": "Skin health/Beauty [Member]",
        "terseLabel": "Skin health/Beauty"
       }
      }
     },
     "localname": "SkinHealthBeautyMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_StateLevelJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State Level Jurisdiction",
        "label": "State Level Jurisdiction [Member]",
        "terseLabel": "State Level Jurisdiction"
       }
      }
     },
     "localname": "StateLevelJurisdictionMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_StelaraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stelara [Member]",
        "label": "Stelara [Member]",
        "terseLabel": "Stelara"
       }
      }
     },
     "localname": "StelaraMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SupplyChainMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Chain",
        "label": "Supply Chain [Member]",
        "terseLabel": "Supply Chain"
       }
      }
     },
     "localname": "SupplyChainMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SurgeryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgery [Member]",
        "label": "Surgery [Member]",
        "terseLabel": "Surgery"
       }
      }
     },
     "localname": "SurgeryMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SurgicalMeshProductsMarketingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Mesh Products Marketing",
        "label": "Surgical Mesh Products Marketing [Member]",
        "terseLabel": "Surgical Mesh Products Marketing"
       }
      }
     },
     "localname": "SurgicalMeshProductsMarketingMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TRAUMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TRAUMA [Member]",
        "label": "TRAUMA [Member]",
        "terseLabel": "TRAUMA"
       }
      }
     },
     "localname": "TRAUMAMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TalcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Talc [Member]",
        "label": "Talc [Member]",
        "terseLabel": "Talc"
       }
      }
     },
     "localname": "TalcMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Increase (Decrease) In Deferred Tax Asset",
        "label": "Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Increase (Decrease) In Deferred Tax Asset",
        "terseLabel": "TCJA, increase (decrease) in deferred tax asset"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017ForeignTaxCreditsIncreaseDecreaseInDeferredTaxAsset",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Net Deferred Tax Expense (Benefit)",
        "label": "Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Net Deferred Tax Expense (Benefit)",
        "terseLabel": "Tax Cuts And Jobs Act Of 2017, foreign tax credits, net deferred tax expense (benefit)"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017ForeignTaxCreditsNetDeferredTaxExpenseBenefit",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Asset",
        "label": "Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Asset",
        "terseLabel": "Reversal of deferred tax asset"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxAsset",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Liability",
        "label": "Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits, Reversal Of Deferred Tax Liability",
        "terseLabel": "Reversal of deferred tax liability"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017ForeignTaxCreditsReversalOfDeferredTaxLiability",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability",
        "label": "Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability",
        "terseLabel": "TCJA, provisional liability"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Noncurrent",
        "label": "Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Noncurrent",
        "terseLabel": "TJCA , provisional liability, non-current"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent",
        "label": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent",
        "terseLabel": "TCJA, undistributed foreign earnings percent related to cash and cash equivalents"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent",
        "label": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent",
        "terseLabel": "TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury stock issued for employee compensation and stock option plans, net of cash proceeds.",
        "label": "Treasury Stock Issued For Employee Compensation And Stock Option Plans Net Of Cash Proceeds",
        "terseLabel": "Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards"
       }
      }
     },
     "localname": "TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_TremfyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tremfaya",
        "label": "Tremfya [Member]",
        "terseLabel": "Tremfya"
       }
      }
     },
     "localname": "TremfyaMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UNITEDSTATESExportsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UNITED STATES Exports [Member]",
        "label": "UNITED STATES Exports [Member]",
        "terseLabel": "UNITED STATES Exports"
       }
      }
     },
     "localname": "UNITEDSTATESExportsMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UPTRAVIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UPTRAVI [Member]",
        "label": "UPTRAVI [Member]",
        "terseLabel": "UPTRAVI"
       }
      }
     },
     "localname": "UPTRAVIMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UnfundedPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unfunded plans.",
        "label": "Unfunded Plans [Member]",
        "terseLabel": "Unfunded Plans"
       }
      }
     },
     "localname": "UnfundedPlansMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UnrecognizedTaxBenefitLiabilityPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefit Liability, Payment",
        "label": "Unrecognized Tax Benefit Liability, Payment",
        "terseLabel": "Payment on unrecognized tax benefit liability"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitLiabilityPayment",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_VerbSurgicalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verb Surgical Inc.",
        "label": "Verb Surgical Inc. [Member]",
        "terseLabel": "Verb Surgical Inc."
       }
      }
     },
     "localname": "VerbSurgicalIncMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_VisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vision[Member]",
        "label": "Vision [Member]",
        "terseLabel": "Vision"
       }
      }
     },
     "localname": "VisionMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WesternHemisphereExcludingUSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Western Hemisphere, excluding U.S. [Member]",
        "label": "Western Hemisphere, excluding U.S. [Member]",
        "terseLabel": "Western Hemisphere excluding U.S."
       }
      }
     },
     "localname": "WesternHemisphereExcludingUSMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_Wholesaler1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wholesaler 1 [Member]",
        "label": "Wholesaler 1 [Member]",
        "terseLabel": "Wholesaler 1"
       }
      }
     },
     "localname": "Wholesaler1Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_Wholesaler2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wholesaler 2 [Member]",
        "label": "Wholesaler 2 [Member]",
        "terseLabel": "Wholesaler 2"
       }
      }
     },
     "localname": "Wholesaler2Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_Wholesaler3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wholesaler 3 [Member]",
        "label": "Wholesaler 3 [Member]",
        "terseLabel": "Wholesaler 3"
       }
      }
     },
     "localname": "Wholesaler3Member",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WholesalerConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wholesaler Concentration Risk",
        "label": "Wholesaler Concentration Risk [Member]",
        "terseLabel": "Wholesaler Concentration Risk"
       }
      }
     },
     "localname": "WholesalerConcentrationRiskMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WomensHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Women's Health [Member]",
        "label": "Women's Health [Member]",
        "terseLabel": "Women's Health"
       }
      }
     },
     "localname": "WomensHealthMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WoundCareandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wound Care and Other [Member]",
        "label": "Wound Care and Other [Member]",
        "terseLabel": "Wound Care and Other"
       }
      }
     },
     "localname": "WoundCareandOtherMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_XareltoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xarelto [Member]",
        "label": "Xarelto [Member]",
        "terseLabel": "XARELTO"
       }
      }
     },
     "localname": "XareltoMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ZYTIGAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZYTIGA [Member]",
        "label": "ZYTIGA [Member]",
        "terseLabel": "ZYTIGA/abiraterone acetate"
       }
      }
     },
     "localname": "ZYTIGAMember",
     "nsuri": "http://www.jnj.com/20220102",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r162",
      "r215",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r241",
      "r245",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r368",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r162",
      "r215",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r241",
      "r245",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r368",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r252",
      "r427",
      "r430",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r377",
      "r411",
      "r524",
      "r529",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r759",
      "r816",
      "r820",
      "r858",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r377",
      "r411",
      "r524",
      "r529",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r759",
      "r816",
      "r820",
      "r858",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r252",
      "r427",
      "r430",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r248",
      "r427",
      "r428",
      "r762",
      "r815",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r248",
      "r427",
      "r428",
      "r762",
      "r815",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r377",
      "r411",
      "r463",
      "r524",
      "r529",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r759",
      "r816",
      "r820",
      "r858",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r377",
      "r411",
      "r463",
      "r524",
      "r529",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r759",
      "r816",
      "r820",
      "r858",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r249",
      "r250",
      "r427",
      "r429",
      "r818",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r249",
      "r250",
      "r427",
      "r429",
      "r818",
      "r844",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r50",
      "r747"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r11",
      "r30",
      "r254",
      "r255"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable trade, less allowances for doubtful accounts $230 (2020, $293)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r24",
      "r771",
      "r798"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Accrued taxes on income (Note 8)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r26",
      "r771",
      "r798"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term taxes payable (Note 1)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r84",
      "r92",
      "r101",
      "r102",
      "r103",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r48",
      "r319"
     ],
     "calculation": {
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r92",
      "r101",
      "r102",
      "r103",
      "r104",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Gain/ (Loss) On Derivatives &amp; Hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r92",
      "r101",
      "r102",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Gain/(Loss) On Securities"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r32",
      "r89",
      "r91",
      "r92",
      "r802",
      "r825",
      "r826"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income (loss) (Note\u00a013)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r101",
      "r102",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r88",
      "r92",
      "r101",
      "r102",
      "r103",
      "r164",
      "r165",
      "r166",
      "r643",
      "r821",
      "r822",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r77",
      "r92",
      "r101",
      "r102",
      "r103",
      "r643",
      "r720",
      "r721",
      "r722",
      "r723",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average useful life of acquired intangibles"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r531",
      "r533",
      "r573",
      "r574"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Employee compensation and stock option plans"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net earnings to cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r577"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r533",
      "r563",
      "r572"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Compensation cost charged for Long term incentive plan"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r34",
      "r256",
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "verboseLabel": "Allowances for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r139",
      "r302",
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization expense of amortizable intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized in net periodic benefit cost (credit) and other comprehensive (income) loss.",
        "label": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax",
        "terseLabel": "Total recognized in net periodic benefit cost and other comprehensive income"
       }
      }
     },
     "localname": "AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]",
        "terseLabel": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]"
       }
      }
     },
     "localname": "AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax",
        "terseLabel": "Deferred net losses (gains) on derivatives included in accumulated other comprehensive income"
       }
      }
     },
     "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r139",
      "r317"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset write-downs"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r156",
      "r223",
      "r236",
      "r243",
      "r283",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r369",
      "r371",
      "r372",
      "r639",
      "r645",
      "r708",
      "r745",
      "r747",
      "r769",
      "r797"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets",
        "verboseLabel": "Identifiable Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r67",
      "r156",
      "r283",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r369",
      "r371",
      "r372",
      "r639",
      "r645",
      "r708",
      "r745",
      "r747"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale, unrecognized gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Available-for-sale, unrecognized loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r259",
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "terseLabel": "Carrying Amount, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r263",
      "r266",
      "r790"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r263",
      "r265",
      "r789"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r263",
      "r267",
      "r791"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "terseLabel": "Total debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "auth_ref": [
      "r263",
      "r267",
      "r787"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "terseLabel": "Total debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]",
        "terseLabel": "Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r263",
      "r264",
      "r788"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r258",
      "r260",
      "r288",
      "r775"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Debt securities",
        "verboseLabel": "Fair value, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Securities [Member]",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r534",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r657",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time deposits"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Building and building equipment"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r520",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r520",
      "r525",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r621"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition related costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r628",
      "r629",
      "r631"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r626",
      "r628",
      "r629",
      "r632"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r138",
      "r634"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration reversal"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r627",
      "r630",
      "r633"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "verboseLabel": "Acquisitions and Divestitures"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r624"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Other assets assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "auth_ref": [
      "r624"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "terseLabel": "Marketable securities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r624"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "terseLabel": "Liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r624"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r9",
      "r44",
      "r141"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash &amp; Cash Equivalents",
        "verboseLabel": "Cash and cash equivalents (Notes\u00a01 and 2)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Current Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-term Investments [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, and Short-term Investments [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r133",
      "r141",
      "r147"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year (Note\u00a01)",
        "periodStartLabel": "Cash and cash equivalents, beginning of year (Note\u00a01)"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r133",
      "r717"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase/(Decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r154",
      "r156",
      "r179",
      "r180",
      "r184",
      "r186",
      "r188",
      "r197",
      "r198",
      "r199",
      "r283",
      "r358",
      "r363",
      "r364",
      "r365",
      "r371",
      "r372",
      "r409",
      "r410",
      "r412",
      "r413",
      "r708",
      "r868"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r421",
      "r422",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralAlreadyPostedAggregateFairValue": {
     "auth_ref": [
      "r680"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.",
        "label": "Collateral Already Posted, Aggregate Fair Value",
        "terseLabel": "Collateral paid"
       }
      }
     },
     "localname": "CollateralAlreadyPostedAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r62",
      "r340",
      "r777",
      "r806"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 19)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Cash dividends paid (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common Stock, Dividends, Per Share, Declared"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r164",
      "r165",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock Issued Amount",
        "verboseLabel": "Common Stock, Par Value $1.00"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value per share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r29",
      "r747"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock\u00a0\u2014 par value $1.00 per share (Note\u00a012) (authorized 4,320,000,000\u00a0shares; issued 3,119,843,000\u00a0shares)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs [Abstract]",
        "terseLabel": "Compensation Related Costs [Abstract]"
       }
      }
     },
     "localname": "CompensationRelatedCostsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsGeneralTextBlock": {
     "auth_ref": [
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items.  Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Compensation Related Costs, General [Text Block]",
        "terseLabel": "Employee Related Obligations"
       }
      }
     },
     "localname": "CompensationRelatedCostsGeneralTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r97",
      "r99",
      "r109",
      "r638",
      "r648",
      "r781",
      "r810"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r108",
      "r119",
      "r780",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "verboseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r205",
      "r206",
      "r252",
      "r706",
      "r707",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r205",
      "r206",
      "r252",
      "r706",
      "r707",
      "r828",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r205",
      "r206",
      "r252",
      "r706",
      "r707",
      "r828",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r205",
      "r206",
      "r252",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r205",
      "r206",
      "r252",
      "r706",
      "r707",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r149",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r377",
      "r387",
      "r388",
      "r389",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r404",
      "r405",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r464",
      "r513",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r245",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate, Non-Segment"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r115",
      "r762"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Products Sold",
        "verboseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "auth_ref": [
      "r464",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "terseLabel": "Cross currency interest rate swaps contracts:",
        "verboseLabel": "Cross currency interest rate swaps"
       }
      }
     },
     "localname": "CrossCurrencyInterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r157",
      "r604",
      "r611"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "U.S. taxes"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r157",
      "r604"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "International taxes"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r157",
      "r604",
      "r611",
      "r613"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total currently payable"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Currently payable:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DamagesFromProductDefectsMember": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk of loss arises with respect to product defects and recalls, or improperly performed services which actually or allegedly resulted in damages suffered by the injured party, excluding major product liability matters.",
        "label": "Damages from Product Defects [Member]",
        "terseLabel": "Damages from Product Defects"
       }
      }
     },
     "localname": "DamagesFromProductDefectsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r144",
      "r146"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of debt"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Short-term borrowings and the current portion of long-term debt"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r153",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r391",
      "r398",
      "r399",
      "r401",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/Borrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r22",
      "r24",
      "r25",
      "r155",
      "r162",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r404",
      "r405",
      "r406",
      "r407",
      "r735",
      "r770",
      "r773",
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": {
     "auth_ref": [
      "r59",
      "r376",
      "r415",
      "r416",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.",
        "label": "Debt Instrument, Convertible, Number of Equity Instruments",
        "terseLabel": "Convertible Debt, number of equity instruments (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r374",
      "r404",
      "r405",
      "r733",
      "r735",
      "r736"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r58",
      "r403",
      "r733",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r58",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r60",
      "r155",
      "r162",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r404",
      "r405",
      "r406",
      "r407",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r60",
      "r155",
      "r162",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r400",
      "r404",
      "r405",
      "r406",
      "r407",
      "r415",
      "r417",
      "r418",
      "r419",
      "r732",
      "r733",
      "r735",
      "r736",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Contractual Maturities of Available for Sale Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "terseLabel": "Debt securities",
        "verboseLabel": "Debt instruments"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Debt, weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails": {
       "order": 4.0,
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.",
        "label": "Deferred Compensation Liability, Current and Noncurrent",
        "terseLabel": "Deferred compensation"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r157",
      "r605",
      "r611"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "U.S. taxes"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r157",
      "r605",
      "r611"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "International taxes"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r582",
      "r583"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "verboseLabel": "Deferred taxes on income (Note\u00a08)"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r139",
      "r157",
      "r605",
      "r611",
      "r612",
      "r613"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred",
        "verboseLabel": "Deferred tax provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r582",
      "r583"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred taxes on income (Note 8)"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r602",
      "r603"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Income reported for tax purposes"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r598"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r598"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred income taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r602",
      "r603"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "terseLabel": "Net realizable operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r602",
      "r603"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Miscellaneous international"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": {
     "auth_ref": [
      "r602",
      "r603"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits",
        "terseLabel": "Employee related obligations"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r602",
      "r603"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r602",
      "r603"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Reserves\u00a0&amp; liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r583",
      "r598"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred income taxes"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r602",
      "r603"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Goodwill and intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r602",
      "r603"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Miscellaneous international"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r602",
      "r603"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Depreciation of property, plant and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": {
     "auth_ref": [
      "r602"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.",
        "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings",
        "negatedTerseLabel": "Undistributed foreign earnings"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities": {
     "auth_ref": [
      "r437",
      "r461",
      "r772",
      "r799"
     ],
     "calculation": {
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails": {
       "order": 1.0,
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan. Excludes other postretirement benefit plan.",
        "label": "Liability, Defined Benefit Pension Plan",
        "terseLabel": "Pension benefits"
       }
      }
     },
     "localname": "DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": {
     "auth_ref": [
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.",
        "label": "Defined Benefit Plan, Accumulated Benefit Obligation",
        "terseLabel": "Accumulated Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": {
     "auth_ref": [
      "r85",
      "r92",
      "r484"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax",
        "totalLabel": "Total before tax effects"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": {
     "auth_ref": [
      "r92",
      "r484"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax",
        "negatedLabel": "Net actuarial loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r92",
      "r484"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax",
        "terseLabel": "Prior service cost (credit)(1)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax": {
     "auth_ref": [
      "r87",
      "r92",
      "r484"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for transition asset (obligation) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Transition Asset (Obligation), before Tax",
        "terseLabel": "Unrecognized net transition obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "auth_ref": [
      "r453",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "terseLabel": "Actual return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r446"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "negatedTerseLabel": "Actuarial (gains) losses(2)"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r439",
      "r479",
      "r507",
      "r513",
      "r514"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Recognized actuarial losses (gains)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r439",
      "r480",
      "r508",
      "r513",
      "r514"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "verboseLabel": "Amortization of prior service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": {
     "auth_ref": [
      "r437",
      "r461"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.",
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position",
        "totalLabel": "Total recognized in the consolidated balance sheet\u00a0\u2014 end of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]",
        "terseLabel": "Amounts Recognized in the Company\u2019s Balance Sheet consist of the following:"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]",
        "terseLabel": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r20",
      "r437",
      "r438",
      "r461",
      "r513",
      "r768",
      "r796"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Non-current assets",
        "verboseLabel": "Prepaid employee related obligations"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]",
        "terseLabel": "Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "terseLabel": "Rate of increase in compensation levels"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "terseLabel": "Service cost discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "auth_ref": [
      "r488",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets",
        "terseLabel": "Expected long-term rate of return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "terseLabel": "Rate of increase in compensation levels"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r441"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "periodEndLabel": "Projected benefit obligation - end of year",
        "periodStartLabel": "Projected benefit obligation - beginning of year",
        "terseLabel": "Projected Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "auth_ref": [
      "r448",
      "r517"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "negatedTerseLabel": "Benefits paid from plan"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation.",
        "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant",
        "terseLabel": "Plan participant contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "auth_ref": [
      "r463",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r491",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "verboseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "terseLabel": "Change in Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "terseLabel": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r455",
      "r464",
      "r466",
      "r511",
      "r513",
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Company contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "auth_ref": [
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "terseLabel": "2027-2031"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "auth_ref": [
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "auth_ref": [
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "auth_ref": [
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "auth_ref": [
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "auth_ref": [
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r439",
      "r478",
      "r506",
      "r513",
      "r514"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r452",
      "r464",
      "r466",
      "r467",
      "r513"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "periodEndLabel": "Plan assets at fair value\u00a0- End of year",
        "periodStartLabel": "Plan assets at fair value\u00a0\u2014 beginning of year",
        "verboseLabel": "Plan Assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Effect of exchange rates"
       }
      }
     },
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "auth_ref": [
      "r437",
      "r461",
      "r513"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "terseLabel": "Projected Benefit Obligation",
        "totalLabel": "Funded status - end of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.",
        "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year",
        "terseLabel": "Healthcare cost trend rate assumed for next year"
       }
      }
     },
     "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r439",
      "r444",
      "r477",
      "r505",
      "r513",
      "r514"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost",
        "verboseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r475",
      "r503",
      "r513",
      "r514"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "terseLabel": "Net periodic benefit cost",
        "totalLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": {
     "auth_ref": [
      "r499",
      "r500",
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation",
        "terseLabel": "Accumulated benefit obligation unfunded plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": {
     "auth_ref": [
      "r499",
      "r500",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "terseLabel": "Plan with accumulated benefit obligation in excess of plan assets, plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "terseLabel": "Projected benefit obligation, unfunded plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAmendments": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment",
        "terseLabel": "Amendments"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAmendments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "auth_ref": [
      "r457",
      "r517"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "negatedTerseLabel": "Benefits paid from plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": {
     "auth_ref": [
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant",
        "terseLabel": "Plan participant contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Effect of exchange rates"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "auth_ref": [
      "r463",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "terseLabel": "Target Allocation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1": {
     "auth_ref": [
      "r440",
      "r482",
      "r510"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment",
        "negatedTerseLabel": "Curtailments and settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r442",
      "r476",
      "r504",
      "r513",
      "r514"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost",
        "verboseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan.",
        "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate",
        "terseLabel": "Rate to which the cost trend rate is assumed to decline (ultimate trend)"
       }
      }
     },
     "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage",
        "terseLabel": "Percent of Plan Assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssetAllocations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]",
        "terseLabel": "Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]",
        "terseLabel": "Net Periodic Benefit Cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Year ultimate health care cost trend rate is expected to be reached, in YYYY format.",
        "label": "Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate",
        "terseLabel": "Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r518"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Matching contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SavingsPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r139",
      "r218"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and Amortization",
        "verboseLabel": "Depreciation and amortization of property and intangibles"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "auth_ref": [
      "r69",
      "r75",
      "r660"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Asset, Fair Value, Gross Liability",
        "negatedTerseLabel": "Credit Support Agreement (CSA)"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r70",
      "r71",
      "r73",
      "r705"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "totalLabel": "Total Net Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": {
     "auth_ref": [
      "r667",
      "r685"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.",
        "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings",
        "terseLabel": "Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing"
       }
      }
     },
     "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r68",
      "r73",
      "r74",
      "r660",
      "r758"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Total Gross Assets"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r68",
      "r73",
      "r74",
      "r660",
      "r758"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Carrying Amount of the Hedged Liability",
        "verboseLabel": "Total Gross Liabilities"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Gain/(Loss) Recognized In Income on Derivative"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentDetailAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument Detail [Abstract]",
        "verboseLabel": "Financial assets and liabilities at fair value"
       }
      }
     },
     "localname": "DerivativeInstrumentDetailAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r73",
      "r658",
      "r661",
      "r669",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r655",
      "r658",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r655",
      "r658",
      "r669",
      "r676",
      "r677",
      "r684",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": {
     "auth_ref": [
      "r690"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred",
        "terseLabel": "Gain/(Loss) Reclassified From Accumulated OCI Into Income"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Assets, at Fair Value",
        "terseLabel": "Derivatives designated as hedging instruments : Assets"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value",
        "terseLabel": "Derivatives designated as hedging instruments : Liabilities"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r70",
      "r71",
      "r73",
      "r705"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "totalLabel": "Total Net Liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossAsset": {
     "auth_ref": [
      "r69",
      "r72",
      "r75",
      "r660"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Liability, Fair Value, Gross Asset",
        "negatedTerseLabel": "Credit Support Agreement (CSA)"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r650",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r649",
      "r651",
      "r652",
      "r655",
      "r656",
      "r664",
      "r669",
      "r681",
      "r683",
      "r687",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r161",
      "r649",
      "r651",
      "r655",
      "r656",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss": {
     "auth_ref": [
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the transactions or other events that will result in the reclassification into earnings of gains or losses reported in accumulated other comprehensive income. May include the time period over which gains or losses will be reclassified to earnings.",
        "label": "Description of Reclassification of Cash Flow Hedge Gain (Loss)",
        "terseLabel": "Description of reclassification of cash flow hedge gain (loss)"
       }
      }
     },
     "localname": "DescriptionOfReclassificationOfCashFlowHedgeGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Common Stock, Stock Option Plans and Stock Compensation Agreements"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember": {
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components classified as held-for-sale or disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]",
        "terseLabel": "Discontinued Operations, Held-for-sale or Disposed of by Sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand, demand deposits with banks or financial institutions, and  other kinds of accounts that have the general characteristics of demand deposits, held by a disposal group.",
        "label": "Disposal Group, Including Discontinued Operation, Cash",
        "terseLabel": "Disposal group, including discontinued operation, cash"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Disposal group, including discontinued operation, consideration"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r520",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Cash dividends paid"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r519",
      "r523",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net earnings per share (Notes 1 and 15)"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r110",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r177",
      "r179",
      "r186",
      "r187",
      "r188",
      "r192",
      "r193",
      "r693",
      "r694",
      "r782",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Basic net earnings per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r110",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r179",
      "r186",
      "r187",
      "r188",
      "r192",
      "r193",
      "r693",
      "r694",
      "r782",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net earnings per share (in dollars per share)",
        "verboseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r189",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "verboseLabel": "Reconciliation of basic net earnings per share to diluted net earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r717"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "verboseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r585"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Tax rates:"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r159",
      "r585",
      "r615"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": {
     "auth_ref": [
      "r585",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent",
        "terseLabel": "Effective income tax rate reconciliation, deduction"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther": {
     "auth_ref": [
      "r585",
      "r615"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Other, Percent",
        "negatedTerseLabel": "Tax benefits on share-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r585",
      "r615"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "International operations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r585",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent",
        "terseLabel": "Effective income tax rate reconciliation, nondeductible expense, impairment losses, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r585",
      "r615"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "All other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent": {
     "auth_ref": [
      "r585"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Percent",
        "terseLabel": "TCJA and related impacts"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation and employee related obligations"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities [Abstract]",
        "terseLabel": "Employee-related Liabilities [Abstract]"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r564"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total compensation cost not yet recognized for option"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period for total compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r563"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Total income tax benefit recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r566"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Exercise of Option, Tax Benefit",
        "terseLabel": "Exercise of options, tax benefit"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Severance"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r101",
      "r102",
      "r103",
      "r164",
      "r165",
      "r166",
      "r168",
      "r174",
      "r176",
      "r196",
      "r284",
      "r414",
      "r420",
      "r567",
      "r568",
      "r569",
      "r607",
      "r608",
      "r692",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r726",
      "r821",
      "r822",
      "r823",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.",
        "label": "Equity, Fair Value Adjustment",
        "terseLabel": "Equity, fair value adjustment"
       }
      }
     },
     "localname": "EquityFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investments accounted under the equity method.",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "terseLabel": "Equity method investments, fair value"
       }
      }
     },
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r704"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity Investments"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r17",
      "r23",
      "r279",
      "r795",
      "r841",
      "r842",
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity securities",
        "verboseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity securities without readily determinable fair value, amount"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r695",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r389",
      "r404",
      "r405",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r513",
      "r696",
      "r749",
      "r750",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "verboseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r695",
      "r696",
      "r697",
      "r698",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r389",
      "r464",
      "r466",
      "r471",
      "r513",
      "r696",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r389",
      "r404",
      "r405",
      "r464",
      "r466",
      "r471",
      "r513",
      "r696",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r389",
      "r404",
      "r405",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r513",
      "r696",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r700"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r699"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r389",
      "r404",
      "r405",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r513",
      "r749",
      "r750",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "verboseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r701",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r657",
      "r664",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Intangible assets useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Intangible Asset Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r303",
      "r306",
      "r310",
      "r314",
      "r763",
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r310",
      "r764"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Finite lived intangible assets gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r303",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r310",
      "r763"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Finite lived intangible assets net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Intangible assets with definite lives:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": {
     "auth_ref": [
      "r662"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value",
        "terseLabel": "Derivatives not designated as hedging instruments : Assets"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": {
     "auth_ref": [
      "r662"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value",
        "terseLabel": "Derivatives not designated as hedging instruments : Liabilities"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyDisclosureTextBlock": {
     "auth_ref": [
      "r716",
      "r728",
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items.",
        "label": "Foreign Currency Disclosure [Text Block]",
        "terseLabel": "International Currency Transalation"
       }
      }
     },
     "localname": "ForeignCurrencyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/InternationalCurrencyTranslation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "auth_ref": [
      "r727",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.",
        "label": "Foreign Currency Exchange Rate, Translation",
        "terseLabel": "Foreign currency exchange rate, translation"
       }
      }
     },
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r709",
      "r711",
      "r713",
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign currency transaction gain (loss), before tax"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTranslationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Translation [Abstract]",
        "terseLabel": "Foreign Currency Translation [Abstract]"
       }
      }
     },
     "localname": "ForeignCurrencyTranslationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r73",
      "r464",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign exchange contracts",
        "verboseLabel": "Forward foreign exchange contracts:"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r519",
      "r523",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "International Plans"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r139",
      "r644"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "terseLabel": "Gain (loss) on divestiture"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfEquityInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence.",
        "label": "Gain (Loss) on Sale of Equity Investments",
        "terseLabel": "Gain (loss) on sale of equity investments"
       }
      }
     },
     "localname": "GainLossOnSaleOfEquityInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedTerseLabel": "Net gain on sale of assets/businesses"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r294",
      "r295",
      "r747",
      "r767"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill end of period",
        "periodStartLabel": "Goodwill beginning of period",
        "terseLabel": "Goodwill (Notes\u00a01 and 5)"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill, related to acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r299",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Currency translation/other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "negatedTerseLabel": "Goodwill, related to divestitures"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r114",
      "r156",
      "r223",
      "r235",
      "r239",
      "r242",
      "r245",
      "r283",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r365",
      "r367",
      "r369",
      "r371",
      "r372",
      "r708"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r678"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r655",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r257",
      "r268",
      "r285",
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss",
        "terseLabel": "Carrying Amount, held-to-maturity"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "auth_ref": [
      "r270",
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain",
        "terseLabel": "Held-to-maturity, unrecognized gain"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r271",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss",
        "negatedTerseLabel": "Held-to-maturity, unrecognized loss"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r269",
      "r272",
      "r775"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Fair Value",
        "terseLabel": "Fair value, held-to-maturity"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldtomaturitySecuritiesMember": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as held-to-maturity.",
        "label": "Held-to-maturity Securities [Member]",
        "terseLabel": "Held-to-maturity Securities"
       }
      }
     },
     "localname": "HeldtomaturitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r139",
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets, excluding goodwill"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r158",
      "r614"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r106",
      "r223",
      "r235",
      "r239",
      "r242",
      "r245",
      "r765",
      "r778",
      "r785",
      "r813"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Earnings before provision for taxes on income",
        "totalLabel": "Earnings before provision for taxes on income"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r158",
      "r614"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "International"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r520",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r321",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r159",
      "r586",
      "r596",
      "r600",
      "r609",
      "r616",
      "r618",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r160",
      "r175",
      "r176",
      "r221",
      "r584",
      "r610",
      "r617",
      "r814"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for taxes on income (Note\u00a08)",
        "totalLabel": "Provision for taxes on income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r100",
      "r580",
      "r581",
      "r596",
      "r597",
      "r599",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": {
     "auth_ref": [
      "r585"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount",
        "terseLabel": "Repatriation of foreign earnings amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r135",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "(Increase)/Decrease in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in assets and liabilities, net of effects from acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Increase in other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "verboseLabel": "(Decrease)/Increase in other current and non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r182",
      "r183",
      "r188"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "verboseLabel": "Convertible debt shares (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r305",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "verboseLabel": "Indefinite-lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Indefinite lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets with indefinite lives:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r305",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.",
        "label": "Debt Security Category [Axis]",
        "terseLabel": "Debt Security Category [Axis]"
       }
      }
     },
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r301",
      "r308"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Total intangible assets - net",
        "verboseLabel": "Intangible assets, net (Notes\u00a01 and 5)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets and Goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Purchase price over fair value of assets acquired"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestCostsCapitalized": {
     "auth_ref": [
      "r731"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest capitalized during the period.",
        "label": "Interest Costs Capitalized",
        "terseLabel": "Interest expense capitalized"
       }
      }
     },
     "localname": "InterestCostsCapitalized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r105",
      "r217",
      "r730",
      "r734",
      "r783"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net of portion capitalized (Note\u00a04)"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestOnConvertibleDebtNetOfTax": {
     "auth_ref": [
      "r178",
      "r181",
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.",
        "label": "Interest on Convertible Debt, Net of Tax",
        "terseLabel": "Interest expense convertible debt"
       }
      }
     },
     "localname": "InterestOnConvertibleDebtNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r132",
      "r134",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest, net of amount capitalized"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r73",
      "r464",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest rate swaps contracts:"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS)"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r35",
      "r292"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r10",
      "r65",
      "r747"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories (Notes\u00a01 and 3)"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "verboseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r15",
      "r66",
      "r150",
      "r195",
      "r290",
      "r291",
      "r293",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r37",
      "r38",
      "r292"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "verboseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r36",
      "r292"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Goods in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r117",
      "r216"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedTerseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r282",
      "r812"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_JudicialRulingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation outcome that occurs as a result of judicial intervention, supervision, or approval.",
        "label": "Judicial Ruling [Member]",
        "terseLabel": "Judicial Ruling"
       }
      }
     },
     "localname": "JudicialRulingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Legal Proceedings"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r54",
      "r156",
      "r237",
      "r283",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r365",
      "r367",
      "r369",
      "r371",
      "r372",
      "r640",
      "r645",
      "r646",
      "r708",
      "r745",
      "r746"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r33",
      "r156",
      "r283",
      "r708",
      "r747",
      "r774",
      "r804"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r57",
      "r156",
      "r283",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r365",
      "r367",
      "r369",
      "r371",
      "r372",
      "r640",
      "r645",
      "r646",
      "r708",
      "r745",
      "r746",
      "r747"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Borrowing capacity under credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermCommercialPaperCurrent": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the current portion of long-term unsecured obligations issued by corporations and other borrowers to investors (with maturities initially due after one year or beyond the operating cycle if longer).",
        "label": "Long-term Commercial Paper, Current",
        "terseLabel": "Borrowed under the commercial paper program"
       }
      }
     },
     "localname": "LongTermCommercialPaperCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r25",
      "r388",
      "r402",
      "r404",
      "r405",
      "r773",
      "r801"
     ],
     "calculation": {
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Aggregate maturities of long-term obligations"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Less current portion",
        "verboseLabel": "Current portion of long term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails",
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r162",
      "r356",
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "After 2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r162",
      "r356",
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r162",
      "r356",
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r162",
      "r356",
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r162",
      "r356",
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r162",
      "r356",
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-term Debt [Member]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt (Note\u00a07)",
        "verboseLabel": "Total long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r60",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r345",
      "r346",
      "r347",
      "r350",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r345",
      "r346",
      "r347",
      "r350",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "verboseLabel": "Product Liability Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r340",
      "r343",
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r340",
      "r343",
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Litigation contingency"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r344",
      "r349",
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss contingency, estimate of possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r345",
      "r346",
      "r347",
      "r350",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of pending claims"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r12",
      "r55"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Current Marketable Securities",
        "verboseLabel": "Marketable securities (Notes\u00a01 and 2)"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities, noncurrent"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "terseLabel": "Marketable securities, realized gain (loss)"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gain (loss) on securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.",
        "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge",
        "terseLabel": "Maximum length of time for hedging transaction exposure"
       }
      }
     },
     "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r133",
      "r137",
      "r140"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r8",
      "r95",
      "r98",
      "r103",
      "r107",
      "r140",
      "r156",
      "r167",
      "r169",
      "r170",
      "r171",
      "r172",
      "r175",
      "r176",
      "r185",
      "r223",
      "r235",
      "r239",
      "r242",
      "r245",
      "r283",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r365",
      "r367",
      "r369",
      "r371",
      "r372",
      "r694",
      "r708",
      "r779",
      "r808"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net earnings",
        "totalLabel": "Net earnings",
        "verboseLabel": "Net earnings"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r144",
      "r145",
      "r146"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "totalLabel": "Net cash paid for acquisitions (Note 18)"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]",
        "verboseLabel": "Acquisitions"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
     "auth_ref": [
      "r144",
      "r145",
      "r146"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired",
        "verboseLabel": "Fair value of assets acquired"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r144",
      "r145",
      "r146"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "negatedLabel": "Fair value of liabilities assumed and noncontrolling interests"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncurrentAssets": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
        "label": "Long-Lived Assets",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r742",
      "r744"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r738"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r740",
      "r743"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r737"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease, right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r657",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets, noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Securities:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r86",
      "r89",
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax",
        "terseLabel": "Prior service cost (credit)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]",
        "terseLabel": "Employee benefit plans:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]",
        "terseLabel": "Derivatives &amp; hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r76",
      "r89",
      "r710",
      "r712",
      "r718"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r89",
      "r93",
      "r94",
      "r483"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax",
        "negatedLabel": "Amortization of prior service (cost) credit"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r80",
      "r81",
      "r89"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r78",
      "r89"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "terseLabel": "Derivatives &amp; hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r78",
      "r89"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Amount of gain or (loss) recognized in AOCI",
        "verboseLabel": "Unrealized gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r89",
      "r93"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Reclassifications to earnings",
        "terseLabel": "Amount of gain or (loss) reclassified from AOCI into income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": {
     "auth_ref": [
      "r79",
      "r89",
      "r666",
      "r686"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax",
        "terseLabel": "Amount of gain or (loss) recognized in AOCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r79",
      "r89",
      "r666",
      "r671",
      "r686"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Gain/(Loss) Recognized In Accumulated OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r76",
      "r90",
      "r714",
      "r725"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r96",
      "r99",
      "r101",
      "r102",
      "r104",
      "r108",
      "r414",
      "r719",
      "r724",
      "r726",
      "r780",
      "r809"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Net change",
        "totalLabel": "Other comprehensive income (loss)",
        "verboseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": {
     "auth_ref": [
      "r85",
      "r89",
      "r483",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax",
        "terseLabel": "Total loss/(income) recognized in other comprehensive income, before tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r85",
      "r89"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTotalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r83",
      "r89",
      "r483"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax",
        "negatedLabel": "Net actuarial (gain) loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": {
     "auth_ref": [
      "r85",
      "r90",
      "r638"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax",
        "negatedTerseLabel": "Employee benefits"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r89",
      "r93",
      "r94",
      "r278"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Reclassifications to earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": {
     "auth_ref": [
      "r89",
      "r93",
      "r94",
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax",
        "terseLabel": "Amortization of net actuarial loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r80",
      "r89"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized holding gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r81",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "auth_ref": [
      "r275",
      "r289",
      "r464",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as other.",
        "label": "Other Debt Obligations [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeMember": {
     "auth_ref": [
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other revenue.",
        "label": "Other Income [Member]",
        "terseLabel": "Other Income"
       }
      }
     },
     "localname": "OtherIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other Intangible Assets",
        "verboseLabel": "Customer relationships and other intangible assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableAxis": {
     "auth_ref": [
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Group of items that represent other investments not readily marketable, including description of investment, fair value, and value as measured by quoted value method.",
        "label": "Other Investment Not Readily Marketable [Axis]",
        "terseLabel": "Other Investment Not Readily Marketable [Axis]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Investment Not Readily Marketable [Line Items]",
        "terseLabel": "Other Investment Not Readily Marketable [Line Items]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableNameDomain": {
     "auth_ref": [
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the investment category or actual investment title.",
        "label": "Other Investment Not Readily Marketable, Name [Domain]",
        "terseLabel": "Other Investment Not Readily Marketable, Name [Domain]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableTable": {
     "auth_ref": [
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the information about other investments not readily marketable, including, but not limited to, description of investment, fair value and value as measured by quoted price.",
        "label": "Other Investment Not Readily Marketable [Table]",
        "terseLabel": "Other Investment Not Readily Marketable [Table]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other (income) expense, net",
        "terseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r434",
      "r437",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r463",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r488",
      "r489",
      "r491",
      "r494",
      "r498",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Other benefit plans",
        "verboseLabel": "Other Benefit Plans"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r437",
      "r461",
      "r772",
      "r799"
     ],
     "calculation": {
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails": {
       "order": 2.0,
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan. Excludes pension plan.",
        "label": "Liability, Other Postretirement Defined Benefit Plan",
        "terseLabel": "Postretirement benefits"
       }
      }
     },
     "localname": "OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r326",
      "r327",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.",
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r122",
      "r125"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other (primarily licenses and milestones)"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfOrdinaryDividends": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.",
        "label": "Payments of Ordinary Dividends",
        "negatedLabel": "Dividends to shareholders"
       }
      }
     },
     "localname": "PaymentsOfOrdinaryDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions, net of cash acquired (Note\u00a018)",
        "terseLabel": "Acquisitions, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r463",
      "r465",
      "r471",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r513",
      "r515",
      "r516",
      "r518",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "verboseLabel": "Pensions and Other Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "auth_ref": [
      "r24",
      "r437",
      "r438",
      "r461",
      "r513"
     ],
     "calculation": {
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1": {
       "order": 1.0,
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0
      },
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.",
        "label": "Liability, Defined Benefit Plan, Current",
        "negatedLabel": "Current liabilities",
        "terseLabel": "Less current benefits payable"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r26",
      "r437",
      "r438",
      "r461",
      "r513"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1": {
       "order": 2.0,
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0
      },
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "negatedLabel": "Non-current liabilities",
        "terseLabel": "Employee related obligations\u00a0\u2014 non-current",
        "verboseLabel": "Employee related obligations (Notes\u00a09 and 10)"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionContributions": {
     "auth_ref": [
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.",
        "label": "Payment for Pension Benefits",
        "terseLabel": "Contribution to pension plans"
       }
      }
     },
     "localname": "PensionContributions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r433",
      "r437",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r463",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r488",
      "r489",
      "r491",
      "r494",
      "r498",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r518",
      "r519",
      "r525",
      "r526",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Retirement plans",
        "verboseLabel": "Retirement Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "auth_ref": [
      "r463",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r491",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]"
       }
      }
     },
     "localname": "PlanAssetCategoriesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r534",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent": {
     "auth_ref": [
      "r435",
      "r436",
      "r776",
      "r807"
     ],
     "calculation": {
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails": {
       "order": 3.0,
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount as of the balance sheet date of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.",
        "label": "Postemployment Benefits Liability",
        "terseLabel": "Postemployment benefits"
       }
      }
     },
     "localname": "PostemploymentBenefitsLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r28",
      "r747"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock\u00a0\u2014 without par value (authorized and unissued 2,000,000\u00a0shares)"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r13",
      "r42",
      "r43"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other receivables"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from divestiture of brands"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "verboseLabel": "Proceeds from long-term debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r128",
      "r131"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "verboseLabel": "Sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfInterestInCorporateUnit": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow resulting from the sale of an interest in a corporate unit during the period.",
        "label": "Proceeds from Sale of Interest in Corporate Unit",
        "terseLabel": "Proceeds from sale of equity interests"
       }
      }
     },
     "localname": "ProceedsFromSaleOfInterestInCorporateUnit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "verboseLabel": "Proceeds from the disposal of assets/businesses, net"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "verboseLabel": "Proceeds from short-term debt"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Project Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Additions",
        "terseLabel": "Additions to Property, Plant &amp; Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAdditions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r48",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r323",
      "r846",
      "r847",
      "r848"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r47",
      "r318"
     ],
     "calculation": {
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment [Member]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r18",
      "r19",
      "r320",
      "r747",
      "r792",
      "r805"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Total property, plant and equipment, net",
        "verboseLabel": "Property, plant and equipment, net (Notes\u00a01 and 4)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r46",
      "r320",
      "r846",
      "r847"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment and Depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r18",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment at Cost and Accumulated Depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r18",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of the assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r111",
      "r286"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "verboseLabel": "Credit losses and accounts receivable allowances"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Summary of unrecognized tax benefits"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Repayment of short-term debt"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.",
        "label": "Repurchase Agreements [Member]",
        "terseLabel": "U.S. Reverse repurchase agreements"
       }
      }
     },
     "localname": "RepurchaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r578",
      "r761",
      "r860"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r578"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "R&amp;D Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "In-process research and development",
        "verboseLabel": "In-process research and development (Note 5)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r325",
      "r327",
      "r330",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r326",
      "r329",
      "r333",
      "r337"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Restructuring costs incurred since announced"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r326",
      "r329",
      "r333",
      "r337"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Pre-tax restructuring charges"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r139",
      "r324",
      "r331",
      "r333"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring (Note 20)",
        "verboseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesMember": {
     "auth_ref": [
      "r331",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.",
        "label": "Restructuring Charges [Member]",
        "terseLabel": "Restructuring Charges"
       }
      }
     },
     "localname": "RestructuringChargesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r326",
      "r327",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r327",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Reserve balance ending",
        "periodStartLabel": "Reserve balance beginning"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReservePeriodIncreaseDecrease": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the accrual for restructuring costs.",
        "label": "Restructuring Reserve, Period Increase (Decrease)",
        "terseLabel": "Activity during the period"
       }
      }
     },
     "localname": "RestructuringReservePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserveSettledWithoutCash2": {
     "auth_ref": [
      "r327",
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.",
        "label": "Restructuring Reserve, Settled without Cash",
        "negatedTerseLabel": "Settled non cash"
       }
      }
     },
     "localname": "RestructuringReserveSettledWithoutCash2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r31",
      "r420",
      "r570",
      "r747",
      "r803",
      "r824",
      "r826"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r164",
      "r165",
      "r166",
      "r168",
      "r174",
      "r176",
      "r284",
      "r567",
      "r568",
      "r569",
      "r607",
      "r608",
      "r692",
      "r821",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r463",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r487",
      "r488",
      "r489",
      "r491",
      "r494",
      "r499",
      "r500",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r519",
      "r523",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r463",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r487",
      "r488",
      "r489",
      "r491",
      "r494",
      "r499",
      "r500",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r519",
      "r523",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r433",
      "r434",
      "r437",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r463",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r488",
      "r489",
      "r491",
      "r494",
      "r498",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r525",
      "r526",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r433",
      "r434",
      "r437",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r463",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r488",
      "r489",
      "r491",
      "r494",
      "r498",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r525",
      "r526",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r214",
      "r215",
      "r234",
      "r240",
      "r241",
      "r248",
      "r249",
      "r252",
      "r426",
      "r427",
      "r762"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Sales to Customers",
        "verboseLabel": "Sales to customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r151",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership before Transaction",
        "terseLabel": "Sale of stock, percentage of ownership before transaction"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r205",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Sales Revenue, Net"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r92",
      "r724",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "verboseLabel": "Components of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "terseLabel": "Company' Retirement Plan Asset Allocation and Target Allocations"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "terseLabel": "Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Equity Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Cash and Cash Equivalent Composition"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r60",
      "r162",
      "r404",
      "r406",
      "r415",
      "r417",
      "r418",
      "r419",
      "r732",
      "r733",
      "r736",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Instruments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Temporary Differences and Carryforwards"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r497",
      "r498",
      "r501",
      "r502",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": {
     "auth_ref": [
      "r497",
      "r498",
      "r501",
      "r502",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.",
        "label": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Effect of Net Investment Hedges"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r658",
      "r669",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of Derivative Activity"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Financial Assets and Liabilities at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "terseLabel": "Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r303",
      "r309",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.",
        "label": "Schedule of Health Care Cost Trend Rates [Table Text Block]",
        "terseLabel": "Assumed Health Care Cost Trend Rates"
       }
      }
     },
     "localname": "ScheduleOfHealthCareCostTrendRatesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r15",
      "r39",
      "r40",
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Aggregate Maturities of Long Term Obligations"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "verboseLabel": "Components of Net Periodic Benefit Cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetFundedStatusTableTextBlock": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of net funded status of pension plans and/or other employee benefit plans.",
        "label": "Schedule of Net Funded Status [Table Text Block]",
        "terseLabel": "Schedule of Net Funded Status"
       }
      }
     },
     "localname": "ScheduleOfNetFundedStatusTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r668",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Schedule of Effect of Derivatives not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r48",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r333",
      "r334",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r327",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Summary of Severance Charges and Associated Spending"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r113",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r223",
      "r226",
      "r238",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r223",
      "r226",
      "r238",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "verboseLabel": "Schedule of Segment Reporting Information"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r546",
      "r551",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Share Units"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r534",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Summary of Options Outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r539",
      "r551",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]",
        "terseLabel": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r210",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r252",
      "r329",
      "r337",
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r210",
      "r212",
      "r213",
      "r223",
      "r227",
      "r239",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segments of Business and Geographic Areas"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Description of the Company And Business Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, marketing and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "verboseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Average fair value of RSU's and PSU's granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r553"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair Value of RSU or PSU units settled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted average assumptions of fair value of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized for issuance under long-term incentive plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grants under long-term incentive plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Summary of option activity under the Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Stock options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Stock options average price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r553"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options canceled/forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Average fair value of option granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r565"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r541",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding end of period",
        "periodStartLabel": "Options outstanding beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Outstanding Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options exercise price end of period (in dollars per share)",
        "periodStartLabel": "Options exercise price beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r532",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised, average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options canceled/forfeited, average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted, average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Price Range, Minimum (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Exercisable number of Options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Outstanding number of Options (in shares)",
        "verboseLabel": "Stock options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Price Range, Maximum (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "verboseLabel": "Stock options expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r558",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Outstanding Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Average Life",
        "verboseLabel": "Stock option average life"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShippingAndHandlingCostPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.",
        "label": "Shipping and Handling Cost, Policy [Policy Text Block]",
        "terseLabel": "Shipping and Handling"
       }
      }
     },
     "localname": "ShippingAndHandlingCostPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShippingAndHandlingMember": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Packing and transport of product.",
        "label": "Shipping and Handling [Member]",
        "terseLabel": "Shipping and Handling"
       }
      }
     },
     "localname": "ShippingAndHandlingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r21",
      "r747",
      "r770",
      "r800"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt",
        "terseLabel": "Loans and notes payable (Note\u00a07)",
        "verboseLabel": "Loans and notes payable"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]",
        "terseLabel": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r148",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Software Development"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SovereignDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by foreign government (not within the country of domicile of the entity).",
        "label": "Sovereign Debt Securities [Member]",
        "terseLabel": "Non-U.S. Sovereign Securities"
       }
      }
     },
     "localname": "SovereignDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r6",
      "r210",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r252",
      "r299",
      "r322",
      "r329",
      "r337",
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r154",
      "r156",
      "r179",
      "r180",
      "r184",
      "r186",
      "r188",
      "r197",
      "r198",
      "r199",
      "r283",
      "r358",
      "r363",
      "r364",
      "r365",
      "r371",
      "r372",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r708",
      "r868"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r64",
      "r101",
      "r102",
      "r103",
      "r164",
      "r165",
      "r166",
      "r168",
      "r174",
      "r176",
      "r196",
      "r284",
      "r414",
      "r420",
      "r567",
      "r568",
      "r569",
      "r607",
      "r608",
      "r692",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r726",
      "r821",
      "r822",
      "r823",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]",
        "verboseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r196",
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "negatedLabel": "Employee compensation and stock option plans (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r29",
      "r414",
      "r420",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "negatedLabel": "Employee compensation and stock option plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityBeforeTreasuryStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.",
        "label": "Stockholders' Equity before Treasury Stock",
        "totalLabel": "Stockholders' Equity before Treasury Stock"
       }
      }
     },
     "localname": "StockholdersEquityBeforeTreasuryStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r102",
      "r156",
      "r164",
      "r165",
      "r166",
      "r168",
      "r174",
      "r283",
      "r284",
      "r420",
      "r567",
      "r568",
      "r569",
      "r607",
      "r608",
      "r636",
      "r637",
      "r647",
      "r692",
      "r708",
      "r719",
      "r720",
      "r726",
      "r822",
      "r823",
      "r871"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r727",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r727",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r727",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r588",
      "r595",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow data"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r63",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock Amount",
        "verboseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r63",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "periodEndLabel": "Treasury Stock, ending balance (shares)",
        "periodStartLabel": "Treasury Stock, beginning balance (shares)",
        "verboseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r29",
      "r414",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "verboseLabel": "Repurchase of common stock (shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Treasury Stock [Text Block]",
        "terseLabel": "Capital and Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r63",
      "r421",
      "r424"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "periodEndLabel": "Treasury Stock, Ending Balance",
        "periodStartLabel": "Treasury Stock, Balance",
        "verboseLabel": "Less: common stock held in treasury, at cost (Note\u00a012) (490,878,000\u00a0shares and 487,331,000\u00a0shares)"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r414",
      "r420",
      "r421"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock",
        "terseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r326",
      "r327",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "Government and agency securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r464",
      "r786",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Gov't Securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r579",
      "r590"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "End of year",
        "periodStartLabel": "Beginning of year",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r591"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Decreases related to prior period tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r593"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r592"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases related to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r591"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases related to prior period tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "auth_ref": [
      "r587"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "terseLabel": "Unrecognized tax benefits, interest on income taxes accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": {
     "auth_ref": [
      "r587"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Expense",
        "terseLabel": "Unrecognized tax benefits, interest on income tax expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "terseLabel": "Increase (decrease) in unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r594"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Lapse of statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r207",
      "r208",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r178",
      "r188"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Average shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Average shares outstanding (Notes 1 and 15)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r177",
      "r188"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Average shares outstanding\u00a0\u2014 basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 15
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2029-109256"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL6284393-111563"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=125513658&loc=d3e32014-111567"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(c))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e14981-108350"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208821"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409950&loc=d3e20396-108366"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79691-111665"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79708-111665"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624258-113959"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061172-113977"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30885-110895"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "820",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=35710923&loc=d3e45360-110995"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r861": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r862": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r863": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r864": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r865": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r866": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r867": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r868": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r869": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r870": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>134
<FILENAME>0000200406-22-000022-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000200406-22-000022-xbrl.zip
M4$L#!!0    ( -2 450)ZI@>128  /TI!  >    97@R,2US=6)S:61I87)I
M97-X9F]R;3$P>&LN:'1M[7UM<R*WTO;W^U?HWM2=V%4V^Y)-LMG-215@;&.#
M37FP]R1?GA(S#:/C&8DC:6SC7_](\X+!"[M9F%16M/(AN]@+3'=?5TMJ]<MO
M_WMTV1[^,>B06*<)&5RW>MTV>7'X\N7'']LO7QX-C\CIL-\C;QNO7I.AI%PQ
MS02GR<N7G8L7Y$6L]?3]RY?W]_>-^Q\;0DY>#J]>VH]Z^S(10D$CTM&+WW^S
M/S'_!QK]_C^__>_A(3D2898"UR240#5$)%.,3\C'"-0M.3PL_U5;3&>236)-
MWKQZ\X9\%/*6W='B]YKI!'ZO/N>WE\7KWU[F7_+;2$2SWW^+V!UAT;]>L'?C
MZ-W//_\X_NG5^.>WOT1T]#/ S^&O%.CXQ]>_PB__[[5YR)?FGQ?O47J6P+]>
MI(P?QF"___W;-XU??IKJ#_<LTO'[UZ]>_=^+_)_^_MM8<&V^3YKW%W\M/N:3
M#]/PH ]IPB;\?2[2B^*MU:]#D0CY_KM7^7\?[&\.QS1ER>S]#T.6@B(7<$^N
M1$KY#P?*F.%0@63CXA\J]@CFF<SCY2_OBT?^Q7Q.PCA4(KQ^8Q^Z\^_3;JL[
M_/Z[US^_^O#F]?)#KW[<T.@7Y#_TO,%U*^@>=9M7W4ZP]F%3*B?&5EI,W_]J
M/C5_=L8C\]SOW[S-#??LZ4<TO)U(D?'HL!1DG/_WH7ZQWJX4ZTS$7 E>F.'[
M[WY\]X&4/SH@-/^2,Y *9B04<BHDM:0[(#&-B(Z!7#>"!J$\(LQ:AM."DD1E
M(\4B1B4S#ZIB<<_)"!)Q3Z@B8DS.*,^HG)6F/RC_-,1J5-]-EIZ$,$6XT.9Y
MYA\\LY]#N?G#/(8D1L%,SQKD$\.LI<5JH_U4&>T9X#0=)3"WF9 12&NOA$X5
MO*_^\B%B:IK0V7O&<SWG;_I0?OI(:"W2_ ON0&H6TJ3\DOS[BE^7K/[UI\:K
MMS]98FOSV#JJOKCD?"/G_$L=??J[7WYIO'OW;NVO7S5>K_W=YS[V]:^-7U^_
M^4L?^S)_Y.*QC6+4E/)_O?CQQ7J\AR& P?N41I%QO._?3!_(ZV4K)##^1&F%
MONIV!;]^R1,8=UL\601A28;W1A:0]E^]^/V"IF"!&<QA.@==J;>=5(GQ(IED
M*F*A5<B2R%\-A]+].21[[@.#!8_W_7<_O?NPD>&?"?_*BKZ3Q/ID+<HUV0S#
MA$KC<P](EX>-G>/.:JF/(*'W1NS=Y<TZ:VM(C+\@@YC*E(:0Y4^FR'6PA?W=
MTT,]]G</]\U;*13I0V2?QS,> ^.3D=VR!UH":-+KM9$P_.D4A8[CO3^;I/UT
M<O0$WW&"/U+2L_& /N5T NEV>SGW%(!V+>]?DB.X@T1,"YMOZMS=$QTMUXW)
M#<NS,0VU.?WSB=FW-S<WO'L*P,SU"Y&:GP,Y%8E];.4)CX/P 4W,Y]D%/@!Y
MQT+PJSL2Q@=3RKCG.S*^7S?.&S48W3WAT5*=TUNSFZ-D&(.DTSPFJWQP#@/=
M.4NI(D>,CD";3VT;'7C&8V!\;G>_GB,A^!#"F)MOG-C<'$_OG:>WD,,'OX!C
MX+>DDT]OT_T!'0/)E=FQ#VC(QBQ$>4:OZX;5/<@WM62"LVU<O'M"M\TCC(7D
MC*)C^G5K3G!$_$:[IMN\6G(*--$Q*H9C7<E;P.&&2=)B(M_(^9T[ I8;8Y=I
MD*1C"TZFAO2 :^<^A >JT)&="05< ?D((V7LCHKL=>WAW,.ZE7PD:97Z[(-P
M.T_T-G M0I$OZS;R&J(ZG ^ <S5+[BA&KE>6OP(%5(9Q6=FZE"R):)VO#PON
M\: -$KBXRW#=I^,-S;597@G:HR-1Y,8BXKG]E#^$O$7'<1$;EC_XLC9,/!?I
MM*AK$Q(:H=@F:..>]'B+V]I"1DP96R^V/O'%;GAH;W,DV0,FLJ,]P ?-X39=
M"=R3^"-5L7E4O<O]7-9A?)#-2)]IN,64_]JG2M$PSA1HC2X27]C\4NI83*G=
MNN,ZHW=YQ"A'%YPKK#Z0(LI"C>N^K1:+NP?TPN+!U/P"4P3^,F8")[F#&=<Q
MV$.:TDQGVI>TX&%Y:?H:_+N+*L!Y*%\V?5ZNCFI=][OXROB>[ACHGNDPKA*B
M_<J^\PSOM'N_8-JX8^5U1\<L%)QT>"0.@TQ.0,Y0K>/;G]C< _MJHWNRV__9
M40*_?SJZX-E0D*DHIJ*\E^:C-+N#3\:$S/55C"-X]?06.E(B,0?DM6]9-XAC
M[<R1XO^QK#Y@2B=P.)) ;P_IV+S_/4WNZ4R]^/M&G?C)#O_D9(=OV>O^0Y,=
M7%-)G9,=W'/(U8+DEZ#=(?[G+6U'#^ Y1:(LNBI-C2H\A#<'^]2\%?B\U&HI
M5P_5@1)KQ&@9 *A8CW4Q/V7AK9 S8W,;0K!;=L]T!$SO-HX:I!G^-V-%1"-/
MQ<;"=;PK?)=S<9<'NXB-&>;+?& C608"J%H6]UD8LPE%=TH_,V^U2WS5,H7Z
MF/'NLW[!Z!I"7+V1,-=05W8_8G3"A=+(6BE@I_M)(D9V?2^&CZ!:WO'665;&
MO^3V"R?;) *X)SQVQN<U.8AHCO7T7MF[OO;5[ND <Z.DN?WGV?J] 1+*^Y7]
M<\VQ\&SN\<;P*AP$(3,VS[O8-\=CRJ3?X:/R T$VG28S<F+$F6)BOE_X^6&;
M)72R/%$8$_G1[OOA+A15!0^JW3[BY?[LM.VYC8#;%V?/NJ-U^1TH;3?VB%9W
MM"$\$7,E>'FH*U\AH3SBO?PJJY.]/HNB!$B'*KWO5WFT]"=MP566@L1T8>^=
MP3(&GH;<D"I[R_P4D5/P.X)%.!PS3GD(6[?.=4\?WC$L(^&$:KBGJ(J^_?Y@
M&0+%K$-">40^0I)P4&HQG1?1K@%M/N_G<-$VJR8)9DI#JC#M&+R;6(;#PK[Q
MD)R=';51N0:_;UB+!CP[!W^(6(; 0IS9NP&4;J"J\CZ"/#N\RB9Z*A4H,@O,
MBM$S0.&DF9HO#VV]4*/7:&/92AR;;V$1OCR#E9 )&IV&WSH@]AE/I23^-('7
M"U2%PS=,L:UZP[BG$;3)"2N1<"U'U.8C<[@W<&@J)4)&-2CO&% ZAL(?Y%$G
M5$ZAECVB>_ _N^P_*T#"N3_ &EKH#7LV YE.8*L4-?<$OQ"R"*X+\SMTM.^'
M%\"2I]249S6(YA=8B(]W_2\Q4%PSA?:6"0_[L1X!2IOWFO[6  ._.UVSNO<'
MF"H/\$;[2FY?9%JRXE+(-PK"0/.E*R#2RA0K4HBV/\:YIPRD0U[_PC5@76VD
MW%..=PP%*);KTO#L"-#N]6%"CV8<YDD"*,?"7FL:XV,^UT*2 96:FZUPS*;S
M@9%MD1J!9Z2+Z4R UP/D.,B'GI"3@5_SL3"_L'BO,<"R[_>#!,$/$MRA08+?
MLL?]AP8)NJ:2.@<)NN>0RX7HHY!)9/C@[Y9VR0.LK=Z3F<IG&=]1%68)E7['
MN?M$S[N<*'BPJ8.9+,O:BT-FCZ5,0X2$]S<@4_./T-%>V,PABKJ--5;R7X (
MM-GQT8KRJ"Z;L"[T%Z!CL[FG/%+/XXJ>[UOSG>1_OEJA@/PU,P<KKM\?_OKI
MF?F?Q43VD=Y!#5-'O1]P1>X+<<<D)4/C#.@T7_?]O3*&13\S.UWJF8Z(Z9?]
M,[^_1TCURU2R!SMQ<EJ;\=U3 EK2YW/(C/$3,;$I9'YEWWFZ5Q:W V;G1SL?
MN4?!],,R?WQYG?<;^MVG_8!J:3C_Z0X/#_,Q#Y@VLC.NLF1%"-]S?^>Y#S)D
M=XPBXCK657X@&0]!VXZ1=&3S=(1DOLL##I9GB:*2W)1I&?[XCH#N5S !'LY\
M?R>L_1VNQ(PF>D::>35@']$*C[NWRU6F<\+GQL>S@\=+]"!D8O/PK'OR8EW1
M _OWD7CPYW($G-;F;4D?(E1[]3[C')30Z-;L8,9U;#[M.F@NE&E[FN\\S9_L
MCBG<CG8%+\SM8VX(J#UL7G4#>YF>ENTW/+UWG=Y#H-(<QH"'V_3.=D]NM!2/
M@32YD2R,26<\%E)C6L21=DRW1E]HDF]XKC33F09,^W6D$Y6&;&1SXS"Q'.U:
M+B1]J*'(P3W)L:[F-R!'3W.1$$7=L%+\1DPRJ*DMIGO2HZ7Y"JL/);6/CRK6
MCG3[_O'T[>O7KVQ37$C$-!]Z,^]=@&HHZ@D(L]2AV\+_2>4(X =?PE89NWJ4
MZ@UOIOK%QKA_937Q8CON+'U&+0_YS& ;/>3G/L-KTFO2:W*G->G;R&[61M;W
MC?5]8WW?V*]1"9:^L:ME7SZ7STW/0'W_W4_O/M2Q7U^U NT&G%9O_G\\8D:I
M$T,PB$AS&NP<B]:=>;A9+6YWET"KQ6Z&&A)[.=G36!JO!O=,/Q8-";%%L^;6
M?C[ =U/KNZ>"VJSO'O#76K^,9Y.](*9\$E.V;R<Z'UA48 EYM6.$I5]S0 S-
M&4]E<D:NS>DI;\*-K$-KUYZ_$7J$_B79.S6<?XQ%YDF/@_36YD^._OG8QVHM
MJ+! 6L#^8W_0LLWZ8R3^H 9DN$>'KT7&259ZCFVPX9Z:O-?X,C:PW(JC]1/-
MH-LDO6Z_.^P<(>']J3  /S?_P\C]IK)-O\JSP=ZY, >&TNOO(Z%Z+O,!N8)I
M-DI82,08)>\7<3"D[)[R$@?F(%$19#-(N*>00GZ4[B!36II'H62@MQO<Y:#\
ME>PH^;_*\&3/?L&?0&T,9:MEP3VE+$B.T1&T*:<1118M+(3&2/_REG3C>V'W
MI*[E7M@]B%MC'^?C.9%P>H6P2#A] C*UXU=/TM$I$E*7(F,D]8D4W#PNF&-;
MXP9+F&YA!"5&AB]GR96#6E1-E[WNJ:26RU[W2) C887HNRMQF\[,1Y"NPLO\
MPMX'U5]PW=1A)KJFR8P$5STD5,_EQ<CP,VH$(^>-<RQ).[G &"F].$>]=8.$
MU\AW[A="WM,9:6*)MA7R8F3W(#//(\@5"P7I4YZ-::@SN5V7$?<TX7?L@7E6
M.A42R$!# U,V[EQRC/1?*$O9/!#KGNB8JW&,U:]Y'GX[-X\<B115[OVRZ!@I
M?SV=*II0TFRA(3M$L,,EZFM,/55LL^EY[LE:QR6J>[AN&1G4G4T!(F](\U8S
M&(F$3CRK=QCI"S;_F9R:[0LD:G.KNR=_'59W#^M5+=P1'5%!VD*E8!Y-^;(7
M%)2W=^CDROQLB]P)]\2N+0+K'LQ;3"C@"LA'&"D-DNQUE:20[&/B>B$R.K(7
M-2UB3,Y$S)7@)!^+/'_5Z[7)WM7U/C'.X)P^TMM8Z6?74KNKG#4"(_ (;;/4
M<Y6EQA=4<Q>WSHEV3PM(>V6U:3K-U.&QF!GS-Z?"K(NW@"EM%G'GK#:5B2 =
M.:+D<M@F04,V$C0[ (RY->U8FL\X 6[/=WZ[CX+C+&\:VJ,C<[;/E'D.X^?[
M9J$SAWR$O2UJ2+1R#_XE!AX;I( !LHY8*)/KVBRA$](\0<)KQ'?NA:7MCGVY
M)@8)NS'OWW/+EZ5/GNMHN%Y9O.8.I^ZI VDM3(Z"PQ:S<WCC W-N[V'9O@=3
MRO!MWT72HI+TV!B"D $/ =/NO8ZK&O> WA8R8HI$0/KPP$)A6=YLV-=M/!7N
MA>CXZ"Y9FF8<4Q >:>^*(QBIPV(8K['ZM!P 1?8&4DPE TWE;)_@:D07B$S'
MI#F6YGD^A8,?0>='T#DP@NY;=L#_T @ZUU12YP@Z][SP$0RR&3D%XP04"9I(
MUIX3"8"O75IAZ^5V2MOL.=S3 .ZRK=+^92\=/RP)(?EKBS&XIX Z8@SNH;TP
M>S#C.C:?>2+DA')D!TW4A*\LWP,MS/YNPXY:[DG?RQX@'8E,HIMWTND$3TTR
ME\+*]M55H^>#RQCH;V#@EWD\I.\.22<%&ZR;D&XZ-0N>)D,(8VZ^?\+LTH^G
M+4LM=PSN(;^C8X-\3CH\$H>!6?E SLA>)Y-B"OO^CFGW?4!I_\%5W4VRW=,%
MTCU_!8& 2I\5BH;P'T4*_ =%3H$F.BY+?:^E7?EGFT/!/7T@3A<U4.!"UIA/
MX)X*/I]/L/.>P)H_@H1TE4Y%?O!#POH!Y31%U\ZEM/@Q-5O=$#+[6 >;6]T]
M^6^ PV-F-GD'I"42=D<EH[R^\;;NT>"8<36R)0)[1W 'B9B:/8'&EE-6Y_VN
M>YQX@D"7*RTSBP"%;1N ^XI_#H$^1/:1//\Q\O]2ZEA,J86 \OD^WADLX<%[
M!$0>H1^0XTQG$N8+0C!3&M)-4SW=4P'B^.#)*2E+1Y\N!'"Q'^DUP$DB1H;J
M77X'2MM3 !E0^W!L6I0=^890*.C?[QR5=P(A-2L FJEK+4@F+$.WV']J;[)7
M-(+=1T+V<K/7E'1$.BF35 ,^UF>43QYCD9&\_[-9!JH] +8.<"C;O)^:MP*?
M[_:/(-,JC+<;S.6>%I!F #TS_O4YLNT^[L/^PM(?@+QCH?GDO2 VRT%,V19-
M_]W31 V>WSWP=SD7J64^.0$%26+</AUK,O[^NS<_O?D@"3._O\M;).0.XI%Q
MNRO@[)88L<U9<2R,S]3FI4\4WG%'<59-@ZB20LE'4+I,G4%V0W#!)N9]Z)S%
M68Z ,S( KFQ$:"@SI0&PQ0=Q;QC.&NV&62PX2'LO4&T9-@P3N2=^+6$B]S!_
M9MYJ3PG-Y-'\W#:)[]HF9'8>B*33&=DK[PJPY0XAO2NHX-!B>:58:,X,I2:P
M90XA[3'[*0 VOAYR3_C:KH?<@WME]Z+3]&(B,:8\XJ:< -<(PP7+Y@\:4SP5
M R@G0CVS]P!+_D\SP7G 7S3W 6GC8???7!GB'@,J*"S4A9!CL^+9]O)^G@1*
MK]"9S*;:3@%&XA-R>;'R?FEK/Q!29Q-;"!!1)%RO1,9*]FJ($*(.0(@[ 516
M[_(0RQF^33F-T.[PNY*IN.8-G7O:0!Z]/Q<2**84GUS@ \P%_Y7I!_'B_LY/
ME*FC XQ[?%B-A@M_EX_0!V!J_@,R\U3/L[W/&^=8%G^4<][7F+T<%.I;?7HO
MD-=\^("^'R3H!PDZ-TCP6_:[7SM(<+5K4@=Y3/* Y*LW*2J3=VZ-6C-A</L-
MBWLNN8+!55YK<%3SX#'W]('\SGF^4?4#Z%!O6&]H&)I?JK((;2#ASF9@^K8T
MR/S!' =V(#J6>%7=UQ;N(?^Y^0_*G:"=/%WDIMH\A>6NE4B< N)6=24J#G,$
M(/$%QQ;WZ(90+UF:[-D/_1,HQGJS!=%1TYTTO__N[2\? B2T/P*>4GF+F_?-
M$R0D]VMZ9?%;S6 D\"SOP3U$@#7H5QE],Z?NGM@70MY3=/WFEHWMR\;Q$7P^
M7[RN\>+N*03GP.EE&"R5&/4BBL4/U%-:Y![F/V=]O:GYW5-#2])'AK6N[/ I
M6HN$[5C;12[9>WF<E$\PQ\3U\['&LK*?9GQ")7*N6WM7UW.7XS%[=ENQNVJH
MQ?KN@7[9^KB*QX8Q98C3<FJPN7NRXQX/N6SY#7=R[HF-=#K4LK4O_T!"\6/&
M_=U;D8B/Z:C>S)3>NNN?>VA?9?:G2L%&L]%N=+$$YTXDP+;I5>X!_QD"C)"W
M]( $TP9Y)*(AL!S?C>#H]_(#/;/1>"1TSSV^>0RL?:"6C;[=Y$_WE%!;+J5[
MP%^V/Z+6[6WS->D(.^%50^)9UMN/=I!M53V#FND'F*@>3"G#VO!ET=Q;I5:Y
MIX$Z4JO< WME]^+X;@W?\SS?892?';9),;N7M.WP7D0CVKM*4L"7/7=&@DQ.
M\J#<#<OG;^; ]U3?>:J?M4DS_&_&BL91\_F[/G4>!^^#&U)>/_HQJSM/=6/L
M/N79F(8ZDW8 0Y\F=*88)<'118.T3H^P<+X2'"7A+VR?/$Z:+21\KZ/NT3V(
MYZ8>2!%E6BAR:1[+_+%Y+81["JBC%L(]L)]=G)&31(S,3KZ5*=O/1CU-4M\B
M-.N>)NH,S;J'?HN#:LY2I]]I^AT]#OK7%;IQ3_0Z0C?N8?UO"-VXIX0:0C?N
MX;WVT(U[*L#<M+*&T(U[4F--E?_;0C?NZ:*>T(U[T*\A=..>T$A;5M4;NG%/
M 4C;6/Q-H1OW-($\JZZVT(U[LF/>T8N8*W..*Z805*\.22!".SWU!S( 29J/
MYJC'D+B!KJ8)OH87*V&PU^03D=#] Y(7Q#^?+KZ[ZBCD]KX@!T$[9ISNDRZ_
M Z53,(^%*#4O%]Z/TUN6RH_3<V2<WK?L>;]VG-X%3<%.1PFRD6(1>]Z7:%=5
M8MQR)IF*6&@5XI>DSRQ)I 7L/_;\LJ-#%;]JA=H5-_%5N.A,9E.]G]<(=; <
M7G.9O5_([7\J#/O/S?^V&Z+CGC[F@GM'D .A'"Z);982UMFJJT%P1E-JGA";
M+RC%]IX@!\$Y\-F6$'!/%[G0W@OD .BS*$J =*C2^_GH]>IZB[3S" 39.VH>
M_]DDN#K%E#T_FY*.2"=EYK@-^-)6OPR8@P(Q>T>G[?96"'%/._4CQ#V6? 5"
MSKP3\4YD 2+BD:8C]M\,\-V>/<GN_44.A@OS52-F=J%[ RFFTEZLRQFV8TFI
M!.\?"DCX@<\^4%&!81"SA$VG-OFNW$\@\0D+@GN_4$!!LCNSC<+F$_YDZ8B.
M[OV&H4!!-85E'U.J#=K1,VLP(!EG$46W/:CD)@8*9"A&=()OJNQJ1-R8@P.G
MZ3YIB\;!QCW-W5-'*;?W"_:5;Z"#D/K-%NF THR,S7Z9T@1;7_N.TH+[V$$)
MAA,T'H#IQZ(NQ[N!PO)D[\\LC.]9@NRFH38HN,>"U5"HFC <,VYP $]].'P_
M382.H94E$RH9)9W+RR,D+J&2V?L#^RK/ L?4>*N&M'?W,+_&]H*K++693#[_
MV7N#940L1))Q11%K"2:[1X0OX,'WX_1.8:E5Y\+!ZJ \4]HBR^7A:C[B@-YQ
ME*UA%#FV& $D/F2%L-Y]7/@0 V9/$- L8GG.+Z/(3AF+HGNGL(R*JF5<I]GO
M8(I#E#GPY^9Q(^%]Q1(JYM4S(F7</#&?=]=#=GWQJ0*\^["OHH; ,QHD2,0=
M;'V+[1[XUY@>S$(Z :YMW-HV[&@W"#1(%TMX8BZ\]P0E'-HQ2P!;K50NM/<(
M2Q#8>**[>YJHP?SN87Z]^<WWI_98N3$"W%-&);/W 24(BFGW!SD&<E#@N;(H
M1/?NH$3"M<PF&9UA\@:ER-X9E!"X 0Z/&23T -.N8$'JEDC8G4US6HB=B+%W
M$04^$M(),QH)N04\W--&*;-W$O;5D0'!@$IJW28J)U$)[7U!Y0L&(#-,?L#*
MZYU ;GUA+Q042TB71YG2>2JTS8D'&3)A-Q+SP5:6-OD=)OBYY$A]Q?PVIMQ5
M!E@<1MW74.[18#4@.ID44S!J&4J@*I,S<LV3(K.A*JQ!XB9J:2#L'C%6PZ*J
MK<*5.>T3&M8A@='D*<_E)!V=(G$*)R#3YRX0N5/X! I513ZY'(_-#[$TB:TC
M0=8]0JQ&QEA(TGF8"JGSUC7=-/]KK]=&XB9J&$3B'@%60^$$%"2)"F,ZUB1M
MC!JG6(X8S>+T[3U"#@._1\!)_XQJ2.E6MU;NZ6(NM1^7N2R5'Y?IR+C,;]GM
M?NVXS-6>Z=1L2ZBR0:T\-&Y.,?E6M0J:)[MY@;9ZKN:)!/#%?<]P49;SY-<E
MH5Y"2C$2'DB3"SY+-RL!=4]?=:#D6^;&UZ$D96IL/C#<(D73/64,,O,L@ESY
MW+P*!T4Q^.;G&_<44<OYQCWHK[8_H@D%;<J?%Z.@I?W"-G'SU GWE%%'ZH1[
MP%\' 2[N\K,&LM+_.F]%W:/ .C!HD#Q'0]Z2VK;+H+PJ[29[\[2*GI@P9611
MY<A-++=COH'(>K0$1A@Z%1+VR4!# ].@D[GHWHW\16!LU^_>/475-A?+/7+\
M%8RLR,'P"7O>DY#SQCF60\D9-4)YWY!;?:RQ[!Q.,[,V2G_+7MC=[!%0M3S/
M!3ZHKP[4/?Q_#@@!)(D-2A>_.V(V4C7*BE %FAR\NB'B'DE60\2G\&-W$B4"
MS/E2,M*C_)8BZT$XE]M[!+7%FN">_%>94C8N>PP1%'E"WB/D",@>(!V)3$X^
MF:(54)D@<0M/6O!^P;[J4TXGD()Y'+]IP.XB^A#9YR-[^;0I5-/8:YBOY1X'
MOH""@113R4!3.=O?>/ZV>UH)1*9CTAS;O#_O%Y80$<243V+*O&M [AJ6@4!:
MP/YC@U'%$1.)G_ C&5?@(GN,1>;= V[WL/'8/?<44=O8/?> _WD,^&)@W#[
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MR[+U *+QE[=7<1<BF B>T+Y1"&5A[M[^(51(E]+<=D'Q_:TA"1?]E8MZ[MT
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M9F]R;3$P>"YH=&WM6=MRVS80?>]7;.2ID\R(5TFV;O&,(],3IZF5D>0F>>J
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MY>EE%31.&"2<Q7#",Y)%G*0PCF,>,0DBQNE)ID0&^WNU5K=\JP*Q\ITA+-M
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M_]4<##GRPU1"+0V=,(>80BJ@4-;1,V<+L%Q/1;&K49SA620T "+L'FO-O4G
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MZIA<G5^R0F2\'[VYD(6Q0ZJ%@0P''RS,:JF[*>T@L3%^R9KV*$L@-:&W",Q
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MFM"4LC6[B'7S2;Z>M$S!#IR;.33$$#.-XION6Z &+>?31L7;1/)=Q'IMJ8Z
M+3-JMY@5.JC%K(F-["(^5>U3VL-L%['NR/^1SDQA483J!0N4W*AP55;IYM:[
M%+=&S^\BUAWGWV1I0,4TO,6M"BT*NV*\I^A];K[V*57=["+6'>'_G/#LC,S<
M8V<7@$LF]8A)?,F>$N/6I&@F7+2[G71?TZ+9+J4Z;@&E@/2.XBJ.C:.3.M/[
M4VK$NMFQZX[TFT-Z;TH]M^(BQP*(F5RN)?4$U)14=O.N.S&X#F+@!%IC H"4
M('"QP)9+: P4V+6DVR(&FQ//[MB_.>Q'Y9!2D(Y= =@1C*6S8QY64TJ3:H\S
MA<AV1_W-H;Z+@9P7#)H9,C7R-+JB86J0L->MR^+OW/T-H?MZ4CJ5>I>4(A>+
M<1OZJE)KC\XCHS/J;QO==S'NCO0S[;%ZBL!!&22(>3F!R"3!.]>TX+:1?A?C
M[L3@/6+0 W;'R#&:2\_0:\>J50!J=[GQUNC^78R[8_][V$^)'"08O@^(>3Y)
M!"((144(O6P3^W<Q[H[Z;U/?E<QC!]^J (21774Q2@5V:"%OW/RML<_ N:W+
MV9/Y>SR>\P,J-Y9GY[YAPZJ8=I/V:=[TX5/5WW&\OC^</WFDBX/;RG_VU+]
MI$O9ESN%!%FSN()MK$"B5EE2L["0N+0>-W_'YQTW+G)C=;M+UV!Q$FJA#A5\
M8&[.?$B%G'*(G/LN+;PBBMX[G,MKEDZARFJ2J5Y?@%(HV8)^ %6L-5!A0.%
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M@:7"JY'(#W[<>,B;N=51*//?Q[0_?H.<*.B)N#]CPR@+QE5C%1CS6\V3YBR
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M+)O4(BUPYY896DD4NXP-OH6P<G2R^99M)VP[89N(9<NQ8HNCA:Q9-HX%3;*
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MQG$78W/%=L+3Z"51+Q6\(\T4X#0ITWS J,6KEI(;7;83GD8OJ4VHOE++WIU
MY[3NAN[6JQ71]RL3-QT]DA-^HP+>)W'=)3&)O&:&<\ \MF2)^,*E+O[N=FH9
M^WK*ML1YECB'EX; \4Y0X%"')LHYC2<@5:Q]:MV\M"UQGB7.V:"UHH%5!_&6
M0!C28$+48"XV0'<OZ>$L\21A!L?D$0W7WP]YJFA5#1]E*' GV3"S9?H @"$K
MX6QESH%*,$<YYK=H 7B':*"Q+]ENF3Y"T,_N7LQJDC9 $1NI 46]!47?0?_7
MM#R/17.7=L(3["2AD 1#:U ;4*MLV%%17%KGDE=8S[E]<"L?G+12?(D1M$AC
M+3"GF;LP8Q:,V7CNY6#;!T^BB[1D7W38\8)LA5J412-"5:$F]'*%=>+;!P]:
M@KPD(/5,J0A]]@.3Y'A^:W(4= $OV/:HS3;$T[J-)-UK'S"*](0I57UT!:Y*
MS:WI'A;>AGA:=Y$FU8;'CM8XWI$NQK'HJ-EH4H;%^]>(-C+=QQ"7Q)BL,H2T
MS#H=LBZ1CM8[ J=[0-\8LT5Z/EK,J-I**I5!8$ \&H>U-CQG+MS8:+%%>GJX
M5[7J#5KBF, X;):!A;UGY%A?O%*X_]2H^(ON^%S?^K=O_EU_F#]]ITNS/ZJ]
M^>[;'[[_321\>CGOI G8@<>T7QO! <E3VLSN<8R/)&-<Z@+R%NO->S RJ8&9
MLLF$;D4SW]^6[U*+R:5F4[=8;]XH ;7@Z8V+3?#9&2HF*0+*T3^_U&+;"U>,
MSC/&)7D 9R4[QOW-!8J9E.J5@,O(8[_4I89(MVH_O6K/ 0-L1__-VW&O$8H7
ML=J):N%L7/NU6@Y;M2>H]IP+N3)(,!3&7,)E-:B5,.$=-L#[D:)-"-=2TDG/
MJ\HZ^ZH[';%;*;7#@";H5ELAAAVUKZ>DD]9E(./$K,..F%J:6+3C-;11>1U,
MU[K^N95T9G1CF#-'YW!1P!2SD!Y]C"8L8N4"T>V7.R=_T;?QW8]O'K5W<IY<
M/Q0Y[UIK;W7ETBZE6W20&,>]^O7+]3>.$7J%JQ3;$3=UQ$G]?*C211:H#@#$
M82W5)U.5$M;+%9Z/VXZXJR-.H2:4F1-&UZ0"RJX56ZLD$F!0^Q5J O=VQ"Z7
MG3>J8"-:RN"),' (>=/0"3U)-,O&IVV-TZUQTH-YN%*)=#8M ,-1"-3<6NWK
MUURO\&#>ML;MK7'.0S!1@(1GR4'01^KZH168QQ6,T+:!ZFQK/*I<SX&<BHP<
MOH[OIE!,A9&*NLP.N%*"*\QC;KD^'? P]N;C>+"Z#-#2U'-(M5K=(M:7-WAL
MN3X0#,BTBB)B3A,FDF);FA2R(#2?<@$8N)^2/A2>_PNEP \\!)Z_^/,7_^VS
M%Y^]__%/SU[=D3PF0PWS:-P#,DAJP;G\499!JK4KE%>V-V[OC9/>OPNO' UY
MT( @,PE$,RQ.]?C"!3!G>^/^WCB%J4;8; 4:#UA:U6;#U)8GAH6V$9=:E+K+
M@A_+AP]CDI/*.L=]\*(FM.!J>EAJ5.N\9.QUEMAPM4WR0"8YA[*8"Y![Z"P5
M!JO&4.U&Z<LR)=NFK&V21S+)*;CUS@X:$RGCV"["7&W*5(IV@!AOW-K"?4@$
M*MFU='(9(X$;:G<R0!#):CGZ1J MW(?$$@1<&>WH1UD48!VUZ2EE]B$+6(:/
MC25;N ^)"J*-@"?4* .FHHI1,!;1#J:TNUT/*]Q3JY9??O7%YU\]?_7LRZ^>
M_>6.(.+:QQ1!/7::@!UWI*5/U6(@QIP;1+8M3K7%2=677F:+@G-B@\E%C^T4
M'J(0<RZK;,S9MCC7%J= %*TX45>R&A$-NJKI&#/=8!RM7\H-4;LH^1C^.(>F
M;/D@ND".5H AF&P!5<59)RC^G!UOFMK^.-T?YV!5;9PK;&C#H4 VV#II\[3U
M74;%V%BU_?$@_CAG3= @C=*;^D!HZ)9<EAE"ZB@V;6Z^VII]-.:90VWI4XVM
M0+@*8G K?3)7,/7-/%NSC\8AX$&]MO!C.C-G-6%-$ .6JJWN+M;6[..Q@7IA
M4F)1  'C'%1Z""]X/CCA FQPX<>7'MP63W"!H":2)[>J8T+OSC9#2N_6I0^F
M*W2NMA]NZ8=SF$;;&*.ON%!(H$_1T8-B&KE%B;A"RVK[X9Y^.(67O+IJK7"L
M8EAH[QKKKS&XMPRBV+RTRYEG[WTX!YP@&L2DFE2.9[BZ8$435^^U8,(5"C;;
M&/<VQED$931U4K<R81IHULE8NW9F1/--4-L89QOCG-EISY'=%;$Y0(;,BCXB
MO92J#7&CU#U3BTOBS0AR6/!"W1N425P"!V1KLQ,[X\:;+=:'08XN&0CFS&U"
M$,B@F-"R3Z;0LI%CB_5Q,.#88G.\@I:: U!9?0JR3,3:V TN@ &/"J]W;=*8
M+$IL#0>F@\VTK(/:R)DZIGF[0#!^NI(Y:38#NC6?K:=-,!,3#$2W%2=7OM'W
MXI.'ELQ)UU(\0RV'98',ODX=4"Q+&T;8(79@^B15E4M&J(4R,TBP(0=4:<HU
MV5R@^TH7XPKO$&[MG%4P#N?2H*BJ@;9C!X9%JW2\R(2&ND/5);1SSNJJ-K./
M261I$(DV P8G]K[ 9\6S)ZR=2WZ>5-9A(*T.& 5@HI:ITXJY&=6(*]3(_XG/
M\T_AQP?YNSBJ/1^WV_)\_2&__??C_ZLWK_6[EV^^^^GXV0=_S]-1^:3=JQ#(
M8ZBTDA".QLR0P$NTDXI?H?F_97K_(@#ZN^L9HJ4P=%;-X&A4J2"LP[3<*SIN
MF5XTZ!MK%]8ZJC90AO7S05F@%\M2_6;[1W];F3[,.,>OL\0EH_]<1R>)RG!H
MT ;*(5Q"E^+6,&]6CM]ZO3H&!!'!P.JS##CF54UZ<@?.@</:%5[4VWH]1Z^G
M\,"AU5JI^>@.1BZ)#8\UHW-$ ;S9DM&'Q]9+QF@Z%JM-GXR^SKS)W !C]M&:
M2@FZPOS:UM#9C8GB.)OZ7"DT3'23<A0DY\25FK1+O$2[-71V0;N3=2D /L:*
M:Z;*=7W F'/:<3#M6/8K-?3%VQ^_>?-7/;[A]>LN)U6Q"S%T6&(\]I"VP@6Q
M%LL)V%NVFSV?L;5YI=A[7,!7*\?-2H3::<%_3._=6VW,LDO76YOGQ73P2869
MD@5&%BM+E]9B):QUY1VT8_KC:_/V$WD!I9D+SI$-Q*91)2.OX]B'68;MX+Y%
M>GJ4'ZF%&U*M*$NOQ5I&09HE(%)_'AO=47Z+],QP7[*D3EHP.AGLV!PX9(R:
MG7'4/ML.]Q]?I)<,P5PI^['UHGF%)2)K3I[F<S2.S#TE]OC".2GY!0(H(4=T
MA&Q%FG"4R=9Z5Z]]A\7'%\XIH0J/=U,<JKH34#=9TEG@/U)&M8$W>UGH,87S
M7^*I__RJ_Q^>?_GR\G69L^:RB";!8K4E<,XJQQ+R#E/3L,C8\7:K_\X5\]&(
M6LXJL=2(+,G98B+20@:'N:%AJ_^^-?F!4Q;S=) T&%XL:BV9C8Y]YK3)9ZO_
M253]NX.C=HS2"%*[HJ@A)D5AGW57_;<-GD)?(=D7\U/6.3N,9E*]J'/KOGZG
M]9N]3+1M\/@V.&=Y?RM6O;480\$5%!M59<>ETMG?/Z2[H>CJ-K@DJ(!2Y@CQ
M.0C*@A3H")U'UA1TB@TJ6YHGP</,DL7K-.T!PDN49 8RJ2>LP_1F.V6V-"\4
MT"L3YAAP/#L"O8*@SLE+F45Z".TJQZ-(\\,J<!^H_O_VXMFS6T)#K&3NV%[2
M*1UT@)'VT7%1K@J7]SR[H6'+_Z/+_QPP(3MNM:*-XS9K-)"A#2<U6R887F.#
MR9;_IY'_*?"CHR[$<12: P:(J4/1F1I:;13=\//X\O]-]V6<[H.S5AO,:=:I
M"2 <[TA,:4"]AREF;V53T/;!4\"AVF84BBK'3?JB2_(ILA+A+ 'KIWM*=OO@
M27!1@94  T=%4"C3!8A&0(Y9AMC8]U,>Q0=/D%6< 7HC6YQN4'48S%*F%8B!
M/J=L5MG:/*W/T\$;8>\6!(ENZVRT(:ZC84>'S0];FZ==Y(EU3)8)BHK'4*NV
MBKQ2/.A>:N)>&_7XVGSUU6=?_^FS\\N)E^0&"9V#M!_0 ,1-QFBS!)6^CF@J
MN].S]7_KRSSAT&EX'W-4J$UXX7/Z[.J1#.T*+QIO_=]#_^?4-,;L*P"$,SM0
M;5K1V361!P"3;?YY$/T_1FWOO^2U2X*0FAS;D*0$&A1)KJQ>TXLI$N@&H6V$
M3VV$DU:%O7L74%=>3  AQ+&R@RZV?H%!MH=?MA$^N1%.02.Q](B5"$^;QQ",
M>LK*$7IV\^.JVT:C!S'"4\25J!U:3AC%X0!U;LT+*/&B]U)B;ES9XCQO0TJW
MUC$607>& 60:U*O"%()F43=";'&>=U>WL&J7FNUXE&%4I>-905T1W0 7^.ZP
M_B#B/'6X^^67SU\\>_GE%U^]>OG%JS\\^^J.#"'*M !!4VLL=)CJ,"EXV'%[
M/7.7/+83/KD3S@$67U"2XMS67X!0%T-C&=JK2YO@^Q&4[81/[X1SG@@OT:<-
ML=($UL]UY9B:35$7P4_?18\+..$35O^> B:5,@9;+8&:8'-(]1ILYMYLM@(;
MD[8EGA@OZ33/XQZ$U6.BMTFV(*F=LF ;L#>W;$L\-7"*W@ND!,28$"L^%&I<
MQ_$>K:^T C<X/8@E'D6F)]UIIJI]6)?@"3Q46_;,48Y]+XG>-LQLF3X 8'A5
M$%Y2K=*@*S"7HT#OSD*62!LPMDP?(.AK6R<HA&%O"JA#I(XR$#0PO%+=0?]7
MRO3E3V__+=[^[?R2X26#/ ?B0,94[M!K-S89,\8H4D;1?1GXJ<ORG* N(,?[
M",<"$8-<Q^:8;7 UTSF\]ETU>/*R/&<@9"IU2^_'8Y"F:!-Q:<;0CB<^.'80
M?XP:TV]@@4M&<SU&YEK#WK/"RH9$<LZ.3 @39M^CGEN?YX;U%BBFU:U7P*K:
ME9=25WCG2H7WV_);GZ?&]];A6&#*0Z; G$U( B@U>Y]US+WBXZ$U<]8"=!>?
M<^)$7E%6N,10*>"LP@L6=\Q]9,V<$P?[0K0"$DV* ,TE%:Q4F_=JT\?[J_0[
M#CZL9LZ)3:,'- <!FV C3$!YI#@*#Z_[G9%?W7[X['=__NS%Y\]^]P#*_% *
MO&N9FCIQ%DFQCL 4.J8IB>I<3NBV]VMO\=^W&-X&EHK6>-!Q[<8YE^ISNCE7
M3\)-"UO\MRVY4_;HXUBEP!5&3QF1*EX%4R1SI^2GB_]I%:9.NG_)V="E:OH$
M%F(W]MX-"YH"[ON7VP5/H&R"#NPN7A;X@-G4ZM4*5&G4DT V"&T7W+\0%.FM
M*Q:?8QZ+?0RQ5NQ%G)S6KS81G>V"\Y5Y#J4@#*PY"G.7XU5,">NMS-+'@#EE
M5VFV,D\BAY0"DXLHS@G#ARVI%DLN1+-VFYL<MC)/>CZ^-B1;,5U*!VH+<!MI
M*C9>83UEMW5^M3)__^S%LZ\^^^,#"/-#L?FN79T8<WKWJ;ZRMTE#9T1*Q(22
M9+S7)6SMW[:ILP0HEETUCW>S93(UG5J9)%A\[J;.UOYM>SH]N)<BE:8D9.6E
M_6FNA0,7DK^O9F_F.;_"=A6?71)^BK3:F[-Y5I"ABHOZ<8S:IZ#AGAO=)KA_
M70:@X531Q""(MA#H&.KJ%ER*$>FFH&V"VY> 6B4J=0SO<R4##;6NA#B""7E,
MJ&7CT),7YDG7277 ^JM '"\RE*+:".><K4C4SKN?LX5Y4O&$:,YH6/I*()6G
M*A'69DPL0KGOD6YAGO1&JF8ODKW1<"BS&ZQXW0')4;WMG=B_6C-__O;XARY?
M;SMIR1,(MQ GH )$9MUI%%2SM):TESP]<56>])ZZENB1':H8^%@'9-:!)IV
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MFW.6<AS[@/[W)Q!WD'U,R9S4.TB1:E&ZKD39*\HQYC!:0QG56MM9\T-+YI3
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M(6E2]I?%2K?H.;;<.5GU@W=3#@=E\OB/&:?3EYW$ILN^S/65SQ$ ,^YYMI"
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MZ,/Y+K-T\Y__L#SSS<[6]I9AFRX)KUU[@W>\%>*=]P='>_H=_@5G+\W2_=$
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M<0.29A"7)0@HF8#$R;,4'3W)V,"9]V-C%_T_E*M^&#NTI,9[C?]F).[T'DU
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M:<LR_T[7I04U_0SK]U:+*75(L>G(U9R).4EJZ7CH Z84W3?ZNJQ'+CQ<X<.
MQ/U&CT;1X\!KH*=>-MA?J)11>ZDH$5X%RZ$KLQ:CGZ.5^H^?*T7+ 1;M'IWH
MP[?[KU=T7GVM!?Z]94J+]5B(=X( 'H\%%KW14['C'==R!W;T-M[6F7_7\.)R
M=?=B"9/C6SVZ@/EM*&H]<[&R#.1R*R58?;^#%Z-7Q+W)G=IRZ1VX--QX^T&F
M,J=)*W:>"T%;L=.*G=7F4MO>>'LLSW0SGBPR6NCSW*C;RJ!6!JTXE[H(?;*S
MG [[,3>ZN:2M_'DVE+5;^=/*G]7FTF#C[1&],/9H*;%^K14^SX:LK?!IA<]J
M<ZEC882N1/NK%3O/A: /%#O+KU9OS_,O(S_9>(NC@B1FW;='^GG0U-]XZ[1(
MHI4\*\^E>C(-['PY;D7/<R%J*WI:T;/:7$K,C;=8ERM+E5'=BI[G0M16]+2B
M9\6YU-EXVTO/XSQ+,8C=BI[G0M16]+2B9\6YU-MX.QT'TTJ>YT+3!TJ>UGN[
MQN0/L;GJ,,G&$M:%5<I_C&!=QC8=QB5-C+U)P[?VN#\7>KLMT&BETDISJ6MO
MO.V>TSA1U=N[J>[(TF*.9T1>_YD+(:N[]8@2J&7#9;"A"^9,7'PWWE->9GD;
MNWXV5 V>NW!YUPJ756?#8./MIS2719:<2X'MAB+=\:Q-?'M.)+:>NS%EMX)F
MM;G0PWS:/!OB'LM6LCP;FEK>,Y<L3BM95IP+R<;;C_*,)@;(%RZE:B[>"ICG
M0EKKN;M@2"M@5IP+_8VW>_ 5XYA&LAP;.W&!35U'>8MCG@^!G[V8>?1P4\N*
M2V!%W]QXV[N4?(2]DHV#*(HY=IJNVD<?3=I'MX+GN5#[;H+GWFU3GW0N[@+9
MTS:%7<>FL/YL4]CGWA76;=7EB@M0#Z"Y'J.%@QN.KHY7J*:W]/X[BLOQ)ER1
MJ)D):IJ+GN. _45*5+)J^ 6.U\R-PU'.^[30 V#T=W'@YRB/6^_E<^(=VWSF
M$LQK)=B*<V&X\?;%D80%G$OQLI4LSX6FSUZR^*UD66TN#%S$1G5>_ 00H?=R
M5!1Q-3V]F])D7,0*Z( 8&B6ZW^S!4.I':UCT?C(&?3M+15M,_*R8Q'[NK6C]
M-LEUU?G0,@&-_S6B./=4S8E38@?^D-2_-Z(N1I=EH]*H##_,C6V%T;-A B=\
MYM(H:&71JK,AX/<IXIF,X-10Z'@T'";J=QP8O4-+V@J?9T-U\MRMMK 5/JO-
MAC:Q-MYN]VEZ!LN*M8T&T(>>Y;(20E_BLF]T.<]&((+4>)"T_A6'%,^::U/4
MU$JI9\,>EOG<*X?"UF);?4XDV%PN+7,@C)(Z*OU6M&EQSXK"OX&L::L45Y\3
M_8VW!V5?YFV7A6=)VU\E99XT"R[<;@7-JC.CATT_FJ[F(WE&<R2(\3[+X6FI
M\><HCPL1<QT=.^G3$I"// ?;#(13,93Z@U8X/1]^N*-T:G-TVQS=)\S1M5US
M-DGWN6?I6F:K5E=<C+H.:M5<J@9&F\:""A=T(&QG^1 ?(XT/&= #?9BMV_+Y
M,,#S=R585BN)5IT1O6:!G1J.D1:M.^%Y$=@RGWL2B=4V/%IY1@QQ[I>J&1H;
M!Q<IH)Q^/,3DVFW8=QJGQCN92H _&*?5GRL4-,W95;_>4+'42JQGPRB_@<1J
M&RFM.B-Z]L;;6C8IL8..3)!9Q8P@.LEAF51[.3>K_!1MV1F[\%3 4T*VAMMS
MXHG?0#BU39A6GA%=;" 9ISP> EZ:YK\9[^N1(,<R/X]YFWWRC A^1\G31E[:
MR,M31EZ\8";R\OFY:\VV/\JJ"U'?0G=G/V9Q.5_).ZEK,8YY7XI1TFK.9T1T
MRWKNI2Q6V]MDY1F1;+Q]G^4#PS([_S:.1X,!S<>MD'DVM'W^0J;MFKH>S.AO
MO#V&?:5E6W[RK(AJ6<^].4DK8=:"&0-S8DA5UCW<Y;*5-,^&N)9UXWSQ5R4.
M>:W_WB!)M1ABJ\&Z;X99H=ICO<Y5 .U<OKF(1=FO#GOSBYJ^K\WI5R@KLF14
M7OV*IO+;?['\U?P"&__NYU-..Y,=EDOZO4.C4N:O:7)!Q\7&JYD%#.*T,[?Z
MNS[XQDOP4;'XOXW;]%[86+"S=_!2+DE"7_$,VK@1V]U/)[L'^]VC4V/_X*1G
M'/4^=(]V=O<_&.\/CK[ CYV/!P?_QM^/3[HGO;W>_LFQ<74K?O)6U^U@\VLQ
MAE9A6<%-$YP?2UNIO3CIQX713=,138PC.<SR$ML/3&V\>OT+UF9;^,\CK@W=
M6W]F_;2 %?V3#H9OZM\FO>\R54(X'+$DYLG8H)/9S2+C(]U=@<-C,/Z-W[%Q
M)_,+FHM.DF7?L0BHF#2#41=8;XR+N.S#]=B>?R!IBA=5W?H+&DFC3W.6P3/S
M[#PN5,50]>FG--9I/7##PCC,XW-,?)XV&38^PG_.E%"#G<:B1Z/+2_RV%8;N
MUGR:4"Z'@'RQ*PT*'?64A7NA+D9G8#%B12QBFN.S7N"*,!F2IN.7!DV*S!C0
ML1'EV< H@49&F>G_#NAW:5R_*5LW,<"C,^?[:]<%!#;2K#244 ;*E'G,2^
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ML!H.B$%!'F,2*.""R\FF;TW=-U,W$N[WGP=_[!\?[+><_4"HH'U5:I?;/7P
M\TX9=N)DG&78C[O')ST $JW2>Z@Y?-4?N]"96RM##)%G.?RA.\!9JU2%)X]/
MNJ?OCWHM,>XK-[:[1[UV ^\+X6@:E[JU:E7CF&VQQ\GL>NY;6=+!$,=E*EFP
MU8S>3,3#U#'VKKN_T^FV,.U>._TN5WA!]*6:D_T.FS75DQ_W>P?'AP>MF7R_
MG7T?YT5I=&,Q[_4]@;UN-L>=Q"2GW<;KZ455OP(]K2/!0*I")B\DIO?(G,N7
MVE3!2HF2Q@FJQZ3N0#4I^<E48;BJ6(3/&WEO3QX\OW8'7=S!V?_MIJ#QS^6
MR=RP3=O:G&OME&:8+*\S(S&;*:V'*-^K^]QF/6M9SMX,RZ$PK1[SWS>O[6AF
MS&6Q@%HXDY-\*J!0(Q-M09]#E?&'3[,)#F0M^SC*IE039.-25S/KM\5 _--3
M\8XI$'.9.6N0 C&WXDD&Q$R&0Q%?(CUS.E37X;FFQ6MC=S 85>6:+^36V=:F
MD??E:$#+#"0#!02+14A8OUMD.8X1X,T_JL97V!(32Y98=B%5KP?L4:1KZ=1W
MBAB'C^ZF:M91-E()0:I)>OW /W8_OP+]>*PA7MV]9!-V;I1G:N(JE_6U YR
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M\60IU710U90/_0Z@?%%HUK/5L;O/2"K$"D2()J/NXK3 "KPD5K/&YNB+T1J
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MGVX3HMUYLK7XA$S$G4%&5L+VE@,\1(D/'@DSN;@QX_^WA!QL"^1@-8=6</H
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M_N.7"P2NB6JPJF'=(/^D*G>O!_E_*-UY*-UY*-U9X]*=:][CN^=^O09>X=N
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M\L"\\)/R!<DMHCUA_2^6PH!.R&4\Q**T2^\SE*C9D&2Q:I\8ZD*.JAG%V<@
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M^(:0$H5,&-K''=/K9AX@QJ/+SQ;1+88!H[? D0"5($&C)1-,(T<,Q\7'*^\
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M= 'A:$_T\"-7W\9D9Z(^>&K<M$84ERNR$5X:$ZJL7D2&J^V.%BXH0T,-#U%
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M=H.A)LH<0;.9I>=!E0G![8I9PWR4\29Z*Z22UN-&)6@@ZC7F&"Z3MG"F?,Q
M(-^&MVB#MFCDW@$9CUQ\'H>SUB5.<L-K>V 7;.,%\$(EAY;>T8KX%A?5SW=J
M@(?:-698<MFM@(]&3QV5J1*"@:^H(VSW%<@=##+D0-G#O9 W"/=;U2*V*L;4
M!V!&NI\<9KS-$RP[4CYQ00NB%@K8D@A6^>KP!*A*U_!@F@TP2/HJM_E$-SZ
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M<L4NS?^TMO\%V15S!)T41>F^\5X>)I]'&Q#> ,>U[_F5!"J!?IFN8V-6NO$
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M,Y+[;AS=;/QBFK0S,V2AA#Z2IRB51Q)1"[0:55M4<6>^&,2CW1 (E]/DX=K
MB)JKU:4;W'J#H&T<^LOD54R:2H;0F$.Y'_/B? 8.*9[FO$"G/_I IADC;3>
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MU%*W%7QH]3^5U /_H$XPK;)P74J6)$Q&M?J&^9:>CIGS=K'T+_['R"83^IF
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MC+,:+1CFBUEQ806[XT=D;6;57$H2Q#'836F$I1NA-8;S4>IDJ2-?_%7"!G2
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MG>5)4PZG2#Q@S61VLJ!P,:Z56MAO"5C&5-[)O?T0'7>V0:7^OXJN%<7,$/-
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M28:7,KP\J@/!ZZL_[BZ^/ASZ@6 3A'T?..[<>70"^$0>3-:M QH(5]<G6;3
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MV[>Q._,]*WA6_OX\A]D1+P2+ILA:[LKT--5V1[:ME@*R1D!T6>LO(^#]"MU
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ME FX;#3;9-$\^X2>N-!#5-]U[-QA-O(PC(>C.+(\@GD5K ^,799N8KN%'2N
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M;4='!_R R0%GM('*S0.D?DH 4A-O__WUQI=(MF.O]@F]N*E-VA+>\ &O?Q/
MX:-=_^74\B;%'2 "G&7>BVN&,)^SP&WAKME69]/%HYL7IU,2P2&9STVMQ)O
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MQ-YMGQWP3.S$*[RTYC3FN4M<6M%FR62"G0%?HNG^%2SJ_F=9+OMT0K2N#7]
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M, $)N&XI)^'#<;DR$A53 L9#1"%9\Y\&+OR5HT8I?0[\</*9@/WO<GH<%[_
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M!:8C//M[O$PGQ=Q0]DL5LSD;+K@&(YH6L=_"6)PMF']WT-*NNY<&<=O;&T%
MX:VMLA47)I6CV6 QC:Q6SJ=':X$XZ%!(TT2@Q*4L%6F"61+.+X@97:]T^4J7
M7Q;(W+?:H@*950*9*6^!B]*8@/! L8A!]?<'L&EB'1*.26$,%HEC)<@\ATJP
M"F16$V3N6U=1@<PJ@<R4?R$F22+B5"##)/8@$R$M#$$JB1,=Q=0RWX\'0(9'
ME29S3Q=#D9J?W^SW=1]/S"0L7'[WZ6!VFP5ZEE#[4$9CL5<SB%N![>+ =F?.
M.34)B6+AO;<X!;!E3"!)N4$\55H;D+*2N0"V"5_'3QEL[P9X3R6K\,7#U$.9
MG15,/0Q,31F>P@HEC9,(8^N/TTJ]=\L9Q"*:1EPZHGB2PQ1>GVU67<%4!5.K
M 5,/9;A6,/4P,#5ENJI88&*90JD1%O&(4*2,$@A$DY,)840($F!*\/4G'1U_
M0)@*INU??:6;#G[:[.?&O\-+/E+=_6NX;L,/RW&W5/<X:^== E@ K24M;;CC
MJZP/XS?7+S;UB[WO7"T/BO<[M;>==E@TY7.KWV5MU3:9:M;V^_!&R[7[O9GI
M73OW&RU,,1I.UY,(YG#6Z66> E]U75/ULY_N]7EF^R<EPHU=6.PT'EVB-(P>
ML.;*2Z9W^^%[AX8UKX5_Y8H$<AI-*E QC*2ISGKN5?G+:YOUSIKJXE76#O<+
M%[TNB*I8";]\4^0;)IQ_7"R*%.LRB?VZ%"Z:XL'%DJV')9OBN?PS1M<YN_IC
MO$ZN_.PQ;DO6!;_9;><ZK.*A!G&+W(B[NJA6BD0#UW ZR;!7P=_XJY]%D-68
M:"=2D5(2*VZ85%:#*:1B'.O4299\)Y2LE5>==$>K=^R0[CKU ZFT[[JO5/-<
M7?36_IH$4B#X*<R89O>K<6<&?<:6VSA_2,?#JVX!$C[L_;V[O[=;^V_5.GM=
M*__:W-VJ[7]]L[^SM;/Y96=[_TH0795IO-V#<7_<V=H\V(:1'\"/QO;NP7YM
M[UWM[5[CTY?MO[=W]W?^V:[M[,+?V[65G] ?6QZ N[U:UJXULF;3G_[RY_BA
M%.3/6\WA@<$>KTL6W07LHWB=RFCAJ$S(>HSO!O;7/U+(Q8L0&&P2WVU CS18
M?G=Y-RO$[B?O<HI?*?/8.]MND/#YG.>/7_;\?7.\L?D_KV3H^8K<1&>O.]K4
M3Z\Y^ORUN'7KI:?7''WU#I)ZBFU"_7-RGQ_<O_$+[@N?_],ZVCK&WO>V=[#]
M:^]] Y[UX63W )Y[:D^/]H<^/]ZXW.:-4_MC[^ D:[1VX!K##T]_7!QM[<!8
MC[+&I?UQ>'ER<CCC\SN^;!P<7^S2S]'>^YV+P],O)[N7WE_XX4?C].ADM[5S
MN4N_G.Z]?Y?][V49/86?IS]8X_3P>Z1QRHS42!(=(QZG"=)*4!118ZU*")6Q
MO+(W^KV\;H_?)'CQD8$GV"1X]0Z>JKA_>=Q_,<G]C";82<M01'P#E33&2"=:
M(!([DDIA#3'TRO;D%?=7W%^U"']"W+\[)?M!2TLC;0&7'0?NMRI"(HEB  ,E
M>&)<9$UZ98?P%>7^*[IT1[?JTOT4VOX^IWN\!*-ZKW_BNC"[UEG7G;AV+_OI
MAN<5-P'J_JS7VF!W=U)_G'%58US5&"\H)^+ZUW>=+ES2KIE!M^O:YJ+6[\(3
MF^'(^F=;C#Q_N?YX6(]'#R8,OTVK/P$FWHZC1*X-%1OUMMBG []-^3@WV_9@
MM&GO5=;VFM,;!YJ3^^),4_5Z60J+7'Y7_:JTJL5I59]G/"K$.4VTHHAA;! '
MU1=I'$DDDY0( 3HQD)L_P1<GLTK53'.)JL+O*<+# EPBCPH/%0+<#@&FO"I&
MXE0*;1%QVB&>P&]:<(>DC2++X2,5Z[4-RF93*"O^7UG^?TR?2,7U*\CUT]X4
M1Y646AADTX0C'G&!))$",988&Q..G1 @]^-[.U(77W=[/V_)4[#WGM,]*MLU
M?]UW8+5F_<SU7E6'C%4>N@>AN:M>O[:[#J9PZ6SMI-,,?0./0>@6KKV:ZF8]
M_YX%@H4?9S# SKWJ^I^@ K7:_I71!OZ=[U^I,^VU1SBSF6_C5MC%3V$3=UU_
M+ZW4I]NJ3V;&;1+3"+/$*912J<!H8@E2/"5(@<',4AY%3+.UC5GEZ>8F4W7P
MSNJ:3 M/(JGX?%7X?,HY0HC&,4MB%($EC(!P(I]RDB G5"J-I"JF#LRD!<6;
M*V9?069_,/_(_9E]/%"29K^<19>NVZE X)8@,.TKX2K2A$B*A%&^1YK (.R5
M0,;%5L5)8N(T]@JYH(2^7B$HJ$SOZU^G78NA0KPL)7AA\>3'3*"_"A ]]LVX
M?^WIH-?WI?KONIW6YM[;G7>=[C[ VUXZ LD*$1>*B,<SYH]Q/!&I O-'$X:X
MT!+)6$FD4B>%L1&GVBX,$:O@T>IBP8-90A46K P63)E("568,!FC5#"+N+4)
MDH1I1)62TF@K:8(K+'@!6/!@AE*%!:N"!=.6$DV,4C9A2)DH BS@\!OH V N
M40W6$J$ZE:N(!57 Z/I77V-M3E3[V"V@O?.S*3Q:[1B11\G-GRIK^MXJ!1B.
M^9&&>%GYBN\$?C]FC2)IC)1@%$5.&\0E39%DJ4:,@9'D%>281@N)"55%B:N/
M#:MJ0U6(L$Q$F#*-,#"^56F"L+02<=A/)-,X1=0QGW0ON6%F<=&C"A:>%2P\
MJ#EU.UBHK*>%P,6T]<0B8M,DH4@Q"7 AK4)*R1@4B!B$@4X3JQ=G/54ESM4]
MJ@3*W]B]VZVS9N?"N9IV;9=F_=I9$YYXMP3>IY"LO2KWJ"+7U[]^ZF8=@%37
M_9D95S-=9X$V_S"=7G]4F*]:'9CL954<_4#1[-/VZ;4JUB?_1J>MVC9\ZQ-L
M5M?ULV[H._\FQY=/'EY SPK[NY]O[UOXXMNPP_!!)]T<V];YR4"=RG:[?;N9
MBYG#NJAS"=7>9-/<'[]*'9(8;'"C;"HTL500;[S%55WT$T*&1RV+7C6$J/HJ
M+!(^I@[1,B*E-!8$^2@XXHE+D#8T0BQA,B522!':5=6IO'>GR@I%5EB_6)@;
M9]70HP*(6P+$U/%5WO_K0,%$J1,2<2LBI+ROF$1 ,EP3IV," #&+#H^B7E0>
M@>M?WX_J)Q=G@;V(^HK%1\9_AY17YPZE1>[0C;$45"A Q+)08P9 *UUK"5!Z
M.6.J:4\H)DH0_$P1-]07:,0621HK12(G1.HC[W4V!TVK2JW51I('[F15(<C+
M0) I:PT+JHB)&7(VB1"G1"#%$HYB+87"2F)B(V^M$195-=W/$SP>S%![#/"H
M\.&6^#!EK%G)4\X2BE*F$P2RA2");0KX8%/,'$M5"L;:O',''@4=JOC9;^*Z
M:>I,L-'<KSRON=95?5<5?:Z0E5: X&8!@OF6]?;2[6+'OL"&59F*=P,X/&-"
M"6$2JEB$F(U]HPNID(JM!0U38B=2;$ "@@*$X\I9_<28?"4-J(JYE\K<4]9-
MPCEP+F4(]%B'>*IC)*G0B#+%-*@PC*9L;0,4VM7P-5=\_61MFXJOE\K74U8)
M8Q@+!XR,$^X;TZ0$"=#'D$Z3! L3I9*J>?4%501I!6V2JL9RY4R4FU1.3"'>
MU;Z:WQ525#[=>Z$CF3%I7,2PB*,4,1<)Q 4V2-.4(II@7YEN581#5(A&LS[=
M%2VFJ"JPGJ8YM'0@J;#BEE@Q'?]13CMB&4IB IJ4Q@[)Q&D4*9,RYK1)K%S;
MB&>]'U7Q]@O'B <MTZPPXB$Q8LK:<FGD=!2!C<4U1;#7$5*66L1X%&$1$<=C
ML[:1W.N@I*HJL[I'597Y&TMY"V[]4_4!&7NU_U:ML]>U$V>/[WJPRE.HAUR5
M>U1QY1L?K+*< U5>AKOZ<3PY;U7OY%VS<_ZW!Y/?'$*7]EVW4JINK53QV2I+
M$R6QH QYM1GQT/V"4()2BIU*H]ABEJQM$%F%IIX0KZ^JB^5.'%[Y:!?)_E-^
MEUC1U%E+$37$(LX40RK1!!&)$T;!D#8TY-T"O5:))T\,!1[8BU))_!5E^2DW
M2F(Q%M@(I(05_KSIU)\W+5#LI,6IL5$2^9-G<;(:$K\RNA_Z$)6746[PH*>H
MS 6Z"N(6 W'1C%%C8B*MBRB2D>\$+)A!0E"!*(6-YAIV/59K&XFXCU%3U1*M
M,',_OE53,??"F'O*9!%,<1:2[B1VB.M8(R6Q1'&LK7 R(9R#R1(M( I4\?8*
M.BQ6R%*I>'QA/#YEHQCM=$P90[ZR#W&5^'(_3%$DB::"*Z,T!P&^0LT$JLC,
M4K-KB]5ZR8DN*Q24"4 W@WYM6V'?;;%OYWS6>$D$Q9K$2%"-$8<=1#)-+,*8
MQ0)L&46X7=N08@&-J58F%VZ!CMKG!A%/RNJI@&&1P#!E^+A$L\0RA=)8@5(D
MDA1);1R*)3:QCG248%"*)+^W6E2APY-!AR<:XZEP8I$X,5.5R @6+D4D85Z!
MB%(D+"@0SI#4*$)$*IT/\,Q&=%=/@5A(GNQ3R.Q[3O=X";9P@#R8W1CFU;(
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M-P.-P57XMPC^<ZHJ)3&OF4&*!X(X(0Q9H&ZDF3:8<JFHUX\>_M>XQXU>JM7
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MIY(@9N ?SH) AE*,A"=8<\JP8:3TBN!JT5;3VE*LM\9T6PQ)E:>^PE,*QZ"
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M[X_@\PM*:F9S;M;/)W/4,%0,I6U+]Y]\W1"DHOR]/&@[VI[,>!:&]XZ/3_O
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M",/HT2"%HV_#3.K3(0Q ;*)G&CT;2,SCMP(*-Z^)FTM=[MW;]8MQ16B\EUA
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M, XB8(TCVGK.K2?/GO,-\:BM^<+4:V+JDJBX.U9>3%1P2(AT./KC6%- B29
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M T^72TOT_,[X>S%Z;JU#$CH,&'$&T&B# X.9!LA9R!6SQM'UF> MYO$"%_@
MY<9,]+R(@2N)@<4 >61YBJ#!P$&>DFA2 4VB3QZ"I%0:%K6_*VJ^L.MMA<>+
M1K^^Q;X8&4?6LX H SPA#%$)"5!((X"]AMIA%Q 63T&E%WY>$S\_@2$C=\BM
M"S%P0B@.BDF@*&]&_S'$ 40\**6)T!"U3?,^A1G(.9;YSL<EC7QGZ$].A_9(
MQQ_UX=#[XVL7KY?$WB6%EW0B"BUM&=*""D6U9LYA(YQSUEBE2]EM>\3:AZ6P
M(72"<*4"D$%I0!5U0'MJ &'6^>AG.!>BRXPV%+DQ%'')SC]=)BZ!PSOC\,7
M870PJ R: 1JL M1P! P1Z1].G=0T0&K:F+LO9;=%;I2RV]N1$4M114\,PB0
MCFP U&L-I,,2!*E<X%P*SD*Q @HWE[+;MG+T4G!1!XRBWI> ."0!948!Z7$
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M@E6O^&AL$&DY@5!S;I2F1@GE#44,<TVMHL&0 ESP *P6O%Q.S!0G"$$@O:2
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MX*>2RR[VK10,7-)]O)Y/L#Z&?D#!@5L6\T6:E=#"G<JPQ= "\I1 R35(&7Y
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M'^LOJ15@M@UPT.^=54NQ@^.XS;8;3?!TP^[XM.HU&!_I<;S35Y^JJ7M>Y^;
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MF]H\MG7_BHI[ZMSL*IKT/"2GJ'*,XT,J@MC!.QM_<?4(PAJXDC"&7W]7OZ\
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M-RRN3IJX[M0LPY&77U_4ZA@-^Y6,/#UL^6K-GC5ZL"3Z&XV9=ZF#<C.[,E/
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M0G/#L?%62D$M<208C$W2MX!IKK4 ORT,KP67=\+E="M1KWD0E%-D<[5#GK1
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MDF$;I*+:, _V#2>@/UEB/NA$N#2*X5*L=/5@NC]EV'KF!<,&&9@VQ'V2R!H
MK"&<B:B9<;H8MLL.4Q&"43I9Z[GD4FA+E-&>,>,%2%ML"TQ7#J9^*IJ;M.1.
M4X1-<(@+E9 1 2/O!":!@@$L%E=4N,#T<6 *:C-A"@Z*8I);2S1)C 6* WB?
M,$&NP'3E8'HP"5/M$P_6*"0-U8A3K9&+*B+),'$@B'FDI8[0TL.4>2*E==9)
MQ0656EN& XD)\T!D(D\'TP+'.\+QZR0<(Z:<XYB0XQ2#UHP$C-L8$9%1*^[
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M"8 T$OG ,S@% W!R#UBUQ@H5A0AL;9/A@LWEQ*9DGNIL[W"6N''&$9:4#2J
M?4L2$<^)S;*KM"#,?IC.9O)4.:^0QC9EYB5#FF&'L"!!LDAE#&$9]Y0*<,>
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MX#X.<!/5"3OM& .'UH&_D[2))G!N$I;>/:O&+0"](T"G^,\8T(DMR>V > Y
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M^#X_T;$D[R\8IM.U6UF(@FF)\N8/&,G2(2<Y108KHH*,+ 2[MCG;0K< ="D
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M6B')O=)HQ892CY-&^PCYDWR#D?L5_'R&AV4;A+-5>5BR(=7]JI.697!3&JW
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MSK_W:#C\Z\A]M.<;AQ_$QOKKK[VWK]G.Q_<'O?U-UEU'(XIO7G0_;D-O:^\
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MPQOZ5_G0T%)@G3WW=[GP\*.[>WB^OMW,17/&?WBS^/'->#5\[^IS.(9EH7Y
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MJHVA:"1KRA<(P;6G4^WI]*)K5>?2TZG:0S.4Q*^_H 2^*8DM*)6CM<1%< 3
M4F*"H43+R((T+%BO:Q>)%X#NN71VJGQJ2BC>O(EB337:K"X0RZ'X*YTCUCE-
M<G0R0 C:.>135C^Z1V9%\.(B>"[]G:I^GC&RMUN6$LU!1.I)I(X10/)%O$A
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M<_/1]/5S.CI-JYW.UE[J(/;QB2^N+^)N#QR<X%5.3MW@H1&$C.9=0OWDE72
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M[UYNK./[+[>_['SLTHVM[<OMCQ^^;.\/#GKXMW;>EJC=.[[S>ZOL][!$_+J
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M)4F#\9(4^4D@^$P\V$QL .%9]L7E4%7K4D%SK&J=#)U5M<X;OBT7DS3<YP1
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MIJ0T<%0@47JQ9@R9JG472X/?41(Q+>NVDHA'8;,5%/=69<^R(<Y30P!B)$:
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M#9F2&!"Y0'TB1C%!6!8B0K3")[N4JK46U8P/K2<)X#F+1GM02GC)C*>),PC
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M")1XQSQ1"7^,@J;,>4GI%7<UW2EOJ)E\,\_DFPBB-9]@GOAL.U 9!$5](DB
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M* ,[%%-N^5=4ZPI!<WK_^IG0653KHN$[%F("J&(M=$2$2HPX$PD9%@C2*J9
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M;L%)! ,*HZ2M4DHZV!Q6+*G"02^1@Z9:4K/14+&DEH6_QIN5@P$LJ @HD&2
MOV(^&J8*6295TEJIX/ *65+/FH3U'.#^Z\SUVCW;G"G*-<?XOFMW0NR@3,5Y
MR[OM9B/4AH^_U*2I'FVX@9\)GF9N_6UX]-9@FBRVVBM@31-Y29AY9E;\,1$?
MDX[EV1L1Q<@<XDXRI(UVB"DML(+_B]:MO65TG9#)#GM#J#T'W&<[<[@W.!=\
M(/'\-J?8T.-&YS0^N-WH)#^U.G_AOS["Y'QMU#K='IV)7<NYZJ(9=BR")X/
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M1DND7"34,!^Q%+F4B(O)U,\'4OUT5GA2^^V^L;M7#^HG<\H*J!< ZG&GC-K
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MDU-&1@$[A23Z?Q_Y>=BY7H>#B%PGVF-D\SCB-[9Y;B^Z:_^\.?(21'<,_>/
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MA'(=$166(DY]S#FO-B?"!T^8\T'%M;=RG1#\LIN7EFSX%]+8O%#%DE#%> \
M93B7.$J4'%%Y/#:P1! 86:XQ-5ABZFSN<PR$4JBB4,7"$F\*53P_58PW@=.,
M,,H5TJDZ52,).0T_F-?<"V -$5,>ER+XO-JQ+AM5/+Q/]0I5X=RC8=J3AE16
MLUG+"_/?!MU<"M'.CV@_3;AO+D;,H[#(2B<0=X0B0R2P+75.*<V9KNJ8Y;J4
MDS6+RS9TKP#^17MA!?!/ /B)1FQ:>*T]F%(A9VL8ZY 35B-BM>!"4\.) \#3
M=?+X:3,%\,L+^&7PI0K@GP+P8QK>"VXD3Q(QX&W0\$& KD\$>:VP-\%YRB@
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MDF.P!BFC#>)*,*1%;GN&L0M*)0E[O$S44M#]1.A^9&"DH'LIT#UF.&#-N9,
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M=Y-Q)HV#$0X:L3$_-MLN=]@>!H?^U3Z'-\30CQ%5,:7"//=AGNW-]_O1&6'
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MO[^EGS6']:-<(N:-1;"BP+6!!X0%@R4EUBA)*ZV-B#4VFM<3ULTY<E4 OCR
MO[L.<)C(*!/U@&VJ$'=2(>T%!]V*<V:%M4:R#' N9[M"K\7I^/7$]E-GI/X8
MT06T]P3MP7702HZ5PTP@+B)80#@0Y$(PB!"9(O>P7@DL($WFSG0JN&WPGORX
MA_7*GKP\>!]>A[>E2NI(<^LYG(^L!(V<IP0Q[#U.G!HG0K4GLUFENXD%)U;)
M>?![I^>J%I'3\ZBM3N\,#>VW&"9](Y]9D8DU)]$%.RPNNI>,Y>CR6/,?O;/]
M+$0ETK]P OTV8]0(HH(F8,5XJ76.-1EDM6&("!&H2M9;"@3*-[6X^_GF=?("
MEVA2TW2Q0B--H)&:'L:-,-@FBJR*''&6/#)<821@93FU0C$J<IZWQ/-4#ER]
M,@DG[1 Z\8E0N=,>^-CIV&[LC0;7&WN7T$Z30SNW1\R'1[%?J&R!5'8^$\>1
MAMDHLB%)I4 \" 941@,*TN$8";<FI"J.<P.5%9]1LS'<G#C.!,D%K/<$:\U\
M 7A&1KA "C0+Q$&E1-IH@JP523!*17 $](YYJMX5D#9WHWV\U+0"SP?!LQ9]
MP10+8F '=2GG1&#&D>/,(T8\]HDE;6.N!BS6N9[0>H*T.=&7 M6'0;5FP<-V
MR7"0"2E%4TYQ8$@G*Y#D0F")>;()U%Y*&I+;L/:';*X;[Q^W/FS=3(G%.]DD
MR_W&#(^*H5[WX(U@2@I3W8^IOL\8Z)Y@P;0.B#H-!CHH$<@R(9 3B7H04<>P
MV-CF9NXTRS5,:E_7>ZPG<34@K#)5L I]/9B^:HJ6)A@V&6(0CCE4DJ1&-LB(
M&!/.DT #Y7YCNRF%^M>^!,U^;V@[@(BQY$\25W(1FL>I/O.SZR9MH\>+\(+!
MJH7>*.?65*VCY^@__X3I0^K&B?_W![8(GV]JFD+X-\])$V),NW%8(DP+W 'P
MC *+8=4\XPP)H0SB6AJD+9C:B?)D4G0>*[VQ3>BFI+..L2EJGH(K'^:46P1N
M5\B9]\/7_>$;WXG'FT=:S0FJ%=Y:+&_5@FTX>:>YL2@$C!%GC",3X5?G,,<)
M)^ER62"SJ;6>WTFX.!BM"W?,H_TUCS6:$.4KJL["*:,6 +2<,FXMV+D<V((;
M39&1D2*N)!94.&-BK%0=?D,IL:+JK#)=/7=5YW&CGH6W%LM;-2>=3(DRD2Q2
M)#$PT1A%3@H)Y*658%%:IW,K)+))Q"QOK:"N4[GY_CG,]?RFO2<7WSM3;HF?
M<2^]O7<FJZZ^O7?FH^P68DO/-V;RPT&3_WJ449L[#'EC^Q6,RK:[K=-^N]=O
MG4?;;]D3D,[AH'5DO\:6B[';ZD??L8-!.[5C: U[F>(R\50_CH"6NL/QE:?]
M.(!?JO3R6@_3,3IV1R<P2O\X/5D?=9$RYV=F;W='U>N-*95923CFA C)>0Q!
M,^$=_.B-P"I&/]X-X)H87F:6ID$P;Q,1PCDNF;(V.$L]$\%S846:='^M/>MQ
M=*"[R<?-[_WS]WA9"5&KG8\<^,YH !/=ZJ76\"BV_OVI0_'PPZ]VT!Z\[?I^
MA!7>2Q,43(H,C^)^[WWL]0]MM_V]>NN[;;1F13?:3_\ZPO[DKZ[]VXSV3CY^
MVWU]].73ZY=X]_M'N/X=AGN)3R<?Q:>_=]MPS;>]_4/V:?_P>SZ,O;?_!<;^
MANY\?PD;]9?SSUB(X)(@2'-*<S\OCZSWN;.73AB3:!4)&]MTZ[:JE:#;=+)0
M7 1C<BL FQ>F%0=Y;VH/CN"O=M ZM?WA5*;ZT^6"CWIGW=@?'+5/ 2K]D1^.
M^I7H^0G3G1WU.IUSE+\5KI^':0U&;M .;=L'W6JS>D0_?FWW1H/..8QGX/MM
M%\/6+#Y;U\GN@MRV_]OU_[E]RX=+-&8J)._#-+WJG<"3SX':!W>=!YA>.QSO
M!7YT,AIS9JL+RY$+_<;!5NOJC1W09?PZO:I=$<!)#Q:@T_X281;AS]U6MS<<
M?PXK-XC7GY;[';<.8S<7A8RM-*I6#T2@*C(\B<L-1BFU?3MO.[ #C8;MW*9O
M<K-9L8$1_D_O# ;5WX0;7(C!\:C?'H1V)7JPV%]M9T)PMM/IG=FNC[4=,&M?
M('>'</%@>--SJL85,]6/)U-AX37R>]\\&3UXRJ2:,@A8Z\/(']T\HHO;P.ST
MV[:S-2-<4[$ZL?W#=K?2%GEEVUW;@6M6"C9$6Q:4-&"H1Z:E2LY:!Y:+@MV,
M?7X]L5(XNJ3;ZP;*A]$)//%\+XU/6@+%OJH0 DL)*S78AV?]VNGY+\^/(K_O
M9EI,L'DQ;,"6,"8AT!D,TLXYA*WBV..0DB<;P'#>GL*L F\]P7G!"YI(O2QQ
MN9AW90P X/+BPDT&%=EFOO[:'IZW*A5JK!*.NADBAV,&SIAP@.'4'@Y>3"5T
M<JN)%32V9>"E.O9T$%],?_@EM >G'7O^HMVMAE9=],M$EB>FT0UZ6F7GC#_^
MY:P=AD<O#%@*4F4%9I*W,'GP^%.R5>DV-=-L_)G 6TJ)6S_&6^2!GPG]L"M_
M-%A"MH20"Q\LW>(/O.LC#?9'MZ5;F#YLO9YDL-S<;;"K4"1&W\UA]CJCNY]-
M@=;.6+T;S+A'?O"*=T@:_,%L^)AUF^7,1]VFNGD^\F;ZO%\?/^O7)^:AK__0
M1+S[N Z;FZ7W:P0M(!=4R^9<=C@]86[> Z,9C:O?]= $O#N\?U.B.(TY8/KQ
MBHZ<?5 3#?DY1'%.OQSL>[K[^UMQL-_Y<G#\#N_M?X3/WGR#L?*=[V_8I]>?
M.CNO_?GNJUH4Y^3]T>[W WQPW#G:RV-[_4[L[K\_.MA_<[X#%M;.?OBR>P)6
MV/>W&*RMF3XJ%G.6/5(H:,T1%THA*Q1&RA&<<+!849:+TK#Y^Z@\@&Q7+,B[
M@C'<N=$O:6!)*K#31013/3F5&&=,6Q&)=:ER01-#@"0*^I\<_;NOKJ,_I&@=
MHQS9X&.NQY^CMX0@&CUAB5&EF<GHOZFR74%_07_;4JR5Y#)XJ3BW5"LA$M,T
M>6PU\[I"OR:4X8+^IT=_O?.1LBYJ*A"F^915B!AI(S72B3" /R8DU[6$O9\N
MJHI3T]!_I_$\K\:5TZCOX*K[^EH:0]5\?)(F\+#S7\_[Q.I]3*N'1)X>P+,7
MB_X^#D:=')?ZK=\[>35>]3_A-7OYVW].%[TP[[V8]^V,U94"#]9+BK0V.0O
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M)Q>F>W2FJ^O14KG@6;2($FT03R0B!W]"1@2;E,IUA;)+$&\J-9NI4*CN@4;
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M_9T2GQ &)0WV\B21#I0BS8UE3EA+<;6K4U6POM98;T*$I&!]H5@_KV$=>^Y
M6]-(!##3>4H).1=SFQ KB0R*<J\64\5JT6U"_CFTKA.WI\/:'9T )#S\'MI?
MM_^[^F<\,M?_Y_;%**]_N$3XT0R__:/8RJ)LN^?_^6_ L>J7P?66Z8.6[4?
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MA^>=@!JE##)X[TTP/'IK,$T66^U54,%$_N"@R2U:Y,NQ".S" 'YK9]_) 8C
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MK/'(,_+JR'8/JV*WS>O\NC !+H-<ST$^^^ZJ?XZ/MU_QDESZ9L8F2N5.H;_
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MX29&*TPPSG%!B =+*A9]J+$\5'-U:6,<SI$K'[C,-1,I,HP;Q"3W.B;E,)7
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MHOJ4-\T&?1 Q/@\#=6ZRH#@2)K&/P3).7;!>$I,LQM(2ZIG,9)%32:@I9-%
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M+T@.3"IC" NEX*M-FGB3)'%.(9=KZD5>WMF,BOC-1?R]AADJXN\1\9V@!/?
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M.Q/$.*T(2R!EL$IPZTNNIEC&&9X*]XV$^YHB%!7N]P#W3@1#2<T-:$H$<X:
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MQSG=H]-YO2WP0>R!O1M"O_Z97 'N&=M3S#[NP?(])NYVUZV:60YWI_\;<7I
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MEQ>&LDXF,JU2$C9".1 6F$M*13 JA41U"^4;I.M5**\#RKW+4(ZB+)H HC,
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M%Z5J.R>&AD $+K2DAB>KXG45"6YNW5=,;OKN<<7D^C#9W3_6F4LC+1"PP1
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M([3$1RA2L_&6.WZ/.K>/^C[%W>9S;W* OTPFJ#UP=GKMBA0,],^_WZ 517!
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ME :*%)6B&2@\;GP\NDQI>Z5W9=/>:MR*Y*S5Y/EMBQC'- ZCGI_>IGP\+0N
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M!&VM-;S%H V)"@XFTZ %< 0J<(Z*ES/F=$B65T6[;M!VTDQ]U-2$K C:PHF
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MG&/+M))<4QNBH]1[-S]KI *%J4!A9TR;B%1IGT^6!^\4XOEXN7%.(Z8-=4:
MR:GDV@8Q,V@Z54'"VX($+3"S8*PRQBU @M ZD2"(EPY3[T*HE(@W@!>-W<W;
MYZ>=$\&E9%$^*(NX810YFSQ*+HJ47'  )P 88IWF>C +CQD_\&^/<C-@$O%A
MF*FN7*0K5Z$.TW8<%$FS-=^TG<=%O*JZN$^O].]8!&M91ZX<)TP[#=+/:1F9
MBH%(]H,S4Y-NMH?2!F%K=]*N_5Z)JZG$56/2G\ZYB=9:1$RB8/,JA;2/ CEN
M?-+.VN0<2"O)%ZB74<6ZLV;=8$/B3# E*6<<[!I&% ^4$LY5X#\Z[OA4UJW\
MWS-AZ7'_-XU2@<%A$2>.Y&H$ NE@%0H)&VJ9#(K,SO]=L?4"&Z J$.P($\##
MC(M@7> X2HX3%R8(\QB^OL<2K63S2S#RF&RFGBA/E40NVMQ^RQMD:.0H<9Z8
M-#&?3%_;4(PM1EGZBG]GS;_9=\R,C2XEPXV)QC(.!,$M?"2]2A7_+A3_CKN.
ME?%1)Q(1Y2X _PJ/C!(8*4% MU:Y!W  W?J.8D 5_[X)_L5):T]YXC)@SK!T
M1#N*!?746.V4JOAWH?AWPI6;+%=..H9,I!%Q%CARS#B4:5<4)_05&,?R6:EF
M55^8IV4;CT[$S[L=S"H'N+!A0CN3LVX)!UPS%J?HC$K.!">,O*?F8!7@6AY4
M_#SA,<1:@N)")8HTU\U0V"(=54!:$N^P4=@(DS-P%7Z#(?%'C:>"DR=Y(051
M4L?@DI>,IQ LH8E3; )EEJ6H[T>3*CUW@?%CHK.PEPHKRI%A'B/N1$)6L(0B
M43AXZF3*3<7?=GIN!2,OF8D'9&2<UEHXPB67-G!O03^A..3J*+C22MX"JHQI
M)<1Q'AFU2 *&@%9B W()<T2\%#PP:[FV.7=7&U)I)16<3'/,T!";C1RNN.<Y
MYY.!!),AER[F).GY&3D58DR%&./>68M9EA-@N'"F$0\IE__2#@%"&)\MVH1!
M#Z%O,;&WPHN7; _NF5=*!<*MX4)H:P3E7@>N,:4:FTK]> -@,N$J#LI0K8U$
MT7J". 5-Q&"JD? 6^V!Q*KPB1"R) E)E_;[)*U<GZY?B*NOW=:QM0YQ+CAI#
M. \>6R&2U9PJBIWRT?R@8T85XWQ-P;4WX<TWEB>7-$-<4Y)S%$0N?6N1)3CP
MZ!4+AH,67.48+1/_3I5B1)0/!A,J$]=.FT@9)8'!<B1IARF"#[-OQ;4OSK7C
M/G3!@E0D-QQSLF@(R)#5P2$7G+-11>.9!FVS2NY=,L:=ZG2I%T9$:RE)C L*
M3&HMPUP$8VTB(E:"=[%8>/S@34P^2)*0M+D') A=9 Q7"$O'8@@^.EKD%E5R
M=WG8=QKN#9I[&Y/%*G+-DC,XGP[F%H#=$5K)W85@VG&?,</&1"XM2@Q;Q%7B
M2%,CD?"&&>T"3E:M;0 ;5Y+W[;*NM6#ATIRL$!UG)K?7\,F39)D@-D1=L>XB
ML.Z$AQ9,'&Z55<CP7)<!&P_J<MXCS[SGU$67ZS)(/JNF]E5&[^,X;]3YD!4=
MZ$B5SSM'DP(SY[PD3(;  S-. K(9C14605JF[^D)7X6NE@<8_60^+XN),AZ0
M$CX@'AQ%EF.'I,:&RA2LS2WP]+IA;[#J714)?\%RNYYXGHR/"D= D^BBQ$([
M^(-H%C"]'TVJ?)D%P(EQGZ/4V@<I/+)4R^RPB$AS!;#!DN!.)Z^,F('/L0**
MMP$44Z7,$)^<!6BPP7/E=6XI"A8V-DXE$BRO](ZW@"?CD4<1L2;4(^*$19Q[
MAD V.,0$55I$KU,LJNT:,>E-J?2.58.3*="$.<XB-\R![LJ-T-8F#R+*DJ1"
M-(14>L="X\2XSY5ZAKWA##$736[1[4'O,*HHJJDE-110!'!"3!;3K#2/E82*
MJ30/*KFUGDE,%4_!.2XLHXH)A1FQP52:QQM E,D2O49A(C1#N744XM9H4#V"
M0;#U/E#'0I"N+-'+JQ*]U955LNY+)^N2*EGWE=K:\)BLE(%FGTV*.C&9'&A3
M@3O+/,ZART+<\1RZI/ +G6G.4"759B75CB?\^-2RY*VW*&@9$3=&(F= LE%M
M/(]"Z3(G<!VK!2E75+'WK-G;A,A"LI8[BKF*S%$3DF=)>)$8X2_.WA4'3\7!
MXQYVV*@4=!*(V4!R=I%#SF.#C$C*,1YU\'AM8[(2=\6]"\N]4Q4+#"%:%TRR
MF)L4C5,&/O*Y<H%G6#V">2N1/&>&'G=Q,RJC(19ID30"5"9(,T\18P9;G:M"
M:@8,O4[%Y"'S*F%PL3E[JKP:!ULOLJHM)+<X&&!B':A5*3<FM;R2RPO%QN,>
M: \[9V)TV5UD$1=8($M .$=NHW21$*- LS;Z.?DQ%?\NKF0V1!JI"0_4>^XC
MT9[8(%,4#'/)TF/8MY+,<S:6QUW 2F)"&8<=LQ1$LZ4&>-H:Q"*+PAE*E7=K
M&W2=Z$7J?+-*^<"TR >F+Y$/_$B/?;D,=SCMGQ<Q6[@5_X\G1C1FL#Z++2.F
M*A-&(Q$!T%]$QRFH>CA9"\,S0A%BO2HBB=.H=E4D<='$R(=S$!^WQ0AA(1 ,
M<L-:I7+RM$,N*H=\+F:J,$^.I-SB81V3V64Q/9_O7C=UX7GCG4%JPPL!^7(#
MEK#6!!$L\3APL&$LCY;EPVPR<).LF1M@59@T)29]OHU)7G.IM8Y(&QP1!\,$
M92&$3&22\Y"\)V1MXSD%72HXJN!HUG 4!&9,!Q>$%UPJ:J/P'CL=%,P[R/G!
M4:4_S1*K]L8.Y7KG8W$*-^#<XHY:!.A%<^U$RRA/PG*2S7"%9Y>(5>%5A5<S
MZ,V7I,V%Q4E.H+%:&A%I4L(&GJ+10E;JT[) TN%8)=>$@_4:(ZPM1YR2@("2
M!6A3FG#O#->YQ@=CSZG,4P%2!4@S#S(*93U0*R7*<\.Q83H!.GE,%*7!ATJ!
M>A-H5?R?$>MB9]=?;!\>.!:3<RXA19Q!7 -RZ:0)BL9ZR01SG.0NHVP=B]D=
MX)\?9!4AD)\+DML836?[[ 3XR\/?H?5MXW^*'^6T7._GC:LI3O'E*S(ZS8R^
M>0)K/>C76IV:]?[LY*QM!S'4NCE0"&Q^(U((E^108<WV8@T^[<=.OK 3![5N
MJL'EM5XL[QW8[[76R2EL=+WVL=N#MW5J_JS7BQU_41OT8+!P7<:45K_6Z0YJ
M-AR=]?.-P*^CE\ S8([G, AX[V#XZ'YMT*V=1F#J#KP<+OT&;'X2A\-O9;[O
M%$^V[5K_S/5;H65[K=@OAE'+)##\,L2!;;7[-1C#G5/LQUC,Z-=NIZ"C8EI_
M#>"?\FTPX5M!U%H91:W7EF''MZXGWXN^;?O]5@*BSTL#'YX5V[EY@Q2*F/&=
M\WTW,:/17 K.:G4"K-8[PNJBD+OSF.QOMM7Y^:<<WOY7;:=3^RL"(0(5P O0
M';,',HNVGTFX.YSV3R5%_*L6OY_"W.-Z)OCZXL_[P\EINWL!9/Q+[,0$'/1'
M&YYVYZ0S/[<*^0H3!S[*' U,UNJ&EJ^YX>V^VP=N_@L>N-T=Q!K!!;-.LM3]
M2S.$8)2#D M%$UOPE&^P%@ FM?^R)Z?O:_\;P^$]% *$$6VO Q,I%PZNR'*G
M6+B,&'V;$=+[#*HUVR\^:^;'A1+Y2NE7KUTOI7S<2F:!DY6<5N>L&,HSA<UH
MS8<+PVE=P8:\/^WVBV&\*P 7EN3]>2L,FJ/,E1LW#N4POK[%.L#*L\']MXR+
MVSEM?ZWX;[0BA3R_GE2A0\!(VO:T']^-?GD_.B75ZA3/*VYZ?V)[AZW.2"/)
MRS>F/Q03+K\>+HK1=:-D7I=A+L7PQ<,EJQ=+-J81E=\Q6N?L_J]QG=S[W3P>
M2^J:/^ZQ=V:6R+4QV+C?>&,3ETZ;^;!0)%IPC6)CS#^I?Y:?W_B99U%8,IBX
M"'IXHD1:[IFQP0G"<F43EZ)AZH 8N3:ZJ]F[7KW#B%POVF-D$VA2[VS[W%[T
MUWZ^M4 G0/!CF#'.[O?CS@]D@A[MV5" HOS)B^^ NA,D"+_"W]=__?M;ZR*&
MHO*6Q3%VF!P;HBT+2AK&;61:JN2L=2%*)3EG=^8)WK:YAXKZKT,]?:O5]^UN
M_ZP7=^$MO[3!()^[H;PW,I1I8^L3!\.8-NCVR?9O8"1_A?MV]UM[1_#Y4?MX
M>^OWYM[7CT=[8/3N_]/$_N3OCOUJSG:.]LX;1\UFXW+O<H_NP?O^;.[!&.$]
M+?B\M?/U,VZ<?(1[MYM@])+&T>8!8\9[E[M3<)YRQ?N$M(*%M!9X5UI%B%*E
M0P1$<PR;V=] K+(\GX;B4?/ P#QFL!TALH@-Q18@*_:]/<V TSN+:QN?;IDN
MHSVH[5[;2I,&YTW&&M,-RHWZX2#F:(-D>^RF)0@F1POLJIM&6ZT+2BA\VSDL
ME-)N!WVI_U4O,R"WLESNC8Q*N'A]:*Z!U=FYJ#5!\0(M"@Q%>#$H7DT[*+X'
M*H;EO;YK]-K[+<="Q\NWIK..'WY_X_[XW<?3_.QN/^O0M29,L7T!OZ5R7CF;
M$!3$3O>D&.-YL^6;Q2,#*-5Y:(6&F&\NOVI:L*V:-A16:?:!U(9F6+:Y>H4%
MG(<\>GS^(^-N#5;SI)L?"\8-K%<>\*GMYX'U0,V\ (T5W@X7E?:T+:8XL$ P
M,)W3TJ,V6@MO^\U::G?/R[EG^WRHVMY:O8O2ILZ?G]BC+MA4%R,WP' 7_GML
M.R<?D>W_N]?VX@Y+^DX3ZS4$Q 0%$_&?F64SSP^] R61WD=$ZS5GP?KRH&8V
M(QA75_./*44_&#,D@"1LN?^%DP,6]7%^F7IM%]9R^'WQ!C! @((RYUS]W>]'
M>%^>3>V\-6@.=_;*LU$X-JX)8&@5EKM4>G3R%>D!GTX>!6QK++RV5X;0K0?U
M8O^L73I1KFZ$]?.@G8%A-K96PQ'GB;1;UK7:I?%N!U=S!!XL3O /^2-?V>]>
M&V'%M3"D =!H)K[BJO41YZ:"AC,#9M(<E';<#[CXI\W>8<Q@:XN7_0T6\N49
MF$O_*G=@#-;&IC,:5'[Q@^\9$D5J X5<FY?7F#A<Q4>Z(N;")Z5_L9;=\C#=
M<]L+(X@8UEP8X55J96=\B5-%48;ULH]:7MY<T;Q8K8>H;NA"'+H"^[?<&=G(
M+J4&80L-*W14EN+V#(?QET/@C2$?=($G;L_Q;E]5[3RC_?!R6/G_F*8\T5,T
MRD<%=\84S=WK.6:_3/;*_!+S7B_129175TSQ]JX_B(ZXE)A&21N%N"$2N404
M<AQL/R=#<+QHH#89+JX!X;;AE_6I2 +'&'"07H(UR271Q@>6<JZQ\KGP77IZ
MVY^*)&9!$D<?#J32(6K"$5/)(FXY14XPAJS)%4ZU%5AEDL"3=3A&)%$@S#14
M00*/A.?*99QP'WUN)$.B4C8(1[TMV\EHH J"INP^7%'%3*CB\"!Z;AVA  _4
M:P *;I$A*A.))II:;Q4#8Y#*R7,"5U0!,N9'0GH]JR2GH*V 2MJ^>+;W^M&^
M++.V7(XEL6*.I0_#<,D?L?=7TRZ2/^EXQ(T"KN7;6U]P8^L#;GQM8/A;[.Q^
M8MN_?0;^_ CO!PX]VF_N3W#C,8SK$,3QY_/&[N?O>Y>?X>]CT3CR>'\+^//K
MWD7C$MY_\K$-W'@!SSR021 OJ$>,TYSE%34R)M<AMB1A[+5SB8W[DX+F@BM8
M>*X\YXHYSZ,54C#/>,ZP'_<GC=:\!HM>*U;]"?ZC'[YTR,0O2SY_^68,9^VX
MD\8)Z1?;;_G-3MAJY:A3V"UR@5:9N+8.#P+H@AJ3A$BD#HA+$)0]?LCS *H!
M#9@'/DXL<[%SLJ6<P##LGA>^D^SSR!Z0C@<+_X;M##M<Q*.O8JY@_X(I77CE
MNK50[OQ]5Z2A@^J6Y(J=;#,-C_J6=N'PO._Z[4^'78$*^;85?3QQL3>\WJP7
M$N_=G&*(IJX%>TH,4>@Z-T\+]CW\G6!TYB%$0NJ2J6JP+S/8YP1GGQ]QG2GB
MZ!\I/F5"ZZ=.K5%JL_W:A]+[=R4=:\,LN(FDQ ?F_+R M,_9<[TYI?S>O4*/
M[('VEN>/5WO^Q-R:_U-K?DR3B;O0Y2E^>4#_F&-UD%6O_K'TU3T><J^-K)O9
M^N-_:)47I'[E*<-+:CX-#T60QM8QW/=W<V_WL\A>L@;]?+EW]/%X;_?C\?YO
M^R<[,,Z]RT^7>Q.'(KZ<P[OI_M>/S>VM]M'^T>?+_:WM5N/KGTWX_WC_9(_O
M'?U]U#@JO&L3E9 )8P96GB.P[QF87Q@C;1A%6CN.P>IG0=NU#54WDV?@WT;+
MD*HKR$RX_9FAEHK;7X3;QZLF$T(YUL8@9X#1>7:I6VL$$M(KF0P60:2U#5$7
MSV[L7''[6^;V9X;0*FY_&6X?D^W::\(<"T@S2Q%W'GXCEB$JO /QSBS7)G.[
M6IIV8*O0YF43!F,/8VFS%<?;<N)C'GZY*?_U_S0E]'WI:JYZP,P.[LH%GW%6
MD1B'NJ_%6&(8;O/V6?;2[Z0"]OH[UYL]A,#ER!)8!GS\--D%1@43L(\HXB00
MMSHAEX2$C72"!P(;37/NR;IDM/[L7LU5T>J%YO/GIHI5?+XX?#YN]1C@:I$D
M05B#,L2)P<@P*5"D(C'073%3=L3GDV4?*CY_2WS^W.2_BL\7B,_'Y+E2F! 6
M.8HF=S_V4B%#1:Y3KRB300BO?,'G7"R4/%^%2O5_= >Q/+TUM&OB]]CSK7Z1
MAP)3RT&J7$.IUCTMN/@T%W]XB8C5-)Z>-X^&,[-NCCI'[ZZVN,2^#]<;_"7O
M;U$B:Z?8W:*R1P5W4\%=8\)\22(DBW%"A DP7PSVR,$.(B,DE2[WL\0X%[/2
M=3PC_\Z2.FS?/!O/S'BIV/CEV7C".B',Z,@BBL$[!,:(089$AI(6,5+O@[0&
MV)CH^JQ"L!4;+R8;S\PVJ=CX%=AX(I&""&%]0 P[B3B/%&DB(C*>4E"F7'31
M9VDL%XJ-5R&@\N_8[[\;F1V]>'K6\\VB9%YI=@QZT?;/>A=#^^,D#IK=4,55
M9EA_]^5-CQ+CON:*)+]VS]KAE_CG]3X7>+<[W.4"]QK%'E>0-Q7D?9Z,GP1E
MM$T)L>ARRUYKP?:($>D8E8[6)$'LVH:1=SA;JF:?;X6/9VI[5'S\&GP\;H%8
MR:F(."%04\ "(8X@9UA")M?&)DK!'V1M0^/Z9'O/BH_?"A_/U/BH^/A5^'C<
M(9@XQ0)'9)G,\0\3D+8>(PF*%0.5*D8=01ZK.X*<<^'C58A[_-KM%,/)88X0
MW6!HAU21C66);(SBO)\ZOE=4G+/M7[LG)]U.B7&WVWJ4N]V'X>VD+=CMZ^+M
MMR._J?4]!G09>]T*]*8"O2\31D@(45 2$Y)8Y22NI)&CS"'/DX[:4IQR[>!A
MTN0">5XJIE_@.$C%](O%]!/G6"A MHH,V90U'94D,L#IR"FA8\2.,4,KIE\-
MII]Y1M>SF;YB[NF8>TRB6\(#Q0&C%'Q 7%.%<G<N!/_[0#W35KJU#5R?+/Y6
MQ5%>]&#*J.F5?>0)E6&QHWG'4E;FO-Y<#[ ,:YI-Y+U6*:^SP\J]R1PP'V34
M!O19)<'Z(5(B:Y1%DC.O35* GKI(>57\^5E@T_+3$OEW5QLC7NOP2X41KX$1
MDX?^M3'!<R0#EXA'21$(!(<\LR0Q*2,-L<2(&>A4%4:\48QXK8,S%4:\"D:,
MEPK0AGHA) HF1,2M]TCGJMN<&.\9IIXG66"$YL_/7WLMC%B%^-+6@P5EYUCR
M;5@?EL'>A>Y9#G^M7MFW1Z[!DHJ)^95^&Q)]52!F*M3W$]8C9S91DAP*FH#U
MZ&TN[.X<TIPK+5CP(J5<_$T_^[3D4_ABB9SLS\>\-\'W+UT$KN+[I_']N$68
M1,06@WH75*"(YQ\Z:(ML)(#13B09BL)0HN+[BN\7H!Q<Q?=/Y/LQ>>\%DRY(
M@IPS!/@^%WL%($:,*^JUY; O*O.]G'&QUY?E^]M=QL>;QHSZ+#W8NFE^'45^
MT! $YNS/AATCBY:2UXU!REX?5ST5;;M]?<:I[+PZZ-ZJJ=!?+YOWQE'MA5@[
MA36*PQ:7_3BZKG8.U[5C/U]LRRZ>HY#?B>T=PTB_V?99O*-[;GY;O;99]&X<
MMB:I7?4JN=GO.+1"T:BW:!_LQW(D[^AY^29W#^>>KN7NO:Z_7HX#[F9GT"KF
MTOH6KS,9/@Q']['7/<D;=S8HIC+9UZCL1?&V/71/[W/T"6^?'RB*.9:$(.$\
M1MPIA9PG& EKB!+$.H/%V@:9S,R^:F@W2^8^[$5X2&\F_#WL.O26^+MHE_UL
M_B;FFK]M;DB8NT:V$LBQSJ#6*=S=>1WGO:]%MH9Z?[6[LYCWE50:C!Z6NWZ7
MS</SZ\<IHFQXGV?03:D/+W47P\;;Y:+T8C@K@;'5*=N6Q_[@JFGPE(V"9]#_
M<SQAK!S03N=&MG]."MN.@YVT1,T^7QL9#\G.Y@$SRH3( C+6 C+*7/\B28F4
M=2#/;*)!$$#&!_J_ID$.(]COS^_@.828>SIK/Z_O)\T OU1]/^6*]?W< AAK
M=_MGO;B3,C@"N!2$\V>)0K]V^X/^J#QY#'_8BZ)[^X(T<+QH;'T9L>_W_=UM
M, [!F/SZX7+[Z!CO['J2>_-NTP]B^[)!=[:^@.'Y^_'.K^/L^[&=^_N",=G.
MO7YWP$#=O@1#]6N# 1NSQN4>W]YM'^V=?.;_7,+[M_R!C5$ZGR+*;7ESZ#";
METF@2 BPMC!,!S+>'50#<T@<F#!&<"V$%A1KDX3TV#H9TWC#QS(/MU8<%EPO
M_ZF5Q4MJ1?62HN5A^?'-C:MM@D L4GG[3^@F^N-!WIZ45]H%KY,T(7&LL8O.
MZ&"5],YI9O7:'(V5S<$]#21O*FU-^Y ADE?79<+W-U;XM*P=<XL3HY1!!N^]
M"89';PVFR6*KO0HJF,@//MT5],$WSX]>5=',+RVX[>:VWBY8,V=GT!SX[I@>
M:)<\D"5#("%#+G7)D%;4H)@,I\XSEC1>VYBLZU\J>:C8Q]K-C2P++I;:WV1>
M;VW4G#1O='Y6?U0\Y99]0#$6M7]W ;5W8^^D]JF3>\9ES2_O6,&C^7K8>GKO
M5>4('GX0Z'TMT AKFZ )MVM4%KU-*=@E[?:5-IQ?EG4RX/6L0 ZG=-@#W3O_
M>>;Z\?_.X*%9WRZ4SP 07SL'/>[&S'XPTB^/N_ VDYW8BUJKWP<U_.PTOWPZ
MR]]9KQC5/#CFN1#".C >DU6*T&!DLG?SUJ3*>BW&;C+69@_6Y[  S%\N)B3=
MYKGMA=OU;3?/!LUN#W H+(6*.P=>_7+>^'P@0(00Z0**T4M0<:-!N34UXD:S
M**AD(NN&4DQFZ(Y;_X7M5,C"?BD+3]MGF=@O1A> <>EC.X;U$9>LYXU)L37(
MOP('9ZN\H+]02[WNR9!\'V*WV\PRSG0E(8"A:5OMHIAK81">#4"+*MFM_UB&
M*KEON?EAM H?N[W?\N0KMKB;+?PE6'X1"P+JBD#8YOX+7F%DJ>0HT)2;MH.N
ME?O34/X 6]A!Z1L!M ?6&/>.UZ>U\.;A0[XEA3W8&*4\:MI^S<4('P%E'687
MTJ%M=>#;5@?NN&H5GOU!A0:<G2?3>$&>>RYDTH?<!B/(CE(W)WCI0^FLJ1CB
M;H8X)(W- \>8-1XKA'T(.5/;(*MPKJJ5$F9%A[;L"EDG3-S+$NM34<'L(PD5
M%3R+"K8W#XC67.:Z]3H( CJ")4@3DI!U5(JH:22AH ) S@> $1!QKD[1BA">
M10@4U$8=.=$R.)1B3M.AT2,'Y("8LM(82A+(R5S/9_+0QA49C'GG^\-031%\
MS"22]W(]&TJGT6=%K'U1&F"#[@!N&8J:@?T.HJ@34VL E_KN82=K_-D5GV7O
M\"(P%0>%IE2\LU#6[C(SLX!; &'UX>2TW;V(\:_8^];R\6X:W;7??RFG/8J
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MB @3 @-\Q0^BZ^B40G%"!YBQ.%50X&H6BK7NMWPNO12?(^PK4ZB+[2OO?XB
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MM+Q;-!%;Y<(1NY\/8HHQ6NR0XQG?'5> ZEHBZ9AFQBCIHQPO!#$W(!QQ\VU
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MZX+T(#XH&3"LI0-6>FBG7, D%WK^5Y*8$=K%$PX;IWJS-VXG"B;OY,UGP>0
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MM\C%T=B5;]B)"]]VLO#98S?IHR?/'S^[=&OE27W]\L-NWAYVU]AMW/BIW'?
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M7UENX?E L>S1XI_7*[+E80%\*C&\R[  =*>$;W[YG?7WW]-E[2G3VUUV[?F
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M"I,"W#U#]W*% O1>[,@:09RW0 X32"P$'F-(;#UG-R:2FXT;@N:)I1V&<O=
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MIB'O&D@I&0@=QA*PYD8=RCSE=PX&RFL9A UC[,D!;@W 2QR@U5!,(00,03N
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M3Y9^:P!>8NF-8XPY&4"VIH?5KH+86(!4/+44AM;"$-2= #YT &\464\ ;PW
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M9J&VLEJUF\V">ZD".VL@;WM4T1NUB Y1&TEJ6FNHA;29$%3*5('=-_OW<H5
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MOWYQFJ(O56T/6]4LGBI!EBFRFWWZ],%Y@,P7B3=38<[4"[G/U#KGTW<(+KC
M<!DRO+$APR>?_^OS3]_[Z!>_^.7'G_Q\\K/\#=8U+O0::P]C^1N\]0Y6,92(
MH8\F#3$%(0LSHO8Z\Z&B1JMZ>7]A5#K:GP@Y(L6M/Q5NYZMR&R"* APRAIAB
MZ[EOIS1V%$(MDI^89$DUY!9:MII19"9!)::6XD@Y6Y9\_LV)\>*/WN%/_O*K
M1?BC"3_8EZ"H@IDJ>&D1L+<,W$L!SQ)JK+TD#]MJRBFFGR[,KQ?SS9-F1&DN
M,6*R9IE+MIY:\31"D?/O3"S,3\#\8%.B<[)*.4'#YH 5"<Q"!AHL$JF)C?9C
MP/RT+&?3[_SEK@C_EW]9><Q;%H%/#(!^L C\W\R%2QQ^X\GP2!R>L4VHTA@H
M2P>D'D"J;_$/"94YAFF,/4Z'ZP#Z.H!^/N,Z&2EAB660XHP%>7# 4LD3H]:^
M#J#O<+++QP?0)69DF4&?1@+TT+<$KX'/)2N&4KP-OKD[V65C'9/9+\C#)[>C
MJG4GS)DM61&,N=5<NJ:RCI_O$N0#I89C39[9@=MV9M5G]"):MPX#G:,X9M$9
ML\1U^OR*2>;L634W&A0QDTGNL9L7TB:QRYG*1Q?)CR3Y0(QI(0F.5B%;2#/[
M4 +I,0"[-YECF6NG27)8)%\8R?_T2/NZTP+L;1SFCSRQ7F5FYR+YH% TQ1HL
MU *MQ$ER3]LQ=&PSPK84>!LPJ3=W-3_@8O?/"^.]8OPXBD^,KE>-Z-G@/9(!
MT^A:+1JT6.X[-!!H'0UBZ9RDY^(\%^)RNR=SME6\M0Z@GVM+& N-BH'2R*AM
M&$H/'C51#J$W7@+@_J8Y/#YC+E@C>H91$#?=8&8;/.<\U9YBGJM7'G'SNMK1
M-L<B^8E)]HIC,TS*-1L:B5H@VJRNQLPW/:P>-/LD^4 !['$DK'7,'",X8%$%
M$2Z0(P]/WF<J&9]" 5PD[Y?D/-?>P2UYF[/Y3#UY_BGUE"B.T4M(2P'<)<D'
M"B F80P^$X]:-MT )]/:(Q01U#03RNK\% K@CDE>E5AKYGNLU')B&+.DEK/-
M=\=F?]B]QLX@/C(@MP!,6"'F.0UF&IK;>!*IY>FKK5Y_K^]?W'+/YU[.\JUK
MK&NL\Z*/68CJ@PO11U\.W^:;WWWSWL]>?.,Z@]VWNIRO:ZQKO(UKK KA'WRV
M>VUZOFEA\,@EC]S52T%BTCQB'7G;]ZR!DRQCVLL*V'_UQZ-- YZY5?..4&GS
MU^>,F^@XP_5$F ?'KF5KS_<LX9[,N1?I3]VX*GA7:I6B)DR5-97426L-U6PF
MW<N8]O)(/]A4\)9-Q\S)2VT5L%B:B7E3:-$EU-J9LVUVE373(OUZ22]BP4*/
MA"UB2D/Z7,]S3W,][RANRYCV\D@_-*;M<P6W2M#'=A*HBX!J,\AI5(NX5;&5
MC722DRVH%^E[(?WAPN/3 OBEHY\-X8-Z8\D:BG&%DG6KY4D-1#93RT@ER!PG
MBGF&Y7*["+YN@D\,S!?!9R/X:"=L2$Y;BTG(U=M,K><O%C+#G()3<G2)F_<
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MU9L[3*L'TA6C/*+5P2.4+AT#DMD<^E%,T#U/=)?\MTN4?W58UFLQ=T,HF^<
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MQDW(V36$",AAJRC- B8M0)02)LAFYNWF+N6%\J6A_,CV&2<&V:M]QOE1/MC
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M&[#5"!'S"+6@>F];,E+3R<G(VBK=+^E49"8>1I%G C)&,AX]1TG)AV]=4)?
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MSOMDOAN8GW>3/"_2WCK"Y1 ^U0*;8(BE1+ R5X=,E[/21#CT&',,C'G-G_\
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MSPS$M^AZ.81/"R=>+=I,Y*$QX?O63BFQ0!0TH80E/G4ZA*O27#?#'\&JX;P
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M,<_(G,)H.!X>R]MC]6"WY]\+QV?&Z)OC5^#X(#AV#37@C+P3K]&]611\QE_
MQ55S35I[7(+C<>SG-O&]2<..3[NF\H*T)&G)RMVHU)F9B#G%F'G04^Q"[Z>'
M;+GQIO:_HYN'E:;<.L[ I70@= 2-RN#9<DL1>PC]X9'>4#Y67'8?Q-VP'K2E
M'%O+*Z"Q/ RI4)KO#(\IS'AVRXTWR/K!_A=#-*P*2MB 0IV8^_QH>0YRS]K;
MW,$GZU+.EB VZ]?+>F;ARB,67\)C2.H]A3ZH1)F'N^W^QEMD_51NC$6H2*V
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M+=]<J02:BT--V2TGIM'3A%EVG>'68'YIG>&\4'O+DZ\ \VF=P2K&4(I"**A
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M*"&!%POS)]U#&:MZJ+JG9=\-Z\\J%&>&\5NAN!S$IRICL:J<J<\3N@K0#,S
MA 2,@JT)R)K1YH$==C?CG3-\9GB^&;X<PT>5L6J=2V8PM'6@9!6\UPR1YIHE
M#MW2NB^XNQDO[&[P];L?_^'[/UAOW]7M:+"?<7O/V*6 [6CPT75!S(X:B%HI
M,Y%P,YG/2#QJ]16)[!K K84H7QT=#3B*SG=<AXPUS@BE*PCU"(.7_7]WT98>
M'OE-3-<4HVS6/[2C0<A"2!/NG@A3D, <@X]*C&DDW#6 &V3]M 8@0EZ[1LC#
M&M!H#;3QS$N$*+22<EN2 KTI13?K]\NZ2\CF@2(C4\0L7'MMB"W%)/,TV#6
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M"7,:PT./1(T?'F/<]LDWQ_ +*PQG1MB[PO *-!\J#&D$6W>)(+7 0#X0K&J
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M[QVSGG.<J:BC=JDDQ2R-)34'*CD.;FEKC3?(^JG6&-RP9S?H5BI0FK&.2:C
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MUWW^"A5&C:D*"HXUBQQ1Q."J2,8956.N!NW&@)B"#WF.)Z,CVCA9W2DN/_'
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ME\Z+8&P52E4VT+VI8"1;XG'3^H5]D[VKU:4@]^Q@<OOYDM]R=CA4Z766+IH
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M!$,\5#9HJBERBG1P"[LR.M)7%^G%%1UM41@I@#.553QKJF/%7942<NR.R%5
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MIN(T-[.MX=22QT;:H^-8Y_@L+4%^J26\P:X@W/F]]O+#SDHJ"$92MBI0!0J
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M7\)2\ Y4Y<(^88SLLJSE=RR*6_W?,PY)4O'(("J!EWU]4 (O!Z,]#/PD '-
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M%WAN:&*K$EX;\%S73K,[YZ5NIJ-NIJ-NIJ,^Y^FHX<N=CGHGNF(/C9'Y\'8
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M>\XD=_CYMS//3Y-(\,AA$1-.&/C,83(43B+!G/,"!E8@OYOD:(C>?"Y%-U[
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M?A6H82EF,;^NIF4#Y"(2L]6_\%NJ@A:+70"'8C%V 7";,J()S*Z2SR#[40[
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MN2&[%\P!D)P+,P^CFKPLFXO9&4 1MF,<$4S!1PN%/F5@G9$U!/@?\)50[?A
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MG<!/@N\)U=6,?$P:T-'$ 4(^["0)>J(Z+Q%346!UJ&] *M2 TQ'"-ZO%8E:
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MO!P@<I9D@>]F+$"YX7(!CD&""7!L6ZZ]->E^3G[1'Y\2CV=9RA,S#X/0]&S
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MIY09KK+<J2L+M7[%=G&4Q=\!?M'<L]U :Q04==\0$#EM=!#2KD=0A=5L8M4
MZ$DBR*=@(]&9O.WN;;Q-EM7;TM+YUYQ\ZI/NJ2J;JN<A4+WG^A9+^\YJL82#
MVS%VZ9/]KKJ>W\JX' VEMCRC=6D,N@:UM2I3EHG=R.+N]?T,^^SH)"#6I'9%
MK9R%IUI?GOB:HL&:8_=#88Q2O$3M#6#_.AVBG)X9:(ST<_V,(J=T+^KX6LVP
M"+Q)X=&J0*<FOL&D(T3J5(7>(XP=X[GJ#=727N\#?<9!CD?#MEBJ3.KLC)*9
MJ!Z^2A'RM/Y-G;1+<1^77>WCKGI4EG"V-;.J#)5JX=MZ4]&M7;QN1'>=4Z=%
M439%EDYGGO=2685X$/13U6(NQ'TWB=&E_@J-3C66*FR[0VFYI@-;J;7:GE=,
MR*$70*8I)O#I29)=^\\&[&D^K6:8LI?Q.950<P*_HF2&RO>!J>%<Z?-YD:W2
M DDS6Q&LN$;S%,$48D6")8BPA&1#TD&,TG#J0-_9A5R)T*X#52F+2'"939MY
MJ\\ &'MJQF>8>4D;%UF*:K%J2<*/(Z<,#7(J:RZT'1+[VEE),<M.E>[@"QG+
MPMJ8$@Z\:?"L$&*AQ0PKI8VAQDE7U,^!VH\)Z*6.$IZ/]5"B[7AG(W>'N"I9
M6<QE&"$#@2+SQMN=J(;!@A5'#J6E$W$@#X(9]GOY]$CXH'#;"J7N;AHJ:VM(
M*RF:5LF4VM&NCV_;X$D1\KNL1,/GSFNH-^2&RZQ5YUJ$J4@A+>.1]XJ\*/B/
M83->BG6M%91WY?>RXUNW6JID:[Z;*Y6R9)LVCHI ]-I FI154^@V4G58=/25
MZIZ"WB6Y),)E!^Q"LYEUWFGG4*AY>MWFTBD^JSQ1 [^(WC5B_2PG4L&K$4:*
MVQV,'[,V^<3:MH:2ZV2]SV -:\GVO6S^*9]AHQ,L!:U/5L)K4(Z_KUVV2,\?
M2^+OGHMIZWAAUWG2];;0.Q!6RJ(T[1HV<TF#B=0HJ$;916$E>*VLS)@SJ@%L
M9/\8369O]*#H>^[X02692V<M;A1(JL'R/0DWT-0PQ3JI:D42>(O21$_(MK1%
M_VA7,/I@$J2'BOZ\TMU*XS)/:2:Q<_S*I=?97')[]T R;N@1>OD<G7YADJ0Y
M/(E^H?UZ.U,YA0-K>F>\K2!GE.K/LUMN745/_ V;%17I=2H[]S%VL>%J9*?(
M]\LJ/97L_J*[_/4&DG<S;D6SWM?51.OEZE]17\@-:RIN(/C'GSI:SS6VN&HA
MXA#7$_WCZY*E_U0_M)A1DE-/\0Q/J.]5OIXLOU*$]\OLKR$,VF]JW-HVUUP[
M6<%$P^DX-A9=U\V*"?]+.WQO\Q,D$Y-[A<3Y.6M&F/>R]V]4ZDH1K5URIV_/
MJAG8YPQ$RL5F*I(" \U5M/ 7@%=668&E_\HOH3]=*;O6^IFVW2 8NL'D5$U0
M?Q5@.[UQLJ[:M/N5KQ^T ;D<6UXC%_H:JO%;_KA-L=ZF6&]3K.]MBG7X<%.L
MKTR9'J18\R3+K!#C^I'EI4Z28#>MQ+/\.&-^'MG]"WH(?<+1UKL_5DQ7P.U@
MN\2WJPO1)G[!L*!9]O:6?U']3[%=_"G\%UD9XCOO+TJ,SK==XRG%9117J8)?
M]3!])*9XV!/-&UJJ=*!9:W=^8\'XQED%6O\#G 3VHHTIY&-&3J^,^34<'0TD
M6OM@-YY(SE.23\30J<ABT^="TOKH''??OX,->)'SU/C/&^-?Q4(.H=/1INU-
M1E:&H(1::5UBF5US>H-P/!5+"LH %<_(*4P.8%C]&2^Y:.)ROVRN_ZX*8\GF
M=]K#F,"OP'XZA,;3?D5]HO9$K'(W7?8@>Y<JA\TL>%TJ']NTI8"U1A-V,.E?
MXSI>;A_;-0@8^J@H?*.!882[;<^4[06O77#?%A7-.K9G-7I6).&T[A2M ,=9
MB9QZ 8KFK=A^944]#\?<I<?;P[WD</M-CG2W:U\'M ;F+GV^&U4D.@7N%76Z
M*I8]-1-.UC] ?7OJ.<]&1$^K>;O &<;D&4XG:ELHM;^A9!3]89@MU"CIQ,L+
M&34;IZ&.<H378=S-?L#J="H]"D*_=EX=K2\/[.&4JZ8JK?=@^&KAWUY_T],Q
M*2P% [UT)$(P\LI"RY;9Z:V6J2_FE"I-I4SH%M('!6ZXB?:)1KV:J:2<D<97
M&W3(Z/+'5J%M1*?$OG(1K+QAI<+%A'ZC5@,-&S>)[[]3A"^[F\J.AHNJ69H=
MX8FU]LK.6"\9Q*CF99&L+MO5CO&J32>_Y(S%RN6KU6='MC\97&IO;VH9;;=4
M&3&&S5%/+E57T5(CUE?<^\BP,ZP\1"-CW"R0'L-^*KS6;&QC"KP(47QC<KMB
MGUX,MEF!$4D=QW@S[>:A(H5@6UY8#*65U=7)1<GQ&,6GVP%KL/C+'<_MZ BP
MJ%Z"_$K1@RJL(?G/)UJ4%G&>=A#]J@-)36*(\<A\A UU&_(U]##U\Q_O)\:;
M-WM=:DG7 U4>$S51E6U2X5B6,MZ+![U:<FU(A;80BN-(DA\%O/*JUUO_:PWW
M>PWS>SWCY5PS;%_?"RQM[EFE;UE-8\,%:&>*S"N3Q;1V>=2';\FHO*=-7E*Z
M,E93M;I.=/T66B-E%#=;GT[4?1HF,>/9JK5I+\5P--ENZ/#O!7[[/?ZHR&NM
MTY52U9CEU_JSVTYY2[U 6!_20"I?%/FMC=W^K@Z?+D_MB,?<=J+$2](D"L(4
M6(V[@>5Z0>!3<:(%TL<RU0_;#I^WE/'L';QX^>53'N96G :VZ45V:GJA'9AQ
M[ODFS\/$<9,DR1W_T3/7VU0#TG;X' D6C]&I9H@-L^TT!<^,$I1:-W6QEX;1
M/5IUA>SZ,B*'U;Q9R&Q;\NMT$^-S8TNM#Y9:CU/[DY6Z>>KXS/3M.#2]V&9F
MY,26:=MVSN/$\8+(NP:U3FB8DD:*&T&+;@IK+;]%E^]^GG*A3#P%"P7A7?2;
MSJ[SB/AV3\/U%*=0<I?64*DOMQG%:V *N\5*Y7NLMZ95JEOUB"Z:0?:O3$!S
M[WVV#\4$NW:(RO>J(9+U4^ER([28_MX4$[5!X;:6^'%K7+]& P&/3]?6_RHP
M4TCUP-!?>(UFNZ-_V5/@;:^;P3GBT;_BR^3A[_OM <N\WMM_LBD;4N0QPB<D
MI)3TJ&^I??K;#E>BDQ308<Z*F?238W+]3$]JE$T]ZZ(Y;=I@O*+8G(-PXRUD
M;4VG52,R4]DL%2:'S'DV7A_]Z_#]T:'\W/M;FN+GA=>)(&T<X^=%]W:.GXB?
M/V=P:6^K<[2*B1:WI_H#3O7]M#H70S3D3X^9,DV'@P>=)W+6 S]MKA@H<6D'
M=618D9U%14>K^1R_V((B6?!T4H.$RIHN.9^@?ZOIJ#B+K/N$U367(T4XGR]$
MXI"H9*/TH:ZQNFJ"3?)$%Q/]ONR7YN6V>UA3NJWOL!0!K5F58A?E"ZEGE0F#
M:^C^I:'(M9. 8Z?*(&'G/:_A8,D140ZSD652(\A'OI3;:VNR.O@I,JFED!Q=
MH5Y88:O6&HS<DL*;04I7 E7M7-??*.RT[I95IW=4_>0O)"JHDL]M918"@]YG
MC&S5^IS?'+\!_B]/Z]5BF5YT2>SXI=:_*S*!R5@5A1F,-C9#U-1,J;8V$0EL
M1##CC^[VHVQ-F?-'P(4>B=8FG'RORE"C,?DJ7!:VEA;=3 ;A-WR0G.+9W7]_
M]VMD)@Y+]-K!^P8=5:\/'%"IC/WZN?6TMW:DRY@]L[X2D;[+M9XCHFB/E."L
MU_R*VO9G<P"#@#G0I:J5OB@RP-0YW#];BO*RAD;-4S;#.;L8V%"V@ $M_'DK
MI^W04O^J"^&#0!D+7%$7XUG$?0YG33LV:),4Z-B;/-PBQ*&//5 $@O9;)7A$
M//(:ZQMQE?>VV*:&#CZHO"^7[4VS$ZZQDH$G_*&@YC4G4Z\;N*@C[.42#YV+
MY'9K79)K%6#M;*;9A73BRJK?IIJ). _"O-7<6 A TGISDPN53CLO&KA&H Z0
MT"J;-L$449%+F_-N=&_[[;:K#WU-Y(*FK$Z+L@(3O!]V:!)0.E73DU5CVP=6
MDJ&E/=UN:&-85M\N7,N;5DG]:LRPR#203+;V:*5Y43-+6=-_?B_C59,Y)%3T
M(1D2!X!.8[CA9B1!NWN5KMC;G3"4O]0Y 8TA-;A!SYP9)E^K@),,D(!,DJ4,
M.%BKUP6*S(6JU9>^J#2][Y$3XI]75;V\,*E(Y&J?KBA_UT>VB*E?(R,E1IUD
M>@!D,]OL@+%KT% #+$:?K#FF$0PNJ#B-6@6H;EAXRYN[-.Z %7S6UL;3/J3;
M661D[7=;.,,\*5%"HR)EW9R/KA&5UD*J3VJX,K$7S,YNOPF'TLX7WC:@WF9'
M;[.C'W)V=/1PLZ.OS'8>-J".O3BUX=-NFGA!%L8XR"[B<90Y86C'UATUH"91
M,1Q!+IM*#.+7^$\5;R'M!!O,"RR'+Y@84*EZ<#3KHAR5C)8K?"&CR-CRI6LI
M*-*%JT9IF >A^[7D)8S_JPZ9;WL=%EOW[>NW^WK2]"5Z\UNSIZD9XL9Y6UI%
M.RRE\_U@YS6<7479VS*78%HL5-:IV,P%6/LESPNL;RN!^[!^[TSZ!E2;&FJU
M(6T):A9B!6T<3B!W%:/#+! "?AT:UI<T:%'9X9KCJ6I>03A5 A"LD:W*DG>U
M8\)KI&.J;J36,,5W%'M@6Q\=>Q2EM$RU@FE9.7_/";6;%#53>2I7ST5^JTRH
M-V]E5QC,*)<>^VU*^249QU=GE+?3JK^I!*"K/-3M;316<W/&$D[<(@U!M#'!
M+OG7_I\M"TV,M^]>?MQ_?[Q[2QY^_QKGM=G!/X(P[XE_7UPS\LC^X?'+-R\/
M]UYN3_#F)RC3BW"8XVF1GB8L/=4SV$8DN?3H:"1-_47[.F%L*KJ0^(WTQ.M]
M(&2/,56V38XH81AKL^C)PATMJ^D<A[*;)'HV1),^6!7Z9K7D2)6?K+2,YE,<
MB]5T$TLO<2?>#['[@JU@:<L[Y4>90"QTE'+&R^1UO?1#_6K-E:]NLFUO(MJS
MJ8HOD8-TSS7\&A0-.RCZO$ ?[;2%H,^_%X*.E];I>;UK"J\/Q+38C4"2JODA
M=LDK&HR?-6K:: O$L(O-E*_FP$JSZD1$C4X8:,6*K!+QRZ[3.#F@01&G4VK;
M]^[EP?[>[HL[$]B7QK3OK\ 6KB3 (._W#]X>'>X;N^_V[PPV/.0S[$?@5+_!
MZ_!56RX*C-O6>U(2_JQJJQ@&C>!Q3C":U>AF'WW33>M,VU*/>P3\Z5SO%O@+
M]EB3=NE8[$::3S((TWK4J=)F].(OK>F]5X6,]^8F6C#6X[6^=3^(E'5QN9%
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M4F,7$.*J) WSJJCG&\# ?4$*M+5CH7V?5Z!><8,OBAHT:54+[?-^"FIQ6LU
M[#7XU]?5M&P 3OP/FR^>JG_=DVW2$W\KED OZ37N]&@!<!!5<R7T]ZNB!$!0
MH)I? N20RA;.8!\)#]7K'CRSKF9"Q7<?%\0!=WX/;M2!C?W%C2D[ ZV_ F#
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M=FUXN@+QC.@?(QRM?F2+!2R>O&7U:B8=[+#+U:R/:-YWW\=/O/R23EEYPG6
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MC1K;$DV!>%FPNI4NH_J&_!9?Y 86JWH!\GL4Q8PX'$8EY8[Q72>D$C^$(EF
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M&F@$X%EK(0XFN'A@(-/)U+1G%,Z38>;)=GY0M!(GML>L!9]&!L[MGYWKHMP
MY0SXG1CZ(A"@ZS2FVQC&[!]$XP8)?MVAQ=".#XS0$<ZOQO>OVW5@O<);'=M_
M&!-T[W M>&AB6X9G,_J-H(<7P#=P:O#\\"@;Q.RP!I@,9D[M\W>YONFYP8$'
M%C%:>2CF\9!1]#)[:1%(?*=A^92]--@+>QC>QG=\)!\EA:+TQ:C )L%Y2AD8
M/TA4[$#Y3%DC,6D$['O/*.),\P)A&1FPGUU:?$*R,N"@C7!T.>._!R24 IK?
M4],8<8)Q@Q'8L*7( >,GZ<Y HTY<9E\@-8Q]  :)T/8=>*RP8(MX5!];@)*'
M&??C@ "X%^'ZTRG0)D@T@U,2IV<Z-_X9L;J4D36UQOA'_"JC5OPVJGN/C2VW
MG[R- \7G;,)&Q\/VJ?.(9KRN3;6!80(N0KAB$,>^Q:'%S3#[*<*=P<6<P4"?
MPGZY=X+',5<%0Y -.@K!&4KD)ZK]8'RTK[;!WK<+K_46-[<8=4")C  ^&:89
M,3UWI4(V=CT0-A.DLE<9?+Z=<)?4>C0<V\+#V2-P6,M!X/!#>@*'-4EE O/V
M_E.[1SK=F]O>U^9]Y[9[<F?M./'IEX#8E,5-2)K5BA*GS5,26$OB^==8OH'T
MVA^;O6M,2< 9MSL?N^3SMUZG?]UIX7'WR?VGYCVYZ[7_;'?O@1#Z=VW^AW03
M EGXYU#IB4HI@919*6<XD4RY:_;N.?5W.IW=05:S+UCE4GH$:R/('5YW>L!(
MM[U^@;3_;K>^W7?^;)/;FYM.J]WC>9K6;>_NMM>\;Y./MW^V>Y@JW)P=C!'=
M=]\%\V&6,@F\LO-T;>_ 03!F!8$KX[MN8/O@)TT??#>TJR:&YU$:\\W!FF2O
M#:)1G&HETC:#*  L< T>OPXNEDN*Y(,-AN9\(3<(0[V/PF21M[SR"C?1.\*X
M%JP'!ODH)CP+X??[GJW_(+=/%G7<L3%EK^X'2\E59CV:!C/)F8$*BUU3.(^?
M/@;6@@>#H$7U0KL,8D/N/*+&=GWGV,\STO< 'C00DT 8;G E/!\YH#RL!PZQ
M%WO;G>9X@;C<-G:73IMG72JO98,'!]!]\%V#N1(MVQKZ&,)Y&AOZF ?Z74R2
MQ((A%_.4#?,+-B4_-J0SV)$% 4&3.I<%,J'4<X,\%(MD<<<L.)U^NQ7DUL#C
M T_T@3$:/^8%NBF7JM%W-&>@ 4#%VV>3SEB$"_ZBE$I*&+-8#S=+:#UJALG"
M)/9ZO^J)#EP,'&D>.;(:V3(B^_3T)'VWODNZ/;G2 <*B/2H. @B+.H?PE$&&
M0I @G!I!BGB.:G3"YZ-:W"@?"@Z]\P"2<8JA3P>E&P]W4M<+Y2K0@$,]#,H&
MH:SE\UJ74^2Y0_##F^#1NOX O76>; 3:&[([/5'N<@.IL.C6C#QI!KK54;Q@
MB"$$6(QG/T6MIZCU%+6>&:KUK&]?ZYF:JLW3V1POV@'S/Z[: D'0=VX.\+#B
M@!(0;UY8QI Q'6Q8CZ"?;"=2Q@_VHZ2/)J?4O6%-TPB/)C0*R!"HDUSPM).G
M&=8<X2&"T>,!))M4<S%53PEF 2XS:@)WK"A?MB:F/;2G+-6U4>4'2['.[FW
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MI;7YI\+ZRC6>R;[5/1N=<%ZU5CY@D.]?^Q6O\]NR91'B.SM)P>+XY?+5DGA
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M\U8SVY(;KM&RS5R^B[\\,^PPI'@2A>@CH8LNFMJ1QU B__?(]O 4(Y=I@(=
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M&0OUTM+V;T6L!FVS53@)V5(#28 [VSRWS"D#1ZD7O<72(RN$D@'*;,T4Q"U
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MW,DJ:'E'W(@F5Q!J]L0E"QO[\HY\G3.%"&P/T9:X#R6 &K#_N?\T$O.=A="
MX2&:)1,\-CV5$Z,(6(?[^+L)7-5TX LTP:JS(?YD07QF^>BJC@8U536HJ9%
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MT)'R,E:UWT>JQM74D%M7%[?9[83DF8)*< U$R =\1%X0KQ8R@E>(N2 4YI8
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M#KWV4M!L")?&$JECN>U&%0%\/4LIO?4G,YP.'L7 G>1FI-[!PCH-,QY7(Y0
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MBZF:#X2FZ2IPZ2=HLI[-IBOLSQ>KDFV%^Q]G+V93G+%YGZ3W$L+B \1EMPK
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M/\^0O1C1%OP>SO!A5/3O6-U*N>!R]O2K?WOMR41Q?]BON\8;^G;Q ?516V/
M/Z8XS)A__*&?__IC7]'^*[EUQ6:N!0I?HO#<)1&-L)Q#[^IC*IHEGL$HW?C4
M0=W31I<D#"#B8/;37L9^;WG(O!Z6T?@<%LO UU,\G_3 ":4SO7@HE&1:&\EB
MX,@*81%<&(DIWB5RLE2,"::?SD9??Z;G$)M2_)>N7[+YEW,Z'T PE_-^*_M$
MO]M3P1DT*3&>$C"=M6,>I6<N&%JAL$X[U=E*ZA-O(K_2D6?CY1H6K\J.[U(U
M !JP.!UU(, Y.P3_QQ]&XXSCO_[(NR#RV7!X 8,/^&4TGO9 Y%)T!B:$X$Q;
MPUD [Y@54I3L1512=T;H]2>?$+$["_0NP:(+@M_CN#_*OPSS2S)W>P:L1ZL+
MTZ 4_1$U@U M4N!<A^@*1-,9PS<>?4(4[R[2NQS+3G;C,9"I41>YT+N8O9+2
M \/L:&/10K HN&/)&*^M+5IVN3/?>OH),;V78.^2K?8A^Y?AM#_]]JH_P+<7
M51R]8"(FGSB#Z,B33!%8D-:RH*)Q(:*+6/8F^?933X#<O01YEU2]/ZD?\*P_
MF9*N3=_".?:L%J4H.B9$!E*RD#3A$9%YB5@4;3 9;$?$WGSRR9"[AT#O$FSV
M)_CU,(W&M(',%OEQ2L?&B]'%<#K^]F*4L>>S<-: 8'16&*85'2/!(GGF&3&*
MZ&1 Z(CO>X&<#/W=B?NN-MC]M>$3_/$ZT\K[I3^_&5OL0Z58&WD*S+E(YD3*
MGG8D;EF.SA4A2A!R?\_P7@@GHP%=B/@N]VY_[I_E/,;)9/&?NES10U6$ BV8
M*0F9-H6SJ))GL41'IF4D%R)TQ/N*QY\,Y_N*]B[?OC.^7]"7[\:?1K\/>TB>
M?0D<F/'!,QU-83[H"BEIKHL2.HINV;YZ^*EQO:-8[S(=.F-Z=MR\&[\?C[[V
MAPE[8'5 VE?(8P#20(N"A;KC1% ! 'CA479+]RT$I\;Y/@)><<>RURW:#6#O
M1Y,I#/YO_\O,RA#9&A&+8$*@(EB^>HK2,65E"H7[;"7OEO<;SS\UUG<7[@K.
M][I8JWO.LS'"W)9,R%$ZSXK4G&DI$XNQ.*:+Y. U:"OV/[JO/_$$>-U9@"N8
MW.OZK :F!^\_CX;+BP"N(@^)7 'PI8()EKZRHH;JC0,,.>3]]^K;3ST!1O<2
MY I6][HG^XCI8DPJ1I;\I_YT@#VD(R&HC,QY,OPUZD@J%C-SPIA"=J$W-N_-
MZNVGG@"K>PER!:M[791]&D/-Z?GX[3R.!KWHLTI ((JBK5^+Y)AW2$A<RE#H
M7RJUOPU]XY$GP.?N(EQ!YEZ78DO-^N6/]!F&9SB[I,-Z):=<8CP60_L_$* D
MR(!7V:BDP#CK.GM-KS_Y!*C=6Z K&.[@HNN?.!C\KR%Y9Q\1)G0ZY->3R46]
MA1&EN&15#723R2ZJFV:B9KPH"QB%BZ6K"\\U$$Z \^Y$O(+\#FZZ_G,TN!A.
M83R+M(PG/1U!RI(S,T98IKE-#+)33"EP!IS5T79U[W'KT2=#]CXB74%R!]=;
M+R[&8UKK/#I:#Q=RSB\F/6FYB1)$O7W)3#OA&"CC62"(JN:Y2-$5UZL1G SE
M'0AX!?,=7'>]'DYQ#&G:_XHO80H+G+W$M:/5N7KHD.5ON*)#1QDF"T](:[?D
M 706RUJ%X&28[T# *])-.KCNFFT^+V"*9Z/QMU[*-@@C)./D = B96;1.\[0
M95NX]=[)KNXW;SSX9'C>79PKZ-WK9FN.YY=S')_13O.W\>CWZ><7H_,O,/S6
M4^A 19V8%.3V:1TB U)$YFQ KU!!CETEFZP$<#)T[R_>%;3O=0TVQ_7Q' :#
MYQ<36N:$ULCY[)J&*6_)=Y \LQ"R8 #:IYR=]K#_G<F*!Y\,S;N+<P6]>]V'
MO4YE_.PB]^DWGDVG.)G.UOEJ &>]R*4KI@9,0B'[T:BJ=4(QM#%8)QWPL'^B
MT?KGGP#9'0EW!><=I)5]_$S.X>4.(WV0')&YI,@A#!)9H"4RJ:(J2"9%S/OG
M=M]][@EPO*<P5W#;04;9^XLXZ*=7@Q%,>T4ZJ3VWC':9PK0GZR%:KYD&1Q9#
M0L>][XC::X\]&69W%>4*8CNX,R,5.Z]):Z/TV\?/,,;)NXMI+;^L5[<]'T4$
M],BLQL!TL9;%FM>85# HHY<0][\C?1C'R5#?F;!7Z$('5V@O:-5C&+P>9OSC
M?^&WGM$BD7M $$I2M.U 8C$YPS!KSI,3CNNN[DUO/?IT&-]#I"M(WNL*;>'2
MO^I/$@S^#\)X65*"Y.I)HRT+:&GO$8&,".DERSE)Z0U9%65_NVS=TT^ ZDX$
MNX+MO:[-EBN]0O6*?C+I%>-T1IGHR$%7 W&!A7KXR()HN+;.F16%O3O6ZMQZ
M^ EPW8585U3J=%)<.<<T+Q>;HQ*&"\AD.*(JN:)*#*0 AE@A><Z#ZZ[^[L[C
M3X[N746[@O"];LZ>$:0\@U4]O\Q%1*<5LUS2F>)!,2C 6=!:2F=5#GK_U+\;
MCSP!8G<7X0HR.ZFJO+:\3Q 'V".G/:5"!J'PEK84DS*='D"^@BRF:.3<B/W]
MK'5/[Y#B:]U.#OC&[B7.5<71/\S[6/PE#483S'_]<3J^P*L?CH93_&/ZRP#K
ML__ZXP3/SN]$AS;7BXL).P/XTILE']</>C& R>1=F;D.S_[H3WID.69;I&5@
M-:W&NL2""=5O"$5;LBN@W'>_4F 29V0MGC33D)]Q,)TL?S)3%,;%HNG-_W@0
M4H<:<T\OF@<U: >R1RV$WF%]_1+8=3PO9_OF1HAZMYKC=*H.=S%U>3BLZ^]S
MI04=DS9J(O'#Z$+R5H,1D7'G#2'CA?GB%(M%\1!HOPSW-EMX_#IPHV?2$55@
M&T&WH/[J%NG7F=G4TY!DS!@8+[4QA#>$A;P1\D4D&:)<*+BWZ&</YF]#.9QE
MV!4_M^G>2[@==LWYU_!?O6?\)VOXV]$4)R\OD#C0"TQ193!)969X#?:@1N8S
M:E:X#3(JI3BDFX3?Z8-UW^<_618[$UJ'K^T,D_EI):3D0/%H98W7::8CDIF2
M)+"4LL\^>&M\V83'U1__M&GL0&0=]K^901(_B1N8_.4686R43C(1(M : S)P
MLD;J3 GH3-#9;4+CFL]_VCQV(;0.>]LL,-W8(I198/(A>AFB8"*FVC?5D\F@
M:,?P&F60!:,49C,B5W[^4R=R?Z&M[6?S[S_?DLD;^G:GUI##R6C0S[79[J5!
M.!F57_[KHC_]=A/&AOTB[_W ?9M(;H[V5F?)R&T!88.P3FACO0<4W"N94HS<
M.-U[X+,[NIBXNK!): TH'9A1,],:@ 4>(B,=$#D5J4#<%RSNX$;B$LO^UR[T
MNGP>#4A!)W-QO1ZFP44-T[ZO>='TQDZGXWZ\F-;+AD^CMZ-AO0 B2ND3SV:9
MM#B9]D"352&U9\$C&1RQ2 9:288F:>^M1V[NRVK;1R)=X#_\;K6G5MV]R#DX
MC1TZ ,M5O,5I;3!TCF]&DTE-\RHB>DZ[:_9D ]'Y&9.EKZ#DK)5+)K71J1LP
MGKQJ["[4!@[]R_[7?J:]?7+-^7P!D\\]0ZY)M)P\%HS5UJTY?8;8D9%,*K#>
MZ="&['6(GCSOG8BZ0[=BB>M9_M?%9#H[H3^-GN4\DRH,WD,_OQZ^@"_]*0QF
M*4.U'WVN>8$XG,"\4R3M;)/^%#_B^&L_X3Q&^0'3Z&S.S7_"X )[$0LX70K#
M0"ZOUB2Y@&0$EJREI(6C%_<EU.^N2JU7]N15\E%1WZ&CM5S?IS'"Y&+\;?:N
MS1 ]2X1[7-<RF?Z*T\^CW#-"9%3*,6\K1E?KALFL93)EJ4$7Y_A]*4B[J^<F
MZ)Z\BG5.08=M2=<;:^^FG\F[E!$E'<*6B5!;JD5#UE>6D0FE"6AT0LDV48TU
M@)Z\,G0AZ Z[EBYAS4#4W6V,GVO YRM>&6ADK;TKG^"/'KFZ&8RE4SIF8%IX
MS8*+M&[CC%5%1G-O(X[=E6$3=$]>,SJGH,-VIAW[="[(Y+DJ+.="FUU2G'PZ
MJ\G<"]$%(VTPZ4"[ROZN^1[7-_-L"9*%E^ %PUBE$9UAP8)D7@4-2H:,_+ZV
M8AU<W1PDYZC9AKJS,!]=GM%<)>L>,!I6BW06/K=*.&V,93[7F_I@:].TX)D!
MHU"B$=&UNL>Z!]:A\XVZH'N=YNPM]@:W$K<P+:('FX!JFG"T$M:1<X[VIV_4
M2O8'4PQ#>Z:!4)CT69%= )%!(*Q1.OH(8;*Y-POY22C$I@E(!]*';43>0 \^
MX)108/X%QD.R32;+- MP-3DWL^S(JM*!K,2@8F+"F9P4^JC3?04FNRO":CR'
MM\H[(&O4N:0;!":>I71Q?C&H\<5UGL,":!#HHN#(>)2^KKW0&2D-4Z'4XD9!
M!V8;:WMCB*>@)6WX.$@"8P 50TF!\5 $TRHA \4S^61HLM1<HKVOTO1))S!V
MKPC[R;=!=./&_>,2DI1&*B<8I*J#4&-N7D&=EX I*M)'U<;G7 'F%$C?5\9K
M;_Z[RLSY>'%^#N-OH_*Q?S:<#4H93FG+JI-R9I<?@W[JX^0MC.L<G:_XLIYY
M@\D.&3L[/FB_3)XN5G=W=JQ/T@(7,>@ T4>ALI#&!,V33;*WXS-WSYM[,1JF
M64%[%<V[\F*,N3_]T)_\=G618EQR)M8&Z\*KVL4@,2]$KM,*4^(Q<>?L _QM
M]J1]\O_F;</?E5](FT;?$">_#,_@#&N\;=YQY5GM@T<*@)-_CL:#_'L_8X][
M"S;:P&*IQ=P^\YHDH%FQJGC!N;"WKPQ7KFR79Q]N?VK \O4<PN:";Y%_L\ \
M[XE9[WP^SB_=:MY(I/VT9C[JH.LL$&0QJ\B"#P )0*)ND_*V'M-)J$K'HN\X
MF?]7$NGYQ?F+T:#:VF,8S"*J,('W.$ZSYJE?<3RA0_'+Q3A]A@D^.QOC[%Z@
ME[A5%K1G8&OPA%270=9UC*L@JE(0$.0&>\CN"$Y"/0Y(0@-C^/UX] 7'TV_O
M!_6X'N9J"GZIP/XQP7(Q>-,OV),\<T!-]GHN=;I4-,PGE(S[8'T.P>I&U;T;
M@#L)%6I%1M>%"BF-+S!_P$A*/OF TXOQ<$(P"?;YJ$J$5I_)8X\&6/;*,)V5
M8@!HF$BN2"",NL0-MI2'GW02O#<0:H>Y,!7=1Q@L07W "8Z_8B\DLGQ,4"PD
M2QM6(N\]V#IR3&OGM1/D&L(&%-_]Y).A=$^A=9C.4M&0(I7^M&9-+ ZC3Z,9
MP![RR(/+FH5H:%'%:^;)QV-&F9*C%]Z&3<K]UGW^R=#9B0 ;))_4;+EWY6^C
M4:[[Q2+K<O)Q-,@][8H) 2U+H3HI2I,]JH%L#,RU/(K+Z%O=8*[#=!+JT+'H
M.QRR.]MW/O>_?.F3#SO,?Z?_IU\YJT G5W;HJ,PU-X'W49"J"A%IQ4;7^4?%
ML6R44H"!E]NM-%?OX9L^\"3(;R?B#H?O7F;/D2$)]>+M#;DA^*%_]ID4ELS(
M9Y,)3B]#P^_*J_X0AJD/@_>CR8R27^JUWZ1/WNV;_F3:\UJKX- S,C1J?28J
M%J6-+)<D(EBI.-S7]FF/',=N%G 2FG=,4CL<%[QZ&6_Z$/N#JVDO6ZS#>(ZE
MCO:R)@NF9006LQ:L6"Y!DWS-O3/CNU+.W5=PPMIY(%J['&K\P$)J\NO6:\E:
M"BYL9BG'R#3:P#QJ0PI%/Q8U@.+;W)UTN(@_@Y8V)[?+2<P;G0<]:8*)5FJ6
M3+!UNK @G],#L]YY89.S*K6):=\+ZX25:1\"NASO_("J]VA% F(DOU7$.FS:
M%/).Z ^506NI72JI37+D&D GK!*[";W+J="K<56GI9?)T),U3\_H3) R&821
MO!;FK>%:I9@=;Y,;>1?+":O UJ+N<GKT:DCOX=L\;LD52,NS9\;2 C66Q"#0
M>48>@?(A)EIQFU3(U7A.6 MV$GF7HZ?OK+BN]!.1.JGU7XO+"SC#GN')2V<\
MXTG6(7Q1TII!,@=*)^368+QU.CR<,[/F62?!=Q/!=CF2^JJT_RN.I_T)J>0O
M?]2R?>S)(A*OK0>-#J[.T%75TY(LVYP\N5Q8?!L'^BZ6D]"%CD3=Y4SJRQS/
M4G V3W6>>_T)_OA ?DYMST >SJ /\V+/5YAK^L)LT"Y]WK<;O]R#XG2.P)G3
MM?>0H+W+:T!F(02P($-I=%QT /ZD].O09'8Y/[N*AS"\N)C6V,G_-XJ39XF\
M)CH]W#^&F=SJ6;TQYE>C,?;/ALLJD]H7AWZ__J>F17R%P:Q'R7PQBUVVYXVN
M;>@R&5?)U0&RBCPN$9BRQ3CG4Y*W6Q2M/+L:P3L)%7PL]'4YV'O'-<WJ6CY]
MAN%&BY.FV& 5,&F%83HF$G;R@H62?/"E'@^JC6YNA?//K*3M".UR&/D]BYOM
M\%\&.,5KF??CT=?^9-;%Z>HVPD0I X;"; Z1:9=B?><\(Y]$<<O!H]\D +PG
MC%/7M29T=#GXO /L5Q?G/=(,Y\FR958723+3F?E:[^.#B)+L6V]PC]-W>T#?
MU6LOBKH<M;XT7*],T!NVZ@?\ K0G+T1W:U?N!1MXD"(RZSG4,(MAT=![$@!\
MBDJ(<.^(W]W=CEW0GH32'8RN+N>]WRN/>7N4FD;+LPQ,1*S)]D[3/FLBDY *
MZA*-U'J#'>K^I[1N''3(NZS]1/CH&@H]OYB0?":39>'.?!X/5P:T<,R(VFK.
M"=H.4\XLE2!=\K:68S397NZ%=>B&0EU3OZZYT-X4-&@!L,"RG*FU 9BF385N
MP#ER,Z']Z;JM"'O+NKT"D!4>E%8L<4U&DK>< 1)3!-6GY&/DV&: U0&(W[1I
M4&O>MQ!QQP63[S_#^!P27DS["0:+W@36*Y#.9G+>?:YS?#B+F!,CG&2U<%F\
MWJ2<>M5G'Z$1Y^ZB'G4HIPZKGR?C:2W#R!?D^HP7Z?8SC<P\1J%<8I%G6ZNQ
MR=843I%[HY3@J*UQ&P6PZ '77E/Z[O8KN@[!B1S3G0BXP_+4:WBN5U@L5'H3
M4-N<T-NP?Q?.84_H;IBZ2WM'8NYPL[X?'*A0,'K/DI6%Z5!F/7/I:.+61$_^
MII4;-5]^C-RO.:0/2/TVTFUACRW*;)Y=E=DLY[0IKFA]F38W[LB7E70 >3-K
M%E8[S'$7?:-6R>L@'>Y\[Y"RV\99)_)NT.[D3F+-\V_/<9@^G\-X/DQ7<Z4B
M!\Y\%($1VL! .,$2RA(+JFQMFUS6AY"=B&'0A(@&<SWNXENB6[P>F^!K.YO\
M 83'<?2[Y?5!I>F E"8M(!_ 64<8<B_(TU6U28L.G@4C,RM8,E@4PL0VI\YQ
ME.:!2X+CZLPV7#3I,SQ!^L":'O 2O^)@-&O0LLCR6QR:*)4,'A+#*,D>,X(D
M(>HT+YZ .U3D0+>IO-D W!&FOG;*Z)UFQ-W2T?&EQ0<8GLUM=#1"Z0*& 41#
MYIF3+(A"YED*!K+Q(8>-)@=MY*]</O9$K)#=1=EA/YQ+$$NUV@!&Y[<0UP <
M_MYA1PIND[B'_#J^7K@.1V$VI'Z<A5)+=(H#TLM \N?9QQ233)L5DS\.&N^Y
M0NB6Q6W$UC%[BZY["R EABAY4:P&*9A.4;&@+&<V(R3);2AFHYF2&_%WX]&'
MO0'86?BC+B37\?GX*_QQ#8B/5KFB$TMD$A 0DUB0 (P.ZU14] DW&^VS&877
M'_T$*=Q9<@V,XK6-"Y]_^T0?,=ML:(T)C!5,*%4;XA3)(E>.858*>>9:VC9S
MFS8 =R)F4BLZ&@Q87 NQ ESX!9M ;'IELP'(X]S:=$[PI@JT)SN'W'JN0;7>
M69"VL 0!F9:\]NS&6F8BG4_99=.HT/UH"O3 #<YCT)]M2&D18AJ5Z>\PQFNW
M!HNS%%";+))@40I>$R;J3%'TK.3D M?<)]%HP. Z2(>_L^F<P-L!ITZD?YB
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MSL$,9-G*[.B/)&1*!CFTJ959 ^C069S'4XP[^1+[$]3 %%L%JWXYQF5X=Q.
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M-IT#0V^%I8TSNEHT1?MHTH+E+!R4)#%P>^CC_=BE(ZW59(^*_FWH>@3%U9O
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MQD:CN&D3 GM:6OU0G/V)*?46I#=0YKGA^;$N@JBY+&1 C$5F;EE)FD25C68
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M87Z)7W$P^E)7_,L?7VA37&8T\LBM JCCW5"3QYDX R2/,W-(6GEG0;4)S6P
M[I24HVLN.KRYJOFPR[CQ7  +6&]QF4; 5=(Y"R)1!O(=94[,)Y583*(H+)X#
M=S>U9&4.\OU/.06Z.Y9EAW<\%=ER,.TJ6)F82H)VJ$I:'7KM6,RTY)1$4-(I
MS[/>@.)['G$J_'8EQ09#?N]-78P%8E%>LA)J#K3V@0$=1XQ;[8(2(J-ITU#A
M<2>(/^JKB,X(;=)[[KXDI@VP?<\]WY'+K?**=R#BT+GG4G/TW@@F,-:BK^@8
ME"R9@#IO+=@4H<W4LJ>5>]Y,1[:1_^&R1*,VW"$&IG/MTVLM[9M.$"KI@Y<6
M<]%MNB8_B2S1K3C;+$MT&X$?,<U<954LEW24\MIGOEA:.8%E0F6I.-G/F+^G
MF7>C*"TH.7CQ2E$R6^\*R\X7VC9M8;Z(6@IHJD7NHH8V]=E/J7AE'RWI3OQ-
MK=1-#?W960O6DP8K9%'7*=@)!/,ZD:LN(3C0PFCE#N8L/8SWNQNUM1O5L1(T
M2,=9 6OQMFX"K*EWM1;:XW&MNN9WU)*<!H?B>H#%F,)%C,R(6&KJ.K#@N&$V
M>VVEY2F6-H;U@;5F!U_K:$JS#2<M^Q,N$"[.[J2T*CXI9I2PM?"4/$Z#EB5;
M/'HI(H^-3*>5> YO,W5$V+K&@+M+NX7_=2UA]1HH#DYK0,:AD+I'GEBTF;.D
M#!F&14NPC6+%J^"<B@;L+^OC3%!;#MF]7E(XJX\B"+D_)--_,AKT,YEV^3D,
M8)CPXV?$Z:3K&LX]8;0H\.Q2,K>J/TU, !' V!)TLBH('ZV+F?:+G*6$-=6?
M>R(Z2&DH& VYR,2"D('ID"1YAR[7'F#>0C'"N=8#X0Y3&GI)T;MK=+SI0^P/
M^M-O/:=K(ZND&=>&7GT/D?G@ XL)#09KN IM+K4V1?AHZS>VT:#U?F&']#0X
MFF<U)/D2S@W[X=ITJMOE?#W!T6GO! M%UN%F2(A-%17G+@D=C"MM#N\= 9^D
MDAV"O*81N^97.T5F&] 6!K:.KD9AF(<L6 D\.O \ZO*]&*C38J!N-LU'I1B/
MI1CHNBUU(X\<-)@8@B+T&)G.RK$HM651"Z5X"&3=Z29:O@[1G^#2>"L%&C4@
MLL'&O K7\NIQ V1-[X778SO.Q7 W'&Z@&'L0<%@5J<$2B'6P9$BUQ#B*.DO
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M*Q.UH[-4*?+$'+!(4&C-3CFTV>O0QMU9 ^B[N=(Y;0W: :R"5;\<XV6 9@.
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M=)(PX63RKEQ-1OF*XQ<P'G_K#\\N1Z6090P5B@RU::JHX4];)\49 LIES,(
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M93_J5G =!A=FD.1/>A4D#V ]Q,R\<&3XR*P9"-)>J>@@(UU61NM-N%S]\:?
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M96*]39LZQ>8W/_XXE+FSX#9<<=@M2B3_8J]C6CO'- B>:SYWM;9!R>C 1Z>
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MNRNLQR.ZS9'X*US;A^ #8\I[9H%V_]I.1=?T?4GNE'<<A?<>U:W[$QW/5'8
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MITV.:=_HVB6:-I7CK6Q3HA!*';DM@M8FR7SP*82@E'>)(V,/9IOV#72(E-/
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MJR6C,:(D1V:7]@64=!ZJKPZAQ))Y-DFF1B?&FP$=F771@]0;N+H;8%U,A"[
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MB,L^D201(3@5+>M\=G@8/&TKG14L]8I__,-/8#@;+PLJ&<$4VJ7X,LM$)(^
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MK[!.-6X:W-V^VQ2B"YCONX/41G0]VDEH&UDW[R#EM&>.,TYRFE>6UI0XDX%
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M]VH 7P4&E @5*9$A%HN?E3L(,FJP69M6E777@SH\!:G%0/L ^T\>11#A_!-
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MCF*<7$%Z^( V[\+:I^V^V>>3#-[7L2=%M>EZO_BX? E^"O_G?_U_4$L#!!0
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M2=MD;;1ZMJ^60ZSM1(;1ZM?$&CUNA:2K/OG'>:6B.PC44^IK'&0H)8+,M3H
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M$E"RI'M4B3DKJI)X"9S(4:OSLE4WC!AR?798^A+/TU]!+1Q[%^[< L[=,'8
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ME3PQ,#]:<Y\\%N'#]KFQ+DV]]$]LQ!T>Z'./BJ*]Q5=Y='P0),YV%,E''5S
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M!*#QTJ^ MVN="X$"J 3?-?_Q(L5LG'B<C7[<V@1)_*PPO9B0Q8C%3B#<!UD
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MCSM)HGL@XW!!DON9&[OE@6BJPT+HGFQ;HU]W3N2DM#I3:<\)[K7DE8S!Y;,
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MUGW]E^_P_;)),<^WGM61GX5*OG8UND#?+(@9J'55ZKOUBIOHR(W;6*\W=W;
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M$M6&K[JS73V>*4,:#$WJNK_/K#[X]GVF!,^]X$D3DX !G2U,.VI<G7*-VD!
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M_&T+UFQB)2ZP;SOZ8Z=DQ5Y78++$>_[IB*UT3^B>L?UP1%;!A:B4>TB>:9=
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M51)3^ASUXRG5S5#9URE;<SV$FQWN144X@,PX^9G$.M.W84SD-=<2!&>(SJS
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M.5C6>,+3DU\+#WAE2STIW?(@*M<:4\#>S'G,+X,'D:BE%&35R"**@8,"5HY
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M?,O\.WV!(EH9T9PH^&8UIB^CGPZG7C'U4HEY.&J62"-"C;L&NH:2RTK>@B%
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MC5;*WLS9W)A63TE)YJ6ZP>T.E'] #1BN/R5_H89?](M^T2_Z1;_H?SK) VZ
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M8900DJE;22#[>O;!W0 Y0\6'WNO16T)]-OV( #C_N0Z"!ZKX&CHER@5E)[[
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MKO]J)MIL([VR+D:8((&N-\3DG1#[+HV4ETVSU/T&V,[A6 ^[^H95U7<R_,?
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M]<3I;X',><WFJ8,$M-HSE&NY"W%C_F"U "-U_N \P0J<?)W'DXYL4G6J)_H
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MC;MG35)5!14WXAW[ZO-ZED^0C@,)T=/22R^(';M);76((&TPJCRA$I&:9#N
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M<'&F>;2A_WJV>J]V>!YG0D.:0VE4R^3K5XW9LD(IIS1$A0\C!B#IB %\.,(
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M%87&9D&J8 #W]G]_/ VC0]U51OP]:Y-PG@S]D12(Q$M;ED$QUG->WWH!05
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M9X17=U#,"0JVDFR)WX<6^T .80>="S2/%3)UD;XO:->6S>XN9Q.1=RUQ2[
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MD6_<YM']$DMT9^VXK>OB$ZWA5"S>$%)X>)ZY2=U\I&/RZ7I\8\TQ&*%\RJ:
M:E$]C=NKSC3'7_N\Y6@OC!.I/<NZ[?4(S&I/OAE_&3HSZ,H0_TV" [^RQ?)8
M&>%YY=,T Z>J2&7C7(8'-]XY VGKLXROU5;[#K<,?*?Y)$C_D.*C('8XO,I)
M6-Y&&/*+!@BJ;XX\N\W5^S26KTC1GI[[8R^KV3&W<PJR9_/YUF .S(^AHB;M
M@C;<1R.S-!A8IKL5L 7AO$MVA!JP[#_FJO #!@F=%9XEG$V5ZV47!;ZVY8Q]
M#I,@^.!PGUR4<*PVQ;D]UCIA,!^T4#BKF,>^5YUJ) Y>> G+')B/J&OK6IBW
M4<;UR&9HJ!B-;[]^" X+T^;#$E^OK0LF^]KH+=TJ^^537;WIK:]V)]X80#O$
MT$%\QQX)V3D0X_AW4;C6 S@&$"!L&'G [OK8USO+IKJ+EPS*;>L>8D;TGK'Y
M7E_:\GL!P;;]O/QG;94(N^A<)#Z*,;>;N20>&J-K(M ?\.6E1>_P@ )7+XVR
M?.N4'Z%5XHU;XU)Z3]]&N%+8(J&F_Z4B96.#)/8 \SW!7E&L0??*=SB$N3[L
MX\65^FIRDZ>+CSQ"N]4"3&)H+-\==TC*T7<'4"DY.*-[3@K%'R#MLY!/M[>/
MH.=JDYS[T0S>\YH;PW$F*D==68!;X2[=1^0[>7]+K<$[^&/UP:$_IOG^(P6'
M56@C$+H@MV\N:QRBT,L43J(BPQ3C ? :N?U5"UC@,24SYIJ"HYBJPYQD: $B
MJXD:B/B97J[M@'7;""TF5(2OW*$[=];\?-PU+(SS?J7]FA4LN%8GZ_L]8"/7
M!CU"K.O@S$E72:E',:MDZ#1+*EHEY76S6[YHM?"2>XFF/9VNP98? ^0>2*[4
MQ@LO9\'[7OL;W7<.ZCQXM!$]P_.">WH:ZRW+,W:-(OF&,KXK^.ZO/@=7/;0U
M_=X7X,XJNRWM&,I\N-\$X<W/G 5I\W9[/Q"Q%]:R2^,2O'VR05):%H-,-&A9
MJTNK"D-J7 .'3>N,5U)>JR+VBTGF*,6_L8?7-\<Y4O8^<9-X=9^KJXN)Z-[6
M8K;QJV9LQ-39?%'"8!%'G=N4%O]CNNITYUZ-MX]PRDZH$6RW/=0Z_>B-+C\+
M<.>O\F<[2;S>_41^:<O78HSXY4@[>PWJBV@^X5>YK89$ .79Y45N7%."G7V2
M[7XP9_?E56<],HSI41&E4@3-5ZX\==M7&F$FD8!')2 Z^;;:0\VR0ED37]TC
M$\C:HDS-D>2E[ P$Y=;03Q"$IBEKNR*#Z4%(VN.OA?WB1B1M[Q3YZ1=Q_4J;
MC[@5U:-V5HUD2(!?!)6W=,RB@(Q]+QJ?%^OW;X \_!9P[!2'\M:M@8\NZ)!K
M+EQ(;-6F"#6]P]N#C\BOQ'["/FU-0Q;Y8+W>X,>[\2M,/G"P(,Y1GMTI"/3\
MLQH/A6R/U"LE5J9M=:_YKW&"["_"O0D 'F[=.+N&UHXH+3Q#8)#R6/T]]J6J
M\']Q>E4N</U7SF270Q6\Y7*Y\?;H.!9+O-X];8KOJ <Q"5"L"!DRTM:1B!:5
MF($R"D#,%Y'*U7+W+.A88G+7SC>*^:%]VQ0="92?8\--+5H+(*Q"6@X-N_HY
MC2'D_>5YIRPD"E<,C*X;59W]U7MMNFH?A[R\U&.W-+6T[H+#7&->O91CN5"K
M] Y8FX[W[@=KJ#F*.@9>-211Y"VJ5BH JR@^O4Z^^TX9&" /_2F<T<CU4S(
M[\<>[21#04: %"Z.Q-WGWND')+:GY"7I\=J,WS^;"G)] 6VE5I$T#<_F/.=/
M8K(./_@NLQ8ZDA%6TF8YU\E_U_M+A94F \VTA4.1[.F6QH$HFZU8NR>E72RU
M?D@558ND/@GQ1=4H#D=2\N#BAQ-O_T V*UN$N$.T+_SB\ V$X(1\@O"]S\+1
MW1T, $M(!8F[E9<]T!Y'W;$ &,V)%X+X1='-F[F27[-2E0;%"[PFR+>AQ_XB
MVM$*/!]TK509Y%CN:Z!^[2/0?9D">:=<:'D96BC03I4O[!%J>19/M'@EYH5/
M7/=M-XH[=EG_ &&H+>MK5J&' 3"JKR-5"@7D7*II/\I#F$IU,HHU\JICKWI<
M\IM6HN@, Q-/2U'>[;88P/O]5</MY\J?1>T)']@SKRHDT[&ITON5&K1(:=44
MH@8,NM*.,H<JTP+2L\AHGS1[KHI^6S%Q/G7N_?WIVC'7ZM(OFB A!R9EEV7T
MU0"T[97653*JPS_;P"O';';C_3T)^"\OG_X7C^H$9"T-?LVZ]R\OZ8>/@9]7
M#QK)LA:V8[>?34')M%A)5Q2%+T'V0)H'GQD=*;J4!7.'E_:(;!FF%!5>V]Y)
MNH@?!#-*,7'.QTT$WCX76B\#5E?I@SMTF].L5QXH8IU<?'XTJV@3TRNNQ?9\
M0:9/KO5!*DXQ:,KUVEX2Z?LT-U]7TC[_C08+%QW_LX]&.>\A+@\==>>=%L?1
M.*<C_:#I,NLE @(=FV@;!YB\*WE_?%/,\H)U#7Z6[.I:EP@_V%1NK)A7D95&
M1#$BL_H#(65%/.,+[2//;44C#P'#1N@+5XO$,W:E!T*ANMLJKQA Z14L:]0.
M'CU+4*4PUY4]4&O_"N,*V,/,*ONKY-/OY,'O+0!D0Q(7GKQ"STJ?,*T.'6W#
MV/J%BNVPK'(B,AT><F<9'9_P#HIW+2J,VQ:]^)K=5*E +*]=AIL),#M=TF3R
M8TP]7TY#,3G\8B\Q&QM<>=/N$($J;W6>L#PI&E3KLK5%%.VXP0)")B$5\&2.
M$\8!H[H+GGV/ K^=A+A2Y V0(((N0!# )1I&*V%OY8*WH_S7NEPT,\<$0^G\
M>!#W-7CH0%(KY>W! 0$Y*HGXHW::N3":#IN7&>HX1$80;]Y!4"=GUAQO^1X8
M)/9B8?Z92MU,Y/0$[0P]VB1]!FXY-JX9B.[=I] TSKS^=J\OU<VS>WV(P% W
M!5AZ<SQSQT*F^M%8A3E(+?DQL[*8ON>OK<\.P.\-W'RCRVZ7LJ1*=&<+H GQ
MJ:Z(MPPM(65)+=5?CY/$[;^O;P@-+V[0B*A?KET/!GT^J+JG85+O/YJM\?ZE
MS(-DVNZ[=4U$<.V)R@CQ(WO:F:*:=S)LK=7\*-)W\M>[YYW *KO%0@R S\F+
M<^=R;CM6MB)*/TE;=MI@\!:HX4#P6=' 76%7TT&#(GRU+B_-:%^^HI7]Y3T5
MLP:P@D6<K?H1I:KX9BO+)H^:U0+;6-56<<:X>31LNY<S8Y'PG8D%*T%97^HS
MQ?<MQ8L7$8ONUQ!=*EXM'C!<C.-LV8[]P()_<>; <Y5*SYRPA[.AQ$^5'\U;
M+Q-5J6BW/L0&K,XPQ#Y3"-G3%;2[1_&$&J%<=3\'GZ]N;%2*N.-?P)O:1&6A
MH@&Y24M$RI/:R#6 26T,_\/<J%<X)&J:B,G ,D^2N3UW6W<B<NAZU];>ZC,E
M-])7]_6./RV4\TT=^LL5&L*V=?WB<J<[:*%"Z3K-8R3N(K+SIC2!0G#>?O B
MB4=.OWSS&$OUR"Y'Y42]I]EG9<:W<'&#KLT"H?F)#5BN:\T)!K#<\JJX]/3:
M55A$GW:HBTKV_9OX$1B1:2B%CDK%E <UL%1H(_$&PG[FD;GRJ#O:Y[_OLVQY
MEG#%^7T*$IN25#'D.)5H__%T)XW(PX)M=C)8[\78; _"LO]KUYI CC>UY6&)
ML^2A?E=3B9ZTC[&UE=_\"P?K0I-(7>;W'&9B/22ZSLS7+BP&6M?N(ODG5]Z%
M.Z"ZR420ZB#!D%L^XVUXNN !K,)6E#%S>F>X<+:-OL["7</Z>T;('& W.K:*
MXD,;O=GQCMXLLET]JLOV@1ZH.'$;8F3+ET%K%68!=VPI$8'GW''UNK.VD)W;
MG.X:X+^N"@U^?,=X,RMU[2=H4^I9Y:DA='$*]7+--5-8@0!Y#CR 2&H6% >A
MO-/.6WX4:H37\$>V29&L "E1MBOX;)V)D*"303\@GFX_?E.?H:C.U=O K4<Y
MQT<97771=6O2XU\FF6GGI3RG0D4UX'0/?7AK4FDX9C6F5BOB06&S9!C JVKM
MD;+D"JSD\$??+B(EMH8X,F]\94(IA'=; JG6#7[_]7HE+ QTISF>A.U!?W+_
M3T!6N -7I-<[G-)1 SK'0X6.5 )$=^0NWVP>7PJXG7N6N0H#F/G,YE #=&@$
MM[(E+[DN>25N-CXN]2A\BXQS7XJBW$;LQ/)_3<QNVM9EKE-.9NS0$&04HC]=
MNOP $!/^G[BY\-AN/PK$<)"+[&FQR<*"0C!#X+,N_>]G! FX#X'4FLP;G6+R
M9QM:XRBQY:0VL4K&W9J:%B;NBN>P-HE^@&/KZO%8OK2RB5[,W$G?KXE&TXPM
MJ.Y OS?)'.R%M$*_@C7)NO+7G_IUVQ*"=QO'X$K(L)5^?2)?DVVX?,/XZF-A
MZWXF-AZ7BV[';B4<EDB;7>"]',K/]7&SW7QK6P3.K )#'2YS>[VH@J\B(?UE
MEJK(EHWNY7X, &^V6RP";C^QU! 1O[+ <)=_:7=^*I\QUS1ZL+DE?UNKF:D:
M: WEW?,(4!2_ADE51=TFCGCGSY/:X4)S4?JF'.F> ]+.,8K8/SX6W373@S2T
MGNSIXP?&G;$)L7<4I%]2>6BRI[U5:]1<G-I4S#I'MZCUNRSB>XSM*%2/VWZ^
M]$NR)0\E%[A.(02TDM,)H9S RLI(+=RWF:J3RSK:&$!A#:""%@/@<;[4RM"U
M+H/)FS]69HN#O2TGS7V=/0/J79<"4S8[4=G)BD_,2Y\TISE\)3V;6#-&M'SF
M]6S,3P?G3^4EN00=8=MOZ5/UDL87W@G\MJ9M]L##_\?EI68@@.D#MU>B[M#A
MKK6U.ZL"WXYNUQFTI[QF0<YPWT_?*L)^M<(U5=:DEF75ZNM/E1,Q[\GZ9^M'
M#PVYL[.+.Y@'!W?F[,B[6G_X<KVM'F/?*R%U.)9CV,!G^KQ2JB+#^RF.! /X
M'^U=9U"3V[J.AB+2I"NA*0AN%% I J&*"!$01$4(! 0",<$ 2J]1V(+TIH#T
M7J1W07KH2(< H00)O8:>#1B.>^]S?KCG'N_<N3-WSKES?KR_OF^>M=ZRUCSK
MF_6]3]FZPL*[B3MPRT\E*O>]4*WL^NBZ=GCE][-Z>/-_V\'O7\AR4<K;?5N4
M]\YI<5.(B=J(JBS1M+4-[?<C8>(CE_V\;E.ZVY78XQ^JO\1QX;@?3MKY.C]V
M:;M =!),>J*H >WP8H:&86NDH/.%F6[I&ABI&*BC[9")V&=,CM%IUD'JC92H
MU;A]Y6+U;XO'K?Q/@X[Z?@LLA.MDN!)^G=WBC)KU*_'I-C2CZ>3IS,K8;X)R
M"<I&Z&ZRG.K0;WQIH]6DS+R;/K/*O]XC/F_''(OP\\@=QN0_IPGRGF0)O>%K
MFKE_IJ'V!!";OL:"<3L!W-"Y=^E%1(]KY/@"R3O/!D'GXG$A/?!*3.Z-< Z5
MXU>%$D](L"A/T'4\&35T9'8D(\ )IMHY[N=2Y'+>J-];5?YS=DI-7 ?).^QR
MZH1>PIL3P!=V>,'\"0!X'"8?@XWA$QBHU: >1J/%MC/K2C[<F[F35WX"J(%!
M#KD]7(L,PM2-06:,*\D3*S[4H5H:1]?#&>QN\:]TN1R-K^/JZ/\^38VQ2Y0=
MBD4H_#)GJ"ZLLCZY\<G^T"FG',C3I=GIFU21[(NH;?==CBZRMRZ#X9(\_(DI
M7;WQF%B:D1F%Q4B+CD-%Q.5]9\=JW)[=#V'U[/Y0OW\L03'O6(O9&SH.DS;:
M.!;+=PW)&G3BO2UF:NZ&N)R9=^]"[;O@UHMZGK7L*^3SBJZRC:0[5>X*2MPC
M$UIUG\L_D7:=4\:-RUN%C2[X%.LY^_!XM@-]>SP@0U^M!&*:SBN,H,'8[_P[
MJ\D\^VX_=")%,YW)&!7J*R*RDUM#J>,^_F!2B*/4*/?PW4A#<F<FA2RBY-$]
M:=E^MI8QO<&O01]X*]E6?1,>?Q.V:6!WM6O"6R5%Y!AY?3_5Y>4%I,#]I((1
M<^$AI9R[^NX[II\=TO'34!WT2VY-:S6>@,^@=\$L$7WWT-$!B.RQ)H1U 4?M
M&<& 6XC?QX]#090_D]"45*%Y,N672P4<J7^I#=U$MHXOAU?5_I(#1Y[@OK3R
MO^?<RT=B4WGARJ)J1]\O6]3'^,V 0JDIC!:.2-J+*A2H&"P4YHXBRB'4!>XP
M*>EY6\@1\Z=_P=E)@[IAW(S*)B7]"Y5&MAMKN[G31J<4C',>?4$ %T2H@*_[
M=/6.J,RF,5\>_'U.N0L&992&(C*(^?WTHD3:U#()Z<Q98Y#H8852]3L#+X[F
MOR)Q@+UR19'>Z:#0TB!R!TKZ4@_RQ1YPFV:,GAWS&<$-BI72W+SV]3;/ZV23
MN.]\Y8="R)::&GL'A?*XO'7,V2PL*"A8TYLT9>' 910S;C7*/86WJ9HW7M@T
M*?)_+OT9PW?7JG+8(D*\L'Y*,H Z'?^\M48C.3S<V3XA6,8&1_DA,/H0PB&E
M8<9?L**A:/4XYFGQ"2#,@7*PRX'ZP'#U+%H[(F%'-S_^LS14H$B0W)E.[CI<
M&2^ONT1HH?!':IE)0AR#(53+]B$+-**0)]IMD^$?US3QC.[S['YN!']/CKQG
M9H!L4L:1N+3!D.VLX6S4'+-$K(&TM2(-J5J$Q]U .'V&F47K.RF(WC<H^9T4
M?/4(,MXKB;:BEVQ-:*UE34D@.83*CQ8-J/#QOR!5M21=_TX*-O<F#*70-BV#
M$XH5_O@[W;:5!'N%H":Q8+CCS&'@=TZ00LY[^)T3$#'<R^>6',3?Q<'J(F&9
M39@$<)>1+% .X#1W>-I+/OW3)[]!G''\!\XKYFI"D3<:'P.%DI]>.7VOP"D;
MZ]HUI-C\_CR?SI<(YI:K#*/,7PG!%-XMD;?/=W.N501='JXEK$VLKBJ+XH_;
MW%B4( H.'7S^#"KBOD0)/UL%V#>_"-1MX3IY1_<RZ&R;<;C<&ZM>+41HK*)J
M$]4KXT%O;E>XJQFDI&&@)=DR@%??;<Z!/;93(%J()VIW2;9@ D._[!Q4.2#^
MU,22Q?1+^JY[[Q9MBQ@M-DEDX%C1#:SS$;63?WW">-WZ+1^P@P[T1 2PIS##
MP_-@*[M5$=1TJZUKH=U@1#R]\I8+"]*Y_D7%*QZWR,@NCI?,WI-$0?'UP$Y>
MB7W>[..]AN]GJ5]/ ,<P_C'GY!W<"> $0,-V MARLM091DN'B(_J#UD;K8O/
M&J6^5STUX*?:-&?OSH?JN?B!\./[CAAS/*;/^#O2>=T30"ON#\E0?^0)0-'N
M!$ R5SX!<&G\.. ?FJ#_)B##^,)<JS0D%S0KS[X2YQPA-72O,?$C#:1Q+MF\
M<^EJ&"FYM8>^-:X9F6N>A^1BPW\K'3J"#JM4V>\16!C4Q.7Z+O $S\P 4X?+
M'\-$U_.MAI4&+SHP22R*> ]5^9!7 TNEP"8.8B< "H/("6!V-9)TT*;,Z!K5
M4GFHGL"=0.\^6)B,<;*9QQ-BPWHO>LZ_/0 .Y0)68<=J_6+>%Y'3]$;X1<-Z
MH_,9("-TY5UX2[:<?A<3@.I EHKU5-'/?7^A)$+N,_]Z-7YDI%9P=@")D'AW
MZ(,,VD<LGHJ^:W]&*)COM\(CG7J8+J2\(?275*T<5JM IXE+-'K.Q6M864'<
MJZLG@!]"-?"7\?Z4'OAIJ?TA/O#O B+]?M:,%9G$2MK#513JSAE!<\2;7"19
M[=F9YB(!*73*Q>O*BP7_R.1*96K:1WQN68S>CL+2Z];CQ;D=+LP3RL9*,XG0
MZD7;<A.E-PE=<>?HC4?9V8I5Q)N5=8@U=L8"[NNY#[JJS?;Z$L5LCL1[AQX5
M?XH&.CQS IE=MDNE\A42$;'?[&56:@?P*O_<H0B;+7K5>K*OA&^^B$W!/7KK
M)!=_&W4FW%E+ZUXU'W?+4+*" >]B&X%^C)P$$S;V>IQ25<?)MM*)C+]BRWQ<
MAI0,=VB?.ECN 3AC_DV6ZO\5R*,M3-!N ]62R&-<W$.09C&6@64S>M:@=VS
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M\P&0JT1WE<!.]@"@H0$\    &T!'D010;W+D-P>/7C@!Z#=YE)N\=6;6KV^
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MIR^^I8?6^@]M^@>+_AA^NAF[1EGZAA7+B4K9,[V%=:)!$M^ZE]<G8SYP5TV
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M/N6JJ%LSSL72/N7._<.5J?^=I_>#?BK;,($O<I0LA&55&C(<6TFJI=R^>#5
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M0S'8'NP6=UJ"ERRWC<*/(:>V<)5 /R0V,/PT;C5847<\W^*5>A%((C([=\9
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M3PG6$8M17%WJV.(;\2Y';8K[W?TQ@<I62GL!U(5GG0/;J9LCUW>79AU#I#]
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MKT(*M1+*XJ_ZNCDSRX3NK4N"E^=)43C*1E@ N:D7LZ8N 8O)47^S>3"H)R&
MGU]!WM5M"<IDS\V1WN\CY4#/=%_FY^P%E8=P[Z:7@][Y;Q N2S#1#>)\<ZL/
MX"V)!=Q'<]@O3-3K"%<YU#Z;()OU1?@P+1+<69IY6,S_W%E4T 9Z'\U5A-(]
M;DNV+&'H2'Q?/"Y0Y$#W*(O#F7).=)UFO1(\P"TIMTB%<IU[=%@56N1Z@1:
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MYI&TX:[8%,$C1[Z38K/?U$Y&J*D6<.X].@637?2S;FVFWH@QH1S.;F5[C)Y
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MY+-*J<+ !M?@Q:>N_[;"-^>K&('8L19Z1S+[G89_XB;"BIZ'6:31M\-^5GQ
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M,493O(M,*$W:R:G-,5U=92L+*PC$-O0)KL93YM2]3O7G8NO;NN"@*Y$V%RR
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MAUJ+!::JHZ-J"\NMXQV1CSS?PE[>+RL+&N<C2((E02KSP^0%1#!/.E5<._X
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M,I4[7/SFODZK7U2_B3K;HV=UO[%I? X]8'"[A\^3V%);HG_L):_C;_D&M_#
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MGI=^VJ'D$W6%MD]0\!TE^2UR_EX'UXBM.<$R$M*5]0_Y>9]HE!<C$OG"=IT
MYJSW:KEE[LE4D'D_L,OP8;1@KF C8!B_<I-BPY:1HWRC(1F?7PDI71?0=$-F
MCW/D5&!$QDE&<MS"=^-7&?8A[9$L$]DSU0WW=+_6[DNYC9=_B'X\\V?+&;P,
M01@5S 72'" T O"\I[C !PDS]!\8,&\?XNA_OT!20A?\DZ44Q YY?VB8!XN0
ML0]\^B<]!G[U-0'IRG$AW\10*FI&92;9DC[,NPGM5@JU:'[\4<9*H_'/_J^>
M&+2^>3+>_@N:O?$ DK0J$%=%[-=RC$S)=9'FY)(OZWW$G">VF:#HRL1<I=+
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MOO$!+J#VQ@":7LG1D^ "KV(02D4PQYA)VR\KL.?^=KE"YH^.73"<1>@G+^E
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M@=JFM'%HO#H4E0L5'VK\Q#S@TY9993"41MOGFW;H35*$T#X-@3"#O]ZRUJ:
MD)8&F]C7BFA:8Y4$)SNRJ$T("$2D@MWLM=65"O I8OJ?)(\8\N=@I-K8".[N
MH&)6Q*E@B]ZK;S-Y\7 D)OO0W]Z!_P.0+F?^??7<146O2/PN@1D4")M_Q#&Z
M?F#.>2+"0C!YK7^]C9\&_CV,7OZS<O@,?1Z23UZKA?/;B=-3C5M6VI&I<=39
MK_[VYORKM2==5)5KN<"%!")'>O GF2TE"!\7G,)RXI%*:::+E/H/H._2I 0Y
M*7HY QXED*9JZ3M-$%Z_B$0>P9N0^4^\2X1%ZMT6AP:CIW,@?\,6:A*AY_B
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M4I#2UX(2@WO( @T&4^C$_.F8&/V^R%5BI-\^?5:]6$7#KR-*?J=U-U='^&3
M0O#;I!;>S6B$_<F8;,?O@#91$LAQ&'E\:&&0C^ESS5K#LLI;=P^5+4CN:W$U
M,*K?IKJ^LI+_I.6ZQVPE",G,/LR(]XO5Y$BB^#(G0'<[-.+];O2E4Y+A9TU0
M]:N@J&Y#EL)Y]?AGMH-A;>L(DISG)IN]R8H8"C5Y)(9I,GQI-V0U]:O-V8-Z
M>]7J84M@R2L]/Y;69Y=$9B>ONOE3_6?FCEG3I/8#-LS M>>K8&%/6.+%WM%
MFC#=YMR[!H^+$NWV@88[&@9T2)=.M9V(+;U:L3%E8]2MDX+]1 60\@1-/T$:
M^3:]'@0(!H01+H#"[YR6]1SR%;5G;-QIY?T!.'E>,F!,EO^<\#'W<\JW%7]A
M:;K[9B?'UL&HBF#EP-&&]U]6@CZ1 Z[7;OQ6M)]T%^.#&!(I)Z6FIY"$DT\E
MQS3MQF^D]WZ/0T?NR;[9J;QCR"\K<+!:S.I5>K!_\%6FL.)*T5:S% N5UWE
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M[STQX??"TK?=5/K(+B&U_?HG!;DC_PM02P,$%     @ U(!15!28Q1Y22
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MS%+[7A\/I59CL7=%-U5>?<\(B=_1NB&SN%>-/TGB\KNYO#0M'D0<9D I75Q
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M#"57U#,W<:?QL<8J->U-\@-LR;S)L(CV]39E95=%'"I-;@UXB>2+A@F8[\P
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M@F-Q?+_03(T/*&XIFH2[B=O",I2RW6-M?AQ>IVOI?4MM8IVE8LFY//^C>_[
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M6!AYS!>?CI6:"F:;((ASDD(FK&6!!LI^J/RA\O^E4N5[;4-L*&[*,H63Z&Q
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M)@_W<X4-63L@]+A1*ELVY.4T3CM!VP%@FWZ92!'&Y%ZPV89M>7:A)EIYSZ)
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M(+\M4#,+&$<[8/CC(SIG/^34;S!R/;AVP+5A;B#YN7MSM6::5XJZP]ZFO3'
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MI18GXS=Q^=99]L630@NK; 4X-^\\P7G% ^;&>8!#QM#""FY]M[Z(O/B@A[3
M'4,M_S;%\8"_7.S_M/U-[-_$_DWL/Q$KI'&'L4JQSZ&YAS1GIW80A ^7AKJ=
M"+1J(YT84ZMRRU7]Y"F1D_,\*6>.)O[ZIEJT^U,ERL0;E'?JB!#3G5-NH@V.
M8X9]QCMCL&'/ID(FND_5T2>*LC8,7MM7;G[PB-7'=\">GS<.$N)XP!7D\!*M
M>([!Z![W84LN,;%0#WW2GA[<,)ZZV9]<64T0G"] )!HT['+?_<FS5S4^4*R2
M[!]K[^R66IFZ>^>/9"IW)ZZ8DXT#0I>HF#E1&GDKJ@7!'XJDKL1&+"-%V(?Z
ML,@7)D.R,M6GT5WJ-<\#+UH?T6T3%K#NFU4.TWNT!S!E)NS(W_!/#:$*HQ)_
M0\X#KHA[:&<K5\9,@Y'R<J$X5*A%W.[-2MF95O4212-V1>0.6B8M[+8%1H#0
M=;*XATA)(E:AVGM&/+G".?0*9B$T]_R<>VA%.RF(O=:V%I0P8OY)^5G(!H'D
MT)-J\4*-^F&&C,8Z&'PE<QZL@ ED:;.];) NVPZQK;R*9LRV0 $%K?0HE[=5
M=&[*L\+LF<\NF[TG3V;OF,RT.&"M6GE/J5/;9@S67RD>3GZMF$0DW=9A [=G
M3/8U0^#V:JN[J@5#BI05^TJW])E1=E&A#LKK7=JQ$)<SQNSR8*6-S09\:\8T
M^?K#F"?N=E0[L\\+IUQ<AMW\95,Q NF>X8OJ-_3U7FSJ_#;TGDBW=H +WX><
M\B%F5 6GN)(L>BX *<(#?$T#FH)E\A UCW3&J_NIU4>:)SW5GSWU0]X)_$R]
M9[XA]4W)4@]WDQH/4%N=@W.K3^<X9C+07/F-)PNV2<XK5.!"(JH<,=O+4+2G
M6\;3]]GUJ3)J$B>^J TL5.G>/!WC%J<SY_FP;:_;2*N,=XASF/I]RSSGS,^#
M1$H.L0:=2O3E 0KL"YP,F)1/6M;E4!U=LKW7=VPWOI5N(QCS[F*0HEW1-)/^
M89Y)HTE=^B*;T>U%C0OB[UH&A_F9(YP8N%IZ <+8+X \'$"]FL@X2DV=$_,J
M<AA'B7X/K=9%GJ*/U7A*6FP;"+R6O*V]HC1#YJSJB8^X\T<:??+ YLU6;2B2
M%5=D)\L?;+9@VS[Q&U1 )&+]GD)ZK3T%_J<\_%87?V5^"@@RK&J[WW+UXLG,
M9N_%@8/I)_@J$P".Q9.$'<"?&P-/(C(/]L%N$>%)(22 ,MB+SZ M@Z.PHEL:
MA1EBGQ-W5P1WBJR&5*>KSPGXF]F&#HOG=MM,7$E2$:IP1 O ]B")DV3?@<3'
MB204I?$% VPW.P AJ9CX+U-D_JH%>?\%,'2#VYNO<YYO,W1U&ZKZK?SEL(U!
M#>_E+JH0GL(B*4!55K]@*>%:B=*@ORZ_9>+)@7H$Y>[1,WVEQ:<N9<X?<'LO
M<2'JY^]G1IZY=6_,E3LM<![LDY N+1#%W91<!%-@8R:'O<ZX#")O.41EHJ6?
M0D^X6K7I=J>67:Q>>@SW7+W,,JF]E1;V12,^]7VRB(#%#C%DC15;*H_51BX7
MF@UDN;&M,MSIA"8PT6Q[WWPCRE]9INY=C)V^8JY!0]7C(9D?=MLBB.KV)V,R
MC:_+JQ]W;$*=?$Z(Q@D'N-H1V-*GC]%C9Q$TBX%&,?P]61@ER@4NF[HO8(V\
M7CCHUF<K9=XS;MY28"!FDG+__N5JWZ=I#O.NC=/_-@+<1U&(R,68'I(DMXM-
M7CNTB[NGA&7Z%WLD^0CRPI_WY]A\?W$F]A\3]SB0\,S;G*<F6JP;H:QQHR@4
MI499AI.[#"I,'3*>XB)JZ<CH5_.[+1J(PV-^.8Z;EK8R<C,.I+4<B+,I5T^^
M@X8T?O* 5&_.D\9]4T1QD/+2U6'.Z(X7E0>('%8B86*7<_=QQ5<0I=96#Y_M
MK0G*^>PXH613._HU9B I3Y99 +. ^8:]Q2G#[0J-[432[8C\V",-0SGVC)!(
M,SVHA0?8UU>GNQ_JL:M6EJBM>N?TMC*!,N+^(G/'CVBGA<\J'XJWZ;$EU*B$
M."R243..3J@WAG%O)PQYO5% P)[0VZ:RK17?_$[ZNQ:58+;]"!E2]VM_>*5%
MT2+>5JX[_J=#=E@XP'KU[P+NYA[%T)M<2>1&?ZXXRV>86'6K+A%5&7:'3=B_
MWV[DAI%G\/6TQT'22^39NRQ^:(FI W-Q<0I\+=O20SH8&U]O2A5#V])7VY;I
MY<>N++R:J,T6I5Y47WRQ>/GMZ9^5I<@//Y*_(6U[S96#6";L@] <O97I0Q]J
MU4L$MVUG]+2):;5.!92$KI[\<LQQVCD?N1RO>RE-OU!%6D+[P/E,P7B"'+S>
M-=BN36%TW.)A"+734+*XOD8DHSVU Y6034A=L55$Q$KZ24RMY;)V9NYX%GCJ
MEV'MO9,ONX@IYX>^/C@IE(3K(_*C?-$D8_L!G*0?>=M<(Q*2=$J<)7U=N+<\
MA6S+&KP:;B?6,%N^Z1;M]RW]TGWOQ2L4CT%!\XT";!'(AK4/J_K%C)^]B:Z;
M&E.O0<T1K.B]Y6ZZ*653A'JZC<[\QW.CW[)"O+TU_L@8[#47E'+\<[O$/@:!
M5# A3V0 IPP-DJ8#M<Y&O2=&]IQ^6Y'NTB50G'-U2C4J:6NIT88S/R2V? U%
MS<&16X#&>43T1R?CMG$*<2H6X[I:G1XR?6C;7K8C)37N=G54<*:#FO7@[*#L
M7LR1^<FTC+>1U]L!;"H\LIZ3I@$++@06G#O7&/<>58&*-WS4R.?.WMV+O90G
M2_SJU1#5TKB]OB%/H#+%YMPC5Q?=5][&\<&I76/H2U6X**P5W:H%3]*F%B>:
M"4/SI-8V,^6A6R,-_.VWCW^/$9.B/\@>LXN]==4S8T!_7L SRA&K (G1BRE;
MHD)@=XC.DPV0'B!DLUR(]0.[]0@K;N4O8R86%Z=M=NMI?HO+N])G/&=QGFJN
MA&D"OYUFWN+\$81*. 07HGIB9"C@#-1,*R%(A Z=J1[4RO.K.M@JFR=^K4\=
MN:\N^JR(?(\< " ^H: =6K/1C"6F$B>\#*0\1%58S1''T7&R>#D,OIDHV"A%
M#@TYP?U2W5?\P*R .7?L2+_9HP#_)<S#4Y+(1Q*RXNR'"^0JO8CEA>%5RL)L
M&BPTL[X+56_I^/:Z<R:2XPY2TPK8&R6_:C63:HQ>6Y;'6+]:^+!I_'YD+^;A
M^ 8+*X=R,TGN!Z0 ;@LT<P:JH/9L<9]6UA^<<QIR8N#C@^XDGSZ;-^Q22RK[
MU%_7?$4N4^;+[VLQQI'\G\YS\HG>^$ARE>R]*_7R#$(SF92YYO1F8UG!F"NY
MQ^ON4_\]$A<;*NJJ0R<K<_6;;"1++CZZ<39.!9F'+M>:93!\N)N(,'"QISO/
M[J2?[LB.C4=Y8TBJG6W9A'M8[=+SANU#K1R?$U5NW0]3O+L-G[[L[1!5JCA1
MQ[VE;[>6YG&3/LX\!SG0R31^]OE(4Q]W1H"?EFUBVY@.0W"P."3@TN=7S,$)
MZG!@88@UZ;!(<79OQ^4Q1^ME__^*CU:T)PG0CJ&6NU;CB)8%,>CF"4Y=4,\P
M#YCE[HZ98+5[*#.D&W-O/G=-#!NTE;X3[GGI(^.#?K&RPSM"04 W#_ G?.MG
M7N%4UR.?L,TXSW'24XUZ7Y;UQ%M?N4P=JE2U%OON:"=2\4+.:]@D_ 5E/A^1
M!%+CN(H\H*\37RG$529L 1?%[B#7S^O%WL.)L:]"3[%PB!749(!SPM=?A/K
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M]S[8T4SI3-DQ',_X&95N6A#5@>8PT:6.$ )\2;.XP02$@S?9Q:IU*M0J;)+
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M6GIF;7M1G>5T)DJN]TO65YY9G'O+_B-:Z$\N 0[H00?1G%C_U<<0-I0/SYS
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M 5ZKL-Q^>\:INLR;A7R"?[.=I3]DGQL7OZ@K)/6$T.5 ;SJ/ 53Z,XE9).S
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MDN54/"P-:^=]H/4^[#;ND37[-V^:%*38'R* O<<3@VW8B/E%P9+-TAA&\RX
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M>P+='@.?*891/2!OAU7^(.J!5C+LQB(=33;H.WM?%*KH7!"6:9)(:!L[B5Q
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M$"G/PU(C&PZJT8_U[.13*(ZA%S2:(-%_MXH/02VVYVBG2?L?P3SWL0T(5EP
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MHP;]2:_4.K?V.&[0G+<XZ6'BLLSDL54PJIH2TS5A^PN*XKTC]R=EV3%E#!\
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M'&N;3.J]@M@O^5#>C^NKN.CBSWISI6M'XFA,"&R3WI/)RH3=M?9V7FI&!#'
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M%GW0AX/M#AZ27$&K,H^>(K)UFW--YWR]T.D9!^4)Q9!,Q0\BJQ4^:_*+9HG
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M9UVDW#>PGT$O/XIZL^'0EEAEWEVN#P;<[V5L8_^ :OD7,.V-V4U952!I'!W
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M9#B(HDL0:$>_GF4;F3(G(,(-(BD.D#P2^O[0AE_?M?M/0I6?;9:?F5V=L_M
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M%AAG@TXO;O+[/^RX__]LP,3C_P%02P,$%     @ U(!15$A>H]0DA   594
M !,   !J;FHM,C R,C Q,#)?9S8N:G!G['L).)31_^_(EB4B6\@H2EF2O1@F
M24@2BJR39(])R#9FBF0GA$(F)%DG^V[L$I*=$69&R)89--[,XDZ_N__O[][_
MO?_[W/L\]WGN\7S?>3WSGO-^M_/]?K[GG#F8/L"#CEZ_9G(-Q'*(!72/^0<Z
M^ 7BTW\ O^\*<@4Q&\O!+,@ =(CE;_M[/?2WL;'^O;*SL;&R<;!S</R#.+D.
M,XF3@^,PSV$N[K^-><?+P\W[]Y^_@_S[KH?865G9N3DY.+G_E]M!.TC@\"'Q
M0T]964Z!#@FPL JP''2#P$P>V?_!'@OH/S260ZQL[!R<3#9XF _4'F6RS\K*
M9)J=R3'SVW#F]R V 7;!DRKZ',<LG#E/^0FI/DO).RQSI;)#V'*$)*MV_W$$
M%[>(J-AQ\=-GY,Z>DU?7T-2Z>$G;X*KA-2-CD^M6M^]8V]RUM7-YX.KF[N'I
MY1\0^"0H."0T\GG4B^B8V+C4M%?I&9FOWV3E%[PO_%#TL;BDJKJFMJZ^H;&I
MLZN[I[?O<_^7T;'QB<FIZ1D<@;CX8VEYY>?J&GE[9_<W90_XL_]7+A80*\M_
M;/]4+@&F7(?^VH#SKUPLAX+^/B# QGY2A4-0WX+3V>_8*=5GAX6NI.15=G#)
MJ%F2A.\_'N$6D54GG";_%>T?DOW/"1;Q;Y+L/PGVG^7"@7A969C&8Q4 04%T
M6G[<6=#_P\3:A_)2!LXJ;YA2A>96L^";ME3S8&A[?=:7X^JM4,>)49WLUQWR
MKG>O/5!YP79<<X,S8;E5CK#5#0,A[$DWWY 5".Z)-1@!(,RVUOZMC,.WWX=_
ME2N?U)6-N]MOY,0OG?NB3?@ %%&(Z@!C\6^QS'MW:#*ZEG]3 Q\TB?#T)YR
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MBT>YOGT\W*/'!X@2CO#?!1(7X?QSIR>S/YA[%R^LJ=CJ#AH6>!;R>\6+W5_
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M2Y4?.Z?QV[Q]"SB/WEPGQ>95D8WB=[$G/$>.'JF/JYE0>[@5'\/[6.0 Y#E
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MZESOJM8K?EQI:TXO\OIPY]D# 5$%F;S'47%UW_%_^TUA_NB[MV/W5XCF=)-
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M0I.EF($;VF@[ ![#-B]G?DWV9,.0?WQ;NS;4X\9B2;JCPCU5(:X[5W3H/FS
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M9RQUYFB'F!9D!6V9T!J91^#DCW1Y\CT6B&3YSK=BOD.'!5KXDX6I^&)_C/;
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M](_U+!_5-94UN:K&IZ1,1265FTHV1IP'CX4<E!FF)5ODW-ELTJG.6QGM$&U
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MGL!E10;M5NYNQNK;D52*]-MG%@8*9BW]XWTTF]-K:K)M=V7WC!CL<,]7?=R
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MA.>>EZU.MD]0LOG5'W?E?7!'RG@1M8-10+]-\UP^B^IQZ(KR1EU@]C;81J/
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M2%.VX[1'M[8""5B QA3%CK% M=K%I08K&')B2*YQCJ9I9?"$T8I/YR/-Q)F
M$A@0(,IPTF$ZP!BCL*%Q="Q=W&"?V1N*S0M7(<:WUP7I-,Z-Y+O$(DG;KN&/
MW*JS2J;8:>OQFM')"S! C@6BOZZI9M=?VL=,LQ\=K)X#5Z!7B&Q;WD)>VOD"
M);]"^X17.J1?I\&HP>,UOM%B5.]-N1_Z)?/0CD2_],5M^G;'RQ4U]W;$&QL)
MIZ%YY:('924-6ICIE 4<_Y=[&SB)5J+?V3\?#X\7%[D'#Y_#S0G=,$12MNZZ
M<+"U40T(F5E/P%34TD]C8[.E]'*?DF!Q+H<&JIO/S;BIE:KIVQ=T:%FL=*]
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MGN:<,[1C]=A=!Z-5X1M]]7SJYO/>PYS1 &8V9I5 TP:*6L 5,5WX9)QD/0[
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M!>%AH>?)K6P@$2M@!D!ZV%BB##,D+QAG?H]^WF^D:/S\]HR$C:"Y2+]]JI.
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MX*VD,J8S3-P:'BZ<>&_GN**I;GULPOO:O;,2/IWO>$TS!GZAJ?Y63$DR_<L
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MAKC+C^"3G2;O)F\[<)F\_+M;[FWW33(5FQ0]K@ A&8WW,%,,LJ P+NY/IKQ
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M3O5?O[4W!>Q[Y%/17*HJO=^O?=E*H>5&P78)"3[SMSNM>A25:&DM*(1B-:;
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M[&82+[4M=]I>>F'_YIW'V=_M0@O\I&]LBQL<5]6ST2J;.N?@\F"1HS0>],)
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M@ZE[&<;1@CK^%/EF>A_CFW)T4,'1W#B%CSHS?R9S;5W[;^VYE=_?6'OJ^TM
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MMK:"FE2AG>^@28V:T$'Z\F$,4_B%]WT%X 8;7Z+%>]U'$D-9Z2!!H[]K8LE
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MQN=FN9"@<(UPQB+S(H[-"KF.>G!"2?N/F;D/@BY>X0N8$&*Q83=UMI&,%-N
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M2J4WWDT\/2OP3)0.(IZF@\;'S@.B)#BY>42/PR;[^$Q.)6DQ%!8EIM2\SUF
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M>8W]JU(6VTVO^YK-W723.FN.2[2]N6M[_O-!5[8;J'(ANN@4T6TM:E[%;NO
MMDQ@IS6@<9D\BZ=PV8^4*@YO%*T?MAODED\+AEM6\?-'>?FLB-T+A-GY(C:,
M8&B5CQ#HKL*1C1BAUHVC_@,3&M<;&X=]<NN&U7\UJP/E9NH?DF.Z5&,GWZO_
MZKWQ9C'1[%1?F#39A7J(@</?C9^HN?1G=\Y;XCH01HR3]<@I*R./-CQ4O]J?
M9K;$^2LPA9B::*O0FTY@N7'^\9F :!@)P0GVHSCP=QF"3-AYX!31W>]]X:H
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M'7$/O>_9=X'AA:/QX;,\PXUL\RLZ%K8$^YK(.Z$KOSC BF.-'\M/.>\[))3
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MT&6&7X7-B%_]R(? V_=?>UCG66=<OJ-27#1DTYPVH[^\-[&<IF&%.L*$M1R
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MB8G-J/&H\6(SC(";HJC1JI$ 8<.%,,/A?MY.BO8+6K#G+*:"\8:H LB)<RF
MZ[(D.V'\Q\DP3(3DRI;*%*J9]>@U&2CZI6*\VF?ME8MWZ;=S=H-6W/K%UO;.
MK16_@,"N\AU[A'U,T"J7+O?CGQ. ).?K$P<HVBXJ-?.KT/'];P<["J:>!N0%
MH2ZM["A]954TFE/QMLP]_G6K/TJL5SZ+RND(D,_=?XBB@X$=V<#DUSYB:$W,
MG1!48\JW&I]M:BU00_Q:PW"<SMJO_Q->*S-'9"A]A+NW5:P[PFJ]P3LG@ -P
M\)G-6G&1I:%C]@I/X>/+'G2@J_-KTN6U$.BX*VO][[7@9 :6IYJ [2.K\Y>>
MNST'T2;2+K**5WD1T<BN-*PUA=#ST.#6AX\F[=MMO:X,SR#2+=$"=X.EYZ?6
M&>WS7.8A6HY9RU_&^2I:A5D#:+%'Z75H.Q8J[S,T( UEZ'@E=97W)CB]J&[L
MUM\TDU#&GP9<-OD?4$L#!!0    ( -2 4537_H*1EV$  (R"   3    :FYJ
M+3(P,C(P,3 R7V<Y+FIP9^R[=U234;LG&HITC70%(2I-I2F@*"V*TD2,H'0A
M*AV$2),@(4&J= $%42$B("I-NM)"1T1$J1)*"@I*D40EO)!V7[[O.W?NS)QU
MYLRL^\>==>=E[:R$[/WL9S_U]TO><+]RR9#=Y\VMS"$\O#R0:^ ?A/L+LNN,
M)^J&%\0+ EX\W&G(60@OS_:U_<B[??'S;3_NX.?GXQ?8(2#PCR$H+ 0.00$!
M(5$A89'M"WPF)BHBMOUB6\@_E_+NX./;(2(H("CR/WUQ.R#B0CSW>9WX> Y"
M>,5Y^,1YN#T0&*CCCG^HQP/YU\7#R\>_0T 05$,4G-"P&U2?CP]4>@>H,?AN
M-/@^A%]\A\2!8V<$)&VO"QX,EM*YFU4DI&1:TREM]X6FK'LC)%981$9VSUXY
M%56U0X>/Z!T_H7_RE,'9<V;F%I96YR]?L7=P=')V\?#T\O;Q]?,/#0N_'8&.
MO!,7GY"8="\Y)3OGP</<O$?YCY\7EY2^*'OYZG5M77U#8]/;=\U=W3V]??WO
M!SZ,C(Z-3TQ^G2)2J//?OB\L_OBY1/_]Y^\Z8P/8W-H^%P^$C^??KG_W7.+@
MN7BW?2"X?2X>WHCM">+\.PX<$Y X8RMX/5CRH,Y=(2G3K**:3F$E73N:](V0
M+R(RRGH4%?KVT?YQLO_<P6+_ET[V?Q_LOYR+"!'CXP&=QR<.@4/8K.<IAR#_
M&PR^?IP?<GJ0X<U^T.I,X4(2"5*M'B_=T(.]Y4IH9$>A!.W[KW=5_EDO(@:E
MT^/MAKY53<SJ'ND[<<)U?TH'38TE+<C0H"_V1&N3[P'%X92U>P:?2A72D[KQ
M\D (\PR=_]-/Y=2#?EOQ1X<UY ]FI??X?X$0<,HBK!M<2.P#[!R\'L42C^/L
MLJ/[K);3SU+V<8[2X)DL4:_B'Y=FSM^01.-6)GC#WCQ*M S:WU;O[?N^&Q4X
M;=;U'F[)@6#'N1#:A35 *R(%*XW]#*NK[EG>PU%BR=#]T=FD,Y/UZXWT7?F!
MRA*N;D0K\9MMK:DZ,MFRN>+*M[XWB5T2)(5;]]Q9STRH%R5)+-UR'T1=]_\S
MK/CDQ7#DK?<I3O?(31:Y/AT4)0=O(XA5+Z:;Z8?KM&/),W6QHUS(3MRUM7C2
M+D0//)T+D?;RTX,**=ST:W0)*DQ5MWJY)!N[ESBWPU)KCQ#YL;G,[^LG]_JL
M:'(A.RQI:ZO.3$O6%7821QUS#)G$A<B9[';+!*R,-%'5.'^G)8.H/:PV\ZZ5
M3KY!88D.9\]$-42]V?V(?9 P9&T>2QK/$68S;Z'C>A4EV ^QQO"TXRB!GS8O
M@4SK6EI&]<ZARN9W9^^5U5L\W$A_?JC;$L%C5<;Y */9KWT599  0A6&E_VH
MW00J#O1W&X1M$+F0I 5:>WG9L(>8OOCT>4]F8,5^'1L-W\N&G:B6SO[Y-9:<
M P1TU"OL.%F,QRO\+A<2W/\21YY);$OE[%)BUR"M&Q-='XX:W0PL*O20"IKO
M;8RR?ZHN97=+=,<-P9/&A_@8<'(U2UJ=L8==1 @8WLOI(@EQ3D[[$R2-^+7@
ME(.?S0M"Y92F/[R9M9!:VY,2D6A^)<LV^7)ABU/U9WN "^[-7\PNAU]'I>!I
M;M ,F%@K%/S7ER; ASY!A(IK]\#NG2#M?C%>B0JZN7YR?YO,Q)J8;3<C^>OY
M4?.LNE651+?R+S#.KE,387C@L$D+N+9S D?&NZN,&T65(&>_.G,A79+S)\/%
M7[M9> <]<XIG3 SNLU/M^G.1KBSD-D,1V@\K>^"X6,:2U.>(#H%^[V8&L4Q!
MB]S!1+&SCT/C")*M(GFU6GG:J92)9RU,Y9\[/VKJ73KWZLAFRG+=QXQSNSH!
M^2:6(^C[BGH --^.PVW@:A=.-Q?"L]*NA%[KOJWOZ&Y(5TO&>&[))!1%/SWP
M&&8@KSY5I>*8?=))XX"#,^\O0Z2OX"RH1M.*+"CA*QV^.LB\@<YC:(YP(=<(
MXKZ*!X#(2C<_G.2Z*IV1%QQ(^1GX_?&<E8/^T1GWLXQ[F&J=/1EB6;E">WS^
MJL8< G)Z9!2E/U>UFKV:)EFC?,2SG?[.ZD0-?-TUL*/9J+:)>:@BNOS;L!BN
M,XH+(6=S-(%%#Z;>3U)#A<.<X9C1A4+%N&Z7X=CU-A/*<8NGKJE6V'$ON4ZU
MIYA:9?6&MR>KWP1L)G A<7%<R/7HLQ=IYJ] G?4!9R_-4DX6TQH@=<WIM;WY
M8"7+NO@K2&_P8Y7(@YQ5\;W04U'AP[PQ\++7FX+],)H[#E!>["9D;"6M]%,1
MQ!%9^J]\J@.-/9D8AA=8OI/0.<X_=Z8N<Z713F-DD] RO?<&\OL^^M6R%3 Y
M=R#?L9^!JJ?.*;";6R51 :]8YA-A\JB=SC^4(&[H)>=1Z]BQ9]\]\BYE'PZ.
M:YR[Q!8(H,O/PU;819Q!)"T<V@6?XD+.C7F.R7;#);![IN>6FO@VF@O^./G^
MGB59+VOV#@X9%JZIRT$X):QC5&-X+W%'=7)8>110N7;PS\',*R-5&D%2/GO0
M6K8J]^@;;E>8]EN;H1R1ZZ!JKH P&(0?:VDRJ?0CGVP<>_%2&,MF[=@PV*K0
M2N4<0F?/]Y;6UKS#/C[";Y,^/@EX\T= /.9&^[%B+J0SM-6,5LT127B.Z]3$
M!2&G7!$TP>16#Y2?6BS+F4RZITW5U-K\U92*+OU3SSQ<1%*V,X4-PEL[CNS>
M?,"S)6V+=#<KF[+!&9P?X+=1JMAM5&6:=O]E3%WA27O^G [^R<5)EHP21[0'
M+*H6:ZGNHC18#W3*F'6]&,WX$/E7(>H"?81HF1Y$*^U"H%2>"#'RYX\X6(B5
MP0_O,%N+1=*N_L2:@$HB_FI_A77":@1[1'$[ +QI^SCF%/V)2T: M;'#R!S1
M.>=24T,4"G_Q4>_WWO!%+/U%ZL:UD\^@(>Q'.'(%\@UT-8<^ZLK.)_@@,FVJ
M@ TP/2+N@%U)J_5PN=_D"?'IJQ:!P0NITTZF1J$V^P+W&G:J?2?/_WC-B8:3
M8SN@@$$<HPMR311_#X!MG)R:7-9>26+>QH)YTN#8CY!'\W/Z#+P3R$@>H'#1
MM!THAO4,-_IM#<WP5PR4]NC]F%L;O!\9HOLH2\'39H5>>TEP;,RQEW,0S-CZ
M +P4[F8U#-N-? -;V2ACV=-17=$[UJ'WB.UM\W'/_&1DSW2IYJ",;CMF!F/6
MW@D=ZQ>[F2%WM?CEO":.W"SGTT\"E+>;!;F$"ZEQ[$BM%E_F"-<0,GLX G29
M:I0OYEB$W\T@+976D*6@_1G&V:\[Q'*2Q4_?RQ<[#8N>\M]R* V-\"GSO[TA
MZ;?!.\<YY.T8X'?![U#&Z5VV:2'FS(N[IJ2;CZIUXKPS@2/(%6TF$ONEW9"=
MPX7X$#).@(4^HWU?/8F6XR=<=K7K]?U/C:,#_+7F-3,EH;4]P_)'Q98'Q$HX
MMT#_5<,;<:ML.I.,[$$HH),8X<A[)SB&P/?J ,4C0$,YYES#Z/.Z<7FS44S+
MB9K?GO@!1?N*ZQ0'I^)'.]+NG2_,Y BAF/;83K"QX<BO\?6RL1Q>4.KQYX 9
MW7^GMD,S$$?MI;.(];*C9RK.[!BO;$5(E%:$N%FJ>H@\KTD.>:KU&3I)5/_]
M!X0BK'T)5*0<A^1^#'0 :AH48V"$>(VQI%4NO"ISF4*?[6-L?%YZG/ DD%@[
M,^W2'WBS.RP]]-:7>_/N5]XY37_&D7-@-+<V0X[(&>8%S$5V*D<#._@XJ0N>
M@A1+__8X,\F;?NY.CZZ9WYU&1U\?RP/">OH2Y]**G)U,OH> "/6O2 J@BP"W
M_FK-/ -N;F8$=@M^$CL&Y].F3]6^UZ[HE]>$-:;C4EM#.+ O89N::BES44[N
M\J)35<JRDLK\FY9%&UEMNVN&01D^H("P=1QP&+XJ6\49QDJS$U@VE&0C\2CC
MS)[ $&;?UA4:</NG!/E(/<_( D61.O5,PDS\TD?10"F>+<&K97V@!W%"<&]"
MPN/^/E(F7%R/((*^?+KQSWITJ-,[\3-!\0FVA14?>^UMS_AXVU^R@JR' _U<
MB.!K=$4O4YBE3[O]D*YFT_B."TG [^044Q"KOMD,QM1-E(1A39 KYHV9.K\W
MY'4K??$I"(S@ G!R+>R-!;@I4?X"^V$8ZE[[ =I:)N;,BZIB"@J*.4T3J*9,
MA4_K.Z 7ZS@C#?$7JEY^C+G^5%U:T*]_+'R3AZ;>Y4B@N1/2876.+.F-'A/Y
MU$XL#QO_-QG5<#)L,\]VLA5!#?!)C%P]6%?SQUU4/:H\A%Z!_ZDOK"4S>^[#
M^I8L4P6TF!7.HWH:[S9I9,C48%F.LVSU$WVB<+LO8@0KG:;]-H1.!_@%:6M0
M$[0$0K_)_CDJ/!UC"=DX?Z@:#+G8+-8-()\VR+CYEJ:VPHP0PTEQU):"T>J4
MR$+3<E0Y4OE)]:.7RA9> 0KCS/O0 >\9B=/[%?$TQ'Q_%YRHVYF#,04.SZ=J
M[_:=V%HH+A[$W>AY/N<T.^@7"ML?/55T2[ZX:M+._F&F&W(8Q=J[R?1&MY"1
MJS Z@B-\EKYD]7?6G&G;.H$Q?N&O<\/:YG8/&V]?VZFF8W1,X^T/D^[#2^/,
M,N9E["A<B."!FEKKQ=6O]6?N/I%/00CZV4277^U7W-P7="5C3XX2IO;]3PDM
M\\4L<_/0TU)<B#^>^(<,7;E,ZT*EP^JK4]85^+H::X^0EAOG9,8:U*,T/[ZL
MO#5QXD]TP=Y9*:,G5^IV\.>D(*?@C [V4T(0/'XWY@X[UT3%C#HL?!4Y[+6K
M9E=!N'^ED;)&\O>9WGWXPTH%;XV3JP<RIQ<Y(OU,,] +9W#D)-B>=A-MEF2Y
M(XW06;WG9ZA?H32]%6O4.*;=G_.R5ZBE==2LU69'.4*RRRO%.<7RU&5%+X4U
MEKP9_6POCI] GF,CYF&QK<(!U,"S7>W[Z2<JFG?.U8:MMZ7,3CA[./?HWLSY
MX/A51-I'I.+]GN88;+,M$BQ==7#6OG$ZE/&976"BC/%DYQ+(N7/'Z.;5M$]3
MU>OL0\#O3].(AE&[V86H9-3"W= 32CBM$:$7C\_(/]T/:9Q<60030'4)WPA?
M\:#"B5#&13 L;J-'^["G:)J5LXL],'ZU%,V*OT.\'X0PE)#PJ'L/@S!C$I$.
MM(Z-78$+ BKV%K>@8PY>]AH]$ $KX_+%M:]Y')$<IAAHDW/K:WO1/@Q3@(*B
M#I)XW2T$[QVT.;$P[?_^4\VP<*&>9->05(R5XO=-\UM[K2/S6!*9'!%F":[3
ME>!!$L=@ 36:E1Y2#HV\DF,]WLI7C<;+]*U]L'JN_M+"OW_@(8QGZ*U76/CA
M&(5V>Q!*^1/\45^U&7?ICOT,]ETX^>D)$$FPSOCL*L!5<R&^ "/:5,$]<F[C
M?8.C[]6OKOW*J-^F:2DJ[]-6;$_#JO4<OT>L$$!3' $F&;7L(I,#V &8,)R<
MKWAT@J,"')Q@N:)Q9O3O#W(WFAPB @)/%OZF"AVH;;)SVOPMHS$MKA21979G
M@R7^A".:1<$#ZH5Y=&A7*A,^PS( DF@+3EQ(/>OP2R!IM7%2_/Q(28CFR'3?
M!P<GEU-7NLX'F>K_.G#:N)_<]"\2  \@@20 +VSR#Q* ^8]) !+U;R3@Q38)
MP&V3@.T>*L:2_"<+\/L7"X#><_@'"] ."CP.L@#F\99NJ>#HY[<EZM__DP4D
M1&UTK0&:U9D$?UPR4BZ,]!7',*H!'E(0=^]T_RQ4?L2RR43095J.1!9]'ZDO
M]CJ(V/5#Y8I?U3/=6[N#=AP">T'Y3Y?VAU4_Z4M$Q3)49,!15?DG5KF6)/ZX
M1+LSW\3[@Y$/0=SDB@<T8*OV-'6.$)NVQJA@/\)"FY*^ 12*C<*:D9])BVA3
M'-)^M'VBD4''U"%N2P[9XP<MJ8=@>0=DWX#!">>,X1JA<7#R?45QNG<+4]RU
MOP@-)4>_J*388+D0:D&5T?5]XJBL<Y>F!S73TGG?+R^4\U)L\_ED+T%'4M1_
M2U(L6 KYY.%T?.UPILDIC XH$XM>0]*1<4'S4V0XU'_UI7C9YO47XZBJHCHE
M1%UROM+<EW<1MZ0MG?>:W 7 ,^Q8!V/3@V$ [&">95T%SKP&HOIP]=:=@G'8
M?4O-];<'?92LI>QFYDA#<IIM\=Z^5V<>I>Y92(^W6"#R;(P[CC=$JY\>^76\
M+>)R4VUM?<*+YM:6?(^4/6->!;/W1)Z)95_<@<7^(-"NKNUF:8#:%?GB:=:(
MZ3R&XRB+AXK;XTJT(@]+ _I442#U?'O4,^K<8:-5DP^^$0-2]Y-^#Z\=%8DW
M\<)$@]%\"==I1;BIG8C<V[Z/T\'A!3PY,!H\]7@ZW*%UHN^=(+'5=W]K?*J*
M>)V\NCW>%Z4/53]$\;!3@; CV+6X0/@4@<$/R$<QS3CCL-V.W872M2V)GV=3
M#U=Y%2[<.'>K5^S(B.5JXDF^! >/!#L+&YKD/*$+1XPBDY*P<)88/5Z."XEO
M=7RAPDDHG^[[T;2[T>+PP?)B ;&*-#[UPPZ06/4_91Q10^;5&0#'$<[3SB"0
M7^)I5BUNB,ZF.>.FD74$;S^]Z@2A/F=0PMG_DIN3ZS5>*E555"-$];-(\_GI
ML 8XH"X;3[BF#1Q<ZZR>CF/<VJ:=UMJ=T^D2$Q,HP9_N!K^KC)10&D,[ZPP'
M M2(Q9&)D_GYR*%\44$=W9>"/Q]*TZM7UD"/WAC'^0X#RHP:\#F"MMB1+M>/
M& VS\7%)[9S$[;;*J@CKSP]R""A],[UC@*G7>^#WK-.>",O"ZU,HQFMPSR;
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MM  $2_KB-*.0_7B:(\RFMPO]1:: =25L?;1H-$@SH;[Y13*?D-*#W@1UX[K
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M!XC:M-2.RE^I.6H1[7?PJK5>*N.1F_M9@D3T"PQ/'+*$1 O)ZWF)"P"YM?X
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M1H^<5ALE\Y[C"0-H0M#U],4DF[K:U!N:::X.JO>ID;?K/U)F[OX59$E8,)X
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MIC@.3R?IL:P:-8]]*AMGLR..W,A&GH\59/ETHFUT;BFY%<-+5T WJ'LB(A@
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M$PBI'ULZ1./#;P%.X:8?CR76)=/O.S'OW!C "7I3#P.8X<NE;Y-;4K_]EQ"
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ML?#.Q&F++TD6[!?Z3A\IW0,(#8F1KE!>T#*@CK6U-)4);$NTE'5=_T0H@0'
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MOBNQC(0)/+ I>!6T)L4V:4F0>HIS,;+3L,%Y@1X0WW+HBX1/<%?/";T,V*(
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MRTS(Y ,DP>X[<TWYJM+<K$R9I.J:V;*U,+PH<2K$T)",S%3_^@7XB* 4$0R
M 5+LW0_=):5(XO@!>>  '.[_ZW]_OU^"KR(OTE7V;S^XKYT?@,C8BJ?9[;_]
M\.O-1XA_^-___D__]+_^+PC_\^W5)_!^Q=;W(BO!NUR04G#P+2WOP&]<%'^
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M:\93V6Q*U[*!CZM<I+?9!Y)G:AMIP81@+))OD!?X#D0>8I!ZOG34H]"3HU?
MG-C3]=&-6IZ; _\$*TAJL$ T:/7]6#/ZCSO\HY$Z_N)VA1M(X*!&?@:>DMR
M!Q]&)EE_)C$:V1--,VR2;C0+&41<SQ3%['F3S5\&F=F=W Q[@/D@\$Z.*/*%
M:^?27N)(*<=8A9*Z$,5J[Y(X(0RB,$D\SP\"XNNJ_--'STW&6W3@9T&6Y9V^
MI#QC[+@P#^=A9.7=4&"^"/.,!'WA'$[&1,K8 GQM1^_VV]LC:,]NF$RQ]@/M
M2M*!*X:MMKQ=%VDFBD)ZQS3-:N>82=>W2-6/5Z**+U-G>XI%Z+L.=C&2GJ<(
M(!+R)^P[GOP_XGB^2Z,@$B81KOI-STVS.C!!7N,$3 $U6_0PX%YOV6(<1L=>
MA6Y @PYJ%4"QI;@!7AV!M.#^#&?+ZGS?H/E)9^SFM#R?<P]X@KG#].&[R%E:
MB,L\9>)*S>;5Z<1F'&0D3&(J/2>/$ 01(3&,/0_!A'E>&%&'>3[1=9_Z&IJ;
M,/VS&[BOD0?_V0W1Z]#3]R-ZV3SN6MGB:&2I:6&""B>H@ *%=(#GU<N8OA]F
MB[F)O+)]#%KRT'28Z/'7>F^?S'O3,:+KRVE=/S1$-D^_RM?AJ]@N8KX7)4F7
MFP.]<B[IQ]RAT'$<!I'O4XACS&'@4^HGD<!)0,RB]8\W:O)23Q.J_U&.41E3
ML9JDFN%7P6/+E-!T61VA :0$"4ES\)4LU\(T4O9H)^BY=G:)'7TIL07;V0P"
M-=Q1CE+KLV,Y'/9HLQ-'P^K2L!L,JWWG,#6J=D\NY/B4W:9T*>JUM':Q"R$:
M^"B!G(D$(LXPI!0[D#"?NC[#E :AF0SUM#8__=F<%:ZFDFIKZ2Y]J%5H56V?
MIAM#&H4RTZ ^ZGF8.#PB&)* JICC.(98^ A&?L!"'#">^%J[29:)GR2LN.)V
MB[59?K?'K9ZP6V)L9$4_0-8()T@U^+"JX7WM32K>&H8_5VV=6\QGUA\%5X&G
MYZS\DMV0[U="I= XS_CYSW]K7*7L]B)C4K+D7S]\5YOJHCE%L? ]SET613#Q
MW1"B !&(@T! 3]!8>I,1CDB@._$^ <?<M*:&"4KR'8@:J!1[ICJ$;Q80RQ6X
MN3K_J#\#/:6?CD_I)V)_9-UJK%#GL506 K7+6EM2A<)+6\#&F#/0])*ZJ#$(
MO&I,T@QG.[5;]-<-)NJ>B985QN\FHZ4("^3VK%2<\O3)%C(L4-!=Y[#QN%.7
M03YMI_2+B#B($N3#J$HAASP.B1MCZ%#95;X7X$0M$&]RJ!I,SSNM&(U"!]+"
MVOS*JIRPX+,H00?DT/6,+INF2Q@#.9INU:(%^#C&$L4>ZT=:E>BV]$(+$7N,
M/;SVL.]B<__U_/W?SC^_^_"^F8;Y(B"8(K6<X$80^4X(X]!%T ]<Z:GZB=H3
MTG5)GSYZ;EYFBT[?5WE&U7&O<#@!(W^\+; !.SG/2-#WP8:3,9%;I4^*D7NT
MW^X>C^?9#9,Y,?N!=OV2 U<,=#72KRD7&5<;W_>K[+I<L3]4(LI%XH=^%",.
M(R>A$'F80A)Q.4F.421\3EB"PB&92 ZTI_4F3I]^I,JLREO,X(&DAX]^F/&K
MZ7^<0M=$+D@+\0S4($&%\JS*2FO1%SG"A%UWY%!CTWHD1TS><4J.76\F$5RD
MBR8IW^.'[^Q.[?2JU)4+(A 1-.)0L*0*JA.0."Z'/(K\,(K<1.U]:'@GAQJ8
MFX_28@0M2*!0ZNG 01+[OW\;U(S\W1NRHOW!'S-]SX=>"/;Z=O7UC;RU^L;_
M!ZD?8?UC]6$??.@D'_0QD]H/^>AUP\;X^EC8-K_FQZ^?TT444)2(0 [M(O(@
M"GP.Y<TQ%"@6V'50%(1:27OZ&IG;A[PY[-EFFS1<2=A+I-Y ?BH](W_,#3/=
M'*P?_P8_7\A1?)VKO*OV!O(^)JP.XGL;FG0 [S/U^>#=>^TIW_TOHKQ;=3*L
M%A])FO]-A06]3PNV7!7K7"P<+_0\%! YI&,7(B88I$Z ()=_(!2'82)B<S70
M:7JF&G%?00?I%OO9X( J@WXP$1/;[$XC,37JK@9+J5'$5LC!%KIMQ3&A:P0=
MTFK^!=3)A);]FF7TA %;^^W3OB3J.#S)'KOSF_=I+EBY?/Q9+-6Y=I41L8HH
M6& 4XY!Y OJ>.G..I:P1YH8P=H03N1X/0J95<&<XA+DIV\>-?(%5 EAMR+\6
MZB<U:R^4+8 WQH [:8W*=_$@GV$4PG5"GQU?RQV_)T96P8[4?4G NTTG=)=.
M0&L'4(9(J:R2MAK%>IW0"0;[^:-WQE1;^:=^&9:.$YQ&:-_V_; '3[=S?Y+A
M3S;M3WO2"8'"JKE<W(FLJ"*255R RL?;'+>OIU'L\28G65&'S)[S_U[7(^8-
M^;Z(/4XHE0,49SZ2\W'LP3A$(60B87Y(2!"[V#BJ]31,LQO FJP2K,$-RBWP
M 2&P)W:8GJL^<3>,/'K5(;5/S&E#F]I:+FTGM5:!CEE@:]>9BH6R'(%KAV;[
MD;HGXIH^HM<.D7LC?RT]>IA./VMEWP&2XO.J?"\*>97:8CPO?A;\MHKSVERP
MB;,Y+S>#S2)@/@\B+X&NK^HV.+X/<1@ZT!=Q3!+$PE 8E?<<#>G<-'UK60&R
M50GXQB+I6DE7J[))>EO;]'Q_&1X)-E[_ZPT&L^C5L2<XS_5_[\&Z D@[P?LG
MG=V8VKWJ;!O5IDXT;B=/]D:.T?O$ZG@R'MI)1YG127\^]HS?X,2)@YN$CM*N
M1*3E6G[!FW2Q* QD6UX(DSCP(1)! DGL,Y@D@>NZ%!'JBP&1.R- G6G03P,8
M,")?YJ7@;Y(:NC",_1FC<_4&FI?JJW^8M+^;Q+X=2V>5W?=X1\PCD6\/SG^,
MG+W'B;:6GE>CJ8$;O4TN1_FPJN4KH5B30]63(N(+PMQ$WA]"YJF#CNK,.G9C
M#\9!0)$?A<05PNS,NE[#)M(QS?'UISC5HJ]4B92!3)2;;+S@0>1U8GAUS)&G
MRRJSZ?XK#/>#];I+<R_8>A>,O0_<LB<1UQ(-GG7'&-DVS&BRN_^KU_2T>[]&
M=.SL^YK=/4S4+M4:454WJ%HXNES)IXHRS46=Y^-Y(;RB"53JGO&B+G'<F(10
M(!9#Y#H<4H^[D/H41PGF.&!:M8'L09K;\LLGE<2P7D^7+E,-786Y/ZKBVV:J
M9J&_DH!BSPD3*#N&0(2H@%@@#P81B3 .'19A;E;=9*(>F[1N28.QF^YI\I[2
M&YNF_5Y&'K<VLW]5KWY?357KD9+VZ+,ZGEF ->E89X_&Y^.@Q2</7#YB=X*O
ME^)+<G124AR:E=PHJ5\0+W1$%(80<U]*;^A1&(N(0X*XG"B$(HST:KA:1S:W
M$;,U3$T:=!8BBMZ5"/![9:3FR4_[W:ZYG/02G3GV(M*T_6B^<F2;<[OK1=;0
M3;M*9)O4G;4AZPT,R"4@^\SI)*]N<[NQ& >ASQ+HH !#Q$4 <1++WO6XXSN<
M>Y0S[:0"^]N8FU@KE-VT[ ;1DX=8[%=,2]R,K'T[M S)0'" 'X-4!*?S-%%\
MJ/YK9):3H)^ ON0$!^Z<+DM!/_0GZ0J.7'IJBJ3B<K5,V>.-^%Z^E?#^6/#8
MX\@- Y4A.I ZAS&DL92]./0(]EB88$=+YXXW-3>YVV:%[NQ:#TV6M,.KGJ]H
MAZV1!; #\@S4,,'OS7\57E !'B79\R%61DJGM-/<"^54.F3VX<1*!^^8.-+B
M\UK)5>/0%>=?2;I4#MK'5?Z3O+=<,(^@A(E0]D4<J]/4 :0H9M#UD>>[<>(E
M5*OLV=A YR96-4Q 6IRJ'"9(UFI?%-PJP 589ZJ4^7*5W4*)Z!ZD\J7+JD@R
M=?9BHF",8_T_<D2&Q5Z=?UA&;>QF2EZ \R=O1V7Q#((S-/MD'A$:Q\#^8X1I
M:%)N+59#M[VAWFM=H;,+:K._T*P2GV?\LR2U_F41^3'C7H0@3[@<99A;Q6[$
MD'/!PXB*R L=,Z?6$,'<AH]-%5K6L<#4US7M!5T7>$1N1_>,&UJ?*'AG[ZO=
M?52E'K86V/24!Y)GV8$V13&Q7SV0I%UW>^B#A@F?2D>F_J<R!WPE2S4_O1*J
M-#%3Y?7D'V1C3_^A<V4=*W>1L5Q(N7XOZO_*WY=KGF:W;<:D*U**#TDB6+F(
M74>01,30"T(*$6$.C!TOAC[#B8\X=K!CE#)Y6OA&DCM!+N86^IM7+?@?5<PL
M4SD2E1Q4/XBMP69J//&KH2?E\^WPD<<!94J=PA%T+#H#6V/K/ZI^?_YO3VZH
M20 M"V#[[E19\6LJMCGD%!F@9L/>F/(RO6AU0)K8A$E'LY?IGN=#X0NA&#:.
MJFP[F7SI'Z_(MU_D0_.4+ L)\'K]\+!,1?%9E%\2B5;D7T6Q((DJ)QL(Z-!8
M#8-R!D%=[$+,F$L#+V8)YF:!WT;MF\C:1/'?Y!NX;V%7&E8TP,W&++-NT!MR
M1J-VY!%C@UL.$I+>7Y[0VX(_JTHYK!+0&F!/Y ?Q9E6CS1!,*K&#R'FND,,>
M,G2%A);;3:QW*]ET7JJ"8>W"3)U[K+//M< NPBRF"60\2B!R$(,T$1BRT D8
MYGZ"L%8![>$0YK9&TL$,E#5G(-LLL(HZ'5_W9/TKZ<Q7QUD*S=)1)W26[DK*
MF%TP^E(*+3L;L2H]^@9_=ZE[DY7V^);M@-64H01:7DXQAC'Q>LI0FG875 8_
M:>)]S<T1]O.B6-_71Q-5%2OEW?YMI9*OJ#4@Y;$N?.1@@I@/8ZK*T:"002+<
M!(I )-0/DS"(M2HD3HAY;E+<H@1?-S GVK\TZ.>1MS+'Z;WY[VIV<CYV+#\#
MFW=B:WRU_C&#'4[SKIK'9J<![G^,?4_SCK"V!3J@Z6%#V*=5=GLC\GLU=LIY
M19, _4H\U&"*+\EEGF8L?2#+B^R_!,EOOJT6+H^=A*N::*[/(6)>##'B% K,
MXXBR,'*P5A&24T#,;9"17Y-O-JH,HEYOF!B;T)%U7\&'"G\S<VI,>#P#"BN0
M8.W)]"E46=7=04 F%=)3J'JNC"<]Z[3 CQORO7,*\*?5BG]+E\OSC#^OC/[\
M]T7L8T+4*H<;JU,<?H1@G,0A#'U$'5<X@KAD2%VV4X%I?;K3YW)J+:A6(=,-
M9N.HZ%.[S2QR9-Q>F#B21!6][EBCMOU:T,=RF@^.'CF9P%&B28:C>I'HDI-)
M/!1M<OJ#7R;;WH?O(F=IL<W;5%6GEB#E,%&DK$X%&@H<!3%/I"(3 A$5!&)&
M0NCXB>_Y@GG11(LE!J#GYLC65;_3%N,V-_^J2<TG&J,FSLBG]0*,O(HR4K?.
M?QGERW;=I#%]F[&O&E2:E\5R@M@I.VH>BR@FP/\Q5E$&=(7MK']&;9L?^G[W
MY?/-^;N;3Q\^7W^X_G+S\X>KYCQN0 CR0_EV$$(=B#PG@(0' 4RPYT=N$E+D
M<MU3WX<:F=OPT> $-= W%5+]D\T'J>P7=EL$C1W8MX>; <>_#Y*D?_[;!ED3
M'0 ?1IK18?!C;/2<!C]XZV3'P8^![YX'/WJMN?A]$K=D^1_K/"UXRBI9_IX6
M"P\["2=N KD?!Q %,894B 1B[%'793QTL98C?K"%N<E>!1)T48+?%4Z#SWH_
MD\>%[V1^QE[-'8L:?;D[F:*)M&Z7*CL"UVM_C[KMOV\R:>N%W=6U_@O-1:VS
M6+)9#!%Y5O4^6:HP._DX%93\7GP5R]5#%6]"'E+I5:9_%WP18I_$F$MW+W95
M,DT<0QQ+%]!+L%!K%)CKG4NW@&5N0GGU9W+_\-?W@&TA5N>+RYZ25-;[Y[BH
M3LCZE&O!M2W@B3&@M09(<T#''M Q:+J^T5?U"?MH(OW?])7\&IKREFHEKM-7
M>=M7:D^%=_JJ\SU9JHAIB=Z>X>74%B8;B"Q1T1VR;#URV&J\;/6=;#R5C\SS
M1ZF_:K7D4YJ)BU+<%PLG23P6NQ121Q5P9G(0BXD?00^+B'**$?:-2M+W-S>W
M(4H)90T7=/&"WQ5B4$$V3!IZA&Z]56M[)(X\XIS$G_$:L1XM5E=WCS0YZ;JL
MGOG/5U0U[QKD.3_+O-S\^(4NT]M*W=ZN"WE)H6H#T[01/"ES*NU4695F>7Z4
M;^&&'D$QXI![PH<H82XD24!59?DH#FB J:.]CCH&P+D)6 =J\><_N:'SU\KI
M!F10-LY1NE3+ W_1CAK?+=^3Q[[];6NC_+?&2M QLW+_.H:>[3OD_<)=;.3(
MOVA73^?=OUB7FWK^H_5'_W3 ?K-3SA%&(^W9Q&&\=@;6=FZCU9NZG6W2:\>-
M'57((/%#E9V1Q9 BSX%.P)E/:!128A0FOK^9N0V^G1,G#4[#0LG[R=2;(YQ.
MT<C#WBX[%O?R]%BP6Q1X?U/35O3M-7>G'&__U3:C^YH$?NOR;I6K18M?54[1
MZW+%_J@#,ZK"+&UPQF6>,G&E(CH^K;Z)O/XIO4_+A>-% 759 !&18H(P09 &
M$8+8)3APG3AP'*,"[V."G9L:54!!A>\,_))FZ?WZOCILSE?+)<D[=10-SYV/
MVN-Z8C>7?AQ9,O>&Y6UCG]K@O&UL'GC2Z95A]2^@,FWL\#R['3!!6)XEP#,(
MQ[-+O5X8GN4VS9><KO](LY\%699W;P59EX^-PQ3Z8> &/(*Q[PN(_-"'A/H^
M9,P5<O0@E#*M4>-P$W/3>H42W%4PW]0X]5< #I!X?)GF=&K&EL\=5@:$W!V@
M1W^)XW2:)EJD,'B)C-84^@GH614X<.-D\_I^X-V9^9$K!WK6:UJ(_UG+CO^@
M,D#=R*>\7]V3-%M(EN+8902&"'FJ;* /L8@81(E+?-_'7/[1R"T^U-+L=&X#
M%%1(@8(*?J_!FI;S.TBOI@]J@[2Q%7 87^;NX#$N[/IR!UN;UA$[9O2.%W7T
MAF%"495!56GBBE(-$Y]7Y94@/%T^_D+R/T2I,NA749/8%PZ-7>D(X5C*1NS%
M,,:<08J8P(2[/B9&A;DUVYV;B%2PP18WD,!!@QQLH1N%JIIVA9[$C$#PR()C
MB5MC 3)DRJH<Z;8]J3@9$O)<JDQO-Y^[_7QQ>=WXTDZ$DR",".2>7]5R<B'U
M'0_2F/M![%/*J58*R:>/G9OL*&3ZTXX./<=G8L.,'ED*%*@!\ZV.X?ISK&$$
M3#2OTB/":$JU:V_/-*IS\613IUV W>G2GK\.\WS.[U=YF?Z]ZL OR4[ZC\"C
MC/'0@1Z-,42.)U2A]0@F1/@)][CO2(?'* -W?X,F+]\T*;>[>('XKI;NJA/]
MI/EW-19O\[,T@<=F+L^1/M#S=.SQ.K*J/2%4$CEB5A4]3JRZ,D>:G-2#T3/_
MN>.B>=? %9E-G?&J),&:J>Q5V6V3?/OMHYK1?4G>K8IR6[\U\)%T8B($0^8B
MB$A2%0"(H4L<AK'PF.,@H[4:<PQS\X2NU_?W)'^L"@X*J8-$O@_@W1W);T6=
MMUYVUHJE*ED5N):2Q8TC*89TE.:JS[CTC[T>U*!O:@%L\;>5 50RD&J-2%Z@
MC "_WU1CQ"CE>4_@TNYZT@ <TZXT#2=J9PWJA$<-$\T](6E7@JUN,[5E>,&E
M_YTF*=E(=%6S/!?\/..=;%55,E2QDZFJFJ;>W)&LS6:U8*X;1*&0^NKYH73Y
M7 *)&P<PPEX449_Y+#&*/)L4_=R$^N*Y9ZC^HRPQ4^-IWP ]'9]MOXX\ NR+
M+U;UQ5K30=?V]M!H:WTU.'?L!PT!>Y(+GH%Z*;"4-("6!WM#QXMTG]5!9UH+
M)AVN7J1SG@]T+P-BX#)&T_C'-$M+\2G]NMOD;R*]O9,.\;GREV_%KX5(ULM/
M:2(6 0Y\KL8Y3R0!1-0-H?ST$_DK0PZ-8N2(Q&3$.P7,W :P%B@@-5*PKJ""
MI<1:+8.TPC8X1^U)7:>Y-C)1AXR]<M)R7=L!E\J0?0/'IM,::T!M#E#V6%Q=
ML<"JW;674P!-NS)C@;J==1L;SS3?A?HU2]89%[P*56RV'007!"6Q*O5.5.0Y
M"R&-1 #ES,*G(@P]%FFG<-GS_+EI9 NQ.I1F<#AT'W7'MZI.)&1DC7K*Q8#=
MJWVDZ&]CG4C.1/M9&Y(>%$Q+*4=Z3._9VMIWUV1[7#V0NYM=?9<-<Q=_S?*-
M)WM#OC>' (OV:)\JH+M>EFEV^U'BO<S35=[D/B7?+U?-(?!%X+G,PXA AD@(
M4>CZD&+!(:'<B6-.DB3$)FZC#5!SD\8->)"+9;4<7:[ @\*N#L^H MLJ6\_#
MRNA@O=5>U/,@I^Z;T55Z:TZ5VZHUJ',P>F,24!\MJ(QJJZ*K6RZ/=IJQ1VF3
M9:N>I15@DWJ8-JE\[FE:??;)]6AJU[:SY/!9E OL>G[B>0C&E&.((I4]&GD,
M)FX<(A:S)!!:'JAF>W.3W3VYT,Y )@X?7QM$LIYT6J1N9%7<D^VOJOL]2IF7
M/B[&*N*RM\V7*M'21T!/ 9;>VP8N'F9ERM/ENI1SYFO!FGI:'[ZSY5IZG4K$
MU)F]==F$1'P@>2;%K9"B5IW?.[]?K;-RP7C(.&,1C&+9#XC$ :0"8<B18)RR
M)(I<(W?0"JJY"5/7*+"U"K1FU;Y&Q["JT'1CFO(^ZD(;9Z VSW"ET4H_:RXY
M3MU[8Z\]3M1QYJN0-HFVNQQI!=FTZY(VR=Q9H+3Z\%/CSU1H?B9?K<=W:SFR
M9&45I;.-9?(CZB#/I])M=%295B(@X0)!)XRQB), 18%AX*MNT_,+@>U$F[70
M4]-='FWB]>1U##)'5M!NY-@&]!EH8$\4)J;'UDBQ84<:?Z& ,#U*#D>!:=X_
M3*_VYS+^4(>AMZG"W#!($L*AZXL (@>IW9; @1X.O8@S+/]HY'AJM#DWM[)-
MC-^ -),F'8[U5,DR<R,+TE4W'7HW=7T#>(3D8@8$6=4@G78GE1\#(IXKC\FM
M ^JQ*?Q9F3=.6)WH^"HM_JAD;>%1/W3"A$ OIJHVD1/#F$81]-P@$H*2Q ^U
M@D./-S4WB7F"M@KNKK-T*\#-X&U2AJR?YN.[P/;(&UEE)N7-H(B;-?ZF*N5V
M"H]F%=VTJ.FKZ];_@.FJNVD9\J3&F]X=YK)Z[KX. ^?SJA3%^[7P'#]H,VV1
MV!4\D2Z;G%?*>6;$(!$AA<)W P?%E)  Z<TS^YJ9WYRR OHOH((*)%;P"WD$
M"K"^%ASD-!*,"\_ET"/<DX,4=B&)4 (#(0** \("[.D.4C88G6)X>L(GEWPJ
MJ."5^SIX"SZL\Q5P7[N^Z_[XROOQS9-_]3PL_]4W2'A^D/?CHY8--D<>KW9>
MS(I(\SBF@RSICU$VV)IH=!K(FM&X=(R.GA'IX*V3C47'P'='H:/7FH\_O]U)
MG 59BOS)$*>&MN:UC*5,(NK&D"0Q4D'P":24"QB'?D@I2J@(M5(;:;4V-_7<
M @9/_2P%6?^;/\[R<8FTRMW(6ME+VP#-/,Z?OGA:Y7$B%1WV&AJ)J#8M/6IZ
M_!F3R:JV.5U]U;_)VGG=\XQ7@0OGVRI"Y[20#3/=#66SA\Y() [68ZFP@PYX
M\'L+W^*2XS#>QCZHV ?AI4\::M"C<510YRF68O]4+)KK<,P%H3 )(SGGXVKG
M5A41=GS.>2)<+TS(HER59*FW";*O$2.O9=/4>%_6C6H#\#9J+<W8ZEZHD#_3
MS=F]C.K)TJD\C2P^AT+ZU *:*N11J]'Y<KGZIG*HC!CI-UEXW\O'])D$\@V/
MWE,C^66^8D+PHBGM4*@@DIM5O6QWO7YX6.7E^6TNJEH/19V,,<UNSUF9?JV"
M3Q94)%(8J ^= !.(8DPA)<2!#J&8RHD0Y8%V=<13P<QM4M0L,!<U=$ VV &I
M,3\:Q!1;Z:WCLZ<I^V!DZ6I- :]:8WZL@^Q>E:L?V]7_QB:P->H,;,P"6[LF
M["3]*=J4G371#&Z:3C.:\=EBN6=">'(3D\T7;9'1G4Y:>^9IL\VNHZT29$=1
MXA$O)# ( A<BCW%(0AY!$2<NX2(6+C)*FW>@G;F-6IOIYM.)I7DB\D.\FDW7
M3V!KJGFY 5&#9]\':!AEFOV\K1>93Q\P^-#$^=#EYB[QIY6:AF=*8D3&'C^O
MU8+6E^3=DJ3WQ6]I>9=FUZ(LEY4<;71IX4:N[^+0A50(.7_&',/8<Q/HHD2^
M/CQ&3J)=\6D8A+D)20U;3119!1Q\JY"#8@-]ZQ+KNU<#N^>XYSL^Z2/KD3(
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MD[+J_U0UGO.L2AVK #7UR2-$2<AX D5,Y-0*>P12QBD,Y1]$$KJ>H$;I <<
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M4>:"-N69#OH,=I0.F2PS!AMY"D;FM//H+TKXS\(^4KC+%2@Z);\A<DQ*AU<
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M.\6804MU$YC,.JH;/6F@VZJJO7 K]\%';S9KW515K%F[;_LR\4+&:4IUE%
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M];OVY=,5O3LCY%&MNW._'V:VM'H#UJ^/%Q"/(C^$./45Q:C]#,2,2:CV+G[
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M1"S DD&>B$CGGJAOVL,8QE1BQG5)'L+L_&3V0LS/6U96#Y6KS9]5\A>0C?"
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MN_4VVSY]$?>9?M1ZJRN%+_T4$1)37:5;<P$+!$R]*(&IE!(%":,X,:HG<VF
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M"O4[J[/#"^/,;?E29LWW3->X &K=THWX=+.+==.8[]6GS5;\Y=_\V/MK:KE
M7<39QT107T(L.%;V1Q! G%(.A91A0M*(LY NM[H[X'0X[T=[(9S=(&NV0CO
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M0^*<3'(_N[W$U'DFP2$%+W0OA+WJ%E<$,CJ9-??%2US-WH3+EEPQBU[JE9A
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MD3"B_A^U<P6NQ7.<I7P?45:+Z0!/,[/_6HP\KR3[X+RY (ZU?=^GO5.S_N1
MHUKS?:H>&O&]UPXCT#=:2MU*IJK*4I1_O'[6+67J H%IQH,L2R"FZO-'<9#
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MMVW_+GLS[MT/L6)%*3ZO"B:^:"J[_VO9G-ZE3,8)X;J5?,8@BB2%.,49C/-
M(*G8)4F,$FXOC#,U4OE_PB#X.4BA^F_X,\[,S8T^+"^;:HX0\NW3-5*"2DQ0
MR0F4H ..C/O@,K?+',$VDD5V"CY'QI@!$#UF6-_=HQE@!BIT32^3RP<P8KDN
M'O6&_F^ED)NY;AU=WLFZ)%J5^[U+?N<!#S"6#$H:"HB2.(,T5U1),IZ%(@P8
M8\28((V'G1I?;B4'M>B@DEUOO=?26S"".?0&?.H%4-_T>AK+NQ9+F_(#5[W9
MYOSK!>:QZ'@+]Z:&>]Z^NE4I^TH)5_1LC5,?6YL_;#SRME9PC\OM[Q[F3]^O
M"!>Z?G3;'EZ0/$ZH,FN#($<0A3H+1@8,1ICG(2(\3W(K#_IP@*G1]4X^.Y_X
M"#@S+_@:.#R3[4XTAU%\E_1VZM@>#3*J*WM.Q4/G]>QUP[[@UV3QQWWQ*-Z*
MIV59K-O7,:<D$9FRO@3E&"**,20X26&NW-@ T0SEL55*V^EA)O<U*PD!;T2T
M^Z#/X&CV65^/CN>/6PL(*G1:$3U\Y/TH./W4SPPUZ@??K^[A9W_AZF$?__OE
M2A0/NEIUM>_^9KFH#C+;;8,PY&G(8A@RF4.$4@0)R@(H<XI"'0*"J%4J?>]H
M4Z."1E@@&FD!:\2UY(5^B!D/HSA4P-*<ZU/=(((TP0+2*&=,I%3$B;"+L7$&
M\CB!-LVQ#I!GX?Z;2[S-Z-@9AIY9N7U'6T%!*ZD'<C;"Q"E']X\X*E4;*7_(
MV&8WV6^I?5@P?3BJ5H+ZOQ\6;4#*:Z$_(UU(2<>FZ$X_,\X5NEDD(4TQ402#
M(Y@',H8"D0Q'J91)*DTWU6P&GAJ=M[*#5[R1_B=]D+^-\:.5!D 7S"MO=,2?
M5L)\,\AJ3B[OMOE"VC,?[4!^NP7Y@Z*G%N1:>'!?@_S9*\CF>VZ^P!YIU\TM
MZ%:[<$.0Z]F'LWK<:#MQ0Y3L[L4-NO_%>PC\4RU=W]:"WRHSD#R(O<.A64(%
MQ2B.((N8A"C!*<14_22"*.<L0EP0.7NJFMY_79/5VLQR'4EZFT_X4 =_7W&C
M@[)_FR/-I^I(DXJ'8J%?%KV+7DL#7JEUBR_G<[+JA*9;AJ*/]:9$-,A"PC",
MHUPGC 8!Q!%&ZIVIXMJ)##EJWI1W"\,LH\F^)ZT&H[\E8L'_A[X?9O[8!&?<
MLR7EJ<7%#6CU!PT 8#^&8I)-+TSF;*I=,'IE_Y_:%L-D0CSVR3 :?F //468
M1)>Q^JA-M6VY8EWD:K-:*9&V%0CO9%/FBLP_ZPW9JKOW6C>0TN6,BW(]HR1*
M@EB]7;HB*40""TB"-(0\QS03L8SS*+?9/G4HV]2\\ZUJH-+MIEO=>Z??3:<X
MIUKNMCJ"5DGP^TY-\&ZAO*^ZT[%E+IG+E\!L@7NAJ?6\B+W8K-JW[7./O]O.
M?0[E&[=YGWM@C_KW>1C"?E-6#??_;LB\D(5:O723V.; 0<:*[!G*H$ 1@2@7
M,<QS(6!,B&Y9$E J4M/]US-C3(W,E9AP*V>5!&$1M'@.Q\M[I@[0\<R'2D)P
M ,R 0.]S")EO>#I :J2]38W8GUO$JE;SC@((+V#0LTMY[L[1-B0OB-[=>[QT
MZ:"V30>=L=_]>*K:6;_?K#?*?*__4!UV%72C7X\/B_\69/6^^"YF(HMQ'&'%
MAK&NCIC) -(PBB")\U17G(E";,R&5TDR-<Y4;UEJU2KHBDFX3*6C0>N9<!L]
M0"-O1;F@5074NFS_V-5&'Z!H?8!6:*QYL>KF-,[\C-?8J9HGVDR%)GH@VGF2
M]3RU?V3=>2H6X%G/DU2*.5H9G(#;W_#IBN>/V?OI>A@.VD Y>*#=BE6NUK-W
M&YWMV1A)(9$\C4D 24I"B&@>0<Q%"ED>2&6+J_\+$I,%Z/#!4UM/:MG,F.L(
MI/X%XAK5/?-]+9;#X*=SNO8Y]^J>CF.O?CMTZH\>.LHW?4Z5]A,]^W>[+XZ+
M8O9NL58.^)O:^_XBGI8K[9YK-WQ3SB1B:<B4"1AA]?&A@.LOD 4P(C0+<1:S
M&!GMBEX::')?9"4K:(0%6VE!+:[9IWH1W?Y/UR5FOC_E@7 9?]JF6)SXU$O!
M?GY8?O]/]8CJ2_\3Z1]A_6/UB5]\^"B?O*F*+0487S^T+>.A ?">%*M_D/E&
MW$G]:YV?-J.8D(2A$ H<4HCB((.$<[5DDS3+,Y:%29S:Q40;CFSS^H]4;UH;
MPC9YO[98AS*(.<M#F/!(QY\C 7&@  \#H3#/49AC;A_)XP'O\2)Q*LSK9%7=
M!%XJR<%W+7I=T_L__A>.PNB_]B-SM _B9X)XS"A*<JZF1:V42-(<DEA@R% N
MPRR)=',QVP :;]/C/P#FPN1 \*X.A?$W(68'>AX@?H&]DKJ$44- -^#V<;EQ
M$3HZ$"3'_5/-QAZYJ:H5(,>=5NUNM]_]_44]>D7F;Y8K91B0=>LPYH$RW7F2
M0B*8T*6-8DAUN6"64A9G&9,2&R<9G!YB:M9\(R78BFF^27@&P\N[LM<CXYE"
MCD 9<+IU!AWSO='K41IIT[-%BVW1>JQ$=;2-V8]#S_[DF1M'VWCL%[R[HWCA
MRH'ET*44NFVAJ#O.WI,?7]2C]:YDL=@H<Z\)-U@NRED0$XQEBF#.> (1RW0K
MA5C9TD'.E9$64*F,9XM>+.9#6]'A")U9MI*#+\9<. !P,]O+#XR^]SNV"#9]
MJ)78%9C@B] ?33$O*ID=9O ,Q\MM#7#SX<>M"FX-RU&=</LG#..LC\NRK!_[
M(!;LN:W^HXP^]8<JN$G760T"%D5A'L"(2J2LM)3 /(LH# )"!&*Y<BFMXE&-
M1IV:X:9EJHX0&ZEO@&CDKC(H&LG!W+K(K=D<F#&8<V0]DU<%ZILNJ.\ZH+9"
M@X].*]]:@>24L<Q&'I6LK, XY"F[F^V]QMOPYS2I.J?PC="8-D:];F]"D*"0
M"]U-,&$9Q(AP*$(F.4]E'@?&O5+/C#$U^M%2_F]0=Y%1@@(MJ;ES= [(R[ZC
M W@\<\@I9 ;XC^<@,G<@'4 UD@<Y##(K+_("&#UNY+D[1_,C+XC>=20O73HP
MEVC]3:QT@ZZO@FU6Q;H0VZ#P+!6,!@%,(D8@RA*N++$TA9))PFF4I)@85;J]
M.-+4Z*\2U#(9YRR*9K:4$VP\<U\E8]50#]S1>?%0.P4>BOA<!,-MULK9T<;-
M0;FD]%%&R<4;AAZ TW5SLCX3(@[3$%'(HDP'H@4(YGD@H RQ3&D6<6H6!G/B
MV5/[Z+]^6Z[6=<](NERMEG]594ET6PQ=%KA)T@%5I,%R<6T_SB[&ID=U@Y#S
M?AQ'US=M^(O+([<C91T?J^V>/_+1V9%BQ\=CQY<,<&;0S[AC*Z"M@8D3PF1,
MH2!QH)R9((*$ICE,(Y8(P6F >6CLS)P>8VH?MI9RW_Y$-L[,&2 -G)GKX?'\
M]9Y"9H@S<^Y=,W=FKH=J)&=F&&1VSDP_&'W.S)D[QW-F^D7?<V8N7#J@AT>[
MC]WL8.^?2'P2Z^,25\V5;3&V$(>AQ"2 /*E:C<<QQ()&,.5"N3Q8\" U[WUT
MK313H]'=T<^:_ #52?#JX,QG(=:@.%W!L+UG0-'"Z^?U,E>/.ENCG=&=/9S3
M?://%.1K[QE0^/#ZB;+H0#+FA(W5F&2DB;-K8>(*Z+[.)E>/,5[#$U=P[/5!
M<?90^U7SLUJ"%^N"S*NR1F53I4@W7_EMH9Y0-3:M:QM5F=DS(3 -68)A%(?*
M@1""0AS1$$8BQFDHLP"GD>D::3GVU%;$K?AU[;IMO;NJ6=-&:U WW@7+2H>Z
M,$!5]ZZ^WK#8W9!9NKSB><3>\_JV@[T6'71D!Y7P30?I6GS;TAZV4)NO61XA
M'VF%<@N]U3HT$+R>5<?VB:.M,0-5[:XH0Q\QL*"O?MR'LMP(_G:S*A8/G^LT
MF&KL:IMZAE&:!X00&!,:0Y0Q#@D-=-_J*!(I0W% D]E"/.AN8&9;R9<'-?J
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M8B$^K,5C.6-YRN* "RAX'$+$D@R2@$B8$A00$DG*(RM:LA5@<B2UDQ]<]*+
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M- IBXY:A9\:8&J-J,6$CYPVH)36O"G\.R'YR= 2/9ZX[A<R CJ+G(#*ODN\
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MP[Q@F$]7S?Z(G;TK![1B+_[]]^5<-^DJWRQ__KCF/S>G:QF.E$&'.:11(G6
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MQ$@W ">402(4#X<BB0,J,0\2H]AKP_&F1J\Z<[\567^BH!+:DF$O0&S(GNZ
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M\\X; U$;0!P7\7#,'.?'&YDZ+BI^S!V7;['W@=_>?OF_MQ_?_7_-ZI=B&:%
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M]-06*HUT]F%F!U!UT^=U  S,>XU@/1+)#T"PCZKK#\9(\7/VH#B%S9W6NR-
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M50W/W%K^HZ7PS*0B :.S:=U4:OWZ!G>HFO?ZAA^K?-X$7@"W8GK#FJ:KJMY
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M@YB2"*),F*X6(849E1BF<9BPD+"4)=9[[L-99 Q&=;+'F]!A7][1))=]]>&
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MXUK/U5AV1#B@ 0:FPC;R%2WNR=Y43VX"3^L&AEX#3WN"-U2_+RL97JOQEPM
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MP3$3H5W>@.5X<S,'#UXDR_=H$-*6%.4/O[%YJ0^Z$7)Q+9'Q2T 7QIR6=>P
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MF$9Q@@FV;O=N-^;<-NVUV#= &8KY43?IW(I^ _)=.ZZEEMZA/;CE%%S>W(\
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M#Z@])JL:JM;GOMT5P3'$TW7^7 ];O,_*R(ML*[DYRMJNK4>3,LW!BQ-V(QW
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M.V;TB]W(Y+<%K946O.K63VD$/A^9-Z2FF"4ZONN+71IVZEICEC"<J#MF>^?
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M6]I"?I>KTFQ?\@$!<:XS:4=:(\[/R$1V>_?FP\UAX(K^Q59V8(0'KXSXO]P
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M)55V$ H9@WF8!S#(6":1E 'FR;#*P$?CS(WZVD5L&T'KDK6.!3G/ 6MG$GF
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M_<^RD?W/I);<_6#P;%"V"&?,0LX9K0I&66"T!6U$0 L2\.8)M*]K^AT:7*Y
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M2\V0?R7%JM[JT656/RS7O_]-\ =Q1[2U79LS62Y%*)(,"D0X1'&<0<HB N,
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MLK.H"R,XU&D&HFZM&)DC:VB!RV1+FYK0P_4SOUWB:0Q/D#6M ^\Y+3=PS(N
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M7E+/OL)T5ALI$:LKF.$'3*?+L_Z#^1^G9Q6*ERJ[KROF6>.[2[WI;$PVEK/
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MK70 M&>Y7G>:KLZCUSNF55@;M<VNUD(2.SHK6C>JL**T5+H8I1H5?_V L.T
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M3;XZG><++FS,-G(9F.44\-9,"0.9" 2!<S#"VIC:P.I^>L:9!GT@/ V@@@Z
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M @4]V: TC488[$?W<43 >X)KB#!W-TT?$:X?BE^N&$\ 3JD"%*SH2&;$6Q:
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MZ@*/.T4\KC1Z\;TV7MQI8ZN$6ZG(HJVV-H-4IJ:P2@17=UN5FDYU,LN@W \
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M)EH^6%0=9$%JA0K6_,W+J_5\@>OU'_AQD\[9W&32(=>2'!QN"P7*)3L@Y\:
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M3ED=(''(P7N[K&/NZN!CXGMK]^^$4AT,7,^RB5($-""=)L?5\PRNBCER8TD
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M-1F"BI0S!HWT,_2@O..R,)O1M-O5NR.13>/PFR<+-U][VZ%AC2L:@P/*.>K
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M[->U3.OVXW6$A ZY,47DV@PJ RBC)<02+/W2&7*V1;-\]@G=?MVRW&@7L$C
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MGP?1 =+O#T;7T_Q"%BDJ"4H+ 4HE<J?96&!!I.0Q:A_:)*);R>D./H>H^FD
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M10>NO6Z3D.]):!>WEVU0.+B>^H+A8WG7AC$90C(4$(/)]?VN\Y;L*S!@)NB
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M.&\<Z"!<TH&S[/0S4=\!7SOR Y-V"&NM@I$W.5QQ](_/T_3Y]?SR(O]T9[-
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MY$@G/CL&X^S!JOHQT?XM]M(^^/FS[:55&?W[\GAN^V5F:*7CY#]J),52=('
M;:F22ZQJG&@/.8R\]07V$Z7\M]AA+:%J*)LMML26Q^QXD'QZCC600S]^/1DO
M1;H(5[4;O[A,1ACI2:!"222G-A=P0410CHS[Y$MFRG>W&?MG0#_QWT%OUOZ%
MLA4J_^TV\[T_>86?1^/*PU>!'I>07VJ#:*QV-9Q:IVG+#*[( (GY8$TN3F7^
M)]C1+W.AGR#\_]O6+>-S*'N[;?ME_9,:5M[8+]()%+X.ZF6V3G=+GNR7J"$Y
M:Y3-Y)1CA]NV^P7V4]<SZ!TY,%0-9;.UI:@>L^,E1<4O412K9$"(J=[O"!O
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M H &H-I=&GU?#RRFH]E?,5S-OZP5KU7$'.$#H/25^* @DN8%$9V41GG'&S7
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M)^TS?@CXJ<GLT_GW#U=A/#\9YU/R:[\NNRU\_TB/6.XR.HZ#Y") LDJ#*L&
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ML&\R7GE6!HL1/C+(@G::TC[7;L<!8LK6\TS&[,,1M]T$53M:7S-=^J?I13]
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MVLM)><V4%&0+LFXF[#Q#4+\S1SH 3QN,[SE6O[;UWT\O</IME-91Z<*C,D8
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MFC,=7.@F*_P'A T)9WL X&$OM!:ET;>=73M;_-=B.IKET7(BPG+7)=I:@?@
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M,'@N:'1M4$L! A0#%     @ U(!15/F%H$<R"   ?R8  !X
M ( !1#(  &5X,S$R+3,P,F-E<G1O9F-F;WAF;W)M,3!X+FAT;5!+ 0(4 Q0
M   ( -2 450[D7)W:04  '(;   >              "  ;(Z  !E>#,R,2TY
M,#9C97)T;V9C96]X9F]R;3$P>"YH=&U02P$"% ,4    " #4@%%4]0A,U&(%
M  !+%P  '@              @ %70   97@S,C(M.3 V8V5R=&]F8V9O>&9O
M<FTQ,'@N:'1M4$L! A0#%     @ U(!15*CH;L8E@ 8 VL]2 !
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M,C R,C Q,#)?9S$N:G!G4$L! A0#%     @ U(!15&(SJ%#_EP  6/$  !0
M             ( !HY8( &IN:BTR,#(R,#$P,E]G,3 N:G!G4$L! A0#%
M  @ U(!15.(<X$E7GP  )/X  !0              ( !U"X) &IN:BTR,#(R
M,#$P,E]G,3$N:G!G4$L! A0#%     @ U(!15)OK_(/)00  [%H  !,
M         ( !7<X) &IN:BTR,#(R,#$P,E]G,BYJ<&=02P$"% ,4    " #4
M@%%4%)C%'E)(  #W6P  $P              @ %7$ H :FYJ+3(P,C(P,3 R
M7V<S+FIP9U!+ 0(4 Q0    ( -2 453//W#-)$$  $Q9   3
M  "  =I8"@!J;FHM,C R,C Q,#)?9S0N:G!G4$L! A0#%     @ U(!15)6+
M37K^EP  OZL  !,              ( !+YH* &IN:BTR,#(R,#$P,E]G-2YJ
M<&=02P$"% ,4    " #4@%%42%ZCU"2$  !5E0  $P              @ %>
M,@L :FYJ+3(P,C(P,3 R7V<V+FIP9U!+ 0(4 Q0    ( -2 450R,M4 JFD
M *F?   3              "  ;.V"P!J;FHM,C R,C Q,#)?9S<N:G!G4$L!
M A0#%     @ U(!15/;I#Q#$3   D6D  !,              ( !CB , &IN
M:BTR,#(R,#$P,E]G."YJ<&=02P$"% ,4    " #4@%%4U_Z"D9=A  ",@@
M$P              @ &#;0P :FYJ+3(P,C(P,3 R7V<Y+FIP9U!+ 0(4 Q0
M   ( -2 451B<Y]-S <" ,\Y%0 4              "  4O/# !J;FHM,C R
M,C Q,#)?;&%B+GAM;%!+ 0(4 Q0    ( -2 4509RK;]/C4! 'HL#@ 4
M          "  4G7#@!J;FHM,C R,C Q,#)?<')E+GAM;%!+!08     %P 7
+ !D&  "Y#!     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
